{"text":"Streptomycin appears to be the most effective agent followed by gentamicin and the least active was netilmicin .","paragraph":"<h3><u>Activity of aminoglycosides against phagocytosed bacteria.</u></h3>The intracellular activity of <b style='color:Tomato;'><i>streptomycin</i></b>, <b style='color:Tomato;'><i>gentamicin</i></b>, and <b style='color:Tomato;'><i>netilmicin</i></b> on Escherichia coli phagocytosed by murine peritoneal macrophages was studied using a sensitive and standardized method. Intracellular activity of <b style='color:Tomato;'><i>streptomycin</i></b> and <b style='color:Tomato;'><i>gentamicin</i></b> at therapeutic concentrations was seen after 1 h of incubation of antibiotics with macrophages containing phagocytosed bacteria, whilst for <b style='color:Tomato;'><i>netilmicin</i></b> a significant intracellular activity was observed only after 3 h exposure. The activity of these antibiotics against intraphagocytic bacteria was significantly lower than that observed against extracellular bacteria. Sub-inhibitory concentrations of <b style='color:Tomato;'><i>streptomycin</i></b> were active against intracellular E. coli. <b style='color:Tomato;'><i>streptomycin</i></b> was also active for a phagocytosed <b style='color:Tomato;'><i>streptomycin</i></b>-resistant strain of E. coli, but this activity was eliminated when the O2-dependent killing mechanisms of macrophages were inhibited by sodium fluoride. The data demonstrate that aminoglycosides may exert a dose-dependent intraphagocytic activity against E. coli that correlates with the time of incubation of the antibiotics with infected macrophages. <b style='color:MediumOrchid;'><i>Streptomycin</i></b> <b style='color:DodgerBlue;'><i>appears</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:MediumOrchid;'><i>netilmicin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In the case of <b style='color:Tomato;'><i>streptomycin</i></b>, the intraphagocytic activity seems to be due, at least in part, to the stimulation of O2-dependent cellular microbactericidal mechanisms.","tokens":[{"text":"Streptomycin","start":0,"end":12,"id":0,"ws":true},{"text":"appears","start":13,"end":20,"id":1,"ws":true},{"text":"to","start":21,"end":23,"id":2,"ws":true},{"text":"be","start":24,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"most","start":31,"end":35,"id":5,"ws":true},{"text":"effective","start":36,"end":45,"id":6,"ws":true},{"text":"agent","start":46,"end":51,"id":7,"ws":true},{"text":"followed","start":52,"end":60,"id":8,"ws":true},{"text":"by","start":61,"end":63,"id":9,"ws":true},{"text":"gentamicin","start":64,"end":74,"id":10,"ws":true},{"text":"and","start":75,"end":78,"id":11,"ws":true},{"text":"the","start":79,"end":82,"id":12,"ws":true},{"text":"least","start":83,"end":88,"id":13,"ws":true},{"text":"active","start":89,"end":95,"id":14,"ws":true},{"text":"was","start":96,"end":99,"id":15,"ws":true},{"text":"netilmicin","start":100,"end":110,"id":16,"ws":true},{"text":".","start":111,"end":112,"id":17,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":64,"end":74,"token_start":10,"token_end":10,"label":"DRUG"},{"start":100,"end":110,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1816186/","_input_hash":602969917,"_task_hash":-1150317317,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Neither behavioral therapy , clomipramine , methylphenidate , buspirone , nor naltrexone was effective in monotherapeutic trials .","paragraph":"<h3><u>Comprehensive management of trichotillomania in a young autistic girl.</u></h3>The coexistence of trichotillomania and autistic disorder has rarely been reported in psychiatric literature. The current study describes successful treatment of trichotillomania in a young autistic girl, using combined <b style='color:Tomato;'><i>clomipramine</i></b> and behavioral therapy. <b style='color:DodgerBlue;'><i>Neither</i></b> <b style='color:DodgerBlue;'><i>behavioral</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clomipramine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methylphenidate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>buspirone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>nor</i></b> <b style='color:MediumOrchid;'><i>naltrexone</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>monotherapeutic</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We postulate a synergistic effect of combined treatment with <b style='color:Tomato;'><i>clomipramine</i></b> and behavioral therapy, suggesting that both pharmacological and behavioral treatment of hair pulling may be necessary for many patients. This model is consistent with the extant literature and suggests that future clinical trials of <b style='color:Tomato;'><i>clomipramine</i></b> for trichotillomania, in both developmentally disabled and normal subjects, must evaluate this multimodal approach.","tokens":[{"text":"Neither","start":0,"end":7,"id":0,"ws":true},{"text":"behavioral","start":8,"end":18,"id":1,"ws":true},{"text":"therapy","start":19,"end":26,"id":2,"ws":true},{"text":",","start":27,"end":28,"id":3,"ws":true},{"text":"clomipramine","start":29,"end":41,"id":4,"ws":true},{"text":",","start":42,"end":43,"id":5,"ws":true},{"text":"methylphenidate","start":44,"end":59,"id":6,"ws":true},{"text":",","start":60,"end":61,"id":7,"ws":true},{"text":"buspirone","start":62,"end":71,"id":8,"ws":true},{"text":",","start":72,"end":73,"id":9,"ws":true},{"text":"nor","start":74,"end":77,"id":10,"ws":true},{"text":"naltrexone","start":78,"end":88,"id":11,"ws":true},{"text":"was","start":89,"end":92,"id":12,"ws":true},{"text":"effective","start":93,"end":102,"id":13,"ws":true},{"text":"in","start":103,"end":105,"id":14,"ws":true},{"text":"monotherapeutic","start":106,"end":121,"id":15,"ws":true},{"text":"trials","start":122,"end":128,"id":16,"ws":true},{"text":".","start":129,"end":130,"id":17,"ws":false}],"spans":[{"start":29,"end":41,"token_start":4,"token_end":4,"label":"DRUG"},{"start":44,"end":59,"token_start":6,"token_end":6,"label":"DRUG"},{"start":62,"end":71,"token_start":8,"token_end":8,"label":"DRUG"},{"start":78,"end":88,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8005911/","_input_hash":2140407778,"_task_hash":1856749713,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Pharmacokinetic PET imaging data analysis quantitatively showed the pharmacological effects of teriparatide-induced suppression of upper gastrointestinal motility and its restoration by granisetron and mosapride .","paragraph":"<h3><u>Exploration of Antiemetics for Osteoporosis Therapy-Induced Nausea and Vomiting Using PET Molecular Imaging Analysis to Gastrointestinal Pharmacokinetics.</u></h3>To select appropriate antiemetics relieving teriparatide-induced nausea and vomiting during osteoporosis treatment using PET molecular imaging and pharmacokinetic analysis. ### methods Rats were pretreated with subcutaneous teriparatide, followed by oral administration of antiemetics with different pharmacological effects. The pharmacokinetics of antiemetics were assessed by oral administration of 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) under free moving conditions in vivo. The effect of teriparatide on the permeability of Caco-2 cell membranes to [(18)F]FDG was assessed in vitro. The effects of antiemetics on teriparatide-induced suppression of gastrointestinal motility in vivo was assayed by positron emission tomography (PET) using orally administered [(18)F]FDG. ### results Teriparatide delayed the time-radioactivity profile of [(18)F]FDG in blood and significantly reduced its absorption rate constant (k a ), determined from non-compartmental analysis, to 60% of control. In contrast, co-administration of <b style='color:Tomato;'><i>granisetron</i></b> or <b style='color:Tomato;'><i>mosapride</i></b> restored the time-radioactivity profile and k a of [(18)F]FDG to control levels. Teriparatide had no effect on Caco-2 membrane permeability to [(18)F]FDG. <b style='color:DodgerBlue;'><i>Pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>PET</i></b> <b style='color:DodgerBlue;'><i>imaging</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>quantitatively</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pharmacological</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>teriparatide-induced</i></b> <b style='color:DodgerBlue;'><i>suppression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>upper</i></b> <b style='color:DodgerBlue;'><i>gastrointestinal</i></b> <b style='color:DodgerBlue;'><i>motility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>restoration</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>granisetron</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mosapride</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions Teriparatide-induced abdominal discomfort might be attributed to GI motility, and PET imaging analysis is a useful tool to for the selection of appropriate antiemetics.","tokens":[{"text":"Pharmacokinetic","start":0,"end":15,"id":0,"ws":true},{"text":"PET","start":16,"end":19,"id":1,"ws":true},{"text":"imaging","start":20,"end":27,"id":2,"ws":true},{"text":"data","start":28,"end":32,"id":3,"ws":true},{"text":"analysis","start":33,"end":41,"id":4,"ws":true},{"text":"quantitatively","start":42,"end":56,"id":5,"ws":true},{"text":"showed","start":57,"end":63,"id":6,"ws":true},{"text":"the","start":64,"end":67,"id":7,"ws":true},{"text":"pharmacological","start":68,"end":83,"id":8,"ws":true},{"text":"effects","start":84,"end":91,"id":9,"ws":true},{"text":"of","start":92,"end":94,"id":10,"ws":true},{"text":"teriparatide-induced","start":95,"end":115,"id":11,"ws":true},{"text":"suppression","start":116,"end":127,"id":12,"ws":true},{"text":"of","start":128,"end":130,"id":13,"ws":true},{"text":"upper","start":131,"end":136,"id":14,"ws":true},{"text":"gastrointestinal","start":137,"end":153,"id":15,"ws":true},{"text":"motility","start":154,"end":162,"id":16,"ws":true},{"text":"and","start":163,"end":166,"id":17,"ws":true},{"text":"its","start":167,"end":170,"id":18,"ws":true},{"text":"restoration","start":171,"end":182,"id":19,"ws":true},{"text":"by","start":183,"end":185,"id":20,"ws":true},{"text":"granisetron","start":186,"end":197,"id":21,"ws":true},{"text":"and","start":198,"end":201,"id":22,"ws":true},{"text":"mosapride","start":202,"end":211,"id":23,"ws":true},{"text":".","start":212,"end":213,"id":24,"ws":false}],"spans":[{"start":186,"end":197,"token_start":21,"token_end":21,"label":"DRUG"},{"start":202,"end":211,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26869173/","_input_hash":119621214,"_task_hash":-594075235,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Differences were observed when palbociclib or ribociclib was used in combination with letrozole or anastrozole or fulvestrant .","paragraph":"<h3><u>First clinical experience with CDK4/6 inhibitors in breast cancer therapy.</u></h3>For hormone receptor-positive, HER2-negative breast cancer patients with metastatic or advanced disease, therapy with CDK4/6 inhibitors in addition to aromatase inhibitors (AIs) or to the estrogen receptor (ER) downregulator <b style='color:Tomato;'><i>fulvestrant</i></b> has resulted in an additional therapy option and a longer progression-free survival. In the Gynecologic-Oncology Clinic, Diakonie-Klinikum Schw\u00e4bisch Hall, we followed and registered our initial clinical experience with CDK4/6 inhibitors, following the side effects and tumor response over two years since they were officially approved for general use in Germany. <b style='color:DodgerBlue;'><i>Differences</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:MediumOrchid;'><i>palbociclib</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ribociclib</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The dynamic side effects and tumor response under therapy with <b style='color:Tomato;'><i>palbociclib</i></b> or <b style='color:Tomato;'><i>ribociclib</i></b> were found to be comparable with the main reported data in the official drug information. The CDK4/6 inhibitors have an important and promising role in the therapy of breast cancer patients. Patient age and therapy duration do not influence the use of <b style='color:Tomato;'><i>palbociclib</i></b> or <b style='color:Tomato;'><i>ribociclib</i></b>, although it may be important which AI is used in combination with <b style='color:Tomato;'><i>palbociclib</i></b>.","tokens":[{"text":"Differences","start":0,"end":11,"id":0,"ws":true},{"text":"were","start":12,"end":16,"id":1,"ws":true},{"text":"observed","start":17,"end":25,"id":2,"ws":true},{"text":"when","start":26,"end":30,"id":3,"ws":true},{"text":"palbociclib","start":31,"end":42,"id":4,"ws":true},{"text":"or","start":43,"end":45,"id":5,"ws":true},{"text":"ribociclib","start":46,"end":56,"id":6,"ws":true},{"text":"was","start":57,"end":60,"id":7,"ws":true},{"text":"used","start":61,"end":65,"id":8,"ws":true},{"text":"in","start":66,"end":68,"id":9,"ws":true},{"text":"combination","start":69,"end":80,"id":10,"ws":true},{"text":"with","start":81,"end":85,"id":11,"ws":true},{"text":"letrozole","start":86,"end":95,"id":12,"ws":true},{"text":"or","start":96,"end":98,"id":13,"ws":true},{"text":"anastrozole","start":99,"end":110,"id":14,"ws":true},{"text":"or","start":111,"end":113,"id":15,"ws":true},{"text":"fulvestrant","start":114,"end":125,"id":16,"ws":true},{"text":".","start":126,"end":127,"id":17,"ws":false}],"spans":[{"start":31,"end":42,"token_start":4,"token_end":4,"label":"DRUG"},{"start":46,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},{"start":86,"end":95,"token_start":12,"token_end":12,"label":"DRUG"},{"start":99,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},{"start":114,"end":125,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33815595/","_input_hash":334314161,"_task_hash":-1077359698,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":4,"child":12,"head_span":{"start":31,"end":42,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":86,"end":95,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":4,"child":14,"head_span":{"start":31,"end":42,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":99,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":4,"child":16,"head_span":{"start":31,"end":42,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":114,"end":125,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"COMB3"}],"radio":[],"answer":"accept"}
{"text":"Resolution of muscle damage followed discontinuation of cyclosporine and lovastatin therapy .","paragraph":"<h3><u>Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.</u></h3>Hyperlipidemia, particularly hypercholesterolemia, occurs in cardiac transplant recipients both as a preexisting condition and as a consequence of immunosuppressive therapy. <b style='color:Tomato;'><i>lovastatin</i></b> (Mevacor) has emerged as an agent that may effectively manage this condition. Few serious side effects of this drug have been observed. We describe two cardiac transplant recipients treated with <b style='color:Tomato;'><i>lovastatin</i></b> in conjunction with their other medications, including <b style='color:Tomato;'><i>cyclosporin</i></b>e, who developed acute renal failure and rhabdomyolysis. <b style='color:DodgerBlue;'><i>Resolution</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>muscle</i></b> <b style='color:DodgerBlue;'><i>damage</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>discontinuation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>lovastatin</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We postulate that hepatic dysfunction secondary to <b style='color:Tomato;'><i>cyclosporin</i></b>e predisposed these patients to <b style='color:Tomato;'><i>lovastatin</i></b>-induced muscle damage. Use of this drug in cardiac and other organ transplant recipients should be accompanied by close surveillance of creatine kinase, hepatic transaminases, and <b style='color:Tomato;'><i>cyclosporin</i></b>e levels.","tokens":[{"text":"Resolution","start":0,"end":10,"id":0,"ws":true},{"text":"of","start":11,"end":13,"id":1,"ws":true},{"text":"muscle","start":14,"end":20,"id":2,"ws":true},{"text":"damage","start":21,"end":27,"id":3,"ws":true},{"text":"followed","start":28,"end":36,"id":4,"ws":true},{"text":"discontinuation","start":37,"end":52,"id":5,"ws":true},{"text":"of","start":53,"end":55,"id":6,"ws":true},{"text":"cyclosporine","start":56,"end":68,"id":7,"ws":true},{"text":"and","start":69,"end":72,"id":8,"ws":true},{"text":"lovastatin","start":73,"end":83,"id":9,"ws":true},{"text":"therapy","start":84,"end":91,"id":10,"ws":true},{"text":".","start":92,"end":93,"id":11,"ws":false}],"spans":[{"start":56,"end":68,"token_start":7,"token_end":7,"label":"DRUG"},{"start":73,"end":83,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/3290520/","_input_hash":-262996699,"_task_hash":351743309,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":56,"end":68,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":73,"end":83,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"In order to elucidate the possible interference of the antiparkinson drug 1-aminoadamantane ( D-1 , PK Merz ) and the antispastic compound 1,3-dimethyl-5-aminoadamantane ( DMAA , D-145 , memantine , Memantine ) on neurotransmitter metabolism , the effect of D-1 and its C-alkyl derivatives memantine , 1-amino-3,5,7-trimethyladamantane ( D-191 ) , and 1-amino-3-(n)-butyladamantane ( D-178 ) on MAO activity in brain , liver , and kidney of the rat was investigated .","paragraph":"<h3><u>Effect of 1-aminoadamantanes on the MAO activity in brain, liver, and kidney of the rat.</u></h3> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>order</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>elucidate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>possible</i></b> <b style='color:DodgerBlue;'><i>interference</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antiparkinson</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>1-aminoadamantane</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>D-1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>PK</i></b> <b style='color:DodgerBlue;'><i>Merz</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antispastic</i></b> <b style='color:DodgerBlue;'><i>compound</i></b> <b style='color:DodgerBlue;'><i>1,3-dimethyl-5-aminoadamantane</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DMAA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>D-145</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>memantine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Memantine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>neurotransmitter</i></b> <b style='color:DodgerBlue;'><i>metabolism</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>D-1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>C-alkyl</i></b> <b style='color:DodgerBlue;'><i>derivatives</i></b> <b style='color:MediumOrchid;'><i>memantine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1-amino-3,5,7-trimethyladamantane</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>D-191</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>1-amino-3-(n)-butyladamantane</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>D-178</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>MAO</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>brain</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>liver</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>kidney</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A radioisotope method using [14C]5-hydroxytryptamine as substrate was used. The highest MAO activity was found in liver followed by brain and kidney (Vmax: 137, 64, and 26 nmol/mg protein X h, respectively). The Km values did not differ significantly for the three tissues (liver: 107 mumol/l; brain: 96 mumol/l; kidney: 86 mumol/l). The MAO activity in liver, brain and kidney was noncompetitively inhibited by all 1-aminoadamantanes studied, each derivative, respectively, showing in all three tissues about the same percentage inhibition. The inhibitory activity was found to be increased with the degree of C-alkylation: D-1 (Ki approximately 1 mmol/l) less than D-145 (Ki approximately 0.1 mmol/l) less than D-191 (Ki approximately 0.07 mmol/l) less than D 178 (Ki approximately 0.02 mmol/l).","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"order","start":3,"end":8,"id":1,"ws":true},{"text":"to","start":9,"end":11,"id":2,"ws":true},{"text":"elucidate","start":12,"end":21,"id":3,"ws":true},{"text":"the","start":22,"end":25,"id":4,"ws":true},{"text":"possible","start":26,"end":34,"id":5,"ws":true},{"text":"interference","start":35,"end":47,"id":6,"ws":true},{"text":"of","start":48,"end":50,"id":7,"ws":true},{"text":"the","start":51,"end":54,"id":8,"ws":true},{"text":"antiparkinson","start":55,"end":68,"id":9,"ws":true},{"text":"drug","start":69,"end":73,"id":10,"ws":true},{"text":"1-aminoadamantane","start":74,"end":91,"id":11,"ws":true},{"text":"(","start":92,"end":93,"id":12,"ws":true},{"text":"D-1","start":94,"end":97,"id":13,"ws":true},{"text":",","start":98,"end":99,"id":14,"ws":true},{"text":"PK","start":100,"end":102,"id":15,"ws":true},{"text":"Merz","start":103,"end":107,"id":16,"ws":true},{"text":")","start":108,"end":109,"id":17,"ws":true},{"text":"and","start":110,"end":113,"id":18,"ws":true},{"text":"the","start":114,"end":117,"id":19,"ws":true},{"text":"antispastic","start":118,"end":129,"id":20,"ws":true},{"text":"compound","start":130,"end":138,"id":21,"ws":true},{"text":"1,3-dimethyl-5-aminoadamantane","start":139,"end":169,"id":22,"ws":true},{"text":"(","start":170,"end":171,"id":23,"ws":true},{"text":"DMAA","start":172,"end":176,"id":24,"ws":true},{"text":",","start":177,"end":178,"id":25,"ws":true},{"text":"D-145","start":179,"end":184,"id":26,"ws":true},{"text":",","start":185,"end":186,"id":27,"ws":true},{"text":"memantine","start":187,"end":196,"id":28,"ws":true},{"text":",","start":197,"end":198,"id":29,"ws":true},{"text":"Memantine","start":199,"end":208,"id":30,"ws":true},{"text":")","start":209,"end":210,"id":31,"ws":true},{"text":"on","start":211,"end":213,"id":32,"ws":true},{"text":"neurotransmitter","start":214,"end":230,"id":33,"ws":true},{"text":"metabolism","start":231,"end":241,"id":34,"ws":true},{"text":",","start":242,"end":243,"id":35,"ws":true},{"text":"the","start":244,"end":247,"id":36,"ws":true},{"text":"effect","start":248,"end":254,"id":37,"ws":true},{"text":"of","start":255,"end":257,"id":38,"ws":true},{"text":"D-1","start":258,"end":261,"id":39,"ws":true},{"text":"and","start":262,"end":265,"id":40,"ws":true},{"text":"its","start":266,"end":269,"id":41,"ws":true},{"text":"C-alkyl","start":270,"end":277,"id":42,"ws":true},{"text":"derivatives","start":278,"end":289,"id":43,"ws":true},{"text":"memantine","start":290,"end":299,"id":44,"ws":true},{"text":",","start":300,"end":301,"id":45,"ws":true},{"text":"1-amino-3,5,7-trimethyladamantane","start":302,"end":335,"id":46,"ws":true},{"text":"(","start":336,"end":337,"id":47,"ws":true},{"text":"D-191","start":338,"end":343,"id":48,"ws":true},{"text":")","start":344,"end":345,"id":49,"ws":true},{"text":",","start":346,"end":347,"id":50,"ws":true},{"text":"and","start":348,"end":351,"id":51,"ws":true},{"text":"1-amino-3-(n)-butyladamantane","start":352,"end":381,"id":52,"ws":true},{"text":"(","start":382,"end":383,"id":53,"ws":true},{"text":"D-178","start":384,"end":389,"id":54,"ws":true},{"text":")","start":390,"end":391,"id":55,"ws":true},{"text":"on","start":392,"end":394,"id":56,"ws":true},{"text":"MAO","start":395,"end":398,"id":57,"ws":true},{"text":"activity","start":399,"end":407,"id":58,"ws":true},{"text":"in","start":408,"end":410,"id":59,"ws":true},{"text":"brain","start":411,"end":416,"id":60,"ws":true},{"text":",","start":417,"end":418,"id":61,"ws":true},{"text":"liver","start":419,"end":424,"id":62,"ws":true},{"text":",","start":425,"end":426,"id":63,"ws":true},{"text":"and","start":427,"end":430,"id":64,"ws":true},{"text":"kidney","start":431,"end":437,"id":65,"ws":true},{"text":"of","start":438,"end":440,"id":66,"ws":true},{"text":"the","start":441,"end":444,"id":67,"ws":true},{"text":"rat","start":445,"end":448,"id":68,"ws":true},{"text":"was","start":449,"end":452,"id":69,"ws":true},{"text":"investigated","start":453,"end":465,"id":70,"ws":true},{"text":".","start":466,"end":467,"id":71,"ws":false}],"spans":[{"start":100,"end":107,"token_start":15,"token_end":16,"label":"DRUG"},{"start":187,"end":196,"token_start":28,"token_end":28,"label":"DRUG"},{"start":199,"end":208,"token_start":30,"token_end":30,"label":"DRUG"},{"start":290,"end":299,"token_start":44,"token_end":44,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6891223/","_input_hash":-1495553761,"_task_hash":1770979485,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Primary chemotherapy with gemcitabine , liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer : results of a phase I trial .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Primary</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>liposomal</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The primary objective was to determine the optimal doses for <b style='color:Tomato;'><i>gemcitabine</i></b> (prolonged infusion), liposomal <b style='color:Tomato;'><i>doxorubicin</i></b> (Myocet) and <b style='color:Tomato;'><i>docetaxel</i></b> as primary (neoadjuvant) chemotherapy for locally advanced breast cancer. Secondary objectives included evaluation of the safety and efficacy of the regimen. Patients (n=19) with histologically confirmed stage II or III breast cancer were treated with liposomal <b style='color:Tomato;'><i>doxorubicin</i></b> (50-60 mg/m2) and <b style='color:Tomato;'><i>docetaxel</i></b> (60-75 mg/m2) on day 1, and <b style='color:Tomato;'><i>gemcitabine</i></b> as 4-h infusion (350-400 mg/m2) on day 4. Treatment was repeated every 3 weeks for a maximum of 6 cycles. The maximum tolerated doses were <b style='color:Tomato;'><i>gemcitabine</i></b> 350 mg/m2, liposomal <b style='color:Tomato;'><i>doxorubicin</i></b> 60 mg/m2 and <b style='color:Tomato;'><i>docetaxel</i></b> 75 mg/m2. Dose-limiting toxicities were stomatitis, diarrhea and infection. The predominant hematologic toxicity was mild-to-moderate myelosuppression with grade 3/4 neutropenia in 20% of cycles. Non-hematologic toxicity was generally mild, with no grade 4 toxicities being observed. Predominant non-hematologic toxicity was stomatitis, which occurred in 95% of patients. Grade 3 toxicities were reported for stomatitis, nausea, diarrhea, infection and constipation. No cases of cardiac, renal, pulmonary or neurotoxicity were observed. The clinical response rate was 83% and histologically confirmed, clinically complete remissions occurred in two patients (11%). We conclude that the combination of <b style='color:Tomato;'><i>gemcitabine</i></b> (prolonged infusion), liposomal <b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> is safe and highly effective in patients with locally advanced breast cancer as defined by maximum tolerated doses. The evaluated schedule is suitable for phase II studies.","tokens":[{"text":"Primary","start":0,"end":7,"id":0,"ws":true},{"text":"chemotherapy","start":8,"end":20,"id":1,"ws":true},{"text":"with","start":21,"end":25,"id":2,"ws":true},{"text":"gemcitabine","start":26,"end":37,"id":3,"ws":true},{"text":",","start":38,"end":39,"id":4,"ws":true},{"text":"liposomal","start":40,"end":49,"id":5,"ws":true},{"text":"doxorubicin","start":50,"end":61,"id":6,"ws":true},{"text":"and","start":62,"end":65,"id":7,"ws":true},{"text":"docetaxel","start":66,"end":75,"id":8,"ws":true},{"text":"in","start":76,"end":78,"id":9,"ws":true},{"text":"patients","start":79,"end":87,"id":10,"ws":true},{"text":"with","start":88,"end":92,"id":11,"ws":true},{"text":"locally","start":93,"end":100,"id":12,"ws":true},{"text":"advanced","start":101,"end":109,"id":13,"ws":true},{"text":"breast","start":110,"end":116,"id":14,"ws":true},{"text":"cancer","start":117,"end":123,"id":15,"ws":true},{"text":":","start":124,"end":125,"id":16,"ws":true},{"text":"results","start":126,"end":133,"id":17,"ws":true},{"text":"of","start":134,"end":136,"id":18,"ws":true},{"text":"a","start":137,"end":138,"id":19,"ws":true},{"text":"phase","start":139,"end":144,"id":20,"ws":true},{"text":"I","start":145,"end":146,"id":21,"ws":true},{"text":"trial","start":147,"end":152,"id":22,"ws":true},{"text":".","start":153,"end":154,"id":23,"ws":false}],"spans":[{"start":26,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},{"start":50,"end":61,"token_start":6,"token_end":6,"label":"DRUG"},{"start":66,"end":75,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15613900/","_input_hash":1351413438,"_task_hash":-515719107,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":3,"child":6,"head_span":{"start":26,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":50,"end":61,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":6,"head_span":{"start":66,"end":75,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":50,"end":61,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"A single bolus of dexamethasone , given before a single large meal , produces a delayed ( 6-hour ) but long-lasting increase in serum leptin ( over 16 hours ) .","paragraph":"<h3><u>Effect of one morning meal and a bolus of dexamethasone on 24-hour variation of serum leptin levels in humans.</u></h3>We have previously shown that morning administration of <b style='color:Tomato;'><i>dexamethasone</i></b> in combination with food induces a doubling of serum <b style='color:Tomato;'><i>leptin</i></b> levels starting at 7 hours after <b style='color:Tomato;'><i>dexamethasone</i></b> administration, with a maximum effect at 10 hours, the latest time point that we have studied. However, <b style='color:Tomato;'><i>dexamethasone</i></b> given in the absence of food had no effect on serum <b style='color:Tomato;'><i>leptin</i></b> at 10 hours. The present experiment was undertaken to determine the duration of the effect of <b style='color:Tomato;'><i>dexamethasone</i></b> on 24-hour serum <b style='color:Tomato;'><i>leptin</i></b> under fasted and fed conditions in humans. ### Research Methods And Procedures Six healthy non-obese male volunteers were studied under the following four conditions: 1) <b style='color:Tomato;'><i>dexamethasone</i></b> (2 mg intravenously, given at 0900 hours) with fasting; 2) <b style='color:Tomato;'><i>dexamethasone</i></b> with food (1,700 kcal, 55% carbohydrate, 15% protein, and 30% fat, given in one meal 2 hours after <b style='color:Tomato;'><i>dexamethasone</i></b> administration at 1100 hours); 3) saline with food (same meal); 4) saline with fasting. Serum <b style='color:Tomato;'><i>leptin</i></b>, glucose, insulin, and cortisol were monitored every 30 minutes for 24 hours. ### results 1) Under the fasting condition, <b style='color:Tomato;'><i>dexamethasone</i></b> increased <b style='color:Tomato;'><i>leptin</i></b> nocturnal secretion between 2100 and 2400 hours. 2) A single meal (1,700 kcal) at 1100 hours increased nocturnal <b style='color:Tomato;'><i>leptin</i></b> secretion when compared with the fasting condition. The peak increase of <b style='color:Tomato;'><i>leptin</i></b> was 123% over baseline between 2100 and 2400 hours, 10 to 14 hours after the meal. 3) In the fed + <b style='color:Tomato;'><i>dexamethasone</i></b> condition, <b style='color:Tomato;'><i>leptin</i></b> levels increased from baseline starting 8 hours after <b style='color:Tomato;'><i>dexamethasone</i></b> injection, reached a maximum increase of 260% between 2100 and 2400 hours, then decreased thereafter, remaining elevated compared to baseline for 16 hours. There was a correlation between 24-hour <b style='color:Tomato;'><i>leptin</i></b> secretion and insulin secretion after a single morning meal. ### discussion <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>before</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>large</i></b> <b style='color:DodgerBlue;'><i>meal</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>produces</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>delayed</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>6-hour</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>long-lasting</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:MediumOrchid;'><i>leptin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>16</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Under fasted conditions, <b style='color:Tomato;'><i>dexamethasone</i></b> does not increase daytime <b style='color:Tomato;'><i>leptin</i></b> but does increase <b style='color:Tomato;'><i>leptin</i></b> during the night.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"single","start":2,"end":8,"id":1,"ws":true},{"text":"bolus","start":9,"end":14,"id":2,"ws":true},{"text":"of","start":15,"end":17,"id":3,"ws":true},{"text":"dexamethasone","start":18,"end":31,"id":4,"ws":true},{"text":",","start":32,"end":33,"id":5,"ws":true},{"text":"given","start":34,"end":39,"id":6,"ws":true},{"text":"before","start":40,"end":46,"id":7,"ws":true},{"text":"a","start":47,"end":48,"id":8,"ws":true},{"text":"single","start":49,"end":55,"id":9,"ws":true},{"text":"large","start":56,"end":61,"id":10,"ws":true},{"text":"meal","start":62,"end":66,"id":11,"ws":true},{"text":",","start":67,"end":68,"id":12,"ws":true},{"text":"produces","start":69,"end":77,"id":13,"ws":true},{"text":"a","start":78,"end":79,"id":14,"ws":true},{"text":"delayed","start":80,"end":87,"id":15,"ws":true},{"text":"(","start":88,"end":89,"id":16,"ws":true},{"text":"6-hour","start":90,"end":96,"id":17,"ws":true},{"text":")","start":97,"end":98,"id":18,"ws":true},{"text":"but","start":99,"end":102,"id":19,"ws":true},{"text":"long-lasting","start":103,"end":115,"id":20,"ws":true},{"text":"increase","start":116,"end":124,"id":21,"ws":true},{"text":"in","start":125,"end":127,"id":22,"ws":true},{"text":"serum","start":128,"end":133,"id":23,"ws":true},{"text":"leptin","start":134,"end":140,"id":24,"ws":true},{"text":"(","start":141,"end":142,"id":25,"ws":true},{"text":"over","start":143,"end":147,"id":26,"ws":true},{"text":"16","start":148,"end":150,"id":27,"ws":true},{"text":"hours","start":151,"end":156,"id":28,"ws":true},{"text":")","start":157,"end":158,"id":29,"ws":true},{"text":".","start":159,"end":160,"id":30,"ws":false}],"spans":[{"start":18,"end":31,"token_start":4,"token_end":4,"label":"DRUG"},{"start":134,"end":140,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11068953/","_input_hash":-643064794,"_task_hash":935272379,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The aim of this single-blind , randomized , controlled trial was to investigate treatment efficacy and safety of aripiprazole as an adjunct to valproic acid ( Ari+Val ) , compared with haloperidol plus valproic acid ( Hal+Val ) , in acute manic patients .","paragraph":"<h3><u>Combination treatment with aripiprazole and valproic acid for acute mania: an 8-week, single-blind, randomized controlled trial.</u></h3>Despite the fact that combination treatment for patients with acute bipolar is prevalent in clinical practice, the outcomes of adjunct treatment with <b style='color:Tomato;'><i>aripiprazole</i></b> and a mood stabilizer have rarely been reported. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>single-blind</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>controlled</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>aripiprazole</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>adjunct</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>valproic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Ari+Val</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>haloperidol</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>valproic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Hal+Val</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>manic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Treatment efficacy was prospectively assessed for 8 weeks in 42 patients with acute mania using the Young Mania Rating Scale and the Clinical Global Impression-Severity of illness scale. Emergent adverse events were assessed by the Drug-Induced Extrapyramidal Symptoms Scale and the Liverpool University Neuroleptic Side Effect Rating Scale. ### results Both Ari+Val and Hal+Val produced a high rate of response (85.7% and 92.9%, respectively) and remission (82.1% and 85.7%, respectively) after the 8-week trial. Changes in the Young Mania Rating Scale and the Clinical Global Impression-Severity of illness scale over the study period and time to remission and response were not significantly different between the 2 groups. Patients treated with Ari+Val showed significantly fewer extrapyramidal adverse events than those treated with Hal+Val (t = -2.048, F = 40, P = 0.048). However, significant weight gain was more prevalent in the Ari+Val group than the Hal+Val group (t = 2.055, F = 40, P = 0.046). ### conclusions Our findings suggest that both combination strategies with Ari+Val and Hal+Val are beneficial for acute manic episode. Although patients receiving Ari+Val showed fewer extrapyramidal symptoms than those taking Hal+Val, careful consideration of adverse events such as weight gain and sedation is warranted.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"this","start":11,"end":15,"id":3,"ws":true},{"text":"single-blind","start":16,"end":28,"id":4,"ws":true},{"text":",","start":29,"end":30,"id":5,"ws":true},{"text":"randomized","start":31,"end":41,"id":6,"ws":true},{"text":",","start":42,"end":43,"id":7,"ws":true},{"text":"controlled","start":44,"end":54,"id":8,"ws":true},{"text":"trial","start":55,"end":60,"id":9,"ws":true},{"text":"was","start":61,"end":64,"id":10,"ws":true},{"text":"to","start":65,"end":67,"id":11,"ws":true},{"text":"investigate","start":68,"end":79,"id":12,"ws":true},{"text":"treatment","start":80,"end":89,"id":13,"ws":true},{"text":"efficacy","start":90,"end":98,"id":14,"ws":true},{"text":"and","start":99,"end":102,"id":15,"ws":true},{"text":"safety","start":103,"end":109,"id":16,"ws":true},{"text":"of","start":110,"end":112,"id":17,"ws":true},{"text":"aripiprazole","start":113,"end":125,"id":18,"ws":true},{"text":"as","start":126,"end":128,"id":19,"ws":true},{"text":"an","start":129,"end":131,"id":20,"ws":true},{"text":"adjunct","start":132,"end":139,"id":21,"ws":true},{"text":"to","start":140,"end":142,"id":22,"ws":true},{"text":"valproic","start":143,"end":151,"id":23,"ws":true},{"text":"acid","start":152,"end":156,"id":24,"ws":true},{"text":"(","start":157,"end":158,"id":25,"ws":true},{"text":"Ari+Val","start":159,"end":166,"id":26,"ws":true},{"text":")","start":167,"end":168,"id":27,"ws":true},{"text":",","start":169,"end":170,"id":28,"ws":true},{"text":"compared","start":171,"end":179,"id":29,"ws":true},{"text":"with","start":180,"end":184,"id":30,"ws":true},{"text":"haloperidol","start":185,"end":196,"id":31,"ws":true},{"text":"plus","start":197,"end":201,"id":32,"ws":true},{"text":"valproic","start":202,"end":210,"id":33,"ws":true},{"text":"acid","start":211,"end":215,"id":34,"ws":true},{"text":"(","start":216,"end":217,"id":35,"ws":true},{"text":"Hal+Val","start":218,"end":225,"id":36,"ws":true},{"text":")","start":226,"end":227,"id":37,"ws":true},{"text":",","start":228,"end":229,"id":38,"ws":true},{"text":"in","start":230,"end":232,"id":39,"ws":true},{"text":"acute","start":233,"end":238,"id":40,"ws":true},{"text":"manic","start":239,"end":244,"id":41,"ws":true},{"text":"patients","start":245,"end":253,"id":42,"ws":true},{"text":".","start":254,"end":255,"id":43,"ws":false}],"spans":[{"start":113,"end":125,"token_start":18,"token_end":18,"label":"DRUG"},{"start":143,"end":151,"token_start":23,"token_end":23,"label":"DRUG"},{"start":185,"end":196,"token_start":31,"token_end":31,"label":"DRUG"},{"start":202,"end":210,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22592508/","_input_hash":814243224,"_task_hash":-276968346,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":18,"child":23,"head_span":{"start":113,"end":125,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":143,"end":151,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":31,"child":33,"head_span":{"start":185,"end":196,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":202,"end":210,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"Because the incidence of nausea and vomiting is significantly reduced when ketorolac is used in place of opioids to attenuate postoperative pain , it would appear to be an appropriate choice of agent to use following propofol anesthesia .","paragraph":"<h3><u>Ketorolac and propofol administration for prevention of nausea and vomiting in patients undergoing minor gynecologic surgery.</u></h3>This clinical review explores the efficacy of the nonsteroidal antiinflammatory agent, <b style='color:Tomato;'><i>ketorolac</i></b> tromethamine, added to an anesthetic regimen utilizing intravenous <b style='color:Tomato;'><i>propofol</i></b>. Both agents have been shown to reduce the incidence of nausea and vomiting postoperatively when administered to patients undergoing minor gynecologic surgery. <b style='color:DodgerBlue;'><i>Because</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>incidence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>nausea</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>vomiting</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:MediumOrchid;'><i>ketorolac</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>place</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>opioids</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>attenuate</i></b> <b style='color:DodgerBlue;'><i>postoperative</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>it</i></b> <b style='color:DodgerBlue;'><i>would</i></b> <b style='color:DodgerBlue;'><i>appear</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>appropriate</i></b> <b style='color:DodgerBlue;'><i>choice</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:MediumOrchid;'><i>propofol</i></b> <b style='color:DodgerBlue;'><i>anesthesia</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The use of this combination of drugs may not only reduce the incidence of postoperative nausea and vomiting in patients undergoing minor gynecologic surgery, but could reduce the duration of hospitalization and enhance recovery from anesthesia.","tokens":[{"text":"Because","start":0,"end":7,"id":0,"ws":true},{"text":"the","start":8,"end":11,"id":1,"ws":true},{"text":"incidence","start":12,"end":21,"id":2,"ws":true},{"text":"of","start":22,"end":24,"id":3,"ws":true},{"text":"nausea","start":25,"end":31,"id":4,"ws":true},{"text":"and","start":32,"end":35,"id":5,"ws":true},{"text":"vomiting","start":36,"end":44,"id":6,"ws":true},{"text":"is","start":45,"end":47,"id":7,"ws":true},{"text":"significantly","start":48,"end":61,"id":8,"ws":true},{"text":"reduced","start":62,"end":69,"id":9,"ws":true},{"text":"when","start":70,"end":74,"id":10,"ws":true},{"text":"ketorolac","start":75,"end":84,"id":11,"ws":true},{"text":"is","start":85,"end":87,"id":12,"ws":true},{"text":"used","start":88,"end":92,"id":13,"ws":true},{"text":"in","start":93,"end":95,"id":14,"ws":true},{"text":"place","start":96,"end":101,"id":15,"ws":true},{"text":"of","start":102,"end":104,"id":16,"ws":true},{"text":"opioids","start":105,"end":112,"id":17,"ws":true},{"text":"to","start":113,"end":115,"id":18,"ws":true},{"text":"attenuate","start":116,"end":125,"id":19,"ws":true},{"text":"postoperative","start":126,"end":139,"id":20,"ws":true},{"text":"pain","start":140,"end":144,"id":21,"ws":true},{"text":",","start":145,"end":146,"id":22,"ws":true},{"text":"it","start":147,"end":149,"id":23,"ws":true},{"text":"would","start":150,"end":155,"id":24,"ws":true},{"text":"appear","start":156,"end":162,"id":25,"ws":true},{"text":"to","start":163,"end":165,"id":26,"ws":true},{"text":"be","start":166,"end":168,"id":27,"ws":true},{"text":"an","start":169,"end":171,"id":28,"ws":true},{"text":"appropriate","start":172,"end":183,"id":29,"ws":true},{"text":"choice","start":184,"end":190,"id":30,"ws":true},{"text":"of","start":191,"end":193,"id":31,"ws":true},{"text":"agent","start":194,"end":199,"id":32,"ws":true},{"text":"to","start":200,"end":202,"id":33,"ws":true},{"text":"use","start":203,"end":206,"id":34,"ws":true},{"text":"following","start":207,"end":216,"id":35,"ws":true},{"text":"propofol","start":217,"end":225,"id":36,"ws":true},{"text":"anesthesia","start":226,"end":236,"id":37,"ws":true},{"text":".","start":237,"end":238,"id":38,"ws":false}],"spans":[{"start":75,"end":84,"token_start":11,"token_end":11,"label":"DRUG"},{"start":217,"end":225,"token_start":36,"token_end":36,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8499507/","_input_hash":-626567879,"_task_hash":-170812796,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":11,"child":36,"head_span":{"start":75,"end":84,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":217,"end":225,"token_start":36,"token_end":36,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The combination of vandetanib and bicalutamide was associated with considerable toxicity and did not have superior efficacy over bicalutamide alone .","paragraph":"<h3><u>A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy na\u00efve castration-resistant prostate cancer.</u></h3>To investigate the efficacy and safety of combining <b style='color:Tomato;'><i>vandetanib</i></b>, an orally available multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR), with <b style='color:Tomato;'><i>bicalutamide</i></b> in patients with metastatic castration-resistant prostate cancer (mCRPC). ### methods This was an open-label, randomized phase II multi-center study. Eligible patients had rising PSA on androgen deprivation therapy, minimal symptoms and were chemotherapy-na\u00efve. Protocol therapy was either <b style='color:Tomato;'><i>vandetanib</i></b> 300 mg oral daily plus <b style='color:Tomato;'><i>bicalutamide</i></b> 50 mg oral daily (Arm A) or <b style='color:Tomato;'><i>bicalutamide</i></b> 50 mg oral daily alone (Arm B) with cross-over to <b style='color:Tomato;'><i>vandetanib</i></b> monotherapy at progression. The primary endpoint was PSA response (\u2265 50 % decline from baseline). ### results Thirty-nine patients were recruited, 19 in Arm A and 20 in Arm B. PSA response was comparable in Arm A and Arm B (18 vs. 19 %). Time to PSA progression was 3.16 months (95 % confidence interval (CI): 1.09, not reached (NR)) for Arm A and 3.09 months (95 % CI: 1.22, NR) for Arm B. Treatment discontinuation due to adverse events was more common in Arm A compared to Arm B (42 vs. 5 %; p\u2009=\u20090.019). Treatment with <b style='color:Tomato;'><i>vandetanib</i></b> was associated with a reduction in soluble VEGFR-2 levels after two cycles but an increase in plasma VEGF levels. ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vandetanib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bicalutamide</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>considerable</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:MediumOrchid;'><i>bicalutamide</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Further evaluation of this combination is not warranted in mCRPC.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combination","start":4,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"vandetanib","start":19,"end":29,"id":3,"ws":true},{"text":"and","start":30,"end":33,"id":4,"ws":true},{"text":"bicalutamide","start":34,"end":46,"id":5,"ws":true},{"text":"was","start":47,"end":50,"id":6,"ws":true},{"text":"associated","start":51,"end":61,"id":7,"ws":true},{"text":"with","start":62,"end":66,"id":8,"ws":true},{"text":"considerable","start":67,"end":79,"id":9,"ws":true},{"text":"toxicity","start":80,"end":88,"id":10,"ws":true},{"text":"and","start":89,"end":92,"id":11,"ws":true},{"text":"did","start":93,"end":96,"id":12,"ws":true},{"text":"not","start":97,"end":100,"id":13,"ws":true},{"text":"have","start":101,"end":105,"id":14,"ws":true},{"text":"superior","start":106,"end":114,"id":15,"ws":true},{"text":"efficacy","start":115,"end":123,"id":16,"ws":true},{"text":"over","start":124,"end":128,"id":17,"ws":true},{"text":"bicalutamide","start":129,"end":141,"id":18,"ws":true},{"text":"alone","start":142,"end":147,"id":19,"ws":true},{"text":".","start":148,"end":149,"id":20,"ws":false}],"spans":[{"start":19,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},{"start":34,"end":46,"token_start":5,"token_end":5,"label":"DRUG"},{"start":129,"end":141,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24671507/","_input_hash":1184777275,"_task_hash":2077580631,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":19,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":34,"end":46,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"Our data indicate that the addition of Aspirin or of Atenolol to Metformin might be beneficial for BC control , and that this activity is likely due to effects on both BC and microenvironment cells .","paragraph":"<h3><u>Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.</u></h3><b style='color:Tomato;'><i>metformin</i></b> can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models. Since <b style='color:Tomato;'><i>metformin</i></b> is frequently used along with <b style='color:Tomato;'><i>aspirin</i></b> or beta-blockers, we investigated the effect of <b style='color:Tomato;'><i>metformin</i></b>, <b style='color:Tomato;'><i>aspirin</i></b> and the beta-blocker <b style='color:Tomato;'><i>atenolol</i></b> in several BC models. In vitro, <b style='color:Tomato;'><i>aspirin</i></b> synergized with <b style='color:Tomato;'><i>metformin</i></b> in inducing apoptosis of triple negative and endocrine-sensitive BC cells, and in activating AMPK in BC and in white adipose tissue (WAT) progenitors known to cooperate to BC progression. Both <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>atenolol</i></b> added to the inhibitory effect of <b style='color:Tomato;'><i>metformin</i></b> against complex I of the respiratory chain. In both immune-deficient and immune-competent preclinical models, <b style='color:Tomato;'><i>atenolol</i></b> increased <b style='color:Tomato;'><i>metformin</i></b> activity against angiogenesis, local and metastatic growth of HER2+ and triple negative BC. <b style='color:Tomato;'><i>aspirin</i></b> increased the activity of <b style='color:Tomato;'><i>metformin</i></b> only in immune-competent HER2+ BC models. Both <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>atenolol</i></b>, when added to <b style='color:Tomato;'><i>metformin</i></b>, significantly reduced the endothelial cell component of tumor vessels, whereas pericytes were reduced by the addition of <b style='color:Tomato;'><i>atenolol</i></b> but not by the addition of <b style='color:Tomato;'><i>aspirin</i></b>. <b style='color:DodgerBlue;'><i>Our</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>indicate</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Aspirin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Atenolol</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>Metformin</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>BC</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>likely</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>BC</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>microenvironment</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Our","start":0,"end":3,"id":0,"ws":true},{"text":"data","start":4,"end":8,"id":1,"ws":true},{"text":"indicate","start":9,"end":17,"id":2,"ws":true},{"text":"that","start":18,"end":22,"id":3,"ws":true},{"text":"the","start":23,"end":26,"id":4,"ws":true},{"text":"addition","start":27,"end":35,"id":5,"ws":true},{"text":"of","start":36,"end":38,"id":6,"ws":true},{"text":"Aspirin","start":39,"end":46,"id":7,"ws":true},{"text":"or","start":47,"end":49,"id":8,"ws":true},{"text":"of","start":50,"end":52,"id":9,"ws":true},{"text":"Atenolol","start":53,"end":61,"id":10,"ws":true},{"text":"to","start":62,"end":64,"id":11,"ws":true},{"text":"Metformin","start":65,"end":74,"id":12,"ws":true},{"text":"might","start":75,"end":80,"id":13,"ws":true},{"text":"be","start":81,"end":83,"id":14,"ws":true},{"text":"beneficial","start":84,"end":94,"id":15,"ws":true},{"text":"for","start":95,"end":98,"id":16,"ws":true},{"text":"BC","start":99,"end":101,"id":17,"ws":true},{"text":"control","start":102,"end":109,"id":18,"ws":true},{"text":",","start":110,"end":111,"id":19,"ws":true},{"text":"and","start":112,"end":115,"id":20,"ws":true},{"text":"that","start":116,"end":120,"id":21,"ws":true},{"text":"this","start":121,"end":125,"id":22,"ws":true},{"text":"activity","start":126,"end":134,"id":23,"ws":true},{"text":"is","start":135,"end":137,"id":24,"ws":true},{"text":"likely","start":138,"end":144,"id":25,"ws":true},{"text":"due","start":145,"end":148,"id":26,"ws":true},{"text":"to","start":149,"end":151,"id":27,"ws":true},{"text":"effects","start":152,"end":159,"id":28,"ws":true},{"text":"on","start":160,"end":162,"id":29,"ws":true},{"text":"both","start":163,"end":167,"id":30,"ws":true},{"text":"BC","start":168,"end":170,"id":31,"ws":true},{"text":"and","start":171,"end":174,"id":32,"ws":true},{"text":"microenvironment","start":175,"end":191,"id":33,"ws":true},{"text":"cells","start":192,"end":197,"id":34,"ws":true},{"text":".","start":198,"end":199,"id":35,"ws":false}],"spans":[{"start":39,"end":46,"token_start":7,"token_end":7,"label":"DRUG"},{"start":53,"end":61,"token_start":10,"token_end":10,"label":"DRUG"},{"start":65,"end":74,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26728433/","_input_hash":-280823635,"_task_hash":-1770480747,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":7,"child":12,"head_span":{"start":39,"end":46,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":65,"end":74,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":12,"head_span":{"start":53,"end":61,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":65,"end":74,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"Coadministration of vorinostat and oxaliplatin induced G2/M phase arrest , triggered caspase-dependent apoptosis , and decreased tumorigenicity both in vitro and in vivo .","paragraph":"<h3><u>Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells.</u></h3><b style='color:Tomato;'><i>oxaliplatin</i></b>-based systemic chemotherapy has been proposed to have efficacy in hepatocellular carcinoma (HCC). We investigated the combination of <b style='color:Tomato;'><i>vorinostat</i></b> and <b style='color:Tomato;'><i>oxaliplatin</i></b> for possible synergism in HCC cells. SMMC7721, BEL7402, and HepG2 cells were treated with <b style='color:Tomato;'><i>vorinostat</i></b> and <b style='color:Tomato;'><i>oxaliplatin</i></b>. Cytotoxicity assay, tumorigenicity assay in vitro, cell cycle analysis, apoptosis analysis, western blot analysis, animal model study, immunohistochemistry, and quantitative PCR were performed. We found that <b style='color:Tomato;'><i>vorinostat</i></b> and <b style='color:Tomato;'><i>oxaliplatin</i></b> inhibited the proliferation of SMMC7721, BEL7402, and HepG2 cells. The combination index (CI) values were all <1, and the dose-reduction index values were all greater than 1 in the three cell lines, indicating a synergistic effect of combination of the two agents. <b style='color:DodgerBlue;'><i>Coadministration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vorinostat</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>G2/M</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>arrest</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>triggered</i></b> <b style='color:DodgerBlue;'><i>caspase-dependent</i></b> <b style='color:DodgerBlue;'><i>apoptosis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>tumorigenicity</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>vorinostat</i></b> suppressed the expression of BRCA1 induced by <b style='color:Tomato;'><i>oxaliplatin</i></b>. In conclusion, cotreatment with <b style='color:Tomato;'><i>vorinostat</i></b> and <b style='color:Tomato;'><i>oxaliplatin</i></b> exhibited synergism in HCC cells. The combination inhibited cell proliferation and tumorigenicity both in vitro and in vivo through induction of cell cycle arrest and apoptosis. Our results predict that a combination of <b style='color:Tomato;'><i>vorinostat</i></b> and <b style='color:Tomato;'><i>oxaliplatin</i></b> may be useful in the treatment of advanced HCC.","tokens":[{"text":"Coadministration","start":0,"end":16,"id":0,"ws":true},{"text":"of","start":17,"end":19,"id":1,"ws":true},{"text":"vorinostat","start":20,"end":30,"id":2,"ws":true},{"text":"and","start":31,"end":34,"id":3,"ws":true},{"text":"oxaliplatin","start":35,"end":46,"id":4,"ws":true},{"text":"induced","start":47,"end":54,"id":5,"ws":true},{"text":"G2/M","start":55,"end":59,"id":6,"ws":true},{"text":"phase","start":60,"end":65,"id":7,"ws":true},{"text":"arrest","start":66,"end":72,"id":8,"ws":true},{"text":",","start":73,"end":74,"id":9,"ws":true},{"text":"triggered","start":75,"end":84,"id":10,"ws":true},{"text":"caspase-dependent","start":85,"end":102,"id":11,"ws":true},{"text":"apoptosis","start":103,"end":112,"id":12,"ws":true},{"text":",","start":113,"end":114,"id":13,"ws":true},{"text":"and","start":115,"end":118,"id":14,"ws":true},{"text":"decreased","start":119,"end":128,"id":15,"ws":true},{"text":"tumorigenicity","start":129,"end":143,"id":16,"ws":true},{"text":"both","start":144,"end":148,"id":17,"ws":true},{"text":"in","start":149,"end":151,"id":18,"ws":true},{"text":"vitro","start":152,"end":157,"id":19,"ws":true},{"text":"and","start":158,"end":161,"id":20,"ws":true},{"text":"in","start":162,"end":164,"id":21,"ws":true},{"text":"vivo","start":165,"end":169,"id":22,"ws":true},{"text":".","start":170,"end":171,"id":23,"ws":false}],"spans":[{"start":20,"end":30,"token_start":2,"token_end":2,"label":"DRUG"},{"start":35,"end":46,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29239146/","_input_hash":-2079045590,"_task_hash":-1437055359,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":20,"end":30,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":35,"end":46,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Randomized open trial of gentamicin and doxycycline for eradication of Bartonella quintana from blood in patients with chronic bacteremia .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Randomized</i></b> <b style='color:DodgerBlue;'><i>open</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxycycline</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>eradication</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Bartonella</i></b> <b style='color:DodgerBlue;'><i>quintana</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>bacteremia</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Chronic Bartonella quintana bacteremia is known to occur in homeless people exposed to lice. We present here the results of an open randomized trial performed to evaluate the efficacy of <b style='color:Tomato;'><i>doxycycline</i></b> in combination with <b style='color:Tomato;'><i>gentamicin</i></b> in the eradication of B. quintana bacteremia. From 1 January 2001 to 1 April 2002, homeless people with blood cultures positive for B. quintana were randomized to receive either no treatment (untreated controls) or a combination of <b style='color:Tomato;'><i>gentamicin</i></b> (3 mg/kg of body weight/day intravenously for 14 days) and <b style='color:Tomato;'><i>doxycycline</i></b> (200 mg/day orally for 28 days). Patients were evaluated from the results of blood cultures performed between day 28 (the end of treatment) and day 90 postinclusion. Intention-to-treat analysis of 20 included patients showed eradication of bacteremia in 7 out of 9 treated patients versus 2 out of 11 untreated controls (P = 0.01). In the per-protocol analysis, eradication was obtained for 7 out of 7 treated patients versus 2 out of 9 untreated controls (P = 0.003). This study demonstrates the efficiency of the combination of <b style='color:Tomato;'><i>doxycycline</i></b> and <b style='color:Tomato;'><i>gentamicin</i></b> in eradicating B. quintana bacteremia.","tokens":[{"text":"Randomized","start":0,"end":10,"id":0,"ws":true},{"text":"open","start":11,"end":15,"id":1,"ws":true},{"text":"trial","start":16,"end":21,"id":2,"ws":true},{"text":"of","start":22,"end":24,"id":3,"ws":true},{"text":"gentamicin","start":25,"end":35,"id":4,"ws":true},{"text":"and","start":36,"end":39,"id":5,"ws":true},{"text":"doxycycline","start":40,"end":51,"id":6,"ws":true},{"text":"for","start":52,"end":55,"id":7,"ws":true},{"text":"eradication","start":56,"end":67,"id":8,"ws":true},{"text":"of","start":68,"end":70,"id":9,"ws":true},{"text":"Bartonella","start":71,"end":81,"id":10,"ws":true},{"text":"quintana","start":82,"end":90,"id":11,"ws":true},{"text":"from","start":91,"end":95,"id":12,"ws":true},{"text":"blood","start":96,"end":101,"id":13,"ws":true},{"text":"in","start":102,"end":104,"id":14,"ws":true},{"text":"patients","start":105,"end":113,"id":15,"ws":true},{"text":"with","start":114,"end":118,"id":16,"ws":true},{"text":"chronic","start":119,"end":126,"id":17,"ws":true},{"text":"bacteremia","start":127,"end":137,"id":18,"ws":true},{"text":".","start":138,"end":139,"id":19,"ws":false}],"spans":[{"start":25,"end":35,"token_start":4,"token_end":4,"label":"DRUG"},{"start":40,"end":51,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12821469/","_input_hash":-263475479,"_task_hash":435956897,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":25,"end":35,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":40,"end":51,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The role of dual antiplatelet therapy combining aspirin and clopidogrel , is controversial .","paragraph":"<h3><u>[TREATMENT WITH DUAL ANTIPLATELET THERAPY FOR SECONDARY PREVENTION OF STROKE - PROS AND CONS].</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>role</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dual</i></b> <b style='color:DodgerBlue;'><i>antiplatelet</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>combining</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>controversial</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There are two settings in which such treatment might be considered: (a) patients presenting with a first ischemic event at high risk for a recurrence; and (b) patients who experience a second ischemic event while being treated with <b style='color:Tomato;'><i>aspirin</i></b> or <b style='color:Tomato;'><i>clopidogrel</i></b> monotherapy. In this paper we review the literature dealing with secondary prevention of ischemic stroke, with an emphasis on dual antiplatelet therapy. We examine international guidelines and present a case study which illustrates the application of this information.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"role","start":4,"end":8,"id":1,"ws":true},{"text":"of","start":9,"end":11,"id":2,"ws":true},{"text":"dual","start":12,"end":16,"id":3,"ws":true},{"text":"antiplatelet","start":17,"end":29,"id":4,"ws":true},{"text":"therapy","start":30,"end":37,"id":5,"ws":true},{"text":"combining","start":38,"end":47,"id":6,"ws":true},{"text":"aspirin","start":48,"end":55,"id":7,"ws":true},{"text":"and","start":56,"end":59,"id":8,"ws":true},{"text":"clopidogrel","start":60,"end":71,"id":9,"ws":true},{"text":",","start":72,"end":73,"id":10,"ws":true},{"text":"is","start":74,"end":76,"id":11,"ws":true},{"text":"controversial","start":77,"end":90,"id":12,"ws":true},{"text":".","start":91,"end":92,"id":13,"ws":false}],"spans":[{"start":48,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},{"start":60,"end":71,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30582310/","_input_hash":-546283639,"_task_hash":-1610601387,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":48,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":60,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"We conducted a dose-escalating study of daunorubicin combined to fixed doses of IM ( imatinib mesylate , 600 mg/d ) and cytarabine ( 200 mg/d for 7 days ) , followed by hematopoietic stem cell transplantation or maintenance therapy with single-agent IM in patients with MBC-CML at onset or after failure of therapy excluding TKIs .","paragraph":"<h3><u>The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).</u></h3>The median survival of patients with chronic myelogenous leukemia in myeloid blast crisis (MBC-CML) is poor even for patients treated with tyrosine kinase inhibitors (TKIs). ### Design And Methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>dose-escalating</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>daunorubicin</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>fixed</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>IM</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>mesylate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>600</i></b> <b style='color:DodgerBlue;'><i>mg/d</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/d</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>single-agent</i></b> <b style='color:DodgerBlue;'><i>IM</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MBC-CML</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>onset</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>excluding</i></b> <b style='color:DodgerBlue;'><i>TKIs</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Thirty-six patients were evaluated. Median follow-up is 6.1 years. <b style='color:Tomato;'><i>daunorubicin</i></b> was escaladed up to 45 mg/m(2)/d 3 days. Twenty eight patients (77.7%) had hematologic response including 20 patients (55.5%) in complete hematologic response (CHR). Patients who received <b style='color:Tomato;'><i>daunorubicin</i></b> at 30-45 mg/m(2)/d had higher CHR rates compared to other patients. Median overall survival was 16 months. Overall survival in patients with hematological response was 35.4 months. Better results were observed in patients diagnosed with MBC-CML at onset. ### conclusions The combination of IM with a standard \"3+7\" regiment was well tolerated and provided a high response rate. More than 55% of the patients achieved CHR and hematopoietic stem cell transplantation (SCT) was feasible in half of the cases. This trial was registered at www.clinicaltrials.gov as # NCT00219765.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"conducted","start":3,"end":12,"id":1,"ws":true},{"text":"a","start":13,"end":14,"id":2,"ws":true},{"text":"dose-escalating","start":15,"end":30,"id":3,"ws":true},{"text":"study","start":31,"end":36,"id":4,"ws":true},{"text":"of","start":37,"end":39,"id":5,"ws":true},{"text":"daunorubicin","start":40,"end":52,"id":6,"ws":true},{"text":"combined","start":53,"end":61,"id":7,"ws":true},{"text":"to","start":62,"end":64,"id":8,"ws":true},{"text":"fixed","start":65,"end":70,"id":9,"ws":true},{"text":"doses","start":71,"end":76,"id":10,"ws":true},{"text":"of","start":77,"end":79,"id":11,"ws":true},{"text":"IM","start":80,"end":82,"id":12,"ws":true},{"text":"(","start":83,"end":84,"id":13,"ws":true},{"text":"imatinib","start":85,"end":93,"id":14,"ws":true},{"text":"mesylate","start":94,"end":102,"id":15,"ws":true},{"text":",","start":103,"end":104,"id":16,"ws":true},{"text":"600","start":105,"end":108,"id":17,"ws":true},{"text":"mg/d","start":109,"end":113,"id":18,"ws":true},{"text":")","start":114,"end":115,"id":19,"ws":true},{"text":"and","start":116,"end":119,"id":20,"ws":true},{"text":"cytarabine","start":120,"end":130,"id":21,"ws":true},{"text":"(","start":131,"end":132,"id":22,"ws":true},{"text":"200","start":133,"end":136,"id":23,"ws":true},{"text":"mg/d","start":137,"end":141,"id":24,"ws":true},{"text":"for","start":142,"end":145,"id":25,"ws":true},{"text":"7","start":146,"end":147,"id":26,"ws":true},{"text":"days","start":148,"end":152,"id":27,"ws":true},{"text":")","start":153,"end":154,"id":28,"ws":true},{"text":",","start":155,"end":156,"id":29,"ws":true},{"text":"followed","start":157,"end":165,"id":30,"ws":true},{"text":"by","start":166,"end":168,"id":31,"ws":true},{"text":"hematopoietic","start":169,"end":182,"id":32,"ws":true},{"text":"stem","start":183,"end":187,"id":33,"ws":true},{"text":"cell","start":188,"end":192,"id":34,"ws":true},{"text":"transplantation","start":193,"end":208,"id":35,"ws":true},{"text":"or","start":209,"end":211,"id":36,"ws":true},{"text":"maintenance","start":212,"end":223,"id":37,"ws":true},{"text":"therapy","start":224,"end":231,"id":38,"ws":true},{"text":"with","start":232,"end":236,"id":39,"ws":true},{"text":"single-agent","start":237,"end":249,"id":40,"ws":true},{"text":"IM","start":250,"end":252,"id":41,"ws":true},{"text":"in","start":253,"end":255,"id":42,"ws":true},{"text":"patients","start":256,"end":264,"id":43,"ws":true},{"text":"with","start":265,"end":269,"id":44,"ws":true},{"text":"MBC-CML","start":270,"end":277,"id":45,"ws":true},{"text":"at","start":278,"end":280,"id":46,"ws":true},{"text":"onset","start":281,"end":286,"id":47,"ws":true},{"text":"or","start":287,"end":289,"id":48,"ws":true},{"text":"after","start":290,"end":295,"id":49,"ws":true},{"text":"failure","start":296,"end":303,"id":50,"ws":true},{"text":"of","start":304,"end":306,"id":51,"ws":true},{"text":"therapy","start":307,"end":314,"id":52,"ws":true},{"text":"excluding","start":315,"end":324,"id":53,"ws":true},{"text":"TKIs","start":325,"end":329,"id":54,"ws":true},{"text":".","start":330,"end":331,"id":55,"ws":false}],"spans":[{"start":40,"end":52,"token_start":6,"token_end":6,"label":"DRUG"},{"start":85,"end":93,"token_start":14,"token_end":14,"label":"DRUG"},{"start":120,"end":130,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21145590/","_input_hash":-551910389,"_task_hash":23187068,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":6,"child":14,"head_span":{"start":40,"end":52,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":85,"end":93,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":21,"child":14,"head_span":{"start":120,"end":130,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":85,"end":93,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"[ Combination chemo-endocrine therapy of metastatic and stage IV breast cancer with cyclophosphamide , adriamycin , prednisolone and tamoxifen (CAPT)--with special reference to management of brain and liver metastasis ] .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>chemo-endocrine</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>(CAPT)--with</i></b> <b style='color:DodgerBlue;'><i>special</i></b> <b style='color:DodgerBlue;'><i>reference</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>management</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>brain</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>liver</i></b> <b style='color:DodgerBlue;'><i>metastasis</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Sixty-three evaluable patients with metastatic and stage IV breast cancer who had not previously undergone chemo-endocrine therapy were treated with a combination chemoendocrine therapy regimen consisting of <b style='color:Tomato;'><i>cyclophosphamide</i></b> 100 mg p.o. every day, adriamycin 10 mg i.v. on day 1 to 5, <b style='color:Tomato;'><i>prednisolone</i></b> 10 mg or 20 mg (20 mg was given on day 1 to 5) p.o. every day, and <b style='color:Tomato;'><i>tamoxifen</i></b> 20 mg p.o. every day. Adriamycin on day 1 to 5 was repeated three times every two weeks. After a total dose of 150 mg of adriamycin, the patients were changed to maintenance therapy consisting of <b style='color:Tomato;'><i>cyclophosphamide</i></b> 100 mg p.o., <b style='color:Tomato;'><i>prednisolone</i></b> 10 mg p.o. and <b style='color:Tomato;'><i>tamoxifen</i></b> 20 mg p.o. every day. After 72 months of the treatment there were 61 patients good for evaluation, 13 patients achieved a complete response (21.3%) with a median survival of 30.5 months and 18 patients had a partial response (29.5%) with a median survival of 21.0 months, and 30 patients failed to respond (49.2%) with a median survival of 8.5 months. There was a significant difference in survival time between responders (CR + PR) and non-responders (NC + PD) (p less than 0.001). Responses by site were seen in lung 10/18 (55.6%), liver 3/6 (50.0%), brain 2/4 (50.0%), bone 6/17 (35.3%) and soft tissue 14/24 (56.3%). A Satisfactory response for brain and liver metastasis, which are usually viewed as a sign of grim prognosis, was obtained similar to other sites of metastasis. Retreatment with CAPT, which was attempted in patients with secondary brain metastasis who responded to CAPT for initial brain metastasis, was uniformly effective. High ration of androgen to corticosteroid, positive estrogen receptors, long disease-free survival (over two years), premenopausal, high Broca' index (above 110) resulted from the chemo-endocrine therapy regimen CAPT. Toxicity was minimal and consisted of nausea, vomiting, alopecia and leucopenia.","tokens":[{"text":"[","start":0,"end":1,"id":0,"ws":true},{"text":"Combination","start":2,"end":13,"id":1,"ws":true},{"text":"chemo-endocrine","start":14,"end":29,"id":2,"ws":true},{"text":"therapy","start":30,"end":37,"id":3,"ws":true},{"text":"of","start":38,"end":40,"id":4,"ws":true},{"text":"metastatic","start":41,"end":51,"id":5,"ws":true},{"text":"and","start":52,"end":55,"id":6,"ws":true},{"text":"stage","start":56,"end":61,"id":7,"ws":true},{"text":"IV","start":62,"end":64,"id":8,"ws":true},{"text":"breast","start":65,"end":71,"id":9,"ws":true},{"text":"cancer","start":72,"end":78,"id":10,"ws":true},{"text":"with","start":79,"end":83,"id":11,"ws":true},{"text":"cyclophosphamide","start":84,"end":100,"id":12,"ws":true},{"text":",","start":101,"end":102,"id":13,"ws":true},{"text":"adriamycin","start":103,"end":113,"id":14,"ws":true},{"text":",","start":114,"end":115,"id":15,"ws":true},{"text":"prednisolone","start":116,"end":128,"id":16,"ws":true},{"text":"and","start":129,"end":132,"id":17,"ws":true},{"text":"tamoxifen","start":133,"end":142,"id":18,"ws":true},{"text":"(CAPT)--with","start":143,"end":155,"id":19,"ws":true},{"text":"special","start":156,"end":163,"id":20,"ws":true},{"text":"reference","start":164,"end":173,"id":21,"ws":true},{"text":"to","start":174,"end":176,"id":22,"ws":true},{"text":"management","start":177,"end":187,"id":23,"ws":true},{"text":"of","start":188,"end":190,"id":24,"ws":true},{"text":"brain","start":191,"end":196,"id":25,"ws":true},{"text":"and","start":197,"end":200,"id":26,"ws":true},{"text":"liver","start":201,"end":206,"id":27,"ws":true},{"text":"metastasis","start":207,"end":217,"id":28,"ws":true},{"text":"]","start":218,"end":219,"id":29,"ws":true},{"text":".","start":220,"end":221,"id":30,"ws":false}],"spans":[{"start":84,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},{"start":103,"end":113,"token_start":14,"token_end":14,"label":"DRUG"},{"start":116,"end":128,"token_start":16,"token_end":16,"label":"DRUG"},{"start":133,"end":142,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2919892/","_input_hash":1943600130,"_task_hash":990671392,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":84,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":103,"end":113,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":16,"child":14,"head_span":{"start":116,"end":128,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":103,"end":113,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":18,"child":16,"head_span":{"start":133,"end":142,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":116,"end":128,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Ra ( rate of production ) was measured during infusion of variable doses of epinephrine with or without variable doses of propranolol , a competitive beta-adrenergic antagonist to isolate the alpha-adrenergic agonist effects .","paragraph":"<h3><u>Alpha-adrenergic agonists stimulate neonatal glucose production less than beta-adrenergic agonists in the lamb.</u></h3><b style='color:Tomato;'><i>epinephrine</i></b>, a catecholamine with both alpha (alpha)- and beta (beta)-adrenergic agonist effects, may produce clinical hyperglycemia in the adult by increasing glucose production and decreasing glucose clearance. However, the relative contribution of alpha v beta adrenergic agonists in control of neonatal glucose kinetics has not been defined. Twenty-three term lambs (weighing 4.4 +/- 0.2 kg, mean +/- SEM, and aged 3.8 +/- 0.4 days) were infused with 0.9% NaCl at 0.6 mL.kg-1 min-1 + 100 microCi/kg D[6-3H]-glucose by prime plus constant infusion for 210 minutes. <b style='color:DodgerBlue;'><i>Ra</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>production</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>measured</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>variable</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>epinephrine</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>variable</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>competitive</i></b> <b style='color:DodgerBlue;'><i>beta-adrenergic</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>isolate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>alpha-adrenergic</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All basal kinetic data were comparable. Under conditions of <b style='color:Tomato;'><i>epinephrine</i></b> infusion, the plasma glucose concentration increased from 95 +/- 10 mg/dL to 129 +/- 18 mg/dL (50 ng.kg-1 min-1 <b style='color:Tomato;'><i>epinephrine</i></b>; P less than .0001) and from 85 +/- 6 mg/dL to 253 +/- 8 mg/dL (500 ng.kg-1 min-1 <b style='color:Tomato;'><i>epinephrine</i></b>; P less than .00001) compared with controls (96 +/- 7 mg/dL to 95 +/- 8 mg/dL). When <b style='color:Tomato;'><i>epinephrine</i></b> and <b style='color:Tomato;'><i>propranolol</i></b> were infused simultaneously, plasma glucose concentration increased from 95 +/- 10 mg/dL to 122 +/- 12 mg/dL (50 ng.kg-1 min-1 <b style='color:Tomato;'><i>epinephrine</i></b> + 1.1 micrograms.kg-1 min-1; P less than .0001) and from 78 +/- 9 mg/dL to 134 +/- 12 mg/dL (500 ng.kg-1 min-1 <b style='color:Tomato;'><i>epinephrine</i></b> + 11 micrograms.kg-1 min-1; P less than .0001) compared with controls (no <b style='color:Tomato;'><i>epinephrine</i></b>, no <b style='color:Tomato;'><i>propranolol</i></b>).(ABSTRACT TRUNCATED AT 250 WORDS)","tokens":[{"text":"Ra","start":0,"end":2,"id":0,"ws":true},{"text":"(","start":3,"end":4,"id":1,"ws":true},{"text":"rate","start":5,"end":9,"id":2,"ws":true},{"text":"of","start":10,"end":12,"id":3,"ws":true},{"text":"production","start":13,"end":23,"id":4,"ws":true},{"text":")","start":24,"end":25,"id":5,"ws":true},{"text":"was","start":26,"end":29,"id":6,"ws":true},{"text":"measured","start":30,"end":38,"id":7,"ws":true},{"text":"during","start":39,"end":45,"id":8,"ws":true},{"text":"infusion","start":46,"end":54,"id":9,"ws":true},{"text":"of","start":55,"end":57,"id":10,"ws":true},{"text":"variable","start":58,"end":66,"id":11,"ws":true},{"text":"doses","start":67,"end":72,"id":12,"ws":true},{"text":"of","start":73,"end":75,"id":13,"ws":true},{"text":"epinephrine","start":76,"end":87,"id":14,"ws":true},{"text":"with","start":88,"end":92,"id":15,"ws":true},{"text":"or","start":93,"end":95,"id":16,"ws":true},{"text":"without","start":96,"end":103,"id":17,"ws":true},{"text":"variable","start":104,"end":112,"id":18,"ws":true},{"text":"doses","start":113,"end":118,"id":19,"ws":true},{"text":"of","start":119,"end":121,"id":20,"ws":true},{"text":"propranolol","start":122,"end":133,"id":21,"ws":true},{"text":",","start":134,"end":135,"id":22,"ws":true},{"text":"a","start":136,"end":137,"id":23,"ws":true},{"text":"competitive","start":138,"end":149,"id":24,"ws":true},{"text":"beta-adrenergic","start":150,"end":165,"id":25,"ws":true},{"text":"antagonist","start":166,"end":176,"id":26,"ws":true},{"text":"to","start":177,"end":179,"id":27,"ws":true},{"text":"isolate","start":180,"end":187,"id":28,"ws":true},{"text":"the","start":188,"end":191,"id":29,"ws":true},{"text":"alpha-adrenergic","start":192,"end":208,"id":30,"ws":true},{"text":"agonist","start":209,"end":216,"id":31,"ws":true},{"text":"effects","start":217,"end":224,"id":32,"ws":true},{"text":".","start":225,"end":226,"id":33,"ws":false}],"spans":[{"start":76,"end":87,"token_start":14,"token_end":14,"label":"DRUG"},{"start":122,"end":133,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2901659/","_input_hash":1312789354,"_task_hash":628875600,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":14,"child":21,"head_span":{"start":76,"end":87,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":122,"end":133,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"The ranking order of the response rate was LD ( best ) , doxorubicin , epirubicin , ED , and DD ( worst ) .","paragraph":"<h3><u>Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials.</u></h3>The effects of anthracycline-based chemical therapies on breast cancer are controversial and inconclusive. We undertook a network meta-analysis to assess the cardiotoxicity and effects of anthracycline therapies in breast cancer. The PubMed, Embase, and Cochrane databases up to August 2018 were reviewed. We identified 19 randomized clinical trials including 3,484 patients with breast cancer which assessed both cardiotoxicity and the effects of anthracycline-based therapies. Eligible studies included the following five treatment strategies: <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>epirubicin</i></b>, liposomal <b style='color:Tomato;'><i>doxorubicin</i></b> (LD), <b style='color:Tomato;'><i>doxorubicin</i></b> + <b style='color:Tomato;'><i>dexrazoxane</i></b> (DD), and <b style='color:Tomato;'><i>epirubicin</i></b> + <b style='color:Tomato;'><i>dexrazoxane</i></b> (ED). In a direct meta-analysis, <b style='color:Tomato;'><i>epirubicin</i></b>, LD, DD, and ED had significantly superior cardioprotective effects compared with <b style='color:Tomato;'><i>doxorubicin</i></b> with odds ratios and 95% CIs of 1.64 (1.04, 2.57), 3.75 (2.46, 5.70), 2.88 (1.93, 4.29), and 3.66 (1.09, 12.33), respectively. <b style='color:Tomato;'><i>doxorubicin</i></b> showed no significant difference of response rate compared with <b style='color:Tomato;'><i>epirubicin</i></b> or LD or DD, respectively. In a network meta-analysis, the ranking order of cardiotoxicity was <b style='color:Tomato;'><i>doxorubicin</i></b> (worst), <b style='color:Tomato;'><i>epirubicin</i></b>, DD, LD, and ED (best). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>ranking</i></b> <b style='color:DodgerBlue;'><i>order</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>LD</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>best</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ED</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>DD</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>worst</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The most favorable balance between benefit and risk was shown for ED (best) followed by LD, DD, <b style='color:Tomato;'><i>epirubicin</i></b>, and <b style='color:Tomato;'><i>doxorubicin</i></b>. In conclusion, LD or ED is the suitable anthracycline treatment for breast cancer in consideration of both cardiotoxicity and efficacy.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"ranking","start":4,"end":11,"id":1,"ws":true},{"text":"order","start":12,"end":17,"id":2,"ws":true},{"text":"of","start":18,"end":20,"id":3,"ws":true},{"text":"the","start":21,"end":24,"id":4,"ws":true},{"text":"response","start":25,"end":33,"id":5,"ws":true},{"text":"rate","start":34,"end":38,"id":6,"ws":true},{"text":"was","start":39,"end":42,"id":7,"ws":true},{"text":"LD","start":43,"end":45,"id":8,"ws":true},{"text":"(","start":46,"end":47,"id":9,"ws":true},{"text":"best","start":48,"end":52,"id":10,"ws":true},{"text":")","start":53,"end":54,"id":11,"ws":true},{"text":",","start":55,"end":56,"id":12,"ws":true},{"text":"doxorubicin","start":57,"end":68,"id":13,"ws":true},{"text":",","start":69,"end":70,"id":14,"ws":true},{"text":"epirubicin","start":71,"end":81,"id":15,"ws":true},{"text":",","start":82,"end":83,"id":16,"ws":true},{"text":"ED","start":84,"end":86,"id":17,"ws":true},{"text":",","start":87,"end":88,"id":18,"ws":true},{"text":"and","start":89,"end":92,"id":19,"ws":true},{"text":"DD","start":93,"end":95,"id":20,"ws":true},{"text":"(","start":96,"end":97,"id":21,"ws":true},{"text":"worst","start":98,"end":103,"id":22,"ws":true},{"text":")","start":104,"end":105,"id":23,"ws":true},{"text":".","start":106,"end":107,"id":24,"ws":false}],"spans":[{"start":57,"end":68,"token_start":13,"token_end":13,"label":"DRUG"},{"start":71,"end":81,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31104059/","_input_hash":1630627583,"_task_hash":-29152511,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Systemic treatment with physostigmine , an inhibitor of acetylcholinesterase , modestly reduced the acquisition and rate of heroin self-administration , and this suppression of heroin intake was reversed by pretreatment with scopolamine but not by mecamylamine .","paragraph":"<h3><u>Role of acetylcholine transmission in nucleus accumbens and ventral tegmental area in heroin-seeking induced by conditioned cues.</u></h3>The involvement of cholinergic transmission in heroin self-administration and the reinstatement of heroin-seeking was examined in rats trained to nose-poke for i.v. heroin. <b style='color:DodgerBlue;'><i>Systemic</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>physostigmine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>acetylcholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>modestly</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>acquisition</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>heroin</i></b> <b style='color:DodgerBlue;'><i>self-administration</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>suppression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>heroin</i></b> <b style='color:DodgerBlue;'><i>intake</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>reversed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>pretreatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>scopolamine</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>mecamylamine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Following 10-14 days of self-administration, rats were left in the home environment for 14 days. Subsequently, rats were evaluated for extinction of nose-pokes during the first hour after being returned to the self-administration apparatus. One hour later a conditioned stimulus (house light, light in the nose-poke hole, sound of the infusion pump) was presented to initiate cue-induced reinstatement. Physostigmine produced a dose-dependent inhibition of cue-induced reinstatement, but only the dose of 0.5 mg/kg significantly decreased nose-poke responding in the extinction test. Chronic treatment with physostigmine (0.1 mg/kg) did not impair performance during acquisition of heroin self-administration. However, during a subsequent reinstatement test conducted in the absence of physostigmine pretreatment, heroin seeking was significantly below that of rats chronically pretreated with saline. To evaluate brain regions mediating the effects of systemic drug treatment on reinstatement, physostigmine was microinjected into the nucleus accumbens (NAc) or ventral tegmental area (VTA). Microinjection of physostigmine into the NAc prior to presenting conditioned cues inhibited the reinstatement of heroin-seeking, without affecting extinction responding. In contrast, microinjection of physostigmine into the VTA augmented the reinstatement induced by conditioned cues and extinction responding. Inactivation of either NAc or VTA by microinjecting tetrodotoxin blocked both extinction responding and cue-induced reinstatement. These data demonstrate that cholinergic transmission influences heroin self-administration and reinstatement. Moreover, cue-induced reinstatement was inhibited by physostigmine in the NAc and potentiated by cholinergic stimulation in the VTA.","tokens":[{"text":"Systemic","start":0,"end":8,"id":0,"ws":true},{"text":"treatment","start":9,"end":18,"id":1,"ws":true},{"text":"with","start":19,"end":23,"id":2,"ws":true},{"text":"physostigmine","start":24,"end":37,"id":3,"ws":true},{"text":",","start":38,"end":39,"id":4,"ws":true},{"text":"an","start":40,"end":42,"id":5,"ws":true},{"text":"inhibitor","start":43,"end":52,"id":6,"ws":true},{"text":"of","start":53,"end":55,"id":7,"ws":true},{"text":"acetylcholinesterase","start":56,"end":76,"id":8,"ws":true},{"text":",","start":77,"end":78,"id":9,"ws":true},{"text":"modestly","start":79,"end":87,"id":10,"ws":true},{"text":"reduced","start":88,"end":95,"id":11,"ws":true},{"text":"the","start":96,"end":99,"id":12,"ws":true},{"text":"acquisition","start":100,"end":111,"id":13,"ws":true},{"text":"and","start":112,"end":115,"id":14,"ws":true},{"text":"rate","start":116,"end":120,"id":15,"ws":true},{"text":"of","start":121,"end":123,"id":16,"ws":true},{"text":"heroin","start":124,"end":130,"id":17,"ws":true},{"text":"self-administration","start":131,"end":150,"id":18,"ws":true},{"text":",","start":151,"end":152,"id":19,"ws":true},{"text":"and","start":153,"end":156,"id":20,"ws":true},{"text":"this","start":157,"end":161,"id":21,"ws":true},{"text":"suppression","start":162,"end":173,"id":22,"ws":true},{"text":"of","start":174,"end":176,"id":23,"ws":true},{"text":"heroin","start":177,"end":183,"id":24,"ws":true},{"text":"intake","start":184,"end":190,"id":25,"ws":true},{"text":"was","start":191,"end":194,"id":26,"ws":true},{"text":"reversed","start":195,"end":203,"id":27,"ws":true},{"text":"by","start":204,"end":206,"id":28,"ws":true},{"text":"pretreatment","start":207,"end":219,"id":29,"ws":true},{"text":"with","start":220,"end":224,"id":30,"ws":true},{"text":"scopolamine","start":225,"end":236,"id":31,"ws":true},{"text":"but","start":237,"end":240,"id":32,"ws":true},{"text":"not","start":241,"end":244,"id":33,"ws":true},{"text":"by","start":245,"end":247,"id":34,"ws":true},{"text":"mecamylamine","start":248,"end":260,"id":35,"ws":true},{"text":".","start":261,"end":262,"id":36,"ws":false}],"spans":[{"start":24,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},{"start":225,"end":236,"token_start":31,"token_end":31,"label":"DRUG"},{"start":248,"end":260,"token_start":35,"token_end":35,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17184925/","_input_hash":-149650776,"_task_hash":838791287,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"First-line lenvatinib , which was shown to be noninferior to sorafenib , excluded patients with main portal trunk invasion .","paragraph":"<h3><u>Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies.</u></h3>Portal vein tumor thrombosis (PVTT) commonly occurs in patients with hepatocellular carcinoma (HCC). Patients with PVTT usually have an aggressive disease course, decreased liver function reserve, limited treatment options, higher recurrence rates after treatment, and, therefore, worse overall survival. Among untreated HCC patients with PVTT, the median overall survival has been reported as low as 2 to 4 months. Historically, many aspects of PVTT have impacted the theoretical and practical safety and efficacy of treatment, for example, disordered blood flow and associated impairment of liver function, heat-sink effects of blood flow in the area of the PVTT, and risk of recurrence due to tumor location in the blood vessel. The current Barcelona Clinic Liver Cancer staging system categorizes HCC patients with PVTT as advanced stage, for which the standard of care is targeted therapy with <b style='color:Tomato;'><i>sorafenib</i></b>. However, <b style='color:Tomato;'><i>sorafenib</i></b> is associated with only marginal benefits among patients with PVTT. <b style='color:DodgerBlue;'><i>First-line</i></b> <b style='color:MediumOrchid;'><i>lenvatinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>noninferior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>excluded</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>main</i></b> <b style='color:DodgerBlue;'><i>portal</i></b> <b style='color:DodgerBlue;'><i>trunk</i></b> <b style='color:DodgerBlue;'><i>invasion</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>regorafenib</i></b> and <b style='color:Tomato;'><i>nivolumab</i></b>, an immune-based therapy, were recently approved in the United States for second-line therapy after <b style='color:Tomato;'><i>sorafenib</i></b>. Preliminary results for <b style='color:Tomato;'><i>cabozantinib</i></b> suggest a benefit in the second-/third-line after <b style='color:Tomato;'><i>sorafenib</i></b> failure. In addition, rapid advances in many fields (surgery, interventional radiology, nuclear medicine, and immunotherapy) have increased the potential treatment options for the management of this complex disease entity. A large portion of the emerging evidence focuses on the broader category of advanced HCC of which PVTT is a subgroup. While many of these studies show promising results, the efficacy among PVTT patients requires validation in prospective studies. Real-world data may help fill the evidence gap for patients not eligible for clinical trials due to common hepatic function requirements. The variety of new treatment advances for the heterogeneous and complex disease entity of HCC with PVTT means that personalized, multidisciplinary management may be necessary to achieve optimal outcomes. In this narrative review, we summarize the evolving management strategies for patients with HCC and PVTT.","tokens":[{"text":"First-line","start":0,"end":10,"id":0,"ws":true},{"text":"lenvatinib","start":11,"end":21,"id":1,"ws":true},{"text":",","start":22,"end":23,"id":2,"ws":true},{"text":"which","start":24,"end":29,"id":3,"ws":true},{"text":"was","start":30,"end":33,"id":4,"ws":true},{"text":"shown","start":34,"end":39,"id":5,"ws":true},{"text":"to","start":40,"end":42,"id":6,"ws":true},{"text":"be","start":43,"end":45,"id":7,"ws":true},{"text":"noninferior","start":46,"end":57,"id":8,"ws":true},{"text":"to","start":58,"end":60,"id":9,"ws":true},{"text":"sorafenib","start":61,"end":70,"id":10,"ws":true},{"text":",","start":71,"end":72,"id":11,"ws":true},{"text":"excluded","start":73,"end":81,"id":12,"ws":true},{"text":"patients","start":82,"end":90,"id":13,"ws":true},{"text":"with","start":91,"end":95,"id":14,"ws":true},{"text":"main","start":96,"end":100,"id":15,"ws":true},{"text":"portal","start":101,"end":107,"id":16,"ws":true},{"text":"trunk","start":108,"end":113,"id":17,"ws":true},{"text":"invasion","start":114,"end":122,"id":18,"ws":true},{"text":".","start":123,"end":124,"id":19,"ws":false}],"spans":[{"start":11,"end":21,"token_start":1,"token_end":1,"label":"DRUG"},{"start":61,"end":70,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30041276/","_input_hash":-1358841430,"_task_hash":-2063176550,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The OAK study evaluated the efficacy and safety of atezolizumab versus docetaxel as second-line or third-line treatment for stage IIIb/IV non-small cell lung cancer .","paragraph":"<h3><u>Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.</u></h3>Treatment-induced accelerated tumor growth is a progression pattern reported with immune checkpoint inhibitors that has never been evaluated in randomized phase III studies because it requires two pretreatment scans. This study aimed to develop clinically relevant and applicable criteria for fast progression (FP), incorporating tumor growth kinetics and early death from disease progression to analyze data from the randomized phase III OAK study. ### methods <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>OAK</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>atezolizumab</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>third-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IIIb/IV</i></b> <b style='color:DodgerBlue;'><i>non-small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> FP rates and associated baseline factors were analyzed. FP was defined as either a \u226550% increase in the sum of largest diameters (SLDs) within 6 weeks of treatment initiation or death due to cancer progression within 12 weeks (absent post-baseline scan). ### results Forty-two of 421 patients (10%) receiving <b style='color:Tomato;'><i>atezolizumab</i></b> and 37 of 402 (9%) receiving <b style='color:Tomato;'><i>docetaxel</i></b> had FP. Twenty patients with FP (48%) receiving <b style='color:Tomato;'><i>atezolizumab</i></b> versus 12 (30%) receiving <b style='color:Tomato;'><i>docetaxel</i></b> had a \u226550%\u2009SLD increase within 6 weeks. FP was significantly associated with an ECOG (Eastern Cooperative Oncology Group) performance status of 1 (vs 0), \u22653 metastatic sites at baseline, and failure of preceding first-line treatment within 6 months, but not with epidermal growth factor receptor mutation, programmed cell death 1 ligand 1 or tumor mutational burden. Overall survival in patients with FP and a \u226550%\u2009SLD increase at week 6 was similar with <b style='color:Tomato;'><i>atezolizumab</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> (unstratified HR 0.89 (95% CI 0.41 to 1.92)). ### conclusions FP rates were similar with <b style='color:Tomato;'><i>atezolizumab</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> in the OAK study, suggesting that FP may not be unique to checkpoint inhibitors, although the underlying mechanisms may differ from those of chemotherapy. Applying the FP criteria to other phase III checkpoint inhibitor trials may further elucidate the risk factors for FP. ### Trial Registration Number NCT02008227.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"OAK","start":4,"end":7,"id":1,"ws":true},{"text":"study","start":8,"end":13,"id":2,"ws":true},{"text":"evaluated","start":14,"end":23,"id":3,"ws":true},{"text":"the","start":24,"end":27,"id":4,"ws":true},{"text":"efficacy","start":28,"end":36,"id":5,"ws":true},{"text":"and","start":37,"end":40,"id":6,"ws":true},{"text":"safety","start":41,"end":47,"id":7,"ws":true},{"text":"of","start":48,"end":50,"id":8,"ws":true},{"text":"atezolizumab","start":51,"end":63,"id":9,"ws":true},{"text":"versus","start":64,"end":70,"id":10,"ws":true},{"text":"docetaxel","start":71,"end":80,"id":11,"ws":true},{"text":"as","start":81,"end":83,"id":12,"ws":true},{"text":"second-line","start":84,"end":95,"id":13,"ws":true},{"text":"or","start":96,"end":98,"id":14,"ws":true},{"text":"third-line","start":99,"end":109,"id":15,"ws":true},{"text":"treatment","start":110,"end":119,"id":16,"ws":true},{"text":"for","start":120,"end":123,"id":17,"ws":true},{"text":"stage","start":124,"end":129,"id":18,"ws":true},{"text":"IIIb/IV","start":130,"end":137,"id":19,"ws":true},{"text":"non-small","start":138,"end":147,"id":20,"ws":true},{"text":"cell","start":148,"end":152,"id":21,"ws":true},{"text":"lung","start":153,"end":157,"id":22,"ws":true},{"text":"cancer","start":158,"end":164,"id":23,"ws":true},{"text":".","start":165,"end":166,"id":24,"ws":false}],"spans":[{"start":51,"end":63,"token_start":9,"token_end":9,"label":"DRUG"},{"start":71,"end":80,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33737340/","_input_hash":1673055061,"_task_hash":-1425498573,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In conclusion , combined treatment with 0.375 IU of bleomycin and 4 mg of triamcinolone acetonide to 1 cm2 was considered to be an acceptable procedure for the treatment of keloids .","paragraph":"<h3><u>Results of a combination of bleomycin and triamcinolone acetonide in the treatment of keloids and hypertrophic scars.</u></h3>While treatment of keloids and hypertrophic scars normally shows modest results, we found that treatment with <b style='color:Tomato;'><i>bleomycin</i></b> was more promising. The present study was divided into two parts. In the first part the aim was to show the results using a combination of <b style='color:Tomato;'><i>bleomycin</i></b> and <b style='color:Tomato;'><i>triamcinolone</i></b> acetonide per cm2 (BTA). In the second part the objective was to determine the response to both drugs in large keloids that were divided into 1 cm2 squares, treating each square with the dose previously used. In the first part of the study, the clinical response of 37 keloids ranging from 0.3 to 1.8 cm2 treated with BTA were followed up over a period of 1- 2 years. 0.375 IU <b style='color:Tomato;'><i>bleomycin</i></b> and 4 mg <b style='color:Tomato;'><i>triamcinolone</i></b> acetonide were injected every 3 months. In the second part of the study we reviewed the clinical response in six patients with large keloids. The monthly dose administered never exceeded 3 IU of <b style='color:Tomato;'><i>bleomycin</i></b>. The first study showed 36 keloids (97.29%) softening after the first dose. In the second study, 5 showed different responses (the response was complete in the four smaller keloids). The largest keloid needed 9 doses to achieve an improvement of 70%. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>conclusion</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>0.375</i></b> <b style='color:DodgerBlue;'><i>IU</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>triamcinolone</i></b> <b style='color:DodgerBlue;'><i>acetonide</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>cm2</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>acceptable</i></b> <b style='color:DodgerBlue;'><i>procedure</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>keloids</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The best results were obtained in keloids over 1 cm2 or when divided into 1 cm2 square areas. Larger series need to be performed in order to confirm these results..","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"conclusion","start":3,"end":13,"id":1,"ws":true},{"text":",","start":14,"end":15,"id":2,"ws":true},{"text":"combined","start":16,"end":24,"id":3,"ws":true},{"text":"treatment","start":25,"end":34,"id":4,"ws":true},{"text":"with","start":35,"end":39,"id":5,"ws":true},{"text":"0.375","start":40,"end":45,"id":6,"ws":true},{"text":"IU","start":46,"end":48,"id":7,"ws":true},{"text":"of","start":49,"end":51,"id":8,"ws":true},{"text":"bleomycin","start":52,"end":61,"id":9,"ws":true},{"text":"and","start":62,"end":65,"id":10,"ws":true},{"text":"4","start":66,"end":67,"id":11,"ws":true},{"text":"mg","start":68,"end":70,"id":12,"ws":true},{"text":"of","start":71,"end":73,"id":13,"ws":true},{"text":"triamcinolone","start":74,"end":87,"id":14,"ws":true},{"text":"acetonide","start":88,"end":97,"id":15,"ws":true},{"text":"to","start":98,"end":100,"id":16,"ws":true},{"text":"1","start":101,"end":102,"id":17,"ws":true},{"text":"cm2","start":103,"end":106,"id":18,"ws":true},{"text":"was","start":107,"end":110,"id":19,"ws":true},{"text":"considered","start":111,"end":121,"id":20,"ws":true},{"text":"to","start":122,"end":124,"id":21,"ws":true},{"text":"be","start":125,"end":127,"id":22,"ws":true},{"text":"an","start":128,"end":130,"id":23,"ws":true},{"text":"acceptable","start":131,"end":141,"id":24,"ws":true},{"text":"procedure","start":142,"end":151,"id":25,"ws":true},{"text":"for","start":152,"end":155,"id":26,"ws":true},{"text":"the","start":156,"end":159,"id":27,"ws":true},{"text":"treatment","start":160,"end":169,"id":28,"ws":true},{"text":"of","start":170,"end":172,"id":29,"ws":true},{"text":"keloids","start":173,"end":180,"id":30,"ws":true},{"text":".","start":181,"end":182,"id":31,"ws":false}],"spans":[{"start":52,"end":61,"token_start":9,"token_end":9,"label":"DRUG"},{"start":74,"end":87,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23793202/","_input_hash":-129456350,"_task_hash":-1591239281,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"A 29-year-old man with juvenile myoclonic epilepsy and medically refractory GTCS on a combination of levetiracetam and topiramate was started on lacosamide adjunctive therapy with the plan to replace topiramate .","paragraph":"<h3><u>Absence status induced by lacosamide adjunctive therapy.</u></h3>Since lacosamide was approved as an adjuvant agent for the treatment of medically refractory focal epilepsy over ten years ago, it is becoming more widely used for the treatment of idiopathic (genetic) generalized epilepsies. Several studies have demonstrated efficacy in reducing primary generalized tonic-clonic seizures (GTCS), but efficacy is less well-characterized for myoclonic and absence seizures. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>29-year-old</i></b> <b style='color:DodgerBlue;'><i>man</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>juvenile</i></b> <b style='color:DodgerBlue;'><i>myoclonic</i></b> <b style='color:DodgerBlue;'><i>epilepsy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>medically</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>GTCS</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>levetiracetam</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>topiramate</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>started</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>lacosamide</i></b> <b style='color:DodgerBlue;'><i>adjunctive</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>plan</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>replace</i></b> <b style='color:MediumOrchid;'><i>topiramate</i></b> <b style='color:DodgerBlue;'><i>.</i></b> While his GTCS became controlled, he was witnessed to have confusional episodes, with waxing and waning responsiveness, lasting a few days, several times a month. After eight months of adjunctive lacosamide therapy, he was admitted to the epilepsy monitoring unit, where paroxysms of generalized spike-and-wave complexes, lasting for 30-90 minutes, were recorded, interrupted only by sleep. During these periods, he demonstrated psychomotor slowing and disorientation on examination. The absence status was successfully broken by lorazepam, and lacosamide was discontinued. The patient had no further confusional episodes at the most recent follow-up visit, four months after discharge.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"29-year-old","start":2,"end":13,"id":1,"ws":true},{"text":"man","start":14,"end":17,"id":2,"ws":true},{"text":"with","start":18,"end":22,"id":3,"ws":true},{"text":"juvenile","start":23,"end":31,"id":4,"ws":true},{"text":"myoclonic","start":32,"end":41,"id":5,"ws":true},{"text":"epilepsy","start":42,"end":50,"id":6,"ws":true},{"text":"and","start":51,"end":54,"id":7,"ws":true},{"text":"medically","start":55,"end":64,"id":8,"ws":true},{"text":"refractory","start":65,"end":75,"id":9,"ws":true},{"text":"GTCS","start":76,"end":80,"id":10,"ws":true},{"text":"on","start":81,"end":83,"id":11,"ws":true},{"text":"a","start":84,"end":85,"id":12,"ws":true},{"text":"combination","start":86,"end":97,"id":13,"ws":true},{"text":"of","start":98,"end":100,"id":14,"ws":true},{"text":"levetiracetam","start":101,"end":114,"id":15,"ws":true},{"text":"and","start":115,"end":118,"id":16,"ws":true},{"text":"topiramate","start":119,"end":129,"id":17,"ws":true},{"text":"was","start":130,"end":133,"id":18,"ws":true},{"text":"started","start":134,"end":141,"id":19,"ws":true},{"text":"on","start":142,"end":144,"id":20,"ws":true},{"text":"lacosamide","start":145,"end":155,"id":21,"ws":true},{"text":"adjunctive","start":156,"end":166,"id":22,"ws":true},{"text":"therapy","start":167,"end":174,"id":23,"ws":true},{"text":"with","start":175,"end":179,"id":24,"ws":true},{"text":"the","start":180,"end":183,"id":25,"ws":true},{"text":"plan","start":184,"end":188,"id":26,"ws":true},{"text":"to","start":189,"end":191,"id":27,"ws":true},{"text":"replace","start":192,"end":199,"id":28,"ws":true},{"text":"topiramate","start":200,"end":210,"id":29,"ws":true},{"text":".","start":211,"end":212,"id":30,"ws":false}],"spans":[{"start":101,"end":114,"token_start":15,"token_end":15,"label":"DRUG"},{"start":119,"end":129,"token_start":17,"token_end":17,"label":"DRUG"},{"start":145,"end":155,"token_start":21,"token_end":21,"label":"DRUG"},{"start":200,"end":210,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30782579/","_input_hash":-169710745,"_task_hash":1138988439,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":15,"child":17,"head_span":{"start":101,"end":114,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":119,"end":129,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":15,"child":21,"head_span":{"start":101,"end":114,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":145,"end":155,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"[ A randomized controlled trial of immunochemotherapy using carmofur ( HCFU ) , mitomycin C and immunopotentiators in advanced gastric cancer following noncurative resection and nonresection ] .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>controlled</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>immunochemotherapy</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>carmofur</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HCFU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>mitomycin</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>immunopotentiators</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>gastric</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>noncurative</i></b> <b style='color:DodgerBlue;'><i>resection</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>nonresection</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The cumulative survival rate of 166 gastric cancer patients after noncurative resection and nonresection treated by combination therapy using <b style='color:Tomato;'><i>carmofur</i></b> (HCFU), <b style='color:Tomato;'><i>mitomycin</i></b> C (MMC) and immunopotentiators was investigated. A randomized controlled trial composed of MMC and immunopotentiators (group A) versus the addition of HCFU to group A (group B) was undertaken. In all patients, the survival curve of group B was superior to that of group A (g. Wilcoxon test, p = 0.078). Noncurative resection or nonresection patients presented significantly higher survival rates in group B (p less than 0.05) after analysis according to the duration of the treatment period (Z-test). Stratification of backgrounds for noncurative patients also showed significantly higher survival rates in group B (p less than 0.05) at S 3, P, stage IV. From these results, it might be suggested that HCFU therapy is useful for gastric cancer patients after noncurative resection and nonresection.","tokens":[{"text":"[","start":0,"end":1,"id":0,"ws":true},{"text":"A","start":2,"end":3,"id":1,"ws":true},{"text":"randomized","start":4,"end":14,"id":2,"ws":true},{"text":"controlled","start":15,"end":25,"id":3,"ws":true},{"text":"trial","start":26,"end":31,"id":4,"ws":true},{"text":"of","start":32,"end":34,"id":5,"ws":true},{"text":"immunochemotherapy","start":35,"end":53,"id":6,"ws":true},{"text":"using","start":54,"end":59,"id":7,"ws":true},{"text":"carmofur","start":60,"end":68,"id":8,"ws":true},{"text":"(","start":69,"end":70,"id":9,"ws":true},{"text":"HCFU","start":71,"end":75,"id":10,"ws":true},{"text":")","start":76,"end":77,"id":11,"ws":true},{"text":",","start":78,"end":79,"id":12,"ws":true},{"text":"mitomycin","start":80,"end":89,"id":13,"ws":true},{"text":"C","start":90,"end":91,"id":14,"ws":true},{"text":"and","start":92,"end":95,"id":15,"ws":true},{"text":"immunopotentiators","start":96,"end":114,"id":16,"ws":true},{"text":"in","start":115,"end":117,"id":17,"ws":true},{"text":"advanced","start":118,"end":126,"id":18,"ws":true},{"text":"gastric","start":127,"end":134,"id":19,"ws":true},{"text":"cancer","start":135,"end":141,"id":20,"ws":true},{"text":"following","start":142,"end":151,"id":21,"ws":true},{"text":"noncurative","start":152,"end":163,"id":22,"ws":true},{"text":"resection","start":164,"end":173,"id":23,"ws":true},{"text":"and","start":174,"end":177,"id":24,"ws":true},{"text":"nonresection","start":178,"end":190,"id":25,"ws":true},{"text":"]","start":191,"end":192,"id":26,"ws":true},{"text":".","start":193,"end":194,"id":27,"ws":false}],"spans":[{"start":60,"end":68,"token_start":8,"token_end":8,"label":"DRUG"},{"start":80,"end":89,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/3088298/","_input_hash":1255766297,"_task_hash":-85685621,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":8,"child":13,"head_span":{"start":60,"end":68,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":80,"end":89,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"We thus undertook an extensive longitudinal immunologic study , including phenotypic , transcriptomic , and functional analyses , on 44 first-line and 27 relapsed/refractory patients enrolled in the GALEN trial ( Obinutuzumab Combined With Lenalidomide for Relapsed or Refractory Follicular B-Cell Lymphoma ) to test the efficacy of lenalidomide and obinutuzumab combination in patients with FL .","paragraph":"<h3><u>Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.</u></h3>The immunomodulatory drug <b style='color:Tomato;'><i>lenalidomide</i></b> is used in patients with follicular lymphoma (FL) with the aim of stimulating T-cell antitumor immune response. However, little is known about the effects of <b style='color:Tomato;'><i>lenalidomide</i></b> on T-cell biology in vivo in patients with FL. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>thus</i></b> <b style='color:DodgerBlue;'><i>undertook</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>extensive</i></b> <b style='color:DodgerBlue;'><i>longitudinal</i></b> <b style='color:DodgerBlue;'><i>immunologic</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>phenotypic</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>transcriptomic</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>analyses</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>44</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>27</i></b> <b style='color:DodgerBlue;'><i>relapsed/refractory</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>enrolled</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>GALEN</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>Obinutuzumab</i></b> <b style='color:DodgerBlue;'><i>Combined</i></b> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:MediumOrchid;'><i>Lenalidomide</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>Relapsed</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>Refractory</i></b> <b style='color:DodgerBlue;'><i>Follicular</i></b> <b style='color:DodgerBlue;'><i>B-Cell</i></b> <b style='color:DodgerBlue;'><i>Lymphoma</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>test</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lenalidomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>obinutuzumab</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>FL</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>lenalidomide</i></b> rapidly and transiently induced an activated T-cell phenotype, including HLA-DR, Tim-3, CD137, and programmed cell death protein 1 (PD-1) upregulation. Furthermore, sequential RNA-sequencing of sorted PD-1+ and PD-1- T-cell subsets revealed that <b style='color:Tomato;'><i>lenalidomide</i></b> triggered a strong enrichment for several gene signatures related to effector memory T-cell features, including proliferation, antigen receptor signaling, and immune synapse restoration; all were validated at the phenotypic level and with ex vivo functional assays. Correlative analyses pinpointed a negative clinical impact of high effector T-cell and regulatory T-cell percentages before and during treatment. Our findings bring new insight in <b style='color:Tomato;'><i>lenalidomide</i></b> mechanisms of action at work in vivo and will fuel a new rationale for the design of combination therapies.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"thus","start":3,"end":7,"id":1,"ws":true},{"text":"undertook","start":8,"end":17,"id":2,"ws":true},{"text":"an","start":18,"end":20,"id":3,"ws":true},{"text":"extensive","start":21,"end":30,"id":4,"ws":true},{"text":"longitudinal","start":31,"end":43,"id":5,"ws":true},{"text":"immunologic","start":44,"end":55,"id":6,"ws":true},{"text":"study","start":56,"end":61,"id":7,"ws":true},{"text":",","start":62,"end":63,"id":8,"ws":true},{"text":"including","start":64,"end":73,"id":9,"ws":true},{"text":"phenotypic","start":74,"end":84,"id":10,"ws":true},{"text":",","start":85,"end":86,"id":11,"ws":true},{"text":"transcriptomic","start":87,"end":101,"id":12,"ws":true},{"text":",","start":102,"end":103,"id":13,"ws":true},{"text":"and","start":104,"end":107,"id":14,"ws":true},{"text":"functional","start":108,"end":118,"id":15,"ws":true},{"text":"analyses","start":119,"end":127,"id":16,"ws":true},{"text":",","start":128,"end":129,"id":17,"ws":true},{"text":"on","start":130,"end":132,"id":18,"ws":true},{"text":"44","start":133,"end":135,"id":19,"ws":true},{"text":"first-line","start":136,"end":146,"id":20,"ws":true},{"text":"and","start":147,"end":150,"id":21,"ws":true},{"text":"27","start":151,"end":153,"id":22,"ws":true},{"text":"relapsed/refractory","start":154,"end":173,"id":23,"ws":true},{"text":"patients","start":174,"end":182,"id":24,"ws":true},{"text":"enrolled","start":183,"end":191,"id":25,"ws":true},{"text":"in","start":192,"end":194,"id":26,"ws":true},{"text":"the","start":195,"end":198,"id":27,"ws":true},{"text":"GALEN","start":199,"end":204,"id":28,"ws":true},{"text":"trial","start":205,"end":210,"id":29,"ws":true},{"text":"(","start":211,"end":212,"id":30,"ws":true},{"text":"Obinutuzumab","start":213,"end":225,"id":31,"ws":true},{"text":"Combined","start":226,"end":234,"id":32,"ws":true},{"text":"With","start":235,"end":239,"id":33,"ws":true},{"text":"Lenalidomide","start":240,"end":252,"id":34,"ws":true},{"text":"for","start":253,"end":256,"id":35,"ws":true},{"text":"Relapsed","start":257,"end":265,"id":36,"ws":true},{"text":"or","start":266,"end":268,"id":37,"ws":true},{"text":"Refractory","start":269,"end":279,"id":38,"ws":true},{"text":"Follicular","start":280,"end":290,"id":39,"ws":true},{"text":"B-Cell","start":291,"end":297,"id":40,"ws":true},{"text":"Lymphoma","start":298,"end":306,"id":41,"ws":true},{"text":")","start":307,"end":308,"id":42,"ws":true},{"text":"to","start":309,"end":311,"id":43,"ws":true},{"text":"test","start":312,"end":316,"id":44,"ws":true},{"text":"the","start":317,"end":320,"id":45,"ws":true},{"text":"efficacy","start":321,"end":329,"id":46,"ws":true},{"text":"of","start":330,"end":332,"id":47,"ws":true},{"text":"lenalidomide","start":333,"end":345,"id":48,"ws":true},{"text":"and","start":346,"end":349,"id":49,"ws":true},{"text":"obinutuzumab","start":350,"end":362,"id":50,"ws":true},{"text":"combination","start":363,"end":374,"id":51,"ws":true},{"text":"in","start":375,"end":377,"id":52,"ws":true},{"text":"patients","start":378,"end":386,"id":53,"ws":true},{"text":"with","start":387,"end":391,"id":54,"ws":true},{"text":"FL","start":392,"end":394,"id":55,"ws":true},{"text":".","start":395,"end":396,"id":56,"ws":false}],"spans":[{"start":213,"end":225,"token_start":31,"token_end":31,"label":"DRUG"},{"start":240,"end":252,"token_start":34,"token_end":34,"label":"DRUG"},{"start":333,"end":345,"token_start":48,"token_end":48,"label":"DRUG"},{"start":350,"end":362,"token_start":50,"token_end":50,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33877296/","_input_hash":-1616537325,"_task_hash":1844761812,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":31,"child":34,"head_span":{"start":213,"end":225,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":240,"end":252,"token_start":34,"token_end":34,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Blockade of beta-receptors by the nonselective beta-blocking agent propranolol did not modify the brachial artery diameter , whereas pindolol increased this parameter for the same degree of blood pressure reduction .","paragraph":"<h3><u>Beta-blockade and brachial artery hemodynamics in hypertension.</u></h3>The effect of systemic adrenergic blockade on hypertensive brachial arteries was studied in humans with pulsed Doppler flowmetry. <b style='color:DodgerBlue;'><i>Blockade</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>beta-receptors</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>nonselective</i></b> <b style='color:DodgerBlue;'><i>beta-blocking</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>modify</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>brachial</i></b> <b style='color:DodgerBlue;'><i>artery</i></b> <b style='color:DodgerBlue;'><i>diameter</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:MediumOrchid;'><i>pindolol</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>parameter</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>degree</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>pressure</i></b> <b style='color:DodgerBlue;'><i>reduction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The beta1-selective blocking agents <b style='color:Tomato;'><i>atenolol</i></b> and <b style='color:Tomato;'><i>bisoprolol</i></b> caused similar decreases in blood pressure and a reduction in the diameters of the brachial artery and abdominal aorta, respectively. The combination of alpha- and beta-blockade produced a rapid drop in blood pressure but did not change the brachial arterial diameter. Thus, following beta-blockade, the arterial diameter increased, did not change, or even decreased despite an adequate blood pressure reduction. It is suggested that beta-blockade in some instances resets the pressure-diameter curve and therefore has a direct action on the arterial wall independent of the mechanical effect of blood pressure reduction.","tokens":[{"text":"Blockade","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"beta-receptors","start":12,"end":26,"id":2,"ws":true},{"text":"by","start":27,"end":29,"id":3,"ws":true},{"text":"the","start":30,"end":33,"id":4,"ws":true},{"text":"nonselective","start":34,"end":46,"id":5,"ws":true},{"text":"beta-blocking","start":47,"end":60,"id":6,"ws":true},{"text":"agent","start":61,"end":66,"id":7,"ws":true},{"text":"propranolol","start":67,"end":78,"id":8,"ws":true},{"text":"did","start":79,"end":82,"id":9,"ws":true},{"text":"not","start":83,"end":86,"id":10,"ws":true},{"text":"modify","start":87,"end":93,"id":11,"ws":true},{"text":"the","start":94,"end":97,"id":12,"ws":true},{"text":"brachial","start":98,"end":106,"id":13,"ws":true},{"text":"artery","start":107,"end":113,"id":14,"ws":true},{"text":"diameter","start":114,"end":122,"id":15,"ws":true},{"text":",","start":123,"end":124,"id":16,"ws":true},{"text":"whereas","start":125,"end":132,"id":17,"ws":true},{"text":"pindolol","start":133,"end":141,"id":18,"ws":true},{"text":"increased","start":142,"end":151,"id":19,"ws":true},{"text":"this","start":152,"end":156,"id":20,"ws":true},{"text":"parameter","start":157,"end":166,"id":21,"ws":true},{"text":"for","start":167,"end":170,"id":22,"ws":true},{"text":"the","start":171,"end":174,"id":23,"ws":true},{"text":"same","start":175,"end":179,"id":24,"ws":true},{"text":"degree","start":180,"end":186,"id":25,"ws":true},{"text":"of","start":187,"end":189,"id":26,"ws":true},{"text":"blood","start":190,"end":195,"id":27,"ws":true},{"text":"pressure","start":196,"end":204,"id":28,"ws":true},{"text":"reduction","start":205,"end":214,"id":29,"ws":true},{"text":".","start":215,"end":216,"id":30,"ws":false}],"spans":[{"start":67,"end":78,"token_start":8,"token_end":8,"label":"DRUG"},{"start":133,"end":141,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11527134/","_input_hash":-161714494,"_task_hash":1214799597,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Nab-paclitaxel has demonstrated improved PFS and tolerability compared with standard cremophor-solubilized paclitaxel ; based on this , we examined the efficacy and safety of combining weekly nab-paclitaxel with carboplatin and bevacizumab in TNMBC .","paragraph":"<h3><u>Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.</u></h3>Triple negative metastatic breast cancer can be difficult to treat with primarily cytotoxic options. <b style='color:DodgerBlue;'><i>Nab-paclitaxel</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>PFS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>tolerability</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>cremophor-solubilized</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combining</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>nab-paclitaxel</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>TNMBC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods In this phase II, multicenter trial, patients with first-line TNMBC received nab-<b style='color:Tomato;'><i>paclitaxel</i></b> (100 mg/m(2)) and <b style='color:Tomato;'><i>carboplatin</i></b> (area under the curve\u00a0= 2) on days 1, 8, 15, and <b style='color:Tomato;'><i>bevacizumab</i></b> (10 mg/kg) on days 1 and 15 of a 28-day cycle. The primary end point was safety and tolerability and secondary end points included PFS, ORR, and CBR. PFS was calculated using the Kaplan-Meier method. ### results Between July 16, 2007, and October 3, 2011, 34 patients were enrolled at 4 centers. Median age was 50.0 (range, 30-76) years and 77% (n = 26) of patients received previous adjuvant therapy. Median PFS was 9.2 months (95% confidence interval [CI], 7.8-25.1 months). The CBR was 94% (95% CI, 80%-99%), and ORR was 85% (95% CI, 69%-95%) for the combination. The regimen was well tolerated with the most common grade 3/4 adverse events being neutropenia (n\u00a0= 18; 53%) and thrombocytopenia (n\u00a0= 6; 18%), with other serous events including 1 grade 3 and 1 grade 4 thrombotic event and 1 febrile neutropenia. ### conclusion The combination of nab-<b style='color:Tomato;'><i>paclitaxel</i></b>, <b style='color:Tomato;'><i>bevacizumab</i></b>, and <b style='color:Tomato;'><i>carboplatin</i></b> as first-line treatment for TNMBC was efficacious and well tolerated. The PFS, CBR, and ORR, and tolerability of the regimen, compares favorably with other standard first-line therapies.","tokens":[{"text":"Nab-paclitaxel","start":0,"end":14,"id":0,"ws":true},{"text":"has","start":15,"end":18,"id":1,"ws":true},{"text":"demonstrated","start":19,"end":31,"id":2,"ws":true},{"text":"improved","start":32,"end":40,"id":3,"ws":true},{"text":"PFS","start":41,"end":44,"id":4,"ws":true},{"text":"and","start":45,"end":48,"id":5,"ws":true},{"text":"tolerability","start":49,"end":61,"id":6,"ws":true},{"text":"compared","start":62,"end":70,"id":7,"ws":true},{"text":"with","start":71,"end":75,"id":8,"ws":true},{"text":"standard","start":76,"end":84,"id":9,"ws":true},{"text":"cremophor-solubilized","start":85,"end":106,"id":10,"ws":true},{"text":"paclitaxel","start":107,"end":117,"id":11,"ws":true},{"text":";","start":118,"end":119,"id":12,"ws":true},{"text":"based","start":120,"end":125,"id":13,"ws":true},{"text":"on","start":126,"end":128,"id":14,"ws":true},{"text":"this","start":129,"end":133,"id":15,"ws":true},{"text":",","start":134,"end":135,"id":16,"ws":true},{"text":"we","start":136,"end":138,"id":17,"ws":true},{"text":"examined","start":139,"end":147,"id":18,"ws":true},{"text":"the","start":148,"end":151,"id":19,"ws":true},{"text":"efficacy","start":152,"end":160,"id":20,"ws":true},{"text":"and","start":161,"end":164,"id":21,"ws":true},{"text":"safety","start":165,"end":171,"id":22,"ws":true},{"text":"of","start":172,"end":174,"id":23,"ws":true},{"text":"combining","start":175,"end":184,"id":24,"ws":true},{"text":"weekly","start":185,"end":191,"id":25,"ws":true},{"text":"nab-paclitaxel","start":192,"end":206,"id":26,"ws":true},{"text":"with","start":207,"end":211,"id":27,"ws":true},{"text":"carboplatin","start":212,"end":223,"id":28,"ws":true},{"text":"and","start":224,"end":227,"id":29,"ws":true},{"text":"bevacizumab","start":228,"end":239,"id":30,"ws":true},{"text":"in","start":240,"end":242,"id":31,"ws":true},{"text":"TNMBC","start":243,"end":248,"id":32,"ws":true},{"text":".","start":249,"end":250,"id":33,"ws":false}],"spans":[{"start":0,"end":14,"token_start":0,"token_end":0,"label":"DRUG"},{"start":107,"end":117,"token_start":11,"token_end":11,"label":"DRUG"},{"start":212,"end":223,"token_start":28,"token_end":28,"label":"DRUG"},{"start":228,"end":239,"token_start":30,"token_end":30,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24099649/","_input_hash":-901015321,"_task_hash":1928681433,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":26,"child":28,"head_span":{"start":192,"end":206,"token_start":26,"token_end":26,"label":null},"child_span":{"start":212,"end":223,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":30,"child":28,"head_span":{"start":228,"end":239,"token_start":30,"token_end":30,"label":"DRUG"},"child_span":{"start":212,"end":223,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Acute renal failure ( ARF ) occurred concomitantly with the administration of gentamicin in combination with clindamycin in three patients in whom no other known predisposing cause of ARF could be demonstrated .","paragraph":"<h3><u>Renal failure following gentamicin in combination with clindamycin.</u></h3> <b style='color:DodgerBlue;'><i>Acute</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ARF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>occurred</i></b> <b style='color:DodgerBlue;'><i>concomitantly</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>clindamycin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>whom</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>known</i></b> <b style='color:DodgerBlue;'><i>predisposing</i></b> <b style='color:DodgerBlue;'><i>cause</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ARF</i></b> <b style='color:DodgerBlue;'><i>could</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The evidence for combined nephrotoxicity consisted of the temporal relationship between administration of the antibiotics and the development of ARF, and the prompt improvement in renal function upon cessation of therapy. Complete or partial recovery of renal function occured in all patients. Renal function should be carefully monitored in patients receiving this antibiotic combination.","tokens":[{"text":"Acute","start":0,"end":5,"id":0,"ws":true},{"text":"renal","start":6,"end":11,"id":1,"ws":true},{"text":"failure","start":12,"end":19,"id":2,"ws":true},{"text":"(","start":20,"end":21,"id":3,"ws":true},{"text":"ARF","start":22,"end":25,"id":4,"ws":true},{"text":")","start":26,"end":27,"id":5,"ws":true},{"text":"occurred","start":28,"end":36,"id":6,"ws":true},{"text":"concomitantly","start":37,"end":50,"id":7,"ws":true},{"text":"with","start":51,"end":55,"id":8,"ws":true},{"text":"the","start":56,"end":59,"id":9,"ws":true},{"text":"administration","start":60,"end":74,"id":10,"ws":true},{"text":"of","start":75,"end":77,"id":11,"ws":true},{"text":"gentamicin","start":78,"end":88,"id":12,"ws":true},{"text":"in","start":89,"end":91,"id":13,"ws":true},{"text":"combination","start":92,"end":103,"id":14,"ws":true},{"text":"with","start":104,"end":108,"id":15,"ws":true},{"text":"clindamycin","start":109,"end":120,"id":16,"ws":true},{"text":"in","start":121,"end":123,"id":17,"ws":true},{"text":"three","start":124,"end":129,"id":18,"ws":true},{"text":"patients","start":130,"end":138,"id":19,"ws":true},{"text":"in","start":139,"end":141,"id":20,"ws":true},{"text":"whom","start":142,"end":146,"id":21,"ws":true},{"text":"no","start":147,"end":149,"id":22,"ws":true},{"text":"other","start":150,"end":155,"id":23,"ws":true},{"text":"known","start":156,"end":161,"id":24,"ws":true},{"text":"predisposing","start":162,"end":174,"id":25,"ws":true},{"text":"cause","start":175,"end":180,"id":26,"ws":true},{"text":"of","start":181,"end":183,"id":27,"ws":true},{"text":"ARF","start":184,"end":187,"id":28,"ws":true},{"text":"could","start":188,"end":193,"id":29,"ws":true},{"text":"be","start":194,"end":196,"id":30,"ws":true},{"text":"demonstrated","start":197,"end":209,"id":31,"ws":true},{"text":".","start":210,"end":211,"id":32,"ws":false}],"spans":[{"start":78,"end":88,"token_start":12,"token_end":12,"label":"DRUG"},{"start":109,"end":120,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/951016/","_input_hash":-1617326454,"_task_hash":-1655981466,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":12,"child":16,"head_span":{"start":78,"end":88,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":109,"end":120,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"However , nicotinic acid , nicotinamide , and pyridoxamine are not able to reverse the effect of isoniazid .","paragraph":"<h3><u>Protection of Escherichia coli from isoniazid inhibition.</u></h3>Inhibition of Escherichia coli by isonicotinic acid hydrazide (<b style='color:Tomato;'><i>isoniazid</i></b>) is a function of the initial cell concentration, concentration of antibiotic, and chemical composition of the medium. An initial concentration of 5 x 10(5) cells/ml in a minimal medium is inhibited by 1 mM <b style='color:Tomato;'><i>isoniazid</i></b>. The E. coli cells are protected from this inhibitory effect by a high concentration of cells in the medium. Protection is also obtained from vitamin-free Casamino Acids, methionine, or choline plus homocystine. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>nicotinic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>nicotinamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>pyridoxamine</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>able</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>reverse</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Colonies arising on minimal medium supplemented with <b style='color:Tomato;'><i>isoniazid</i></b> are not due to selection of resistant mutants, because this resistance is transitory and not passed on to the daughter cells. It is hypothesized that this transitory resistance is a manifestation of the cells' ability to transfer the methyl group of methionine to either <b style='color:Tomato;'><i>isoniazid</i></b> or accumulated nicotinic acid and/or <b style='color:Tomato;'><i>nicotinamide</i></b>.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"nicotinic","start":10,"end":19,"id":2,"ws":true},{"text":"acid","start":20,"end":24,"id":3,"ws":true},{"text":",","start":25,"end":26,"id":4,"ws":true},{"text":"nicotinamide","start":27,"end":39,"id":5,"ws":true},{"text":",","start":40,"end":41,"id":6,"ws":true},{"text":"and","start":42,"end":45,"id":7,"ws":true},{"text":"pyridoxamine","start":46,"end":58,"id":8,"ws":true},{"text":"are","start":59,"end":62,"id":9,"ws":true},{"text":"not","start":63,"end":66,"id":10,"ws":true},{"text":"able","start":67,"end":71,"id":11,"ws":true},{"text":"to","start":72,"end":74,"id":12,"ws":true},{"text":"reverse","start":75,"end":82,"id":13,"ws":true},{"text":"the","start":83,"end":86,"id":14,"ws":true},{"text":"effect","start":87,"end":93,"id":15,"ws":true},{"text":"of","start":94,"end":96,"id":16,"ws":true},{"text":"isoniazid","start":97,"end":106,"id":17,"ws":true},{"text":".","start":107,"end":108,"id":18,"ws":false}],"spans":[{"start":27,"end":39,"token_start":5,"token_end":5,"label":"DRUG"},{"start":97,"end":106,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/4599120/","_input_hash":-1474829394,"_task_hash":-1557493805,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"To explore the role of augmenting neutrophil function in B-cell lymphoma , we conducted a phase II study evaluating the safety and clinical efficacy of pegfilgrastim and rituximab in low-grade CD20","paragraph":"<h3><u>A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>explore</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>role</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>augmenting</i></b> <b style='color:DodgerBlue;'><i>neutrophil</i></b> <b style='color:DodgerBlue;'><i>function</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>B-cell</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>evaluating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pegfilgrastim</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>low-grade</i></b> <b style='color:DodgerBlue;'><i>CD20</i></b> ### Patients And Methods Twenty patients with indolent B-NHL were treated with <b style='color:Tomato;'><i>rituximab</i></b> (375\u00a0mg/m ### results The patient demographics included median age of 64 years, 70% were male, 70% had follicular lymphoma, and 90% had stage III-IV disease. The median number of previous therapies was 2 (range, 0-5); 90% had received previous anti-CD20 monoclonal antibody therapy. The addition of peg<b style='color:Tomato;'><i>filgrastim</i></b> to <b style='color:Tomato;'><i>rituximab</i></b> did not increase <b style='color:Tomato;'><i>rituximab</i></b>-related toxicities. The overall response rate was 60% (12 of 20), with a complete response (CR) rate of 35% (7 of 20). The median progression-free survival (PFS) duration was 17.9 months (95% confidence interval, 9.9-27.6 months); the median overall survival was not reached. A shorter time-to-peak oxidative burst after the first dose of peg<b style='color:Tomato;'><i>filgrastim</i></b> was associated with greater CR rates (P\u00a0= .04) and longer PFS (P\u00a0= .03). ### conclusion The peg<b style='color:Tomato;'><i>filgrastim</i></b>-<b style='color:Tomato;'><i>rituximab</i></b> combination was well tolerated, with favorable outcomes compared with historical controls. A\u00a0shorter time-to-peak oxidative burst was associated with higher CR rates and longer PFS. Our results support further evaluation of strategies that enhance the innate immune system to improve <b style='color:Tomato;'><i>rituximab</i></b> activity in B-NHL.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"explore","start":3,"end":10,"id":1,"ws":true},{"text":"the","start":11,"end":14,"id":2,"ws":true},{"text":"role","start":15,"end":19,"id":3,"ws":true},{"text":"of","start":20,"end":22,"id":4,"ws":true},{"text":"augmenting","start":23,"end":33,"id":5,"ws":true},{"text":"neutrophil","start":34,"end":44,"id":6,"ws":true},{"text":"function","start":45,"end":53,"id":7,"ws":true},{"text":"in","start":54,"end":56,"id":8,"ws":true},{"text":"B-cell","start":57,"end":63,"id":9,"ws":true},{"text":"lymphoma","start":64,"end":72,"id":10,"ws":true},{"text":",","start":73,"end":74,"id":11,"ws":true},{"text":"we","start":75,"end":77,"id":12,"ws":true},{"text":"conducted","start":78,"end":87,"id":13,"ws":true},{"text":"a","start":88,"end":89,"id":14,"ws":true},{"text":"phase","start":90,"end":95,"id":15,"ws":true},{"text":"II","start":96,"end":98,"id":16,"ws":true},{"text":"study","start":99,"end":104,"id":17,"ws":true},{"text":"evaluating","start":105,"end":115,"id":18,"ws":true},{"text":"the","start":116,"end":119,"id":19,"ws":true},{"text":"safety","start":120,"end":126,"id":20,"ws":true},{"text":"and","start":127,"end":130,"id":21,"ws":true},{"text":"clinical","start":131,"end":139,"id":22,"ws":true},{"text":"efficacy","start":140,"end":148,"id":23,"ws":true},{"text":"of","start":149,"end":151,"id":24,"ws":true},{"text":"pegfilgrastim","start":152,"end":165,"id":25,"ws":true},{"text":"and","start":166,"end":169,"id":26,"ws":true},{"text":"rituximab","start":170,"end":179,"id":27,"ws":true},{"text":"in","start":180,"end":182,"id":28,"ws":true},{"text":"low-grade","start":183,"end":192,"id":29,"ws":true},{"text":"CD20","start":193,"end":197,"id":30,"ws":false}],"spans":[{"start":152,"end":165,"token_start":25,"token_end":25,"label":"DRUG"},{"start":170,"end":179,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29233743/","_input_hash":18592601,"_task_hash":1721207902,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":25,"child":27,"head_span":{"start":152,"end":165,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":170,"end":179,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Thirty-one animals were allocated randomly to three groups , all administered four boluses of 0.25 mg/kg rTPA every 10 min for 30 min , 17 mg/kg aspirin intravenously , and heparin ( as a 100 IU/kg bolus followed by infusion of 50 IU/kg heparin per h ) , hirudin ( as a 2 mg/kg bolus followed by infusion of 1 mg/kg hirudin per h ) , or Yagin ( as an 80 micrograms/kg bolus followed by infusion of 43 micrograms/kg Yagin per h ) .","paragraph":"<h3><u>Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model.</u></h3>To compare the efficacy of Yagin, a factor Xa inhibitor derived from the leech Hirudo medicinalis, with those of <b style='color:Tomato;'><i>heparin</i></b> and hirudin as adjuncts to recombinant tissue-type plasminogen activator (rTPA) thrombolysis in a rabbit thrombosis model. ### methods <b style='color:DodgerBlue;'><i>Thirty-one</i></b> <b style='color:DodgerBlue;'><i>animals</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>allocated</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>all</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>boluses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>0.25</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>rTPA</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>17</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>heparin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>IU/kg</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>IU/kg</i></b> <b style='color:MediumOrchid;'><i>heparin</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>hirudin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>hirudin</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>Yagin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>micrograms/kg</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>43</i></b> <b style='color:DodgerBlue;'><i>micrograms/kg</i></b> <b style='color:DodgerBlue;'><i>Yagin</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Administration of Yagin was associated with a significant acceleration of the reflow time, this time being 14.5 +/- 1.2 min with Yagin, 25.8 +/- 5.2 min with <b style='color:Tomato;'><i>heparin</i></b> (P < 0.0001, versus Yagin), and 28.7 +/- 16.0 min with hirudin (P = 0.012, versus Yagin). Overall patency did not differ significantly among the three groups. ### conclusions At the indicated single doses, inhibition of factor Xa by a relatively low concentration of Yagin was found to be superior than that with either <b style='color:Tomato;'><i>heparin</i></b> or hirudin for accelerating rTPA thrombolysis.","tokens":[{"text":"Thirty-one","start":0,"end":10,"id":0,"ws":true},{"text":"animals","start":11,"end":18,"id":1,"ws":true},{"text":"were","start":19,"end":23,"id":2,"ws":true},{"text":"allocated","start":24,"end":33,"id":3,"ws":true},{"text":"randomly","start":34,"end":42,"id":4,"ws":true},{"text":"to","start":43,"end":45,"id":5,"ws":true},{"text":"three","start":46,"end":51,"id":6,"ws":true},{"text":"groups","start":52,"end":58,"id":7,"ws":true},{"text":",","start":59,"end":60,"id":8,"ws":true},{"text":"all","start":61,"end":64,"id":9,"ws":true},{"text":"administered","start":65,"end":77,"id":10,"ws":true},{"text":"four","start":78,"end":82,"id":11,"ws":true},{"text":"boluses","start":83,"end":90,"id":12,"ws":true},{"text":"of","start":91,"end":93,"id":13,"ws":true},{"text":"0.25","start":94,"end":98,"id":14,"ws":true},{"text":"mg/kg","start":99,"end":104,"id":15,"ws":true},{"text":"rTPA","start":105,"end":109,"id":16,"ws":true},{"text":"every","start":110,"end":115,"id":17,"ws":true},{"text":"10","start":116,"end":118,"id":18,"ws":true},{"text":"min","start":119,"end":122,"id":19,"ws":true},{"text":"for","start":123,"end":126,"id":20,"ws":true},{"text":"30","start":127,"end":129,"id":21,"ws":true},{"text":"min","start":130,"end":133,"id":22,"ws":true},{"text":",","start":134,"end":135,"id":23,"ws":true},{"text":"17","start":136,"end":138,"id":24,"ws":true},{"text":"mg/kg","start":139,"end":144,"id":25,"ws":true},{"text":"aspirin","start":145,"end":152,"id":26,"ws":true},{"text":"intravenously","start":153,"end":166,"id":27,"ws":true},{"text":",","start":167,"end":168,"id":28,"ws":true},{"text":"and","start":169,"end":172,"id":29,"ws":true},{"text":"heparin","start":173,"end":180,"id":30,"ws":true},{"text":"(","start":181,"end":182,"id":31,"ws":true},{"text":"as","start":183,"end":185,"id":32,"ws":true},{"text":"a","start":186,"end":187,"id":33,"ws":true},{"text":"100","start":188,"end":191,"id":34,"ws":true},{"text":"IU/kg","start":192,"end":197,"id":35,"ws":true},{"text":"bolus","start":198,"end":203,"id":36,"ws":true},{"text":"followed","start":204,"end":212,"id":37,"ws":true},{"text":"by","start":213,"end":215,"id":38,"ws":true},{"text":"infusion","start":216,"end":224,"id":39,"ws":true},{"text":"of","start":225,"end":227,"id":40,"ws":true},{"text":"50","start":228,"end":230,"id":41,"ws":true},{"text":"IU/kg","start":231,"end":236,"id":42,"ws":true},{"text":"heparin","start":237,"end":244,"id":43,"ws":true},{"text":"per","start":245,"end":248,"id":44,"ws":true},{"text":"h","start":249,"end":250,"id":45,"ws":true},{"text":")","start":251,"end":252,"id":46,"ws":true},{"text":",","start":253,"end":254,"id":47,"ws":true},{"text":"hirudin","start":255,"end":262,"id":48,"ws":true},{"text":"(","start":263,"end":264,"id":49,"ws":true},{"text":"as","start":265,"end":267,"id":50,"ws":true},{"text":"a","start":268,"end":269,"id":51,"ws":true},{"text":"2","start":270,"end":271,"id":52,"ws":true},{"text":"mg/kg","start":272,"end":277,"id":53,"ws":true},{"text":"bolus","start":278,"end":283,"id":54,"ws":true},{"text":"followed","start":284,"end":292,"id":55,"ws":true},{"text":"by","start":293,"end":295,"id":56,"ws":true},{"text":"infusion","start":296,"end":304,"id":57,"ws":true},{"text":"of","start":305,"end":307,"id":58,"ws":true},{"text":"1","start":308,"end":309,"id":59,"ws":true},{"text":"mg/kg","start":310,"end":315,"id":60,"ws":true},{"text":"hirudin","start":316,"end":323,"id":61,"ws":true},{"text":"per","start":324,"end":327,"id":62,"ws":true},{"text":"h","start":328,"end":329,"id":63,"ws":true},{"text":")","start":330,"end":331,"id":64,"ws":true},{"text":",","start":332,"end":333,"id":65,"ws":true},{"text":"or","start":334,"end":336,"id":66,"ws":true},{"text":"Yagin","start":337,"end":342,"id":67,"ws":true},{"text":"(","start":343,"end":344,"id":68,"ws":true},{"text":"as","start":345,"end":347,"id":69,"ws":true},{"text":"an","start":348,"end":350,"id":70,"ws":true},{"text":"80","start":351,"end":353,"id":71,"ws":true},{"text":"micrograms/kg","start":354,"end":367,"id":72,"ws":true},{"text":"bolus","start":368,"end":373,"id":73,"ws":true},{"text":"followed","start":374,"end":382,"id":74,"ws":true},{"text":"by","start":383,"end":385,"id":75,"ws":true},{"text":"infusion","start":386,"end":394,"id":76,"ws":true},{"text":"of","start":395,"end":397,"id":77,"ws":true},{"text":"43","start":398,"end":400,"id":78,"ws":true},{"text":"micrograms/kg","start":401,"end":414,"id":79,"ws":true},{"text":"Yagin","start":415,"end":420,"id":80,"ws":true},{"text":"per","start":421,"end":424,"id":81,"ws":true},{"text":"h","start":425,"end":426,"id":82,"ws":true},{"text":")","start":427,"end":428,"id":83,"ws":true},{"text":".","start":429,"end":430,"id":84,"ws":false}],"spans":[{"start":105,"end":109,"token_start":16,"token_end":16,"label":"DRUG"},{"start":145,"end":152,"token_start":26,"token_end":26,"label":"DRUG"},{"start":173,"end":180,"token_start":30,"token_end":30,"label":"DRUG"},{"start":237,"end":244,"token_start":43,"token_end":43,"label":"DRUG"},{"start":255,"end":262,"token_start":48,"token_end":48,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9116933/","_input_hash":-117863177,"_task_hash":758722916,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":16,"child":26,"head_span":{"start":105,"end":109,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":145,"end":152,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":26,"child":30,"head_span":{"start":145,"end":152,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":173,"end":180,"token_start":30,"token_end":30,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":48,"child":43,"head_span":{"start":255,"end":262,"token_start":48,"token_end":48,"label":"DRUG"},"child_span":{"start":237,"end":244,"token_start":43,"token_end":43,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":30,"child":43,"head_span":{"start":173,"end":180,"token_start":30,"token_end":30,"label":"DRUG"},"child_span":{"start":237,"end":244,"token_start":43,"token_end":43,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In vivo evofosfamide was tumor suppressive as a single agent and cooperated with paclitaxel to reduce mammary tumor growth .","paragraph":"<h3><u>Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.</u></h3>Tumor hypoxia is a major cause of treatment failure for a variety of malignancies. However, hypoxia offers treatment opportunities, exemplified by the development of compounds that target hypoxic regions within tumors. <b style='color:Tomato;'><i>evofosfamide</i></b> (TH-302) is a prodrug created by the conjugation of 2-nitroimidazole to bromo-isophosphoramide mustard (Br-IPM). When <b style='color:Tomato;'><i>evofosfamide</i></b> is delivered to hypoxic regions, the DNA cross-linking effector, Br-IPM, is released. This study assessed the cytotoxic activity of <b style='color:Tomato;'><i>evofosfamide</i></b> in vitro and its antitumor activity against osteolytic breast cancer either alone or in combination with <b style='color:Tomato;'><i>paclitaxel</i></b> in vivo. A panel of human breast cancer cell lines were treated with <b style='color:Tomato;'><i>evofosfamide</i></b> under hypoxia and assessed for cell viability. Osteolytic MDA-MB-231-TXSA cells were transplanted into the mammary fat pad, or into tibiae of mice, allowed to establish and treated with <b style='color:Tomato;'><i>evofosfamide</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or both. Tumor burden was monitored using bioluminescence, and cancer-induced bone destruction was measured using micro-CT. In vitro, <b style='color:Tomato;'><i>evofosfamide</i></b> was selectively cytotoxic under hypoxic conditions. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:MediumOrchid;'><i>evofosfamide</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>suppressive</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cooperated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>reduce</i></b> <b style='color:DodgerBlue;'><i>mammary</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Breast cancer cells transplanted into the tibiae of mice developed osteolytic lesions. In contrast, treatment with <b style='color:Tomato;'><i>evofosfamide</i></b> or <b style='color:Tomato;'><i>paclitaxel</i></b> resulted in a significant delay in tumor growth and an overall reduction in tumor burden in bone, whereas combined treatment resulted in a significantly greater reduction in tumor burden in the tibia of mice. <b style='color:Tomato;'><i>evofosfamide</i></b> cooperates with <b style='color:Tomato;'><i>paclitaxel</i></b> and exhibits potent tumor suppressive activity against breast cancer growth in the mammary gland and in bone.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"vivo","start":3,"end":7,"id":1,"ws":true},{"text":"evofosfamide","start":8,"end":20,"id":2,"ws":true},{"text":"was","start":21,"end":24,"id":3,"ws":true},{"text":"tumor","start":25,"end":30,"id":4,"ws":true},{"text":"suppressive","start":31,"end":42,"id":5,"ws":true},{"text":"as","start":43,"end":45,"id":6,"ws":true},{"text":"a","start":46,"end":47,"id":7,"ws":true},{"text":"single","start":48,"end":54,"id":8,"ws":true},{"text":"agent","start":55,"end":60,"id":9,"ws":true},{"text":"and","start":61,"end":64,"id":10,"ws":true},{"text":"cooperated","start":65,"end":75,"id":11,"ws":true},{"text":"with","start":76,"end":80,"id":12,"ws":true},{"text":"paclitaxel","start":81,"end":91,"id":13,"ws":true},{"text":"to","start":92,"end":94,"id":14,"ws":true},{"text":"reduce","start":95,"end":101,"id":15,"ws":true},{"text":"mammary","start":102,"end":109,"id":16,"ws":true},{"text":"tumor","start":110,"end":115,"id":17,"ws":true},{"text":"growth","start":116,"end":122,"id":18,"ws":true},{"text":".","start":123,"end":124,"id":19,"ws":false}],"spans":[{"start":8,"end":20,"token_start":2,"token_end":2,"label":"DRUG"},{"start":81,"end":91,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26749324/","_input_hash":1602014695,"_task_hash":-822805448,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":2,"child":13,"head_span":{"start":8,"end":20,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":81,"end":91,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Paclitaxel and vinorelbine are among the most active new agents in metastatic breast cancer .","paragraph":"<h3><u>Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.</u></h3> <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>among</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both in vitro and in vivo studies have shown that the combined administration of these two microtubule-targeting agents is feasible and worthwhile. Based on the promising preclinical data, patients with metastatic breast cancer no longer amenable to conventional treatment were entered into a phase I/II study in which the <b style='color:Tomato;'><i>vinorelbine</i></b> dose was fixed at 30 mg/sqm and <b style='color:Tomato;'><i>paclitaxel</i></b> was started at 90 mg/sqm and then subsequently escalated by 30 mg/sqm per step. Cycles were repeated every 21 days. Hematopoietic growth factor support was provided from the 4th dose level onwards. Grade III neutropenia was observed only in 2 patients treated at the 5th dose level. Thrombocytopenia never reached grade 3. Neurotoxicity was considered dose-limiting, since grade 3 peripheral neuropathy occurred in all three patients treated at the 6th dose level. Other toxicities were mild. <b style='color:Tomato;'><i>paclitaxel</i></b> 210 mg/sqm and <b style='color:Tomato;'><i>vinorelbine</i></b> 30 mg/sqm was the selected combination for phase II. Overall response rate in 34 evaluable patients was 38% (95% confidence interval (C.I.), 22% to 54%). In particular, 3 complete responses (9%) and 10 partial responses (29%) were observed. The observed level of antitumor activity, with an overall response rate of 38% and a median duration of response of 12 months, is of interest, since the study was targeted only to anthracycline-pretreated patients, most of whom had adverse prognostic features. The evaluation of a combination of <b style='color:Tomato;'><i>vinorelbine</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> as first-line therapy in metastatic breast cancer seems worthwhile and is currently undergoing.","tokens":[{"text":"Paclitaxel","start":0,"end":10,"id":0,"ws":true},{"text":"and","start":11,"end":14,"id":1,"ws":true},{"text":"vinorelbine","start":15,"end":26,"id":2,"ws":true},{"text":"are","start":27,"end":30,"id":3,"ws":true},{"text":"among","start":31,"end":36,"id":4,"ws":true},{"text":"the","start":37,"end":40,"id":5,"ws":true},{"text":"most","start":41,"end":45,"id":6,"ws":true},{"text":"active","start":46,"end":52,"id":7,"ws":true},{"text":"new","start":53,"end":56,"id":8,"ws":true},{"text":"agents","start":57,"end":63,"id":9,"ws":true},{"text":"in","start":64,"end":66,"id":10,"ws":true},{"text":"metastatic","start":67,"end":77,"id":11,"ws":true},{"text":"breast","start":78,"end":84,"id":12,"ws":true},{"text":"cancer","start":85,"end":91,"id":13,"ws":true},{"text":".","start":92,"end":93,"id":14,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":15,"end":26,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9493980/","_input_hash":1278136203,"_task_hash":662238224,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Treatments included recombinant human leptin ( 10 - 100nM ) , recombinant human IL-6 ( 0.3 - 3nM ) , or recombinant human erythropoietin ( Epo ) ( 10mU/ml ) .","paragraph":"<h3><u>Leptin receptor JAK2/STAT3 signaling modulates expression of Frizzled receptors in articular chondrocytes.</u></h3>Differentiated articular chondrocytes express a functional bisoform of the <b style='color:Tomato;'><i>leptin</i></b> receptor (LRb); however, <b style='color:Tomato;'><i>leptin</i></b>-LRb signaling in these cells is poorly understood. We hypothesized that <b style='color:Tomato;'><i>leptin</i></b>-LRb signaling in articular chondrocytes functions to modulate canonical Wnt signaling events by altering the expression of Frizzled (FZD) receptors. ### methods Human chondrocyte cell lines and primary articular chondrocytes were grown in serum containing growth media for 24h, followed by a media change to Dulbecco's modified Eagle's medium (DMEM) containing 1% Nutridoma-SP to obtain a serum-deficient environment for 24h before treatment. <b style='color:DodgerBlue;'><i>Treatments</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>recombinant</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:MediumOrchid;'><i>leptin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>100nM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>recombinant</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>IL-6</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.3</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>3nM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>recombinant</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:MediumOrchid;'><i>erythropoietin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Epo</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mU/ml</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Cells were harvested 30min-48h after treatment and whole cell lysates were analyzed using immunoblots or luciferase assays. ### results Treatment of cells with <b style='color:Tomato;'><i>leptin</i></b> resulted in activation of Janus kinase 2 (JAK2) and subsequent phosphorylation of specific tyrosine residues on LRb, followed by dose- and time-dependent increases in the expression of Frizzled-1 (FZD1) and Frizzled-7 (FZD7). <b style='color:Tomato;'><i>leptin</i></b>-mediated increases in the expression of FZD1 were blocked by pre-treatment with the protein synthesis inhibitor cycloheximide or the JAK2 inhibitor AG490. Experiments using a series of hybrid Epo extracellular domain-<b style='color:Tomato;'><i>leptin</i></b> intracellular domain receptors (ELR) harboring mutations of specific tyrosine residues in the cytoplasmic tail showed that increases in the expression of FZD1 were dependent on LRb-mediated phosphorylation of STAT3, but not ERK1/2 or STAT5. <b style='color:Tomato;'><i>leptin</i></b> pre-treatment of chondrocytes prior to Wnt3a stimulation resulted in an increased magnitude of canonical Wnt signaling. ### conclusion These experiments show that <b style='color:Tomato;'><i>leptin</i></b>-LRb signaling in articular chondrocytes modulates expression of canonical Wnt signaling receptors and suggests that direct cross-talk between these pathways is important in determining chondrocyte homeostasis.","tokens":[{"text":"Treatments","start":0,"end":10,"id":0,"ws":true},{"text":"included","start":11,"end":19,"id":1,"ws":true},{"text":"recombinant","start":20,"end":31,"id":2,"ws":true},{"text":"human","start":32,"end":37,"id":3,"ws":true},{"text":"leptin","start":38,"end":44,"id":4,"ws":true},{"text":"(","start":45,"end":46,"id":5,"ws":true},{"text":"10","start":47,"end":49,"id":6,"ws":true},{"text":"-","start":50,"end":51,"id":7,"ws":true},{"text":"100nM","start":52,"end":57,"id":8,"ws":true},{"text":")","start":58,"end":59,"id":9,"ws":true},{"text":",","start":60,"end":61,"id":10,"ws":true},{"text":"recombinant","start":62,"end":73,"id":11,"ws":true},{"text":"human","start":74,"end":79,"id":12,"ws":true},{"text":"IL-6","start":80,"end":84,"id":13,"ws":true},{"text":"(","start":85,"end":86,"id":14,"ws":true},{"text":"0.3","start":87,"end":90,"id":15,"ws":true},{"text":"-","start":91,"end":92,"id":16,"ws":true},{"text":"3nM","start":93,"end":96,"id":17,"ws":true},{"text":")","start":97,"end":98,"id":18,"ws":true},{"text":",","start":99,"end":100,"id":19,"ws":true},{"text":"or","start":101,"end":103,"id":20,"ws":true},{"text":"recombinant","start":104,"end":115,"id":21,"ws":true},{"text":"human","start":116,"end":121,"id":22,"ws":true},{"text":"erythropoietin","start":122,"end":136,"id":23,"ws":true},{"text":"(","start":137,"end":138,"id":24,"ws":true},{"text":"Epo","start":139,"end":142,"id":25,"ws":true},{"text":")","start":143,"end":144,"id":26,"ws":true},{"text":"(","start":145,"end":146,"id":27,"ws":true},{"text":"10mU/ml","start":147,"end":154,"id":28,"ws":true},{"text":")","start":155,"end":156,"id":29,"ws":true},{"text":".","start":157,"end":158,"id":30,"ws":false}],"spans":[{"start":38,"end":44,"token_start":4,"token_end":4,"label":"DRUG"},{"start":122,"end":136,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20868760/","_input_hash":-1740623549,"_task_hash":194071785,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Lenalidomide is currently being tested in combination with both standard and novel agents , including bortezomib , for patients with relapsed/refractory multiple myeloma .","paragraph":"<h3><u>Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.</u></h3>The immunomodulatory drug (IMiD) <b style='color:Tomato;'><i>lenalidomide</i></b> is a more potent immunomodulator than <b style='color:Tomato;'><i>thalidomide</i></b> with respect to its effects on cytokine modulation and increased T-cell proliferation. Of all the IMiDs, clinical trial data are most mature for <b style='color:Tomato;'><i>lenalidomide</i></b>. In phase I studies, dose-limiting toxicities of <b style='color:Tomato;'><i>lenalidomide</i></b> were limited to myelosuppression and a response rate of 72% was seen in relapsed/refractory patients. Three phase II studies subsequently evaluated the efficacy of single-agent <b style='color:Tomato;'><i>lenalidomide</i></b> or <b style='color:Tomato;'><i>lenalidomide</i></b> in combination with <b style='color:Tomato;'><i>dexamethasone</i></b>. As a single agent for post-transplant salvage therapy, <b style='color:Tomato;'><i>lenalidomide</i></b> 25 mg every 3 weeks has shown response rates as high as 44%. For patients with relapsed/refractory multiple myeloma, the MM-007 study has shown that <b style='color:Tomato;'><i>lenalidomide</i></b> alone or in combination with <b style='color:Tomato;'><i>dexamethasone</i></b> provides response rates between 37% and 41%. In MM-007, median progression-free survival was 5.5 months at early analysis and the median overall survival has yet to be reached. Preliminary data for the single-arm, multicenter, open-label MM-014 study showed that median time to progression was 5.6 months. Response rates indicate that 70% of patients had stable disease or better as the best response to treatment. Two randomized, phase III trials (MM-009 and MM-010) evaluated <b style='color:Tomato;'><i>lenalidomide</i></b> with high-dose <b style='color:Tomato;'><i>dexamethasone</i></b> versus high-dose <b style='color:Tomato;'><i>dexamethasone</i></b> alone for the treatment of relapsed/refractory multiple myeloma. Both MM-009 and MM-010 provided remarkably similar response rates for patients receiving <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b>. In both trials response rates with the combination were greater than twice the response rates seen with high-dose <b style='color:Tomato;'><i>dexamethasone</i></b> alone. Indeed, an independent Data Monitoring Committee determined that both trials exceeded the prespecified efficacy value of P<.0015, recommending that the trials be discontinued and that <b style='color:Tomato;'><i>lenalidomide</i></b> be offered to patients on the <b style='color:Tomato;'><i>dexamethasone</i></b> arm of the trial if clinically indicated. Toxicities observed in studies of <b style='color:Tomato;'><i>lenalidomide</i></b> alone were low; the incidence of peripheral neuropathy was significantly lower than those noted in trials using <b style='color:Tomato;'><i>thalidomide</i></b>. Thrombocytopenia was a significant grade 3 or 4 toxicity observed; however, it was manageable with dose reduction. In contrast with high-dose <b style='color:Tomato;'><i>dexamethasone</i></b>, deep vein thrombosis has emerged as an important toxicity. <b style='color:MediumOrchid;'><i>Lenalidomide</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>currently</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>tested</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>novel</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>relapsed/refractory</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>myeloma</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Lenalidomide","start":0,"end":12,"id":0,"ws":true},{"text":"is","start":13,"end":15,"id":1,"ws":true},{"text":"currently","start":16,"end":25,"id":2,"ws":true},{"text":"being","start":26,"end":31,"id":3,"ws":true},{"text":"tested","start":32,"end":38,"id":4,"ws":true},{"text":"in","start":39,"end":41,"id":5,"ws":true},{"text":"combination","start":42,"end":53,"id":6,"ws":true},{"text":"with","start":54,"end":58,"id":7,"ws":true},{"text":"both","start":59,"end":63,"id":8,"ws":true},{"text":"standard","start":64,"end":72,"id":9,"ws":true},{"text":"and","start":73,"end":76,"id":10,"ws":true},{"text":"novel","start":77,"end":82,"id":11,"ws":true},{"text":"agents","start":83,"end":89,"id":12,"ws":true},{"text":",","start":90,"end":91,"id":13,"ws":true},{"text":"including","start":92,"end":101,"id":14,"ws":true},{"text":"bortezomib","start":102,"end":112,"id":15,"ws":true},{"text":",","start":113,"end":114,"id":16,"ws":true},{"text":"for","start":115,"end":118,"id":17,"ws":true},{"text":"patients","start":119,"end":127,"id":18,"ws":true},{"text":"with","start":128,"end":132,"id":19,"ws":true},{"text":"relapsed/refractory","start":133,"end":152,"id":20,"ws":true},{"text":"multiple","start":153,"end":161,"id":21,"ws":true},{"text":"myeloma","start":162,"end":169,"id":22,"ws":true},{"text":".","start":170,"end":171,"id":23,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":102,"end":112,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16344100/","_input_hash":1359763474,"_task_hash":-790446239,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":0,"child":15,"head_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":102,"end":112,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":0,"child":15,"head_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":102,"end":112,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":15,"child":0,"head_span":{"start":102,"end":112,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":0,"child":15,"head_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":102,"end":112,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":15,"child":0,"head_span":{"start":102,"end":112,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":0,"child":15,"head_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":102,"end":112,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"[ Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder ] .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>fluvoxamine</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>extended-release</i></b> <b style='color:MediumOrchid;'><i>methylphenidate</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>treatment-refractory</i></b> <b style='color:DodgerBlue;'><i>obsessive-compulsive</i></b> <b style='color:DodgerBlue;'><i>disorder</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>To observe the clinical efficacy of dopamine modulator <b style='color:Tomato;'><i>methylphenidate</i></b> (MPH) of extended-release formulations (MPH-ER) augmentation of ongoing <b style='color:Tomato;'><i>fluvoxamine</i></b> treatment in refractory obsessive-compulsive disorder (OCD) and its effects on patient's anxiety and sleep quality.\u2029 Methods: A pilot randomized, placebo-controlled, and double-blind trial was conducted at an outpatient, single-center academic setting. Participants included 44 adults with serotonin reuptake inhibitor treatment-refractory OCD and they received a stable <b style='color:Tomato;'><i>fluvoxamine</i></b> pharmacotherapy with Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores higher than 20. The 44 patients were randomly assigned into a study group and a control group, with 22 patiencs in each group. <b style='color:Tomato;'><i>fluvoxamine</i></b> and MPH-ER were given to the study group, while <b style='color:Tomato;'><i>fluvoxamine</i></b> and placebo were given to the control group, with 8 weeks of the treatment course. Y-BOCS, Hamilton Anxiety Scale (HAMA) were used to assess the efficacy, Pittsburgh Sleep Quality Index (PSQI) was used to evaluate the sleep quality, and Treatment Emergent Symptom Scale (TESS) was used to evaluate the side effects. Data were analyzed in the intention-to-treat sample.\u2029 Results: The improvement in the Y-BOCS total score, Y-BOCS obsession subscale score and HAMA score were more prominent in the study group than those in the control group (P<0.001). There was no significant difference in PSQI score and TESS score between the two groups. MPH-ER was well tolerated.\u2029 Conclusion: <b style='color:Tomato;'><i>fluvoxamine</i></b> combined with MPH-ER is effective in the treatment of refractory obsessive-compulsive disorder. It can improve anxiety and has no adverse effect on sleep quality.","tokens":[{"text":"[","start":0,"end":1,"id":0,"ws":true},{"text":"Efficacy","start":2,"end":10,"id":1,"ws":true},{"text":"of","start":11,"end":13,"id":2,"ws":true},{"text":"fluvoxamine","start":14,"end":25,"id":3,"ws":true},{"text":"combined","start":26,"end":34,"id":4,"ws":true},{"text":"with","start":35,"end":39,"id":5,"ws":true},{"text":"extended-release","start":40,"end":56,"id":6,"ws":true},{"text":"methylphenidate","start":57,"end":72,"id":7,"ws":true},{"text":"on","start":73,"end":75,"id":8,"ws":true},{"text":"treatment-refractory","start":76,"end":96,"id":9,"ws":true},{"text":"obsessive-compulsive","start":97,"end":117,"id":10,"ws":true},{"text":"disorder","start":118,"end":126,"id":11,"ws":true},{"text":"]","start":127,"end":128,"id":12,"ws":true},{"text":".","start":129,"end":130,"id":13,"ws":false}],"spans":[{"start":14,"end":25,"token_start":3,"token_end":3,"label":"DRUG"},{"start":57,"end":72,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30643068/","_input_hash":-767498389,"_task_hash":1931454393,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":3,"child":7,"head_span":{"start":14,"end":25,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":57,"end":72,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The aim of this paper is to compare intravitreous aflibercept versus dexamethasone implant followed by aflibercept ( sequential treatment group ) in patients with diabetic macular edema ( DME ) .","paragraph":"<h3><u>Sequential Dexamethasone and Aflibercept Treatment in Patients with Diabetic Macular Edema: Structural and Functional Outcomes at 52 Weeks.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>paper</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>intravitreous</i></b> <b style='color:MediumOrchid;'><i>aflibercept</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>implant</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>aflibercept</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>diabetic</i></b> <b style='color:DodgerBlue;'><i>macular</i></b> <b style='color:DodgerBlue;'><i>edema</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DME</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods We conducted an observational retrospective study in na\u00efve DME patients, 15 treated only with <b style='color:Tomato;'><i>aflibercept</i></b> (a monthly injection for the first 5 consecutive doses, followed by an injection every 2 months), and 15 treated with a single <b style='color:Tomato;'><i>dexamethasone</i></b> implant followed by bimonthly <b style='color:Tomato;'><i>aflibercept</i></b>. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and qualitative features as well as adverse events were assessed at baseline and at 2, 6, and 12 months. ### results BCVA increased from 70.8 \u00b1 4.1 to 83.5 \u00b1 2.7 letters with <b style='color:Tomato;'><i>aflibercept</i></b> and from 75.6 \u00b1 2.7 to 86.5 \u00b1 2.5 with sequential treatment (p = 0.551). CMT decreased from 411 \u00b1 26.1 to 288.1 \u00b1 10.5 with <b style='color:Tomato;'><i>aflibercept</i></b> and from 411.4 \u00b1 24.3 to 260.8 \u00b1 17.9 in the sequential treatment group. The differences between the 2 groups, in terms of visual gain and decreased MT, were not statistically significant (p > 0.05). Nine and 6 injections and 9 and 7 monitoring visits were performed. ### conclusion Sequential treatment in DME, starting with <b style='color:Tomato;'><i>dexamethasone</i></b> and followed by <b style='color:Tomato;'><i>aflibercept</i></b>, is a promising alternative that can reduce the treatment burden in the first year without statistically significant differences in terms of visual gain and decreased MT compared to <b style='color:Tomato;'><i>aflibercept</i></b> only.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"this","start":11,"end":15,"id":3,"ws":true},{"text":"paper","start":16,"end":21,"id":4,"ws":true},{"text":"is","start":22,"end":24,"id":5,"ws":true},{"text":"to","start":25,"end":27,"id":6,"ws":true},{"text":"compare","start":28,"end":35,"id":7,"ws":true},{"text":"intravitreous","start":36,"end":49,"id":8,"ws":true},{"text":"aflibercept","start":50,"end":61,"id":9,"ws":true},{"text":"versus","start":62,"end":68,"id":10,"ws":true},{"text":"dexamethasone","start":69,"end":82,"id":11,"ws":true},{"text":"implant","start":83,"end":90,"id":12,"ws":true},{"text":"followed","start":91,"end":99,"id":13,"ws":true},{"text":"by","start":100,"end":102,"id":14,"ws":true},{"text":"aflibercept","start":103,"end":114,"id":15,"ws":true},{"text":"(","start":115,"end":116,"id":16,"ws":true},{"text":"sequential","start":117,"end":127,"id":17,"ws":true},{"text":"treatment","start":128,"end":137,"id":18,"ws":true},{"text":"group","start":138,"end":143,"id":19,"ws":true},{"text":")","start":144,"end":145,"id":20,"ws":true},{"text":"in","start":146,"end":148,"id":21,"ws":true},{"text":"patients","start":149,"end":157,"id":22,"ws":true},{"text":"with","start":158,"end":162,"id":23,"ws":true},{"text":"diabetic","start":163,"end":171,"id":24,"ws":true},{"text":"macular","start":172,"end":179,"id":25,"ws":true},{"text":"edema","start":180,"end":185,"id":26,"ws":true},{"text":"(","start":186,"end":187,"id":27,"ws":true},{"text":"DME","start":188,"end":191,"id":28,"ws":true},{"text":")","start":192,"end":193,"id":29,"ws":true},{"text":".","start":194,"end":195,"id":30,"ws":false}],"spans":[{"start":50,"end":61,"token_start":9,"token_end":9,"label":"DRUG"},{"start":69,"end":82,"token_start":11,"token_end":11,"label":"DRUG"},{"start":103,"end":114,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29996128/","_input_hash":1169541204,"_task_hash":-1114662394,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":11,"child":15,"head_span":{"start":69,"end":82,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":103,"end":114,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Analysis of HER Family ( HER1 - 4 ) Expression as a Biomarker in Combination Therapy with Pertuzumab , Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Analysis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>HER</i></b> <b style='color:DodgerBlue;'><i>Family</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HER1</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>Expression</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>Biomarker</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>Therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Pertuzumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Trastuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Docetaxel</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>Breast</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Chemotherapy with <b style='color:Tomato;'><i>trastuzumab</i></b>, <b style='color:Tomato;'><i>pertuzumab</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> (TPD regimen) is now strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER)2-positive breast cancer. In this study, we analyzed the expression of HER 1-4 proteins, and investigated whether or not their expression was predictive of the response of advanced HER2-positive breast cancer to chemotherapy with the TPD regimen. ### Patients And Methods The study consisted of 29 cases in which TPD regimen chemotherapy was carried out from September 2013 to November 2015. The expression levels of estrogen receptor (ER), progesterone receptor (PgR), Ki67, HER1, HER2, HER3 and HER4 were evaluated using immunostaining employing needle biopsy specimens. ### results The overall response rate (ORR) was significantly higher in the HER3-positive group than in the HER3-negative group (p=0.002). In prognostic analysis, the HER3-positive group showed a significant progression-free survival extension over the HER3-negative group (p=0.042, log-rank). In univariate analysis, objective response (p=0.004, hazard ratio(HR)=0.123) and positive HER3 expression (p=0.023, HR=0.279) significantly contributed to extension of progression-free survival interval. ### conclusion HER3 expression may be a useful factor for predicting the response of HER2-positive breast cancer to chemotherapy with the TPD regimen.","tokens":[{"text":"Analysis","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"HER","start":12,"end":15,"id":2,"ws":true},{"text":"Family","start":16,"end":22,"id":3,"ws":true},{"text":"(","start":23,"end":24,"id":4,"ws":true},{"text":"HER1","start":25,"end":29,"id":5,"ws":true},{"text":"-","start":30,"end":31,"id":6,"ws":true},{"text":"4","start":32,"end":33,"id":7,"ws":true},{"text":")","start":34,"end":35,"id":8,"ws":true},{"text":"Expression","start":36,"end":46,"id":9,"ws":true},{"text":"as","start":47,"end":49,"id":10,"ws":true},{"text":"a","start":50,"end":51,"id":11,"ws":true},{"text":"Biomarker","start":52,"end":61,"id":12,"ws":true},{"text":"in","start":62,"end":64,"id":13,"ws":true},{"text":"Combination","start":65,"end":76,"id":14,"ws":true},{"text":"Therapy","start":77,"end":84,"id":15,"ws":true},{"text":"with","start":85,"end":89,"id":16,"ws":true},{"text":"Pertuzumab","start":90,"end":100,"id":17,"ws":true},{"text":",","start":101,"end":102,"id":18,"ws":true},{"text":"Trastuzumab","start":103,"end":114,"id":19,"ws":true},{"text":"and","start":115,"end":118,"id":20,"ws":true},{"text":"Docetaxel","start":119,"end":128,"id":21,"ws":true},{"text":"for","start":129,"end":132,"id":22,"ws":true},{"text":"Advanced","start":133,"end":141,"id":23,"ws":true},{"text":"HER2-positive","start":142,"end":155,"id":24,"ws":true},{"text":"Breast","start":156,"end":162,"id":25,"ws":true},{"text":"Cancer","start":163,"end":169,"id":26,"ws":true},{"text":".","start":170,"end":171,"id":27,"ws":false}],"spans":[{"start":90,"end":100,"token_start":17,"token_end":17,"label":"DRUG"},{"start":103,"end":114,"token_start":19,"token_end":19,"label":"DRUG"},{"start":119,"end":128,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29599351/","_input_hash":1999238941,"_task_hash":-1728277947,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":17,"child":19,"head_span":{"start":90,"end":100,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":103,"end":114,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":21,"child":19,"head_span":{"start":119,"end":128,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":103,"end":114,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Hepatic arterial infusion of floxuridine and systemic administration of gemcitabine and oxaliplatin .","paragraph":"<h3><u>Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.</u></h3>Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients. ### objective To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC. ### Design Setting And Participants A single-institution, phase 2 clinical trial including 38 patients was conducted with HAI <b style='color:Tomato;'><i>floxuridine</i></b> plus systemic <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>oxaliplatin</i></b> in patients with unresectable IHC at Memorial Sloan Kettering Cancer Center between May 20, 2013, and June 27, 2019. A confirmatory phase 1/2 study using the same therapy was conducted during the same time period at Washington University in St Louis. Patients with histologically confirmed, unresectable IHC were eligible. Resectable metastatic disease to regional lymph nodes and prior systemic therapy were permitted. Patients with distant metastatic disease were excluded. ### interventions <b style='color:DodgerBlue;'><i>Hepatic</i></b> <b style='color:DodgerBlue;'><i>arterial</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>floxuridine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Main Outcomes And Measures The primary outcome was progression-free survival (PFS) of 80% at 6 months. ### results For the phase 2 clinical trial at Memorial Sloan Kettering Cancer Center, 42 patients with unresectable IHC were included and, of these, 38 patients were treated (13 [34%] men; median [range] age at diagnosis, 64 [39-81] years). The median follow-up was 30.5 months. Twenty-two patients (58%) achieved a partial radiographic response, and 32 patients (84%) achieved disease control at 6 months. Four patients had sufficient response to undergo resection, and 1 patient had a complete pathologic response. The median PFS was 11.8 months (1-sided 90% CI, 11.1) with a 6-month PFS rate of 84.1% (90% CI, 74.8%-infinity), thereby meeting the primary end point (6-month PFS rate, 80%). The median OS was 25.0 months (95% CI, 20.6-not reached), and the 1-year OS rate was 89.5% (95% CI, 80.2%-99.8%). Patients with resectable regional lymph nodes (18 [47%]) showed no difference in OS compared with patients with node-negative disease (24-month OS: lymph node negative: 60%; 95% CI, 40%-91% vs lymph node positive: 50%; 95% CI, 30%-83%; P\u2009=\u2009.66). Four patients (11%) had grade 4 toxic effects requiring removal from the study (1 portal hypertension, 2 gastroduodenal artery aneurysms, 1 infection in the pump pocket). Subgroup analysis showed significant improvement in survival in patients with IDH1/2 mutated tumors (2-year OS, 90%; 95% CI, 73%-99%) vs wild-type (2-year OS, 33%; 95% CI, 18%-63%) (P\u2009=\u2009.01). In the Washington University in St Louis confirmatory cohort, 9 patients (90%) achieved disease control at 6 months; the most common grade 3 toxic effect was elevated results of liver function tests, and median PFS was 12.8 months (1-sided 90% CI, 6.4). ### Conclusions And Relevance Hepatic arterial infusion plus systemic chemotherapy appears to be highly active and tolerable in patients with unresectable IHC; further evaluation is warranted.","tokens":[{"text":"Hepatic","start":0,"end":7,"id":0,"ws":true},{"text":"arterial","start":8,"end":16,"id":1,"ws":true},{"text":"infusion","start":17,"end":25,"id":2,"ws":true},{"text":"of","start":26,"end":28,"id":3,"ws":true},{"text":"floxuridine","start":29,"end":40,"id":4,"ws":true},{"text":"and","start":41,"end":44,"id":5,"ws":true},{"text":"systemic","start":45,"end":53,"id":6,"ws":true},{"text":"administration","start":54,"end":68,"id":7,"ws":true},{"text":"of","start":69,"end":71,"id":8,"ws":true},{"text":"gemcitabine","start":72,"end":83,"id":9,"ws":true},{"text":"and","start":84,"end":87,"id":10,"ws":true},{"text":"oxaliplatin","start":88,"end":99,"id":11,"ws":true},{"text":".","start":100,"end":101,"id":12,"ws":false}],"spans":[{"start":29,"end":40,"token_start":4,"token_end":4,"label":"DRUG"},{"start":72,"end":83,"token_start":9,"token_end":9,"label":"DRUG"},{"start":88,"end":99,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31670750/","_input_hash":-274891872,"_task_hash":1589466704,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":4,"child":9,"head_span":{"start":29,"end":40,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":72,"end":83,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":11,"head_span":{"start":72,"end":83,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":88,"end":99,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Data from the New Zealand Intensive Medicines Monitoring Programme indicate that celecoxib 200 mg/day and rofecoxib 25 mg/day are/were the most commonly prescribed doses and that 6 % of patients had taken rofecoxib 50 mg/day for longer than recommended .","paragraph":"<h3><u>Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?</u></h3>Chronic pain in the elderly is frequently a result of arthritic disorders, particularly osteoarthritis. The cyclo-oxygenase (COX)-2 inhibitors are as effective as standard NSAIDs for the relief of pain and for improving function in elderly patients with osteoarthritis and rheumatoid arthritis. COX-2 inhibitors increase the risk of serious gastroduodenal adverse reactions but there is evidence that they carry a lower risk for these adverse effects than standard NSAIDs, except when there is concurrent <b style='color:Tomato;'><i>aspirin</i></b> use. Since gastroduodenal disorders are the most frequently reported serious adverse effects of NSAIDs and these disorders occur more frequently in the elderly, COX-2 inhibitors offer an alternative to standard NSAIDs in this age group. However, they are not appropriate for many patients with cardiovascular and renal disease. The adverse reaction profile of the COX-2 inhibitors has confirmed the role of the COX-2 enzyme in renal function, salt and water homeostasis and the vascular endothelium. Thus, like standard NSAIDs, COX-2 inhibitors can cause renal failure, hypertension and exacerbation of cardiac failure. Of note is that these disorders are dose related. Thus, there are good reasons to avoid high doses of COX-2 inhibitors in the elderly. Clinical trials indicate that daily doses of <b style='color:Tomato;'><i>rofecoxib</i></b> 12.5 mg, <b style='color:Tomato;'><i>celecoxib</i></b> 100-200 mg, <b style='color:Tomato;'><i>valdecoxib</i></b> 10mg and <b style='color:Tomato;'><i>etoricoxib</i></b> 60 mg are the minimum effective doses of these agents. <b style='color:DodgerBlue;'><i>Data</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>New</i></b> <b style='color:DodgerBlue;'><i>Zealand</i></b> <b style='color:DodgerBlue;'><i>Intensive</i></b> <b style='color:DodgerBlue;'><i>Medicines</i></b> <b style='color:DodgerBlue;'><i>Monitoring</i></b> <b style='color:DodgerBlue;'><i>Programme</i></b> <b style='color:DodgerBlue;'><i>indicate</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/day</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rofecoxib</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>mg/day</i></b> <b style='color:DodgerBlue;'><i>are/were</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>commonly</i></b> <b style='color:DodgerBlue;'><i>prescribed</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>taken</i></b> <b style='color:MediumOrchid;'><i>rofecoxib</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg/day</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>longer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Recent research indicates that COX-2 inhibitors have a thrombotic potential, especially in high doses and when use is prolonged, and this further limits the extent to which they can be used in the elderly. Important interactions with COX-2 inhibitors in the elderly include those with <b style='color:Tomato;'><i>warfarin</i></b>, which can result in loss of control of anticoagulation, and those with ACE inhibitors, angiotensin II type 1 receptor antagonists and diuretics, which can result in loss of control of blood pressure and cardiac failure and, in hypovolaemic conditions, renal failure. The clinical significance of an interaction between <b style='color:Tomato;'><i>celecoxib</i></b> and <b style='color:Tomato;'><i>aspirin</i></b> to reduce the antiplatelet effect of the latter drug is unknown. Preliminary information from spontaneous reporting systems indicates that there may be differences in the risk of cardiac failure and hypertension between standard NSAIDs and COX-2 inhibitors and between <b style='color:Tomato;'><i>rofecoxib</i></b> and <b style='color:Tomato;'><i>celecoxib</i></b>. More formal studies using equivalent doses are needed to test this observation. Use of COX-2 inhibitors may be considered in the elderly to reduce the risk of gastroduodenal complications associated with standard NSAIDs but only when consideration has first been given to use of less toxic medicines as alternatives or supplements, the appropriate dose of the COX-2 inhibitor or standard NSAID, the presence and possible impact of co-morbidities, and the implications of taking COX-2 inhibitors with any concomitant medications. Equally important is regular monitoring of the patient taking a COX-2 inhibitor for efficacy and adverse effects, and ensuring that the patient has a continuing need to keep taking the drug. Close attention also needs to be paid to intercurrent illnesses and new prescriptions that may reduce the safety of the COX-2 inhibitor. A standard NSAID plus a proton pump inhibitor may be equally effective as a COX-2 inhibitor in reducing the risk of gastroduodenal toxicity and if used the same prescribing advice applies. Current knowledge concerning the thrombotic potential of COX-2 inhibitors suggests that this combination, if tolerated, may be preferable to a COX-2 inhibitor, particularly where prolonged use is required. This knowledge also indicates that for patients with or at high risk of ischaemic heart disease or stroke, COX-2 inhibitors are contraindicated.","tokens":[{"text":"Data","start":0,"end":4,"id":0,"ws":true},{"text":"from","start":5,"end":9,"id":1,"ws":true},{"text":"the","start":10,"end":13,"id":2,"ws":true},{"text":"New","start":14,"end":17,"id":3,"ws":true},{"text":"Zealand","start":18,"end":25,"id":4,"ws":true},{"text":"Intensive","start":26,"end":35,"id":5,"ws":true},{"text":"Medicines","start":36,"end":45,"id":6,"ws":true},{"text":"Monitoring","start":46,"end":56,"id":7,"ws":true},{"text":"Programme","start":57,"end":66,"id":8,"ws":true},{"text":"indicate","start":67,"end":75,"id":9,"ws":true},{"text":"that","start":76,"end":80,"id":10,"ws":true},{"text":"celecoxib","start":81,"end":90,"id":11,"ws":true},{"text":"200","start":91,"end":94,"id":12,"ws":true},{"text":"mg/day","start":95,"end":101,"id":13,"ws":true},{"text":"and","start":102,"end":105,"id":14,"ws":true},{"text":"rofecoxib","start":106,"end":115,"id":15,"ws":true},{"text":"25","start":116,"end":118,"id":16,"ws":true},{"text":"mg/day","start":119,"end":125,"id":17,"ws":true},{"text":"are/were","start":126,"end":134,"id":18,"ws":true},{"text":"the","start":135,"end":138,"id":19,"ws":true},{"text":"most","start":139,"end":143,"id":20,"ws":true},{"text":"commonly","start":144,"end":152,"id":21,"ws":true},{"text":"prescribed","start":153,"end":163,"id":22,"ws":true},{"text":"doses","start":164,"end":169,"id":23,"ws":true},{"text":"and","start":170,"end":173,"id":24,"ws":true},{"text":"that","start":174,"end":178,"id":25,"ws":true},{"text":"6","start":179,"end":180,"id":26,"ws":true},{"text":"%","start":181,"end":182,"id":27,"ws":true},{"text":"of","start":183,"end":185,"id":28,"ws":true},{"text":"patients","start":186,"end":194,"id":29,"ws":true},{"text":"had","start":195,"end":198,"id":30,"ws":true},{"text":"taken","start":199,"end":204,"id":31,"ws":true},{"text":"rofecoxib","start":205,"end":214,"id":32,"ws":true},{"text":"50","start":215,"end":217,"id":33,"ws":true},{"text":"mg/day","start":218,"end":224,"id":34,"ws":true},{"text":"for","start":225,"end":228,"id":35,"ws":true},{"text":"longer","start":229,"end":235,"id":36,"ws":true},{"text":"than","start":236,"end":240,"id":37,"ws":true},{"text":"recommended","start":241,"end":252,"id":38,"ws":true},{"text":".","start":253,"end":254,"id":39,"ws":false}],"spans":[{"start":81,"end":90,"token_start":11,"token_end":11,"label":"DRUG"},{"start":106,"end":115,"token_start":15,"token_end":15,"label":"DRUG"},{"start":205,"end":214,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15813652/","_input_hash":905235402,"_task_hash":1331266131,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Patients with advanced solid tumors received standard doses of paclitaxel and carboplatin on day 1 followed by either 0.1 mg/Kg or 0.2 mg/Kg CP-870,893 on day 3 ( Schedule A ) or day 8 ( Schedule B ) , repeated every 21 d.","paragraph":"<h3><u>Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.</u></h3>CD40 is a cell-surface molecule that critically regulates immune responses. CP-870,893 is a fully human, CD40-specific agonist monoclonal antibody (mAb) exerting clinical antineoplastic activity. Here, the safety of CP-870,893 combined with <b style='color:Tomato;'><i>carboplatin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> was assessed in a Phase I study. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>solid</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>0.1</i></b> <b style='color:DodgerBlue;'><i>mg/Kg</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>0.2</i></b> <b style='color:DodgerBlue;'><i>mg/Kg</i></b> <b style='color:DodgerBlue;'><i>CP-870,893</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Schedule</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Schedule</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>repeated</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>d.</i></b> The primary objective was to determine safety and maximum-tolerated dose (MTD) of CP-870,893. Secondary objectives included the evaluation of antitumor responses, pharmacokinetics and immune modulation. Thirty-two patients were treated with CP-870,893, 16 patients on each schedule. Two dose-limiting toxicities were observed (grade 3 cytokine release and transient ischemic attack), each at the 0.2 mg/Kg dose level, which was estimated to be the MTD. The most common treatment-related adverse event was fatigue (81%). Of 30 evaluable patients, 6 (20%) exhibited partial responses constituting best responses as defined by RECIST. Following CP-870,893 infusion, the peripheral blood manifested an acute depletion of B cells associated with upregulation of immune co-stimulatory molecules. T-cell numbers did not change significantly from baseline, but transient tumor-specific T-cell responses were observed in a small number of evaluable patients. The CD40 agonist mAb CP-870,893, given on either of two schedules in combination with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>, was safe for patients affected with advanced solid tumors. Biological and clinical responses were observed, providing a rationale for Phase II studies.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"with","start":9,"end":13,"id":1,"ws":true},{"text":"advanced","start":14,"end":22,"id":2,"ws":true},{"text":"solid","start":23,"end":28,"id":3,"ws":true},{"text":"tumors","start":29,"end":35,"id":4,"ws":true},{"text":"received","start":36,"end":44,"id":5,"ws":true},{"text":"standard","start":45,"end":53,"id":6,"ws":true},{"text":"doses","start":54,"end":59,"id":7,"ws":true},{"text":"of","start":60,"end":62,"id":8,"ws":true},{"text":"paclitaxel","start":63,"end":73,"id":9,"ws":true},{"text":"and","start":74,"end":77,"id":10,"ws":true},{"text":"carboplatin","start":78,"end":89,"id":11,"ws":true},{"text":"on","start":90,"end":92,"id":12,"ws":true},{"text":"day","start":93,"end":96,"id":13,"ws":true},{"text":"1","start":97,"end":98,"id":14,"ws":true},{"text":"followed","start":99,"end":107,"id":15,"ws":true},{"text":"by","start":108,"end":110,"id":16,"ws":true},{"text":"either","start":111,"end":117,"id":17,"ws":true},{"text":"0.1","start":118,"end":121,"id":18,"ws":true},{"text":"mg/Kg","start":122,"end":127,"id":19,"ws":true},{"text":"or","start":128,"end":130,"id":20,"ws":true},{"text":"0.2","start":131,"end":134,"id":21,"ws":true},{"text":"mg/Kg","start":135,"end":140,"id":22,"ws":true},{"text":"CP-870,893","start":141,"end":151,"id":23,"ws":true},{"text":"on","start":152,"end":154,"id":24,"ws":true},{"text":"day","start":155,"end":158,"id":25,"ws":true},{"text":"3","start":159,"end":160,"id":26,"ws":true},{"text":"(","start":161,"end":162,"id":27,"ws":true},{"text":"Schedule","start":163,"end":171,"id":28,"ws":true},{"text":"A","start":172,"end":173,"id":29,"ws":true},{"text":")","start":174,"end":175,"id":30,"ws":true},{"text":"or","start":176,"end":178,"id":31,"ws":true},{"text":"day","start":179,"end":182,"id":32,"ws":true},{"text":"8","start":183,"end":184,"id":33,"ws":true},{"text":"(","start":185,"end":186,"id":34,"ws":true},{"text":"Schedule","start":187,"end":195,"id":35,"ws":true},{"text":"B","start":196,"end":197,"id":36,"ws":true},{"text":")","start":198,"end":199,"id":37,"ws":true},{"text":",","start":200,"end":201,"id":38,"ws":true},{"text":"repeated","start":202,"end":210,"id":39,"ws":true},{"text":"every","start":211,"end":216,"id":40,"ws":true},{"text":"21","start":217,"end":219,"id":41,"ws":true},{"text":"d.","start":220,"end":222,"id":42,"ws":false}],"spans":[{"start":63,"end":73,"token_start":9,"token_end":9,"label":"DRUG"},{"start":78,"end":89,"token_start":11,"token_end":11,"label":"DRUG"},{"start":141,"end":151,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23483678/","_input_hash":-2008498010,"_task_hash":614884322,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":63,"end":73,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":78,"end":89,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":11,"child":23,"head_span":{"start":78,"end":89,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":141,"end":151,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Chemoimmunotherapy with cyclophosphamide , doxorubicin , vincristine , and prednisolone combined with rituximab ( R-CHOP ) is currently the first-line therapy for diffuse large B-cell lymphoma ( DLBCL ) .","paragraph":"<h3><u>Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.</u></h3> <b style='color:DodgerBlue;'><i>Chemoimmunotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>R-CHOP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>currently</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>diffuse</i></b> <b style='color:DodgerBlue;'><i>large</i></b> <b style='color:DodgerBlue;'><i>B-cell</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DLBCL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, management of elderly patients is challenging and often requires dose reductions or prolonged treatment intervals. We investigated the proper dose of R-CHOP for them. ### methods At our institute, for DLBCL patients aged 65-79 and \u226580 years, we had reduced CHOP dose to 5/6 and 7/12, respectively, and retrospectively evaluated the reduced-dose R-CHOP. ### results Although the median age in the standard, 5/6, and 7/12-dose groups was 57, 73, and 84 years, respectively (p\u2009<\u20090.001), the 3-year event-free survival (EFS) rate did not differ between the standard and 5/6-dose groups (60.2 and 56.7%); however, 7/12-dose group had significantly inferior survival (25.9%). When patients aged 60-80 were evaluated, no difference in EFS was observed between the standard and 5/6-dose groups using the same international prognostic index. The neutrophil nadir and the frequency of infection were comparable among the three dose groups. ### Discussion And Conclusions Reduced-dose R-CHOP chemotherapy is a promising treatment for elderly patients with DLBCL in terms of efficacy and toxicity.","tokens":[{"text":"Chemoimmunotherapy","start":0,"end":18,"id":0,"ws":true},{"text":"with","start":19,"end":23,"id":1,"ws":true},{"text":"cyclophosphamide","start":24,"end":40,"id":2,"ws":true},{"text":",","start":41,"end":42,"id":3,"ws":true},{"text":"doxorubicin","start":43,"end":54,"id":4,"ws":true},{"text":",","start":55,"end":56,"id":5,"ws":true},{"text":"vincristine","start":57,"end":68,"id":6,"ws":true},{"text":",","start":69,"end":70,"id":7,"ws":true},{"text":"and","start":71,"end":74,"id":8,"ws":true},{"text":"prednisolone","start":75,"end":87,"id":9,"ws":true},{"text":"combined","start":88,"end":96,"id":10,"ws":true},{"text":"with","start":97,"end":101,"id":11,"ws":true},{"text":"rituximab","start":102,"end":111,"id":12,"ws":true},{"text":"(","start":112,"end":113,"id":13,"ws":true},{"text":"R-CHOP","start":114,"end":120,"id":14,"ws":true},{"text":")","start":121,"end":122,"id":15,"ws":true},{"text":"is","start":123,"end":125,"id":16,"ws":true},{"text":"currently","start":126,"end":135,"id":17,"ws":true},{"text":"the","start":136,"end":139,"id":18,"ws":true},{"text":"first-line","start":140,"end":150,"id":19,"ws":true},{"text":"therapy","start":151,"end":158,"id":20,"ws":true},{"text":"for","start":159,"end":162,"id":21,"ws":true},{"text":"diffuse","start":163,"end":170,"id":22,"ws":true},{"text":"large","start":171,"end":176,"id":23,"ws":true},{"text":"B-cell","start":177,"end":183,"id":24,"ws":true},{"text":"lymphoma","start":184,"end":192,"id":25,"ws":true},{"text":"(","start":193,"end":194,"id":26,"ws":true},{"text":"DLBCL","start":195,"end":200,"id":27,"ws":true},{"text":")","start":201,"end":202,"id":28,"ws":true},{"text":".","start":203,"end":204,"id":29,"ws":false}],"spans":[{"start":24,"end":40,"token_start":2,"token_end":2,"label":"DRUG"},{"start":43,"end":54,"token_start":4,"token_end":4,"label":"DRUG"},{"start":57,"end":68,"token_start":6,"token_end":6,"label":"DRUG"},{"start":75,"end":87,"token_start":9,"token_end":9,"label":"DRUG"},{"start":102,"end":111,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30101679/","_input_hash":1662495688,"_task_hash":-1904178057,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":24,"end":40,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":43,"end":54,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":6,"child":4,"head_span":{"start":57,"end":68,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":43,"end":54,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":6,"head_span":{"start":75,"end":87,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":57,"end":68,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":9,"head_span":{"start":102,"end":111,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":75,"end":87,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The purpose of our study was to compare the survival of porcine lung allografts after induction with either cyclosporine A ( CsA ) or tacrolimus .","paragraph":"<h3><u>Tacrolimus versus cyclosporine induction therapy in pulmonary transplantation in miniature swine.</u></h3><b style='color:Tomato;'><i>tacrolimus</i></b> has been shown to provide superior immunosuppression in various solid organ transplant settings. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>purpose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>our</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>porcine</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>allografts</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CsA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>tacrolimus</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Single lung transplantation from MHC mismatched donors was performed in 10 minipigs. Immunosuppression included 1.5 mg/kg per day <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> and 1.0 mg/kg per day <b style='color:Tomato;'><i>azathioprine</i></b>. CsA (n=5) was adjusted to trough levels of 300-500 ng/ml, <b style='color:Tomato;'><i>tacrolimus</i></b> (n=5) was adjusted to 16-26 ng/ml. All immunosuppressive drugs were discontinued on postoperative day (POD) 28. Allograft survival was monitored by sequential chest radiographs, bronchoscopy and transbronchial biopsy histology. Peripheral blood leukocytes were scanned for donor chimerism and CD3, CD4, CD8 and CD25 expression. ### results The animals survived a 4-week course of immunosuppression without radiological or histological signs of rejection on POD 28. Median allograft survival in CsA-treated animals was 55+/-15 days and all animals rejected their grafts within 42 days after withdrawal of immunosuppression. In <b style='color:Tomato;'><i>tacrolimus</i></b>-treated animals, median survival was 152+/-65 days with the longest survivor being electively sacrificed on POD 390 (P=0.0064). The degree of donor leukocyte chimerism and the frequency of CD4+CD25+ T-cells were higher in the <b style='color:Tomato;'><i>tacrolimus</i></b> group, however, these differences were not statistically significant. ### conclusion The results of our study show that primary immunosuppression with <b style='color:Tomato;'><i>tacrolimus</i></b> is superior to <b style='color:Tomato;'><i>cyclosporin</i></b>e after pulmonary allotransplantation in a large animal model.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"purpose","start":4,"end":11,"id":1,"ws":true},{"text":"of","start":12,"end":14,"id":2,"ws":true},{"text":"our","start":15,"end":18,"id":3,"ws":true},{"text":"study","start":19,"end":24,"id":4,"ws":true},{"text":"was","start":25,"end":28,"id":5,"ws":true},{"text":"to","start":29,"end":31,"id":6,"ws":true},{"text":"compare","start":32,"end":39,"id":7,"ws":true},{"text":"the","start":40,"end":43,"id":8,"ws":true},{"text":"survival","start":44,"end":52,"id":9,"ws":true},{"text":"of","start":53,"end":55,"id":10,"ws":true},{"text":"porcine","start":56,"end":63,"id":11,"ws":true},{"text":"lung","start":64,"end":68,"id":12,"ws":true},{"text":"allografts","start":69,"end":79,"id":13,"ws":true},{"text":"after","start":80,"end":85,"id":14,"ws":true},{"text":"induction","start":86,"end":95,"id":15,"ws":true},{"text":"with","start":96,"end":100,"id":16,"ws":true},{"text":"either","start":101,"end":107,"id":17,"ws":true},{"text":"cyclosporine","start":108,"end":120,"id":18,"ws":true},{"text":"A","start":121,"end":122,"id":19,"ws":true},{"text":"(","start":123,"end":124,"id":20,"ws":true},{"text":"CsA","start":125,"end":128,"id":21,"ws":true},{"text":")","start":129,"end":130,"id":22,"ws":true},{"text":"or","start":131,"end":133,"id":23,"ws":true},{"text":"tacrolimus","start":134,"end":144,"id":24,"ws":true},{"text":".","start":145,"end":146,"id":25,"ws":false}],"spans":[{"start":108,"end":120,"token_start":18,"token_end":18,"label":"DRUG"},{"start":134,"end":144,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16054825/","_input_hash":-330025569,"_task_hash":1436666138,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Thirty-two patients with advanced breast carcinoma were randomized to receive increasing doses of paclitaxel ( 45 , 65 , 80 , 90 and 100 mg/m2 ) or docetaxel ( 30 , 35 , 40 , 45 and 50 mg/m2 ) together with the CMF agents at the same dose as that used in the conventional regimen .","paragraph":"<h3><u>Design and development of new combinations of the CMF agents with taxanes (paclitaxel or docetaxel) in advanced breast cancer: a feasibility study.</u></h3>We previously designed and tested combinations made up of the CMF agents, two at a time by rotation, and of <b style='color:Tomato;'><i>doxorubicin</i></b> or <b style='color:Tomato;'><i>epirubicin</i></b>. The present study was aimed to similarly test new combinations made up of the CMF agents, two at a time by rotation, and <b style='color:Tomato;'><i>paclitaxel</i></b> or <b style='color:Tomato;'><i>docetaxel</i></b>. ### methods The doses of each taxane were escalated with the objective of reaching at least a single dose level of 90 mg/m2 of <b style='color:Tomato;'><i>paclitaxel</i></b> and 45 mg/m2 of <b style='color:Tomato;'><i>docetaxel</i></b> on days 1 and 8 of each four-week cycle. <b style='color:DodgerBlue;'><i>Thirty-two</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>increasing</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>45</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>65</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>90</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>45</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>CMF</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>conventional</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Each dose level was administered to a triplet of patients. No direct comparison of the two taxanes was made. ### results The fourth dose level was reached for <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b>. The most important toxicities were grade 4 neutropenia and grade 1-2 nausea/vomiting and stomatitis. The objective response rate, assessed only after the third cycle at any dose level, was 31% (95% CI, 15-47%). ### conclusions The combinations of the CMF agents (two at a time in rotation) with <b style='color:Tomato;'><i>paclitaxel</i></b> (90 mg/m2) or <b style='color:Tomato;'><i>docetaxel</i></b> (45 mg/m2) on days 1 and 8 of each four-week cycle are feasible and lead to definite signs of therapeutic activity, and the side effects are generally mild. Further studies are therefore warranted.","tokens":[{"text":"Thirty-two","start":0,"end":10,"id":0,"ws":true},{"text":"patients","start":11,"end":19,"id":1,"ws":true},{"text":"with","start":20,"end":24,"id":2,"ws":true},{"text":"advanced","start":25,"end":33,"id":3,"ws":true},{"text":"breast","start":34,"end":40,"id":4,"ws":true},{"text":"carcinoma","start":41,"end":50,"id":5,"ws":true},{"text":"were","start":51,"end":55,"id":6,"ws":true},{"text":"randomized","start":56,"end":66,"id":7,"ws":true},{"text":"to","start":67,"end":69,"id":8,"ws":true},{"text":"receive","start":70,"end":77,"id":9,"ws":true},{"text":"increasing","start":78,"end":88,"id":10,"ws":true},{"text":"doses","start":89,"end":94,"id":11,"ws":true},{"text":"of","start":95,"end":97,"id":12,"ws":true},{"text":"paclitaxel","start":98,"end":108,"id":13,"ws":true},{"text":"(","start":109,"end":110,"id":14,"ws":true},{"text":"45","start":111,"end":113,"id":15,"ws":true},{"text":",","start":114,"end":115,"id":16,"ws":true},{"text":"65","start":116,"end":118,"id":17,"ws":true},{"text":",","start":119,"end":120,"id":18,"ws":true},{"text":"80","start":121,"end":123,"id":19,"ws":true},{"text":",","start":124,"end":125,"id":20,"ws":true},{"text":"90","start":126,"end":128,"id":21,"ws":true},{"text":"and","start":129,"end":132,"id":22,"ws":true},{"text":"100","start":133,"end":136,"id":23,"ws":true},{"text":"mg/m2","start":137,"end":142,"id":24,"ws":true},{"text":")","start":143,"end":144,"id":25,"ws":true},{"text":"or","start":145,"end":147,"id":26,"ws":true},{"text":"docetaxel","start":148,"end":157,"id":27,"ws":true},{"text":"(","start":158,"end":159,"id":28,"ws":true},{"text":"30","start":160,"end":162,"id":29,"ws":true},{"text":",","start":163,"end":164,"id":30,"ws":true},{"text":"35","start":165,"end":167,"id":31,"ws":true},{"text":",","start":168,"end":169,"id":32,"ws":true},{"text":"40","start":170,"end":172,"id":33,"ws":true},{"text":",","start":173,"end":174,"id":34,"ws":true},{"text":"45","start":175,"end":177,"id":35,"ws":true},{"text":"and","start":178,"end":181,"id":36,"ws":true},{"text":"50","start":182,"end":184,"id":37,"ws":true},{"text":"mg/m2","start":185,"end":190,"id":38,"ws":true},{"text":")","start":191,"end":192,"id":39,"ws":true},{"text":"together","start":193,"end":201,"id":40,"ws":true},{"text":"with","start":202,"end":206,"id":41,"ws":true},{"text":"the","start":207,"end":210,"id":42,"ws":true},{"text":"CMF","start":211,"end":214,"id":43,"ws":true},{"text":"agents","start":215,"end":221,"id":44,"ws":true},{"text":"at","start":222,"end":224,"id":45,"ws":true},{"text":"the","start":225,"end":228,"id":46,"ws":true},{"text":"same","start":229,"end":233,"id":47,"ws":true},{"text":"dose","start":234,"end":238,"id":48,"ws":true},{"text":"as","start":239,"end":241,"id":49,"ws":true},{"text":"that","start":242,"end":246,"id":50,"ws":true},{"text":"used","start":247,"end":251,"id":51,"ws":true},{"text":"in","start":252,"end":254,"id":52,"ws":true},{"text":"the","start":255,"end":258,"id":53,"ws":true},{"text":"conventional","start":259,"end":271,"id":54,"ws":true},{"text":"regimen","start":272,"end":279,"id":55,"ws":true},{"text":".","start":280,"end":281,"id":56,"ws":false}],"spans":[{"start":98,"end":108,"token_start":13,"token_end":13,"label":"DRUG"},{"start":148,"end":157,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15315305/","_input_hash":583904334,"_task_hash":1892592196,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In a 52-week , open-label , multicenter , extension study , HDL-C , TG , and LDL-C levels continued to improve , or were maintained , during combination therapy with once-daily fenofibric acid 135 mg plus a moderate-dose statin ( atorvastatin 40 mg , rosuvastatin 20 mg , or simvastatin 40 mg ) .","paragraph":"<h3><u>Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.</u></h3><b style='color:Tomato;'><i>fenofibric</i></b> acid activates peroxisome proliferator-activated receptor alpha to modify fatty acid and lipid metabolism. <b style='color:Tomato;'><i>fenofibric</i></b> acid is the first member of the fibric acid derivatives (fibrates) class approved for use as combination therapy with HMG-CoA reductase inhibitors (statins). In three randomized, double-blind, multicenter, phase III trials in adult patients with mixed dyslipidemia, up to 12 weeks' treatment with once-daily <b style='color:Tomato;'><i>fenofibric</i></b> acid 135 mg plus a low- or moderate-dose statin (<b style='color:Tomato;'><i>atorvastatin</i></b> 20 or 40 mg, <b style='color:Tomato;'><i>rosuvastatin</i></b> 10 or 20 mg, or <b style='color:Tomato;'><i>simvastatin</i></b> 20 or 40 mg) improved high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels to a significantly greater extent than statin monotherapy, and improved low-density lipoprotein cholesterol (LDL-C) levels to a significantly greater extent than <b style='color:Tomato;'><i>fenofibric</i></b> acid monotherapy. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>52-week</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>open-label</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>extension</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>HDL-C</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>TG</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>LDL-C</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>continued</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>maintained</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>once-daily</i></b> <b style='color:MediumOrchid;'><i>fenofibric</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>135</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>moderate-dose</i></b> <b style='color:DodgerBlue;'><i>statin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>atorvastatin</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>rosuvastatin</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Once-daily <b style='color:Tomato;'><i>fenofibric</i></b> acid 135 mg plus a statin was generally as well tolerated as monotherapy with <b style='color:Tomato;'><i>fenofibric</i></b> acid 135 mg/day or the corresponding statin dosage in the three phase III trials in patients with mixed dyslipidemia. The incidence of adverse events was similar between the combination therapy group and both monotherapy groups. In the extension trial, once-daily <b style='color:Tomato;'><i>fenofibric</i></b> acid 135 mg plus a moderate-dose statin (<b style='color:Tomato;'><i>atorvastatin</i></b> 40 mg, <b style='color:Tomato;'><i>rosuvastatin</i></b> 20 mg, or <b style='color:Tomato;'><i>simvastatin</i></b> 40 mg) for up to 52 weeks was generally well tolerated.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"a","start":3,"end":4,"id":1,"ws":true},{"text":"52-week","start":5,"end":12,"id":2,"ws":true},{"text":",","start":13,"end":14,"id":3,"ws":true},{"text":"open-label","start":15,"end":25,"id":4,"ws":true},{"text":",","start":26,"end":27,"id":5,"ws":true},{"text":"multicenter","start":28,"end":39,"id":6,"ws":true},{"text":",","start":40,"end":41,"id":7,"ws":true},{"text":"extension","start":42,"end":51,"id":8,"ws":true},{"text":"study","start":52,"end":57,"id":9,"ws":true},{"text":",","start":58,"end":59,"id":10,"ws":true},{"text":"HDL-C","start":60,"end":65,"id":11,"ws":true},{"text":",","start":66,"end":67,"id":12,"ws":true},{"text":"TG","start":68,"end":70,"id":13,"ws":true},{"text":",","start":71,"end":72,"id":14,"ws":true},{"text":"and","start":73,"end":76,"id":15,"ws":true},{"text":"LDL-C","start":77,"end":82,"id":16,"ws":true},{"text":"levels","start":83,"end":89,"id":17,"ws":true},{"text":"continued","start":90,"end":99,"id":18,"ws":true},{"text":"to","start":100,"end":102,"id":19,"ws":true},{"text":"improve","start":103,"end":110,"id":20,"ws":true},{"text":",","start":111,"end":112,"id":21,"ws":true},{"text":"or","start":113,"end":115,"id":22,"ws":true},{"text":"were","start":116,"end":120,"id":23,"ws":true},{"text":"maintained","start":121,"end":131,"id":24,"ws":true},{"text":",","start":132,"end":133,"id":25,"ws":true},{"text":"during","start":134,"end":140,"id":26,"ws":true},{"text":"combination","start":141,"end":152,"id":27,"ws":true},{"text":"therapy","start":153,"end":160,"id":28,"ws":true},{"text":"with","start":161,"end":165,"id":29,"ws":true},{"text":"once-daily","start":166,"end":176,"id":30,"ws":true},{"text":"fenofibric","start":177,"end":187,"id":31,"ws":true},{"text":"acid","start":188,"end":192,"id":32,"ws":true},{"text":"135","start":193,"end":196,"id":33,"ws":true},{"text":"mg","start":197,"end":199,"id":34,"ws":true},{"text":"plus","start":200,"end":204,"id":35,"ws":true},{"text":"a","start":205,"end":206,"id":36,"ws":true},{"text":"moderate-dose","start":207,"end":220,"id":37,"ws":true},{"text":"statin","start":221,"end":227,"id":38,"ws":true},{"text":"(","start":228,"end":229,"id":39,"ws":true},{"text":"atorvastatin","start":230,"end":242,"id":40,"ws":true},{"text":"40","start":243,"end":245,"id":41,"ws":true},{"text":"mg","start":246,"end":248,"id":42,"ws":true},{"text":",","start":249,"end":250,"id":43,"ws":true},{"text":"rosuvastatin","start":251,"end":263,"id":44,"ws":true},{"text":"20","start":264,"end":266,"id":45,"ws":true},{"text":"mg","start":267,"end":269,"id":46,"ws":true},{"text":",","start":270,"end":271,"id":47,"ws":true},{"text":"or","start":272,"end":274,"id":48,"ws":true},{"text":"simvastatin","start":275,"end":286,"id":49,"ws":true},{"text":"40","start":287,"end":289,"id":50,"ws":true},{"text":"mg","start":290,"end":292,"id":51,"ws":true},{"text":")","start":293,"end":294,"id":52,"ws":true},{"text":".","start":295,"end":296,"id":53,"ws":false}],"spans":[{"start":177,"end":187,"token_start":31,"token_end":31,"label":"DRUG"},{"start":230,"end":242,"token_start":40,"token_end":40,"label":"DRUG"},{"start":251,"end":263,"token_start":44,"token_end":44,"label":"DRUG"},{"start":275,"end":286,"token_start":49,"token_end":49,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19929038/","_input_hash":689039642,"_task_hash":-898542825,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":31,"child":40,"head_span":{"start":177,"end":187,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":230,"end":242,"token_start":40,"token_end":40,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":31,"child":44,"head_span":{"start":177,"end":187,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":251,"end":263,"token_start":44,"token_end":44,"label":"DRUG"},"color":"#d9fbad","label":"POS3"},{"head":31,"child":49,"head_span":{"start":177,"end":187,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":275,"end":286,"token_start":49,"token_end":49,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21","POS31"],"answer":"accept"}
{"text":"Cystoid Macular Edema during Treatment with Paclitaxel and Bevacizumab in a Patient with Metastatic Breast Cancer : A Case Report and Literature Review .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Cystoid</i></b> <b style='color:DodgerBlue;'><i>Macular</i></b> <b style='color:DodgerBlue;'><i>Edema</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Bevacizumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>Patient</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>Metastatic</i></b> <b style='color:DodgerBlue;'><i>Breast</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>Case</i></b> <b style='color:DodgerBlue;'><i>Report</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Literature</i></b> <b style='color:DodgerBlue;'><i>Review</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>We present a case of a metastatic breast cancer patient with cystoid macular edema (CME) occurring during treatment with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b>. She had a history of neoadjuvant chemotherapy and partial mastectomy plus axillary lymph node dissection for stage IIB left-breast cancer. Twenty-four months later, she was diagnosed with multiple bone metastases and underwent chemotherapy with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b>. Thirty-three months after the initiation of the chemotherapy, she noticed bilateral blurred vision. The retinal thickening with macular edema was observed by optical coherence tomography, resulting in a diagnosis of CME. With cessation of <b style='color:Tomato;'><i>paclitaxel</i></b> and administrating ocular instillation of a nonsteroidal anti-inflammatory drug, her macular edema gradually reduced and disappeared in a month. While CME caused by chemotherapy is very rare, taxane may cause ocular adverse events such as CME. It is important to urge patients to consult an ophthalmologist promptly when they have visual complaints during taxane chemotherapy.","tokens":[{"text":"Cystoid","start":0,"end":7,"id":0,"ws":true},{"text":"Macular","start":8,"end":15,"id":1,"ws":true},{"text":"Edema","start":16,"end":21,"id":2,"ws":true},{"text":"during","start":22,"end":28,"id":3,"ws":true},{"text":"Treatment","start":29,"end":38,"id":4,"ws":true},{"text":"with","start":39,"end":43,"id":5,"ws":true},{"text":"Paclitaxel","start":44,"end":54,"id":6,"ws":true},{"text":"and","start":55,"end":58,"id":7,"ws":true},{"text":"Bevacizumab","start":59,"end":70,"id":8,"ws":true},{"text":"in","start":71,"end":73,"id":9,"ws":true},{"text":"a","start":74,"end":75,"id":10,"ws":true},{"text":"Patient","start":76,"end":83,"id":11,"ws":true},{"text":"with","start":84,"end":88,"id":12,"ws":true},{"text":"Metastatic","start":89,"end":99,"id":13,"ws":true},{"text":"Breast","start":100,"end":106,"id":14,"ws":true},{"text":"Cancer","start":107,"end":113,"id":15,"ws":true},{"text":":","start":114,"end":115,"id":16,"ws":true},{"text":"A","start":116,"end":117,"id":17,"ws":true},{"text":"Case","start":118,"end":122,"id":18,"ws":true},{"text":"Report","start":123,"end":129,"id":19,"ws":true},{"text":"and","start":130,"end":133,"id":20,"ws":true},{"text":"Literature","start":134,"end":144,"id":21,"ws":true},{"text":"Review","start":145,"end":151,"id":22,"ws":true},{"text":".","start":152,"end":153,"id":23,"ws":false}],"spans":[{"start":44,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},{"start":59,"end":70,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/28868019/","_input_hash":319577669,"_task_hash":1596982348,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":44,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":59,"end":70,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"To compare the safety and efficacy of 2 doses of lamivudine given in combination with zidovudine with continued zidovudine monotherapy .","paragraph":"<h3><u>Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lamivudine</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>zidovudine</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>continued</i></b> <b style='color:MediumOrchid;'><i>zidovudine</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### design Double-blind, randomized, multicenter, comparative trial of 223 patients treated for 24 weeks. ### setting Patients from 32 hospitals in Europe were enrolled throughout a 1-year period. ### patients Adult human immunodeficiency virus type 1 (HIV-1)-positive, <b style='color:Tomato;'><i>zidovudine</i></b>-experienced ( > or = 24 weeks prior <b style='color:Tomato;'><i>zidovudine</i></b>) patients with CD4+ cell counts between 0.10 and 0.40 x 10(9)/L (100-400 cells/microL). ### intervention Patients received either 200 mg of <b style='color:Tomato;'><i>zidovudine</i></b> every 8 hours, 150 mg of <b style='color:Tomato;'><i>lamivudine</i></b> every 12 hours plus <b style='color:Tomato;'><i>zidovudine</i></b>, or 300 mg of <b style='color:Tomato;'><i>lamivudine</i></b> every 12 hours plus <b style='color:Tomato;'><i>zidovudine</i></b> for 24 weeks. All patients were then allowed to receive <b style='color:Tomato;'><i>zidovudine</i></b> and open-label <b style='color:Tomato;'><i>lamivudine</i></b> combination therapy. Twelve patients withdrew because of adverse events during the 24-week treatment period. ### Main Outcome Measures Efficacy was measured by evaluating immunological and viral load changes, and safety was assessed by evaluating clinical manifestations and laboratory indexes of toxic effects. ### results Patients receiving low- or high-dose combination therapy had greater treatment effects compared with patients receiving continued <b style='color:Tomato;'><i>zidovudine</i></b> monotherapy during the first 24 weeks as documented by changes in CD4+ cell counts (+0.04 vs +0.03 vs -0.02 x 10(9)/L, respectively; P < .001); log10 HIV-1 RNA as measured by the Roche assay (-0.96 vs -0.77 vs +0.07 copies/mL, respectively; P < .001) or log10 HIV-1 RNA measured by the quantitative nucleic acid sequence-based amplification assay (-0.59 vs -1.06 vs -0.02 copies/mL, respectively; P < .011); and immune-complex dissociated (ICD) p24 antigen (-74% vs -68% vs +27%, respectively; P < .001). There were no statistically significant differences in viral measurements, in CD4+ cell counts, or in safety profile between the groups receiving 2 doses of <b style='color:Tomato;'><i>lamivudine</i></b> in combination with <b style='color:Tomato;'><i>zidovudine</i></b>. The effects on CD4+ cell counts and ICD p24 antigen were sustained throughout 48 weeks for patients continuing combination therapy. Patients switching to combination therapy at week 24 showed improvement. ### conclusion In <b style='color:Tomato;'><i>zidovudine</i></b>-experienced HIV-1-infected patients, combination treatment with <b style='color:Tomato;'><i>lamivudine</i></b> and <b style='color:Tomato;'><i>zidovudine</i></b> is well tolerated and provides greater and more sustained increases in CD4+ cell counts and decreases in viral load than continued <b style='color:Tomato;'><i>zidovudine</i></b> monotherapy.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"compare","start":3,"end":10,"id":1,"ws":true},{"text":"the","start":11,"end":14,"id":2,"ws":true},{"text":"safety","start":15,"end":21,"id":3,"ws":true},{"text":"and","start":22,"end":25,"id":4,"ws":true},{"text":"efficacy","start":26,"end":34,"id":5,"ws":true},{"text":"of","start":35,"end":37,"id":6,"ws":true},{"text":"2","start":38,"end":39,"id":7,"ws":true},{"text":"doses","start":40,"end":45,"id":8,"ws":true},{"text":"of","start":46,"end":48,"id":9,"ws":true},{"text":"lamivudine","start":49,"end":59,"id":10,"ws":true},{"text":"given","start":60,"end":65,"id":11,"ws":true},{"text":"in","start":66,"end":68,"id":12,"ws":true},{"text":"combination","start":69,"end":80,"id":13,"ws":true},{"text":"with","start":81,"end":85,"id":14,"ws":true},{"text":"zidovudine","start":86,"end":96,"id":15,"ws":true},{"text":"with","start":97,"end":101,"id":16,"ws":true},{"text":"continued","start":102,"end":111,"id":17,"ws":true},{"text":"zidovudine","start":112,"end":122,"id":18,"ws":true},{"text":"monotherapy","start":123,"end":134,"id":19,"ws":true},{"text":".","start":135,"end":136,"id":20,"ws":false}],"spans":[{"start":49,"end":59,"token_start":10,"token_end":10,"label":"DRUG"},{"start":86,"end":96,"token_start":15,"token_end":15,"label":"DRUG"},{"start":112,"end":122,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8656502/","_input_hash":609816829,"_task_hash":300666480,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":10,"child":15,"head_span":{"start":49,"end":59,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":86,"end":96,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Bradykinin enhanced the effect of carbachol by about 10 - 15 % .","paragraph":"<h3><u>Ca(2+)-independent, Ca(2+)-dependent, and carbachol-mediated arachidonic acid release from rat brain cortex membrane.</u></h3>Synaptoneurosomes obtained from the cortex of rat brain prelabeled with [14C]arachidonic acid [( 14C]AA) were used as a source of substrate and enzyme in studies on the regulation of AA release. A significant amount of AA is liberated in the presence of 2 mM EGTA, independently of Ca2+, primarily from phosphatidic acid and polyphosphoinositides (poly-PI). Quinacrine, an inhibitor of phospholipase A2 (PLA2), suppressed AA release by about 60% and <b style='color:Tomato;'><i>neomycin</i></b>, a putative inhibitor of phospholipase C (PLC), reduced AA release by about 30%. An additive effect was exhibited when both inhibitors were given together. Ca2+ activated AA release. The level of Ca2+ present in the synaptoneurosomal preparation (endogenous level) and 5 microM CaCl2 enhance AA liberation by approximately 25%, whereas 2 mM CaCl2 resulted in a 50% increase in AA release relative to EGTA. The source for Ca(2+)-dependent AA release is predominantly phosphatidylinositol (PI); however, a small pool may also be liberated from neutral lipids. <b style='color:Tomato;'><i>carbachol</i></b>, an agonist of the cholinergic receptor, stimulated Ca(2+)-dependent AA release by about 17%. <b style='color:MediumOrchid;'><i>Bradykinin</i></b> <b style='color:DodgerBlue;'><i>enhanced</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>carbachol</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>about</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This agonist-mediated AA release occurs specifically from phosphoinositides (PI + poly-PI). Quinacrine almost completely suppresses calcium-and <b style='color:Tomato;'><i>carbachol</i></b>-mediated AA release. <b style='color:Tomato;'><i>neomycin</i></b> inhibits this process by about 30% and totally suppresses the effect of <b style='color:Tomato;'><i>bradykinin</i></b>. Our results indicate that both phospholipases PLA2 and PLC with subsequent action of DAG lipase are responsible for Ca(2+)-independent AA release. Ca(2+)-dependent and <b style='color:Tomato;'><i>carbachol</i></b>-mediated AA liberation occurs mainly as the result of PLA2 action. A small pool of AA is probably also released by PLC, which seems to be exclusively responsible for the effect of <b style='color:Tomato;'><i>bradykinin</i></b>.","tokens":[{"text":"Bradykinin","start":0,"end":10,"id":0,"ws":true},{"text":"enhanced","start":11,"end":19,"id":1,"ws":true},{"text":"the","start":20,"end":23,"id":2,"ws":true},{"text":"effect","start":24,"end":30,"id":3,"ws":true},{"text":"of","start":31,"end":33,"id":4,"ws":true},{"text":"carbachol","start":34,"end":43,"id":5,"ws":true},{"text":"by","start":44,"end":46,"id":6,"ws":true},{"text":"about","start":47,"end":52,"id":7,"ws":true},{"text":"10","start":53,"end":55,"id":8,"ws":true},{"text":"-","start":56,"end":57,"id":9,"ws":true},{"text":"15","start":58,"end":60,"id":10,"ws":true},{"text":"%","start":61,"end":62,"id":11,"ws":true},{"text":".","start":63,"end":64,"id":12,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":34,"end":43,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1910075/","_input_hash":-1875296338,"_task_hash":1207641834,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":0,"child":5,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":34,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The results suggest that third-line chemotherapy with combined bevacizumab and S-1 is safe and may delay the progression of mCRC resistant to oxaliplatin and irinotecan with mutated KRAS .","paragraph":"<h3><u>A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).</u></h3>No salvage treatment had been established for metastatic colorectal cancer (mCRC) with mutated KRAS before the emergence of the new drugs <b style='color:Tomato;'><i>regorafenib</i></b> and TAS-102. We performed a phase II study of third-line chemotherapy with combined <b style='color:Tomato;'><i>bevacizumab</i></b> and S-1 for mCRC. ### methods Subjects were mCRC patients with mutated KRAS who showed disease aggravation even after two regimens with <b style='color:Tomato;'><i>oxaliplatin</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b>. <b style='color:Tomato;'><i>bevacizumab</i></b> was given intravenously every 2 weeks, and S-1 was administered orally on days 1-28 of a 42-day cycle. The primary endpoint was disease control rate (DCR). ### results In total, 31 subjects were enrolled between August 2009 and June 2011. Three subjects in whom antitumor effects could not be evaluated were excluded. The median follow-up period was 8.6 months. The DCR was 67.9%, the response rate 0%, median progression-free survival 3.7 months, and overall survival 8.6 months. In 30 subjects evaluated for safety, there was no treatment-related death. The most common adverse events were anorexia (grade \u22653, 20%), diarrhea (grade 3, 10%), and decreased hemoglobin (grade \u22653, 17%). ### conclusions <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>third-line</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>S-1</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>safe</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>delay</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>mutated</i></b> <b style='color:DodgerBlue;'><i>KRAS</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"results","start":4,"end":11,"id":1,"ws":true},{"text":"suggest","start":12,"end":19,"id":2,"ws":true},{"text":"that","start":20,"end":24,"id":3,"ws":true},{"text":"third-line","start":25,"end":35,"id":4,"ws":true},{"text":"chemotherapy","start":36,"end":48,"id":5,"ws":true},{"text":"with","start":49,"end":53,"id":6,"ws":true},{"text":"combined","start":54,"end":62,"id":7,"ws":true},{"text":"bevacizumab","start":63,"end":74,"id":8,"ws":true},{"text":"and","start":75,"end":78,"id":9,"ws":true},{"text":"S-1","start":79,"end":82,"id":10,"ws":true},{"text":"is","start":83,"end":85,"id":11,"ws":true},{"text":"safe","start":86,"end":90,"id":12,"ws":true},{"text":"and","start":91,"end":94,"id":13,"ws":true},{"text":"may","start":95,"end":98,"id":14,"ws":true},{"text":"delay","start":99,"end":104,"id":15,"ws":true},{"text":"the","start":105,"end":108,"id":16,"ws":true},{"text":"progression","start":109,"end":120,"id":17,"ws":true},{"text":"of","start":121,"end":123,"id":18,"ws":true},{"text":"mCRC","start":124,"end":128,"id":19,"ws":true},{"text":"resistant","start":129,"end":138,"id":20,"ws":true},{"text":"to","start":139,"end":141,"id":21,"ws":true},{"text":"oxaliplatin","start":142,"end":153,"id":22,"ws":true},{"text":"and","start":154,"end":157,"id":23,"ws":true},{"text":"irinotecan","start":158,"end":168,"id":24,"ws":true},{"text":"with","start":169,"end":173,"id":25,"ws":true},{"text":"mutated","start":174,"end":181,"id":26,"ws":true},{"text":"KRAS","start":182,"end":186,"id":27,"ws":true},{"text":".","start":187,"end":188,"id":28,"ws":false}],"spans":[{"start":63,"end":74,"token_start":8,"token_end":8,"label":"DRUG"},{"start":79,"end":82,"token_start":10,"token_end":10,"label":"DRUG"},{"start":142,"end":153,"token_start":22,"token_end":22,"label":"DRUG"},{"start":158,"end":168,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27229742/","_input_hash":974518442,"_task_hash":1060507232,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":63,"end":74,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":79,"end":82,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":22,"child":24,"head_span":{"start":142,"end":153,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":158,"end":168,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS10"],"answer":"accept"}
{"text":"In accordance with their different pharmacological profiles , the three NLs iloperidone , clozapine , and haloperidol have different effects in this preclinical cognitive task .","paragraph":"<h3><u>Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm.</u></h3>Because cognitive function, particularly working memory (WM), is severely impaired in schizophrenia, evaluation of neuroleptic medication should include investigation of possible effects on cognition. <b style='color:Tomato;'><i>iloperidone</i></b> is a promising, novel atypical neuroleptic drug (NL), for which no cognitive data is presently available. ### objective To investigate whether the novel atypical NL <b style='color:Tomato;'><i>iloperidone</i></b> would affect performance of rats on a WM test, using a delayed non-matching-to-position (DNMTP) paradigm, and compare its effects with those of the atypical NL <b style='color:Tomato;'><i>clozapine</i></b> and the typical NL <b style='color:Tomato;'><i>haloperidol</i></b>. ### methods Male Lister Hooded rats trained to criterion in an operant DNMTP task (0-64 s delay intervals) were administered vehicle, <b style='color:Tomato;'><i>iloperidone</i></b> (0.03, 0.1 mg/kg, i.p.), <b style='color:Tomato;'><i>clozapine</i></b> (0.1, 0.3 mg/kg, s.c.), <b style='color:Tomato;'><i>haloperidol</i></b> (0.003, 0.01, 0.03 mg/kg, s.c.), or <b style='color:Tomato;'><i>scopolamine</i></b> (0.05 mg/kg, s.c.). Together with choice accuracy, the motor performance of the task was measured. ### results It was found that: (1) <b style='color:Tomato;'><i>iloperidone</i></b> significantly improved choice accuracy delay-dependently while impairing task performance; (2) the atypical NL <b style='color:Tomato;'><i>clozapine</i></b> had no effect on choice accuracy and parameters related to motor function, but significantly increased the number of uncompleted trials; (3) <b style='color:Tomato;'><i>haloperidol</i></b> did not affect choice accuracy except at the longest delay with the highest dose, but in contrast to <b style='color:Tomato;'><i>clozapine</i></b> it significantly impaired task performance. ### conclusion <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>accordance</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>pharmacological</i></b> <b style='color:DodgerBlue;'><i>profiles</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>NLs</i></b> <b style='color:MediumOrchid;'><i>iloperidone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clozapine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>haloperidol</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>preclinical</i></b> <b style='color:DodgerBlue;'><i>cognitive</i></b> <b style='color:DodgerBlue;'><i>task</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These results might provide important information for the development of NLs with beneficial effects on cognition.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"accordance","start":3,"end":13,"id":1,"ws":true},{"text":"with","start":14,"end":18,"id":2,"ws":true},{"text":"their","start":19,"end":24,"id":3,"ws":true},{"text":"different","start":25,"end":34,"id":4,"ws":true},{"text":"pharmacological","start":35,"end":50,"id":5,"ws":true},{"text":"profiles","start":51,"end":59,"id":6,"ws":true},{"text":",","start":60,"end":61,"id":7,"ws":true},{"text":"the","start":62,"end":65,"id":8,"ws":true},{"text":"three","start":66,"end":71,"id":9,"ws":true},{"text":"NLs","start":72,"end":75,"id":10,"ws":true},{"text":"iloperidone","start":76,"end":87,"id":11,"ws":true},{"text":",","start":88,"end":89,"id":12,"ws":true},{"text":"clozapine","start":90,"end":99,"id":13,"ws":true},{"text":",","start":100,"end":101,"id":14,"ws":true},{"text":"and","start":102,"end":105,"id":15,"ws":true},{"text":"haloperidol","start":106,"end":117,"id":16,"ws":true},{"text":"have","start":118,"end":122,"id":17,"ws":true},{"text":"different","start":123,"end":132,"id":18,"ws":true},{"text":"effects","start":133,"end":140,"id":19,"ws":true},{"text":"in","start":141,"end":143,"id":20,"ws":true},{"text":"this","start":144,"end":148,"id":21,"ws":true},{"text":"preclinical","start":149,"end":160,"id":22,"ws":true},{"text":"cognitive","start":161,"end":170,"id":23,"ws":true},{"text":"task","start":171,"end":175,"id":24,"ws":true},{"text":".","start":176,"end":177,"id":25,"ws":false}],"spans":[{"start":76,"end":87,"token_start":11,"token_end":11,"label":"DRUG"},{"start":90,"end":99,"token_start":13,"token_end":13,"label":"DRUG"},{"start":106,"end":117,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12827343/","_input_hash":758476254,"_task_hash":-703574187,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Here , we report that combinatorial treatment using EGFRis , such as gefitinib or erlotinib , with PI3K/AKT pathway inhibitors ( PI3K/AKTis ) demonstrated a synergistic , anti-proliferative effect in cell lines of the basal-like ( BL ) subtype , a subtype of TNBC .","paragraph":"<h3><u>Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.</u></h3>Triple-negative breast cancers (TNBCs) are known to be intrinsically resistant to inhibitors for epidermal growth factor receptor (EGFR). Until now, clinical trials for TNBCs using EGFR inhibitors (EGFRis) as single agents have yielded disappointing results. <b style='color:DodgerBlue;'><i>Here</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>report</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>combinatorial</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>EGFRis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>PI3K/AKT</i></b> <b style='color:DodgerBlue;'><i>pathway</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PI3K/AKTis</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>anti-proliferative</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lines</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>basal-like</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>BL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>subtype</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>subtype</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>TNBC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Western blot analysis revealed that the <b style='color:Tomato;'><i>gefitinib</i></b>/PI-103 combination significantly reduced the level of both phospho-AKT and phospho-ERK in two susceptible BL subtype cell lines, SUM149PT and MDA-MB-468, whereas it had little or no effect on the level of phospho-ERK in two non-susceptible cell lines (HS578T and MDA-MB-231) of mesenchymal stem-like (MSL) TNBC subtype. The <b style='color:Tomato;'><i>gefitinib</i></b>/PI-103 combination also significantly induced caspase-3/7-mediated PARP cleavage and reduced two anti-apoptotic proteins, XIAP and Bcl-2 in the susceptible cell lines. In addition, the level of myeloid cell leukemia 1 (Mcl-1) protein was markedly decreased by <b style='color:Tomato;'><i>gefitinib</i></b>/PI-103 combination in the BL TNBC cells, but showed no significant change by this combination in MSL subtype cells. These results suggest that pharmacological inhibition of EGFR used in combination of PI3K/AKTis is a potential therapeutic approach to treat a subtype of TNBCs.","tokens":[{"text":"Here","start":0,"end":4,"id":0,"ws":true},{"text":",","start":5,"end":6,"id":1,"ws":true},{"text":"we","start":7,"end":9,"id":2,"ws":true},{"text":"report","start":10,"end":16,"id":3,"ws":true},{"text":"that","start":17,"end":21,"id":4,"ws":true},{"text":"combinatorial","start":22,"end":35,"id":5,"ws":true},{"text":"treatment","start":36,"end":45,"id":6,"ws":true},{"text":"using","start":46,"end":51,"id":7,"ws":true},{"text":"EGFRis","start":52,"end":58,"id":8,"ws":true},{"text":",","start":59,"end":60,"id":9,"ws":true},{"text":"such","start":61,"end":65,"id":10,"ws":true},{"text":"as","start":66,"end":68,"id":11,"ws":true},{"text":"gefitinib","start":69,"end":78,"id":12,"ws":true},{"text":"or","start":79,"end":81,"id":13,"ws":true},{"text":"erlotinib","start":82,"end":91,"id":14,"ws":true},{"text":",","start":92,"end":93,"id":15,"ws":true},{"text":"with","start":94,"end":98,"id":16,"ws":true},{"text":"PI3K/AKT","start":99,"end":107,"id":17,"ws":true},{"text":"pathway","start":108,"end":115,"id":18,"ws":true},{"text":"inhibitors","start":116,"end":126,"id":19,"ws":true},{"text":"(","start":127,"end":128,"id":20,"ws":true},{"text":"PI3K/AKTis","start":129,"end":139,"id":21,"ws":true},{"text":")","start":140,"end":141,"id":22,"ws":true},{"text":"demonstrated","start":142,"end":154,"id":23,"ws":true},{"text":"a","start":155,"end":156,"id":24,"ws":true},{"text":"synergistic","start":157,"end":168,"id":25,"ws":true},{"text":",","start":169,"end":170,"id":26,"ws":true},{"text":"anti-proliferative","start":171,"end":189,"id":27,"ws":true},{"text":"effect","start":190,"end":196,"id":28,"ws":true},{"text":"in","start":197,"end":199,"id":29,"ws":true},{"text":"cell","start":200,"end":204,"id":30,"ws":true},{"text":"lines","start":205,"end":210,"id":31,"ws":true},{"text":"of","start":211,"end":213,"id":32,"ws":true},{"text":"the","start":214,"end":217,"id":33,"ws":true},{"text":"basal-like","start":218,"end":228,"id":34,"ws":true},{"text":"(","start":229,"end":230,"id":35,"ws":true},{"text":"BL","start":231,"end":233,"id":36,"ws":true},{"text":")","start":234,"end":235,"id":37,"ws":true},{"text":"subtype","start":236,"end":243,"id":38,"ws":true},{"text":",","start":244,"end":245,"id":39,"ws":true},{"text":"a","start":246,"end":247,"id":40,"ws":true},{"text":"subtype","start":248,"end":255,"id":41,"ws":true},{"text":"of","start":256,"end":258,"id":42,"ws":true},{"text":"TNBC","start":259,"end":263,"id":43,"ws":true},{"text":".","start":264,"end":265,"id":44,"ws":false}],"spans":[{"start":69,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},{"start":82,"end":91,"token_start":14,"token_end":14,"label":"DRUG"},{"start":129,"end":139,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23601074/","_input_hash":-1148755087,"_task_hash":856553887,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":12,"child":21,"head_span":{"start":69,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":129,"end":139,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":14,"child":21,"head_span":{"start":82,"end":91,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":129,"end":139,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"Patients received gemcitabine 1000 mg/m\u00b2 intravenously on days 1 and 8 , capecitabine 1300 mg/m\u00b2 oral daily from day 1 to 14 , and dovitinib oral daily 5 days on and 2 days off , every 21-day cycle .","paragraph":"<h3><u>A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.</u></h3>Preclinical studies demonstrated antitumor activity of <b style='color:Tomato;'><i>dovitinib</i></b> in pancreatic cancer models. This phase Ib study aimed to determine the maximum tolerated dose (MTD) of <b style='color:Tomato;'><i>dovitinib</i></b> in combination with <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>capecitabine</i></b> and to characterize the safety and pharmacokinetic profile in patients with advanced pancreatic and biliary tract cancers and solid malignancies. ### Materials And Methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg/m\u00b2</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>1300</i></b> <b style='color:DodgerBlue;'><i>mg/m\u00b2</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>dovitinib</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>off</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21-day</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The standard 3+3 dose escalation design was utilized and the study expanded to treat an additional 20 advanced pancreatic and biliary tract cancers patients at MTD. ### results A total of 29 patients were enrolled. One patient experienced dose-limiting grade 3 colitis. Two patients developed clinically significant neuropathy after the first cycle requiring dose reduction. The MTD was not reached and <b style='color:Tomato;'><i>dovitinib</i></b> 300\u2009mg was declared the recommended dose for expansion. The most frequent grade 2 or worse adverse events were fatigue (45%), neutropenia (41%), thrombocytopenia (34%), anemia (24%), nausea (24%), and palmer-plantar erythrodysaesthesia syndrome (21%). Partial responses were observed in 5 patients. Pharmacokinetic studies showed no drug-drug interaction between <b style='color:Tomato;'><i>dovitinib</i></b>, <b style='color:Tomato;'><i>capecitabine</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b>. Fibroblast growth factor 23 plasma level increased in 4 of 5 patients during the first cycle of treatment. ### conclusions <b style='color:Tomato;'><i>dovitinib</i></b> 300\u2009mg daily is the recommended dose when combined with <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>capecitabine</i></b>, achieving clinically relevant plasma concentrations. The study combination demonstrated encouraging efficacy signals in advanced pancreatic cancer.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"received","start":9,"end":17,"id":1,"ws":true},{"text":"gemcitabine","start":18,"end":29,"id":2,"ws":true},{"text":"1000","start":30,"end":34,"id":3,"ws":true},{"text":"mg/m\u00b2","start":35,"end":40,"id":4,"ws":true},{"text":"intravenously","start":41,"end":54,"id":5,"ws":true},{"text":"on","start":55,"end":57,"id":6,"ws":true},{"text":"days","start":58,"end":62,"id":7,"ws":true},{"text":"1","start":63,"end":64,"id":8,"ws":true},{"text":"and","start":65,"end":68,"id":9,"ws":true},{"text":"8","start":69,"end":70,"id":10,"ws":true},{"text":",","start":71,"end":72,"id":11,"ws":true},{"text":"capecitabine","start":73,"end":85,"id":12,"ws":true},{"text":"1300","start":86,"end":90,"id":13,"ws":true},{"text":"mg/m\u00b2","start":91,"end":96,"id":14,"ws":true},{"text":"oral","start":97,"end":101,"id":15,"ws":true},{"text":"daily","start":102,"end":107,"id":16,"ws":true},{"text":"from","start":108,"end":112,"id":17,"ws":true},{"text":"day","start":113,"end":116,"id":18,"ws":true},{"text":"1","start":117,"end":118,"id":19,"ws":true},{"text":"to","start":119,"end":121,"id":20,"ws":true},{"text":"14","start":122,"end":124,"id":21,"ws":true},{"text":",","start":125,"end":126,"id":22,"ws":true},{"text":"and","start":127,"end":130,"id":23,"ws":true},{"text":"dovitinib","start":131,"end":140,"id":24,"ws":true},{"text":"oral","start":141,"end":145,"id":25,"ws":true},{"text":"daily","start":146,"end":151,"id":26,"ws":true},{"text":"5","start":152,"end":153,"id":27,"ws":true},{"text":"days","start":154,"end":158,"id":28,"ws":true},{"text":"on","start":159,"end":161,"id":29,"ws":true},{"text":"and","start":162,"end":165,"id":30,"ws":true},{"text":"2","start":166,"end":167,"id":31,"ws":true},{"text":"days","start":168,"end":172,"id":32,"ws":true},{"text":"off","start":173,"end":176,"id":33,"ws":true},{"text":",","start":177,"end":178,"id":34,"ws":true},{"text":"every","start":179,"end":184,"id":35,"ws":true},{"text":"21-day","start":185,"end":191,"id":36,"ws":true},{"text":"cycle","start":192,"end":197,"id":37,"ws":true},{"text":".","start":198,"end":199,"id":38,"ws":false}],"spans":[{"start":18,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},{"start":73,"end":85,"token_start":12,"token_end":12,"label":"DRUG"},{"start":131,"end":140,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30418178/","_input_hash":898376362,"_task_hash":-741620658,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":2,"child":12,"head_span":{"start":18,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":73,"end":85,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":2,"child":24,"head_span":{"start":18,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":131,"end":140,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"A reduced dose of oxaliplatin 105 mg/m(2 ) on day 1 with doxorubicin at 20 mg/m(2)/dose on days 1 - 3 was well tolerated .","paragraph":"<h3><u>Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.</u></h3>Patients with relapsed or refractory neuroblastoma have poor long-term survival. New therapeutic regimens are needed. <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin are commonly used in the treatment of high-risk neuroblastoma. <b style='color:Tomato;'><i>oxaliplatin</i></b>, a platinum compound with a 1,2-diaminocyclohexan carrier ligand, is more potent than cisplatin with less nephrotoxicity and ototoxicity. We treated seven relapsed/refractory neuroblastoma patients using <b style='color:Tomato;'><i>oxaliplatin</i></b> (105-130 mg/m(2)) and <b style='color:Tomato;'><i>doxorubicin</i></b> (60-75 mg/m(2)) together with <b style='color:Tomato;'><i>dexrazoxane</i></b> (10 mg/mg of <b style='color:Tomato;'><i>doxorubicin</i></b>) administered intravenously every three weeks. Prolonged thrombocytopenia causing treatment delay was observed when <b style='color:Tomato;'><i>oxaliplatin</i></b> was administered at 130 mg/m(2). <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>105</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg/m(2)/dose</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>tolerated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Sensory neuropathies were mild and transient. No cardiotoxicity was noted despite all patients having a history of prior anthracycline exposure. Best responses included 1 complete response, 1 partial response, 1 mixed response, 3 stable diseases. In our cohort of heavily pretreated relapsed and refractory neuroblastoma patients, the combination of <b style='color:Tomato;'><i>oxaliplatin</i></b> and <b style='color:Tomato;'><i>doxorubicin</i></b> demonstrated anti-tumor activity and merits further investigation.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"reduced","start":2,"end":9,"id":1,"ws":true},{"text":"dose","start":10,"end":14,"id":2,"ws":true},{"text":"of","start":15,"end":17,"id":3,"ws":true},{"text":"oxaliplatin","start":18,"end":29,"id":4,"ws":true},{"text":"105","start":30,"end":33,"id":5,"ws":true},{"text":"mg/m(2","start":34,"end":40,"id":6,"ws":true},{"text":")","start":41,"end":42,"id":7,"ws":true},{"text":"on","start":43,"end":45,"id":8,"ws":true},{"text":"day","start":46,"end":49,"id":9,"ws":true},{"text":"1","start":50,"end":51,"id":10,"ws":true},{"text":"with","start":52,"end":56,"id":11,"ws":true},{"text":"doxorubicin","start":57,"end":68,"id":12,"ws":true},{"text":"at","start":69,"end":71,"id":13,"ws":true},{"text":"20","start":72,"end":74,"id":14,"ws":true},{"text":"mg/m(2)/dose","start":75,"end":87,"id":15,"ws":true},{"text":"on","start":88,"end":90,"id":16,"ws":true},{"text":"days","start":91,"end":95,"id":17,"ws":true},{"text":"1","start":96,"end":97,"id":18,"ws":true},{"text":"-","start":98,"end":99,"id":19,"ws":true},{"text":"3","start":100,"end":101,"id":20,"ws":true},{"text":"was","start":102,"end":105,"id":21,"ws":true},{"text":"well","start":106,"end":110,"id":22,"ws":true},{"text":"tolerated","start":111,"end":120,"id":23,"ws":true},{"text":".","start":121,"end":122,"id":24,"ws":false}],"spans":[{"start":18,"end":29,"token_start":4,"token_end":4,"label":"DRUG"},{"start":57,"end":68,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25551355/","_input_hash":-2102172499,"_task_hash":-136453510,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":4,"child":12,"head_span":{"start":18,"end":29,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":57,"end":68,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In terms of recurrent disease , two positive phase III trials revealed that trebananib and cediranib are effective anti-angiogenic agents for this indication .","paragraph":"<h3><u>Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer.</u></h3>In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody <b style='color:Tomato;'><i>bevacizumab</i></b>, several alternative anti-angiogenic treatment strategies for ovarian cancer patients have been evaluated in clinical trials. Apart from targeting extracellular receptors by the antibody <b style='color:Tomato;'><i>aflibercept</i></b> or the peptibody <b style='color:Tomato;'><i>trebananib</i></b>, the multikinase inhibitors <b style='color:Tomato;'><i>pazopanib</i></b>, <b style='color:Tomato;'><i>nintedanib</i></b>, <b style='color:Tomato;'><i>cediranib</i></b>, <b style='color:Tomato;'><i>sunitinib</i></b>, and <b style='color:Tomato;'><i>sorafenib</i></b> were developed to interfere with VEGF receptors and multiple additional intracellular pathways. <b style='color:Tomato;'><i>nintedanib</i></b> and <b style='color:Tomato;'><i>pazopanib</i></b> significantly improved progression-free survival in two positive phase III trials for first-line therapy. A reliable effect on overall survival could, however, not be observed for any anti-angiogenic first-line therapies so far. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>terms</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>revealed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>trebananib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cediranib</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>anti-angiogenic</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>indication</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Patient selection and biomarker guided prediction of response seems to be a central aspect for future studies. Combining anti-angiogenics with other targeted therapies to possibly spare chemotherapy in certain constellations represents another very interesting future perspective for clinical trials. This short review gives an overview of current clinical trials for anti-angiogenic treatment strategies beyond <b style='color:Tomato;'><i>bevacizumab</i></b>. In this context, possible future perspectives combining anti-angiogenics with other targeted therapies and the need for specific biomarkers predicting response are elucidated.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"terms","start":3,"end":8,"id":1,"ws":true},{"text":"of","start":9,"end":11,"id":2,"ws":true},{"text":"recurrent","start":12,"end":21,"id":3,"ws":true},{"text":"disease","start":22,"end":29,"id":4,"ws":true},{"text":",","start":30,"end":31,"id":5,"ws":true},{"text":"two","start":32,"end":35,"id":6,"ws":true},{"text":"positive","start":36,"end":44,"id":7,"ws":true},{"text":"phase","start":45,"end":50,"id":8,"ws":true},{"text":"III","start":51,"end":54,"id":9,"ws":true},{"text":"trials","start":55,"end":61,"id":10,"ws":true},{"text":"revealed","start":62,"end":70,"id":11,"ws":true},{"text":"that","start":71,"end":75,"id":12,"ws":true},{"text":"trebananib","start":76,"end":86,"id":13,"ws":true},{"text":"and","start":87,"end":90,"id":14,"ws":true},{"text":"cediranib","start":91,"end":100,"id":15,"ws":true},{"text":"are","start":101,"end":104,"id":16,"ws":true},{"text":"effective","start":105,"end":114,"id":17,"ws":true},{"text":"anti-angiogenic","start":115,"end":130,"id":18,"ws":true},{"text":"agents","start":131,"end":137,"id":19,"ws":true},{"text":"for","start":138,"end":141,"id":20,"ws":true},{"text":"this","start":142,"end":146,"id":21,"ws":true},{"text":"indication","start":147,"end":157,"id":22,"ws":true},{"text":".","start":158,"end":159,"id":23,"ws":false}],"spans":[{"start":76,"end":86,"token_start":13,"token_end":13,"label":"DRUG"},{"start":91,"end":100,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26500886/","_input_hash":1293244351,"_task_hash":875172385,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"A total of 80 patients were randomized , including 44 to the combination group ( tamsulosin 0.4 mg and tolterodine early release 4 mg ) and 36 to the monotherapy group ( tamsulosin 0.4 mg and placebo ) .","paragraph":"<h3><u>Does Combination Therapy with Tamsulosin and Tolterodine Improve Ureteral Stent Discomfort Compared with Tamsulosin Alone? A Double-Blind, Randomized, Controlled Trial.</u></h3>Ureteral stent discomfort is a significant postoperative problem for\u00a0many patients. Despite the use of narcotics and \u03b1-blockers patients often experience bothersome lower urinary tract symptoms and pain, which impair daily activities. We compared combination therapy with an \u03b1-blocker and an anticholinergic to monotherapy with an \u03b1-blocker. ### Materials And Methods A double-blind, randomized, controlled trial was performed from December 2012 to April 2014. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>44</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>tamsulosin</i></b> <b style='color:DodgerBlue;'><i>0.4</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tolterodine</i></b> <b style='color:DodgerBlue;'><i>early</i></b> <b style='color:DodgerBlue;'><i>release</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>36</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>tamsulosin</i></b> <b style='color:DodgerBlue;'><i>0.4</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Patients with preexisting ureteral stent placement or current anticholinergic therapy were excluded from study. Patients completed USSQ (Urinary Stent Symptom Questionnaire) before stent placement on the day of surgery, the day after stent placement, the morning of stent removal and the day after stent removal. The questionnaire included questions regarding urinary symptoms, general health, body pain, and work and sexual history. ### results A total of 80 patients (40 males and 40 females) were studied. Mean age was 51.5 vs 51.3 years (p = 0.95) and mean body mass index was 33.6 vs 31.9\u00a0kg/m(2) (p = 0.44) in monotherapy group 1 vs combination therapy group 2. Between\u00a0the 2 groups there was no significant difference in urinary symptoms, body pain and activities of daily living from baseline to just before stent removal (p = 0.95, 0.40 and 0.95, respectively). Although there was no difference between the groups, both showed improvement in urinary symptoms from the time of\u00a0initial stent insertion to just prior to stent removal (difference -0.50 for combination therapy and -0.40 for monotherapy). The mean stent indwelling time of 9.6 and 8.7 days in the combination and monotherapy groups, respectively, did not differ (p = 0.67). On ANOVA it had no significant impact on results (p = 0.64). ### conclusions Combination therapy with <b style='color:Tomato;'><i>tamsulosin</i></b> and <b style='color:Tomato;'><i>tolterodine</i></b> does not appear to improve urinary symptoms, bodily pain or quality of life in patients after ureteral stent placement for nephrolithiasis compared to <b style='color:Tomato;'><i>tamsulosin</i></b> alone. Both groups experienced worse urinary symptoms, pain and quality of life with a stent, suggesting that further research is necessary to improve stent discomfort.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"total","start":2,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"80","start":11,"end":13,"id":3,"ws":true},{"text":"patients","start":14,"end":22,"id":4,"ws":true},{"text":"were","start":23,"end":27,"id":5,"ws":true},{"text":"randomized","start":28,"end":38,"id":6,"ws":true},{"text":",","start":39,"end":40,"id":7,"ws":true},{"text":"including","start":41,"end":50,"id":8,"ws":true},{"text":"44","start":51,"end":53,"id":9,"ws":true},{"text":"to","start":54,"end":56,"id":10,"ws":true},{"text":"the","start":57,"end":60,"id":11,"ws":true},{"text":"combination","start":61,"end":72,"id":12,"ws":true},{"text":"group","start":73,"end":78,"id":13,"ws":true},{"text":"(","start":79,"end":80,"id":14,"ws":true},{"text":"tamsulosin","start":81,"end":91,"id":15,"ws":true},{"text":"0.4","start":92,"end":95,"id":16,"ws":true},{"text":"mg","start":96,"end":98,"id":17,"ws":true},{"text":"and","start":99,"end":102,"id":18,"ws":true},{"text":"tolterodine","start":103,"end":114,"id":19,"ws":true},{"text":"early","start":115,"end":120,"id":20,"ws":true},{"text":"release","start":121,"end":128,"id":21,"ws":true},{"text":"4","start":129,"end":130,"id":22,"ws":true},{"text":"mg","start":131,"end":133,"id":23,"ws":true},{"text":")","start":134,"end":135,"id":24,"ws":true},{"text":"and","start":136,"end":139,"id":25,"ws":true},{"text":"36","start":140,"end":142,"id":26,"ws":true},{"text":"to","start":143,"end":145,"id":27,"ws":true},{"text":"the","start":146,"end":149,"id":28,"ws":true},{"text":"monotherapy","start":150,"end":161,"id":29,"ws":true},{"text":"group","start":162,"end":167,"id":30,"ws":true},{"text":"(","start":168,"end":169,"id":31,"ws":true},{"text":"tamsulosin","start":170,"end":180,"id":32,"ws":true},{"text":"0.4","start":181,"end":184,"id":33,"ws":true},{"text":"mg","start":185,"end":187,"id":34,"ws":true},{"text":"and","start":188,"end":191,"id":35,"ws":true},{"text":"placebo","start":192,"end":199,"id":36,"ws":true},{"text":")","start":200,"end":201,"id":37,"ws":true},{"text":".","start":202,"end":203,"id":38,"ws":false}],"spans":[{"start":81,"end":91,"token_start":15,"token_end":15,"label":"DRUG"},{"start":103,"end":114,"token_start":19,"token_end":19,"label":"DRUG"},{"start":170,"end":180,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26393904/","_input_hash":-1401015447,"_task_hash":402045347,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":15,"child":19,"head_span":{"start":81,"end":91,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":103,"end":114,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"However , thiostrepton , dexamethasone , 2-methoxyestradiol , \u03b4-tocotrienol , quercetin , and quinine sulphate were effective in pancreatic , prostate , breast , lungs , melanoma , \u0392-lymphocytes , and T-cells ( Jurkat : 40 % to 95 % ) compared to respective controls .","paragraph":"<h3><u>Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs.</u></h3>Cancer is second most common cause of death in the United State. There are over 100 different types of cancer associated with different human organs, predominantly breast, liver, pancreas, prostate, colon, rectum, lung, and stomach. We have recently reported properties of pro-inflammatory (for treatment of various types of cancers), and anti-inflammatory (for cardiovascular disease and diabetes) compounds. The major problem associated with development of anticancer drugs is their lack of solubility in aqueous solutions and severe side effects in cancer patients. Therefore, the present study was carried out to check anticancer properties of selected compounds, mostly aqueous soluble, in cancer cell lines from different organs. ### methods The anticancer properties, anti-proliferative, and pro-apoptotic activity of novel naturally occurring or FDA approved, nontoxic, proteasome inhibitors/activators were compared. In addition to that, effect of \u03b4-tocotrienol on expression of proteasome subunits (X, Y, Z, LMP7, LMP2, LMP10), ICAM-1, VCAM-1, and TNF-\u03b1 using total RNAs derived from plasmas of hepatitis C patients was investigated. ### results Our data demonstrated that following compounds are very effective in inducing apoptosis of cancer cells: Thiostrepton, <b style='color:Tomato;'><i>dexamethasone</i></b>, 2-methoxyestradiol, \u03b4-tocotrienol, quercetin, <b style='color:Tomato;'><i>amiloride</i></b>, and <b style='color:Tomato;'><i>quinine</i></b> sulfate have significant anti-proliferation properties in Hela cells (44% - 87%) with doses of 2.5-20\u00a0\u03bcM, compared to respective controls. Anti-proliferation properties of thiostrepton, 2-methoxyestradiol, \u03b4-tocotrienol, and quercetin were 70% - 92%. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>thiostrepton</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>2-methoxyestradiol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>\u03b4-tocotrienol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>quercetin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>quinine</i></b> <b style='color:DodgerBlue;'><i>sulphate</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>pancreatic</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>lungs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>\u0392-lymphocytes</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>T-cells</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Jurkat</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>95</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>respective</i></b> <b style='color:DodgerBlue;'><i>controls</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In lung cancer cells, these compounds were effective between 5 and 40\u00a0\u03bcM. The IC ### conclusions These data demonstrate effectiveness of several natural-occurring compounds with anti-proliferative properties against cancer cells of several organs of humans. Thiostrepton, <b style='color:Tomato;'><i>dexamethasone</i></b>, 2-methoxyestradiol, \u03b4-tocotrienol and quercetin are very effective for apoptosis of cancer cells in liver, pancreas, prostate, breast, lung, melanoma, \u0392-lymphocytes and T-cells. The results have provided an opportunity to test these compounds either individually or in combination as dietary supplements in humans for treatment of various types of cancers.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"thiostrepton","start":10,"end":22,"id":2,"ws":true},{"text":",","start":23,"end":24,"id":3,"ws":true},{"text":"dexamethasone","start":25,"end":38,"id":4,"ws":true},{"text":",","start":39,"end":40,"id":5,"ws":true},{"text":"2-methoxyestradiol","start":41,"end":59,"id":6,"ws":true},{"text":",","start":60,"end":61,"id":7,"ws":true},{"text":"\u03b4-tocotrienol","start":62,"end":75,"id":8,"ws":true},{"text":",","start":76,"end":77,"id":9,"ws":true},{"text":"quercetin","start":78,"end":87,"id":10,"ws":true},{"text":",","start":88,"end":89,"id":11,"ws":true},{"text":"and","start":90,"end":93,"id":12,"ws":true},{"text":"quinine","start":94,"end":101,"id":13,"ws":true},{"text":"sulphate","start":102,"end":110,"id":14,"ws":true},{"text":"were","start":111,"end":115,"id":15,"ws":true},{"text":"effective","start":116,"end":125,"id":16,"ws":true},{"text":"in","start":126,"end":128,"id":17,"ws":true},{"text":"pancreatic","start":129,"end":139,"id":18,"ws":true},{"text":",","start":140,"end":141,"id":19,"ws":true},{"text":"prostate","start":142,"end":150,"id":20,"ws":true},{"text":",","start":151,"end":152,"id":21,"ws":true},{"text":"breast","start":153,"end":159,"id":22,"ws":true},{"text":",","start":160,"end":161,"id":23,"ws":true},{"text":"lungs","start":162,"end":167,"id":24,"ws":true},{"text":",","start":168,"end":169,"id":25,"ws":true},{"text":"melanoma","start":170,"end":178,"id":26,"ws":true},{"text":",","start":179,"end":180,"id":27,"ws":true},{"text":"\u0392-lymphocytes","start":181,"end":194,"id":28,"ws":true},{"text":",","start":195,"end":196,"id":29,"ws":true},{"text":"and","start":197,"end":200,"id":30,"ws":true},{"text":"T-cells","start":201,"end":208,"id":31,"ws":true},{"text":"(","start":209,"end":210,"id":32,"ws":true},{"text":"Jurkat","start":211,"end":217,"id":33,"ws":true},{"text":":","start":218,"end":219,"id":34,"ws":true},{"text":"40","start":220,"end":222,"id":35,"ws":true},{"text":"%","start":223,"end":224,"id":36,"ws":true},{"text":"to","start":225,"end":227,"id":37,"ws":true},{"text":"95","start":228,"end":230,"id":38,"ws":true},{"text":"%","start":231,"end":232,"id":39,"ws":true},{"text":")","start":233,"end":234,"id":40,"ws":true},{"text":"compared","start":235,"end":243,"id":41,"ws":true},{"text":"to","start":244,"end":246,"id":42,"ws":true},{"text":"respective","start":247,"end":257,"id":43,"ws":true},{"text":"controls","start":258,"end":266,"id":44,"ws":true},{"text":".","start":267,"end":268,"id":45,"ws":false}],"spans":[{"start":25,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},{"start":94,"end":101,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29606130/","_input_hash":137181739,"_task_hash":-1830266318,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Of them , 47 patients started with docetaxel at cycle one due to reaction to paclitaxel ( n=32 ) , fear of NT ( n=4 ) , and other reasons ( n=11 ) , whereas 59 patients switched to docetaxel during cycle 2 - 6 due to NT ( n=32 ) , reaction to paclitaxel ( n=19 ) , and other reasons ( n=8 ) .","paragraph":"<h3><u>Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study.</u></h3>To describe characteristics associated with neurotoxicity (NT) in advanced ovarian cancer patients treated on Gynecologic Oncology Group 218 and examine effect of substituting <b style='color:Tomato;'><i>docetaxel</i></b> for <b style='color:Tomato;'><i>paclitaxel</i></b> in these patients. ### methods The development of NT was defined as Common Toxicity Criteria grade (G)\u22651. The association between substitution with <b style='color:Tomato;'><i>docetaxel</i></b> and NT improvement was explored with generalized estimating equations adjusting for treatment cycle and NT grading at previous cycle. ### results Of 1864 evaluable patients, 1329 (71%) developed G\u22651 NT during the study. Nearly half appeared within the first two cycles of chemotherapy, with 31% experiencing G\u22652. Older patients or those with worse quality of life (QoL) scores at baseline (p<0.05) were more likely to experience NT. One-hundred-six patients received <b style='color:Tomato;'><i>docetaxel</i></b> as substitute for <b style='color:Tomato;'><i>paclitaxel</i></b>. <b style='color:DodgerBlue;'><i>Of</i></b> <b style='color:DodgerBlue;'><i>them</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>47</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>started</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>reaction</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=32</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>fear</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NT</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=4</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>reasons</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=11</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:DodgerBlue;'><i>59</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>switched</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>NT</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=32</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>reaction</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=19</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>reasons</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=8</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Although the protocol instructed otherwise, the majority continued <b style='color:Tomato;'><i>paclitaxel</i></b> despite G\u22652 NT symptoms. There was no evidence that substitution with <b style='color:Tomato;'><i>docetaxel</i></b> improved NT (Odds Ratio: 1.57; 95% CI 0.98-2.54; p>0.05). Of 59 patients who switched to <b style='color:Tomato;'><i>docetaxel</i></b>, only seven (12%) discontinued taxane prior to chemotherapy completion. A roughly equal chance of worsening NT was reported on <b style='color:Tomato;'><i>paclitaxel</i></b> (6%) as on <b style='color:Tomato;'><i>docetaxel</i></b> (5%). ### conclusions Age and worse QoL at baseline are associated with NT. Substitution of <b style='color:Tomato;'><i>docetaxel</i></b> did not improve NT symptoms.","tokens":[{"text":"Of","start":0,"end":2,"id":0,"ws":true},{"text":"them","start":3,"end":7,"id":1,"ws":true},{"text":",","start":8,"end":9,"id":2,"ws":true},{"text":"47","start":10,"end":12,"id":3,"ws":true},{"text":"patients","start":13,"end":21,"id":4,"ws":true},{"text":"started","start":22,"end":29,"id":5,"ws":true},{"text":"with","start":30,"end":34,"id":6,"ws":true},{"text":"docetaxel","start":35,"end":44,"id":7,"ws":true},{"text":"at","start":45,"end":47,"id":8,"ws":true},{"text":"cycle","start":48,"end":53,"id":9,"ws":true},{"text":"one","start":54,"end":57,"id":10,"ws":true},{"text":"due","start":58,"end":61,"id":11,"ws":true},{"text":"to","start":62,"end":64,"id":12,"ws":true},{"text":"reaction","start":65,"end":73,"id":13,"ws":true},{"text":"to","start":74,"end":76,"id":14,"ws":true},{"text":"paclitaxel","start":77,"end":87,"id":15,"ws":true},{"text":"(","start":88,"end":89,"id":16,"ws":true},{"text":"n=32","start":90,"end":94,"id":17,"ws":true},{"text":")","start":95,"end":96,"id":18,"ws":true},{"text":",","start":97,"end":98,"id":19,"ws":true},{"text":"fear","start":99,"end":103,"id":20,"ws":true},{"text":"of","start":104,"end":106,"id":21,"ws":true},{"text":"NT","start":107,"end":109,"id":22,"ws":true},{"text":"(","start":110,"end":111,"id":23,"ws":true},{"text":"n=4","start":112,"end":115,"id":24,"ws":true},{"text":")","start":116,"end":117,"id":25,"ws":true},{"text":",","start":118,"end":119,"id":26,"ws":true},{"text":"and","start":120,"end":123,"id":27,"ws":true},{"text":"other","start":124,"end":129,"id":28,"ws":true},{"text":"reasons","start":130,"end":137,"id":29,"ws":true},{"text":"(","start":138,"end":139,"id":30,"ws":true},{"text":"n=11","start":140,"end":144,"id":31,"ws":true},{"text":")","start":145,"end":146,"id":32,"ws":true},{"text":",","start":147,"end":148,"id":33,"ws":true},{"text":"whereas","start":149,"end":156,"id":34,"ws":true},{"text":"59","start":157,"end":159,"id":35,"ws":true},{"text":"patients","start":160,"end":168,"id":36,"ws":true},{"text":"switched","start":169,"end":177,"id":37,"ws":true},{"text":"to","start":178,"end":180,"id":38,"ws":true},{"text":"docetaxel","start":181,"end":190,"id":39,"ws":true},{"text":"during","start":191,"end":197,"id":40,"ws":true},{"text":"cycle","start":198,"end":203,"id":41,"ws":true},{"text":"2","start":204,"end":205,"id":42,"ws":true},{"text":"-","start":206,"end":207,"id":43,"ws":true},{"text":"6","start":208,"end":209,"id":44,"ws":true},{"text":"due","start":210,"end":213,"id":45,"ws":true},{"text":"to","start":214,"end":216,"id":46,"ws":true},{"text":"NT","start":217,"end":219,"id":47,"ws":true},{"text":"(","start":220,"end":221,"id":48,"ws":true},{"text":"n=32","start":222,"end":226,"id":49,"ws":true},{"text":")","start":227,"end":228,"id":50,"ws":true},{"text":",","start":229,"end":230,"id":51,"ws":true},{"text":"reaction","start":231,"end":239,"id":52,"ws":true},{"text":"to","start":240,"end":242,"id":53,"ws":true},{"text":"paclitaxel","start":243,"end":253,"id":54,"ws":true},{"text":"(","start":254,"end":255,"id":55,"ws":true},{"text":"n=19","start":256,"end":260,"id":56,"ws":true},{"text":")","start":261,"end":262,"id":57,"ws":true},{"text":",","start":263,"end":264,"id":58,"ws":true},{"text":"and","start":265,"end":268,"id":59,"ws":true},{"text":"other","start":269,"end":274,"id":60,"ws":true},{"text":"reasons","start":275,"end":282,"id":61,"ws":true},{"text":"(","start":283,"end":284,"id":62,"ws":true},{"text":"n=8","start":285,"end":288,"id":63,"ws":true},{"text":")","start":289,"end":290,"id":64,"ws":true},{"text":".","start":291,"end":292,"id":65,"ws":false}],"spans":[{"start":35,"end":44,"token_start":7,"token_end":7,"label":"DRUG"},{"start":77,"end":87,"token_start":15,"token_end":15,"label":"DRUG"},{"start":181,"end":190,"token_start":39,"token_end":39,"label":"DRUG"},{"start":243,"end":253,"token_start":54,"token_end":54,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25529832/","_input_hash":-1827636829,"_task_hash":-690308385,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption , prednisolone and cyclophosphamide .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rapidly</i></b> <b style='color:DodgerBlue;'><i>progressive</i></b> <b style='color:DodgerBlue;'><i>glomerulonephritis</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>extracorporeal</i></b> <b style='color:DodgerBlue;'><i>immunoadsorption</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Ten patients with rapidly progressive glomerulonephritis and acute renal failure were treated with extracorporeal immunoadsorption, <b style='color:Tomato;'><i>prednisolone</i></b>, and <b style='color:Tomato;'><i>cyclophosphamide</i></b>. Three patients had systemic lupus erythematosus, five had microscopic polyarteritis and two had Wegener's granulomatosis. All ten patients were dialysis-dependent prior to immunoadsorption. Nine of ten patients rapidly regained renal function and seven continue to have independent renal function between 9 and 30 months after immunoadsorption. Three patients at presentation were not dialysis dependent. Despite treatment with <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, and oral <b style='color:Tomato;'><i>prednisolone</i></b>, renal function continued to deteriorate and they required dialysis. Immunoadsorption was then started without alteration in baseline immunosuppression. Within a mean of 4.6 days, range 3-7 days, renal function improved and the patients no longer required dialysis. Antineutrophil cytoplasmic antibodies and double-stranded DNA antibodies were rapidly removed by immunoadsorption. Only one patient with systemic lupus erythematosus and two with microscopic polyarteritis had significant resynthesis of antibody at 1 month post-immunoadsorption. Renal biopsy before and after immunoadsorption and immunosuppressive therapy showed resolution of glomerular crescents and no evidence of active disease. Immunoadsorption coupled with <b style='color:Tomato;'><i>prednisolone</i></b> and <b style='color:Tomato;'><i>cyclophosphamide</i></b> may be of value in the treatment of rapidly progressive glomerulonephritis.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"of","start":10,"end":12,"id":1,"ws":true},{"text":"rapidly","start":13,"end":20,"id":2,"ws":true},{"text":"progressive","start":21,"end":32,"id":3,"ws":true},{"text":"glomerulonephritis","start":33,"end":51,"id":4,"ws":true},{"text":"by","start":52,"end":54,"id":5,"ws":true},{"text":"extracorporeal","start":55,"end":69,"id":6,"ws":true},{"text":"immunoadsorption","start":70,"end":86,"id":7,"ws":true},{"text":",","start":87,"end":88,"id":8,"ws":true},{"text":"prednisolone","start":89,"end":101,"id":9,"ws":true},{"text":"and","start":102,"end":105,"id":10,"ws":true},{"text":"cyclophosphamide","start":106,"end":122,"id":11,"ws":true},{"text":".","start":123,"end":124,"id":12,"ws":false}],"spans":[{"start":89,"end":101,"token_start":9,"token_end":9,"label":"DRUG"},{"start":106,"end":122,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1956551/","_input_hash":-2103102166,"_task_hash":-871959282,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":89,"end":101,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":106,"end":122,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"[ Doxifluridine , medroxyprogesterone acetate and cyclophosphamide ( DMpC ) combination therapy is effective against recurrent triple negative breast cancer -- a case report ] .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:MediumOrchid;'><i>Doxifluridine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>medroxyprogesterone</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DMpC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>triple</i></b> <b style='color:DodgerBlue;'><i>negative</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>--</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>case</i></b> <b style='color:DodgerBlue;'><i>report</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>We report a postmenopausal recurrent breast cancer patient with triple negative disease who presented with right recurrent nerve palsy. Nine years previously, she had undergone a mastectomy. FDG-PET scan revealed neck lymph node metastases from the breast cancer. The recurrent nerve palsy was thus considered to have been caused by the lymph node metastases. The patient was orally administered DMpC (<b style='color:Tomato;'><i>doxifluridine</i></b>, <b style='color:Tomato;'><i>medroxyprogesterone</i></b> acetate and <b style='color:Tomato;'><i>cyclophosphamide</i></b>) combination therapy. This resulted in a remarkable response after five months, with the recurrent nerve palsy completely disappearing at six months. No side effects from the treatment were observed. The patient was well and the treatment was being continued without relapse at nine months. Oral anti-cancer treatments such as DMpC appear to have few side effects and might be an effective treatment option for recurrent breast cancer patients with triple negative disease.","tokens":[{"text":"[","start":0,"end":1,"id":0,"ws":true},{"text":"Doxifluridine","start":2,"end":15,"id":1,"ws":true},{"text":",","start":16,"end":17,"id":2,"ws":true},{"text":"medroxyprogesterone","start":18,"end":37,"id":3,"ws":true},{"text":"acetate","start":38,"end":45,"id":4,"ws":true},{"text":"and","start":46,"end":49,"id":5,"ws":true},{"text":"cyclophosphamide","start":50,"end":66,"id":6,"ws":true},{"text":"(","start":67,"end":68,"id":7,"ws":true},{"text":"DMpC","start":69,"end":73,"id":8,"ws":true},{"text":")","start":74,"end":75,"id":9,"ws":true},{"text":"combination","start":76,"end":87,"id":10,"ws":true},{"text":"therapy","start":88,"end":95,"id":11,"ws":true},{"text":"is","start":96,"end":98,"id":12,"ws":true},{"text":"effective","start":99,"end":108,"id":13,"ws":true},{"text":"against","start":109,"end":116,"id":14,"ws":true},{"text":"recurrent","start":117,"end":126,"id":15,"ws":true},{"text":"triple","start":127,"end":133,"id":16,"ws":true},{"text":"negative","start":134,"end":142,"id":17,"ws":true},{"text":"breast","start":143,"end":149,"id":18,"ws":true},{"text":"cancer","start":150,"end":156,"id":19,"ws":true},{"text":"--","start":157,"end":159,"id":20,"ws":true},{"text":"a","start":160,"end":161,"id":21,"ws":true},{"text":"case","start":162,"end":166,"id":22,"ws":true},{"text":"report","start":167,"end":173,"id":23,"ws":true},{"text":"]","start":174,"end":175,"id":24,"ws":true},{"text":".","start":176,"end":177,"id":25,"ws":false}],"spans":[{"start":2,"end":15,"token_start":1,"token_end":1,"label":"DRUG"},{"start":18,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},{"start":50,"end":66,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19098418/","_input_hash":2087265277,"_task_hash":-1410589239,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":1,"child":3,"head_span":{"start":2,"end":15,"token_start":1,"token_end":1,"label":"DRUG"},"child_span":{"start":18,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":6,"child":3,"head_span":{"start":50,"end":66,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":18,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Superposition predicted that oral dosing of 1800-mg valganciclovir two times daily would fail to produce and maintain effective plasma concentrations of ganciclovir .","paragraph":"<h3><u>Pharmacokinetics of ganciclovir and valganciclovir in the adult horse.</u></h3>Equine herpes myeloencephalopathy, resulting from equine herpes virus type 1 (EHV-1) infection, is associated with substantial morbidity and mortality in the horse. As compared to other antiviral drugs, such as acyclovir, <b style='color:Tomato;'><i>ganciclovir</i></b> has enhanced potency against EHV-1. This study investigated the pharmacokinetics of <b style='color:Tomato;'><i>ganciclovir</i></b> and its oral prodrug, val<b style='color:Tomato;'><i>ganciclovir</i></b>, in six adult horses in a randomized cross-over design. <b style='color:Tomato;'><i>ganciclovir</i></b> sodium was administered intravenously as a slow bolus at a dose of 2.5 mg/kg, and val<b style='color:Tomato;'><i>ganciclovir</i></b> was administered orally at a dose of 1800 mg per horse. Intravenously administered <b style='color:Tomato;'><i>ganciclovir</i></b> disposition was best described by a three-compartment model with a prolonged terminal half-life of 72 \u00b1 9 h. Following the oral administration of val<b style='color:Tomato;'><i>ganciclovir</i></b>, the mean observed maximum serum <b style='color:Tomato;'><i>ganciclovir</i></b> concentration was 0.58 \u00b1 0.37 \u03bcg/mL, and bioavailability of <b style='color:Tomato;'><i>ganciclovir</i></b> from oral val<b style='color:Tomato;'><i>ganciclovir</i></b> was 41 \u00b1 20%. <b style='color:DodgerBlue;'><i>Superposition</i></b> <b style='color:DodgerBlue;'><i>predicted</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>dosing</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>1800-mg</i></b> <b style='color:MediumOrchid;'><i>valganciclovir</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>times</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>would</i></b> <b style='color:DodgerBlue;'><i>fail</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>maintain</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ganciclovir</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, superposition suggested that i.v. administration of <b style='color:Tomato;'><i>ganciclovir</i></b> at 2.5 mg/kg every 8 h for 24 h followed by maintenance dosing of 2.5 mg/kg every 12 h would maintain effective <b style='color:Tomato;'><i>ganciclovir</i></b> serum concentrations in most horses throughout the dosing interval.","tokens":[{"text":"Superposition","start":0,"end":13,"id":0,"ws":true},{"text":"predicted","start":14,"end":23,"id":1,"ws":true},{"text":"that","start":24,"end":28,"id":2,"ws":true},{"text":"oral","start":29,"end":33,"id":3,"ws":true},{"text":"dosing","start":34,"end":40,"id":4,"ws":true},{"text":"of","start":41,"end":43,"id":5,"ws":true},{"text":"1800-mg","start":44,"end":51,"id":6,"ws":true},{"text":"valganciclovir","start":52,"end":66,"id":7,"ws":true},{"text":"two","start":67,"end":70,"id":8,"ws":true},{"text":"times","start":71,"end":76,"id":9,"ws":true},{"text":"daily","start":77,"end":82,"id":10,"ws":true},{"text":"would","start":83,"end":88,"id":11,"ws":true},{"text":"fail","start":89,"end":93,"id":12,"ws":true},{"text":"to","start":94,"end":96,"id":13,"ws":true},{"text":"produce","start":97,"end":104,"id":14,"ws":true},{"text":"and","start":105,"end":108,"id":15,"ws":true},{"text":"maintain","start":109,"end":117,"id":16,"ws":true},{"text":"effective","start":118,"end":127,"id":17,"ws":true},{"text":"plasma","start":128,"end":134,"id":18,"ws":true},{"text":"concentrations","start":135,"end":149,"id":19,"ws":true},{"text":"of","start":150,"end":152,"id":20,"ws":true},{"text":"ganciclovir","start":153,"end":164,"id":21,"ws":true},{"text":".","start":165,"end":166,"id":22,"ws":false}],"spans":[{"start":52,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},{"start":153,"end":164,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23301502/","_input_hash":1671572018,"_task_hash":724432557,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The levels of 3 NF-kappaB transcription factors , the activating inhibitors of NF-kappaB ( IkappaB ) kinases , and the NF-kappaB target matrix metalloproteinase 9 ( MMP9 ) were assessed by immunohistochemistry in specimens of ovarian cancer that were obtained at diagnosis from a cohort of 33 patients who subsequently received combined paclitaxel , cisplatin , and cyclophosphamide .","paragraph":"<h3><u>Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer.</u></h3>Recent work has suggested a role for nuclear factor kappaB (NF-kappaB) in the propagation of ovarian cancer cell lines, but the significance and mechanism of NF-kappaB in ovarian cancer is unknown. The authors hypothesized that the NF-kappaB pathway is over activated in aggressive ovarian cancers. ### methods <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>NF-kappaB</i></b> <b style='color:DodgerBlue;'><i>transcription</i></b> <b style='color:DodgerBlue;'><i>factors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>activating</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NF-kappaB</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>IkappaB</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>kinases</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>NF-kappaB</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>matrix</i></b> <b style='color:DodgerBlue;'><i>metalloproteinase</i></b> <b style='color:DodgerBlue;'><i>9</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MMP9</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>assessed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>immunohistochemistry</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>specimens</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>obtained</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>diagnosis</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>cohort</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>33</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>subsequently</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Associations were made between NF-kappaB pathway proteins and outcome. The validation of coexpression was performed at the gene level in 2 independently collected cohorts of 185 and 153 ovarian cancers. ### results The presence of NF-kappaB proteins in newly diagnosed advanced ovarian cancers was established, and a potential association with overall survival was identified. Transcription factors p65 and v-rel reticuloendotheliosis viral oncogene homolog B (RelB) were coexpressed with IkappaB kinase alpha, 1 component of a key trimolecular regulatory complex. Coexpression of the NF-kappaB machinery suggested activity of NF-kappaB signaling in these ovarian tumors. A significant association of p50 with poor overall survival was observed (P = .02). MMP9 expression had the opposite association, in which patients who had tumors without MMP9 staining had the poorest prognosis (P = .01), and this association held true at the gene expression level in an independently collected cohort of 185 ovarian cancers. ### conclusions The deregulation of NF-kappaB activity may influence outcome in women who receive standard therapy for advanced ovarian cancer. Modification of the NF-kappaB pathway may present an opportunity to improve outcome in the subset of women who have pathway activity.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"levels","start":4,"end":10,"id":1,"ws":true},{"text":"of","start":11,"end":13,"id":2,"ws":true},{"text":"3","start":14,"end":15,"id":3,"ws":true},{"text":"NF-kappaB","start":16,"end":25,"id":4,"ws":true},{"text":"transcription","start":26,"end":39,"id":5,"ws":true},{"text":"factors","start":40,"end":47,"id":6,"ws":true},{"text":",","start":48,"end":49,"id":7,"ws":true},{"text":"the","start":50,"end":53,"id":8,"ws":true},{"text":"activating","start":54,"end":64,"id":9,"ws":true},{"text":"inhibitors","start":65,"end":75,"id":10,"ws":true},{"text":"of","start":76,"end":78,"id":11,"ws":true},{"text":"NF-kappaB","start":79,"end":88,"id":12,"ws":true},{"text":"(","start":89,"end":90,"id":13,"ws":true},{"text":"IkappaB","start":91,"end":98,"id":14,"ws":true},{"text":")","start":99,"end":100,"id":15,"ws":true},{"text":"kinases","start":101,"end":108,"id":16,"ws":true},{"text":",","start":109,"end":110,"id":17,"ws":true},{"text":"and","start":111,"end":114,"id":18,"ws":true},{"text":"the","start":115,"end":118,"id":19,"ws":true},{"text":"NF-kappaB","start":119,"end":128,"id":20,"ws":true},{"text":"target","start":129,"end":135,"id":21,"ws":true},{"text":"matrix","start":136,"end":142,"id":22,"ws":true},{"text":"metalloproteinase","start":143,"end":160,"id":23,"ws":true},{"text":"9","start":161,"end":162,"id":24,"ws":true},{"text":"(","start":163,"end":164,"id":25,"ws":true},{"text":"MMP9","start":165,"end":169,"id":26,"ws":true},{"text":")","start":170,"end":171,"id":27,"ws":true},{"text":"were","start":172,"end":176,"id":28,"ws":true},{"text":"assessed","start":177,"end":185,"id":29,"ws":true},{"text":"by","start":186,"end":188,"id":30,"ws":true},{"text":"immunohistochemistry","start":189,"end":209,"id":31,"ws":true},{"text":"in","start":210,"end":212,"id":32,"ws":true},{"text":"specimens","start":213,"end":222,"id":33,"ws":true},{"text":"of","start":223,"end":225,"id":34,"ws":true},{"text":"ovarian","start":226,"end":233,"id":35,"ws":true},{"text":"cancer","start":234,"end":240,"id":36,"ws":true},{"text":"that","start":241,"end":245,"id":37,"ws":true},{"text":"were","start":246,"end":250,"id":38,"ws":true},{"text":"obtained","start":251,"end":259,"id":39,"ws":true},{"text":"at","start":260,"end":262,"id":40,"ws":true},{"text":"diagnosis","start":263,"end":272,"id":41,"ws":true},{"text":"from","start":273,"end":277,"id":42,"ws":true},{"text":"a","start":278,"end":279,"id":43,"ws":true},{"text":"cohort","start":280,"end":286,"id":44,"ws":true},{"text":"of","start":287,"end":289,"id":45,"ws":true},{"text":"33","start":290,"end":292,"id":46,"ws":true},{"text":"patients","start":293,"end":301,"id":47,"ws":true},{"text":"who","start":302,"end":305,"id":48,"ws":true},{"text":"subsequently","start":306,"end":318,"id":49,"ws":true},{"text":"received","start":319,"end":327,"id":50,"ws":true},{"text":"combined","start":328,"end":336,"id":51,"ws":true},{"text":"paclitaxel","start":337,"end":347,"id":52,"ws":true},{"text":",","start":348,"end":349,"id":53,"ws":true},{"text":"cisplatin","start":350,"end":359,"id":54,"ws":true},{"text":",","start":360,"end":361,"id":55,"ws":true},{"text":"and","start":362,"end":365,"id":56,"ws":true},{"text":"cyclophosphamide","start":366,"end":382,"id":57,"ws":true},{"text":".","start":383,"end":384,"id":58,"ws":false}],"spans":[{"start":337,"end":347,"token_start":52,"token_end":52,"label":"DRUG"},{"start":366,"end":382,"token_start":57,"token_end":57,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20564628/","_input_hash":126861050,"_task_hash":-1105237500,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":52,"child":54,"head_span":{"start":337,"end":347,"token_start":52,"token_end":52,"label":"DRUG"},"child_span":{"start":350,"end":359,"token_start":54,"token_end":54,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":57,"child":54,"head_span":{"start":366,"end":382,"token_start":57,"token_end":57,"label":"DRUG"},"child_span":{"start":350,"end":359,"token_start":54,"token_end":54,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"The clonidine DV suppression was reliably reversed by yohimbine ( 1.75 micrograms ) , but by none of the other adrenoceptor antagonists or naloxone .","paragraph":"<h3><u>The role of brain norepinephrine in clonidine suppression of isolation-induced distress in the domestic chick.</u></h3>Distress vocalizations (DV) induced by social isolation were measured in 1-day-old domestic chicks after intracerebroventricular injections of drugs believed to exert their effects through the noradrenergic system. The alpha-adrenoreceptor agonist <b style='color:Tomato;'><i>clonidine</i></b> reliably suppressed DV rates at doses low as 0.08 micrograms. When given alone, <b style='color:Tomato;'><i>phentolamine</i></b>, <b style='color:Tomato;'><i>phenoxybenzamine</i></b>, <b style='color:Tomato;'><i>propranolol</i></b>, <b style='color:Tomato;'><i>sotalol</i></b>, and <b style='color:Tomato;'><i>yohimbine</i></b> (adrenoreceptor antagonists) did not reliably alter DV rates at doses that were not toxic. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:MediumOrchid;'><i>clonidine</i></b> <b style='color:DodgerBlue;'><i>DV</i></b> <b style='color:DodgerBlue;'><i>suppression</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>reliably</i></b> <b style='color:DodgerBlue;'><i>reversed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>yohimbine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1.75</i></b> <b style='color:DodgerBlue;'><i>micrograms</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>none</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>adrenoceptor</i></b> <b style='color:DodgerBlue;'><i>antagonists</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>naloxone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> 6-Hydroxydopamine at doses as high as 120 micrograms, which essentially eliminated forebrain nor<b style='color:Tomato;'><i>epinephrine</i></b>, failed to suppress DV rates reliably when given alone and, when given in combination with <b style='color:Tomato;'><i>clonidine</i></b> (0.1 micrograms) or morphine (0.05 micrograms), failed to reverse the severe DV suppression imposed by these drugs. The results suggest that <b style='color:Tomato;'><i>clonidine</i></b> suppresses DV rates in or by some means other than prejunctional alpha 2-adrenoreceptor stimulation.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"clonidine","start":4,"end":13,"id":1,"ws":true},{"text":"DV","start":14,"end":16,"id":2,"ws":true},{"text":"suppression","start":17,"end":28,"id":3,"ws":true},{"text":"was","start":29,"end":32,"id":4,"ws":true},{"text":"reliably","start":33,"end":41,"id":5,"ws":true},{"text":"reversed","start":42,"end":50,"id":6,"ws":true},{"text":"by","start":51,"end":53,"id":7,"ws":true},{"text":"yohimbine","start":54,"end":63,"id":8,"ws":true},{"text":"(","start":64,"end":65,"id":9,"ws":true},{"text":"1.75","start":66,"end":70,"id":10,"ws":true},{"text":"micrograms","start":71,"end":81,"id":11,"ws":true},{"text":")","start":82,"end":83,"id":12,"ws":true},{"text":",","start":84,"end":85,"id":13,"ws":true},{"text":"but","start":86,"end":89,"id":14,"ws":true},{"text":"by","start":90,"end":92,"id":15,"ws":true},{"text":"none","start":93,"end":97,"id":16,"ws":true},{"text":"of","start":98,"end":100,"id":17,"ws":true},{"text":"the","start":101,"end":104,"id":18,"ws":true},{"text":"other","start":105,"end":110,"id":19,"ws":true},{"text":"adrenoceptor","start":111,"end":123,"id":20,"ws":true},{"text":"antagonists","start":124,"end":135,"id":21,"ws":true},{"text":"or","start":136,"end":138,"id":22,"ws":true},{"text":"naloxone","start":139,"end":147,"id":23,"ws":true},{"text":".","start":148,"end":149,"id":24,"ws":false}],"spans":[{"start":4,"end":13,"token_start":1,"token_end":1,"label":"DRUG"},{"start":54,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},{"start":139,"end":147,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6407049/","_input_hash":111823806,"_task_hash":-2067608680,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"There was heterogeneity in tumour responsiveness to sunitinib or sorafenib according to CAIX status ; the mean shrinkage was -17 % vs -25 % for sunitinib-treated patients with high vs low tumour CAIX expression , compared to -13 % vs + 9 % for sorafenib-treated patients ( P interaction , 0.05 ) .","paragraph":"<h3><u>Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.</u></h3>To investigate the utility of tumour carbonic anhydrase IX (CAIX) expression and histological features for predicting the outcome in patients with metastatic clear-cell renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy. ### Patients And Methods We identified 118 patients with mRCC initiating first-line VEGF-targeted therapy, including 94 with clinical and histological data, and available tissue. The primary endpoint was to detect an interaction between <b style='color:Tomato;'><i>sorafenib</i></b> vs <b style='color:Tomato;'><i>sunitinib</i></b> treatment and CAIX status on tumour shrinkage. Other treatment outcomes were also assessed. ### results <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>heterogeneity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>tumour</i></b> <b style='color:DodgerBlue;'><i>responsiveness</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>according</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>CAIX</i></b> <b style='color:DodgerBlue;'><i>status</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>shrinkage</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>-17</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>-25</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>sunitinib-treated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>low</i></b> <b style='color:DodgerBlue;'><i>tumour</i></b> <b style='color:DodgerBlue;'><i>CAIX</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>-13</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>9</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>sorafenib-treated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>0.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A higher tumour clear-cell component was independently associated with greater tumour shrinkage (P= 0.02), response (P= 0.02) and treatment duration (P= 0.02). ### conclusions Although CAIX expression had no prognostic value in patients with clear-cell mRCC treated with VEGF-targeted therapy, it might be a predictive biomarker for response to <b style='color:Tomato;'><i>sorafenib</i></b> treatment. Patients with a higher clear-cell component in their tumours are likely to have a superior clinical benefit from VEGF-targeted therapy.","tokens":[{"text":"There","start":0,"end":5,"id":0,"ws":true},{"text":"was","start":6,"end":9,"id":1,"ws":true},{"text":"heterogeneity","start":10,"end":23,"id":2,"ws":true},{"text":"in","start":24,"end":26,"id":3,"ws":true},{"text":"tumour","start":27,"end":33,"id":4,"ws":true},{"text":"responsiveness","start":34,"end":48,"id":5,"ws":true},{"text":"to","start":49,"end":51,"id":6,"ws":true},{"text":"sunitinib","start":52,"end":61,"id":7,"ws":true},{"text":"or","start":62,"end":64,"id":8,"ws":true},{"text":"sorafenib","start":65,"end":74,"id":9,"ws":true},{"text":"according","start":75,"end":84,"id":10,"ws":true},{"text":"to","start":85,"end":87,"id":11,"ws":true},{"text":"CAIX","start":88,"end":92,"id":12,"ws":true},{"text":"status","start":93,"end":99,"id":13,"ws":true},{"text":";","start":100,"end":101,"id":14,"ws":true},{"text":"the","start":102,"end":105,"id":15,"ws":true},{"text":"mean","start":106,"end":110,"id":16,"ws":true},{"text":"shrinkage","start":111,"end":120,"id":17,"ws":true},{"text":"was","start":121,"end":124,"id":18,"ws":true},{"text":"-17","start":125,"end":128,"id":19,"ws":true},{"text":"%","start":129,"end":130,"id":20,"ws":true},{"text":"vs","start":131,"end":133,"id":21,"ws":true},{"text":"-25","start":134,"end":137,"id":22,"ws":true},{"text":"%","start":138,"end":139,"id":23,"ws":true},{"text":"for","start":140,"end":143,"id":24,"ws":true},{"text":"sunitinib-treated","start":144,"end":161,"id":25,"ws":true},{"text":"patients","start":162,"end":170,"id":26,"ws":true},{"text":"with","start":171,"end":175,"id":27,"ws":true},{"text":"high","start":176,"end":180,"id":28,"ws":true},{"text":"vs","start":181,"end":183,"id":29,"ws":true},{"text":"low","start":184,"end":187,"id":30,"ws":true},{"text":"tumour","start":188,"end":194,"id":31,"ws":true},{"text":"CAIX","start":195,"end":199,"id":32,"ws":true},{"text":"expression","start":200,"end":210,"id":33,"ws":true},{"text":",","start":211,"end":212,"id":34,"ws":true},{"text":"compared","start":213,"end":221,"id":35,"ws":true},{"text":"to","start":222,"end":224,"id":36,"ws":true},{"text":"-13","start":225,"end":228,"id":37,"ws":true},{"text":"%","start":229,"end":230,"id":38,"ws":true},{"text":"vs","start":231,"end":233,"id":39,"ws":true},{"text":"+","start":234,"end":235,"id":40,"ws":true},{"text":"9","start":236,"end":237,"id":41,"ws":true},{"text":"%","start":238,"end":239,"id":42,"ws":true},{"text":"for","start":240,"end":243,"id":43,"ws":true},{"text":"sorafenib-treated","start":244,"end":261,"id":44,"ws":true},{"text":"patients","start":262,"end":270,"id":45,"ws":true},{"text":"(","start":271,"end":272,"id":46,"ws":true},{"text":"P","start":273,"end":274,"id":47,"ws":true},{"text":"interaction","start":275,"end":286,"id":48,"ws":true},{"text":",","start":287,"end":288,"id":49,"ws":true},{"text":"0.05","start":289,"end":293,"id":50,"ws":true},{"text":")","start":294,"end":295,"id":51,"ws":true},{"text":".","start":296,"end":297,"id":52,"ws":false}],"spans":[{"start":52,"end":61,"token_start":7,"token_end":7,"label":"DRUG"},{"start":65,"end":74,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20230385/","_input_hash":715394695,"_task_hash":781488155,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Randomized</i></b> <b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>Trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Seribantumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Erlotinib</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>Wild-Type</i></b> <b style='color:DodgerBlue;'><i>Non-Small</i></b> <b style='color:DodgerBlue;'><i>Cell</i></b> <b style='color:DodgerBlue;'><i>Lung</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>seribantumab</i></b> (MM-121) is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 ( ### Materials And Methods Patients with ### results One hundred twenty-nine patients received <b style='color:Tomato;'><i>seribantumab</i></b> + <b style='color:Tomato;'><i>erlotinib</i></b> ( ### conclusion The addition of <b style='color:Tomato;'><i>seribantumab</i></b> to <b style='color:Tomato;'><i>erlotinib</i></b> did not result in improved PFS in unselected patients. However, predefined retrospective exploratory analyses suggest that detectable HRG mRNA levels identified patients who might benefit from <b style='color:Tomato;'><i>seribantumab</i></b>. An ongoing clinical trial of <b style='color:Tomato;'><i>seribantumab</i></b>, in combination with <b style='color:Tomato;'><i>docetaxel</i></b>, is underway in patients with advanced NSCLC and high HRG mRNA expression (NCT02387216). ### Implications For Practice The poor prognosis of patients with non-small cell lung cancer (NSCLC) underscores the need for more effective treatment options, highlighting the unmet medical need in this patient population. The results of this study show that a novel biomarker, heregulin, may help to identify patients with advanced NSCLC who could benefit from treatment with <b style='color:Tomato;'><i>seribantumab</i></b>. On the basis of the observed safety profile and promising clinical efficacy, a prospective, randomized, open-label, international, multicenter phase II trial (SHERLOC, NCT02387216) is under way to investigate the efficacy and safety of <b style='color:Tomato;'><i>seribantumab</i></b> in combination with <b style='color:Tomato;'><i>docetaxel</i></b> in patients with heregulin-positive advanced adenocarcinoma.","tokens":[{"text":"Randomized","start":0,"end":10,"id":0,"ws":true},{"text":"Phase","start":11,"end":16,"id":1,"ws":true},{"text":"II","start":17,"end":19,"id":2,"ws":true},{"text":"Trial","start":20,"end":25,"id":3,"ws":true},{"text":"of","start":26,"end":28,"id":4,"ws":true},{"text":"Seribantumab","start":29,"end":41,"id":5,"ws":true},{"text":"in","start":42,"end":44,"id":6,"ws":true},{"text":"Combination","start":45,"end":56,"id":7,"ws":true},{"text":"with","start":57,"end":61,"id":8,"ws":true},{"text":"Erlotinib","start":62,"end":71,"id":9,"ws":true},{"text":"in","start":72,"end":74,"id":10,"ws":true},{"text":"Patients","start":75,"end":83,"id":11,"ws":true},{"text":"with","start":84,"end":88,"id":12,"ws":true},{"text":"EGFR","start":89,"end":93,"id":13,"ws":true},{"text":"Wild-Type","start":94,"end":103,"id":14,"ws":true},{"text":"Non-Small","start":104,"end":113,"id":15,"ws":true},{"text":"Cell","start":114,"end":118,"id":16,"ws":true},{"text":"Lung","start":119,"end":123,"id":17,"ws":true},{"text":"Cancer","start":124,"end":130,"id":18,"ws":true},{"text":".","start":131,"end":132,"id":19,"ws":false}],"spans":[{"start":29,"end":41,"token_start":5,"token_end":5,"label":"DRUG"},{"start":62,"end":71,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30975923/","_input_hash":1717360567,"_task_hash":1409545858,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":5,"child":9,"head_span":{"start":29,"end":41,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":62,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Under these circumstances , both epinephrine ( EPI ) and neuropeptide Y ( NPY ) are released .","paragraph":"<h3><u>NPY modulates epinephrine-induced leukocytosis via Y-1 and Y-5 receptor activation in vivo: sympathetic co-transmission during leukocyte mobilization.</u></h3>Sympathetic nervous system (SNS) activation mobilizes blood leukocytes. <b style='color:DodgerBlue;'><i>Under</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>circumstances</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:MediumOrchid;'><i>epinephrine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>EPI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>neuropeptide</i></b> <b style='color:DodgerBlue;'><i>Y</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NPY</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>released</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Therefore, we investigated a possible interaction between these transmitters during leukocyte mobilization, using intravenous catheterization of male adult Lewis rats. Intravenous application of NPY followed by EPI, dose-dependently facilitated, intensified and inhibited EPI-induced leukocytosis with subset-specificity for NK-cells, monocytes, and B-lymphocytes. Pharmacological assessment of NPY receptors involved revealed a Y-1R-mediated inhibition and a Y-5R-mediated facilitation. RT-PCR on peripheral blood mononuclear cells (PBMC) detected Y-1R mRNA only, suggesting direct Y-1R-mediated effects on leukocytes and indirect effects via the Y-5R. Thus, via a specific Y-1R/Y-5R interplay, NPY acts as a neuroimmune co-transmitter in vivo.","tokens":[{"text":"Under","start":0,"end":5,"id":0,"ws":true},{"text":"these","start":6,"end":11,"id":1,"ws":true},{"text":"circumstances","start":12,"end":25,"id":2,"ws":true},{"text":",","start":26,"end":27,"id":3,"ws":true},{"text":"both","start":28,"end":32,"id":4,"ws":true},{"text":"epinephrine","start":33,"end":44,"id":5,"ws":true},{"text":"(","start":45,"end":46,"id":6,"ws":true},{"text":"EPI","start":47,"end":50,"id":7,"ws":true},{"text":")","start":51,"end":52,"id":8,"ws":true},{"text":"and","start":53,"end":56,"id":9,"ws":true},{"text":"neuropeptide","start":57,"end":69,"id":10,"ws":true},{"text":"Y","start":70,"end":71,"id":11,"ws":true},{"text":"(","start":72,"end":73,"id":12,"ws":true},{"text":"NPY","start":74,"end":77,"id":13,"ws":true},{"text":")","start":78,"end":79,"id":14,"ws":true},{"text":"are","start":80,"end":83,"id":15,"ws":true},{"text":"released","start":84,"end":92,"id":16,"ws":true},{"text":".","start":93,"end":94,"id":17,"ws":false}],"spans":[{"start":33,"end":44,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12417430/","_input_hash":-758737709,"_task_hash":-244348338,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Trabectedin in combination with pegylated liposomal doxorubicin ( PLD ) has been fully available privately in the UK since 2009 for treating patients with ROC .","paragraph":"<h3><u>Real-life experience using trabectedin plus pegylated liposomal doxorubicin combination to treat patients with relapsed ovarian cancer.</u></h3>The goal of recurrent ovarian cancer (ROC) treatment is no longer just palliation, but prolonging survival. This is usually through administering a new line of chemotherapy at each relapse. A novel treatment sequencing strategy to achieve this is through the intercalation of an effective non-platinum alternative, in between platinum-based therapies. <b style='color:MediumOrchid;'><i>Trabectedin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>pegylated</i></b> <b style='color:DodgerBlue;'><i>liposomal</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PLD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>fully</i></b> <b style='color:DodgerBlue;'><i>available</i></b> <b style='color:DodgerBlue;'><i>privately</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>UK</i></b> <b style='color:DodgerBlue;'><i>since</i></b> <b style='color:DodgerBlue;'><i>2009</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ROC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A single institution's experience with the <b style='color:Tomato;'><i>trabectedin</i></b> + PLD combination, as a non-platinum/non-taxane alternative, to intercalate between platinum-based therapies is reported here. To date 6 patients have been successfully treated with <b style='color:Tomato;'><i>trabectedin</i></b> + PLD at Broomfield Hospital, Chelmsford, Essex. Here we describe a new, practice-changing treatment approach in a real-life case study of a heavily-treated patient with advanced ROC treated with <b style='color:Tomato;'><i>trabectedin</i></b> + PLD at fourth-line and then subsequently rechallenged at seventh-line; with treatment continuing until disease progression.","tokens":[{"text":"Trabectedin","start":0,"end":11,"id":0,"ws":true},{"text":"in","start":12,"end":14,"id":1,"ws":true},{"text":"combination","start":15,"end":26,"id":2,"ws":true},{"text":"with","start":27,"end":31,"id":3,"ws":true},{"text":"pegylated","start":32,"end":41,"id":4,"ws":true},{"text":"liposomal","start":42,"end":51,"id":5,"ws":true},{"text":"doxorubicin","start":52,"end":63,"id":6,"ws":true},{"text":"(","start":64,"end":65,"id":7,"ws":true},{"text":"PLD","start":66,"end":69,"id":8,"ws":true},{"text":")","start":70,"end":71,"id":9,"ws":true},{"text":"has","start":72,"end":75,"id":10,"ws":true},{"text":"been","start":76,"end":80,"id":11,"ws":true},{"text":"fully","start":81,"end":86,"id":12,"ws":true},{"text":"available","start":87,"end":96,"id":13,"ws":true},{"text":"privately","start":97,"end":106,"id":14,"ws":true},{"text":"in","start":107,"end":109,"id":15,"ws":true},{"text":"the","start":110,"end":113,"id":16,"ws":true},{"text":"UK","start":114,"end":116,"id":17,"ws":true},{"text":"since","start":117,"end":122,"id":18,"ws":true},{"text":"2009","start":123,"end":127,"id":19,"ws":true},{"text":"for","start":128,"end":131,"id":20,"ws":true},{"text":"treating","start":132,"end":140,"id":21,"ws":true},{"text":"patients","start":141,"end":149,"id":22,"ws":true},{"text":"with","start":150,"end":154,"id":23,"ws":true},{"text":"ROC","start":155,"end":158,"id":24,"ws":true},{"text":".","start":159,"end":160,"id":25,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":52,"end":63,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26759528/","_input_hash":202780827,"_task_hash":862939044,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":0,"child":6,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":52,"end":63,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"More interestingly , lumefantrine tolerance is associated with an increase in chloroquine susceptibility , raising the possibility of re-introducing chloroquine .","paragraph":"<h3><u>Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine.</u></h3>Coartem(\u00ae), the combination of <b style='color:Tomato;'><i>artemether</i></b> (an <b style='color:Tomato;'><i>artemisinin</i></b> derivative) and <b style='color:Tomato;'><i>lumefantrine</i></b>, has been adopted as the first-line treatment for uncomplicated malaria in many countries. The emergence of resistance to <b style='color:Tomato;'><i>artemisinin</i></b> derivatives has now been proven in South-East Asia, and there is concern that this may spread to other endemic areas. Strategies to contain and control the spread of <b style='color:Tomato;'><i>artemisinin</i></b> resistance have been proposed. On the other hand, not much attention has been given to <b style='color:Tomato;'><i>lumefantrine</i></b>. Indeed, for more than 7 years, reports have been emerging that the use of Coartem(\u00ae) is associated with rapid selection of <b style='color:Tomato;'><i>lumefantrine</i></b>-tolerant parasites. These parasites can survive in the presence of sub-therapeutic <b style='color:Tomato;'><i>lumefantrine</i></b> concentrations, and, interestingly, this in vivo phenotype is translated in vitro into reduced susceptibility to <b style='color:Tomato;'><i>lumefantrine</i></b>. As a result, such parasites could form the setting in which <b style='color:Tomato;'><i>lumefantrine</i></b> resistance would emerge. Thus, identifying genetic markers that reflect this phenotype (both in vitro and in vivo) could yield information on the mechanisms of <b style='color:Tomato;'><i>lumefantrine</i></b> resistance. <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>interestingly</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>lumefantrine</i></b> <b style='color:DodgerBlue;'><i>tolerance</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>susceptibility</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>raising</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>possibility</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>re-introducing</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this work, we have reviewed the current knowledge, and we present existing challenges and gaps with regard to the mechanisms of in vivo tolerance and in vitro reduced susceptibility to <b style='color:Tomato;'><i>lumefantrine</i></b>. The re-introduction of <b style='color:Tomato;'><i>chloroquine</i></b> in areas of high <b style='color:Tomato;'><i>lumefantrine</i></b> resistance is also discussed.","tokens":[{"text":"More","start":0,"end":4,"id":0,"ws":true},{"text":"interestingly","start":5,"end":18,"id":1,"ws":true},{"text":",","start":19,"end":20,"id":2,"ws":true},{"text":"lumefantrine","start":21,"end":33,"id":3,"ws":true},{"text":"tolerance","start":34,"end":43,"id":4,"ws":true},{"text":"is","start":44,"end":46,"id":5,"ws":true},{"text":"associated","start":47,"end":57,"id":6,"ws":true},{"text":"with","start":58,"end":62,"id":7,"ws":true},{"text":"an","start":63,"end":65,"id":8,"ws":true},{"text":"increase","start":66,"end":74,"id":9,"ws":true},{"text":"in","start":75,"end":77,"id":10,"ws":true},{"text":"chloroquine","start":78,"end":89,"id":11,"ws":true},{"text":"susceptibility","start":90,"end":104,"id":12,"ws":true},{"text":",","start":105,"end":106,"id":13,"ws":true},{"text":"raising","start":107,"end":114,"id":14,"ws":true},{"text":"the","start":115,"end":118,"id":15,"ws":true},{"text":"possibility","start":119,"end":130,"id":16,"ws":true},{"text":"of","start":131,"end":133,"id":17,"ws":true},{"text":"re-introducing","start":134,"end":148,"id":18,"ws":true},{"text":"chloroquine","start":149,"end":160,"id":19,"ws":true},{"text":".","start":161,"end":162,"id":20,"ws":false}],"spans":[{"start":21,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},{"start":78,"end":89,"token_start":11,"token_end":11,"label":"DRUG"},{"start":149,"end":160,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22761327/","_input_hash":-86853250,"_task_hash":2044021103,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Estramustine has been shown to potentiate the antimicrotubule effects of vinblastine .","paragraph":"<h3><u>Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.</u></h3>It is well known that metastatic renal cell carcinoma (RCC) exhibits constitutive resistance to chemotherapeutic agents. Antimicrotubule agents such as <b style='color:Tomato;'><i>vinblastine</i></b> are associated with low but reproducible response rates (approximately 12%) in patients with RCC. <b style='color:MediumOrchid;'><i>Estramustine</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>potentiate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antimicrotubule</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The authors sought to increase the activity of <b style='color:Tomato;'><i>vinblastine</i></b> in RCC through the addition of <b style='color:Tomato;'><i>estramustine</i></b>. ### methods Twenty-one patients with metastatic RCC not previously treated with chemotherapy received oral <b style='color:Tomato;'><i>estramustine</i></b> phosphate, 600 mg/m(2), on Days 1, 2, and 3 weekly for 6 weeks, and intravenous <b style='color:Tomato;'><i>vinblastine</i></b>, 4 mg/m(2) on Day 2 weekly for 6 weeks, repeated every 8 weeks. Twenty-one patients received 31 cycles of therapy. ### results Two patients experienced Grade 3 and 4 hematologic toxicity, and three patients had Grade 3 nonhematologic toxicity consisting of neurologic toxicity, hepatic toxicity, or angioneurotic edema. One patient had a partial response with decreased liver metastases for 48 weeks; 9 patients had stable disease, for a median duration of 14 weeks (range, 11-31 weeks); and 11 patients demonstrated disease progression. The median overall time to progression was 8 weeks and the median overall survival period was 24 weeks. ### conclusions Although well tolerated, the combination of oral <b style='color:Tomato;'><i>estramustine</i></b> phosphate with <b style='color:Tomato;'><i>vinblastine</i></b> administered on this schedule had minimal activity in patients with metastatic RCC.","tokens":[{"text":"Estramustine","start":0,"end":12,"id":0,"ws":true},{"text":"has","start":13,"end":16,"id":1,"ws":true},{"text":"been","start":17,"end":21,"id":2,"ws":true},{"text":"shown","start":22,"end":27,"id":3,"ws":true},{"text":"to","start":28,"end":30,"id":4,"ws":true},{"text":"potentiate","start":31,"end":41,"id":5,"ws":true},{"text":"the","start":42,"end":45,"id":6,"ws":true},{"text":"antimicrotubule","start":46,"end":61,"id":7,"ws":true},{"text":"effects","start":62,"end":69,"id":8,"ws":true},{"text":"of","start":70,"end":72,"id":9,"ws":true},{"text":"vinblastine","start":73,"end":84,"id":10,"ws":true},{"text":".","start":85,"end":86,"id":11,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":73,"end":84,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/14584064/","_input_hash":1357303578,"_task_hash":-2133874542,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":10,"child":0,"head_span":{"start":73,"end":84,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Cohort 7 ( gemcitabine 600 mg/m/wk and carboplatin 2 AUC ) showed 4 dose limiting toxicities : 2 grade 3 esophagitis ; one grade 3 febrile neutropenia ; and one grade 4 neutropenia .","paragraph":"<h3><u>RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy (\"ping-pong trial\") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer.</u></h3>The optimal dose of <b style='color:Tomato;'><i>gemcitabine</i></b> that can be used with concurrent radiation therapy for locally advanced non-small cell lung cancer has not been well defined. This trial addresses this question in an alternating sequence \"ping-pong\" design trial to find the maximum tolerated dose (MTD) for <b style='color:Tomato;'><i>gemcitabine</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b> (Sequence A) or <b style='color:Tomato;'><i>gemcitabine</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> (Sequence B) and thoracic radiation therapy followed by adjuvant <b style='color:Tomato;'><i>gemcitabine</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b> chemotherapy. ### Patients And Methods Thirty-five patients with histologically confirmed Stage IIIA/B non-small cell lung cancer were entered into two separate sequences, each with multiple cohorts. A dose level was considered acceptable if, of the first six eligible patients on each cohort, fewer than three experienced dose limiting toxicities. ### results Sequence B of this 2 sequence \"ping-pong\" trial closed early due to toxicity in cohort 2 (<b style='color:Tomato;'><i>gemcitabine</i></b> 300 mg/m/wk and <b style='color:Tomato;'><i>paclitaxel</i></b> 30 mg/m/wk). On Sequence A, the MTD was the cohort 5 dose: <b style='color:Tomato;'><i>gemcitabine</i></b> 450 mg/m/wk and <b style='color:Tomato;'><i>carboplatin</i></b> 2 area under curve (AUC) concurrently with thoracic radiation. <b style='color:DodgerBlue;'><i>Cohort</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>600</i></b> <b style='color:DodgerBlue;'><i>mg/m/wk</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>limiting</i></b> <b style='color:DodgerBlue;'><i>toxicities</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>grade</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>esophagitis</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>grade</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>febrile</i></b> <b style='color:DodgerBlue;'><i>neutropenia</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>grade</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>neutropenia</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusion Concurrent <b style='color:Tomato;'><i>gemcitabine</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> chemoradiation regimen followed by adjuvant <b style='color:Tomato;'><i>gemcitabine</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b> produced excessive toxicity at the lowest tested dose combination and was not suitable for further study in this trial. Meanwhile, the MTD of concurrent <b style='color:Tomato;'><i>gemcitabine</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b> chemoradiation was determined to be <b style='color:Tomato;'><i>gemcitabine</i></b> 450 mg/m and <b style='color:Tomato;'><i>carboplatin</i></b> AUC-2. This combination was found to be tolerable. Although not a primary end point, survival results are summarized as well.","tokens":[{"text":"Cohort","start":0,"end":6,"id":0,"ws":true},{"text":"7","start":7,"end":8,"id":1,"ws":true},{"text":"(","start":9,"end":10,"id":2,"ws":true},{"text":"gemcitabine","start":11,"end":22,"id":3,"ws":true},{"text":"600","start":23,"end":26,"id":4,"ws":true},{"text":"mg/m/wk","start":27,"end":34,"id":5,"ws":true},{"text":"and","start":35,"end":38,"id":6,"ws":true},{"text":"carboplatin","start":39,"end":50,"id":7,"ws":true},{"text":"2","start":51,"end":52,"id":8,"ws":true},{"text":"AUC","start":53,"end":56,"id":9,"ws":true},{"text":")","start":57,"end":58,"id":10,"ws":true},{"text":"showed","start":59,"end":65,"id":11,"ws":true},{"text":"4","start":66,"end":67,"id":12,"ws":true},{"text":"dose","start":68,"end":72,"id":13,"ws":true},{"text":"limiting","start":73,"end":81,"id":14,"ws":true},{"text":"toxicities","start":82,"end":92,"id":15,"ws":true},{"text":":","start":93,"end":94,"id":16,"ws":true},{"text":"2","start":95,"end":96,"id":17,"ws":true},{"text":"grade","start":97,"end":102,"id":18,"ws":true},{"text":"3","start":103,"end":104,"id":19,"ws":true},{"text":"esophagitis","start":105,"end":116,"id":20,"ws":true},{"text":";","start":117,"end":118,"id":21,"ws":true},{"text":"one","start":119,"end":122,"id":22,"ws":true},{"text":"grade","start":123,"end":128,"id":23,"ws":true},{"text":"3","start":129,"end":130,"id":24,"ws":true},{"text":"febrile","start":131,"end":138,"id":25,"ws":true},{"text":"neutropenia","start":139,"end":150,"id":26,"ws":true},{"text":";","start":151,"end":152,"id":27,"ws":true},{"text":"and","start":153,"end":156,"id":28,"ws":true},{"text":"one","start":157,"end":160,"id":29,"ws":true},{"text":"grade","start":161,"end":166,"id":30,"ws":true},{"text":"4","start":167,"end":168,"id":31,"ws":true},{"text":"neutropenia","start":169,"end":180,"id":32,"ws":true},{"text":".","start":181,"end":182,"id":33,"ws":false}],"spans":[{"start":11,"end":22,"token_start":3,"token_end":3,"label":"DRUG"},{"start":39,"end":50,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19096311/","_input_hash":-1295498406,"_task_hash":1937262419,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":3,"child":7,"head_span":{"start":11,"end":22,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":39,"end":50,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Treatment with IFN-\u03b1 plus bevacizumab or standard targeted therapy ( sunitinib ) may lead to similar one-year overall mortality ( RR 0.37 , 95 % CI 0.13 to 1.08 ; 1 study ; 83 participants ; low-quality evidence ) and AEs of grade 3 or greater ( RR 1.18 , 95 % CI 0.85 to 1.62 ; 1 study ; 82 participants ; low-quality evidence ) .","paragraph":"<h3><u>Immunotherapy for metastatic renal cell carcinoma.</u></h3>Since the mid-2000s, the field of metastatic renal cell carcinoma (mRCC) has experienced a paradigm shift from non-specific therapy with broad-acting cytokines to specific regimens, which directly target the cancer, the tumour microenvironment, or both.Current guidelines recommend targeted therapies with agents such as <b style='color:Tomato;'><i>sunitinib</i></b>, <b style='color:Tomato;'><i>pazopanib</i></b> or tem<b style='color:Tomato;'><i>sirolimus</i></b> (for people with poor prognosis) as the standard of care for first-line treatment of people with mRCC and mention non-specific cytokines as an alternative option for selected patients.In November 2015, <b style='color:Tomato;'><i>nivolumab</i></b>, a checkpoint inhibitor directed against programmed death-1 (PD-1), was approved as the first specific immunotherapeutic agent as second-line therapy in previously treated mRCC patients. ### objectives To assess the effects of immunotherapies either alone or in combination with standard targeted therapies for the treatment of metastatic renal cell carcinoma and their efficacy to maximize patient benefit. ### Search Methods We searched the Cochrane Library, MEDLINE (Ovid), Embase (Ovid), ISI Web of Science and registers of ongoing clinical trials in November 2016 without language restrictions. We scanned reference lists and contacted experts in the field to obtain further information. ### Selection Criteria We included randomized controlled trials (RCTs) and quasi-RCTs with or without blinding involving people with mRCC. ### Data Collection And Analysis We collected and analyzed studies according to the published protocol. Summary statistics for the primary endpoints were risk ratios (RRs) and mean differences (MD) with their 95% confidence intervals (CIs). We rated the quality of evidence using GRADE methodology and summarized the quality and magnitude of relative and absolute effects for each primary outcome in our 'Summary of findings' tables. ### Main Results We identified eight studies with 4732 eligible participants and an additional 13 ongoing studies. We categorized studies into comparisons, all against standard therapy accordingly as first-line (five comparisons) or second-line therapy (one comparison) for mRCC.Interferon (IFN)-\u03b1 monotherapy probably increases one-year overall mortality compared to standard targeted therapies with tem<b style='color:Tomato;'><i>sirolimus</i></b> or <b style='color:Tomato;'><i>sunitinib</i></b> (RR 1.30, 95% CI 1.13 to 1.51; 2 studies; 1166 participants; moderate-quality evidence), may lead to similar quality of life (QoL) (e.g. MD -5.58 points, 95% CI -7.25 to -3.91 for Functional Assessment of Cancer - General (FACT-G); 1 study; 730 participants; low-quality evidence) and may slightly increase the incidence of adverse events (AEs) grade 3 or greater (RR 1.17, 95% CI 1.03 to 1.32; 1 study; 408 participants; low-quality evidence).There is probably no difference between IFN-\u03b1 plus tem<b style='color:Tomato;'><i>sirolimus</i></b> and tem<b style='color:Tomato;'><i>sirolimus</i></b> alone for one-year overall mortality (RR 1.13, 95% CI 0.95 to 1.34; 1 study; 419 participants; moderate-quality evidence), but the incidence of AEs of 3 or greater may be increased (RR 1.30, 95% CI 1.17 to 1.45; 1 study; 416 participants; low-quality evidence). There was no information on QoL.IFN-\u03b1 alone may slightly increase one-year overall mortality compared to IFN-\u03b1 plus <b style='color:Tomato;'><i>bevacizumab</i></b> (RR 1.17, 95% CI 1.00 to 1.36; 2 studies; 1381 participants; low-quality evidence). This effect is probably accompanied by a lower incidence of AEs of grade 3 or greater (RR 0.77, 95% CI 0.71 to 0.84; 2 studies; 1350 participants; moderate-quality evidence). QoL could not be evaluated due to insufficient data. <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>IFN-\u03b1</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>lead</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>one-year</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>mortality</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RR</i></b> <b style='color:DodgerBlue;'><i>0.37</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>95</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>CI</i></b> <b style='color:DodgerBlue;'><i>0.13</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>1.08</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>83</i></b> <b style='color:DodgerBlue;'><i>participants</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>low-quality</i></b> <b style='color:DodgerBlue;'><i>evidence</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>AEs</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>grade</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RR</i></b> <b style='color:DodgerBlue;'><i>1.18</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>95</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>CI</i></b> <b style='color:DodgerBlue;'><i>0.85</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>1.62</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>82</i></b> <b style='color:DodgerBlue;'><i>participants</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>low-quality</i></b> <b style='color:DodgerBlue;'><i>evidence</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> QoL could not be evaluated due to insufficient data.Treatment with vaccines (e.g. MVA-5T4 or IMA901) or standard therapy may lead to similar one-year overall mortality (RR 1.10, 95% CI 0.91 to 1.32; low-quality evidence) and AEs of grade 3 or greater (RR 1.16, 95% CI 0.97 to 1.39; 2 studies; 1065 participants; low-quality evidence). QoL could not be evaluated due to insufficient data.In previously treated patients, targeted immunotherapy (<b style='color:Tomato;'><i>nivolumab</i></b>) probably reduces one-year overall mortality compared to standard targeted therapy with <b style='color:Tomato;'><i>everolimus</i></b> (RR 0.70, 95% CI 0.56 to 0.87; 1 study; 821 participants; moderate-quality evidence), probably improves QoL (e.g. RR 1.51, 95% CI 1.28 to 1.78 for clinically relevant improvement of the FACT-Kidney Symptom Index Disease Related Symptoms (FKSI-DRS); 1 study, 704 participants; moderate-quality evidence) and probably reduces the incidence of AEs grade 3 or greater (RR 0.51, 95% CI 0.40 to 0.65; 1 study; 803 participants; moderate-quality evidence). ### Authors Conclusions Evidence of moderate quality demonstrates that IFN-\u03b1 monotherapy increases mortality compared to standard targeted therapies alone, whereas there is no difference if IFN is combined with standard targeted therapies. Evidence of low quality demonstrates that QoL is worse with IFN alone and that severe AEs are increased with IFN alone or in combination. There is low-quality evidence that IFN-\u03b1 alone increases mortality but moderate-quality evidence on decreased AEs compared to IFN-\u03b1 plus <b style='color:Tomato;'><i>bevacizumab</i></b>. Low-quality evidence shows no difference for IFN-\u03b1 plus <b style='color:Tomato;'><i>bevacizumab</i></b> compared to <b style='color:Tomato;'><i>sunitinib</i></b> with respect to mortality and severe AEs. Low-quality evidence demonstrates no difference of vaccine treatment compared to standard targeted therapies in mortality and AEs, whereas there is moderate-quality evidence that targeted immunotherapies reduce mortality and AEs and improve QoL.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"with","start":10,"end":14,"id":1,"ws":true},{"text":"IFN-\u03b1","start":15,"end":20,"id":2,"ws":true},{"text":"plus","start":21,"end":25,"id":3,"ws":true},{"text":"bevacizumab","start":26,"end":37,"id":4,"ws":true},{"text":"or","start":38,"end":40,"id":5,"ws":true},{"text":"standard","start":41,"end":49,"id":6,"ws":true},{"text":"targeted","start":50,"end":58,"id":7,"ws":true},{"text":"therapy","start":59,"end":66,"id":8,"ws":true},{"text":"(","start":67,"end":68,"id":9,"ws":true},{"text":"sunitinib","start":69,"end":78,"id":10,"ws":true},{"text":")","start":79,"end":80,"id":11,"ws":true},{"text":"may","start":81,"end":84,"id":12,"ws":true},{"text":"lead","start":85,"end":89,"id":13,"ws":true},{"text":"to","start":90,"end":92,"id":14,"ws":true},{"text":"similar","start":93,"end":100,"id":15,"ws":true},{"text":"one-year","start":101,"end":109,"id":16,"ws":true},{"text":"overall","start":110,"end":117,"id":17,"ws":true},{"text":"mortality","start":118,"end":127,"id":18,"ws":true},{"text":"(","start":128,"end":129,"id":19,"ws":true},{"text":"RR","start":130,"end":132,"id":20,"ws":true},{"text":"0.37","start":133,"end":137,"id":21,"ws":true},{"text":",","start":138,"end":139,"id":22,"ws":true},{"text":"95","start":140,"end":142,"id":23,"ws":true},{"text":"%","start":143,"end":144,"id":24,"ws":true},{"text":"CI","start":145,"end":147,"id":25,"ws":true},{"text":"0.13","start":148,"end":152,"id":26,"ws":true},{"text":"to","start":153,"end":155,"id":27,"ws":true},{"text":"1.08","start":156,"end":160,"id":28,"ws":true},{"text":";","start":161,"end":162,"id":29,"ws":true},{"text":"1","start":163,"end":164,"id":30,"ws":true},{"text":"study","start":165,"end":170,"id":31,"ws":true},{"text":";","start":171,"end":172,"id":32,"ws":true},{"text":"83","start":173,"end":175,"id":33,"ws":true},{"text":"participants","start":176,"end":188,"id":34,"ws":true},{"text":";","start":189,"end":190,"id":35,"ws":true},{"text":"low-quality","start":191,"end":202,"id":36,"ws":true},{"text":"evidence","start":203,"end":211,"id":37,"ws":true},{"text":")","start":212,"end":213,"id":38,"ws":true},{"text":"and","start":214,"end":217,"id":39,"ws":true},{"text":"AEs","start":218,"end":221,"id":40,"ws":true},{"text":"of","start":222,"end":224,"id":41,"ws":true},{"text":"grade","start":225,"end":230,"id":42,"ws":true},{"text":"3","start":231,"end":232,"id":43,"ws":true},{"text":"or","start":233,"end":235,"id":44,"ws":true},{"text":"greater","start":236,"end":243,"id":45,"ws":true},{"text":"(","start":244,"end":245,"id":46,"ws":true},{"text":"RR","start":246,"end":248,"id":47,"ws":true},{"text":"1.18","start":249,"end":253,"id":48,"ws":true},{"text":",","start":254,"end":255,"id":49,"ws":true},{"text":"95","start":256,"end":258,"id":50,"ws":true},{"text":"%","start":259,"end":260,"id":51,"ws":true},{"text":"CI","start":261,"end":263,"id":52,"ws":true},{"text":"0.85","start":264,"end":268,"id":53,"ws":true},{"text":"to","start":269,"end":271,"id":54,"ws":true},{"text":"1.62","start":272,"end":276,"id":55,"ws":true},{"text":";","start":277,"end":278,"id":56,"ws":true},{"text":"1","start":279,"end":280,"id":57,"ws":true},{"text":"study","start":281,"end":286,"id":58,"ws":true},{"text":";","start":287,"end":288,"id":59,"ws":true},{"text":"82","start":289,"end":291,"id":60,"ws":true},{"text":"participants","start":292,"end":304,"id":61,"ws":true},{"text":";","start":305,"end":306,"id":62,"ws":true},{"text":"low-quality","start":307,"end":318,"id":63,"ws":true},{"text":"evidence","start":319,"end":327,"id":64,"ws":true},{"text":")","start":328,"end":329,"id":65,"ws":true},{"text":".","start":330,"end":331,"id":66,"ws":false}],"spans":[{"start":26,"end":37,"token_start":4,"token_end":4,"label":"DRUG"},{"start":69,"end":78,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/28504837/","_input_hash":-2147196630,"_task_hash":-840269859,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":15,"end":20,"token_start":2,"token_end":2,"label":null},"child_span":{"start":26,"end":37,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"In vitro , ETV4 depletion inhibited cell survival but did not influence sensitivity to MEKi selumetinib or trametinib .","paragraph":"<h3><u>Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.</u></h3>Aiming to improve treatment options for BRAF wild-type melanoma, we previously conducted the DOC-MEK study of <b style='color:Tomato;'><i>docetaxel</i></b> with MEK inhibitor (MEKi) <b style='color:Tomato;'><i>selumetinib</i></b> or placebo, revealing trends to prolongation of progression-free survival (hazard ratio 0.75, P\u2009=\u20090.130), and improved response rates (32% vs 14%, P\u2009=\u20090.059) with <b style='color:Tomato;'><i>docetaxel</i></b> plus <b style='color:Tomato;'><i>selumetinib</i></b>. NRAS status did not associate with outcome. Here, the aim was to identify novel biomarkers of response to MEKi. ### methods A MEK 6 gene signature was quantified using NanoString and correlated with clinical outcomes. Two components of the gene signature were investigated by gene silencing in BRAF/NRAS wild-type melanoma cells. ### results In melanomas of patients on the <b style='color:Tomato;'><i>selumetinib</i></b> but not the placebo arm, two gene signature components, dual-specificity protein phosphatase 4 (DUSP4) and ETS translocation variant 4 (ETV4), were expressed more highly in responders than non-responders. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ETV4</i></b> <b style='color:DodgerBlue;'><i>depletion</i></b> <b style='color:DodgerBlue;'><i>inhibited</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>influence</i></b> <b style='color:DodgerBlue;'><i>sensitivity</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>MEKi</i></b> <b style='color:MediumOrchid;'><i>selumetinib</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>trametinib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In contrast, DUSP4-depleted cells showed enhanced cell survival and increased resistance to both <b style='color:Tomato;'><i>selumetinib</i></b> and <b style='color:Tomato;'><i>trametinib</i></b>. ### conclusions ETV4 and DUSP4 associated with clinical response to <b style='color:Tomato;'><i>docetaxel</i></b> plus <b style='color:Tomato;'><i>selumetinib</i></b>. DUSP4 depletion induced MEKi resistance, suggesting that DUSP4 is not only a biomarker but also a mediator of MEKi sensitivity. ### Clinical Trial Registration DOC-MEK (EudraCT no: 2009-018153-23).","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"vitro","start":3,"end":8,"id":1,"ws":true},{"text":",","start":9,"end":10,"id":2,"ws":true},{"text":"ETV4","start":11,"end":15,"id":3,"ws":true},{"text":"depletion","start":16,"end":25,"id":4,"ws":true},{"text":"inhibited","start":26,"end":35,"id":5,"ws":true},{"text":"cell","start":36,"end":40,"id":6,"ws":true},{"text":"survival","start":41,"end":49,"id":7,"ws":true},{"text":"but","start":50,"end":53,"id":8,"ws":true},{"text":"did","start":54,"end":57,"id":9,"ws":true},{"text":"not","start":58,"end":61,"id":10,"ws":true},{"text":"influence","start":62,"end":71,"id":11,"ws":true},{"text":"sensitivity","start":72,"end":83,"id":12,"ws":true},{"text":"to","start":84,"end":86,"id":13,"ws":true},{"text":"MEKi","start":87,"end":91,"id":14,"ws":true},{"text":"selumetinib","start":92,"end":103,"id":15,"ws":true},{"text":"or","start":104,"end":106,"id":16,"ws":true},{"text":"trametinib","start":107,"end":117,"id":17,"ws":true},{"text":".","start":118,"end":119,"id":18,"ws":false}],"spans":[{"start":92,"end":103,"token_start":15,"token_end":15,"label":"DRUG"},{"start":107,"end":117,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31839677/","_input_hash":-1892343538,"_task_hash":-1796743659,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Our study aimed to analyze the influence of sorafenib and sunitinib on the frequency of Treg in patients with metastatic RCC ( mRCC ) .","paragraph":"<h3><u>Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.</u></h3>Induction of regulatory T cells (Treg) is an important mechanism leading to tolerance against tumors. Increased levels of Treg have been described in renal cell carcinoma (RCC) patients and seem to correlate with an adverse outcome. <b style='color:DodgerBlue;'><i>Our</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>aimed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>analyze</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>influence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>frequency</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Treg</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>RCC</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mRCC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Treg were analyzed by flow cytometry in the peripheral blood (PB) of patients (n=19) with histologically confirmed mRCC under treatment with either <b style='color:Tomato;'><i>sunitinib</i></b> (50 mg/d, n=11) or <b style='color:Tomato;'><i>sorafenib</i></b> (800 mg/d, n=8). Blood samples were taken before treatment and during the first, second, and third months of therapy. Flow cytometric analysis of PB mononuclear cells was performed using fluorochrome-labeled antibodies against CD3, CD4, CD25, and FOXp3. During the first month of therapy, patients treated with <b style='color:Tomato;'><i>sorafenib</i></b> showed a significant increase in FOXp3CD3CD4CD25 Treg (13.5 vs. 36.3% of gated cells, P=0.02, or 0.35 vs. 0.49% of total cells) and the ratio FOXp3 T cells/FOXp3 T cells (0.16 vs. 0.56 of gated cells, P=0.02). These elevated levels persisted throughout the treatment period. There was no influence of <b style='color:Tomato;'><i>sunitinib</i></b> on the frequency of Treg in our cohort of patients. <b style='color:Tomato;'><i>sorafenib</i></b>, but not <b style='color:Tomato;'><i>sunitinib</i></b>, leads to an early and sustained increase in Treg in PB of mRCC patients. In immunoresponsive tumors such as RCC, immunological effects of kinase inhibitors are particularly relevant for the design of combination trials with immunotherapeutic agents. Our study suggests that <b style='color:Tomato;'><i>sorafenib</i></b> should be avoided in such a therapeutic setting.","tokens":[{"text":"Our","start":0,"end":3,"id":0,"ws":true},{"text":"study","start":4,"end":9,"id":1,"ws":true},{"text":"aimed","start":10,"end":15,"id":2,"ws":true},{"text":"to","start":16,"end":18,"id":3,"ws":true},{"text":"analyze","start":19,"end":26,"id":4,"ws":true},{"text":"the","start":27,"end":30,"id":5,"ws":true},{"text":"influence","start":31,"end":40,"id":6,"ws":true},{"text":"of","start":41,"end":43,"id":7,"ws":true},{"text":"sorafenib","start":44,"end":53,"id":8,"ws":true},{"text":"and","start":54,"end":57,"id":9,"ws":true},{"text":"sunitinib","start":58,"end":67,"id":10,"ws":true},{"text":"on","start":68,"end":70,"id":11,"ws":true},{"text":"the","start":71,"end":74,"id":12,"ws":true},{"text":"frequency","start":75,"end":84,"id":13,"ws":true},{"text":"of","start":85,"end":87,"id":14,"ws":true},{"text":"Treg","start":88,"end":92,"id":15,"ws":true},{"text":"in","start":93,"end":95,"id":16,"ws":true},{"text":"patients","start":96,"end":104,"id":17,"ws":true},{"text":"with","start":105,"end":109,"id":18,"ws":true},{"text":"metastatic","start":110,"end":120,"id":19,"ws":true},{"text":"RCC","start":121,"end":124,"id":20,"ws":true},{"text":"(","start":125,"end":126,"id":21,"ws":true},{"text":"mRCC","start":127,"end":131,"id":22,"ws":true},{"text":")","start":132,"end":133,"id":23,"ws":true},{"text":".","start":134,"end":135,"id":24,"ws":false}],"spans":[{"start":44,"end":53,"token_start":8,"token_end":8,"label":"DRUG"},{"start":58,"end":67,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22156795/","_input_hash":-447360525,"_task_hash":-1283565977,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Naloxone ( 5 x 10(-7 ) mol/kg iv ) and atropine ( 0.1 mg/kg iv ) induced isolated orad contractions .","paragraph":"<h3><u>Rhythmic oscillating complex: characterization, induction, and relationship to MMC in chickens.</u></h3>Migrating myoelectrical complexes (MMCs) and rhythmic oscillating complexes (ROCs) have been investigated in chickens prepared for electromyography. Animals were chronically implanted with electrodes in stomach, duodenum, jejunum, ileum, ceca, and rectum. MMCs showing phases I-III were found in the jejunum and ileum both in fed and fasted states. Repetitive spike bursts were recorded in the duodenum (0.5-1/h), disrupting the gastroduodenal coordination and preceding a phase III in the jejunum. ROCs appeared spontaneously in fasted animals and in 75% of the recordings during the dark period. Four consecutive intestinal myoelectrical patterns have been described during a ROC. Briefly, they consisted in series of high-speed propagated abroad contractions of great amplitude that progressively changed into others of orad direction. In relation to the MMC, the ROC pattern appeared just after a phase III reached the distal ileum, and a pattern of duodenal repetitive spike bursts, followed by a migrating phase III in the jejunum, started at the duodenum after a ROC. No myoelectrical changes were recorded in cecorectal activity during ROC. Vagotomized animals showed the ROC pattern. Neither apomorphine (5-100 micrograms/kg iv) nor cholecystokinin (10(-9) mol/kg iv) induced ROCs. <b style='color:MediumOrchid;'><i>Naloxone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>x</i></b> <b style='color:DodgerBlue;'><i>10(-7</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>mol/kg</i></b> <b style='color:DodgerBlue;'><i>iv</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>atropine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.1</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>iv</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>isolated</i></b> <b style='color:DodgerBlue;'><i>orad</i></b> <b style='color:DodgerBlue;'><i>contractions</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Myoelectrical and functional similarities can be found between retrograde giant contractions, described in mammals, and ROCs. However, they differ in their origin and mechanism of induction.","tokens":[{"text":"Naloxone","start":0,"end":8,"id":0,"ws":true},{"text":"(","start":9,"end":10,"id":1,"ws":true},{"text":"5","start":11,"end":12,"id":2,"ws":true},{"text":"x","start":13,"end":14,"id":3,"ws":true},{"text":"10(-7","start":15,"end":20,"id":4,"ws":true},{"text":")","start":21,"end":22,"id":5,"ws":true},{"text":"mol/kg","start":23,"end":29,"id":6,"ws":true},{"text":"iv","start":30,"end":32,"id":7,"ws":true},{"text":")","start":33,"end":34,"id":8,"ws":true},{"text":"and","start":35,"end":38,"id":9,"ws":true},{"text":"atropine","start":39,"end":47,"id":10,"ws":true},{"text":"(","start":48,"end":49,"id":11,"ws":true},{"text":"0.1","start":50,"end":53,"id":12,"ws":true},{"text":"mg/kg","start":54,"end":59,"id":13,"ws":true},{"text":"iv","start":60,"end":62,"id":14,"ws":true},{"text":")","start":63,"end":64,"id":15,"ws":true},{"text":"induced","start":65,"end":72,"id":16,"ws":true},{"text":"isolated","start":73,"end":81,"id":17,"ws":true},{"text":"orad","start":82,"end":86,"id":18,"ws":true},{"text":"contractions","start":87,"end":99,"id":19,"ws":true},{"text":".","start":100,"end":101,"id":20,"ws":false}],"spans":[{"start":0,"end":8,"token_start":0,"token_end":0,"label":"DRUG"},{"start":39,"end":47,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8178997/","_input_hash":-1446527752,"_task_hash":-339175586,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"FACT-P change from baseline over time was better for abiraterone than for enzalutamide in the \u226575-yr model ( p=0.003 ) , with no difference in the < 75-yr model ( p>0.9 ) .","paragraph":"<h3><u>Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.</u></h3><b style='color:Tomato;'><i>abiraterone</i></b> and <b style='color:Tomato;'><i>enzalutamide</i></b> are associated with side effects that may impair health-related quality of life (HRQoL). ### objective To assess patient-reported HRQoL, depression symptoms, and cognitive function for <b style='color:Tomato;'><i>abiraterone</i></b> versus <b style='color:Tomato;'><i>enzalutamide</i></b>. ### Design Setting And Participants We randomized 202 patients in a phase II study of <b style='color:Tomato;'><i>abiraterone</i></b> versus <b style='color:Tomato;'><i>enzalutamide</i></b> for first-line treatment of metastatic castration-resistant prostate cancer (ClinicalTrials.gov: NCT02125357). ### intervention Patients completed Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Patient Health Questionnaire-9 (PHQ-9) questionnaires, and Montreal Cognitive Assessment (MoCA) cognitive assessments at baseline and on treatment. ### Outcome Measurements And Statistical Analysis To compare the change in FACT-P scores over time between treatment arms, we used a mixed model for repeated measures (MMRM). For FACT-P domains where there was an interaction between the treatment arm and age, we constructed separate models for patients aged <75 and \u226575yr. We compared the proportion of patients with clinically meaningful change from baseline for FACT-P, and the proportion of patients with an abnormal score and median change from baseline for PHQ-9 and MoCA using Fisher's exact test and Mann-Whitney U test. ### Results And Limitations In the MMRM analysis, there was a positive test for interaction in the treatment arm by age for total FACT-P (p=0.048). <b style='color:DodgerBlue;'><i>FACT-P</i></b> <b style='color:DodgerBlue;'><i>change</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>baseline</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>better</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>\u226575-yr</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p=0.003</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>difference</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>75-yr</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p>0.9</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A higher proportion of patients experienced clinically meaningful worsening with <b style='color:Tomato;'><i>enzalutamide</i></b> for the physical and functional well-being domains (37% vs 21%, p=0.013; 39% vs 23%, p=0.015). The distribution of change in PHQ-9 scores from baseline favored <b style='color:Tomato;'><i>abiraterone</i></b> at weeks 4, 8, and 12. These analyses were not prespecified, and results should be considered to be hypothesis generating. ### conclusions Patient-reported outcomes favored <b style='color:Tomato;'><i>abiraterone</i></b> compared with <b style='color:Tomato;'><i>enzalutamide</i></b> with differences in FACT-P HRQoL and PHQ-9 depression scores. Differences in the total FACT-P scores were seen only in the elderly patient subgroup. ### Patient Summary In this report, we examined the change in patient-reported quality-of-life scores from the start of treatment over time for patients treated with <b style='color:Tomato;'><i>abiraterone</i></b> versus <b style='color:Tomato;'><i>enzalutamide</i></b> for metastatic castration-resistant prostate cancer. We found that elderly patients treated with <b style='color:Tomato;'><i>abiraterone</i></b> had better quality of life over time, with no difference between treatments for the younger subgroup of patients.","tokens":[{"text":"FACT-P","start":0,"end":6,"id":0,"ws":true},{"text":"change","start":7,"end":13,"id":1,"ws":true},{"text":"from","start":14,"end":18,"id":2,"ws":true},{"text":"baseline","start":19,"end":27,"id":3,"ws":true},{"text":"over","start":28,"end":32,"id":4,"ws":true},{"text":"time","start":33,"end":37,"id":5,"ws":true},{"text":"was","start":38,"end":41,"id":6,"ws":true},{"text":"better","start":42,"end":48,"id":7,"ws":true},{"text":"for","start":49,"end":52,"id":8,"ws":true},{"text":"abiraterone","start":53,"end":64,"id":9,"ws":true},{"text":"than","start":65,"end":69,"id":10,"ws":true},{"text":"for","start":70,"end":73,"id":11,"ws":true},{"text":"enzalutamide","start":74,"end":86,"id":12,"ws":true},{"text":"in","start":87,"end":89,"id":13,"ws":true},{"text":"the","start":90,"end":93,"id":14,"ws":true},{"text":"\u226575-yr","start":94,"end":100,"id":15,"ws":true},{"text":"model","start":101,"end":106,"id":16,"ws":true},{"text":"(","start":107,"end":108,"id":17,"ws":true},{"text":"p=0.003","start":109,"end":116,"id":18,"ws":true},{"text":")","start":117,"end":118,"id":19,"ws":true},{"text":",","start":119,"end":120,"id":20,"ws":true},{"text":"with","start":121,"end":125,"id":21,"ws":true},{"text":"no","start":126,"end":128,"id":22,"ws":true},{"text":"difference","start":129,"end":139,"id":23,"ws":true},{"text":"in","start":140,"end":142,"id":24,"ws":true},{"text":"the","start":143,"end":146,"id":25,"ws":true},{"text":"<","start":147,"end":148,"id":26,"ws":true},{"text":"75-yr","start":149,"end":154,"id":27,"ws":true},{"text":"model","start":155,"end":160,"id":28,"ws":true},{"text":"(","start":161,"end":162,"id":29,"ws":true},{"text":"p>0.9","start":163,"end":168,"id":30,"ws":true},{"text":")","start":169,"end":170,"id":31,"ws":true},{"text":".","start":171,"end":172,"id":32,"ws":false}],"spans":[{"start":53,"end":64,"token_start":9,"token_end":9,"label":"DRUG"},{"start":74,"end":86,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30591354/","_input_hash":225543979,"_task_hash":1778171408,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The possibility that verapamil might increase the sensibility of colorectal carcinomas to doxorubicin was studied in 24 patients without previous cytotoxic chemotherapy .","paragraph":"<h3><u>Doxorubicin in combination with verapamil in advanced colorectal cancer. A phase II trial.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>possibility</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>sensibility</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>carcinomas</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>previous</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The treatment started with oral <b style='color:Tomato;'><i>verapamil</i></b>, which was escalated up to the individual maximum tolerable dose (defined by prolongation of P-Q in ECG, fall in blood pressure, or dizziness). The median maximum tolerable dose was 600 mg (range 320-1,440 mg). During continued <b style='color:Tomato;'><i>verapamil</i></b> administration the patients then got weekly infusions of <b style='color:Tomato;'><i>doxorubicin</i></b>, 25 mg/m2. The median number of <b style='color:Tomato;'><i>doxorubicin</i></b> courses was 8 (range 2-22). Among 21 patients evaluable for response and toxicity two partial remissions occurred but no complete remission. The study did not indicate enhanced cardiac, hematological or non-hematological toxicity from the combined treatment.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"possibility","start":4,"end":15,"id":1,"ws":true},{"text":"that","start":16,"end":20,"id":2,"ws":true},{"text":"verapamil","start":21,"end":30,"id":3,"ws":true},{"text":"might","start":31,"end":36,"id":4,"ws":true},{"text":"increase","start":37,"end":45,"id":5,"ws":true},{"text":"the","start":46,"end":49,"id":6,"ws":true},{"text":"sensibility","start":50,"end":61,"id":7,"ws":true},{"text":"of","start":62,"end":64,"id":8,"ws":true},{"text":"colorectal","start":65,"end":75,"id":9,"ws":true},{"text":"carcinomas","start":76,"end":86,"id":10,"ws":true},{"text":"to","start":87,"end":89,"id":11,"ws":true},{"text":"doxorubicin","start":90,"end":101,"id":12,"ws":true},{"text":"was","start":102,"end":105,"id":13,"ws":true},{"text":"studied","start":106,"end":113,"id":14,"ws":true},{"text":"in","start":114,"end":116,"id":15,"ws":true},{"text":"24","start":117,"end":119,"id":16,"ws":true},{"text":"patients","start":120,"end":128,"id":17,"ws":true},{"text":"without","start":129,"end":136,"id":18,"ws":true},{"text":"previous","start":137,"end":145,"id":19,"ws":true},{"text":"cytotoxic","start":146,"end":155,"id":20,"ws":true},{"text":"chemotherapy","start":156,"end":168,"id":21,"ws":true},{"text":".","start":169,"end":170,"id":22,"ws":false}],"spans":[{"start":21,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},{"start":90,"end":101,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2009180/","_input_hash":301149233,"_task_hash":849427868,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":3,"child":12,"head_span":{"start":21,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":90,"end":101,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Twenty-six patients presenting with advanced breast cancer with a taxane- and vinorelbine-free line of chemotherapy were included and treated with vinorelbine ( 20 mg/m2 on D1 , D15 ) , followed by paclitaxel ( 175 mg/m2 on D1 ) , every 3 weeks .","paragraph":"<h3><u>Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer.</u></h3><b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> are two drugs active against breast cancer. A phase II study was initiated with the aim of assessing the efficacy and feasibility of the combination. <b style='color:DodgerBlue;'><i>Twenty-six</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>presenting</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>taxane-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>vinorelbine-free</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>D1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>D15</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>D1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A 48% (95% CI: 35-61) response rate was obtained in the 23 patients evaluable for response. <b style='color:Tomato;'><i>vinorelbine</i></b> was administered on D15, as scheduled, in 72% of cycles. The main toxicity observed was grade III to IV neutropenia in 73% of patients. Febrile neutropenia was reported in three patients. Disease-free survival was 118 days, and overall median survival was 361 days. This combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> is feasible and effective in patients with early relapse or previously treated with first-line chemotherapy for metastatic disease.","tokens":[{"text":"Twenty-six","start":0,"end":10,"id":0,"ws":true},{"text":"patients","start":11,"end":19,"id":1,"ws":true},{"text":"presenting","start":20,"end":30,"id":2,"ws":true},{"text":"with","start":31,"end":35,"id":3,"ws":true},{"text":"advanced","start":36,"end":44,"id":4,"ws":true},{"text":"breast","start":45,"end":51,"id":5,"ws":true},{"text":"cancer","start":52,"end":58,"id":6,"ws":true},{"text":"with","start":59,"end":63,"id":7,"ws":true},{"text":"a","start":64,"end":65,"id":8,"ws":true},{"text":"taxane-","start":66,"end":73,"id":9,"ws":true},{"text":"and","start":74,"end":77,"id":10,"ws":true},{"text":"vinorelbine-free","start":78,"end":94,"id":11,"ws":true},{"text":"line","start":95,"end":99,"id":12,"ws":true},{"text":"of","start":100,"end":102,"id":13,"ws":true},{"text":"chemotherapy","start":103,"end":115,"id":14,"ws":true},{"text":"were","start":116,"end":120,"id":15,"ws":true},{"text":"included","start":121,"end":129,"id":16,"ws":true},{"text":"and","start":130,"end":133,"id":17,"ws":true},{"text":"treated","start":134,"end":141,"id":18,"ws":true},{"text":"with","start":142,"end":146,"id":19,"ws":true},{"text":"vinorelbine","start":147,"end":158,"id":20,"ws":true},{"text":"(","start":159,"end":160,"id":21,"ws":true},{"text":"20","start":161,"end":163,"id":22,"ws":true},{"text":"mg/m2","start":164,"end":169,"id":23,"ws":true},{"text":"on","start":170,"end":172,"id":24,"ws":true},{"text":"D1","start":173,"end":175,"id":25,"ws":true},{"text":",","start":176,"end":177,"id":26,"ws":true},{"text":"D15","start":178,"end":181,"id":27,"ws":true},{"text":")","start":182,"end":183,"id":28,"ws":true},{"text":",","start":184,"end":185,"id":29,"ws":true},{"text":"followed","start":186,"end":194,"id":30,"ws":true},{"text":"by","start":195,"end":197,"id":31,"ws":true},{"text":"paclitaxel","start":198,"end":208,"id":32,"ws":true},{"text":"(","start":209,"end":210,"id":33,"ws":true},{"text":"175","start":211,"end":214,"id":34,"ws":true},{"text":"mg/m2","start":215,"end":220,"id":35,"ws":true},{"text":"on","start":221,"end":223,"id":36,"ws":true},{"text":"D1","start":224,"end":226,"id":37,"ws":true},{"text":")","start":227,"end":228,"id":38,"ws":true},{"text":",","start":229,"end":230,"id":39,"ws":true},{"text":"every","start":231,"end":236,"id":40,"ws":true},{"text":"3","start":237,"end":238,"id":41,"ws":true},{"text":"weeks","start":239,"end":244,"id":42,"ws":true},{"text":".","start":245,"end":246,"id":43,"ws":false}],"spans":[{"start":147,"end":158,"token_start":20,"token_end":20,"label":"DRUG"},{"start":198,"end":208,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15170156/","_input_hash":-696081160,"_task_hash":-774600859,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":20,"child":32,"head_span":{"start":147,"end":158,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":198,"end":208,"token_start":32,"token_end":32,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Although monotherapy with cytotoxic agents , including docetaxel and pemetrexed , is recommended for patients with previously treated advanced non-small cell lung cancer ( NSCLC ) , its outcomes are unsatisfactory .","paragraph":"<h3><u>Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.</u></h3>In terms of efficacy and safety, good results were obtained with S-1 and <b style='color:Tomato;'><i>paclitaxel</i></b> (PTX) combination therapy.The findings suggest that S-1 and PTX combination therapy is a feasible treatment option in patients with previously treated non-small cell lung cancer. ### background <b style='color:DodgerBlue;'><i>Although</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>non-small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>unsatisfactory</i></b> <b style='color:DodgerBlue;'><i>.</i></b> S-1 is an oral fluoropyrimidine agent that consists of <b style='color:Tomato;'><i>tegafur</i></b>, 5- chloro-2, 4-dihydroxypyridine, and potassium oxonate. S-1 is approved for patients with gastric cancer in 7 Asian countries and 15 European countries. It is also approved for patients with eight type of cancers, including NSCLC, in Japan. We evaluated the efficacy and toxicity of S-1 and <b style='color:Tomato;'><i>paclitaxel</i></b> (PTX) combination therapy in patients with previously treated NSCLC. ### methods Oral S-1 was administered thrice weekly on days 1-14 at 80, 100, and 120 mg/day in patients with body surface areas of <1.25, 1.25-1.5, and >1.5 m ### results Forty patients were enrolled, with response and disease control rates of 27.5% and 75.0%, respectively (Fig. 1). Median PFS and OS were 6.5 and 20.7 months, respectively. Grade 3/4 anemia and thrombocytopenia were seen in five (12%) and one (2%) patients, respectively. Febrile neutropenia occurred in three patients (7%). Common grade 3/4 nonhematological toxicities were stomatitis (5% of patients), diarrhea (7% of patients), and interstitial lung disease (one patient). No treatment-related deaths were observed. ### conclusion This S-1 and PTX cotherapy dose and schedule showed satisfactory efficacy, with mild toxicities, in patients with previously treated advanced NSCLC.","tokens":[{"text":"Although","start":0,"end":8,"id":0,"ws":true},{"text":"monotherapy","start":9,"end":20,"id":1,"ws":true},{"text":"with","start":21,"end":25,"id":2,"ws":true},{"text":"cytotoxic","start":26,"end":35,"id":3,"ws":true},{"text":"agents","start":36,"end":42,"id":4,"ws":true},{"text":",","start":43,"end":44,"id":5,"ws":true},{"text":"including","start":45,"end":54,"id":6,"ws":true},{"text":"docetaxel","start":55,"end":64,"id":7,"ws":true},{"text":"and","start":65,"end":68,"id":8,"ws":true},{"text":"pemetrexed","start":69,"end":79,"id":9,"ws":true},{"text":",","start":80,"end":81,"id":10,"ws":true},{"text":"is","start":82,"end":84,"id":11,"ws":true},{"text":"recommended","start":85,"end":96,"id":12,"ws":true},{"text":"for","start":97,"end":100,"id":13,"ws":true},{"text":"patients","start":101,"end":109,"id":14,"ws":true},{"text":"with","start":110,"end":114,"id":15,"ws":true},{"text":"previously","start":115,"end":125,"id":16,"ws":true},{"text":"treated","start":126,"end":133,"id":17,"ws":true},{"text":"advanced","start":134,"end":142,"id":18,"ws":true},{"text":"non-small","start":143,"end":152,"id":19,"ws":true},{"text":"cell","start":153,"end":157,"id":20,"ws":true},{"text":"lung","start":158,"end":162,"id":21,"ws":true},{"text":"cancer","start":163,"end":169,"id":22,"ws":true},{"text":"(","start":170,"end":171,"id":23,"ws":true},{"text":"NSCLC","start":172,"end":177,"id":24,"ws":true},{"text":")","start":178,"end":179,"id":25,"ws":true},{"text":",","start":180,"end":181,"id":26,"ws":true},{"text":"its","start":182,"end":185,"id":27,"ws":true},{"text":"outcomes","start":186,"end":194,"id":28,"ws":true},{"text":"are","start":195,"end":198,"id":29,"ws":true},{"text":"unsatisfactory","start":199,"end":213,"id":30,"ws":true},{"text":".","start":214,"end":215,"id":31,"ws":false}],"spans":[{"start":55,"end":64,"token_start":7,"token_end":7,"label":"DRUG"},{"start":69,"end":79,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31040252/","_input_hash":1123837289,"_task_hash":-1707963348,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Although congestive heart failure has been reported with the combination of a beta blocker and either verapamil or nifedipine , it has not previously been reported for combination therapy that includes diltiazem .","paragraph":"<h3><u>Combination therapy with diltiazem and propranolol: precipitation of congestive heart failure.</u></h3> <b style='color:DodgerBlue;'><i>Although</i></b> <b style='color:DodgerBlue;'><i>congestive</i></b> <b style='color:DodgerBlue;'><i>heart</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>beta</i></b> <b style='color:DodgerBlue;'><i>blocker</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>nifedipine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>it</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>includes</i></b> <b style='color:MediumOrchid;'><i>diltiazem</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The following case documents the occurrence of clinical congestive failure in a patient with baseline left ventricular dysfunction and severe angina pectoris. Although the patients had tolerated <b style='color:Tomato;'><i>propranolol</i></b> therapy for years without difficulty, and high-dose <b style='color:Tomato;'><i>diltiazem</i></b> monotherapy with an excellent clinical response, the combination of <b style='color:Tomato;'><i>diltiazem</i></b> and <b style='color:Tomato;'><i>propranolol</i></b> resulted in the development of congestive heart failure. Thus, although generally well tolerated, given the suitable scenario of reduced left ventricular function, the combination of <b style='color:Tomato;'><i>diltiazem</i></b> and a beta blocker may adversely affect left ventricular performance.","tokens":[{"text":"Although","start":0,"end":8,"id":0,"ws":true},{"text":"congestive","start":9,"end":19,"id":1,"ws":true},{"text":"heart","start":20,"end":25,"id":2,"ws":true},{"text":"failure","start":26,"end":33,"id":3,"ws":true},{"text":"has","start":34,"end":37,"id":4,"ws":true},{"text":"been","start":38,"end":42,"id":5,"ws":true},{"text":"reported","start":43,"end":51,"id":6,"ws":true},{"text":"with","start":52,"end":56,"id":7,"ws":true},{"text":"the","start":57,"end":60,"id":8,"ws":true},{"text":"combination","start":61,"end":72,"id":9,"ws":true},{"text":"of","start":73,"end":75,"id":10,"ws":true},{"text":"a","start":76,"end":77,"id":11,"ws":true},{"text":"beta","start":78,"end":82,"id":12,"ws":true},{"text":"blocker","start":83,"end":90,"id":13,"ws":true},{"text":"and","start":91,"end":94,"id":14,"ws":true},{"text":"either","start":95,"end":101,"id":15,"ws":true},{"text":"verapamil","start":102,"end":111,"id":16,"ws":true},{"text":"or","start":112,"end":114,"id":17,"ws":true},{"text":"nifedipine","start":115,"end":125,"id":18,"ws":true},{"text":",","start":126,"end":127,"id":19,"ws":true},{"text":"it","start":128,"end":130,"id":20,"ws":true},{"text":"has","start":131,"end":134,"id":21,"ws":true},{"text":"not","start":135,"end":138,"id":22,"ws":true},{"text":"previously","start":139,"end":149,"id":23,"ws":true},{"text":"been","start":150,"end":154,"id":24,"ws":true},{"text":"reported","start":155,"end":163,"id":25,"ws":true},{"text":"for","start":164,"end":167,"id":26,"ws":true},{"text":"combination","start":168,"end":179,"id":27,"ws":true},{"text":"therapy","start":180,"end":187,"id":28,"ws":true},{"text":"that","start":188,"end":192,"id":29,"ws":true},{"text":"includes","start":193,"end":201,"id":30,"ws":true},{"text":"diltiazem","start":202,"end":211,"id":31,"ws":true},{"text":".","start":212,"end":213,"id":32,"ws":false}],"spans":[{"start":102,"end":111,"token_start":16,"token_end":16,"label":"DRUG"},{"start":115,"end":125,"token_start":18,"token_end":18,"label":"DRUG"},{"start":202,"end":211,"token_start":31,"token_end":31,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/4006348/","_input_hash":1214581893,"_task_hash":869786212,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Relationships between heart rate , exercise tolerance and cardiac output in atrial fibrillation : the effects of treatment with digoxin , verapamil and diltiazem .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Relationships</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>heart</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>exercise</i></b> <b style='color:DodgerBlue;'><i>tolerance</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cardiac</i></b> <b style='color:DodgerBlue;'><i>output</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>atrial</i></b> <b style='color:DodgerBlue;'><i>fibrillation</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>digoxin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>diltiazem</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Six patients with chronic atrial fibrillation (AF) took single doses of <b style='color:Tomato;'><i>digoxin</i></b>, <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>diltiazem</i></b>, alone and in combination. Three hours after dosing, resting and post-exercise heart rate, exercise tolerance and resting and post-exercise cardiac output were measured. Post-exercise heart rates ranged from 167 bpm (after placebo) to 122 bpm (after <b style='color:Tomato;'><i>digoxin</i></b> plus <b style='color:Tomato;'><i>diltiazem</i></b>) (P less than 0.05). However, the lower ventricular rates seen after treatment with the calcium antagonists were not associated with improved exercise tolerance, which did not differ significantly between the various treatments. Reduction of the ventricular rate was associated with a small increase in stroke volume but the benefits of this were offset by a rate related reduction in cardiac output. Further reduction of the rapid ventricular rates seen in digitalized patients with AF does not appear to be of benefit in terms of improving either exercise tolerance or cardiac output.","tokens":[{"text":"Relationships","start":0,"end":13,"id":0,"ws":true},{"text":"between","start":14,"end":21,"id":1,"ws":true},{"text":"heart","start":22,"end":27,"id":2,"ws":true},{"text":"rate","start":28,"end":32,"id":3,"ws":true},{"text":",","start":33,"end":34,"id":4,"ws":true},{"text":"exercise","start":35,"end":43,"id":5,"ws":true},{"text":"tolerance","start":44,"end":53,"id":6,"ws":true},{"text":"and","start":54,"end":57,"id":7,"ws":true},{"text":"cardiac","start":58,"end":65,"id":8,"ws":true},{"text":"output","start":66,"end":72,"id":9,"ws":true},{"text":"in","start":73,"end":75,"id":10,"ws":true},{"text":"atrial","start":76,"end":82,"id":11,"ws":true},{"text":"fibrillation","start":83,"end":95,"id":12,"ws":true},{"text":":","start":96,"end":97,"id":13,"ws":true},{"text":"the","start":98,"end":101,"id":14,"ws":true},{"text":"effects","start":102,"end":109,"id":15,"ws":true},{"text":"of","start":110,"end":112,"id":16,"ws":true},{"text":"treatment","start":113,"end":122,"id":17,"ws":true},{"text":"with","start":123,"end":127,"id":18,"ws":true},{"text":"digoxin","start":128,"end":135,"id":19,"ws":true},{"text":",","start":136,"end":137,"id":20,"ws":true},{"text":"verapamil","start":138,"end":147,"id":21,"ws":true},{"text":"and","start":148,"end":151,"id":22,"ws":true},{"text":"diltiazem","start":152,"end":161,"id":23,"ws":true},{"text":".","start":162,"end":163,"id":24,"ws":false}],"spans":[{"start":128,"end":135,"token_start":19,"token_end":19,"label":"DRUG"},{"start":138,"end":147,"token_start":21,"token_end":21,"label":"DRUG"},{"start":152,"end":161,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/3169046/","_input_hash":-1780052837,"_task_hash":-2090029961,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":19,"child":21,"head_span":{"start":128,"end":135,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":138,"end":147,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":23,"child":21,"head_span":{"start":152,"end":161,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":138,"end":147,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Oxaliplatin , which is effective for colorectal cancer ( CRC ) in combination with 5-fluorouracil ( 5-FU ) and leucovorin ( LV ) , is widely used for metastatic CRC .","paragraph":"<h3><u>Scheduled prospective tri-weekly modified FOLFOX6 maintenance chemotherapy in the treatment of metastatic colorectal cancer.</u></h3> <b style='color:MediumOrchid;'><i>Oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CRC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>widely</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>CRC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> With the increasing use of <b style='color:Tomato;'><i>oxaliplatin</i></b>, however, serious adverse events have been experienced, including hematologic and neurologic toxicities. The aim of this study was to evaluate whether tri-weekly modified FOLFOX6 (mFOLFOX6) maintenance chemotherapy is associated with a low incidence of severe hematologic and neurologic toxicities in the treatment of patients with metastatic CRC. ### methodology We developed a new treatment regimen with mFOLFOX6 biweekly for 8-10 consecutive cycles (induction phase) followed by a 3-week rest period, after which treatment was resumed with cycles of tri-weekly mFOLFOX6 at standard doses (maintenance phase). Validity and complications were investigated retrospectively. ### results Twenty-nine patients were enrolled in this study. The median progression-free survival (PFS) and overall survival (OS) times were 9.4 months and 23 months, respectively. All patients had peripheral neuropathy during treatment, but grade 3 neurotoxicity was observed in only 2 patients (6.9%). ### conclusions mFOLFOX6 maintenance chemotherapy was associated with a very low incidence of grade 3 hematologic and neurologic toxicities. The toxicities associated with PFS and OS were comparable to those reported in the treatment of patients with metastatic CRC. A tri-weekly mFOLFOX maintenance strategy of alternative treatment with a less-toxic regimen may reduce toxicity and maintain efficacy.","tokens":[{"text":"Oxaliplatin","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"which","start":14,"end":19,"id":2,"ws":true},{"text":"is","start":20,"end":22,"id":3,"ws":true},{"text":"effective","start":23,"end":32,"id":4,"ws":true},{"text":"for","start":33,"end":36,"id":5,"ws":true},{"text":"colorectal","start":37,"end":47,"id":6,"ws":true},{"text":"cancer","start":48,"end":54,"id":7,"ws":true},{"text":"(","start":55,"end":56,"id":8,"ws":true},{"text":"CRC","start":57,"end":60,"id":9,"ws":true},{"text":")","start":61,"end":62,"id":10,"ws":true},{"text":"in","start":63,"end":65,"id":11,"ws":true},{"text":"combination","start":66,"end":77,"id":12,"ws":true},{"text":"with","start":78,"end":82,"id":13,"ws":true},{"text":"5-fluorouracil","start":83,"end":97,"id":14,"ws":true},{"text":"(","start":98,"end":99,"id":15,"ws":true},{"text":"5-FU","start":100,"end":104,"id":16,"ws":true},{"text":")","start":105,"end":106,"id":17,"ws":true},{"text":"and","start":107,"end":110,"id":18,"ws":true},{"text":"leucovorin","start":111,"end":121,"id":19,"ws":true},{"text":"(","start":122,"end":123,"id":20,"ws":true},{"text":"LV","start":124,"end":126,"id":21,"ws":true},{"text":")","start":127,"end":128,"id":22,"ws":true},{"text":",","start":129,"end":130,"id":23,"ws":true},{"text":"is","start":131,"end":133,"id":24,"ws":true},{"text":"widely","start":134,"end":140,"id":25,"ws":true},{"text":"used","start":141,"end":145,"id":26,"ws":true},{"text":"for","start":146,"end":149,"id":27,"ws":true},{"text":"metastatic","start":150,"end":160,"id":28,"ws":true},{"text":"CRC","start":161,"end":164,"id":29,"ws":true},{"text":".","start":165,"end":166,"id":30,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":111,"end":121,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22234064/","_input_hash":-238881650,"_task_hash":-854156656,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":0,"child":14,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":83,"end":97,"token_start":14,"token_end":14,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":19,"child":14,"head_span":{"start":111,"end":121,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":83,"end":97,"token_start":14,"token_end":14,"label":null},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The cytotoxicity of sequential combinations of a taxoid [ paclitaxel ( TAX ) or docetaxel ( TXT ) ] with a vinca alkaloid [ vinorelbine ( NVB ) ] was compared in differentiated and undifferentiated HT29-D4 cells .","paragraph":"<h3><u>The effect of combining antitubulin agents on differentiated and undifferentiated human colon cancer cells.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>cytotoxicity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>taxoid</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TAX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TXT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>vinca</i></b> <b style='color:DodgerBlue;'><i>alkaloid</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NVB</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>differentiated</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>undifferentiated</i></b> <b style='color:DodgerBlue;'><i>HT29-D4</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Agents were titrated from low doses inducing no modification of microtubule network to high doses corresponding to the clinically relevant concentrations that block mitosis. For undifferentiated cells, the sequential combination NVB/TAX was more efficient than TAX/NVB (22% cell survival versus 37% for 5 nM TAX and NVB). Surprisingly, we successively obtained synergism for low doses of both compounds [NVB (1-5 nM) and TAX (1-15 nM)], then additivity and finally antagonism when one of the compounds was at the concentration inducing mitotic block. The three patterns of results were also obtained with NVB/TXT combinations. For the synergistic combinations at the lowest concentrations, cytotoxicity occurred by apoptosis following mitosis. For differentiated cells, the most cytotoxic combinations were 1 microM TAX or TXT for 3 days followed by 1 microM NVB for 3 days, and 0.75 nM TAX or TXT for 9 days followed by 1 microM NVB for 3 days, the latter producing synergistic effects. Cytotoxicity occurred by apoptosis for the two states of differentiation. Major differences depending on cell phenotype were demonstrated: low sensitivity of differentiated cells to antitubulin agents and the difference in apoptotic pathways since mitosis is not involved in differentiated cells.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"cytotoxicity","start":4,"end":16,"id":1,"ws":true},{"text":"of","start":17,"end":19,"id":2,"ws":true},{"text":"sequential","start":20,"end":30,"id":3,"ws":true},{"text":"combinations","start":31,"end":43,"id":4,"ws":true},{"text":"of","start":44,"end":46,"id":5,"ws":true},{"text":"a","start":47,"end":48,"id":6,"ws":true},{"text":"taxoid","start":49,"end":55,"id":7,"ws":true},{"text":"[","start":56,"end":57,"id":8,"ws":true},{"text":"paclitaxel","start":58,"end":68,"id":9,"ws":true},{"text":"(","start":69,"end":70,"id":10,"ws":true},{"text":"TAX","start":71,"end":74,"id":11,"ws":true},{"text":")","start":75,"end":76,"id":12,"ws":true},{"text":"or","start":77,"end":79,"id":13,"ws":true},{"text":"docetaxel","start":80,"end":89,"id":14,"ws":true},{"text":"(","start":90,"end":91,"id":15,"ws":true},{"text":"TXT","start":92,"end":95,"id":16,"ws":true},{"text":")","start":96,"end":97,"id":17,"ws":true},{"text":"]","start":98,"end":99,"id":18,"ws":true},{"text":"with","start":100,"end":104,"id":19,"ws":true},{"text":"a","start":105,"end":106,"id":20,"ws":true},{"text":"vinca","start":107,"end":112,"id":21,"ws":true},{"text":"alkaloid","start":113,"end":121,"id":22,"ws":true},{"text":"[","start":122,"end":123,"id":23,"ws":true},{"text":"vinorelbine","start":124,"end":135,"id":24,"ws":true},{"text":"(","start":136,"end":137,"id":25,"ws":true},{"text":"NVB","start":138,"end":141,"id":26,"ws":true},{"text":")","start":142,"end":143,"id":27,"ws":true},{"text":"]","start":144,"end":145,"id":28,"ws":true},{"text":"was","start":146,"end":149,"id":29,"ws":true},{"text":"compared","start":150,"end":158,"id":30,"ws":true},{"text":"in","start":159,"end":161,"id":31,"ws":true},{"text":"differentiated","start":162,"end":176,"id":32,"ws":true},{"text":"and","start":177,"end":180,"id":33,"ws":true},{"text":"undifferentiated","start":181,"end":197,"id":34,"ws":true},{"text":"HT29-D4","start":198,"end":205,"id":35,"ws":true},{"text":"cells","start":206,"end":211,"id":36,"ws":true},{"text":".","start":212,"end":213,"id":37,"ws":false}],"spans":[{"start":58,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},{"start":80,"end":89,"token_start":14,"token_end":14,"label":"DRUG"},{"start":124,"end":135,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9625431/","_input_hash":-1616576367,"_task_hash":-396876470,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":9,"child":24,"head_span":{"start":58,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":124,"end":135,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":14,"child":24,"head_span":{"start":80,"end":89,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":124,"end":135,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"Time to first deterioration was delayed with nivolumab + ipilimumab versus chemotherapy across LCSS and EQ-5D summary measures .","paragraph":"<h3><u>Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.</u></h3>In the phase III CheckMate 227 study, first-line <b style='color:Tomato;'><i>nivolumab</i></b>\u00a0+\u00a0<b style='color:Tomato;'><i>ipilimumab</i></b> significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; \u226510 mutations/megabase). ### aim To evaluate patient-reported outcomes (PROs) in this population. ### methods Disease-related symptoms and general health status were assessed using the validated PRO questionnaires Lung Cancer Symptom Scale (LCSS) and EQ-5D, respectively. LCSS average symptom burden index (ASBI) and three-item global index (3-IGI)\u00a0and EQ-5D visual analogue scale (VAS) and utility index (UI) scores and changes from baseline were analysed descriptively. Longitudinal changes were assessed by mixed-effect model repeated measures (MMRMs) and time to first deterioration/improvement analyses. ### results In the high TMB population, PRO questionnaire completion rates were \u223c90% at baseline and >80% for most on-treatment assessments. During treatment, mean changes from baseline with <b style='color:Tomato;'><i>nivolumab</i></b>\u00a0+\u00a0<b style='color:Tomato;'><i>ipilimumab</i></b> showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) or improved following induction (EQ-5D VAS). MMRM-assessed changes in symptom burden were improved with <b style='color:Tomato;'><i>nivolumab</i></b>\u00a0+\u00a0<b style='color:Tomato;'><i>ipilimumab</i></b> versus chemotherapy. Symptom deterioration by week 12 was lower with <b style='color:Tomato;'><i>nivolumab</i></b>\u00a0+\u00a0<b style='color:Tomato;'><i>ipilimumab</i></b> versus chemotherapy (22.3% versus 35.0%; absolute risk reduction: 12.7% [95% confidence interval 2.4-22.5]), irrespective of discontinuation. <b style='color:DodgerBlue;'><i>Time</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>deterioration</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>delayed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>across</i></b> <b style='color:DodgerBlue;'><i>LCSS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>EQ-5D</i></b> <b style='color:DodgerBlue;'><i>summary</i></b> <b style='color:DodgerBlue;'><i>measures</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusion First-line <b style='color:Tomato;'><i>nivolumab</i></b>\u00a0+\u00a0<b style='color:Tomato;'><i>ipilimumab</i></b> demonstrated early, sustained improvements in PROs versus chemotherapy in patients with advanced NSCLC and high TMB. ### Clinical Trial Registration NCT02477826.","tokens":[{"text":"Time","start":0,"end":4,"id":0,"ws":true},{"text":"to","start":5,"end":7,"id":1,"ws":true},{"text":"first","start":8,"end":13,"id":2,"ws":true},{"text":"deterioration","start":14,"end":27,"id":3,"ws":true},{"text":"was","start":28,"end":31,"id":4,"ws":true},{"text":"delayed","start":32,"end":39,"id":5,"ws":true},{"text":"with","start":40,"end":44,"id":6,"ws":true},{"text":"nivolumab","start":45,"end":54,"id":7,"ws":true},{"text":"+","start":55,"end":56,"id":8,"ws":true},{"text":"ipilimumab","start":57,"end":67,"id":9,"ws":true},{"text":"versus","start":68,"end":74,"id":10,"ws":true},{"text":"chemotherapy","start":75,"end":87,"id":11,"ws":true},{"text":"across","start":88,"end":94,"id":12,"ws":true},{"text":"LCSS","start":95,"end":99,"id":13,"ws":true},{"text":"and","start":100,"end":103,"id":14,"ws":true},{"text":"EQ-5D","start":104,"end":109,"id":15,"ws":true},{"text":"summary","start":110,"end":117,"id":16,"ws":true},{"text":"measures","start":118,"end":126,"id":17,"ws":true},{"text":".","start":127,"end":128,"id":18,"ws":false}],"spans":[{"start":45,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},{"start":57,"end":67,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31195357/","_input_hash":734466457,"_task_hash":1630300272,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":45,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":57,"end":67,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"In the present study , we investigated the effect atorvastatin , celecoxib and tipifarnib in combination on proliferation and apoptosis in Panc-1 sphere-forming cells .","paragraph":"<h3><u>Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.</u></h3>Cancer stem cell (CSC) plays an important role in pancreatic cancer pathogenesis and treatment failure. CSCs are characterized by their ability to form tumor spheres in serum-free medium and expression of CSC related markers. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:MediumOrchid;'><i>atorvastatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>tipifarnib</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>proliferation</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>apoptosis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Panc-1</i></b> <b style='color:DodgerBlue;'><i>sphere-forming</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The sphere-forming cells were isolated from Panc-1\u00a0cells by sphere-forming method. These sphere-forming cells showed CSC properties. The levels of CD44, CD133 and ALDH1A1 in the sphere-forming cells were increased. Moreover, Panc-1 sphere-forming cells were resistant to chemotherapeutic drug <b style='color:Tomato;'><i>gemcitabine</i></b>. Combined <b style='color:Tomato;'><i>atorvastatin</i></b> with <b style='color:Tomato;'><i>celecoxib</i></b> and tipifarnib synergistically decreased the sphere forming ability of Panc-1\u00a0cells and the drug combination also strongly inhibited cell proliferation and promoted apoptosis in the sphere-forming cells. The effects of the drug combination on the Panc-1 sphere-forming cells were associated with decreases in the levels of CD44, CD133 and ALDH1A1, and suppression of Akt and NF-\u03baB activation. Results of the present study indicate that the combination of <b style='color:Tomato;'><i>atorvastatin</i></b>, <b style='color:Tomato;'><i>celecoxib</i></b> and tipifarnib may represent an effective approach for inhibiting pancreatic CSCs.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"present","start":7,"end":14,"id":2,"ws":true},{"text":"study","start":15,"end":20,"id":3,"ws":true},{"text":",","start":21,"end":22,"id":4,"ws":true},{"text":"we","start":23,"end":25,"id":5,"ws":true},{"text":"investigated","start":26,"end":38,"id":6,"ws":true},{"text":"the","start":39,"end":42,"id":7,"ws":true},{"text":"effect","start":43,"end":49,"id":8,"ws":true},{"text":"atorvastatin","start":50,"end":62,"id":9,"ws":true},{"text":",","start":63,"end":64,"id":10,"ws":true},{"text":"celecoxib","start":65,"end":74,"id":11,"ws":true},{"text":"and","start":75,"end":78,"id":12,"ws":true},{"text":"tipifarnib","start":79,"end":89,"id":13,"ws":true},{"text":"in","start":90,"end":92,"id":14,"ws":true},{"text":"combination","start":93,"end":104,"id":15,"ws":true},{"text":"on","start":105,"end":107,"id":16,"ws":true},{"text":"proliferation","start":108,"end":121,"id":17,"ws":true},{"text":"and","start":122,"end":125,"id":18,"ws":true},{"text":"apoptosis","start":126,"end":135,"id":19,"ws":true},{"text":"in","start":136,"end":138,"id":20,"ws":true},{"text":"Panc-1","start":139,"end":145,"id":21,"ws":true},{"text":"sphere-forming","start":146,"end":160,"id":22,"ws":true},{"text":"cells","start":161,"end":166,"id":23,"ws":true},{"text":".","start":167,"end":168,"id":24,"ws":false}],"spans":[{"start":50,"end":62,"token_start":9,"token_end":9,"label":"DRUG"},{"start":65,"end":74,"token_start":11,"token_end":11,"label":"DRUG"},{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33359649/","_input_hash":813707278,"_task_hash":-1876245255,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":50,"end":62,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":65,"end":74,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":11,"child":13,"head_span":{"start":65,"end":74,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"As SD , donepezil , galantamine , rivastigmine , and memantine are now usable .","paragraph":"<h3><u>[The Use of Symptomatic Drugs for Dementia].</u></h3>The treatment of Alzheimer's disease (AD) can be roughly divided into Disease-modifying Drugs (DMD) and Symptomatic Drugs (SD). Major strategies of DMD are the amyloid vaccine therapy and \u03b2/\u03b3-secretase inhibitors, which have been developed with high expectations as fundamental treatments for AD. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>SD</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>donepezil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>galantamine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>rivastigmine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>memantine</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>now</i></b> <b style='color:DodgerBlue;'><i>usable</i></b> <b style='color:DodgerBlue;'><i>.</i></b> While <b style='color:Tomato;'><i>memantine</i></b> is an NMDA receptor inhibitor, the remaining three agents are cholinesterase inhibitors. The inhibitory mechanisms of the four agents exhibit some differ- ences. Although they may offer tips for proper use, the SD guidelines have so far stated that there are no significant differences among SD. The guidelines also state that no SD can stop the progression of AD and that their use for MCI should not be encouraged. There are some criticisms about the use of SD because they are not root treatments. In contrast, there are some reports that SD delay AD progression, preserve ADL, reduce the care burden and have an effect on BPSD. Therefore, in proper combination with non-drug treat- ments, the use of SD is considered to be valuable.","tokens":[{"text":"As","start":0,"end":2,"id":0,"ws":true},{"text":"SD","start":3,"end":5,"id":1,"ws":true},{"text":",","start":6,"end":7,"id":2,"ws":true},{"text":"donepezil","start":8,"end":17,"id":3,"ws":true},{"text":",","start":18,"end":19,"id":4,"ws":true},{"text":"galantamine","start":20,"end":31,"id":5,"ws":true},{"text":",","start":32,"end":33,"id":6,"ws":true},{"text":"rivastigmine","start":34,"end":46,"id":7,"ws":true},{"text":",","start":47,"end":48,"id":8,"ws":true},{"text":"and","start":49,"end":52,"id":9,"ws":true},{"text":"memantine","start":53,"end":62,"id":10,"ws":true},{"text":"are","start":63,"end":66,"id":11,"ws":true},{"text":"now","start":67,"end":70,"id":12,"ws":true},{"text":"usable","start":71,"end":77,"id":13,"ws":true},{"text":".","start":78,"end":79,"id":14,"ws":false}],"spans":[{"start":8,"end":17,"token_start":3,"token_end":3,"label":"DRUG"},{"start":20,"end":31,"token_start":5,"token_end":5,"label":"DRUG"},{"start":34,"end":46,"token_start":7,"token_end":7,"label":"DRUG"},{"start":53,"end":62,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30620505/","_input_hash":-640682936,"_task_hash":1531480396,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Raloxifene is a selective estrogen receptor modulator which is structurally similar to tamoxifen .","paragraph":"<h3><u>The pharmacokinetics of raloxifene and its interaction with apigenin in rat.</u></h3> <b style='color:MediumOrchid;'><i>Raloxifene</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>estrogen</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>structurally</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> As flavonoids can interact with <b style='color:Tomato;'><i>raloxifene</i></b> in vitro, we evaluated the in vivo pharmacokinetics of <b style='color:Tomato;'><i>raloxifene</i></b> in rats when co-administered with apigenin. ### methods The pharmacokinetics of <b style='color:Tomato;'><i>raloxifene</i></b> in the absence or presence of apigenin was investigated in rats after different dosage regimens. The plasma concentrations before and after enzymatic hydrolysis were analyzed by HPLC, and the pharmacokinetic profiles of <b style='color:Tomato;'><i>raloxifene</i></b> administered alone and in combination with apigenin were compared. ### results Co-administration of apigenin with <b style='color:Tomato;'><i>raloxifene</i></b> in a 1:2 ratio by weight resulted in a 55% and 37% increase in the C(max) and AUC of intact <b style='color:Tomato;'><i>raloxifene</i></b>, respectively. When equal proportions of <b style='color:Tomato;'><i>raloxifene</i></b> and apigenin (1:1) were administered, the C(max) and AUC of intact <b style='color:Tomato;'><i>raloxifene</i></b> were increased by 173% and 97% respectively. This increase in intact <b style='color:Tomato;'><i>raloxifene</i></b> was not associated with an increase in total <b style='color:Tomato;'><i>raloxifene</i></b> (intact plus conjugated <b style='color:Tomato;'><i>raloxifene</i></b>) because AUC and C(max) of total <b style='color:Tomato;'><i>raloxifene</i></b> when administered alone or in combination with apigenin were found to be similar. The results indicated that apigenin inhibited the glucuronidation and sulfation of <b style='color:Tomato;'><i>raloxifene</i></b> in the intestine bringing about an increased bioavailability of the drug. ### conclusions The results showed that apigenin decreased the first-pass metabolism of <b style='color:Tomato;'><i>raloxifene</i></b> but did not increase its absorption from the gastrointestinal tract.","tokens":[{"text":"Raloxifene","start":0,"end":10,"id":0,"ws":true},{"text":"is","start":11,"end":13,"id":1,"ws":true},{"text":"a","start":14,"end":15,"id":2,"ws":true},{"text":"selective","start":16,"end":25,"id":3,"ws":true},{"text":"estrogen","start":26,"end":34,"id":4,"ws":true},{"text":"receptor","start":35,"end":43,"id":5,"ws":true},{"text":"modulator","start":44,"end":53,"id":6,"ws":true},{"text":"which","start":54,"end":59,"id":7,"ws":true},{"text":"is","start":60,"end":62,"id":8,"ws":true},{"text":"structurally","start":63,"end":75,"id":9,"ws":true},{"text":"similar","start":76,"end":83,"id":10,"ws":true},{"text":"to","start":84,"end":86,"id":11,"ws":true},{"text":"tamoxifen","start":87,"end":96,"id":12,"ws":true},{"text":".","start":97,"end":98,"id":13,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":87,"end":96,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21088662/","_input_hash":-1244115257,"_task_hash":175730932,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"There were three uterine ruptures , 1/44 ( 2 % ) in group 1 and 2/457 ( 0.4 % ) in group 2 ( p = 0.132 , NS ) ; all three women had received mifepristone followed by vaginal misoprostol .","paragraph":"<h3><u>Second trimester abortion in women with and without previous uterine scar: Eleven years experience from a developing country.</u></h3>To study the safety of second trimester abortion in women with previous uterine scar. ### methods We screened the records of 518 women who underwent an abortion between 12 and 20 weeks' gestation at the Postgraduate Institute of Medical Education and Research, Chandigarh, India, from January 2000 to December 2010. Methods used for abortion were: (i) vaginal <b style='color:Tomato;'><i>misoprostol</i></b> with or without pre-treatment with <b style='color:Tomato;'><i>mifepristone</i></b>, and (ii) intracervical <b style='color:Tomato;'><i>dinoprost</i></b>ol gel or vaginal <b style='color:Tomato;'><i>misoprostol</i></b> \u00b1 extra-amniotic saline \u00b1 <b style='color:Tomato;'><i>oxytocin</i></b> infusion. Seventeen women, aborted by means of a hysterotomy, were excluded from further analysis. ### results Of the remaining 501 women, 44 had a uterine scar (Group 1) and 457 had none (Group 2). In Group 1, 40/44 (91%) and in Group 2, 452/457 (99%) women aborted successfully. The mean induction-abortion interval (IAI) was similar in the two groups (15.03 \u00b1 10.69 hours and 12.52 \u00b1 9.0 hours in Groups 1 and 2, respectively; p = 0.083). <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>uterine</i></b> <b style='color:DodgerBlue;'><i>ruptures</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1/44</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2/457</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.4</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.132</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NS</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>all</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>mifepristone</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>vaginal</i></b> <b style='color:MediumOrchid;'><i>misoprostol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusion In women with a scarred uterus, midtrimester abortion may be successfully achieved using any of the aforementioned regimens.","tokens":[{"text":"There","start":0,"end":5,"id":0,"ws":true},{"text":"were","start":6,"end":10,"id":1,"ws":true},{"text":"three","start":11,"end":16,"id":2,"ws":true},{"text":"uterine","start":17,"end":24,"id":3,"ws":true},{"text":"ruptures","start":25,"end":33,"id":4,"ws":true},{"text":",","start":34,"end":35,"id":5,"ws":true},{"text":"1/44","start":36,"end":40,"id":6,"ws":true},{"text":"(","start":41,"end":42,"id":7,"ws":true},{"text":"2","start":43,"end":44,"id":8,"ws":true},{"text":"%","start":45,"end":46,"id":9,"ws":true},{"text":")","start":47,"end":48,"id":10,"ws":true},{"text":"in","start":49,"end":51,"id":11,"ws":true},{"text":"group","start":52,"end":57,"id":12,"ws":true},{"text":"1","start":58,"end":59,"id":13,"ws":true},{"text":"and","start":60,"end":63,"id":14,"ws":true},{"text":"2/457","start":64,"end":69,"id":15,"ws":true},{"text":"(","start":70,"end":71,"id":16,"ws":true},{"text":"0.4","start":72,"end":75,"id":17,"ws":true},{"text":"%","start":76,"end":77,"id":18,"ws":true},{"text":")","start":78,"end":79,"id":19,"ws":true},{"text":"in","start":80,"end":82,"id":20,"ws":true},{"text":"group","start":83,"end":88,"id":21,"ws":true},{"text":"2","start":89,"end":90,"id":22,"ws":true},{"text":"(","start":91,"end":92,"id":23,"ws":true},{"text":"p","start":93,"end":94,"id":24,"ws":true},{"text":"=","start":95,"end":96,"id":25,"ws":true},{"text":"0.132","start":97,"end":102,"id":26,"ws":true},{"text":",","start":103,"end":104,"id":27,"ws":true},{"text":"NS","start":105,"end":107,"id":28,"ws":true},{"text":")","start":108,"end":109,"id":29,"ws":true},{"text":";","start":110,"end":111,"id":30,"ws":true},{"text":"all","start":112,"end":115,"id":31,"ws":true},{"text":"three","start":116,"end":121,"id":32,"ws":true},{"text":"women","start":122,"end":127,"id":33,"ws":true},{"text":"had","start":128,"end":131,"id":34,"ws":true},{"text":"received","start":132,"end":140,"id":35,"ws":true},{"text":"mifepristone","start":141,"end":153,"id":36,"ws":true},{"text":"followed","start":154,"end":162,"id":37,"ws":true},{"text":"by","start":163,"end":165,"id":38,"ws":true},{"text":"vaginal","start":166,"end":173,"id":39,"ws":true},{"text":"misoprostol","start":174,"end":185,"id":40,"ws":true},{"text":".","start":186,"end":187,"id":41,"ws":false}],"spans":[{"start":141,"end":153,"token_start":36,"token_end":36,"label":"DRUG"},{"start":174,"end":185,"token_start":40,"token_end":40,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21929363/","_input_hash":-221556043,"_task_hash":-461070467,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"Recipients received the dual endothelin-1 ( ET-1 ) receptor blocker , bosentan ( 100 mg/kg ) , the angiotensin-converting enzyme ( ACE ) inhibitor , ramipril ( 5 mg/kg ) , bosentan plus ramipril ( doses as just noted ) or vehicle .","paragraph":"<h3><u>Effects of blockade of the renin-angiotensin and endothelin systems on experimental bronchiolitis obliterans.</u></h3>Blockade of the renin-angiotensin and the endothelin (ET) systems ameliorates fibrous airway obliteration in rat tracheal allografts. The aim of this study was to test which of these pharmacologic interventions attenuates the process more effectively, and whether combination therapy confers additional benefit. ### methods Rat tracheas were heterotopically transplanted from Brown-Norway donors into Lewis recipients. <b style='color:DodgerBlue;'><i>Recipients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dual</i></b> <b style='color:MediumOrchid;'><i>endothelin-1</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ET-1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>blocker</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>bosentan</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>angiotensin-converting</i></b> <b style='color:DodgerBlue;'><i>enzyme</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ACE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ramipril</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>bosentan</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ramipril</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>just</i></b> <b style='color:DodgerBlue;'><i>noted</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>vehicle</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Grafts were harvested at Days 7 and 21 for morphometric studies and molecular analysis by real-time polymerase chain reaction (PCR). ### results At Day 21, <b style='color:Tomato;'><i>bosentan</i></b> and <b style='color:Tomato;'><i>ramipril</i></b> treatment reduced the percentage of luminal occlusion compared with vehicle to a similar extent. In animals that received the combined treatment, luminal obliteration was further reduced compared with the respective monotherapies. Furthermore, rats treated with <b style='color:Tomato;'><i>bosentan</i></b> plus <b style='color:Tomato;'><i>ramipril</i></b> showed a lower percent of epithelial necrosis. The beneficial effects of <b style='color:Tomato;'><i>bosentan</i></b> and <b style='color:Tomato;'><i>ramipril</i></b>, alone or in combination, were associated with reduced mRNA levels of transforming growth factor (TGF)-beta1 and platelet-derived growth factor (PDGF)-A in the tracheal allografts. ### conclusions Our data suggest that ET receptor blockade prevents fibrous airway obliteration to a similar extent as ACE inhibition in this model. Interruption of both pathways provides superior graft protection as compared with single-system blockade.","tokens":[{"text":"Recipients","start":0,"end":10,"id":0,"ws":true},{"text":"received","start":11,"end":19,"id":1,"ws":true},{"text":"the","start":20,"end":23,"id":2,"ws":true},{"text":"dual","start":24,"end":28,"id":3,"ws":true},{"text":"endothelin-1","start":29,"end":41,"id":4,"ws":true},{"text":"(","start":42,"end":43,"id":5,"ws":true},{"text":"ET-1","start":44,"end":48,"id":6,"ws":true},{"text":")","start":49,"end":50,"id":7,"ws":true},{"text":"receptor","start":51,"end":59,"id":8,"ws":true},{"text":"blocker","start":60,"end":67,"id":9,"ws":true},{"text":",","start":68,"end":69,"id":10,"ws":true},{"text":"bosentan","start":70,"end":78,"id":11,"ws":true},{"text":"(","start":79,"end":80,"id":12,"ws":true},{"text":"100","start":81,"end":84,"id":13,"ws":true},{"text":"mg/kg","start":85,"end":90,"id":14,"ws":true},{"text":")","start":91,"end":92,"id":15,"ws":true},{"text":",","start":93,"end":94,"id":16,"ws":true},{"text":"the","start":95,"end":98,"id":17,"ws":true},{"text":"angiotensin-converting","start":99,"end":121,"id":18,"ws":true},{"text":"enzyme","start":122,"end":128,"id":19,"ws":true},{"text":"(","start":129,"end":130,"id":20,"ws":true},{"text":"ACE","start":131,"end":134,"id":21,"ws":true},{"text":")","start":135,"end":136,"id":22,"ws":true},{"text":"inhibitor","start":137,"end":146,"id":23,"ws":true},{"text":",","start":147,"end":148,"id":24,"ws":true},{"text":"ramipril","start":149,"end":157,"id":25,"ws":true},{"text":"(","start":158,"end":159,"id":26,"ws":true},{"text":"5","start":160,"end":161,"id":27,"ws":true},{"text":"mg/kg","start":162,"end":167,"id":28,"ws":true},{"text":")","start":168,"end":169,"id":29,"ws":true},{"text":",","start":170,"end":171,"id":30,"ws":true},{"text":"bosentan","start":172,"end":180,"id":31,"ws":true},{"text":"plus","start":181,"end":185,"id":32,"ws":true},{"text":"ramipril","start":186,"end":194,"id":33,"ws":true},{"text":"(","start":195,"end":196,"id":34,"ws":true},{"text":"doses","start":197,"end":202,"id":35,"ws":true},{"text":"as","start":203,"end":205,"id":36,"ws":true},{"text":"just","start":206,"end":210,"id":37,"ws":true},{"text":"noted","start":211,"end":216,"id":38,"ws":true},{"text":")","start":217,"end":218,"id":39,"ws":true},{"text":"or","start":219,"end":221,"id":40,"ws":true},{"text":"vehicle","start":222,"end":229,"id":41,"ws":true},{"text":".","start":230,"end":231,"id":42,"ws":false}],"spans":[{"start":29,"end":41,"token_start":4,"token_end":4,"label":"DRUG"},{"start":70,"end":78,"token_start":11,"token_end":11,"label":"DRUG"},{"start":149,"end":157,"token_start":25,"token_end":25,"label":"DRUG"},{"start":172,"end":180,"token_start":31,"token_end":31,"label":"DRUG"},{"start":186,"end":194,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17097496/","_input_hash":-1701635141,"_task_hash":-1347245697,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":31,"child":33,"head_span":{"start":172,"end":180,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":186,"end":194,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"After surgery , she received a sequential chemotherapy , ie , intraabdominal injection of carboplatin ( CBDCA 300 mg/m2 ) and div administration of paclitaxel ( PTX 180 mg/m2 ) as a standard regimen for advanced ovarian cancer .","paragraph":"<h3><u>[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].</u></h3>A 46-year-old woman who had received mastectomy for breast cancer 6 years earlier complained of abdominal distension. Computed tomography and ultrasonography revealed massive ascites and ovarian swelling of both sides. She was diagnosed as having primary ovarian cancer and peritoneal dissemination, and underwent a total hysterectomy as well as ovarectomy on both sides. <b style='color:DodgerBlue;'><i>After</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>she</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ie</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intraabdominal</i></b> <b style='color:DodgerBlue;'><i>injection</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CBDCA</i></b> <b style='color:DodgerBlue;'><i>300</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>div</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PTX</i></b> <b style='color:DodgerBlue;'><i>180</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, detailed histological examinations showed that the ovarian cancer had metastasized from her breast cancer. It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted. Therefore, no standard therapy has been established for breast cancer metastasizing to the ovarium. Our patient received 4 cycles of weekly administration of PTX (PTX 80 mg/m2, 3 consecutive weeks, 1-week break), followed by oral administration of <b style='color:Tomato;'><i>doxifluridine</i></b>+<b style='color:Tomato;'><i>anastrozole</i></b> on an outpatient basis. No evidence of recurrence of breast cancer has been noted 1 year after surgery. This result suggests that weekly administration of PTX and intraabdominal injection of CBDCA might be beneficial in the treatment of recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation.","tokens":[{"text":"After","start":0,"end":5,"id":0,"ws":true},{"text":"surgery","start":6,"end":13,"id":1,"ws":true},{"text":",","start":14,"end":15,"id":2,"ws":true},{"text":"she","start":16,"end":19,"id":3,"ws":true},{"text":"received","start":20,"end":28,"id":4,"ws":true},{"text":"a","start":29,"end":30,"id":5,"ws":true},{"text":"sequential","start":31,"end":41,"id":6,"ws":true},{"text":"chemotherapy","start":42,"end":54,"id":7,"ws":true},{"text":",","start":55,"end":56,"id":8,"ws":true},{"text":"ie","start":57,"end":59,"id":9,"ws":true},{"text":",","start":60,"end":61,"id":10,"ws":true},{"text":"intraabdominal","start":62,"end":76,"id":11,"ws":true},{"text":"injection","start":77,"end":86,"id":12,"ws":true},{"text":"of","start":87,"end":89,"id":13,"ws":true},{"text":"carboplatin","start":90,"end":101,"id":14,"ws":true},{"text":"(","start":102,"end":103,"id":15,"ws":true},{"text":"CBDCA","start":104,"end":109,"id":16,"ws":true},{"text":"300","start":110,"end":113,"id":17,"ws":true},{"text":"mg/m2","start":114,"end":119,"id":18,"ws":true},{"text":")","start":120,"end":121,"id":19,"ws":true},{"text":"and","start":122,"end":125,"id":20,"ws":true},{"text":"div","start":126,"end":129,"id":21,"ws":true},{"text":"administration","start":130,"end":144,"id":22,"ws":true},{"text":"of","start":145,"end":147,"id":23,"ws":true},{"text":"paclitaxel","start":148,"end":158,"id":24,"ws":true},{"text":"(","start":159,"end":160,"id":25,"ws":true},{"text":"PTX","start":161,"end":164,"id":26,"ws":true},{"text":"180","start":165,"end":168,"id":27,"ws":true},{"text":"mg/m2","start":169,"end":174,"id":28,"ws":true},{"text":")","start":175,"end":176,"id":29,"ws":true},{"text":"as","start":177,"end":179,"id":30,"ws":true},{"text":"a","start":180,"end":181,"id":31,"ws":true},{"text":"standard","start":182,"end":190,"id":32,"ws":true},{"text":"regimen","start":191,"end":198,"id":33,"ws":true},{"text":"for","start":199,"end":202,"id":34,"ws":true},{"text":"advanced","start":203,"end":211,"id":35,"ws":true},{"text":"ovarian","start":212,"end":219,"id":36,"ws":true},{"text":"cancer","start":220,"end":226,"id":37,"ws":true},{"text":".","start":227,"end":228,"id":38,"ws":false}],"spans":[{"start":90,"end":101,"token_start":14,"token_end":14,"label":"DRUG"},{"start":148,"end":158,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15791819/","_input_hash":2141280884,"_task_hash":1750490926,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":24,"child":14,"head_span":{"start":148,"end":158,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":90,"end":101,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In the comparison between rivaroxaban-based triple therapy and ticagrelor + aspirin , the RR was 1 and its 95 % CI remained within a post-hoc margin of \u00b1 15 % .","paragraph":"<h3><u>New oral anticoagulants in acute coronary syndrome: is there any advantage over existing treatments?</u></h3>After an acute coronary syndrome, dual antiplatelet therapy with <b style='color:Tomato;'><i>clopidogrel</i></b> plus <b style='color:Tomato;'><i>aspirin</i></b> is still a standard of care, but several new approaches have been investigated. ### objectives The present study re-examined the studies published thus far on this topic to evaluate the effectiveness of dual antiplatelet therapy in comparison to some of these new approaches (mainly, <b style='color:Tomato;'><i>ticagrelor</i></b> + <b style='color:Tomato;'><i>aspirin</i></b> and dual therapy plus a new oral anticoagulant [NOAC]; i.e., \"triple therapy\"). ### Materials And Methods The clinical material was directly derived from that reported in recent meta-analyses. Our re-analysis relied on standard equivalence methods in which interpretation is based on Relative Risks (RRs) along with their 95% Confidence Intervals (CI). The equivalence margins employed in our statistical testing were directly derived from those reported in randomized studies. ### results The equivalence margins were initially set at RR ranging from 0.775 to 1.29. According to these margins, triple therapy based on any NOAC proved to be superior to dual therapy alone, but at the same time demonstrated its equivalence with dual therapy. The results for <b style='color:Tomato;'><i>apixaban</i></b>-based triple therapy were inconclusive (not superior, not not-inferior, not equivalent and, of course, not inferior to the controls). Those for <b style='color:Tomato;'><i>rivaroxaban</i></b>-based triple therapy showed that this combination treatment was superior to dual therapy alone and failed to meet the criterion of equivalence. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>comparison</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>rivaroxaban-based</i></b> <b style='color:DodgerBlue;'><i>triple</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ticagrelor</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>RR</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>95</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>CI</i></b> <b style='color:DodgerBlue;'><i>remained</i></b> <b style='color:DodgerBlue;'><i>within</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>post-hoc</i></b> <b style='color:DodgerBlue;'><i>margin</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>\u00b1</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions Even if one considers the most effective NOAC in combination with <b style='color:Tomato;'><i>clopidogrel</i></b> + <b style='color:Tomato;'><i>ticagrelor</i></b>, this triple therapy is not more effective than <b style='color:Tomato;'><i>ticagrelor</i></b> + <b style='color:Tomato;'><i>aspirin</i></b>. On the other hand, the increased risk of bleeding with triple regimens is well demonstrated. We therefore conclude that these triple regimens did not play any important roles in the patients experiencing an acute coronary syndrome.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"comparison","start":7,"end":17,"id":2,"ws":true},{"text":"between","start":18,"end":25,"id":3,"ws":true},{"text":"rivaroxaban-based","start":26,"end":43,"id":4,"ws":true},{"text":"triple","start":44,"end":50,"id":5,"ws":true},{"text":"therapy","start":51,"end":58,"id":6,"ws":true},{"text":"and","start":59,"end":62,"id":7,"ws":true},{"text":"ticagrelor","start":63,"end":73,"id":8,"ws":true},{"text":"+","start":74,"end":75,"id":9,"ws":true},{"text":"aspirin","start":76,"end":83,"id":10,"ws":true},{"text":",","start":84,"end":85,"id":11,"ws":true},{"text":"the","start":86,"end":89,"id":12,"ws":true},{"text":"RR","start":90,"end":92,"id":13,"ws":true},{"text":"was","start":93,"end":96,"id":14,"ws":true},{"text":"1","start":97,"end":98,"id":15,"ws":true},{"text":"and","start":99,"end":102,"id":16,"ws":true},{"text":"its","start":103,"end":106,"id":17,"ws":true},{"text":"95","start":107,"end":109,"id":18,"ws":true},{"text":"%","start":110,"end":111,"id":19,"ws":true},{"text":"CI","start":112,"end":114,"id":20,"ws":true},{"text":"remained","start":115,"end":123,"id":21,"ws":true},{"text":"within","start":124,"end":130,"id":22,"ws":true},{"text":"a","start":131,"end":132,"id":23,"ws":true},{"text":"post-hoc","start":133,"end":141,"id":24,"ws":true},{"text":"margin","start":142,"end":148,"id":25,"ws":true},{"text":"of","start":149,"end":151,"id":26,"ws":true},{"text":"\u00b1","start":152,"end":153,"id":27,"ws":true},{"text":"15","start":154,"end":156,"id":28,"ws":true},{"text":"%","start":157,"end":158,"id":29,"ws":true},{"text":".","start":159,"end":160,"id":30,"ws":false}],"spans":[{"start":63,"end":73,"token_start":8,"token_end":8,"label":"DRUG"},{"start":76,"end":83,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25177676/","_input_hash":-269217492,"_task_hash":-2017896052,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":63,"end":73,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":76,"end":83,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"The incidence of cross-resistance between indinavir , nelfinavir , ritonavir and saquinavir was high ( 60 - 90 % ) .","paragraph":"<h3><u>Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.</u></h3>To assess the patterns of HIV phenotypic cross-resistance to protease inhibitors (PI) in patients experiencing viral load rebound on combination therapy including a PI. ### methods Phenotypic analysis of sensitivity to <b style='color:Tomato;'><i>indinavir</i></b>, <b style='color:Tomato;'><i>nelfinavir</i></b>, <b style='color:Tomato;'><i>saquinavir</i></b>, <b style='color:Tomato;'><i>ritonavir</i></b> and <b style='color:Tomato;'><i>amprenavir</i></b> was carried out using a single-cycle recombinant virus assay. Viral protease was sequenced by automated dideoxynucleotide chain termination. ### results Of the 108 patients studied, 68 had received <b style='color:Tomato;'><i>indinavir</i></b>, 50 <b style='color:Tomato;'><i>ritonavir</i></b>, 25 <b style='color:Tomato;'><i>saquinavir</i></b> and eight <b style='color:Tomato;'><i>nelfinavir</i></b>. The majority (71%) had received only one PI. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>incidence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cross-resistance</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>indinavir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>nelfinavir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ritonavir</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>saquinavir</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>90</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Cross-resistance to <b style='color:Tomato;'><i>amprenavir</i></b> was less frequent (37-40%). However there was some correlation between levels of sensitivity to <b style='color:Tomato;'><i>amprenavir</i></b> and <b style='color:Tomato;'><i>indinavir</i></b> (r2 = 0.34; P < 0.01). Conversely, the correlation between levels of sensitivity to <b style='color:Tomato;'><i>indinavir</i></b> and <b style='color:Tomato;'><i>saquinavir</i></b> was poor (r2 = 0.25), particularly for patients who had not received <b style='color:Tomato;'><i>saquinavir</i></b>. The degree of cross-resistance correlated with the level of resistance and with the total number of mutations in the protease gene (P < 0.05, chi square test) but could not be significantly correlated to any one particular mutation or combination of mutations. Mutation 184V was significantly associated with cross-resistance to <b style='color:Tomato;'><i>amprenavir</i></b>, with no mutations at codon 50 observed, while mutations associated with cross-resistance to <b style='color:Tomato;'><i>saquinavir</i></b> differed according to the treatment received. ### conclusions These results suggest that, although the total number of protease mutations correlates with the degree of cross-resistance, the specific mechanisms accounting for primary resistance and for cross-resistance may be different.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"incidence","start":4,"end":13,"id":1,"ws":true},{"text":"of","start":14,"end":16,"id":2,"ws":true},{"text":"cross-resistance","start":17,"end":33,"id":3,"ws":true},{"text":"between","start":34,"end":41,"id":4,"ws":true},{"text":"indinavir","start":42,"end":51,"id":5,"ws":true},{"text":",","start":52,"end":53,"id":6,"ws":true},{"text":"nelfinavir","start":54,"end":64,"id":7,"ws":true},{"text":",","start":65,"end":66,"id":8,"ws":true},{"text":"ritonavir","start":67,"end":76,"id":9,"ws":true},{"text":"and","start":77,"end":80,"id":10,"ws":true},{"text":"saquinavir","start":81,"end":91,"id":11,"ws":true},{"text":"was","start":92,"end":95,"id":12,"ws":true},{"text":"high","start":96,"end":100,"id":13,"ws":true},{"text":"(","start":101,"end":102,"id":14,"ws":true},{"text":"60","start":103,"end":105,"id":15,"ws":true},{"text":"-","start":106,"end":107,"id":16,"ws":true},{"text":"90","start":108,"end":110,"id":17,"ws":true},{"text":"%","start":111,"end":112,"id":18,"ws":true},{"text":")","start":113,"end":114,"id":19,"ws":true},{"text":".","start":115,"end":116,"id":20,"ws":false}],"spans":[{"start":42,"end":51,"token_start":5,"token_end":5,"label":"DRUG"},{"start":54,"end":64,"token_start":7,"token_end":7,"label":"DRUG"},{"start":67,"end":76,"token_start":9,"token_end":9,"label":"DRUG"},{"start":81,"end":91,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10546858/","_input_hash":1792203080,"_task_hash":1453810932,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Maintenance</i></b> <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:DodgerBlue;'><i>Low-Dose</i></b> <b style='color:MediumOrchid;'><i>Mercaptopurine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:MediumOrchid;'><i>Allopurinol</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Children</i></b> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:DodgerBlue;'><i>Acute</i></b> <b style='color:DodgerBlue;'><i>Lymphoblastic</i></b> <b style='color:DodgerBlue;'><i>Leukemia</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Mercaptopurine-Induced</i></b> <b style='color:DodgerBlue;'><i>Pancreatitis</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>mercaptopurine</i></b> (6-<b style='color:Tomato;'><i>mercaptopurine</i></b>, 6MP) is a mainstay of curative therapy in childhood acute lymphoblastic leukemia (ALL), and contributes to its 90% overall survival rate. We present two patients with ALL who suffered with severe pancreatitis secondary to 6MP. Through the use of <b style='color:Tomato;'><i>allopurinol</i></b> in conjunction with reduced dose 6MP, we were able to continue 6MP without further pancreatitis. This report contributes to the small body of literature on 6MP associated pancreatitis in childhood ALL and describes a novel approach to continued use of 6MP during therapy.","tokens":[{"text":"Maintenance","start":0,"end":11,"id":0,"ws":true},{"text":"Treatment","start":12,"end":21,"id":1,"ws":true},{"text":"With","start":22,"end":26,"id":2,"ws":true},{"text":"Low-Dose","start":27,"end":35,"id":3,"ws":true},{"text":"Mercaptopurine","start":36,"end":50,"id":4,"ws":true},{"text":"in","start":51,"end":53,"id":5,"ws":true},{"text":"Combination","start":54,"end":65,"id":6,"ws":true},{"text":"With","start":66,"end":70,"id":7,"ws":true},{"text":"Allopurinol","start":71,"end":82,"id":8,"ws":true},{"text":"in","start":83,"end":85,"id":9,"ws":true},{"text":"Children","start":86,"end":94,"id":10,"ws":true},{"text":"With","start":95,"end":99,"id":11,"ws":true},{"text":"Acute","start":100,"end":105,"id":12,"ws":true},{"text":"Lymphoblastic","start":106,"end":119,"id":13,"ws":true},{"text":"Leukemia","start":120,"end":128,"id":14,"ws":true},{"text":"and","start":129,"end":132,"id":15,"ws":true},{"text":"Mercaptopurine-Induced","start":133,"end":155,"id":16,"ws":true},{"text":"Pancreatitis","start":156,"end":168,"id":17,"ws":true},{"text":".","start":169,"end":170,"id":18,"ws":false}],"spans":[{"start":36,"end":50,"token_start":4,"token_end":4,"label":"DRUG"},{"start":71,"end":82,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26878433/","_input_hash":1490479126,"_task_hash":1148292388,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":8,"child":4,"head_span":{"start":71,"end":82,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":36,"end":50,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The aim of this study was to assess the predictive and prognostic value of clinical response to second line treatment ( with capecitabine or with a two-drug regimen including irinotecan ) and to analyze its relation to selected clinical and pathological variables with respect to time to disease progression .","paragraph":"<h3><u>Second-Line Chemotherapy of Advanced Colorectal Cancer: Predictive and Prognostic Factors.</u></h3>Colorectal cancer progression presents a significant clinical problem. After its dissemination, the foundation of its treatment comprises of palliative chemotherapy. ### objectives <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>assess</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>predictive</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>prognostic</i></b> <b style='color:DodgerBlue;'><i>value</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>second</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>two-drug</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>analyze</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>relation</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>selected</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>pathological</i></b> <b style='color:DodgerBlue;'><i>variables</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>respect</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Material And Methods The retrospective analysis of 164 patients with advanced colorectal cancer treated in 2001- -2008 included chosen clinical, pathological and follow-up data. ### results Response to second-line chemotherapy was observed in 34 out of 164 patients: In 18/82 in the <b style='color:Tomato;'><i>irinotecan</i></b> group (22%) and in 16/82 in the <b style='color:Tomato;'><i>capecitabine</i></b> group (19.5%). The mean survival time to progression following the second line of treatment amounted to 5.85 and 6.2 months respectively. Statistically, a higher number of patients in good condition of 0 to 1 was documented in the group responding to treatment. Significant correlation was documented between primary stage of the disease and time to progression in patients treated with <b style='color:Tomato;'><i>capecitabine</i></b> (p = 0.0258). The recurrence of the disease was observed in 44/45 patients following operation with radical intention but with an insufficient number of excised lymph nodes. A significantly longer time to progression was observed in women treated with <b style='color:Tomato;'><i>capecitabine</i></b>. In logistic regression, lack of treatment response was found to be an independent factor affecting the time to disease progression. Patients who did not respond to the second line of treatment demonstrated a significantly shorter time to disease progression than patients who responded to it and they showed a significantly higher number of patients with leucopenia during treatment. ### conclusions Clinical response to treatment in both treated groups is of significant importance for the probability of local recurrence of the disease, preservation of a good patient's condition and the higher level of leukocytes during treatment.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"this","start":11,"end":15,"id":3,"ws":true},{"text":"study","start":16,"end":21,"id":4,"ws":true},{"text":"was","start":22,"end":25,"id":5,"ws":true},{"text":"to","start":26,"end":28,"id":6,"ws":true},{"text":"assess","start":29,"end":35,"id":7,"ws":true},{"text":"the","start":36,"end":39,"id":8,"ws":true},{"text":"predictive","start":40,"end":50,"id":9,"ws":true},{"text":"and","start":51,"end":54,"id":10,"ws":true},{"text":"prognostic","start":55,"end":65,"id":11,"ws":true},{"text":"value","start":66,"end":71,"id":12,"ws":true},{"text":"of","start":72,"end":74,"id":13,"ws":true},{"text":"clinical","start":75,"end":83,"id":14,"ws":true},{"text":"response","start":84,"end":92,"id":15,"ws":true},{"text":"to","start":93,"end":95,"id":16,"ws":true},{"text":"second","start":96,"end":102,"id":17,"ws":true},{"text":"line","start":103,"end":107,"id":18,"ws":true},{"text":"treatment","start":108,"end":117,"id":19,"ws":true},{"text":"(","start":118,"end":119,"id":20,"ws":true},{"text":"with","start":120,"end":124,"id":21,"ws":true},{"text":"capecitabine","start":125,"end":137,"id":22,"ws":true},{"text":"or","start":138,"end":140,"id":23,"ws":true},{"text":"with","start":141,"end":145,"id":24,"ws":true},{"text":"a","start":146,"end":147,"id":25,"ws":true},{"text":"two-drug","start":148,"end":156,"id":26,"ws":true},{"text":"regimen","start":157,"end":164,"id":27,"ws":true},{"text":"including","start":165,"end":174,"id":28,"ws":true},{"text":"irinotecan","start":175,"end":185,"id":29,"ws":true},{"text":")","start":186,"end":187,"id":30,"ws":true},{"text":"and","start":188,"end":191,"id":31,"ws":true},{"text":"to","start":192,"end":194,"id":32,"ws":true},{"text":"analyze","start":195,"end":202,"id":33,"ws":true},{"text":"its","start":203,"end":206,"id":34,"ws":true},{"text":"relation","start":207,"end":215,"id":35,"ws":true},{"text":"to","start":216,"end":218,"id":36,"ws":true},{"text":"selected","start":219,"end":227,"id":37,"ws":true},{"text":"clinical","start":228,"end":236,"id":38,"ws":true},{"text":"and","start":237,"end":240,"id":39,"ws":true},{"text":"pathological","start":241,"end":253,"id":40,"ws":true},{"text":"variables","start":254,"end":263,"id":41,"ws":true},{"text":"with","start":264,"end":268,"id":42,"ws":true},{"text":"respect","start":269,"end":276,"id":43,"ws":true},{"text":"to","start":277,"end":279,"id":44,"ws":true},{"text":"time","start":280,"end":284,"id":45,"ws":true},{"text":"to","start":285,"end":287,"id":46,"ws":true},{"text":"disease","start":288,"end":295,"id":47,"ws":true},{"text":"progression","start":296,"end":307,"id":48,"ws":true},{"text":".","start":308,"end":309,"id":49,"ws":false}],"spans":[{"start":125,"end":137,"token_start":22,"token_end":22,"label":"DRUG"},{"start":175,"end":185,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27629847/","_input_hash":109916564,"_task_hash":-882335232,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":22,"child":29,"head_span":{"start":125,"end":137,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":175,"end":185,"token_start":29,"token_end":29,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Changes</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>absorption</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>synthesis</i></b> <b style='color:DodgerBlue;'><i>caused</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>ezetimibe</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>men</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>This study evaluates changes in cholesterol balance in hypercholesterolemic subjects following treatment with an inhibitor of cholesterol absorption or cholesterol synthesis or coadministration of both agents. This was a randomized, double blind, placebo-controlled, four-period crossover study to evaluate the effects of coadministering 10 mg <b style='color:Tomato;'><i>ezetimibe</i></b> with 20 mg <b style='color:Tomato;'><i>simvastatin</i></b> (<b style='color:Tomato;'><i>ezetimibe</i></b>/<b style='color:Tomato;'><i>simvastatin</i></b>) on cholesterol absorption and synthesis relative to either drug alone or placebo in 41 subjects. Each treatment period lasted 7 weeks. <b style='color:Tomato;'><i>ezetimibe</i></b> and <b style='color:Tomato;'><i>ezetimibe</i></b>/<b style='color:Tomato;'><i>simvastatin</i></b> decreased fractional cholesterol absorption by 65% and 59%, respectively (P < 0.001 for both relative to placebo). <b style='color:Tomato;'><i>simvastatin</i></b> did not significantly affect cholesterol absorption. <b style='color:Tomato;'><i>ezetimibe</i></b> and <b style='color:Tomato;'><i>ezetimibe</i></b>/<b style='color:Tomato;'><i>simvastatin</i></b> increased fecal sterol excretion (corrected for dietary cholesterol), which also represents net steady state cholesterol synthesis, by 109% and 79%, respectively (P < 0.001). <b style='color:Tomato;'><i>ezetimibe</i></b>, <b style='color:Tomato;'><i>simvastatin</i></b>, and <b style='color:Tomato;'><i>ezetimibe</i></b>/<b style='color:Tomato;'><i>simvastatin</i></b> decreased plasma LDL-cholesterol by 20, 38, and 55%, respectively. The coadministered therapy was well tolerated. The decreases in net cholesterol synthesis and increased fecal sterol excretion yielded nearly additive reductions in LDL-cholesterol for the coadministration of <b style='color:Tomato;'><i>ezetimibe</i></b> and <b style='color:Tomato;'><i>simvastatin</i></b>.","tokens":[{"text":"Changes","start":0,"end":7,"id":0,"ws":true},{"text":"in","start":8,"end":10,"id":1,"ws":true},{"text":"cholesterol","start":11,"end":22,"id":2,"ws":true},{"text":"absorption","start":23,"end":33,"id":3,"ws":true},{"text":"and","start":34,"end":37,"id":4,"ws":true},{"text":"cholesterol","start":38,"end":49,"id":5,"ws":true},{"text":"synthesis","start":50,"end":59,"id":6,"ws":true},{"text":"caused","start":60,"end":66,"id":7,"ws":true},{"text":"by","start":67,"end":69,"id":8,"ws":true},{"text":"ezetimibe","start":70,"end":79,"id":9,"ws":true},{"text":"and/or","start":80,"end":86,"id":10,"ws":true},{"text":"simvastatin","start":87,"end":98,"id":11,"ws":true},{"text":"in","start":99,"end":101,"id":12,"ws":true},{"text":"men","start":102,"end":105,"id":13,"ws":true},{"text":".","start":106,"end":107,"id":14,"ws":false}],"spans":[{"start":70,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},{"start":87,"end":98,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19380898/","_input_hash":2060678417,"_task_hash":-580376587,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":70,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":87,"end":98,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The US government regulated precursor chemicals , ephedrine and pseudoephedrine , multiple times to limit methamphetamine production/availability and thus methamphetamine problems .","paragraph":"<h3><u>Impacts of federal precursor chemical regulations on methamphetamine arrests.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>US</i></b> <b style='color:DodgerBlue;'><i>government</i></b> <b style='color:DodgerBlue;'><i>regulated</i></b> <b style='color:DodgerBlue;'><i>precursor</i></b> <b style='color:DodgerBlue;'><i>chemicals</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ephedrine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>pseudoephedrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>times</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>limit</i></b> <b style='color:MediumOrchid;'><i>methamphetamine</i></b> <b style='color:DodgerBlue;'><i>production/availability</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>thus</i></b> <b style='color:MediumOrchid;'><i>methamphetamine</i></b> <b style='color:DodgerBlue;'><i>problems</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Research has found that the regulations reduced <b style='color:Tomato;'><i>methamphetamine</i></b> hospital admissions, but authors have argued that other problems were unaffected. This study examines whether the regulations impacted <b style='color:Tomato;'><i>methamphetamine</i></b> arrests. ### design ARIMA-intervention time-series analysis with control series. ### setting California (1982-2001). ### measurements Dependent variable series: monthly <b style='color:Tomato;'><i>methamphetamine</i></b> arrests. Control series: monthly marijuana arrests and cocaine/heroin arrests. ### interventions Bulk powder ephedrine and <b style='color:Tomato;'><i>pseudoephedrine</i></b>: regulated November 1989. Products containing ephedrine as the single active medicinal ingredient: regulated August 1995. <b style='color:Tomato;'><i>pseudoephedrine</i></b> products: regulated October 1997. Large-scale producers used ephedrine and <b style='color:Tomato;'><i>pseudoephedrine</i></b> in these forms. Ephedrine combined with other active medicinal ingredients (e.g. various cold medicines)-used mainly by small-scale producers: regulated October 1996. ### findings The regulation targeting small-scale producers (1996) had no significant impact. In contrast, <b style='color:Tomato;'><i>methamphetamine</i></b> arrests stopped rising and dropped 31% to 45% each of the three times precursor chemicals used by large-scale producers were regulated. Within 3 years of the bulk powder regulation (1989) and again within 2 years of the ephedrine single ingredient regulation (1995), arrests fully rebounded. During the 4 years following the last regulation (<b style='color:Tomato;'><i>pseudoephedrine</i></b> products, 1997) arrests only partially rebounded. These effects parallel those reported on hospital admissions. The control series were generally unaffected. ### conclusions Precursor regulations targeting large-scale producers impacted <b style='color:Tomato;'><i>methamphetamine</i></b> arrests, a criminal justice problem, much as they impacted the public health problem of <b style='color:Tomato;'><i>methamphetamine</i></b> hospital admissions. Ongoing research is needed to determine whether these problems eventually fully rebound from the last regulation.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"US","start":4,"end":6,"id":1,"ws":true},{"text":"government","start":7,"end":17,"id":2,"ws":true},{"text":"regulated","start":18,"end":27,"id":3,"ws":true},{"text":"precursor","start":28,"end":37,"id":4,"ws":true},{"text":"chemicals","start":38,"end":47,"id":5,"ws":true},{"text":",","start":48,"end":49,"id":6,"ws":true},{"text":"ephedrine","start":50,"end":59,"id":7,"ws":true},{"text":"and","start":60,"end":63,"id":8,"ws":true},{"text":"pseudoephedrine","start":64,"end":79,"id":9,"ws":true},{"text":",","start":80,"end":81,"id":10,"ws":true},{"text":"multiple","start":82,"end":90,"id":11,"ws":true},{"text":"times","start":91,"end":96,"id":12,"ws":true},{"text":"to","start":97,"end":99,"id":13,"ws":true},{"text":"limit","start":100,"end":105,"id":14,"ws":true},{"text":"methamphetamine","start":106,"end":121,"id":15,"ws":true},{"text":"production/availability","start":122,"end":145,"id":16,"ws":true},{"text":"and","start":146,"end":149,"id":17,"ws":true},{"text":"thus","start":150,"end":154,"id":18,"ws":true},{"text":"methamphetamine","start":155,"end":170,"id":19,"ws":true},{"text":"problems","start":171,"end":179,"id":20,"ws":true},{"text":".","start":180,"end":181,"id":21,"ws":false}],"spans":[{"start":64,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},{"start":106,"end":121,"token_start":15,"token_end":15,"label":"DRUG"},{"start":155,"end":170,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15784062/","_input_hash":-629534182,"_task_hash":-1189202745,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine , lomustine , and vincristine ( PCV ) chemotherapy to radiotherapy ( RT ) .","paragraph":"<h3><u>Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.</u></h3>Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>now</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>findings</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>procarbazine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>lomustine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PCV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Adult patients with newly diagnosed anaplastic oligodendroglial tumors were randomly assigned to either 59.4 Gy of RT or the same RT followed by six cycles of adjuvant PCV. An exploratory analysis of the correlation between 1p/19q status and survival was part of the study. Retrospectively, the methylation status of the methyl-guanine methyl transferase gene promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined. The primary end points were overall survival (OS) and progression-free survival based on intent-to-treat analysis. ### results A total of 368 patients were enrolled. With a median follow-up of 140 months, OS in the RT/PCV arm was significantly longer (42.3 v 30.6 months in the RT arm, hazard ratio [HR], 0.75; 95% CI, 0.60 to 0.95). In the 80 patients with a 1p/19q codeletion, OS was increased, with a trend toward more benefit from adjuvant PCV (OS not reached in the RT/PCV group v 112 months in the RT group; HR, 0.56; 95% CI, 0.31 to 1.03). IDH mutational status was also of prognostic significance. ### conclusion The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors. 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/19q-deleted tumors.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"now","start":3,"end":6,"id":1,"ws":true},{"text":"present","start":7,"end":14,"id":2,"ws":true},{"text":"the","start":15,"end":18,"id":3,"ws":true},{"text":"long-term","start":19,"end":28,"id":4,"ws":true},{"text":"follow-up","start":29,"end":38,"id":5,"ws":true},{"text":"findings","start":39,"end":47,"id":6,"ws":true},{"text":"of","start":48,"end":50,"id":7,"ws":true},{"text":"a","start":51,"end":52,"id":8,"ws":true},{"text":"randomized","start":53,"end":63,"id":9,"ws":true},{"text":"phase","start":64,"end":69,"id":10,"ws":true},{"text":"III","start":70,"end":73,"id":11,"ws":true},{"text":"study","start":74,"end":79,"id":12,"ws":true},{"text":"on","start":80,"end":82,"id":13,"ws":true},{"text":"the","start":83,"end":86,"id":14,"ws":true},{"text":"addition","start":87,"end":95,"id":15,"ws":true},{"text":"of","start":96,"end":98,"id":16,"ws":true},{"text":"six","start":99,"end":102,"id":17,"ws":true},{"text":"cycles","start":103,"end":109,"id":18,"ws":true},{"text":"of","start":110,"end":112,"id":19,"ws":true},{"text":"procarbazine","start":113,"end":125,"id":20,"ws":true},{"text":",","start":126,"end":127,"id":21,"ws":true},{"text":"lomustine","start":128,"end":137,"id":22,"ws":true},{"text":",","start":138,"end":139,"id":23,"ws":true},{"text":"and","start":140,"end":143,"id":24,"ws":true},{"text":"vincristine","start":144,"end":155,"id":25,"ws":true},{"text":"(","start":156,"end":157,"id":26,"ws":true},{"text":"PCV","start":158,"end":161,"id":27,"ws":true},{"text":")","start":162,"end":163,"id":28,"ws":true},{"text":"chemotherapy","start":164,"end":176,"id":29,"ws":true},{"text":"to","start":177,"end":179,"id":30,"ws":true},{"text":"radiotherapy","start":180,"end":192,"id":31,"ws":true},{"text":"(","start":193,"end":194,"id":32,"ws":true},{"text":"RT","start":195,"end":197,"id":33,"ws":true},{"text":")","start":198,"end":199,"id":34,"ws":true},{"text":".","start":200,"end":201,"id":35,"ws":false}],"spans":[{"start":113,"end":125,"token_start":20,"token_end":20,"label":"DRUG"},{"start":128,"end":137,"token_start":22,"token_end":22,"label":"DRUG"},{"start":144,"end":155,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23071237/","_input_hash":1994652939,"_task_hash":-432329763,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":113,"end":125,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":128,"end":137,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":25,"child":22,"head_span":{"start":144,"end":155,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":128,"end":137,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":25,"child":31,"head_span":{"start":144,"end":155,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":180,"end":192,"token_start":31,"token_end":31,"label":null},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"A phase II clinical trial was conducted to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine in very old patients with inoperable ( stage IIIb or IV ) NSCLC .","paragraph":"<h3><u>A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older.</u></h3><b style='color:Tomato;'><i>vinorelbine</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> are two active single agents with mild toxicity profiles that are used in the treatment of non-small-cell lung cancer (NSCLC). Whether or not very old NSCLC patients, such as those aged 80 years or older, should still be considered for chemotherapy is unknown, since their response to the treatment is also unknown. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>very</i></b> <b style='color:DodgerBlue;'><i>old</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>inoperable</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IIIb</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>vinorelbine</i></b> 20 mg/m(2) was given as a 10-min intravenous infusion, followed by a 30-min intravenous infusion of <b style='color:Tomato;'><i>gemcitabine</i></b> 800 mg/m(2) on days 1, 8, and 15 of each 28-day cycle. From March 1998 to December 2001, 20 patients (16 males, four females) were enrolled in the study. The median age was 83 years, within the range 80-88 years. The median number of treatment cycles per patient was four. With the exception of one, all patients received at least two cycles of treatment. Thirteen patients achieved a partial response, with an overall response rate of 65% (95% confidence interval, 44.1-85.9%). Median survival was 10 months. The significant (WHO grade 3/4) toxicities were myelosuppression, including leukopenia in five (25%) patients, neutropenia in eight (40%), anaemia in six (30%), and thrombocytopenia in three (15%) patients. Febrile neutropenia occurred in two patients and accounted for one treatment-related death. Non-haematological toxicity was generally mild, except one patient who suffered from grade 3 interstitial pneumonitis. Another patient suffered from a cerebral infarction after three cycles of treatment. In conclusion, the combination of <b style='color:Tomato;'><i>vinorelbine</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> in very old patients with advanced NSCLC is a highly active regimen with an acceptable toxicity profile.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"phase","start":2,"end":7,"id":1,"ws":true},{"text":"II","start":8,"end":10,"id":2,"ws":true},{"text":"clinical","start":11,"end":19,"id":3,"ws":true},{"text":"trial","start":20,"end":25,"id":4,"ws":true},{"text":"was","start":26,"end":29,"id":5,"ws":true},{"text":"conducted","start":30,"end":39,"id":6,"ws":true},{"text":"to","start":40,"end":42,"id":7,"ws":true},{"text":"evaluate","start":43,"end":51,"id":8,"ws":true},{"text":"the","start":52,"end":55,"id":9,"ws":true},{"text":"efficacy","start":56,"end":64,"id":10,"ws":true},{"text":"and","start":65,"end":68,"id":11,"ws":true},{"text":"toxicity","start":69,"end":77,"id":12,"ws":true},{"text":"of","start":78,"end":80,"id":13,"ws":true},{"text":"vinorelbine","start":81,"end":92,"id":14,"ws":true},{"text":"plus","start":93,"end":97,"id":15,"ws":true},{"text":"gemcitabine","start":98,"end":109,"id":16,"ws":true},{"text":"in","start":110,"end":112,"id":17,"ws":true},{"text":"very","start":113,"end":117,"id":18,"ws":true},{"text":"old","start":118,"end":121,"id":19,"ws":true},{"text":"patients","start":122,"end":130,"id":20,"ws":true},{"text":"with","start":131,"end":135,"id":21,"ws":true},{"text":"inoperable","start":136,"end":146,"id":22,"ws":true},{"text":"(","start":147,"end":148,"id":23,"ws":true},{"text":"stage","start":149,"end":154,"id":24,"ws":true},{"text":"IIIb","start":155,"end":159,"id":25,"ws":true},{"text":"or","start":160,"end":162,"id":26,"ws":true},{"text":"IV","start":163,"end":165,"id":27,"ws":true},{"text":")","start":166,"end":167,"id":28,"ws":true},{"text":"NSCLC","start":168,"end":173,"id":29,"ws":true},{"text":".","start":174,"end":175,"id":30,"ws":false}],"spans":[{"start":81,"end":92,"token_start":14,"token_end":14,"label":"DRUG"},{"start":98,"end":109,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12711125/","_input_hash":2080813707,"_task_hash":-1542936782,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":81,"end":92,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":98,"end":109,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Tobramycin was probably less effective than gentamicin in combination with the penicillinase-resistant penicillins against enterococci .","paragraph":"<h3><u>Comparative in vitro activity of nafcillin, oxacillin, and methicillin in combination with gentamicin and tobramycin against enterococci.</u></h3>The in vitro activity of <b style='color:Tomato;'><i>nafcillin</i></b>, <b style='color:Tomato;'><i>oxacillin</i></b>, and methicillin alone and in combination with <b style='color:Tomato;'><i>gentamicin</i></b> and <b style='color:Tomato;'><i>tobramycin</i></b> against 30 strains of enterococci was investigated. The penicillinase-resistant penicillins were less active than penicillin and <b style='color:Tomato;'><i>ampicillin</i></b> against the enterococci. <b style='color:Tomato;'><i>nafcillin</i></b> was more active than <b style='color:Tomato;'><i>oxacillin</i></b> and methicillin. Sixty-six percent of strains were inhibited by <b style='color:Tomato;'><i>nafcillin</i></b> at 6.25 mug/ml, but none was inhibited by <b style='color:Tomato;'><i>oxacillin</i></b> and methicillin at the same concentration. At 12.5 mug/ml, 83, 16, and 0% were inhibited by <b style='color:Tomato;'><i>nafcillin</i></b>, <b style='color:Tomato;'><i>oxacillin</i></b>, and methicillin, respectively. By using a variety of criteria and analyses, it was shown that none of the antibiotic combinations studied demonstrated enhanced killing of all strains of enterococci. <b style='color:Tomato;'><i>nafcillin</i></b>-<b style='color:Tomato;'><i>gentamicin</i></b> was the best combination, and enhanced killing was demonstrated against most strains. <b style='color:Tomato;'><i>oxacillin</i></b> was more effective than methicillin when combined with <b style='color:Tomato;'><i>gentamicin</i></b>. <b style='color:MediumOrchid;'><i>Tobramycin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>probably</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>penicillinase-resistant</i></b> <b style='color:DodgerBlue;'><i>penicillins</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>enterococci</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Tobramycin","start":0,"end":10,"id":0,"ws":true},{"text":"was","start":11,"end":14,"id":1,"ws":true},{"text":"probably","start":15,"end":23,"id":2,"ws":true},{"text":"less","start":24,"end":28,"id":3,"ws":true},{"text":"effective","start":29,"end":38,"id":4,"ws":true},{"text":"than","start":39,"end":43,"id":5,"ws":true},{"text":"gentamicin","start":44,"end":54,"id":6,"ws":true},{"text":"in","start":55,"end":57,"id":7,"ws":true},{"text":"combination","start":58,"end":69,"id":8,"ws":true},{"text":"with","start":70,"end":74,"id":9,"ws":true},{"text":"the","start":75,"end":78,"id":10,"ws":true},{"text":"penicillinase-resistant","start":79,"end":102,"id":11,"ws":true},{"text":"penicillins","start":103,"end":114,"id":12,"ws":true},{"text":"against","start":115,"end":122,"id":13,"ws":true},{"text":"enterococci","start":123,"end":134,"id":14,"ws":true},{"text":".","start":135,"end":136,"id":15,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":44,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/836017/","_input_hash":611981779,"_task_hash":1981686877,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":6,"child":12,"head_span":{"start":44,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":103,"end":114,"token_start":12,"token_end":12,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":0,"child":12,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":103,"end":114,"token_start":12,"token_end":12,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Despite the absence of strong data , entecavir and telbivudine seem to be the preferred options for nucleoside analogue-naive CHB patients with chronic kidney disease , depending on viraemia and severity of renal dysfunction .","paragraph":"<h3><u>Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.</u></h3>The treatment of chronic hepatitis B (CHB) in patients with chronic kidney disease (CKD) is based on nucleoside (<b style='color:Tomato;'><i>lamivudine</i></b>, <b style='color:Tomato;'><i>telbivudine</i></b>, <b style='color:Tomato;'><i>entecavir</i></b>) or nucleotide (<b style='color:Tomato;'><i>adefovir</i></b>, <b style='color:Tomato;'><i>tenofovir</i></b>) analogues (NAs), but it may be complex and the information is scarce. <b style='color:Tomato;'><i>entecavir</i></b> and <b style='color:Tomato;'><i>tenofovir</i></b> represent the currently recommended first-line NAs for NA-naive CHB patients, while <b style='color:Tomato;'><i>tenofovir</i></b> is the NA of choice for CHB patients with resistance to nucleosides. ### aim To review the efficacy and safety of NAs in adult CHB patients with CKD and to provide reasonable recommendations for their optimal management. ### methods Literature search in PubMed/Medline and manual search of relevant articles, reviews and book chapters. ### results NAs are cleared by kidneys and their dosage should be adjusted in patients with creatinine clearance <50\u00a0mL/min. There are concerns about nephrotoxic potential of the nucleotides, particularly <b style='color:Tomato;'><i>adefovir</i></b>, while improvements of creatinine clearance have been reported under <b style='color:Tomato;'><i>telbivudine</i></b>. Most existing data in CHB patients with CKD are for <b style='color:Tomato;'><i>lamivudine</i></b> and, less frequently, for other NAs, mostly <b style='color:Tomato;'><i>entecavir</i></b>. Besides CHB, NA should be used in case of immunosuppressive therapy in any HBsAg-positive patient with CKD including renal transplant (RT) recipients and in anti-HBs-positive recipients of kidney grafts from HBsAg-positive donors. ### conclusions Chronic hepatitis B patients with chronic kidney disease receiving nucleoside analogues should be followed carefully for treatment efficacy and renal safety. <b style='color:DodgerBlue;'><i>Despite</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>strong</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>entecavir</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>telbivudine</i></b> <b style='color:DodgerBlue;'><i>seem</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>options</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>nucleoside</i></b> <b style='color:DodgerBlue;'><i>analogue-naive</i></b> <b style='color:DodgerBlue;'><i>CHB</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>kidney</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>depending</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>viraemia</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>severity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>dysfunction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> More studies are certainly needed in this setting.","tokens":[{"text":"Despite","start":0,"end":7,"id":0,"ws":true},{"text":"the","start":8,"end":11,"id":1,"ws":true},{"text":"absence","start":12,"end":19,"id":2,"ws":true},{"text":"of","start":20,"end":22,"id":3,"ws":true},{"text":"strong","start":23,"end":29,"id":4,"ws":true},{"text":"data","start":30,"end":34,"id":5,"ws":true},{"text":",","start":35,"end":36,"id":6,"ws":true},{"text":"entecavir","start":37,"end":46,"id":7,"ws":true},{"text":"and","start":47,"end":50,"id":8,"ws":true},{"text":"telbivudine","start":51,"end":62,"id":9,"ws":true},{"text":"seem","start":63,"end":67,"id":10,"ws":true},{"text":"to","start":68,"end":70,"id":11,"ws":true},{"text":"be","start":71,"end":73,"id":12,"ws":true},{"text":"the","start":74,"end":77,"id":13,"ws":true},{"text":"preferred","start":78,"end":87,"id":14,"ws":true},{"text":"options","start":88,"end":95,"id":15,"ws":true},{"text":"for","start":96,"end":99,"id":16,"ws":true},{"text":"nucleoside","start":100,"end":110,"id":17,"ws":true},{"text":"analogue-naive","start":111,"end":125,"id":18,"ws":true},{"text":"CHB","start":126,"end":129,"id":19,"ws":true},{"text":"patients","start":130,"end":138,"id":20,"ws":true},{"text":"with","start":139,"end":143,"id":21,"ws":true},{"text":"chronic","start":144,"end":151,"id":22,"ws":true},{"text":"kidney","start":152,"end":158,"id":23,"ws":true},{"text":"disease","start":159,"end":166,"id":24,"ws":true},{"text":",","start":167,"end":168,"id":25,"ws":true},{"text":"depending","start":169,"end":178,"id":26,"ws":true},{"text":"on","start":179,"end":181,"id":27,"ws":true},{"text":"viraemia","start":182,"end":190,"id":28,"ws":true},{"text":"and","start":191,"end":194,"id":29,"ws":true},{"text":"severity","start":195,"end":203,"id":30,"ws":true},{"text":"of","start":204,"end":206,"id":31,"ws":true},{"text":"renal","start":207,"end":212,"id":32,"ws":true},{"text":"dysfunction","start":213,"end":224,"id":33,"ws":true},{"text":".","start":225,"end":226,"id":34,"ws":false}],"spans":[{"start":37,"end":46,"token_start":7,"token_end":7,"label":"DRUG"},{"start":51,"end":62,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24299322/","_input_hash":1590525858,"_task_hash":1765201580,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Inclusion criteria were proven infection with evidence of a bacterial strain of PA resistant to all \u03b2-lactams and treated with the association of at least aztreonam plus cefepime .","paragraph":"<h3><u>Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to \u03b2-lactams in ICU patients: A pilot study.</u></h3>Resistance to all \u03b2-lactams is emerging among Pseudomonas aeruginosa (PA) clinical isolates. <b style='color:Tomato;'><i>aztreonam</i></b> and <b style='color:Tomato;'><i>cefepime</i></b> act synergistically in vitro against AmpC overproducing PA isolates. The objective of this study was to evaluate the clinical efficacy of this treatment in ICU patients infected with multidrug-resistant PA. ### Material And Methods Retrospective study (2 years, 2 ICUs) in a tertiary university hospital. <b style='color:DodgerBlue;'><i>Inclusion</i></b> <b style='color:DodgerBlue;'><i>criteria</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>evidence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>bacterial</i></b> <b style='color:DodgerBlue;'><i>strain</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>PA</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>all</i></b> <b style='color:DodgerBlue;'><i>\u03b2-lactams</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>association</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:MediumOrchid;'><i>aztreonam</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cefepime</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Treatment was considered effective for pneumonia using CPIS scores at the end of treatment and for other infections, using the SOFA score and signs of infection improvement at the end of treatment. Infectious episodes were classified as cure or failure. ### results Thirteen patients were included (10 nosocomial pneumonia, 3 nosocomial intra-abdominal infections). The median [25th-75th percentiles] admission SAPS2 score was 54 [51-69] and the median SOFA score at the beginning of infection was 7 [4-8]. The median CPIS scores for pneumonia at the beginning and end of treatment were 9 [7-10.5] and 2 [0.75-5.5]. The duration of treatment with the combination of <b style='color:Tomato;'><i>aztreonam</i></b> plus <b style='color:Tomato;'><i>cefepime</i></b> was 14 days [9.5-16]. Nine episodes were classified as cures and 4 as failures, indicating a clinical efficacy of 69.2%. Overall mortality was 38.5%. ### discussion These data suggest that the association of <b style='color:Tomato;'><i>cefepime</i></b> plus <b style='color:Tomato;'><i>aztreonam</i></b> could be an attractive alternative in the treatment of infections with multidrug-resistant PA to all \u03b2-lactams with a clinical efficacy rate of 69%.","tokens":[{"text":"Inclusion","start":0,"end":9,"id":0,"ws":true},{"text":"criteria","start":10,"end":18,"id":1,"ws":true},{"text":"were","start":19,"end":23,"id":2,"ws":true},{"text":"proven","start":24,"end":30,"id":3,"ws":true},{"text":"infection","start":31,"end":40,"id":4,"ws":true},{"text":"with","start":41,"end":45,"id":5,"ws":true},{"text":"evidence","start":46,"end":54,"id":6,"ws":true},{"text":"of","start":55,"end":57,"id":7,"ws":true},{"text":"a","start":58,"end":59,"id":8,"ws":true},{"text":"bacterial","start":60,"end":69,"id":9,"ws":true},{"text":"strain","start":70,"end":76,"id":10,"ws":true},{"text":"of","start":77,"end":79,"id":11,"ws":true},{"text":"PA","start":80,"end":82,"id":12,"ws":true},{"text":"resistant","start":83,"end":92,"id":13,"ws":true},{"text":"to","start":93,"end":95,"id":14,"ws":true},{"text":"all","start":96,"end":99,"id":15,"ws":true},{"text":"\u03b2-lactams","start":100,"end":109,"id":16,"ws":true},{"text":"and","start":110,"end":113,"id":17,"ws":true},{"text":"treated","start":114,"end":121,"id":18,"ws":true},{"text":"with","start":122,"end":126,"id":19,"ws":true},{"text":"the","start":127,"end":130,"id":20,"ws":true},{"text":"association","start":131,"end":142,"id":21,"ws":true},{"text":"of","start":143,"end":145,"id":22,"ws":true},{"text":"at","start":146,"end":148,"id":23,"ws":true},{"text":"least","start":149,"end":154,"id":24,"ws":true},{"text":"aztreonam","start":155,"end":164,"id":25,"ws":true},{"text":"plus","start":165,"end":169,"id":26,"ws":true},{"text":"cefepime","start":170,"end":178,"id":27,"ws":true},{"text":".","start":179,"end":180,"id":28,"ws":false}],"spans":[{"start":155,"end":164,"token_start":25,"token_end":25,"label":"DRUG"},{"start":170,"end":178,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26004874/","_input_hash":-164111142,"_task_hash":-1185345343,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":25,"child":27,"head_span":{"start":155,"end":164,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":170,"end":178,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Comparison of the additive effects of nipradilol and carteolol to latanoprost in open-angle glaucoma .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Comparison</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>additive</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>nipradilol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carteolol</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>latanoprost</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>open-angle</i></b> <b style='color:DodgerBlue;'><i>glaucoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>To compare the effects of nipradilol and <b style='color:Tomato;'><i>carteolol</i></b> on intraocular pressure (IOP) when added to <b style='color:Tomato;'><i>latanoprost</i></b> treatment for glaucoma patients. ### methods Fifty patients with primary open-angle glaucoma were treated with <b style='color:Tomato;'><i>latanoprost</i></b> 0.005% once daily for 3 months. Then they were assigned to one of two groups randomly. One group received nipradilol 0.25% twice daily (nipradilol preceding group; n = 25), and the other <b style='color:Tomato;'><i>carteolol</i></b> hydrochloride 2% twice daily (<b style='color:Tomato;'><i>carteolol</i></b> preceding group; n = 25), for 3 months in addition to <b style='color:Tomato;'><i>latanoprost</i></b>. Then, nipradilol and <b style='color:Tomato;'><i>carteolol</i></b> were switched, and the subjects were treated for 3 more months. One eye was selected randomly for analysis. ### results In the nipradilol preceding group, IOP was 21.4 +/- 2.3 mmHg (mean +/- SD) at baseline, and 16.8 +/- 1.9 mmHg at the end of <b style='color:Tomato;'><i>latanoprost</i></b> monotherapy (P < 0.01). The addition of nipradilol decreased IOP to 15.8 +/- 1.7 mmHg, and the change to <b style='color:Tomato;'><i>carteolol</i></b>, to 15.3 +/- 2.0 mmHg. In the <b style='color:Tomato;'><i>carteolol</i></b> preceding group, IOP was 21.2 +/- 2.0 mmHg at baseline, and 17.0 +/- 2.1 mmHg at the end of <b style='color:Tomato;'><i>latanoprost</i></b> monotherapy (P < 0.01). The addition of <b style='color:Tomato;'><i>carteolol</i></b> decreased IOP to 15.4 +/- 1.8 mmHg, and the change to nipradilol, to 16.3 +/- 1.9 mmHg. Additional IOP reduction was greater with <b style='color:Tomato;'><i>carteolol</i></b> than with nipradilol (cross-over analysis of variance; P = 0.0005). ### conclusions Both nipradilol and <b style='color:Tomato;'><i>carteolol</i></b> have additive effects when used in combination with <b style='color:Tomato;'><i>latanoprost</i></b>. <b style='color:Tomato;'><i>carteolol</i></b>, however, may have a more potent effect than nipradilol.","tokens":[{"text":"Comparison","start":0,"end":10,"id":0,"ws":true},{"text":"of","start":11,"end":13,"id":1,"ws":true},{"text":"the","start":14,"end":17,"id":2,"ws":true},{"text":"additive","start":18,"end":26,"id":3,"ws":true},{"text":"effects","start":27,"end":34,"id":4,"ws":true},{"text":"of","start":35,"end":37,"id":5,"ws":true},{"text":"nipradilol","start":38,"end":48,"id":6,"ws":true},{"text":"and","start":49,"end":52,"id":7,"ws":true},{"text":"carteolol","start":53,"end":62,"id":8,"ws":true},{"text":"to","start":63,"end":65,"id":9,"ws":true},{"text":"latanoprost","start":66,"end":77,"id":10,"ws":true},{"text":"in","start":78,"end":80,"id":11,"ws":true},{"text":"open-angle","start":81,"end":91,"id":12,"ws":true},{"text":"glaucoma","start":92,"end":100,"id":13,"ws":true},{"text":".","start":101,"end":102,"id":14,"ws":false}],"spans":[{"start":38,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":53,"end":62,"token_start":8,"token_end":8,"label":"DRUG"},{"start":66,"end":77,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16453185/","_input_hash":31849482,"_task_hash":1212317438,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":53,"end":62,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":66,"end":77,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":6,"child":10,"head_span":{"start":38,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":66,"end":77,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The poly(ADP-ribose ) polymerase ( PARP ) inhibitor olaparib has recently received approval from the Food and Drug Administration ( FDA ) and European Medicines Agency ( EMA ) , with a second agent ( rucaparib ) likely to be approved in the near future .","paragraph":"<h3><u>Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.</u></h3>: High-grade serous ovarian cancer is characterized by genomic instability, with one half of all tumors displaying defects in the important DNA repair pathway of homologous recombination. Given the action of poly(ADP-ribose) polymerase (PARP) inhibitors in targeting tumors with deficiencies in this repair pathway by loss of BRCA1/2, ovarian tumors could be an attractive population for clinical application of this therapy. PARP inhibitors have moved into clinical practice in the past few years, with approval from the Food and Drug Administration (FDA) and European Medicines Agency (EMA) within the past 2 years. The U.S. FDA approval of <b style='color:Tomato;'><i>olaparib</i></b> applies to fourth line treatment in germline BRCA-mutant ovarian cancer, and European EMA approval to <b style='color:Tomato;'><i>olaparib</i></b> maintenance in both germline and somatic BRCA-mutant platinum-sensitive ovarian cancer. In order to widen the ovarian cancer patient population that would benefit from PARP inhibitors, predictive biomarkers based on a clear understanding of the mechanism of action are required. Additionally, a better understanding of the toxicity profile is needed if PARP inhibitors are to be used in the curative, rather than the palliative, setting. We reviewed the development of PARP inhibitors in phase I-III clinical trials, including combination trials of PARP inhibitors and chemotherapy/antiangiogenics, the approval for these agents, the mechanisms of resistance, and the outstanding issues, including the development of biomarkers and the rate of long-term hematologic toxicities with these agents. ### Implications For Practice <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>poly(ADP-ribose</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>polymerase</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PARP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:MediumOrchid;'><i>olaparib</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>recently</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>approval</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Food</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Drug</i></b> <b style='color:DodgerBlue;'><i>Administration</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FDA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>European</i></b> <b style='color:DodgerBlue;'><i>Medicines</i></b> <b style='color:DodgerBlue;'><i>Agency</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>EMA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>second</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>rucaparib</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>likely</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>approved</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>near</i></b> <b style='color:DodgerBlue;'><i>future</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, the patient population with potential benefit from PARP inhibitors is likely wider than that of germline BRCA mutation-associated disease, and biomarkers are in development to enable the selection of patients with the potential for clinical benefit from these agents. Questions remain regarding the toxicities of PARP inhibitors, limiting the use of these agents in the prophylactic or adjuvant setting until more information is available. The indications for <b style='color:Tomato;'><i>olaparib</i></b> as indicated by the FDA and EMA are reviewed.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"poly(ADP-ribose","start":4,"end":19,"id":1,"ws":true},{"text":")","start":20,"end":21,"id":2,"ws":true},{"text":"polymerase","start":22,"end":32,"id":3,"ws":true},{"text":"(","start":33,"end":34,"id":4,"ws":true},{"text":"PARP","start":35,"end":39,"id":5,"ws":true},{"text":")","start":40,"end":41,"id":6,"ws":true},{"text":"inhibitor","start":42,"end":51,"id":7,"ws":true},{"text":"olaparib","start":52,"end":60,"id":8,"ws":true},{"text":"has","start":61,"end":64,"id":9,"ws":true},{"text":"recently","start":65,"end":73,"id":10,"ws":true},{"text":"received","start":74,"end":82,"id":11,"ws":true},{"text":"approval","start":83,"end":91,"id":12,"ws":true},{"text":"from","start":92,"end":96,"id":13,"ws":true},{"text":"the","start":97,"end":100,"id":14,"ws":true},{"text":"Food","start":101,"end":105,"id":15,"ws":true},{"text":"and","start":106,"end":109,"id":16,"ws":true},{"text":"Drug","start":110,"end":114,"id":17,"ws":true},{"text":"Administration","start":115,"end":129,"id":18,"ws":true},{"text":"(","start":130,"end":131,"id":19,"ws":true},{"text":"FDA","start":132,"end":135,"id":20,"ws":true},{"text":")","start":136,"end":137,"id":21,"ws":true},{"text":"and","start":138,"end":141,"id":22,"ws":true},{"text":"European","start":142,"end":150,"id":23,"ws":true},{"text":"Medicines","start":151,"end":160,"id":24,"ws":true},{"text":"Agency","start":161,"end":167,"id":25,"ws":true},{"text":"(","start":168,"end":169,"id":26,"ws":true},{"text":"EMA","start":170,"end":173,"id":27,"ws":true},{"text":")","start":174,"end":175,"id":28,"ws":true},{"text":",","start":176,"end":177,"id":29,"ws":true},{"text":"with","start":178,"end":182,"id":30,"ws":true},{"text":"a","start":183,"end":184,"id":31,"ws":true},{"text":"second","start":185,"end":191,"id":32,"ws":true},{"text":"agent","start":192,"end":197,"id":33,"ws":true},{"text":"(","start":198,"end":199,"id":34,"ws":true},{"text":"rucaparib","start":200,"end":209,"id":35,"ws":true},{"text":")","start":210,"end":211,"id":36,"ws":true},{"text":"likely","start":212,"end":218,"id":37,"ws":true},{"text":"to","start":219,"end":221,"id":38,"ws":true},{"text":"be","start":222,"end":224,"id":39,"ws":true},{"text":"approved","start":225,"end":233,"id":40,"ws":true},{"text":"in","start":234,"end":236,"id":41,"ws":true},{"text":"the","start":237,"end":240,"id":42,"ws":true},{"text":"near","start":241,"end":245,"id":43,"ws":true},{"text":"future","start":246,"end":252,"id":44,"ws":true},{"text":".","start":253,"end":254,"id":45,"ws":false}],"spans":[{"start":52,"end":60,"token_start":8,"token_end":8,"label":"DRUG"},{"start":200,"end":209,"token_start":35,"token_end":35,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27022037/","_input_hash":-735189998,"_task_hash":706383763,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Fluvoxamine is a fairly potent inhibitor of CYP2C19 and it has the potential for causing drug-drug interactions with substrates for CYP2C19 such as imipramine , clomipramine , amitriptyline and diazepam .","paragraph":"<h3><u>Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.</u></h3>The potent CYP1A2 inhibitor <b style='color:Tomato;'><i>fluvoxamine</i></b> has recently been shown also to be an effective inhibitor of the CYP2C19-mediated metabolism of the antimalarial drug <b style='color:Tomato;'><i>proguanil</i></b> in vivo. The purpose of the present study was to confirm this interaction in vitro. ### methods A high-performance liquid chromatography (HPLC) method was developed to assay 4-chlorophenylbiguanide (4-CPBG) and cycloguanil formed from <b style='color:Tomato;'><i>proguanil</i></b> by microsomes prepared from human liver. The limit of detection was 0.08 nmol mg-'. h-I. ### results The formation of 4-CPBG and cycloguanil could be described by one-enzyme kinetics, indicating that the formation of the two metabolites is almost exclusively catalysed by a single enzyme, i.e. CYP2C19 within the concentration range used, or that the contribution of an alternative low-affinity enzyme, probably CYP3A4, is very low. This notion was confirmed by the lack of potent inhibition by four CYP3A4 inhibitors: <b style='color:Tomato;'><i>ketoconazole</i></b>, <b style='color:Tomato;'><i>bromocriptine</i></b>, midazolam and dihydroergotamine. <b style='color:Tomato;'><i>fluvoxamine</i></b> was a very effective inhibitor of the oxidation of <b style='color:Tomato;'><i>proguanil</i></b>, displaying Ki values of 0.69 micromol x l(-1) for the inhibition of cycloguanil formation and 4.7 micromol x l(-1) for the inhibition of 4-CPBG formation. As expected, the CYP2C19 substrate <b style='color:Tomato;'><i>omeprazole</i></b> inhibited the formation of both metabolites with an IC50 of 10 micromol x l(-1). Nor<b style='color:Tomato;'><i>fluoxetine</i></b> and <b style='color:Tomato;'><i>sulfaphenazole</i></b> inhibited <b style='color:Tomato;'><i>proguanil</i></b> oxidation with Ki values of 7.3-16 micromol x l(-1), suggesting that the two compounds are moderate inhibitors of CYP2C19. ### conclusions <b style='color:MediumOrchid;'><i>Fluvoxamine</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fairly</i></b> <b style='color:DodgerBlue;'><i>potent</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CYP2C19</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>it</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>causing</i></b> <b style='color:DodgerBlue;'><i>drug-drug</i></b> <b style='color:DodgerBlue;'><i>interactions</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>substrates</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>CYP2C19</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>imipramine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clomipramine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amitriptyline</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>diazepam</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of <b style='color:Tomato;'><i>fluvoxamine</i></b> and <b style='color:Tomato;'><i>proguanil</i></b> can not be recommended.","tokens":[{"text":"Fluvoxamine","start":0,"end":11,"id":0,"ws":true},{"text":"is","start":12,"end":14,"id":1,"ws":true},{"text":"a","start":15,"end":16,"id":2,"ws":true},{"text":"fairly","start":17,"end":23,"id":3,"ws":true},{"text":"potent","start":24,"end":30,"id":4,"ws":true},{"text":"inhibitor","start":31,"end":40,"id":5,"ws":true},{"text":"of","start":41,"end":43,"id":6,"ws":true},{"text":"CYP2C19","start":44,"end":51,"id":7,"ws":true},{"text":"and","start":52,"end":55,"id":8,"ws":true},{"text":"it","start":56,"end":58,"id":9,"ws":true},{"text":"has","start":59,"end":62,"id":10,"ws":true},{"text":"the","start":63,"end":66,"id":11,"ws":true},{"text":"potential","start":67,"end":76,"id":12,"ws":true},{"text":"for","start":77,"end":80,"id":13,"ws":true},{"text":"causing","start":81,"end":88,"id":14,"ws":true},{"text":"drug-drug","start":89,"end":98,"id":15,"ws":true},{"text":"interactions","start":99,"end":111,"id":16,"ws":true},{"text":"with","start":112,"end":116,"id":17,"ws":true},{"text":"substrates","start":117,"end":127,"id":18,"ws":true},{"text":"for","start":128,"end":131,"id":19,"ws":true},{"text":"CYP2C19","start":132,"end":139,"id":20,"ws":true},{"text":"such","start":140,"end":144,"id":21,"ws":true},{"text":"as","start":145,"end":147,"id":22,"ws":true},{"text":"imipramine","start":148,"end":158,"id":23,"ws":true},{"text":",","start":159,"end":160,"id":24,"ws":true},{"text":"clomipramine","start":161,"end":173,"id":25,"ws":true},{"text":",","start":174,"end":175,"id":26,"ws":true},{"text":"amitriptyline","start":176,"end":189,"id":27,"ws":true},{"text":"and","start":190,"end":193,"id":28,"ws":true},{"text":"diazepam","start":194,"end":202,"id":29,"ws":true},{"text":".","start":203,"end":204,"id":30,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":148,"end":158,"token_start":23,"token_end":23,"label":"DRUG"},{"start":161,"end":173,"token_start":25,"token_end":25,"label":"DRUG"},{"start":176,"end":189,"token_start":27,"token_end":27,"label":"DRUG"},{"start":194,"end":202,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9923577/","_input_hash":-879189063,"_task_hash":-193956022,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":0,"child":23,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":148,"end":158,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":0,"child":25,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":161,"end":173,"token_start":25,"token_end":25,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":0,"child":27,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":176,"end":189,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"COMB3"}],"radio":[],"answer":"accept"}
{"text":"We have compared amphotericin B , flucytosine , ketoconazole and fluconazole susceptibilities of 40 clinical isolates of Candida albicans by broth microdilution in two different media : RPMI 1640 ( RPMI ) and the same medium supplemented with 18 g of glucose per L ( RPMI-2 % glucose ) .","paragraph":"<h3><u>Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>flucytosine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ketoconazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluconazole</i></b> <b style='color:DodgerBlue;'><i>susceptibilities</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>isolates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Candida</i></b> <b style='color:DodgerBlue;'><i>albicans</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>microdilution</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>media</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>RPMI</i></b> <b style='color:DodgerBlue;'><i>1640</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RPMI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>medium</i></b> <b style='color:DodgerBlue;'><i>supplemented</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>g</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>glucose</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>L</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RPMI-2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>glucose</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Preparation of media, drugs and inocula, as well as incubation temperature, followed the recommendations of the National Committee for Clinical Laboratory Standards (Villanova, PA, USA) antifungal agent working group for broth macrodilution tests with antifungal agents. Microtitre plates were agitated for 5 min before spectrophotometric readings were performed with an automatic plate reader. MIC endpoints were defined in three different ways: (i) MIC-100% for <b style='color:Tomato;'><i>amphotericin</i></b> B and <b style='color:Tomato;'><i>flucytosine</i></b>; (ii) MIC-80% for azole-drugs and also for <b style='color:Tomato;'><i>flucytosine</i></b>; (iii) IC1/2 for azole-drugs. The MIC endpoints were compared between the two different media in order to ascertain which was the best criterion. For <b style='color:Tomato;'><i>amphotericin</i></b> B, 100% of strains had a maximum difference of a twofold dilution in both media. For <b style='color:Tomato;'><i>flucytosine</i></b>, MIC values were very similar in both media, irrespective of the MIC endpoint chosen, MIC-100% or MIC-80%. For azole-drugs the (MIC-80%)50 and (MIC-80%)90 in RPMI were higher than those in RPMI-2% glucose. However, (IC1/2)50 and (IC1/2)90 were identical in both media as well as (MIC-80%)50 and (MIC-80%)90 in RPMI-2% glucose, The limited growth of yeasts in RPMI precludes the selection of an azole-MIC-80% endpoint, although the MIC determination was performed with an objective turbidimetric method (spectrophotometric reading plus mathematical MIC calculation). The use of RPMI-2% glucose produces the same MIC whatever methods was used, IC1/2 or MIC-80%. However, some minor discrepancies can be expected between IC1/2 and MIC-80% when strains with higher \"trailing effect\" are being tested. Therefore, we recommended IC1/2 in RPMI-2% glucose as the method of choice for MIC calculation, until more studies correlating in-vitro results with clinical outcome have been performed.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"have","start":3,"end":7,"id":1,"ws":true},{"text":"compared","start":8,"end":16,"id":2,"ws":true},{"text":"amphotericin","start":17,"end":29,"id":3,"ws":true},{"text":"B","start":30,"end":31,"id":4,"ws":true},{"text":",","start":32,"end":33,"id":5,"ws":true},{"text":"flucytosine","start":34,"end":45,"id":6,"ws":true},{"text":",","start":46,"end":47,"id":7,"ws":true},{"text":"ketoconazole","start":48,"end":60,"id":8,"ws":true},{"text":"and","start":61,"end":64,"id":9,"ws":true},{"text":"fluconazole","start":65,"end":76,"id":10,"ws":true},{"text":"susceptibilities","start":77,"end":93,"id":11,"ws":true},{"text":"of","start":94,"end":96,"id":12,"ws":true},{"text":"40","start":97,"end":99,"id":13,"ws":true},{"text":"clinical","start":100,"end":108,"id":14,"ws":true},{"text":"isolates","start":109,"end":117,"id":15,"ws":true},{"text":"of","start":118,"end":120,"id":16,"ws":true},{"text":"Candida","start":121,"end":128,"id":17,"ws":true},{"text":"albicans","start":129,"end":137,"id":18,"ws":true},{"text":"by","start":138,"end":140,"id":19,"ws":true},{"text":"broth","start":141,"end":146,"id":20,"ws":true},{"text":"microdilution","start":147,"end":160,"id":21,"ws":true},{"text":"in","start":161,"end":163,"id":22,"ws":true},{"text":"two","start":164,"end":167,"id":23,"ws":true},{"text":"different","start":168,"end":177,"id":24,"ws":true},{"text":"media","start":178,"end":183,"id":25,"ws":true},{"text":":","start":184,"end":185,"id":26,"ws":true},{"text":"RPMI","start":186,"end":190,"id":27,"ws":true},{"text":"1640","start":191,"end":195,"id":28,"ws":true},{"text":"(","start":196,"end":197,"id":29,"ws":true},{"text":"RPMI","start":198,"end":202,"id":30,"ws":true},{"text":")","start":203,"end":204,"id":31,"ws":true},{"text":"and","start":205,"end":208,"id":32,"ws":true},{"text":"the","start":209,"end":212,"id":33,"ws":true},{"text":"same","start":213,"end":217,"id":34,"ws":true},{"text":"medium","start":218,"end":224,"id":35,"ws":true},{"text":"supplemented","start":225,"end":237,"id":36,"ws":true},{"text":"with","start":238,"end":242,"id":37,"ws":true},{"text":"18","start":243,"end":245,"id":38,"ws":true},{"text":"g","start":246,"end":247,"id":39,"ws":true},{"text":"of","start":248,"end":250,"id":40,"ws":true},{"text":"glucose","start":251,"end":258,"id":41,"ws":true},{"text":"per","start":259,"end":262,"id":42,"ws":true},{"text":"L","start":263,"end":264,"id":43,"ws":true},{"text":"(","start":265,"end":266,"id":44,"ws":true},{"text":"RPMI-2","start":267,"end":273,"id":45,"ws":true},{"text":"%","start":274,"end":275,"id":46,"ws":true},{"text":"glucose","start":276,"end":283,"id":47,"ws":true},{"text":")","start":284,"end":285,"id":48,"ws":true},{"text":".","start":286,"end":287,"id":49,"ws":false}],"spans":[{"start":17,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},{"start":34,"end":45,"token_start":6,"token_end":6,"label":"DRUG"},{"start":48,"end":60,"token_start":8,"token_end":8,"label":"DRUG"},{"start":65,"end":76,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7559186/","_input_hash":2070092889,"_task_hash":2112239501,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Over the past decade , paclitaxel , docetaxel , vinorelbine , gemcitabine , irinotecan , and topotecan have been introduced into the clinic .","paragraph":"<h3><u>Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine.</u></h3>Platinum-based chemotherapy is considered standard treatment for advanced non-small-cell lung cancer (NSCLC). However, toxicity of most platinum-based regimens is substantial and requires close monitoring and supportive care. <b style='color:DodgerBlue;'><i>Over</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>past</i></b> <b style='color:DodgerBlue;'><i>decade</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>introduced</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>clinic</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These newer agents have shown promising activity against NSCLC with a favorable toxicity profile as single agents. For patients with metastatic NSCLC, palliation is the main goal of therapy. Therefore, treatment should be easy to administer on an outpatient basis. We explored a novel combination therapy avoiding platinum. Patients with recurrent or metastatic NSCLC were treated with intravenous (i.v.) <b style='color:Tomato;'><i>topotecan</i></b> (0.5-1.0 mg/m(2)/day x 5) and i.v. <b style='color:Tomato;'><i>vinorelbine</i></b> (20-30 mg/m(2)/day on day 1 and day 5) in 21-day cycles. Dose-limiting toxicity (DLT) was defined separately with or without the addition of granulocyte colony-stimulating factor (G-CSF) support. Twenty-nine patients have been enrolled to date. At i.v. <b style='color:Tomato;'><i>topotecan</i></b> doses of 0.75-1.0 mg/m(2)/day and i.v. <b style='color:Tomato;'><i>vinorelbine</i></b> of 25 mg/m(2)/day, neutropenia was frequent but of short duration (<7 days). The DLT of i.v. <b style='color:Tomato;'><i>topotecan</i></b> (0.85 mg/m(2)) in the absence of G-CSF support was based on myelosuppression with neutropenic fever. With the addition of G-CSF, a DLT has not been reached. Nonhematologic toxicities included mild to moderate fatigue and constipation. An overall clinical response rate of 42% was achieved, with responses noted at all dose levels. At a short median follow-up of 15 months, the median survival for all patients is 13 months. In conclusion, the combination regimen of <b style='color:Tomato;'><i>topotecan</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> is feasible for outpatient administration and is well tolerated with less toxicity than platinum-based regimens. Preliminary response data demonstrate good tumor activity, suggesting that this regimen could make an excellent palliative treatment for advanced NSCLC.","tokens":[{"text":"Over","start":0,"end":4,"id":0,"ws":true},{"text":"the","start":5,"end":8,"id":1,"ws":true},{"text":"past","start":9,"end":13,"id":2,"ws":true},{"text":"decade","start":14,"end":20,"id":3,"ws":true},{"text":",","start":21,"end":22,"id":4,"ws":true},{"text":"paclitaxel","start":23,"end":33,"id":5,"ws":true},{"text":",","start":34,"end":35,"id":6,"ws":true},{"text":"docetaxel","start":36,"end":45,"id":7,"ws":true},{"text":",","start":46,"end":47,"id":8,"ws":true},{"text":"vinorelbine","start":48,"end":59,"id":9,"ws":true},{"text":",","start":60,"end":61,"id":10,"ws":true},{"text":"gemcitabine","start":62,"end":73,"id":11,"ws":true},{"text":",","start":74,"end":75,"id":12,"ws":true},{"text":"irinotecan","start":76,"end":86,"id":13,"ws":true},{"text":",","start":87,"end":88,"id":14,"ws":true},{"text":"and","start":89,"end":92,"id":15,"ws":true},{"text":"topotecan","start":93,"end":102,"id":16,"ws":true},{"text":"have","start":103,"end":107,"id":17,"ws":true},{"text":"been","start":108,"end":112,"id":18,"ws":true},{"text":"introduced","start":113,"end":123,"id":19,"ws":true},{"text":"into","start":124,"end":128,"id":20,"ws":true},{"text":"the","start":129,"end":132,"id":21,"ws":true},{"text":"clinic","start":133,"end":139,"id":22,"ws":true},{"text":".","start":140,"end":141,"id":23,"ws":false}],"spans":[{"start":23,"end":33,"token_start":5,"token_end":5,"label":"DRUG"},{"start":36,"end":45,"token_start":7,"token_end":7,"label":"DRUG"},{"start":48,"end":59,"token_start":9,"token_end":9,"label":"DRUG"},{"start":62,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},{"start":76,"end":86,"token_start":13,"token_end":13,"label":"DRUG"},{"start":93,"end":102,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11598413/","_input_hash":370835701,"_task_hash":739658303,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Alternatively , it may be that the adverse effects of pindolol and propranolol are due to the simultaneous blockade of both beta 1- and beta 2-adrenoceptors .","paragraph":"<h3><u>Central propranolol and pindolol, but not atenolol nor metoprolol, inhibit sexual behavior in male rats.</u></h3>Are the anti-sexual effects of <b style='color:Tomato;'><i>propranolol</i></b> and <b style='color:Tomato;'><i>pindolol</i></b> due to actions within the brain? To answer this, these agents were administered directly into the brain ventricular system (ICV). Additionally, <b style='color:Tomato;'><i>atenolol</i></b> and <b style='color:Tomato;'><i>metoprolol</i></b> were evaluated to see whether differential delivery to the brain contributed to the observed lack of effect of systemically administered beta 1-adrenoceptor antagonists. ICV administration of <b style='color:Tomato;'><i>pindolol</i></b> (45 or 90 micrograms) was followed by a suppression of copulation. At 45 micrograms, inhibition was limited to performance aspects of copulation, whereas at 90 micrograms, decrements in motivational and performance aspects of copulation were evident. ICV administration of <b style='color:Tomato;'><i>propranolol</i></b> also suppressed copulatory behavior. At 45 micrograms, no significant effects were observed, whereas at 90 micrograms decrements in motivational and performance aspects of copulation were evident. In contrast, ICV administration of the beta 1-adrenoceptor antagonists, <b style='color:Tomato;'><i>atenolol</i></b> and <b style='color:Tomato;'><i>metoprolol</i></b>, was not associated with any major modifications in copulatory behavior. We suggest that the inhibitory effects of <b style='color:Tomato;'><i>propranolol</i></b> and <b style='color:Tomato;'><i>pindolol</i></b> may involve interactions with 5-HT1A receptors in the CNS. <b style='color:DodgerBlue;'><i>Alternatively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>it</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pindolol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>simultaneous</i></b> <b style='color:DodgerBlue;'><i>blockade</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>beta</i></b> <b style='color:DodgerBlue;'><i>1-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>beta</i></b> <b style='color:DodgerBlue;'><i>2-adrenoceptors</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Alternatively","start":0,"end":13,"id":0,"ws":true},{"text":",","start":14,"end":15,"id":1,"ws":true},{"text":"it","start":16,"end":18,"id":2,"ws":true},{"text":"may","start":19,"end":22,"id":3,"ws":true},{"text":"be","start":23,"end":25,"id":4,"ws":true},{"text":"that","start":26,"end":30,"id":5,"ws":true},{"text":"the","start":31,"end":34,"id":6,"ws":true},{"text":"adverse","start":35,"end":42,"id":7,"ws":true},{"text":"effects","start":43,"end":50,"id":8,"ws":true},{"text":"of","start":51,"end":53,"id":9,"ws":true},{"text":"pindolol","start":54,"end":62,"id":10,"ws":true},{"text":"and","start":63,"end":66,"id":11,"ws":true},{"text":"propranolol","start":67,"end":78,"id":12,"ws":true},{"text":"are","start":79,"end":82,"id":13,"ws":true},{"text":"due","start":83,"end":86,"id":14,"ws":true},{"text":"to","start":87,"end":89,"id":15,"ws":true},{"text":"the","start":90,"end":93,"id":16,"ws":true},{"text":"simultaneous","start":94,"end":106,"id":17,"ws":true},{"text":"blockade","start":107,"end":115,"id":18,"ws":true},{"text":"of","start":116,"end":118,"id":19,"ws":true},{"text":"both","start":119,"end":123,"id":20,"ws":true},{"text":"beta","start":124,"end":128,"id":21,"ws":true},{"text":"1-","start":129,"end":131,"id":22,"ws":true},{"text":"and","start":132,"end":135,"id":23,"ws":true},{"text":"beta","start":136,"end":140,"id":24,"ws":true},{"text":"2-adrenoceptors","start":141,"end":156,"id":25,"ws":true},{"text":".","start":157,"end":158,"id":26,"ws":false}],"spans":[{"start":54,"end":62,"token_start":10,"token_end":10,"label":"DRUG"},{"start":67,"end":78,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8838601/","_input_hash":-206388755,"_task_hash":-555842489,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The combinations of irinotecan and mitomycin C or oxaliplatin have given very good results with high objective response rates and good tolerance .","paragraph":"<h3><u>[Irinotecan in combination for colon cancer].</u></h3>As a single agent, <b style='color:Tomato;'><i>irinotecan</i></b> has demonstrated efficacy in metastatic 5FU resistant colorectal metastatic cancer. Chemotherapy with <b style='color:Tomato;'><i>fluorouracil</i></b> (5FU) plus <b style='color:Tomato;'><i>leucovorin</i></b> remains a standard in the treatment of patients with metastatic colorectal cancer. It seemed logical to test the combination of this reference treatment and the new agent. The first trials gave rather disappointing results, suggesting an inhibition of the metabolism of <b style='color:Tomato;'><i>irinotecan</i></b> into SN38 when 5FU was present in the circulation. More recent studies have given totally different results with a very good tolerance and strong efficacy of the combination of weekly folinic acid + 5FU and <b style='color:Tomato;'><i>irinotecan</i></b> or LV5FU2 (the so-called de Gramont regimen) and <b style='color:Tomato;'><i>irinotecan</i></b>. The results were so good that these new schedules are currently developed as first line regimen. Another way to combine 5FU, folinic acid and <b style='color:Tomato;'><i>irinotecan</i></b> is to alternate a cycle of 5FU, folinic acid and a cycle of <b style='color:Tomato;'><i>irinotecan</i></b>. Such an alternated schedule has given encouraging results with an objective response rate greater than 30% and a long median survival time (more than 16 months). It is also very easy to combine <b style='color:Tomato;'><i>irinotecan</i></b> with other drug which have demonstrated activity in the treatment of colorectal cancer. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitomycin</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>very</i></b> <b style='color:DodgerBlue;'><i>good</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>objective</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>good</i></b> <b style='color:DodgerBlue;'><i>tolerance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>irinotecan</i></b> plays now an important part in the treatment of metastatic colorectal cancer. This part becomes larger due to the results of the combination trials already presented which have shown strong efficacy and good tolerance.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combinations","start":4,"end":16,"id":1,"ws":true},{"text":"of","start":17,"end":19,"id":2,"ws":true},{"text":"irinotecan","start":20,"end":30,"id":3,"ws":true},{"text":"and","start":31,"end":34,"id":4,"ws":true},{"text":"mitomycin","start":35,"end":44,"id":5,"ws":true},{"text":"C","start":45,"end":46,"id":6,"ws":true},{"text":"or","start":47,"end":49,"id":7,"ws":true},{"text":"oxaliplatin","start":50,"end":61,"id":8,"ws":true},{"text":"have","start":62,"end":66,"id":9,"ws":true},{"text":"given","start":67,"end":72,"id":10,"ws":true},{"text":"very","start":73,"end":77,"id":11,"ws":true},{"text":"good","start":78,"end":82,"id":12,"ws":true},{"text":"results","start":83,"end":90,"id":13,"ws":true},{"text":"with","start":91,"end":95,"id":14,"ws":true},{"text":"high","start":96,"end":100,"id":15,"ws":true},{"text":"objective","start":101,"end":110,"id":16,"ws":true},{"text":"response","start":111,"end":119,"id":17,"ws":true},{"text":"rates","start":120,"end":125,"id":18,"ws":true},{"text":"and","start":126,"end":129,"id":19,"ws":true},{"text":"good","start":130,"end":134,"id":20,"ws":true},{"text":"tolerance","start":135,"end":144,"id":21,"ws":true},{"text":".","start":145,"end":146,"id":22,"ws":false}],"spans":[{"start":20,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},{"start":35,"end":44,"token_start":5,"token_end":5,"label":"DRUG"},{"start":50,"end":61,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9932084/","_input_hash":1058730831,"_task_hash":-1883704268,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":20,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":35,"end":44,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":3,"child":8,"head_span":{"start":20,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":50,"end":61,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"The NHB of strategy A was 31.6 QALMs versus strategy C when palbociclib was included in strategy C ; similarly , strategy A had a NHB of 13.8 QALMs versus strategy C when pertuzumab was included in strategy C. Monte-Carlo simulation demonstrated that the main factor influencing NHB of strategy A over strategy C was the cost of systemic therapy .","paragraph":"<h3><u>Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis.</u></h3>To estimate the cost-effectiveness of liver resection followed by adjuvant systemic therapy relative to systemic therapy alone for patients with breast cancer liver metastasis. ### background Data on cost-effectiveness of liver resection for advanced breast cancer with liver metastasis are lacking. ### methods A decision-analytic Markov model was constructed to evaluate the cost-effectiveness of liver resection followed by postoperative conventional systemic therapy (strategy A) versus conventional therapy alone (strategy B) versus newer targeted therapy alone (strategy C). The implications of using different chemotherapeutic regimens based on estrogen receptor and human epidermal growth factor receptor 2 status was also assessed. Outcomes included quality-adjusted life months (QALMs), incremental cost-effectiveness ratio, and net health benefit (NHB). ### results NHB of strategy A was 10.9 QALMs compared with strategy B when <b style='color:Tomato;'><i>letrozole</i></b> was used as systemic therapy, whereas it was only 0.3 QALMs when <b style='color:Tomato;'><i>docetaxel</i></b>\u200a+\u200a<b style='color:Tomato;'><i>trastuzumab</i></b> was used as a systemic therapy. The addition of newer biological agents (strategy C) significantly decreased the cost-effectiveness of strategy B (conventional systemic therapy alone). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>NHB</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>31.6</i></b> <b style='color:DodgerBlue;'><i>QALMs</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:MediumOrchid;'><i>palbociclib</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>similarly</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>NHB</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>13.8</i></b> <b style='color:DodgerBlue;'><i>QALMs</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>C.</i></b> <b style='color:DodgerBlue;'><i>Monte-Carlo</i></b> <b style='color:DodgerBlue;'><i>simulation</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>main</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>influencing</i></b> <b style='color:DodgerBlue;'><i>NHB</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cost</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions Liver resection in patients with breast cancer liver metastasis proved to be cost-effective when compared with systemic therapy alone, particularly in estrogen receptor-positive tumors or when newer agents were used.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"NHB","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"strategy","start":11,"end":19,"id":3,"ws":true},{"text":"A","start":20,"end":21,"id":4,"ws":true},{"text":"was","start":22,"end":25,"id":5,"ws":true},{"text":"31.6","start":26,"end":30,"id":6,"ws":true},{"text":"QALMs","start":31,"end":36,"id":7,"ws":true},{"text":"versus","start":37,"end":43,"id":8,"ws":true},{"text":"strategy","start":44,"end":52,"id":9,"ws":true},{"text":"C","start":53,"end":54,"id":10,"ws":true},{"text":"when","start":55,"end":59,"id":11,"ws":true},{"text":"palbociclib","start":60,"end":71,"id":12,"ws":true},{"text":"was","start":72,"end":75,"id":13,"ws":true},{"text":"included","start":76,"end":84,"id":14,"ws":true},{"text":"in","start":85,"end":87,"id":15,"ws":true},{"text":"strategy","start":88,"end":96,"id":16,"ws":true},{"text":"C","start":97,"end":98,"id":17,"ws":true},{"text":";","start":99,"end":100,"id":18,"ws":true},{"text":"similarly","start":101,"end":110,"id":19,"ws":true},{"text":",","start":111,"end":112,"id":20,"ws":true},{"text":"strategy","start":113,"end":121,"id":21,"ws":true},{"text":"A","start":122,"end":123,"id":22,"ws":true},{"text":"had","start":124,"end":127,"id":23,"ws":true},{"text":"a","start":128,"end":129,"id":24,"ws":true},{"text":"NHB","start":130,"end":133,"id":25,"ws":true},{"text":"of","start":134,"end":136,"id":26,"ws":true},{"text":"13.8","start":137,"end":141,"id":27,"ws":true},{"text":"QALMs","start":142,"end":147,"id":28,"ws":true},{"text":"versus","start":148,"end":154,"id":29,"ws":true},{"text":"strategy","start":155,"end":163,"id":30,"ws":true},{"text":"C","start":164,"end":165,"id":31,"ws":true},{"text":"when","start":166,"end":170,"id":32,"ws":true},{"text":"pertuzumab","start":171,"end":181,"id":33,"ws":true},{"text":"was","start":182,"end":185,"id":34,"ws":true},{"text":"included","start":186,"end":194,"id":35,"ws":true},{"text":"in","start":195,"end":197,"id":36,"ws":true},{"text":"strategy","start":198,"end":206,"id":37,"ws":true},{"text":"C.","start":207,"end":209,"id":38,"ws":true},{"text":"Monte-Carlo","start":210,"end":221,"id":39,"ws":true},{"text":"simulation","start":222,"end":232,"id":40,"ws":true},{"text":"demonstrated","start":233,"end":245,"id":41,"ws":true},{"text":"that","start":246,"end":250,"id":42,"ws":true},{"text":"the","start":251,"end":254,"id":43,"ws":true},{"text":"main","start":255,"end":259,"id":44,"ws":true},{"text":"factor","start":260,"end":266,"id":45,"ws":true},{"text":"influencing","start":267,"end":278,"id":46,"ws":true},{"text":"NHB","start":279,"end":282,"id":47,"ws":true},{"text":"of","start":283,"end":285,"id":48,"ws":true},{"text":"strategy","start":286,"end":294,"id":49,"ws":true},{"text":"A","start":295,"end":296,"id":50,"ws":true},{"text":"over","start":297,"end":301,"id":51,"ws":true},{"text":"strategy","start":302,"end":310,"id":52,"ws":true},{"text":"C","start":311,"end":312,"id":53,"ws":true},{"text":"was","start":313,"end":316,"id":54,"ws":true},{"text":"the","start":317,"end":320,"id":55,"ws":true},{"text":"cost","start":321,"end":325,"id":56,"ws":true},{"text":"of","start":326,"end":328,"id":57,"ws":true},{"text":"systemic","start":329,"end":337,"id":58,"ws":true},{"text":"therapy","start":338,"end":345,"id":59,"ws":true},{"text":".","start":346,"end":347,"id":60,"ws":false}],"spans":[{"start":60,"end":71,"token_start":12,"token_end":12,"label":"DRUG"},{"start":171,"end":181,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/28266967/","_input_hash":443902227,"_task_hash":-487815903,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In the second study 12 patients with small cell undifferentiated cancers were treated with carboplatin , etoposide and ifosfamide .","paragraph":"<h3><u>Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.</u></h3>Two clinical studies were undertaken to study the toxicity profile and effects of interleukin-3 (rhIL-3) on chemotherapy-induced myelosuppression. Fifteen patients with recurrent ovarian carcinoma were treated with high dose <b style='color:Tomato;'><i>carboplatin</i></b> (800 mg m-2). All patients received 5.0 micrograms/kg/d rhIL-3 subcutaneously but timing and duration of rhIL-3 treatment differed. Constitutional symptoms were the major toxicity and in addition to the <b style='color:Tomato;'><i>carboplatin</i></b>-induced nausea and vomiting the combination was poorly tolerated. In 5/15 patients receiving high dose <b style='color:Tomato;'><i>carboplatin</i></b> rhIL-3 administration was discontinued due to nephrotoxicity (2 x), hypotension, severe malaise and bone pain. In this study, rhIL-3 ameliorated chemotherapy-induced neutropenia as well as thrombocytopenia and reduced the requirement for platelet transfusions in the second cycle of chemotherapy. However, rhIL-3 failed to prevent cumulative platelet toxicity. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>second</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>undifferentiated</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Three dose levels of rhIL-3 were explored (0.125, 5.0 and 7.5 micrograms/kg/d). In this study, toxicity of the treatment was mild, however, no beneficial haematologic effects of rhIL-3 could be demonstrated. In conclusion, the haematological effects of rhIL-3 were modest and dependent on the chemotherapeutic regimen, timing and duration of rhIL-3 treatment (in relation to the expected nadir). In general rhIL-3-induced toxicity was mild, but combination with high dose <b style='color:Tomato;'><i>carboplatin</i></b> could be hazardous if rhIL-3 is initiated at 24 h after the cytostatic agent.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"second","start":7,"end":13,"id":2,"ws":true},{"text":"study","start":14,"end":19,"id":3,"ws":true},{"text":"12","start":20,"end":22,"id":4,"ws":true},{"text":"patients","start":23,"end":31,"id":5,"ws":true},{"text":"with","start":32,"end":36,"id":6,"ws":true},{"text":"small","start":37,"end":42,"id":7,"ws":true},{"text":"cell","start":43,"end":47,"id":8,"ws":true},{"text":"undifferentiated","start":48,"end":64,"id":9,"ws":true},{"text":"cancers","start":65,"end":72,"id":10,"ws":true},{"text":"were","start":73,"end":77,"id":11,"ws":true},{"text":"treated","start":78,"end":85,"id":12,"ws":true},{"text":"with","start":86,"end":90,"id":13,"ws":true},{"text":"carboplatin","start":91,"end":102,"id":14,"ws":true},{"text":",","start":103,"end":104,"id":15,"ws":true},{"text":"etoposide","start":105,"end":114,"id":16,"ws":true},{"text":"and","start":115,"end":118,"id":17,"ws":true},{"text":"ifosfamide","start":119,"end":129,"id":18,"ws":true},{"text":".","start":130,"end":131,"id":19,"ws":false}],"spans":[{"start":91,"end":102,"token_start":14,"token_end":14,"label":"DRUG"},{"start":105,"end":114,"token_start":16,"token_end":16,"label":"DRUG"},{"start":119,"end":129,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7692922/","_input_hash":261666132,"_task_hash":378574346,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"They are now sufficiently detailed to have been of use in the development of new drug compounds like ranolazine and ivabradine .","paragraph":"<h3><u>Pharmacodynamic effects in the cardiovascular system: the modeller's view.</u></h3>Cardiovascular disease, and the cardiovascular side effects of drugs, are essentially multifactorial problems involving interactions between many proteins, dependent on highly organized cell, tissue and organ structures. This is one reason why the side effects of drugs are often unanticipated. It is impossible to unravel such problems without using a systems approach, i.e. focussing on processes, not just molecular components. This inevitably involves modelling as the interactions require quantitative analysis. Modelling is a tool of analysis aimed at understanding, first, and predicting, eventually. We illustrate these principles using modelling of the heart. Models of the cardiac myocyte have benefited from several decades of interaction between experimentation and simulation. <b style='color:DodgerBlue;'><i>They</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>now</i></b> <b style='color:DodgerBlue;'><i>sufficiently</i></b> <b style='color:DodgerBlue;'><i>detailed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>development</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>compounds</i></b> <b style='color:DodgerBlue;'><i>like</i></b> <b style='color:MediumOrchid;'><i>ranolazine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ivabradine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> With the help of cardiac modelling, we have also been able to unravel the mechanisms underlying the beneficial effect of sodium calcium exchange block for long QT syndrome (LQTS) 2 and LQTS3 patients. Detailed models of the interaction between ion channels and blocking agents provide the basis for modelling drug action from basic principles and predict changes in the inhomogeneous tissue of the heart. We demonstrate that mathematical models are beneficial for unravelling the complex interactions of pharmacodynamics in the heart. Embedding these detailed biophysical cellular scale models into anatomically correct models of the ventricle geometry will enable reconstructions of Torsades de Pointes arrhythmias and of fibrillation, providing a mechanism for linking detailed cellular scale experimental data to clinical applications.","tokens":[{"text":"They","start":0,"end":4,"id":0,"ws":true},{"text":"are","start":5,"end":8,"id":1,"ws":true},{"text":"now","start":9,"end":12,"id":2,"ws":true},{"text":"sufficiently","start":13,"end":25,"id":3,"ws":true},{"text":"detailed","start":26,"end":34,"id":4,"ws":true},{"text":"to","start":35,"end":37,"id":5,"ws":true},{"text":"have","start":38,"end":42,"id":6,"ws":true},{"text":"been","start":43,"end":47,"id":7,"ws":true},{"text":"of","start":48,"end":50,"id":8,"ws":true},{"text":"use","start":51,"end":54,"id":9,"ws":true},{"text":"in","start":55,"end":57,"id":10,"ws":true},{"text":"the","start":58,"end":61,"id":11,"ws":true},{"text":"development","start":62,"end":73,"id":12,"ws":true},{"text":"of","start":74,"end":76,"id":13,"ws":true},{"text":"new","start":77,"end":80,"id":14,"ws":true},{"text":"drug","start":81,"end":85,"id":15,"ws":true},{"text":"compounds","start":86,"end":95,"id":16,"ws":true},{"text":"like","start":96,"end":100,"id":17,"ws":true},{"text":"ranolazine","start":101,"end":111,"id":18,"ws":true},{"text":"and","start":112,"end":115,"id":19,"ws":true},{"text":"ivabradine","start":116,"end":126,"id":20,"ws":true},{"text":".","start":127,"end":128,"id":21,"ws":false}],"spans":[{"start":101,"end":111,"token_start":18,"token_end":18,"label":"DRUG"},{"start":116,"end":126,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20470255/","_input_hash":-1596321634,"_task_hash":-705602640,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Based on clinical knowledge , we re-prioritized 30 potentially repurposable drugs against COVID-19 ( including pseudoephedrine , andrographolide , chloroquine , abacavir , and thalidomide ) .","paragraph":"<h3><u>Network bioinformatics analysis provides insight into drug repurposing for COVID-19.</u></h3>The COVID-19 disease caused by the SARS-CoV-2 virus is a health crisis worldwide. While developing novel drugs and vaccines is long, repurposing existing drugs against COVID-19 can yield treatments with known preclinical, pharmacokinetic, pharmacodynamic, and toxicity profiles, which can rapidly enter clinical trials. In this study, we present a novel network-based drug repurposing platform to identify candidates for the treatment of COVID-19. At the time of the initial outbreak, knowledge about SARS-CoV-2 was lacking, but based on its similarity with other viruses, we sought to identify repurposing candidates to be tested rapidly at the clinical or preclinical levels. We first analyzed the genome sequence of SARS-CoV-2 and confirmed SARS as the closest virus by genome similarity, followed by MERS and other human coronaviruses. Using text mining and database searches, we obtained 34 COVID-19-related genes to seed the construction of a molecular network where our module detection and drug prioritization algorithms identified 24 disease-related human pathways, five modules, and 78 drugs to repurpose. <b style='color:DodgerBlue;'><i>Based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>knowledge</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>re-prioritized</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>potentially</i></b> <b style='color:DodgerBlue;'><i>repurposable</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>COVID-19</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>pseudoephedrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>andrographolide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>abacavir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Our work shows how in silico repurposing analyses can yield testable candidates to accelerate the response to novel disease outbreaks.","tokens":[{"text":"Based","start":0,"end":5,"id":0,"ws":true},{"text":"on","start":6,"end":8,"id":1,"ws":true},{"text":"clinical","start":9,"end":17,"id":2,"ws":true},{"text":"knowledge","start":18,"end":27,"id":3,"ws":true},{"text":",","start":28,"end":29,"id":4,"ws":true},{"text":"we","start":30,"end":32,"id":5,"ws":true},{"text":"re-prioritized","start":33,"end":47,"id":6,"ws":true},{"text":"30","start":48,"end":50,"id":7,"ws":true},{"text":"potentially","start":51,"end":62,"id":8,"ws":true},{"text":"repurposable","start":63,"end":75,"id":9,"ws":true},{"text":"drugs","start":76,"end":81,"id":10,"ws":true},{"text":"against","start":82,"end":89,"id":11,"ws":true},{"text":"COVID-19","start":90,"end":98,"id":12,"ws":true},{"text":"(","start":99,"end":100,"id":13,"ws":true},{"text":"including","start":101,"end":110,"id":14,"ws":true},{"text":"pseudoephedrine","start":111,"end":126,"id":15,"ws":true},{"text":",","start":127,"end":128,"id":16,"ws":true},{"text":"andrographolide","start":129,"end":144,"id":17,"ws":true},{"text":",","start":145,"end":146,"id":18,"ws":true},{"text":"chloroquine","start":147,"end":158,"id":19,"ws":true},{"text":",","start":159,"end":160,"id":20,"ws":true},{"text":"abacavir","start":161,"end":169,"id":21,"ws":true},{"text":",","start":170,"end":171,"id":22,"ws":true},{"text":"and","start":172,"end":175,"id":23,"ws":true},{"text":"thalidomide","start":176,"end":187,"id":24,"ws":true},{"text":")","start":188,"end":189,"id":25,"ws":true},{"text":".","start":190,"end":191,"id":26,"ws":false}],"spans":[{"start":111,"end":126,"token_start":15,"token_end":15,"label":"DRUG"},{"start":129,"end":144,"token_start":17,"token_end":17,"label":"DRUG"},{"start":147,"end":158,"token_start":19,"token_end":19,"label":"DRUG"},{"start":161,"end":169,"token_start":21,"token_end":21,"label":"DRUG"},{"start":176,"end":187,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33817623/","_input_hash":-935706669,"_task_hash":-339765315,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In conscious dogs ( control ) and at 1.25 MAC halothane , epinephrine increased the SEA values ( shifted activation from SA node ) and blood pressure , and decreased heart rate ; however , with atropine , SEA values were unaffected by epinephrine , although blood pressure and heart rate were elevated .","paragraph":"<h3><u>Anesthetics and automaticity of dominant and latent pacemakers in chronically instrumented dogs. I. Methodology, conscious state, and halothane anesthesia: comparison with and without muscarinic blockade during exposure to epinephrine.</u></h3>Supraventricular dysrhythmias are common during anesthesia, but have been incompletely investigated. Mechanisms may involve altered automaticity of subsidiary pacemakers and participation of vagal reflexes. The following hypotheses were tested: (1) shifts from the sinoatrial (SA) node to subsidiary pacemakers require intact vagal reflexes and (2) <b style='color:Tomato;'><i>halothane</i></b> sensitizes the heart to <b style='color:Tomato;'><i>epinephrine</i></b>-induced atrial pacemaker shifts. ### methods Epicardial electrodes were implanted in eight dogs on both atrial appendages, the right ventricle, along the sulcus terminalis, and at the His bundle. Weekly testing awake (control), awake with <b style='color:Tomato;'><i>atropine</i></b> methylnitrate, with 1 and 2 micrograms <b style='color:Tomato;'><i>epinephrine</i></b>.kg-1.min-1 (3 min-infusions), and under 1.25 and 2 MAC <b style='color:Tomato;'><i>halothane</i></b> was performed. Electrograms were analyzed for the site of earliest activation (SEA), which was scored 1-6 depending on the distance from the SA node, and expressed as the SEA value. ### results <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>conscious</i></b> <b style='color:DodgerBlue;'><i>dogs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>1.25</i></b> <b style='color:DodgerBlue;'><i>MAC</i></b> <b style='color:MediumOrchid;'><i>halothane</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>epinephrine</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>SEA</i></b> <b style='color:DodgerBlue;'><i>values</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>shifted</i></b> <b style='color:DodgerBlue;'><i>activation</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>SA</i></b> <b style='color:DodgerBlue;'><i>node</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>pressure</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>heart</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>however</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>atropine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>SEA</i></b> <b style='color:DodgerBlue;'><i>values</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>unaffected</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>epinephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>although</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>pressure</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>heart</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>elevated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> At 2 MAC, <b style='color:Tomato;'><i>atropine</i></b> did not affect the <b style='color:Tomato;'><i>epinephrine</i></b>-induced increase in SEA values. <b style='color:Tomato;'><i>halothane</i></b> increased SEA values when combined with 1 micrograms <b style='color:Tomato;'><i>epinephrine</i></b>.kg-1.min-1. ### conclusions Pacemaker shifts account for atrial dysrhythmias in the conscious state and during 1.25 MAC <b style='color:Tomato;'><i>halothane</i></b> with <b style='color:Tomato;'><i>epinephrine</i></b>, and require vagal participation. <b style='color:Tomato;'><i>halothane</i></b> sensitizes the heart to <b style='color:Tomato;'><i>epinephrine</i></b>-induced atrial dysrhythmias. <b style='color:Tomato;'><i>atropine</i></b> and <b style='color:Tomato;'><i>halothane</i></b> facilitate His bundle beats during exposure to <b style='color:Tomato;'><i>epinephrine</i></b>.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"conscious","start":3,"end":12,"id":1,"ws":true},{"text":"dogs","start":13,"end":17,"id":2,"ws":true},{"text":"(","start":18,"end":19,"id":3,"ws":true},{"text":"control","start":20,"end":27,"id":4,"ws":true},{"text":")","start":28,"end":29,"id":5,"ws":true},{"text":"and","start":30,"end":33,"id":6,"ws":true},{"text":"at","start":34,"end":36,"id":7,"ws":true},{"text":"1.25","start":37,"end":41,"id":8,"ws":true},{"text":"MAC","start":42,"end":45,"id":9,"ws":true},{"text":"halothane","start":46,"end":55,"id":10,"ws":true},{"text":",","start":56,"end":57,"id":11,"ws":true},{"text":"epinephrine","start":58,"end":69,"id":12,"ws":true},{"text":"increased","start":70,"end":79,"id":13,"ws":true},{"text":"the","start":80,"end":83,"id":14,"ws":true},{"text":"SEA","start":84,"end":87,"id":15,"ws":true},{"text":"values","start":88,"end":94,"id":16,"ws":true},{"text":"(","start":95,"end":96,"id":17,"ws":true},{"text":"shifted","start":97,"end":104,"id":18,"ws":true},{"text":"activation","start":105,"end":115,"id":19,"ws":true},{"text":"from","start":116,"end":120,"id":20,"ws":true},{"text":"SA","start":121,"end":123,"id":21,"ws":true},{"text":"node","start":124,"end":128,"id":22,"ws":true},{"text":")","start":129,"end":130,"id":23,"ws":true},{"text":"and","start":131,"end":134,"id":24,"ws":true},{"text":"blood","start":135,"end":140,"id":25,"ws":true},{"text":"pressure","start":141,"end":149,"id":26,"ws":true},{"text":",","start":150,"end":151,"id":27,"ws":true},{"text":"and","start":152,"end":155,"id":28,"ws":true},{"text":"decreased","start":156,"end":165,"id":29,"ws":true},{"text":"heart","start":166,"end":171,"id":30,"ws":true},{"text":"rate","start":172,"end":176,"id":31,"ws":true},{"text":";","start":177,"end":178,"id":32,"ws":true},{"text":"however","start":179,"end":186,"id":33,"ws":true},{"text":",","start":187,"end":188,"id":34,"ws":true},{"text":"with","start":189,"end":193,"id":35,"ws":true},{"text":"atropine","start":194,"end":202,"id":36,"ws":true},{"text":",","start":203,"end":204,"id":37,"ws":true},{"text":"SEA","start":205,"end":208,"id":38,"ws":true},{"text":"values","start":209,"end":215,"id":39,"ws":true},{"text":"were","start":216,"end":220,"id":40,"ws":true},{"text":"unaffected","start":221,"end":231,"id":41,"ws":true},{"text":"by","start":232,"end":234,"id":42,"ws":true},{"text":"epinephrine","start":235,"end":246,"id":43,"ws":true},{"text":",","start":247,"end":248,"id":44,"ws":true},{"text":"although","start":249,"end":257,"id":45,"ws":true},{"text":"blood","start":258,"end":263,"id":46,"ws":true},{"text":"pressure","start":264,"end":272,"id":47,"ws":true},{"text":"and","start":273,"end":276,"id":48,"ws":true},{"text":"heart","start":277,"end":282,"id":49,"ws":true},{"text":"rate","start":283,"end":287,"id":50,"ws":true},{"text":"were","start":288,"end":292,"id":51,"ws":true},{"text":"elevated","start":293,"end":301,"id":52,"ws":true},{"text":".","start":302,"end":303,"id":53,"ws":false}],"spans":[{"start":46,"end":55,"token_start":10,"token_end":10,"label":"DRUG"},{"start":58,"end":69,"token_start":12,"token_end":12,"label":"DRUG"},{"start":194,"end":202,"token_start":36,"token_end":36,"label":"DRUG"},{"start":235,"end":246,"token_start":43,"token_end":43,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8267207/","_input_hash":1455368615,"_task_hash":-1624188928,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"To study the release of free endotoxin from Escherichia coli exposed to varying concentrations of the penicillin-binding protein ( PBP ) 3-specific beta-lactam antibiotic cefuroxime , the aminoglycoside tobramycin , and a combination of the two , and to test the relationship between bacterial killing rate and endotoxin release .","paragraph":"<h3><u>Endotoxin release from Escherichia coli after exposure to tobramycin: dose-dependency and reduction in cefuroxime-induced endotoxin release.</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>release</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>free</i></b> <b style='color:DodgerBlue;'><i>endotoxin</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>Escherichia</i></b> <b style='color:DodgerBlue;'><i>coli</i></b> <b style='color:DodgerBlue;'><i>exposed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>varying</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>penicillin-binding</i></b> <b style='color:DodgerBlue;'><i>protein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PBP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>3-specific</i></b> <b style='color:DodgerBlue;'><i>beta-lactam</i></b> <b style='color:DodgerBlue;'><i>antibiotic</i></b> <b style='color:MediumOrchid;'><i>cefuroxime</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>aminoglycoside</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>test</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>relationship</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>bacterial</i></b> <b style='color:DodgerBlue;'><i>killing</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>endotoxin</i></b> <b style='color:DodgerBlue;'><i>release</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A clinical isolate of Escherichia coli in logarithmic phase was exposed to 0.1, 2, 10, and 50 x minimum inhibitory concentration (MIC) of <b style='color:Tomato;'><i>cefuroxime</i></b>, <b style='color:Tomato;'><i>tobramycin</i></b>, and a combination of the two. Samples for viable counts and endotoxin analysis were drawn immediately before and after the addition of the antibiotics and at 1, 2, 4, 6, and 24 h. All experiments were performed in triplicate. For the analysis of endotoxin, a chromogenic limulus amoebocyte lysate assay was used. ### results Endotoxin liberation was found to be proportional to the number of killed bacteria for each antibiotic regimen at each concentration level justifying the endotoxin-liberating potential to be expressed as release of endotoxin per killed bacterium, an expression that was independent of the inoculum size. At all concentration levels there was a statistically significant difference between the treatments, with the highest release of endotoxin per killed bacterium for <b style='color:Tomato;'><i>cefuroxime</i></b>, lower for <b style='color:Tomato;'><i>tobramycin</i></b> and the lowest for the combination of the two drugs (P < 0.001). With increasing doses, there was a significant reduction (P < 0.001) in the propensity to release endotoxin. When the bacterial killing rate was correlated to the propensity to release endotoxin in bacteria exposed to <b style='color:Tomato;'><i>tobramycin</i></b> or the combination of <b style='color:Tomato;'><i>tobramycin</i></b> and <b style='color:Tomato;'><i>cefuroxime</i></b>, a significant negative correlation was found (P < 0.01). This reduction in endotoxin release was not caused by an unspecific endotoxin binding of <b style='color:Tomato;'><i>tobramycin</i></b>. ### conclusions Addition of <b style='color:Tomato;'><i>tobramycin</i></b> reduced the <b style='color:Tomato;'><i>cefuroxime</i></b>-induced endotoxin release per killed bacterium to a level which was even lower than that of <b style='color:Tomato;'><i>tobramycin</i></b> alone in spite of an increased killing rate. Increasing concentrations of <b style='color:Tomato;'><i>tobramycin</i></b> led to reduction in endotoxin release, which may be of benefit when dosing aminoglycosides once daily.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"study","start":3,"end":8,"id":1,"ws":true},{"text":"the","start":9,"end":12,"id":2,"ws":true},{"text":"release","start":13,"end":20,"id":3,"ws":true},{"text":"of","start":21,"end":23,"id":4,"ws":true},{"text":"free","start":24,"end":28,"id":5,"ws":true},{"text":"endotoxin","start":29,"end":38,"id":6,"ws":true},{"text":"from","start":39,"end":43,"id":7,"ws":true},{"text":"Escherichia","start":44,"end":55,"id":8,"ws":true},{"text":"coli","start":56,"end":60,"id":9,"ws":true},{"text":"exposed","start":61,"end":68,"id":10,"ws":true},{"text":"to","start":69,"end":71,"id":11,"ws":true},{"text":"varying","start":72,"end":79,"id":12,"ws":true},{"text":"concentrations","start":80,"end":94,"id":13,"ws":true},{"text":"of","start":95,"end":97,"id":14,"ws":true},{"text":"the","start":98,"end":101,"id":15,"ws":true},{"text":"penicillin-binding","start":102,"end":120,"id":16,"ws":true},{"text":"protein","start":121,"end":128,"id":17,"ws":true},{"text":"(","start":129,"end":130,"id":18,"ws":true},{"text":"PBP","start":131,"end":134,"id":19,"ws":true},{"text":")","start":135,"end":136,"id":20,"ws":true},{"text":"3-specific","start":137,"end":147,"id":21,"ws":true},{"text":"beta-lactam","start":148,"end":159,"id":22,"ws":true},{"text":"antibiotic","start":160,"end":170,"id":23,"ws":true},{"text":"cefuroxime","start":171,"end":181,"id":24,"ws":true},{"text":",","start":182,"end":183,"id":25,"ws":true},{"text":"the","start":184,"end":187,"id":26,"ws":true},{"text":"aminoglycoside","start":188,"end":202,"id":27,"ws":true},{"text":"tobramycin","start":203,"end":213,"id":28,"ws":true},{"text":",","start":214,"end":215,"id":29,"ws":true},{"text":"and","start":216,"end":219,"id":30,"ws":true},{"text":"a","start":220,"end":221,"id":31,"ws":true},{"text":"combination","start":222,"end":233,"id":32,"ws":true},{"text":"of","start":234,"end":236,"id":33,"ws":true},{"text":"the","start":237,"end":240,"id":34,"ws":true},{"text":"two","start":241,"end":244,"id":35,"ws":true},{"text":",","start":245,"end":246,"id":36,"ws":true},{"text":"and","start":247,"end":250,"id":37,"ws":true},{"text":"to","start":251,"end":253,"id":38,"ws":true},{"text":"test","start":254,"end":258,"id":39,"ws":true},{"text":"the","start":259,"end":262,"id":40,"ws":true},{"text":"relationship","start":263,"end":275,"id":41,"ws":true},{"text":"between","start":276,"end":283,"id":42,"ws":true},{"text":"bacterial","start":284,"end":293,"id":43,"ws":true},{"text":"killing","start":294,"end":301,"id":44,"ws":true},{"text":"rate","start":302,"end":306,"id":45,"ws":true},{"text":"and","start":307,"end":310,"id":46,"ws":true},{"text":"endotoxin","start":311,"end":320,"id":47,"ws":true},{"text":"release","start":321,"end":328,"id":48,"ws":true},{"text":".","start":329,"end":330,"id":49,"ws":false}],"spans":[{"start":171,"end":181,"token_start":24,"token_end":24,"label":"DRUG"},{"start":203,"end":213,"token_start":28,"token_end":28,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11168076/","_input_hash":-1336017018,"_task_hash":1991348927,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":24,"child":28,"head_span":{"start":171,"end":181,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":203,"end":213,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"As CDK7 inhibitors are currently under clinical evaluation in patients , our data suggest the addition of the TKI ponatinib or lapatinib in CDK7 inhibitor clinical trials in patients .","paragraph":"<h3><u>Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.</u></h3>Patients with neuroblastoma due to MYCN oncogene amplification and consequent N-Myc oncoprotein overexpression have very poor prognosis. The cyclin-dependent kinase 7 (CDK7)/super-enhancer inhibitor THZ1 suppresses MYCN gene transcription, reduces neuroblastoma cell proliferation, but does not cause significant cell death. The protein kinase phosphatase 1 nuclear targeting subunit (PNUTS) has recently been shown to interact with c-Myc protein and suppresses c-Myc protein degradation. Here we screened the U.S. Food and Drug Administration-Approved Oncology Drugs Set V from the National Cancer Institute, and identified tyrosine kinase inhibitors (TKIs), including <b style='color:Tomato;'><i>ponatinib</i></b> and <b style='color:Tomato;'><i>lapatinib</i></b>, as the Approved Oncology Drugs exerting the best synergistic anticancer effects with THZ1 in MYCN-amplified neuroblastoma cells. Combination therapy with THZ1 and <b style='color:Tomato;'><i>ponatinib</i></b> or <b style='color:Tomato;'><i>lapatinib</i></b> synergistically induced neuroblastoma cell apoptosis, while having little effects in normal nonmalignant cells. Differential gene expression analysis identified PNUTS as one of the genes most synergistically reduced by the combination therapy. Reverse transcription polymerase chain reaction and immunoblot analyses confirmed that THZ1 and the TKIs synergistically downregulated PNUTS mRNA and protein expression and reduced N-Myc protein but not N-Myc mRNA expression. In addition, PNUTS knockdown resulted in decreased N-Myc protein but not mRNA expression and decreased MYCN-amplified neuroblastoma cell proliferation and survival. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>CDK7</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>currently</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>evaluation</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>our</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>TKI</i></b> <b style='color:MediumOrchid;'><i>ponatinib</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lapatinib</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>CDK7</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"As","start":0,"end":2,"id":0,"ws":true},{"text":"CDK7","start":3,"end":7,"id":1,"ws":true},{"text":"inhibitors","start":8,"end":18,"id":2,"ws":true},{"text":"are","start":19,"end":22,"id":3,"ws":true},{"text":"currently","start":23,"end":32,"id":4,"ws":true},{"text":"under","start":33,"end":38,"id":5,"ws":true},{"text":"clinical","start":39,"end":47,"id":6,"ws":true},{"text":"evaluation","start":48,"end":58,"id":7,"ws":true},{"text":"in","start":59,"end":61,"id":8,"ws":true},{"text":"patients","start":62,"end":70,"id":9,"ws":true},{"text":",","start":71,"end":72,"id":10,"ws":true},{"text":"our","start":73,"end":76,"id":11,"ws":true},{"text":"data","start":77,"end":81,"id":12,"ws":true},{"text":"suggest","start":82,"end":89,"id":13,"ws":true},{"text":"the","start":90,"end":93,"id":14,"ws":true},{"text":"addition","start":94,"end":102,"id":15,"ws":true},{"text":"of","start":103,"end":105,"id":16,"ws":true},{"text":"the","start":106,"end":109,"id":17,"ws":true},{"text":"TKI","start":110,"end":113,"id":18,"ws":true},{"text":"ponatinib","start":114,"end":123,"id":19,"ws":true},{"text":"or","start":124,"end":126,"id":20,"ws":true},{"text":"lapatinib","start":127,"end":136,"id":21,"ws":true},{"text":"in","start":137,"end":139,"id":22,"ws":true},{"text":"CDK7","start":140,"end":144,"id":23,"ws":true},{"text":"inhibitor","start":145,"end":154,"id":24,"ws":true},{"text":"clinical","start":155,"end":163,"id":25,"ws":true},{"text":"trials","start":164,"end":170,"id":26,"ws":true},{"text":"in","start":171,"end":173,"id":27,"ws":true},{"text":"patients","start":174,"end":182,"id":28,"ws":true},{"text":".","start":183,"end":184,"id":29,"ws":false}],"spans":[{"start":114,"end":123,"token_start":19,"token_end":19,"label":"DRUG"},{"start":127,"end":136,"token_start":21,"token_end":21,"label":"DRUG"},{"start":140,"end":154,"token_start":23,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32086952/","_input_hash":-490121205,"_task_hash":-1070183876,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":21,"child":24,"head_span":{"start":127,"end":136,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":140,"end":154,"token_start":23,"token_end":24,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":19,"child":24,"head_span":{"start":114,"end":123,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":140,"end":154,"token_start":23,"token_end":24,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"An effective treatment for operable breast cancer , NCT with epirubicin plus paclitaxel results in significant downstaging or eliminating of primary tumors in breast cancer , thus expanding the indication of breast conservation therapy .","paragraph":"<h3><u>[Feasibility of breast conservation surgery after neoadjuvant chemotherapy for breast cancer].</u></h3>To investigate the efficacy of neoadjuvant chemotherapy (NCT) and the feasibility of conservative breast surgery after reducing the size of a primary tumor by NCT in patients with operable breast cancer. ### methods Thirty patients with stage IIB and IIIA breast cancer underwent NCT including <b style='color:Tomato;'><i>epirubicin</i></b> 60 mg/m(2) by intravenous injection on day 1 and <b style='color:Tomato;'><i>paclitaxel</i></b> 150 mg/m(2) by 3-hour continuous infusion on day 2 with 21 days as a cycle from July 2001 to April 2003. All patients received 3 - 4 cycles of NCT. Breast conservation treatment or modified mastectomy was performed after the tumor was reduced to less than 3 cm in diameter. The nonresponders received modified mastectomy. ### results The overall response rate (ORR) was 93% (28/30) for the primary tumors of breast, Fifteen patients (50%) obtained clinical complete response (cCR), including 7 cases (23%) with pathologic complete response (pCR). Thirteen cases (43%) achieved clinical partial response (cPR), and 2 (7%) no change (NC). No case showed progression of disease. Twenty-six (87%) cases were downstaged according to the TNM system classification. The median initial tumor size was 4 cm (3 - 10 cm) before NCT and was reduced to 0.8 cm (0 - 6 cm) after NCT. All 30 patients received operation. Eighteen (60%) of them were candidates for breast conserving therapy, and actually only 11 (37%) selected such surgery. ### conclusion <b style='color:DodgerBlue;'><i>An</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>operable</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NCT</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>downstaging</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>eliminating</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>thus</i></b> <b style='color:DodgerBlue;'><i>expanding</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>indication</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>conservation</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"An","start":0,"end":2,"id":0,"ws":true},{"text":"effective","start":3,"end":12,"id":1,"ws":true},{"text":"treatment","start":13,"end":22,"id":2,"ws":true},{"text":"for","start":23,"end":26,"id":3,"ws":true},{"text":"operable","start":27,"end":35,"id":4,"ws":true},{"text":"breast","start":36,"end":42,"id":5,"ws":true},{"text":"cancer","start":43,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"NCT","start":52,"end":55,"id":8,"ws":true},{"text":"with","start":56,"end":60,"id":9,"ws":true},{"text":"epirubicin","start":61,"end":71,"id":10,"ws":true},{"text":"plus","start":72,"end":76,"id":11,"ws":true},{"text":"paclitaxel","start":77,"end":87,"id":12,"ws":true},{"text":"results","start":88,"end":95,"id":13,"ws":true},{"text":"in","start":96,"end":98,"id":14,"ws":true},{"text":"significant","start":99,"end":110,"id":15,"ws":true},{"text":"downstaging","start":111,"end":122,"id":16,"ws":true},{"text":"or","start":123,"end":125,"id":17,"ws":true},{"text":"eliminating","start":126,"end":137,"id":18,"ws":true},{"text":"of","start":138,"end":140,"id":19,"ws":true},{"text":"primary","start":141,"end":148,"id":20,"ws":true},{"text":"tumors","start":149,"end":155,"id":21,"ws":true},{"text":"in","start":156,"end":158,"id":22,"ws":true},{"text":"breast","start":159,"end":165,"id":23,"ws":true},{"text":"cancer","start":166,"end":172,"id":24,"ws":true},{"text":",","start":173,"end":174,"id":25,"ws":true},{"text":"thus","start":175,"end":179,"id":26,"ws":true},{"text":"expanding","start":180,"end":189,"id":27,"ws":true},{"text":"the","start":190,"end":193,"id":28,"ws":true},{"text":"indication","start":194,"end":204,"id":29,"ws":true},{"text":"of","start":205,"end":207,"id":30,"ws":true},{"text":"breast","start":208,"end":214,"id":31,"ws":true},{"text":"conservation","start":215,"end":227,"id":32,"ws":true},{"text":"therapy","start":228,"end":235,"id":33,"ws":true},{"text":".","start":236,"end":237,"id":34,"ws":false}],"spans":[{"start":61,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},{"start":77,"end":87,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15949385/","_input_hash":-1984666315,"_task_hash":375635042,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":61,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":77,"end":87,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure : A clinical study conducted at the Northern Israel Oncology Center .","paragraph":"<h3><u><b style='color:MediumOrchid;'><i>Carboplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>malignant</i></b> <b style='color:DodgerBlue;'><i>glioma</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>surgical</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Northern</i></b> <b style='color:DodgerBlue;'><i>Israel</i></b> <b style='color:DodgerBlue;'><i>Oncology</i></b> <b style='color:DodgerBlue;'><i>Center</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>We conducted a phase II study using <b style='color:Tomato;'><i>carboplatin</i></b> and <b style='color:Tomato;'><i>etoposide</i></b> on patients with recurrent malignant glioma to investigate tumor response. ### methods From January 1995 to March 1997, 21 patients with recurrent malignant glioma were treated with a <b style='color:Tomato;'><i>carboplatin</i></b> (300 mg/m(2), day 1)/<b style='color:Tomato;'><i>etoposide</i></b> (100 mg/m(2), days 1-3) regimen every 3-4 weeks. The following radiologic parameters were evaluated: tumor size, central lucency, degree of contrast enhancement, and mass effect. No patient had received chemotherapy previously. Dose escalation corresponded to hematologic tolerance and to general and neurologic performance status. Most patients were treated postoperatively with involved field radiotherapy followed by a boost to the tumor area, as defined on the presurgery computed tomography scan or on magnetic resonance imaging. Mean interval to introduction of chemotherapy was 8.8 months (range, 7-36 months). Patients received a mean of four cycles [range, 2-8 cycles]. ### results Only 2 patients showed moderate radiological response, while 12 patients died of progressive disease. Mean time to progression following discontinuation of chemotherapy was 5.8 months (range, 1-11 months). The other patients survived with persistent disease and are being treated palliatively. Toxicity was manageable (1, neutropenic sepsis; 1, thrombocytopenia (45,000/mm(3)); 2, temporarily elevated transaminase level; 2, steroid-induced erosive gastritis). ### conclusions This phase II regimen proved to be ineffective in recurrent malignant glioma. Further studies incorporating innovative drug regimens and schedules are warranted. J. Surg. Oncol., 1999;71:167-170.","tokens":[{"text":"Carboplatin","start":0,"end":11,"id":0,"ws":true},{"text":"and","start":12,"end":15,"id":1,"ws":true},{"text":"etoposide","start":16,"end":25,"id":2,"ws":true},{"text":"for","start":26,"end":29,"id":3,"ws":true},{"text":"recurrent","start":30,"end":39,"id":4,"ws":true},{"text":"malignant","start":40,"end":49,"id":5,"ws":true},{"text":"glioma","start":50,"end":56,"id":6,"ws":true},{"text":"following","start":57,"end":66,"id":7,"ws":true},{"text":"surgical","start":67,"end":75,"id":8,"ws":true},{"text":"and","start":76,"end":79,"id":9,"ws":true},{"text":"radiotherapy","start":80,"end":92,"id":10,"ws":true},{"text":"failure","start":93,"end":100,"id":11,"ws":true},{"text":":","start":101,"end":102,"id":12,"ws":true},{"text":"A","start":103,"end":104,"id":13,"ws":true},{"text":"clinical","start":105,"end":113,"id":14,"ws":true},{"text":"study","start":114,"end":119,"id":15,"ws":true},{"text":"conducted","start":120,"end":129,"id":16,"ws":true},{"text":"at","start":130,"end":132,"id":17,"ws":true},{"text":"the","start":133,"end":136,"id":18,"ws":true},{"text":"Northern","start":137,"end":145,"id":19,"ws":true},{"text":"Israel","start":146,"end":152,"id":20,"ws":true},{"text":"Oncology","start":153,"end":161,"id":21,"ws":true},{"text":"Center","start":162,"end":168,"id":22,"ws":true},{"text":".","start":169,"end":170,"id":23,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":16,"end":25,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10404133/","_input_hash":619655091,"_task_hash":-1983902007,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":16,"end":25,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"ABC transporter inhibition plus dexamethasone enhances the efficacy of CED dasatinib , resulting in enhanced tumor cellular apoptosis and improved survival in H3.3K27 M mutant DIPG .","paragraph":"<h3><u>ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.</u></h3>An impermeable blood-brain barrier and drug efflux via ATP-binding cassette (ABC) transporters such as p-glycoprotein may contribute to underwhelming efficacy of peripherally delivered agents to treat diffuse intrinsic pontine glioma (DIPG). ### objective To explore the pharmacological augmentation of convection-enhanced delivery (CED) infusate for DIPG. ### methods The efficacy of CED <b style='color:Tomato;'><i>dasatinib</i></b>, a tyrosine kinase inhibitor, in a transgenic H3.3K27M mutant murine model was assessed. mRNA expression of ABCB1 (p-glycoprotein) was analyzed in 14 tumor types in 274 children. In Vitro viability studies of <b style='color:Tomato;'><i>dasatinib</i></b>, the p-glycoprotein inhibitor, tariquidar, and <b style='color:Tomato;'><i>dexamethasone</i></b> were performed in 2 H3.3K27M mutant cell lines. Magnetic resonance imaging (MRI) was used to evaluate CED infusate (gadolinium/<b style='color:Tomato;'><i>dasatinib</i></b>) distribution in animals pretreated with tariquidar and <b style='color:Tomato;'><i>dexamethasone</i></b>. Histological assessment of apoptosis was performed. ### results Continuous delivery CED <b style='color:Tomato;'><i>dasatinib</i></b> improved median overall survival (OS) of animals harboring DIPG in comparison to vehicle (39.5 and 28.5 d, respectively; P\u00a0=\u00a0.0139). Mean ABCB1 expression was highest in K27M gliomas. In Vitro, the addition of tariquidar and <b style='color:Tomato;'><i>dexamethasone</i></b> further enhanced the efficacy of <b style='color:Tomato;'><i>dasatinib</i></b> (P\u00a0<\u00a0.001). In Vivo, MRI demonstrated no difference in infusion dispersion between animals pretreated with <b style='color:Tomato;'><i>dexamethasone</i></b> plus tariquidar prior to CED <b style='color:Tomato;'><i>dasatinib</i></b> compared to the CED <b style='color:Tomato;'><i>dasatinib</i></b>. However, tumor apoptosis was the highest in the pretreatment group (P\u00a0<\u00a0.001). Correspondingly, median OS was longer in the pretreatment group (49 d) than the <b style='color:Tomato;'><i>dasatinib</i></b> alone group (39 d) and no treatment controls (31.5 d, P\u00a0=\u00a0.0305). ### conclusion <b style='color:DodgerBlue;'><i>ABC</i></b> <b style='color:DodgerBlue;'><i>transporter</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>enhances</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CED</i></b> <b style='color:MediumOrchid;'><i>dasatinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>resulting</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>enhanced</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>cellular</i></b> <b style='color:DodgerBlue;'><i>apoptosis</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>H3.3K27</i></b> <b style='color:DodgerBlue;'><i>M</i></b> <b style='color:DodgerBlue;'><i>mutant</i></b> <b style='color:DodgerBlue;'><i>DIPG</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"ABC","start":0,"end":3,"id":0,"ws":true},{"text":"transporter","start":4,"end":15,"id":1,"ws":true},{"text":"inhibition","start":16,"end":26,"id":2,"ws":true},{"text":"plus","start":27,"end":31,"id":3,"ws":true},{"text":"dexamethasone","start":32,"end":45,"id":4,"ws":true},{"text":"enhances","start":46,"end":54,"id":5,"ws":true},{"text":"the","start":55,"end":58,"id":6,"ws":true},{"text":"efficacy","start":59,"end":67,"id":7,"ws":true},{"text":"of","start":68,"end":70,"id":8,"ws":true},{"text":"CED","start":71,"end":74,"id":9,"ws":true},{"text":"dasatinib","start":75,"end":84,"id":10,"ws":true},{"text":",","start":85,"end":86,"id":11,"ws":true},{"text":"resulting","start":87,"end":96,"id":12,"ws":true},{"text":"in","start":97,"end":99,"id":13,"ws":true},{"text":"enhanced","start":100,"end":108,"id":14,"ws":true},{"text":"tumor","start":109,"end":114,"id":15,"ws":true},{"text":"cellular","start":115,"end":123,"id":16,"ws":true},{"text":"apoptosis","start":124,"end":133,"id":17,"ws":true},{"text":"and","start":134,"end":137,"id":18,"ws":true},{"text":"improved","start":138,"end":146,"id":19,"ws":true},{"text":"survival","start":147,"end":155,"id":20,"ws":true},{"text":"in","start":156,"end":158,"id":21,"ws":true},{"text":"H3.3K27","start":159,"end":166,"id":22,"ws":true},{"text":"M","start":167,"end":168,"id":23,"ws":true},{"text":"mutant","start":169,"end":175,"id":24,"ws":true},{"text":"DIPG","start":176,"end":180,"id":25,"ws":true},{"text":".","start":181,"end":182,"id":26,"ws":false}],"spans":[{"start":32,"end":45,"token_start":4,"token_end":4,"label":"DRUG"},{"start":75,"end":84,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31225627/","_input_hash":-1563510109,"_task_hash":-1649562032,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":4,"child":10,"head_span":{"start":32,"end":45,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":75,"end":84,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Those who received prednisone alone could have mitoxantrone added after 6 weeks if there was no improvement in pain .","paragraph":"<h3><u>Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.</u></h3>A combination of <b style='color:Tomato;'><i>mitoxantrone</i></b> plus <b style='color:Tomato;'><i>prednisone</i></b> is preferable to <b style='color:Tomato;'><i>prednisone</i></b> alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer. The purpose of this study was to assess the effects of these treatments on health-related quality of life (HQL). ### Patients And Methods Men with metastatic prostate cancer (n = 161) were randomized to receive either daily <b style='color:Tomato;'><i>prednisone</i></b> alone or <b style='color:Tomato;'><i>mitoxantrone</i></b> (every 3 weeks) plus <b style='color:Tomato;'><i>prednisone</i></b>. <b style='color:DodgerBlue;'><i>Those</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>could</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>added</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>if</i></b> <b style='color:DodgerBlue;'><i>there</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>improvement</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>.</i></b> HQL was assessed before treatment initiation and then every 3 weeks using the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire C30 (EORTC QLQ-C30) and the Quality of Life Module-Prostate 14 (QOLM-P14), a trial-specific module developed for this study. An intent-to-treat analysis was used to determine the mean duration of HQL improvement and differences in improvement duration between groups of patients. ### results At 6 weeks, both groups showed improvement in several HQL domains, and only physical functioning and pain were better in the <b style='color:Tomato;'><i>mitoxantrone</i></b>-plus-<b style='color:Tomato;'><i>prednisone</i></b> group than in the <b style='color:Tomato;'><i>prednisone</i></b>-alone group. After 6 weeks, patients taking <b style='color:Tomato;'><i>prednisone</i></b> showed no improvement in HQL scores, whereas those taking <b style='color:Tomato;'><i>mitoxantrone</i></b> plus <b style='color:Tomato;'><i>prednisone</i></b> showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01), and the improvement (> 10 units on a scale of 0 to100) lasted longer than in the <b style='color:Tomato;'><i>prednisone</i></b>-alone group (.004 < P <.05). The addition of <b style='color:Tomato;'><i>mitoxantrone</i></b> to <b style='color:Tomato;'><i>prednisone</i></b> after failure of <b style='color:Tomato;'><i>prednisone</i></b> alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003). ### conclusion Treatment with <b style='color:Tomato;'><i>mitoxantrone</i></b> plus <b style='color:Tomato;'><i>prednisone</i></b> was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with <b style='color:Tomato;'><i>prednisone</i></b> alone.","tokens":[{"text":"Those","start":0,"end":5,"id":0,"ws":true},{"text":"who","start":6,"end":9,"id":1,"ws":true},{"text":"received","start":10,"end":18,"id":2,"ws":true},{"text":"prednisone","start":19,"end":29,"id":3,"ws":true},{"text":"alone","start":30,"end":35,"id":4,"ws":true},{"text":"could","start":36,"end":41,"id":5,"ws":true},{"text":"have","start":42,"end":46,"id":6,"ws":true},{"text":"mitoxantrone","start":47,"end":59,"id":7,"ws":true},{"text":"added","start":60,"end":65,"id":8,"ws":true},{"text":"after","start":66,"end":71,"id":9,"ws":true},{"text":"6","start":72,"end":73,"id":10,"ws":true},{"text":"weeks","start":74,"end":79,"id":11,"ws":true},{"text":"if","start":80,"end":82,"id":12,"ws":true},{"text":"there","start":83,"end":88,"id":13,"ws":true},{"text":"was","start":89,"end":92,"id":14,"ws":true},{"text":"no","start":93,"end":95,"id":15,"ws":true},{"text":"improvement","start":96,"end":107,"id":16,"ws":true},{"text":"in","start":108,"end":110,"id":17,"ws":true},{"text":"pain","start":111,"end":115,"id":18,"ws":true},{"text":".","start":116,"end":117,"id":19,"ws":false}],"spans":[{"start":19,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},{"start":47,"end":59,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10561201/","_input_hash":1696932048,"_task_hash":-1653751871,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":3,"child":7,"head_span":{"start":19,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":47,"end":59,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>prospective</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>combining</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>mesylate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Philadelphia-positive</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>myelogenous</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>In chronic myelogenous leukemia (CML) <b style='color:Tomato;'><i>imatinib</i></b> mesylate has been shown to selectively inhibit the tyrosine kinase domain of the oncogenic bcr-abl fusion protein. Using this agent alone high rates of cytogenetic responses were recorded. However, several mechanisms of resistance have been described. In vitro studies examining the effects of <b style='color:Tomato;'><i>imatinib</i></b> mesylate plus <b style='color:Tomato;'><i>cytarabine</i></b> have shown synergistic antiproliferative effects of this combination. Thus, the CML French Group decided to perform a phase 2 trial testing a combination of <b style='color:Tomato;'><i>imatinib</i></b> mesylate and low-dose <b style='color:Tomato;'><i>cytarabine</i></b> in 30 previously untreated patients in chronic phase. Treatment was administered on 28-day cycles. Patients were treated continuously with <b style='color:Tomato;'><i>imatinib</i></b> mesylate orally at a dose of 400 mg daily. <b style='color:Tomato;'><i>cytarabine</i></b> was given on days 15 to 28 of each cycle at an initial dose of 20 mg/m2/d via subcutaneous injection. Adverse events were frequently observed with grade 3 or 4 hematologic toxicities and nonhematologic toxicities in 53% (n = 16) and 23% (n = 7) of patients, respectively. The cumulative incidence of complete cytogenetic response (CCR) at 12 months was 83% and at 6 months 100% of the patients achieved complete hematologic response (CHR). We concluded that the combination was safe and promising given the rates of response.","tokens":[{"text":"Results","start":0,"end":7,"id":0,"ws":true},{"text":"of","start":8,"end":10,"id":1,"ws":true},{"text":"a","start":11,"end":12,"id":2,"ws":true},{"text":"prospective","start":13,"end":24,"id":3,"ws":true},{"text":"phase","start":25,"end":30,"id":4,"ws":true},{"text":"2","start":31,"end":32,"id":5,"ws":true},{"text":"study","start":33,"end":38,"id":6,"ws":true},{"text":"combining","start":39,"end":48,"id":7,"ws":true},{"text":"imatinib","start":49,"end":57,"id":8,"ws":true},{"text":"mesylate","start":58,"end":66,"id":9,"ws":true},{"text":"and","start":67,"end":70,"id":10,"ws":true},{"text":"cytarabine","start":71,"end":81,"id":11,"ws":true},{"text":"for","start":82,"end":85,"id":12,"ws":true},{"text":"the","start":86,"end":89,"id":13,"ws":true},{"text":"treatment","start":90,"end":99,"id":14,"ws":true},{"text":"of","start":100,"end":102,"id":15,"ws":true},{"text":"Philadelphia-positive","start":103,"end":124,"id":16,"ws":true},{"text":"patients","start":125,"end":133,"id":17,"ws":true},{"text":"with","start":134,"end":138,"id":18,"ws":true},{"text":"chronic","start":139,"end":146,"id":19,"ws":true},{"text":"myelogenous","start":147,"end":158,"id":20,"ws":true},{"text":"leukemia","start":159,"end":167,"id":21,"ws":true},{"text":"in","start":168,"end":170,"id":22,"ws":true},{"text":"chronic","start":171,"end":178,"id":23,"ws":true},{"text":"phase","start":179,"end":184,"id":24,"ws":true},{"text":".","start":185,"end":186,"id":25,"ws":false}],"spans":[{"start":49,"end":57,"token_start":8,"token_end":8,"label":"DRUG"},{"start":71,"end":81,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12933584/","_input_hash":-1797670384,"_task_hash":-263828858,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":8,"child":11,"head_span":{"start":49,"end":57,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":71,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine : a multicenter , phase II trial of the Swiss Group for Clinical Cancer Research .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Patient-reported</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>biliary</i></b> <b style='color:DodgerBlue;'><i>tract</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Swiss</i></b> <b style='color:DodgerBlue;'><i>Group</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>Clinical</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>Research</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>To evaluate the effects of palliative chemotherapy with <b style='color:Tomato;'><i>gemcitabine</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> (GemCap) on patient-reported outcomes measured using clinical benefit response (CBR) and quality-of-life (QOL) measures in patients with advanced biliary tract cancer. ### Patients And Methods Patients had to manifest symptoms of advanced biliary tract cancer and have at least one of the following: impaired Karnofsky performance score (60 to 80), average analgesic consumption >or= 10 mg of morphine equivalents per day, and average pain intensity score of >or= 20 mm out of 100 mm. Treatment consisted of oral <b style='color:Tomato;'><i>capecitabine</i></b> 650 mg/m(2) twice daily on days 1 through 14 plus <b style='color:Tomato;'><i>gemcitabine</i></b> 1,000 mg/m(2) as a 30-minute infusion on days 1 and 8 every 3 weeks until progression. The primary end point was the number of patients categorized as having a CBR or stable CBR (SCBR) during the first three treatment cycles. ### results Forty-four patients were enrolled (bile duct cancer, n = 36; gallbladder cancers, n = 8). The main grade 3 or 4 adverse events included hematologic toxicity and fatigue. After three cycles, 36% of patients achieved a CBR, and 34% achieved an SCBR. Over the full course of treatment, 57% of patients achieved a CBR, and 18% achieved an SCBR. Improved QOL was observed in patients with a CBR or SCBR. The objective response rate was 25%. Median time to progression and overall survival times were 7.2 months and 13.2 months, respectively. ### conclusion Chemotherapy with GemCap is well tolerated and effective and leads to a high CBR rate. Patient-reported outcomes are useful for evaluating the effects of palliative chemotherapy in patients with biliary tract cancer.","tokens":[{"text":"Patient-reported","start":0,"end":16,"id":0,"ws":true},{"text":"outcomes","start":17,"end":25,"id":1,"ws":true},{"text":"of","start":26,"end":28,"id":2,"ws":true},{"text":"patients","start":29,"end":37,"id":3,"ws":true},{"text":"with","start":38,"end":42,"id":4,"ws":true},{"text":"advanced","start":43,"end":51,"id":5,"ws":true},{"text":"biliary","start":52,"end":59,"id":6,"ws":true},{"text":"tract","start":60,"end":65,"id":7,"ws":true},{"text":"cancers","start":66,"end":73,"id":8,"ws":true},{"text":"receiving","start":74,"end":83,"id":9,"ws":true},{"text":"gemcitabine","start":84,"end":95,"id":10,"ws":true},{"text":"plus","start":96,"end":100,"id":11,"ws":true},{"text":"capecitabine","start":101,"end":113,"id":12,"ws":true},{"text":":","start":114,"end":115,"id":13,"ws":true},{"text":"a","start":116,"end":117,"id":14,"ws":true},{"text":"multicenter","start":118,"end":129,"id":15,"ws":true},{"text":",","start":130,"end":131,"id":16,"ws":true},{"text":"phase","start":132,"end":137,"id":17,"ws":true},{"text":"II","start":138,"end":140,"id":18,"ws":true},{"text":"trial","start":141,"end":146,"id":19,"ws":true},{"text":"of","start":147,"end":149,"id":20,"ws":true},{"text":"the","start":150,"end":153,"id":21,"ws":true},{"text":"Swiss","start":154,"end":159,"id":22,"ws":true},{"text":"Group","start":160,"end":165,"id":23,"ws":true},{"text":"for","start":166,"end":169,"id":24,"ws":true},{"text":"Clinical","start":170,"end":178,"id":25,"ws":true},{"text":"Cancer","start":179,"end":185,"id":26,"ws":true},{"text":"Research","start":186,"end":194,"id":27,"ws":true},{"text":".","start":195,"end":196,"id":28,"ws":false}],"spans":[{"start":84,"end":95,"token_start":10,"token_end":10,"label":"DRUG"},{"start":101,"end":113,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18669455/","_input_hash":1931225822,"_task_hash":-895287533,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":84,"end":95,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":101,"end":113,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"3 . Systemic ( i.v . ) pretreatment with furosemide ( 2 - 10 mg kg-1 ) increased urine volume and dose-dependently inhibited the pressor response to i.c.v . clonidine ( 10 micrograms ) , and a long-lasting depressor response to clonidine was observed .","paragraph":"<h3><u>Furosemide inhibits the centrally-mediated pressor response to clonidine in conscious, normotensive rats.</u></h3>1. The effect of <b style='color:Tomato;'><i>furosemide</i></b> on the pressor response induced by intracerebroventricular (i.c.v.) injection of <b style='color:Tomato;'><i>clonidine</i></b> was investigated in freely moving, normotensive rats with chronically implanted arterial catheters. 2. When injected i.c.v., <b style='color:Tomato;'><i>clonidine</i></b> at doses of 5 and 10 micrograms produced a dose-dependent pressor response and a decrease in heart rate. No depressor response was induced by <b style='color:Tomato;'><i>clonidine</i></b>. <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>Systemic</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>pretreatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>furosemide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>kg-1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>urine</i></b> <b style='color:DodgerBlue;'><i>volume</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>dose-dependently</i></b> <b style='color:DodgerBlue;'><i>inhibited</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pressor</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>i.c.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:MediumOrchid;'><i>clonidine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>micrograms</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>long-lasting</i></b> <b style='color:DodgerBlue;'><i>depressor</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>clonidine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, <b style='color:Tomato;'><i>furosemide</i></b> treatment did not alter the bradycardia produced in response to <b style='color:Tomato;'><i>clonidine</i></b>. 4. The systemic treatment with <b style='color:Tomato;'><i>furosemide</i></b> (10 mg kg-1, i.v.) had no effect on the pressor response to i.v. noradrenaline. 5. These results suggest that reduction of body fluid volume inhibits the centrally-mediated pressor response to <b style='color:Tomato;'><i>clonidine</i></b> and leads to the hypotensive effect. We also suggest that combined treatment with a diuretic increases the hypotensive efficacy of <b style='color:Tomato;'><i>clonidine</i></b>.","tokens":[{"text":"3","start":0,"end":1,"id":0,"ws":true},{"text":".","start":2,"end":3,"id":1,"ws":true},{"text":"Systemic","start":4,"end":12,"id":2,"ws":true},{"text":"(","start":13,"end":14,"id":3,"ws":true},{"text":"i.v","start":15,"end":18,"id":4,"ws":true},{"text":".","start":19,"end":20,"id":5,"ws":true},{"text":")","start":21,"end":22,"id":6,"ws":true},{"text":"pretreatment","start":23,"end":35,"id":7,"ws":true},{"text":"with","start":36,"end":40,"id":8,"ws":true},{"text":"furosemide","start":41,"end":51,"id":9,"ws":true},{"text":"(","start":52,"end":53,"id":10,"ws":true},{"text":"2","start":54,"end":55,"id":11,"ws":true},{"text":"-","start":56,"end":57,"id":12,"ws":true},{"text":"10","start":58,"end":60,"id":13,"ws":true},{"text":"mg","start":61,"end":63,"id":14,"ws":true},{"text":"kg-1","start":64,"end":68,"id":15,"ws":true},{"text":")","start":69,"end":70,"id":16,"ws":true},{"text":"increased","start":71,"end":80,"id":17,"ws":true},{"text":"urine","start":81,"end":86,"id":18,"ws":true},{"text":"volume","start":87,"end":93,"id":19,"ws":true},{"text":"and","start":94,"end":97,"id":20,"ws":true},{"text":"dose-dependently","start":98,"end":114,"id":21,"ws":true},{"text":"inhibited","start":115,"end":124,"id":22,"ws":true},{"text":"the","start":125,"end":128,"id":23,"ws":true},{"text":"pressor","start":129,"end":136,"id":24,"ws":true},{"text":"response","start":137,"end":145,"id":25,"ws":true},{"text":"to","start":146,"end":148,"id":26,"ws":true},{"text":"i.c.v","start":149,"end":154,"id":27,"ws":true},{"text":".","start":155,"end":156,"id":28,"ws":true},{"text":"clonidine","start":157,"end":166,"id":29,"ws":true},{"text":"(","start":167,"end":168,"id":30,"ws":true},{"text":"10","start":169,"end":171,"id":31,"ws":true},{"text":"micrograms","start":172,"end":182,"id":32,"ws":true},{"text":")","start":183,"end":184,"id":33,"ws":true},{"text":",","start":185,"end":186,"id":34,"ws":true},{"text":"and","start":187,"end":190,"id":35,"ws":true},{"text":"a","start":191,"end":192,"id":36,"ws":true},{"text":"long-lasting","start":193,"end":205,"id":37,"ws":true},{"text":"depressor","start":206,"end":215,"id":38,"ws":true},{"text":"response","start":216,"end":224,"id":39,"ws":true},{"text":"to","start":225,"end":227,"id":40,"ws":true},{"text":"clonidine","start":228,"end":237,"id":41,"ws":true},{"text":"was","start":238,"end":241,"id":42,"ws":true},{"text":"observed","start":242,"end":250,"id":43,"ws":true},{"text":".","start":251,"end":252,"id":44,"ws":false}],"spans":[{"start":41,"end":51,"token_start":9,"token_end":9,"label":"DRUG"},{"start":157,"end":166,"token_start":29,"token_end":29,"label":"DRUG"},{"start":228,"end":237,"token_start":41,"token_end":41,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1797326/","_input_hash":732324884,"_task_hash":-2005909752,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":9,"child":29,"head_span":{"start":41,"end":51,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":157,"end":166,"token_start":29,"token_end":29,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Nine studies connected to the network for the PFS analysis in which necitumumab in combination with gemcitabine and cisplatin was associated with the lowest HR .","paragraph":"<h3><u>First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis.</u></h3>The objectives of this systematic review and meta-analysis were to compare the survival, toxicity, and quality of life of patients treated with <b style='color:Tomato;'><i>necitumumab</i></b> in combination with <b style='color:Tomato;'><i>gemcitabine</i></b> and cisplatin. These agents were investigated in published randomized controlled trials (RCTs) of patients with squamous non-small cell lung cancer (NSCLC) in the first-line setting. ### methods The systematic review was executed on January 27, 2015, and updated on August 21, 2016, using a pre-specified search strategy. Searches were conducted using PubMed, Medline, and EMBASE, with supplemental searches using the Evidence Based Medicine Reviews and ClinicalTrials.gov to identify RCTs published in English from 1995-2016 and reporting at least one of the primary outcomes [overall survival (OS), progression-free survival (PFS), toxicity, or quality of life] in patients who received first-line treatment for advanced or metastatic squamous NSCLC. Study quality and risk of bias were assessed using the Physiotherapy Evidence Database (PEDro) scale and Cochrane risk of bias tool, respectively. A Baysian network meta-analysis was performed on the primary outcomes. Hazard ratios (HRs) were evaluated for the primary analysis; secondary analyses were conducted using median OS data. Planned sensitivity analyses were conducted including reanalysis using a Frequentist approach and limiting analyses to subsets based on clinical and demographic covariates. ### results The systematic literature review resulted in identification of 4,016 unique publications; 40 publications (35 unique trials) were eligible for inclusion. Eight studies connected to a common network for the OS analysis using HR data. The majority of studies were not limited to squamous NSCLC, thus analyzable data were limited to a subset of data within the published trials. <b style='color:Tomato;'><i>carboplatin</i></b> + S-1 and <b style='color:Tomato;'><i>necitumumab</i></b> in combination with <b style='color:Tomato;'><i>gemcitabine</i></b> and cisplatin were associated with lower HRs for OS versus all other comparators. <b style='color:DodgerBlue;'><i>Nine</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>connected</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>network</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>PFS</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:MediumOrchid;'><i>necitumumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lowest</i></b> <b style='color:DodgerBlue;'><i>HR</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Data were not available to analyze toxicity or quality of life. ### conclusions Although the results suggest that <b style='color:Tomato;'><i>carboplatin</i></b> + S-1 and <b style='color:Tomato;'><i>necitumumab</i></b> in combination with <b style='color:Tomato;'><i>gemcitabine</i></b> and cisplatin may have value in terms of OS versus other comparators, the results should be interpreted with caution due to the limited number of studies (with few focused exclusively on squamous NSCLC) and wide credible intervals.","tokens":[{"text":"Nine","start":0,"end":4,"id":0,"ws":true},{"text":"studies","start":5,"end":12,"id":1,"ws":true},{"text":"connected","start":13,"end":22,"id":2,"ws":true},{"text":"to","start":23,"end":25,"id":3,"ws":true},{"text":"the","start":26,"end":29,"id":4,"ws":true},{"text":"network","start":30,"end":37,"id":5,"ws":true},{"text":"for","start":38,"end":41,"id":6,"ws":true},{"text":"the","start":42,"end":45,"id":7,"ws":true},{"text":"PFS","start":46,"end":49,"id":8,"ws":true},{"text":"analysis","start":50,"end":58,"id":9,"ws":true},{"text":"in","start":59,"end":61,"id":10,"ws":true},{"text":"which","start":62,"end":67,"id":11,"ws":true},{"text":"necitumumab","start":68,"end":79,"id":12,"ws":true},{"text":"in","start":80,"end":82,"id":13,"ws":true},{"text":"combination","start":83,"end":94,"id":14,"ws":true},{"text":"with","start":95,"end":99,"id":15,"ws":true},{"text":"gemcitabine","start":100,"end":111,"id":16,"ws":true},{"text":"and","start":112,"end":115,"id":17,"ws":true},{"text":"cisplatin","start":116,"end":125,"id":18,"ws":true},{"text":"was","start":126,"end":129,"id":19,"ws":true},{"text":"associated","start":130,"end":140,"id":20,"ws":true},{"text":"with","start":141,"end":145,"id":21,"ws":true},{"text":"the","start":146,"end":149,"id":22,"ws":true},{"text":"lowest","start":150,"end":156,"id":23,"ws":true},{"text":"HR","start":157,"end":159,"id":24,"ws":true},{"text":".","start":160,"end":161,"id":25,"ws":false}],"spans":[{"start":68,"end":79,"token_start":12,"token_end":12,"label":"DRUG"},{"start":100,"end":111,"token_start":16,"token_end":16,"label":"DRUG"},{"start":116,"end":125,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30746213/","_input_hash":1477401853,"_task_hash":350460878,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":12,"child":16,"head_span":{"start":68,"end":79,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":100,"end":111,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":16,"child":18,"head_span":{"start":100,"end":111,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":116,"end":125,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"To evaluate the efficacy and toxicities of gemcitabine combined with ifosfamide and anthracycline chemotherapy for recurrent platinum resistant ovarian epithelial cancer .","paragraph":"<h3><u>[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>toxicities</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anthracycline</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>epithelial</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods <b style='color:Tomato;'><i>gemcitabine</i></b> 800 mg/m(2) (day 1, 8), <b style='color:Tomato;'><i>ifosfamide</i></b> 1.5 g/m(2) (day 1 - 3), adriamycin 40 mg/m(2) or <b style='color:Tomato;'><i>epirubicin</i></b> 60 mg/m(2) (day 1) or <b style='color:Tomato;'><i>mitoxantrone</i></b> 10 mg/m(2) (day 1, 8) were used in recurrent platinum resistant/refractory ovarian cancer patients, the cycle was repeated at interval of 21 to 28 days. ### results A total of 60 patients received 172 cycles combined chemotherapy. There were no one cases complete response, while partial response 22 (37%, 22/60), stable 23 (38%, 23/60) and progression 15 (25%, 15/60) were observed, with clinical benefit rate 75% (45/60). The median time of progression-free survival was 7 months, and the median overall survival time was 20 months. The main side effect was hematologic toxicity with leukopenia rate of 82% (49/60), among which III-IV accounted for 31% (15/49). Digestive reaction was all in I-II, accounted for 42% (25/60). ### conclusion The regimen of <b style='color:Tomato;'><i>gemcitabine</i></b> combined with <b style='color:Tomato;'><i>ifosfamide</i></b> and anthracycline is feasible, tolerable and effective in patients with recurrent platinum resistant/refractory epithelial ovarian cancer.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"evaluate","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"efficacy","start":16,"end":24,"id":3,"ws":true},{"text":"and","start":25,"end":28,"id":4,"ws":true},{"text":"toxicities","start":29,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"gemcitabine","start":43,"end":54,"id":7,"ws":true},{"text":"combined","start":55,"end":63,"id":8,"ws":true},{"text":"with","start":64,"end":68,"id":9,"ws":true},{"text":"ifosfamide","start":69,"end":79,"id":10,"ws":true},{"text":"and","start":80,"end":83,"id":11,"ws":true},{"text":"anthracycline","start":84,"end":97,"id":12,"ws":true},{"text":"chemotherapy","start":98,"end":110,"id":13,"ws":true},{"text":"for","start":111,"end":114,"id":14,"ws":true},{"text":"recurrent","start":115,"end":124,"id":15,"ws":true},{"text":"platinum","start":125,"end":133,"id":16,"ws":true},{"text":"resistant","start":134,"end":143,"id":17,"ws":true},{"text":"ovarian","start":144,"end":151,"id":18,"ws":true},{"text":"epithelial","start":152,"end":162,"id":19,"ws":true},{"text":"cancer","start":163,"end":169,"id":20,"ws":true},{"text":".","start":170,"end":171,"id":21,"ws":false}],"spans":[{"start":43,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},{"start":69,"end":79,"token_start":10,"token_end":10,"label":"DRUG"},{"start":84,"end":97,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21211276/","_input_hash":-46406489,"_task_hash":2110540052,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":69,"end":79,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":84,"end":97,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":7,"child":10,"head_span":{"start":43,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":69,"end":79,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Combination of erlotinib and sorafenib , synergistic in GSC11 , induced apoptosis and autophagic cell death associated with suppressed Akt and ERK signaling pathways and decreased nuclear PKM2 and \u03b2-catenin in vitro , and tended to improve survival of nude mice bearing GSC11 brain tumor .","paragraph":"<h3><u>Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.</u></h3>The majority of glioblastomas have aberrant receptor tyrosine kinase (RTK)/RAS/phosphoinositide 3 kinase (PI3K) signaling pathways and malignant glioma cells are thought to be addicted to these signaling pathways for their survival and proliferation. However, recent studies suggest that monotherapies or inappropriate combination therapies using the molecular targeted drugs have limited efficacy possibly because of tumor heterogeneities, signaling redundancy and crosstalk in intracellular signaling network, indicating necessity of rationale and methods for efficient personalized combination treatments. Here, we evaluated the growth of colonies obtained from glioma tumor-initiating cells (GICs) derived from glioma sphere culture (GSC) in agarose and examined the effects of combination treatments on GICs using targeted drugs that affect the signaling pathways to which most glioma cells are addicted. ### methods Human GICs were cultured in agarose and treated with inhibitors of RTKs, non-receptor kinases or transcription factors. The colony number and volume were analyzed using a colony counter, and Chou-Talalay combination indices were evaluated. Autophagy and apoptosis were also analyzed. Phosphorylation of proteins was evaluated by reverse phase protein array and immunoblotting. ### results Increases of colony number and volume in agarose correlated with the Gompertz function. GICs showed diverse drug sensitivity, but inhibitions of RTK and RAF/MEK or PI3K by combinations such as EGFR inhibitor and MEK inhibitor, <b style='color:Tomato;'><i>sorafenib</i></b> and U0126, <b style='color:Tomato;'><i>erlotinib</i></b> and BKM120, and EGFR inhibitor and <b style='color:Tomato;'><i>sorafenib</i></b> showed synergy in different subtypes of GICs. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>GSC11</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>apoptosis</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>autophagic</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>death</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>suppressed</i></b> <b style='color:DodgerBlue;'><i>Akt</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>ERK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>nuclear</i></b> <b style='color:DodgerBlue;'><i>PKM2</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>\u03b2-catenin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>tended</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>nude</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>bearing</i></b> <b style='color:DodgerBlue;'><i>GSC11</i></b> <b style='color:DodgerBlue;'><i>brain</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Reverse phase protein array analysis of the synergistic treatment indicated involvement of not only MEK and PI3K signaling pathways but also others associated with glucose metabolism, fatty acid metabolism, gene transcription, histone methylation, iron transport, stress response, cell cycle, and apoptosis. ### conclusion Inhibiting RTK and RAF/MEK or PI3K could induce synergistic cytotoxicity but personalization is necessary. Examining colonies in agarose initiated by GICs from each patient may be useful for drug sensitivity testing in personalized cancer therapy.","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"of","start":12,"end":14,"id":1,"ws":true},{"text":"erlotinib","start":15,"end":24,"id":2,"ws":true},{"text":"and","start":25,"end":28,"id":3,"ws":true},{"text":"sorafenib","start":29,"end":38,"id":4,"ws":true},{"text":",","start":39,"end":40,"id":5,"ws":true},{"text":"synergistic","start":41,"end":52,"id":6,"ws":true},{"text":"in","start":53,"end":55,"id":7,"ws":true},{"text":"GSC11","start":56,"end":61,"id":8,"ws":true},{"text":",","start":62,"end":63,"id":9,"ws":true},{"text":"induced","start":64,"end":71,"id":10,"ws":true},{"text":"apoptosis","start":72,"end":81,"id":11,"ws":true},{"text":"and","start":82,"end":85,"id":12,"ws":true},{"text":"autophagic","start":86,"end":96,"id":13,"ws":true},{"text":"cell","start":97,"end":101,"id":14,"ws":true},{"text":"death","start":102,"end":107,"id":15,"ws":true},{"text":"associated","start":108,"end":118,"id":16,"ws":true},{"text":"with","start":119,"end":123,"id":17,"ws":true},{"text":"suppressed","start":124,"end":134,"id":18,"ws":true},{"text":"Akt","start":135,"end":138,"id":19,"ws":true},{"text":"and","start":139,"end":142,"id":20,"ws":true},{"text":"ERK","start":143,"end":146,"id":21,"ws":true},{"text":"signaling","start":147,"end":156,"id":22,"ws":true},{"text":"pathways","start":157,"end":165,"id":23,"ws":true},{"text":"and","start":166,"end":169,"id":24,"ws":true},{"text":"decreased","start":170,"end":179,"id":25,"ws":true},{"text":"nuclear","start":180,"end":187,"id":26,"ws":true},{"text":"PKM2","start":188,"end":192,"id":27,"ws":true},{"text":"and","start":193,"end":196,"id":28,"ws":true},{"text":"\u03b2-catenin","start":197,"end":206,"id":29,"ws":true},{"text":"in","start":207,"end":209,"id":30,"ws":true},{"text":"vitro","start":210,"end":215,"id":31,"ws":true},{"text":",","start":216,"end":217,"id":32,"ws":true},{"text":"and","start":218,"end":221,"id":33,"ws":true},{"text":"tended","start":222,"end":228,"id":34,"ws":true},{"text":"to","start":229,"end":231,"id":35,"ws":true},{"text":"improve","start":232,"end":239,"id":36,"ws":true},{"text":"survival","start":240,"end":248,"id":37,"ws":true},{"text":"of","start":249,"end":251,"id":38,"ws":true},{"text":"nude","start":252,"end":256,"id":39,"ws":true},{"text":"mice","start":257,"end":261,"id":40,"ws":true},{"text":"bearing","start":262,"end":269,"id":41,"ws":true},{"text":"GSC11","start":270,"end":275,"id":42,"ws":true},{"text":"brain","start":276,"end":281,"id":43,"ws":true},{"text":"tumor","start":282,"end":287,"id":44,"ws":true},{"text":".","start":288,"end":289,"id":45,"ws":false}],"spans":[{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},{"start":29,"end":38,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26861698/","_input_hash":-2015905784,"_task_hash":-127037352,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":29,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"In the first trial , paclitaxel and doxorubicin were alternated every 3 weeks in doses of 200 mg/m2 and 75 mg/m2 , respectively , for patients who had received no more than one prior chemotherapeutic regimen .","paragraph":"<h3><u>Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.</u></h3><b style='color:Tomato;'><i>paclitaxel</i></b> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), the first taxane to enter routine clinical practice, has aroused considerable interest due to its novel mechanism of action and its significant activity in metastatic breast cancer. Given this activity, it seemed logical to attempt to combine <b style='color:Tomato;'><i>paclitaxel</i></b> with <b style='color:Tomato;'><i>doxorubicin</i></b>, the other most active single agent in metastatic breast cancer. The Eastern Cooperative Oncology Group performed two trials investigating <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> combinations in patients with advanced breast cancer in an attempt to identify a tolerable dose and schedule of the combination. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>alternated</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>chemotherapeutic</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Therapy was well tolerated in this setting. At these doses, <b style='color:Tomato;'><i>paclitaxel</i></b> induced more granulocytopenia and less thrombocytopenia than did <b style='color:Tomato;'><i>doxorubicin</i></b>. Objective responses (complete and partial responses) were seen in seven of 12 patients; two other patients had improved disease (relief of pain in bony metastases). A second limited-institution Eastern Cooperative Oncology Group trial evaluated <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>doxorubicin</i></b> given in combination. In this phase I trial, <b style='color:Tomato;'><i>doxorubicin</i></b> was given as an intravenous push and <b style='color:Tomato;'><i>paclitaxel</i></b> as a 24-hour continuous infusion. The sequence of drug administration (D-->P or P-->D) was alternated both between and within patients, so that we might evaluate the effect of administration schedule on toxicity. Therapy was begun at an initial <b style='color:Tomato;'><i>paclitaxel</i></b> dose of 150 mg/m2 and an initial <b style='color:Tomato;'><i>doxorubicin</i></b> dose of 50 mg/m2 in six patients, with a subsequent six patients receiving 175 and 60 mg/m2, respectively, of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>doxorubicin</i></b>. In addition, patients received granulocyte colony-stimulating factor 5 micrograms/kg/d. While therapy at the initial dose level was well tolerated, dose-limiting mucositis was seen at the second dose level, although only when <b style='color:Tomato;'><i>paclitaxel</i></b> preceded <b style='color:Tomato;'><i>doxorubicin</i></b>. This suggests that sequence of drug administration in <b style='color:Tomato;'><i>paclitaxel</i></b>-based regimens may play an important role as a determinant of toxicity and (perhaps) efficacy, a finding similar to that seen when <b style='color:Tomato;'><i>paclitaxel</i></b> and cisplatin were combined in patients with ovarian cancer. Based on this study, we identified the sequence of <b style='color:Tomato;'><i>doxorubicin</i></b> (50 mg/m2) followed by <b style='color:Tomato;'><i>paclitaxel</i></b> (150 mg/m2) to be the maximum tolerated dose. This combination is currently being compared with <b style='color:Tomato;'><i>paclitaxel</i></b> alone and <b style='color:Tomato;'><i>doxorubicin</i></b> alone in patients with advanced breast cancer in an intergroup trial led by the Eastern Cooperative Oncology Group.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"first","start":7,"end":12,"id":2,"ws":true},{"text":"trial","start":13,"end":18,"id":3,"ws":true},{"text":",","start":19,"end":20,"id":4,"ws":true},{"text":"paclitaxel","start":21,"end":31,"id":5,"ws":true},{"text":"and","start":32,"end":35,"id":6,"ws":true},{"text":"doxorubicin","start":36,"end":47,"id":7,"ws":true},{"text":"were","start":48,"end":52,"id":8,"ws":true},{"text":"alternated","start":53,"end":63,"id":9,"ws":true},{"text":"every","start":64,"end":69,"id":10,"ws":true},{"text":"3","start":70,"end":71,"id":11,"ws":true},{"text":"weeks","start":72,"end":77,"id":12,"ws":true},{"text":"in","start":78,"end":80,"id":13,"ws":true},{"text":"doses","start":81,"end":86,"id":14,"ws":true},{"text":"of","start":87,"end":89,"id":15,"ws":true},{"text":"200","start":90,"end":93,"id":16,"ws":true},{"text":"mg/m2","start":94,"end":99,"id":17,"ws":true},{"text":"and","start":100,"end":103,"id":18,"ws":true},{"text":"75","start":104,"end":106,"id":19,"ws":true},{"text":"mg/m2","start":107,"end":112,"id":20,"ws":true},{"text":",","start":113,"end":114,"id":21,"ws":true},{"text":"respectively","start":115,"end":127,"id":22,"ws":true},{"text":",","start":128,"end":129,"id":23,"ws":true},{"text":"for","start":130,"end":133,"id":24,"ws":true},{"text":"patients","start":134,"end":142,"id":25,"ws":true},{"text":"who","start":143,"end":146,"id":26,"ws":true},{"text":"had","start":147,"end":150,"id":27,"ws":true},{"text":"received","start":151,"end":159,"id":28,"ws":true},{"text":"no","start":160,"end":162,"id":29,"ws":true},{"text":"more","start":163,"end":167,"id":30,"ws":true},{"text":"than","start":168,"end":172,"id":31,"ws":true},{"text":"one","start":173,"end":176,"id":32,"ws":true},{"text":"prior","start":177,"end":182,"id":33,"ws":true},{"text":"chemotherapeutic","start":183,"end":199,"id":34,"ws":true},{"text":"regimen","start":200,"end":207,"id":35,"ws":true},{"text":".","start":208,"end":209,"id":36,"ws":false}],"spans":[{"start":21,"end":31,"token_start":5,"token_end":5,"label":"DRUG"},{"start":36,"end":47,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7939756/","_input_hash":453768740,"_task_hash":669278767,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":7,"child":5,"head_span":{"start":36,"end":47,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":21,"end":31,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Thirty-one patients with histologically proven small cell lung cancer were treated with cyclophosphamide 1 g m-2 and etoposide ( VP16 - 213 ) 125 mg m-2 both intravenously on day 1 followed by etoposide 250 mg m-2 orally on days 2 - 3 for a maximum of six courses at 3 weekly intervals .","paragraph":"<h3><u>Combination cyclophosphamide and etoposide in treatment of small cell lung cancer.</u></h3> <b style='color:DodgerBlue;'><i>Thirty-one</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>histologically</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>g</i></b> <b style='color:DodgerBlue;'><i>m-2</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VP16</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>213</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>125</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>m-2</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>250</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>m-2</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>maximum</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>courses</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>intervals</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Fourteen patients had limited and 17 patients had extensive disease. Twenty-five patients were evaluable for response. Objective response was observed in 18 patients (58%) with 6 (19%) complete and 12 (39%) partial responses. Median survival of the entire group of patients was 30 weeks. There was significant survival benefit among the responders (P less than 0.005) when compared with non-responders. One patient (3.3%) developed grade 4 while 60% of patients developed grade 1-2 haematological toxicity. Other side effects were relatively mild. We conclude that combination <b style='color:Tomato;'><i>cyclophosphamide</i></b> and <b style='color:Tomato;'><i>etoposide</i></b> was active in small cell lung cancer and relatively well tolerated.","tokens":[{"text":"Thirty-one","start":0,"end":10,"id":0,"ws":true},{"text":"patients","start":11,"end":19,"id":1,"ws":true},{"text":"with","start":20,"end":24,"id":2,"ws":true},{"text":"histologically","start":25,"end":39,"id":3,"ws":true},{"text":"proven","start":40,"end":46,"id":4,"ws":true},{"text":"small","start":47,"end":52,"id":5,"ws":true},{"text":"cell","start":53,"end":57,"id":6,"ws":true},{"text":"lung","start":58,"end":62,"id":7,"ws":true},{"text":"cancer","start":63,"end":69,"id":8,"ws":true},{"text":"were","start":70,"end":74,"id":9,"ws":true},{"text":"treated","start":75,"end":82,"id":10,"ws":true},{"text":"with","start":83,"end":87,"id":11,"ws":true},{"text":"cyclophosphamide","start":88,"end":104,"id":12,"ws":true},{"text":"1","start":105,"end":106,"id":13,"ws":true},{"text":"g","start":107,"end":108,"id":14,"ws":true},{"text":"m-2","start":109,"end":112,"id":15,"ws":true},{"text":"and","start":113,"end":116,"id":16,"ws":true},{"text":"etoposide","start":117,"end":126,"id":17,"ws":true},{"text":"(","start":127,"end":128,"id":18,"ws":true},{"text":"VP16","start":129,"end":133,"id":19,"ws":true},{"text":"-","start":134,"end":135,"id":20,"ws":true},{"text":"213","start":136,"end":139,"id":21,"ws":true},{"text":")","start":140,"end":141,"id":22,"ws":true},{"text":"125","start":142,"end":145,"id":23,"ws":true},{"text":"mg","start":146,"end":148,"id":24,"ws":true},{"text":"m-2","start":149,"end":152,"id":25,"ws":true},{"text":"both","start":153,"end":157,"id":26,"ws":true},{"text":"intravenously","start":158,"end":171,"id":27,"ws":true},{"text":"on","start":172,"end":174,"id":28,"ws":true},{"text":"day","start":175,"end":178,"id":29,"ws":true},{"text":"1","start":179,"end":180,"id":30,"ws":true},{"text":"followed","start":181,"end":189,"id":31,"ws":true},{"text":"by","start":190,"end":192,"id":32,"ws":true},{"text":"etoposide","start":193,"end":202,"id":33,"ws":true},{"text":"250","start":203,"end":206,"id":34,"ws":true},{"text":"mg","start":207,"end":209,"id":35,"ws":true},{"text":"m-2","start":210,"end":213,"id":36,"ws":true},{"text":"orally","start":214,"end":220,"id":37,"ws":true},{"text":"on","start":221,"end":223,"id":38,"ws":true},{"text":"days","start":224,"end":228,"id":39,"ws":true},{"text":"2","start":229,"end":230,"id":40,"ws":true},{"text":"-","start":231,"end":232,"id":41,"ws":true},{"text":"3","start":233,"end":234,"id":42,"ws":true},{"text":"for","start":235,"end":238,"id":43,"ws":true},{"text":"a","start":239,"end":240,"id":44,"ws":true},{"text":"maximum","start":241,"end":248,"id":45,"ws":true},{"text":"of","start":249,"end":251,"id":46,"ws":true},{"text":"six","start":252,"end":255,"id":47,"ws":true},{"text":"courses","start":256,"end":263,"id":48,"ws":true},{"text":"at","start":264,"end":266,"id":49,"ws":true},{"text":"3","start":267,"end":268,"id":50,"ws":true},{"text":"weekly","start":269,"end":275,"id":51,"ws":true},{"text":"intervals","start":276,"end":285,"id":52,"ws":true},{"text":".","start":286,"end":287,"id":53,"ws":false}],"spans":[{"start":88,"end":104,"token_start":12,"token_end":12,"label":"DRUG"},{"start":117,"end":126,"token_start":17,"token_end":17,"label":"DRUG"},{"start":193,"end":202,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2160034/","_input_hash":-665126207,"_task_hash":598669028,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":12,"child":17,"head_span":{"start":88,"end":104,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":117,"end":126,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Pemetrexed plus carboplatin followed by pemetrexed , docetaxel , atezolizumab and S-1 were performed in sequence .","paragraph":"<h3><u>Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation.</u></h3>In non-small cell lung cancer (NSCLC), uncommon epidermal growth factor receptor (EGFR) mutations are mutations other than Ex19 deletion and Ex21 L858R, which are common mutations highly sensitive to EGFR-tyrosine kinase inhibitors. <b style='color:Tomato;'><i>afatinib</i></b>, a second-generation EGFR-tyrosine kinase inhibitor, has been shown to be effective in patients with uncommon mutations. <b style='color:Tomato;'><i>dacomitinib</i></b>, another second-generation EGFR-tyrosine kinase inhibitor, has not previously been shown to be effective in patients with uncommon mutations. Here, we report the efficacy of <b style='color:Tomato;'><i>dacomitinib</i></b> for uncommon EGFR mutations in a 71-year-old woman diagnosed with metastatic lung adenocarcinoma with uncommon EGFR mutation (Ex18 G719A). <b style='color:Tomato;'><i>afatinib</i></b> was administered as the first-line treatment, and a remarkable antitumor effect was observed. However, the tumor grew after 14\u2009months. <b style='color:MediumOrchid;'><i>Pemetrexed</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>atezolizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>S-1</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>sequence</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Although approximately four years had passed since the start of treatment, her physical condition was good. The patient started <b style='color:Tomato;'><i>dacomitinib</i></b> as the sixth-line treatment. Lesions were markedly reduced and treatment with <b style='color:Tomato;'><i>dacomitinib</i></b> was continued for 7.8 months. <b style='color:Tomato;'><i>dacomitinib</i></b> is a possible treatment option for NSCLC with uncommon mutations.","tokens":[{"text":"Pemetrexed","start":0,"end":10,"id":0,"ws":true},{"text":"plus","start":11,"end":15,"id":1,"ws":true},{"text":"carboplatin","start":16,"end":27,"id":2,"ws":true},{"text":"followed","start":28,"end":36,"id":3,"ws":true},{"text":"by","start":37,"end":39,"id":4,"ws":true},{"text":"pemetrexed","start":40,"end":50,"id":5,"ws":true},{"text":",","start":51,"end":52,"id":6,"ws":true},{"text":"docetaxel","start":53,"end":62,"id":7,"ws":true},{"text":",","start":63,"end":64,"id":8,"ws":true},{"text":"atezolizumab","start":65,"end":77,"id":9,"ws":true},{"text":"and","start":78,"end":81,"id":10,"ws":true},{"text":"S-1","start":82,"end":85,"id":11,"ws":true},{"text":"were","start":86,"end":90,"id":12,"ws":true},{"text":"performed","start":91,"end":100,"id":13,"ws":true},{"text":"in","start":101,"end":103,"id":14,"ws":true},{"text":"sequence","start":104,"end":112,"id":15,"ws":true},{"text":".","start":113,"end":114,"id":16,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},{"start":40,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},{"start":53,"end":62,"token_start":7,"token_end":7,"label":"DRUG"},{"start":65,"end":77,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33651475/","_input_hash":-2006697010,"_task_hash":203791512,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":2,"head_span":{"start":40,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":7,"child":5,"head_span":{"start":53,"end":62,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":40,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":7,"head_span":{"start":65,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":53,"end":62,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"as neoadjuvant chemotherapy , and two cycles of doxorubicin/cisplatin and ifosfamide , and two cycles of high-dose methotrexate ( 10 - 12 g/m(2 ) ) were given post-operatively .","paragraph":"<h3><u>Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.</u></h3>From 1997 to 2003, 40 patients (all <40 years of age) with non-metastatic osteosarcoma of the extremities were treated with OOS-D and definitive surgery. Two cycles of <b style='color:Tomato;'><i>doxorubicin</i></b> 90 mg/m(2) plus cisplatin 120 mg/m(2) and <b style='color:Tomato;'><i>ifosfamide</i></b> 15 g/m(2) were given <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>doxorubicin/cisplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>g/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>post-operatively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All patients underwent limb salvage surgeries, and 66% showed good response to neoadjuvant chemotherapy.  With a median follow-up period of 117 months, 31 of the evaluable 40 patients were continuously disease-free, 7 were currently alive with no evidence of disease, and 2 died of disease. There was no local recurrence. The 5-year event-free and overall survival rates were 83 and 98%, respectively.  The 10-year event-free and overall survival rates were 80 and 95%, respectively. The major form of toxicity was haematological one.","tokens":[{"text":"as","start":0,"end":2,"id":0,"ws":true},{"text":"neoadjuvant","start":3,"end":14,"id":1,"ws":true},{"text":"chemotherapy","start":15,"end":27,"id":2,"ws":true},{"text":",","start":28,"end":29,"id":3,"ws":true},{"text":"and","start":30,"end":33,"id":4,"ws":true},{"text":"two","start":34,"end":37,"id":5,"ws":true},{"text":"cycles","start":38,"end":44,"id":6,"ws":true},{"text":"of","start":45,"end":47,"id":7,"ws":true},{"text":"doxorubicin/cisplatin","start":48,"end":69,"id":8,"ws":true},{"text":"and","start":70,"end":73,"id":9,"ws":true},{"text":"ifosfamide","start":74,"end":84,"id":10,"ws":true},{"text":",","start":85,"end":86,"id":11,"ws":true},{"text":"and","start":87,"end":90,"id":12,"ws":true},{"text":"two","start":91,"end":94,"id":13,"ws":true},{"text":"cycles","start":95,"end":101,"id":14,"ws":true},{"text":"of","start":102,"end":104,"id":15,"ws":true},{"text":"high-dose","start":105,"end":114,"id":16,"ws":true},{"text":"methotrexate","start":115,"end":127,"id":17,"ws":true},{"text":"(","start":128,"end":129,"id":18,"ws":true},{"text":"10","start":130,"end":132,"id":19,"ws":true},{"text":"-","start":133,"end":134,"id":20,"ws":true},{"text":"12","start":135,"end":137,"id":21,"ws":true},{"text":"g/m(2","start":138,"end":143,"id":22,"ws":true},{"text":")","start":144,"end":145,"id":23,"ws":true},{"text":")","start":146,"end":147,"id":24,"ws":true},{"text":"were","start":148,"end":152,"id":25,"ws":true},{"text":"given","start":153,"end":158,"id":26,"ws":true},{"text":"post-operatively","start":159,"end":175,"id":27,"ws":true},{"text":".","start":176,"end":177,"id":28,"ws":false}],"spans":[{"start":48,"end":69,"token_start":8,"token_end":8,"label":"DRUG"},{"start":74,"end":84,"token_start":10,"token_end":10,"label":"DRUG"},{"start":115,"end":127,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23433444/","_input_hash":-855441672,"_task_hash":-73706837,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":48,"end":69,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":74,"end":84,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":17,"head_span":{"start":74,"end":84,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":115,"end":127,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The initial response ( IR ) was sustained for a mean ( s.d . ) of 309 ( 244 ) days with vildagliptin versus 270 ( 223 ) days for glimepiride ( p < 0.001 ) ( IR = nadir HbA1c where change from baseline > or = 0.5 % or HbA1c < or = 6.5 % within the first six months of treatment .","paragraph":"<h3><u>Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.</u></h3>To show that <b style='color:Tomato;'><i>vildagliptin</i></b> added to <b style='color:Tomato;'><i>metformin</i></b> is non-inferior to <b style='color:Tomato;'><i>glimepiride</i></b> in reducing HbA1c levels from baseline over 2 years. ### methods A randomized, double-blind, active-comparator study of patients with type 2 diabetes mellitus inadequately controlled (HbA1c 6.5-8.5%) by <b style='color:Tomato;'><i>metformin</i></b> monotherapy. Patients received <b style='color:Tomato;'><i>vildagliptin</i></b> (50 mg twice daily) or <b style='color:Tomato;'><i>glimepiride</i></b> (up to 6 mg/day) added to <b style='color:Tomato;'><i>metformin</i></b>. ### results In all, 3118 patients were randomized (<b style='color:Tomato;'><i>vildagliptin</i></b>, n = 1562; <b style='color:Tomato;'><i>glimepiride</i></b>, n = 1556). From similar baseline values (7.3%), after 2 years adjusted mean (s.e.) change in HbA1c was comparable between <b style='color:Tomato;'><i>vildagliptin</i></b> and <b style='color:Tomato;'><i>glimepiride</i></b> treatment: -0.1% (0.0%) and -0.1% (0.0%), respectively. The primary objective of non-inferiority was met. A similar proportion of patients reached HbA1c <7% (36.9 and 38.3%, respectively), but with <b style='color:Tomato;'><i>vildagliptin</i></b> more patients reached this target without hypoglycaemia (36.0% vs. 28.8%; p = 0.004). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>IR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>sustained</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>s.d</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>309</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>244</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vildagliptin</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>270</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>223</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>glimepiride</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>0.001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>IR</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>nadir</i></b> <b style='color:DodgerBlue;'><i>HbA1c</i></b> <b style='color:DodgerBlue;'><i>where</i></b> <b style='color:DodgerBlue;'><i>change</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>baseline</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>HbA1c</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>6.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>within</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After IR was detected, sustained response = time between nadir and an increase of >0.3% above IR). Independent of disease duration, age was a predictor of effect sustainability. Fewer patients experienced hypoglycaemia with <b style='color:Tomato;'><i>vildagliptin</i></b> (2.3% vs. 18.2% with <b style='color:Tomato;'><i>glimepiride</i></b>) with a 14-fold difference in the number of hypoglycaemic events (59 vs. 838). <b style='color:Tomato;'><i>vildagliptin</i></b> had a beneficial effect on body weight [mean (s.e.) change from baseline -0.3 (0.1) kg; between-group difference -1.5 kg; p < 0.001]. Overall, both treatments were well tolerated and displayed similar safety profiles. ### conclusions <b style='color:Tomato;'><i>vildagliptin</i></b> add-on has similar efficacy to <b style='color:Tomato;'><i>glimepiride</i></b> after 2 years' treatment, with markedly reduced hypoglycaemia risk and no weight gain.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"initial","start":4,"end":11,"id":1,"ws":true},{"text":"response","start":12,"end":20,"id":2,"ws":true},{"text":"(","start":21,"end":22,"id":3,"ws":true},{"text":"IR","start":23,"end":25,"id":4,"ws":true},{"text":")","start":26,"end":27,"id":5,"ws":true},{"text":"was","start":28,"end":31,"id":6,"ws":true},{"text":"sustained","start":32,"end":41,"id":7,"ws":true},{"text":"for","start":42,"end":45,"id":8,"ws":true},{"text":"a","start":46,"end":47,"id":9,"ws":true},{"text":"mean","start":48,"end":52,"id":10,"ws":true},{"text":"(","start":53,"end":54,"id":11,"ws":true},{"text":"s.d","start":55,"end":58,"id":12,"ws":true},{"text":".","start":59,"end":60,"id":13,"ws":true},{"text":")","start":61,"end":62,"id":14,"ws":true},{"text":"of","start":63,"end":65,"id":15,"ws":true},{"text":"309","start":66,"end":69,"id":16,"ws":true},{"text":"(","start":70,"end":71,"id":17,"ws":true},{"text":"244","start":72,"end":75,"id":18,"ws":true},{"text":")","start":76,"end":77,"id":19,"ws":true},{"text":"days","start":78,"end":82,"id":20,"ws":true},{"text":"with","start":83,"end":87,"id":21,"ws":true},{"text":"vildagliptin","start":88,"end":100,"id":22,"ws":true},{"text":"versus","start":101,"end":107,"id":23,"ws":true},{"text":"270","start":108,"end":111,"id":24,"ws":true},{"text":"(","start":112,"end":113,"id":25,"ws":true},{"text":"223","start":114,"end":117,"id":26,"ws":true},{"text":")","start":118,"end":119,"id":27,"ws":true},{"text":"days","start":120,"end":124,"id":28,"ws":true},{"text":"for","start":125,"end":128,"id":29,"ws":true},{"text":"glimepiride","start":129,"end":140,"id":30,"ws":true},{"text":"(","start":141,"end":142,"id":31,"ws":true},{"text":"p","start":143,"end":144,"id":32,"ws":true},{"text":"<","start":145,"end":146,"id":33,"ws":true},{"text":"0.001","start":147,"end":152,"id":34,"ws":true},{"text":")","start":153,"end":154,"id":35,"ws":true},{"text":"(","start":155,"end":156,"id":36,"ws":true},{"text":"IR","start":157,"end":159,"id":37,"ws":true},{"text":"=","start":160,"end":161,"id":38,"ws":true},{"text":"nadir","start":162,"end":167,"id":39,"ws":true},{"text":"HbA1c","start":168,"end":173,"id":40,"ws":true},{"text":"where","start":174,"end":179,"id":41,"ws":true},{"text":"change","start":180,"end":186,"id":42,"ws":true},{"text":"from","start":187,"end":191,"id":43,"ws":true},{"text":"baseline","start":192,"end":200,"id":44,"ws":true},{"text":">","start":201,"end":202,"id":45,"ws":true},{"text":"or","start":203,"end":205,"id":46,"ws":true},{"text":"=","start":206,"end":207,"id":47,"ws":true},{"text":"0.5","start":208,"end":211,"id":48,"ws":true},{"text":"%","start":212,"end":213,"id":49,"ws":true},{"text":"or","start":214,"end":216,"id":50,"ws":true},{"text":"HbA1c","start":217,"end":222,"id":51,"ws":true},{"text":"<","start":223,"end":224,"id":52,"ws":true},{"text":"or","start":225,"end":227,"id":53,"ws":true},{"text":"=","start":228,"end":229,"id":54,"ws":true},{"text":"6.5","start":230,"end":233,"id":55,"ws":true},{"text":"%","start":234,"end":235,"id":56,"ws":true},{"text":"within","start":236,"end":242,"id":57,"ws":true},{"text":"the","start":243,"end":246,"id":58,"ws":true},{"text":"first","start":247,"end":252,"id":59,"ws":true},{"text":"six","start":253,"end":256,"id":60,"ws":true},{"text":"months","start":257,"end":263,"id":61,"ws":true},{"text":"of","start":264,"end":266,"id":62,"ws":true},{"text":"treatment","start":267,"end":276,"id":63,"ws":true},{"text":".","start":277,"end":278,"id":64,"ws":false}],"spans":[{"start":88,"end":100,"token_start":22,"token_end":22,"label":"DRUG"},{"start":129,"end":140,"token_start":30,"token_end":30,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20649630/","_input_hash":-1877299602,"_task_hash":-171138069,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The aim of this phase I study was to determine the maximum tolerated dose of a 3-h infusion of paclitaxel , combined with carboplatin at a fixed AUC of 7 mg ml-1 min every 4 weeks for up to six cycles and to evaluate any possible pharmacokinetic interaction .","paragraph":"<h3><u>A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>maximum</i></b> <b style='color:DodgerBlue;'><i>tolerated</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>3-h</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fixed</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>ml-1</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>up</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>possible</i></b> <b style='color:DodgerBlue;'><i>pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twelve chemonaive patients with ovarian cancer were treated with <b style='color:Tomato;'><i>paclitaxel</i></b> followed by a 30-min infusion of <b style='color:Tomato;'><i>carboplatin</i></b>. <b style='color:Tomato;'><i>paclitaxel</i></b> dose was escalated from 150 mg m-2 to 225 mg m-2 in cohorts of three patients. <b style='color:Tomato;'><i>carboplatin</i></b> dose was based on renal function. Pharmacokinetic studies were performed in nine patients (at least two at each dose level). A total of 66 courses were evaluable for assessment. Grade 3 or 4 neutropenia was seen in 70% of the courses, however hospitalization was not required. Grade 3 or 4 thrombocytopenia occurred in 24% of the courses. Alopecia, myalgia and peripheral neuropathy were common but rarely severe. The pharmacokinetics of <b style='color:Tomato;'><i>paclitaxel</i></b> was non-linear and did not appear to be influenced by co-administration of <b style='color:Tomato;'><i>carboplatin</i></b>. The AUC of <b style='color:Tomato;'><i>carboplatin</i></b> was 7.0 +/- 1.4 mg ml-1 min, indicating that there was no pharmacokinetic interaction. The combination of <b style='color:Tomato;'><i>carboplatin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> may be administered as first-line treatment for advanced ovarian cancer. Although myelosuppression is the dose-limiting toxicity of the component drugs, the severity of thrombocytopenia was less than anticipated. The results of this study, with only a small number of patients, need to be confirmed in future investigations.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"this","start":11,"end":15,"id":3,"ws":true},{"text":"phase","start":16,"end":21,"id":4,"ws":true},{"text":"I","start":22,"end":23,"id":5,"ws":true},{"text":"study","start":24,"end":29,"id":6,"ws":true},{"text":"was","start":30,"end":33,"id":7,"ws":true},{"text":"to","start":34,"end":36,"id":8,"ws":true},{"text":"determine","start":37,"end":46,"id":9,"ws":true},{"text":"the","start":47,"end":50,"id":10,"ws":true},{"text":"maximum","start":51,"end":58,"id":11,"ws":true},{"text":"tolerated","start":59,"end":68,"id":12,"ws":true},{"text":"dose","start":69,"end":73,"id":13,"ws":true},{"text":"of","start":74,"end":76,"id":14,"ws":true},{"text":"a","start":77,"end":78,"id":15,"ws":true},{"text":"3-h","start":79,"end":82,"id":16,"ws":true},{"text":"infusion","start":83,"end":91,"id":17,"ws":true},{"text":"of","start":92,"end":94,"id":18,"ws":true},{"text":"paclitaxel","start":95,"end":105,"id":19,"ws":true},{"text":",","start":106,"end":107,"id":20,"ws":true},{"text":"combined","start":108,"end":116,"id":21,"ws":true},{"text":"with","start":117,"end":121,"id":22,"ws":true},{"text":"carboplatin","start":122,"end":133,"id":23,"ws":true},{"text":"at","start":134,"end":136,"id":24,"ws":true},{"text":"a","start":137,"end":138,"id":25,"ws":true},{"text":"fixed","start":139,"end":144,"id":26,"ws":true},{"text":"AUC","start":145,"end":148,"id":27,"ws":true},{"text":"of","start":149,"end":151,"id":28,"ws":true},{"text":"7","start":152,"end":153,"id":29,"ws":true},{"text":"mg","start":154,"end":156,"id":30,"ws":true},{"text":"ml-1","start":157,"end":161,"id":31,"ws":true},{"text":"min","start":162,"end":165,"id":32,"ws":true},{"text":"every","start":166,"end":171,"id":33,"ws":true},{"text":"4","start":172,"end":173,"id":34,"ws":true},{"text":"weeks","start":174,"end":179,"id":35,"ws":true},{"text":"for","start":180,"end":183,"id":36,"ws":true},{"text":"up","start":184,"end":186,"id":37,"ws":true},{"text":"to","start":187,"end":189,"id":38,"ws":true},{"text":"six","start":190,"end":193,"id":39,"ws":true},{"text":"cycles","start":194,"end":200,"id":40,"ws":true},{"text":"and","start":201,"end":204,"id":41,"ws":true},{"text":"to","start":205,"end":207,"id":42,"ws":true},{"text":"evaluate","start":208,"end":216,"id":43,"ws":true},{"text":"any","start":217,"end":220,"id":44,"ws":true},{"text":"possible","start":221,"end":229,"id":45,"ws":true},{"text":"pharmacokinetic","start":230,"end":245,"id":46,"ws":true},{"text":"interaction","start":246,"end":257,"id":47,"ws":true},{"text":".","start":258,"end":259,"id":48,"ws":false}],"spans":[{"start":95,"end":105,"token_start":19,"token_end":19,"label":"DRUG"},{"start":122,"end":133,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9010040/","_input_hash":-1442875809,"_task_hash":1218200973,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":23,"child":19,"head_span":{"start":122,"end":133,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":95,"end":105,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Efficacy of tramadol in combination with doxepin or venlafaxine in inhibition of nociceptive process in the rat model of neuropathic pain : an isobolographic analysis .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tramadol</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>doxepin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>venlafaxine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>nociceptive</i></b> <b style='color:DodgerBlue;'><i>process</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>neuropathic</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>isobolographic</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Neuropathic pain constitutes a serious therapeutic problem. In most cases polytherapy is necessary. <b style='color:Tomato;'><i>tramadol</i></b> and antidepressants have common mechanisms of action and are frequently used together in clinical practice, thus interaction between them is very important. In the present study isobolographic analysis for equivalent doses of drugs was applied to examine the nature of interaction between <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>doxepin</i></b> or <b style='color:Tomato;'><i>venlafaxine</i></b> in a neuropathic pain model in rats. Allodynia and hyperalgesia were assessed after intraperitoneal administration of each drug alone or in combination. Dose response curves were obtained and ED(50) doses were calculated. All drugs were effective in reducing thermal hyperalgesia and mechanical allodynia, however <b style='color:Tomato;'><i>doxepin</i></b> was more effective than <b style='color:Tomato;'><i>venlafaxine</i></b>. Combined administration of <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>doxepin</i></b> demonstrated synergistic action in reducing thermal hyperalgesia and additive action in reducing mechanical allodynia. Combined administration of <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>venlafaxine</i></b> showed additive action in reducing hyperalgesia and allodynia. Moreover, combined administration of <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>doxepin</i></b> was more effective than combined administration of <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>venlafaxine</i></b>. The experiments demonstrated that the nature of interaction between <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>doxepin</i></b> is synergistic, which is not the case for <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>venlafaxine</i></b>, what provides a valuable information referring to clinical practice, rationalizing administration of such drug combination.","tokens":[{"text":"Efficacy","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"tramadol","start":12,"end":20,"id":2,"ws":true},{"text":"in","start":21,"end":23,"id":3,"ws":true},{"text":"combination","start":24,"end":35,"id":4,"ws":true},{"text":"with","start":36,"end":40,"id":5,"ws":true},{"text":"doxepin","start":41,"end":48,"id":6,"ws":true},{"text":"or","start":49,"end":51,"id":7,"ws":true},{"text":"venlafaxine","start":52,"end":63,"id":8,"ws":true},{"text":"in","start":64,"end":66,"id":9,"ws":true},{"text":"inhibition","start":67,"end":77,"id":10,"ws":true},{"text":"of","start":78,"end":80,"id":11,"ws":true},{"text":"nociceptive","start":81,"end":92,"id":12,"ws":true},{"text":"process","start":93,"end":100,"id":13,"ws":true},{"text":"in","start":101,"end":103,"id":14,"ws":true},{"text":"the","start":104,"end":107,"id":15,"ws":true},{"text":"rat","start":108,"end":111,"id":16,"ws":true},{"text":"model","start":112,"end":117,"id":17,"ws":true},{"text":"of","start":118,"end":120,"id":18,"ws":true},{"text":"neuropathic","start":121,"end":132,"id":19,"ws":true},{"text":"pain","start":133,"end":137,"id":20,"ws":true},{"text":":","start":138,"end":139,"id":21,"ws":true},{"text":"an","start":140,"end":142,"id":22,"ws":true},{"text":"isobolographic","start":143,"end":157,"id":23,"ws":true},{"text":"analysis","start":158,"end":166,"id":24,"ws":true},{"text":".","start":167,"end":168,"id":25,"ws":false}],"spans":[{"start":12,"end":20,"token_start":2,"token_end":2,"label":"DRUG"},{"start":41,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":52,"end":63,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20065499/","_input_hash":-922832735,"_task_hash":-1117305017,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":2,"child":6,"head_span":{"start":12,"end":20,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":41,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":2,"head_span":{"start":52,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":12,"end":20,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11"],"answer":"accept"}
{"text":"All those treated with mefloquine plus artemether survived and their parasite clearance time and fever clearance time were significantly shorter than those of patients receiving quinine .","paragraph":"<h3><u>The effect of mefloquine-artemether compared with quinine on patients with complicated falciparum malaria.</u></h3>30 pairs of patients with complicated Plasmodium falciparum malaria (with anaemia, hyperpyrexia, jaundice or more than 5% of erythrocytes parasitized) were studied. Patients with cerebral signs and symptoms were excluded. One group of patients was treated with oral <b style='color:Tomato;'><i>mefloquine</i></b> (750 mg) and <b style='color:Tomato;'><i>artemether</i></b> (600 mg by injection, 200 mg initially and 100 mg every 12 h). The second group of patients was treated with <b style='color:Tomato;'><i>quinine</i></b> (10 mg/kg orally every 8 h for 7 d). All patients were admitted to hospital for 7 d and examined subsequently on days 14, 21 and 28. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>mefloquine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>artemether</i></b> <b style='color:DodgerBlue;'><i>survived</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>parasite</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>fever</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>shorter</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>quinine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> 2 patients treated with <b style='color:Tomato;'><i>quinine</i></b> died. There was no recrudescence in any patient of either group.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"those","start":4,"end":9,"id":1,"ws":true},{"text":"treated","start":10,"end":17,"id":2,"ws":true},{"text":"with","start":18,"end":22,"id":3,"ws":true},{"text":"mefloquine","start":23,"end":33,"id":4,"ws":true},{"text":"plus","start":34,"end":38,"id":5,"ws":true},{"text":"artemether","start":39,"end":49,"id":6,"ws":true},{"text":"survived","start":50,"end":58,"id":7,"ws":true},{"text":"and","start":59,"end":62,"id":8,"ws":true},{"text":"their","start":63,"end":68,"id":9,"ws":true},{"text":"parasite","start":69,"end":77,"id":10,"ws":true},{"text":"clearance","start":78,"end":87,"id":11,"ws":true},{"text":"time","start":88,"end":92,"id":12,"ws":true},{"text":"and","start":93,"end":96,"id":13,"ws":true},{"text":"fever","start":97,"end":102,"id":14,"ws":true},{"text":"clearance","start":103,"end":112,"id":15,"ws":true},{"text":"time","start":113,"end":117,"id":16,"ws":true},{"text":"were","start":118,"end":122,"id":17,"ws":true},{"text":"significantly","start":123,"end":136,"id":18,"ws":true},{"text":"shorter","start":137,"end":144,"id":19,"ws":true},{"text":"than","start":145,"end":149,"id":20,"ws":true},{"text":"those","start":150,"end":155,"id":21,"ws":true},{"text":"of","start":156,"end":158,"id":22,"ws":true},{"text":"patients","start":159,"end":167,"id":23,"ws":true},{"text":"receiving","start":168,"end":177,"id":24,"ws":true},{"text":"quinine","start":178,"end":185,"id":25,"ws":true},{"text":".","start":186,"end":187,"id":26,"ws":false}],"spans":[{"start":23,"end":33,"token_start":4,"token_end":4,"label":"DRUG"},{"start":39,"end":49,"token_start":6,"token_end":6,"label":"DRUG"},{"start":178,"end":185,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/3075350/","_input_hash":-2408159,"_task_hash":779874448,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":23,"end":33,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":39,"end":49,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Reported is a case of a 58-year-old female treated in the past with cytostatics and rituximab for follicular lymphoma , in whom HBV infection was detected during a follow-up of the contacts of her partner diagnosed with acute viral hepatitis B. At the beginning , the patient had a very high serum level of HBV DNA ( 4.3 \u00d7 108 IU/mL ) and therefore she was treated with combined antiviral therapy ( lamivudine and tenofovir ) .","paragraph":"<h3><u>[Viral hepatitis B in a patient with follicular lymphoma treated with biological therapy].</u></h3>Reactivation, recurrence or acute infection with hepatitis B virus (HBV) represent severe complications of biological therapy. <b style='color:DodgerBlue;'><i>Reported</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>case</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>58-year-old</i></b> <b style='color:DodgerBlue;'><i>female</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>past</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cytostatics</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>follicular</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>whom</i></b> <b style='color:DodgerBlue;'><i>HBV</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>detected</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>contacts</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>her</i></b> <b style='color:DodgerBlue;'><i>partner</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>viral</i></b> <b style='color:DodgerBlue;'><i>hepatitis</i></b> <b style='color:DodgerBlue;'><i>B.</i></b> <b style='color:DodgerBlue;'><i>At</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>beginning</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>very</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>level</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>HBV</i></b> <b style='color:DodgerBlue;'><i>DNA</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>4.3</i></b> <b style='color:DodgerBlue;'><i>\u00d7</i></b> <b style='color:DodgerBlue;'><i>108</i></b> <b style='color:DodgerBlue;'><i>IU/mL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>she</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>antiviral</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>lamivudine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tenofovir</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After 10 months, the serum level of HBV DNA decreased significantly (3,100 IU/mL) and the combined antiviral therapy was switched to monotherapy with <b style='color:Tomato;'><i>tenofovir</i></b>. Another 5 months later, the serum level of HBV DNA was only 950 IU/mL. This case demonstrates important clinical problems connected with HBV infection in immunocompromised persons.","tokens":[{"text":"Reported","start":0,"end":8,"id":0,"ws":true},{"text":"is","start":9,"end":11,"id":1,"ws":true},{"text":"a","start":12,"end":13,"id":2,"ws":true},{"text":"case","start":14,"end":18,"id":3,"ws":true},{"text":"of","start":19,"end":21,"id":4,"ws":true},{"text":"a","start":22,"end":23,"id":5,"ws":true},{"text":"58-year-old","start":24,"end":35,"id":6,"ws":true},{"text":"female","start":36,"end":42,"id":7,"ws":true},{"text":"treated","start":43,"end":50,"id":8,"ws":true},{"text":"in","start":51,"end":53,"id":9,"ws":true},{"text":"the","start":54,"end":57,"id":10,"ws":true},{"text":"past","start":58,"end":62,"id":11,"ws":true},{"text":"with","start":63,"end":67,"id":12,"ws":true},{"text":"cytostatics","start":68,"end":79,"id":13,"ws":true},{"text":"and","start":80,"end":83,"id":14,"ws":true},{"text":"rituximab","start":84,"end":93,"id":15,"ws":true},{"text":"for","start":94,"end":97,"id":16,"ws":true},{"text":"follicular","start":98,"end":108,"id":17,"ws":true},{"text":"lymphoma","start":109,"end":117,"id":18,"ws":true},{"text":",","start":118,"end":119,"id":19,"ws":true},{"text":"in","start":120,"end":122,"id":20,"ws":true},{"text":"whom","start":123,"end":127,"id":21,"ws":true},{"text":"HBV","start":128,"end":131,"id":22,"ws":true},{"text":"infection","start":132,"end":141,"id":23,"ws":true},{"text":"was","start":142,"end":145,"id":24,"ws":true},{"text":"detected","start":146,"end":154,"id":25,"ws":true},{"text":"during","start":155,"end":161,"id":26,"ws":true},{"text":"a","start":162,"end":163,"id":27,"ws":true},{"text":"follow-up","start":164,"end":173,"id":28,"ws":true},{"text":"of","start":174,"end":176,"id":29,"ws":true},{"text":"the","start":177,"end":180,"id":30,"ws":true},{"text":"contacts","start":181,"end":189,"id":31,"ws":true},{"text":"of","start":190,"end":192,"id":32,"ws":true},{"text":"her","start":193,"end":196,"id":33,"ws":true},{"text":"partner","start":197,"end":204,"id":34,"ws":true},{"text":"diagnosed","start":205,"end":214,"id":35,"ws":true},{"text":"with","start":215,"end":219,"id":36,"ws":true},{"text":"acute","start":220,"end":225,"id":37,"ws":true},{"text":"viral","start":226,"end":231,"id":38,"ws":true},{"text":"hepatitis","start":232,"end":241,"id":39,"ws":true},{"text":"B.","start":242,"end":244,"id":40,"ws":true},{"text":"At","start":245,"end":247,"id":41,"ws":true},{"text":"the","start":248,"end":251,"id":42,"ws":true},{"text":"beginning","start":252,"end":261,"id":43,"ws":true},{"text":",","start":262,"end":263,"id":44,"ws":true},{"text":"the","start":264,"end":267,"id":45,"ws":true},{"text":"patient","start":268,"end":275,"id":46,"ws":true},{"text":"had","start":276,"end":279,"id":47,"ws":true},{"text":"a","start":280,"end":281,"id":48,"ws":true},{"text":"very","start":282,"end":286,"id":49,"ws":true},{"text":"high","start":287,"end":291,"id":50,"ws":true},{"text":"serum","start":292,"end":297,"id":51,"ws":true},{"text":"level","start":298,"end":303,"id":52,"ws":true},{"text":"of","start":304,"end":306,"id":53,"ws":true},{"text":"HBV","start":307,"end":310,"id":54,"ws":true},{"text":"DNA","start":311,"end":314,"id":55,"ws":true},{"text":"(","start":315,"end":316,"id":56,"ws":true},{"text":"4.3","start":317,"end":320,"id":57,"ws":true},{"text":"\u00d7","start":321,"end":322,"id":58,"ws":true},{"text":"108","start":323,"end":326,"id":59,"ws":true},{"text":"IU/mL","start":327,"end":332,"id":60,"ws":true},{"text":")","start":333,"end":334,"id":61,"ws":true},{"text":"and","start":335,"end":338,"id":62,"ws":true},{"text":"therefore","start":339,"end":348,"id":63,"ws":true},{"text":"she","start":349,"end":352,"id":64,"ws":true},{"text":"was","start":353,"end":356,"id":65,"ws":true},{"text":"treated","start":357,"end":364,"id":66,"ws":true},{"text":"with","start":365,"end":369,"id":67,"ws":true},{"text":"combined","start":370,"end":378,"id":68,"ws":true},{"text":"antiviral","start":379,"end":388,"id":69,"ws":true},{"text":"therapy","start":389,"end":396,"id":70,"ws":true},{"text":"(","start":397,"end":398,"id":71,"ws":true},{"text":"lamivudine","start":399,"end":409,"id":72,"ws":true},{"text":"and","start":410,"end":413,"id":73,"ws":true},{"text":"tenofovir","start":414,"end":423,"id":74,"ws":true},{"text":")","start":424,"end":425,"id":75,"ws":true},{"text":".","start":426,"end":427,"id":76,"ws":false}],"spans":[{"start":84,"end":93,"token_start":15,"token_end":15,"label":"DRUG"},{"start":399,"end":409,"token_start":72,"token_end":72,"label":"DRUG"},{"start":414,"end":423,"token_start":74,"token_end":74,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21452121/","_input_hash":613403452,"_task_hash":303151912,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":72,"child":74,"head_span":{"start":399,"end":409,"token_start":72,"token_end":72,"label":"DRUG"},"child_span":{"start":414,"end":423,"token_start":74,"token_end":74,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Currently available adrenal steroidogenesis inhibitors , including ketoconazole , metyrapone , etomidate , and mitotane , have variable efficacy and significant side effects , and none are approved by the US Food and Drug Administration for CS .","paragraph":"<h3><u>Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.</u></h3>Endogenous Cushing's syndrome (CS) is a rare disease that results from exposure to high levels of cortisol; Cushing's disease (CD) is the most frequent form of CS. Patients with CS suffer from a variety of comorbidities that increase the risk of mortality. Surgical resection of the disease-causing lesion is generally the first-line treatment of CS. However, some patients may not be eligible for surgery due to comorbidities, and approximately 25\u00a0% of patients, especially those with CD, have recurrent disease. For these patients, adrenal steroidogenesis inhibitors may control cortisol elevation and subsequent symptomatology. CS is rare overall, and clinical studies of adrenal steroidogenesis inhibitors are often small and, in many cases, data are limited regarding the efficacy and safety of these treatments. Our aim was to better characterize the profiles of efficacy and safety of currently available adrenal steroidogenesis inhibitors, including drugs currently in development. ### methods We performed a systematic review of the literature regarding adrenal steroidogenesis inhibitors, focusing on novel drugs. ### results <b style='color:DodgerBlue;'><i>Currently</i></b> <b style='color:DodgerBlue;'><i>available</i></b> <b style='color:DodgerBlue;'><i>adrenal</i></b> <b style='color:DodgerBlue;'><i>steroidogenesis</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>ketoconazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>metyrapone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>etomidate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitotane</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>variable</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>side</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>none</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>approved</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>US</i></b> <b style='color:DodgerBlue;'><i>Food</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Drug</i></b> <b style='color:DodgerBlue;'><i>Administration</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>CS</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Therefore, there is a clear need for novel, prospectively studied agents that have greater efficacy and a low rate of adverse side effects. Efficacy and safety data of current and emerging adrenal steroidogenesis inhibitors, including osilodrostat (LCI699) and levo<b style='color:Tomato;'><i>ketoconazole</i></b> (COR-003), show promising results that will have to be confirmed in larger-scale phase 3 studies (currently ongoing). ### conclusions The management of CS, and particularly CD, remains challenging. Adrenal steroidogenesis inhibitors can be of major interest to control the hypercortisolism at any time point, either before or after surgery, as discussed in this review.","tokens":[{"text":"Currently","start":0,"end":9,"id":0,"ws":true},{"text":"available","start":10,"end":19,"id":1,"ws":true},{"text":"adrenal","start":20,"end":27,"id":2,"ws":true},{"text":"steroidogenesis","start":28,"end":43,"id":3,"ws":true},{"text":"inhibitors","start":44,"end":54,"id":4,"ws":true},{"text":",","start":55,"end":56,"id":5,"ws":true},{"text":"including","start":57,"end":66,"id":6,"ws":true},{"text":"ketoconazole","start":67,"end":79,"id":7,"ws":true},{"text":",","start":80,"end":81,"id":8,"ws":true},{"text":"metyrapone","start":82,"end":92,"id":9,"ws":true},{"text":",","start":93,"end":94,"id":10,"ws":true},{"text":"etomidate","start":95,"end":104,"id":11,"ws":true},{"text":",","start":105,"end":106,"id":12,"ws":true},{"text":"and","start":107,"end":110,"id":13,"ws":true},{"text":"mitotane","start":111,"end":119,"id":14,"ws":true},{"text":",","start":120,"end":121,"id":15,"ws":true},{"text":"have","start":122,"end":126,"id":16,"ws":true},{"text":"variable","start":127,"end":135,"id":17,"ws":true},{"text":"efficacy","start":136,"end":144,"id":18,"ws":true},{"text":"and","start":145,"end":148,"id":19,"ws":true},{"text":"significant","start":149,"end":160,"id":20,"ws":true},{"text":"side","start":161,"end":165,"id":21,"ws":true},{"text":"effects","start":166,"end":173,"id":22,"ws":true},{"text":",","start":174,"end":175,"id":23,"ws":true},{"text":"and","start":176,"end":179,"id":24,"ws":true},{"text":"none","start":180,"end":184,"id":25,"ws":true},{"text":"are","start":185,"end":188,"id":26,"ws":true},{"text":"approved","start":189,"end":197,"id":27,"ws":true},{"text":"by","start":198,"end":200,"id":28,"ws":true},{"text":"the","start":201,"end":204,"id":29,"ws":true},{"text":"US","start":205,"end":207,"id":30,"ws":true},{"text":"Food","start":208,"end":212,"id":31,"ws":true},{"text":"and","start":213,"end":216,"id":32,"ws":true},{"text":"Drug","start":217,"end":221,"id":33,"ws":true},{"text":"Administration","start":222,"end":236,"id":34,"ws":true},{"text":"for","start":237,"end":240,"id":35,"ws":true},{"text":"CS","start":241,"end":243,"id":36,"ws":true},{"text":".","start":244,"end":245,"id":37,"ws":false}],"spans":[{"start":67,"end":79,"token_start":7,"token_end":7,"label":"DRUG"},{"start":82,"end":92,"token_start":9,"token_end":9,"label":"DRUG"},{"start":95,"end":104,"token_start":11,"token_end":11,"label":"DRUG"},{"start":111,"end":119,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27600150/","_input_hash":-132880978,"_task_hash":1756656753,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The differential effects of haloperidol and methamphetamine on time estimation in the rat .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>differential</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>haloperidol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methamphetamine</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>estimation</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Forty rats were trained to make a left lever response if a signal (white noise) was 2.5s and to make a right lever response if the signal was 6.3s. When seven intermediate signal durations, to which responses were not reinforced, were randomly interspersed the probability of a right-lever ('long') response increased as a function of signal duration. <b style='color:Tomato;'><i>methamphetamine</i></b> shifted this psychometric function leftward and decreased its slope: <b style='color:Tomato;'><i>haloperidol</i></b> also decreased the slope but shifted the function rightward. A combination of <b style='color:Tomato;'><i>haloperidol</i></b> and <b style='color:Tomato;'><i>methamphetamine</i></b> led to a function similar to the saline control function. The leftward shift probably reflects an increase in the speed of an internal clock, and the rightward shift probably reflects a decrease in its speed. Since <b style='color:Tomato;'><i>methamphetamine</i></b> releases several catecholamines, including dopamine, and <b style='color:Tomato;'><i>haloperidol</i></b> blocks dopamine receptors, it is plausible that the horizontal location of the psychometric function (the speed of the clock) is related to the effective level of dopamine.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"differential","start":4,"end":16,"id":1,"ws":true},{"text":"effects","start":17,"end":24,"id":2,"ws":true},{"text":"of","start":25,"end":27,"id":3,"ws":true},{"text":"haloperidol","start":28,"end":39,"id":4,"ws":true},{"text":"and","start":40,"end":43,"id":5,"ws":true},{"text":"methamphetamine","start":44,"end":59,"id":6,"ws":true},{"text":"on","start":60,"end":62,"id":7,"ws":true},{"text":"time","start":63,"end":67,"id":8,"ws":true},{"text":"estimation","start":68,"end":78,"id":9,"ws":true},{"text":"in","start":79,"end":81,"id":10,"ws":true},{"text":"the","start":82,"end":85,"id":11,"ws":true},{"text":"rat","start":86,"end":89,"id":12,"ws":true},{"text":".","start":90,"end":91,"id":13,"ws":false}],"spans":[{"start":28,"end":39,"token_start":4,"token_end":4,"label":"DRUG"},{"start":44,"end":59,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6403957/","_input_hash":-432926380,"_task_hash":169142185,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In the present study , we evaluated the efficacy and safety of the weekly combination of etoposide , leucovorin ( LV ) and 5-fluorouracil ( 5-FU ) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer ( ACC ) , previously treated with weekly LV+5-FU .","paragraph":"<h3><u>Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer.</u></h3> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>relapsed/refractory</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>LV+5-FU</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>etoposide</i></b> was administered at 3 different dose levels (DLs), in 3 groups of 20 patients each (total: 60); DL-I: <b style='color:Tomato;'><i>etoposide</i></b> 80 mg/m2, DL-II: <b style='color:Tomato;'><i>etoposide</i></b> 120 mg/m2, and DL-III: <b style='color:Tomato;'><i>etoposide</i></b> 180 mg/m2, in 45 min i.v. infusion, and followed in all levels by LV 100 mg/m2 i.v. over 1 hour and 5-FU 500 mg/m2 i.v. bolus. Treatment was administered weekly until disease progression or unacceptable toxicity. No patients at DL-I responded, while 2 patients at DL-II and 3 at DL-III had a partial response (PR). Stable disease (SD) rates were as follows; at DL-I: 2, DL-II: 8 and DL-III: 9. More patients in DL-I progressed (n = 19) compared to DL-II (n=10) and DL-II (n = 8) (p < 0.0007). Time to progression was for DL-I, -II, -III: 17, 15, and 14 weeks, respectively. Median survival was DL-I, -II, -III: 30, 30, and 32.5 weeks, respectively. Toxicity consisted mainly of neutropenia, diarrhea and mucositis at all DLs, and was significantly more severe in DL-III. No difference was noted in responses between DL-II and DL-III. The authors conclude that the combination of <b style='color:Tomato;'><i>etoposide</i></b> with LV+5-FU has limited activity when administered after failure of weekly LV+5-FU in patients with ACC and should not be recommended for further evaluation.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"present","start":7,"end":14,"id":2,"ws":true},{"text":"study","start":15,"end":20,"id":3,"ws":true},{"text":",","start":21,"end":22,"id":4,"ws":true},{"text":"we","start":23,"end":25,"id":5,"ws":true},{"text":"evaluated","start":26,"end":35,"id":6,"ws":true},{"text":"the","start":36,"end":39,"id":7,"ws":true},{"text":"efficacy","start":40,"end":48,"id":8,"ws":true},{"text":"and","start":49,"end":52,"id":9,"ws":true},{"text":"safety","start":53,"end":59,"id":10,"ws":true},{"text":"of","start":60,"end":62,"id":11,"ws":true},{"text":"the","start":63,"end":66,"id":12,"ws":true},{"text":"weekly","start":67,"end":73,"id":13,"ws":true},{"text":"combination","start":74,"end":85,"id":14,"ws":true},{"text":"of","start":86,"end":88,"id":15,"ws":true},{"text":"etoposide","start":89,"end":98,"id":16,"ws":true},{"text":",","start":99,"end":100,"id":17,"ws":true},{"text":"leucovorin","start":101,"end":111,"id":18,"ws":true},{"text":"(","start":112,"end":113,"id":19,"ws":true},{"text":"LV","start":114,"end":116,"id":20,"ws":true},{"text":")","start":117,"end":118,"id":21,"ws":true},{"text":"and","start":119,"end":122,"id":22,"ws":true},{"text":"5-fluorouracil","start":123,"end":137,"id":23,"ws":true},{"text":"(","start":138,"end":139,"id":24,"ws":true},{"text":"5-FU","start":140,"end":144,"id":25,"ws":true},{"text":")","start":145,"end":146,"id":26,"ws":true},{"text":"when","start":147,"end":151,"id":27,"ws":true},{"text":"administered","start":152,"end":164,"id":28,"ws":true},{"text":"as","start":165,"end":167,"id":29,"ws":true},{"text":"second-line","start":168,"end":179,"id":30,"ws":true},{"text":"chemotherapy","start":180,"end":192,"id":31,"ws":true},{"text":"in","start":193,"end":195,"id":32,"ws":true},{"text":"patients","start":196,"end":204,"id":33,"ws":true},{"text":"with","start":205,"end":209,"id":34,"ws":true},{"text":"relapsed/refractory","start":210,"end":229,"id":35,"ws":true},{"text":"advanced","start":230,"end":238,"id":36,"ws":true},{"text":"colorectal","start":239,"end":249,"id":37,"ws":true},{"text":"cancer","start":250,"end":256,"id":38,"ws":true},{"text":"(","start":257,"end":258,"id":39,"ws":true},{"text":"ACC","start":259,"end":262,"id":40,"ws":true},{"text":")","start":263,"end":264,"id":41,"ws":true},{"text":",","start":265,"end":266,"id":42,"ws":true},{"text":"previously","start":267,"end":277,"id":43,"ws":true},{"text":"treated","start":278,"end":285,"id":44,"ws":true},{"text":"with","start":286,"end":290,"id":45,"ws":true},{"text":"weekly","start":291,"end":297,"id":46,"ws":true},{"text":"LV+5-FU","start":298,"end":305,"id":47,"ws":true},{"text":".","start":306,"end":307,"id":48,"ws":false}],"spans":[{"start":89,"end":98,"token_start":16,"token_end":16,"label":"DRUG"},{"start":101,"end":111,"token_start":18,"token_end":18,"label":"DRUG"},{"start":123,"end":137,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12420860/","_input_hash":19588298,"_task_hash":-577091587,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":16,"child":18,"head_span":{"start":89,"end":98,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":101,"end":111,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":23,"child":18,"head_span":{"start":123,"end":137,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":101,"end":111,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Patients with wild-type KRAS exon 2 mCRC previously treated with fluorouracil- , oxaliplatin- and irinotecan-based chemotherapies were randomised ( 1:1 ) to either panitumumab plus irinotecan ( panitumumab arm ) or cetuximab plus irinotecan ( cetuximab arm ) .","paragraph":"<h3><u>Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan\u00a0and oxaliplatin (WJOG 6510G).</u></h3><b style='color:Tomato;'><i>cetuximab</i></b> has been shown to be clinically active when given in combination with <b style='color:Tomato;'><i>irinotecan</i></b> in patients with <b style='color:Tomato;'><i>irinotecan</i></b>-refractory metastatic colorectal cancer (mCRC). However, it has remained unclear whether <b style='color:Tomato;'><i>panitumumab</i></b> is effective when combined with <b style='color:Tomato;'><i>irinotecan</i></b>. We compared efficacies of both regimens in this randomised phase II study. ### Patients And Methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>wild-type</i></b> <b style='color:DodgerBlue;'><i>KRAS</i></b> <b style='color:DodgerBlue;'><i>exon</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>fluorouracil-</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>oxaliplatin-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>irinotecan-based</i></b> <b style='color:DodgerBlue;'><i>chemotherapies</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomised</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1:1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>panitumumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>panitumumab</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end-point was progression-free survival (PFS). The planned sample size was 120, expecting a hazard ratio (HR) of 1.0 with non-inferiority margin of 1.3 (one-sided alpha error 0.2 and power 0.7). Major secondary end-points were overall survival (OS), response rate\u00a0and safety. ### results From December 2011 to September 2014, 121 patients were enrolled, and 61 and 59 patients were randomised to the <b style='color:Tomato;'><i>panitumumab</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b> arms, respectively (1 patient excluded). Most patients (97%) had received prior chemotherapies containing <b style='color:Tomato;'><i>bevacizumab</i></b>. The median PFS was 5.42 months in the <b style='color:Tomato;'><i>panitumumab</i></b> arm and 4.27 months in the <b style='color:Tomato;'><i>cetuximab</i></b> arm (HR\u00a0=\u00a00.64, 95% confidence interval [CI]\u00a0=\u00a00.44-0.94, P\u00a0<\u00a00.001 for non-inferiority, P\u00a0=\u00a00.058 for superiority), and median OS was 14.85 and 11.53 months (HR\u00a0=\u00a00.66, 95% CI\u00a0=\u00a00.44-1.00, P\u00a0=\u00a00.050 for superiority), respectively. The incidence of grade 3 or 4 hypomagnesaemia was higher in the <b style='color:Tomato;'><i>panitumumab</i></b> arm than that in the <b style='color:Tomato;'><i>cetuximab</i></b> arm (17% vs. 7%). ### conclusion <b style='color:Tomato;'><i>panitumumab</i></b> may be non-inferior to <b style='color:Tomato;'><i>cetuximab</i></b> in combination with <b style='color:Tomato;'><i>irinotecan</i></b> in survival of patients with <b style='color:Tomato;'><i>irinotecan</i></b>-refractory mCRC.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"with","start":9,"end":13,"id":1,"ws":true},{"text":"wild-type","start":14,"end":23,"id":2,"ws":true},{"text":"KRAS","start":24,"end":28,"id":3,"ws":true},{"text":"exon","start":29,"end":33,"id":4,"ws":true},{"text":"2","start":34,"end":35,"id":5,"ws":true},{"text":"mCRC","start":36,"end":40,"id":6,"ws":true},{"text":"previously","start":41,"end":51,"id":7,"ws":true},{"text":"treated","start":52,"end":59,"id":8,"ws":true},{"text":"with","start":60,"end":64,"id":9,"ws":true},{"text":"fluorouracil-","start":65,"end":78,"id":10,"ws":true},{"text":",","start":79,"end":80,"id":11,"ws":true},{"text":"oxaliplatin-","start":81,"end":93,"id":12,"ws":true},{"text":"and","start":94,"end":97,"id":13,"ws":true},{"text":"irinotecan-based","start":98,"end":114,"id":14,"ws":true},{"text":"chemotherapies","start":115,"end":129,"id":15,"ws":true},{"text":"were","start":130,"end":134,"id":16,"ws":true},{"text":"randomised","start":135,"end":145,"id":17,"ws":true},{"text":"(","start":146,"end":147,"id":18,"ws":true},{"text":"1:1","start":148,"end":151,"id":19,"ws":true},{"text":")","start":152,"end":153,"id":20,"ws":true},{"text":"to","start":154,"end":156,"id":21,"ws":true},{"text":"either","start":157,"end":163,"id":22,"ws":true},{"text":"panitumumab","start":164,"end":175,"id":23,"ws":true},{"text":"plus","start":176,"end":180,"id":24,"ws":true},{"text":"irinotecan","start":181,"end":191,"id":25,"ws":true},{"text":"(","start":192,"end":193,"id":26,"ws":true},{"text":"panitumumab","start":194,"end":205,"id":27,"ws":true},{"text":"arm","start":206,"end":209,"id":28,"ws":true},{"text":")","start":210,"end":211,"id":29,"ws":true},{"text":"or","start":212,"end":214,"id":30,"ws":true},{"text":"cetuximab","start":215,"end":224,"id":31,"ws":true},{"text":"plus","start":225,"end":229,"id":32,"ws":true},{"text":"irinotecan","start":230,"end":240,"id":33,"ws":true},{"text":"(","start":241,"end":242,"id":34,"ws":true},{"text":"cetuximab","start":243,"end":252,"id":35,"ws":true},{"text":"arm","start":253,"end":256,"id":36,"ws":true},{"text":")","start":257,"end":258,"id":37,"ws":true},{"text":".","start":259,"end":260,"id":38,"ws":false}],"spans":[{"start":65,"end":78,"token_start":10,"token_end":10,"label":"DRUG"},{"start":81,"end":93,"token_start":12,"token_end":12,"label":"DRUG"},{"start":98,"end":114,"token_start":14,"token_end":14,"label":"DRUG"},{"start":164,"end":175,"token_start":23,"token_end":23,"label":"DRUG"},{"start":181,"end":191,"token_start":25,"token_end":25,"label":"DRUG"},{"start":194,"end":205,"token_start":27,"token_end":27,"label":"DRUG"},{"start":215,"end":224,"token_start":31,"token_end":31,"label":"DRUG"},{"start":230,"end":240,"token_start":33,"token_end":33,"label":"DRUG"},{"start":243,"end":252,"token_start":35,"token_end":35,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32526634/","_input_hash":481094641,"_task_hash":-344895595,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":23,"child":25,"head_span":{"start":164,"end":175,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":181,"end":191,"token_start":25,"token_end":25,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":31,"child":33,"head_span":{"start":215,"end":224,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":230,"end":240,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Epirubicin , oxaliplatin , and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer ( REAL3 ):","paragraph":"<h3><u><b style='color:MediumOrchid;'><i>Epirubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:MediumOrchid;'><i>panitumumab</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>oesophagogastric</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>REAL3</i></b> <b style='color:DodgerBlue;'><i>):</i></b></u></h3>EGFR overexpression occurs in 27-55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody <b style='color:Tomato;'><i>panitumumab</i></b> to <b style='color:Tomato;'><i>epirubicin</i></b>, <b style='color:Tomato;'><i>oxaliplatin</i></b>, and <b style='color:Tomato;'><i>capecitabine</i></b> (EOC) in patients with advanced oesophagogastric adenocarcinoma. ### methods In this randomised, open-label phase 3 trial (REAL3), we enrolled patients with untreated, metastatic, or locally advanced oesophagogastric adenocarcinoma at 63 centres (tertiary referral centres, teaching hospitals, and district general hospitals) in the UK. Eligible patients were randomly allocated (1:1) to receive up to eight 21-day cycles of open-label EOC (<b style='color:Tomato;'><i>epirubicin</i></b> 50 mg/m(2) and <b style='color:Tomato;'><i>oxaliplatin</i></b> 130 mg/m(2) on day 1 and <b style='color:Tomato;'><i>capecitabine</i></b> 1250 mg/m(2) per day on days 1-21) or modified-dose EOC plus <b style='color:Tomato;'><i>panitumumab</i></b> (mEOC+P; <b style='color:Tomato;'><i>epirubicin</i></b> 50 mg/m(2) and <b style='color:Tomato;'><i>oxaliplatin</i></b> 100 mg/m(2) on day 1, <b style='color:Tomato;'><i>capecitabine</i></b> 1000 mg/m(2) per day on days 1-21, and <b style='color:Tomato;'><i>panitumumab</i></b> 9 mg/kg on day 1). Randomisation was blocked and stratified for centre region, extent of disease, and performance status. The primary endpoint was overall survival in the intention-to-treat population. We assessed safety in all patients who received at least one dose of study drug. After a preplanned independent data monitoring committee review in October, 2011, trial recruitment was halted and <b style='color:Tomato;'><i>panitumumab</i></b> withdrawn. Data for patients on treatment were censored at this timepoint. This study is registered with ClinicalTrials.gov, number NCT00824785. ### findings Between June 2, 2008, and Oct 17, 2011, we enrolled 553 eligible patients. Median overall survival in 275 patients allocated EOC was 11.3 months (95% CI 9.6-13.0) compared with 8.8 months (7.7-9.8) in 278 patients allocated mEOC+P (hazard ratio [HR] 1.37, 95% CI 1.07-1.76; p=0.013). mEOC+P was associated with increased incidence of grade 3-4 diarrhoea (48 [17%] of 276 patients allocated mEOC+P vs 29 [11%] of 266 patients allocated EOC), rash (29 [11%] vs two [1%]), mucositis (14 [5%] vs none), and hypomagnesaemia (13 [5%] vs none) but reduced incidence of haematological toxicity (grade \u2265 3 neutropenia 35 [13%] vs 74 [28%]). ### interpretation Addition of <b style='color:Tomato;'><i>panitumumab</i></b> to EOC chemotherapy does not increase overall survival and cannot be recommended for use in an unselected population with advanced oesophagogastric adenocarcinoma. ### funding Amgen, UK National Institute for Health Research Biomedical Research Centre.","tokens":[{"text":"Epirubicin","start":0,"end":10,"id":0,"ws":true},{"text":",","start":11,"end":12,"id":1,"ws":true},{"text":"oxaliplatin","start":13,"end":24,"id":2,"ws":true},{"text":",","start":25,"end":26,"id":3,"ws":true},{"text":"and","start":27,"end":30,"id":4,"ws":true},{"text":"capecitabine","start":31,"end":43,"id":5,"ws":true},{"text":"with","start":44,"end":48,"id":6,"ws":true},{"text":"or","start":49,"end":51,"id":7,"ws":true},{"text":"without","start":52,"end":59,"id":8,"ws":true},{"text":"panitumumab","start":60,"end":71,"id":9,"ws":true},{"text":"for","start":72,"end":75,"id":10,"ws":true},{"text":"patients","start":76,"end":84,"id":11,"ws":true},{"text":"with","start":85,"end":89,"id":12,"ws":true},{"text":"previously","start":90,"end":100,"id":13,"ws":true},{"text":"untreated","start":101,"end":110,"id":14,"ws":true},{"text":"advanced","start":111,"end":119,"id":15,"ws":true},{"text":"oesophagogastric","start":120,"end":136,"id":16,"ws":true},{"text":"cancer","start":137,"end":143,"id":17,"ws":true},{"text":"(","start":144,"end":145,"id":18,"ws":true},{"text":"REAL3","start":146,"end":151,"id":19,"ws":true},{"text":"):","start":152,"end":154,"id":20,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":13,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},{"start":31,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},{"start":60,"end":71,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23594787/","_input_hash":1878828073,"_task_hash":862381563,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":13,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":2,"head_span":{"start":31,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":13,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":9,"head_span":{"start":31,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":60,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":2,"child":9,"head_span":{"start":13,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":60,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":0,"child":9,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":60,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["POS11","NEG11"],"answer":"accept"}
{"text":"Diazoxide , nifedipine and 2-deoxy glucose suppressed ( p < 0.05 ) glucose stimulated insulin secretion in AtT20HI-GLUT2-GK-6 cells .","paragraph":"<h3><u>Cellular characterization of pituitary adenoma cell line (AtT20 cell) transfected with insulin, glucose transporter type 2 (GLUT2) and glucokinase genes: insulin secretion in response to physiological concentrations of glucose.</u></h3>We investigated the mechanisms of insulin secretion by transfecting into a pituitary adenoma cell line (AtT20) a combination of genes encoding human insulin (HI), glucose transporter type 2 (GLUT2) and glucokinase (GK), followed by studying the characteristics of these cells. In static incubation, a cell line transfected with insulin gene alone (AtT20HI) secreted mature human insulin but this was not in a glucose-dependent manner. Other cell lines transfected with insulin and GLUT2 genes (AtT20HI-GLUT2-3) or with insulin and GK genes (AtT20HI-GK-1) secreted insulin in response to glucose concentrations of only less than 1 mmol/l. In contrast, cell lines transfected with insulin, GLUT2 and GK genes (AtT20HI-GLUT2-GK-6, AtT20HI-GLUT2-GK-7 and AtT20HI-GLUT2-GK-10) showed a glucose-dependent insulin secretion up to 25 mmol/l glucose. Glucose utilization and oxidation were increased in AtT20HI-GLUT2-GK cell lines but not in AtT20HI, AtT20HI-GLUT2-3 and AtT20HI-GK-1 cells at physiological glucose concentrations, compared with AtT20 cells. <b style='color:MediumOrchid;'><i>Diazoxide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>nifedipine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2-deoxy</i></b> <b style='color:DodgerBlue;'><i>glucose</i></b> <b style='color:DodgerBlue;'><i>suppressed</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>0.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>glucose</i></b> <b style='color:DodgerBlue;'><i>stimulated</i></b> <b style='color:DodgerBlue;'><i>insulin</i></b> <b style='color:DodgerBlue;'><i>secretion</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>AtT20HI-GLUT2-GK-6</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Glibenclamide, KCl or <b style='color:Tomato;'><i>corticotropin</i></b> releasing factor (CRF) stimulated (p < 0.05) insulin secretion both in AtT20HI and AtT20HI-GLUT2-GK-6 cells. Insulin secretion stimulated by glibenclamide, KCl or CRF was further enhanced by the addition of 25 mmol/l glucose in AtT20HI-GLUT2-GK-6 cells but not in AtT20HI cells. In perifusion experiments, a stepwise increase in glucose concentration from 5 to 25 mmol/l stimulated insulin secretion in AtT20HI-GLUT2-GK cell lines but the response lacked a clear first phase of insulin secretion. Our results suggest that both GLUT2 and glucokinase are necessary for the glucose stimulated insulin secretion in at least rodent cell lines, and that other element(s) are necessary for a biphasic insulin secretion typically observed in beta cells.","tokens":[{"text":"Diazoxide","start":0,"end":9,"id":0,"ws":true},{"text":",","start":10,"end":11,"id":1,"ws":true},{"text":"nifedipine","start":12,"end":22,"id":2,"ws":true},{"text":"and","start":23,"end":26,"id":3,"ws":true},{"text":"2-deoxy","start":27,"end":34,"id":4,"ws":true},{"text":"glucose","start":35,"end":42,"id":5,"ws":true},{"text":"suppressed","start":43,"end":53,"id":6,"ws":true},{"text":"(","start":54,"end":55,"id":7,"ws":true},{"text":"p","start":56,"end":57,"id":8,"ws":true},{"text":"<","start":58,"end":59,"id":9,"ws":true},{"text":"0.05","start":60,"end":64,"id":10,"ws":true},{"text":")","start":65,"end":66,"id":11,"ws":true},{"text":"glucose","start":67,"end":74,"id":12,"ws":true},{"text":"stimulated","start":75,"end":85,"id":13,"ws":true},{"text":"insulin","start":86,"end":93,"id":14,"ws":true},{"text":"secretion","start":94,"end":103,"id":15,"ws":true},{"text":"in","start":104,"end":106,"id":16,"ws":true},{"text":"AtT20HI-GLUT2-GK-6","start":107,"end":125,"id":17,"ws":true},{"text":"cells","start":126,"end":131,"id":18,"ws":true},{"text":".","start":132,"end":133,"id":19,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":12,"end":22,"token_start":2,"token_end":2,"label":"DRUG"},{"start":27,"end":42,"token_start":4,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9867217/","_input_hash":1226126973,"_task_hash":392157566,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":12,"end":22,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":2,"child":5,"head_span":{"start":12,"end":22,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":27,"end":42,"token_start":4,"token_end":5,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Reducing the duration of medication use postoperatively may also minimize the possible side effects of ketorolac and codeine , which could develop with extended periods of use .","paragraph":"<h3><u>Evaluation of ketorolac (Toradol) with varying amounts of codeine for postoperative extraction pain control.</u></h3>This study analyzes the combination of oral <b style='color:Tomato;'><i>ketorolac</i></b> 10 mg with varying amounts of <b style='color:Tomato;'><i>codeine</i></b> phosphate, and the postoperative pain relief that developed from these combinations. Five groups of patients were administered the <b style='color:Tomato;'><i>codeine</i></b>/<b style='color:Tomato;'><i>ketorolac</i></b> combinations. Variations of the combinations were analyzed to ascertain if an optimal analgesic ratio existed. All controllable variables involved with the surgical procedure were held constant to allow for better evaluation of postoperative pain. Results obtained from 67 patients indicated that the best pain relief was achieved with a combination of 10 mg <b style='color:Tomato;'><i>ketorolac</i></b> and 15 mg <b style='color:Tomato;'><i>codeine</i></b> phosphate. <b style='color:Tomato;'><i>codeine</i></b> alone provided adequate analgesia, but the addition of <b style='color:Tomato;'><i>ketorolac</i></b> reduced the patients' perceived side effects. The presence of <b style='color:Tomato;'><i>codeine</i></b> in the analgesic combination was also shown to reduce the number of days that the patient required the medication postoperatively. <b style='color:DodgerBlue;'><i>Reducing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>duration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>medication</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>postoperatively</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>minimize</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>possible</i></b> <b style='color:DodgerBlue;'><i>side</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ketorolac</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>codeine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>could</i></b> <b style='color:DodgerBlue;'><i>develop</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>extended</i></b> <b style='color:DodgerBlue;'><i>periods</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Reducing","start":0,"end":8,"id":0,"ws":true},{"text":"the","start":9,"end":12,"id":1,"ws":true},{"text":"duration","start":13,"end":21,"id":2,"ws":true},{"text":"of","start":22,"end":24,"id":3,"ws":true},{"text":"medication","start":25,"end":35,"id":4,"ws":true},{"text":"use","start":36,"end":39,"id":5,"ws":true},{"text":"postoperatively","start":40,"end":55,"id":6,"ws":true},{"text":"may","start":56,"end":59,"id":7,"ws":true},{"text":"also","start":60,"end":64,"id":8,"ws":true},{"text":"minimize","start":65,"end":73,"id":9,"ws":true},{"text":"the","start":74,"end":77,"id":10,"ws":true},{"text":"possible","start":78,"end":86,"id":11,"ws":true},{"text":"side","start":87,"end":91,"id":12,"ws":true},{"text":"effects","start":92,"end":99,"id":13,"ws":true},{"text":"of","start":100,"end":102,"id":14,"ws":true},{"text":"ketorolac","start":103,"end":112,"id":15,"ws":true},{"text":"and","start":113,"end":116,"id":16,"ws":true},{"text":"codeine","start":117,"end":124,"id":17,"ws":true},{"text":",","start":125,"end":126,"id":18,"ws":true},{"text":"which","start":127,"end":132,"id":19,"ws":true},{"text":"could","start":133,"end":138,"id":20,"ws":true},{"text":"develop","start":139,"end":146,"id":21,"ws":true},{"text":"with","start":147,"end":151,"id":22,"ws":true},{"text":"extended","start":152,"end":160,"id":23,"ws":true},{"text":"periods","start":161,"end":168,"id":24,"ws":true},{"text":"of","start":169,"end":171,"id":25,"ws":true},{"text":"use","start":172,"end":175,"id":26,"ws":true},{"text":".","start":176,"end":177,"id":27,"ws":false}],"spans":[{"start":103,"end":112,"token_start":15,"token_end":15,"label":"DRUG"},{"start":117,"end":124,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12190134/","_input_hash":-1280865924,"_task_hash":-1776961753,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":15,"child":17,"head_span":{"start":103,"end":112,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":117,"end":124,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma .","paragraph":"<h3><u>Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.</u></h3> <b style='color:MediumOrchid;'><i>Lenalidomide</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>reference</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>relapsed</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>myeloma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of the proteasome inhibitor <b style='color:Tomato;'><i>carfilzomib</i></b> with <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. ### methods We randomly assigned 792 patients with relapsed multiple myeloma to <b style='color:Tomato;'><i>carfilzomib</i></b> with <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> (<b style='color:Tomato;'><i>carfilzomib</i></b> group) or <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> alone (control group). The primary end point was progression-free survival. ### results Progression-free survival was significantly improved with <b style='color:Tomato;'><i>carfilzomib</i></b> (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the <b style='color:Tomato;'><i>carfilzomib</i></b> and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the <b style='color:Tomato;'><i>carfilzomib</i></b> and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the <b style='color:Tomato;'><i>carfilzomib</i></b> and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the <b style='color:Tomato;'><i>carfilzomib</i></b> group reported superior health-related quality of life. ### conclusions In patients with relapsed multiple myeloma, the addition of <b style='color:Tomato;'><i>carfilzomib</i></b> to <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).","tokens":[{"text":"Lenalidomide","start":0,"end":12,"id":0,"ws":true},{"text":"plus","start":13,"end":17,"id":1,"ws":true},{"text":"dexamethasone","start":18,"end":31,"id":2,"ws":true},{"text":"is","start":32,"end":34,"id":3,"ws":true},{"text":"a","start":35,"end":36,"id":4,"ws":true},{"text":"reference","start":37,"end":46,"id":5,"ws":true},{"text":"treatment","start":47,"end":56,"id":6,"ws":true},{"text":"for","start":57,"end":60,"id":7,"ws":true},{"text":"relapsed","start":61,"end":69,"id":8,"ws":true},{"text":"multiple","start":70,"end":78,"id":9,"ws":true},{"text":"myeloma","start":79,"end":86,"id":10,"ws":true},{"text":".","start":87,"end":88,"id":11,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":18,"end":31,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25482145/","_input_hash":-942881164,"_task_hash":-1758155141,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":18,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Following definitive treatment , patients were randomized to either cyclophosphamide 1 g/m2 intravenously every 3 weeks for 2 years , estramustine phosphate 600 mg/m2 orally daily for 2 years or to observation only .","paragraph":"<h3><u>Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation.</u></h3>Because of efficacy demonstrated with chemotherapy in patients with metastatic disease, the National Prostate Cancer Project in 1978 initiated two protocols evaluating adjuvant therapy following surgery (Protocol 900) and irradiation (Protocol 1000) for patients with localized disease at high risk for relapse. ### methods All patients underwent staging pelvic lymph node dissection. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>definitive</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>g/m2</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>estramustine</i></b> <b style='color:DodgerBlue;'><i>phosphate</i></b> <b style='color:DodgerBlue;'><i>600</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>observation</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Accession closed in 1985 and included 184 patients in Protocol 900 (170 evaluable) and 253 in Protocol 1000 (233 evaluable). ### results Nodal involvement was identified in 198 patients (49% of total): 29% in Protocol 900 and 63% in protocol 1000. Median progression-free survival (PFS) and survival have been greater for patients in Protocol 900 regardless of adjuvant, reflecting their lower pathologic stage. Median PFS is significantly greater for patients in Protocol 1000 receiving <b style='color:Tomato;'><i>estramustine</i></b> (52.2 months) compared to <b style='color:Tomato;'><i>cyclophosphamide</i></b> (35.0 months). Median PFS for patients with nodal involvement in Protocol 1000 receiving <b style='color:Tomato;'><i>estramustine</i></b> is increased (43.5 months) compared to no treatment (21.5 months). Patients with limited nodal involvement in Protocol 1000 have a longer median PFS (45.6 months) compared to patients with extensive disease (23.6 months). But in the latter group patients receiving <b style='color:Tomato;'><i>estramustine</i></b> experienced a significantly longer median PFS (43.5 months) compared to <b style='color:Tomato;'><i>cyclophosphamide</i></b> (29.1 months) or no adjuvant (13.5 months). Increased PFS with <b style='color:Tomato;'><i>estramustine</i></b> adjuvant was also noted in stage C patients (only Protocol 900) and in those with high-grade (grade 3) tumors (both protocols). ### conclusions With now over 10 years mean follow-up for this series of patients, we conclude that adjuvant <b style='color:Tomato;'><i>estramustine</i></b> is beneficial for prostate cancer patients receiving definitive irradiation. This benefit is particularly noted in those patients with extensive nodal involvement (N+, D-1).","tokens":[{"text":"Following","start":0,"end":9,"id":0,"ws":true},{"text":"definitive","start":10,"end":20,"id":1,"ws":true},{"text":"treatment","start":21,"end":30,"id":2,"ws":true},{"text":",","start":31,"end":32,"id":3,"ws":true},{"text":"patients","start":33,"end":41,"id":4,"ws":true},{"text":"were","start":42,"end":46,"id":5,"ws":true},{"text":"randomized","start":47,"end":57,"id":6,"ws":true},{"text":"to","start":58,"end":60,"id":7,"ws":true},{"text":"either","start":61,"end":67,"id":8,"ws":true},{"text":"cyclophosphamide","start":68,"end":84,"id":9,"ws":true},{"text":"1","start":85,"end":86,"id":10,"ws":true},{"text":"g/m2","start":87,"end":91,"id":11,"ws":true},{"text":"intravenously","start":92,"end":105,"id":12,"ws":true},{"text":"every","start":106,"end":111,"id":13,"ws":true},{"text":"3","start":112,"end":113,"id":14,"ws":true},{"text":"weeks","start":114,"end":119,"id":15,"ws":true},{"text":"for","start":120,"end":123,"id":16,"ws":true},{"text":"2","start":124,"end":125,"id":17,"ws":true},{"text":"years","start":126,"end":131,"id":18,"ws":true},{"text":",","start":132,"end":133,"id":19,"ws":true},{"text":"estramustine","start":134,"end":146,"id":20,"ws":true},{"text":"phosphate","start":147,"end":156,"id":21,"ws":true},{"text":"600","start":157,"end":160,"id":22,"ws":true},{"text":"mg/m2","start":161,"end":166,"id":23,"ws":true},{"text":"orally","start":167,"end":173,"id":24,"ws":true},{"text":"daily","start":174,"end":179,"id":25,"ws":true},{"text":"for","start":180,"end":183,"id":26,"ws":true},{"text":"2","start":184,"end":185,"id":27,"ws":true},{"text":"years","start":186,"end":191,"id":28,"ws":true},{"text":"or","start":192,"end":194,"id":29,"ws":true},{"text":"to","start":195,"end":197,"id":30,"ws":true},{"text":"observation","start":198,"end":209,"id":31,"ws":true},{"text":"only","start":210,"end":214,"id":32,"ws":true},{"text":".","start":215,"end":216,"id":33,"ws":false}],"spans":[{"start":68,"end":84,"token_start":9,"token_end":9,"label":"DRUG"},{"start":134,"end":146,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8791049/","_input_hash":1773548335,"_task_hash":-1919144287,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The authors report on anemia observed during preoperative paclitaxel and carboplatin chemotherapy in patients with advanced head and neck carcinoma and discuss how the use of recombinant human erythropoietin ( r-HuEPO ) ameliorates this anemia , reducing the need for subsequent packed red blood cell ( PRBC ) transfusions .","paragraph":"<h3><u>Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>authors</i></b> <b style='color:DodgerBlue;'><i>report</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>anemia</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>preoperative</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>head</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>neck</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>discuss</i></b> <b style='color:DodgerBlue;'><i>how</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recombinant</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:MediumOrchid;'><i>erythropoietin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>r-HuEPO</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>ameliorates</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>anemia</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>reducing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>need</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>subsequent</i></b> <b style='color:DodgerBlue;'><i>packed</i></b> <b style='color:DodgerBlue;'><i>red</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PRBC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>transfusions</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Response to r-HuEPO was defined as reduced hemoglobin fall during preoperative chemotherapy and reduced transfusion requirements during surgery. Thirty-six patients with advanced head and neck carcinoma were evaluable after treatment with preoperative chemotherapy using <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>. Group 1 was comprised of 14 patients who empirically received r-HuEPO at a dose of 150 U/kg 3 times per week for 3 weeks; in patients deemed nonresponders, the dose was increased to 300 U/kg and 450 U/kg in the subsequent courses. Group 2 was comprised of 22 patients who did not receive r-HuEPO. ### results During preoperative chemotherapy, the mean hemoglobin fall was 0.5 g/dL in Group 1 (P = 0.40). In Group 2 there was a statistically significant mean hemoglobin fall of 3.3 g/dL (P < 0.0001). There was also a nonstatistically significant trend toward fewer PRBC transfusions: none of 14 patients (0%) in Group 1 versus 4 of 22 patients (18%) in Group 2 (P = 0.141). ### conclusions A significant fall in hemoglobin and an increase in the need for transfusions were observed in head and neck carcinoma patients receiving <b style='color:Tomato;'><i>carboplatin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> chemotherapy prior to surgery. Empiric r-HuEPO therapy appeared to prevent anemia and reduced the need for PRBC transfusions.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"authors","start":4,"end":11,"id":1,"ws":true},{"text":"report","start":12,"end":18,"id":2,"ws":true},{"text":"on","start":19,"end":21,"id":3,"ws":true},{"text":"anemia","start":22,"end":28,"id":4,"ws":true},{"text":"observed","start":29,"end":37,"id":5,"ws":true},{"text":"during","start":38,"end":44,"id":6,"ws":true},{"text":"preoperative","start":45,"end":57,"id":7,"ws":true},{"text":"paclitaxel","start":58,"end":68,"id":8,"ws":true},{"text":"and","start":69,"end":72,"id":9,"ws":true},{"text":"carboplatin","start":73,"end":84,"id":10,"ws":true},{"text":"chemotherapy","start":85,"end":97,"id":11,"ws":true},{"text":"in","start":98,"end":100,"id":12,"ws":true},{"text":"patients","start":101,"end":109,"id":13,"ws":true},{"text":"with","start":110,"end":114,"id":14,"ws":true},{"text":"advanced","start":115,"end":123,"id":15,"ws":true},{"text":"head","start":124,"end":128,"id":16,"ws":true},{"text":"and","start":129,"end":132,"id":17,"ws":true},{"text":"neck","start":133,"end":137,"id":18,"ws":true},{"text":"carcinoma","start":138,"end":147,"id":19,"ws":true},{"text":"and","start":148,"end":151,"id":20,"ws":true},{"text":"discuss","start":152,"end":159,"id":21,"ws":true},{"text":"how","start":160,"end":163,"id":22,"ws":true},{"text":"the","start":164,"end":167,"id":23,"ws":true},{"text":"use","start":168,"end":171,"id":24,"ws":true},{"text":"of","start":172,"end":174,"id":25,"ws":true},{"text":"recombinant","start":175,"end":186,"id":26,"ws":true},{"text":"human","start":187,"end":192,"id":27,"ws":true},{"text":"erythropoietin","start":193,"end":207,"id":28,"ws":true},{"text":"(","start":208,"end":209,"id":29,"ws":true},{"text":"r-HuEPO","start":210,"end":217,"id":30,"ws":true},{"text":")","start":218,"end":219,"id":31,"ws":true},{"text":"ameliorates","start":220,"end":231,"id":32,"ws":true},{"text":"this","start":232,"end":236,"id":33,"ws":true},{"text":"anemia","start":237,"end":243,"id":34,"ws":true},{"text":",","start":244,"end":245,"id":35,"ws":true},{"text":"reducing","start":246,"end":254,"id":36,"ws":true},{"text":"the","start":255,"end":258,"id":37,"ws":true},{"text":"need","start":259,"end":263,"id":38,"ws":true},{"text":"for","start":264,"end":267,"id":39,"ws":true},{"text":"subsequent","start":268,"end":278,"id":40,"ws":true},{"text":"packed","start":279,"end":285,"id":41,"ws":true},{"text":"red","start":286,"end":289,"id":42,"ws":true},{"text":"blood","start":290,"end":295,"id":43,"ws":true},{"text":"cell","start":296,"end":300,"id":44,"ws":true},{"text":"(","start":301,"end":302,"id":45,"ws":true},{"text":"PRBC","start":303,"end":307,"id":46,"ws":true},{"text":")","start":308,"end":309,"id":47,"ws":true},{"text":"transfusions","start":310,"end":322,"id":48,"ws":true},{"text":".","start":323,"end":324,"id":49,"ws":false}],"spans":[{"start":58,"end":68,"token_start":8,"token_end":8,"label":"DRUG"},{"start":73,"end":84,"token_start":10,"token_end":10,"label":"DRUG"},{"start":193,"end":207,"token_start":28,"token_end":28,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9118049/","_input_hash":-115747160,"_task_hash":-1156151995,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":10,"child":8,"head_span":{"start":73,"end":84,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":58,"end":68,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":28,"head_span":{"start":73,"end":84,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":193,"end":207,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>fluconazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>flucytosine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>murine</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cryptococcal</i></b> <b style='color:DodgerBlue;'><i>meningitis</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>This study elucidates the role of combined <b style='color:Tomato;'><i>fluconazole</i></b> and <b style='color:Tomato;'><i>flucytosine</i></b> as therapy for cryptococcosis in the murine model of meningitis. Three strains of Cryptococcus neoformans for which the range of <b style='color:Tomato;'><i>fluconazole</i></b> MICs was wide--2 microg/ml (susceptible strain), 8 microg/ml (moderately susceptible strain), and 32 microg/ml (resistant strain)--were used for infection. One day postinfection, the mice were randomized into eight treatment groups: placebo; <b style='color:Tomato;'><i>flucytosine</i></b> (40 mg/kg of body weight/day); <b style='color:Tomato;'><i>fluconazole</i></b> at 3 mg/kg/day (low dosage), 10 mg/kg/day (moderate dosage), or 20 mg/kg/day (high dosage); and combined <b style='color:Tomato;'><i>flucytosine</i></b> and <b style='color:Tomato;'><i>fluconazole</i></b> at low, moderate, or high doses of <b style='color:Tomato;'><i>fluconazole</i></b>. Three major findings were demonstrated: (i) correlation between the MICs for the isolates and the in vivo effectiveness of <b style='color:Tomato;'><i>fluconazole</i></b> as assessed by the reduction in cryptococcal brain burden, (ii) a dose-response curve (a higher dose of <b style='color:Tomato;'><i>fluconazole</i></b> was significantly more efficacious than a lower dose [P < 0.001]), and (iii) synergism between <b style='color:Tomato;'><i>fluconazole</i></b> and <b style='color:Tomato;'><i>flucytosine</i></b> (therapy with a combination of <b style='color:Tomato;'><i>fluconazole</i></b> and <b style='color:Tomato;'><i>flucytosine</i></b> was superior to therapy with either agent alone [P < 0.01]).","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"therapy","start":12,"end":19,"id":1,"ws":true},{"text":"with","start":20,"end":24,"id":2,"ws":true},{"text":"fluconazole","start":25,"end":36,"id":3,"ws":true},{"text":"and","start":37,"end":40,"id":4,"ws":true},{"text":"flucytosine","start":41,"end":52,"id":5,"ws":true},{"text":"in","start":53,"end":55,"id":6,"ws":true},{"text":"the","start":56,"end":59,"id":7,"ws":true},{"text":"murine","start":60,"end":66,"id":8,"ws":true},{"text":"model","start":67,"end":72,"id":9,"ws":true},{"text":"of","start":73,"end":75,"id":10,"ws":true},{"text":"cryptococcal","start":76,"end":88,"id":11,"ws":true},{"text":"meningitis","start":89,"end":99,"id":12,"ws":true},{"text":".","start":100,"end":101,"id":13,"ws":false}],"spans":[{"start":25,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},{"start":41,"end":52,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9145879/","_input_hash":1182230001,"_task_hash":1415328540,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":25,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":41,"end":52,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In 2005 , after a significant disease-free survival benefit was reported for letrozole as compared with tamoxifen , a protocol amendment facilitated the crossover to letrozole of patients who were still receiving tamoxifen alone ; Cox models and Kaplan-Meier estimates with inverse probability of censoring weighting ( IPCW ) are used to account for selective crossover to letrozole of patients ( n=619 ) in the tamoxifen arm .","paragraph":"<h3><u>Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8\u00b71 years median follow-up.</u></h3>Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8\u00b71 years median follow-up. ### methods BIG 1-98 is a randomised, phase 3, double-blind trial of postmenopausal women with hormone receptor-positive early breast cancer that compares 5 years of <b style='color:Tomato;'><i>tamoxifen</i></b> or <b style='color:Tomato;'><i>letrozole</i></b> monotherapy, or sequential treatment with 2 years of one of these drugs followed by 3 years of the other. Randomisation was done with permuted blocks, and stratified according to the two-arm or four-arm randomisation option, participating institution, and chemotherapy use. Patients, investigators, data managers, and medical reviewers were masked. The primary efficacy endpoint was disease-free survival (events were invasive breast cancer relapse, second primaries [contralateral breast and non-breast], or death without previous cancer event). Secondary endpoints were overall survival, distant recurrence-free interval (DRFI), and breast cancer-free interval (BCFI). The monotherapy comparison included patients randomly assigned to <b style='color:Tomato;'><i>tamoxifen</i></b> or <b style='color:Tomato;'><i>letrozole</i></b> for 5 years. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>2005</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>disease-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>amendment</i></b> <b style='color:DodgerBlue;'><i>facilitated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>crossover</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>still</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>Cox</i></b> <b style='color:DodgerBlue;'><i>models</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Kaplan-Meier</i></b> <b style='color:DodgerBlue;'><i>estimates</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>inverse</i></b> <b style='color:DodgerBlue;'><i>probability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>censoring</i></b> <b style='color:DodgerBlue;'><i>weighting</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>IPCW</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>account</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>crossover</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=619</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Comparison of sequential treatments to <b style='color:Tomato;'><i>letrozole</i></b> monotherapy included patients enrolled and randomly assigned to <b style='color:Tomato;'><i>letrozole</i></b> for 5 years, <b style='color:Tomato;'><i>letrozole</i></b> for 2 years followed by <b style='color:Tomato;'><i>tamoxifen</i></b> for 3 years, or <b style='color:Tomato;'><i>tamoxifen</i></b> for 2 years followed by <b style='color:Tomato;'><i>letrozole</i></b> for 3 years. Treatment has ended for all patients and detailed safety results for adverse events that occurred during the 5 years of treatment have been reported elsewhere. Follow-up is continuing for those enrolled in the four-arm option. BIG 1-98 is registered at clinicaltrials.govNCT00004205. ### findings 8010 patients were included in the trial, with a median follow-up of 8\u00b71 years (range 0-12\u00b74). 2459 were randomly assigned to monotherapy with <b style='color:Tomato;'><i>tamoxifen</i></b> for 5 years and 2463 to monotherapy with <b style='color:Tomato;'><i>letrozole</i></b> for 5 years. In the four-arm option of the trial, 1546 were randomly assigned to <b style='color:Tomato;'><i>letrozole</i></b> for 5 years, 1548 to <b style='color:Tomato;'><i>tamoxifen</i></b> for 5 years, 1540 to <b style='color:Tomato;'><i>letrozole</i></b> for 2 years followed by <b style='color:Tomato;'><i>tamoxifen</i></b> for 3 years, and 1548 to <b style='color:Tomato;'><i>tamoxifen</i></b> for 2 years followed by <b style='color:Tomato;'><i>letrozole</i></b> for 3 years. At a median follow-up of 8\u00b77 years from randomisation (range 0-12\u00b74), <b style='color:Tomato;'><i>letrozole</i></b> monotherapy was significantly better than <b style='color:Tomato;'><i>tamoxifen</i></b>, whether by IPCW or intention-to-treat analysis (IPCW disease-free survival HR 0\u00b782 [95% CI 0\u00b774-0\u00b792], overall survival HR 0\u00b779 [0\u00b769-0\u00b790], DRFI HR 0\u00b779 [0\u00b768-0\u00b792], BCFI HR 0\u00b780 [0\u00b770-0\u00b792]; intention-to-treat disease-free survival HR 0\u00b786 [0\u00b778-0\u00b796], overall survival HR 0\u00b787 [0\u00b777-0\u00b7999], DRFI HR 0\u00b786 [0\u00b774-0\u00b7998], BCFI HR 0\u00b786 [0\u00b776-0\u00b798]). At a median follow-up of 8\u00b70 years from randomisation (range 0-11\u00b72) for the comparison of the sequential groups with <b style='color:Tomato;'><i>letrozole</i></b> monotherapy, there were no statistically significant differences in any of the four endpoints for either sequence. 8-year intention-to-treat estimates (each with SE \u22641\u00b71%) for <b style='color:Tomato;'><i>letrozole</i></b> monotherapy, <b style='color:Tomato;'><i>letrozole</i></b> followed by <b style='color:Tomato;'><i>tamoxifen</i></b>, and <b style='color:Tomato;'><i>tamoxifen</i></b> followed by <b style='color:Tomato;'><i>letrozole</i></b> were 78\u00b76%, 77\u00b78%, 77\u00b73% for disease-free survival; 87\u00b75%, 87\u00b77%, 85\u00b79% for overall survival; 89\u00b79%, 88\u00b77%, 88\u00b71% for DRFI; and 86\u00b71%, 85\u00b73%, 84\u00b73% for BCFI. ### interpretation For postmenopausal women with endocrine-responsive early breast cancer, a reduction in breast cancer recurrence and mortality is obtained by <b style='color:Tomato;'><i>letrozole</i></b> monotherapy when compared with <b style='color:Tomato;'><i>tamoxifen</i></b> montherapy. Sequential treatments involving <b style='color:Tomato;'><i>tamoxifen</i></b> and <b style='color:Tomato;'><i>letrozole</i></b> do not improve outcome compared with <b style='color:Tomato;'><i>letrozole</i></b> monotherapy, but might be useful strategies when considering an individual patient's risk of recurrence and treatment tolerability. ### funding Novartis, United States National Cancer Institute, International Breast Cancer Study Group.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"2005","start":3,"end":7,"id":1,"ws":true},{"text":",","start":8,"end":9,"id":2,"ws":true},{"text":"after","start":10,"end":15,"id":3,"ws":true},{"text":"a","start":16,"end":17,"id":4,"ws":true},{"text":"significant","start":18,"end":29,"id":5,"ws":true},{"text":"disease-free","start":30,"end":42,"id":6,"ws":true},{"text":"survival","start":43,"end":51,"id":7,"ws":true},{"text":"benefit","start":52,"end":59,"id":8,"ws":true},{"text":"was","start":60,"end":63,"id":9,"ws":true},{"text":"reported","start":64,"end":72,"id":10,"ws":true},{"text":"for","start":73,"end":76,"id":11,"ws":true},{"text":"letrozole","start":77,"end":86,"id":12,"ws":true},{"text":"as","start":87,"end":89,"id":13,"ws":true},{"text":"compared","start":90,"end":98,"id":14,"ws":true},{"text":"with","start":99,"end":103,"id":15,"ws":true},{"text":"tamoxifen","start":104,"end":113,"id":16,"ws":true},{"text":",","start":114,"end":115,"id":17,"ws":true},{"text":"a","start":116,"end":117,"id":18,"ws":true},{"text":"protocol","start":118,"end":126,"id":19,"ws":true},{"text":"amendment","start":127,"end":136,"id":20,"ws":true},{"text":"facilitated","start":137,"end":148,"id":21,"ws":true},{"text":"the","start":149,"end":152,"id":22,"ws":true},{"text":"crossover","start":153,"end":162,"id":23,"ws":true},{"text":"to","start":163,"end":165,"id":24,"ws":true},{"text":"letrozole","start":166,"end":175,"id":25,"ws":true},{"text":"of","start":176,"end":178,"id":26,"ws":true},{"text":"patients","start":179,"end":187,"id":27,"ws":true},{"text":"who","start":188,"end":191,"id":28,"ws":true},{"text":"were","start":192,"end":196,"id":29,"ws":true},{"text":"still","start":197,"end":202,"id":30,"ws":true},{"text":"receiving","start":203,"end":212,"id":31,"ws":true},{"text":"tamoxifen","start":213,"end":222,"id":32,"ws":true},{"text":"alone","start":223,"end":228,"id":33,"ws":true},{"text":";","start":229,"end":230,"id":34,"ws":true},{"text":"Cox","start":231,"end":234,"id":35,"ws":true},{"text":"models","start":235,"end":241,"id":36,"ws":true},{"text":"and","start":242,"end":245,"id":37,"ws":true},{"text":"Kaplan-Meier","start":246,"end":258,"id":38,"ws":true},{"text":"estimates","start":259,"end":268,"id":39,"ws":true},{"text":"with","start":269,"end":273,"id":40,"ws":true},{"text":"inverse","start":274,"end":281,"id":41,"ws":true},{"text":"probability","start":282,"end":293,"id":42,"ws":true},{"text":"of","start":294,"end":296,"id":43,"ws":true},{"text":"censoring","start":297,"end":306,"id":44,"ws":true},{"text":"weighting","start":307,"end":316,"id":45,"ws":true},{"text":"(","start":317,"end":318,"id":46,"ws":true},{"text":"IPCW","start":319,"end":323,"id":47,"ws":true},{"text":")","start":324,"end":325,"id":48,"ws":true},{"text":"are","start":326,"end":329,"id":49,"ws":true},{"text":"used","start":330,"end":334,"id":50,"ws":true},{"text":"to","start":335,"end":337,"id":51,"ws":true},{"text":"account","start":338,"end":345,"id":52,"ws":true},{"text":"for","start":346,"end":349,"id":53,"ws":true},{"text":"selective","start":350,"end":359,"id":54,"ws":true},{"text":"crossover","start":360,"end":369,"id":55,"ws":true},{"text":"to","start":370,"end":372,"id":56,"ws":true},{"text":"letrozole","start":373,"end":382,"id":57,"ws":true},{"text":"of","start":383,"end":385,"id":58,"ws":true},{"text":"patients","start":386,"end":394,"id":59,"ws":true},{"text":"(","start":395,"end":396,"id":60,"ws":true},{"text":"n=619","start":397,"end":402,"id":61,"ws":true},{"text":")","start":403,"end":404,"id":62,"ws":true},{"text":"in","start":405,"end":407,"id":63,"ws":true},{"text":"the","start":408,"end":411,"id":64,"ws":true},{"text":"tamoxifen","start":412,"end":421,"id":65,"ws":true},{"text":"arm","start":422,"end":425,"id":66,"ws":true},{"text":".","start":426,"end":427,"id":67,"ws":false}],"spans":[{"start":77,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},{"start":104,"end":113,"token_start":16,"token_end":16,"label":"DRUG"},{"start":166,"end":175,"token_start":25,"token_end":25,"label":"DRUG"},{"start":213,"end":222,"token_start":32,"token_end":32,"label":"DRUG"},{"start":373,"end":382,"token_start":57,"token_end":57,"label":"DRUG"},{"start":412,"end":421,"token_start":65,"token_end":65,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22018631/","_input_hash":-946691606,"_task_hash":-371986293,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":25,"child":32,"head_span":{"start":166,"end":175,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":213,"end":222,"token_start":32,"token_end":32,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"The consumption of meropenem or doripenem was calculated using the Anatomic Therapeutic Chemical classification and defined daily doses methodology .","paragraph":"<h3><u>Correlation between the consumption of meropenem or doripenem and meropenem susceptibility of Pseudomonas aeruginosa in a university hospital in Japan.</u></h3>The appropriate use of carbapenems is essential in order to prevent resistance in Pseudomonas aeruginosa. We investigated the correlation between the consumption of <b style='color:Tomato;'><i>meropenem</i></b> or <b style='color:Tomato;'><i>doripenem</i></b> and the susceptibility of P. aeruginosa to <b style='color:Tomato;'><i>meropenem</i></b> in a Japanese university hospital from 2004 to 2009. The susceptibility data of P. aeruginosa and the annual consumption of <b style='color:Tomato;'><i>meropenem</i></b> or <b style='color:Tomato;'><i>doripenem</i></b> were analyzed. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>consumption</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>meropenem</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>doripenem</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>calculated</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Anatomic</i></b> <b style='color:DodgerBlue;'><i>Therapeutic</i></b> <b style='color:DodgerBlue;'><i>Chemical</i></b> <b style='color:DodgerBlue;'><i>classification</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>defined</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>methodology</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>meropenem</i></b> consumption decreased and <b style='color:Tomato;'><i>doripenem</i></b> consumption increased and throughout the entire investigation period, total consumption of <b style='color:Tomato;'><i>meropenem</i></b> plus <b style='color:Tomato;'><i>doripenem</i></b> was stable. Although the annual number of isolated P. aeruginosa has not changed, the annual number of isolated multidrug resistant P. aeruginosa decreased by measures against nosocomial infection. The rate of <b style='color:Tomato;'><i>meropenem</i></b> resistant P. aeruginosa decreased in a time-dependent manner. <b style='color:Tomato;'><i>meropenem</i></b> consumption was positively correlated with the <b style='color:Tomato;'><i>meropenem</i></b> resistance rate among P. aeruginosa (r = 0.9455, p<0.01). The total consumption of <b style='color:Tomato;'><i>meropenem</i></b> and <b style='color:Tomato;'><i>doripenem</i></b> was not correlated with the <b style='color:Tomato;'><i>meropenem</i></b> resistance rate (r = -0.6601, p>0.1). These results suggested that even if the total consumption of <b style='color:Tomato;'><i>meropenem</i></b> plus <b style='color:Tomato;'><i>doripenem</i></b> was not changed, <b style='color:Tomato;'><i>meropenem</i></b> susceptibility among P. aeruginosa improved by the decrease of <b style='color:Tomato;'><i>meropenem</i></b> consumption. Although <b style='color:Tomato;'><i>meropenem</i></b> and <b style='color:Tomato;'><i>doripenem</i></b> have been suggested to show cross-resistance with each other, the reduction of <b style='color:Tomato;'><i>meropenem</i></b> consumption might be effective for preventing an increase of <b style='color:Tomato;'><i>meropenem</i></b>-resistant P. aeruginosa.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"consumption","start":4,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"meropenem","start":19,"end":28,"id":3,"ws":true},{"text":"or","start":29,"end":31,"id":4,"ws":true},{"text":"doripenem","start":32,"end":41,"id":5,"ws":true},{"text":"was","start":42,"end":45,"id":6,"ws":true},{"text":"calculated","start":46,"end":56,"id":7,"ws":true},{"text":"using","start":57,"end":62,"id":8,"ws":true},{"text":"the","start":63,"end":66,"id":9,"ws":true},{"text":"Anatomic","start":67,"end":75,"id":10,"ws":true},{"text":"Therapeutic","start":76,"end":87,"id":11,"ws":true},{"text":"Chemical","start":88,"end":96,"id":12,"ws":true},{"text":"classification","start":97,"end":111,"id":13,"ws":true},{"text":"and","start":112,"end":115,"id":14,"ws":true},{"text":"defined","start":116,"end":123,"id":15,"ws":true},{"text":"daily","start":124,"end":129,"id":16,"ws":true},{"text":"doses","start":130,"end":135,"id":17,"ws":true},{"text":"methodology","start":136,"end":147,"id":18,"ws":true},{"text":".","start":148,"end":149,"id":19,"ws":false}],"spans":[{"start":19,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},{"start":32,"end":41,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22687536/","_input_hash":1114884058,"_task_hash":380056829,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"After successful phase II studies , recent phase III trials established combinations of chlorambucil with anti-CD20 antibodies such as rituximab , ofatumumab and obinutuzumab as a valuable treatment option for these patients .","paragraph":"<h3><u>Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.</u></h3>For many decades, <b style='color:Tomato;'><i>chlorambucil</i></b> was the standard of care for chronic lymphocytic leukemia (CLL), but meanwhile has been replaced by purine analog-based chemoimmunotherapy. Monotherapy with the alkylator only retained significance in the treatment of older patients unfit for standard treatment. <b style='color:DodgerBlue;'><i>After</i></b> <b style='color:DodgerBlue;'><i>successful</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>recent</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>established</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>chlorambucil</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>anti-CD20</i></b> <b style='color:DodgerBlue;'><i>antibodies</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ofatumumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>obinutuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>valuable</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>option</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Today, <b style='color:Tomato;'><i>chlorambucil</i></b> therefore should be used as a chemotherapy backbone for antibody-based chemoimmunotherapy in this patient population rather than as monotherapy. Starting from the past role of <b style='color:Tomato;'><i>chlorambucil</i></b> in CLL treatment, we here review the most recent efforts to elaborate <b style='color:Tomato;'><i>chlorambucil</i></b>-based chemoimmunotherapy in CLL and discuss clinically relevant questions that arise from this approach.","tokens":[{"text":"After","start":0,"end":5,"id":0,"ws":true},{"text":"successful","start":6,"end":16,"id":1,"ws":true},{"text":"phase","start":17,"end":22,"id":2,"ws":true},{"text":"II","start":23,"end":25,"id":3,"ws":true},{"text":"studies","start":26,"end":33,"id":4,"ws":true},{"text":",","start":34,"end":35,"id":5,"ws":true},{"text":"recent","start":36,"end":42,"id":6,"ws":true},{"text":"phase","start":43,"end":48,"id":7,"ws":true},{"text":"III","start":49,"end":52,"id":8,"ws":true},{"text":"trials","start":53,"end":59,"id":9,"ws":true},{"text":"established","start":60,"end":71,"id":10,"ws":true},{"text":"combinations","start":72,"end":84,"id":11,"ws":true},{"text":"of","start":85,"end":87,"id":12,"ws":true},{"text":"chlorambucil","start":88,"end":100,"id":13,"ws":true},{"text":"with","start":101,"end":105,"id":14,"ws":true},{"text":"anti-CD20","start":106,"end":115,"id":15,"ws":true},{"text":"antibodies","start":116,"end":126,"id":16,"ws":true},{"text":"such","start":127,"end":131,"id":17,"ws":true},{"text":"as","start":132,"end":134,"id":18,"ws":true},{"text":"rituximab","start":135,"end":144,"id":19,"ws":true},{"text":",","start":145,"end":146,"id":20,"ws":true},{"text":"ofatumumab","start":147,"end":157,"id":21,"ws":true},{"text":"and","start":158,"end":161,"id":22,"ws":true},{"text":"obinutuzumab","start":162,"end":174,"id":23,"ws":true},{"text":"as","start":175,"end":177,"id":24,"ws":true},{"text":"a","start":178,"end":179,"id":25,"ws":true},{"text":"valuable","start":180,"end":188,"id":26,"ws":true},{"text":"treatment","start":189,"end":198,"id":27,"ws":true},{"text":"option","start":199,"end":205,"id":28,"ws":true},{"text":"for","start":206,"end":209,"id":29,"ws":true},{"text":"these","start":210,"end":215,"id":30,"ws":true},{"text":"patients","start":216,"end":224,"id":31,"ws":true},{"text":".","start":225,"end":226,"id":32,"ws":false}],"spans":[{"start":88,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},{"start":135,"end":144,"token_start":19,"token_end":19,"label":"DRUG"},{"start":147,"end":157,"token_start":21,"token_end":21,"label":"DRUG"},{"start":162,"end":174,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25219593/","_input_hash":217161781,"_task_hash":564488024,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":13,"child":19,"head_span":{"start":88,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":135,"end":144,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":13,"child":21,"head_span":{"start":88,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":147,"end":157,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":13,"child":23,"head_span":{"start":88,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":162,"end":174,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#d9fbad","label":"POS3"}],"radio":["POS10","POS20","POS30"],"answer":"accept"}
{"text":"CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab ( FIRE-3 trial ) .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>CEA</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>KRAS</i></b> <b style='color:DodgerBlue;'><i>exon</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>wild-type</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>extended</i></b> <b style='color:DodgerBlue;'><i>RAS</i></b> <b style='color:DodgerBlue;'><i>wild-type</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>FOLFIRI</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FIRE-3</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>To examine the relation of carcinoembryonic antigen (CEA) response with tumor response and survival in patients with (K)RAS wild-type metastatic colorectal cancer receiving first-line chemotherapy in the FIRE-3 trial comparing FOLFIRI plus <b style='color:Tomato;'><i>cetuximab</i></b> versus FOLFIRI plus <b style='color:Tomato;'><i>bevacizumab</i></b>. ### Patients And Methods CEA response assessed as the percentage of CEA decrease from baseline to nadir was evaluated for its association with tumor response and survival. Receiver operating characteristic analysis revealed an optimal cut-off value of 75% using the maximum of sensitivity and specificity for CEA response to discriminate CEA responders from non-responders. In addition, the time to CEA nadir was calculated. ### results Of 592 patients in the intent-to-treat population, 472 were eligible for analysis of CEA (<b style='color:Tomato;'><i>cetuximab</i></b> arm: 230 and <b style='color:Tomato;'><i>bevacizumab</i></b> arm: 242). Maximal relative CEA decrease (%) significantly (P = 0.003) differed between the <b style='color:Tomato;'><i>cetuximab</i></b> arm (median 83.0%; IQR 40.9%-94.7%) and the <b style='color:Tomato;'><i>bevacizumab</i></b> arm (median 72.3%; IQR 26.3%-91.0%). In a longitudinal analysis, the CEA decrease occurred faster in the <b style='color:Tomato;'><i>cetuximab</i></b> arm and was greater than in the <b style='color:Tomato;'><i>bevacizumab</i></b> arm at all evaluated time points until 56 weeks after treatment start. CEA nadir occurred after 3.3 months (<b style='color:Tomato;'><i>cetuximab</i></b> arm) and 3.5 months (<b style='color:Tomato;'><i>bevacizumab</i></b> arm), (P = 0.49). In the <b style='color:Tomato;'><i>cetuximab</i></b> arm, CEA responders showed a significantly longer progression-free survival [11.8 versus 7.4 months; hazard ratio (HR) 1.53; 95% Cl, 1.15-2.04; P = 0.004] and longer overall survival (36.6 versus 21.3 months; HR 1.73; 95% Cl, 1.24-2.43; P = 0.001) than CEA non-responders. Analysis of extended RAS wild-type patients revealed similar results. ### conclusion In the FIRE-3 trial, CEA decrease was significantly faster and greater in the <b style='color:Tomato;'><i>cetuximab</i></b> arm than in the <b style='color:Tomato;'><i>bevacizumab</i></b> arm and correlated with the prolonged survival observed in patients receiving FOLFIRI plus <b style='color:Tomato;'><i>cetuximab</i></b>. ### Clinical Trials Number NCT00433927 (ClinicalTrials.gov); AIO KRK0306 FIRE-3.","tokens":[{"text":"CEA","start":0,"end":3,"id":0,"ws":true},{"text":"response","start":4,"end":12,"id":1,"ws":true},{"text":"is","start":13,"end":15,"id":2,"ws":true},{"text":"associated","start":16,"end":26,"id":3,"ws":true},{"text":"with","start":27,"end":31,"id":4,"ws":true},{"text":"tumor","start":32,"end":37,"id":5,"ws":true},{"text":"response","start":38,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"survival","start":51,"end":59,"id":8,"ws":true},{"text":"in","start":60,"end":62,"id":9,"ws":true},{"text":"patients","start":63,"end":71,"id":10,"ws":true},{"text":"with","start":72,"end":76,"id":11,"ws":true},{"text":"KRAS","start":77,"end":81,"id":12,"ws":true},{"text":"exon","start":82,"end":86,"id":13,"ws":true},{"text":"2","start":87,"end":88,"id":14,"ws":true},{"text":"wild-type","start":89,"end":98,"id":15,"ws":true},{"text":"and","start":99,"end":102,"id":16,"ws":true},{"text":"extended","start":103,"end":111,"id":17,"ws":true},{"text":"RAS","start":112,"end":115,"id":18,"ws":true},{"text":"wild-type","start":116,"end":125,"id":19,"ws":true},{"text":"metastatic","start":126,"end":136,"id":20,"ws":true},{"text":"colorectal","start":137,"end":147,"id":21,"ws":true},{"text":"cancer","start":148,"end":154,"id":22,"ws":true},{"text":"receiving","start":155,"end":164,"id":23,"ws":true},{"text":"first-line","start":165,"end":175,"id":24,"ws":true},{"text":"FOLFIRI","start":176,"end":183,"id":25,"ws":true},{"text":"plus","start":184,"end":188,"id":26,"ws":true},{"text":"cetuximab","start":189,"end":198,"id":27,"ws":true},{"text":"or","start":199,"end":201,"id":28,"ws":true},{"text":"bevacizumab","start":202,"end":213,"id":29,"ws":true},{"text":"(","start":214,"end":215,"id":30,"ws":true},{"text":"FIRE-3","start":216,"end":222,"id":31,"ws":true},{"text":"trial","start":223,"end":228,"id":32,"ws":true},{"text":")","start":229,"end":230,"id":33,"ws":true},{"text":".","start":231,"end":232,"id":34,"ws":false}],"spans":[{"start":176,"end":183,"token_start":25,"token_end":25,"label":"DRUG"},{"start":189,"end":198,"token_start":27,"token_end":27,"label":"DRUG"},{"start":202,"end":213,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27234640/","_input_hash":1965150843,"_task_hash":-1314260106,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":25,"child":27,"head_span":{"start":176,"end":183,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":189,"end":198,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Unorthodox antibiotic combinations including ciprofloxacin against high-level gentamicin resistant enterococci .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Unorthodox</i></b> <b style='color:DodgerBlue;'><i>antibiotic</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>ciprofloxacin</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>high-level</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>enterococci</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Development of high-level <b style='color:Tomato;'><i>gentamicin</i></b> resistance among enterococci represents a serious therapeutic problem as it precludes synergy between aminoglycosides and cell-wall active agents. As part of a search for active antibiotic combinations against enterococci with high-level <b style='color:Tomato;'><i>gentamicin</i></b> resistance, we tested by the time kill curve method the efficacy of <b style='color:Tomato;'><i>ciprofloxacin</i></b> combined with <b style='color:Tomato;'><i>ampicillin</i></b>, <b style='color:Tomato;'><i>trimethoprim</i></b>-sulphamethoxazole, <b style='color:Tomato;'><i>vancomycin</i></b> or <b style='color:Tomato;'><i>teicoplanin</i></b> against ten isolates of Enterococcus faecium, three of Enterococcus casseliflavus and 13 of Enterococcus faecalis that exhibited a MIC of <b style='color:Tomato;'><i>gentamicin</i></b> > or = 2000 mg/L. Most of the E. faecium were also resistant to <b style='color:Tomato;'><i>ampicillin</i></b> and to <b style='color:Tomato;'><i>ciprofloxacin</i></b>. The combination of <b style='color:Tomato;'><i>ciprofloxacin</i></b> with <b style='color:Tomato;'><i>ampicillin</i></b> was bactericidal against five of seven E. faecium strains that exhibited a <b style='color:Tomato;'><i>ciprofloxacin</i></b> MIC < or = 4 mg/L, but was inactive against the three E. faecium that were highly resistant to <b style='color:Tomato;'><i>ciprofloxacin</i></b>. This combination was also bactericidal against the E. casseliflavus and all the E. faecalis strains. The combination of <b style='color:Tomato;'><i>ciprofloxacin</i></b> with <b style='color:Tomato;'><i>trimethoprim</i></b>-sulphamethoxazole was bactericidal against five of the seven E. faecium and seven of the nine E. faecalis strains with a <b style='color:Tomato;'><i>ciprofloxacin</i></b> MIC < or = 4 mg/L. No bactericidal activity of this combination was seen against the enterococci that were highly resistant to either <b style='color:Tomato;'><i>ciprofloxacin</i></b> or to <b style='color:Tomato;'><i>trimethoprim</i></b>-sulphamethoxazole. The combination of <b style='color:Tomato;'><i>ciprofloxacin</i></b> with glycopeptides was inactive against E. faecium and E. casseliflavus and against E. faecalis, it was either ineffective or antagonistic; in only one case it was bactericidal. Five strains of E. faecium were resistant to all antibiotic combinations tested.","tokens":[{"text":"Unorthodox","start":0,"end":10,"id":0,"ws":true},{"text":"antibiotic","start":11,"end":21,"id":1,"ws":true},{"text":"combinations","start":22,"end":34,"id":2,"ws":true},{"text":"including","start":35,"end":44,"id":3,"ws":true},{"text":"ciprofloxacin","start":45,"end":58,"id":4,"ws":true},{"text":"against","start":59,"end":66,"id":5,"ws":true},{"text":"high-level","start":67,"end":77,"id":6,"ws":true},{"text":"gentamicin","start":78,"end":88,"id":7,"ws":true},{"text":"resistant","start":89,"end":98,"id":8,"ws":true},{"text":"enterococci","start":99,"end":110,"id":9,"ws":true},{"text":".","start":111,"end":112,"id":10,"ws":false}],"spans":[{"start":45,"end":58,"token_start":4,"token_end":4,"label":"DRUG"},{"start":78,"end":88,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8722538/","_input_hash":2130018385,"_task_hash":-985602480,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The Tamoxifen Exemestane Adjuvant Multinational ( TEAM ) phase 3 trial was conducted in hospitals in nine countries .","paragraph":"<h3><u>Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.</u></h3>Aromatase inhibitors improved disease-free survival compared with <b style='color:Tomato;'><i>tamoxifen</i></b> when given as an initial adjuvant treatment or after 2-3 years of <b style='color:Tomato;'><i>tamoxifen</i></b> to postmenopausal women with hormone-receptor-positive breast cancer. We therefore compared the long-term effects of <b style='color:Tomato;'><i>exemestane</i></b> monotherapy with sequential treatment (<b style='color:Tomato;'><i>tamoxifen</i></b> followed by <b style='color:Tomato;'><i>exemestane</i></b>). ### methods <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:MediumOrchid;'><i>Tamoxifen</i></b> <b style='color:MediumOrchid;'><i>Exemestane</i></b> <b style='color:DodgerBlue;'><i>Adjuvant</i></b> <b style='color:DodgerBlue;'><i>Multinational</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TEAM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>hospitals</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>nine</i></b> <b style='color:DodgerBlue;'><i>countries</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Postmenopausal women (median age 64 years, range 35-96) with hormone-receptor-positive breast cancer were randomly assigned in a 1:1 ratio to open-label <b style='color:Tomato;'><i>exemestane</i></b> (25 mg once a day, orally) alone or following <b style='color:Tomato;'><i>tamoxifen</i></b> (20 mg once a day, orally) for 5 years. Randomisation was by use of a computer-generated random permuted block method. The primary endpoint was disease-free survival (DFS) at 5 years. Main analyses were by intention to treat. The trial is registered with ClinicalTrials.gov, NCT00279448, NCT00032136, and NCT00036270; NTR 267; Ethics Commission Trial27/2001; and UMIN, C000000057. ### findings 9779 patients were assigned to sequential treatment (n=4875) or <b style='color:Tomato;'><i>exemestane</i></b> alone (n=4904), and 4868 and 4898 were analysed by intention to treat, respectively. 4154 (85%) patients in the sequential group and 4186 (86%) in the <b style='color:Tomato;'><i>exemestane</i></b> alone group were disease free at 5 years (hazard ratio 0\u00b797, 95% CI 0\u00b788-1\u00b708; p=0\u00b760). In the safety analysis, sequential treatment was associated with a higher incidence of gynaecological symptoms (942 [20%] of 4814 vs 523 [11%] of 4852), venous thrombosis (99 [2%] vs 47 [1%]), and endometrial abnormalities (191 [4%] vs 19 [<1%]) than was <b style='color:Tomato;'><i>exemestane</i></b> alone. Musculoskeletal adverse events (2448 [50%] vs 2133 [44%]), hypertension (303 [6%] vs 219 [5%]), and hyperlipidaemia (230 [5%] vs 136 [3%]) were reported more frequently with <b style='color:Tomato;'><i>exemestane</i></b> alone. ### interpretation Treatment regimens of <b style='color:Tomato;'><i>exemestane</i></b> alone or after <b style='color:Tomato;'><i>tamoxifen</i></b> might be judged to be appropriate options for postmenopausal women with hormone-receptor-positive early breast cancer. ### funding Pfizer.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"Tamoxifen","start":4,"end":13,"id":1,"ws":true},{"text":"Exemestane","start":14,"end":24,"id":2,"ws":true},{"text":"Adjuvant","start":25,"end":33,"id":3,"ws":true},{"text":"Multinational","start":34,"end":47,"id":4,"ws":true},{"text":"(","start":48,"end":49,"id":5,"ws":true},{"text":"TEAM","start":50,"end":54,"id":6,"ws":true},{"text":")","start":55,"end":56,"id":7,"ws":true},{"text":"phase","start":57,"end":62,"id":8,"ws":true},{"text":"3","start":63,"end":64,"id":9,"ws":true},{"text":"trial","start":65,"end":70,"id":10,"ws":true},{"text":"was","start":71,"end":74,"id":11,"ws":true},{"text":"conducted","start":75,"end":84,"id":12,"ws":true},{"text":"in","start":85,"end":87,"id":13,"ws":true},{"text":"hospitals","start":88,"end":97,"id":14,"ws":true},{"text":"in","start":98,"end":100,"id":15,"ws":true},{"text":"nine","start":101,"end":105,"id":16,"ws":true},{"text":"countries","start":106,"end":115,"id":17,"ws":true},{"text":".","start":116,"end":117,"id":18,"ws":false}],"spans":[{"start":4,"end":13,"token_start":1,"token_end":1,"label":"DRUG"},{"start":14,"end":24,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21247627/","_input_hash":1302458618,"_task_hash":-737988859,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":1,"child":2,"head_span":{"start":4,"end":13,"token_start":1,"token_end":1,"label":"DRUG"},"child_span":{"start":14,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Patients used 2.16 ( range 0.0 - 6.3 ) formoterol and 2.34 ( range 0.1 - 7.5 ) terbutaline relief inhalations x day(-1 ) .","paragraph":"<h3><u>Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma.</u></h3>The present study compared the safety of 4.5 microg <b style='color:Tomato;'><i>formoterol</i></b> with 0.5 mg <b style='color:Tomato;'><i>terbutaline</i></b>, both by Turbuhaler and used as needed, in addition to regular <b style='color:Tomato;'><i>formoterol</i></b> in moderate asthma. In this double-blind parallel-group study, 357 patients taking a moderate-to-high dose of inhaled corticosteroids and additional <b style='color:Tomato;'><i>terbutaline</i></b> (2-5 inhalations x day(-1) during run-in) were randomised to either <b style='color:Tomato;'><i>formoterol</i></b> or <b style='color:Tomato;'><i>terbutaline</i></b> as needed in addition to <b style='color:Tomato;'><i>formoterol</i></b> 9 microg b.i.d. over 12 weeks. Adverse events, serum potassium levels, electrocardiogram, vital signs and lung function were assessed monthly; peak expiratory flow and severe asthma exacerbations were recorded daily. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>2.16</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>range</i></b> <b style='color:DodgerBlue;'><i>0.0</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>6.3</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:MediumOrchid;'><i>formoterol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2.34</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>range</i></b> <b style='color:DodgerBlue;'><i>0.1</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>7.5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:MediumOrchid;'><i>terbutaline</i></b> <b style='color:DodgerBlue;'><i>relief</i></b> <b style='color:DodgerBlue;'><i>inhalations</i></b> <b style='color:DodgerBlue;'><i>x</i></b> <b style='color:DodgerBlue;'><i>day(-1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> No clinically significant differences in safety variables were found between treatments. Statistically greater increases in cardiac frequency (2.6 beats x min(-1), p=0.03) were found on <b style='color:Tomato;'><i>terbutaline</i></b>. There were 44 and 52 severe asthma exacerbations with <b style='color:Tomato;'><i>formoterol</i></b> and <b style='color:Tomato;'><i>terbutaline</i></b>, respectively, with no significant difference in time to first exacerbation. There was also no difference between treatments for other efficacy measures (peak expiratory flow, forced expiratory volume in one second and morning/evening symptom scores). <b style='color:Tomato;'><i>formoterol</i></b> 4.5 microg as needed was at least as safe, well tolerated and effective as <b style='color:Tomato;'><i>terbutaline</i></b> 0.5 mg in stable patients (requiring up to 6 relief inhalations x day(-1)) taking <b style='color:Tomato;'><i>formoterol</i></b> plus inhaled corticosteroids regularly over 12 weeks.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"used","start":9,"end":13,"id":1,"ws":true},{"text":"2.16","start":14,"end":18,"id":2,"ws":true},{"text":"(","start":19,"end":20,"id":3,"ws":true},{"text":"range","start":21,"end":26,"id":4,"ws":true},{"text":"0.0","start":27,"end":30,"id":5,"ws":true},{"text":"-","start":31,"end":32,"id":6,"ws":true},{"text":"6.3","start":33,"end":36,"id":7,"ws":true},{"text":")","start":37,"end":38,"id":8,"ws":true},{"text":"formoterol","start":39,"end":49,"id":9,"ws":true},{"text":"and","start":50,"end":53,"id":10,"ws":true},{"text":"2.34","start":54,"end":58,"id":11,"ws":true},{"text":"(","start":59,"end":60,"id":12,"ws":true},{"text":"range","start":61,"end":66,"id":13,"ws":true},{"text":"0.1","start":67,"end":70,"id":14,"ws":true},{"text":"-","start":71,"end":72,"id":15,"ws":true},{"text":"7.5","start":73,"end":76,"id":16,"ws":true},{"text":")","start":77,"end":78,"id":17,"ws":true},{"text":"terbutaline","start":79,"end":90,"id":18,"ws":true},{"text":"relief","start":91,"end":97,"id":19,"ws":true},{"text":"inhalations","start":98,"end":109,"id":20,"ws":true},{"text":"x","start":110,"end":111,"id":21,"ws":true},{"text":"day(-1","start":112,"end":118,"id":22,"ws":true},{"text":")","start":119,"end":120,"id":23,"ws":true},{"text":".","start":121,"end":122,"id":24,"ws":false}],"spans":[{"start":39,"end":49,"token_start":9,"token_end":9,"label":"DRUG"},{"start":79,"end":90,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12412676/","_input_hash":2081304222,"_task_hash":1766398299,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":9,"child":18,"head_span":{"start":39,"end":49,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":79,"end":90,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Preoperative chemotherapy with FLOT ( 5-FU , leucovorin , oxaliplatin and docetaxel ) without radiation therapy is the standard treatment in the West .","paragraph":"<h3><u>Advances in the treatment of gastric cancer: 2019.</u></h3>The aim of this study was to review studies published within the past year regarding management of gastric cancer. ### Recent Findings Laparoscopic gastrectomy achieves equivalent survival compared with open gastrectomy in early stage and locally advanced gastric cancer. Adjuvant chemotherapy with 6 months of S-1 and <b style='color:Tomato;'><i>oxaliplatin</i></b> was superior to 12 months of S-1, and the addition of postoperative radiation therapy did not improve survival. The FLOT regimen is the new standard for preoperative chemotherapy. In metastatic gastric cancer, the addition of <b style='color:Tomato;'><i>docetaxel</i></b> to S-1 and cisplatin failed to improve overall survival over two-drug chemotherapy. The addition of the immune checkpoint inhibitor <b style='color:Tomato;'><i>pembrolizumab</i></b> to chemotherapy failed to improve overall survival compared with chemotherapy alone. ### summary Laparoscopic gastrectomy is acceptable in early and locally advanced gastric cancer. Combination adjuvant chemotherapy is superior to S-1 monotherapy. Adjuvant radiation therapy after D2 gastrectomy for node-positive gastric cancer does not improve survival. <b style='color:DodgerBlue;'><i>Preoperative</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>FLOT</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>radiation</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>West</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Two-drug chemotherapy is the optimal initial treatment in metastatic disease. Adding <b style='color:Tomato;'><i>pembrolizumab</i></b> to front-line chemotherapy did not improve survival, with use of immune checkpoint inhibitors reserved to treat chemotherapy refractory metastatic disease.","tokens":[{"text":"Preoperative","start":0,"end":12,"id":0,"ws":true},{"text":"chemotherapy","start":13,"end":25,"id":1,"ws":true},{"text":"with","start":26,"end":30,"id":2,"ws":true},{"text":"FLOT","start":31,"end":35,"id":3,"ws":true},{"text":"(","start":36,"end":37,"id":4,"ws":true},{"text":"5-FU","start":38,"end":42,"id":5,"ws":true},{"text":",","start":43,"end":44,"id":6,"ws":true},{"text":"leucovorin","start":45,"end":55,"id":7,"ws":true},{"text":",","start":56,"end":57,"id":8,"ws":true},{"text":"oxaliplatin","start":58,"end":69,"id":9,"ws":true},{"text":"and","start":70,"end":73,"id":10,"ws":true},{"text":"docetaxel","start":74,"end":83,"id":11,"ws":true},{"text":")","start":84,"end":85,"id":12,"ws":true},{"text":"without","start":86,"end":93,"id":13,"ws":true},{"text":"radiation","start":94,"end":103,"id":14,"ws":true},{"text":"therapy","start":104,"end":111,"id":15,"ws":true},{"text":"is","start":112,"end":114,"id":16,"ws":true},{"text":"the","start":115,"end":118,"id":17,"ws":true},{"text":"standard","start":119,"end":127,"id":18,"ws":true},{"text":"treatment","start":128,"end":137,"id":19,"ws":true},{"text":"in","start":138,"end":140,"id":20,"ws":true},{"text":"the","start":141,"end":144,"id":21,"ws":true},{"text":"West","start":145,"end":149,"id":22,"ws":true},{"text":".","start":150,"end":151,"id":23,"ws":false}],"spans":[{"start":38,"end":42,"token_start":5,"token_end":5,"label":"DRUG"},{"start":45,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},{"start":58,"end":69,"token_start":9,"token_end":9,"label":"DRUG"},{"start":74,"end":83,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31436556/","_input_hash":-1036681752,"_task_hash":-943852634,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":38,"end":42,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":45,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":11,"head_span":{"start":58,"end":69,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":74,"end":83,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":7,"head_span":{"start":58,"end":69,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":45,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma : CALGB 50401 ( Alliance ) .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Randomized</i></b> <b style='color:DodgerBlue;'><i>Trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Lenalidomide</i></b> <b style='color:DodgerBlue;'><i>Alone</i></b> <b style='color:DodgerBlue;'><i>Versus</i></b> <b style='color:MediumOrchid;'><i>Lenalidomide</i></b> <b style='color:DodgerBlue;'><i>Plus</i></b> <b style='color:MediumOrchid;'><i>Rituximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:DodgerBlue;'><i>Recurrent</i></b> <b style='color:DodgerBlue;'><i>Follicular</i></b> <b style='color:DodgerBlue;'><i>Lymphoma</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>CALGB</i></b> <b style='color:DodgerBlue;'><i>50401</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Alliance</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>rituximab</i></b> (LR) are active agents in follicular lymphoma (FL). Combination regimens have not been previously assessed in randomized studies. ### Patients And Methods The Cancer and Leukemia Group B (Alliance) 50401 trial is a randomized phase II trial studying <b style='color:Tomato;'><i>rituximab</i></b> (375 mg/m(2) weekly for 4 weeks), <b style='color:Tomato;'><i>lenalidomide</i></b> (15 mg per day on days 1 to 21, followed by 7 days of rest, in cycle 1 and then 20 mg per day on days 1 to 21, followed by 7 days of rest, in cycles 2 to 12), or LR. The <b style='color:Tomato;'><i>rituximab</i></b>-alone arm was discontinued as a result of poor accrual. Eligibility included recurrent FL and prior <b style='color:Tomato;'><i>rituximab</i></b> with time to progression of \u2265 6 months from last dose. <b style='color:Tomato;'><i>aspirin</i></b> or <b style='color:Tomato;'><i>heparin</i></b> was recommended for patients at high thrombosis risk. ### results Ninety-one patients (<b style='color:Tomato;'><i>lenalidomide</i></b>, n = 45; LR, n = 46) received treatment; median age was 63 years (range, 34 to 89 years), and 58% were intermediate or high risk according to the Follicular Lymphoma International Prognostic Index. In the <b style='color:Tomato;'><i>lenalidomide</i></b> and LR arms, grade 3 to 4 adverse events occurred in 58% and 53% of patients, with 9% and 11% of patients experiencing grade 4 toxicity, respectively; grade 3 to 4 adverse events included neutropenia (16% v 20%, respectively), fatigue (9% v 13%, respectively), and thrombosis (16% [n = 7] v 4% [n = 2], respectively; P = .157). Thirty-six percent of <b style='color:Tomato;'><i>lenalidomide</i></b> patients and 63% of LR patients completed 12 cycles. <b style='color:Tomato;'><i>lenalidomide</i></b> alone was associated with more treatment failures, with 22% of patients discontinuing treatment as a result of adverse events. Dose-intensity exceeded 80% in both arms. Overall response rate was 53% (20% complete response) and 76% (39% complete response) for <b style='color:Tomato;'><i>lenalidomide</i></b> alone and LR, respectively (P = .029). At the median follow-up of 2.5 years, median time to progression was 1.1 year for <b style='color:Tomato;'><i>lenalidomide</i></b> alone and 2 years for LR (P = .0023). ### conclusion LR is more active than <b style='color:Tomato;'><i>lenalidomide</i></b> alone in recurrent FL with similar toxicity, warranting further study in B-cell non-Hodgkin lymphoma as a platform for addition of novel agents.","tokens":[{"text":"Randomized","start":0,"end":10,"id":0,"ws":true},{"text":"Trial","start":11,"end":16,"id":1,"ws":true},{"text":"of","start":17,"end":19,"id":2,"ws":true},{"text":"Lenalidomide","start":20,"end":32,"id":3,"ws":true},{"text":"Alone","start":33,"end":38,"id":4,"ws":true},{"text":"Versus","start":39,"end":45,"id":5,"ws":true},{"text":"Lenalidomide","start":46,"end":58,"id":6,"ws":true},{"text":"Plus","start":59,"end":63,"id":7,"ws":true},{"text":"Rituximab","start":64,"end":73,"id":8,"ws":true},{"text":"in","start":74,"end":76,"id":9,"ws":true},{"text":"Patients","start":77,"end":85,"id":10,"ws":true},{"text":"With","start":86,"end":90,"id":11,"ws":true},{"text":"Recurrent","start":91,"end":100,"id":12,"ws":true},{"text":"Follicular","start":101,"end":111,"id":13,"ws":true},{"text":"Lymphoma","start":112,"end":120,"id":14,"ws":true},{"text":":","start":121,"end":122,"id":15,"ws":true},{"text":"CALGB","start":123,"end":128,"id":16,"ws":true},{"text":"50401","start":129,"end":134,"id":17,"ws":true},{"text":"(","start":135,"end":136,"id":18,"ws":true},{"text":"Alliance","start":137,"end":145,"id":19,"ws":true},{"text":")","start":146,"end":147,"id":20,"ws":true},{"text":".","start":148,"end":149,"id":21,"ws":false}],"spans":[{"start":20,"end":32,"token_start":3,"token_end":3,"label":"DRUG"},{"start":46,"end":58,"token_start":6,"token_end":6,"label":"DRUG"},{"start":64,"end":73,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26304886/","_input_hash":-2053138454,"_task_hash":544291367,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":46,"end":58,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":64,"end":73,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis : implications for future clinical trials .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Potential</i></b> <b style='color:DodgerBlue;'><i>cost-effectiveness</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>rifampin</i></b> <b style='color:DodgerBlue;'><i>vs.</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>latent</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>implications</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>future</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Standard treatment for latent tuberculosis infection (LTBI) is 9 months daily <b style='color:Tomato;'><i>isoniazid</i></b> (9INH). An alternative is 4 months daily <b style='color:Tomato;'><i>rifampin</i></b> (4RMP), associated with better completion and less toxicity; however, its efficacy remains uncertain. ### objectives To assess the cost-effectiveness of these regimens for treating LTBI in human immunodeficiency virus negative persons, using results from a recent clinical trial, plus different scenarios for 4RMP efficacy, and to estimate the costs of an adequately powered noninferiority trial and resulting savings from substitution with 4RMP. ### design A decision-analysis model tracked TB contacts and lower-risk tuberculin reactors receiving 9INH, 4RMP or no treatment. For different 4RMP efficacy scenarios, we estimated the cost-effectiveness, sample size and cost of non-inferiority trials, and potential cost savings substituting 4RMP for 9INH for 10 years in Canada. ### results With an assumed 4RMP efficacy of 60%, 9INH was more effective but slightly more expensive. Above a threshold efficacy of 69%, 4RMP was cheaper and more effective than 9INH. If the true efficacy of 4RMP is \u226575%, a trial powered to detect non-inferiority with a lower limit of 60% estimated efficacy (~20 000 subjects) may lead to cost savings within 10 years, even with the extreme assumption that Canada bears the entire cost. ### conclusion 4RMP may be a reasonable alternative to 9INH. Costs of a large-scale non-inferiority trial may be offset by subsequent savings.","tokens":[{"text":"Potential","start":0,"end":9,"id":0,"ws":true},{"text":"cost-effectiveness","start":10,"end":28,"id":1,"ws":true},{"text":"of","start":29,"end":31,"id":2,"ws":true},{"text":"rifampin","start":32,"end":40,"id":3,"ws":true},{"text":"vs.","start":41,"end":44,"id":4,"ws":true},{"text":"isoniazid","start":45,"end":54,"id":5,"ws":true},{"text":"for","start":55,"end":58,"id":6,"ws":true},{"text":"latent","start":59,"end":65,"id":7,"ws":true},{"text":"tuberculosis","start":66,"end":78,"id":8,"ws":true},{"text":":","start":79,"end":80,"id":9,"ws":true},{"text":"implications","start":81,"end":93,"id":10,"ws":true},{"text":"for","start":94,"end":97,"id":11,"ws":true},{"text":"future","start":98,"end":104,"id":12,"ws":true},{"text":"clinical","start":105,"end":113,"id":13,"ws":true},{"text":"trials","start":114,"end":120,"id":14,"ws":true},{"text":".","start":121,"end":122,"id":15,"ws":false}],"spans":[{"start":32,"end":40,"token_start":3,"token_end":3,"label":"DRUG"},{"start":45,"end":54,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22283892/","_input_hash":965071236,"_task_hash":1293090769,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The third-generation aromatase inhibitors ( AIs ) , including anastrozole , exemestane and letrozole , have demonstrated improved efficacy versus tamoxifen for the adjuvant endocrine treatment of postmenopausal patients with hormone receptor-positive breast cancer .","paragraph":"<h3><u>Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>third-generation</i></b> <b style='color:DodgerBlue;'><i>aromatase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AIs</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>endocrine</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>hormone</i></b> <b style='color:DodgerBlue;'><i>receptor-positive</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> AIs can be used in several adjuvant endocrine settings: as upfront therapy, switch to an AI after 2-3years of <b style='color:Tomato;'><i>tamoxifen</i></b> or extended therapy following 5years of <b style='color:Tomato;'><i>tamoxifen</i></b>. In the switch setting, two different types of study designs have been utilized. One is a late randomization design which randomizes patients who are disease-free after 2-3years of <b style='color:Tomato;'><i>tamoxifen</i></b> to receive an AI versus continuation of <b style='color:Tomato;'><i>tamoxifen</i></b>. In contrast, an early randomization design randomizes all patients immediately after primary treatment and prior to starting <b style='color:Tomato;'><i>tamoxifen</i></b>. Efficacy benefits with AIs have been shown in several trials evaluating the late randomization strategy, including the Intergroup <b style='color:Tomato;'><i>exemestane</i></b> Study, the Italian <b style='color:Tomato;'><i>tamoxifen</i></b> <b style='color:Tomato;'><i>anastrozole</i></b> trial and the <b style='color:Tomato;'><i>anastrozole</i></b>-Nolvadex 95 trial. Similarly, early randomization studies, including the Austrian Breast and Colorectal Cancer Study Group-8 and the Breast International Group (BIG) 1-98 trial, have demonstrated the effectiveness of receiving an AI after <b style='color:Tomato;'><i>tamoxifen</i></b>. Two trials are assessing an early switch strategy versus upfront AI therapy: the BIG 1-98 trial and the ongoing <b style='color:Tomato;'><i>tamoxifen</i></b> <b style='color:Tomato;'><i>exemestane</i></b> Adjuvant Multicentre trial are assessing switching from <b style='color:Tomato;'><i>tamoxifen</i></b> to an AI after 2-3years versus upfront AI therapy. This paper reviews studies that have investigated a switch strategy with AIs and considers the implications of these data on treatment choice for postmenopausal patients with hormone receptor-positive breast cancer.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"third-generation","start":4,"end":20,"id":1,"ws":true},{"text":"aromatase","start":21,"end":30,"id":2,"ws":true},{"text":"inhibitors","start":31,"end":41,"id":3,"ws":true},{"text":"(","start":42,"end":43,"id":4,"ws":true},{"text":"AIs","start":44,"end":47,"id":5,"ws":true},{"text":")","start":48,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"including","start":52,"end":61,"id":8,"ws":true},{"text":"anastrozole","start":62,"end":73,"id":9,"ws":true},{"text":",","start":74,"end":75,"id":10,"ws":true},{"text":"exemestane","start":76,"end":86,"id":11,"ws":true},{"text":"and","start":87,"end":90,"id":12,"ws":true},{"text":"letrozole","start":91,"end":100,"id":13,"ws":true},{"text":",","start":101,"end":102,"id":14,"ws":true},{"text":"have","start":103,"end":107,"id":15,"ws":true},{"text":"demonstrated","start":108,"end":120,"id":16,"ws":true},{"text":"improved","start":121,"end":129,"id":17,"ws":true},{"text":"efficacy","start":130,"end":138,"id":18,"ws":true},{"text":"versus","start":139,"end":145,"id":19,"ws":true},{"text":"tamoxifen","start":146,"end":155,"id":20,"ws":true},{"text":"for","start":156,"end":159,"id":21,"ws":true},{"text":"the","start":160,"end":163,"id":22,"ws":true},{"text":"adjuvant","start":164,"end":172,"id":23,"ws":true},{"text":"endocrine","start":173,"end":182,"id":24,"ws":true},{"text":"treatment","start":183,"end":192,"id":25,"ws":true},{"text":"of","start":193,"end":195,"id":26,"ws":true},{"text":"postmenopausal","start":196,"end":210,"id":27,"ws":true},{"text":"patients","start":211,"end":219,"id":28,"ws":true},{"text":"with","start":220,"end":224,"id":29,"ws":true},{"text":"hormone","start":225,"end":232,"id":30,"ws":true},{"text":"receptor-positive","start":233,"end":250,"id":31,"ws":true},{"text":"breast","start":251,"end":257,"id":32,"ws":true},{"text":"cancer","start":258,"end":264,"id":33,"ws":true},{"text":".","start":265,"end":266,"id":34,"ws":false}],"spans":[{"start":62,"end":73,"token_start":9,"token_end":9,"label":"DRUG"},{"start":76,"end":86,"token_start":11,"token_end":11,"label":"DRUG"},{"start":91,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},{"start":146,"end":155,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19944537/","_input_hash":-1183619449,"_task_hash":1605091716,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway .","paragraph":"<h3><u><b style='color:MediumOrchid;'><i>Digoxin</i></b> <b style='color:DodgerBlue;'><i>sensitizes</i></b> <b style='color:DodgerBlue;'><i>gemcitabine-resistant</i></b> <b style='color:DodgerBlue;'><i>pancreatic</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>via</i></b> <b style='color:DodgerBlue;'><i>inhibiting</i></b> <b style='color:DodgerBlue;'><i>Nrf2</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathway</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Chemoresistance is a major therapeutic obstacle in the treatment of human pancreatic ductal adenocarcinoma (PDAC). As an oxidative stress responsive transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) regulates the expression of cytoprotective genes. Nrf2 not only plays a critical role in chemoprevention, but also contributes to chemoresistance. In this study, we found that <b style='color:Tomato;'><i>digoxin</i></b> markedly reversed drug resistance of <b style='color:Tomato;'><i>gemcitabine</i></b> by inhibiting Nrf2 signaling in SW1990/Gem and Panc-1/Gem cells. Further research revealed that <b style='color:Tomato;'><i>digoxin</i></b> regulated Nrf2 at transcriptional level. In in vivo study, we found that <b style='color:Tomato;'><i>digoxin</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> in combination inhibited tumor growth more substantially when compared with <b style='color:Tomato;'><i>gemcitabine</i></b> treatment alone in SW1990/Gem-shControl cells-derived xenografts. In the meantime, SW1990/Gem-shNrf2 cells-derived xenografts responded to <b style='color:Tomato;'><i>gemcitabine</i></b> and combination treatment similarly, suggesting that <b style='color:Tomato;'><i>digoxin</i></b> sensitized <b style='color:Tomato;'><i>gemcitabine</i></b>-resistant human pancreatic cancer to <b style='color:Tomato;'><i>gemcitabine</i></b>, which was Nrf2 dependent. These results demonstrated that <b style='color:Tomato;'><i>digoxin</i></b> might be used as a promising adjuvant sensitizer to reverse chemoresistance of <b style='color:Tomato;'><i>gemcitabine</i></b>-resistant pancreatic cancer to <b style='color:Tomato;'><i>gemcitabine</i></b> via inhibiting Nrf2 signaling.","tokens":[{"text":"Digoxin","start":0,"end":7,"id":0,"ws":true},{"text":"sensitizes","start":8,"end":18,"id":1,"ws":true},{"text":"gemcitabine-resistant","start":19,"end":40,"id":2,"ws":true},{"text":"pancreatic","start":41,"end":51,"id":3,"ws":true},{"text":"cancer","start":52,"end":58,"id":4,"ws":true},{"text":"cells","start":59,"end":64,"id":5,"ws":true},{"text":"to","start":65,"end":67,"id":6,"ws":true},{"text":"gemcitabine","start":68,"end":79,"id":7,"ws":true},{"text":"via","start":80,"end":83,"id":8,"ws":true},{"text":"inhibiting","start":84,"end":94,"id":9,"ws":true},{"text":"Nrf2","start":95,"end":99,"id":10,"ws":true},{"text":"signaling","start":100,"end":109,"id":11,"ws":true},{"text":"pathway","start":110,"end":117,"id":12,"ws":true},{"text":".","start":118,"end":119,"id":13,"ws":false}],"spans":[{"start":0,"end":7,"token_start":0,"token_end":0,"label":"DRUG"},{"start":68,"end":79,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30735911/","_input_hash":113902591,"_task_hash":1162244214,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":0,"child":7,"head_span":{"start":0,"end":7,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":68,"end":79,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Tumor suppression was further enhanced when rapamycin was combined with 5-fluorouracil and/or oxaliplatin .","paragraph":"<h3><u>Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.</u></h3>The mTOR-inhibitor <b style='color:Tomato;'><i>rapamycin</i></b> has shown antitumor activity in various tumors. Bedside observations have suggested that <b style='color:Tomato;'><i>rapamycin</i></b> may be effective as a treatment for colorectal carcinomatosis. ### methods We established an orthotopic syngenic model by transplanting CT26 peritoneal tumors in Balb/C mice and an orthotopic xenograft model by transplanting SW620 peritoneal tumors in nu/nu mice. Expression levels of tissue inhibitor of matrix-metalloproteinases 1 (TIMP-1) in the tumor and serum was determined by enzyme-linked immunosorbent assay. ### results <b style='color:Tomato;'><i>rapamycin</i></b> significantly suppressed growth of syngenic and xenografted peritoneal tumors. The effect was similar with intraperitoneal or oral <b style='color:Tomato;'><i>rapamycin</i></b> administration. <b style='color:DodgerBlue;'><i>Tumor</i></b> <b style='color:DodgerBlue;'><i>suppression</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>enhanced</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination treatment showed no acute toxicity. TIMP-1 serum levels correlated well (CC = 0.75; P < 0.01) with <b style='color:Tomato;'><i>rapamycin</i></b> treatment. ### conclusions <b style='color:Tomato;'><i>rapamycin</i></b> suppressed advanced stage colorectal cancer, even with oral administration. Combining <b style='color:Tomato;'><i>rapamycin</i></b> with current chemotherapy regimens significantly increased antitumor efficacy without apparent toxicity. The treatment efficacy correlated with serum TIMP-1 levels, suggesting its potential as a surrogate marker in future clinical trials.","tokens":[{"text":"Tumor","start":0,"end":5,"id":0,"ws":true},{"text":"suppression","start":6,"end":17,"id":1,"ws":true},{"text":"was","start":18,"end":21,"id":2,"ws":true},{"text":"further","start":22,"end":29,"id":3,"ws":true},{"text":"enhanced","start":30,"end":38,"id":4,"ws":true},{"text":"when","start":39,"end":43,"id":5,"ws":true},{"text":"rapamycin","start":44,"end":53,"id":6,"ws":true},{"text":"was","start":54,"end":57,"id":7,"ws":true},{"text":"combined","start":58,"end":66,"id":8,"ws":true},{"text":"with","start":67,"end":71,"id":9,"ws":true},{"text":"5-fluorouracil","start":72,"end":86,"id":10,"ws":true},{"text":"and/or","start":87,"end":93,"id":11,"ws":true},{"text":"oxaliplatin","start":94,"end":105,"id":12,"ws":true},{"text":".","start":106,"end":107,"id":13,"ws":false}],"spans":[{"start":44,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},{"start":72,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},{"start":94,"end":105,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19565301/","_input_hash":1666208349,"_task_hash":1880882230,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":6,"child":10,"head_span":{"start":44,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":72,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":6,"child":12,"head_span":{"start":44,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":94,"end":105,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":10,"child":12,"head_span":{"start":72,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":94,"end":105,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"These structural motifs represent typical azoles , such as econazole , fluconazole , and metyrapone .","paragraph":"<h3><u>How do azoles inhibit cytochrome P450 enzymes? A density functional study.</u></h3>To examine how azole inhibitors interact with the heme active site of the cytochrome P450 enzymes, we have performed a series of density functional theory studies on azole binding. These are the first density functional studies on azole interactions with a heme center and give fundamental insight into how azoles inhibit the catalytic function of P450 enzymes. Since azoles come in many varieties, we tested three typical azole motifs representing a broad range of azole and azole-type inhibitors: methylimidazolate, methyltriazolate, and pyridine. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>structural</i></b> <b style='color:DodgerBlue;'><i>motifs</i></b> <b style='color:DodgerBlue;'><i>represent</i></b> <b style='color:DodgerBlue;'><i>typical</i></b> <b style='color:DodgerBlue;'><i>azoles</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>econazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>fluconazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metyrapone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The calculations show that azole binding is a stepwise mechanism whereby first the water molecule from the resting state of P450 is released from the sixth binding site of the heme to create a pentacoordinated active site followed by coordination of the azole nitrogen to the heme iron. This process leads to the breaking of a hydrogen bond between the resting state water molecule and the approaching inhibitor molecule. Although, formally, the water molecule is released in the first step of the reaction mechanism and a pentacoordinated heme is created, this does not lead to an observed spin state crossing. Thus, we show that release of a water molecule from the resting state of P450 enzymes to create a pentacoordinated heme will lead to a doublet to quartet spin state crossing at an Fe-OH(2) distance of approximately 3.0 A, while the azole substitution process takes place at shorter distances. Azoles bind heme with significantly stronger binding energies than a water molecule, so that these inhibitors block the catalytic cycle of the enzyme and prevent oxygen binding and the catalysis of substrate oxidation. Perturbations within the active site (e.g., a polarized environment) have little effect on the relative energies of azole binding. Studies with an extra hydrogen-bonded ethanol molecule in the model, mimicking the active site of the CYP121 P450, show that the resting state and azole binding structures are close in energy, which may lead to chemical equilibrium between the two structures, as indeed observed with recent protein structural studies that have demonstrated two distinct azole binding mechanisms to P450 heme.","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"structural","start":6,"end":16,"id":1,"ws":true},{"text":"motifs","start":17,"end":23,"id":2,"ws":true},{"text":"represent","start":24,"end":33,"id":3,"ws":true},{"text":"typical","start":34,"end":41,"id":4,"ws":true},{"text":"azoles","start":42,"end":48,"id":5,"ws":true},{"text":",","start":49,"end":50,"id":6,"ws":true},{"text":"such","start":51,"end":55,"id":7,"ws":true},{"text":"as","start":56,"end":58,"id":8,"ws":true},{"text":"econazole","start":59,"end":68,"id":9,"ws":true},{"text":",","start":69,"end":70,"id":10,"ws":true},{"text":"fluconazole","start":71,"end":82,"id":11,"ws":true},{"text":",","start":83,"end":84,"id":12,"ws":true},{"text":"and","start":85,"end":88,"id":13,"ws":true},{"text":"metyrapone","start":89,"end":99,"id":14,"ws":true},{"text":".","start":100,"end":101,"id":15,"ws":false}],"spans":[{"start":59,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},{"start":71,"end":82,"token_start":11,"token_end":11,"label":"DRUG"},{"start":89,"end":99,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18563875/","_input_hash":-1596635366,"_task_hash":2108069580,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The present systematic review and network meta-analysis was performed to conduct indirect comparisons on efficacy and safety profile among ICIs , including atezolizumab , durvalumab , pembrolizumab , and nivolumab as first-line treatment in patients with ES-SCLC .","paragraph":"<h3><u>Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.</u></h3>In recent years, immune checkpoint inhibitors (ICIs) including <b style='color:Tomato;'><i>atezolizumab</i></b>, <b style='color:Tomato;'><i>durvalumab</i></b>, <b style='color:Tomato;'><i>pembrolizumab</i></b>, and <b style='color:Tomato;'><i>nivolumab</i></b> have reported their efficacy and safety profile in patients with extensive-stage small cell lung cancer (ES-SCLC). However, given the diverse efficacy and inconsistent safety among the ICIs, with the absence of head-to-head researches designed to evaluate the efficacy among them, it might bring with confusion on selection in clinical practice. ### objectives <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>systematic</i></b> <b style='color:DodgerBlue;'><i>review</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>network</i></b> <b style='color:DodgerBlue;'><i>meta-analysis</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>conduct</i></b> <b style='color:DodgerBlue;'><i>indirect</i></b> <b style='color:DodgerBlue;'><i>comparisons</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>profile</i></b> <b style='color:DodgerBlue;'><i>among</i></b> <b style='color:DodgerBlue;'><i>ICIs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>atezolizumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>durvalumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ES-SCLC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### design Several databases were retrieved with established criteria until June 20, 2020, with the main MeSH Terms and their similarities. Hazard ratios of overall survival (OS) and progression-free survival (PFS), odds ratios (ORs) of disease control rate (DCR), objective response rate (ORR), and adverse events (AEs) were compared indirectly with network meta-analysis. ### Data Sources Medline, Cochrane library, and Embase. ### Eligibility Criteria Prospective, randomized, controlled clinical studies, which reported PFS, OS, and AEs. ### Data Extraction And Synthesis Clinical characteristics were extracted by the 2 authors independently. Comparisons of HRs were calculated for PFS and OS by random effect model. ORR, DCR, and AEs were presented with ORs. Based on surface under the cumulative ranking curve, and forest plots, efficacy and safety of the treatments were ranked, with predicted histogram described. ### results In total, there were 4 studies including 1547 patients who met the eligibility criteria and enrolled. For indirect comparisons, no significant difference on PFS was observed between <b style='color:Tomato;'><i>atezolizumab</i></b> and <b style='color:Tomato;'><i>durvalumab</i></b> (HR 0.96, 95% CI, 0.72-1.29), or between <b style='color:Tomato;'><i>atezolizumab</i></b> and <b style='color:Tomato;'><i>pembrolizumab</i></b> (HR 1.05, 95% CI, 0.78-1.43), or between <b style='color:Tomato;'><i>atezolizumab</i></b> and <b style='color:Tomato;'><i>nivolumab</i></b> (HR 1.18, 95% CI, 0.79-1.79), or between <b style='color:Tomato;'><i>durvalumab</i></b> and <b style='color:Tomato;'><i>pembrolizumab</i></b> (HR 1.10, 95% CI, 0.84-1.43). or between <b style='color:Tomato;'><i>durvalumab</i></b> and <b style='color:Tomato;'><i>nivolumab</i></b> (HR 1.23, 95% CI, 0.83-1.82), or between <b style='color:Tomato;'><i>pembrolizumab</i></b> and <b style='color:Tomato;'><i>nivolumab</i></b> (HR 1.12, 95% CI, 0.76-1.66), nor significant difference on OS observed between <b style='color:Tomato;'><i>atezolizumab</i></b> and <b style='color:Tomato;'><i>durvalumab</i></b> (HR 0.93, 95% CI, 0.67-1.30), or between <b style='color:Tomato;'><i>atezolizumab</i></b> and <b style='color:Tomato;'><i>pembrolizumab</i></b> (HR 0.88, 95% CI, 0.62-1.24), or between <b style='color:Tomato;'><i>atezolizumab</i></b> and <b style='color:Tomato;'><i>nivolumab</i></b> (HR 1.04, 95% CI, 0.66-1.66), or between <b style='color:Tomato;'><i>durvalumab</i></b> and <b style='color:Tomato;'><i>pembrolizumab</i></b> (HR 0.94, 95% CI, 0.70-1.25), or between <b style='color:Tomato;'><i>durvalumab</i></b> and <b style='color:Tomato;'><i>nivolumab</i></b> (HR 1.12, 95% CI, 0.73-1.71), or between <b style='color:Tomato;'><i>pembrolizumab</i></b> and <b style='color:Tomato;'><i>nivolumab</i></b> (HR 1.19, 95% CI, 0.77-1.84). However, <b style='color:Tomato;'><i>durvalumab</i></b> was shown statistical superiority on ORR when compared with <b style='color:Tomato;'><i>atezolizumab</i></b> (HR 0.79, 95% CI, 0.64-0.98), also with significantly higher risk on immune-related AEs when compared with <b style='color:Tomato;'><i>atezolizumab</i></b> (OR 0.22, 95% CI, 0.10-0.50), and <b style='color:Tomato;'><i>pembrolizumab</i></b> (OR 3.12, 95% CI, 1.27-7.64). ### conclusions Results of the study revealed that there was no statistical difference on PFS or OS among agents of <b style='color:Tomato;'><i>atezolizumab</i></b>, <b style='color:Tomato;'><i>durvalumab</i></b>, <b style='color:Tomato;'><i>pembrolizumab</i></b>, and <b style='color:Tomato;'><i>nivolumab</i></b> as first-line treatment in patients with ES-SCLC. However, <b style='color:Tomato;'><i>durvalumab</i></b> was shown superiority on ORR when compared with <b style='color:Tomato;'><i>atezolizumab</i></b>, also with significantly higher risk on immune-related AEs.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"present","start":4,"end":11,"id":1,"ws":true},{"text":"systematic","start":12,"end":22,"id":2,"ws":true},{"text":"review","start":23,"end":29,"id":3,"ws":true},{"text":"and","start":30,"end":33,"id":4,"ws":true},{"text":"network","start":34,"end":41,"id":5,"ws":true},{"text":"meta-analysis","start":42,"end":55,"id":6,"ws":true},{"text":"was","start":56,"end":59,"id":7,"ws":true},{"text":"performed","start":60,"end":69,"id":8,"ws":true},{"text":"to","start":70,"end":72,"id":9,"ws":true},{"text":"conduct","start":73,"end":80,"id":10,"ws":true},{"text":"indirect","start":81,"end":89,"id":11,"ws":true},{"text":"comparisons","start":90,"end":101,"id":12,"ws":true},{"text":"on","start":102,"end":104,"id":13,"ws":true},{"text":"efficacy","start":105,"end":113,"id":14,"ws":true},{"text":"and","start":114,"end":117,"id":15,"ws":true},{"text":"safety","start":118,"end":124,"id":16,"ws":true},{"text":"profile","start":125,"end":132,"id":17,"ws":true},{"text":"among","start":133,"end":138,"id":18,"ws":true},{"text":"ICIs","start":139,"end":143,"id":19,"ws":true},{"text":",","start":144,"end":145,"id":20,"ws":true},{"text":"including","start":146,"end":155,"id":21,"ws":true},{"text":"atezolizumab","start":156,"end":168,"id":22,"ws":true},{"text":",","start":169,"end":170,"id":23,"ws":true},{"text":"durvalumab","start":171,"end":181,"id":24,"ws":true},{"text":",","start":182,"end":183,"id":25,"ws":true},{"text":"pembrolizumab","start":184,"end":197,"id":26,"ws":true},{"text":",","start":198,"end":199,"id":27,"ws":true},{"text":"and","start":200,"end":203,"id":28,"ws":true},{"text":"nivolumab","start":204,"end":213,"id":29,"ws":true},{"text":"as","start":214,"end":216,"id":30,"ws":true},{"text":"first-line","start":217,"end":227,"id":31,"ws":true},{"text":"treatment","start":228,"end":237,"id":32,"ws":true},{"text":"in","start":238,"end":240,"id":33,"ws":true},{"text":"patients","start":241,"end":249,"id":34,"ws":true},{"text":"with","start":250,"end":254,"id":35,"ws":true},{"text":"ES-SCLC","start":255,"end":262,"id":36,"ws":true},{"text":".","start":263,"end":264,"id":37,"ws":false}],"spans":[{"start":156,"end":168,"token_start":22,"token_end":22,"label":"DRUG"},{"start":171,"end":181,"token_start":24,"token_end":24,"label":"DRUG"},{"start":184,"end":197,"token_start":26,"token_end":26,"label":"DRUG"},{"start":204,"end":213,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33847617/","_input_hash":1960876169,"_task_hash":-776997284,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Treatments included once daily erlotinib , which was given alone for the first 7 days of treatments , then in combination with once daily sirolimus .","paragraph":"<h3><u>A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.</u></h3>In order to achieve higher dosages than previously used in clinical trials, we conducted a phase I trial to determine the maximum tolerated dose (MTD) for the combination of <b style='color:Tomato;'><i>erlotinib</i></b> and <b style='color:Tomato;'><i>sirolimus</i></b> for the treatments of recurrent malignant gliomas. Patients with pathologically proven World Health Organization (WHO) grade III glioma and grade IV glioblastoma and radiographically proven tumor recurrence were eligible for this study. <b style='color:DodgerBlue;'><i>Treatments</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatments</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>then</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:MediumOrchid;'><i>sirolimus</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>sirolimus</i></b> was given with a loading dose on day 8 followed by a maintenance dose starting on day 9. Dose-limiting toxicity (DLT) was determined over the first 28 days of treatments, and the MTD was determined in a 3 + 3 classic study design. 19 patients were enrolled, and 13 patients were eligible for MTD determination. The MTD was determined to be 150 mg daily for <b style='color:Tomato;'><i>erlotinib</i></b> and 5 mg daily (after a 15 mg loading dose) for <b style='color:Tomato;'><i>sirolimus</i></b>. The DLTs included rash and mucositis (despite maximal medical managements), hypophosphatemia, altered mental status, and neutropenia. The combination of <b style='color:Tomato;'><i>erlotinib</i></b> and <b style='color:Tomato;'><i>sirolimus</i></b> is difficult to tolerate at dosages higher than previously reported in phase II trials.","tokens":[{"text":"Treatments","start":0,"end":10,"id":0,"ws":true},{"text":"included","start":11,"end":19,"id":1,"ws":true},{"text":"once","start":20,"end":24,"id":2,"ws":true},{"text":"daily","start":25,"end":30,"id":3,"ws":true},{"text":"erlotinib","start":31,"end":40,"id":4,"ws":true},{"text":",","start":41,"end":42,"id":5,"ws":true},{"text":"which","start":43,"end":48,"id":6,"ws":true},{"text":"was","start":49,"end":52,"id":7,"ws":true},{"text":"given","start":53,"end":58,"id":8,"ws":true},{"text":"alone","start":59,"end":64,"id":9,"ws":true},{"text":"for","start":65,"end":68,"id":10,"ws":true},{"text":"the","start":69,"end":72,"id":11,"ws":true},{"text":"first","start":73,"end":78,"id":12,"ws":true},{"text":"7","start":79,"end":80,"id":13,"ws":true},{"text":"days","start":81,"end":85,"id":14,"ws":true},{"text":"of","start":86,"end":88,"id":15,"ws":true},{"text":"treatments","start":89,"end":99,"id":16,"ws":true},{"text":",","start":100,"end":101,"id":17,"ws":true},{"text":"then","start":102,"end":106,"id":18,"ws":true},{"text":"in","start":107,"end":109,"id":19,"ws":true},{"text":"combination","start":110,"end":121,"id":20,"ws":true},{"text":"with","start":122,"end":126,"id":21,"ws":true},{"text":"once","start":127,"end":131,"id":22,"ws":true},{"text":"daily","start":132,"end":137,"id":23,"ws":true},{"text":"sirolimus","start":138,"end":147,"id":24,"ws":true},{"text":".","start":148,"end":149,"id":25,"ws":false}],"spans":[{"start":31,"end":40,"token_start":4,"token_end":4,"label":"DRUG"},{"start":138,"end":147,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22918789/","_input_hash":-139977506,"_task_hash":-1888720374,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":4,"child":24,"head_span":{"start":31,"end":40,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":138,"end":147,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Cabazitaxel effectively killed PC-3R cells , and MDR1 knockdown improved the sensitivity of PC-3R cells to docetaxel but not to cabazitaxel .","paragraph":"<h3><u>Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.</u></h3><b style='color:Tomato;'><i>docetaxel</i></b> is used as the first-line chemotherapy for castration-resistant prostate cancer (CRPC), but <b style='color:Tomato;'><i>docetaxel</i></b> resistance occurs in part owing to induction of P-glycoprotein (P-gp) encoded by multidrug resistance protein 1 (MDR1) gene. A recently developed taxane-<b style='color:Tomato;'><i>cabazitaxel</i></b>-has poor affinity for P-gp and is thereby effective in <b style='color:Tomato;'><i>docetaxel</i></b>-resistant CRPC. It has been recently demonstrated that exosomes in the body fluids could serve as a diagnostic marker because they contain proteins and RNAs specific to the cells from which they are derived. In this study, we aimed to investigate if P-gp in blood exosomes could be a marker to diagnose <b style='color:Tomato;'><i>docetaxel</i></b> resistance and select a taxoid for patients with CRPC. ### Methods And Materials Exosomes were isolated by differential centrifugation from <b style='color:Tomato;'><i>docetaxel</i></b>-resistant prostate cancer (PC-3) cells (PC-3R) and their parental PC-3 cells and from the serum of patients. Silencing of P-gp was performed by small interfering RNA transfection. Protein expression was examined by Western blot analysis. Viability of cells treated with <b style='color:Tomato;'><i>docetaxel</i></b> or <b style='color:Tomato;'><i>cabazitaxel</i></b> was determined by water soluble tetrazolium salt (WST) assay. ### results The level of P-gp was higher in exosomes as well as cell lysates from PC-3R cells than in those from PC-3 cells. <b style='color:MediumOrchid;'><i>Cabazitaxel</i></b> <b style='color:DodgerBlue;'><i>effectively</i></b> <b style='color:DodgerBlue;'><i>killed</i></b> <b style='color:DodgerBlue;'><i>PC-3R</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDR1</i></b> <b style='color:DodgerBlue;'><i>knockdown</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>sensitivity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>PC-3R</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>cabazitaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The P-gp level in blood exosomes was relatively higher in clinically <b style='color:Tomato;'><i>docetaxel</i></b>-resistant patients than in therapy-na\u00efve patients. ### conclusions Our results suggest that detection of P-gp in blood exosomes, which is involved in resistance to <b style='color:Tomato;'><i>docetaxel</i></b> but not to <b style='color:Tomato;'><i>cabazitaxel</i></b>, could be useful to diagnose <b style='color:Tomato;'><i>docetaxel</i></b> resistance and select an appropriate taxoid for patients with CRPC-<b style='color:Tomato;'><i>docetaxel</i></b> or <b style='color:Tomato;'><i>cabazitaxel</i></b>.","tokens":[{"text":"Cabazitaxel","start":0,"end":11,"id":0,"ws":true},{"text":"effectively","start":12,"end":23,"id":1,"ws":true},{"text":"killed","start":24,"end":30,"id":2,"ws":true},{"text":"PC-3R","start":31,"end":36,"id":3,"ws":true},{"text":"cells","start":37,"end":42,"id":4,"ws":true},{"text":",","start":43,"end":44,"id":5,"ws":true},{"text":"and","start":45,"end":48,"id":6,"ws":true},{"text":"MDR1","start":49,"end":53,"id":7,"ws":true},{"text":"knockdown","start":54,"end":63,"id":8,"ws":true},{"text":"improved","start":64,"end":72,"id":9,"ws":true},{"text":"the","start":73,"end":76,"id":10,"ws":true},{"text":"sensitivity","start":77,"end":88,"id":11,"ws":true},{"text":"of","start":89,"end":91,"id":12,"ws":true},{"text":"PC-3R","start":92,"end":97,"id":13,"ws":true},{"text":"cells","start":98,"end":103,"id":14,"ws":true},{"text":"to","start":104,"end":106,"id":15,"ws":true},{"text":"docetaxel","start":107,"end":116,"id":16,"ws":true},{"text":"but","start":117,"end":120,"id":17,"ws":true},{"text":"not","start":121,"end":124,"id":18,"ws":true},{"text":"to","start":125,"end":127,"id":19,"ws":true},{"text":"cabazitaxel","start":128,"end":139,"id":20,"ws":true},{"text":".","start":140,"end":141,"id":21,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":107,"end":116,"token_start":16,"token_end":16,"label":"DRUG"},{"start":128,"end":139,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26027763/","_input_hash":2074706082,"_task_hash":-1323763211,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The results suggest that rational therapy for severe CHF includes addition of the aldosterone antagonist spironolactone to low doses of captopril ( or another ACE inhibitor ) and high doses of loop diuretics , provided renal function is adequate .","paragraph":"<h3><u>Captopril and spironolactone therapy for refractory congestive heart failure.</u></h3>Short- and long-term clinical effects of the angiotensin-converting enzyme (ACE) inhibitor <b style='color:Tomato;'><i>captopril</i></b> in severe congestive heart failure (CHF) were evaluated during a 3-year open study of 124 inpatients with New York Heart Association (NYHA) functional class III or IV CHF refractory to treatment with cardiac glycosides and high doses of loop diuretics. <b style='color:Tomato;'><i>captopril</i></b> was added to each patient's regimen, which comprised combinations of <b style='color:Tomato;'><i>furosemide</i></b> (124 patients), digitalis (117 patients), and <b style='color:Tomato;'><i>spironolactone</i></b> (90 patients). By the end of the first month of <b style='color:Tomato;'><i>captopril</i></b> administration, improvement in NYHA functional class was seen in 89 patients (72%). During the first year of <b style='color:Tomato;'><i>captopril</i></b> treatment, the number of hospital admissions and hospital days declined significantly (p < 0.001) and functional class improved significantly (p < 0.001). Although most patients tolerated <b style='color:Tomato;'><i>captopril</i></b> well, 44% experienced hypotension, which in 10% of patients necessitated termination of <b style='color:Tomato;'><i>captopril</i></b> therapy. Although mean serum potassium levels tended to increase, serious hyperkalemia did not occur. After 1 year, a subset of 30 patients who had not initially received <b style='color:Tomato;'><i>spironolactone</i></b> deteriorated clinically and manifested increasing urinary aldosterone levels. Hypotension precluded increasing the <b style='color:Tomato;'><i>captopril</i></b> dose, but introduction of <b style='color:Tomato;'><i>spironolactone</i></b> improved clinical status in this cohort. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>rational</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>CHF</i></b> <b style='color:DodgerBlue;'><i>includes</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>aldosterone</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:MediumOrchid;'><i>spironolactone</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>low</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>another</i></b> <b style='color:DodgerBlue;'><i>ACE</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>loop</i></b> <b style='color:DodgerBlue;'><i>diuretics</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>provided</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>function</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>adequate</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"results","start":4,"end":11,"id":1,"ws":true},{"text":"suggest","start":12,"end":19,"id":2,"ws":true},{"text":"that","start":20,"end":24,"id":3,"ws":true},{"text":"rational","start":25,"end":33,"id":4,"ws":true},{"text":"therapy","start":34,"end":41,"id":5,"ws":true},{"text":"for","start":42,"end":45,"id":6,"ws":true},{"text":"severe","start":46,"end":52,"id":7,"ws":true},{"text":"CHF","start":53,"end":56,"id":8,"ws":true},{"text":"includes","start":57,"end":65,"id":9,"ws":true},{"text":"addition","start":66,"end":74,"id":10,"ws":true},{"text":"of","start":75,"end":77,"id":11,"ws":true},{"text":"the","start":78,"end":81,"id":12,"ws":true},{"text":"aldosterone","start":82,"end":93,"id":13,"ws":true},{"text":"antagonist","start":94,"end":104,"id":14,"ws":true},{"text":"spironolactone","start":105,"end":119,"id":15,"ws":true},{"text":"to","start":120,"end":122,"id":16,"ws":true},{"text":"low","start":123,"end":126,"id":17,"ws":true},{"text":"doses","start":127,"end":132,"id":18,"ws":true},{"text":"of","start":133,"end":135,"id":19,"ws":true},{"text":"captopril","start":136,"end":145,"id":20,"ws":true},{"text":"(","start":146,"end":147,"id":21,"ws":true},{"text":"or","start":148,"end":150,"id":22,"ws":true},{"text":"another","start":151,"end":158,"id":23,"ws":true},{"text":"ACE","start":159,"end":162,"id":24,"ws":true},{"text":"inhibitor","start":163,"end":172,"id":25,"ws":true},{"text":")","start":173,"end":174,"id":26,"ws":true},{"text":"and","start":175,"end":178,"id":27,"ws":true},{"text":"high","start":179,"end":183,"id":28,"ws":true},{"text":"doses","start":184,"end":189,"id":29,"ws":true},{"text":"of","start":190,"end":192,"id":30,"ws":true},{"text":"loop","start":193,"end":197,"id":31,"ws":true},{"text":"diuretics","start":198,"end":207,"id":32,"ws":true},{"text":",","start":208,"end":209,"id":33,"ws":true},{"text":"provided","start":210,"end":218,"id":34,"ws":true},{"text":"renal","start":219,"end":224,"id":35,"ws":true},{"text":"function","start":225,"end":233,"id":36,"ws":true},{"text":"is","start":234,"end":236,"id":37,"ws":true},{"text":"adequate","start":237,"end":245,"id":38,"ws":true},{"text":".","start":246,"end":247,"id":39,"ws":false}],"spans":[{"start":105,"end":119,"token_start":15,"token_end":15,"label":"DRUG"},{"start":136,"end":145,"token_start":20,"token_end":20,"label":"DRUG"},{"start":193,"end":207,"token_start":31,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8422001/","_input_hash":502076918,"_task_hash":-2120561096,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":15,"child":20,"head_span":{"start":105,"end":119,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":136,"end":145,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":20,"child":32,"head_span":{"start":136,"end":145,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":193,"end":207,"token_start":31,"token_end":32,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The MICs of erythromycin and clindamycin for most of the LAB were within the normal range of susceptibility .","paragraph":"<h3><u>Antibiotic resistance in lactic acid bacteria isolated from some pharmaceutical and dairy products.</u></h3>A total of 244 lactic acid bacteria (LAB) strains were isolated from 180 dairy and pharmaceutical products that were collected from different areas in Minia governorate, Egypt. LAB were identified phenotypically on basis of morphological, physiological and biochemical characteristics. Lactobacillus isolates were further confirmed using PCR-based assay. By combination of phenotypic with molecular identification Lactobacillus spp. were found to be the dominant genus (138, 76.7%) followed by Streptococcus spp. (65, 36.1%) and Lactococcus spp. (27, 15%). Some contaminant organisms such as (Staphylococcus spp., Escherichia coli, Salmonella spp., mould and yeast) were isolated from the collected dairy samples but pharmaceutical products were free of such contaminants. Susceptibility of LAB isolates to antibiotics representing all major classes was tested by agar dilution method. Generally, LAB were highly susceptible to Beta-lactams except penicillin. Lactobacilli were resistant to <b style='color:Tomato;'><i>vancomycin</i></b>, however lactococci and streptococci proved to be very susceptible. Most strains were susceptible to <b style='color:Tomato;'><i>tetracycline</i></b> and showed a wide range of <b style='color:Tomato;'><i>streptomycin</i></b> MICs. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>erythromycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clindamycin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>LAB</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>within</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>normal</i></b> <b style='color:DodgerBlue;'><i>range</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>susceptibility</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Sixteen Lactobacillus, 8 Lactococcus and 8 Streptococcus isolates including all <b style='color:Tomato;'><i>tetracycline</i></b> and/or <b style='color:Tomato;'><i>erythromycin</i></b> resistant strains were tested for the presence of <b style='color:Tomato;'><i>tetracycline</i></b> and/or <b style='color:Tomato;'><i>erythromycin</i></b> resistant genes [tet(M) and/or erm(B)]. PCR assays shows that some resistant strains harbor tet(M) and/or erm(B) resistance genes.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"MICs","start":4,"end":8,"id":1,"ws":true},{"text":"of","start":9,"end":11,"id":2,"ws":true},{"text":"erythromycin","start":12,"end":24,"id":3,"ws":true},{"text":"and","start":25,"end":28,"id":4,"ws":true},{"text":"clindamycin","start":29,"end":40,"id":5,"ws":true},{"text":"for","start":41,"end":44,"id":6,"ws":true},{"text":"most","start":45,"end":49,"id":7,"ws":true},{"text":"of","start":50,"end":52,"id":8,"ws":true},{"text":"the","start":53,"end":56,"id":9,"ws":true},{"text":"LAB","start":57,"end":60,"id":10,"ws":true},{"text":"were","start":61,"end":65,"id":11,"ws":true},{"text":"within","start":66,"end":72,"id":12,"ws":true},{"text":"the","start":73,"end":76,"id":13,"ws":true},{"text":"normal","start":77,"end":83,"id":14,"ws":true},{"text":"range","start":84,"end":89,"id":15,"ws":true},{"text":"of","start":90,"end":92,"id":16,"ws":true},{"text":"susceptibility","start":93,"end":107,"id":17,"ws":true},{"text":".","start":108,"end":109,"id":18,"ws":false}],"spans":[{"start":12,"end":24,"token_start":3,"token_end":3,"label":"DRUG"},{"start":29,"end":40,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24948910/","_input_hash":1103413111,"_task_hash":1587683157,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Based on HRs for RFS/DFS , the risk of recurrence with nivolumab was similar to that of pembrolizumab and lower than that of ipilimumab 3 mg/kg , ipilimumab 10 mg/kg , or interferon .","paragraph":"<h3><u>Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis.</u></h3>Immune checkpoint inhibitors and targeted therapies are approved for adjuvant treatment of patients with resected melanoma; however, they have not been compared in randomized controlled trials (RCTs). We compared the efficacy and safety of adjuvant <b style='color:Tomato;'><i>nivolumab</i></b> with other approved treatments using available evidence from RCTs in a Bayesian network meta-analysis (NMA). ### methods A systematic literature review was conducted through May 2019 to identify relevant RCTs evaluating approved adjuvant treatments. Outcomes of interest included recurrence-free survival (RFS)/disease-free survival (DFS), distant metastasis-free survival (DMFS), all-cause grade 3/4 adverse events (AEs), discontinuations, and discontinuations due to AEs. Time-to-event outcomes (RFS/DFS and DMFS) were analyzed both assuming that hazard ratios (HRs) are constant over time and that they vary. ### results Of 26 identified RCTs, 19 were included in the NMA following a feasibility assessment. <b style='color:DodgerBlue;'><i>Based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>HRs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>RFS/DFS</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>interferon</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Risk of recurrence with <b style='color:Tomato;'><i>nivolumab</i></b> was similar to that of <b style='color:Tomato;'><i>dabrafenib</i></b> plus <b style='color:Tomato;'><i>trametinib</i></b> at 12\u2009months, however, was lower beyond 12\u2009months (HR [95% credible interval] at 24\u2009months, 0.46 [0.27-0.78]; at 36\u2009months, 0.28 [0.14-0.59]). Based on HRs for DMFS, the risk of developing distant metastases was lower with <b style='color:Tomato;'><i>nivolumab</i></b> than with <b style='color:Tomato;'><i>ipilimumab</i></b> 10\u2009mg/kg or interferon and was similar to <b style='color:Tomato;'><i>dabrafenib</i></b> plus <b style='color:Tomato;'><i>trametinib</i></b>. ### conclusion Adjuvant therapy with <b style='color:Tomato;'><i>nivolumab</i></b> provides an effective treatment option with a promising risk-benefit profile.","tokens":[{"text":"Based","start":0,"end":5,"id":0,"ws":true},{"text":"on","start":6,"end":8,"id":1,"ws":true},{"text":"HRs","start":9,"end":12,"id":2,"ws":true},{"text":"for","start":13,"end":16,"id":3,"ws":true},{"text":"RFS/DFS","start":17,"end":24,"id":4,"ws":true},{"text":",","start":25,"end":26,"id":5,"ws":true},{"text":"the","start":27,"end":30,"id":6,"ws":true},{"text":"risk","start":31,"end":35,"id":7,"ws":true},{"text":"of","start":36,"end":38,"id":8,"ws":true},{"text":"recurrence","start":39,"end":49,"id":9,"ws":true},{"text":"with","start":50,"end":54,"id":10,"ws":true},{"text":"nivolumab","start":55,"end":64,"id":11,"ws":true},{"text":"was","start":65,"end":68,"id":12,"ws":true},{"text":"similar","start":69,"end":76,"id":13,"ws":true},{"text":"to","start":77,"end":79,"id":14,"ws":true},{"text":"that","start":80,"end":84,"id":15,"ws":true},{"text":"of","start":85,"end":87,"id":16,"ws":true},{"text":"pembrolizumab","start":88,"end":101,"id":17,"ws":true},{"text":"and","start":102,"end":105,"id":18,"ws":true},{"text":"lower","start":106,"end":111,"id":19,"ws":true},{"text":"than","start":112,"end":116,"id":20,"ws":true},{"text":"that","start":117,"end":121,"id":21,"ws":true},{"text":"of","start":122,"end":124,"id":22,"ws":true},{"text":"ipilimumab","start":125,"end":135,"id":23,"ws":true},{"text":"3","start":136,"end":137,"id":24,"ws":true},{"text":"mg/kg","start":138,"end":143,"id":25,"ws":true},{"text":",","start":144,"end":145,"id":26,"ws":true},{"text":"ipilimumab","start":146,"end":156,"id":27,"ws":true},{"text":"10","start":157,"end":159,"id":28,"ws":true},{"text":"mg/kg","start":160,"end":165,"id":29,"ws":true},{"text":",","start":166,"end":167,"id":30,"ws":true},{"text":"or","start":168,"end":170,"id":31,"ws":true},{"text":"interferon","start":171,"end":181,"id":32,"ws":true},{"text":".","start":182,"end":183,"id":33,"ws":false}],"spans":[{"start":55,"end":64,"token_start":11,"token_end":11,"label":"DRUG"},{"start":88,"end":101,"token_start":17,"token_end":17,"label":"DRUG"},{"start":125,"end":135,"token_start":23,"token_end":23,"label":"DRUG"},{"start":146,"end":156,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33402121/","_input_hash":1093190495,"_task_hash":214136276,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Combination therapy of infliximab and methotrexate is more effective in reducing clinical and biochemical disease activity than gold with methylprednisolone treatment in RA patients during 22 weeks of treatment , especially in the first 6 weeks .","paragraph":"<h3><u>[Analysis of efficacy and safety of multiple intravenous infusion of anti-tumor necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis].</u></h3>The objective of the paper was compare the effects and tolerability of combined therapy of multiple intravenous infusions of anti-tumour necrosis factor-alfa (TNF-alfa) monoclonal antibody (Remicade) with <b style='color:Tomato;'><i>methotrexate</i></b> versus treatment with sodium aurothiomalate and intramuscular depot <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> in rheumatoid arthritis (RA). We investigate also the interval necessary to obtain the improvement in both treatment groups. 36 patients commencing intramuscular sodium aurothiomalate therapy with intramuscular depot <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> acetate at weeks 0, 4, 8 and 12 in addition to chrysotherapy were compared in retrospective analysis with 32 patients starting with multiple intravenous infusions of <b style='color:Tomato;'><i>infliximab</i></b>, anti-TNF-alfa monoclonal antibody (Remicade) and <b style='color:Tomato;'><i>methotrexate</i></b> at a stable dose. Patients were assessed by composite clinical score (DAS 28) and C-reactive protein during 22 weeks of therapy. At week 2 and 6 a significantly greater percentage of <b style='color:Tomato;'><i>infliximab</i></b>-treated than gold-treated RA patients achieved improvement in each clinical measurement of disease activity. At 22 week of treatment moderate and good response according to EULAR criteria was achieved in 91% of <b style='color:Tomato;'><i>infliximab</i></b>-treated patients and 58% gold treated patients (p < 0.001). Adverse events were more frequently observed in <b style='color:Tomato;'><i>infliximab</i></b>-treated patients, but only gold-treated patients discontinued treatment because adverse events (2 patients due to proteinuria, 2 patients due to mucocutaneous changes and one patient due to leucopenia). The higher percentage of adverse events in <b style='color:Tomato;'><i>infliximab</i></b>-treated patients was caused mainly by the occurrence of infusion reactions (23 reactions out of 160 infusions); most of them were mild (somnolentia and headache) and transient. Viral infections (including herpes simplex and zoster) were more common in patients treated with <b style='color:Tomato;'><i>infliximab</i></b> and <b style='color:Tomato;'><i>methotrexate</i></b>. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>infliximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>reducing</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>biochemical</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>gold</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>RA</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>22</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"therapy","start":12,"end":19,"id":1,"ws":true},{"text":"of","start":20,"end":22,"id":2,"ws":true},{"text":"infliximab","start":23,"end":33,"id":3,"ws":true},{"text":"and","start":34,"end":37,"id":4,"ws":true},{"text":"methotrexate","start":38,"end":50,"id":5,"ws":true},{"text":"is","start":51,"end":53,"id":6,"ws":true},{"text":"more","start":54,"end":58,"id":7,"ws":true},{"text":"effective","start":59,"end":68,"id":8,"ws":true},{"text":"in","start":69,"end":71,"id":9,"ws":true},{"text":"reducing","start":72,"end":80,"id":10,"ws":true},{"text":"clinical","start":81,"end":89,"id":11,"ws":true},{"text":"and","start":90,"end":93,"id":12,"ws":true},{"text":"biochemical","start":94,"end":105,"id":13,"ws":true},{"text":"disease","start":106,"end":113,"id":14,"ws":true},{"text":"activity","start":114,"end":122,"id":15,"ws":true},{"text":"than","start":123,"end":127,"id":16,"ws":true},{"text":"gold","start":128,"end":132,"id":17,"ws":true},{"text":"with","start":133,"end":137,"id":18,"ws":true},{"text":"methylprednisolone","start":138,"end":156,"id":19,"ws":true},{"text":"treatment","start":157,"end":166,"id":20,"ws":true},{"text":"in","start":167,"end":169,"id":21,"ws":true},{"text":"RA","start":170,"end":172,"id":22,"ws":true},{"text":"patients","start":173,"end":181,"id":23,"ws":true},{"text":"during","start":182,"end":188,"id":24,"ws":true},{"text":"22","start":189,"end":191,"id":25,"ws":true},{"text":"weeks","start":192,"end":197,"id":26,"ws":true},{"text":"of","start":198,"end":200,"id":27,"ws":true},{"text":"treatment","start":201,"end":210,"id":28,"ws":true},{"text":",","start":211,"end":212,"id":29,"ws":true},{"text":"especially","start":213,"end":223,"id":30,"ws":true},{"text":"in","start":224,"end":226,"id":31,"ws":true},{"text":"the","start":227,"end":230,"id":32,"ws":true},{"text":"first","start":231,"end":236,"id":33,"ws":true},{"text":"6","start":237,"end":238,"id":34,"ws":true},{"text":"weeks","start":239,"end":244,"id":35,"ws":true},{"text":".","start":245,"end":246,"id":36,"ws":false}],"spans":[{"start":23,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},{"start":38,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},{"start":138,"end":156,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12685246/","_input_hash":-102465531,"_task_hash":-582924133,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":23,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":38,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":17,"child":19,"head_span":{"start":128,"end":132,"token_start":17,"token_end":17,"label":null},"child_span":{"start":138,"end":156,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Serum homocysteine , cholesterol , retinol , alpha-tocopherol , glycosylated hemoglobin and inflammatory response during therapy with bevacizumab , oxaliplatin , 5-fluorouracil and leucovorin .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Serum</i></b> <b style='color:DodgerBlue;'><i>homocysteine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>retinol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alpha-tocopherol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>glycosylated</i></b> <b style='color:DodgerBlue;'><i>hemoglobin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>inflammatory</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Targeted agents present with a new spectrum of side-effects, including toxicities that negatively impact the risk of atherosclerosis. The aim of the present study was to evaluate the effect of the combination of targeted therapy and chemotherapy on serum homocysteine and other laboratory parameters of cardiovascular risk in patients with metastatic colorectal carcinoma. ### Patients And Methods Thirty-one patients with metastatic colorectal carcinoma treated with the combination of <b style='color:Tomato;'><i>bevacizumab</i></b>, <b style='color:Tomato;'><i>oxaliplatin</i></b>, 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and <b style='color:Tomato;'><i>leucovorin</i></b> were studied before and during the therapy. ### results Serum homocysteine decreased significantly throughout the course of treatment. Total cholesterol and low-density lipoprotein cholesterol also decreased significantly during the first month of therapy. In contrast, serum retinol significantly increased during the second and third months of treatment. A significant increase in glycosylated hemoglobin was also observed. After an initial rise, serum C-reactive protein (CRP) and carcinoembryonic antigen (CEA) were significantly lower compared to baseline throughout the course of treatment. Serum ferritin increased throughout most of the course of treatment. A significant correlation was observed between CRP and high-density lipoprotein cholesterol, retinol, ferritin, and CEA. CEA correlated with hemoglobin, retinol, and ferritin. Retinol correlated significantly with hemoglobin. ### conclusion Tumor control, reflected in lower CEA, resulted in suppression of the acute phase response and generally in favorable effects on laboratory parameters indicative of risk factors of atherosclerosis, including lower homocysteine concentrations, and lower total and LDL cholesterol.","tokens":[{"text":"Serum","start":0,"end":5,"id":0,"ws":true},{"text":"homocysteine","start":6,"end":18,"id":1,"ws":true},{"text":",","start":19,"end":20,"id":2,"ws":true},{"text":"cholesterol","start":21,"end":32,"id":3,"ws":true},{"text":",","start":33,"end":34,"id":4,"ws":true},{"text":"retinol","start":35,"end":42,"id":5,"ws":true},{"text":",","start":43,"end":44,"id":6,"ws":true},{"text":"alpha-tocopherol","start":45,"end":61,"id":7,"ws":true},{"text":",","start":62,"end":63,"id":8,"ws":true},{"text":"glycosylated","start":64,"end":76,"id":9,"ws":true},{"text":"hemoglobin","start":77,"end":87,"id":10,"ws":true},{"text":"and","start":88,"end":91,"id":11,"ws":true},{"text":"inflammatory","start":92,"end":104,"id":12,"ws":true},{"text":"response","start":105,"end":113,"id":13,"ws":true},{"text":"during","start":114,"end":120,"id":14,"ws":true},{"text":"therapy","start":121,"end":128,"id":15,"ws":true},{"text":"with","start":129,"end":133,"id":16,"ws":true},{"text":"bevacizumab","start":134,"end":145,"id":17,"ws":true},{"text":",","start":146,"end":147,"id":18,"ws":true},{"text":"oxaliplatin","start":148,"end":159,"id":19,"ws":true},{"text":",","start":160,"end":161,"id":20,"ws":true},{"text":"5-fluorouracil","start":162,"end":176,"id":21,"ws":true},{"text":"and","start":177,"end":180,"id":22,"ws":true},{"text":"leucovorin","start":181,"end":191,"id":23,"ws":true},{"text":".","start":192,"end":193,"id":24,"ws":false}],"spans":[{"start":134,"end":145,"token_start":17,"token_end":17,"label":"DRUG"},{"start":148,"end":159,"token_start":19,"token_end":19,"label":"DRUG"},{"start":162,"end":176,"token_start":21,"token_end":21,"label":"DRUG"},{"start":181,"end":191,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20032440/","_input_hash":626081300,"_task_hash":-2050444588,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":17,"child":19,"head_span":{"start":134,"end":145,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":148,"end":159,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":19,"child":21,"head_span":{"start":148,"end":159,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":162,"end":176,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":21,"child":23,"head_span":{"start":162,"end":176,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":181,"end":191,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Reversal of drug resistance by planetary ball milled ( PBM ) nanoparticle loaded with resveratrol and docetaxel in prostate cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Reversal</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>planetary</i></b> <b style='color:DodgerBlue;'><i>ball</i></b> <b style='color:DodgerBlue;'><i>milled</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PBM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>nanoparticle</i></b> <b style='color:DodgerBlue;'><i>loaded</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>resveratrol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The folate receptor (FR) is a valued target that is highly expressed in various cancers, which will expedite the development of ligand-receptor binding based cancer therapeutics. In the present investigation, through tissue microarray analysis, we report higher levels of folate receptor expression in prostate cancer (PCa) tissue derived from patients, which were minimal in normal tissue. For folate-receptor based targeted therapy of PCa, we generated novel planetary ball milled (PBM) nanoparticles (NPs) encapsulated with <b style='color:Tomato;'><i>resveratrol</i></b> (RES), and in combination with <b style='color:Tomato;'><i>docetaxel</i></b> (DTX) and conjugated with folic acid (FA) on the surface. The cytotoxic effect of FA-conjugated DTX-nanoparticles was found effectual that reduced the concentration of free drug (DTX) to 28 times. Flow cytometry analysis showed a significant increase in the number of apoptotic cells by 30.92% and 65.9% in the FA-conjugated RES and in combination with DTX nanoparticle formulation respectively. However, only 8.9% apoptotic cells were found with control (empty NP). The expressions of NF-kB p65, COX-2, pro (BAX, BAK) and anti-apoptotic (BCL-2, BCL-XL) genes were significantly reduced after treatment with FA-RES\u00a0+\u00a0DTX-NP. In addition, the FA-conjugated DTX formulation exhibited additional cytotoxic effects with the down-regulation of survivin and an increased expression of Cleaved Caspase-3 in PCa cells. Further, we observed that treating DTX resistant PCa cells with FA-RES\u00a0+\u00a0DTX-NP exhibited a reversal of the ABC-transporter markers thereby limiting the multidrug resistance phenotype of the cancer cells. Our results strongly suggested that FA conjugated nanoparticle drugs acted as effective inhibitors of drug efflux that effectually enhances the intracellular concentration of the drug to exhibit their cytotoxic effect.","tokens":[{"text":"Reversal","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"drug","start":12,"end":16,"id":2,"ws":true},{"text":"resistance","start":17,"end":27,"id":3,"ws":true},{"text":"by","start":28,"end":30,"id":4,"ws":true},{"text":"planetary","start":31,"end":40,"id":5,"ws":true},{"text":"ball","start":41,"end":45,"id":6,"ws":true},{"text":"milled","start":46,"end":52,"id":7,"ws":true},{"text":"(","start":53,"end":54,"id":8,"ws":true},{"text":"PBM","start":55,"end":58,"id":9,"ws":true},{"text":")","start":59,"end":60,"id":10,"ws":true},{"text":"nanoparticle","start":61,"end":73,"id":11,"ws":true},{"text":"loaded","start":74,"end":80,"id":12,"ws":true},{"text":"with","start":81,"end":85,"id":13,"ws":true},{"text":"resveratrol","start":86,"end":97,"id":14,"ws":true},{"text":"and","start":98,"end":101,"id":15,"ws":true},{"text":"docetaxel","start":102,"end":111,"id":16,"ws":true},{"text":"in","start":112,"end":114,"id":17,"ws":true},{"text":"prostate","start":115,"end":123,"id":18,"ws":true},{"text":"cancer","start":124,"end":130,"id":19,"ws":true},{"text":".","start":131,"end":132,"id":20,"ws":false}],"spans":[{"start":86,"end":97,"token_start":14,"token_end":14,"label":"DRUG"},{"start":102,"end":111,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29678549/","_input_hash":1903734758,"_task_hash":-393600527,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":86,"end":97,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":102,"end":111,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Records of 63 patients diagnosis of IHCC who received Gemcitabine and Carboplatin ( G-C Regimen ) chemotherapy as a first line were retrospectively reviewed .","paragraph":"<h3><u>Gemcitabine with carboplatin for advanced intrahepatic cholangiocarcinoma: A study from North India Cancer Centre.</u></h3><b style='color:Tomato;'><i>gemcitabine</i></b> plus cisplatin has been established as a standard chemotherapy regimen for advanced biliary tract cancers (BTCs) based on the phase III UK ABC-02 study, which included all types of biliary cancers. There is very limited data regarding the effectiveness of known chemotherapeutic regimens especially in IHCC. ### methods <b style='color:DodgerBlue;'><i>Records</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>63</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>diagnosis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>IHCC</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>Gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Carboplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>G-C</i></b> <b style='color:DodgerBlue;'><i>Regimen</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>retrospectively</i></b> <b style='color:DodgerBlue;'><i>reviewed</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary aim of this study was to assess the response rate of <b style='color:Tomato;'><i>gemcitabine</i></b> <b style='color:Tomato;'><i>carboplatin</i></b>-based chemotherapy as a first line therapy in advanced intrahepatic cholangiocarcinoma (IHCC). The secondary objectives were to assess toxicity, progression free survival and overall survival. ### results There were 38 men and 25 women in our study with a median age of 56.75 years (range 31-78 years). Of the 38+25= 63 patients, 21 patients (33.8%) progressed, 5 patients (8.06%) had complete response, 25 patients (40.3%) had partial response, 12 patients (19.3%) had stable disease. Overall response rate was 48.36% and tumor control rate was 67.6%. Progression free survival was 5.3 months and overall survival of 10.3 months was seen. The most common grade 3-4 toxicities were anemia, neutropenia, and thrombocytopenia. Most common nonhematological toxicity was fatigue. ### conclusion <b style='color:Tomato;'><i>gemcitabine</i></b> in combination with <b style='color:Tomato;'><i>carboplatin</i></b> has activity against advanced IHCC. Our results are comparable with other <b style='color:Tomato;'><i>gemcitabine</i></b> <b style='color:Tomato;'><i>carboplatin</i></b> studies as well as <b style='color:Tomato;'><i>gemcitabine</i></b> cisplatin-based studies.","tokens":[{"text":"Records","start":0,"end":7,"id":0,"ws":true},{"text":"of","start":8,"end":10,"id":1,"ws":true},{"text":"63","start":11,"end":13,"id":2,"ws":true},{"text":"patients","start":14,"end":22,"id":3,"ws":true},{"text":"diagnosis","start":23,"end":32,"id":4,"ws":true},{"text":"of","start":33,"end":35,"id":5,"ws":true},{"text":"IHCC","start":36,"end":40,"id":6,"ws":true},{"text":"who","start":41,"end":44,"id":7,"ws":true},{"text":"received","start":45,"end":53,"id":8,"ws":true},{"text":"Gemcitabine","start":54,"end":65,"id":9,"ws":true},{"text":"and","start":66,"end":69,"id":10,"ws":true},{"text":"Carboplatin","start":70,"end":81,"id":11,"ws":true},{"text":"(","start":82,"end":83,"id":12,"ws":true},{"text":"G-C","start":84,"end":87,"id":13,"ws":true},{"text":"Regimen","start":88,"end":95,"id":14,"ws":true},{"text":")","start":96,"end":97,"id":15,"ws":true},{"text":"chemotherapy","start":98,"end":110,"id":16,"ws":true},{"text":"as","start":111,"end":113,"id":17,"ws":true},{"text":"a","start":114,"end":115,"id":18,"ws":true},{"text":"first","start":116,"end":121,"id":19,"ws":true},{"text":"line","start":122,"end":126,"id":20,"ws":true},{"text":"were","start":127,"end":131,"id":21,"ws":true},{"text":"retrospectively","start":132,"end":147,"id":22,"ws":true},{"text":"reviewed","start":148,"end":156,"id":23,"ws":true},{"text":".","start":157,"end":158,"id":24,"ws":false}],"spans":[{"start":54,"end":65,"token_start":9,"token_end":9,"label":"DRUG"},{"start":70,"end":81,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30693882/","_input_hash":-1298190503,"_task_hash":785351110,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":54,"end":65,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":70,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Drugs most commonly implicated in ADRs were amoxicillin + clavulanate ( 21.87 % ) followed by ceftriaxone ( 20.31 % ) .","paragraph":"<h3><u>Adverse Drug Reactions in Hospitalized Pediatric Patients: A Prospective Observational Study.</u></h3>To determine the incidence, pattern, causality, preventability, severity and predictors of adverse drug reactions (ADRs) in pediatric population. ### methods It was a prospective, observational study that included patients of either sex, of any age treated in the pediatric wards of a tertiary care hospital. Study patients were followed throughout their hospital stay. Whenever an ADR was detected, all the required data was collected and analyzed. Data was analyzed for incidence, causality (by using WHO Probability scale and Naranjo's algorithm), preventability (by using Modified Shumock and Thornton scale), severity (by using Modified Hartwig and Siegel scale) and predictors of ADRs. ### results Of the 1775 children admitted in the pediatrics ward, 1082 patients met study criteria and were enrolled into the study. A total of 64 ADRs were identified from 54 patients. The incidence of ADRs was 4.99\u00a0%. Male patients experienced majority (68.52\u00a0%) of ADRs. <b style='color:DodgerBlue;'><i>Drugs</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>commonly</i></b> <b style='color:DodgerBlue;'><i>implicated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>ADRs</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>clavulanate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>21.87</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>ceftriaxone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20.31</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Most (51.56\u00a0%) of the ADRs reported belonged to the system organ class, gastrointestinal system disorders. Among the ADRs reported, 82.85\u00a0% of ADRs were mild. Majority (87.5\u00a0%) of the ADRs were of 'probable' causality category and 96.9\u00a0% were not preventable. There was a significant association between occurrence of ADRs and the use of \u22654 number of medications, age (infants) and gender (male). ### conclusions Among the pediatric population, infants, male gender and those receiving \u22654 number of medications are at risk of developing ADRs. Constant monitoring is required to address the safety issue in pediatric population especially in infants and patients receiving \u22654 drugs.","tokens":[{"text":"Drugs","start":0,"end":5,"id":0,"ws":true},{"text":"most","start":6,"end":10,"id":1,"ws":true},{"text":"commonly","start":11,"end":19,"id":2,"ws":true},{"text":"implicated","start":20,"end":30,"id":3,"ws":true},{"text":"in","start":31,"end":33,"id":4,"ws":true},{"text":"ADRs","start":34,"end":38,"id":5,"ws":true},{"text":"were","start":39,"end":43,"id":6,"ws":true},{"text":"amoxicillin","start":44,"end":55,"id":7,"ws":true},{"text":"+","start":56,"end":57,"id":8,"ws":true},{"text":"clavulanate","start":58,"end":69,"id":9,"ws":true},{"text":"(","start":70,"end":71,"id":10,"ws":true},{"text":"21.87","start":72,"end":77,"id":11,"ws":true},{"text":"%","start":78,"end":79,"id":12,"ws":true},{"text":")","start":80,"end":81,"id":13,"ws":true},{"text":"followed","start":82,"end":90,"id":14,"ws":true},{"text":"by","start":91,"end":93,"id":15,"ws":true},{"text":"ceftriaxone","start":94,"end":105,"id":16,"ws":true},{"text":"(","start":106,"end":107,"id":17,"ws":true},{"text":"20.31","start":108,"end":113,"id":18,"ws":true},{"text":"%","start":114,"end":115,"id":19,"ws":true},{"text":")","start":116,"end":117,"id":20,"ws":true},{"text":".","start":118,"end":119,"id":21,"ws":false}],"spans":[{"start":44,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},{"start":58,"end":69,"token_start":9,"token_end":9,"label":"DRUG"},{"start":94,"end":105,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26916890/","_input_hash":1802714067,"_task_hash":1007422582,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":44,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":58,"end":69,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"Dexamethasone and piroxicam provided in the diet were found to significantly inhibit lung tumors induced by 60 mg/kg vinyl carbamate at 24 weeks whereas myo-inositol also provided in the diet , did not significantly inhibit tumor formation .","paragraph":"<h3><u>Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice.</u></h3>The ability of potential chemopreventive agents to prevent vinyl carbamate-induced lung tumors was determined in 2 different experiments. Female strain A mice administered intraperitoneally either a single injection of 60 mg/kg vinyl carbamate that induced 24.0 +/- 1.72 tumors/mouse at 24 weeks or 2 injections of 16 mg/kg vinyl carbamate each (32 mg/kg total dose) that induced 43.2 +/- 3.2 tumors/mouse at 20 weeks. Lung carcinomas were found as early as 16 weeks. <b style='color:MediumOrchid;'><i>Dexamethasone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>piroxicam</i></b> <b style='color:DodgerBlue;'><i>provided</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>diet</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>inhibit</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>vinyl</i></b> <b style='color:DodgerBlue;'><i>carbamate</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:DodgerBlue;'><i>myo-inositol</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>provided</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>diet</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>inhibit</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>formation</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In animals given 6 16-mg/kg doses of vinyl carbamate, tumor multiplicity was reduced roughly 25% by alpha-difluoromethylornithine and green tea and reduced 50% by <b style='color:Tomato;'><i>dexamethasone</i></b> and <b style='color:Tomato;'><i>piroxicam</i></b>. Combinations of these agents were also tested using a total dose of 32 mg/kg of vinyl carbamate. Although alpha-difluoromethylornithine and green tea did not result in a significant inhibition of lung tumor formation if used alone, the combination of alpha-difluoromethylornithine and green tea resulted in a significant reduction of tumor multiplicity. The combinations of alpha-difluoromethylornithine or green tea with either <b style='color:Tomato;'><i>dexamethasone</i></b> or <b style='color:Tomato;'><i>piroxicam</i></b> or the combination of <b style='color:Tomato;'><i>dexamethasone</i></b> and <b style='color:Tomato;'><i>piroxicam</i></b> did not decrease tumor multiplicity greater than achieved by <b style='color:Tomato;'><i>dexamethasone</i></b> and <b style='color:Tomato;'><i>piroxicam</i></b> alone. In summary, selected chemopreventive agents previously shown to inhibit lung tumors by other chemical carcinogens also inhibited vinyl carbamate-induced lung tumors.","tokens":[{"text":"Dexamethasone","start":0,"end":13,"id":0,"ws":true},{"text":"and","start":14,"end":17,"id":1,"ws":true},{"text":"piroxicam","start":18,"end":27,"id":2,"ws":true},{"text":"provided","start":28,"end":36,"id":3,"ws":true},{"text":"in","start":37,"end":39,"id":4,"ws":true},{"text":"the","start":40,"end":43,"id":5,"ws":true},{"text":"diet","start":44,"end":48,"id":6,"ws":true},{"text":"were","start":49,"end":53,"id":7,"ws":true},{"text":"found","start":54,"end":59,"id":8,"ws":true},{"text":"to","start":60,"end":62,"id":9,"ws":true},{"text":"significantly","start":63,"end":76,"id":10,"ws":true},{"text":"inhibit","start":77,"end":84,"id":11,"ws":true},{"text":"lung","start":85,"end":89,"id":12,"ws":true},{"text":"tumors","start":90,"end":96,"id":13,"ws":true},{"text":"induced","start":97,"end":104,"id":14,"ws":true},{"text":"by","start":105,"end":107,"id":15,"ws":true},{"text":"60","start":108,"end":110,"id":16,"ws":true},{"text":"mg/kg","start":111,"end":116,"id":17,"ws":true},{"text":"vinyl","start":117,"end":122,"id":18,"ws":true},{"text":"carbamate","start":123,"end":132,"id":19,"ws":true},{"text":"at","start":133,"end":135,"id":20,"ws":true},{"text":"24","start":136,"end":138,"id":21,"ws":true},{"text":"weeks","start":139,"end":144,"id":22,"ws":true},{"text":"whereas","start":145,"end":152,"id":23,"ws":true},{"text":"myo-inositol","start":153,"end":165,"id":24,"ws":true},{"text":"also","start":166,"end":170,"id":25,"ws":true},{"text":"provided","start":171,"end":179,"id":26,"ws":true},{"text":"in","start":180,"end":182,"id":27,"ws":true},{"text":"the","start":183,"end":186,"id":28,"ws":true},{"text":"diet","start":187,"end":191,"id":29,"ws":true},{"text":",","start":192,"end":193,"id":30,"ws":true},{"text":"did","start":194,"end":197,"id":31,"ws":true},{"text":"not","start":198,"end":201,"id":32,"ws":true},{"text":"significantly","start":202,"end":215,"id":33,"ws":true},{"text":"inhibit","start":216,"end":223,"id":34,"ws":true},{"text":"tumor","start":224,"end":229,"id":35,"ws":true},{"text":"formation","start":230,"end":239,"id":36,"ws":true},{"text":".","start":240,"end":241,"id":37,"ws":false}],"spans":[{"start":0,"end":13,"token_start":0,"token_end":0,"label":"DRUG"},{"start":18,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},{"start":117,"end":132,"token_start":18,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11195469/","_input_hash":-368672526,"_task_hash":1275930704,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":13,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":18,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"We identified 938 patients with RCC who had initially been treated with sunitinib ( n = 554 ) or sorafenib ( n = 384 ) .","paragraph":"<h3><u>Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.</u></h3>To characterize the contemporary use of oral-targeted therapies (ie, <b style='color:Tomato;'><i>sunitinib</i></b>, <b style='color:Tomato;'><i>sorafenib</i></b>) among patients with renal cell carcinoma (RCC) and to assess the factors associated with short-term and sequential treatment. ### methods We used an administrative claims database of privately insured patients to evaluate oral-targeted therapy use among patients with RCC from 2006 to 2007. After identifying patients with RCC who had received <b style='color:Tomato;'><i>sunitinib</i></b> and/or <b style='color:Tomato;'><i>sorafenib</i></b>, we determined the prevalence of patients treated with short-term and/or sequential therapy. We performed bivariate and multivariate analyses to estimate the associations between the patient characteristics and receipt of short-term and/or sequential treatment regimens. ### results <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>identified</i></b> <b style='color:DodgerBlue;'><i>938</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>RCC</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>554</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>384</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this group, 36% and 23% of patients had received short-term or sequential therapy, respectively. Most patients (61%) who had received sequential therapy had undergone short-term treatment with \u22651 drugs, with second-line <b style='color:Tomato;'><i>sorafenib</i></b> more likely to be given as short-term therapy than <b style='color:Tomato;'><i>sunitinib</i></b> (63% vs 34%, P < .001). Short-term therapy was more common in female patients (odds ratio 1.53, 95% confidence interval 1.12-2.09) and patients in the Southern United States (odds ratio 1.71, 95% confidence interval 1.05-2.80). Sequential therapy was more common among patients receiving <b style='color:Tomato;'><i>sorafenib</i></b> first (odds ratio 2.30, 95% confidence interval 1.64-3.21). ### conclusions Short-term and sequential oral targeted therapy use was relatively prevalent among patients with RCC. For patients treated with <b style='color:Tomato;'><i>sunitinib</i></b> and <b style='color:Tomato;'><i>sorafenib</i></b>, the patterns of short-term use varied by the sequence of medications, suggesting differences in the effectiveness or tolerability of each regimen. These findings highlight the need for future studies to characterize the \"real-world\" clinical outcomes and economic effect associated with these treatment courses.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"identified","start":3,"end":13,"id":1,"ws":true},{"text":"938","start":14,"end":17,"id":2,"ws":true},{"text":"patients","start":18,"end":26,"id":3,"ws":true},{"text":"with","start":27,"end":31,"id":4,"ws":true},{"text":"RCC","start":32,"end":35,"id":5,"ws":true},{"text":"who","start":36,"end":39,"id":6,"ws":true},{"text":"had","start":40,"end":43,"id":7,"ws":true},{"text":"initially","start":44,"end":53,"id":8,"ws":true},{"text":"been","start":54,"end":58,"id":9,"ws":true},{"text":"treated","start":59,"end":66,"id":10,"ws":true},{"text":"with","start":67,"end":71,"id":11,"ws":true},{"text":"sunitinib","start":72,"end":81,"id":12,"ws":true},{"text":"(","start":82,"end":83,"id":13,"ws":true},{"text":"n","start":84,"end":85,"id":14,"ws":true},{"text":"=","start":86,"end":87,"id":15,"ws":true},{"text":"554","start":88,"end":91,"id":16,"ws":true},{"text":")","start":92,"end":93,"id":17,"ws":true},{"text":"or","start":94,"end":96,"id":18,"ws":true},{"text":"sorafenib","start":97,"end":106,"id":19,"ws":true},{"text":"(","start":107,"end":108,"id":20,"ws":true},{"text":"n","start":109,"end":110,"id":21,"ws":true},{"text":"=","start":111,"end":112,"id":22,"ws":true},{"text":"384","start":113,"end":116,"id":23,"ws":true},{"text":")","start":117,"end":118,"id":24,"ws":true},{"text":".","start":119,"end":120,"id":25,"ws":false}],"spans":[{"start":72,"end":81,"token_start":12,"token_end":12,"label":"DRUG"},{"start":97,"end":106,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21256539/","_input_hash":1229048412,"_task_hash":-2045860467,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"( 3 ) Observed facilitatory effects of caerulein on the hypothalamic defensive attack were very similar to those observed with dopamine ( DA ) agonists such as methamphetamine and apomorphine and opposite to those with DA antagonists such as haloperidol and chlorpromazine .","paragraph":"<h3><u>Facilitatory effects of caerulein on hypothalamic defensive attack in cats.</u></h3>Effects of intraventricularly microinjected caerulein (0.1, 1.0 and 10.0 micrograms) on the thresholds for hypothalamically elicited defensive attack and influences of <b style='color:Tomato;'><i>haloperidol</i></b> (0.5 mg/kg, i.p.) on the effects were studied in chronic cats. Directed attack and hissing were selected for threshold determination, and thresholds for these responses were measured under two situations: one with provocations by a human, and the other without such provocation. Results were as follows. (1) Caerulein lowered all thresholds in generally equal decrements and in a dose-related manner, accompanied by a general behavioral arousal. (2) Prior injection of <b style='color:Tomato;'><i>haloperidol</i></b> prevented the effects of caerulein, suggesting an antagonism-like interaction between <b style='color:Tomato;'><i>haloperidol</i></b> and caerulein. <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>Observed</i></b> <b style='color:DodgerBlue;'><i>facilitatory</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>caerulein</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>hypothalamic</i></b> <b style='color:DodgerBlue;'><i>defensive</i></b> <b style='color:DodgerBlue;'><i>attack</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>very</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>dopamine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>agonists</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>methamphetamine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>apomorphine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>opposite</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>DA</i></b> <b style='color:DodgerBlue;'><i>antagonists</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>haloperidol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>chlorpromazine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These findings suggest that caerulein exerts its facilitatory effects on the excitability of the ventromedial hypothalamic nucleus through its synergistic interaction with DA.","tokens":[{"text":"(","start":0,"end":1,"id":0,"ws":true},{"text":"3","start":2,"end":3,"id":1,"ws":true},{"text":")","start":4,"end":5,"id":2,"ws":true},{"text":"Observed","start":6,"end":14,"id":3,"ws":true},{"text":"facilitatory","start":15,"end":27,"id":4,"ws":true},{"text":"effects","start":28,"end":35,"id":5,"ws":true},{"text":"of","start":36,"end":38,"id":6,"ws":true},{"text":"caerulein","start":39,"end":48,"id":7,"ws":true},{"text":"on","start":49,"end":51,"id":8,"ws":true},{"text":"the","start":52,"end":55,"id":9,"ws":true},{"text":"hypothalamic","start":56,"end":68,"id":10,"ws":true},{"text":"defensive","start":69,"end":78,"id":11,"ws":true},{"text":"attack","start":79,"end":85,"id":12,"ws":true},{"text":"were","start":86,"end":90,"id":13,"ws":true},{"text":"very","start":91,"end":95,"id":14,"ws":true},{"text":"similar","start":96,"end":103,"id":15,"ws":true},{"text":"to","start":104,"end":106,"id":16,"ws":true},{"text":"those","start":107,"end":112,"id":17,"ws":true},{"text":"observed","start":113,"end":121,"id":18,"ws":true},{"text":"with","start":122,"end":126,"id":19,"ws":true},{"text":"dopamine","start":127,"end":135,"id":20,"ws":true},{"text":"(","start":136,"end":137,"id":21,"ws":true},{"text":"DA","start":138,"end":140,"id":22,"ws":true},{"text":")","start":141,"end":142,"id":23,"ws":true},{"text":"agonists","start":143,"end":151,"id":24,"ws":true},{"text":"such","start":152,"end":156,"id":25,"ws":true},{"text":"as","start":157,"end":159,"id":26,"ws":true},{"text":"methamphetamine","start":160,"end":175,"id":27,"ws":true},{"text":"and","start":176,"end":179,"id":28,"ws":true},{"text":"apomorphine","start":180,"end":191,"id":29,"ws":true},{"text":"and","start":192,"end":195,"id":30,"ws":true},{"text":"opposite","start":196,"end":204,"id":31,"ws":true},{"text":"to","start":205,"end":207,"id":32,"ws":true},{"text":"those","start":208,"end":213,"id":33,"ws":true},{"text":"with","start":214,"end":218,"id":34,"ws":true},{"text":"DA","start":219,"end":221,"id":35,"ws":true},{"text":"antagonists","start":222,"end":233,"id":36,"ws":true},{"text":"such","start":234,"end":238,"id":37,"ws":true},{"text":"as","start":239,"end":241,"id":38,"ws":true},{"text":"haloperidol","start":242,"end":253,"id":39,"ws":true},{"text":"and","start":254,"end":257,"id":40,"ws":true},{"text":"chlorpromazine","start":258,"end":272,"id":41,"ws":true},{"text":".","start":273,"end":274,"id":42,"ws":false}],"spans":[{"start":160,"end":175,"token_start":27,"token_end":27,"label":"DRUG"},{"start":242,"end":253,"token_start":39,"token_end":39,"label":"DRUG"},{"start":258,"end":272,"token_start":41,"token_end":41,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/3179708/","_input_hash":-1263621431,"_task_hash":2078413213,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The NIBIT-MESO-1 study demonstrated the efficacy and safety of tremelimumab combined with durvalumab in patient with unresectable mesothelioma followed up for a median of 52 months [ IQR 49 - 53 ] .","paragraph":"<h3><u>Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>NIBIT-MESO-1</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tremelimumab</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>durvalumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>unresectable</i></b> <b style='color:DodgerBlue;'><i>mesothelioma</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>up</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>52</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>IQR</i></b> <b style='color:DodgerBlue;'><i>49</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>53</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we report 4-year survival and outcomes after retreatment, and the role of tumour mutational burden (TMB) in identifying patients who might have a better outcome in response to combined therapy. ### methods NIBIT-MESO-1 was an open-label, non-randomised, phase 2 trial of patients with unresectable pleural or peritoneal mesothelioma who received intravenous <b style='color:Tomato;'><i>tremelimumab</i></b> (1 mg/kg bodyweight) and <b style='color:Tomato;'><i>durvalumab</i></b> (20 mg/kg bodyweight) every 4 weeks for four doses, followed by maintenance intravenous <b style='color:Tomato;'><i>durvalumab</i></b> at the same dose and schedule for nine doses. In this follow-up study, patients with disease progression following initial clinical benefit-ie, a partial repsonse or stable disease-were eligible for retreatment and with the same doses and schedules for <b style='color:Tomato;'><i>tremelimumab</i></b> and <b style='color:Tomato;'><i>durvalumab</i></b> as used in the NIBIT-MESO-1 trial. The primary endpoint, immune-related objective response rate, was evaluated per immune-related modified Response Evaluation Criteria in Solid Tumors (RECIST) or immune-related RECIST 1.1 criteria for patients with pleural or peritoneal malignant mesothelioma, respectively. Key secondary endpoints were overall survival and safety, and TMB was also evaluated post hoc in patients who had tumour tissue available before treatment. The intention-to-treat population was used for analysis of all efficacy endpoints. This study is registered with ClinicalTrials.gov, number NCT02588131. ### findings 40 patients were enrolled in the NIBIT-MESO-1 study between Oct 30, 2015, and Oct 12, 2016. At data cut-off, April 30, 2020, five (13%) of 40 patients were alive, and 35 (88%) patients had died of progressive disease. At a median follow-up of 52 months (IQR 49-53), median overall survival was 16\u00b75 months (95% CI 13\u00b77-19\u00b72). Survival was 20% (eight of 40 patients) at 36 months and 15% (six of 40 patients) and 48 months. 17 (43%) of 40 patients met the criteria for enrolment in the retreatment study and were retreated with at least one dose of <b style='color:Tomato;'><i>tremelimumab</i></b> and <b style='color:Tomato;'><i>durvalumab</i></b>. No immune-related objective responses were observed in the 17 retreated patients. Seven (41%) of 17 patients achieved immune-related stable disease. From the start of retreatment to a median follow-up of 24 months (22\u00b70-25\u00b70), median overall survival was 12\u00b75 months (95% CI 0\u00b70-25\u00b78), and survival at 12 months was 52\u00b79%, at 18 months was 35\u00b73%, and at 24 months was 23\u00b75%. There were no grade 3-4 immune-related adverse events in the retreatment cohort. In a post-hoc analysis of 28 patients for whom tumour tissue before treatment was available, patients with a TMB higher than the median value of 8\u00b73 mutations per Mb had a higher median overall survival compared with patients with TMB below the median value, but this difference was non-significant. Moreover, when patients were additionally stratified for ICI retreatment (n=13), there was a significant difference in survival between those with a TMB higher than the median of 8\u00b73 mutations per Mb and those with TMB lower than the median in the retreated cohort (41\u00b73 months vs 17\u00b74 months; p=0\u00b702). ### interpretation <b style='color:Tomato;'><i>tremelimumab</i></b> combined with <b style='color:Tomato;'><i>durvalumab</i></b> was associated with long-term survival in patients with mesothelioma. Retreatment was safe and resulted in clinically meaningful outcomes, thus suggesting its potential application in the clinical practice of mesothalioma patients. ### funding NIBIT Foundation, Fondazione AIRC, AstraZeneca.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"NIBIT-MESO-1","start":4,"end":16,"id":1,"ws":true},{"text":"study","start":17,"end":22,"id":2,"ws":true},{"text":"demonstrated","start":23,"end":35,"id":3,"ws":true},{"text":"the","start":36,"end":39,"id":4,"ws":true},{"text":"efficacy","start":40,"end":48,"id":5,"ws":true},{"text":"and","start":49,"end":52,"id":6,"ws":true},{"text":"safety","start":53,"end":59,"id":7,"ws":true},{"text":"of","start":60,"end":62,"id":8,"ws":true},{"text":"tremelimumab","start":63,"end":75,"id":9,"ws":true},{"text":"combined","start":76,"end":84,"id":10,"ws":true},{"text":"with","start":85,"end":89,"id":11,"ws":true},{"text":"durvalumab","start":90,"end":100,"id":12,"ws":true},{"text":"in","start":101,"end":103,"id":13,"ws":true},{"text":"patient","start":104,"end":111,"id":14,"ws":true},{"text":"with","start":112,"end":116,"id":15,"ws":true},{"text":"unresectable","start":117,"end":129,"id":16,"ws":true},{"text":"mesothelioma","start":130,"end":142,"id":17,"ws":true},{"text":"followed","start":143,"end":151,"id":18,"ws":true},{"text":"up","start":152,"end":154,"id":19,"ws":true},{"text":"for","start":155,"end":158,"id":20,"ws":true},{"text":"a","start":159,"end":160,"id":21,"ws":true},{"text":"median","start":161,"end":167,"id":22,"ws":true},{"text":"of","start":168,"end":170,"id":23,"ws":true},{"text":"52","start":171,"end":173,"id":24,"ws":true},{"text":"months","start":174,"end":180,"id":25,"ws":true},{"text":"[","start":181,"end":182,"id":26,"ws":true},{"text":"IQR","start":183,"end":186,"id":27,"ws":true},{"text":"49","start":187,"end":189,"id":28,"ws":true},{"text":"-","start":190,"end":191,"id":29,"ws":true},{"text":"53","start":192,"end":194,"id":30,"ws":true},{"text":"]","start":195,"end":196,"id":31,"ws":true},{"text":".","start":197,"end":198,"id":32,"ws":false}],"spans":[{"start":63,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},{"start":90,"end":100,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33844995/","_input_hash":-592658905,"_task_hash":-448978464,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":9,"child":12,"head_span":{"start":63,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":90,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Sorafenib has been the standard of care for a decade , and promising results for regorafenib as a second-line and lenvatinib as a first-line treatment were reported only 1 or 2 years ago .","paragraph":"<h3><u>Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.</u></h3>Hepatocellular carcinoma (HCC) is the most common malignancy worldwide, and is especially common in China. A total of 70%-80% of patients are diagnosed at an advanced stage and can receive only palliative care. <b style='color:MediumOrchid;'><i>Sorafenib</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>care</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>decade</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>promising</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>regorafenib</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>lenvatinib</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>ago</i></b> <b style='color:DodgerBlue;'><i>.</i></b> FOLFOX4 was recently recommended as a clinical practice guideline by the China Food and Drug Administration. All approved systemic therapies remain unsatisfactory, with limited objective response rates and poor overall survival. Immune checkpoint inhibitors (CPIs) offer great promise in the treatment of a rapidly expanding spectrum of solid tumors. Immune checkpoint molecules are involved in almost the whole process of viral-related hepatitis with cirrhosis and HCC and in the most important resistance mechanism of <b style='color:Tomato;'><i>sorafenib</i></b>. The approval of <b style='color:Tomato;'><i>nivolumab</i></b> by the U.S. Food and Drug Administration on September 23, 2017, for the treatment of patients with HCC, based only on a phase I/II clinical trial, is a strong hint that immunotherapy will introduce a new era of HCC therapy. CPI-based strategies will soon be a main approach in anticancer treatment for HCC, and we will observe the rapid advances in the therapeutic use of CPIs, even in an adjuvant setting, with great interest. How shall we face the opportunities and challenges? Can we dramatically improve the prognosis of patients with HCC? This review may provide some informed guidance. IMPLICATIONS FOR PRACTICE: Immune checkpoint molecules are involved in almost the whole process of viral-related hepatitis with cirrhosis and hepatocellular carcinoma (HCC) and in the most important resistance mechanism of <b style='color:Tomato;'><i>sorafenib</i></b>. As all approved systemic therapies in HCC remain unsatisfactory, checkpoint inhibitor (CPI)-based strategies will soon be a main approach in anticancer treatment for advanced stage of HCC, even in an adjuvant setting. In virus-related HCC, especially hepatitis B virus-related HCC, whether CPIs can control virus relapse should be further investigated. Combination strategies involving conventional therapies and immunotherapies are needed to increase clinical benefit and minimize adverse toxicities with regard to the underlying liver disease.","tokens":[{"text":"Sorafenib","start":0,"end":9,"id":0,"ws":true},{"text":"has","start":10,"end":13,"id":1,"ws":true},{"text":"been","start":14,"end":18,"id":2,"ws":true},{"text":"the","start":19,"end":22,"id":3,"ws":true},{"text":"standard","start":23,"end":31,"id":4,"ws":true},{"text":"of","start":32,"end":34,"id":5,"ws":true},{"text":"care","start":35,"end":39,"id":6,"ws":true},{"text":"for","start":40,"end":43,"id":7,"ws":true},{"text":"a","start":44,"end":45,"id":8,"ws":true},{"text":"decade","start":46,"end":52,"id":9,"ws":true},{"text":",","start":53,"end":54,"id":10,"ws":true},{"text":"and","start":55,"end":58,"id":11,"ws":true},{"text":"promising","start":59,"end":68,"id":12,"ws":true},{"text":"results","start":69,"end":76,"id":13,"ws":true},{"text":"for","start":77,"end":80,"id":14,"ws":true},{"text":"regorafenib","start":81,"end":92,"id":15,"ws":true},{"text":"as","start":93,"end":95,"id":16,"ws":true},{"text":"a","start":96,"end":97,"id":17,"ws":true},{"text":"second-line","start":98,"end":109,"id":18,"ws":true},{"text":"and","start":110,"end":113,"id":19,"ws":true},{"text":"lenvatinib","start":114,"end":124,"id":20,"ws":true},{"text":"as","start":125,"end":127,"id":21,"ws":true},{"text":"a","start":128,"end":129,"id":22,"ws":true},{"text":"first-line","start":130,"end":140,"id":23,"ws":true},{"text":"treatment","start":141,"end":150,"id":24,"ws":true},{"text":"were","start":151,"end":155,"id":25,"ws":true},{"text":"reported","start":156,"end":164,"id":26,"ws":true},{"text":"only","start":165,"end":169,"id":27,"ws":true},{"text":"1","start":170,"end":171,"id":28,"ws":true},{"text":"or","start":172,"end":174,"id":29,"ws":true},{"text":"2","start":175,"end":176,"id":30,"ws":true},{"text":"years","start":177,"end":182,"id":31,"ws":true},{"text":"ago","start":183,"end":186,"id":32,"ws":true},{"text":".","start":187,"end":188,"id":33,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":81,"end":92,"token_start":15,"token_end":15,"label":"DRUG"},{"start":114,"end":124,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30819826/","_input_hash":-1632316519,"_task_hash":-2109845674,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The addition of trastuzumab , pertuzumab , bevacizumab , or lapatinib to chemotherapy significantly ( P < .05 ) improved objective response rate ( ORR ) , time to failure ( TTF ) , and overall survival ( OS ) in patients with HER2-positive ( HER2(+ ) ) disease .","paragraph":"<h3><u>Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.</u></h3>Breast cancer is the most common cancer and the most frequent cause of death in women. Targeted therapies offer a possibility of effective and individualized therapy based on the molecular profile of the tumor. The aim of this systematic review was to evaluate the efficacy and safety of targeted agents added to chemotherapy or endocrine therapy in patients with previously untreated metastatic breast cancer (MBC) depending on their human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status (positive or negative). The systematic literature search was performed in PubMed, EMBASE, and the Cochrane Library to identify randomized controlled trials (RCTs). Thirteen trials were included. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lapatinib</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>objective</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ORR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TTF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>OS</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HER2(+</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>trastuzumab</i></b> or <b style='color:Tomato;'><i>lapatinib</i></b> combined with endocrine therapy significantly (P < .05) improved ORR, time to progression (TTP), and progression-free survival (PFS) in patients with HER2(+) and HR(+) disease. In patients with HER2-negative (HER2(-)) cancer, <b style='color:Tomato;'><i>bevacizumab</i></b> or <b style='color:Tomato;'><i>lapatinib</i></b> added to chemotherapy significantly (P < .05), improved ORR but did not prolong PFS and OS (P > .05). In patients with HER2(-) and HR(-) disease, <b style='color:Tomato;'><i>trastuzumab</i></b> combined with chemotherapy did not significantly improve (P > .05) ORR or PFS. Targeted therapies also increased the overall risk of adverse events. So far, there is a lack of published results for <b style='color:Tomato;'><i>everolimus</i></b> and <b style='color:Tomato;'><i>trastuzumab</i></b> <b style='color:Tomato;'><i>emtansine</i></b> trials in patients with previously untreated MBC. The addition of targeted therapy to chemotherapy or endocrine therapy using HER2 and HR status significantly improved ORR, PFS, and OS in patients with previously untreated MBC.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"addition","start":4,"end":12,"id":1,"ws":true},{"text":"of","start":13,"end":15,"id":2,"ws":true},{"text":"trastuzumab","start":16,"end":27,"id":3,"ws":true},{"text":",","start":28,"end":29,"id":4,"ws":true},{"text":"pertuzumab","start":30,"end":40,"id":5,"ws":true},{"text":",","start":41,"end":42,"id":6,"ws":true},{"text":"bevacizumab","start":43,"end":54,"id":7,"ws":true},{"text":",","start":55,"end":56,"id":8,"ws":true},{"text":"or","start":57,"end":59,"id":9,"ws":true},{"text":"lapatinib","start":60,"end":69,"id":10,"ws":true},{"text":"to","start":70,"end":72,"id":11,"ws":true},{"text":"chemotherapy","start":73,"end":85,"id":12,"ws":true},{"text":"significantly","start":86,"end":99,"id":13,"ws":true},{"text":"(","start":100,"end":101,"id":14,"ws":true},{"text":"P","start":102,"end":103,"id":15,"ws":true},{"text":"<","start":104,"end":105,"id":16,"ws":true},{"text":".05","start":106,"end":109,"id":17,"ws":true},{"text":")","start":110,"end":111,"id":18,"ws":true},{"text":"improved","start":112,"end":120,"id":19,"ws":true},{"text":"objective","start":121,"end":130,"id":20,"ws":true},{"text":"response","start":131,"end":139,"id":21,"ws":true},{"text":"rate","start":140,"end":144,"id":22,"ws":true},{"text":"(","start":145,"end":146,"id":23,"ws":true},{"text":"ORR","start":147,"end":150,"id":24,"ws":true},{"text":")","start":151,"end":152,"id":25,"ws":true},{"text":",","start":153,"end":154,"id":26,"ws":true},{"text":"time","start":155,"end":159,"id":27,"ws":true},{"text":"to","start":160,"end":162,"id":28,"ws":true},{"text":"failure","start":163,"end":170,"id":29,"ws":true},{"text":"(","start":171,"end":172,"id":30,"ws":true},{"text":"TTF","start":173,"end":176,"id":31,"ws":true},{"text":")","start":177,"end":178,"id":32,"ws":true},{"text":",","start":179,"end":180,"id":33,"ws":true},{"text":"and","start":181,"end":184,"id":34,"ws":true},{"text":"overall","start":185,"end":192,"id":35,"ws":true},{"text":"survival","start":193,"end":201,"id":36,"ws":true},{"text":"(","start":202,"end":203,"id":37,"ws":true},{"text":"OS","start":204,"end":206,"id":38,"ws":true},{"text":")","start":207,"end":208,"id":39,"ws":true},{"text":"in","start":209,"end":211,"id":40,"ws":true},{"text":"patients","start":212,"end":220,"id":41,"ws":true},{"text":"with","start":221,"end":225,"id":42,"ws":true},{"text":"HER2-positive","start":226,"end":239,"id":43,"ws":true},{"text":"(","start":240,"end":241,"id":44,"ws":true},{"text":"HER2(+","start":242,"end":248,"id":45,"ws":true},{"text":")","start":249,"end":250,"id":46,"ws":true},{"text":")","start":251,"end":252,"id":47,"ws":true},{"text":"disease","start":253,"end":260,"id":48,"ws":true},{"text":".","start":261,"end":262,"id":49,"ws":false}],"spans":[{"start":16,"end":27,"token_start":3,"token_end":3,"label":"DRUG"},{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},{"start":43,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},{"start":60,"end":69,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25441421/","_input_hash":-1048615256,"_task_hash":-433153419,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":3,"child":12,"head_span":{"start":16,"end":27,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":73,"end":85,"token_start":12,"token_end":12,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":12,"head_span":{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":73,"end":85,"token_start":12,"token_end":12,"label":null},"color":"#ffd882","label":"POS2"},{"head":7,"child":12,"head_span":{"start":43,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":73,"end":85,"token_start":12,"token_end":12,"label":null},"color":"#d9fbad","label":"POS3"}],"radio":["POS10","POS20","POS30"],"answer":"accept"}
{"text":"The feasibility and efficacy of an intensified procarbazine-free consolidation regimen VECOPA ( vinblastine , etoposide , cyclophosphamide , vincristine , prednisone , doxorubicin ) were investigated .","paragraph":"<h3><u>Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial.</u></h3>The GPOH-HD (Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie-Hodgkin Disease) strategy for children and adolescents with intermediate and advanced stage Hodgkin lymphoma is based on two induction cycles of OEPA (<b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>prednisone</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>) followed by COPP (<b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>procarbazine</i></b>, <b style='color:Tomato;'><i>prednisone</i></b>) or COPDAC (<b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>prednisone</i></b>, <b style='color:Tomato;'><i>dacarbazine</i></b>) consolidation. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>intensified</i></b> <b style='color:DodgerBlue;'><i>procarbazine-free</i></b> <b style='color:DodgerBlue;'><i>consolidation</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>VECOPA</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Following two OEPA and one or two VECOPA cycles, involved field radiotherapy was applied. The main endpoint was feasibility. Secondary endpoints were toxicity, proportion of delayed cycles, granulocyte-colony stimulating factor use, and event-free and overall survival. The regimen was well tolerated with mostly hematotoxicity exceeding Common Toxicity Criteria grade 2. In most patients with advanced stage the second VECOPA cycle was delayed despite hematopoietic recovery and absence of serious adverse events. Event-free survival at 36 months was 0.86 (95% confidence interval 0.70-1). The VECOPA regimen is effective and tolerable. However, its time-intensification was not fully exploited within this trial.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"feasibility","start":4,"end":15,"id":1,"ws":true},{"text":"and","start":16,"end":19,"id":2,"ws":true},{"text":"efficacy","start":20,"end":28,"id":3,"ws":true},{"text":"of","start":29,"end":31,"id":4,"ws":true},{"text":"an","start":32,"end":34,"id":5,"ws":true},{"text":"intensified","start":35,"end":46,"id":6,"ws":true},{"text":"procarbazine-free","start":47,"end":64,"id":7,"ws":true},{"text":"consolidation","start":65,"end":78,"id":8,"ws":true},{"text":"regimen","start":79,"end":86,"id":9,"ws":true},{"text":"VECOPA","start":87,"end":93,"id":10,"ws":true},{"text":"(","start":94,"end":95,"id":11,"ws":true},{"text":"vinblastine","start":96,"end":107,"id":12,"ws":true},{"text":",","start":108,"end":109,"id":13,"ws":true},{"text":"etoposide","start":110,"end":119,"id":14,"ws":true},{"text":",","start":120,"end":121,"id":15,"ws":true},{"text":"cyclophosphamide","start":122,"end":138,"id":16,"ws":true},{"text":",","start":139,"end":140,"id":17,"ws":true},{"text":"vincristine","start":141,"end":152,"id":18,"ws":true},{"text":",","start":153,"end":154,"id":19,"ws":true},{"text":"prednisone","start":155,"end":165,"id":20,"ws":true},{"text":",","start":166,"end":167,"id":21,"ws":true},{"text":"doxorubicin","start":168,"end":179,"id":22,"ws":true},{"text":")","start":180,"end":181,"id":23,"ws":true},{"text":"were","start":182,"end":186,"id":24,"ws":true},{"text":"investigated","start":187,"end":199,"id":25,"ws":true},{"text":".","start":200,"end":201,"id":26,"ws":false}],"spans":[{"start":96,"end":107,"token_start":12,"token_end":12,"label":"DRUG"},{"start":110,"end":119,"token_start":14,"token_end":14,"label":"DRUG"},{"start":122,"end":138,"token_start":16,"token_end":16,"label":"DRUG"},{"start":141,"end":152,"token_start":18,"token_end":18,"label":"DRUG"},{"start":155,"end":165,"token_start":20,"token_end":20,"label":"DRUG"},{"start":168,"end":179,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25204374/","_input_hash":-1137194698,"_task_hash":-273439235,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":96,"end":107,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":110,"end":119,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":14,"child":16,"head_span":{"start":110,"end":119,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":122,"end":138,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":16,"child":18,"head_span":{"start":122,"end":138,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":141,"end":152,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":18,"child":20,"head_span":{"start":141,"end":152,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":155,"end":165,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":20,"child":22,"head_span":{"start":155,"end":165,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":168,"end":179,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The combination regimen of nivolumab plus ipilimumab demonstrates activity in metastatic uveal melanoma , with deep and sustained confirmed responses .","paragraph":"<h3><u>Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.</u></h3>Metastatic uveal melanoma has poor overall survival (OS) and no approved systemic therapy options. Studies of single-agent immunotherapy regimens have shown minimal benefit. There is the potential for improved responses with the use of combination immunotherapy. ### Patients And Methods We conducted a phase II study of <b style='color:Tomato;'><i>nivolumab</i></b> with <b style='color:Tomato;'><i>ipilimumab</i></b> in patients with metastatic uveal melanoma. Any number of prior treatments was permitted. Patients received <b style='color:Tomato;'><i>nivolumab</i></b> 1 mg/kg and <b style='color:Tomato;'><i>ipilimumab</i></b> 3 mg/kg for four cycles, followed by <b style='color:Tomato;'><i>nivolumab</i></b> maintenance therapy for up to 2 years. The primary outcome of the study was overall response rate (ORR) as determined by RECIST 1.1 criteria. Progression-free survival (PFS), OS, and adverse events were also assessed. ### results Thirty-five patients were enrolled, and 33 patients were evaluable for efficacy. The ORR was 18%, including one confirmed complete response and five confirmed partial responses. The median PFS was 5.5 months (95% CI, 3.4 to 9.5 months), and the median OS was 19.1 months (95% CI, 9.6 months to NR). Forty percent of patients experienced a grade 3-4 treatment-related adverse event. ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>demonstrates</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>uveal</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>deep</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>sustained</i></b> <b style='color:DodgerBlue;'><i>confirmed</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combination","start":4,"end":15,"id":1,"ws":true},{"text":"regimen","start":16,"end":23,"id":2,"ws":true},{"text":"of","start":24,"end":26,"id":3,"ws":true},{"text":"nivolumab","start":27,"end":36,"id":4,"ws":true},{"text":"plus","start":37,"end":41,"id":5,"ws":true},{"text":"ipilimumab","start":42,"end":52,"id":6,"ws":true},{"text":"demonstrates","start":53,"end":65,"id":7,"ws":true},{"text":"activity","start":66,"end":74,"id":8,"ws":true},{"text":"in","start":75,"end":77,"id":9,"ws":true},{"text":"metastatic","start":78,"end":88,"id":10,"ws":true},{"text":"uveal","start":89,"end":94,"id":11,"ws":true},{"text":"melanoma","start":95,"end":103,"id":12,"ws":true},{"text":",","start":104,"end":105,"id":13,"ws":true},{"text":"with","start":106,"end":110,"id":14,"ws":true},{"text":"deep","start":111,"end":115,"id":15,"ws":true},{"text":"and","start":116,"end":119,"id":16,"ws":true},{"text":"sustained","start":120,"end":129,"id":17,"ws":true},{"text":"confirmed","start":130,"end":139,"id":18,"ws":true},{"text":"responses","start":140,"end":149,"id":19,"ws":true},{"text":".","start":150,"end":151,"id":20,"ws":false}],"spans":[{"start":27,"end":36,"token_start":4,"token_end":4,"label":"DRUG"},{"start":42,"end":52,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33125309/","_input_hash":-1960347536,"_task_hash":1596022185,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":27,"end":36,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":42,"end":52,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The FDA reviewed data in electronic format from a randomized controlled clinical trial of 1106 adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase , comparing imatinib with the combination of IFN-alpha and cytarabine .","paragraph":"<h3><u>Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.</u></h3>The purpose is to describe the Food and Drug Administration (FDA) review and approval of <b style='color:Tomato;'><i>imatinib</i></b> (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in chronic phase. ### Experimental Design <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>FDA</i></b> <b style='color:DodgerBlue;'><i>reviewed</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>electronic</i></b> <b style='color:DodgerBlue;'><i>format</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>controlled</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>1106</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>newly</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>Philadelphia</i></b> <b style='color:DodgerBlue;'><i>chromosome-positive</i></b> <b style='color:DodgerBlue;'><i>CML</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>IFN-alpha</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results <b style='color:Tomato;'><i>imatinib</i></b> showed clinically and statistically significantly better results for time-to-progression to accelerated phase or blast crisis, progression-free survival, complete hematological response rate, and cytogenetic response rate. With a median follow-up of 14 months, a maximum follow-up of 19.5 months, and an expected median survival of 5-6 years on the IFN-alpha/<b style='color:Tomato;'><i>cytarabine</i></b> control arm, few of the expected progressions to accelerated or blast phase or deaths have occurred. <b style='color:Tomato;'><i>imatinib</i></b> was also better tolerated. Edema, nausea, rigors, neutropenia, and headache were more frequent in women. Only 57% of the IFN-alpha target dose was administered, and only 68% of patients received any <b style='color:Tomato;'><i>cytarabine</i></b>. However, this does not appear to adequately explain the superiority of <b style='color:Tomato;'><i>imatinib</i></b> observed in this trial. Results of a population pharmacokinetic study in a subgroup of 371 patients and a separate <b style='color:Tomato;'><i>rifampin</i></b>-<b style='color:Tomato;'><i>imatinib</i></b> drug-drug interaction study in healthy volunteers are presented. ### conclusions On December 20, 2002, <b style='color:Tomato;'><i>imatinib</i></b> was granted accelerated approval under subpart H, rather than regular approval. Follow-up is short compared with the natural history of chronic phase CML or more mature results with established therapies such as IFN-alpha or transplantation. If <b style='color:Tomato;'><i>imatinib</i></b> should stop working after 1.5-2 years, the results could be importantly different from the present analysis. As a Phase IV postmarketing commitment, the applicant has agreed to provide follow-up reports on this <b style='color:Tomato;'><i>imatinib</i></b> study annually for the next 6 years.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"FDA","start":4,"end":7,"id":1,"ws":true},{"text":"reviewed","start":8,"end":16,"id":2,"ws":true},{"text":"data","start":17,"end":21,"id":3,"ws":true},{"text":"in","start":22,"end":24,"id":4,"ws":true},{"text":"electronic","start":25,"end":35,"id":5,"ws":true},{"text":"format","start":36,"end":42,"id":6,"ws":true},{"text":"from","start":43,"end":47,"id":7,"ws":true},{"text":"a","start":48,"end":49,"id":8,"ws":true},{"text":"randomized","start":50,"end":60,"id":9,"ws":true},{"text":"controlled","start":61,"end":71,"id":10,"ws":true},{"text":"clinical","start":72,"end":80,"id":11,"ws":true},{"text":"trial","start":81,"end":86,"id":12,"ws":true},{"text":"of","start":87,"end":89,"id":13,"ws":true},{"text":"1106","start":90,"end":94,"id":14,"ws":true},{"text":"adult","start":95,"end":100,"id":15,"ws":true},{"text":"patients","start":101,"end":109,"id":16,"ws":true},{"text":"with","start":110,"end":114,"id":17,"ws":true},{"text":"newly","start":115,"end":120,"id":18,"ws":true},{"text":"diagnosed","start":121,"end":130,"id":19,"ws":true},{"text":"Philadelphia","start":131,"end":143,"id":20,"ws":true},{"text":"chromosome-positive","start":144,"end":163,"id":21,"ws":true},{"text":"CML","start":164,"end":167,"id":22,"ws":true},{"text":"in","start":168,"end":170,"id":23,"ws":true},{"text":"chronic","start":171,"end":178,"id":24,"ws":true},{"text":"phase","start":179,"end":184,"id":25,"ws":true},{"text":",","start":185,"end":186,"id":26,"ws":true},{"text":"comparing","start":187,"end":196,"id":27,"ws":true},{"text":"imatinib","start":197,"end":205,"id":28,"ws":true},{"text":"with","start":206,"end":210,"id":29,"ws":true},{"text":"the","start":211,"end":214,"id":30,"ws":true},{"text":"combination","start":215,"end":226,"id":31,"ws":true},{"text":"of","start":227,"end":229,"id":32,"ws":true},{"text":"IFN-alpha","start":230,"end":239,"id":33,"ws":true},{"text":"and","start":240,"end":243,"id":34,"ws":true},{"text":"cytarabine","start":244,"end":254,"id":35,"ws":true},{"text":".","start":255,"end":256,"id":36,"ws":false}],"spans":[{"start":197,"end":205,"token_start":28,"token_end":28,"label":"DRUG"},{"start":230,"end":239,"token_start":33,"token_end":33,"label":"DRUG"},{"start":244,"end":254,"token_start":35,"token_end":35,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12796358/","_input_hash":-2061684921,"_task_hash":117573876,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":33,"child":35,"head_span":{"start":230,"end":239,"token_start":33,"token_end":33,"label":"DRUG"},"child_span":{"start":244,"end":254,"token_start":35,"token_end":35,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"A total of 164 patients with recurrent ovarian cancer were selected and randomly divided into two groups : experimental group ( n=82 , BEV + paclitaxel + carboplatin ) and control group ( n=82 , paclitaxel + carboplatin ) .","paragraph":"<h3><u>Therapeutic effect of bevacizumab combined with paclitaxel and carboplatin on recurrent ovarian cancer.</u></h3>To observe the clinical efficacy and safety of <b style='color:Tomato;'><i>bevacizumab</i></b> (BEV) combined with <b style='color:Tomato;'><i>paclitaxel</i></b> on recurrent ovarian cancer. ### methods <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>164</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>selected</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>divided</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=82</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>BEV</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=82</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The clinical therapeutic effects including objective response rate (ORR), complete response (CR) rate, partial response (PR) rate, stable disease (SD), progressive disease (PD), progression free survival (PFS) and overall survival (OS) were evaluated, together with the adverse clinical reactions and improvement of quality of life (QoL). Immunohistochemistry was used to detect the expression of phosphate and tension homology deleted on chromosome ten (PTEN). ### results The PFS, OS and ORR of patients in the experimental group were significantly higher than those in the control group (p<0.05). In addition, the incidence rates of allergy, gastrointestinal reactions and leukopenia were significantly lower in the experimental group compared with those in the control group (p<0.05). There was no significant difference in QoL score between the two groups before treatment (p>0.05). However, after treatment, the QoL score in the experimental group was increased significantly compared with the control group (p<0.05). Moreover, the expression of PTEN in PR, SD and PD patients was lower, with significant difference between the two groups (p<0.05). ### conclusion The clinical therapeutic effect of BEV combined with <b style='color:Tomato;'><i>paclitaxel</i></b> in patients with recurrent ovarian cancer was improved, suggesting it might be beneficial for the treatment of ovarian cancer.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"total","start":2,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"164","start":11,"end":14,"id":3,"ws":true},{"text":"patients","start":15,"end":23,"id":4,"ws":true},{"text":"with","start":24,"end":28,"id":5,"ws":true},{"text":"recurrent","start":29,"end":38,"id":6,"ws":true},{"text":"ovarian","start":39,"end":46,"id":7,"ws":true},{"text":"cancer","start":47,"end":53,"id":8,"ws":true},{"text":"were","start":54,"end":58,"id":9,"ws":true},{"text":"selected","start":59,"end":67,"id":10,"ws":true},{"text":"and","start":68,"end":71,"id":11,"ws":true},{"text":"randomly","start":72,"end":80,"id":12,"ws":true},{"text":"divided","start":81,"end":88,"id":13,"ws":true},{"text":"into","start":89,"end":93,"id":14,"ws":true},{"text":"two","start":94,"end":97,"id":15,"ws":true},{"text":"groups","start":98,"end":104,"id":16,"ws":true},{"text":":","start":105,"end":106,"id":17,"ws":true},{"text":"experimental","start":107,"end":119,"id":18,"ws":true},{"text":"group","start":120,"end":125,"id":19,"ws":true},{"text":"(","start":126,"end":127,"id":20,"ws":true},{"text":"n=82","start":128,"end":132,"id":21,"ws":true},{"text":",","start":133,"end":134,"id":22,"ws":true},{"text":"BEV","start":135,"end":138,"id":23,"ws":true},{"text":"+","start":139,"end":140,"id":24,"ws":true},{"text":"paclitaxel","start":141,"end":151,"id":25,"ws":true},{"text":"+","start":152,"end":153,"id":26,"ws":true},{"text":"carboplatin","start":154,"end":165,"id":27,"ws":true},{"text":")","start":166,"end":167,"id":28,"ws":true},{"text":"and","start":168,"end":171,"id":29,"ws":true},{"text":"control","start":172,"end":179,"id":30,"ws":true},{"text":"group","start":180,"end":185,"id":31,"ws":true},{"text":"(","start":186,"end":187,"id":32,"ws":true},{"text":"n=82","start":188,"end":192,"id":33,"ws":true},{"text":",","start":193,"end":194,"id":34,"ws":true},{"text":"paclitaxel","start":195,"end":205,"id":35,"ws":true},{"text":"+","start":206,"end":207,"id":36,"ws":true},{"text":"carboplatin","start":208,"end":219,"id":37,"ws":true},{"text":")","start":220,"end":221,"id":38,"ws":true},{"text":".","start":222,"end":223,"id":39,"ws":false}],"spans":[{"start":141,"end":151,"token_start":25,"token_end":25,"label":"DRUG"},{"start":154,"end":165,"token_start":27,"token_end":27,"label":"DRUG"},{"start":195,"end":205,"token_start":35,"token_end":35,"label":"DRUG"},{"start":208,"end":219,"token_start":37,"token_end":37,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31424654/","_input_hash":255029221,"_task_hash":-611066734,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":23,"child":25,"head_span":{"start":135,"end":138,"token_start":23,"token_end":23,"label":null},"child_span":{"start":141,"end":151,"token_start":25,"token_end":25,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":27,"child":25,"head_span":{"start":154,"end":165,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":141,"end":151,"token_start":25,"token_end":25,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":35,"child":37,"head_span":{"start":195,"end":205,"token_start":35,"token_end":35,"label":"DRUG"},"child_span":{"start":208,"end":219,"token_start":37,"token_end":37,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Successful treatment of an adult with Kasabach-Merritt syndrome using thalidomide , vincristine , and prednisone .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Successful</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>Kasabach-Merritt</i></b> <b style='color:DodgerBlue;'><i>syndrome</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Kasabach-Merritt syndrome is a rare disease that mainly occurs in infants and adolescents. It usually manifests as disseminated intravascular coagulation and severe bleeding, and is associated with high mortality. However, its low incidence and clinical rarity in adults mean that there is currently no well-verified treatment regimen for this disease. We report on an effective novel therapeutic regimen in a patient with Kasabach-Merritt syndrome. ### methods A woman with Kasabach-Merritt syndrome presented with a recurrent subcutaneous mass and disseminated intravascular coagulation, and was treated with <b style='color:Tomato;'><i>prednisone</i></b>, <b style='color:Tomato;'><i>vincristine</i></b> and <b style='color:Tomato;'><i>thalidomide</i></b>. ### results This treatment regimen successfully resolved the patient's symptoms, with tumor regression. The patient remained disease-free after 6 years of follow-up. ### conclusions <b style='color:Tomato;'><i>prednisone</i></b> combined with <b style='color:Tomato;'><i>vincristine</i></b> and <b style='color:Tomato;'><i>thalidomide</i></b> may be an effective treatment for Kasabach-Merritt syndrome, but further studies are needed to verify the use of this regimen.","tokens":[{"text":"Successful","start":0,"end":10,"id":0,"ws":true},{"text":"treatment","start":11,"end":20,"id":1,"ws":true},{"text":"of","start":21,"end":23,"id":2,"ws":true},{"text":"an","start":24,"end":26,"id":3,"ws":true},{"text":"adult","start":27,"end":32,"id":4,"ws":true},{"text":"with","start":33,"end":37,"id":5,"ws":true},{"text":"Kasabach-Merritt","start":38,"end":54,"id":6,"ws":true},{"text":"syndrome","start":55,"end":63,"id":7,"ws":true},{"text":"using","start":64,"end":69,"id":8,"ws":true},{"text":"thalidomide","start":70,"end":81,"id":9,"ws":true},{"text":",","start":82,"end":83,"id":10,"ws":true},{"text":"vincristine","start":84,"end":95,"id":11,"ws":true},{"text":",","start":96,"end":97,"id":12,"ws":true},{"text":"and","start":98,"end":101,"id":13,"ws":true},{"text":"prednisone","start":102,"end":112,"id":14,"ws":true},{"text":".","start":113,"end":114,"id":15,"ws":false}],"spans":[{"start":70,"end":81,"token_start":9,"token_end":9,"label":"DRUG"},{"start":84,"end":95,"token_start":11,"token_end":11,"label":"DRUG"},{"start":102,"end":112,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30806107/","_input_hash":1375470345,"_task_hash":1785747830,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":70,"end":81,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":84,"end":95,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":11,"child":14,"head_span":{"start":84,"end":95,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":102,"end":112,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Superiority of sirolimus ( rapamycin ) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Superiority</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>sirolimus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>augmenting</i></b> <b style='color:DodgerBlue;'><i>allograft</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>xenograft</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>antilymphocyte</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>donor-specific</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>sirolimus</i></b> is a potent immunosuppressive agent with great therapeutic potential. The objective of our study was to evaluate the efficacy of <b style='color:Tomato;'><i>sirolimus</i></b> versus <b style='color:Tomato;'><i>cyclosporin</i></b>e in augmenting the unresponsiveness induced by an antilymphocyte serum (ALS)/donor-specific bone marrow (BM)-based regimen across three levels of histoincompatibility: class I and II disparate (DBA/2 to B6AF1), complete mismatch (AKR to C57BL/6), and xenograft (ACI rat to B6AF1). ### methods Full-thickness skin grafts were taken from donors and placed on recipients in standard fashion. Seven groups of recipient mice (n=10-28) received various combinations of the following treatment protocols: <b style='color:Tomato;'><i>sirolimus</i></b>, 1.5 mg/kg (3.0 mg/kg for xenografts) every other day from day 0 to day 12; <b style='color:Tomato;'><i>cyclosporin</i></b>e, 50 mg/kg every other day from day 10 through 22; ALS, 0.5 ml on days -1 and 2 for allografts and days -1, 2, and 4 for xenografts; and BM, 25 million donor-specific cells IV on day 7. ### results The administration of ALS or ALS/BM resulted in modest but significant prolongation of skin graft survival in all combinations tested. <b style='color:Tomato;'><i>cyclosporin</i></b>e combined with ALS or ALS/BM significantly extended allograft survival compared with ALS or ALS/BM alone (P<0.05) but had no effect on xenograft survival. In contrast, the combination of <b style='color:Tomato;'><i>sirolimus</i></b> with ALS or ALS/BM resulted in a two- to threefold increase in allograft survival and over a fourfold increase in xenograft survival when compared with the comparable <b style='color:Tomato;'><i>cyclosporin</i></b>e-based regimen. Additionally, lymphocytes isolated from class I and II incompatible mice with skin grafts surviving >100 days demonstrated markedly reduced interleukin 2 and interferon-gamma secretion in response to irradiated donor-specific lymphocytes in culture. ### conclusions In the regimens tested, <b style='color:Tomato;'><i>sirolimus</i></b> was superior to <b style='color:Tomato;'><i>cyclosporin</i></b>e in augmenting donor BM-induced skin graft prolongation in ALS-treated mice across all levels of histoincompatibility.","tokens":[{"text":"Superiority","start":0,"end":11,"id":0,"ws":true},{"text":"of","start":12,"end":14,"id":1,"ws":true},{"text":"sirolimus","start":15,"end":24,"id":2,"ws":true},{"text":"(","start":25,"end":26,"id":3,"ws":true},{"text":"rapamycin","start":27,"end":36,"id":4,"ws":true},{"text":")","start":37,"end":38,"id":5,"ws":true},{"text":"over","start":39,"end":43,"id":6,"ws":true},{"text":"cyclosporine","start":44,"end":56,"id":7,"ws":true},{"text":"in","start":57,"end":59,"id":8,"ws":true},{"text":"augmenting","start":60,"end":70,"id":9,"ws":true},{"text":"allograft","start":71,"end":80,"id":10,"ws":true},{"text":"and","start":81,"end":84,"id":11,"ws":true},{"text":"xenograft","start":85,"end":94,"id":12,"ws":true},{"text":"survival","start":95,"end":103,"id":13,"ws":true},{"text":"in","start":104,"end":106,"id":14,"ws":true},{"text":"mice","start":107,"end":111,"id":15,"ws":true},{"text":"treated","start":112,"end":119,"id":16,"ws":true},{"text":"with","start":120,"end":124,"id":17,"ws":true},{"text":"antilymphocyte","start":125,"end":139,"id":18,"ws":true},{"text":"serum","start":140,"end":145,"id":19,"ws":true},{"text":"and","start":146,"end":149,"id":20,"ws":true},{"text":"donor-specific","start":150,"end":164,"id":21,"ws":true},{"text":"bone","start":165,"end":169,"id":22,"ws":true},{"text":"marrow","start":170,"end":176,"id":23,"ws":true},{"text":".","start":177,"end":178,"id":24,"ws":false}],"spans":[{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},{"start":27,"end":36,"token_start":4,"token_end":4,"label":"DRUG"},{"start":44,"end":56,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9039923/","_input_hash":164148955,"_task_hash":800843899,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Profiling of drug-metabolizing enzymes/transporters in CD33 + acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine , Cytarabine and Idarubicin .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Profiling</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>drug-metabolizing</i></b> <b style='color:DodgerBlue;'><i>enzymes/transporters</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>CD33</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myeloid</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>Gemtuzumab-Ozogamicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Fludarabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Cytarabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Idarubicin</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Genetic heterogeneity in drug-metabolizing enzyme/transporter (DMET) genes affects specific drug-related cancer phenotypes. To investigate the relationships between genetic variation and response to treatment in acute myeloid leukemia (AML), we genotyped 1931 variants on DMET genes in 94 CD33-positive AML patients enrolled in a phase III multicenter clinical trial combining Gemtuzumab-<b style='color:Tomato;'><i>ozogamicin</i></b> (GO) with <b style='color:Tomato;'><i>fludarabine</i></b>-<b style='color:Tomato;'><i>cytarabine</i></b>-<b style='color:Tomato;'><i>idarubicin</i></b> (FLAI) regimen, with the DMET Plus platform. Two ADH1A variants showed statistically significant differences (odds ratio (OR)=5.68, P=0.0006; OR=5.35, P=0.0009) in allele frequencies between patients in complete/partial remission and patients without response, two substitutions on CYP2E1 (OR=0.13, P=0.001; OR=0.09, P=0.003) and one on SLCO1B1 (OR=4.68, P=0.002) were found to differently influence liver toxicity, and two nucleotide changes on SULTB1 and SLC22A12 genes correlated with response to GO (OR=0.24, P=0.0009; OR=2.75, P=0.0029). Genetic variants were thus found for the first time to be potentially associated with differential response and toxicity in AML patients treated with a combination of GO-FLAI regimen.","tokens":[{"text":"Profiling","start":0,"end":9,"id":0,"ws":true},{"text":"of","start":10,"end":12,"id":1,"ws":true},{"text":"drug-metabolizing","start":13,"end":30,"id":2,"ws":true},{"text":"enzymes/transporters","start":31,"end":51,"id":3,"ws":true},{"text":"in","start":52,"end":54,"id":4,"ws":true},{"text":"CD33","start":55,"end":59,"id":5,"ws":true},{"text":"+","start":60,"end":61,"id":6,"ws":true},{"text":"acute","start":62,"end":67,"id":7,"ws":true},{"text":"myeloid","start":68,"end":75,"id":8,"ws":true},{"text":"leukemia","start":76,"end":84,"id":9,"ws":true},{"text":"patients","start":85,"end":93,"id":10,"ws":true},{"text":"treated","start":94,"end":101,"id":11,"ws":true},{"text":"with","start":102,"end":106,"id":12,"ws":true},{"text":"Gemtuzumab-Ozogamicin","start":107,"end":128,"id":13,"ws":true},{"text":"and","start":129,"end":132,"id":14,"ws":true},{"text":"Fludarabine","start":133,"end":144,"id":15,"ws":true},{"text":",","start":145,"end":146,"id":16,"ws":true},{"text":"Cytarabine","start":147,"end":157,"id":17,"ws":true},{"text":"and","start":158,"end":161,"id":18,"ws":true},{"text":"Idarubicin","start":162,"end":172,"id":19,"ws":true},{"text":".","start":173,"end":174,"id":20,"ws":false}],"spans":[{"start":107,"end":128,"token_start":13,"token_end":13,"label":"DRUG"},{"start":133,"end":144,"token_start":15,"token_end":15,"label":"DRUG"},{"start":147,"end":157,"token_start":17,"token_end":17,"label":"DRUG"},{"start":162,"end":172,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22584460/","_input_hash":-1106265043,"_task_hash":609859858,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":107,"end":128,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":133,"end":144,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":15,"child":17,"head_span":{"start":133,"end":144,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":147,"end":157,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":17,"child":19,"head_span":{"start":147,"end":157,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":162,"end":172,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In addition , anti-PCSK9 drugs ( evolocumab and alirocumab ) provide an effective solution for patients with familial hypercholesterolemia ( FH ) and statin intolerance at very high cardiovascular risk .","paragraph":"<h3><u>Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs.</u></h3>Prevention and treatment of dyslipidemia should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, as they have been shown to reduce the risk of major vascular events by lowering low-density lipoprotein cholesterol (LDL-C). However, due to adherence to statin therapy or statin resistance, many patients do not reach LDL-C target levels. <b style='color:Tomato;'><i>ezetimibe</i></b>, fibrates, and nicotinic acid represent the second-choice drugs to be used in combination with statins if lipid targets cannot be reached. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>anti-PCSK9</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>evolocumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>alirocumab</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>provide</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>solution</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>familial</i></b> <b style='color:DodgerBlue;'><i>hypercholesterolemia</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FH</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>statin</i></b> <b style='color:DodgerBlue;'><i>intolerance</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>very</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Recently, studies demonstrated the effects of two novel lipid-lowering agents (<b style='color:Tomato;'><i>lomitapide</i></b> and mipomersen) for the management of homozygous FH by decreasing LDL-C values and reducing cardiovascular events. However, the costs for these new therapies made the cost-effectiveness debate more complicated.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"addition","start":3,"end":11,"id":1,"ws":true},{"text":",","start":12,"end":13,"id":2,"ws":true},{"text":"anti-PCSK9","start":14,"end":24,"id":3,"ws":true},{"text":"drugs","start":25,"end":30,"id":4,"ws":true},{"text":"(","start":31,"end":32,"id":5,"ws":true},{"text":"evolocumab","start":33,"end":43,"id":6,"ws":true},{"text":"and","start":44,"end":47,"id":7,"ws":true},{"text":"alirocumab","start":48,"end":58,"id":8,"ws":true},{"text":")","start":59,"end":60,"id":9,"ws":true},{"text":"provide","start":61,"end":68,"id":10,"ws":true},{"text":"an","start":69,"end":71,"id":11,"ws":true},{"text":"effective","start":72,"end":81,"id":12,"ws":true},{"text":"solution","start":82,"end":90,"id":13,"ws":true},{"text":"for","start":91,"end":94,"id":14,"ws":true},{"text":"patients","start":95,"end":103,"id":15,"ws":true},{"text":"with","start":104,"end":108,"id":16,"ws":true},{"text":"familial","start":109,"end":117,"id":17,"ws":true},{"text":"hypercholesterolemia","start":118,"end":138,"id":18,"ws":true},{"text":"(","start":139,"end":140,"id":19,"ws":true},{"text":"FH","start":141,"end":143,"id":20,"ws":true},{"text":")","start":144,"end":145,"id":21,"ws":true},{"text":"and","start":146,"end":149,"id":22,"ws":true},{"text":"statin","start":150,"end":156,"id":23,"ws":true},{"text":"intolerance","start":157,"end":168,"id":24,"ws":true},{"text":"at","start":169,"end":171,"id":25,"ws":true},{"text":"very","start":172,"end":176,"id":26,"ws":true},{"text":"high","start":177,"end":181,"id":27,"ws":true},{"text":"cardiovascular","start":182,"end":196,"id":28,"ws":true},{"text":"risk","start":197,"end":201,"id":29,"ws":true},{"text":".","start":202,"end":203,"id":30,"ws":false}],"spans":[{"start":33,"end":43,"token_start":6,"token_end":6,"label":"DRUG"},{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29361723/","_input_hash":1233389599,"_task_hash":-754149707,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Likewise , emotional , functional well-being , and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group ( P<0.05 ) .","paragraph":"<h3><u>[A randomized clinical study of Gefitinib and pemetrexed as second line therapy for advanced non-squamous non-small cell lung cancer].</u></h3><b style='color:Tomato;'><i>gefitinib</i></b> and <b style='color:Tomato;'><i>pemetrexed</i></b> are drugs used as second-line therapy for advanced non-small cell lung cancer (NSCLC), although studies comparing the two drugs are limited. The aim of this study is to explore the effects, safety, and quality of life (QoL) of <b style='color:Tomato;'><i>gefitinib</i></b> and <b style='color:Tomato;'><i>pemetrexed</i></b> on patients with advanced non-squamous NSCLC. ### methods Forty-six advanced non-squamous NSCLC patients who failed to first-line therapy were randomly divided into two groups with 23 patients each, one using oral <b style='color:Tomato;'><i>gefitinib</i></b> (<b style='color:Tomato;'><i>gefitinib</i></b> group) and the other using intravenous injection <b style='color:Tomato;'><i>pemetrexed</i></b> (<b style='color:Tomato;'><i>pemetrexed</i></b> group). The effects, safety, and QoL were determined and analyzed. ### results For the <b style='color:Tomato;'><i>pemetrexed</i></b> group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months. In the <b style='color:Tomato;'><i>gefitinib</i></b> group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months. Compared with the <b style='color:Tomato;'><i>pemetrexed</i></b> group, the ORR, DCR, and mPFS in the <b style='color:Tomato;'><i>gefitinib</i></b> group exhibited no statistical significance (P>0.05). Furthermore, the most common toxicities in the <b style='color:Tomato;'><i>pemetrexed</i></b> group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in <b style='color:Tomato;'><i>gefitinib</i></b> group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%). Compared with baseline, the QoL improved in both groups but to different degrees. <b style='color:DodgerBlue;'><i>Likewise</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>emotional</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>well-being</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>QoL</i></b> <b style='color:DodgerBlue;'><i>aspects</i></b> <b style='color:DodgerBlue;'><i>specifically</i></b> <b style='color:DodgerBlue;'><i>related</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>better</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>Gefitinib</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>Pemetrexed</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P<0.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions The effects of <b style='color:Tomato;'><i>pemetrexed</i></b> and <b style='color:Tomato;'><i>gefitinib</i></b> as second line therapy were similar, although with different AEs. Both drugs could improve the QoL, but <b style='color:Tomato;'><i>gefitinib</i></b> showed better overall results than <b style='color:Tomato;'><i>pemetrexed</i></b>.","tokens":[{"text":"Likewise","start":0,"end":8,"id":0,"ws":true},{"text":",","start":9,"end":10,"id":1,"ws":true},{"text":"emotional","start":11,"end":20,"id":2,"ws":true},{"text":",","start":21,"end":22,"id":3,"ws":true},{"text":"functional","start":23,"end":33,"id":4,"ws":true},{"text":"well-being","start":34,"end":44,"id":5,"ws":true},{"text":",","start":45,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"QoL","start":51,"end":54,"id":8,"ws":true},{"text":"aspects","start":55,"end":62,"id":9,"ws":true},{"text":"specifically","start":63,"end":75,"id":10,"ws":true},{"text":"related","start":76,"end":83,"id":11,"ws":true},{"text":"to","start":84,"end":86,"id":12,"ws":true},{"text":"lung","start":87,"end":91,"id":13,"ws":true},{"text":"cancer","start":92,"end":98,"id":14,"ws":true},{"text":"were","start":99,"end":103,"id":15,"ws":true},{"text":"better","start":104,"end":110,"id":16,"ws":true},{"text":"improved","start":111,"end":119,"id":17,"ws":true},{"text":"in","start":120,"end":122,"id":18,"ws":true},{"text":"the","start":123,"end":126,"id":19,"ws":true},{"text":"Gefitinib","start":127,"end":136,"id":20,"ws":true},{"text":"group","start":137,"end":142,"id":21,"ws":true},{"text":"than","start":143,"end":147,"id":22,"ws":true},{"text":"in","start":148,"end":150,"id":23,"ws":true},{"text":"the","start":151,"end":154,"id":24,"ws":true},{"text":"Pemetrexed","start":155,"end":165,"id":25,"ws":true},{"text":"group","start":166,"end":171,"id":26,"ws":true},{"text":"(","start":172,"end":173,"id":27,"ws":true},{"text":"P<0.05","start":174,"end":180,"id":28,"ws":true},{"text":")","start":181,"end":182,"id":29,"ws":true},{"text":".","start":183,"end":184,"id":30,"ws":false}],"spans":[{"start":127,"end":136,"token_start":20,"token_end":20,"label":"DRUG"},{"start":155,"end":165,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23945243/","_input_hash":1859641829,"_task_hash":1091363367,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"To determine efficacy and safety of the association of IL-1 receptor antagonist anakinra plus methylprednisolone in severe COVID-19 pneumonia with hyperinflammation .","paragraph":"<h3><u>Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.</u></h3>Immunomodulants have been proposed to mitigate SARS-Cov-2-induced cytokine storm, which drives acute respiratory distress syndrome in COVID-19. ### objective <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>association</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>IL-1</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:MediumOrchid;'><i>anakinra</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>COVID-19</i></b> <b style='color:DodgerBlue;'><i>pneumonia</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>hyperinflammation</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Secondary analysis of prospective observational cohort studies at an Italian tertiary health-care facility. COVID-19 patients consecutively hospitalized (02/25/2020 to 03/30/2020), with hyperinflammation (ferritin \u22651000ng/mL and/or C-reactive protein >10mg/dL) and respiratory failure (oxygen therapy from 0.4 FiO2 Venturi mask to invasive mechanical ventilation) were evaluated to investigate the effect of high-dose <b style='color:Tomato;'><i>anakinra</i></b> plus <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> on survival. Patients were followed from study inclusion to day 28 or death. Crude and adjusted (sex, age, baseline PaO ### results 120 COVID-19 patients with hyperinflammation (median age 62 years, 80.0% males, median PaO ### conclusions Treatment with <b style='color:Tomato;'><i>anakinra</i></b> plus <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> may be a valid therapeutic option in COVID-19 patients with hyperinflammation and respiratory failure, also on mechanical ventilation. Randomized, controlled trials including use of either agent alone are needed to confirm these results.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"determine","start":3,"end":12,"id":1,"ws":true},{"text":"efficacy","start":13,"end":21,"id":2,"ws":true},{"text":"and","start":22,"end":25,"id":3,"ws":true},{"text":"safety","start":26,"end":32,"id":4,"ws":true},{"text":"of","start":33,"end":35,"id":5,"ws":true},{"text":"the","start":36,"end":39,"id":6,"ws":true},{"text":"association","start":40,"end":51,"id":7,"ws":true},{"text":"of","start":52,"end":54,"id":8,"ws":true},{"text":"IL-1","start":55,"end":59,"id":9,"ws":true},{"text":"receptor","start":60,"end":68,"id":10,"ws":true},{"text":"antagonist","start":69,"end":79,"id":11,"ws":true},{"text":"anakinra","start":80,"end":88,"id":12,"ws":true},{"text":"plus","start":89,"end":93,"id":13,"ws":true},{"text":"methylprednisolone","start":94,"end":112,"id":14,"ws":true},{"text":"in","start":113,"end":115,"id":15,"ws":true},{"text":"severe","start":116,"end":122,"id":16,"ws":true},{"text":"COVID-19","start":123,"end":131,"id":17,"ws":true},{"text":"pneumonia","start":132,"end":141,"id":18,"ws":true},{"text":"with","start":142,"end":146,"id":19,"ws":true},{"text":"hyperinflammation","start":147,"end":164,"id":20,"ws":true},{"text":".","start":165,"end":166,"id":21,"ws":false}],"spans":[{"start":80,"end":88,"token_start":12,"token_end":12,"label":"DRUG"},{"start":94,"end":112,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33220354/","_input_hash":-84801278,"_task_hash":-1044793918,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":80,"end":88,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":94,"end":112,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"When rats were given Li for 3 days , followed by a single injection of imipramine , the concentrations of desipramine in the brain and serum were higher than those in the vehicle-treated rat , although the imipramine concentrations in both tissues did not differ in Li- and in vehicle-treated rats .","paragraph":"<h3><u>Effects of lithium on alterations of pharmacokinetics of imipramine and on the related changes of monoamines in rat brain.</u></h3>Rats were given chronically i.p. <b style='color:Tomato;'><i>imipramine</i></b> (20 mg/kg), LiCl (1 mg/kg) or both drugs to examine the effects of lithium (Li) on the alterations of <b style='color:Tomato;'><i>imipramine</i></b> pharmacokinetics in the whole brain and on the <b style='color:Tomato;'><i>imipramine</i></b>-related changes of nor<b style='color:Tomato;'><i>epinephrine</i></b> (NE) and serotonin (5-HT) levels in the brain. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>rats</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>Li</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>injection</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>imipramine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>desipramine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>brain</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>vehicle-treated</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>although</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>imipramine</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>differ</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Li-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vehicle-treated</i></b> <b style='color:DodgerBlue;'><i>rats</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In rats receiving both drugs for 10 days, the steady state levels of <b style='color:Tomato;'><i>imipramine</i></b> and <b style='color:Tomato;'><i>desipramine</i></b> in the brain were the same as those in the vehicle-treated rats but the steady state level of <b style='color:Tomato;'><i>desipramine</i></b> was reached earlier with Li treatments presumably because of the enhanced demethylation of <b style='color:Tomato;'><i>imipramine</i></b>. Consequently, the <b style='color:Tomato;'><i>desipramine</i></b>-dependent alterations of NE and 3-methoxy-4-hydroxyphenylglycol levels in the brain appeared to be induced earlier and more markedly when Li was given simultaneously. As the 5-hydroxyindole acetic acid (5-HIAA) levels were elevated in the brains of Li-treated rats and reduced in brains of <b style='color:Tomato;'><i>imipramine</i></b>-treated rats as compared with the level in vehicle-treated rats, the 5-HIAA level in rats receiving both drugs was equivalent to that in vehicle-treated rats.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"rats","start":5,"end":9,"id":1,"ws":true},{"text":"were","start":10,"end":14,"id":2,"ws":true},{"text":"given","start":15,"end":20,"id":3,"ws":true},{"text":"Li","start":21,"end":23,"id":4,"ws":true},{"text":"for","start":24,"end":27,"id":5,"ws":true},{"text":"3","start":28,"end":29,"id":6,"ws":true},{"text":"days","start":30,"end":34,"id":7,"ws":true},{"text":",","start":35,"end":36,"id":8,"ws":true},{"text":"followed","start":37,"end":45,"id":9,"ws":true},{"text":"by","start":46,"end":48,"id":10,"ws":true},{"text":"a","start":49,"end":50,"id":11,"ws":true},{"text":"single","start":51,"end":57,"id":12,"ws":true},{"text":"injection","start":58,"end":67,"id":13,"ws":true},{"text":"of","start":68,"end":70,"id":14,"ws":true},{"text":"imipramine","start":71,"end":81,"id":15,"ws":true},{"text":",","start":82,"end":83,"id":16,"ws":true},{"text":"the","start":84,"end":87,"id":17,"ws":true},{"text":"concentrations","start":88,"end":102,"id":18,"ws":true},{"text":"of","start":103,"end":105,"id":19,"ws":true},{"text":"desipramine","start":106,"end":117,"id":20,"ws":true},{"text":"in","start":118,"end":120,"id":21,"ws":true},{"text":"the","start":121,"end":124,"id":22,"ws":true},{"text":"brain","start":125,"end":130,"id":23,"ws":true},{"text":"and","start":131,"end":134,"id":24,"ws":true},{"text":"serum","start":135,"end":140,"id":25,"ws":true},{"text":"were","start":141,"end":145,"id":26,"ws":true},{"text":"higher","start":146,"end":152,"id":27,"ws":true},{"text":"than","start":153,"end":157,"id":28,"ws":true},{"text":"those","start":158,"end":163,"id":29,"ws":true},{"text":"in","start":164,"end":166,"id":30,"ws":true},{"text":"the","start":167,"end":170,"id":31,"ws":true},{"text":"vehicle-treated","start":171,"end":186,"id":32,"ws":true},{"text":"rat","start":187,"end":190,"id":33,"ws":true},{"text":",","start":191,"end":192,"id":34,"ws":true},{"text":"although","start":193,"end":201,"id":35,"ws":true},{"text":"the","start":202,"end":205,"id":36,"ws":true},{"text":"imipramine","start":206,"end":216,"id":37,"ws":true},{"text":"concentrations","start":217,"end":231,"id":38,"ws":true},{"text":"in","start":232,"end":234,"id":39,"ws":true},{"text":"both","start":235,"end":239,"id":40,"ws":true},{"text":"tissues","start":240,"end":247,"id":41,"ws":true},{"text":"did","start":248,"end":251,"id":42,"ws":true},{"text":"not","start":252,"end":255,"id":43,"ws":true},{"text":"differ","start":256,"end":262,"id":44,"ws":true},{"text":"in","start":263,"end":265,"id":45,"ws":true},{"text":"Li-","start":266,"end":269,"id":46,"ws":true},{"text":"and","start":270,"end":273,"id":47,"ws":true},{"text":"in","start":274,"end":276,"id":48,"ws":true},{"text":"vehicle-treated","start":277,"end":292,"id":49,"ws":true},{"text":"rats","start":293,"end":297,"id":50,"ws":true},{"text":".","start":298,"end":299,"id":51,"ws":false}],"spans":[{"start":71,"end":81,"token_start":15,"token_end":15,"label":"DRUG"},{"start":106,"end":117,"token_start":20,"token_end":20,"label":"DRUG"},{"start":206,"end":216,"token_start":37,"token_end":37,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2625134/","_input_hash":-386093514,"_task_hash":-1278757705,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":4,"child":15,"head_span":{"start":21,"end":23,"token_start":4,"token_end":4,"label":null},"child_span":{"start":71,"end":81,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Using population-based data from the province of Ontario , the benefit of first-line ipilimumab was estimated by comparing outcomes of patients treated with first-line dacarbazine over the period 2007 - 2009 with patients treated over the period 2010 - 2015 with first-line ipilimumab .","paragraph":"<h3><u>A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma.</u></h3><b style='color:Tomato;'><i>ipilimumab</i></b> is an anti-CTLA4 monoclonal antibody with demonstrated efficacy for metastatic melanoma in randomized controlled trials, including in the first-line setting. Population-based outcomes directly compared with historic chemotherapy treatment in metastatic or unresectable melanoma are lacking. <b style='color:DodgerBlue;'><i>Using</i></b> <b style='color:DodgerBlue;'><i>population-based</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>province</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Ontario</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>estimated</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>period</i></b> <b style='color:DodgerBlue;'><i>2007</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2009</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>period</i></b> <b style='color:DodgerBlue;'><i>2010</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2015</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Cutaneous and noncutaneous cases were included. The administrative data set utilized was high-dimensional; meaning, there was a large number of variables relative to the sample size. To adjust for important confounders among the many available variables, we utilized a double-selection method, a modified machine learning algorithm to extract the important variables that were related to both survival times and treatment usage. Time-dependent treatment modeling was utilized. Among the 2793 melanoma patients receiving palliative treatment (systemic therapy, surgery, or radiation) in Ontario (2007-2015), there were 289 patients treated with first-line <b style='color:Tomato;'><i>ipilimumab</i></b> (2010-2015) and 175 patients treated with first-line <b style='color:Tomato;'><i>dacarbazine</i></b> (2007-2009). For first-line <b style='color:Tomato;'><i>ipilimumab</i></b>, the adjusted hazard ratio compared with <b style='color:Tomato;'><i>dacarbazine</i></b> for overall survival (OS) was 0.63 (95% confidence interval: 0.47-0.84) with a 1-year survival of 46.5 versus 18.9% with <b style='color:Tomato;'><i>dacarbazine</i></b>. In subgroup analysis, <b style='color:Tomato;'><i>ipilimumab</i></b> was associated with improved OS across groups (age, sex, comorbidity, income quintile, previous interferon). First-line <b style='color:Tomato;'><i>ipilimumab</i></b> was found to have a significant OS benefit compared with historical controls in a population including those patients not routinely included in clinical trials. The treatment effect was similar to randomized controlled trials, suggesting a meaningful benefit when utilized in a population-based setting.","tokens":[{"text":"Using","start":0,"end":5,"id":0,"ws":true},{"text":"population-based","start":6,"end":22,"id":1,"ws":true},{"text":"data","start":23,"end":27,"id":2,"ws":true},{"text":"from","start":28,"end":32,"id":3,"ws":true},{"text":"the","start":33,"end":36,"id":4,"ws":true},{"text":"province","start":37,"end":45,"id":5,"ws":true},{"text":"of","start":46,"end":48,"id":6,"ws":true},{"text":"Ontario","start":49,"end":56,"id":7,"ws":true},{"text":",","start":57,"end":58,"id":8,"ws":true},{"text":"the","start":59,"end":62,"id":9,"ws":true},{"text":"benefit","start":63,"end":70,"id":10,"ws":true},{"text":"of","start":71,"end":73,"id":11,"ws":true},{"text":"first-line","start":74,"end":84,"id":12,"ws":true},{"text":"ipilimumab","start":85,"end":95,"id":13,"ws":true},{"text":"was","start":96,"end":99,"id":14,"ws":true},{"text":"estimated","start":100,"end":109,"id":15,"ws":true},{"text":"by","start":110,"end":112,"id":16,"ws":true},{"text":"comparing","start":113,"end":122,"id":17,"ws":true},{"text":"outcomes","start":123,"end":131,"id":18,"ws":true},{"text":"of","start":132,"end":134,"id":19,"ws":true},{"text":"patients","start":135,"end":143,"id":20,"ws":true},{"text":"treated","start":144,"end":151,"id":21,"ws":true},{"text":"with","start":152,"end":156,"id":22,"ws":true},{"text":"first-line","start":157,"end":167,"id":23,"ws":true},{"text":"dacarbazine","start":168,"end":179,"id":24,"ws":true},{"text":"over","start":180,"end":184,"id":25,"ws":true},{"text":"the","start":185,"end":188,"id":26,"ws":true},{"text":"period","start":189,"end":195,"id":27,"ws":true},{"text":"2007","start":196,"end":200,"id":28,"ws":true},{"text":"-","start":201,"end":202,"id":29,"ws":true},{"text":"2009","start":203,"end":207,"id":30,"ws":true},{"text":"with","start":208,"end":212,"id":31,"ws":true},{"text":"patients","start":213,"end":221,"id":32,"ws":true},{"text":"treated","start":222,"end":229,"id":33,"ws":true},{"text":"over","start":230,"end":234,"id":34,"ws":true},{"text":"the","start":235,"end":238,"id":35,"ws":true},{"text":"period","start":239,"end":245,"id":36,"ws":true},{"text":"2010","start":246,"end":250,"id":37,"ws":true},{"text":"-","start":251,"end":252,"id":38,"ws":true},{"text":"2015","start":253,"end":257,"id":39,"ws":true},{"text":"with","start":258,"end":262,"id":40,"ws":true},{"text":"first-line","start":263,"end":273,"id":41,"ws":true},{"text":"ipilimumab","start":274,"end":284,"id":42,"ws":true},{"text":".","start":285,"end":286,"id":43,"ws":false}],"spans":[{"start":85,"end":95,"token_start":13,"token_end":13,"label":"DRUG"},{"start":168,"end":179,"token_start":24,"token_end":24,"label":"DRUG"},{"start":274,"end":284,"token_start":42,"token_end":42,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30789386/","_input_hash":-1307283051,"_task_hash":-848490144,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In the present study the combination of tamoxifen and bromocriptine was tried for the suppression of prolactin in prolactin secreting adenomas which were resistant to suppression with bromoergocriptine alone .","paragraph":"<h3><u>[Bromocriptine and tamoxifen--a new therapeutic approach in suppression-resistant prolactin-secreting adenomas].</u></h3> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bromocriptine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>tried</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>suppression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>prolactin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>prolactin</i></b> <b style='color:DodgerBlue;'><i>secreting</i></b> <b style='color:DodgerBlue;'><i>adenomas</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>suppression</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>bromoergocriptine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> 10 women under treatment with 2.5-10 mg of parlodel (<b style='color:Tomato;'><i>bromocriptine</i></b>) for pituitary tumours of various sizes were additionally treated with <b style='color:Tomato;'><i>tamoxifen</i></b> 10-20 mg. (nolvadex) daily. Two patients had a previous incomplete resection for chromophobe adenomas. The other patients refused operation. Two women were also studied who did not tolerate a bromoergocriptine therapy because of side effects. In 6 of the 10 women with combination treatment a satisfactory suppression of the prolactin was observed. Four women were cleared of their amenorrhoea and galactorrhoea. One woman conceived. One woman lost her frigidity. Three women, among those the two with severe side effects from bromoergocriptine, tolerated the combined treatment well. Four women showed no success with the combined treatment. The effectiveness of the combined treatment was not correlated with the size of the tumour nor the clinical or biochemical baseline. The results lead to the conclusion that <b style='color:Tomato;'><i>tamoxifen</i></b> is capable of improving the suppression of prolactin or render the adenomas suppressible in a large number of cases.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"present","start":7,"end":14,"id":2,"ws":true},{"text":"study","start":15,"end":20,"id":3,"ws":true},{"text":"the","start":21,"end":24,"id":4,"ws":true},{"text":"combination","start":25,"end":36,"id":5,"ws":true},{"text":"of","start":37,"end":39,"id":6,"ws":true},{"text":"tamoxifen","start":40,"end":49,"id":7,"ws":true},{"text":"and","start":50,"end":53,"id":8,"ws":true},{"text":"bromocriptine","start":54,"end":67,"id":9,"ws":true},{"text":"was","start":68,"end":71,"id":10,"ws":true},{"text":"tried","start":72,"end":77,"id":11,"ws":true},{"text":"for","start":78,"end":81,"id":12,"ws":true},{"text":"the","start":82,"end":85,"id":13,"ws":true},{"text":"suppression","start":86,"end":97,"id":14,"ws":true},{"text":"of","start":98,"end":100,"id":15,"ws":true},{"text":"prolactin","start":101,"end":110,"id":16,"ws":true},{"text":"in","start":111,"end":113,"id":17,"ws":true},{"text":"prolactin","start":114,"end":123,"id":18,"ws":true},{"text":"secreting","start":124,"end":133,"id":19,"ws":true},{"text":"adenomas","start":134,"end":142,"id":20,"ws":true},{"text":"which","start":143,"end":148,"id":21,"ws":true},{"text":"were","start":149,"end":153,"id":22,"ws":true},{"text":"resistant","start":154,"end":163,"id":23,"ws":true},{"text":"to","start":164,"end":166,"id":24,"ws":true},{"text":"suppression","start":167,"end":178,"id":25,"ws":true},{"text":"with","start":179,"end":183,"id":26,"ws":true},{"text":"bromoergocriptine","start":184,"end":201,"id":27,"ws":true},{"text":"alone","start":202,"end":207,"id":28,"ws":true},{"text":".","start":208,"end":209,"id":29,"ws":false}],"spans":[{"start":40,"end":49,"token_start":7,"token_end":7,"label":"DRUG"},{"start":54,"end":67,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6924910/","_input_hash":712663056,"_task_hash":1607711575,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":40,"end":49,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":54,"end":67,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The present case suggests that combination therapy with thalidomide and dexamethasone is still an alternative treatment regimen for resistant extramedullary plasmacytoma with a plasmablastic morphology .","paragraph":"<h3><u>Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone.</u></h3>A 74-year-old man with multiple myeloma was refractory to <b style='color:Tomato;'><i>melphalan</i></b>/<b style='color:Tomato;'><i>prednisolone</i></b> (MP), high-dose <b style='color:Tomato;'><i>dexamethasone</i></b> and VAD chemotherapy. He had the following poor prognostic factors: 1) multiple extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature myeloma cells with plasmablastic morphology, and 4) predominance of MPC1-CD49e-CD45+ phenotype immature myeloma cells. Combination therapy with <b style='color:Tomato;'><i>thalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> resulted in a rapid response and a partial remission despite his multiple poor prognostic factors. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>case</i></b> <b style='color:DodgerBlue;'><i>suggests</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>still</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>alternative</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>extramedullary</i></b> <b style='color:DodgerBlue;'><i>plasmacytoma</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>plasmablastic</i></b> <b style='color:DodgerBlue;'><i>morphology</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"present","start":4,"end":11,"id":1,"ws":true},{"text":"case","start":12,"end":16,"id":2,"ws":true},{"text":"suggests","start":17,"end":25,"id":3,"ws":true},{"text":"that","start":26,"end":30,"id":4,"ws":true},{"text":"combination","start":31,"end":42,"id":5,"ws":true},{"text":"therapy","start":43,"end":50,"id":6,"ws":true},{"text":"with","start":51,"end":55,"id":7,"ws":true},{"text":"thalidomide","start":56,"end":67,"id":8,"ws":true},{"text":"and","start":68,"end":71,"id":9,"ws":true},{"text":"dexamethasone","start":72,"end":85,"id":10,"ws":true},{"text":"is","start":86,"end":88,"id":11,"ws":true},{"text":"still","start":89,"end":94,"id":12,"ws":true},{"text":"an","start":95,"end":97,"id":13,"ws":true},{"text":"alternative","start":98,"end":109,"id":14,"ws":true},{"text":"treatment","start":110,"end":119,"id":15,"ws":true},{"text":"regimen","start":120,"end":127,"id":16,"ws":true},{"text":"for","start":128,"end":131,"id":17,"ws":true},{"text":"resistant","start":132,"end":141,"id":18,"ws":true},{"text":"extramedullary","start":142,"end":156,"id":19,"ws":true},{"text":"plasmacytoma","start":157,"end":169,"id":20,"ws":true},{"text":"with","start":170,"end":174,"id":21,"ws":true},{"text":"a","start":175,"end":176,"id":22,"ws":true},{"text":"plasmablastic","start":177,"end":190,"id":23,"ws":true},{"text":"morphology","start":191,"end":201,"id":24,"ws":true},{"text":".","start":202,"end":203,"id":25,"ws":false}],"spans":[{"start":56,"end":67,"token_start":8,"token_end":8,"label":"DRUG"},{"start":72,"end":85,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19834276/","_input_hash":1939938823,"_task_hash":1642536107,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":56,"end":67,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":72,"end":85,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Among 788 eligible patients , the median ( SD ) age was 59 ( 22 - 74 ) years ; 263 patients were assigned to doxorubicin plus cisplatin treatment , 263 patients to docetaxel plus cisplatin treatment , and 262 patients to paclitaxel plus carboplatin treatment .","paragraph":"<h3><u>Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.</u></h3>The efficacy of taxane plus platinum regimens has been demonstrated for advanced or recurrent endometrial cancer; however, it has not been assessed in postoperative adjuvant chemotherapy for endometrial cancer. ### objective To evaluate the clinical benefit of taxane plus platinum compared with standard <b style='color:Tomato;'><i>doxorubicin</i></b> plus cisplatin as postoperative adjuvant chemotherapy in endometrial cancer. ### Design Setting And Participants In this multicenter, open-label, phase 3 randomized clinical trial, patients with endometrial cancer at high-risk stage I or II or stage III or IV that did not extend beyond the abdominal cavity and had 2 cm or greater residual tumor were included from 118 institutions in Japan from November 24, 2006, to January 7, 2011. Data was analyzed from March 15, 2017, to June 30, 2017. ### interventions Eligible patients were randomly assigned (1:1:1) to receive 6 cycles of <b style='color:Tomato;'><i>doxorubicin</i></b>, 60 mg/m2, plus cisplatin, 50 mg/m2, on day 1; <b style='color:Tomato;'><i>docetaxel</i></b>, 70 mg/m2, plus cisplatin, 60 mg/m2, on day 1; or <b style='color:Tomato;'><i>paclitaxel</i></b>, 180 mg/m2, plus <b style='color:Tomato;'><i>carboplatin</i></b> (area under the curve, 6.0 mg/mL\u2009\u00d7\u2009min) on day 1 every 3 weeks. ### Main Outcomes And Measures The primary end point was progression-free survival. Secondary end points were overall survival, occurrence of adverse events, tolerability, and status of lymph node dissection. ### results <b style='color:DodgerBlue;'><i>Among</i></b> <b style='color:DodgerBlue;'><i>788</i></b> <b style='color:DodgerBlue;'><i>eligible</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>age</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>59</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>22</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>74</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>263</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>263</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>262</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The number of patients who did not complete 6 cycles was 53 (20.1%) for the <b style='color:Tomato;'><i>doxorubicin</i></b> plus cisplatin group, 45 (17.1%) for the <b style='color:Tomato;'><i>docetaxel</i></b> plus cisplatin group, and 63 (24.0%) for the <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>carboplatin</i></b> group. Tolerability of these regimens were not statistically different. After a median follow-up period of 7 years, there was no statistical difference of progression-free survival (<b style='color:Tomato;'><i>doxorubicin</i></b> plus cisplatin, 191; <b style='color:Tomato;'><i>docetaxel</i></b> plus cisplatin, 208; <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>carboplatin</i></b>, 187; P\u2009=\u2009.12) or overall survival (<b style='color:Tomato;'><i>doxorubicin</i></b> plus cisplatin, 217; <b style='color:Tomato;'><i>docetaxel</i></b> plus cisplatin, 223; <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>carboplatin</i></b>, 215; P\u2009=\u2009.67) among the 3 groups. The 5-year progression-free survival rate was 73.3% for the <b style='color:Tomato;'><i>doxorubicin</i></b> plus cisplatin group, 79.0% for the <b style='color:Tomato;'><i>docetaxel</i></b> plus cisplatin group, and 73.9% for the <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>carboplatin</i></b> group, while the 5-year overall survival rates were 82.7%, 88.1%, and 86.1%, respectively. ### Conclusions And Relevance There was no significant difference of survival among patients receiving <b style='color:Tomato;'><i>doxorubicin</i></b> plus cisplatin, <b style='color:Tomato;'><i>docetaxel</i></b> plus cisplatin, or <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>carboplatin</i></b> as postoperative adjuvant chemotherapy for endometrial cancer. Because each regimen showed adequate tolerability but different toxic effects, taxane plus platinum regimens may be a reasonable alternative to treatment with <b style='color:Tomato;'><i>doxorubicin</i></b> plus cisplatin. ### Trial Registration UMIN-CTR identifier: UMIN000000522.","tokens":[{"text":"Among","start":0,"end":5,"id":0,"ws":true},{"text":"788","start":6,"end":9,"id":1,"ws":true},{"text":"eligible","start":10,"end":18,"id":2,"ws":true},{"text":"patients","start":19,"end":27,"id":3,"ws":true},{"text":",","start":28,"end":29,"id":4,"ws":true},{"text":"the","start":30,"end":33,"id":5,"ws":true},{"text":"median","start":34,"end":40,"id":6,"ws":true},{"text":"(","start":41,"end":42,"id":7,"ws":true},{"text":"SD","start":43,"end":45,"id":8,"ws":true},{"text":")","start":46,"end":47,"id":9,"ws":true},{"text":"age","start":48,"end":51,"id":10,"ws":true},{"text":"was","start":52,"end":55,"id":11,"ws":true},{"text":"59","start":56,"end":58,"id":12,"ws":true},{"text":"(","start":59,"end":60,"id":13,"ws":true},{"text":"22","start":61,"end":63,"id":14,"ws":true},{"text":"-","start":64,"end":65,"id":15,"ws":true},{"text":"74","start":66,"end":68,"id":16,"ws":true},{"text":")","start":69,"end":70,"id":17,"ws":true},{"text":"years","start":71,"end":76,"id":18,"ws":true},{"text":";","start":77,"end":78,"id":19,"ws":true},{"text":"263","start":79,"end":82,"id":20,"ws":true},{"text":"patients","start":83,"end":91,"id":21,"ws":true},{"text":"were","start":92,"end":96,"id":22,"ws":true},{"text":"assigned","start":97,"end":105,"id":23,"ws":true},{"text":"to","start":106,"end":108,"id":24,"ws":true},{"text":"doxorubicin","start":109,"end":120,"id":25,"ws":true},{"text":"plus","start":121,"end":125,"id":26,"ws":true},{"text":"cisplatin","start":126,"end":135,"id":27,"ws":true},{"text":"treatment","start":136,"end":145,"id":28,"ws":true},{"text":",","start":146,"end":147,"id":29,"ws":true},{"text":"263","start":148,"end":151,"id":30,"ws":true},{"text":"patients","start":152,"end":160,"id":31,"ws":true},{"text":"to","start":161,"end":163,"id":32,"ws":true},{"text":"docetaxel","start":164,"end":173,"id":33,"ws":true},{"text":"plus","start":174,"end":178,"id":34,"ws":true},{"text":"cisplatin","start":179,"end":188,"id":35,"ws":true},{"text":"treatment","start":189,"end":198,"id":36,"ws":true},{"text":",","start":199,"end":200,"id":37,"ws":true},{"text":"and","start":201,"end":204,"id":38,"ws":true},{"text":"262","start":205,"end":208,"id":39,"ws":true},{"text":"patients","start":209,"end":217,"id":40,"ws":true},{"text":"to","start":218,"end":220,"id":41,"ws":true},{"text":"paclitaxel","start":221,"end":231,"id":42,"ws":true},{"text":"plus","start":232,"end":236,"id":43,"ws":true},{"text":"carboplatin","start":237,"end":248,"id":44,"ws":true},{"text":"treatment","start":249,"end":258,"id":45,"ws":true},{"text":".","start":259,"end":260,"id":46,"ws":false}],"spans":[{"start":59,"end":60,"token_start":13,"token_end":13,"label":"DRUG"},{"start":109,"end":120,"token_start":25,"token_end":25,"label":"DRUG"},{"start":126,"end":135,"token_start":27,"token_end":27,"label":"DRUG"},{"start":164,"end":173,"token_start":33,"token_end":33,"label":"DRUG"},{"start":179,"end":188,"token_start":35,"token_end":35,"label":"DRUG"},{"start":221,"end":231,"token_start":42,"token_end":42,"label":"DRUG"},{"start":237,"end":248,"token_start":44,"token_end":44,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30896757/","_input_hash":-1594167191,"_task_hash":-464850626,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":25,"child":27,"head_span":{"start":109,"end":120,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":126,"end":135,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":33,"child":35,"head_span":{"start":164,"end":173,"token_start":33,"token_end":33,"label":"DRUG"},"child_span":{"start":179,"end":188,"token_start":35,"token_end":35,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":42,"child":44,"head_span":{"start":221,"end":231,"token_start":42,"token_end":42,"label":"DRUG"},"child_span":{"start":237,"end":248,"token_start":44,"token_end":44,"label":"DRUG"},"color":"#d9fbad","label":"POS3"}],"radio":["POS11","POS21","POS31"],"answer":"accept"}
{"text":"Metformin inhibits obesity but has no effect in reducing myocardial hypertrophy caused by Rosiglitazone .","paragraph":"<h3><u>Effects of metformin on rosiglitazone-induced cardiac hypertrophy in mice.</u></h3>Thiazolidinediones (TZD) can cause adipose tissue accumulation and myocardial hypertrophy. This study aimed to determine if combined <b style='color:Tomato;'><i>metformin</i></b> (Glucophage) and <b style='color:Tomato;'><i>rosiglitazone</i></b> (Avandia) could reduce the risk of heart failure caused by <b style='color:Tomato;'><i>rosiglitazone</i></b> in BALB/c mice. BALB/c mice were treated with oral <b style='color:Tomato;'><i>rosiglitazone</i></b>/<b style='color:Tomato;'><i>metformin</i></b> twice daily for four weeks. <b style='color:Tomato;'><i>metformin</i></b> or <b style='color:Tomato;'><i>rosiglitazone</i></b> alone and non-treated mice acted as double control. Myocardial hypertrophy and associated side effects of the combined therapy were determined through isolated heart and body weights. Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot were applied to evaluate expression of sulfonylurea receptor 2A (SUR2A) and Kir 6.2. The activities of peroxisome proliferator activated receptor alpha (PPARalpha) in the myocardium were also observed. <b style='color:Tomato;'><i>rosiglitazone</i></b>/<b style='color:Tomato;'><i>metformin</i></b> decreased body weight gain and food intake, and inhibited an increasing adipose ratio but did not reduce myocardial hypertrophy. <b style='color:Tomato;'><i>rosiglitazone</i></b> increased Kir6.2/SUR2A, Kir6.2/SUR2B, and PPARalpha gene expression. The <b style='color:Tomato;'><i>rosiglitazone</i></b>/<b style='color:Tomato;'><i>metformin</i></b> combination further increased these gene expressions, especially PPARalpha. <b style='color:MediumOrchid;'><i>Metformin</i></b> <b style='color:DodgerBlue;'><i>inhibits</i></b> <b style='color:DodgerBlue;'><i>obesity</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>reducing</i></b> <b style='color:DodgerBlue;'><i>myocardial</i></b> <b style='color:DodgerBlue;'><i>hypertrophy</i></b> <b style='color:DodgerBlue;'><i>caused</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>Rosiglitazone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Whether <b style='color:Tomato;'><i>metformin</i></b> can reduce side effects of TZDs in humans warrants further study.","tokens":[{"text":"Metformin","start":0,"end":9,"id":0,"ws":true},{"text":"inhibits","start":10,"end":18,"id":1,"ws":true},{"text":"obesity","start":19,"end":26,"id":2,"ws":true},{"text":"but","start":27,"end":30,"id":3,"ws":true},{"text":"has","start":31,"end":34,"id":4,"ws":true},{"text":"no","start":35,"end":37,"id":5,"ws":true},{"text":"effect","start":38,"end":44,"id":6,"ws":true},{"text":"in","start":45,"end":47,"id":7,"ws":true},{"text":"reducing","start":48,"end":56,"id":8,"ws":true},{"text":"myocardial","start":57,"end":67,"id":9,"ws":true},{"text":"hypertrophy","start":68,"end":79,"id":10,"ws":true},{"text":"caused","start":80,"end":86,"id":11,"ws":true},{"text":"by","start":87,"end":89,"id":12,"ws":true},{"text":"Rosiglitazone","start":90,"end":103,"id":13,"ws":true},{"text":".","start":104,"end":105,"id":14,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":90,"end":103,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20823565/","_input_hash":913437323,"_task_hash":1982717253,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":0,"child":13,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":90,"end":103,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"The primary endpoint of this study was to determine the maximal tolerated dose of the combination of dose-escalating curcumin and standard dose of docetaxel chemotherapy in advanced and metastatic breast cancer patients .","paragraph":"<h3><u>Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.</u></h3>Since the improvement of chemotherapy with safe molecules is needed for a better efficacy without supplementary toxicity, we investigated the feasibility and tolerability of the combination of <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>curcumin</i></b>, a polyphenolic derivative extracted from Curcuma longa root. ### results Fourteen patients were accrued in this open-label phase I trial. At the last dose level of <b style='color:Tomato;'><i>curcumin</i></b>, three dose-limiting toxicities were observed and two out of three patients at this dose level refused to continue treatment, leading us to define the maximal tolerated dose of <b style='color:Tomato;'><i>curcumin</i></b> at 8,000 mg/d. Eight patients out of 14 had measurable lesions according to RECIST criteria, with five PR and three SD. Some improvements as biological and clinical responses were observed in most patients. ### Patients And Methods Patients with advanced or metastatic breast cancer were eligible. <b style='color:Tomato;'><i>docetaxel</i></b> (100 mg/m(2)) was administered as a 1 h i.v. infusion every 3 w on d 1 for six cycles. <b style='color:Tomato;'><i>curcumin</i></b> was orally given from 500 mg/d for seven consecutive d by cycle (from d-4 to d+2) and escalated until a dose-limiting toxicity should occur. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>endpoint</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>maximal</i></b> <b style='color:DodgerBlue;'><i>tolerated</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dose-escalating</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Secondary objectives included toxicity, safety, vascular endothelial growth factor and tumor markers measurements and assessment of objective and clinical responses to the combination therapy. ### conclusion The recommended dose of <b style='color:Tomato;'><i>curcumin</i></b> is 6,000 mg/d for seven consecutive d every 3 w in combination with a standard dose of <b style='color:Tomato;'><i>docetaxel</i></b>. From the encouraging efficacy results, a comparative phase II trial of this regimen plus <b style='color:Tomato;'><i>docetaxel</i></b> versus <b style='color:Tomato;'><i>docetaxel</i></b> alone is ongoing in advanced and metastatic breast cancer patients.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"primary","start":4,"end":11,"id":1,"ws":true},{"text":"endpoint","start":12,"end":20,"id":2,"ws":true},{"text":"of","start":21,"end":23,"id":3,"ws":true},{"text":"this","start":24,"end":28,"id":4,"ws":true},{"text":"study","start":29,"end":34,"id":5,"ws":true},{"text":"was","start":35,"end":38,"id":6,"ws":true},{"text":"to","start":39,"end":41,"id":7,"ws":true},{"text":"determine","start":42,"end":51,"id":8,"ws":true},{"text":"the","start":52,"end":55,"id":9,"ws":true},{"text":"maximal","start":56,"end":63,"id":10,"ws":true},{"text":"tolerated","start":64,"end":73,"id":11,"ws":true},{"text":"dose","start":74,"end":78,"id":12,"ws":true},{"text":"of","start":79,"end":81,"id":13,"ws":true},{"text":"the","start":82,"end":85,"id":14,"ws":true},{"text":"combination","start":86,"end":97,"id":15,"ws":true},{"text":"of","start":98,"end":100,"id":16,"ws":true},{"text":"dose-escalating","start":101,"end":116,"id":17,"ws":true},{"text":"curcumin","start":117,"end":125,"id":18,"ws":true},{"text":"and","start":126,"end":129,"id":19,"ws":true},{"text":"standard","start":130,"end":138,"id":20,"ws":true},{"text":"dose","start":139,"end":143,"id":21,"ws":true},{"text":"of","start":144,"end":146,"id":22,"ws":true},{"text":"docetaxel","start":147,"end":156,"id":23,"ws":true},{"text":"chemotherapy","start":157,"end":169,"id":24,"ws":true},{"text":"in","start":170,"end":172,"id":25,"ws":true},{"text":"advanced","start":173,"end":181,"id":26,"ws":true},{"text":"and","start":182,"end":185,"id":27,"ws":true},{"text":"metastatic","start":186,"end":196,"id":28,"ws":true},{"text":"breast","start":197,"end":203,"id":29,"ws":true},{"text":"cancer","start":204,"end":210,"id":30,"ws":true},{"text":"patients","start":211,"end":219,"id":31,"ws":true},{"text":".","start":220,"end":221,"id":32,"ws":false}],"spans":[{"start":117,"end":125,"token_start":18,"token_end":18,"label":"DRUG"},{"start":147,"end":156,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19901561/","_input_hash":1347911585,"_task_hash":2093203033,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":18,"child":23,"head_span":{"start":117,"end":125,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":147,"end":156,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Diltiazem suppressed tension in human myocardium over the range of membrane potentials associated with Ca2 + channel activity , while at more positive potentials , diltiazem appeared to have little effect on the tension-voltage relations .","paragraph":"<h3><u>Mechanisms of action of diltiazem in isolated human atrial and ventricular myocardium.</u></h3>A comparative study of human atrial fibers (HAF), human ventricular fibers (HVF), frog ventricle, and frog skeletal muscle demonstrated marked differences in tension development in the presence of <b style='color:Tomato;'><i>diltiazem</i></b>. There was no significant difference between the tension developed by HAF and by HVF over a range of <b style='color:Tomato;'><i>diltiazem</i></b> concentrations when the differences in resting membrane potential were corrected by increasing external K+ concentration. In human myocardium, <b style='color:Tomato;'><i>diltiazem</i></b> resulted in both a voltage and use-dependent blockade of the calcium channel. Comparison of the tension-dose response curves in human myocardium, frog ventricle and skeletal muscle showed that <b style='color:Tomato;'><i>diltiazem</i></b> was most effective at decreasing tension in frog heart, and least effective in skeletal muscle with human myocardium being intermediate. In skeletal muscle, neither tension development nor the birefringence signal related to the Ca2+ release from the sarcoplasmic reticulum was significantly altered by <b style='color:Tomato;'><i>diltiazem</i></b> in concentrations less than 10(-6) M, but in concentrations greater than 10(-5) M both were suppressed. <b style='color:MediumOrchid;'><i>Diltiazem</i></b> <b style='color:DodgerBlue;'><i>suppressed</i></b> <b style='color:DodgerBlue;'><i>tension</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>myocardium</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>range</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>potentials</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>Ca2</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>channel</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>potentials</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>diltiazem</i></b> <b style='color:DodgerBlue;'><i>appeared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>little</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>tension-voltage</i></b> <b style='color:DodgerBlue;'><i>relations</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>diltiazem</i></b> had no effect upon tension development induced by acetyl strophanthidin in human myocardium or upon the Ca2+ sensitivity of chemically skinned atrial or ventricular fibers. Thus the tension-suppressant effect of <b style='color:Tomato;'><i>diltiazem</i></b> in human myocardium appears to be mediated by a combination of voltage-dependent block of the Ca2+ channel and inhibition of Ca2+ release from internal stores, and not from alterations in either Na+-Ca2+ coupled transport or Ca2+ sensitivity of the myofilaments.","tokens":[{"text":"Diltiazem","start":0,"end":9,"id":0,"ws":true},{"text":"suppressed","start":10,"end":20,"id":1,"ws":true},{"text":"tension","start":21,"end":28,"id":2,"ws":true},{"text":"in","start":29,"end":31,"id":3,"ws":true},{"text":"human","start":32,"end":37,"id":4,"ws":true},{"text":"myocardium","start":38,"end":48,"id":5,"ws":true},{"text":"over","start":49,"end":53,"id":6,"ws":true},{"text":"the","start":54,"end":57,"id":7,"ws":true},{"text":"range","start":58,"end":63,"id":8,"ws":true},{"text":"of","start":64,"end":66,"id":9,"ws":true},{"text":"membrane","start":67,"end":75,"id":10,"ws":true},{"text":"potentials","start":76,"end":86,"id":11,"ws":true},{"text":"associated","start":87,"end":97,"id":12,"ws":true},{"text":"with","start":98,"end":102,"id":13,"ws":true},{"text":"Ca2","start":103,"end":106,"id":14,"ws":true},{"text":"+","start":107,"end":108,"id":15,"ws":true},{"text":"channel","start":109,"end":116,"id":16,"ws":true},{"text":"activity","start":117,"end":125,"id":17,"ws":true},{"text":",","start":126,"end":127,"id":18,"ws":true},{"text":"while","start":128,"end":133,"id":19,"ws":true},{"text":"at","start":134,"end":136,"id":20,"ws":true},{"text":"more","start":137,"end":141,"id":21,"ws":true},{"text":"positive","start":142,"end":150,"id":22,"ws":true},{"text":"potentials","start":151,"end":161,"id":23,"ws":true},{"text":",","start":162,"end":163,"id":24,"ws":true},{"text":"diltiazem","start":164,"end":173,"id":25,"ws":true},{"text":"appeared","start":174,"end":182,"id":26,"ws":true},{"text":"to","start":183,"end":185,"id":27,"ws":true},{"text":"have","start":186,"end":190,"id":28,"ws":true},{"text":"little","start":191,"end":197,"id":29,"ws":true},{"text":"effect","start":198,"end":204,"id":30,"ws":true},{"text":"on","start":205,"end":207,"id":31,"ws":true},{"text":"the","start":208,"end":211,"id":32,"ws":true},{"text":"tension-voltage","start":212,"end":227,"id":33,"ws":true},{"text":"relations","start":228,"end":237,"id":34,"ws":true},{"text":".","start":238,"end":239,"id":35,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":164,"end":173,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/3498047/","_input_hash":1989411359,"_task_hash":1133613091,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The subjects were then randomly assigned to treatment with either propranolol or metoprolol and repeated the exercise protocol after 1 week of treatment .","paragraph":"<h3><u>Dynamic exercise leads to an increase in circulating ICAM-1: further evidence for adrenergic modulation of cell adhesion.</u></h3>Acute mental and physical stress lead to a marked lymphocytosis, with circulating natural killer cell numbers showing the most prominent increase. Many studies have linked these acute stress effects on lymphocytes with an increase in catecholamine levels. However, the molecular mechanisms which mediate this redistribution of lymphocytes from lymphocyte reservoirs into the circulation remain unknown. We hypothesized that this form of lymphocytosis was in part due to shedding of cell adhesion molecules from the cell surface and a subsequent detachment of lymphocytes adhering to the vascular endothelium in lymphocyte reservoirs. In this study, healthy human volunteers (n = 12) were exercised on a treadmill until exhaustion. The circulating levels of the soluble cell adhesion molecules ICAM-1 and E-Selectin were determined by ELISA. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>subjects</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>then</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>metoprolol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>repeated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>exercise</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>week</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Prior to drug treatment, soluble ICAM-1 levels rose from 258 +/- 19 to 321 +/- 28 ng/ml following exercise and returned to approximate baseline levels of 263 +/- 22 ng/ml after 1 h of rest. This highly significant effect of exercise on circulating ICAM-1 levels (p < .005) was mitigated after treatment with the beta-adrenergic antagonists. Soluble E-Selectin levels were not significantly affected by exercise. These results suggest that dynamic exercise leads to shedding of the cell adhesion molecule ICAM-1 via adrenergic mechanisms. We believe that these findings will contribute to the understanding of how physical and mental stress modulate lymphocyte migration and adhesion.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"subjects","start":4,"end":12,"id":1,"ws":true},{"text":"were","start":13,"end":17,"id":2,"ws":true},{"text":"then","start":18,"end":22,"id":3,"ws":true},{"text":"randomly","start":23,"end":31,"id":4,"ws":true},{"text":"assigned","start":32,"end":40,"id":5,"ws":true},{"text":"to","start":41,"end":43,"id":6,"ws":true},{"text":"treatment","start":44,"end":53,"id":7,"ws":true},{"text":"with","start":54,"end":58,"id":8,"ws":true},{"text":"either","start":59,"end":65,"id":9,"ws":true},{"text":"propranolol","start":66,"end":77,"id":10,"ws":true},{"text":"or","start":78,"end":80,"id":11,"ws":true},{"text":"metoprolol","start":81,"end":91,"id":12,"ws":true},{"text":"and","start":92,"end":95,"id":13,"ws":true},{"text":"repeated","start":96,"end":104,"id":14,"ws":true},{"text":"the","start":105,"end":108,"id":15,"ws":true},{"text":"exercise","start":109,"end":117,"id":16,"ws":true},{"text":"protocol","start":118,"end":126,"id":17,"ws":true},{"text":"after","start":127,"end":132,"id":18,"ws":true},{"text":"1","start":133,"end":134,"id":19,"ws":true},{"text":"week","start":135,"end":139,"id":20,"ws":true},{"text":"of","start":140,"end":142,"id":21,"ws":true},{"text":"treatment","start":143,"end":152,"id":22,"ws":true},{"text":".","start":153,"end":154,"id":23,"ws":false}],"spans":[{"start":66,"end":77,"token_start":10,"token_end":10,"label":"DRUG"},{"start":81,"end":91,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9512820/","_input_hash":-1341300761,"_task_hash":1227881833,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"This case highlights the potential efficacy of combining nivolumab and regorafenib in the treatment of SBAs .","paragraph":"<h3><u>Nivolumab plus regorafenib in patients with small bowel adenocarcinoma: A case report.</u></h3>Small bowel adenocarcinomas (SBAs) are rare cancers that have a distinct clinical characteristic and genetic profile. The only potentially curative treatment for localized SBAs is surgery, and treatment options are limited for patients in the advanced stage of disease. ### Patient Concerns A 39-year-old woman presented in October 2015 with a complaint of persistent vomiting for 8\u200amonths. ### diagnosis The patient had obstruction caused by a 3\u200a\u00d7\u200a2\u200acm mass at the ascending part of the duodenum and suspected metastasis in the right adnexal region. Postoperative pathology showed a moderately differentiated adenocarcinoma with serosal invasion. The diagnosis was stage IV duodenum adenocarcinoma with right adnexal metastasis. ### interventions After the failure of multi-line treatment with chemotherapy and targeted therapy, she was treated with the immune checkpoint inhibitor <b style='color:Tomato;'><i>nivolumab</i></b> plus <b style='color:Tomato;'><i>regorafenib</i></b>. ### outcomes Disease control lasted for 15\u200amonths with markedly improved symptoms. ### conclusion To the best of our knowledge, this is the first case of small bowel adenocarcinoma that has been treated with <b style='color:Tomato;'><i>nivolumab</i></b> combined with <b style='color:Tomato;'><i>regorafenib</i></b>. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>case</i></b> <b style='color:DodgerBlue;'><i>highlights</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combining</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>regorafenib</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>SBAs</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"case","start":5,"end":9,"id":1,"ws":true},{"text":"highlights","start":10,"end":20,"id":2,"ws":true},{"text":"the","start":21,"end":24,"id":3,"ws":true},{"text":"potential","start":25,"end":34,"id":4,"ws":true},{"text":"efficacy","start":35,"end":43,"id":5,"ws":true},{"text":"of","start":44,"end":46,"id":6,"ws":true},{"text":"combining","start":47,"end":56,"id":7,"ws":true},{"text":"nivolumab","start":57,"end":66,"id":8,"ws":true},{"text":"and","start":67,"end":70,"id":9,"ws":true},{"text":"regorafenib","start":71,"end":82,"id":10,"ws":true},{"text":"in","start":83,"end":85,"id":11,"ws":true},{"text":"the","start":86,"end":89,"id":12,"ws":true},{"text":"treatment","start":90,"end":99,"id":13,"ws":true},{"text":"of","start":100,"end":102,"id":14,"ws":true},{"text":"SBAs","start":103,"end":107,"id":15,"ws":true},{"text":".","start":108,"end":109,"id":16,"ws":false}],"spans":[{"start":57,"end":66,"token_start":8,"token_end":8,"label":"DRUG"},{"start":71,"end":82,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33530218/","_input_hash":-1268039474,"_task_hash":1623299423,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":57,"end":66,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":71,"end":82,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Of the substances tested for inhibition of 11beta-HSD-I and -II , chenodeoxycholic acid was the only one that selectively inhibited 11beta-HSD-I ( IC(50 ) for reduction : 2.8x10(-6)mol/l , IC(50 ) for oxidation : 4.4x10(-6)mol/l ) , whereas ketoconazole preferentially inhibited oxidation and reduction reactions catalyzed by 11beta-HSD-II .","paragraph":"<h3><u>In the search for specific inhibitors of human 11beta-hydroxysteroid-dehydrogenases (11beta-HSDs): chenodeoxycholic acid selectively inhibits 11beta-HSD-I.</u></h3>Selective inhibitors of 11beta-hydroxysteroid-dehydrogenase type I may be of therapeutical interest for two reasons: i) 9alpha-Fluorinated 11-dehydrosteroids like 11-dehydro-<b style='color:Tomato;'><i>dexamethasone</i></b> (DH-D) are rapidly activated by human kidney 11beta-hydroxysteroid-dehydrogenase type II (11beta-HSD-II) to <b style='color:Tomato;'><i>dexamethasone</i></b> (D). If the same reaction by hepatic 11beta-HSD-I could be selectively inhibited, DH-D could be used for selective renal immunosuppressive therapy. ii) Reduction of <b style='color:Tomato;'><i>cortisone</i></b> to cortisol in the liver may increase insulin resistance in type 2 diabetes mellitus, and inhibition of the enzyme may lead to a decrease in gluconeogenesis. Therefore, we characterized the metabolism of DH-D by human hepatic 11beta-HSD-I and tried to find a selective inhibitor of this isoenzyme. ### methods For kinetic analysis of 11beta-HSD-I, we used microsomes prepared from unaffected parts of liver segments, resected because of hepatocarcinoma or metastatic disease. For inhibition experiments, we also tested 11beta-HSD-II activity with human kidney cortex microsomes. The inhibitory potency of several compounds was evaluated for oxidation and reduction in concentrations from 10(-9) to 10(-5)mol/l. ### results Whereas D was not oxidized by human liver microsomes at all, cortisol was oxidized to <b style='color:Tomato;'><i>cortisone</i></b> with a maximum velocity (V(max)) of 95pmol/mg per min. The reduction of DH-D to D (V(max)=742pmol/mg per min, Michaelis--Menten constant (K(m))=1.6 micromol/l) was faster than that of <b style='color:Tomato;'><i>cortisone</i></b> to cortisol (V(max)=187pmol/mg per min). All reactions tested in liver microsomes showed the characteristics of 11beta-HSD-I: K(m) values in the micromolar range, preferred cosubstrate NADP(H), no product inhibition. <b style='color:DodgerBlue;'><i>Of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>substances</i></b> <b style='color:DodgerBlue;'><i>tested</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>11beta-HSD-I</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>-II</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>selectively</i></b> <b style='color:DodgerBlue;'><i>inhibited</i></b> <b style='color:DodgerBlue;'><i>11beta-HSD-I</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>IC(50</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>reduction</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>2.8x10(-6)mol/l</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>IC(50</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>oxidation</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>4.4x10(-6)mol/l</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:MediumOrchid;'><i>ketoconazole</i></b> <b style='color:DodgerBlue;'><i>preferentially</i></b> <b style='color:DodgerBlue;'><i>inhibited</i></b> <b style='color:DodgerBlue;'><i>oxidation</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>reduction</i></b> <b style='color:DodgerBlue;'><i>reactions</i></b> <b style='color:DodgerBlue;'><i>catalyzed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>11beta-HSD-II</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>metyrapone</i></b>, which is reduced to metyrapol by hepatic 11beta-HSD-I, inhibited steroid reductase activity of 11beta-HSD-I and -II and oxidative activity of 11beta-HSD-II. These findings can be explained by substrate competition for reductase reactions and by product inhibition of the oxidation, which is a well-known characteristic of 11beta-HSD-II. ### conclusions Our in vitro results may offer a new concept for renal glucocorticoid targeting. Oral administration of small amounts of DH-D (low substrate affinity for 11beta-HSD-I) in combination with <b style='color:Tomato;'><i>chenodeoxy<b style='color:Tomato;'><i>cholic</i></b></i></b> acid (selective inhibition of 11beta-HSD-I) may prevent hepatic first pass reduction of DH-D, thus allowing selective activation of DH-D to D by the high affinity 11beta-HSD-II in the kidney. Moreover, selective inhibitors of the hepatic 11beta-HSD-I, like <b style='color:Tomato;'><i>chenodeoxy<b style='color:Tomato;'><i>cholic</i></b></i></b> acid, may become useful in the therapy of patients with hepatic insulin resistance including diabetes mellitus type II, because cortisol enhances gluconeogenesis.","tokens":[{"text":"Of","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"substances","start":7,"end":17,"id":2,"ws":true},{"text":"tested","start":18,"end":24,"id":3,"ws":true},{"text":"for","start":25,"end":28,"id":4,"ws":true},{"text":"inhibition","start":29,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"11beta-HSD-I","start":43,"end":55,"id":7,"ws":true},{"text":"and","start":56,"end":59,"id":8,"ws":true},{"text":"-II","start":60,"end":63,"id":9,"ws":true},{"text":",","start":64,"end":65,"id":10,"ws":true},{"text":"chenodeoxycholic","start":66,"end":82,"id":11,"ws":true},{"text":"acid","start":83,"end":87,"id":12,"ws":true},{"text":"was","start":88,"end":91,"id":13,"ws":true},{"text":"the","start":92,"end":95,"id":14,"ws":true},{"text":"only","start":96,"end":100,"id":15,"ws":true},{"text":"one","start":101,"end":104,"id":16,"ws":true},{"text":"that","start":105,"end":109,"id":17,"ws":true},{"text":"selectively","start":110,"end":121,"id":18,"ws":true},{"text":"inhibited","start":122,"end":131,"id":19,"ws":true},{"text":"11beta-HSD-I","start":132,"end":144,"id":20,"ws":true},{"text":"(","start":145,"end":146,"id":21,"ws":true},{"text":"IC(50","start":147,"end":152,"id":22,"ws":true},{"text":")","start":153,"end":154,"id":23,"ws":true},{"text":"for","start":155,"end":158,"id":24,"ws":true},{"text":"reduction","start":159,"end":168,"id":25,"ws":true},{"text":":","start":169,"end":170,"id":26,"ws":true},{"text":"2.8x10(-6)mol/l","start":171,"end":186,"id":27,"ws":true},{"text":",","start":187,"end":188,"id":28,"ws":true},{"text":"IC(50","start":189,"end":194,"id":29,"ws":true},{"text":")","start":195,"end":196,"id":30,"ws":true},{"text":"for","start":197,"end":200,"id":31,"ws":true},{"text":"oxidation","start":201,"end":210,"id":32,"ws":true},{"text":":","start":211,"end":212,"id":33,"ws":true},{"text":"4.4x10(-6)mol/l","start":213,"end":228,"id":34,"ws":true},{"text":")","start":229,"end":230,"id":35,"ws":true},{"text":",","start":231,"end":232,"id":36,"ws":true},{"text":"whereas","start":233,"end":240,"id":37,"ws":true},{"text":"ketoconazole","start":241,"end":253,"id":38,"ws":true},{"text":"preferentially","start":254,"end":268,"id":39,"ws":true},{"text":"inhibited","start":269,"end":278,"id":40,"ws":true},{"text":"oxidation","start":279,"end":288,"id":41,"ws":true},{"text":"and","start":289,"end":292,"id":42,"ws":true},{"text":"reduction","start":293,"end":302,"id":43,"ws":true},{"text":"reactions","start":303,"end":312,"id":44,"ws":true},{"text":"catalyzed","start":313,"end":322,"id":45,"ws":true},{"text":"by","start":323,"end":325,"id":46,"ws":true},{"text":"11beta-HSD-II","start":326,"end":339,"id":47,"ws":true},{"text":".","start":340,"end":341,"id":48,"ws":false}],"spans":[{"start":66,"end":82,"token_start":11,"token_end":11,"label":"DRUG"},{"start":241,"end":253,"token_start":38,"token_end":38,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10664531/","_input_hash":815115394,"_task_hash":1109901108,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Anti-tumor effects of etoposide ( VP-16 ) , vincristine and mitomycin C were evaluated with four human neuroblastoma xenograft , according to Battelle Columbus Laboratories protocol .","paragraph":"<h3><u>[In vivo assessment on the therapeutic effects of etoposide, vincristine and mitomycin C against human neuroblastoma].</u></h3> <b style='color:DodgerBlue;'><i>Anti-tumor</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VP-16</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitomycin</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>neuroblastoma</i></b> <b style='color:DodgerBlue;'><i>xenograft</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>according</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>Battelle</i></b> <b style='color:DodgerBlue;'><i>Columbus</i></b> <b style='color:DodgerBlue;'><i>Laboratories</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>etoposide</i></b> is one of the agents which has been reported to be effective against advanced neuroblastoma clinically, if combined with other agents. While <b style='color:Tomato;'><i>vincristine</i></b> was effective against 1 out 4 neuroblastoma xenografts, TS-N-2, with 58.1% maximum inhibition rate, <b style='color:Tomato;'><i>etoposide</i></b> was assessed ineffective as a single agent in all of the 3 xenografts used. Since <b style='color:Tomato;'><i>etoposide</i></b> had no effect on the weight gain in nude mice in this xenograft experiment, the dose of <b style='color:Tomato;'><i>etoposide</i></b> was increased two-fold against 2 xenografts, but found ineffective also in the increased dose. <b style='color:Tomato;'><i>mitomycin</i></b> C, which has not been used in childhood malignant tumors, was effective against 2 out of 4 xenografts, TNB-9 and SK-N-AS, with 72.0% and 78.4% maximum inhibition rates, respectively.","tokens":[{"text":"Anti-tumor","start":0,"end":10,"id":0,"ws":true},{"text":"effects","start":11,"end":18,"id":1,"ws":true},{"text":"of","start":19,"end":21,"id":2,"ws":true},{"text":"etoposide","start":22,"end":31,"id":3,"ws":true},{"text":"(","start":32,"end":33,"id":4,"ws":true},{"text":"VP-16","start":34,"end":39,"id":5,"ws":true},{"text":")","start":40,"end":41,"id":6,"ws":true},{"text":",","start":42,"end":43,"id":7,"ws":true},{"text":"vincristine","start":44,"end":55,"id":8,"ws":true},{"text":"and","start":56,"end":59,"id":9,"ws":true},{"text":"mitomycin","start":60,"end":69,"id":10,"ws":true},{"text":"C","start":70,"end":71,"id":11,"ws":true},{"text":"were","start":72,"end":76,"id":12,"ws":true},{"text":"evaluated","start":77,"end":86,"id":13,"ws":true},{"text":"with","start":87,"end":91,"id":14,"ws":true},{"text":"four","start":92,"end":96,"id":15,"ws":true},{"text":"human","start":97,"end":102,"id":16,"ws":true},{"text":"neuroblastoma","start":103,"end":116,"id":17,"ws":true},{"text":"xenograft","start":117,"end":126,"id":18,"ws":true},{"text":",","start":127,"end":128,"id":19,"ws":true},{"text":"according","start":129,"end":138,"id":20,"ws":true},{"text":"to","start":139,"end":141,"id":21,"ws":true},{"text":"Battelle","start":142,"end":150,"id":22,"ws":true},{"text":"Columbus","start":151,"end":159,"id":23,"ws":true},{"text":"Laboratories","start":160,"end":172,"id":24,"ws":true},{"text":"protocol","start":173,"end":181,"id":25,"ws":true},{"text":".","start":182,"end":183,"id":26,"ws":false}],"spans":[{"start":22,"end":31,"token_start":3,"token_end":3,"label":"DRUG"},{"start":44,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},{"start":60,"end":69,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1905121/","_input_hash":-46337316,"_task_hash":1135383808,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Biliary bile acids were mainly amidates of cholic acid and chenodeoxycholic acid , with the former predominating .","paragraph":"<h3><u>The effect of alfalfa-corn diets on cholesterol metabolism and gallstones in prairie dogs.</u></h3>Cholesterol gallstones were present in prairie dogs fed alfalfa plus corn with and without exogenous cholesterol (0.4%). The diets fed to the animals for eight weeks contained alfalfa plus corn in fixed proportions of 50:50, 85:15 and 15:85 (w/w). At sacrifice, all animals were healthy but had not gained weight; no deaths occurred during the experiment. Cholesterol gallstones were present in all groups. In the absence of exogenous cholesterol, the highest stone incidence was found in the animals which received the lowest fiber (highest corn) diets (alfalfa plus corn, 50:50, 67%; alfalfa plus corn, 15:85, 83%). Cholesterol gallstone incidence was 100% when exogenous cholesterol was added to the alfalfa plus corn diets (50:50 and 15:85). No pigment gallstones were detected in any animal. Liver and plasma cholesterol concentrations were highest in the animals receiving alfalfa plus corn (15:85) plus 0.4% cholesterol (4.29 mg/g, and 356 mg/dl, respectively). These values were lowest in animals receiving 85% alfalfa plus 15% corn without cholesterol (2.19 mg/g and 88 mg/dl, respectively). Lithogenic indices were below 1.00 in all groups. <b style='color:DodgerBlue;'><i>Biliary</i></b> <b style='color:DodgerBlue;'><i>bile</i></b> <b style='color:DodgerBlue;'><i>acids</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>mainly</i></b> <b style='color:DodgerBlue;'><i>amidates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>former</i></b> <b style='color:DodgerBlue;'><i>predominating</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Thus, gallstones can be formed in prairie dogs in the absence of exogenous cholesterol; gallstone incidence is reduced by dietary fiber.","tokens":[{"text":"Biliary","start":0,"end":7,"id":0,"ws":true},{"text":"bile","start":8,"end":12,"id":1,"ws":true},{"text":"acids","start":13,"end":18,"id":2,"ws":true},{"text":"were","start":19,"end":23,"id":3,"ws":true},{"text":"mainly","start":24,"end":30,"id":4,"ws":true},{"text":"amidates","start":31,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"cholic","start":43,"end":49,"id":7,"ws":true},{"text":"acid","start":50,"end":54,"id":8,"ws":true},{"text":"and","start":55,"end":58,"id":9,"ws":true},{"text":"chenodeoxycholic","start":59,"end":75,"id":10,"ws":true},{"text":"acid","start":76,"end":80,"id":11,"ws":true},{"text":",","start":81,"end":82,"id":12,"ws":true},{"text":"with","start":83,"end":87,"id":13,"ws":true},{"text":"the","start":88,"end":91,"id":14,"ws":true},{"text":"former","start":92,"end":98,"id":15,"ws":true},{"text":"predominating","start":99,"end":112,"id":16,"ws":true},{"text":".","start":113,"end":114,"id":17,"ws":false}],"spans":[{"start":43,"end":49,"token_start":7,"token_end":7,"label":"DRUG"},{"start":59,"end":75,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2159098/","_input_hash":-1652766477,"_task_hash":1825452693,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Cutaneous T-cell lymphoma-like drug eruption in an HIV-positive patient taking vancomycin and rifampin .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Cutaneous</i></b> <b style='color:DodgerBlue;'><i>T-cell</i></b> <b style='color:DodgerBlue;'><i>lymphoma-like</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>eruption</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>HIV-positive</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>taking</i></b> <b style='color:MediumOrchid;'><i>vancomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rifampin</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Cutaneous T-cell pseudolymphoma (CTPL) is a benign reactive T-cell lymphoproliferative subtype of pseudolymphoma. Some variants of CTPL can resemble the plaques of mycosis fungoides (MF). The vast majority of drug-induced cases have been associated with anticonvulsants. There is only one report in the literature documenting a case of <b style='color:Tomato;'><i>vancomycin</i></b>-induced CTPL. ### methods We report a cutaneous T-cell lymphoma-like eruption in a human immunodeficiency virus (HIV)-positive patient recently started on <b style='color:Tomato;'><i>vancomycin</i></b> and <b style='color:Tomato;'><i>rifampin</i></b>. ### results A skin biopsy showed several histologic features of MF with immunohistochemical and T-cell receptor gene rearrangement studies suggestive of CTPL. This atypical T-cell reaction mimicking MF completely resolved on cessation of <b style='color:Tomato;'><i>rifampin</i></b> followed by <b style='color:Tomato;'><i>vancomycin</i></b>. ### conclusion Considering drug-induced causes of MF-like histologic changes is crucial to prevent unnecessary treatment for MF.","tokens":[{"text":"Cutaneous","start":0,"end":9,"id":0,"ws":true},{"text":"T-cell","start":10,"end":16,"id":1,"ws":true},{"text":"lymphoma-like","start":17,"end":30,"id":2,"ws":true},{"text":"drug","start":31,"end":35,"id":3,"ws":true},{"text":"eruption","start":36,"end":44,"id":4,"ws":true},{"text":"in","start":45,"end":47,"id":5,"ws":true},{"text":"an","start":48,"end":50,"id":6,"ws":true},{"text":"HIV-positive","start":51,"end":63,"id":7,"ws":true},{"text":"patient","start":64,"end":71,"id":8,"ws":true},{"text":"taking","start":72,"end":78,"id":9,"ws":true},{"text":"vancomycin","start":79,"end":89,"id":10,"ws":true},{"text":"and","start":90,"end":93,"id":11,"ws":true},{"text":"rifampin","start":94,"end":102,"id":12,"ws":true},{"text":".","start":103,"end":104,"id":13,"ws":false}],"spans":[{"start":79,"end":89,"token_start":10,"token_end":10,"label":"DRUG"},{"start":94,"end":102,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24138984/","_input_hash":-1428465625,"_task_hash":576269816,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":79,"end":89,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":94,"end":102,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"Our findings suggest that roflumilast reduces exacerbations and hospital admissions in patients with severe chronic obstructive pulmonary disease and chronic bronchitis who are at risk of frequent and severe exacerbations despite inhaled corticosteroid and longacting \u03b22 agonist therapy , even in combination with tiotropium .","paragraph":"<h3><u>Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.</u></h3><b style='color:Tomato;'><i>roflumilast</i></b> reduces exacerbations in patients with severe chronic obstructive pulmonary disease. Its effect in patients using fixed combinations of inhaled corticosteroids and longacting \u03b22 agonists is unknown. We postulated that <b style='color:Tomato;'><i>roflumilast</i></b> would reduce exacerbations in patients with severe chronic obstructive pulmonary disease at risk for exacerbations, even in combination with inhaled corticosteroid and longacting \u03b22 agonist treatment. ### methods For this 1-year double-blind, placebo-controlled, parallel group, multicentre, phase 3-4 trial, the <b style='color:Tomato;'><i>roflumilast</i></b> and Exacerbations in patients receiving Appropriate Combination Therapy (REACT) study, we enrolled patients with severe chronic obstructive pulmonary disease from 203 centres (outpatient clinics, hospitals, specialised pulmonologists, and family doctors) in 21 countries. Eligible patients were 40 years of age or older with a smoking history of at least 20 pack-years and a diagnosis of chronic obstructive pulmonary disease with severe airflow limitation, symptoms of chronic bronchitis, and at least two exacerbations in the previous year. We used a computerised central randomisation system to randomly assign patients in a 1:1 ratio to the two treatment groups: <b style='color:Tomato;'><i>roflumilast</i></b> 500 \u03bcg or placebo given orally once daily together with a fixed inhaled corticosteroid and longacting \u03b22 agonist combination. Background <b style='color:Tomato;'><i>tiotropium</i></b> treatment was allowed. All patients and investigators were masked to group assignment. The primary outcome was the rate of moderate to severe chronic obstructive pulmonary disease exacerbations per patient per year, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01329029. ### findings Between April 3, 2011, and May 27, 2014, we enrolled 1945 eligible participants and randomly assigned 973 to the <b style='color:Tomato;'><i>roflumilast</i></b> group and 972 to the placebo group. The rate of moderate-to-severe chronic obstructive pulmonary disease exacerbations was 13\u00b72% lower in the <b style='color:Tomato;'><i>roflumilast</i></b> group than in the placebo group according to a Poisson regression analysis (<b style='color:Tomato;'><i>roflumilast</i></b> 0\u00b7805 vs placebo 0\u00b7927; rate ratio [RR] 0\u00b7868 [95% CI 0\u00b7753-1\u00b7002], p=0\u00b70529), and 14\u00b72% lower according to a predefined sensitivity analysis using negative binomial regression (0\u00b7823 vs 0\u00b7959; 0\u00b7858 [0\u00b7740-0\u00b7995], p=0\u00b70424). Adverse events were reported by 648 (67%) of 968 patients receiving <b style='color:Tomato;'><i>roflumilast</i></b> and by 572 (59%) of 967 patients in the placebo group; adverse event-associated patient withdrawal from the study was also more common in the <b style='color:Tomato;'><i>roflumilast</i></b> group (104/968 [11%]) than in the placebo group (52/967 [5%]). The most frequently reported serious adverse events were chronic obstructive pulmonary disease exacerbations and pneumonia, and 17 (1\u00b78%) deaths occurred in the <b style='color:Tomato;'><i>roflumilast</i></b> group compared with 18 (1\u00b79%) in the placebo group. ### interpretation <b style='color:DodgerBlue;'><i>Our</i></b> <b style='color:DodgerBlue;'><i>findings</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>roflumilast</i></b> <b style='color:DodgerBlue;'><i>reduces</i></b> <b style='color:DodgerBlue;'><i>exacerbations</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>hospital</i></b> <b style='color:DodgerBlue;'><i>admissions</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>obstructive</i></b> <b style='color:DodgerBlue;'><i>pulmonary</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>bronchitis</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>frequent</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>exacerbations</i></b> <b style='color:DodgerBlue;'><i>despite</i></b> <b style='color:DodgerBlue;'><i>inhaled</i></b> <b style='color:DodgerBlue;'><i>corticosteroid</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>longacting</i></b> <b style='color:DodgerBlue;'><i>\u03b22</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tiotropium</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### funding Takeda.","tokens":[{"text":"Our","start":0,"end":3,"id":0,"ws":true},{"text":"findings","start":4,"end":12,"id":1,"ws":true},{"text":"suggest","start":13,"end":20,"id":2,"ws":true},{"text":"that","start":21,"end":25,"id":3,"ws":true},{"text":"roflumilast","start":26,"end":37,"id":4,"ws":true},{"text":"reduces","start":38,"end":45,"id":5,"ws":true},{"text":"exacerbations","start":46,"end":59,"id":6,"ws":true},{"text":"and","start":60,"end":63,"id":7,"ws":true},{"text":"hospital","start":64,"end":72,"id":8,"ws":true},{"text":"admissions","start":73,"end":83,"id":9,"ws":true},{"text":"in","start":84,"end":86,"id":10,"ws":true},{"text":"patients","start":87,"end":95,"id":11,"ws":true},{"text":"with","start":96,"end":100,"id":12,"ws":true},{"text":"severe","start":101,"end":107,"id":13,"ws":true},{"text":"chronic","start":108,"end":115,"id":14,"ws":true},{"text":"obstructive","start":116,"end":127,"id":15,"ws":true},{"text":"pulmonary","start":128,"end":137,"id":16,"ws":true},{"text":"disease","start":138,"end":145,"id":17,"ws":true},{"text":"and","start":146,"end":149,"id":18,"ws":true},{"text":"chronic","start":150,"end":157,"id":19,"ws":true},{"text":"bronchitis","start":158,"end":168,"id":20,"ws":true},{"text":"who","start":169,"end":172,"id":21,"ws":true},{"text":"are","start":173,"end":176,"id":22,"ws":true},{"text":"at","start":177,"end":179,"id":23,"ws":true},{"text":"risk","start":180,"end":184,"id":24,"ws":true},{"text":"of","start":185,"end":187,"id":25,"ws":true},{"text":"frequent","start":188,"end":196,"id":26,"ws":true},{"text":"and","start":197,"end":200,"id":27,"ws":true},{"text":"severe","start":201,"end":207,"id":28,"ws":true},{"text":"exacerbations","start":208,"end":221,"id":29,"ws":true},{"text":"despite","start":222,"end":229,"id":30,"ws":true},{"text":"inhaled","start":230,"end":237,"id":31,"ws":true},{"text":"corticosteroid","start":238,"end":252,"id":32,"ws":true},{"text":"and","start":253,"end":256,"id":33,"ws":true},{"text":"longacting","start":257,"end":267,"id":34,"ws":true},{"text":"\u03b22","start":268,"end":270,"id":35,"ws":true},{"text":"agonist","start":271,"end":278,"id":36,"ws":true},{"text":"therapy","start":279,"end":286,"id":37,"ws":true},{"text":",","start":287,"end":288,"id":38,"ws":true},{"text":"even","start":289,"end":293,"id":39,"ws":true},{"text":"in","start":294,"end":296,"id":40,"ws":true},{"text":"combination","start":297,"end":308,"id":41,"ws":true},{"text":"with","start":309,"end":313,"id":42,"ws":true},{"text":"tiotropium","start":314,"end":324,"id":43,"ws":true},{"text":".","start":325,"end":326,"id":44,"ws":false}],"spans":[{"start":26,"end":37,"token_start":4,"token_end":4,"label":"DRUG"},{"start":314,"end":324,"token_start":43,"token_end":43,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25684586/","_input_hash":-1265223608,"_task_hash":-1393701930,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":43,"child":4,"head_span":{"start":314,"end":324,"token_start":43,"token_end":43,"label":"DRUG"},"child_span":{"start":26,"end":37,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"This academic , matched-cohort study , compared 2-year outcomes of 11 consecutive IMN patients who received second-line rituximab therapy for NS persisting or relapsing after previous treatment with steroids alone or combined with alkylating agents , cyclosporine , or immunoglobulin G , with those of 11 age- ( \u00b1 5 years ) , gender- and proteinuria- ( \u00b1 1 g/24h ) matched reference patients given first-line rituximab therapy .","paragraph":"<h3><u>Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study.</u></h3>First-line immunosuppression with the B-cell depleting antibody <b style='color:Tomato;'><i>rituximab</i></b> reduced proteinuria and induced remission of the disease in patients with nephrotic syndrome (NS) secondary to idiopathic membranous nephropathy (IMN). Here we evaluated whether <b style='color:Tomato;'><i>rituximab</i></b> is equally effective in patients who failed to respond to previous immunosuppressive treatment. ### methods <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>academic</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>matched-cohort</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>2-year</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>11</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>IMN</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>NS</i></b> <b style='color:DodgerBlue;'><i>persisting</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>relapsing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>previous</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>steroids</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>alkylating</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>immunoglobulin</i></b> <b style='color:DodgerBlue;'><i>G</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>11</i></b> <b style='color:DodgerBlue;'><i>age-</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>\u00b1</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>gender-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>proteinuria-</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>\u00b1</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>g/24h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>matched</i></b> <b style='color:DodgerBlue;'><i>reference</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Patients' and reference patients' baseline characteristics were similar. Compared to baseline, 24-hour proteinuria similarly declined at 1 and 2 years post-<b style='color:Tomato;'><i>rituximab</i></b> (by 50.5 \u00b1 25.1% and 60.9 \u00b1 17.4% in patients and by 52.7 \u00b1 31.5% and 69.4 \u00b1 40.4% in reference patients, respectively; p < 0.01 for all comparisons vs. baseline). 8 patients and 7 reference patients achieved full (3 vs. 2) or partial (5 per cohort) proteinuria remission. Hypoalbuminemia and hyperlipidemia normalized in both groups. Self-limited infusion-related reactions occurred in 1 subject per cohort. ### conclusion <b style='color:Tomato;'><i>rituximab</i></b> reduced proteinuria in IMN patients with no or only transient response to unselective immunosuppression as effectively and safely as in patients without previous immunosuppression.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"academic","start":5,"end":13,"id":1,"ws":true},{"text":",","start":14,"end":15,"id":2,"ws":true},{"text":"matched-cohort","start":16,"end":30,"id":3,"ws":true},{"text":"study","start":31,"end":36,"id":4,"ws":true},{"text":",","start":37,"end":38,"id":5,"ws":true},{"text":"compared","start":39,"end":47,"id":6,"ws":true},{"text":"2-year","start":48,"end":54,"id":7,"ws":true},{"text":"outcomes","start":55,"end":63,"id":8,"ws":true},{"text":"of","start":64,"end":66,"id":9,"ws":true},{"text":"11","start":67,"end":69,"id":10,"ws":true},{"text":"consecutive","start":70,"end":81,"id":11,"ws":true},{"text":"IMN","start":82,"end":85,"id":12,"ws":true},{"text":"patients","start":86,"end":94,"id":13,"ws":true},{"text":"who","start":95,"end":98,"id":14,"ws":true},{"text":"received","start":99,"end":107,"id":15,"ws":true},{"text":"second-line","start":108,"end":119,"id":16,"ws":true},{"text":"rituximab","start":120,"end":129,"id":17,"ws":true},{"text":"therapy","start":130,"end":137,"id":18,"ws":true},{"text":"for","start":138,"end":141,"id":19,"ws":true},{"text":"NS","start":142,"end":144,"id":20,"ws":true},{"text":"persisting","start":145,"end":155,"id":21,"ws":true},{"text":"or","start":156,"end":158,"id":22,"ws":true},{"text":"relapsing","start":159,"end":168,"id":23,"ws":true},{"text":"after","start":169,"end":174,"id":24,"ws":true},{"text":"previous","start":175,"end":183,"id":25,"ws":true},{"text":"treatment","start":184,"end":193,"id":26,"ws":true},{"text":"with","start":194,"end":198,"id":27,"ws":true},{"text":"steroids","start":199,"end":207,"id":28,"ws":true},{"text":"alone","start":208,"end":213,"id":29,"ws":true},{"text":"or","start":214,"end":216,"id":30,"ws":true},{"text":"combined","start":217,"end":225,"id":31,"ws":true},{"text":"with","start":226,"end":230,"id":32,"ws":true},{"text":"alkylating","start":231,"end":241,"id":33,"ws":true},{"text":"agents","start":242,"end":248,"id":34,"ws":true},{"text":",","start":249,"end":250,"id":35,"ws":true},{"text":"cyclosporine","start":251,"end":263,"id":36,"ws":true},{"text":",","start":264,"end":265,"id":37,"ws":true},{"text":"or","start":266,"end":268,"id":38,"ws":true},{"text":"immunoglobulin","start":269,"end":283,"id":39,"ws":true},{"text":"G","start":284,"end":285,"id":40,"ws":true},{"text":",","start":286,"end":287,"id":41,"ws":true},{"text":"with","start":288,"end":292,"id":42,"ws":true},{"text":"those","start":293,"end":298,"id":43,"ws":true},{"text":"of","start":299,"end":301,"id":44,"ws":true},{"text":"11","start":302,"end":304,"id":45,"ws":true},{"text":"age-","start":305,"end":309,"id":46,"ws":true},{"text":"(","start":310,"end":311,"id":47,"ws":true},{"text":"\u00b1","start":312,"end":313,"id":48,"ws":true},{"text":"5","start":314,"end":315,"id":49,"ws":true},{"text":"years","start":316,"end":321,"id":50,"ws":true},{"text":")","start":322,"end":323,"id":51,"ws":true},{"text":",","start":324,"end":325,"id":52,"ws":true},{"text":"gender-","start":326,"end":333,"id":53,"ws":true},{"text":"and","start":334,"end":337,"id":54,"ws":true},{"text":"proteinuria-","start":338,"end":350,"id":55,"ws":true},{"text":"(","start":351,"end":352,"id":56,"ws":true},{"text":"\u00b1","start":353,"end":354,"id":57,"ws":true},{"text":"1","start":355,"end":356,"id":58,"ws":true},{"text":"g/24h","start":357,"end":362,"id":59,"ws":true},{"text":")","start":363,"end":364,"id":60,"ws":true},{"text":"matched","start":365,"end":372,"id":61,"ws":true},{"text":"reference","start":373,"end":382,"id":62,"ws":true},{"text":"patients","start":383,"end":391,"id":63,"ws":true},{"text":"given","start":392,"end":397,"id":64,"ws":true},{"text":"first-line","start":398,"end":408,"id":65,"ws":true},{"text":"rituximab","start":409,"end":418,"id":66,"ws":true},{"text":"therapy","start":419,"end":426,"id":67,"ws":true},{"text":".","start":427,"end":428,"id":68,"ws":false}],"spans":[{"start":120,"end":129,"token_start":17,"token_end":17,"label":"DRUG"},{"start":251,"end":263,"token_start":36,"token_end":36,"label":"DRUG"},{"start":409,"end":418,"token_start":66,"token_end":66,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21508634/","_input_hash":-337355207,"_task_hash":-465550323,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Induction chemotherapy with cisplatin , doxorubicin , and cyclophosphamide ( CAP ) in a combined modality approach for locally advanced and inflammatory breast cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Induction</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CAP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>modality</i></b> <b style='color:DodgerBlue;'><i>approach</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>inflammatory</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Thirty-one patients with locally advanced and inflammatory breast carcinoma (stage IIIA and IIIB) were treated with a combined modality approach between 1985 and 1989. All patients received as induction chemotherapy a combination of cisplatin, <b style='color:Tomato;'><i>doxorubicin</i></b>, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> (CAP). Responsive patients and patients with operable stable disease underwent modified radical mastectomy followed by concurrent radiotherapy and CMF (<b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, 5-<b style='color:Tomato;'><i>fluorouracil</i></b>) adjuvant chemotherapy. Thirty patients were evaluable for response to CAP. The rate of objective response to induction chemotherapy was 76.7% with 2 patients (6.7%) obtaining a complete response and 21 patients (70%) a partial response. Twenty-five patients were rendered disease-free after induction chemotherapy and surgery. Only 2 of these had pathological complete response (8%). The median overall survival was 48.7 months, the median time to progression was 22.4 months and the median disease-free survival was 29.1 months. The patients with noninflammatory breast tumor had a significantly better overall survival, disease-free survival, and time to progression. The overall survival and the time to progression were statistically superior in patients with primary tumor size < or = 8 cm. At a median follow-up of 6 years, 29% (95% CI, 13.05 to 45.01) of patients were alive and 28% (95% CI, 10.4 to 45.6) were disease-free. This combined modality treatment seems feasible with quite acceptable toxicity; the CAP combination is an effective alternative to the other standard chemotherapeutic regimens. Our results, although encouraging, are still poor, and new drugs and strategies are required to improve the long-term outcome.","tokens":[{"text":"Induction","start":0,"end":9,"id":0,"ws":true},{"text":"chemotherapy","start":10,"end":22,"id":1,"ws":true},{"text":"with","start":23,"end":27,"id":2,"ws":true},{"text":"cisplatin","start":28,"end":37,"id":3,"ws":true},{"text":",","start":38,"end":39,"id":4,"ws":true},{"text":"doxorubicin","start":40,"end":51,"id":5,"ws":true},{"text":",","start":52,"end":53,"id":6,"ws":true},{"text":"and","start":54,"end":57,"id":7,"ws":true},{"text":"cyclophosphamide","start":58,"end":74,"id":8,"ws":true},{"text":"(","start":75,"end":76,"id":9,"ws":true},{"text":"CAP","start":77,"end":80,"id":10,"ws":true},{"text":")","start":81,"end":82,"id":11,"ws":true},{"text":"in","start":83,"end":85,"id":12,"ws":true},{"text":"a","start":86,"end":87,"id":13,"ws":true},{"text":"combined","start":88,"end":96,"id":14,"ws":true},{"text":"modality","start":97,"end":105,"id":15,"ws":true},{"text":"approach","start":106,"end":114,"id":16,"ws":true},{"text":"for","start":115,"end":118,"id":17,"ws":true},{"text":"locally","start":119,"end":126,"id":18,"ws":true},{"text":"advanced","start":127,"end":135,"id":19,"ws":true},{"text":"and","start":136,"end":139,"id":20,"ws":true},{"text":"inflammatory","start":140,"end":152,"id":21,"ws":true},{"text":"breast","start":153,"end":159,"id":22,"ws":true},{"text":"cancer","start":160,"end":166,"id":23,"ws":true},{"text":".","start":167,"end":168,"id":24,"ws":false}],"spans":[{"start":28,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},{"start":40,"end":51,"token_start":5,"token_end":5,"label":"DRUG"},{"start":58,"end":74,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8554028/","_input_hash":-1787492906,"_task_hash":-351056307,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":28,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":40,"end":51,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":8,"head_span":{"start":40,"end":51,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":58,"end":74,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Methotrexate was efficient in one patient , hydroxychloroquine showed benefit in only 1 out of 3 patients .","paragraph":"<h3><u>Oral involvement in sarcoidosis: report of 12 cases.</u></h3>To assess the clinical features, treatment and outcome of oral sarcoidosis and to determine whether oral involvement is associated with a particular clinical phenotype of sarcoidosis. ### design Multicentric retrospective study. ### methods Retrospective chart review. Each patient was matched with four controls. ### results Twelve patients (9 women, 3 men) were identified. Their median age at sarcoidosis diagnosis was 38 years. Oral involvement was the first clinical evidence of sarcoidosis in seven cases and was a relapse symptom in five cases. Clinical presentations were nodules (n = 7) or ulcers (n = 5) and were mostly solitary. The tongue was the commonest site affected (n = 4), followed by lips (n = 3), oral mucosa (n = 2), palate (n = 2) and gingiva (n = 1). Patients with oral sarcoidosis were significantly younger and had more frequent lacrimal or salivary glands and upper airway tract clinical involvement than the controls; increased angiotensin-converting enzyme was less frequent in oral sarcoidosis. Multiple treatments of oral sarcoidosis were used: no treatment (n = 3), surgery (n = 2), corticosteroids (n = 7), hydroxy<b style='color:Tomato;'><i>chloroquine</i></b> (n = 3), <b style='color:Tomato;'><i>methotrexate</i></b> (n = 2), <b style='color:Tomato;'><i>doxycycline</i></b> (n = 1). <b style='color:MediumOrchid;'><i>Methotrexate</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>efficient</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>hydroxychloroquine</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>out</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Three patients presented oral relapses. After a mean follow-up of 6 years, 10 patients experienced a complete (n = 7) or partial (n = 3) remission of oral sarcoidosis; stability was observed in the remaining two cases. ### conclusion Although oral manifestations of sarcoidosis are unusual, physicians should be aware that this specific localization is frequently the first manifestation of the disease. Treatment modalities range from observation in asymptomatic patients to immunosuppressants for severe involvement.","tokens":[{"text":"Methotrexate","start":0,"end":12,"id":0,"ws":true},{"text":"was","start":13,"end":16,"id":1,"ws":true},{"text":"efficient","start":17,"end":26,"id":2,"ws":true},{"text":"in","start":27,"end":29,"id":3,"ws":true},{"text":"one","start":30,"end":33,"id":4,"ws":true},{"text":"patient","start":34,"end":41,"id":5,"ws":true},{"text":",","start":42,"end":43,"id":6,"ws":true},{"text":"hydroxychloroquine","start":44,"end":62,"id":7,"ws":true},{"text":"showed","start":63,"end":69,"id":8,"ws":true},{"text":"benefit","start":70,"end":77,"id":9,"ws":true},{"text":"in","start":78,"end":80,"id":10,"ws":true},{"text":"only","start":81,"end":85,"id":11,"ws":true},{"text":"1","start":86,"end":87,"id":12,"ws":true},{"text":"out","start":88,"end":91,"id":13,"ws":true},{"text":"of","start":92,"end":94,"id":14,"ws":true},{"text":"3","start":95,"end":96,"id":15,"ws":true},{"text":"patients","start":97,"end":105,"id":16,"ws":true},{"text":".","start":106,"end":107,"id":17,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":44,"end":62,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22422021/","_input_hash":228418452,"_task_hash":-996686854,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Our results show high rates of DR-TB in Nigerian HIV-infected individuals ( 7.0 % for rifampin [ RIF ] and 9.3 % for RIF or isoniazid [ INH ] ) .","paragraph":"<h3><u>Genetic determinants of drug-resistant tuberculosis among HIV-infected patients in Nigeria.</u></h3>Tuberculosis (TB) is the most common opportunistic infection in human immunodeficiency virus (HIV)-infected patients and the emergence of drug-resistant tuberculosis (DR-TB) is a growing problem in resource-limited settings. Adequate infrastructure for testing drug sensitivity and sufficient evidence of first-line resistance are currently unavailable in Nigeria. We collected sputum samples from HIV-infected patients enrolled in the Harvard PEPFAR/APIN Plus program over 12 months at two PEPFAR antiretroviral therapy (ART) clinics in the southwest and north central regions in Nigeria. Smear-positive sputum samples were submitted for GenoType MTBDRplus testing (n = 415); mutations were confirmed through sequencing. <b style='color:DodgerBlue;'><i>Our</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>show</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>DR-TB</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Nigerian</i></b> <b style='color:DodgerBlue;'><i>HIV-infected</i></b> <b style='color:DodgerBlue;'><i>individuals</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>7.0</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>rifampin</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>RIF</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>9.3</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>RIF</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>INH</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Total RIF resistance indicative of MDR-TB in treatment-naive patients was 5.52%, far exceeding the World Health Organization predictions (0 to 4.3%). RIF resistance was found in 6/213 (2.8%) cases, INH resistance was found in 3/215 (1.4%) cases, and MDR-TB was found in 8/223 (3.6%) cases. We found significantly different amounts of DR-TB by location (18.18% in the south of the country versus 3.91% in the north central region [P < 0.01]). Furthermore, RIF resistance was genetically distinct, suggesting possible location-specific strains are responsible for the transmission of drug resistance (P < 0.04). Finally, GenoType MTBDRplus correctly identified the drug-resistant samples compared to sequencing in 96.8% of cases. We found that total DR-TB in HIV-infection is high and that transmission of drug-resistant TB in HIV-infected patients in Nigeria is higher than predicted.","tokens":[{"text":"Our","start":0,"end":3,"id":0,"ws":true},{"text":"results","start":4,"end":11,"id":1,"ws":true},{"text":"show","start":12,"end":16,"id":2,"ws":true},{"text":"high","start":17,"end":21,"id":3,"ws":true},{"text":"rates","start":22,"end":27,"id":4,"ws":true},{"text":"of","start":28,"end":30,"id":5,"ws":true},{"text":"DR-TB","start":31,"end":36,"id":6,"ws":true},{"text":"in","start":37,"end":39,"id":7,"ws":true},{"text":"Nigerian","start":40,"end":48,"id":8,"ws":true},{"text":"HIV-infected","start":49,"end":61,"id":9,"ws":true},{"text":"individuals","start":62,"end":73,"id":10,"ws":true},{"text":"(","start":74,"end":75,"id":11,"ws":true},{"text":"7.0","start":76,"end":79,"id":12,"ws":true},{"text":"%","start":80,"end":81,"id":13,"ws":true},{"text":"for","start":82,"end":85,"id":14,"ws":true},{"text":"rifampin","start":86,"end":94,"id":15,"ws":true},{"text":"[","start":95,"end":96,"id":16,"ws":true},{"text":"RIF","start":97,"end":100,"id":17,"ws":true},{"text":"]","start":101,"end":102,"id":18,"ws":true},{"text":"and","start":103,"end":106,"id":19,"ws":true},{"text":"9.3","start":107,"end":110,"id":20,"ws":true},{"text":"%","start":111,"end":112,"id":21,"ws":true},{"text":"for","start":113,"end":116,"id":22,"ws":true},{"text":"RIF","start":117,"end":120,"id":23,"ws":true},{"text":"or","start":121,"end":123,"id":24,"ws":true},{"text":"isoniazid","start":124,"end":133,"id":25,"ws":true},{"text":"[","start":134,"end":135,"id":26,"ws":true},{"text":"INH","start":136,"end":139,"id":27,"ws":true},{"text":"]","start":140,"end":141,"id":28,"ws":true},{"text":")","start":142,"end":143,"id":29,"ws":true},{"text":".","start":144,"end":145,"id":30,"ws":false}],"spans":[{"start":86,"end":94,"token_start":15,"token_end":15,"label":"DRUG"},{"start":124,"end":133,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22740709/","_input_hash":2077547563,"_task_hash":-1292361964,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Sorafenib is an orally active multikinase inhibitor , and bortezomib is a proteasome inhibitor that affects multiple signaling pathways .","paragraph":"<h3><u>Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma.</u></h3> <b style='color:MediumOrchid;'><i>Sorafenib</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>multikinase</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>proteasome</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>affects</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>sorafenib</i></b> has clinical activity in renal cell carcinoma (RCC), whereas <b style='color:Tomato;'><i>bortezomib</i></b> has demonstrated activity against RCC cell lines in vitro, with in vitro studies showing synergism between the two agents in the induction of apoptosis in neoplastic cell lines. In this phase II study, we explored the efficacy and toxicity of this regimen. ### methods Adult patients with cytologically confirmed clear cell RCC with no prior chemotherapy, Zubrod performance status of 0-1, serum creatinine <1.5 mg/dL, and normal liver function tests were treated with <b style='color:Tomato;'><i>sorafenib</i></b> 200 mg orally b.i.d. with <b style='color:Tomato;'><i>bortezomib</i></b> 1 mg/m(2) intravenously on days 1, 4, 8, and 11 every 21 days. Treatment was continued until disease progression or unacceptable toxicity. The primary objective was median progression-free survival (PFS) of at least 70 weeks. ### results Seventeen patients were enrolled between April 2011 and January 2013. Median age was 62 years (range: 44-75 years). Four of 17 patients had known brain metastasis on enrollment. Median number of cycles was 4 (range: 1 to \u226545). No patient had complete response, 1 had partial response, 12 had stable disease, and 4 had progressive disease (response rate of 6%; 95% confidence interval: 0%-29%) with treatment. Median PFS was 13.7 weeks, and median overall survival was 110 weeks. The study was halted for futility. ### conclusion The combination of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>bortezomib</i></b> was well tolerated; however, response rate and PFS were comparable to <b style='color:Tomato;'><i>sorafenib</i></b> monotherapy. This regimen is not recommended for further development.","tokens":[{"text":"Sorafenib","start":0,"end":9,"id":0,"ws":true},{"text":"is","start":10,"end":12,"id":1,"ws":true},{"text":"an","start":13,"end":15,"id":2,"ws":true},{"text":"orally","start":16,"end":22,"id":3,"ws":true},{"text":"active","start":23,"end":29,"id":4,"ws":true},{"text":"multikinase","start":30,"end":41,"id":5,"ws":true},{"text":"inhibitor","start":42,"end":51,"id":6,"ws":true},{"text":",","start":52,"end":53,"id":7,"ws":true},{"text":"and","start":54,"end":57,"id":8,"ws":true},{"text":"bortezomib","start":58,"end":68,"id":9,"ws":true},{"text":"is","start":69,"end":71,"id":10,"ws":true},{"text":"a","start":72,"end":73,"id":11,"ws":true},{"text":"proteasome","start":74,"end":84,"id":12,"ws":true},{"text":"inhibitor","start":85,"end":94,"id":13,"ws":true},{"text":"that","start":95,"end":99,"id":14,"ws":true},{"text":"affects","start":100,"end":107,"id":15,"ws":true},{"text":"multiple","start":108,"end":116,"id":16,"ws":true},{"text":"signaling","start":117,"end":126,"id":17,"ws":true},{"text":"pathways","start":127,"end":135,"id":18,"ws":true},{"text":".","start":136,"end":137,"id":19,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":58,"end":68,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25777345/","_input_hash":769267850,"_task_hash":-912920055,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Hypertensive rats in separate groups were treated with either candesartan ( 1 mg/kg body weight ) alone or a combination of candesartan ( 1 mg/kg body weight ) and rofecoxib ( 10 mg/kg body weight ) orally and daily for 6 weeks .","paragraph":"<h3><u>Effect of rofecoxib on antihypertensive effects of candesartan in experimental models of hypertension.</u></h3>Given the high prevalence of hypertension, concomitant use of nonsteroidal anti-inflammatory drugs and antihypertensive medications is commonly encountered in clinical practice. The present study was designed to study the effect of indomethacin, <b style='color:Tomato;'><i>nimesulide</i></b>, and <b style='color:Tomato;'><i>rofecoxib</i></b> on blood pressure (BP) in normotensive and hypertensive rats and also to investigate the effect of <b style='color:Tomato;'><i>rofecoxib</i></b> on BP control in <b style='color:Tomato;'><i>candesartan</i></b>-treated hypertensive rats. Male Wistar rats weighing 150-200 g were divided into three groups: control, DOCA-hypertensive, and L-NAME-hypertensive rats. All the rats were given indomethacin (15 mg/kg body weight), <b style='color:Tomato;'><i>nimesulide</i></b> (20 mg/kg body weight), <b style='color:Tomato;'><i>rofecoxib</i></b> (10 mg/kg body weight), or vehicle orally and daily for 6 weeks. <b style='color:DodgerBlue;'><i>Hypertensive</i></b> <b style='color:DodgerBlue;'><i>rats</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>separate</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>candesartan</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>candesartan</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rofecoxib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> BP measurements were performed using tail cuff method at baseline and 1-week intervals throughout the treatment period. All the three COX inhibitors resulted in increase in BP, but mean change in BP was the highest with <b style='color:Tomato;'><i>rofecoxib</i></b>. <b style='color:Tomato;'><i>rofecoxib</i></b>-treated L-NAME-hypertensive rats exhibited a significant increase in mean arterial pressure at 6 weeks (168.3+/-5.7 mmHg) as compared with DOCA-hypertensive rats (128.818+/-7.2 mmHg). Administration of <b style='color:Tomato;'><i>rofecoxib</i></b> L-NAME-hypertensive rats treated with <b style='color:Tomato;'><i>candesartan</i></b> resulted in a significant increase in BP. Systolic BP at 0 week (107.0+/-4.2 mmHg) rose to 141.6+/-2.0 mmHg at 6 weeks. Systolic BP at 2, 4, and 6 weeks was significantly higher as compared with (L-NAME+<b style='color:Tomato;'><i>candesartan</i></b>)- and (<b style='color:Tomato;'><i>rofecoxib</i></b>+<b style='color:Tomato;'><i>candesartan</i></b>)-treated group. In conclusion, concomitant use of <b style='color:Tomato;'><i>rofecoxib</i></b> resulted in poor BP control by <b style='color:Tomato;'><i>candesartan</i></b> in L-NAME-hypertensive rats.","tokens":[{"text":"Hypertensive","start":0,"end":12,"id":0,"ws":true},{"text":"rats","start":13,"end":17,"id":1,"ws":true},{"text":"in","start":18,"end":20,"id":2,"ws":true},{"text":"separate","start":21,"end":29,"id":3,"ws":true},{"text":"groups","start":30,"end":36,"id":4,"ws":true},{"text":"were","start":37,"end":41,"id":5,"ws":true},{"text":"treated","start":42,"end":49,"id":6,"ws":true},{"text":"with","start":50,"end":54,"id":7,"ws":true},{"text":"either","start":55,"end":61,"id":8,"ws":true},{"text":"candesartan","start":62,"end":73,"id":9,"ws":true},{"text":"(","start":74,"end":75,"id":10,"ws":true},{"text":"1","start":76,"end":77,"id":11,"ws":true},{"text":"mg/kg","start":78,"end":83,"id":12,"ws":true},{"text":"body","start":84,"end":88,"id":13,"ws":true},{"text":"weight","start":89,"end":95,"id":14,"ws":true},{"text":")","start":96,"end":97,"id":15,"ws":true},{"text":"alone","start":98,"end":103,"id":16,"ws":true},{"text":"or","start":104,"end":106,"id":17,"ws":true},{"text":"a","start":107,"end":108,"id":18,"ws":true},{"text":"combination","start":109,"end":120,"id":19,"ws":true},{"text":"of","start":121,"end":123,"id":20,"ws":true},{"text":"candesartan","start":124,"end":135,"id":21,"ws":true},{"text":"(","start":136,"end":137,"id":22,"ws":true},{"text":"1","start":138,"end":139,"id":23,"ws":true},{"text":"mg/kg","start":140,"end":145,"id":24,"ws":true},{"text":"body","start":146,"end":150,"id":25,"ws":true},{"text":"weight","start":151,"end":157,"id":26,"ws":true},{"text":")","start":158,"end":159,"id":27,"ws":true},{"text":"and","start":160,"end":163,"id":28,"ws":true},{"text":"rofecoxib","start":164,"end":173,"id":29,"ws":true},{"text":"(","start":174,"end":175,"id":30,"ws":true},{"text":"10","start":176,"end":178,"id":31,"ws":true},{"text":"mg/kg","start":179,"end":184,"id":32,"ws":true},{"text":"body","start":185,"end":189,"id":33,"ws":true},{"text":"weight","start":190,"end":196,"id":34,"ws":true},{"text":")","start":197,"end":198,"id":35,"ws":true},{"text":"orally","start":199,"end":205,"id":36,"ws":true},{"text":"and","start":206,"end":209,"id":37,"ws":true},{"text":"daily","start":210,"end":215,"id":38,"ws":true},{"text":"for","start":216,"end":219,"id":39,"ws":true},{"text":"6","start":220,"end":221,"id":40,"ws":true},{"text":"weeks","start":222,"end":227,"id":41,"ws":true},{"text":".","start":228,"end":229,"id":42,"ws":false}],"spans":[{"start":62,"end":73,"token_start":9,"token_end":9,"label":"DRUG"},{"start":124,"end":135,"token_start":21,"token_end":21,"label":"DRUG"},{"start":164,"end":173,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15834454/","_input_hash":-830832239,"_task_hash":1297585410,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":29,"child":21,"head_span":{"start":164,"end":173,"token_start":29,"token_end":29,"label":"DRUG"},"child_span":{"start":124,"end":135,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"The highest weight gain in the cyclophosphamide , methotrexate and fluorouracil group was 2\u00b79 kg ( 5 % ) vs. 0\u00b79 kg ( 1 % ) in the anthracycline-based group .","paragraph":"<h3><u>Weight change trajectory in women with breast cancer receiving chemotherapy and the effect of different regimens.</u></h3>To investigate the trajectory of weight change in Taiwanese women with breast cancer after starting chemotherapy and the impact of chemotherapy regimens on weight change while controlling for age, menopausal status, body mass index, lymph node involvement and changes in habits of dietary fat intake and exercise. ### background Weight gain after adjuvant chemotherapy in women with breast cancer has negative impact on health outcomes. ### design Longitudinal, clinical observational study. ### methods Weights were repeatedly measured in 147 women with breast cancer stages I-III. Hierarchical linear modelling was used to analyse these longitudinal data. ### results The overall pattern of weight change was a cubic form beginning with a mean of 56\u00b79 kg before chemotherapy. It gradually increased to 59\u00b74 kg at 8\u00b75 months after the first chemotherapy followed by a decrease to 58\u00b75 kg at 21\u00b75 months. During the last 2\u00b75 months, weight increased slightly and never returned to the initial level. After controlling for confounders, steeper weight change was observed among women receiving <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b> and <b style='color:Tomato;'><i>fluorouracil</i></b>. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>highest</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>gain</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>2\u00b79</i></b> <b style='color:DodgerBlue;'><i>kg</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>vs.</i></b> <b style='color:DodgerBlue;'><i>0\u00b79</i></b> <b style='color:DodgerBlue;'><i>kg</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anthracycline-based</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusion The trajectory of body weight change within two years after chemotherapy shows a trend of gradual ascent, followed by a small decline and a slight increase in the last 2\u00b75 months. The chemotherapy regimen can predict the trend after controlling for other confounders; women on <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b> and <b style='color:Tomato;'><i>fluorouracil</i></b> have a steeper weight change. ### Relevance To Clinical Practice Nurses can inform women with breast cancer about the expected changes in body weight after chemotherapy to reduce their uncertainty. Future studies on effective interventions to minimise chemotherapy-induced weight gain are needed.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"highest","start":4,"end":11,"id":1,"ws":true},{"text":"weight","start":12,"end":18,"id":2,"ws":true},{"text":"gain","start":19,"end":23,"id":3,"ws":true},{"text":"in","start":24,"end":26,"id":4,"ws":true},{"text":"the","start":27,"end":30,"id":5,"ws":true},{"text":"cyclophosphamide","start":31,"end":47,"id":6,"ws":true},{"text":",","start":48,"end":49,"id":7,"ws":true},{"text":"methotrexate","start":50,"end":62,"id":8,"ws":true},{"text":"and","start":63,"end":66,"id":9,"ws":true},{"text":"fluorouracil","start":67,"end":79,"id":10,"ws":true},{"text":"group","start":80,"end":85,"id":11,"ws":true},{"text":"was","start":86,"end":89,"id":12,"ws":true},{"text":"2\u00b79","start":90,"end":93,"id":13,"ws":true},{"text":"kg","start":94,"end":96,"id":14,"ws":true},{"text":"(","start":97,"end":98,"id":15,"ws":true},{"text":"5","start":99,"end":100,"id":16,"ws":true},{"text":"%","start":101,"end":102,"id":17,"ws":true},{"text":")","start":103,"end":104,"id":18,"ws":true},{"text":"vs.","start":105,"end":108,"id":19,"ws":true},{"text":"0\u00b79","start":109,"end":112,"id":20,"ws":true},{"text":"kg","start":113,"end":115,"id":21,"ws":true},{"text":"(","start":116,"end":117,"id":22,"ws":true},{"text":"1","start":118,"end":119,"id":23,"ws":true},{"text":"%","start":120,"end":121,"id":24,"ws":true},{"text":")","start":122,"end":123,"id":25,"ws":true},{"text":"in","start":124,"end":126,"id":26,"ws":true},{"text":"the","start":127,"end":130,"id":27,"ws":true},{"text":"anthracycline-based","start":131,"end":150,"id":28,"ws":true},{"text":"group","start":151,"end":156,"id":29,"ws":true},{"text":".","start":157,"end":158,"id":30,"ws":false}],"spans":[{"start":31,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},{"start":50,"end":62,"token_start":8,"token_end":8,"label":"DRUG"},{"start":67,"end":79,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24393441/","_input_hash":1559494561,"_task_hash":863584461,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":31,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":50,"end":62,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":8,"child":10,"head_span":{"start":50,"end":62,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":67,"end":79,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus ( RAD001 ) and alemtuzumab : a Phase I/II study .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>relapsed/refractory</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>lymphocytic</i></b> <b style='color:DodgerBlue;'><i>leukemia/small</i></b> <b style='color:DodgerBlue;'><i>lymphocytic</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RAD001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL), and especially those with purine analogue refractory disease or TP53 deletion/mutation, had a poor prognosis prior to the introduction of therapy targeting B cell receptor signaling. The mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) inhibitor <b style='color:Tomato;'><i>everolimus</i></b> has biological activity in CLL and can mobilize CLL cells from the lymphoid tissues into the circulation. In this clinical trial we determined the maximum tolerated dose (MTD) of <b style='color:Tomato;'><i>everolimus</i></b> together with eight weeks of standard dose subcutaneous <b style='color:Tomato;'><i>alemtuzumab</i></b> (Phase I) and then evaluated the tolerability and efficacy of therapy of relapsed/refractory CLL with the combination of <b style='color:Tomato;'><i>everolimus</i></b> and <b style='color:Tomato;'><i>alemtuzumab</i></b> (Phase II). The maximum tolerated dose of oral <b style='color:Tomato;'><i>everolimus</i></b> was 2.5\u2009mg three times/week. Therapy with <b style='color:Tomato;'><i>everolimus</i></b> and <b style='color:Tomato;'><i>alemtuzumab</i></b> was tolerable, but not sufficiently efficacious (33% partial responses, no complete responses) to recommend further development of the regimen.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"of","start":10,"end":12,"id":1,"ws":true},{"text":"relapsed/refractory","start":13,"end":32,"id":2,"ws":true},{"text":"chronic","start":33,"end":40,"id":3,"ws":true},{"text":"lymphocytic","start":41,"end":52,"id":4,"ws":true},{"text":"leukemia/small","start":53,"end":67,"id":5,"ws":true},{"text":"lymphocytic","start":68,"end":79,"id":6,"ws":true},{"text":"lymphoma","start":80,"end":88,"id":7,"ws":true},{"text":"with","start":89,"end":93,"id":8,"ws":true},{"text":"everolimus","start":94,"end":104,"id":9,"ws":true},{"text":"(","start":105,"end":106,"id":10,"ws":true},{"text":"RAD001","start":107,"end":113,"id":11,"ws":true},{"text":")","start":114,"end":115,"id":12,"ws":true},{"text":"and","start":116,"end":119,"id":13,"ws":true},{"text":"alemtuzumab","start":120,"end":131,"id":14,"ws":true},{"text":":","start":132,"end":133,"id":15,"ws":true},{"text":"a","start":134,"end":135,"id":16,"ws":true},{"text":"Phase","start":136,"end":141,"id":17,"ws":true},{"text":"I/II","start":142,"end":146,"id":18,"ws":true},{"text":"study","start":147,"end":152,"id":19,"ws":true},{"text":".","start":153,"end":154,"id":20,"ws":false}],"spans":[{"start":94,"end":104,"token_start":9,"token_end":9,"label":"DRUG"},{"start":120,"end":131,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26699397/","_input_hash":936588146,"_task_hash":-903180674,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":14,"child":9,"head_span":{"start":120,"end":131,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":94,"end":104,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Since primary amines similar to that of lisinopril readily form Schiff bases with acetaldehyde , these data suggest that both captopril and lisinopril may act to detoxify the acetaldehyde effect upon plasma , albeit by different mechanisms .","paragraph":"<h3><u>Captopril and lisinopril decrease acetaldehyde effects upon the prothrombin time.</u></h3><b style='color:Tomato;'><i>captopril</i></b>, a thiol-containing antihypertensive drug, and <b style='color:Tomato;'><i>lisinopril</i></b>, an amino-containing antihypertensive drug, will both prolong the prothrombin time (PT) of Level I plasma. Acetaldehyde, a product of ethanol metabolism, also prolongs PT. In a study to examine the interrelationship between hypertension, hemostasis, and alcoholism, an examination of the impact of acetaldehyde on the effects of <b style='color:Tomato;'><i>captopril</i></b> and <b style='color:Tomato;'><i>lisinopril</i></b> upon PT was undertaken. It was observed that the pre-mixing of 7.7 x 10(-3) M <b style='color:Tomato;'><i>captopril</i></b> with 40.6 mM acetaldehyde for 30 min at R.T. prior to the addition to plasma results in a prolongation of PT which is less than that caused by acetaldehyde alone. Successive additions of <b style='color:Tomato;'><i>captopril</i></b> and acetaldehyde to plasma also yield a PT which is less than that of acetaldehyde alone. These data suggest that <b style='color:Tomato;'><i>captopril</i></b> may partially inactivate and detoxify the acetaldehyde effect on hemostasis upon interaction to form a thiohemiacetal. <b style='color:Tomato;'><i>captopril</i></b> may prolong PT by the reduction of the S-S bridges in the coagulation factors. <b style='color:Tomato;'><i>lisinopril</i></b> behaves similarly to <b style='color:Tomato;'><i>captopril</i></b>, prolonging PT. Successive additions of <b style='color:Tomato;'><i>lisinopril</i></b> and acetaldehyde, or pre-mixtures thereof, to plasma result in a lesser prolongation of clotting time relative to acetaldehyde alone. <b style='color:DodgerBlue;'><i>Since</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>amines</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lisinopril</i></b> <b style='color:DodgerBlue;'><i>readily</i></b> <b style='color:DodgerBlue;'><i>form</i></b> <b style='color:DodgerBlue;'><i>Schiff</i></b> <b style='color:DodgerBlue;'><i>bases</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>acetaldehyde</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>lisinopril</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>act</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>detoxify</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>acetaldehyde</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>upon</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>albeit</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>mechanisms</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Since","start":0,"end":5,"id":0,"ws":true},{"text":"primary","start":6,"end":13,"id":1,"ws":true},{"text":"amines","start":14,"end":20,"id":2,"ws":true},{"text":"similar","start":21,"end":28,"id":3,"ws":true},{"text":"to","start":29,"end":31,"id":4,"ws":true},{"text":"that","start":32,"end":36,"id":5,"ws":true},{"text":"of","start":37,"end":39,"id":6,"ws":true},{"text":"lisinopril","start":40,"end":50,"id":7,"ws":true},{"text":"readily","start":51,"end":58,"id":8,"ws":true},{"text":"form","start":59,"end":63,"id":9,"ws":true},{"text":"Schiff","start":64,"end":70,"id":10,"ws":true},{"text":"bases","start":71,"end":76,"id":11,"ws":true},{"text":"with","start":77,"end":81,"id":12,"ws":true},{"text":"acetaldehyde","start":82,"end":94,"id":13,"ws":true},{"text":",","start":95,"end":96,"id":14,"ws":true},{"text":"these","start":97,"end":102,"id":15,"ws":true},{"text":"data","start":103,"end":107,"id":16,"ws":true},{"text":"suggest","start":108,"end":115,"id":17,"ws":true},{"text":"that","start":116,"end":120,"id":18,"ws":true},{"text":"both","start":121,"end":125,"id":19,"ws":true},{"text":"captopril","start":126,"end":135,"id":20,"ws":true},{"text":"and","start":136,"end":139,"id":21,"ws":true},{"text":"lisinopril","start":140,"end":150,"id":22,"ws":true},{"text":"may","start":151,"end":154,"id":23,"ws":true},{"text":"act","start":155,"end":158,"id":24,"ws":true},{"text":"to","start":159,"end":161,"id":25,"ws":true},{"text":"detoxify","start":162,"end":170,"id":26,"ws":true},{"text":"the","start":171,"end":174,"id":27,"ws":true},{"text":"acetaldehyde","start":175,"end":187,"id":28,"ws":true},{"text":"effect","start":188,"end":194,"id":29,"ws":true},{"text":"upon","start":195,"end":199,"id":30,"ws":true},{"text":"plasma","start":200,"end":206,"id":31,"ws":true},{"text":",","start":207,"end":208,"id":32,"ws":true},{"text":"albeit","start":209,"end":215,"id":33,"ws":true},{"text":"by","start":216,"end":218,"id":34,"ws":true},{"text":"different","start":219,"end":228,"id":35,"ws":true},{"text":"mechanisms","start":229,"end":239,"id":36,"ws":true},{"text":".","start":240,"end":241,"id":37,"ws":false}],"spans":[{"start":40,"end":50,"token_start":7,"token_end":7,"label":"DRUG"},{"start":126,"end":135,"token_start":20,"token_end":20,"label":"DRUG"},{"start":140,"end":150,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17932766/","_input_hash":1502462362,"_task_hash":1694595858,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Capecitabine and oxaliplatin have been shown to be as effective as fluorouracil and cisplatin , respectively .","paragraph":"<h3><u>Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.</u></h3>At present, there is no standard regimen for the treatment of gastroesophageal cancer. <b style='color:Tomato;'><i>docetaxel</i></b>, cisplatin and <b style='color:Tomato;'><i>fluorouracil</i></b> (DCF) has been shown to be an effective regimen; however, toxicity is an area of concern in the palliative case setting. <b style='color:MediumOrchid;'><i>Capecitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> To reduce the toxicity of DCF while maintaining efficacy, we conducted this study to evaluate the efficacy of <b style='color:Tomato;'><i>docetaxel</i></b>, <b style='color:Tomato;'><i>oxaliplatin</i></b> and <b style='color:Tomato;'><i>capecitabine</i></b> (DOX) combination in advanced gastroesophageal cancer. ### methods Patients with histologically confirmed metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction received <b style='color:Tomato;'><i>docetaxel</i></b> 25 mg/m2 and <b style='color:Tomato;'><i>oxaliplatin</i></b> 50 mg/m2 on days 1 and 8 with <b style='color:Tomato;'><i>capecitabine</i></b> 625 mg/m2 twice daily from day 1-14, in 21-day cycles. The primary endpoint was overall response rate (ORR). ### results Of 21 patients, there were 16 males and 5 females with a median age of 57 years, range 37-80 years. The primary tumor was located at the gastroesophageal junction in 7 patients and in other parts of the stomach in the remaining 14 patients. One patient had locally advanced tumor without distant metastases and 20 patients presented with metastatic disease. Grade 3/4 toxicities included diarrhea (24%), hand-foot syndrome (5%) and febrile neutropenia (5%). The ORR was 29%. The median survival was 8.4 months. At the time of analysis, 5 of the 21 patients (24%) were alive. ### conclusions The DOX combination is tolerable, active and a promising day-care regimen for advanced gastroesophageal cancer.","tokens":[{"text":"Capecitabine","start":0,"end":12,"id":0,"ws":true},{"text":"and","start":13,"end":16,"id":1,"ws":true},{"text":"oxaliplatin","start":17,"end":28,"id":2,"ws":true},{"text":"have","start":29,"end":33,"id":3,"ws":true},{"text":"been","start":34,"end":38,"id":4,"ws":true},{"text":"shown","start":39,"end":44,"id":5,"ws":true},{"text":"to","start":45,"end":47,"id":6,"ws":true},{"text":"be","start":48,"end":50,"id":7,"ws":true},{"text":"as","start":51,"end":53,"id":8,"ws":true},{"text":"effective","start":54,"end":63,"id":9,"ws":true},{"text":"as","start":64,"end":66,"id":10,"ws":true},{"text":"fluorouracil","start":67,"end":79,"id":11,"ws":true},{"text":"and","start":80,"end":83,"id":12,"ws":true},{"text":"cisplatin","start":84,"end":93,"id":13,"ws":true},{"text":",","start":94,"end":95,"id":14,"ws":true},{"text":"respectively","start":96,"end":108,"id":15,"ws":true},{"text":".","start":109,"end":110,"id":16,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":17,"end":28,"token_start":2,"token_end":2,"label":"DRUG"},{"start":67,"end":79,"token_start":11,"token_end":11,"label":"DRUG"},{"start":84,"end":93,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20543537/","_input_hash":-31164785,"_task_hash":272062344,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":17,"end":28,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":11,"child":13,"head_span":{"start":67,"end":79,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":84,"end":93,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"To compare cardiopulmonary and sedative effects following administration of dexmedetomidine alone or with butorphanol , methadone , morphine or tramadol in healthy sheep .","paragraph":"<h3><u>Behavioral and cardiopulmonary effects of dexmedetomidine alone and in combination with butorphanol, methadone, morphine or tramadol in conscious sheep.</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>cardiopulmonary</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>sedative</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>dexmedetomidine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>butorphanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methadone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>morphine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>tramadol</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>healthy</i></b> <b style='color:DodgerBlue;'><i>sheep</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Study Design Randomized crossover study. ### animals Six Santa In\u00eas sheep, five females, one male, aged 12-28\u00a0months and weighing 40.1\u00a0\u00b1\u00a06.2\u00a0kg. ### methods Sheep were assigned treatments of dexme<b style='color:Tomato;'><i>detomidine</i></b> (0.005\u00a0mg\u00a0kg(-1) ; D); D and butorphanol (0.15\u00a0mg\u00a0kg(-1) ; DB); D and <b style='color:Tomato;'><i>methadone</i></b> (0.5\u00a0mg\u00a0kg(-1) ; DM); D and morphine (0.5\u00a0mg kg(-1) ; DMO); or D and <b style='color:Tomato;'><i>tramadol</i></b> (5.0\u00a0mg\u00a0kg(-1) ; DT). All drugs were administered intravenously with at least 7\u00a0days between each treatment. Rectal temperature, heart rate (HR), respiratory rate (fR ), invasive arterial pressure, blood gases and electrolytes were measured prior to administration of drugs (baseline, T0) and every 15\u00a0minutes following drug administration for 120\u00a0minutes (T15-T120). Sedation was scored by three observers blinded to treatment. ### results HR decreased in all treatments and fR decreased in DM at T30 and DMO at T30 and T45. PaCO2 was increased in D, DB and DM compared with baseline, and PaO2 decreased in D at T15 and T45; in DB at T15 to T75; in DM at T15 to T60; in DMO at T15; and in DT at T15, T30 and T75. There was a decrease in temperature in D, DB and DM. An increased pH was measured in D at all time points and in DT at T30-T120. HCO3- and base excess were increased in all treatments compared with baseline. There were no statistical differences in sedation scores. ### Conclusions And Clinical Relevance The combination of dexme<b style='color:Tomato;'><i>detomidine</i></b> with butorphanol, <b style='color:Tomato;'><i>methadone</i></b>, morphine or <b style='color:Tomato;'><i>tramadol</i></b> resulted in similar changes in cardiopulmonary function and did not improve sedation when compared with dexme<b style='color:Tomato;'><i>detomidine</i></b> alone.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"compare","start":3,"end":10,"id":1,"ws":true},{"text":"cardiopulmonary","start":11,"end":26,"id":2,"ws":true},{"text":"and","start":27,"end":30,"id":3,"ws":true},{"text":"sedative","start":31,"end":39,"id":4,"ws":true},{"text":"effects","start":40,"end":47,"id":5,"ws":true},{"text":"following","start":48,"end":57,"id":6,"ws":true},{"text":"administration","start":58,"end":72,"id":7,"ws":true},{"text":"of","start":73,"end":75,"id":8,"ws":true},{"text":"dexmedetomidine","start":76,"end":91,"id":9,"ws":true},{"text":"alone","start":92,"end":97,"id":10,"ws":true},{"text":"or","start":98,"end":100,"id":11,"ws":true},{"text":"with","start":101,"end":105,"id":12,"ws":true},{"text":"butorphanol","start":106,"end":117,"id":13,"ws":true},{"text":",","start":118,"end":119,"id":14,"ws":true},{"text":"methadone","start":120,"end":129,"id":15,"ws":true},{"text":",","start":130,"end":131,"id":16,"ws":true},{"text":"morphine","start":132,"end":140,"id":17,"ws":true},{"text":"or","start":141,"end":143,"id":18,"ws":true},{"text":"tramadol","start":144,"end":152,"id":19,"ws":true},{"text":"in","start":153,"end":155,"id":20,"ws":true},{"text":"healthy","start":156,"end":163,"id":21,"ws":true},{"text":"sheep","start":164,"end":169,"id":22,"ws":true},{"text":".","start":170,"end":171,"id":23,"ws":false}],"spans":[{"start":76,"end":91,"token_start":9,"token_end":9,"label":"DRUG"},{"start":106,"end":117,"token_start":13,"token_end":13,"label":"DRUG"},{"start":120,"end":129,"token_start":15,"token_end":15,"label":"DRUG"},{"start":132,"end":140,"token_start":17,"token_end":17,"label":"DRUG"},{"start":144,"end":152,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26848935/","_input_hash":-1763864041,"_task_hash":306609576,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":9,"child":15,"head_span":{"start":76,"end":91,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":120,"end":129,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":9,"child":13,"head_span":{"start":76,"end":91,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":106,"end":117,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":9,"child":17,"head_span":{"start":76,"end":91,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":132,"end":140,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"COMB3"}],"radio":[],"answer":"accept"}
{"text":"We found that melatonin in combination with all-trans retinoic acid and somatostatin potentiated the effects of melatonin alone on MCF-7 cell viability and growth inhibition ; this phenomenon was associated with altered conductance through Ca\u00b2\u207a and voltage-activated K\u207a ( BK ) channels , and with substantial impairments of Notch-1 and epidermal growth factor (EGF)-mediated signaling .","paragraph":"<h3><u>Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules.</u></h3><b style='color:Tomato;'><i>melatonin</i></b> has been shown to inhibit breast cancer cell growth in numerous studies. However, our understanding of the therapeutic effects of this hormone is still marginal and there is little information concerning its combination with other antitumor agents to achieve additional potential benefits. All-trans retinoic acids or <b style='color:Tomato;'><i>somatostatin</i></b> have been used in combination with <b style='color:Tomato;'><i>melatonin</i></b> in several pre-clinical and clinical trials, but they have never been combined altogether as an anti-breast cancer treatment. In the present study, we investigated whether the association of <b style='color:Tomato;'><i>melatonin</i></b>, all-trans retinoic acid and <b style='color:Tomato;'><i>somatostatin</i></b> leads to an enhanced anticancer activity in MCF-7 breast cancer cells. In such conditions, MCF-7 cells were investigated for cell growth/viability and proliferation, as well as for the expression of cyclin A, and components of the Notch and EGFR pathways, by Western blotting and confocal immunofluorescence. Electrophysiological, morphological, and biochemical analysis were also performed to reveal signs of cell damage and death. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>melatonin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>all-trans</i></b> <b style='color:DodgerBlue;'><i>retinoic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>somatostatin</i></b> <b style='color:DodgerBlue;'><i>potentiated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>melatonin</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>viability</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>phenomenon</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>altered</i></b> <b style='color:DodgerBlue;'><i>conductance</i></b> <b style='color:DodgerBlue;'><i>through</i></b> <b style='color:DodgerBlue;'><i>Ca\u00b2\u207a</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>voltage-activated</i></b> <b style='color:DodgerBlue;'><i>K\u207a</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>BK</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>channels</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>substantial</i></b> <b style='color:DodgerBlue;'><i>impairments</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Notch-1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>epidermal</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>(EGF)-mediated</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combined treatment also caused a marked reduction in mitochondrial membrane potential and intracellular ATP production as well as induction of necrotic cell death. Taken together our results indicate that co-administration of <b style='color:Tomato;'><i>melatonin</i></b> with all-trans retinoic acid and <b style='color:Tomato;'><i>somatostatin</i></b> may be of significant therapeutic benefit in breast cancer.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"found","start":3,"end":8,"id":1,"ws":true},{"text":"that","start":9,"end":13,"id":2,"ws":true},{"text":"melatonin","start":14,"end":23,"id":3,"ws":true},{"text":"in","start":24,"end":26,"id":4,"ws":true},{"text":"combination","start":27,"end":38,"id":5,"ws":true},{"text":"with","start":39,"end":43,"id":6,"ws":true},{"text":"all-trans","start":44,"end":53,"id":7,"ws":true},{"text":"retinoic","start":54,"end":62,"id":8,"ws":true},{"text":"acid","start":63,"end":67,"id":9,"ws":true},{"text":"and","start":68,"end":71,"id":10,"ws":true},{"text":"somatostatin","start":72,"end":84,"id":11,"ws":true},{"text":"potentiated","start":85,"end":96,"id":12,"ws":true},{"text":"the","start":97,"end":100,"id":13,"ws":true},{"text":"effects","start":101,"end":108,"id":14,"ws":true},{"text":"of","start":109,"end":111,"id":15,"ws":true},{"text":"melatonin","start":112,"end":121,"id":16,"ws":true},{"text":"alone","start":122,"end":127,"id":17,"ws":true},{"text":"on","start":128,"end":130,"id":18,"ws":true},{"text":"MCF-7","start":131,"end":136,"id":19,"ws":true},{"text":"cell","start":137,"end":141,"id":20,"ws":true},{"text":"viability","start":142,"end":151,"id":21,"ws":true},{"text":"and","start":152,"end":155,"id":22,"ws":true},{"text":"growth","start":156,"end":162,"id":23,"ws":true},{"text":"inhibition","start":163,"end":173,"id":24,"ws":true},{"text":";","start":174,"end":175,"id":25,"ws":true},{"text":"this","start":176,"end":180,"id":26,"ws":true},{"text":"phenomenon","start":181,"end":191,"id":27,"ws":true},{"text":"was","start":192,"end":195,"id":28,"ws":true},{"text":"associated","start":196,"end":206,"id":29,"ws":true},{"text":"with","start":207,"end":211,"id":30,"ws":true},{"text":"altered","start":212,"end":219,"id":31,"ws":true},{"text":"conductance","start":220,"end":231,"id":32,"ws":true},{"text":"through","start":232,"end":239,"id":33,"ws":true},{"text":"Ca\u00b2\u207a","start":240,"end":244,"id":34,"ws":true},{"text":"and","start":245,"end":248,"id":35,"ws":true},{"text":"voltage-activated","start":249,"end":266,"id":36,"ws":true},{"text":"K\u207a","start":267,"end":269,"id":37,"ws":true},{"text":"(","start":270,"end":271,"id":38,"ws":true},{"text":"BK","start":272,"end":274,"id":39,"ws":true},{"text":")","start":275,"end":276,"id":40,"ws":true},{"text":"channels","start":277,"end":285,"id":41,"ws":true},{"text":",","start":286,"end":287,"id":42,"ws":true},{"text":"and","start":288,"end":291,"id":43,"ws":true},{"text":"with","start":292,"end":296,"id":44,"ws":true},{"text":"substantial","start":297,"end":308,"id":45,"ws":true},{"text":"impairments","start":309,"end":320,"id":46,"ws":true},{"text":"of","start":321,"end":323,"id":47,"ws":true},{"text":"Notch-1","start":324,"end":331,"id":48,"ws":true},{"text":"and","start":332,"end":335,"id":49,"ws":true},{"text":"epidermal","start":336,"end":345,"id":50,"ws":true},{"text":"growth","start":346,"end":352,"id":51,"ws":true},{"text":"factor","start":353,"end":359,"id":52,"ws":true},{"text":"(EGF)-mediated","start":360,"end":374,"id":53,"ws":true},{"text":"signaling","start":375,"end":384,"id":54,"ws":true},{"text":".","start":385,"end":386,"id":55,"ws":false}],"spans":[{"start":14,"end":23,"token_start":3,"token_end":3,"label":"DRUG"},{"start":44,"end":67,"token_start":7,"token_end":9,"label":"DRUG"},{"start":72,"end":84,"token_start":11,"token_end":11,"label":"DRUG"},{"start":112,"end":121,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22532966/","_input_hash":-430367610,"_task_hash":1431879429,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":3,"child":9,"head_span":{"start":14,"end":23,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":44,"end":67,"token_start":7,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":11,"head_span":{"start":44,"end":67,"token_start":7,"token_end":9,"label":"DRUG"},"child_span":{"start":72,"end":84,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"It was concluded that cytosine arabinoside in combination with vincristine and prednisone is an effective but toxic antileukemic regimen which did not produce a major improvement in remission duration .","paragraph":"<h3><u>Treatment of adult acute lymphoblastic leukemia with cytosine arabinoside, vincristine, and prednisone.</u></h3>Thirteen adults with acute lymphoblastic leukemia were entered into a protocol in which cytosine arabinoside infusion was added to <b style='color:Tomato;'><i>vincristine</i></b> and <b style='color:Tomato;'><i>prednisone</i></b> as remission induction and periodic intensification therapy. Central nervous system prophylaxis consisting of cranial irradiation and intrathecal <b style='color:Tomato;'><i>methotrexate</i></b> was given, and all patients received continuous oral 6-<b style='color:Tomato;'><i>mercaptopurine</i></b> and <b style='color:Tomato;'><i>methotrexate</i></b> as maintenance treatment. Myelotoxicity was severe during induction, with prolonged granulocyte and platelet count nadirs noted. Nine of 13 patients (69%) obtained a complete remission and one (8%) obtained a partial remission. The median duration of complete remission was 38.1 weeks. <b style='color:DodgerBlue;'><i>It</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>concluded</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>cytosine</i></b> <b style='color:DodgerBlue;'><i>arabinoside</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>toxic</i></b> <b style='color:DodgerBlue;'><i>antileukemic</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>major</i></b> <b style='color:DodgerBlue;'><i>improvement</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>duration</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"It","start":0,"end":2,"id":0,"ws":true},{"text":"was","start":3,"end":6,"id":1,"ws":true},{"text":"concluded","start":7,"end":16,"id":2,"ws":true},{"text":"that","start":17,"end":21,"id":3,"ws":true},{"text":"cytosine","start":22,"end":30,"id":4,"ws":true},{"text":"arabinoside","start":31,"end":42,"id":5,"ws":true},{"text":"in","start":43,"end":45,"id":6,"ws":true},{"text":"combination","start":46,"end":57,"id":7,"ws":true},{"text":"with","start":58,"end":62,"id":8,"ws":true},{"text":"vincristine","start":63,"end":74,"id":9,"ws":true},{"text":"and","start":75,"end":78,"id":10,"ws":true},{"text":"prednisone","start":79,"end":89,"id":11,"ws":true},{"text":"is","start":90,"end":92,"id":12,"ws":true},{"text":"an","start":93,"end":95,"id":13,"ws":true},{"text":"effective","start":96,"end":105,"id":14,"ws":true},{"text":"but","start":106,"end":109,"id":15,"ws":true},{"text":"toxic","start":110,"end":115,"id":16,"ws":true},{"text":"antileukemic","start":116,"end":128,"id":17,"ws":true},{"text":"regimen","start":129,"end":136,"id":18,"ws":true},{"text":"which","start":137,"end":142,"id":19,"ws":true},{"text":"did","start":143,"end":146,"id":20,"ws":true},{"text":"not","start":147,"end":150,"id":21,"ws":true},{"text":"produce","start":151,"end":158,"id":22,"ws":true},{"text":"a","start":159,"end":160,"id":23,"ws":true},{"text":"major","start":161,"end":166,"id":24,"ws":true},{"text":"improvement","start":167,"end":178,"id":25,"ws":true},{"text":"in","start":179,"end":181,"id":26,"ws":true},{"text":"remission","start":182,"end":191,"id":27,"ws":true},{"text":"duration","start":192,"end":200,"id":28,"ws":true},{"text":".","start":201,"end":202,"id":29,"ws":false}],"spans":[{"start":22,"end":42,"token_start":4,"token_end":5,"label":"DRUG"},{"start":63,"end":74,"token_start":9,"token_end":9,"label":"DRUG"},{"start":79,"end":89,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/356988/","_input_hash":-1052511294,"_task_hash":-1696388063,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":5,"child":9,"head_span":{"start":22,"end":42,"token_start":4,"token_end":5,"label":"DRUG"},"child_span":{"start":63,"end":74,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":9,"child":11,"head_span":{"start":63,"end":74,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":79,"end":89,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"Patients were categorized into 10 groups according to the index OAC ( warfarin , rivaroxaban , dabigatran , apixaban , and edoxaban ) and whether or not they received PPI co-therapy , and were followed up for incidence of major GIB .","paragraph":"<h3><u>Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding.</u></h3>The risk of gastrointestinal bleeding (GIB) can be mitigated by proton pump inhibitor (PPI) co-therapy in patients with atrial fibrillation (AF) treated with anticoagulants. We aimed to evaluate the effect of PPIs on the risk of GIB in Asian patients with AF, treated with oral anticoagulants (OACs), and with a prior history of upper GIB. ### methods Using a nationwide claims database, OAC-na\u00efve patients with AF and a history of upper GIB before initiating OAC treatment between January 2010 and April 2018 were included. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>categorized</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>according</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>index</i></b> <b style='color:DodgerBlue;'><i>OAC</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>warfarin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>rivaroxaban</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>dabigatran</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apixaban</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>edoxaban</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>whether</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>they</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>PPI</i></b> <b style='color:DodgerBlue;'><i>co-therapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>up</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>incidence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>major</i></b> <b style='color:DodgerBlue;'><i>GIB</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Among a total of 42,048 patients, 40% were prescribed PPIs as co-therapy with OACs. Over a median 0.6\u00a0years (interquartile ranges 0.2-1.7\u00a0years) of follow-up, <b style='color:Tomato;'><i>rivaroxaban</i></b> use without PPIs showed the highest crude incidence of major GIB (2.62 per 100 person-years), followed by the use of <b style='color:Tomato;'><i>warfarin</i></b> without a PPI (2.20 per 100 person-years). Compared to the patients without PPI use, PPI co-therapy was associated with a significantly lower risk of major GIB, by 40% and 36%, in the <b style='color:Tomato;'><i>rivaroxaban</i></b> and <b style='color:Tomato;'><i>warfarin</i></b> groups, respectively. In <b style='color:Tomato;'><i>dabigatran</i></b>, <b style='color:Tomato;'><i>apixaban</i></b>, and <b style='color:Tomato;'><i>edoxaban</i></b> users, PPI co-therapy did not show a significant reduction in the risk of major GIB. ### conclusion Among patients with AF receiving anticoagulant treatment and with a prior history of upper GIB, PPI co-therapy was associated with a significant reduction in the risk of major GIB in patients treated with <b style='color:Tomato;'><i>rivaroxaban</i></b> and <b style='color:Tomato;'><i>warfarin</i></b>.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"were","start":9,"end":13,"id":1,"ws":true},{"text":"categorized","start":14,"end":25,"id":2,"ws":true},{"text":"into","start":26,"end":30,"id":3,"ws":true},{"text":"10","start":31,"end":33,"id":4,"ws":true},{"text":"groups","start":34,"end":40,"id":5,"ws":true},{"text":"according","start":41,"end":50,"id":6,"ws":true},{"text":"to","start":51,"end":53,"id":7,"ws":true},{"text":"the","start":54,"end":57,"id":8,"ws":true},{"text":"index","start":58,"end":63,"id":9,"ws":true},{"text":"OAC","start":64,"end":67,"id":10,"ws":true},{"text":"(","start":68,"end":69,"id":11,"ws":true},{"text":"warfarin","start":70,"end":78,"id":12,"ws":true},{"text":",","start":79,"end":80,"id":13,"ws":true},{"text":"rivaroxaban","start":81,"end":92,"id":14,"ws":true},{"text":",","start":93,"end":94,"id":15,"ws":true},{"text":"dabigatran","start":95,"end":105,"id":16,"ws":true},{"text":",","start":106,"end":107,"id":17,"ws":true},{"text":"apixaban","start":108,"end":116,"id":18,"ws":true},{"text":",","start":117,"end":118,"id":19,"ws":true},{"text":"and","start":119,"end":122,"id":20,"ws":true},{"text":"edoxaban","start":123,"end":131,"id":21,"ws":true},{"text":")","start":132,"end":133,"id":22,"ws":true},{"text":"and","start":134,"end":137,"id":23,"ws":true},{"text":"whether","start":138,"end":145,"id":24,"ws":true},{"text":"or","start":146,"end":148,"id":25,"ws":true},{"text":"not","start":149,"end":152,"id":26,"ws":true},{"text":"they","start":153,"end":157,"id":27,"ws":true},{"text":"received","start":158,"end":166,"id":28,"ws":true},{"text":"PPI","start":167,"end":170,"id":29,"ws":true},{"text":"co-therapy","start":171,"end":181,"id":30,"ws":true},{"text":",","start":182,"end":183,"id":31,"ws":true},{"text":"and","start":184,"end":187,"id":32,"ws":true},{"text":"were","start":188,"end":192,"id":33,"ws":true},{"text":"followed","start":193,"end":201,"id":34,"ws":true},{"text":"up","start":202,"end":204,"id":35,"ws":true},{"text":"for","start":205,"end":208,"id":36,"ws":true},{"text":"incidence","start":209,"end":218,"id":37,"ws":true},{"text":"of","start":219,"end":221,"id":38,"ws":true},{"text":"major","start":222,"end":227,"id":39,"ws":true},{"text":"GIB","start":228,"end":231,"id":40,"ws":true},{"text":".","start":232,"end":233,"id":41,"ws":false}],"spans":[{"start":70,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},{"start":81,"end":92,"token_start":14,"token_end":14,"label":"DRUG"},{"start":95,"end":105,"token_start":16,"token_end":16,"label":"DRUG"},{"start":108,"end":116,"token_start":18,"token_end":18,"label":"DRUG"},{"start":123,"end":131,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33730289/","_input_hash":1120132441,"_task_hash":-451505530,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Celecoxib induced a synergistic or an additive cytotoxic effect in combination with doxorubicin , etoposide , irinotecan or vincristine in vitro .","paragraph":"<h3><u>Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.</u></h3>Neuroblastoma is the most common and deadly solid tumor of childhood. Cyclooxygenase-2 is expressed in clinical neuroblastoma tumors and cell lines and inhibitors of this enzyme induce apoptosis in human neuroblastoma cells in vitro and in neuroblastoma xenografts in vivo. We hypothesized that the cyclooxygenase-2-specific inhibitor <b style='color:Tomato;'><i>celecoxib</i></b> could enhance the cytotoxic effect of chemotherapeutic drugs currently used in neuroblastoma treatment. Furthermore, we investigated if prophylactic treatment with <b style='color:Tomato;'><i>celecoxib</i></b> could prevent neuroblastoma tumor development in vivo. ### Experimental Design Neuroblastoma cell cytotoxicity of chemotherapeutic drugs in combination with <b style='color:Tomato;'><i>celecoxib</i></b> was examined. In vivo, athymic rats carrying established SH-SY5Y xenografts were treated with <b style='color:Tomato;'><i>celecoxib</i></b> in combination with <b style='color:Tomato;'><i>irinotecan</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b> or <b style='color:Tomato;'><i>etoposide</i></b>, or with either drug alone. For prevention studies, rats received <b style='color:Tomato;'><i>celecoxib</i></b> in the diet, 250 to 2,500 ppm, from the time of tumor cell injection. ### results <b style='color:MediumOrchid;'><i>Celecoxib</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>additive</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In vivo, treatment with <b style='color:Tomato;'><i>celecoxib</i></b> in combination with <b style='color:Tomato;'><i>irinotecan</i></b> or <b style='color:Tomato;'><i>doxorubicin</i></b> induced a significant growth inhibition of established neuroblastoma tumors. Rats receiving <b style='color:Tomato;'><i>celecoxib</i></b> in the diet showed a distinct dose-dependent delay in tumor development compared with untreated rats. Plasma levels of <b style='color:Tomato;'><i>celecoxib</i></b> were comparable with levels obtainable in humans. ### conclusions <b style='color:Tomato;'><i>celecoxib</i></b> potentiates the antitumor effect of chemotherapeutic drugs currently used in neuroblastoma treatment, which argues for clinical trials combining these drugs. <b style='color:Tomato;'><i>celecoxib</i></b> could also be a potential drug for treatment of minimal residual disease.","tokens":[{"text":"Celecoxib","start":0,"end":9,"id":0,"ws":true},{"text":"induced","start":10,"end":17,"id":1,"ws":true},{"text":"a","start":18,"end":19,"id":2,"ws":true},{"text":"synergistic","start":20,"end":31,"id":3,"ws":true},{"text":"or","start":32,"end":34,"id":4,"ws":true},{"text":"an","start":35,"end":37,"id":5,"ws":true},{"text":"additive","start":38,"end":46,"id":6,"ws":true},{"text":"cytotoxic","start":47,"end":56,"id":7,"ws":true},{"text":"effect","start":57,"end":63,"id":8,"ws":true},{"text":"in","start":64,"end":66,"id":9,"ws":true},{"text":"combination","start":67,"end":78,"id":10,"ws":true},{"text":"with","start":79,"end":83,"id":11,"ws":true},{"text":"doxorubicin","start":84,"end":95,"id":12,"ws":true},{"text":",","start":96,"end":97,"id":13,"ws":true},{"text":"etoposide","start":98,"end":107,"id":14,"ws":true},{"text":",","start":108,"end":109,"id":15,"ws":true},{"text":"irinotecan","start":110,"end":120,"id":16,"ws":true},{"text":"or","start":121,"end":123,"id":17,"ws":true},{"text":"vincristine","start":124,"end":135,"id":18,"ws":true},{"text":"in","start":136,"end":138,"id":19,"ws":true},{"text":"vitro","start":139,"end":144,"id":20,"ws":true},{"text":".","start":145,"end":146,"id":21,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":84,"end":95,"token_start":12,"token_end":12,"label":"DRUG"},{"start":98,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},{"start":110,"end":120,"token_start":16,"token_end":16,"label":"DRUG"},{"start":124,"end":135,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17289900/","_input_hash":929973262,"_task_hash":-1466629453,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":0,"child":12,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":84,"end":95,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":0,"child":14,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":98,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":0,"child":16,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":110,"end":120,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#d9fbad","label":"POS3"}],"radio":["POS10","POS20","POS30"],"answer":"accept"}
{"text":"In vivo , midostaurin alone powerfully prolonged the survival of mice bearing the resistant BL cells compared to rituximab alone treatments .","paragraph":"<h3><u>Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis.</u></h3>An intensive short-term chemotherapy regimen has substantially prolonged the overall survival of Burkitt's lymphoma (BL) patients, which has been further improved by addition of <b style='color:Tomato;'><i>rituximab</i></b>. However, the inevitable development of resistance to <b style='color:Tomato;'><i>rituximab</i></b> and the toxicity of chemotherapy remain obstacles. We first prepared two BL cell lines resistant to <b style='color:Tomato;'><i>rituximab</i></b>-mediated CDC. Using a phosphorylation antibody microarray, we revealed that PI3K/AKT pathway contained the most phosphorylated proteins/hits, while apoptosis pathway that may be regulated by PKC displayed the greatest fold enrichment in the resistant cells. The PI3K/AKT inhibitor IPI-145 failed to reverse the resistance. In contrast, the pan-PKC inhibitor <b style='color:Tomato;'><i>midostaurin</i></b> exhibited potent antitumor activity in both original and resistant cells, alone or in combination with <b style='color:Tomato;'><i>rituximab</i></b>. Notably, <b style='color:Tomato;'><i>midostaurin</i></b> promoted apoptosis by reducing the phosphorylation of PKC and consequently of downstream Bad, Bcl-2 and NF-\u03baB. Therefore, <b style='color:Tomato;'><i>midostaurin</i></b> improved <b style='color:Tomato;'><i>rituximab</i></b> activity by supplementing pro-apoptotic effects. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>midostaurin</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>powerfully</i></b> <b style='color:DodgerBlue;'><i>prolonged</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>bearing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>BL</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>treatments</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Addition of <b style='color:Tomato;'><i>midostaurin</i></b> to <b style='color:Tomato;'><i>rituximab</i></b> led to dramatically improved survival compared to <b style='color:Tomato;'><i>rituximab</i></b> but not <b style='color:Tomato;'><i>midostaurin</i></b> monotherapy. Our findings call for further evaluation of <b style='color:Tomato;'><i>midostaurin</i></b> alone or in combination with <b style='color:Tomato;'><i>rituximab</i></b> in treating resistant BL in particular.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"vivo","start":3,"end":7,"id":1,"ws":true},{"text":",","start":8,"end":9,"id":2,"ws":true},{"text":"midostaurin","start":10,"end":21,"id":3,"ws":true},{"text":"alone","start":22,"end":27,"id":4,"ws":true},{"text":"powerfully","start":28,"end":38,"id":5,"ws":true},{"text":"prolonged","start":39,"end":48,"id":6,"ws":true},{"text":"the","start":49,"end":52,"id":7,"ws":true},{"text":"survival","start":53,"end":61,"id":8,"ws":true},{"text":"of","start":62,"end":64,"id":9,"ws":true},{"text":"mice","start":65,"end":69,"id":10,"ws":true},{"text":"bearing","start":70,"end":77,"id":11,"ws":true},{"text":"the","start":78,"end":81,"id":12,"ws":true},{"text":"resistant","start":82,"end":91,"id":13,"ws":true},{"text":"BL","start":92,"end":94,"id":14,"ws":true},{"text":"cells","start":95,"end":100,"id":15,"ws":true},{"text":"compared","start":101,"end":109,"id":16,"ws":true},{"text":"to","start":110,"end":112,"id":17,"ws":true},{"text":"rituximab","start":113,"end":122,"id":18,"ws":true},{"text":"alone","start":123,"end":128,"id":19,"ws":true},{"text":"treatments","start":129,"end":139,"id":20,"ws":true},{"text":".","start":140,"end":141,"id":21,"ws":false}],"spans":[{"start":10,"end":21,"token_start":3,"token_end":3,"label":"DRUG"},{"start":113,"end":122,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30584254/","_input_hash":939925951,"_task_hash":1672044932,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Treatment of GIST882-R with imatinib in combination with gefitinib , an EGFR inhibitor , partially prevented cell growth , implying that EGFR may be involved in acquisition of secondary imatinib resistance in GIST .","paragraph":"<h3><u>Augmentation of multiple protein kinase activities associated with secondary imatinib resistance in gastrointestinal stromal tumors as revealed by quantitative phosphoproteome analysis.</u></h3>Mutations in the Kit receptor tyrosine kinase gene (KIT), which result in constitutive activation of the protein (KIT), are causally related to the development of gastrointestinal stromal tumors (GISTs). <b style='color:Tomato;'><i>imatinib</i></b>, a targeted anticancer drug, exerts a therapeutic effect against GISTs by repressing the kinase activity of KIT. Long-term administration of this drug, however, causes the emergence of <b style='color:Tomato;'><i>imatinib</i></b>-resistant GISTs. We performed quantitative phosphoproteome analysis using a cell-based GIST model system comprising an <b style='color:Tomato;'><i>imatinib</i></b>-sensitive GIST cell line (GIST882), GIST882 under treatment with <b style='color:Tomato;'><i>imatinib</i></b> (GIST882-IM), and secondary <b style='color:Tomato;'><i>imatinib</i></b>-resistant GIST882 (GIST882-R). Phosphorylated peptides were purified from each cell line using titania-based affinity chromatography or anti-phosphotyrosine immunoprecipitation, and then subjected to LC-MS/MS based quantitative phosphoproteome analysis. Using this method we identified augmentation of the kinase activities of multiple elements of the signal transduction pathway, especially KIT and EGFR. Although, these elements were up-regulated in GIST882-R, no additionally mutated KIT mRNA was found in secondary <b style='color:Tomato;'><i>imatinib</i></b>-resistant GIST cells. <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>GIST882-R</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>partially</i></b> <b style='color:DodgerBlue;'><i>prevented</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>implying</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>involved</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acquisition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>secondary</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>GIST</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Biological Significance In this study, we performed a quantitative phosphoproteome analysis using a cell culture-based GIST model system. The goal of the study was to investigate the mechanism of acquired resistance in GISTs against <b style='color:Tomato;'><i>imatinib</i></b>, a molecularly targeted drug that inhibits kinase activity of the KIT protein and that has been approved for the treatment of GISTs. In <b style='color:Tomato;'><i>imatinib</i></b>-resistant GIST cells, we observed elevated expression of KIT and restoration of its kinase activity, as well as activation of multiple proliferative signaling pathways. Our results indicate that the effects of even so-called 'molecularly targeted' drugs, are broad rather than convergent, and that the mechanisms of action of such drugs during continuous administration are extremely complex.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"of","start":10,"end":12,"id":1,"ws":true},{"text":"GIST882-R","start":13,"end":22,"id":2,"ws":true},{"text":"with","start":23,"end":27,"id":3,"ws":true},{"text":"imatinib","start":28,"end":36,"id":4,"ws":true},{"text":"in","start":37,"end":39,"id":5,"ws":true},{"text":"combination","start":40,"end":51,"id":6,"ws":true},{"text":"with","start":52,"end":56,"id":7,"ws":true},{"text":"gefitinib","start":57,"end":66,"id":8,"ws":true},{"text":",","start":67,"end":68,"id":9,"ws":true},{"text":"an","start":69,"end":71,"id":10,"ws":true},{"text":"EGFR","start":72,"end":76,"id":11,"ws":true},{"text":"inhibitor","start":77,"end":86,"id":12,"ws":true},{"text":",","start":87,"end":88,"id":13,"ws":true},{"text":"partially","start":89,"end":98,"id":14,"ws":true},{"text":"prevented","start":99,"end":108,"id":15,"ws":true},{"text":"cell","start":109,"end":113,"id":16,"ws":true},{"text":"growth","start":114,"end":120,"id":17,"ws":true},{"text":",","start":121,"end":122,"id":18,"ws":true},{"text":"implying","start":123,"end":131,"id":19,"ws":true},{"text":"that","start":132,"end":136,"id":20,"ws":true},{"text":"EGFR","start":137,"end":141,"id":21,"ws":true},{"text":"may","start":142,"end":145,"id":22,"ws":true},{"text":"be","start":146,"end":148,"id":23,"ws":true},{"text":"involved","start":149,"end":157,"id":24,"ws":true},{"text":"in","start":158,"end":160,"id":25,"ws":true},{"text":"acquisition","start":161,"end":172,"id":26,"ws":true},{"text":"of","start":173,"end":175,"id":27,"ws":true},{"text":"secondary","start":176,"end":185,"id":28,"ws":true},{"text":"imatinib","start":186,"end":194,"id":29,"ws":true},{"text":"resistance","start":195,"end":205,"id":30,"ws":true},{"text":"in","start":206,"end":208,"id":31,"ws":true},{"text":"GIST","start":209,"end":213,"id":32,"ws":true},{"text":".","start":214,"end":215,"id":33,"ws":false}],"spans":[{"start":28,"end":36,"token_start":4,"token_end":4,"label":"DRUG"},{"start":57,"end":66,"token_start":8,"token_end":8,"label":"DRUG"},{"start":186,"end":194,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25554490/","_input_hash":148492975,"_task_hash":164771478,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":4,"child":8,"head_span":{"start":28,"end":36,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":57,"end":66,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"This is the first paper suggesting the possibility of combination treatment of tamoxifen with risperidone in breast cancer patients , providing a conceivable resolution of tamoxifen-induced side effects without interfering the efficacy of tamoxifen against breast cancer .","paragraph":"<h3><u>Combination treatment of tamoxifen with risperidone in breast cancer.</u></h3><b style='color:Tomato;'><i>tamoxifen</i></b> has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre- and post-menopause women. <b style='color:Tomato;'><i>tamoxifen</i></b> exerts its cytotoxic effect primarily through cytostasis which is associated with the accumulation of cells in the G0/G1 phase of the cell cycle. Apoptotic activity can also be exerted by <b style='color:Tomato;'><i>tamoxifen</i></b> which involves cleavage of caspase 9, caspase 7, caspase 3, and poly-ADP-ribose polymerase (PARP). Down-regulation of anti-apoptotic proteins Bcl-2 and Bcl-xL and up-regulation of pro-apoptotic proteins Bax and Bak have also been observed. In addition, stress response protein of GRP 94 and GRP 78 have also been induced by <b style='color:Tomato;'><i>tamoxifen</i></b> in our study. However, side effects occur during <b style='color:Tomato;'><i>tamoxifen</i></b> treatment in breast cancer patients. Researching into combination regimen of <b style='color:Tomato;'><i>tamoxifen</i></b> and drug(s) that relieves <b style='color:Tomato;'><i>tamoxifen</i></b>-induced hot flushes is important, because drug interactions may decrease <b style='color:Tomato;'><i>tamoxifen</i></b> efficacy. <b style='color:Tomato;'><i>risperidone</i></b> has been shown to be effective in reducing or eliminating hot flushes on women with hormonal variations. In this present study, we demonstrated that combination of <b style='color:Tomato;'><i>tamoxifen</i></b> with <b style='color:Tomato;'><i>risperidone</i></b> did not interfered <b style='color:Tomato;'><i>tamoxifen</i></b>-induced cytotoxic effects in both in vitro and in vivo models, while <b style='color:Tomato;'><i>fluoxetine</i></b> abrogated the effects of <b style='color:Tomato;'><i>tamoxifen</i></b>. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>paper</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>possibility</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>risperidone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>providing</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>conceivable</i></b> <b style='color:DodgerBlue;'><i>resolution</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>tamoxifen-induced</i></b> <b style='color:DodgerBlue;'><i>side</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>interfering</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"is","start":5,"end":7,"id":1,"ws":true},{"text":"the","start":8,"end":11,"id":2,"ws":true},{"text":"first","start":12,"end":17,"id":3,"ws":true},{"text":"paper","start":18,"end":23,"id":4,"ws":true},{"text":"suggesting","start":24,"end":34,"id":5,"ws":true},{"text":"the","start":35,"end":38,"id":6,"ws":true},{"text":"possibility","start":39,"end":50,"id":7,"ws":true},{"text":"of","start":51,"end":53,"id":8,"ws":true},{"text":"combination","start":54,"end":65,"id":9,"ws":true},{"text":"treatment","start":66,"end":75,"id":10,"ws":true},{"text":"of","start":76,"end":78,"id":11,"ws":true},{"text":"tamoxifen","start":79,"end":88,"id":12,"ws":true},{"text":"with","start":89,"end":93,"id":13,"ws":true},{"text":"risperidone","start":94,"end":105,"id":14,"ws":true},{"text":"in","start":106,"end":108,"id":15,"ws":true},{"text":"breast","start":109,"end":115,"id":16,"ws":true},{"text":"cancer","start":116,"end":122,"id":17,"ws":true},{"text":"patients","start":123,"end":131,"id":18,"ws":true},{"text":",","start":132,"end":133,"id":19,"ws":true},{"text":"providing","start":134,"end":143,"id":20,"ws":true},{"text":"a","start":144,"end":145,"id":21,"ws":true},{"text":"conceivable","start":146,"end":157,"id":22,"ws":true},{"text":"resolution","start":158,"end":168,"id":23,"ws":true},{"text":"of","start":169,"end":171,"id":24,"ws":true},{"text":"tamoxifen-induced","start":172,"end":189,"id":25,"ws":true},{"text":"side","start":190,"end":194,"id":26,"ws":true},{"text":"effects","start":195,"end":202,"id":27,"ws":true},{"text":"without","start":203,"end":210,"id":28,"ws":true},{"text":"interfering","start":211,"end":222,"id":29,"ws":true},{"text":"the","start":223,"end":226,"id":30,"ws":true},{"text":"efficacy","start":227,"end":235,"id":31,"ws":true},{"text":"of","start":236,"end":238,"id":32,"ws":true},{"text":"tamoxifen","start":239,"end":248,"id":33,"ws":true},{"text":"against","start":249,"end":256,"id":34,"ws":true},{"text":"breast","start":257,"end":263,"id":35,"ws":true},{"text":"cancer","start":264,"end":270,"id":36,"ws":true},{"text":".","start":271,"end":272,"id":37,"ws":false}],"spans":[{"start":79,"end":88,"token_start":12,"token_end":12,"label":"DRUG"},{"start":94,"end":105,"token_start":14,"token_end":14,"label":"DRUG"},{"start":239,"end":248,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24886861/","_input_hash":-1945432642,"_task_hash":434847071,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":79,"end":88,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":94,"end":105,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Amoxicillin , erythromycin , and levofloxacin at supra-MIC concentrations were very active against planktonic cells of 3 selected strains but lower on biofilm-associated organisms in 2 strains and null against the third .","paragraph":"<h3><u>Biofilm formation by Streptococcus pneumoniae strains and effects of human serum albumin, ibuprofen, N-acetyl-l-cysteine, amoxicillin, erythromycin, and levofloxacin.</u></h3>Streptococcus pneumoniae ability to produce biofilms may induce persistent infections and difficulties for eradication in vivo. We investigated the ability of 11 pneumococcal strains (serotypes 3, 6B, 9V, 19F, and 23F) to form biofilms on polystyrene plates at 16 and 24 h. The extent of biofilm was greater at 24 h in 10 strains, being the highest magnitude for serotype 3 strains. Human serum albumin at 25,000 microg/mL and <b style='color:Tomato;'><i>ibuprofen</i></b> at 128 microg/mL significantly reduced biofilm formation in 7 and 5 strains, respectively. <b style='color:MediumOrchid;'><i>Amoxicillin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>erythromycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>supra-MIC</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>very</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>planktonic</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>selected</i></b> <b style='color:DodgerBlue;'><i>strains</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>biofilm-associated</i></b> <b style='color:DodgerBlue;'><i>organisms</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>strains</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>null</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>third</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Although N-acetyl-l-cysteine had very little activity against both planktonic and biofilm-forming organisms, when combined with the 3 antibiotics, a slightly enhanced activity against biofilm-embedded organisms in 1 strain and combined with <b style='color:Tomato;'><i>amoxicillin</i></b> in another one was observed.","tokens":[{"text":"Amoxicillin","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"erythromycin","start":14,"end":26,"id":2,"ws":true},{"text":",","start":27,"end":28,"id":3,"ws":true},{"text":"and","start":29,"end":32,"id":4,"ws":true},{"text":"levofloxacin","start":33,"end":45,"id":5,"ws":true},{"text":"at","start":46,"end":48,"id":6,"ws":true},{"text":"supra-MIC","start":49,"end":58,"id":7,"ws":true},{"text":"concentrations","start":59,"end":73,"id":8,"ws":true},{"text":"were","start":74,"end":78,"id":9,"ws":true},{"text":"very","start":79,"end":83,"id":10,"ws":true},{"text":"active","start":84,"end":90,"id":11,"ws":true},{"text":"against","start":91,"end":98,"id":12,"ws":true},{"text":"planktonic","start":99,"end":109,"id":13,"ws":true},{"text":"cells","start":110,"end":115,"id":14,"ws":true},{"text":"of","start":116,"end":118,"id":15,"ws":true},{"text":"3","start":119,"end":120,"id":16,"ws":true},{"text":"selected","start":121,"end":129,"id":17,"ws":true},{"text":"strains","start":130,"end":137,"id":18,"ws":true},{"text":"but","start":138,"end":141,"id":19,"ws":true},{"text":"lower","start":142,"end":147,"id":20,"ws":true},{"text":"on","start":148,"end":150,"id":21,"ws":true},{"text":"biofilm-associated","start":151,"end":169,"id":22,"ws":true},{"text":"organisms","start":170,"end":179,"id":23,"ws":true},{"text":"in","start":180,"end":182,"id":24,"ws":true},{"text":"2","start":183,"end":184,"id":25,"ws":true},{"text":"strains","start":185,"end":192,"id":26,"ws":true},{"text":"and","start":193,"end":196,"id":27,"ws":true},{"text":"null","start":197,"end":201,"id":28,"ws":true},{"text":"against","start":202,"end":209,"id":29,"ws":true},{"text":"the","start":210,"end":213,"id":30,"ws":true},{"text":"third","start":214,"end":219,"id":31,"ws":true},{"text":".","start":220,"end":221,"id":32,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":14,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},{"start":33,"end":45,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20638597/","_input_hash":-670566058,"_task_hash":920280049,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":14,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":2,"child":5,"head_span":{"start":14,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":33,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"A double-blind , parallel , placebo-controlled study was performed to assess the efficacy of a combination drug product containing the antihistamine , triprolidine , and the sympathomimetic , pseudoephedrine , in the treatment of allergic rhinitis .","paragraph":"<h3><u>An evaluation of triprolidine and pseudoephedrine in the treatment of allergic rhinitis.</u></h3> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>parallel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>placebo-controlled</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>assess</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>product</i></b> <b style='color:DodgerBlue;'><i>containing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antihistamine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>triprolidine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>sympathomimetic</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>pseudoephedrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>allergic</i></b> <b style='color:DodgerBlue;'><i>rhinitis</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Allergic rhinitis was defined on the basis of coexistent nasal congestion and an aggregate symptom complex score which exceeded a pre-established value. <b style='color:Tomato;'><i>pseudoephedrine</i></b> and <b style='color:Tomato;'><i>triprolidine</i></b> were shown to make distinct and separate contributions to the treatment of allergic rhinitis defined in this manner.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"double-blind","start":2,"end":14,"id":1,"ws":true},{"text":",","start":15,"end":16,"id":2,"ws":true},{"text":"parallel","start":17,"end":25,"id":3,"ws":true},{"text":",","start":26,"end":27,"id":4,"ws":true},{"text":"placebo-controlled","start":28,"end":46,"id":5,"ws":true},{"text":"study","start":47,"end":52,"id":6,"ws":true},{"text":"was","start":53,"end":56,"id":7,"ws":true},{"text":"performed","start":57,"end":66,"id":8,"ws":true},{"text":"to","start":67,"end":69,"id":9,"ws":true},{"text":"assess","start":70,"end":76,"id":10,"ws":true},{"text":"the","start":77,"end":80,"id":11,"ws":true},{"text":"efficacy","start":81,"end":89,"id":12,"ws":true},{"text":"of","start":90,"end":92,"id":13,"ws":true},{"text":"a","start":93,"end":94,"id":14,"ws":true},{"text":"combination","start":95,"end":106,"id":15,"ws":true},{"text":"drug","start":107,"end":111,"id":16,"ws":true},{"text":"product","start":112,"end":119,"id":17,"ws":true},{"text":"containing","start":120,"end":130,"id":18,"ws":true},{"text":"the","start":131,"end":134,"id":19,"ws":true},{"text":"antihistamine","start":135,"end":148,"id":20,"ws":true},{"text":",","start":149,"end":150,"id":21,"ws":true},{"text":"triprolidine","start":151,"end":163,"id":22,"ws":true},{"text":",","start":164,"end":165,"id":23,"ws":true},{"text":"and","start":166,"end":169,"id":24,"ws":true},{"text":"the","start":170,"end":173,"id":25,"ws":true},{"text":"sympathomimetic","start":174,"end":189,"id":26,"ws":true},{"text":",","start":190,"end":191,"id":27,"ws":true},{"text":"pseudoephedrine","start":192,"end":207,"id":28,"ws":true},{"text":",","start":208,"end":209,"id":29,"ws":true},{"text":"in","start":210,"end":212,"id":30,"ws":true},{"text":"the","start":213,"end":216,"id":31,"ws":true},{"text":"treatment","start":217,"end":226,"id":32,"ws":true},{"text":"of","start":227,"end":229,"id":33,"ws":true},{"text":"allergic","start":230,"end":238,"id":34,"ws":true},{"text":"rhinitis","start":239,"end":247,"id":35,"ws":true},{"text":".","start":248,"end":249,"id":36,"ws":false}],"spans":[{"start":151,"end":163,"token_start":22,"token_end":22,"label":"DRUG"},{"start":192,"end":207,"token_start":28,"token_end":28,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7258744/","_input_hash":1149097172,"_task_hash":2114118492,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":22,"child":28,"head_span":{"start":151,"end":163,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":192,"end":207,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"A randomized Phase III trial demonstrated noninferiority of APF530 500 mg SC ( granisetron 10 mg ) to intravenous palonosetron 0.25 mg in preventing CINV in patients receiving MEC or HEC in acute ( 0 - 24 hours ) and delayed ( 24 - 120 hours ) settings , with activity over 120 hours .","paragraph":"<h3><u>Biochronomer\u2122 technology and the development of APF530, a sustained release formulation of granisetron.</u></h3><b style='color:Tomato;'><i>granisetron</i></b> and other 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are first-line agents for preventing chemotherapy-induced nausea and vomiting (CINV). Current treatment guidelines prefer the longer-acting agent, <b style='color:Tomato;'><i>palonosetron</i></b>, for CINV prevention in some chemotherapy regimens. A new <b style='color:Tomato;'><i>granisetron</i></b> formulation, APF530, has been developed as an alternative long-acting agent. APF530 utilizes Biochronomer(\u2122) technology to formulate a viscous tri(ethylene glycol) poly(orthoester)-based formulation that delivers - by single subcutaneous (SC) injection - therapeutic <b style='color:Tomato;'><i>granisetron</i></b> concentrations over 5 days. The poly(orthoester) polymer family contain an orthoester linkage; these bioerodible polymer systems are specifically designed for controlled, sustained drug delivery. Pharmacokinetics and pharmacodynamics of APF530 250, 500, or 750 mg SC (<b style='color:Tomato;'><i>granisetron</i></b> 5, 10, or 15 mg, respectively) administered 30-60 minutes before chemotherapy were evaluated in two Phase II trials in cancer patients receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy. Pharmacokinetics were dose proportional, with slow <b style='color:Tomato;'><i>granisetron</i></b> absorption and elimination. Both trials demonstrated similar results for median half-life, time to maximum concentration, and exposure for APF530 250 and 500 mg, with no differences between patients receiving MEC or HEC. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>noninferiority</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>APF530</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>SC</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>granisetron</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>palonosetron</i></b> <b style='color:DodgerBlue;'><i>0.25</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>preventing</i></b> <b style='color:DodgerBlue;'><i>CINV</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>MEC</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>HEC</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>delayed</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>settings</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Mean maximum <b style='color:Tomato;'><i>granisetron</i></b> plasma concentrations were 10.8 and 17.8 ng/mL, and mean half-lives were 30.8 and 35.9 hours after SC administration of APF530 250 and 500 mg, respectively. Therapeutic <b style='color:Tomato;'><i>granisetron</i></b> concentrations were maintained for greater than 120 hours (5 days) in both APF530 dose groups. These data suggest that APF530 - an SC-administered formulation of <b style='color:Tomato;'><i>granisetron</i></b> delivered via Biochronomer technology - represents an effective treatment option for the prevention of both acute and delayed CINV in patients receiving either MEC or HEC.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"randomized","start":2,"end":12,"id":1,"ws":true},{"text":"Phase","start":13,"end":18,"id":2,"ws":true},{"text":"III","start":19,"end":22,"id":3,"ws":true},{"text":"trial","start":23,"end":28,"id":4,"ws":true},{"text":"demonstrated","start":29,"end":41,"id":5,"ws":true},{"text":"noninferiority","start":42,"end":56,"id":6,"ws":true},{"text":"of","start":57,"end":59,"id":7,"ws":true},{"text":"APF530","start":60,"end":66,"id":8,"ws":true},{"text":"500","start":67,"end":70,"id":9,"ws":true},{"text":"mg","start":71,"end":73,"id":10,"ws":true},{"text":"SC","start":74,"end":76,"id":11,"ws":true},{"text":"(","start":77,"end":78,"id":12,"ws":true},{"text":"granisetron","start":79,"end":90,"id":13,"ws":true},{"text":"10","start":91,"end":93,"id":14,"ws":true},{"text":"mg","start":94,"end":96,"id":15,"ws":true},{"text":")","start":97,"end":98,"id":16,"ws":true},{"text":"to","start":99,"end":101,"id":17,"ws":true},{"text":"intravenous","start":102,"end":113,"id":18,"ws":true},{"text":"palonosetron","start":114,"end":126,"id":19,"ws":true},{"text":"0.25","start":127,"end":131,"id":20,"ws":true},{"text":"mg","start":132,"end":134,"id":21,"ws":true},{"text":"in","start":135,"end":137,"id":22,"ws":true},{"text":"preventing","start":138,"end":148,"id":23,"ws":true},{"text":"CINV","start":149,"end":153,"id":24,"ws":true},{"text":"in","start":154,"end":156,"id":25,"ws":true},{"text":"patients","start":157,"end":165,"id":26,"ws":true},{"text":"receiving","start":166,"end":175,"id":27,"ws":true},{"text":"MEC","start":176,"end":179,"id":28,"ws":true},{"text":"or","start":180,"end":182,"id":29,"ws":true},{"text":"HEC","start":183,"end":186,"id":30,"ws":true},{"text":"in","start":187,"end":189,"id":31,"ws":true},{"text":"acute","start":190,"end":195,"id":32,"ws":true},{"text":"(","start":196,"end":197,"id":33,"ws":true},{"text":"0","start":198,"end":199,"id":34,"ws":true},{"text":"-","start":200,"end":201,"id":35,"ws":true},{"text":"24","start":202,"end":204,"id":36,"ws":true},{"text":"hours","start":205,"end":210,"id":37,"ws":true},{"text":")","start":211,"end":212,"id":38,"ws":true},{"text":"and","start":213,"end":216,"id":39,"ws":true},{"text":"delayed","start":217,"end":224,"id":40,"ws":true},{"text":"(","start":225,"end":226,"id":41,"ws":true},{"text":"24","start":227,"end":229,"id":42,"ws":true},{"text":"-","start":230,"end":231,"id":43,"ws":true},{"text":"120","start":232,"end":235,"id":44,"ws":true},{"text":"hours","start":236,"end":241,"id":45,"ws":true},{"text":")","start":242,"end":243,"id":46,"ws":true},{"text":"settings","start":244,"end":252,"id":47,"ws":true},{"text":",","start":253,"end":254,"id":48,"ws":true},{"text":"with","start":255,"end":259,"id":49,"ws":true},{"text":"activity","start":260,"end":268,"id":50,"ws":true},{"text":"over","start":269,"end":273,"id":51,"ws":true},{"text":"120","start":274,"end":277,"id":52,"ws":true},{"text":"hours","start":278,"end":283,"id":53,"ws":true},{"text":".","start":284,"end":285,"id":54,"ws":false}],"spans":[{"start":79,"end":90,"token_start":13,"token_end":13,"label":"DRUG"},{"start":114,"end":126,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27186139/","_input_hash":710174417,"_task_hash":-2112930405,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Classical NSAIDs are still the most logical choice for agents that will slow the progression or delay the onset of AD and other neurodegenerative diseases despite failures of naproxen , celecoxib and rofecoxib in AD clinical trials .","paragraph":"<h3><u>Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease.</u></h3>Inflammation is characteristic of a broad spectrum of neurodegenerative diseases. These include Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases, amyotrophic lateral sclerosis, all of the tauopathies, multiple sclerosis and many other less common conditions. Morphologically, the level of inflammation is determined by the concentration and degree of activation of microglial cells. Biochemically, it is judged by the presence of a spectrum of inflammatory mediators. Epidemiological evidence indicates that anti-inflammatory agents such as non-steroidal anti-inflammatory drugs (NSAIDs) have a sparing effect on AD and PD indicating that inflammation exacerbates the pathology in these diseases. NSAIDs are protective in transgenic animal models of AD, providing further evidence of the negative consequences of inflammation. Here we describe an in vitro model, which was used to study the protective effects of NSAIDs in AD. This model is based on neuronal cell killing by stimulated microglia or microglia-like cells. In this model NSAIDs show protective effects at a therapeutically relevant level, which is in the low micromolar range. There are reports suggesting that NSAIDs act independently of cyclooxygenase (COX) inhibition, but only at higher doses. <b style='color:DodgerBlue;'><i>Classical</i></b> <b style='color:DodgerBlue;'><i>NSAIDs</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>still</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>logical</i></b> <b style='color:DodgerBlue;'><i>choice</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>will</i></b> <b style='color:DodgerBlue;'><i>slow</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>delay</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>onset</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>AD</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>neurodegenerative</i></b> <b style='color:DodgerBlue;'><i>diseases</i></b> <b style='color:DodgerBlue;'><i>despite</i></b> <b style='color:DodgerBlue;'><i>failures</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>naproxen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rofecoxib</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>AD</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Several other classes of anti-inflammatory drugs have been identified as potentially beneficial in this and similar assay systems. Therefore combination therapy with other anti-inflammatory agents that work through different mechanisms of action might prove to be a superior therapeutic strategy.","tokens":[{"text":"Classical","start":0,"end":9,"id":0,"ws":true},{"text":"NSAIDs","start":10,"end":16,"id":1,"ws":true},{"text":"are","start":17,"end":20,"id":2,"ws":true},{"text":"still","start":21,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"most","start":31,"end":35,"id":5,"ws":true},{"text":"logical","start":36,"end":43,"id":6,"ws":true},{"text":"choice","start":44,"end":50,"id":7,"ws":true},{"text":"for","start":51,"end":54,"id":8,"ws":true},{"text":"agents","start":55,"end":61,"id":9,"ws":true},{"text":"that","start":62,"end":66,"id":10,"ws":true},{"text":"will","start":67,"end":71,"id":11,"ws":true},{"text":"slow","start":72,"end":76,"id":12,"ws":true},{"text":"the","start":77,"end":80,"id":13,"ws":true},{"text":"progression","start":81,"end":92,"id":14,"ws":true},{"text":"or","start":93,"end":95,"id":15,"ws":true},{"text":"delay","start":96,"end":101,"id":16,"ws":true},{"text":"the","start":102,"end":105,"id":17,"ws":true},{"text":"onset","start":106,"end":111,"id":18,"ws":true},{"text":"of","start":112,"end":114,"id":19,"ws":true},{"text":"AD","start":115,"end":117,"id":20,"ws":true},{"text":"and","start":118,"end":121,"id":21,"ws":true},{"text":"other","start":122,"end":127,"id":22,"ws":true},{"text":"neurodegenerative","start":128,"end":145,"id":23,"ws":true},{"text":"diseases","start":146,"end":154,"id":24,"ws":true},{"text":"despite","start":155,"end":162,"id":25,"ws":true},{"text":"failures","start":163,"end":171,"id":26,"ws":true},{"text":"of","start":172,"end":174,"id":27,"ws":true},{"text":"naproxen","start":175,"end":183,"id":28,"ws":true},{"text":",","start":184,"end":185,"id":29,"ws":true},{"text":"celecoxib","start":186,"end":195,"id":30,"ws":true},{"text":"and","start":196,"end":199,"id":31,"ws":true},{"text":"rofecoxib","start":200,"end":209,"id":32,"ws":true},{"text":"in","start":210,"end":212,"id":33,"ws":true},{"text":"AD","start":213,"end":215,"id":34,"ws":true},{"text":"clinical","start":216,"end":224,"id":35,"ws":true},{"text":"trials","start":225,"end":231,"id":36,"ws":true},{"text":".","start":232,"end":233,"id":37,"ws":false}],"spans":[{"start":175,"end":183,"token_start":28,"token_end":28,"label":"DRUG"},{"start":186,"end":195,"token_start":30,"token_end":30,"label":"DRUG"},{"start":200,"end":209,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15974901/","_input_hash":-796826148,"_task_hash":-107330078,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Between 1987 and 2003 , patients 18 years old were given adjuvant chemotherapy consisting of one of two ' paediatric ' regimens ( depending on the time of presentation ) and craniospinal local-boost radiotherapy : regimen A ( n = 12 ) , vincristine ( VCR ) , intrathecal and/or intravenous methotrexate and conventional radiotherapy ; or regimen B ( n = 11 ) sequencing intensive doses of multiple agents followed by hyperfractionated accelerated radiotherapy ( HART ) .","paragraph":"<h3><u>Survival of adults treated for medulloblastoma using paediatric protocols.</u></h3>We retrospectively studied 26 consecutive adults treated for medulloblastoma using paediatric protocols. <b style='color:DodgerBlue;'><i>Between</i></b> <b style='color:DodgerBlue;'><i>1987</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2003</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>old</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>'</i></b> <b style='color:DodgerBlue;'><i>paediatric</i></b> <b style='color:DodgerBlue;'><i>'</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>depending</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>presentation</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>craniospinal</i></b> <b style='color:DodgerBlue;'><i>local-boost</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VCR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intrathecal</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>conventional</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>11</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>sequencing</i></b> <b style='color:DodgerBlue;'><i>intensive</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>hyperfractionated</i></b> <b style='color:DodgerBlue;'><i>accelerated</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HART</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A VCR-<b style='color:Tomato;'><i>lomustine</i></b>-based maintenance followed both regimens. Three additional patients received a tailored treatment due to their impaired neurological status after surgery. The median age at diagnosis was 26 years (range 18-41 years). With a median follow-up of 46 months, 5-year disease-free and overall survival rates were 65+/-11% and 73+/-10%, respectively, for the series as a whole. All patients who received regimen B (5 of whom had metastatic Chang M2-M3 disease) are alive with no evidence of disease at 39 months. Although the number of patients is limited, our data suggest that the sandwich sequential, moderately intensive chemotherapy in combination with HART is an effective treatment for medulloblastoma in adults, and this approach seems to overcome previously-recognised risk factors.","tokens":[{"text":"Between","start":0,"end":7,"id":0,"ws":true},{"text":"1987","start":8,"end":12,"id":1,"ws":true},{"text":"and","start":13,"end":16,"id":2,"ws":true},{"text":"2003","start":17,"end":21,"id":3,"ws":true},{"text":",","start":22,"end":23,"id":4,"ws":true},{"text":"patients","start":24,"end":32,"id":5,"ws":true},{"text":"18","start":33,"end":35,"id":6,"ws":true},{"text":"years","start":36,"end":41,"id":7,"ws":true},{"text":"old","start":42,"end":45,"id":8,"ws":true},{"text":"were","start":46,"end":50,"id":9,"ws":true},{"text":"given","start":51,"end":56,"id":10,"ws":true},{"text":"adjuvant","start":57,"end":65,"id":11,"ws":true},{"text":"chemotherapy","start":66,"end":78,"id":12,"ws":true},{"text":"consisting","start":79,"end":89,"id":13,"ws":true},{"text":"of","start":90,"end":92,"id":14,"ws":true},{"text":"one","start":93,"end":96,"id":15,"ws":true},{"text":"of","start":97,"end":99,"id":16,"ws":true},{"text":"two","start":100,"end":103,"id":17,"ws":true},{"text":"'","start":104,"end":105,"id":18,"ws":true},{"text":"paediatric","start":106,"end":116,"id":19,"ws":true},{"text":"'","start":117,"end":118,"id":20,"ws":true},{"text":"regimens","start":119,"end":127,"id":21,"ws":true},{"text":"(","start":128,"end":129,"id":22,"ws":true},{"text":"depending","start":130,"end":139,"id":23,"ws":true},{"text":"on","start":140,"end":142,"id":24,"ws":true},{"text":"the","start":143,"end":146,"id":25,"ws":true},{"text":"time","start":147,"end":151,"id":26,"ws":true},{"text":"of","start":152,"end":154,"id":27,"ws":true},{"text":"presentation","start":155,"end":167,"id":28,"ws":true},{"text":")","start":168,"end":169,"id":29,"ws":true},{"text":"and","start":170,"end":173,"id":30,"ws":true},{"text":"craniospinal","start":174,"end":186,"id":31,"ws":true},{"text":"local-boost","start":187,"end":198,"id":32,"ws":true},{"text":"radiotherapy","start":199,"end":211,"id":33,"ws":true},{"text":":","start":212,"end":213,"id":34,"ws":true},{"text":"regimen","start":214,"end":221,"id":35,"ws":true},{"text":"A","start":222,"end":223,"id":36,"ws":true},{"text":"(","start":224,"end":225,"id":37,"ws":true},{"text":"n","start":226,"end":227,"id":38,"ws":true},{"text":"=","start":228,"end":229,"id":39,"ws":true},{"text":"12","start":230,"end":232,"id":40,"ws":true},{"text":")","start":233,"end":234,"id":41,"ws":true},{"text":",","start":235,"end":236,"id":42,"ws":true},{"text":"vincristine","start":237,"end":248,"id":43,"ws":true},{"text":"(","start":249,"end":250,"id":44,"ws":true},{"text":"VCR","start":251,"end":254,"id":45,"ws":true},{"text":")","start":255,"end":256,"id":46,"ws":true},{"text":",","start":257,"end":258,"id":47,"ws":true},{"text":"intrathecal","start":259,"end":270,"id":48,"ws":true},{"text":"and/or","start":271,"end":277,"id":49,"ws":true},{"text":"intravenous","start":278,"end":289,"id":50,"ws":true},{"text":"methotrexate","start":290,"end":302,"id":51,"ws":true},{"text":"and","start":303,"end":306,"id":52,"ws":true},{"text":"conventional","start":307,"end":319,"id":53,"ws":true},{"text":"radiotherapy","start":320,"end":332,"id":54,"ws":true},{"text":";","start":333,"end":334,"id":55,"ws":true},{"text":"or","start":335,"end":337,"id":56,"ws":true},{"text":"regimen","start":338,"end":345,"id":57,"ws":true},{"text":"B","start":346,"end":347,"id":58,"ws":true},{"text":"(","start":348,"end":349,"id":59,"ws":true},{"text":"n","start":350,"end":351,"id":60,"ws":true},{"text":"=","start":352,"end":353,"id":61,"ws":true},{"text":"11","start":354,"end":356,"id":62,"ws":true},{"text":")","start":357,"end":358,"id":63,"ws":true},{"text":"sequencing","start":359,"end":369,"id":64,"ws":true},{"text":"intensive","start":370,"end":379,"id":65,"ws":true},{"text":"doses","start":380,"end":385,"id":66,"ws":true},{"text":"of","start":386,"end":388,"id":67,"ws":true},{"text":"multiple","start":389,"end":397,"id":68,"ws":true},{"text":"agents","start":398,"end":404,"id":69,"ws":true},{"text":"followed","start":405,"end":413,"id":70,"ws":true},{"text":"by","start":414,"end":416,"id":71,"ws":true},{"text":"hyperfractionated","start":417,"end":434,"id":72,"ws":true},{"text":"accelerated","start":435,"end":446,"id":73,"ws":true},{"text":"radiotherapy","start":447,"end":459,"id":74,"ws":true},{"text":"(","start":460,"end":461,"id":75,"ws":true},{"text":"HART","start":462,"end":466,"id":76,"ws":true},{"text":")","start":467,"end":468,"id":77,"ws":true},{"text":".","start":469,"end":470,"id":78,"ws":false}],"spans":[{"start":237,"end":248,"token_start":43,"token_end":43,"label":"DRUG"},{"start":290,"end":302,"token_start":51,"token_end":51,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15869875/","_input_hash":-1431707466,"_task_hash":104155681,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":43,"child":51,"head_span":{"start":237,"end":248,"token_start":43,"token_end":43,"label":"DRUG"},"child_span":{"start":290,"end":302,"token_start":51,"token_end":51,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"The US Food and Drug Administration ( FDA ) recommends that \" concomitant use of drugs that inhibit CYP2C19 ( e.g. , omeprazole ) should be discouraged . \" As the presence of PPIs and clopidogrel in plasma is short lived , separation by 12 - 20 h should in theory prevent competitive inhibition of CYP metabolism and minimize any potential , though unproven , clinical interaction .","paragraph":"<h3><u>Proton pump inhibitor and clopidogrel interaction: fact or fiction?</u></h3>Current consensus recommendations state that patients prescribed <b style='color:Tomato;'><i>clopidogrel</i></b> plus <b style='color:Tomato;'><i>aspirin</i></b> should receive a proton pump inhibitor (PPI) to reduce gastrointestinal bleeding. <b style='color:Tomato;'><i>clopidogrel</i></b> is converted to its active metabolite by cytochrome P450 (CYP) enzymes. <b style='color:Tomato;'><i>clopidogrel</i></b> users with decreased CYP2C19 function have less inhibition of platelet aggregation and increased cardiovascular (CV) events. As PPI metabolism also involves CYP2C19, it was hypothesized that competition by PPIs might interfere with <b style='color:Tomato;'><i>clopidogrel</i></b>'s action. <b style='color:Tomato;'><i>omeprazole</i></b>, but not other PPIs, worsens surrogate markers of <b style='color:Tomato;'><i>clopidogrel</i></b> efficacy. Some (but not all) observational studies show that <b style='color:Tomato;'><i>clopidogrel</i></b> users prescribed PPIs have increased risks of CV events (hazard/odds ratios=1.25-1.5). When effect sizes are small to moderate (relative risks<1.5-2.0), however, it is only possible to conclude whether statistical associations are valid in randomized trials. A randomized trial of <b style='color:Tomato;'><i>omeprazole</i></b> vs. placebo in <b style='color:Tomato;'><i>clopidogrel</i></b> users showed no difference in CV events (hazard ratio=1.02,0.70-1.51). Thus, current evidence does not justify a conclusion that PPIs are associated with CV events among <b style='color:Tomato;'><i>clopidogrel</i></b> users, let alone a judgment of causality. Nonetheless, positive results from some observational studies and biological plausibility have led some health-care providers to accept that PPIs reduce <b style='color:Tomato;'><i>clopidogrel</i></b>'s efficacy. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>US</i></b> <b style='color:DodgerBlue;'><i>Food</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Drug</i></b> <b style='color:DodgerBlue;'><i>Administration</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FDA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>recommends</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>\"</i></b> <b style='color:DodgerBlue;'><i>concomitant</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>inhibit</i></b> <b style='color:DodgerBlue;'><i>CYP2C19</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>e.g.</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>should</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>discouraged</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>\"</i></b> <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>PPIs</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>short</i></b> <b style='color:DodgerBlue;'><i>lived</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>separation</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>should</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>theory</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>competitive</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CYP</i></b> <b style='color:DodgerBlue;'><i>metabolism</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>minimize</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>though</i></b> <b style='color:DodgerBlue;'><i>unproven</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> PPI may be given before breakfast and <b style='color:Tomato;'><i>clopidogrel</i></b> at bedtime, or PPI may be taken before dinner and <b style='color:Tomato;'><i>clopidogrel</i></b> at lunchtime.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"US","start":4,"end":6,"id":1,"ws":true},{"text":"Food","start":7,"end":11,"id":2,"ws":true},{"text":"and","start":12,"end":15,"id":3,"ws":true},{"text":"Drug","start":16,"end":20,"id":4,"ws":true},{"text":"Administration","start":21,"end":35,"id":5,"ws":true},{"text":"(","start":36,"end":37,"id":6,"ws":true},{"text":"FDA","start":38,"end":41,"id":7,"ws":true},{"text":")","start":42,"end":43,"id":8,"ws":true},{"text":"recommends","start":44,"end":54,"id":9,"ws":true},{"text":"that","start":55,"end":59,"id":10,"ws":true},{"text":"\"","start":60,"end":61,"id":11,"ws":true},{"text":"concomitant","start":62,"end":73,"id":12,"ws":true},{"text":"use","start":74,"end":77,"id":13,"ws":true},{"text":"of","start":78,"end":80,"id":14,"ws":true},{"text":"drugs","start":81,"end":86,"id":15,"ws":true},{"text":"that","start":87,"end":91,"id":16,"ws":true},{"text":"inhibit","start":92,"end":99,"id":17,"ws":true},{"text":"CYP2C19","start":100,"end":107,"id":18,"ws":true},{"text":"(","start":108,"end":109,"id":19,"ws":true},{"text":"e.g.","start":110,"end":114,"id":20,"ws":true},{"text":",","start":115,"end":116,"id":21,"ws":true},{"text":"omeprazole","start":117,"end":127,"id":22,"ws":true},{"text":")","start":128,"end":129,"id":23,"ws":true},{"text":"should","start":130,"end":136,"id":24,"ws":true},{"text":"be","start":137,"end":139,"id":25,"ws":true},{"text":"discouraged","start":140,"end":151,"id":26,"ws":true},{"text":".","start":152,"end":153,"id":27,"ws":true},{"text":"\"","start":154,"end":155,"id":28,"ws":true},{"text":"As","start":156,"end":158,"id":29,"ws":true},{"text":"the","start":159,"end":162,"id":30,"ws":true},{"text":"presence","start":163,"end":171,"id":31,"ws":true},{"text":"of","start":172,"end":174,"id":32,"ws":true},{"text":"PPIs","start":175,"end":179,"id":33,"ws":true},{"text":"and","start":180,"end":183,"id":34,"ws":true},{"text":"clopidogrel","start":184,"end":195,"id":35,"ws":true},{"text":"in","start":196,"end":198,"id":36,"ws":true},{"text":"plasma","start":199,"end":205,"id":37,"ws":true},{"text":"is","start":206,"end":208,"id":38,"ws":true},{"text":"short","start":209,"end":214,"id":39,"ws":true},{"text":"lived","start":215,"end":220,"id":40,"ws":true},{"text":",","start":221,"end":222,"id":41,"ws":true},{"text":"separation","start":223,"end":233,"id":42,"ws":true},{"text":"by","start":234,"end":236,"id":43,"ws":true},{"text":"12","start":237,"end":239,"id":44,"ws":true},{"text":"-","start":240,"end":241,"id":45,"ws":true},{"text":"20","start":242,"end":244,"id":46,"ws":true},{"text":"h","start":245,"end":246,"id":47,"ws":true},{"text":"should","start":247,"end":253,"id":48,"ws":true},{"text":"in","start":254,"end":256,"id":49,"ws":true},{"text":"theory","start":257,"end":263,"id":50,"ws":true},{"text":"prevent","start":264,"end":271,"id":51,"ws":true},{"text":"competitive","start":272,"end":283,"id":52,"ws":true},{"text":"inhibition","start":284,"end":294,"id":53,"ws":true},{"text":"of","start":295,"end":297,"id":54,"ws":true},{"text":"CYP","start":298,"end":301,"id":55,"ws":true},{"text":"metabolism","start":302,"end":312,"id":56,"ws":true},{"text":"and","start":313,"end":316,"id":57,"ws":true},{"text":"minimize","start":317,"end":325,"id":58,"ws":true},{"text":"any","start":326,"end":329,"id":59,"ws":true},{"text":"potential","start":330,"end":339,"id":60,"ws":true},{"text":",","start":340,"end":341,"id":61,"ws":true},{"text":"though","start":342,"end":348,"id":62,"ws":true},{"text":"unproven","start":349,"end":357,"id":63,"ws":true},{"text":",","start":358,"end":359,"id":64,"ws":true},{"text":"clinical","start":360,"end":368,"id":65,"ws":true},{"text":"interaction","start":369,"end":380,"id":66,"ws":true},{"text":".","start":381,"end":382,"id":67,"ws":false}],"spans":[{"start":117,"end":127,"token_start":22,"token_end":22,"label":"DRUG"},{"start":184,"end":195,"token_start":35,"token_end":35,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19904241/","_input_hash":-388572547,"_task_hash":1928480581,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":22,"child":35,"head_span":{"start":117,"end":127,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":184,"end":195,"token_start":35,"token_end":35,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Long-term overall- and progression-free survival after pentostatin , cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Long-term</i></b> <b style='color:DodgerBlue;'><i>overall-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>progression-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>pentostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>indolent</i></b> <b style='color:DodgerBlue;'><i>non-Hodgkin</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>In a prospective phase II trial, pentostatin combined with <b style='color:Tomato;'><i>cyclophosphamide</i></b> and <b style='color:Tomato;'><i>rituximab</i></b> (PCR) induced strong responses and was well-tolerated in previously untreated patients with advanced-stage, indolent non-Hodgkin lymphoma (iNHL). After a median patient follow-up of more than 108\u00a0months, we performed an intent-to-treat analysis of our 83 participants. Progression-free survival (PFS) rates at 108\u00a0months for follicular lymphoma (FL), marginal zone lymphoma (MZL) and small lymphocytic lymphoma (SLL) were 71%, 67% and 15%, respectively, and were affected by clinicopathological characteristics. Ten-year PFS rates for those with beta-2-microglobulin levels <2\u00b72 and \u22652\u00b72\u00a0mg/l prior to treatment were 71% and 21%, respectively. Patients without bone marrow involvement had 10-year PFS rates of 72% vs. 29% for those with involvement. At time of analysis, the median overall survival (OS) had not been reached. The OS rate was 64% at 10\u00a0years and differed significantly based on histology: 94% for FL, 66% for MZL and 39% for SLL. Long-term toxicities included 18 (21\u00b77%) patients with second malignancies and 2 (2\u00b74%) who developed myelodysplastic syndrome after receiving additional lines of chemotherapy. Our 10-year follow-up analysis confirms that PCR is an effective, robust and tolerable treatment regimen for patients with iNHL.","tokens":[{"text":"Long-term","start":0,"end":9,"id":0,"ws":true},{"text":"overall-","start":10,"end":18,"id":1,"ws":true},{"text":"and","start":19,"end":22,"id":2,"ws":true},{"text":"progression-free","start":23,"end":39,"id":3,"ws":true},{"text":"survival","start":40,"end":48,"id":4,"ws":true},{"text":"after","start":49,"end":54,"id":5,"ws":true},{"text":"pentostatin","start":55,"end":66,"id":6,"ws":true},{"text":",","start":67,"end":68,"id":7,"ws":true},{"text":"cyclophosphamide","start":69,"end":85,"id":8,"ws":true},{"text":"and","start":86,"end":89,"id":9,"ws":true},{"text":"rituximab","start":90,"end":99,"id":10,"ws":true},{"text":"therapy","start":100,"end":107,"id":11,"ws":true},{"text":"for","start":108,"end":111,"id":12,"ws":true},{"text":"indolent","start":112,"end":120,"id":13,"ws":true},{"text":"non-Hodgkin","start":121,"end":132,"id":14,"ws":true},{"text":"lymphoma","start":133,"end":141,"id":15,"ws":true},{"text":".","start":142,"end":143,"id":16,"ws":false}],"spans":[{"start":69,"end":85,"token_start":8,"token_end":8,"label":"DRUG"},{"start":90,"end":99,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30820940/","_input_hash":541687394,"_task_hash":-382835800,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":55,"end":66,"token_start":6,"token_end":6,"label":null},"child_span":{"start":69,"end":85,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":10,"head_span":{"start":69,"end":85,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":90,"end":99,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Once-weekly isoniazid and rifapentine for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection .","paragraph":"<h3><u>Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.</u></h3> <b style='color:DodgerBlue;'><i>Once-weekly</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rifapentine</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>option</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>persons</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>immunodeficiency</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>latent</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This study aimed to examine pharmacokinetic drug-drug interactions between this regimen and <b style='color:Tomato;'><i>dolutegravir</i></b>, a first-line antiretroviral medication. ### methods This was a single-center, open-label, fixed-sequence, drug-drug interaction study in healthy volunteers. Subjects received oral <b style='color:Tomato;'><i>dolutegravir</i></b> 50 mg once daily alone (days 1-4) and concomitantly with once-weekly <b style='color:Tomato;'><i>isoniazid</i></b> 900 mg, <b style='color:Tomato;'><i>rifapentine</i></b> 900 mg, and <b style='color:Tomato;'><i>pyridoxine</i></b> 50 mg (days 5-19). <b style='color:Tomato;'><i>dolutegravir</i></b> concentrations were measured on days 4, 14, and 19, and <b style='color:Tomato;'><i>rifapentine</i></b>, 25-desacetyl-<b style='color:Tomato;'><i>rifapentine</i></b>, and <b style='color:Tomato;'><i>isoniazid</i></b> concentrations were measured on day 19. Cytokines and antidrug antibodies to <b style='color:Tomato;'><i>isoniazid</i></b> and <b style='color:Tomato;'><i>rifapentine</i></b> were examined at select time points. ### results The study was terminated following the development of flu-like syndrome and elevated aminotransferase levels in 2 of 4 subjects after the third <b style='color:Tomato;'><i>isoniazid</i></b>-<b style='color:Tomato;'><i>rifapentine</i></b> dose. Markedly elevated levels of interferon-\u03b3, CXCL10, C-reactive protein, and other cytokines were temporally associated with symptoms. Antidrug antibodies were infrequently detected. <b style='color:Tomato;'><i>dolutegravir</i></b> area under the curve (AUC) was decreased by 46% (90% confidence interval, 27-110%; P = .13) on day 14. <b style='color:Tomato;'><i>rifapentine</i></b> and 25-desacetyl <b style='color:Tomato;'><i>rifapentine</i></b> levels on day 19 were comparable to reference data, whereas <b style='color:Tomato;'><i>isoniazid</i></b> AUCs were approximately 67%-92% higher in the subjects who developed toxicities. ### conclusions The combined use of <b style='color:Tomato;'><i>dolutegravir</i></b> with once-weekly <b style='color:Tomato;'><i>isoniazid</i></b>-<b style='color:Tomato;'><i>rifapentine</i></b> resulted in unexpected and serious toxicities that were mediated by endogenous cytokine release. Additional investigations are necessary to examine the safety and efficacy of coadministering these medications. ### Clinical Trials Registration NCT02771249.","tokens":[{"text":"Once-weekly","start":0,"end":11,"id":0,"ws":true},{"text":"isoniazid","start":12,"end":21,"id":1,"ws":true},{"text":"and","start":22,"end":25,"id":2,"ws":true},{"text":"rifapentine","start":26,"end":37,"id":3,"ws":true},{"text":"for","start":38,"end":41,"id":4,"ws":true},{"text":"3","start":42,"end":43,"id":5,"ws":true},{"text":"months","start":44,"end":50,"id":6,"ws":true},{"text":"is","start":51,"end":53,"id":7,"ws":true},{"text":"a","start":54,"end":55,"id":8,"ws":true},{"text":"treatment","start":56,"end":65,"id":9,"ws":true},{"text":"option","start":66,"end":72,"id":10,"ws":true},{"text":"in","start":73,"end":75,"id":11,"ws":true},{"text":"persons","start":76,"end":83,"id":12,"ws":true},{"text":"with","start":84,"end":88,"id":13,"ws":true},{"text":"human","start":89,"end":94,"id":14,"ws":true},{"text":"immunodeficiency","start":95,"end":111,"id":15,"ws":true},{"text":"virus","start":112,"end":117,"id":16,"ws":true},{"text":"and","start":118,"end":121,"id":17,"ws":true},{"text":"latent","start":122,"end":128,"id":18,"ws":true},{"text":"tuberculosis","start":129,"end":141,"id":19,"ws":true},{"text":"infection","start":142,"end":151,"id":20,"ws":true},{"text":".","start":152,"end":153,"id":21,"ws":false}],"spans":[{"start":12,"end":21,"token_start":1,"token_end":1,"label":"DRUG"},{"start":26,"end":37,"token_start":3,"token_end":3,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29415190/","_input_hash":-655714867,"_task_hash":645335847,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":1,"child":3,"head_span":{"start":12,"end":21,"token_start":1,"token_end":1,"label":"DRUG"},"child_span":{"start":26,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"We investigated the effects of these inhibitors on other anticancer drugs including docetaxel , vinblastine , doxorubicin , 10-Hydroxycamptothecin ( 10-HCPT ) and cisplatin and find that both inhibitors induces DU145-TxR cells to be more sensitive only to the microtubule-targeting drugs ( paclitaxel , docetaxel and vinblastine ) .","paragraph":"<h3><u>The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.</u></h3>Resistance is a significant limitation to the effectiveness of cancer therapies. The PI3K/Akt and MAP kinase pathways play important roles in a variety of normal cellular processes and tumorigenesis. This study is designed to explore the relationship of these signaling pathways with multidrug resistance in prostate cancer (PCa). The PI3K/Akt and MAP kinase pathways were investigated utilizing <b style='color:Tomato;'><i>paclitaxel</i></b> resistant DU145-TxR PCa cells and their parental non-resistant DU145 cells to determine their relationship with resistance to <b style='color:Tomato;'><i>paclitaxel</i></b> and other anticancer drugs. Our results demonstrate that the PI3K/Akt and MAP kinase pathways are upregulated in DU145-TxR cells compared to the DU145 cells. Inactivating these pathways using the PI3K/Akt pathway inhibitor LY294002 or the MAP kinase pathway inhibitor PD98059 renders the DU145-TxR cells more sensitive to <b style='color:Tomato;'><i>paclitaxel</i></b>. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>anticancer</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10-Hydroxycamptothecin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10-HCPT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>find</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>induces</i></b> <b style='color:DodgerBlue;'><i>DU145-TxR</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>sensitive</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>microtubule-targeting</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Furthermore, the treatment with these inhibitors induces cleaved-PARP production in DU145-TxR cells, suggesting that apoptosis induction might be one of the mechanisms for the reversal of drug resistance. In conclusion, the PI3K/Akt and MAP kinase pathways are associated with resistance to multiple chemotherapeutic drugs. Inactivating these pathways renders these PCa cells more sensitive to microtubule-targeting drugs such as <b style='color:Tomato;'><i>paclitaxel</i></b>, <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>vinblastine</i></b>. Combination therapies with novel inhibitors of these two signaling pathways potentially represents a more effective treatment for drug resistant PCa.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"investigated","start":3,"end":15,"id":1,"ws":true},{"text":"the","start":16,"end":19,"id":2,"ws":true},{"text":"effects","start":20,"end":27,"id":3,"ws":true},{"text":"of","start":28,"end":30,"id":4,"ws":true},{"text":"these","start":31,"end":36,"id":5,"ws":true},{"text":"inhibitors","start":37,"end":47,"id":6,"ws":true},{"text":"on","start":48,"end":50,"id":7,"ws":true},{"text":"other","start":51,"end":56,"id":8,"ws":true},{"text":"anticancer","start":57,"end":67,"id":9,"ws":true},{"text":"drugs","start":68,"end":73,"id":10,"ws":true},{"text":"including","start":74,"end":83,"id":11,"ws":true},{"text":"docetaxel","start":84,"end":93,"id":12,"ws":true},{"text":",","start":94,"end":95,"id":13,"ws":true},{"text":"vinblastine","start":96,"end":107,"id":14,"ws":true},{"text":",","start":108,"end":109,"id":15,"ws":true},{"text":"doxorubicin","start":110,"end":121,"id":16,"ws":true},{"text":",","start":122,"end":123,"id":17,"ws":true},{"text":"10-Hydroxycamptothecin","start":124,"end":146,"id":18,"ws":true},{"text":"(","start":147,"end":148,"id":19,"ws":true},{"text":"10-HCPT","start":149,"end":156,"id":20,"ws":true},{"text":")","start":157,"end":158,"id":21,"ws":true},{"text":"and","start":159,"end":162,"id":22,"ws":true},{"text":"cisplatin","start":163,"end":172,"id":23,"ws":true},{"text":"and","start":173,"end":176,"id":24,"ws":true},{"text":"find","start":177,"end":181,"id":25,"ws":true},{"text":"that","start":182,"end":186,"id":26,"ws":true},{"text":"both","start":187,"end":191,"id":27,"ws":true},{"text":"inhibitors","start":192,"end":202,"id":28,"ws":true},{"text":"induces","start":203,"end":210,"id":29,"ws":true},{"text":"DU145-TxR","start":211,"end":220,"id":30,"ws":true},{"text":"cells","start":221,"end":226,"id":31,"ws":true},{"text":"to","start":227,"end":229,"id":32,"ws":true},{"text":"be","start":230,"end":232,"id":33,"ws":true},{"text":"more","start":233,"end":237,"id":34,"ws":true},{"text":"sensitive","start":238,"end":247,"id":35,"ws":true},{"text":"only","start":248,"end":252,"id":36,"ws":true},{"text":"to","start":253,"end":255,"id":37,"ws":true},{"text":"the","start":256,"end":259,"id":38,"ws":true},{"text":"microtubule-targeting","start":260,"end":281,"id":39,"ws":true},{"text":"drugs","start":282,"end":287,"id":40,"ws":true},{"text":"(","start":288,"end":289,"id":41,"ws":true},{"text":"paclitaxel","start":290,"end":300,"id":42,"ws":true},{"text":",","start":301,"end":302,"id":43,"ws":true},{"text":"docetaxel","start":303,"end":312,"id":44,"ws":true},{"text":"and","start":313,"end":316,"id":45,"ws":true},{"text":"vinblastine","start":317,"end":328,"id":46,"ws":true},{"text":")","start":329,"end":330,"id":47,"ws":true},{"text":".","start":331,"end":332,"id":48,"ws":false}],"spans":[{"start":84,"end":93,"token_start":12,"token_end":12,"label":"DRUG"},{"start":96,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},{"start":110,"end":121,"token_start":16,"token_end":16,"label":"DRUG"},{"start":290,"end":300,"token_start":42,"token_end":42,"label":"DRUG"},{"start":303,"end":312,"token_start":44,"token_end":44,"label":"DRUG"},{"start":317,"end":328,"token_start":46,"token_end":46,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25640606/","_input_hash":1870680176,"_task_hash":1850379618,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Group B : From January , 1976 to December , 1980 , 55 evaluable patients participated in a consecutive study that added Adriamycin ( doxorubicin ) and cyclophosphamide to the former induction regimen .","paragraph":"<h3><u>Comparison of two consecutive trials for treatment of childhood non-Hodgkin's lymphoma.</u></h3>Two consecutive trials for the treatment of childhood non-Hodgkin's lymphoma were evaluated, carried out by the same cooperative groups. Group A: From June, 1973 to December, 1975, 50 evaluable patients under 16 years of age participated in a study that included <b style='color:Tomato;'><i>vincristine</i></b> and <b style='color:Tomato;'><i>prednisone</i></b> plus surgery and/or radiotherapy as induction. This was followed by 2400 rad of cranial radiotherapy plus 5 doses of intrathecal <b style='color:Tomato;'><i>methotrexate</i></b>-<b style='color:Tomato;'><i>dexamethasone</i></b> and anti-leukemia (6-<b style='color:Tomato;'><i>mercaptopurine</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>) or anti-lymphoma (<b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>procarbazine</i></b>, and <b style='color:Tomato;'><i>prednisone</i></b>) maintenance treatment. <b style='color:DodgerBlue;'><i>Group</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>From</i></b> <b style='color:DodgerBlue;'><i>January</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1976</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>December</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1980</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>55</i></b> <b style='color:DodgerBlue;'><i>evaluable</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>added</i></b> <b style='color:DodgerBlue;'><i>Adriamycin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>former</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Central nervous system (CNS) prevention was performed with 5 doses of intrathecal <b style='color:Tomato;'><i>methotrexate</i></b>-<b style='color:Tomato;'><i>dexamethasone</i></b>. Maintenance treatment was the same. Prognostic factors as stage and primary site were comparable in both groups. A total of 33 (66%) of 50 children of Group A and 48 (87%) of 55 children of Group B achieved complete remission (P less than 0.005). Disease-free survival at 60 months was 27% in Group A and 49% in Group B; for Stage I-II, 30% in Group A and 85% in Group B (P less than 0.025); for Stage III-IV 28% in Group A and 36% in Group B (not significant). In Group A, 9.1% and in Group B, 8.3% had primary CNS relapse. Both maintenance schedules had the same relapse rate. It was concluded that: (1) the addition of Adriamycin and <b style='color:Tomato;'><i>cyclophosphamide</i></b> to <b style='color:Tomato;'><i>vincristine</i></b>-<b style='color:Tomato;'><i>prednisone</i></b> in Group B produces a higher rate of complete remission in Stage III-IV, a higher rate of disease-free survival in Stage I-II, and a higher survival rate in all stages; (2) CNS prevention with intrathecal <b style='color:Tomato;'><i>methotrexate</i></b>-<b style='color:Tomato;'><i>dexamethasone</i></b> is equally effective as cranial radiation plus intrathecal <b style='color:Tomato;'><i>methotrexate</i></b>-<b style='color:Tomato;'><i>dexamethasone</i></b>; and (3) anti-leukemia and anti-lymphoma maintenance are equally effective in the context of this study.","tokens":[{"text":"Group","start":0,"end":5,"id":0,"ws":true},{"text":"B","start":6,"end":7,"id":1,"ws":true},{"text":":","start":8,"end":9,"id":2,"ws":true},{"text":"From","start":10,"end":14,"id":3,"ws":true},{"text":"January","start":15,"end":22,"id":4,"ws":true},{"text":",","start":23,"end":24,"id":5,"ws":true},{"text":"1976","start":25,"end":29,"id":6,"ws":true},{"text":"to","start":30,"end":32,"id":7,"ws":true},{"text":"December","start":33,"end":41,"id":8,"ws":true},{"text":",","start":42,"end":43,"id":9,"ws":true},{"text":"1980","start":44,"end":48,"id":10,"ws":true},{"text":",","start":49,"end":50,"id":11,"ws":true},{"text":"55","start":51,"end":53,"id":12,"ws":true},{"text":"evaluable","start":54,"end":63,"id":13,"ws":true},{"text":"patients","start":64,"end":72,"id":14,"ws":true},{"text":"participated","start":73,"end":85,"id":15,"ws":true},{"text":"in","start":86,"end":88,"id":16,"ws":true},{"text":"a","start":89,"end":90,"id":17,"ws":true},{"text":"consecutive","start":91,"end":102,"id":18,"ws":true},{"text":"study","start":103,"end":108,"id":19,"ws":true},{"text":"that","start":109,"end":113,"id":20,"ws":true},{"text":"added","start":114,"end":119,"id":21,"ws":true},{"text":"Adriamycin","start":120,"end":130,"id":22,"ws":true},{"text":"(","start":131,"end":132,"id":23,"ws":true},{"text":"doxorubicin","start":133,"end":144,"id":24,"ws":true},{"text":")","start":145,"end":146,"id":25,"ws":true},{"text":"and","start":147,"end":150,"id":26,"ws":true},{"text":"cyclophosphamide","start":151,"end":167,"id":27,"ws":true},{"text":"to","start":168,"end":170,"id":28,"ws":true},{"text":"the","start":171,"end":174,"id":29,"ws":true},{"text":"former","start":175,"end":181,"id":30,"ws":true},{"text":"induction","start":182,"end":191,"id":31,"ws":true},{"text":"regimen","start":192,"end":199,"id":32,"ws":true},{"text":".","start":200,"end":201,"id":33,"ws":false}],"spans":[{"start":133,"end":144,"token_start":24,"token_end":24,"label":"DRUG"},{"start":151,"end":167,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6388820/","_input_hash":2014933255,"_task_hash":1016909622,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"After surgery , 1,384 patients were randomly assigned to receive epirubicin plus cyclophosphamide ( EC ; 90 and 600 mg/m(2 ) , respectively , \u00d7 four cycles ) , followed by docetaxel ( 100 mg/m(2 ) \u00d7 four cycles ; EC-T ) or epirubicin plus docetaxel ( ET ; 90 and 75 mg/m(2 ) , respectively , \u00d7 four cycles ) , followed by capecitabine ( 1,250 mg/m(2 ) twice a day on days 1 to 14 , \u00d7 four cycles ; ET-X ) ; all regimens were given every 3 weeks .","paragraph":"<h3><u>Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.</u></h3><b style='color:Tomato;'><i>capecitabine</i></b> is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of <b style='color:Tomato;'><i>capecitabine</i></b> into a regimen of <b style='color:Tomato;'><i>epirubicin</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> for node-positive early BC. ### Patients And Methods Patients with operable node-positive BC (T1-3/N1-3) were eligible. <b style='color:DodgerBlue;'><i>After</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1,384</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>EC</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>90</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>600</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>\u00d7</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>\u00d7</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>EC-T</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ET</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>90</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>\u00d7</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1,250</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>\u00d7</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>ET-X</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>all</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end point was invasive disease-free survival. Secondary end points included safety (with an alopecia-specific study) and overall survival (OS). ### results After a median follow-up of 6.6 years and 297 events, 86% of patients who received EC-T and 82% of those who received ET-X were invasive disease free at 5 years (hazard ratio, 1.30; 95% CI, 1.03 to 1.64; log-rank P = .03). The OS difference between arms was not statistically significant (hazard ratio, 1.13; 95% CI, 0.82 to 1.55; log-rank P = .46). The most frequent grade 3 to 4 adverse events in the EC-T versus ET-X arms were neutropenia (19% v 10%), with 7% febrile neutropenia across arms; fatigue (13% v 11%); diarrhea (3% v 11%); hand-foot syndrome (2% v 20%); mucositis (6% v 5%); vomiting (both, 5%); and myalgia (4.5% v 1%). Incomplete scalp hair recovery was more frequent in the EC-T than ET-X arm (30% v 14%), and patients who received EC-T wore wigs significantly longer than those who received ET-X (8.35 v 6.03 months). ### conclusion Invasive disease-free survival, but not OS, was significantly superior for patients with node-positive early BC who received the adjuvant standard schedule EC-T than for those who received the experimental ET-X regimen. Toxicity profiles differed substantially across arms.","tokens":[{"text":"After","start":0,"end":5,"id":0,"ws":true},{"text":"surgery","start":6,"end":13,"id":1,"ws":true},{"text":",","start":14,"end":15,"id":2,"ws":true},{"text":"1,384","start":16,"end":21,"id":3,"ws":true},{"text":"patients","start":22,"end":30,"id":4,"ws":true},{"text":"were","start":31,"end":35,"id":5,"ws":true},{"text":"randomly","start":36,"end":44,"id":6,"ws":true},{"text":"assigned","start":45,"end":53,"id":7,"ws":true},{"text":"to","start":54,"end":56,"id":8,"ws":true},{"text":"receive","start":57,"end":64,"id":9,"ws":true},{"text":"epirubicin","start":65,"end":75,"id":10,"ws":true},{"text":"plus","start":76,"end":80,"id":11,"ws":true},{"text":"cyclophosphamide","start":81,"end":97,"id":12,"ws":true},{"text":"(","start":98,"end":99,"id":13,"ws":true},{"text":"EC","start":100,"end":102,"id":14,"ws":true},{"text":";","start":103,"end":104,"id":15,"ws":true},{"text":"90","start":105,"end":107,"id":16,"ws":true},{"text":"and","start":108,"end":111,"id":17,"ws":true},{"text":"600","start":112,"end":115,"id":18,"ws":true},{"text":"mg/m(2","start":116,"end":122,"id":19,"ws":true},{"text":")","start":123,"end":124,"id":20,"ws":true},{"text":",","start":125,"end":126,"id":21,"ws":true},{"text":"respectively","start":127,"end":139,"id":22,"ws":true},{"text":",","start":140,"end":141,"id":23,"ws":true},{"text":"\u00d7","start":142,"end":143,"id":24,"ws":true},{"text":"four","start":144,"end":148,"id":25,"ws":true},{"text":"cycles","start":149,"end":155,"id":26,"ws":true},{"text":")","start":156,"end":157,"id":27,"ws":true},{"text":",","start":158,"end":159,"id":28,"ws":true},{"text":"followed","start":160,"end":168,"id":29,"ws":true},{"text":"by","start":169,"end":171,"id":30,"ws":true},{"text":"docetaxel","start":172,"end":181,"id":31,"ws":true},{"text":"(","start":182,"end":183,"id":32,"ws":true},{"text":"100","start":184,"end":187,"id":33,"ws":true},{"text":"mg/m(2","start":188,"end":194,"id":34,"ws":true},{"text":")","start":195,"end":196,"id":35,"ws":true},{"text":"\u00d7","start":197,"end":198,"id":36,"ws":true},{"text":"four","start":199,"end":203,"id":37,"ws":true},{"text":"cycles","start":204,"end":210,"id":38,"ws":true},{"text":";","start":211,"end":212,"id":39,"ws":true},{"text":"EC-T","start":213,"end":217,"id":40,"ws":true},{"text":")","start":218,"end":219,"id":41,"ws":true},{"text":"or","start":220,"end":222,"id":42,"ws":true},{"text":"epirubicin","start":223,"end":233,"id":43,"ws":true},{"text":"plus","start":234,"end":238,"id":44,"ws":true},{"text":"docetaxel","start":239,"end":248,"id":45,"ws":true},{"text":"(","start":249,"end":250,"id":46,"ws":true},{"text":"ET","start":251,"end":253,"id":47,"ws":true},{"text":";","start":254,"end":255,"id":48,"ws":true},{"text":"90","start":256,"end":258,"id":49,"ws":true},{"text":"and","start":259,"end":262,"id":50,"ws":true},{"text":"75","start":263,"end":265,"id":51,"ws":true},{"text":"mg/m(2","start":266,"end":272,"id":52,"ws":true},{"text":")","start":273,"end":274,"id":53,"ws":true},{"text":",","start":275,"end":276,"id":54,"ws":true},{"text":"respectively","start":277,"end":289,"id":55,"ws":true},{"text":",","start":290,"end":291,"id":56,"ws":true},{"text":"\u00d7","start":292,"end":293,"id":57,"ws":true},{"text":"four","start":294,"end":298,"id":58,"ws":true},{"text":"cycles","start":299,"end":305,"id":59,"ws":true},{"text":")","start":306,"end":307,"id":60,"ws":true},{"text":",","start":308,"end":309,"id":61,"ws":true},{"text":"followed","start":310,"end":318,"id":62,"ws":true},{"text":"by","start":319,"end":321,"id":63,"ws":true},{"text":"capecitabine","start":322,"end":334,"id":64,"ws":true},{"text":"(","start":335,"end":336,"id":65,"ws":true},{"text":"1,250","start":337,"end":342,"id":66,"ws":true},{"text":"mg/m(2","start":343,"end":349,"id":67,"ws":true},{"text":")","start":350,"end":351,"id":68,"ws":true},{"text":"twice","start":352,"end":357,"id":69,"ws":true},{"text":"a","start":358,"end":359,"id":70,"ws":true},{"text":"day","start":360,"end":363,"id":71,"ws":true},{"text":"on","start":364,"end":366,"id":72,"ws":true},{"text":"days","start":367,"end":371,"id":73,"ws":true},{"text":"1","start":372,"end":373,"id":74,"ws":true},{"text":"to","start":374,"end":376,"id":75,"ws":true},{"text":"14","start":377,"end":379,"id":76,"ws":true},{"text":",","start":380,"end":381,"id":77,"ws":true},{"text":"\u00d7","start":382,"end":383,"id":78,"ws":true},{"text":"four","start":384,"end":388,"id":79,"ws":true},{"text":"cycles","start":389,"end":395,"id":80,"ws":true},{"text":";","start":396,"end":397,"id":81,"ws":true},{"text":"ET-X","start":398,"end":402,"id":82,"ws":true},{"text":")","start":403,"end":404,"id":83,"ws":true},{"text":";","start":405,"end":406,"id":84,"ws":true},{"text":"all","start":407,"end":410,"id":85,"ws":true},{"text":"regimens","start":411,"end":419,"id":86,"ws":true},{"text":"were","start":420,"end":424,"id":87,"ws":true},{"text":"given","start":425,"end":430,"id":88,"ws":true},{"text":"every","start":431,"end":436,"id":89,"ws":true},{"text":"3","start":437,"end":438,"id":90,"ws":true},{"text":"weeks","start":439,"end":444,"id":91,"ws":true},{"text":".","start":445,"end":446,"id":92,"ws":false}],"spans":[{"start":65,"end":75,"token_start":10,"token_end":10,"label":"DRUG"},{"start":81,"end":97,"token_start":12,"token_end":12,"label":"DRUG"},{"start":172,"end":181,"token_start":31,"token_end":31,"label":"DRUG"},{"start":223,"end":233,"token_start":43,"token_end":43,"label":"DRUG"},{"start":239,"end":248,"token_start":45,"token_end":45,"label":"DRUG"},{"start":322,"end":334,"token_start":64,"token_end":64,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26416999/","_input_hash":-1784750690,"_task_hash":-1239430557,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":65,"end":75,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":81,"end":97,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":31,"child":10,"head_span":{"start":172,"end":181,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":65,"end":75,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":43,"child":45,"head_span":{"start":223,"end":233,"token_start":43,"token_end":43,"label":"DRUG"},"child_span":{"start":239,"end":248,"token_start":45,"token_end":45,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":64,"child":43,"head_span":{"start":322,"end":334,"token_start":64,"token_end":64,"label":"DRUG"},"child_span":{"start":223,"end":233,"token_start":43,"token_end":43,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["POS11","NEG11"],"answer":"accept"}
{"text":"This prospective study recruited 152 patients with locally advanced breast cancer who underwent four-cycle weekly paclitaxel plus carboplatin without trastuzumab .","paragraph":"<h3><u>Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer.</u></h3>Aneusomy 17 causes inconsistency in fluorescence in situ hybridization (FISH)-based human epidermal growth factor receptor (HER)-2 status assessment using different algorithms (copy number or the HER-2/centromere enumerator probe 17 [CEP-17] ratio). We investigated the effects of FISH-based HER-2 status assessment and aneusomy 17 on responsiveness to neoadjuvant chemotherapy (NAC). ### Patients And Methods <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>prospective</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>recruited</i></b> <b style='color:DodgerBlue;'><i>152</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>underwent</i></b> <b style='color:DodgerBlue;'><i>four-cycle</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results The pathologic complete remission (pCR) rate in the breast and axilla was 24.3% (95% confidence interval [CI], 17.7%-32.0%). Although HER-2 status, assessed by either HER-2/CEP-17 ratio-based FISH or copy number-based FISH, was a predictor of NAC sensitivity, ratio-assessed HER-2 status had a poorer performance in determining patients' responsiveness to NAC (p = .029). Patients who were not HER-2 amplified when assessed using the HER-2/CEP-17 ratio but were HER-2 amplified when assessed using copy number (~5%) were eventually proven to be responsive to NAC, with a pCR rate of 57% (95% CI, 18.4%-90.1%). In contrast, patients who were HER-2 amplified when assessed by the ratio but not HER-2 amplified when assessed using copy number (~3%) were completely irresponsive. Higher HER-2 copy numbers represented increasing chances of a pCR (adjusted odds ratio, 3.09; 95% CI, 1.35-7.08), with an apparent gene-dose effect (p for trend < .001). ### conclusion It is likely that HER-2 copy number but not the HER-2/CEP-17 ratio determines NAC sensitivity. Additional studies to validate our findings are warranted.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"prospective","start":5,"end":16,"id":1,"ws":true},{"text":"study","start":17,"end":22,"id":2,"ws":true},{"text":"recruited","start":23,"end":32,"id":3,"ws":true},{"text":"152","start":33,"end":36,"id":4,"ws":true},{"text":"patients","start":37,"end":45,"id":5,"ws":true},{"text":"with","start":46,"end":50,"id":6,"ws":true},{"text":"locally","start":51,"end":58,"id":7,"ws":true},{"text":"advanced","start":59,"end":67,"id":8,"ws":true},{"text":"breast","start":68,"end":74,"id":9,"ws":true},{"text":"cancer","start":75,"end":81,"id":10,"ws":true},{"text":"who","start":82,"end":85,"id":11,"ws":true},{"text":"underwent","start":86,"end":95,"id":12,"ws":true},{"text":"four-cycle","start":96,"end":106,"id":13,"ws":true},{"text":"weekly","start":107,"end":113,"id":14,"ws":true},{"text":"paclitaxel","start":114,"end":124,"id":15,"ws":true},{"text":"plus","start":125,"end":129,"id":16,"ws":true},{"text":"carboplatin","start":130,"end":141,"id":17,"ws":true},{"text":"without","start":142,"end":149,"id":18,"ws":true},{"text":"trastuzumab","start":150,"end":161,"id":19,"ws":true},{"text":".","start":162,"end":163,"id":20,"ws":false}],"spans":[{"start":114,"end":124,"token_start":15,"token_end":15,"label":"DRUG"},{"start":130,"end":141,"token_start":17,"token_end":17,"label":"DRUG"},{"start":150,"end":161,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22561335/","_input_hash":-235279311,"_task_hash":-164823833,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":15,"child":17,"head_span":{"start":114,"end":124,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":130,"end":141,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"High response rate and acceptable toxicity of a combination of rituximab , vinorelbine , ifosfamide , mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse : results of the R-NIMP GOELAMS study .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>High</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>acceptable</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>diffuse</i></b> <b style='color:DodgerBlue;'><i>large</i></b> <b style='color:DodgerBlue;'><i>B-cell</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>relapse</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>R-NIMP</i></b> <b style='color:DodgerBlue;'><i>GOELAMS</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The optimal management of relapsed diffuse large B-cell lymphoma (DLBCL) is not standardized. The Groupe Ouest Est des Leuc\u00e9mies et aAutres Maladies du Sang developed a combination of <b style='color:Tomato;'><i>vinorelbine</i></b>, <b style='color:Tomato;'><i>ifosfamide</i></b>, <b style='color:Tomato;'><i>mitoxantrone</i></b> and <b style='color:Tomato;'><i>prednisone</i></b> (NIMP) for the treatment of relapsed DLBCL, and assessed its efficacy and safety in association with <b style='color:Tomato;'><i>rituximab</i></b> (R). This multicentric phase II study included 50 patients with DLBCL in first relapse, aged 18-75 years. Patients received <b style='color:Tomato;'><i>rituximab</i></b> 375 mg/m\u00b2 day 1, <b style='color:Tomato;'><i>ifosfamide</i></b> 1000 mg/m\u00b2 days 1-5, <b style='color:Tomato;'><i>vinorelbine</i></b> 25 mg/m\u00b2 days 1 and 15, <b style='color:Tomato;'><i>mitoxantrone</i></b> 10 mg/m\u00b2 day 1, and <b style='color:Tomato;'><i>prednisone</i></b> 1 mg/kg days 1-5, every 28 days for three cycles. Responding patients underwent autologous transplantation or received three additional R-NIMP cycles. All patients were evaluable for toxicity and 49 for response. Centralized pathology review confirmed DLBCL in all cases. Toxicities were mainly haematological with infectious events needing hospitalization in nine cases. Two toxic deaths were observed. After three cycles, 22 patients (44%) achieved complete response/unconfirmed complete response, 11 achieved partial response (24%), 2 had stable disease and 13 progressed. The non-germinal centre B immunophenotype was associated with shorter progression-free survival. in conclusion, the R-NIMP regimen displayed significant activity in relapsed DLBCL, with acceptable toxicity and should be considered a candidate for combination with new agents.","tokens":[{"text":"High","start":0,"end":4,"id":0,"ws":true},{"text":"response","start":5,"end":13,"id":1,"ws":true},{"text":"rate","start":14,"end":18,"id":2,"ws":true},{"text":"and","start":19,"end":22,"id":3,"ws":true},{"text":"acceptable","start":23,"end":33,"id":4,"ws":true},{"text":"toxicity","start":34,"end":42,"id":5,"ws":true},{"text":"of","start":43,"end":45,"id":6,"ws":true},{"text":"a","start":46,"end":47,"id":7,"ws":true},{"text":"combination","start":48,"end":59,"id":8,"ws":true},{"text":"of","start":60,"end":62,"id":9,"ws":true},{"text":"rituximab","start":63,"end":72,"id":10,"ws":true},{"text":",","start":73,"end":74,"id":11,"ws":true},{"text":"vinorelbine","start":75,"end":86,"id":12,"ws":true},{"text":",","start":87,"end":88,"id":13,"ws":true},{"text":"ifosfamide","start":89,"end":99,"id":14,"ws":true},{"text":",","start":100,"end":101,"id":15,"ws":true},{"text":"mitoxantrone","start":102,"end":114,"id":16,"ws":true},{"text":"and","start":115,"end":118,"id":17,"ws":true},{"text":"prednisone","start":119,"end":129,"id":18,"ws":true},{"text":"for","start":130,"end":133,"id":19,"ws":true},{"text":"the","start":134,"end":137,"id":20,"ws":true},{"text":"treatment","start":138,"end":147,"id":21,"ws":true},{"text":"of","start":148,"end":150,"id":22,"ws":true},{"text":"diffuse","start":151,"end":158,"id":23,"ws":true},{"text":"large","start":159,"end":164,"id":24,"ws":true},{"text":"B-cell","start":165,"end":171,"id":25,"ws":true},{"text":"lymphoma","start":172,"end":180,"id":26,"ws":true},{"text":"in","start":181,"end":183,"id":27,"ws":true},{"text":"first","start":184,"end":189,"id":28,"ws":true},{"text":"relapse","start":190,"end":197,"id":29,"ws":true},{"text":":","start":198,"end":199,"id":30,"ws":true},{"text":"results","start":200,"end":207,"id":31,"ws":true},{"text":"of","start":208,"end":210,"id":32,"ws":true},{"text":"the","start":211,"end":214,"id":33,"ws":true},{"text":"R-NIMP","start":215,"end":221,"id":34,"ws":true},{"text":"GOELAMS","start":222,"end":229,"id":35,"ws":true},{"text":"study","start":230,"end":235,"id":36,"ws":true},{"text":".","start":236,"end":237,"id":37,"ws":false}],"spans":[{"start":63,"end":72,"token_start":10,"token_end":10,"label":"DRUG"},{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},{"start":89,"end":99,"token_start":14,"token_end":14,"label":"DRUG"},{"start":102,"end":114,"token_start":16,"token_end":16,"label":"DRUG"},{"start":119,"end":129,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23692641/","_input_hash":1204374341,"_task_hash":1760526765,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":63,"end":72,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":14,"head_span":{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":89,"end":99,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":14,"child":16,"head_span":{"start":89,"end":99,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":102,"end":114,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":18,"child":16,"head_span":{"start":119,"end":129,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":102,"end":114,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"A second complete remission was obtained with RFC chemotherapy regimen ( rituximab , fludarabine , and cyclophosphamide ) .","paragraph":"<h3><u>Bing and neel syndrome.</u></h3>Introduction. We report the case of a Bing and Neel syndrome revealed by an isolated left ptosis. Case Report. a 57-year-old man was followed up since October 2003 for a typical Waldenstr\u00f6m's macroglobulinemia. A first complete remission was obtained with <b style='color:Tomato;'><i>chlorambucil</i></b>. In August 2004, he relapsed. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>second</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>obtained</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>RFC</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>fludarabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In October 2009, the patient presented with an isolated left ptosis revealing a Bing and Neel syndrome. The diagnosis was suspected on MRI and confirmed by the detection in the CSF of a monoclonal IgM similar to the one found in the plasma. A quite good partial remission has been obtained after one course of RDHAP (<b style='color:Tomato;'><i>rituximab</i></b>, <b style='color:Tomato;'><i>dexamethasone</i></b>, <b style='color:Tomato;'><i>cytarabine</i></b>, and cisplatin) and 3 courses of RDHOx (<b style='color:Tomato;'><i>rituximab</i></b>, <b style='color:Tomato;'><i>dexamethasone</i></b>, <b style='color:Tomato;'><i>cytarabine</i></b>, and <b style='color:Tomato;'><i>oxaliplatin</i></b>), in addition to ten intrahectal chemotherapy injections. The treatment was followed by intensification and autologous stem cell transplantation. At D58, the patient died due to a septic shock. Conclusion. BNS is a rare and potentially treatable complication of WM. It should be considered in patients with neurologic symptoms and a history of WM.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"second","start":2,"end":8,"id":1,"ws":true},{"text":"complete","start":9,"end":17,"id":2,"ws":true},{"text":"remission","start":18,"end":27,"id":3,"ws":true},{"text":"was","start":28,"end":31,"id":4,"ws":true},{"text":"obtained","start":32,"end":40,"id":5,"ws":true},{"text":"with","start":41,"end":45,"id":6,"ws":true},{"text":"RFC","start":46,"end":49,"id":7,"ws":true},{"text":"chemotherapy","start":50,"end":62,"id":8,"ws":true},{"text":"regimen","start":63,"end":70,"id":9,"ws":true},{"text":"(","start":71,"end":72,"id":10,"ws":true},{"text":"rituximab","start":73,"end":82,"id":11,"ws":true},{"text":",","start":83,"end":84,"id":12,"ws":true},{"text":"fludarabine","start":85,"end":96,"id":13,"ws":true},{"text":",","start":97,"end":98,"id":14,"ws":true},{"text":"and","start":99,"end":102,"id":15,"ws":true},{"text":"cyclophosphamide","start":103,"end":119,"id":16,"ws":true},{"text":")","start":120,"end":121,"id":17,"ws":true},{"text":".","start":122,"end":123,"id":18,"ws":false}],"spans":[{"start":73,"end":82,"token_start":11,"token_end":11,"label":"DRUG"},{"start":85,"end":96,"token_start":13,"token_end":13,"label":"DRUG"},{"start":103,"end":119,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22988532/","_input_hash":591963233,"_task_hash":-169541465,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":73,"end":82,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":85,"end":96,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":16,"child":13,"head_span":{"start":103,"end":119,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":85,"end":96,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"At a median duration of follow-up of 18.2 months , anastrozole was at least equivalent to tamoxifen in terms of median TTP ( 8.5 and 7.0 months , respectively ; estimated hazard ratio [ tamoxifen relative to anastrozole ] , 1.13 [ lower 95 % confidence level , 1.00 ] ) .","paragraph":"<h3><u>Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.</u></h3>Two randomized, double-blind trials have compared <b style='color:Tomato;'><i>tamoxifen</i></b> 20 mg daily and the selective, nonsteroidal aromatase inhibitor <b style='color:Tomato;'><i>anastrozole</i></b> 1 mg daily as first-line therapy for advanced breast carcinoma (ABC) in postmenopausal women. The trials were prospectively designed to allow for combined data analyses. ### methods The combined study population included 1021 postmenopausal women (median age, 67 years [range, 30-92]) with ABC whose tumors were either estrogen and/or progesterone receptor positive or of unknown receptor status. Primary endpoints were time to progression (TTP), objective response, and tolerability. ### results <b style='color:DodgerBlue;'><i>At</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>duration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>18.2</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>equivalent</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>terms</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>TTP</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>8.5</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>7.0</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>estimated</i></b> <b style='color:DodgerBlue;'><i>hazard</i></b> <b style='color:DodgerBlue;'><i>ratio</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>relative</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1.13</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>95</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>confidence</i></b> <b style='color:DodgerBlue;'><i>level</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1.00</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In a retrospective subgroup analysis, <b style='color:Tomato;'><i>anastrozole</i></b> was superior to <b style='color:Tomato;'><i>tamoxifen</i></b> with respect to TTP (median values of 10.7 and 6.4 months for <b style='color:Tomato;'><i>anastrozole</i></b> and <b style='color:Tomato;'><i>tamoxifen</i></b>, respectively, two-sided P = 0.022) in patients with estrogen and/or progesterone receptor positive tumors (60% of combined trial population). In terms of objective response, 29.0% of <b style='color:Tomato;'><i>anastrozole</i></b> and 27.1% of <b style='color:Tomato;'><i>tamoxifen</i></b> patients achieved either a complete response (CR) or a partial response (PR). Clinical benefit (CR + PR + stabilization of > or = 24 weeks) rates were 57.1% and 52.0% for <b style='color:Tomato;'><i>anastrozole</i></b> and <b style='color:Tomato;'><i>tamoxifen</i></b>, respectively. Both <b style='color:Tomato;'><i>anastrozole</i></b> and <b style='color:Tomato;'><i>tamoxifen</i></b> were well tolerated. <b style='color:Tomato;'><i>anastrozole</i></b> led to significantly fewer venous thromboembolic (P = 0.043; not adjusted for multiple comparisons) events, and vaginal bleeding was reported in fewer patients treated with <b style='color:Tomato;'><i>anastrozole</i></b> than with <b style='color:Tomato;'><i>tamoxifen</i></b>. ### conclusions In postmenopausal women with hormonally sensitive ABC, <b style='color:Tomato;'><i>anastrozole</i></b> should be considered as the new standard first-line treatment.","tokens":[{"text":"At","start":0,"end":2,"id":0,"ws":true},{"text":"a","start":3,"end":4,"id":1,"ws":true},{"text":"median","start":5,"end":11,"id":2,"ws":true},{"text":"duration","start":12,"end":20,"id":3,"ws":true},{"text":"of","start":21,"end":23,"id":4,"ws":true},{"text":"follow-up","start":24,"end":33,"id":5,"ws":true},{"text":"of","start":34,"end":36,"id":6,"ws":true},{"text":"18.2","start":37,"end":41,"id":7,"ws":true},{"text":"months","start":42,"end":48,"id":8,"ws":true},{"text":",","start":49,"end":50,"id":9,"ws":true},{"text":"anastrozole","start":51,"end":62,"id":10,"ws":true},{"text":"was","start":63,"end":66,"id":11,"ws":true},{"text":"at","start":67,"end":69,"id":12,"ws":true},{"text":"least","start":70,"end":75,"id":13,"ws":true},{"text":"equivalent","start":76,"end":86,"id":14,"ws":true},{"text":"to","start":87,"end":89,"id":15,"ws":true},{"text":"tamoxifen","start":90,"end":99,"id":16,"ws":true},{"text":"in","start":100,"end":102,"id":17,"ws":true},{"text":"terms","start":103,"end":108,"id":18,"ws":true},{"text":"of","start":109,"end":111,"id":19,"ws":true},{"text":"median","start":112,"end":118,"id":20,"ws":true},{"text":"TTP","start":119,"end":122,"id":21,"ws":true},{"text":"(","start":123,"end":124,"id":22,"ws":true},{"text":"8.5","start":125,"end":128,"id":23,"ws":true},{"text":"and","start":129,"end":132,"id":24,"ws":true},{"text":"7.0","start":133,"end":136,"id":25,"ws":true},{"text":"months","start":137,"end":143,"id":26,"ws":true},{"text":",","start":144,"end":145,"id":27,"ws":true},{"text":"respectively","start":146,"end":158,"id":28,"ws":true},{"text":";","start":159,"end":160,"id":29,"ws":true},{"text":"estimated","start":161,"end":170,"id":30,"ws":true},{"text":"hazard","start":171,"end":177,"id":31,"ws":true},{"text":"ratio","start":178,"end":183,"id":32,"ws":true},{"text":"[","start":184,"end":185,"id":33,"ws":true},{"text":"tamoxifen","start":186,"end":195,"id":34,"ws":true},{"text":"relative","start":196,"end":204,"id":35,"ws":true},{"text":"to","start":205,"end":207,"id":36,"ws":true},{"text":"anastrozole","start":208,"end":219,"id":37,"ws":true},{"text":"]","start":220,"end":221,"id":38,"ws":true},{"text":",","start":222,"end":223,"id":39,"ws":true},{"text":"1.13","start":224,"end":228,"id":40,"ws":true},{"text":"[","start":229,"end":230,"id":41,"ws":true},{"text":"lower","start":231,"end":236,"id":42,"ws":true},{"text":"95","start":237,"end":239,"id":43,"ws":true},{"text":"%","start":240,"end":241,"id":44,"ws":true},{"text":"confidence","start":242,"end":252,"id":45,"ws":true},{"text":"level","start":253,"end":258,"id":46,"ws":true},{"text":",","start":259,"end":260,"id":47,"ws":true},{"text":"1.00","start":261,"end":265,"id":48,"ws":true},{"text":"]","start":266,"end":267,"id":49,"ws":true},{"text":")","start":268,"end":269,"id":50,"ws":true},{"text":".","start":270,"end":271,"id":51,"ws":false}],"spans":[{"start":51,"end":62,"token_start":10,"token_end":10,"label":"DRUG"},{"start":90,"end":99,"token_start":16,"token_end":16,"label":"DRUG"},{"start":186,"end":195,"token_start":34,"token_end":34,"label":"DRUG"},{"start":208,"end":219,"token_start":37,"token_end":37,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11745278/","_input_hash":-1128889706,"_task_hash":1445104170,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"A favourable response to chemotherapy can be expected in up to 60 % of patients receiving a combination of streptozocin plus doxorubicin , and in up to 40 % of patients receiving dacarbazine .","paragraph":"<h3><u>Endocrine tumours of the gastrointestinal tract: Chemotherapy.</u></h3>Malignant neuroendocrine tumours are less sensitive to chemotherapy than other epithelial malignancies. If chemotherapy is considered, tumours of pancreatic origin have a higher sensitivity than tumours from the gastrointestinal tract ('carcinoids'). Chemotherapy with streptozocin combinations and with <b style='color:Tomato;'><i>dacarbazine</i></b> should be considered in patients with progressive malignant neuroendocrine tumours of the pancreas. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>favourable</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>expected</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>up</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>streptozocin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>up</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A survival benefit has been shown for streptozocin combinations. Treatment regimens are effective in functioning and non-functioning tumours. The response to treatment cannot be predicted. Poorly differentiated neuroendocrine tumours, independent of their origin, respond to a combination of <b style='color:Tomato;'><i>etoposide</i></b> plus cisplatin. Chemotherapy is, however, almost ineffective in patients with well-differentiated neuroendocrine tumours originating in the gastrointestinal tract ('carcinoids').","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"favourable","start":2,"end":12,"id":1,"ws":true},{"text":"response","start":13,"end":21,"id":2,"ws":true},{"text":"to","start":22,"end":24,"id":3,"ws":true},{"text":"chemotherapy","start":25,"end":37,"id":4,"ws":true},{"text":"can","start":38,"end":41,"id":5,"ws":true},{"text":"be","start":42,"end":44,"id":6,"ws":true},{"text":"expected","start":45,"end":53,"id":7,"ws":true},{"text":"in","start":54,"end":56,"id":8,"ws":true},{"text":"up","start":57,"end":59,"id":9,"ws":true},{"text":"to","start":60,"end":62,"id":10,"ws":true},{"text":"60","start":63,"end":65,"id":11,"ws":true},{"text":"%","start":66,"end":67,"id":12,"ws":true},{"text":"of","start":68,"end":70,"id":13,"ws":true},{"text":"patients","start":71,"end":79,"id":14,"ws":true},{"text":"receiving","start":80,"end":89,"id":15,"ws":true},{"text":"a","start":90,"end":91,"id":16,"ws":true},{"text":"combination","start":92,"end":103,"id":17,"ws":true},{"text":"of","start":104,"end":106,"id":18,"ws":true},{"text":"streptozocin","start":107,"end":119,"id":19,"ws":true},{"text":"plus","start":120,"end":124,"id":20,"ws":true},{"text":"doxorubicin","start":125,"end":136,"id":21,"ws":true},{"text":",","start":137,"end":138,"id":22,"ws":true},{"text":"and","start":139,"end":142,"id":23,"ws":true},{"text":"in","start":143,"end":145,"id":24,"ws":true},{"text":"up","start":146,"end":148,"id":25,"ws":true},{"text":"to","start":149,"end":151,"id":26,"ws":true},{"text":"40","start":152,"end":154,"id":27,"ws":true},{"text":"%","start":155,"end":156,"id":28,"ws":true},{"text":"of","start":157,"end":159,"id":29,"ws":true},{"text":"patients","start":160,"end":168,"id":30,"ws":true},{"text":"receiving","start":169,"end":178,"id":31,"ws":true},{"text":"dacarbazine","start":179,"end":190,"id":32,"ws":true},{"text":".","start":191,"end":192,"id":33,"ws":false}],"spans":[{"start":107,"end":119,"token_start":19,"token_end":19,"label":"DRUG"},{"start":125,"end":136,"token_start":21,"token_end":21,"label":"DRUG"},{"start":179,"end":190,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16183533/","_input_hash":1371239062,"_task_hash":-1382925913,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":19,"child":21,"head_span":{"start":107,"end":119,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":125,"end":136,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"A substantial literature now strongly supports the specific involvement of serotonin 5-HT(1B ) and 5-HT(2C ) receptor subtypes in satiety and in the anorectic effect of agents such as fenfluramine and fluoxetine .","paragraph":"<h3><u>Behavioural satiety sequence (BSS): separating wheat from chaff in the behavioural pharmacology of appetite.</u></h3>The history of anti-obesity drug development is far from glorious, with transient magic bullets and only a handful of agents currently licensed for clinical use. In view of recent progress in our understanding of the multiplicity of signalling pathways involved in appetite regulation, and the resultant deluge of reports on the anorectic efficacy of novel therapies, it seems timely to stress the need to differentiate treatments that suppress intake by primary means from those that only indirectly achieve this endpoint. The current article reviews the conceptual history of the behavioural satiety sequence (BSS), also known as the behavioural sequence of satiety, post-ingestive satiety, and the postprandial satiety sequence. Early research confirmed that natural satiation, produced by a caloric load on the gut, is associated with a predictable transition from feeding through grooming to resting. Although many less naturalistic manipulations are also capable of reducing food intake, very few do so without disrupting the normal structure of this feeding cycle. Thus, while CCK and d-<b style='color:Tomato;'><i>fenfluramine</i></b> reduce intake by accelerating but otherwise maintaining the integrity of the BSS, other anorectic interventions disrupt the BSS through response competition (e.g. d-amphetamine), nausea/discomfort (e.g. lithium chloride) and/or interference with taste-mediated positive feedback (e.g. <b style='color:Tomato;'><i>quinine</i></b> adulteration of the diet). <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>substantial</i></b> <b style='color:DodgerBlue;'><i>literature</i></b> <b style='color:DodgerBlue;'><i>now</i></b> <b style='color:DodgerBlue;'><i>strongly</i></b> <b style='color:DodgerBlue;'><i>supports</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>specific</i></b> <b style='color:DodgerBlue;'><i>involvement</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>serotonin</i></b> <b style='color:DodgerBlue;'><i>5-HT(1B</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5-HT(2C</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>subtypes</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>satiety</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anorectic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>fenfluramine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluoxetine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Recent BSS analyses have also identified rather selective anorectic profiles for the dual noradrenaline and 5-HT reuptake inhibitor <b style='color:Tomato;'><i>sibutramine</i></b>, the orexin-1 receptor antagonist SB-334867, and the broad spectrum opioid receptor antagonist <b style='color:Tomato;'><i>naloxone</i></b>. However, similar analyses have offered little/no support for the anorectic potential of the gut peptide PYY(3-36) while the acute anorectic efficacy of cannabinoid CB1 receptor antagonist/inverse agonists appears largely to be secondary to response competition. In contrast, studies with low-dose combinations of <b style='color:Tomato;'><i>naloxone</i></b> and CB1 receptor antagonist/inverse agonists have very recently confirmed the potential of drug polytherapies not only in appetite suppression but also in attenuating/eliminating unwanted side-effects. In sum, as BSS analysis offers a reliable means of differentiating the wheat (primary anorectics) from the chaff (secondary anorectics), it should form an integral part of early phase testing in any anti-obesity drug screening programme.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"substantial","start":2,"end":13,"id":1,"ws":true},{"text":"literature","start":14,"end":24,"id":2,"ws":true},{"text":"now","start":25,"end":28,"id":3,"ws":true},{"text":"strongly","start":29,"end":37,"id":4,"ws":true},{"text":"supports","start":38,"end":46,"id":5,"ws":true},{"text":"the","start":47,"end":50,"id":6,"ws":true},{"text":"specific","start":51,"end":59,"id":7,"ws":true},{"text":"involvement","start":60,"end":71,"id":8,"ws":true},{"text":"of","start":72,"end":74,"id":9,"ws":true},{"text":"serotonin","start":75,"end":84,"id":10,"ws":true},{"text":"5-HT(1B","start":85,"end":92,"id":11,"ws":true},{"text":")","start":93,"end":94,"id":12,"ws":true},{"text":"and","start":95,"end":98,"id":13,"ws":true},{"text":"5-HT(2C","start":99,"end":106,"id":14,"ws":true},{"text":")","start":107,"end":108,"id":15,"ws":true},{"text":"receptor","start":109,"end":117,"id":16,"ws":true},{"text":"subtypes","start":118,"end":126,"id":17,"ws":true},{"text":"in","start":127,"end":129,"id":18,"ws":true},{"text":"satiety","start":130,"end":137,"id":19,"ws":true},{"text":"and","start":138,"end":141,"id":20,"ws":true},{"text":"in","start":142,"end":144,"id":21,"ws":true},{"text":"the","start":145,"end":148,"id":22,"ws":true},{"text":"anorectic","start":149,"end":158,"id":23,"ws":true},{"text":"effect","start":159,"end":165,"id":24,"ws":true},{"text":"of","start":166,"end":168,"id":25,"ws":true},{"text":"agents","start":169,"end":175,"id":26,"ws":true},{"text":"such","start":176,"end":180,"id":27,"ws":true},{"text":"as","start":181,"end":183,"id":28,"ws":true},{"text":"fenfluramine","start":184,"end":196,"id":29,"ws":true},{"text":"and","start":197,"end":200,"id":30,"ws":true},{"text":"fluoxetine","start":201,"end":211,"id":31,"ws":true},{"text":".","start":212,"end":213,"id":32,"ws":false}],"spans":[{"start":184,"end":196,"token_start":29,"token_end":29,"label":"DRUG"},{"start":201,"end":211,"token_start":31,"token_end":31,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20214921/","_input_hash":-673520798,"_task_hash":327018884,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Pilocarpine also induced secretion at a concentration as low as 1 \u03bcM and was the most powerful secretagogue at 10 \u03bcM. Secretion was induced by carbachol at 0.1 \u03bcM , with maximum secretion at 1.0 \u03bcM.","paragraph":"<h3><u>Cevimeline-induced monophasic salivation from the mouse submandibular gland: decreased Na+ content in saliva results from specific and early activation of Na+/H+ exchange.</u></h3><b style='color:Tomato;'><i>cevimeline</i></b> and <b style='color:Tomato;'><i>pilocarpine</i></b> are muscarinic agonists used clinically to treat dry mouth. In this study, we explored fluid secretion from mouse submandibular glands to determine the mechanism of <b style='color:Tomato;'><i>cevimeline</i></b>, <b style='color:Tomato;'><i>pilocarpine</i></b>, and an experimentally used agent <b style='color:Tomato;'><i>carbachol</i></b>. <b style='color:Tomato;'><i>cevimeline</i></b> evoked almost the same amount of secretion at concentrations from 30 \u03bcM to 1 mM. <b style='color:MediumOrchid;'><i>Pilocarpine</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>secretion</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>concentration</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>low</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>\u03bcM</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>powerful</i></b> <b style='color:DodgerBlue;'><i>secretagogue</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>\u03bcM.</i></b> <b style='color:DodgerBlue;'><i>Secretion</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>carbachol</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>0.1</i></b> <b style='color:DodgerBlue;'><i>\u03bcM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>maximum</i></b> <b style='color:DodgerBlue;'><i>secretion</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>1.0</i></b> <b style='color:DodgerBlue;'><i>\u03bcM.</i></b> <b style='color:Tomato;'><i>cevimeline</i></b> induced monophasic secretion at all concentrations tested, whereas higher concentrations of <b style='color:Tomato;'><i>pilocarpine</i></b> and <b style='color:Tomato;'><i>carbachol</i></b> induced secretion with variable kinetics, i.e., an initial transient high flow rate, followed by decreased secretion after 2 to 3 min. In the presence of an epithelial Na(+) channel blocker, <b style='color:Tomato;'><i>amiloride</i></b>, neither <b style='color:Tomato;'><i>carbachol</i></b> nor <b style='color:Tomato;'><i>pilocarpine</i></b> affected the Na(+) level of secreted saliva; however, it significantly increased the Na(+) content of <b style='color:Tomato;'><i>cevimeline</i></b>-induced saliva. The intracellular Ca(2+) response of acinar cells was almost identical among all three agents, although recovery after drug removal was slower for <b style='color:Tomato;'><i>cevimeline</i></b> and <b style='color:Tomato;'><i>pilocarpine</i></b>. A profound decrease in intracellular pH was observed during <b style='color:Tomato;'><i>pilocarpine</i></b> and <b style='color:Tomato;'><i>carbachol</i></b> treatment, whereas intracellular acidification induced by <b style='color:Tomato;'><i>cevimeline</i></b> was only seen in the presence of a Na(+)/H(+) exchange inhibitor. When external HCO(3)(-) was removed, <b style='color:Tomato;'><i>cevimeline</i></b>-induced saliva significantly decreased. These findings suggest that <b style='color:Tomato;'><i>cevimeline</i></b> specifically activates Na(+)/H(+) exchange and may promote Na(+) reabsorption by stabilizing epithelial sodium channel activity.","tokens":[{"text":"Pilocarpine","start":0,"end":11,"id":0,"ws":true},{"text":"also","start":12,"end":16,"id":1,"ws":true},{"text":"induced","start":17,"end":24,"id":2,"ws":true},{"text":"secretion","start":25,"end":34,"id":3,"ws":true},{"text":"at","start":35,"end":37,"id":4,"ws":true},{"text":"a","start":38,"end":39,"id":5,"ws":true},{"text":"concentration","start":40,"end":53,"id":6,"ws":true},{"text":"as","start":54,"end":56,"id":7,"ws":true},{"text":"low","start":57,"end":60,"id":8,"ws":true},{"text":"as","start":61,"end":63,"id":9,"ws":true},{"text":"1","start":64,"end":65,"id":10,"ws":true},{"text":"\u03bcM","start":66,"end":68,"id":11,"ws":true},{"text":"and","start":69,"end":72,"id":12,"ws":true},{"text":"was","start":73,"end":76,"id":13,"ws":true},{"text":"the","start":77,"end":80,"id":14,"ws":true},{"text":"most","start":81,"end":85,"id":15,"ws":true},{"text":"powerful","start":86,"end":94,"id":16,"ws":true},{"text":"secretagogue","start":95,"end":107,"id":17,"ws":true},{"text":"at","start":108,"end":110,"id":18,"ws":true},{"text":"10","start":111,"end":113,"id":19,"ws":true},{"text":"\u03bcM.","start":114,"end":117,"id":20,"ws":true},{"text":"Secretion","start":118,"end":127,"id":21,"ws":true},{"text":"was","start":128,"end":131,"id":22,"ws":true},{"text":"induced","start":132,"end":139,"id":23,"ws":true},{"text":"by","start":140,"end":142,"id":24,"ws":true},{"text":"carbachol","start":143,"end":152,"id":25,"ws":true},{"text":"at","start":153,"end":155,"id":26,"ws":true},{"text":"0.1","start":156,"end":159,"id":27,"ws":true},{"text":"\u03bcM","start":160,"end":162,"id":28,"ws":true},{"text":",","start":163,"end":164,"id":29,"ws":true},{"text":"with","start":165,"end":169,"id":30,"ws":true},{"text":"maximum","start":170,"end":177,"id":31,"ws":true},{"text":"secretion","start":178,"end":187,"id":32,"ws":true},{"text":"at","start":188,"end":190,"id":33,"ws":true},{"text":"1.0","start":191,"end":194,"id":34,"ws":true},{"text":"\u03bcM.","start":195,"end":198,"id":35,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":143,"end":152,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21239510/","_input_hash":-1256315084,"_task_hash":-2010058269,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"This phase II study was conducted to establish whether induction chemotherapy with carboplatin ( CBDCA ) and paclitaxel ( PTX ) plus bevacizumab prior to surgery reduces the risk of progression .","paragraph":"<h3><u>Phase II trial of induction chemotherapy with carboplatin and paclitaxel plus bevacizumab in patients with stage IIIA to IV nonsquamous non-small cell lung cancer.</u></h3>Surgery remains the best curative treatment option for non-small cell lung cancer (NSCLC), but is of benefit only to patients with localized disease. A meta-analysis showed a significant beneficial effect of induction chemotherapy on survival, but there is still no clear evidence. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>establish</i></b> <b style='color:DodgerBlue;'><i>whether</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CBDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>reduces</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods The subjects of this study were 29 patients with treatment-naive nonsquamous NSCLC (clinical stages IIIA to IV). Patients received PTX (200\u00a0mg/m ### results The overall response rate was 72.4%. Of the 29 patients, ten underwent surgery after the induction chemotherapy and complete resection was achieved in 7 (70%). The median progression-free-survival (PFS) time and the 3-year PFS rate were 0.92\u00a0years and 16.2%, respectively. The median overall survival (OS) time and the 3-year OS rate were 1.96\u00a0years and 44.9%, respectively. ### conclusion Combined modality therapy with surgery after induction chemotherapy with CBDCA and PTX plus <b style='color:Tomato;'><i>bevacizumab</i></b> is clinically feasible and tolerable for patients with unknown or negative molecular profiles.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"phase","start":5,"end":10,"id":1,"ws":true},{"text":"II","start":11,"end":13,"id":2,"ws":true},{"text":"study","start":14,"end":19,"id":3,"ws":true},{"text":"was","start":20,"end":23,"id":4,"ws":true},{"text":"conducted","start":24,"end":33,"id":5,"ws":true},{"text":"to","start":34,"end":36,"id":6,"ws":true},{"text":"establish","start":37,"end":46,"id":7,"ws":true},{"text":"whether","start":47,"end":54,"id":8,"ws":true},{"text":"induction","start":55,"end":64,"id":9,"ws":true},{"text":"chemotherapy","start":65,"end":77,"id":10,"ws":true},{"text":"with","start":78,"end":82,"id":11,"ws":true},{"text":"carboplatin","start":83,"end":94,"id":12,"ws":true},{"text":"(","start":95,"end":96,"id":13,"ws":true},{"text":"CBDCA","start":97,"end":102,"id":14,"ws":true},{"text":")","start":103,"end":104,"id":15,"ws":true},{"text":"and","start":105,"end":108,"id":16,"ws":true},{"text":"paclitaxel","start":109,"end":119,"id":17,"ws":true},{"text":"(","start":120,"end":121,"id":18,"ws":true},{"text":"PTX","start":122,"end":125,"id":19,"ws":true},{"text":")","start":126,"end":127,"id":20,"ws":true},{"text":"plus","start":128,"end":132,"id":21,"ws":true},{"text":"bevacizumab","start":133,"end":144,"id":22,"ws":true},{"text":"prior","start":145,"end":150,"id":23,"ws":true},{"text":"to","start":151,"end":153,"id":24,"ws":true},{"text":"surgery","start":154,"end":161,"id":25,"ws":true},{"text":"reduces","start":162,"end":169,"id":26,"ws":true},{"text":"the","start":170,"end":173,"id":27,"ws":true},{"text":"risk","start":174,"end":178,"id":28,"ws":true},{"text":"of","start":179,"end":181,"id":29,"ws":true},{"text":"progression","start":182,"end":193,"id":30,"ws":true},{"text":".","start":194,"end":195,"id":31,"ws":false}],"spans":[{"start":83,"end":94,"token_start":12,"token_end":12,"label":"DRUG"},{"start":109,"end":119,"token_start":17,"token_end":17,"label":"DRUG"},{"start":133,"end":144,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30826861/","_input_hash":404223389,"_task_hash":154443100,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":22,"child":17,"head_span":{"start":133,"end":144,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":109,"end":119,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":17,"child":12,"head_span":{"start":109,"end":119,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":83,"end":94,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In women of childbearing potential , valproate should be considered if levetiracetam and lamotrigine have failed to control seizures at this stage .","paragraph":"<h3><u>Treatment options in juvenile myoclonic epilepsy.</u></h3>Juvenile myoclonic epilepsy (JME) is characterized by excellent response to treatment, if diagnosed correctly. Lifestyle advice is an integral part of the treatment of JME; it should include recommendations on avoidance of common triggers such as sleep deprivation and alcohol excess and emphasis on the importance of compliance with medication. The drug of first choice in the treatment of JME is sodium valproate, which has a response rate of up to 80%. Valproate should be avoided in women of childbearing age because of significantly increased risks of fetal malformations and neurodevelopmental delay. <b style='color:Tomato;'><i>levetiracetam</i></b> or <b style='color:Tomato;'><i>lamotrigine</i></b> are alternative first-line options if valproate is contraindicated. With limited data from trials to support either of these drugs, the choice should take into account comorbidity factors and patient priorities. Because of its low side effect profile, excellent tolerability, and lack of interactions with other drugs, <b style='color:Tomato;'><i>levetiracetam</i></b> is our preferred alternative first-line agent. <b style='color:Tomato;'><i>lamotrigine</i></b> is another first-line option but may exacerbate myoclonus. The failure of valproate or failure of two first-line antiepileptic drugs suggests that combination therapy is indicated. Drug interactions and the patient's gender, age, and comorbidities need to be considered. <b style='color:Tomato;'><i>levetiracetam</i></b>, <b style='color:Tomato;'><i>lamotrigine</i></b>, and valproate are suitable adjuncts, with a synergistic effect reported from the combination of valproate and <b style='color:Tomato;'><i>lamotrigine</i></b>. <b style='color:Tomato;'><i>clonazepam</i></b> is a useful adjunct for myoclonus and can be used in combination with <b style='color:Tomato;'><i>lamotrigine</i></b> to avoid <b style='color:Tomato;'><i>lamotrigine</i></b>'s myoclonic effects. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>childbearing</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>valproate</i></b> <b style='color:DodgerBlue;'><i>should</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>if</i></b> <b style='color:MediumOrchid;'><i>levetiracetam</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>lamotrigine</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>failed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>seizures</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>topiramate</i></b> is a cost-effective alternative monotherapy, but because of its poor tolerability, we recommend it as add-on treatment only. <b style='color:Tomato;'><i>zonisamide</i></b> should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data. Phenobarbital is the most cost-effective drug and can be used to control the seizures of JME when antiepileptic drugs are limited or too costly. <b style='color:Tomato;'><i>carbamazepine</i></b>, <b style='color:Tomato;'><i>oxcarbazepine</i></b>, and <b style='color:Tomato;'><i>phenytoin</i></b> can exacerbate absences and myoclonus and are therefore contraindicated, although they can improve control of tonic-clonic seizures when these are refractory to other medication. <b style='color:Tomato;'><i>gabapentin</i></b>, pregabalin, <b style='color:Tomato;'><i>tiagabine</i></b>, and <b style='color:Tomato;'><i>vigabatrin</i></b> are contraindicated and can worsen seizures. (<b style='color:Tomato;'><i>tiagabine</i></b> and <b style='color:Tomato;'><i>vigabatrin</i></b> have been reported to induce absence status epilepticus.) Surgical alternatives in refractory cases are rarely contemplated but may include vagus nerve stimulation and callosotomy. Deep brain stimulation is an experimental technique that may prove useful in managing refractory cases of JME.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"women","start":3,"end":8,"id":1,"ws":true},{"text":"of","start":9,"end":11,"id":2,"ws":true},{"text":"childbearing","start":12,"end":24,"id":3,"ws":true},{"text":"potential","start":25,"end":34,"id":4,"ws":true},{"text":",","start":35,"end":36,"id":5,"ws":true},{"text":"valproate","start":37,"end":46,"id":6,"ws":true},{"text":"should","start":47,"end":53,"id":7,"ws":true},{"text":"be","start":54,"end":56,"id":8,"ws":true},{"text":"considered","start":57,"end":67,"id":9,"ws":true},{"text":"if","start":68,"end":70,"id":10,"ws":true},{"text":"levetiracetam","start":71,"end":84,"id":11,"ws":true},{"text":"and","start":85,"end":88,"id":12,"ws":true},{"text":"lamotrigine","start":89,"end":100,"id":13,"ws":true},{"text":"have","start":101,"end":105,"id":14,"ws":true},{"text":"failed","start":106,"end":112,"id":15,"ws":true},{"text":"to","start":113,"end":115,"id":16,"ws":true},{"text":"control","start":116,"end":123,"id":17,"ws":true},{"text":"seizures","start":124,"end":132,"id":18,"ws":true},{"text":"at","start":133,"end":135,"id":19,"ws":true},{"text":"this","start":136,"end":140,"id":20,"ws":true},{"text":"stage","start":141,"end":146,"id":21,"ws":true},{"text":".","start":147,"end":148,"id":22,"ws":false}],"spans":[{"start":37,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},{"start":71,"end":84,"token_start":11,"token_end":11,"label":"DRUG"},{"start":89,"end":100,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21494841/","_input_hash":1193201561,"_task_hash":444415473,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Patients with clinically localized , intermediate- or high-grade non-Hodgkin 's lymphoma usually receive initial treatment with a doxorubicin-containing regimen such as cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) .","paragraph":"<h3><u>Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.</u></h3> <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>clinically</i></b> <b style='color:DodgerBlue;'><i>localized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intermediate-</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>high-grade</i></b> <b style='color:DodgerBlue;'><i>non-Hodgkin</i></b> <b style='color:DodgerBlue;'><i>'s</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>usually</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>doxorubicin-containing</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CHOP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pilot studies suggest that eight cycles of CHOP alone or three cycles of CHOP followed by involved-field radiotherapy are effective in such patients. ### methods We compared these two approaches in a prospective, randomized, multi-institutional study. The end points were progression-free survival, overall survival, and life-threatening or fatal toxic effects. Two hundred eligible patients were randomly assigned to receive CHOP plus radiotherapy, and 201 received CHOP alone. ### results Patients treated with three cycles of CHOP plus radiotherapy had significantly better progression-free survival (P=0.03) and overall survival (P=0.02) than patients treated with CHOP alone. The five-year estimates of progression-free survival for patients receiving CHOP plus radiotherapy and for patients receiving CHOP alone were 77 percent and 64 percent, respectively. The five-year estimates of overall survival for patients receiving CHOP plus radiotherapy and for patients receiving CHOP alone were 82 percent and 72 percent, respectively. The adverse effects included one death in each treatment group. Life-threatening toxic effects of any type were seen in 61 of 200 patients treated with CHOP plus radiotherapy and in 80 of 201 patients treated with CHOP alone (P=0.06). The left ventricular function was decreased in seven patients who received CHOP alone, whereas no cardiac events were recorded in the group receiving CHOP plus radiotherapy (P=0.02). ### conclusions Three cycles of CHOP followed by involved-field radiotherapy are superior to eight cycles of CHOP alone for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"with","start":9,"end":13,"id":1,"ws":true},{"text":"clinically","start":14,"end":24,"id":2,"ws":true},{"text":"localized","start":25,"end":34,"id":3,"ws":true},{"text":",","start":35,"end":36,"id":4,"ws":true},{"text":"intermediate-","start":37,"end":50,"id":5,"ws":true},{"text":"or","start":51,"end":53,"id":6,"ws":true},{"text":"high-grade","start":54,"end":64,"id":7,"ws":true},{"text":"non-Hodgkin","start":65,"end":76,"id":8,"ws":true},{"text":"'s","start":77,"end":79,"id":9,"ws":true},{"text":"lymphoma","start":80,"end":88,"id":10,"ws":true},{"text":"usually","start":89,"end":96,"id":11,"ws":true},{"text":"receive","start":97,"end":104,"id":12,"ws":true},{"text":"initial","start":105,"end":112,"id":13,"ws":true},{"text":"treatment","start":113,"end":122,"id":14,"ws":true},{"text":"with","start":123,"end":127,"id":15,"ws":true},{"text":"a","start":128,"end":129,"id":16,"ws":true},{"text":"doxorubicin-containing","start":130,"end":152,"id":17,"ws":true},{"text":"regimen","start":153,"end":160,"id":18,"ws":true},{"text":"such","start":161,"end":165,"id":19,"ws":true},{"text":"as","start":166,"end":168,"id":20,"ws":true},{"text":"cyclophosphamide","start":169,"end":185,"id":21,"ws":true},{"text":",","start":186,"end":187,"id":22,"ws":true},{"text":"doxorubicin","start":188,"end":199,"id":23,"ws":true},{"text":",","start":200,"end":201,"id":24,"ws":true},{"text":"vincristine","start":202,"end":213,"id":25,"ws":true},{"text":",","start":214,"end":215,"id":26,"ws":true},{"text":"and","start":216,"end":219,"id":27,"ws":true},{"text":"prednisone","start":220,"end":230,"id":28,"ws":true},{"text":"(","start":231,"end":232,"id":29,"ws":true},{"text":"CHOP","start":233,"end":237,"id":30,"ws":true},{"text":")","start":238,"end":239,"id":31,"ws":true},{"text":".","start":240,"end":241,"id":32,"ws":false}],"spans":[{"start":169,"end":185,"token_start":21,"token_end":21,"label":"DRUG"},{"start":188,"end":199,"token_start":23,"token_end":23,"label":"DRUG"},{"start":202,"end":213,"token_start":25,"token_end":25,"label":"DRUG"},{"start":220,"end":230,"token_start":28,"token_end":28,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9647875/","_input_hash":-52267910,"_task_hash":882936576,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":21,"child":23,"head_span":{"start":169,"end":185,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":188,"end":199,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":25,"child":23,"head_span":{"start":202,"end":213,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":188,"end":199,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":28,"child":25,"head_span":{"start":220,"end":230,"token_start":28,"token_end":28,"label":"DRUG"},"child_span":{"start":202,"end":213,"token_start":25,"token_end":25,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"To evaluate the effects of a fixed combination of olmesartan/amlodipine compared with olmesartan or amlodipine alone on some parameters of endothelial damage in diabetic , hypertensive patients .","paragraph":"<h3><u>Olmesartan Combined With Amlodipine on Oxidative Stress Parameters in Type 2 Diabetics, Compared With Single Therapies: A Randomized, Controlled, Clinical Trial.</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fixed</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>olmesartan/amlodipine</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>olmesartan</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>amlodipine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>some</i></b> <b style='color:DodgerBlue;'><i>parameters</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>endothelial</i></b> <b style='color:DodgerBlue;'><i>damage</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>diabetic</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>hypertensive</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b>We enrolled 221 patients; 74 were randomized to <b style='color:Tomato;'><i>olmesartan</i></b> 20\u200amg, 72 to <b style='color:Tomato;'><i>amlodipine</i></b> 10\u200amg, and 75 to <b style='color:Tomato;'><i>olmesartan</i></b>/<b style='color:Tomato;'><i>amlodipine</i></b> fixed combination 20/5\u200amg for 12 months. We assessed blood pressure monthly; in addition, we also assessed at baseline, and after 6 and 12 months, the following parameters: lipoprotein (a), myeloperoxidase (MPO), isoprostanes, and paraoxonase-1 (PON-1). Blood pressure values obtained with fixed <b style='color:Tomato;'><i>olmesartan</i></b>/<b style='color:Tomato;'><i>amlodipine</i></b> combination were significantly lower than those reached with single monotherapies. There was a reduction of lipoprotein (a), and isoprostanes levels with <b style='color:Tomato;'><i>olmesartan</i></b>/<b style='color:Tomato;'><i>amlodipine</i></b> fixed combination, both compared with baseline, and with single monotherapies. On the other hand, there was an increase of PON-1 with fixed <b style='color:Tomato;'><i>olmesartan</i></b>/<b style='color:Tomato;'><i>amlodipine</i></b> combination, both compared with baseline, and with single drugs. All treatments reduced MPO compared with baseline; however, in group-to-group comparison, MPO reduction was greater with <b style='color:Tomato;'><i>olmesartan</i></b>/<b style='color:Tomato;'><i>amlodipine</i></b> fixed combination. Fixed combination of <b style='color:Tomato;'><i>olmesartan</i></b>/<b style='color:Tomato;'><i>amlodipine</i></b> was more effective than single monotherapies in reducing oxidative stress, especially in increasing PON-1, and reducing isoprostanes levels in diabetic and hypertensive patients.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"evaluate","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"effects","start":16,"end":23,"id":3,"ws":true},{"text":"of","start":24,"end":26,"id":4,"ws":true},{"text":"a","start":27,"end":28,"id":5,"ws":true},{"text":"fixed","start":29,"end":34,"id":6,"ws":true},{"text":"combination","start":35,"end":46,"id":7,"ws":true},{"text":"of","start":47,"end":49,"id":8,"ws":true},{"text":"olmesartan/amlodipine","start":50,"end":71,"id":9,"ws":true},{"text":"compared","start":72,"end":80,"id":10,"ws":true},{"text":"with","start":81,"end":85,"id":11,"ws":true},{"text":"olmesartan","start":86,"end":96,"id":12,"ws":true},{"text":"or","start":97,"end":99,"id":13,"ws":true},{"text":"amlodipine","start":100,"end":110,"id":14,"ws":true},{"text":"alone","start":111,"end":116,"id":15,"ws":true},{"text":"on","start":117,"end":119,"id":16,"ws":true},{"text":"some","start":120,"end":124,"id":17,"ws":true},{"text":"parameters","start":125,"end":135,"id":18,"ws":true},{"text":"of","start":136,"end":138,"id":19,"ws":true},{"text":"endothelial","start":139,"end":150,"id":20,"ws":true},{"text":"damage","start":151,"end":157,"id":21,"ws":true},{"text":"in","start":158,"end":160,"id":22,"ws":true},{"text":"diabetic","start":161,"end":169,"id":23,"ws":true},{"text":",","start":170,"end":171,"id":24,"ws":true},{"text":"hypertensive","start":172,"end":184,"id":25,"ws":true},{"text":"patients","start":185,"end":193,"id":26,"ws":true},{"text":".","start":194,"end":195,"id":27,"ws":false}],"spans":[{"start":86,"end":96,"token_start":12,"token_end":12,"label":"DRUG"},{"start":100,"end":110,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27043671/","_input_hash":-178468396,"_task_hash":413651677,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":86,"end":96,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":100,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Numerous phase II and III clinical trials have demonstrated a higher activity of combined gemcitabine plus docetaxel schedules against non-small cell lung cancer ( NSCLC ) than that of both agents in monotherapy .","paragraph":"<h3><u>Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.</u></h3> <b style='color:DodgerBlue;'><i>Numerous</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>schedules</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>non-small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase II study evaluated a 3-week based schedule of <b style='color:Tomato;'><i>docetaxel</i></b> 85 mg/m(2) (1-h i.v. infusion, d8) combined with <b style='color:Tomato;'><i>gemcitabine</i></b> 1,000 mg/m(2) (30-min i.v. infusion; d1,8) as first-line chemotherapy for patients with advanced NSCLC. ### results Forty-one patients with non-resectable, stage IIIB/IV, and bidimensionally measurable disease were enrolled. A total of 182 chemotherapy cycles (median 6, range 1-6) was administered to 40 patients during the study; one patient did not receive chemotherapy due to a protocol deviation. Two patients were not evaluable for treatment efficacy. The overall response rate found was 44% (95% CI, 29-59%): three patients (7%) had a complete response and 15 patients (37%) had a partial response (median duration of response = 4.0 months). With a median follow-up of 8.7 months, the median time to disease progression was 4.4 months and the median overall survival was 7.3 months. The combined <b style='color:Tomato;'><i>gemcitabine</i></b> plus <b style='color:Tomato;'><i>docetaxel</i></b> chemotherapy was well tolerated except for pulmonary toxicity. The main grade 3-4 hematological toxicity was neutropenia (28% of patients, 9% of cycles). Two cases of febrile neutropenia were reported. The main grade 3-4 non-hematological toxicity was pulmonary toxicity (23% of patients, 6% of cycles). ### conclusion <b style='color:Tomato;'><i>gemcitabine</i></b> 1,000 mg/m(2) on days 1 and 8 in combination with <b style='color:Tomato;'><i>docetaxel</i></b> 85 mg/m(2) on day 8 given in 3-week cycles is an active and well-tolerated first-line chemotherapeutic regimen for advanced NSCLC.","tokens":[{"text":"Numerous","start":0,"end":8,"id":0,"ws":true},{"text":"phase","start":9,"end":14,"id":1,"ws":true},{"text":"II","start":15,"end":17,"id":2,"ws":true},{"text":"and","start":18,"end":21,"id":3,"ws":true},{"text":"III","start":22,"end":25,"id":4,"ws":true},{"text":"clinical","start":26,"end":34,"id":5,"ws":true},{"text":"trials","start":35,"end":41,"id":6,"ws":true},{"text":"have","start":42,"end":46,"id":7,"ws":true},{"text":"demonstrated","start":47,"end":59,"id":8,"ws":true},{"text":"a","start":60,"end":61,"id":9,"ws":true},{"text":"higher","start":62,"end":68,"id":10,"ws":true},{"text":"activity","start":69,"end":77,"id":11,"ws":true},{"text":"of","start":78,"end":80,"id":12,"ws":true},{"text":"combined","start":81,"end":89,"id":13,"ws":true},{"text":"gemcitabine","start":90,"end":101,"id":14,"ws":true},{"text":"plus","start":102,"end":106,"id":15,"ws":true},{"text":"docetaxel","start":107,"end":116,"id":16,"ws":true},{"text":"schedules","start":117,"end":126,"id":17,"ws":true},{"text":"against","start":127,"end":134,"id":18,"ws":true},{"text":"non-small","start":135,"end":144,"id":19,"ws":true},{"text":"cell","start":145,"end":149,"id":20,"ws":true},{"text":"lung","start":150,"end":154,"id":21,"ws":true},{"text":"cancer","start":155,"end":161,"id":22,"ws":true},{"text":"(","start":162,"end":163,"id":23,"ws":true},{"text":"NSCLC","start":164,"end":169,"id":24,"ws":true},{"text":")","start":170,"end":171,"id":25,"ws":true},{"text":"than","start":172,"end":176,"id":26,"ws":true},{"text":"that","start":177,"end":181,"id":27,"ws":true},{"text":"of","start":182,"end":184,"id":28,"ws":true},{"text":"both","start":185,"end":189,"id":29,"ws":true},{"text":"agents","start":190,"end":196,"id":30,"ws":true},{"text":"in","start":197,"end":199,"id":31,"ws":true},{"text":"monotherapy","start":200,"end":211,"id":32,"ws":true},{"text":".","start":212,"end":213,"id":33,"ws":false}],"spans":[{"start":90,"end":101,"token_start":14,"token_end":14,"label":"DRUG"},{"start":107,"end":116,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17273825/","_input_hash":-2132526612,"_task_hash":-2094506418,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":90,"end":101,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":107,"end":116,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The use of HDCT-SCT in CNS metastases needs to be carefully considered , possibly by adding thiotepa or topotecan to improve tumor control .","paragraph":"<h3><u>Stem-Cell Therapy Following High-Dose Chemotherapy in Advanced Retinoblastoma: A Systematic Review.</u></h3>To analyze the risk and benefit of high-dose chemotherapy followed by stem cell transplantation (HDCT-SCT) treatment in patients with advanced retinoblastoma. ### design Systematic review. ### methods A comprehensive literature search from 4 online databases, including PubMed, Scopus, EBSCO, and Cochrane was done for original studies evaluating the use of HDCT followed by SCT in the treatment of patients with advanced retinoblastoma. The last search was performed on April 15, 2020. ### results A total of 35 studies consisting of 160 patients were considered suitable for inclusion. After HDCT-SCT treatment, 108/160 (67.5%) patients were alive with no evidence of disease at the last follow-up. The incidence of secondary malignancy in our data was also relatively low, which was 16/160 (10%) patients. The side effects were mainly hematological and gastrointestinal toxicities. The prognosis for metastatic cases especially the one to the central nervous system (CNS) remains poor, as shown in our data that 22 of 44 (50%) patients died due to the evidence of disease, and 12 of 44 (27%) patients acquired CNS relapse and died. ### conclusions HDCT-SCT is a promising treatment option in patients with advanced retinoblastoma. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>HDCT-SCT</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>CNS</i></b> <b style='color:DodgerBlue;'><i>metastases</i></b> <b style='color:DodgerBlue;'><i>needs</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>carefully</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>possibly</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>adding</i></b> <b style='color:MediumOrchid;'><i>thiotepa</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Further randomized clinical trials are needed to draw firm conclusion regarding its safety and efficacy.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"use","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"HDCT-SCT","start":11,"end":19,"id":3,"ws":true},{"text":"in","start":20,"end":22,"id":4,"ws":true},{"text":"CNS","start":23,"end":26,"id":5,"ws":true},{"text":"metastases","start":27,"end":37,"id":6,"ws":true},{"text":"needs","start":38,"end":43,"id":7,"ws":true},{"text":"to","start":44,"end":46,"id":8,"ws":true},{"text":"be","start":47,"end":49,"id":9,"ws":true},{"text":"carefully","start":50,"end":59,"id":10,"ws":true},{"text":"considered","start":60,"end":70,"id":11,"ws":true},{"text":",","start":71,"end":72,"id":12,"ws":true},{"text":"possibly","start":73,"end":81,"id":13,"ws":true},{"text":"by","start":82,"end":84,"id":14,"ws":true},{"text":"adding","start":85,"end":91,"id":15,"ws":true},{"text":"thiotepa","start":92,"end":100,"id":16,"ws":true},{"text":"or","start":101,"end":103,"id":17,"ws":true},{"text":"topotecan","start":104,"end":113,"id":18,"ws":true},{"text":"to","start":114,"end":116,"id":19,"ws":true},{"text":"improve","start":117,"end":124,"id":20,"ws":true},{"text":"tumor","start":125,"end":130,"id":21,"ws":true},{"text":"control","start":131,"end":138,"id":22,"ws":true},{"text":".","start":139,"end":140,"id":23,"ws":false}],"spans":[{"start":92,"end":100,"token_start":16,"token_end":16,"label":"DRUG"},{"start":104,"end":113,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33481395/","_input_hash":1702182425,"_task_hash":2025261830,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Targeted agents for HNSCC expected to improve the effectiveness of current therapy include EGFR inhibitors ( Cetuximab , Panitumumab , Zalutumumab ) , EGFR tyrosine kinase inhibitors ( Gefitinib , Erloitinib ) , VEGFR inhibitors ( Bevacizumab , Vandetanib ) , and various inhibitors of , e.g. , Src-family kinase , PARP , proteasome , mTOR , COX , and heat shock protein .","paragraph":"<h3><u>Targeted therapy in head and neck cancer.</u></h3>Head and neck squamous cell carcinoma (HNSCC) of multi-factorial etiopathogenesis is rising worldwide. Treatment-associated toxicity problems and treatment failure in advanced disease stages with conventional therapies have necessitated a focus on alternative strategies. Molecular targeted therapy, with the potential for increased selectivity and fewer adverse effects, hold promise in the treatment of HNSCC. In an attempt to improve outcomes in HNSCC, targeted therapeutic strategies have been developed. These strategies are focusing on the molecular biology of HNSCC in an attempt to target selected pathways involved in carcinogenesis. Inhibiting tumor growth and metastasis by focusing on specific protein or signal transduction pathways or by targeting the tumor microenvironment or vasculature are some of the new approaches. <b style='color:DodgerBlue;'><i>Targeted</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>HNSCC</i></b> <b style='color:DodgerBlue;'><i>expected</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effectiveness</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>current</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>include</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>Cetuximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Panitumumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Zalutumumab</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>tyrosine</i></b> <b style='color:DodgerBlue;'><i>kinase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>Gefitinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Erloitinib</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>VEGFR</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>Bevacizumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Vandetanib</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>various</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>e.g.</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Src-family</i></b> <b style='color:DodgerBlue;'><i>kinase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>PARP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>proteasome</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>mTOR</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>COX</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>heat</i></b> <b style='color:DodgerBlue;'><i>shock</i></b> <b style='color:DodgerBlue;'><i>protein</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Moreover, targeted molecular therapy can also act as a complement to other existing cancer therapies. Several studies have demonstrated that the combination of targeting techniques with conventional current treatment protocols may improve the treatment outcome and disease control, without exacerbating the treatment related toxicities. Some of the targeted approaches have been proved as promising therapeutic potentials and are already in use, whereas remainder exhibits mixed result and necessitates further studies. Identification of predictive biomarkers of resistance or sensitivity to these therapies remains a fundamental challenge in the optimal selection of patients most likely to benefit from targeted treatment.","tokens":[{"text":"Targeted","start":0,"end":8,"id":0,"ws":true},{"text":"agents","start":9,"end":15,"id":1,"ws":true},{"text":"for","start":16,"end":19,"id":2,"ws":true},{"text":"HNSCC","start":20,"end":25,"id":3,"ws":true},{"text":"expected","start":26,"end":34,"id":4,"ws":true},{"text":"to","start":35,"end":37,"id":5,"ws":true},{"text":"improve","start":38,"end":45,"id":6,"ws":true},{"text":"the","start":46,"end":49,"id":7,"ws":true},{"text":"effectiveness","start":50,"end":63,"id":8,"ws":true},{"text":"of","start":64,"end":66,"id":9,"ws":true},{"text":"current","start":67,"end":74,"id":10,"ws":true},{"text":"therapy","start":75,"end":82,"id":11,"ws":true},{"text":"include","start":83,"end":90,"id":12,"ws":true},{"text":"EGFR","start":91,"end":95,"id":13,"ws":true},{"text":"inhibitors","start":96,"end":106,"id":14,"ws":true},{"text":"(","start":107,"end":108,"id":15,"ws":true},{"text":"Cetuximab","start":109,"end":118,"id":16,"ws":true},{"text":",","start":119,"end":120,"id":17,"ws":true},{"text":"Panitumumab","start":121,"end":132,"id":18,"ws":true},{"text":",","start":133,"end":134,"id":19,"ws":true},{"text":"Zalutumumab","start":135,"end":146,"id":20,"ws":true},{"text":")","start":147,"end":148,"id":21,"ws":true},{"text":",","start":149,"end":150,"id":22,"ws":true},{"text":"EGFR","start":151,"end":155,"id":23,"ws":true},{"text":"tyrosine","start":156,"end":164,"id":24,"ws":true},{"text":"kinase","start":165,"end":171,"id":25,"ws":true},{"text":"inhibitors","start":172,"end":182,"id":26,"ws":true},{"text":"(","start":183,"end":184,"id":27,"ws":true},{"text":"Gefitinib","start":185,"end":194,"id":28,"ws":true},{"text":",","start":195,"end":196,"id":29,"ws":true},{"text":"Erloitinib","start":197,"end":207,"id":30,"ws":true},{"text":")","start":208,"end":209,"id":31,"ws":true},{"text":",","start":210,"end":211,"id":32,"ws":true},{"text":"VEGFR","start":212,"end":217,"id":33,"ws":true},{"text":"inhibitors","start":218,"end":228,"id":34,"ws":true},{"text":"(","start":229,"end":230,"id":35,"ws":true},{"text":"Bevacizumab","start":231,"end":242,"id":36,"ws":true},{"text":",","start":243,"end":244,"id":37,"ws":true},{"text":"Vandetanib","start":245,"end":255,"id":38,"ws":true},{"text":")","start":256,"end":257,"id":39,"ws":true},{"text":",","start":258,"end":259,"id":40,"ws":true},{"text":"and","start":260,"end":263,"id":41,"ws":true},{"text":"various","start":264,"end":271,"id":42,"ws":true},{"text":"inhibitors","start":272,"end":282,"id":43,"ws":true},{"text":"of","start":283,"end":285,"id":44,"ws":true},{"text":",","start":286,"end":287,"id":45,"ws":true},{"text":"e.g.","start":288,"end":292,"id":46,"ws":true},{"text":",","start":293,"end":294,"id":47,"ws":true},{"text":"Src-family","start":295,"end":305,"id":48,"ws":true},{"text":"kinase","start":306,"end":312,"id":49,"ws":true},{"text":",","start":313,"end":314,"id":50,"ws":true},{"text":"PARP","start":315,"end":319,"id":51,"ws":true},{"text":",","start":320,"end":321,"id":52,"ws":true},{"text":"proteasome","start":322,"end":332,"id":53,"ws":true},{"text":",","start":333,"end":334,"id":54,"ws":true},{"text":"mTOR","start":335,"end":339,"id":55,"ws":true},{"text":",","start":340,"end":341,"id":56,"ws":true},{"text":"COX","start":342,"end":345,"id":57,"ws":true},{"text":",","start":346,"end":347,"id":58,"ws":true},{"text":"and","start":348,"end":351,"id":59,"ws":true},{"text":"heat","start":352,"end":356,"id":60,"ws":true},{"text":"shock","start":357,"end":362,"id":61,"ws":true},{"text":"protein","start":363,"end":370,"id":62,"ws":true},{"text":".","start":371,"end":372,"id":63,"ws":false}],"spans":[{"start":109,"end":118,"token_start":16,"token_end":16,"label":"DRUG"},{"start":121,"end":132,"token_start":18,"token_end":18,"label":"DRUG"},{"start":135,"end":146,"token_start":20,"token_end":20,"label":"DRUG"},{"start":185,"end":194,"token_start":28,"token_end":28,"label":"DRUG"},{"start":231,"end":242,"token_start":36,"token_end":36,"label":"DRUG"},{"start":245,"end":255,"token_start":38,"token_end":38,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22373581/","_input_hash":1992909817,"_task_hash":2010784943,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We performed a retrospective analysis of 114 severely head injured patients who were admitted to the neurocritical care unit of Level 1 trauma center and who received vasopressors ( phenylephrine , norepinephrine , dopamine , vasopressin or epinephrine ) to increase blood pressure","paragraph":"<h3><u>Vasopressor use and effect on blood pressure after severe adult traumatic brain injury.</u></h3>We describe institutional vasopressor usage, and examine the effect of vasopressors on hemodynamics: heart rate (HR), mean arterial blood pressure (MAP), intracranial pressure (ICP), cerebral perfusion pressure (CPP), brain tissue oxygenation (PbtO(2)), and jugular venous oximetry (SjVO(2)) in adults with severe traumatic brain injury (TBI). ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>retrospective</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>114</i></b> <b style='color:DodgerBlue;'><i>severely</i></b> <b style='color:DodgerBlue;'><i>head</i></b> <b style='color:DodgerBlue;'><i>injured</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>admitted</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>neurocritical</i></b> <b style='color:DodgerBlue;'><i>care</i></b> <b style='color:DodgerBlue;'><i>unit</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Level</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>trauma</i></b> <b style='color:DodgerBlue;'><i>center</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>vasopressors</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>phenylephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>norepinephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>dopamine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vasopressin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>epinephrine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>pressure</i></b> ### results <b style='color:Tomato;'><i>phenylephrine</i></b> was the most commonly used vasopressor (43%), followed by nor<b style='color:Tomato;'><i>epinephrine</i></b> (30%), dopamine (22%), and <b style='color:Tomato;'><i>vasopressin</i></b> (5%). Adjusted for age, gender, injury severity score, vasopressor dose, baseline blood pressure, fluid administration, <b style='color:Tomato;'><i>propofol</i></b> sedation, and hypertonic saline infusion, <b style='color:Tomato;'><i>phenylephrine</i></b> use was associated with 8 mmHg higher mean arterial pressure (MAP) than dopamine (P = 0.03), and 12 mmHg higher cerebral perfusion pressure (CPP) than nor<b style='color:Tomato;'><i>epinephrine</i></b> (P = 0.02) during the 3 h after vasopressor start. There was no difference in ICP between the drug groups, either at baseline or after vasopressor treatment. ### conclusions Most severe TBI patients received <b style='color:Tomato;'><i>phenylephrine</i></b>. Patients who received <b style='color:Tomato;'><i>phenylephrine</i></b> had higher MAP and CPP than patients who received dopamine and nor<b style='color:Tomato;'><i>epinephrine</i></b>, respectively.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"performed","start":3,"end":12,"id":1,"ws":true},{"text":"a","start":13,"end":14,"id":2,"ws":true},{"text":"retrospective","start":15,"end":28,"id":3,"ws":true},{"text":"analysis","start":29,"end":37,"id":4,"ws":true},{"text":"of","start":38,"end":40,"id":5,"ws":true},{"text":"114","start":41,"end":44,"id":6,"ws":true},{"text":"severely","start":45,"end":53,"id":7,"ws":true},{"text":"head","start":54,"end":58,"id":8,"ws":true},{"text":"injured","start":59,"end":66,"id":9,"ws":true},{"text":"patients","start":67,"end":75,"id":10,"ws":true},{"text":"who","start":76,"end":79,"id":11,"ws":true},{"text":"were","start":80,"end":84,"id":12,"ws":true},{"text":"admitted","start":85,"end":93,"id":13,"ws":true},{"text":"to","start":94,"end":96,"id":14,"ws":true},{"text":"the","start":97,"end":100,"id":15,"ws":true},{"text":"neurocritical","start":101,"end":114,"id":16,"ws":true},{"text":"care","start":115,"end":119,"id":17,"ws":true},{"text":"unit","start":120,"end":124,"id":18,"ws":true},{"text":"of","start":125,"end":127,"id":19,"ws":true},{"text":"Level","start":128,"end":133,"id":20,"ws":true},{"text":"1","start":134,"end":135,"id":21,"ws":true},{"text":"trauma","start":136,"end":142,"id":22,"ws":true},{"text":"center","start":143,"end":149,"id":23,"ws":true},{"text":"and","start":150,"end":153,"id":24,"ws":true},{"text":"who","start":154,"end":157,"id":25,"ws":true},{"text":"received","start":158,"end":166,"id":26,"ws":true},{"text":"vasopressors","start":167,"end":179,"id":27,"ws":true},{"text":"(","start":180,"end":181,"id":28,"ws":true},{"text":"phenylephrine","start":182,"end":195,"id":29,"ws":true},{"text":",","start":196,"end":197,"id":30,"ws":true},{"text":"norepinephrine","start":198,"end":212,"id":31,"ws":true},{"text":",","start":213,"end":214,"id":32,"ws":true},{"text":"dopamine","start":215,"end":223,"id":33,"ws":true},{"text":",","start":224,"end":225,"id":34,"ws":true},{"text":"vasopressin","start":226,"end":237,"id":35,"ws":true},{"text":"or","start":238,"end":240,"id":36,"ws":true},{"text":"epinephrine","start":241,"end":252,"id":37,"ws":true},{"text":")","start":253,"end":254,"id":38,"ws":true},{"text":"to","start":255,"end":257,"id":39,"ws":true},{"text":"increase","start":258,"end":266,"id":40,"ws":true},{"text":"blood","start":267,"end":272,"id":41,"ws":true},{"text":"pressure","start":273,"end":281,"id":42,"ws":false}],"spans":[{"start":182,"end":195,"token_start":29,"token_end":29,"label":"DRUG"},{"start":226,"end":237,"token_start":35,"token_end":35,"label":"DRUG"},{"start":241,"end":252,"token_start":37,"token_end":37,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20878264/","_input_hash":1014912764,"_task_hash":-1016595944,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"While 5-fluorouracil used as single agent in patients with metastatic colorectal cancer has an objective response rate around 20 % , the administration of combinations of irinotecan with 5-fluorouracil/folinic acid or oxaliplatin with 5-fluorouracil/folinic acid results in significantly increased response rates and improved survival .","paragraph":"<h3><u>FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.</u></h3> <b style='color:DodgerBlue;'><i>While</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>objective</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>around</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil/folinic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil/folinic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, the side effects of systemic therapy such as myelotoxicity, neurotoxicity or gastrointestinal toxicity may lead to life-threatening complications and have a major impact on the quality of life of the patients. Therefore, biomarkers that would be instrumental in the choice of optimal type, combination and dose of drugs for an individual patient are urgently needed. The efficacy and toxicity of anticancer drugs in tumor cells is determined by the effective concentration in tumor cells, healthy tissues and by the presence and quantity of the drug targets. Enzymes active in drug metabolism and transport represent important determinants of the therapeutic outcome. The aim of this review was to summarize published data on associations of gene and protein expression, and genetic variability of putative biomarkers with response to therapy of colorectal cancer to 5-<b style='color:Tomato;'><i>fluorouracil</i></b>/<b style='color:Tomato;'><i>leucovorin</i></b>/<b style='color:Tomato;'><i>oxaliplatin</i></b> and 5-<b style='color:Tomato;'><i>fluorouracil</i></b>/leukovorin/<b style='color:Tomato;'><i>irinotecan</i></b> regimens. Gaps in the knowledge identified by this review may aid the design of future research and clinical trials.","tokens":[{"text":"While","start":0,"end":5,"id":0,"ws":true},{"text":"5-fluorouracil","start":6,"end":20,"id":1,"ws":true},{"text":"used","start":21,"end":25,"id":2,"ws":true},{"text":"as","start":26,"end":28,"id":3,"ws":true},{"text":"single","start":29,"end":35,"id":4,"ws":true},{"text":"agent","start":36,"end":41,"id":5,"ws":true},{"text":"in","start":42,"end":44,"id":6,"ws":true},{"text":"patients","start":45,"end":53,"id":7,"ws":true},{"text":"with","start":54,"end":58,"id":8,"ws":true},{"text":"metastatic","start":59,"end":69,"id":9,"ws":true},{"text":"colorectal","start":70,"end":80,"id":10,"ws":true},{"text":"cancer","start":81,"end":87,"id":11,"ws":true},{"text":"has","start":88,"end":91,"id":12,"ws":true},{"text":"an","start":92,"end":94,"id":13,"ws":true},{"text":"objective","start":95,"end":104,"id":14,"ws":true},{"text":"response","start":105,"end":113,"id":15,"ws":true},{"text":"rate","start":114,"end":118,"id":16,"ws":true},{"text":"around","start":119,"end":125,"id":17,"ws":true},{"text":"20","start":126,"end":128,"id":18,"ws":true},{"text":"%","start":129,"end":130,"id":19,"ws":true},{"text":",","start":131,"end":132,"id":20,"ws":true},{"text":"the","start":133,"end":136,"id":21,"ws":true},{"text":"administration","start":137,"end":151,"id":22,"ws":true},{"text":"of","start":152,"end":154,"id":23,"ws":true},{"text":"combinations","start":155,"end":167,"id":24,"ws":true},{"text":"of","start":168,"end":170,"id":25,"ws":true},{"text":"irinotecan","start":171,"end":181,"id":26,"ws":true},{"text":"with","start":182,"end":186,"id":27,"ws":true},{"text":"5-fluorouracil/folinic","start":187,"end":209,"id":28,"ws":true},{"text":"acid","start":210,"end":214,"id":29,"ws":true},{"text":"or","start":215,"end":217,"id":30,"ws":true},{"text":"oxaliplatin","start":218,"end":229,"id":31,"ws":true},{"text":"with","start":230,"end":234,"id":32,"ws":true},{"text":"5-fluorouracil/folinic","start":235,"end":257,"id":33,"ws":true},{"text":"acid","start":258,"end":262,"id":34,"ws":true},{"text":"results","start":263,"end":270,"id":35,"ws":true},{"text":"in","start":271,"end":273,"id":36,"ws":true},{"text":"significantly","start":274,"end":287,"id":37,"ws":true},{"text":"increased","start":288,"end":297,"id":38,"ws":true},{"text":"response","start":298,"end":306,"id":39,"ws":true},{"text":"rates","start":307,"end":312,"id":40,"ws":true},{"text":"and","start":313,"end":316,"id":41,"ws":true},{"text":"improved","start":317,"end":325,"id":42,"ws":true},{"text":"survival","start":326,"end":334,"id":43,"ws":true},{"text":".","start":335,"end":336,"id":44,"ws":false}],"spans":[{"start":171,"end":181,"token_start":26,"token_end":26,"label":"DRUG"},{"start":218,"end":229,"token_start":31,"token_end":31,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25132748/","_input_hash":-1949618094,"_task_hash":-1742346110,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":26,"child":28,"head_span":{"start":171,"end":181,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":187,"end":209,"token_start":28,"token_end":28,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":31,"child":33,"head_span":{"start":218,"end":229,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":235,"end":257,"token_start":33,"token_end":33,"label":null},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"Chemotherapy was given in 405 of 410 treatment periods with dacarbazine , fotemustine , vindesine , carboplatin and temozolomide in different schedules .","paragraph":"<h3><u>Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.</u></h3>Metastatic melanoma shows different local response rates in organs to systemic or local treatment modalities. Whereas skin, soft tissue, lymph node and lung metastases seem to have better local response rates, the local response of metastases localized in the liver, brain and bone seems to be low. ### objectives The organ-specific response rate, local response rate of each therapeutic measure and survival of 68 patients with stage IV disease were evaluated. ### methods Four hundred and ten treatment periods (1-18 per patient) in 17 different organs of 43 men and 25 women (mean age 55 years, range 19-79) with measurable, widespread, surgically incurable disease were analysed. <b style='color:DodgerBlue;'><i>Chemotherapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>405</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>410</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>periods</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>fotemustine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>vindesine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>schedules</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Local treatment modalities comprising radiotherapy, gamma knife radiosurgery and local hyperthermia were given in 71 of 410 treatment periods. ### results Local response (complete or partial local remission) was achieved in 52 treatment periods (12.7%). When local treatment modalities, either combined with systemic therapy or not, were compared with systemic therapeutic modalities alone, a local response of 24% was achieved with local measures, compared with 10% in systemic treatment only (P = 0.003). When a spontaneous remission rate of less than 5% is considered, however, local as well as systemic treatments had a significant effect (P < 0.001). Organ-specific response rates to local therapies showed no statistically significant differences between the various organs involved. When systemic treatments without local measures were taken into account, lung metastases, cutaneous/subcutaneous metastases and adrenal metastases performed significantly better than liver metastases. When different treatment modalities were considered, there was no significant difference between the three local measures applied (radiotherapy, gamma knife radiosurgery and hyperthermia). Among the systemic therapies, <b style='color:Tomato;'><i>dacarbazine</i></b> high dose and <b style='color:Tomato;'><i>carboplatin</i></b> monochemotherapy were superior to combined regimens using fotemustine. A local response, irrespective of the mode of therapy, was significantly associated with longer survival (median 16 months) compared with no local response or local progressive disease (median 7 months; P < 0.0001). When the first treatment period of each patient was considered, local response was no longer a significant predictor. ### conclusions The study shows that local therapeutic measures are superior in inducing a local response than systemic therapies alone. Induction of remission may be associated with longer survival. Chemotherapy, despite limited local response rates, is still statistically superior to an estimated spontaneous remission rate.","tokens":[{"text":"Chemotherapy","start":0,"end":12,"id":0,"ws":true},{"text":"was","start":13,"end":16,"id":1,"ws":true},{"text":"given","start":17,"end":22,"id":2,"ws":true},{"text":"in","start":23,"end":25,"id":3,"ws":true},{"text":"405","start":26,"end":29,"id":4,"ws":true},{"text":"of","start":30,"end":32,"id":5,"ws":true},{"text":"410","start":33,"end":36,"id":6,"ws":true},{"text":"treatment","start":37,"end":46,"id":7,"ws":true},{"text":"periods","start":47,"end":54,"id":8,"ws":true},{"text":"with","start":55,"end":59,"id":9,"ws":true},{"text":"dacarbazine","start":60,"end":71,"id":10,"ws":true},{"text":",","start":72,"end":73,"id":11,"ws":true},{"text":"fotemustine","start":74,"end":85,"id":12,"ws":true},{"text":",","start":86,"end":87,"id":13,"ws":true},{"text":"vindesine","start":88,"end":97,"id":14,"ws":true},{"text":",","start":98,"end":99,"id":15,"ws":true},{"text":"carboplatin","start":100,"end":111,"id":16,"ws":true},{"text":"and","start":112,"end":115,"id":17,"ws":true},{"text":"temozolomide","start":116,"end":128,"id":18,"ws":true},{"text":"in","start":129,"end":131,"id":19,"ws":true},{"text":"different","start":132,"end":141,"id":20,"ws":true},{"text":"schedules","start":142,"end":151,"id":21,"ws":true},{"text":".","start":152,"end":153,"id":22,"ws":false}],"spans":[{"start":60,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},{"start":100,"end":111,"token_start":16,"token_end":16,"label":"DRUG"},{"start":116,"end":128,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16225601/","_input_hash":-1674361638,"_task_hash":-164267360,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"[ Effect of nedaplatin , 5-FU , and leucovorin combined with radiation therapy in unresectable esophageal carcinoma ] .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nedaplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>radiation</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>unresectable</i></b> <b style='color:DodgerBlue;'><i>esophageal</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>A 51-year-old male was assessed as having esophageal squamous cell carcinoma with trachea invasion and cervical lymph node metastasis. After one course of chemotherapy using cisplatin (CDDP), 5-<b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU) and <b style='color:Tomato;'><i>leucovorin</i></b> (LV), the patient had progressive disease (PD) of the primary lesion and metastatic lymph nodes, and a side effect of severe nausea. One course of <b style='color:Tomato;'><i>nedaplatin</i></b>, 5-FU and LV combined with radiation was performed alternatively. The effect was evaluated as a partial response (PR) of the primary lesion and metastatic lymph nodes. There were no adverse side effects such as nausea or renal dysfunction except for pancytopenia of grade 2. Increased serum levels of vascular endothelial growth factor (s-VEGF) decreased after the chemoradiotherapy and increased again during continued radiotherapy alone. More information is needed as to whether changes in s-VEGF relate to the clinical effects of the treatment.","tokens":[{"text":"[","start":0,"end":1,"id":0,"ws":true},{"text":"Effect","start":2,"end":8,"id":1,"ws":true},{"text":"of","start":9,"end":11,"id":2,"ws":true},{"text":"nedaplatin","start":12,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"5-FU","start":25,"end":29,"id":5,"ws":true},{"text":",","start":30,"end":31,"id":6,"ws":true},{"text":"and","start":32,"end":35,"id":7,"ws":true},{"text":"leucovorin","start":36,"end":46,"id":8,"ws":true},{"text":"combined","start":47,"end":55,"id":9,"ws":true},{"text":"with","start":56,"end":60,"id":10,"ws":true},{"text":"radiation","start":61,"end":70,"id":11,"ws":true},{"text":"therapy","start":71,"end":78,"id":12,"ws":true},{"text":"in","start":79,"end":81,"id":13,"ws":true},{"text":"unresectable","start":82,"end":94,"id":14,"ws":true},{"text":"esophageal","start":95,"end":105,"id":15,"ws":true},{"text":"carcinoma","start":106,"end":115,"id":16,"ws":true},{"text":"]","start":116,"end":117,"id":17,"ws":true},{"text":".","start":118,"end":119,"id":18,"ws":false}],"spans":[{"start":12,"end":22,"token_start":3,"token_end":3,"label":"DRUG"},{"start":36,"end":46,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12795101/","_input_hash":1650618473,"_task_hash":-861244702,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":12,"end":22,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":25,"end":29,"token_start":5,"token_end":5,"label":null},"color":"#ffd882","label":"POS2"},{"head":8,"child":5,"head_span":{"start":36,"end":46,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":25,"end":29,"token_start":5,"token_end":5,"label":null},"color":"#ffd882","label":"POS2"}],"radio":["POS21"],"answer":"accept"}
{"text":"After 5 years , approximately 30.8 % of etanercept patients and 68.8 % of monoclonal antibody patients ( adalimumab 71.2 % ; infliximab 67.2 % ) were still being treated .","paragraph":"<h3><u>Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France.</u></h3>While several registries have already evaluated the retention of anti-TNF therapy in psoriatic arthritis (PsA), they sometimes reach divergent conclusions. Our study therefore sought to assess therapeutic retention rates and predictive factors of response in a patient cohort from Auvergne, France, followed up in routine clinical practice. ### methods Medical records of all PsA patients treated from 2002 to May 2015 were analysed. PsA diagnosis was established based on the CASPAR criteria. ### results In total, 102 patients were analysed, comprising 62 men (44.6\u00b112.6 years) and 40 women (37.8\u00b113.4). Mean PsA evolution was 2.7 years (0.8-11.2). The most common forms were peripheral (47/102, 45.1%) and mixed (46/102, 46.1%) PsA. The anti-TNF treatment initiated was <b style='color:Tomato;'><i>etanercept</i></b> in 47 cases (45.2%), <b style='color:Tomato;'><i>adalimumab</i></b> in 29 (27.9%), <b style='color:Tomato;'><i>infliximab</i></b> in 20 (19.2%), and <b style='color:Tomato;'><i>golimumab</i></b> in six [5.8%]. In 28 cases (27.4%), anti-TNF was associated with <b style='color:Tomato;'><i>methotrexate</i></b> (MTX). Overall, the median duration of anti-TNF retention was 76.5 months. The hazard ratios (HR) for treatment cessation did not significantly differ between the <b style='color:Tomato;'><i>etanercept</i></b> and monoclonal antibody groups (HR=1.35[0.96-1.93], p=0.08). <b style='color:DodgerBlue;'><i>After</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>approximately</i></b> <b style='color:DodgerBlue;'><i>30.8</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>etanercept</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>68.8</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>monoclonal</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>adalimumab</i></b> <b style='color:DodgerBlue;'><i>71.2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:MediumOrchid;'><i>infliximab</i></b> <b style='color:DodgerBlue;'><i>67.2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>still</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Combining with MTX did not prolong the overall retention rate (HR=0.85[0.37-1.96], p=0.71). Tobacco use was predictive of discontinuation (p=0.03). ### conclusions Our study demonstrates good anti-TNF treatment retention in PsA patients, as well as confirming the deleterious effect of smoking while providing no argument in favour of combined treatment with MTX to improve maintenance.","tokens":[{"text":"After","start":0,"end":5,"id":0,"ws":true},{"text":"5","start":6,"end":7,"id":1,"ws":true},{"text":"years","start":8,"end":13,"id":2,"ws":true},{"text":",","start":14,"end":15,"id":3,"ws":true},{"text":"approximately","start":16,"end":29,"id":4,"ws":true},{"text":"30.8","start":30,"end":34,"id":5,"ws":true},{"text":"%","start":35,"end":36,"id":6,"ws":true},{"text":"of","start":37,"end":39,"id":7,"ws":true},{"text":"etanercept","start":40,"end":50,"id":8,"ws":true},{"text":"patients","start":51,"end":59,"id":9,"ws":true},{"text":"and","start":60,"end":63,"id":10,"ws":true},{"text":"68.8","start":64,"end":68,"id":11,"ws":true},{"text":"%","start":69,"end":70,"id":12,"ws":true},{"text":"of","start":71,"end":73,"id":13,"ws":true},{"text":"monoclonal","start":74,"end":84,"id":14,"ws":true},{"text":"antibody","start":85,"end":93,"id":15,"ws":true},{"text":"patients","start":94,"end":102,"id":16,"ws":true},{"text":"(","start":103,"end":104,"id":17,"ws":true},{"text":"adalimumab","start":105,"end":115,"id":18,"ws":true},{"text":"71.2","start":116,"end":120,"id":19,"ws":true},{"text":"%","start":121,"end":122,"id":20,"ws":true},{"text":";","start":123,"end":124,"id":21,"ws":true},{"text":"infliximab","start":125,"end":135,"id":22,"ws":true},{"text":"67.2","start":136,"end":140,"id":23,"ws":true},{"text":"%","start":141,"end":142,"id":24,"ws":true},{"text":")","start":143,"end":144,"id":25,"ws":true},{"text":"were","start":145,"end":149,"id":26,"ws":true},{"text":"still","start":150,"end":155,"id":27,"ws":true},{"text":"being","start":156,"end":161,"id":28,"ws":true},{"text":"treated","start":162,"end":169,"id":29,"ws":true},{"text":".","start":170,"end":171,"id":30,"ws":false}],"spans":[{"start":40,"end":50,"token_start":8,"token_end":8,"label":"DRUG"},{"start":105,"end":115,"token_start":18,"token_end":18,"label":"DRUG"},{"start":125,"end":135,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27607233/","_input_hash":-643977915,"_task_hash":127840274,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"( 4 mg/day ) ; in group 3 , 69 patients administered metformin ( 1,000 mg/day ) and rosiglitazone ( 4 mg/day ) for 6 months ,","paragraph":"<h3><u>Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial.</u></h3>To compare the effects of <b style='color:Tomato;'><i>metformin</i></b>, <b style='color:Tomato;'><i>rosiglitazone</i></b>, and their combination in obese polycystic ovary syndrome (PCOS) patients with insulin resistance. ### design Prospective randomized controlled trail. ### setting Tertiary teaching hospital. ### Patient S Obese Chinese women (body mass index [BMI] \u226525 kg/m ### Intervention S In group 1, 68 patients administered <b style='color:Tomato;'><i>metformin</i></b> (1,500 mg/day); in group 2, 67 patients administered <b style='color:Tomato;'><i>rosiglitazone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>mg/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>69</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1,000</i></b> <b style='color:DodgerBlue;'><i>mg/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rosiglitazone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>mg/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>,</i></b> all with the same diet and regular exercise lifestyle recommendation. ### Main Outcome Measure S Average menstrual interval, anthropometric measurements, androgen-related parameters, and metabolic features of insulin, carbohydrates, and lipids, with intention-to-treat analysis. ### Result S The baseline parameters showed no statistically significant differences. After the 6-month treatment, most participants showed an improved menstrual pattern. There were statistically significant decreases in acne scores, weight, BMI, waist circumference, waist-to-hip ratio, and serum testosterone. The metabolic indexes of insulin, carbohydrates, and lipids were improved obviously compared with the baseline in each group. Among the three groups, the patients administered 1,500 mg/day <b style='color:Tomato;'><i>metformin</i></b> experienced greater reductions in weight. However, the <b style='color:Tomato;'><i>rosiglitazone</i></b> users (alone or combined with <b style='color:Tomato;'><i>metformin</i></b>) showed a more notable decline in total cholesterol and triglyceride levels. ### Conclusion S Considering the benefits of <b style='color:Tomato;'><i>metformin</i></b> on weight loss, high-dose <b style='color:Tomato;'><i>metformin</i></b> (1,500 mg/day) along with lifestyle modification should be recommended for obese, insulin-resistant women with PCOS. <b style='color:Tomato;'><i>rosiglitazone</i></b> alone or combined with low-dosage <b style='color:Tomato;'><i>metformin</i></b> plus lifestyle modification should be considered for the women with abnormal lipid profiles. ### Clinical Trial Registration Number ChiCTR-TRC-13003642 (Chinese Clinical Trial Registry).","tokens":[{"text":"(","start":0,"end":1,"id":0,"ws":true},{"text":"4","start":2,"end":3,"id":1,"ws":true},{"text":"mg/day","start":4,"end":10,"id":2,"ws":true},{"text":")","start":11,"end":12,"id":3,"ws":true},{"text":";","start":13,"end":14,"id":4,"ws":true},{"text":"in","start":15,"end":17,"id":5,"ws":true},{"text":"group","start":18,"end":23,"id":6,"ws":true},{"text":"3","start":24,"end":25,"id":7,"ws":true},{"text":",","start":26,"end":27,"id":8,"ws":true},{"text":"69","start":28,"end":30,"id":9,"ws":true},{"text":"patients","start":31,"end":39,"id":10,"ws":true},{"text":"administered","start":40,"end":52,"id":11,"ws":true},{"text":"metformin","start":53,"end":62,"id":12,"ws":true},{"text":"(","start":63,"end":64,"id":13,"ws":true},{"text":"1,000","start":65,"end":70,"id":14,"ws":true},{"text":"mg/day","start":71,"end":77,"id":15,"ws":true},{"text":")","start":78,"end":79,"id":16,"ws":true},{"text":"and","start":80,"end":83,"id":17,"ws":true},{"text":"rosiglitazone","start":84,"end":97,"id":18,"ws":true},{"text":"(","start":98,"end":99,"id":19,"ws":true},{"text":"4","start":100,"end":101,"id":20,"ws":true},{"text":"mg/day","start":102,"end":108,"id":21,"ws":true},{"text":")","start":109,"end":110,"id":22,"ws":true},{"text":"for","start":111,"end":114,"id":23,"ws":true},{"text":"6","start":115,"end":116,"id":24,"ws":true},{"text":"months","start":117,"end":123,"id":25,"ws":true},{"text":",","start":124,"end":125,"id":26,"ws":false}],"spans":[{"start":53,"end":62,"token_start":12,"token_end":12,"label":"DRUG"},{"start":84,"end":97,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31718828/","_input_hash":676819633,"_task_hash":2024227395,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":12,"child":18,"head_span":{"start":53,"end":62,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":84,"end":97,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In the intention-to-treat analysis , 57 % of patients that received tenecteplase and 53 % of patients that received alteplase reached good functional outcome ( modified Rankin Scale score of 0 - 1 ) at 3 months ( odds ratio , 1.19 ; 95 % CI , 0.68 - 2.10 ) .","paragraph":"<h3><u>Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale.</u></h3>Background and Purpose- Thrombolysis with <b style='color:Tomato;'><i>alteplase</i></b> has beneficial effect on outcome and is safe within 4.5 hours. The present study compares the efficacy and safety of <b style='color:Tomato;'><i>tenecteplase</i></b> and <b style='color:Tomato;'><i>alteplase</i></b> in patients treated 3 to 4.5 hours after ischemic stroke. Methods- The data are from a prespecified substudy of patients included in The NOR-TEST (Norwegian <b style='color:Tomato;'><i>tenecteplase</i></b> Stroke Trial), a randomized control trial comparing <b style='color:Tomato;'><i>tenecteplase</i></b> with <b style='color:Tomato;'><i>alteplase</i></b>. Results- The median admission National Institutes of Health Stroke Scale for this study population was 3 (interquartile range, 2-6). <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>intention-to-treat</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>57</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>tenecteplase</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>53</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>alteplase</i></b> <b style='color:DodgerBlue;'><i>reached</i></b> <b style='color:DodgerBlue;'><i>good</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>outcome</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>modified</i></b> <b style='color:DodgerBlue;'><i>Rankin</i></b> <b style='color:DodgerBlue;'><i>Scale</i></b> <b style='color:DodgerBlue;'><i>score</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>0</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>odds</i></b> <b style='color:DodgerBlue;'><i>ratio</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1.19</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>95</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>CI</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>0.68</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2.10</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The rates of intracranial hemorrhage in the first 48 hours were 5.7% in the <b style='color:Tomato;'><i>tenecteplase</i></b> group and 6.7% in the <b style='color:Tomato;'><i>alteplase</i></b> group (odds ratio, 0.84; 95% CI, 0.26-2.70). At 3 months, mortality was 5.7% and 4.5%, respectively. After excluding stroke mimics and patients with modified Rankin Scale score of >1 before stroke, the proportion of patients with good functional outcome was 61% in the <b style='color:Tomato;'><i>tenecteplase</i></b> group and 57% in the <b style='color:Tomato;'><i>alteplase</i></b> group (odds ratio, 1.24; 95% CI, 0.65-2.37). Conclusions- <b style='color:Tomato;'><i>tenecteplase</i></b> is at least as effective as <b style='color:Tomato;'><i>alteplase</i></b> to achieve a good clinical outcome in patients with mild stroke treated between 3 and 4.5 hours after ischemic stroke. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT01949948.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"intention-to-treat","start":7,"end":25,"id":2,"ws":true},{"text":"analysis","start":26,"end":34,"id":3,"ws":true},{"text":",","start":35,"end":36,"id":4,"ws":true},{"text":"57","start":37,"end":39,"id":5,"ws":true},{"text":"%","start":40,"end":41,"id":6,"ws":true},{"text":"of","start":42,"end":44,"id":7,"ws":true},{"text":"patients","start":45,"end":53,"id":8,"ws":true},{"text":"that","start":54,"end":58,"id":9,"ws":true},{"text":"received","start":59,"end":67,"id":10,"ws":true},{"text":"tenecteplase","start":68,"end":80,"id":11,"ws":true},{"text":"and","start":81,"end":84,"id":12,"ws":true},{"text":"53","start":85,"end":87,"id":13,"ws":true},{"text":"%","start":88,"end":89,"id":14,"ws":true},{"text":"of","start":90,"end":92,"id":15,"ws":true},{"text":"patients","start":93,"end":101,"id":16,"ws":true},{"text":"that","start":102,"end":106,"id":17,"ws":true},{"text":"received","start":107,"end":115,"id":18,"ws":true},{"text":"alteplase","start":116,"end":125,"id":19,"ws":true},{"text":"reached","start":126,"end":133,"id":20,"ws":true},{"text":"good","start":134,"end":138,"id":21,"ws":true},{"text":"functional","start":139,"end":149,"id":22,"ws":true},{"text":"outcome","start":150,"end":157,"id":23,"ws":true},{"text":"(","start":158,"end":159,"id":24,"ws":true},{"text":"modified","start":160,"end":168,"id":25,"ws":true},{"text":"Rankin","start":169,"end":175,"id":26,"ws":true},{"text":"Scale","start":176,"end":181,"id":27,"ws":true},{"text":"score","start":182,"end":187,"id":28,"ws":true},{"text":"of","start":188,"end":190,"id":29,"ws":true},{"text":"0","start":191,"end":192,"id":30,"ws":true},{"text":"-","start":193,"end":194,"id":31,"ws":true},{"text":"1","start":195,"end":196,"id":32,"ws":true},{"text":")","start":197,"end":198,"id":33,"ws":true},{"text":"at","start":199,"end":201,"id":34,"ws":true},{"text":"3","start":202,"end":203,"id":35,"ws":true},{"text":"months","start":204,"end":210,"id":36,"ws":true},{"text":"(","start":211,"end":212,"id":37,"ws":true},{"text":"odds","start":213,"end":217,"id":38,"ws":true},{"text":"ratio","start":218,"end":223,"id":39,"ws":true},{"text":",","start":224,"end":225,"id":40,"ws":true},{"text":"1.19","start":226,"end":230,"id":41,"ws":true},{"text":";","start":231,"end":232,"id":42,"ws":true},{"text":"95","start":233,"end":235,"id":43,"ws":true},{"text":"%","start":236,"end":237,"id":44,"ws":true},{"text":"CI","start":238,"end":240,"id":45,"ws":true},{"text":",","start":241,"end":242,"id":46,"ws":true},{"text":"0.68","start":243,"end":247,"id":47,"ws":true},{"text":"-","start":248,"end":249,"id":48,"ws":true},{"text":"2.10","start":250,"end":254,"id":49,"ws":true},{"text":")","start":255,"end":256,"id":50,"ws":true},{"text":".","start":257,"end":258,"id":51,"ws":false}],"spans":[{"start":68,"end":80,"token_start":11,"token_end":11,"label":"DRUG"},{"start":116,"end":125,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30602354/","_input_hash":-810095337,"_task_hash":-209817558,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The patient was treated with dexamethasone and ethinyl estradiol with cessation of anti-hypertensive therapy .","paragraph":"<h3><u>Congenital Adrenal Hyperplasia due to 17-alpha-hydoxylase/17,20-lyase Deficiency Presenting with Hypertension and Pseudohermaphroditism: First Case Report from Oman.</u></h3>This is the first report of congenital adrenal hyperplasia (CAH) due to combined 17\u03b1-hydroxylase/17,20 lyase deficiency in an Omani patient who was initially treated for many years as a case of hypertension. CAH is an uncommon disorder that results from a defect in steroid hormones biosynthesis in the adrenal cortex. The clinical presentation depends on the site of enzymatic mutations and the types of accumulated steroid precursors. A 22-year-old woman who was diagnosed to have hypertension since the age of 10 years who was treated with anti-hypertensive therapy was referred to the National Diabetes and Endocrine Centre, Royal Hospital, Oman. The patient also had primary amenorrhea and features of sexual infantilism. Full laboratory and radio-imaging investigations were done. Adrenal steroids, pituitary function and karyotyping study were performed and the diagnosis was confirmed by molecular mutation study. Laboratory investigations revealed adrenal steroids and pituitary hormones profile in addition to 46XY karyotype that are consistent with the diagnosis of CAH due to 17\u03b1-hydroxylase deficiency. Extensive laboratory workup revealed low levels of serum cortisol (and its precursors 17\u03b1-<b style='color:Tomato;'><i>hydroxyprogesterone</i></b> and 11-deoxycortisol), adrenal androgens (<b style='color:Tomato;'><i>dehydroepiandrosterone</i></b> sulfate and androstenedione), and estrogen (estradiol); and high levels of mineralocorticoids precursors (11-<b style='color:Tomato;'><i>deoxycorticosterone</i></b> and corticosterone) with high levels of ACTH, FSH and LH. Mutation analysis revealed CYP17A1-homozygous mutation (c.287G>A p.Arg96Gln) resulting in the complete absence of 17\u03b1-hydroxylase/17,20-lyase activity. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ethinyl</i></b> <b style='color:DodgerBlue;'><i>estradiol</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cessation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>anti-hypertensive</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A review of the literature was conducted to identify previous studies related to this subtype of CAH. This is the first biochemically and genetically proven case of CAH due to 17\u03b1-hydroxylase/17,20-lyase deficiency in Oman and in the Arab World described in the literature.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"patient","start":4,"end":11,"id":1,"ws":true},{"text":"was","start":12,"end":15,"id":2,"ws":true},{"text":"treated","start":16,"end":23,"id":3,"ws":true},{"text":"with","start":24,"end":28,"id":4,"ws":true},{"text":"dexamethasone","start":29,"end":42,"id":5,"ws":true},{"text":"and","start":43,"end":46,"id":6,"ws":true},{"text":"ethinyl","start":47,"end":54,"id":7,"ws":true},{"text":"estradiol","start":55,"end":64,"id":8,"ws":true},{"text":"with","start":65,"end":69,"id":9,"ws":true},{"text":"cessation","start":70,"end":79,"id":10,"ws":true},{"text":"of","start":80,"end":82,"id":11,"ws":true},{"text":"anti-hypertensive","start":83,"end":100,"id":12,"ws":true},{"text":"therapy","start":101,"end":108,"id":13,"ws":true},{"text":".","start":109,"end":110,"id":14,"ws":false}],"spans":[{"start":29,"end":42,"token_start":5,"token_end":5,"label":"DRUG"},{"start":47,"end":54,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24498484/","_input_hash":-219145917,"_task_hash":-2128021926,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":29,"end":42,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":47,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Exposure of bss1 to clinically-used antiepileptic drugs ( phenytoin or gabapentin ) significantly reduces synchrony .","paragraph":"<h3><u>Calcium Imaging of Neuronal Activity in Drosophila Can Identify Anticonvulsive Compounds.</u></h3>Although there are now a number of antiepileptic drugs (AEDs) available, approximately one-third of epilepsy patients respond poorly to drug intervention. The reasons for this are complex, but are probably reflective of the increasing number of identified mutations that predispose individuals to this disease. Thus, there is a clear requirement for the development of novel treatments to address this unmet clinical need. The existence of gene mutations that mimic a seizure-like behaviour in the fruit fly, Drosophila melanogaster, offers the possibility to exploit the powerful genetics of this insect to identify novel cellular targets to facilitate design of more effective AEDs. In this study we use neuronal expression of GCaMP, a potent calcium reporter, to image neuronal activity using a non-invasive and rapid method. Expression in motoneurons in the isolated CNS of third instar larvae shows waves of calcium-activity that pass between segments of the ventral nerve cord. Time between calcium peaks, in the same neurons, between adjacent segments usually show a temporal separation of greater than 200 ms. Exposure to proconvulsants (picrotoxin or 4-aminopyridine) reduces separation to below 200 ms showing increased synchrony of activity across adjacent segments. Increased synchrony, characteristic of epilepsy, is similarly observed in genetic seizure mutants: bangsenseless1 (bss1) and paralyticK1270T (paraK1270T). <b style='color:DodgerBlue;'><i>Exposure</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>bss1</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>clinically-used</i></b> <b style='color:DodgerBlue;'><i>antiepileptic</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>phenytoin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>gabapentin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>reduces</i></b> <b style='color:DodgerBlue;'><i>synchrony</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study we use the measure of synchronicity to evaluate the effectiveness of known and novel anticonvulsive compounds (antipain, isethionate, etopiside <b style='color:Tomato;'><i>rapamycin</i></b> and dipyramidole) to reduce seizure-like CNS activity. We further show that such compounds also reduce the Drosophila voltage-gated persistent Na+ current (INaP) in an identified motoneuron (aCC). Our combined assays provide a rapid and reliable method to screen unknown compounds for potential to function as anticonvulsants.","tokens":[{"text":"Exposure","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"bss1","start":12,"end":16,"id":2,"ws":true},{"text":"to","start":17,"end":19,"id":3,"ws":true},{"text":"clinically-used","start":20,"end":35,"id":4,"ws":true},{"text":"antiepileptic","start":36,"end":49,"id":5,"ws":true},{"text":"drugs","start":50,"end":55,"id":6,"ws":true},{"text":"(","start":56,"end":57,"id":7,"ws":true},{"text":"phenytoin","start":58,"end":67,"id":8,"ws":true},{"text":"or","start":68,"end":70,"id":9,"ws":true},{"text":"gabapentin","start":71,"end":81,"id":10,"ws":true},{"text":")","start":82,"end":83,"id":11,"ws":true},{"text":"significantly","start":84,"end":97,"id":12,"ws":true},{"text":"reduces","start":98,"end":105,"id":13,"ws":true},{"text":"synchrony","start":106,"end":115,"id":14,"ws":true},{"text":".","start":116,"end":117,"id":15,"ws":false}],"spans":[{"start":58,"end":67,"token_start":8,"token_end":8,"label":"DRUG"},{"start":71,"end":81,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26863447/","_input_hash":-107944255,"_task_hash":-328180407,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"When compared with the combination of amphotericin B plus flucytosine , fluconazole was similarly effective in early treatment of acute and subacute disseminated candidiasis .","paragraph":"<h3><u>Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis.</u></h3>To investigate the potential use of <b style='color:Tomato;'><i>fluconazole</i></b> for prevention and treatment of disseminated candidiasis in granulocytopenic patients, its in vivo antifungal activity was studied in three models of disseminated candidiasis in persistently granulocytopenic rabbits: acute, subacute, and chronic disseminated candidiasis. <b style='color:Tomato;'><i>fluconazole</i></b> was compared with the combination of <b style='color:Tomato;'><i>amphotericin</i></b> B and <b style='color:Tomato;'><i>flucytosine</i></b> for preventive, early, and late treatment of disseminated candidiasis, depending on the model. <b style='color:Tomato;'><i>fluconazole</i></b> was most effective when used for preventive or early treatment of acute and subacute disseminated candidiasis. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>flucytosine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>fluconazole</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>similarly</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>early</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>subacute</i></b> <b style='color:DodgerBlue;'><i>disseminated</i></b> <b style='color:DodgerBlue;'><i>candidiasis</i></b> <b style='color:DodgerBlue;'><i>.</i></b> When treatment was delayed 6 days after established infection, <b style='color:Tomato;'><i>fluconazole</i></b> was less active in clearing tissues in comparison with its activity in preventive and early treatment. The combination of <b style='color:Tomato;'><i>amphotericin</i></b> B plus <b style='color:Tomato;'><i>flucytosine</i></b>, however, was significantly more active than <b style='color:Tomato;'><i>fluconazole</i></b> in treatment of chronic disseminated candidiasis in all tissues. In summary, <b style='color:Tomato;'><i>fluconazole</i></b> was most effective against disseminated candidiasis in persistently granulocytopenic rabbits when used for prevention or early treatment.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"compared","start":5,"end":13,"id":1,"ws":true},{"text":"with","start":14,"end":18,"id":2,"ws":true},{"text":"the","start":19,"end":22,"id":3,"ws":true},{"text":"combination","start":23,"end":34,"id":4,"ws":true},{"text":"of","start":35,"end":37,"id":5,"ws":true},{"text":"amphotericin","start":38,"end":50,"id":6,"ws":true},{"text":"B","start":51,"end":52,"id":7,"ws":true},{"text":"plus","start":53,"end":57,"id":8,"ws":true},{"text":"flucytosine","start":58,"end":69,"id":9,"ws":true},{"text":",","start":70,"end":71,"id":10,"ws":true},{"text":"fluconazole","start":72,"end":83,"id":11,"ws":true},{"text":"was","start":84,"end":87,"id":12,"ws":true},{"text":"similarly","start":88,"end":97,"id":13,"ws":true},{"text":"effective","start":98,"end":107,"id":14,"ws":true},{"text":"in","start":108,"end":110,"id":15,"ws":true},{"text":"early","start":111,"end":116,"id":16,"ws":true},{"text":"treatment","start":117,"end":126,"id":17,"ws":true},{"text":"of","start":127,"end":129,"id":18,"ws":true},{"text":"acute","start":130,"end":135,"id":19,"ws":true},{"text":"and","start":136,"end":139,"id":20,"ws":true},{"text":"subacute","start":140,"end":148,"id":21,"ws":true},{"text":"disseminated","start":149,"end":161,"id":22,"ws":true},{"text":"candidiasis","start":162,"end":173,"id":23,"ws":true},{"text":".","start":174,"end":175,"id":24,"ws":false}],"spans":[{"start":38,"end":50,"token_start":6,"token_end":6,"label":"DRUG"},{"start":58,"end":69,"token_start":9,"token_end":9,"label":"DRUG"},{"start":72,"end":83,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2138654/","_input_hash":1546626488,"_task_hash":813616515,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":6,"child":9,"head_span":{"start":38,"end":50,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":58,"end":69,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside , vincristine , and prednisone ( ROAP ) .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>age</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myelogenous</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rubidazone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cytosine</i></b> <b style='color:DodgerBlue;'><i>arabinoside</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ROAP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>We administered a combination of rubidazone, cytosine arabinoside, <b style='color:Tomato;'><i>vincristine</i></b>, and <b style='color:Tomato;'><i>prednisone</i></b> (ROAP) to 91 patients with acute myelogenous leukemia who were 50 yr of age or older. These patients had been identified in previous studies to be a group with a relatively poor prognosis. One-third of the patients had an antecedent hematologic disorder prior to treatment. Forty patients (48%) obtained a complete hematologic and clinical remission. A history of an antecedent hematologic disorder, male sex, and absence of Auer rods were adverse factors for achieving remission in this older population. More than half of the patients achieved remission in one course. The major cause of failure to obtain a remission was death due to infection, 40% of which were caused by fungi. Resistance to chemotherapy, although uncommon, was noted more frequently in patients with an antecedent hematologic disorder. Univariate and multivariate prognostic factor analysis was used to compare these patients with a historical control group treated with a program in which adriamycin was used instead of rubidazone (AdOAP). No significant difference in remission rate was detected. Cyclocytidine was used as a maintenance agent in this study, and while the median remission duration was only 37 wk, 30% of patients are expected to be in remission for 2 yr. Chemotherapy programs combining an anthracycline with cytosine arabinoside, given to older patients in similar fasion to younger patients will achieve remissions in one-half of a group of older patients. These remissions are of comparable quality to those of younger patients. Mathematical models derived from analysis of prognostic factors are of use in identifying patients likely to fail these programs who are in need of innovative approaches to treatment.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"of","start":10,"end":12,"id":1,"ws":true},{"text":"patients","start":13,"end":21,"id":2,"ws":true},{"text":"over","start":22,"end":26,"id":3,"ws":true},{"text":"50","start":27,"end":29,"id":4,"ws":true},{"text":"years","start":30,"end":35,"id":5,"ws":true},{"text":"of","start":36,"end":38,"id":6,"ws":true},{"text":"age","start":39,"end":42,"id":7,"ws":true},{"text":"with","start":43,"end":47,"id":8,"ws":true},{"text":"acute","start":48,"end":53,"id":9,"ws":true},{"text":"myelogenous","start":54,"end":65,"id":10,"ws":true},{"text":"leukemia","start":66,"end":74,"id":11,"ws":true},{"text":"with","start":75,"end":79,"id":12,"ws":true},{"text":"a","start":80,"end":81,"id":13,"ws":true},{"text":"combination","start":82,"end":93,"id":14,"ws":true},{"text":"of","start":94,"end":96,"id":15,"ws":true},{"text":"rubidazone","start":97,"end":107,"id":16,"ws":true},{"text":"and","start":108,"end":111,"id":17,"ws":true},{"text":"cytosine","start":112,"end":120,"id":18,"ws":true},{"text":"arabinoside","start":121,"end":132,"id":19,"ws":true},{"text":",","start":133,"end":134,"id":20,"ws":true},{"text":"vincristine","start":135,"end":146,"id":21,"ws":true},{"text":",","start":147,"end":148,"id":22,"ws":true},{"text":"and","start":149,"end":152,"id":23,"ws":true},{"text":"prednisone","start":153,"end":163,"id":24,"ws":true},{"text":"(","start":164,"end":165,"id":25,"ws":true},{"text":"ROAP","start":166,"end":170,"id":26,"ws":true},{"text":")","start":171,"end":172,"id":27,"ws":true},{"text":".","start":173,"end":174,"id":28,"ws":false}],"spans":[{"start":97,"end":107,"token_start":16,"token_end":16,"label":"DRUG"},{"start":112,"end":132,"token_start":18,"token_end":19,"label":"DRUG"},{"start":135,"end":146,"token_start":21,"token_end":21,"label":"DRUG"},{"start":153,"end":163,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6942848/","_input_hash":534911235,"_task_hash":339662980,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":16,"child":19,"head_span":{"start":97,"end":107,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":112,"end":132,"token_start":18,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":21,"child":24,"head_span":{"start":135,"end":146,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":153,"end":163,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":19,"child":21,"head_span":{"start":112,"end":132,"token_start":18,"token_end":19,"label":"DRUG"},"child_span":{"start":135,"end":146,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The in vitro effect of nicotine ( 10(-7 ) mol l-1 ) on red blood cell ( RBC ) deformability in essential hypertension , efficacy of antihypertensive treatment ( with the combination of enalapril , nifedipine and indapamid ) on hypertension-induced decrease in RBC deformability and interaction between nicotine and efficacy of antihypertensive treatment were investigated in the blood samples obtained from 16 patients with untreated hypertension ( UH ) and 18 patients with treated hypertension ( TH ) .","paragraph":"<h3><u>In vitro effect of nicotine on red blood cell deformability in untreated and treated essential hypertension.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nicotine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10(-7</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>mol</i></b> <b style='color:DodgerBlue;'><i>l-1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>red</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RBC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>deformability</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>essential</i></b> <b style='color:DodgerBlue;'><i>hypertension</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>antihypertensive</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>enalapril</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>nifedipine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>indapamid</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>hypertension-induced</i></b> <b style='color:DodgerBlue;'><i>decrease</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>RBC</i></b> <b style='color:DodgerBlue;'><i>deformability</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>nicotine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>antihypertensive</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>samples</i></b> <b style='color:DodgerBlue;'><i>obtained</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>16</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>hypertension</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>UH</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>hypertension</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TH</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Fourteen healthy subjects served as normotensive (NT) group. RBC deformability was assessed by using a gravity-driven microfiltration technique. In the UH group, the RBC deformability was found to be significantly lower than those in NT (0.623 +/- 0.06 versus 0.753 +/- 0.078, p < 0.001) and in TH (0.623 +/- 0.06 versus 0.732 +/- 0.055, p < 0.001) groups. The RBC deformability in the TH group was not significantly different than that in the NT group (0.753 +/- 0.078 versus 0.732 +/- 0.055, p > 0.05). <b style='color:Tomato;'><i>nicotine</i></b>, in vitro, decreased deformability in the NT (0.668 +/- 0.067 versus 0.753 +/- 0.078, p > 0.0001), UH (0.509 +/- 0.052 versus 0.623 +/- 0.06, p < 0.0001) and TH (0.651 +/- 0.046 versus 0.732 +/- 0.055, p < 0.001) groups. The effect on the UH group was significantly greater than those in the NT (p < 0.0001) and TH (p < 0.0001) groups. These results suggest that <b style='color:Tomato;'><i>nicotine</i></b> and hypertension independently and cumulatively decrease the RBC deformability and <b style='color:Tomato;'><i>nicotine</i></b> inhibits the efficacy of antihypertensive treatment on RBC deformability.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"in","start":4,"end":6,"id":1,"ws":true},{"text":"vitro","start":7,"end":12,"id":2,"ws":true},{"text":"effect","start":13,"end":19,"id":3,"ws":true},{"text":"of","start":20,"end":22,"id":4,"ws":true},{"text":"nicotine","start":23,"end":31,"id":5,"ws":true},{"text":"(","start":32,"end":33,"id":6,"ws":true},{"text":"10(-7","start":34,"end":39,"id":7,"ws":true},{"text":")","start":40,"end":41,"id":8,"ws":true},{"text":"mol","start":42,"end":45,"id":9,"ws":true},{"text":"l-1","start":46,"end":49,"id":10,"ws":true},{"text":")","start":50,"end":51,"id":11,"ws":true},{"text":"on","start":52,"end":54,"id":12,"ws":true},{"text":"red","start":55,"end":58,"id":13,"ws":true},{"text":"blood","start":59,"end":64,"id":14,"ws":true},{"text":"cell","start":65,"end":69,"id":15,"ws":true},{"text":"(","start":70,"end":71,"id":16,"ws":true},{"text":"RBC","start":72,"end":75,"id":17,"ws":true},{"text":")","start":76,"end":77,"id":18,"ws":true},{"text":"deformability","start":78,"end":91,"id":19,"ws":true},{"text":"in","start":92,"end":94,"id":20,"ws":true},{"text":"essential","start":95,"end":104,"id":21,"ws":true},{"text":"hypertension","start":105,"end":117,"id":22,"ws":true},{"text":",","start":118,"end":119,"id":23,"ws":true},{"text":"efficacy","start":120,"end":128,"id":24,"ws":true},{"text":"of","start":129,"end":131,"id":25,"ws":true},{"text":"antihypertensive","start":132,"end":148,"id":26,"ws":true},{"text":"treatment","start":149,"end":158,"id":27,"ws":true},{"text":"(","start":159,"end":160,"id":28,"ws":true},{"text":"with","start":161,"end":165,"id":29,"ws":true},{"text":"the","start":166,"end":169,"id":30,"ws":true},{"text":"combination","start":170,"end":181,"id":31,"ws":true},{"text":"of","start":182,"end":184,"id":32,"ws":true},{"text":"enalapril","start":185,"end":194,"id":33,"ws":true},{"text":",","start":195,"end":196,"id":34,"ws":true},{"text":"nifedipine","start":197,"end":207,"id":35,"ws":true},{"text":"and","start":208,"end":211,"id":36,"ws":true},{"text":"indapamid","start":212,"end":221,"id":37,"ws":true},{"text":")","start":222,"end":223,"id":38,"ws":true},{"text":"on","start":224,"end":226,"id":39,"ws":true},{"text":"hypertension-induced","start":227,"end":247,"id":40,"ws":true},{"text":"decrease","start":248,"end":256,"id":41,"ws":true},{"text":"in","start":257,"end":259,"id":42,"ws":true},{"text":"RBC","start":260,"end":263,"id":43,"ws":true},{"text":"deformability","start":264,"end":277,"id":44,"ws":true},{"text":"and","start":278,"end":281,"id":45,"ws":true},{"text":"interaction","start":282,"end":293,"id":46,"ws":true},{"text":"between","start":294,"end":301,"id":47,"ws":true},{"text":"nicotine","start":302,"end":310,"id":48,"ws":true},{"text":"and","start":311,"end":314,"id":49,"ws":true},{"text":"efficacy","start":315,"end":323,"id":50,"ws":true},{"text":"of","start":324,"end":326,"id":51,"ws":true},{"text":"antihypertensive","start":327,"end":343,"id":52,"ws":true},{"text":"treatment","start":344,"end":353,"id":53,"ws":true},{"text":"were","start":354,"end":358,"id":54,"ws":true},{"text":"investigated","start":359,"end":371,"id":55,"ws":true},{"text":"in","start":372,"end":374,"id":56,"ws":true},{"text":"the","start":375,"end":378,"id":57,"ws":true},{"text":"blood","start":379,"end":384,"id":58,"ws":true},{"text":"samples","start":385,"end":392,"id":59,"ws":true},{"text":"obtained","start":393,"end":401,"id":60,"ws":true},{"text":"from","start":402,"end":406,"id":61,"ws":true},{"text":"16","start":407,"end":409,"id":62,"ws":true},{"text":"patients","start":410,"end":418,"id":63,"ws":true},{"text":"with","start":419,"end":423,"id":64,"ws":true},{"text":"untreated","start":424,"end":433,"id":65,"ws":true},{"text":"hypertension","start":434,"end":446,"id":66,"ws":true},{"text":"(","start":447,"end":448,"id":67,"ws":true},{"text":"UH","start":449,"end":451,"id":68,"ws":true},{"text":")","start":452,"end":453,"id":69,"ws":true},{"text":"and","start":454,"end":457,"id":70,"ws":true},{"text":"18","start":458,"end":460,"id":71,"ws":true},{"text":"patients","start":461,"end":469,"id":72,"ws":true},{"text":"with","start":470,"end":474,"id":73,"ws":true},{"text":"treated","start":475,"end":482,"id":74,"ws":true},{"text":"hypertension","start":483,"end":495,"id":75,"ws":true},{"text":"(","start":496,"end":497,"id":76,"ws":true},{"text":"TH","start":498,"end":500,"id":77,"ws":true},{"text":")","start":501,"end":502,"id":78,"ws":true},{"text":".","start":503,"end":504,"id":79,"ws":false}],"spans":[{"start":23,"end":31,"token_start":5,"token_end":5,"label":"DRUG"},{"start":185,"end":194,"token_start":33,"token_end":33,"label":"DRUG"},{"start":197,"end":207,"token_start":35,"token_end":35,"label":"DRUG"},{"start":302,"end":310,"token_start":48,"token_end":48,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7709169/","_input_hash":-1975197256,"_task_hash":-790878853,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":5,"child":33,"head_span":{"start":23,"end":31,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":185,"end":194,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":33,"child":35,"head_span":{"start":185,"end":194,"token_start":33,"token_end":33,"label":"DRUG"},"child_span":{"start":197,"end":207,"token_start":35,"token_end":35,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"answer":"ignore"}
{"text":"Patients progressing after first-line chemotherapy are treated with docetaxel , pemetrexed or erlotinib .","paragraph":"<h3><u>Chemotherapy of advanced non-small cell lung cancer.</u></h3>Patients with advanced NSCLC receive palliative chemotherapy with platinum-based doublets. Cisplatin-based doublets are preferred in patients with good performance status, whereas <b style='color:Tomato;'><i>carboplatin</i></b>-based protocols are preferred in patients with impaired organ functions (kidney, heart). Customized chemotherapy appears promising but still remains experimental. Improvements of the outcome of first-line chemotherapy have been achieved by the addition of <b style='color:Tomato;'><i>cetuximab</i></b> in patients with EGFR-positive NSCLC and of <b style='color:Tomato;'><i>bevacizumab</i></b> in selected patients with non-squamous cell NSCLC. The optimal combination of chemotherapy with targeted therapies remains a challenge. Maintenance therapy and early second-line chemotherapy might improve outcome but are not yet considered as standard treatments. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Finally, the efficacy of new anticancer treatments should be assessed by several clinical endpoints with overall survival remaining the most important endpoint in patients with advanced NSCLC.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"progressing","start":9,"end":20,"id":1,"ws":true},{"text":"after","start":21,"end":26,"id":2,"ws":true},{"text":"first-line","start":27,"end":37,"id":3,"ws":true},{"text":"chemotherapy","start":38,"end":50,"id":4,"ws":true},{"text":"are","start":51,"end":54,"id":5,"ws":true},{"text":"treated","start":55,"end":62,"id":6,"ws":true},{"text":"with","start":63,"end":67,"id":7,"ws":true},{"text":"docetaxel","start":68,"end":77,"id":8,"ws":true},{"text":",","start":78,"end":79,"id":9,"ws":true},{"text":"pemetrexed","start":80,"end":90,"id":10,"ws":true},{"text":"or","start":91,"end":93,"id":11,"ws":true},{"text":"erlotinib","start":94,"end":103,"id":12,"ws":true},{"text":".","start":104,"end":105,"id":13,"ws":false}],"spans":[{"start":68,"end":77,"token_start":8,"token_end":8,"label":"DRUG"},{"start":80,"end":90,"token_start":10,"token_end":10,"label":"DRUG"},{"start":94,"end":103,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19955802/","_input_hash":-2005189816,"_task_hash":-1392155729,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"To compare the therapeutic effect of \u03b1(2 ) and \u03b1(4 ) integrin-blocking antibodies to conventional inflammatory bowel disease drugs methotrexate , 5-aminosalicylic acid and azathioprine in the dextran sulphate sodium mouse colitis model .","paragraph":"<h3><u>Effective treatment of mouse experimental colitis by alpha 2 integrin antibody: comparison with alpha 4 antibody and conventional therapy.</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>\u03b1(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>\u03b1(4</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>integrin-blocking</i></b> <b style='color:DodgerBlue;'><i>antibodies</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>conventional</i></b> <b style='color:DodgerBlue;'><i>inflammatory</i></b> <b style='color:DodgerBlue;'><i>bowel</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>5-aminosalicylic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>azathioprine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dextran</i></b> <b style='color:DodgerBlue;'><i>sulphate</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>mouse</i></b> <b style='color:DodgerBlue;'><i>colitis</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Colitis was induced in balb/c mice with 2.5-3.0% dextran sulphate sodium. Treatment was given daily for 7 days after the onset of colitis, by rectal installation. Clinical signs of disease were assessed daily using a disease activity index. After 19 days, all animals were killed and colon samples collected for histological grading and mRNA/protein analysis. All treatment groups were compared with an untreated control group and a treatment group receiving dextran sulphate sodium alone to monitor the potential degree of clinical remission. ### results Treatment with anti-\u03b1(2) antibodies and <b style='color:Tomato;'><i>methotrexate</i></b> reduced the body weight loss. At the end of treatment, anti-\u03b1(2) antibodies reduced rectal bleeding, while <b style='color:Tomato;'><i>methotrexate</i></b> reduced the disease activity index score. Histological evaluation showed that anti-\u03b1(2) antibodies, <b style='color:Tomato;'><i>methotrexate</i></b>, 5-<b style='color:Tomato;'><i>aminosalicylic acid</i></b> and <b style='color:Tomato;'><i>azathioprine</i></b> treatment reduced the acute inflammation; <b style='color:Tomato;'><i>methotrexate</i></b> was the only treatment with effect on the crypt score. Compared with the dextran sulphate sodium alone group, the <b style='color:Tomato;'><i>methotrexate</i></b> group showed down-regulation of IL-1\u03b2 at the mRNA level, while the anti-\u03b1(2) antibody group displayed decreased protein expression of iNOS and IL-1\u03b2. ### conclusions Specific blocking of extravascular trafficking of leucocytes with \u03b1(2)-antibodies could be a new beneficial drug target in inflammatory bowel disease.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"compare","start":3,"end":10,"id":1,"ws":true},{"text":"the","start":11,"end":14,"id":2,"ws":true},{"text":"therapeutic","start":15,"end":26,"id":3,"ws":true},{"text":"effect","start":27,"end":33,"id":4,"ws":true},{"text":"of","start":34,"end":36,"id":5,"ws":true},{"text":"\u03b1(2","start":37,"end":40,"id":6,"ws":true},{"text":")","start":41,"end":42,"id":7,"ws":true},{"text":"and","start":43,"end":46,"id":8,"ws":true},{"text":"\u03b1(4","start":47,"end":50,"id":9,"ws":true},{"text":")","start":51,"end":52,"id":10,"ws":true},{"text":"integrin-blocking","start":53,"end":70,"id":11,"ws":true},{"text":"antibodies","start":71,"end":81,"id":12,"ws":true},{"text":"to","start":82,"end":84,"id":13,"ws":true},{"text":"conventional","start":85,"end":97,"id":14,"ws":true},{"text":"inflammatory","start":98,"end":110,"id":15,"ws":true},{"text":"bowel","start":111,"end":116,"id":16,"ws":true},{"text":"disease","start":117,"end":124,"id":17,"ws":true},{"text":"drugs","start":125,"end":130,"id":18,"ws":true},{"text":"methotrexate","start":131,"end":143,"id":19,"ws":true},{"text":",","start":144,"end":145,"id":20,"ws":true},{"text":"5-aminosalicylic","start":146,"end":162,"id":21,"ws":true},{"text":"acid","start":163,"end":167,"id":22,"ws":true},{"text":"and","start":168,"end":171,"id":23,"ws":true},{"text":"azathioprine","start":172,"end":184,"id":24,"ws":true},{"text":"in","start":185,"end":187,"id":25,"ws":true},{"text":"the","start":188,"end":191,"id":26,"ws":true},{"text":"dextran","start":192,"end":199,"id":27,"ws":true},{"text":"sulphate","start":200,"end":208,"id":28,"ws":true},{"text":"sodium","start":209,"end":215,"id":29,"ws":true},{"text":"mouse","start":216,"end":221,"id":30,"ws":true},{"text":"colitis","start":222,"end":229,"id":31,"ws":true},{"text":"model","start":230,"end":235,"id":32,"ws":true},{"text":".","start":236,"end":237,"id":33,"ws":false}],"spans":[{"start":131,"end":143,"token_start":19,"token_end":19,"label":"DRUG"},{"start":146,"end":167,"token_start":21,"token_end":22,"label":"DRUG"},{"start":172,"end":184,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23009282/","_input_hash":-346687764,"_task_hash":486038667,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":19,"child":22,"head_span":{"start":131,"end":143,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":146,"end":167,"token_start":21,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":22,"child":24,"head_span":{"start":146,"end":167,"token_start":21,"token_end":22,"label":"DRUG"},"child_span":{"start":172,"end":184,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Further analyses demonstrated that gemcitabine could significantly interfere with the cytotoxic effects of paclitaxel on both mitotic arrest and apoptotic cell death unless paclitaxel is administered before gemcitabine .","paragraph":"<h3><u>Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis.</u></h3><b style='color:Tomato;'><i>paclitaxel</i></b>, the first member of taxanes, is one of the most active chemotherapeutic agents developed in the last decade for the treatment of advanced breast cancer and many other types of solid tumors. The promising clinical activity of <b style='color:Tomato;'><i>paclitaxel</i></b> has also promoted considerable interest in combining this drug with other anti-tumor agents. In this study, we assessed the cytotoxic interaction between <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> administered at various schedules to human breast and ovarian cancer cells. Through a series of in vitro assays including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, DNA fragmentation, and flow cytometric analyses, we found that <b style='color:Tomato;'><i>gemcitabine</i></b> could significantly antagonize the cytotoxic effects of <b style='color:Tomato;'><i>paclitaxel</i></b> when tumor cells were exposed to the two drugs simultaneously or exposed to <b style='color:Tomato;'><i>gemcitabine</i></b> before <b style='color:Tomato;'><i>paclitaxel</i></b>. However, there was little antagonistic interaction observed when <b style='color:Tomato;'><i>paclitaxel</i></b> was administered before <b style='color:Tomato;'><i>gemcitabine</i></b>. <b style='color:DodgerBlue;'><i>Further</i></b> <b style='color:DodgerBlue;'><i>analyses</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>could</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>interfere</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>mitotic</i></b> <b style='color:DodgerBlue;'><i>arrest</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>apoptotic</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>death</i></b> <b style='color:DodgerBlue;'><i>unless</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>before</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In addition, biochemical examinations revealed that pretreatment or cotreatment of <b style='color:Tomato;'><i>gemcitabine</i></b> inhibited <b style='color:Tomato;'><i>paclitaxel</i></b>-induced IkappaBalpha degradation and bcl-2 phosphorylation that are believed to play critical roles in the signal pathways leading to apoptotic cell death. These results indicate that the interaction between <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> is highly schedule dependent. Exposure of tumor cells to <b style='color:Tomato;'><i>gemcitabine</i></b> before <b style='color:Tomato;'><i>paclitaxel</i></b> or two drugs simultaneously could result in pronounced antagonism. The optimal schedule for this combination might be sequential exposure to <b style='color:Tomato;'><i>paclitaxel</i></b> followed by <b style='color:Tomato;'><i>gemcitabine</i></b>.","tokens":[{"text":"Further","start":0,"end":7,"id":0,"ws":true},{"text":"analyses","start":8,"end":16,"id":1,"ws":true},{"text":"demonstrated","start":17,"end":29,"id":2,"ws":true},{"text":"that","start":30,"end":34,"id":3,"ws":true},{"text":"gemcitabine","start":35,"end":46,"id":4,"ws":true},{"text":"could","start":47,"end":52,"id":5,"ws":true},{"text":"significantly","start":53,"end":66,"id":6,"ws":true},{"text":"interfere","start":67,"end":76,"id":7,"ws":true},{"text":"with","start":77,"end":81,"id":8,"ws":true},{"text":"the","start":82,"end":85,"id":9,"ws":true},{"text":"cytotoxic","start":86,"end":95,"id":10,"ws":true},{"text":"effects","start":96,"end":103,"id":11,"ws":true},{"text":"of","start":104,"end":106,"id":12,"ws":true},{"text":"paclitaxel","start":107,"end":117,"id":13,"ws":true},{"text":"on","start":118,"end":120,"id":14,"ws":true},{"text":"both","start":121,"end":125,"id":15,"ws":true},{"text":"mitotic","start":126,"end":133,"id":16,"ws":true},{"text":"arrest","start":134,"end":140,"id":17,"ws":true},{"text":"and","start":141,"end":144,"id":18,"ws":true},{"text":"apoptotic","start":145,"end":154,"id":19,"ws":true},{"text":"cell","start":155,"end":159,"id":20,"ws":true},{"text":"death","start":160,"end":165,"id":21,"ws":true},{"text":"unless","start":166,"end":172,"id":22,"ws":true},{"text":"paclitaxel","start":173,"end":183,"id":23,"ws":true},{"text":"is","start":184,"end":186,"id":24,"ws":true},{"text":"administered","start":187,"end":199,"id":25,"ws":true},{"text":"before","start":200,"end":206,"id":26,"ws":true},{"text":"gemcitabine","start":207,"end":218,"id":27,"ws":true},{"text":".","start":219,"end":220,"id":28,"ws":false}],"spans":[{"start":35,"end":46,"token_start":4,"token_end":4,"label":"DRUG"},{"start":107,"end":117,"token_start":13,"token_end":13,"label":"DRUG"},{"start":173,"end":183,"token_start":23,"token_end":23,"label":"DRUG"},{"start":207,"end":218,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16855376/","_input_hash":-1404988449,"_task_hash":-541544959,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":23,"child":27,"head_span":{"start":173,"end":183,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":207,"end":218,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Standard anticonvulsants such as phenytoin , the barbiturates , carbamazepine , and the succinimides have been ineffective .","paragraph":"<h3><u>Treatment of infantile spasms.</u></h3>To summarize and evaluate the literature regarding the clinical features, epidemiology, etiology, pathophysiology, and treatment of infantile spasms. ### Data Sources A literature search of articles from January 1966 to July 1993 using MEDLINE, EM-Base, and Current Concepts/Life Sciences, as well as bibliographies of relevant articles. ### Study Selection All identified original and review publications regarding the clinical features, epidemiology, etiology, pathophysiology, and treatment of infantile spasms were reviewed. Emphasis was placed on original studies published since 1975. ### Data Extraction Data from published research were extracted and evaluated according to study design, sample size, dosing regimen, outcome measures, and treatment efficacy and safety. ### Data Synthesis Infantile spasms constitute a rare epileptic syndrome with a poor long-term prognosis for normal intellectual development. The spasms are characterized by a brief symmetric contraction of the muscles of the neck, trunk, and/or extremities, often occurring in a series of 2 to more than 100 spasms during a single episode. The disorder is age-specific, with the peak onset of symptoms occurring between 2 and 8 months of age. Spasms of no identifiable cause in infants with normal development prior to the onset of infantile spasms are classified as cryptogenic or idiopathic, whereas those with an identifiable cause are classified as symptomatic. Long-term prognosis is best in cryptogenic cases, with 30-70 percent attaining normal intellect compared with 5-19 percent in symptomatic cases. The etiology and pathophysiology are not well understood. Recent theory postulates that infantile spasms may be caused by an excess of <b style='color:Tomato;'><i>corticotropin</i></b>-releasing hormone activity during infancy. The suspected association between the whole-cell pertussis vaccine and infantile spasms is coincidental. Few well-designed, prospective, controlled clinical trials for the treatment of infantile spasms have been conducted. ### conclusions <b style='color:DodgerBlue;'><i>Standard</i></b> <b style='color:DodgerBlue;'><i>anticonvulsants</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>phenytoin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>barbiturates</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>carbamazepine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>succinimides</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>ineffective</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Of the anticonvulsants, only the benzodiazepines, <b style='color:Tomato;'><i>valproic</i></b> acid, and <b style='color:Tomato;'><i>vigabatrin</i></b> have shown efficacy in reducing spasm frequency and severity. Hormonal therapy with adrenocorticotropic hormone (ACTH) and/or <b style='color:Tomato;'><i>prednisone</i></b> has been the most frequently studied treatment modality and appears to be the most effective. Hormonal therapy achieves complete spasm control in 50-75 percent of infants within four weeks of initiation. Opinions differ regarding the relative efficacy between ACTH and <b style='color:Tomato;'><i>prednisone</i></b>, the need for early initiation of hormonal treatment, and the benefits of high dosages of ACTH (> 40 units/d). No treatment has been shown conclusively to improve the long-term intellectual development of these infants. Neurosurgery may be the treatment of choice in select cases when a localized central nervous system abnormality can be demonstrated. Well-designed, blind, prospective clinical trials are needed to answer definitively many lingering questions regarding the treatment of infantile spasms.","tokens":[{"text":"Standard","start":0,"end":8,"id":0,"ws":true},{"text":"anticonvulsants","start":9,"end":24,"id":1,"ws":true},{"text":"such","start":25,"end":29,"id":2,"ws":true},{"text":"as","start":30,"end":32,"id":3,"ws":true},{"text":"phenytoin","start":33,"end":42,"id":4,"ws":true},{"text":",","start":43,"end":44,"id":5,"ws":true},{"text":"the","start":45,"end":48,"id":6,"ws":true},{"text":"barbiturates","start":49,"end":61,"id":7,"ws":true},{"text":",","start":62,"end":63,"id":8,"ws":true},{"text":"carbamazepine","start":64,"end":77,"id":9,"ws":true},{"text":",","start":78,"end":79,"id":10,"ws":true},{"text":"and","start":80,"end":83,"id":11,"ws":true},{"text":"the","start":84,"end":87,"id":12,"ws":true},{"text":"succinimides","start":88,"end":100,"id":13,"ws":true},{"text":"have","start":101,"end":105,"id":14,"ws":true},{"text":"been","start":106,"end":110,"id":15,"ws":true},{"text":"ineffective","start":111,"end":122,"id":16,"ws":true},{"text":".","start":123,"end":124,"id":17,"ws":false}],"spans":[{"start":33,"end":42,"token_start":4,"token_end":4,"label":"DRUG"},{"start":64,"end":77,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7919570/","_input_hash":1754802795,"_task_hash":288470055,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Molecular targeting of Aurora A by curcumin restores chemosensitivity by increasing the efficacy of doxorubicin in breast cancer.<br />.","paragraph":"<h3><u>Curcumin Rescues Doxorubicin Responsiveness via Regulating Aurora a Signaling Network in Breast Cancer Cells.</u></h3>Insensitivity towards anthracycline drugs like <b style='color:Tomato;'><i>doxorubicin</i></b> poses a significant challenge in the treatment of breast cancer. Among several factors, Aurora A (a mitotic serine threonine kinase) plays crucial roles in acquiring non-responsiveness towards <b style='color:Tomato;'><i>doxorubicin</i></b>. However, the mechanisms underlying need to be elucidated. The present study was therefore designed to evaluate the underlying mechanisms of Aurora A mediated <b style='color:Tomato;'><i>doxorubicin</i></b> insensitivity in MCF-7Dox/R, an isolated resistant-subline of MCF-7 (breast adenocarcinoma cell line). Effect of <b style='color:Tomato;'><i>curcumin</i></b>, a natural phytochemical in restoring <b style='color:Tomato;'><i>doxorubicin</i></b> sensitivity by targeting Aurora A was assessed furthermore. ### methods A <b style='color:Tomato;'><i>doxorubicin</i></b> resistant subline (MCF-7Dox/R) was isolated from the parental MCF-7 cells by treating the cell with gradual step-wise increasing concentration of the drug. Expressions of Aurora A and its target proteins (Akt, I\u03baB\u03b1 and NF\u03baB) were assessed in both parental and MCF-7Dox/R cells. Both the cell lines were pretreated with <b style='color:Tomato;'><i>curcumin</i></b> prior to <b style='color:Tomato;'><i>doxorubicin</i></b> treatment. Cellular proliferation rate was measured using BrdU (5-bromo-2'-deoxyuridine) assay kit. Intracellular <b style='color:Tomato;'><i>doxorubicin</i></b> accumulation was estimated spectrofluorimetrically. Cellular uptake of <b style='color:Tomato;'><i>curcumin</i></b> (spectrophotometric and spectrofluorimetric method) and its nuclear localization was confirmed by confocal microscopic study. Protein expressions were determined by western blot analysis. Localization of Aurora A was ascertained by immunofluorescence assay. To explore the possible outcome of impact of <b style='color:Tomato;'><i>curcumin</i></b> on Aurora A, cell-cycle distribution and apoptosis were performed subsequently. ### results Higher expressions of Aurora A in MCF-7Dox/R cells led to phosphorylation of Akt as well as I\u03baB\u03b1. Phosphorylated I\u03baB\u03b1 preceded release of NF\u03baB. Phospho-Akt, NF\u03baB consequentially decreased <b style='color:Tomato;'><i>doxorubicin</i></b> accumulation by enhancing the expressions of ABCG2 and Pgp1 respectively. <b style='color:Tomato;'><i>curcumin</i></b> by regulating Aurora A and its target molecules sensitized resistant subline towards <b style='color:Tomato;'><i>doxorubicin</i></b> mediated G2/M-arrest and apoptosis. ### conclusion <b style='color:DodgerBlue;'><i>Molecular</i></b> <b style='color:DodgerBlue;'><i>targeting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Aurora</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>restores</i></b> <b style='color:DodgerBlue;'><i>chemosensitivity</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>increasing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer.<br</i></b> <b style='color:DodgerBlue;'><i>/>.</i></b>","tokens":[{"text":"Molecular","start":0,"end":9,"id":0,"ws":true},{"text":"targeting","start":10,"end":19,"id":1,"ws":true},{"text":"of","start":20,"end":22,"id":2,"ws":true},{"text":"Aurora","start":23,"end":29,"id":3,"ws":true},{"text":"A","start":30,"end":31,"id":4,"ws":true},{"text":"by","start":32,"end":34,"id":5,"ws":true},{"text":"curcumin","start":35,"end":43,"id":6,"ws":true},{"text":"restores","start":44,"end":52,"id":7,"ws":true},{"text":"chemosensitivity","start":53,"end":69,"id":8,"ws":true},{"text":"by","start":70,"end":72,"id":9,"ws":true},{"text":"increasing","start":73,"end":83,"id":10,"ws":true},{"text":"the","start":84,"end":87,"id":11,"ws":true},{"text":"efficacy","start":88,"end":96,"id":12,"ws":true},{"text":"of","start":97,"end":99,"id":13,"ws":true},{"text":"doxorubicin","start":100,"end":111,"id":14,"ws":true},{"text":"in","start":112,"end":114,"id":15,"ws":true},{"text":"breast","start":115,"end":121,"id":16,"ws":true},{"text":"cancer.<br","start":122,"end":132,"id":17,"ws":true},{"text":"/>.","start":133,"end":136,"id":18,"ws":false}],"spans":[{"start":35,"end":43,"token_start":6,"token_end":6,"label":"DRUG"},{"start":100,"end":111,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33773562/","_input_hash":-365673359,"_task_hash":-469195948,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":6,"child":14,"head_span":{"start":35,"end":43,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":100,"end":111,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma .","paragraph":"<h3><u><b style='color:MediumOrchid;'><i>Daratumumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>Lenalidomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Dexamethasone</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>Untreated</i></b> <b style='color:DodgerBlue;'><i>Myeloma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>lenalidomide</i></b> plus <b style='color:Tomato;'><i>dexamethasone</i></b> is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of <b style='color:Tomato;'><i>daratumumab</i></b> would significantly reduce the risk of disease progression or death in this population. ### methods We randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive <b style='color:Tomato;'><i>daratumumab</i></b> plus <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> (<b style='color:Tomato;'><i>daratumumab</i></b> group) or <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> alone (control group). Treatment was to continue until the occurrence of disease progression or unacceptable side effects. The primary end point was progression-free survival. ### results At a median follow-up of 28.0 months, disease progression or death had occurred in 240 patients (97 of 368 patients [26.4%] in the <b style='color:Tomato;'><i>daratumumab</i></b> group and 143 of 369 patients [38.8%] in the control group). The estimated percentage of patients who were alive without disease progression at 30 months was 70.6% (95% confidence interval [CI], 65.0 to 75.4) in the <b style='color:Tomato;'><i>daratumumab</i></b> group and 55.6% (95% CI, 49.5 to 61.3) in the control group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.43 to 0.73; P<0.001). The percentage of patients with a complete response or better was 47.6% in the <b style='color:Tomato;'><i>daratumumab</i></b> group and 24.9% in the control group (P<0.001). A total of 24.2% of the patients in the <b style='color:Tomato;'><i>daratumumab</i></b> group, as compared with 7.3% of the patients in the control group, had results below the threshold for minimal residual disease (1 tumor cell per 10 ### conclusions Among patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received <b style='color:Tomato;'><i>daratumumab</i></b> plus <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> than among those who received <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> alone. A higher incidence of neutropenia and pneumonia was observed in the <b style='color:Tomato;'><i>daratumumab</i></b> group. (Funded by Janssen Research and Development; MAIA ClinicalTrials.gov number, NCT02252172.).","tokens":[{"text":"Daratumumab","start":0,"end":11,"id":0,"ws":true},{"text":"plus","start":12,"end":16,"id":1,"ws":true},{"text":"Lenalidomide","start":17,"end":29,"id":2,"ws":true},{"text":"and","start":30,"end":33,"id":3,"ws":true},{"text":"Dexamethasone","start":34,"end":47,"id":4,"ws":true},{"text":"for","start":48,"end":51,"id":5,"ws":true},{"text":"Untreated","start":52,"end":61,"id":6,"ws":true},{"text":"Myeloma","start":62,"end":69,"id":7,"ws":true},{"text":".","start":70,"end":71,"id":8,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":17,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},{"start":34,"end":47,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31141632/","_input_hash":409989442,"_task_hash":1658537154,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":17,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":4,"child":2,"head_span":{"start":34,"end":47,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":17,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Noninferiority was concluded if the lower limit of the 2-sided 95 % CI for the difference ( doripenem minus meropenem ) in the proportion of patients classified as clinical cures was > or=-15 % .","paragraph":"<h3><u>Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.</u></h3>Complicated intra-abdominal infections (cIAIs) require surgical intervention and empiric antibacterial therapy. <b style='color:Tomato;'><i>doripenem</i></b>, a broad-spectrum carbapenem, provides coverage of key gram-negative and -positive aerobes and anaerobes encountered in cIAI. ### objective This study was designed to compare the efficacy and safety profile of <b style='color:Tomato;'><i>doripenem</i></b> and <b style='color:Tomato;'><i>meropenem</i></b> in hospitalized adult patients with cIAI. ### methods In this prospective, multicenter, doubleblind, noninferiority study, hospitalized adults with cIAI were randomly assigned to receive <b style='color:Tomato;'><i>doripenem</i></b> 500 mg IV q8h or <b style='color:Tomato;'><i>meropenem</i></b> 1 g IV q8h. After a minimum of 9 doses and adequate clinical improvement (relative to before the start of IV study drug, decreased body temperature and white blood cell count, improved or absent signs and symptoms of cIAI, and return of normal bowel function), patients could be switched to oral <b style='color:Tomato;'><i>amoxicillin</i></b>/clavulanate. Antibacterial therapy (IV plus subsequent oral) was given for a total of 5 to 14 days. The coprimary efficacy end points were the clinical cure rate (complete resolution or significant improvement of signs or symptoms of the index infection) in patients microbiologically evaluable (>or=1 baseline pathogen isolated from an intra-abdominal culture that was susceptible to both IV study drug therapies) at the test-of-cure (TOC) visit (21-60 days after the completion of study drug therapy) and the clinical cure rate in the microbiological modified intent-to-treat (mMITT) population (a bacterial pathogen identified at baseline, regardless of its susceptibility to the study drug). <b style='color:DodgerBlue;'><i>Noninferiority</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>concluded</i></b> <b style='color:DodgerBlue;'><i>if</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>limit</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>2-sided</i></b> <b style='color:DodgerBlue;'><i>95</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>CI</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>difference</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>doripenem</i></b> <b style='color:DodgerBlue;'><i>minus</i></b> <b style='color:MediumOrchid;'><i>meropenem</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>proportion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>classified</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>cures</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>or=-15</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results A total of 476 patients were enrolled. The microbiologically evaluable population (319 patients) was 62.7% male and 67.7% white, with a mean age and weight of 46.7 years and 77.2 kg, respectively. In this population, <b style='color:Tomato;'><i>doripenem</i></b> and <b style='color:Tomato;'><i>meropenem</i></b> were associated with clinical cure rates at the TOC visit of 85.9% and 85.3%, respectively. The corresponding treatment difference was 0.6% (95% CI, -7.7% to 9.0%); this difference was not statistically significant. Similarly, in the mMITT population (385 patients), the clinical cure rates were 77.9% and 78.9%, respectively, and the corresponding 1.0% treatment difference was not statistically significant (95% CI, -9.7% to 7.7%). Clinical cure rates were not significantly different between the 2 treatment arms in key subgroups (eg, age, sex, race, baseline Acute Physiology and Chronic Health Evaluation II score, primary infection site). Microbiological eradication rates for common pathogens isolated at study entry were not significantly different between the 2 treatment groups. <b style='color:Tomato;'><i>doripenem</i></b> was well tolerated in the population studied. In the intent-to-treat population (471 patients), 83.0% and 78.0% of patients experienced >or=1 adverse event (AE) and 13.2% and 14.0% experienced >or=1 serious AE in the <b style='color:Tomato;'><i>doripenem</i></b> and <b style='color:Tomato;'><i>meropenem</i></b> treatment arms, respectively. In the <b style='color:Tomato;'><i>doripenem</i></b> and <b style='color:Tomato;'><i>meropenem</i></b> treatment arms, AEs resulted in study drug discontinuation in 5.1% and 2.1% of patients and death in 2.1% and 3.0% of patients, respectively. ### conclusions The present study found that <b style='color:Tomato;'><i>doripenem</i></b> (500 mg q8h) was effective in the treatment of cIAI, was therapeutically noninferior to <b style='color:Tomato;'><i>meropenem</i></b> (1 g q8h), with a safety profile not significantly different from that of <b style='color:Tomato;'><i>meropenem</i></b> in this selected population of patients with cIAI.","tokens":[{"text":"Noninferiority","start":0,"end":14,"id":0,"ws":true},{"text":"was","start":15,"end":18,"id":1,"ws":true},{"text":"concluded","start":19,"end":28,"id":2,"ws":true},{"text":"if","start":29,"end":31,"id":3,"ws":true},{"text":"the","start":32,"end":35,"id":4,"ws":true},{"text":"lower","start":36,"end":41,"id":5,"ws":true},{"text":"limit","start":42,"end":47,"id":6,"ws":true},{"text":"of","start":48,"end":50,"id":7,"ws":true},{"text":"the","start":51,"end":54,"id":8,"ws":true},{"text":"2-sided","start":55,"end":62,"id":9,"ws":true},{"text":"95","start":63,"end":65,"id":10,"ws":true},{"text":"%","start":66,"end":67,"id":11,"ws":true},{"text":"CI","start":68,"end":70,"id":12,"ws":true},{"text":"for","start":71,"end":74,"id":13,"ws":true},{"text":"the","start":75,"end":78,"id":14,"ws":true},{"text":"difference","start":79,"end":89,"id":15,"ws":true},{"text":"(","start":90,"end":91,"id":16,"ws":true},{"text":"doripenem","start":92,"end":101,"id":17,"ws":true},{"text":"minus","start":102,"end":107,"id":18,"ws":true},{"text":"meropenem","start":108,"end":117,"id":19,"ws":true},{"text":")","start":118,"end":119,"id":20,"ws":true},{"text":"in","start":120,"end":122,"id":21,"ws":true},{"text":"the","start":123,"end":126,"id":22,"ws":true},{"text":"proportion","start":127,"end":137,"id":23,"ws":true},{"text":"of","start":138,"end":140,"id":24,"ws":true},{"text":"patients","start":141,"end":149,"id":25,"ws":true},{"text":"classified","start":150,"end":160,"id":26,"ws":true},{"text":"as","start":161,"end":163,"id":27,"ws":true},{"text":"clinical","start":164,"end":172,"id":28,"ws":true},{"text":"cures","start":173,"end":178,"id":29,"ws":true},{"text":"was","start":179,"end":182,"id":30,"ws":true},{"text":">","start":183,"end":184,"id":31,"ws":true},{"text":"or=-15","start":185,"end":191,"id":32,"ws":true},{"text":"%","start":192,"end":193,"id":33,"ws":true},{"text":".","start":194,"end":195,"id":34,"ws":false}],"spans":[{"start":92,"end":101,"token_start":17,"token_end":17,"label":"DRUG"},{"start":108,"end":117,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18555934/","_input_hash":-1631434525,"_task_hash":-1096036509,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We further illustrate the practical considerations of managing irAEs by presenting three cases of immune-related toxicity in melanoma patients treated with nivolumab or pembrolizumab .","paragraph":"<h3><u>Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.</u></h3>: Immune checkpoint inhibitors have emerged as a mainstay of melanoma therapy and are playing an increasingly important role in the treatment of other tumor types. The clinical benefit afforded by these treatments can be accompanied by a unique spectrum of adverse events, called immune-related adverse events (irAEs), which reflect the drug's immune-based mechanism of action. IrAEs typically originate in the skin, gastrointestinal tract, liver, and endocrine system, although other organ systems may also be affected. This article provides an overview of irAEs associated with anti-programmed death-1 (anti-PD-1) antibodies (<b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>pembrolizumab</i></b>) as monotherapy or in combination with anti-cytotoxic T-lymphocyte antigen-4 inhibition (<b style='color:Tomato;'><i>ipilimumab</i></b>), followed by a discussion of irAEs of special clinical interest based on the potential for morbidity, frequent steroid use, and inpatient admission. We review clinical trial data and provide recommendations on how to manage irAEs associated with anti-PD-1 agents based on clinical experience and established management guidelines. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>illustrate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>practical</i></b> <b style='color:DodgerBlue;'><i>considerations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>managing</i></b> <b style='color:DodgerBlue;'><i>irAEs</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>presenting</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>immune-related</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A better understanding of the identification and management of irAEs will help inform health care providers about the risks associated with anti-PD-1 treatment, to ensure the safe and appropriate use of these important new treatments. ### Implications For Practice Immune checkpoint inhibitors have demonstrated significant clinical benefit in advanced melanoma and other tumor types. These treatments are associated with immune-related adverse events (irAEs), which most commonly affect the skin and gastrointestinal tract, and, to a lesser extent, the liver, endocrine system, and other organs. This review focuses on the management of irAEs after treatment with anti-programmed death-1 (anti-PD-1) antibodies (<b style='color:Tomato;'><i>nivolumab</i></b> or <b style='color:Tomato;'><i>pembrolizumab</i></b>) as monotherapy or in combination with anti-cytotoxic T-lymphocyte antigen-4 inhibition (<b style='color:Tomato;'><i>ipilimumab</i></b>) in patients with advanced melanoma. A better understanding of the management of irAEs will help ensure the safe and appropriate use of anti-PD-1 agents in melanoma and other tumor types.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"further","start":3,"end":10,"id":1,"ws":true},{"text":"illustrate","start":11,"end":21,"id":2,"ws":true},{"text":"the","start":22,"end":25,"id":3,"ws":true},{"text":"practical","start":26,"end":35,"id":4,"ws":true},{"text":"considerations","start":36,"end":50,"id":5,"ws":true},{"text":"of","start":51,"end":53,"id":6,"ws":true},{"text":"managing","start":54,"end":62,"id":7,"ws":true},{"text":"irAEs","start":63,"end":68,"id":8,"ws":true},{"text":"by","start":69,"end":71,"id":9,"ws":true},{"text":"presenting","start":72,"end":82,"id":10,"ws":true},{"text":"three","start":83,"end":88,"id":11,"ws":true},{"text":"cases","start":89,"end":94,"id":12,"ws":true},{"text":"of","start":95,"end":97,"id":13,"ws":true},{"text":"immune-related","start":98,"end":112,"id":14,"ws":true},{"text":"toxicity","start":113,"end":121,"id":15,"ws":true},{"text":"in","start":122,"end":124,"id":16,"ws":true},{"text":"melanoma","start":125,"end":133,"id":17,"ws":true},{"text":"patients","start":134,"end":142,"id":18,"ws":true},{"text":"treated","start":143,"end":150,"id":19,"ws":true},{"text":"with","start":151,"end":155,"id":20,"ws":true},{"text":"nivolumab","start":156,"end":165,"id":21,"ws":true},{"text":"or","start":166,"end":168,"id":22,"ws":true},{"text":"pembrolizumab","start":169,"end":182,"id":23,"ws":true},{"text":".","start":183,"end":184,"id":24,"ws":false}],"spans":[{"start":156,"end":165,"token_start":21,"token_end":21,"label":"DRUG"},{"start":169,"end":182,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27401894/","_input_hash":-48906776,"_task_hash":-509555020,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Randomized</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:MediumOrchid;'><i>lonafarnib</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>epithelial</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IIB-IV</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>This study evaluates whether a molecular targeted therapy with the farnesyltransferase inhibitor <b style='color:Tomato;'><i>lonafarnib</i></b> added to standard chemotherapy in first-line treatment of advanced ovarian cancer (OC) could improve progression-free (PFS) and overall survival (OS). ### Patients And Methods We performed a prospective randomized phase II study to compare standard therapy <b style='color:Tomato;'><i>carboplatin</i></b> (C; AUC 5) and <b style='color:Tomato;'><i>paclitaxel</i></b> (T; 175 mg/m(2)) in primary advanced OC with or without <b style='color:Tomato;'><i>lonafarnib</i></b> (L). <b style='color:Tomato;'><i>lonafarnib</i></b> was given in a dose of 100mg orally twice a day during chemotherapy and was increased afterwards to 200mg up to six months as a maintenance therapy. ### results 105 patients were recruited (53 patients were randomized to receive LTC, 52 to TC). Hematologic toxicity was similar in both arms. Grade 3 and 4 non-hematological toxicity, occurred significantly more often with LTC (23% versus 4%, p=0.005) and was associated with a higher dropout rate. PFS and OS were not significantly different among both arms. The LTC arm showed inferiority in the stratum with residual tumor of more than 1cm: median PFS was 11.5 months (95% CI: 7.4-14.2) compared with 16.4 (95% CI: 10.3-40.4) for TC (p=0.0141; HR=0.36 (95% CI: 0.15-0.84)) with median OS 20.6 months (95% CI: 13.1-31.0) and 43.4 months (95% CI: 15.7-) for the TC arm (p=0.012; HR=0.32 (95% CI: 0.13-0.8)). ### conclusion The addition of <b style='color:Tomato;'><i>lonafarnib</i></b> did not improve PFS or OS. Patients with a residual tumor of more than 1cm had significantly shorter PFS and OS. Incorporation of <b style='color:Tomato;'><i>lonafarnib</i></b> into future studies for primary therapy of OC is not recommended.","tokens":[{"text":"Randomized","start":0,"end":10,"id":0,"ws":true},{"text":"phase","start":11,"end":16,"id":1,"ws":true},{"text":"II","start":17,"end":19,"id":2,"ws":true},{"text":"trial","start":20,"end":25,"id":3,"ws":true},{"text":"of","start":26,"end":28,"id":4,"ws":true},{"text":"carboplatin","start":29,"end":40,"id":5,"ws":true},{"text":"and","start":41,"end":44,"id":6,"ws":true},{"text":"paclitaxel","start":45,"end":55,"id":7,"ws":true},{"text":"with","start":56,"end":60,"id":8,"ws":true},{"text":"or","start":61,"end":63,"id":9,"ws":true},{"text":"without","start":64,"end":71,"id":10,"ws":true},{"text":"lonafarnib","start":72,"end":82,"id":11,"ws":true},{"text":"in","start":83,"end":85,"id":12,"ws":true},{"text":"first-line","start":86,"end":96,"id":13,"ws":true},{"text":"treatment","start":97,"end":106,"id":14,"ws":true},{"text":"of","start":107,"end":109,"id":15,"ws":true},{"text":"epithelial","start":110,"end":120,"id":16,"ws":true},{"text":"ovarian","start":121,"end":128,"id":17,"ws":true},{"text":"cancer","start":129,"end":135,"id":18,"ws":true},{"text":"stage","start":136,"end":141,"id":19,"ws":true},{"text":"IIB-IV","start":142,"end":148,"id":20,"ws":true},{"text":".","start":149,"end":150,"id":21,"ws":false}],"spans":[{"start":29,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},{"start":45,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},{"start":72,"end":82,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22564713/","_input_hash":747770856,"_task_hash":440874334,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":29,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":45,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":7,"child":11,"head_span":{"start":45,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":72,"end":82,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":5,"child":7,"head_span":{"start":29,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":45,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","NEG11"],"answer":"accept"}
{"text":"One subject who received oxaprozin for 12 days and , in addition , aspirin for the last five days developed a rash that subsided after both drugs were discontinued ; one subject treated with aspirin experienced tinnitus .","paragraph":"<h3><u>Effects of oxaprozin alone or in combination with aspirin on hemostasis and plasma protein binding.</u></h3><b style='color:Tomato;'><i>oxaprozin</i></b>, a new nonsteroidal antiinflammatory agent, was studied alone and in combination with <b style='color:Tomato;'><i>aspirin</i></b> for its effects on hemostasis and protein binding in 10 healthy adults. When both <b style='color:Tomato;'><i>oxaprozin</i></b> and <b style='color:Tomato;'><i>aspirin</i></b> were given separately for seven days and in combination for five days, both drugs prolonged bleeding time and inhibited collagen- and <b style='color:Tomato;'><i>epinephrine</i></b>-induced platelet aggregation to a similar degree. The effects of the combination of <b style='color:Tomato;'><i>oxaprozin</i></b> and <b style='color:Tomato;'><i>aspirin</i></b> were not additive. The data from the protein binding study showed that <b style='color:Tomato;'><i>oxaprozin</i></b> was more than 99 per cent bound to plasma proteins. <b style='color:Tomato;'><i>aspirin</i></b> displaced <b style='color:Tomato;'><i>oxaprozin</i></b> from its binding sites. As a result, the rate of plasma clearance of <b style='color:Tomato;'><i>oxaprozin</i></b> significantly increased from 20 to 26 ml/min/kg (P less than 0.05), and the plasma half-life decreased from 45 to 40 hours. Platelet count and the humoral clotting mechanism were not affected by either drug alone or in combination. There was no clinical evidence of bleeding. <b style='color:DodgerBlue;'><i>One</i></b> <b style='color:DodgerBlue;'><i>subject</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>oxaprozin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>last</i></b> <b style='color:DodgerBlue;'><i>five</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>rash</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>subsided</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>discontinued</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>subject</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>experienced</i></b> <b style='color:DodgerBlue;'><i>tinnitus</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These data suggest that <b style='color:Tomato;'><i>oxaprozin</i></b>, like <b style='color:Tomato;'><i>aspirin</i></b> and other nonsteroidal antiinflammatory drugs, should be used with caution when administered to patients who have suffered trauma, who undergo surgery, or who have known defects in hemostasis.","tokens":[{"text":"One","start":0,"end":3,"id":0,"ws":true},{"text":"subject","start":4,"end":11,"id":1,"ws":true},{"text":"who","start":12,"end":15,"id":2,"ws":true},{"text":"received","start":16,"end":24,"id":3,"ws":true},{"text":"oxaprozin","start":25,"end":34,"id":4,"ws":true},{"text":"for","start":35,"end":38,"id":5,"ws":true},{"text":"12","start":39,"end":41,"id":6,"ws":true},{"text":"days","start":42,"end":46,"id":7,"ws":true},{"text":"and","start":47,"end":50,"id":8,"ws":true},{"text":",","start":51,"end":52,"id":9,"ws":true},{"text":"in","start":53,"end":55,"id":10,"ws":true},{"text":"addition","start":56,"end":64,"id":11,"ws":true},{"text":",","start":65,"end":66,"id":12,"ws":true},{"text":"aspirin","start":67,"end":74,"id":13,"ws":true},{"text":"for","start":75,"end":78,"id":14,"ws":true},{"text":"the","start":79,"end":82,"id":15,"ws":true},{"text":"last","start":83,"end":87,"id":16,"ws":true},{"text":"five","start":88,"end":92,"id":17,"ws":true},{"text":"days","start":93,"end":97,"id":18,"ws":true},{"text":"developed","start":98,"end":107,"id":19,"ws":true},{"text":"a","start":108,"end":109,"id":20,"ws":true},{"text":"rash","start":110,"end":114,"id":21,"ws":true},{"text":"that","start":115,"end":119,"id":22,"ws":true},{"text":"subsided","start":120,"end":128,"id":23,"ws":true},{"text":"after","start":129,"end":134,"id":24,"ws":true},{"text":"both","start":135,"end":139,"id":25,"ws":true},{"text":"drugs","start":140,"end":145,"id":26,"ws":true},{"text":"were","start":146,"end":150,"id":27,"ws":true},{"text":"discontinued","start":151,"end":163,"id":28,"ws":true},{"text":";","start":164,"end":165,"id":29,"ws":true},{"text":"one","start":166,"end":169,"id":30,"ws":true},{"text":"subject","start":170,"end":177,"id":31,"ws":true},{"text":"treated","start":178,"end":185,"id":32,"ws":true},{"text":"with","start":186,"end":190,"id":33,"ws":true},{"text":"aspirin","start":191,"end":198,"id":34,"ws":true},{"text":"experienced","start":199,"end":210,"id":35,"ws":true},{"text":"tinnitus","start":211,"end":219,"id":36,"ws":true},{"text":".","start":220,"end":221,"id":37,"ws":false}],"spans":[{"start":25,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},{"start":67,"end":74,"token_start":13,"token_end":13,"label":"DRUG"},{"start":191,"end":198,"token_start":34,"token_end":34,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6863578/","_input_hash":-631930754,"_task_hash":-1422821104,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":4,"child":13,"head_span":{"start":25,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":67,"end":74,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"To determine the long-term tolerability of prophylactic administration of pyrazinamide and levofloxacin in patients possibly exposed to multidrug-resistant tuberculosis ( MDRTB ) after undergoing solid organ transplantation .","paragraph":"<h3><u>Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population.</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>tolerability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>prophylactic</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pyrazinamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>possibly</i></b> <b style='color:DodgerBlue;'><i>exposed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>multidrug-resistant</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MDRTB</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>undergoing</i></b> <b style='color:DodgerBlue;'><i>solid</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### design Retrospective analysis. ### setting Community outpatient clinic. ### patients Forty-eight recipients of solid organ transplants beginning prophylaxis for MDRTB during August 1999 after possible exposure to a single index case of multidrug-resistant Mycobacterium tuberculosis within our community ### intervention Prophylaxis consisted of <b style='color:Tomato;'><i>pyrazinamide</i></b> 30 mg/kg/day plus <b style='color:Tomato;'><i>levofloxacin</i></b> 500 mg/day, administered for 1 year. ### Measurements And Main Results Thirteen (27.1%) of the 48 patients completed therapy; 27 (56.3%) discontinued therapy within 4 months due to adverse drug events. Gastrointestinal intolerance was the major adverse event resulting in early discontinuation. ### conclusion Prophylaxis of MDRTB with <b style='color:Tomato;'><i>levofloxacin</i></b> and <b style='color:Tomato;'><i>pyrazinamide</i></b> was associated with limited tolerability due to the high frequency of adverse events. While we search for a better tolerated prophylactic regimen, close monitoring for adverse reactions is recommended.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"determine","start":3,"end":12,"id":1,"ws":true},{"text":"the","start":13,"end":16,"id":2,"ws":true},{"text":"long-term","start":17,"end":26,"id":3,"ws":true},{"text":"tolerability","start":27,"end":39,"id":4,"ws":true},{"text":"of","start":40,"end":42,"id":5,"ws":true},{"text":"prophylactic","start":43,"end":55,"id":6,"ws":true},{"text":"administration","start":56,"end":70,"id":7,"ws":true},{"text":"of","start":71,"end":73,"id":8,"ws":true},{"text":"pyrazinamide","start":74,"end":86,"id":9,"ws":true},{"text":"and","start":87,"end":90,"id":10,"ws":true},{"text":"levofloxacin","start":91,"end":103,"id":11,"ws":true},{"text":"in","start":104,"end":106,"id":12,"ws":true},{"text":"patients","start":107,"end":115,"id":13,"ws":true},{"text":"possibly","start":116,"end":124,"id":14,"ws":true},{"text":"exposed","start":125,"end":132,"id":15,"ws":true},{"text":"to","start":133,"end":135,"id":16,"ws":true},{"text":"multidrug-resistant","start":136,"end":155,"id":17,"ws":true},{"text":"tuberculosis","start":156,"end":168,"id":18,"ws":true},{"text":"(","start":169,"end":170,"id":19,"ws":true},{"text":"MDRTB","start":171,"end":176,"id":20,"ws":true},{"text":")","start":177,"end":178,"id":21,"ws":true},{"text":"after","start":179,"end":184,"id":22,"ws":true},{"text":"undergoing","start":185,"end":195,"id":23,"ws":true},{"text":"solid","start":196,"end":201,"id":24,"ws":true},{"text":"organ","start":202,"end":207,"id":25,"ws":true},{"text":"transplantation","start":208,"end":223,"id":26,"ws":true},{"text":".","start":224,"end":225,"id":27,"ws":false}],"spans":[{"start":74,"end":86,"token_start":9,"token_end":9,"label":"DRUG"},{"start":91,"end":103,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12066961/","_input_hash":-295180058,"_task_hash":-1547116997,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":74,"end":86,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":91,"end":103,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Additive effect of the combination of griseofulvin and ketoconazole against Microsporum canis in vitro .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Additive</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>griseofulvin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ketoconazole</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>Microsporum</i></b> <b style='color:DodgerBlue;'><i>canis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The susceptibility of 28 strains of Microsporum canis to <b style='color:Tomato;'><i>griseofulvin</i></b>, to <b style='color:Tomato;'><i>ketoconazole</i></b> and to a combination of both antifungal drugs was determined. <b style='color:Tomato;'><i>griseofulvin</i></b> proved to be more active than <b style='color:Tomato;'><i>ketoconazole</i></b>. The combination of both antifungal agents was found to exert an additive effect.","tokens":[{"text":"Additive","start":0,"end":8,"id":0,"ws":true},{"text":"effect","start":9,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"the","start":19,"end":22,"id":3,"ws":true},{"text":"combination","start":23,"end":34,"id":4,"ws":true},{"text":"of","start":35,"end":37,"id":5,"ws":true},{"text":"griseofulvin","start":38,"end":50,"id":6,"ws":true},{"text":"and","start":51,"end":54,"id":7,"ws":true},{"text":"ketoconazole","start":55,"end":67,"id":8,"ws":true},{"text":"against","start":68,"end":75,"id":9,"ws":true},{"text":"Microsporum","start":76,"end":87,"id":10,"ws":true},{"text":"canis","start":88,"end":93,"id":11,"ws":true},{"text":"in","start":94,"end":96,"id":12,"ws":true},{"text":"vitro","start":97,"end":102,"id":13,"ws":true},{"text":".","start":103,"end":104,"id":14,"ws":false}],"spans":[{"start":38,"end":50,"token_start":6,"token_end":6,"label":"DRUG"},{"start":55,"end":67,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2608097/","_input_hash":2130587174,"_task_hash":169417825,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":38,"end":50,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":55,"end":67,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Aprepitant plus ondansetron may increase acute-CR , may have benefit regarding CINV 's effect on QoL , and is safe for 5-day temozolomide compared to ondansetron .","paragraph":"<h3><u>Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.</u></h3>CINV remains a distressing side effect experienced by glioma patients receiving multi-day <b style='color:Tomato;'><i>temozolomide</i></b> therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists. Antiemetic research with <b style='color:Tomato;'><i>aprepitant</i></b> has routinely excluded glioma patients. In this randomized open-label phase II study, use of a nonstandard 5-day regimen of <b style='color:Tomato;'><i>aprepitant</i></b> for glioma patients was investigated. ### methods One hundred thirty-six glioma patients receiving their first cycle of adjuvant <b style='color:Tomato;'><i>temozolomide</i></b> (150-200\u00a0mg/m ### results Patients were 61% male, 97% white, 48% with KPS >\u200990%, 60% non-smokers, mean age 54, 92% with low alcohol use, and 46% with a CINV history. The CC was 58.6% (Arm-A) and 54.5% (Arm-B). Acute-complete response (CR) rates, defined as CC on day 1 in Arm-A and -B, were 97.1% and 87.9%, respectively (p\u2009=\u20090.056). Treatment-related toxicities were mild or moderate in severity. ### conclusions <b style='color:MediumOrchid;'><i>Aprepitant</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ondansetron</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>acute-CR</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>regarding</i></b> <b style='color:DodgerBlue;'><i>CINV</i></b> <b style='color:DodgerBlue;'><i>'s</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>QoL</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>safe</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5-day</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>ondansetron</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This study provides no evidence that <b style='color:Tomato;'><i>aprepitant</i></b> increases CC rate over <b style='color:Tomato;'><i>ondansetron</i></b> alone.","tokens":[{"text":"Aprepitant","start":0,"end":10,"id":0,"ws":true},{"text":"plus","start":11,"end":15,"id":1,"ws":true},{"text":"ondansetron","start":16,"end":27,"id":2,"ws":true},{"text":"may","start":28,"end":31,"id":3,"ws":true},{"text":"increase","start":32,"end":40,"id":4,"ws":true},{"text":"acute-CR","start":41,"end":49,"id":5,"ws":true},{"text":",","start":50,"end":51,"id":6,"ws":true},{"text":"may","start":52,"end":55,"id":7,"ws":true},{"text":"have","start":56,"end":60,"id":8,"ws":true},{"text":"benefit","start":61,"end":68,"id":9,"ws":true},{"text":"regarding","start":69,"end":78,"id":10,"ws":true},{"text":"CINV","start":79,"end":83,"id":11,"ws":true},{"text":"'s","start":84,"end":86,"id":12,"ws":true},{"text":"effect","start":87,"end":93,"id":13,"ws":true},{"text":"on","start":94,"end":96,"id":14,"ws":true},{"text":"QoL","start":97,"end":100,"id":15,"ws":true},{"text":",","start":101,"end":102,"id":16,"ws":true},{"text":"and","start":103,"end":106,"id":17,"ws":true},{"text":"is","start":107,"end":109,"id":18,"ws":true},{"text":"safe","start":110,"end":114,"id":19,"ws":true},{"text":"for","start":115,"end":118,"id":20,"ws":true},{"text":"5-day","start":119,"end":124,"id":21,"ws":true},{"text":"temozolomide","start":125,"end":137,"id":22,"ws":true},{"text":"compared","start":138,"end":146,"id":23,"ws":true},{"text":"to","start":147,"end":149,"id":24,"ws":true},{"text":"ondansetron","start":150,"end":161,"id":25,"ws":true},{"text":".","start":162,"end":163,"id":26,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},{"start":125,"end":137,"token_start":22,"token_end":22,"label":"DRUG"},{"start":150,"end":161,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31440823/","_input_hash":-1844568564,"_task_hash":-2015927903,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Finally , a further synergistically improved myeloma cell lysis with the daratumumab-IPH2102 combination was observed by adding lenalidomide , which suggests that more effective treatment strategies can be designed for multiple myeloma by combining daratumumab with agents that independently modulate natural killer cell function .","paragraph":"<h3><u>Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.</u></h3>Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated cytotoxicity is an important effector mechanism of <b style='color:Tomato;'><i>daratumumab</i></b>, we explored the possibility of improving <b style='color:Tomato;'><i>daratumumab</i></b>-mediated cell-mediated cytotoxicity by blocking natural killer cell inhibitory receptors with the human monoclonal anti-KIR antibody IPH2102, next to activation of natural killer cells with the immune modulatory drug <b style='color:Tomato;'><i>lenalidomide</i></b>. In 4-hour antibody-dependent cell-mediated cytotoxicity assays, IPH2102 did not induce lysis of multiple myeloma cell lines, but it did significantly augment <b style='color:Tomato;'><i>daratumumab</i></b>-induced myeloma cell lysis. Also in an ex vivo setting, IPH2102 synergistically improved <b style='color:Tomato;'><i>daratumumab</i></b>-dependent lysis of primary myeloma cells in bone marrow mononuclear cells (n=21), especially in patients carrying the Fc\u03b3RIIIa-158F allele or the Fc\u03b3RIIa-131R allele, who bind IgG1 with lower affinity than patients carrying the Fc\u03b3RIIIa-158V allele or the Fc\u03b3RIIa-131H allele. <b style='color:DodgerBlue;'><i>Finally</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>synergistically</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>myeloma</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lysis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>daratumumab-IPH2102</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>adding</i></b> <b style='color:MediumOrchid;'><i>lenalidomide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>suggests</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>strategies</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>designed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>myeloma</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>combining</i></b> <b style='color:MediumOrchid;'><i>daratumumab</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>independently</i></b> <b style='color:DodgerBlue;'><i>modulate</i></b> <b style='color:DodgerBlue;'><i>natural</i></b> <b style='color:DodgerBlue;'><i>killer</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>function</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Finally","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"a","start":10,"end":11,"id":2,"ws":true},{"text":"further","start":12,"end":19,"id":3,"ws":true},{"text":"synergistically","start":20,"end":35,"id":4,"ws":true},{"text":"improved","start":36,"end":44,"id":5,"ws":true},{"text":"myeloma","start":45,"end":52,"id":6,"ws":true},{"text":"cell","start":53,"end":57,"id":7,"ws":true},{"text":"lysis","start":58,"end":63,"id":8,"ws":true},{"text":"with","start":64,"end":68,"id":9,"ws":true},{"text":"the","start":69,"end":72,"id":10,"ws":true},{"text":"daratumumab-IPH2102","start":73,"end":92,"id":11,"ws":true},{"text":"combination","start":93,"end":104,"id":12,"ws":true},{"text":"was","start":105,"end":108,"id":13,"ws":true},{"text":"observed","start":109,"end":117,"id":14,"ws":true},{"text":"by","start":118,"end":120,"id":15,"ws":true},{"text":"adding","start":121,"end":127,"id":16,"ws":true},{"text":"lenalidomide","start":128,"end":140,"id":17,"ws":true},{"text":",","start":141,"end":142,"id":18,"ws":true},{"text":"which","start":143,"end":148,"id":19,"ws":true},{"text":"suggests","start":149,"end":157,"id":20,"ws":true},{"text":"that","start":158,"end":162,"id":21,"ws":true},{"text":"more","start":163,"end":167,"id":22,"ws":true},{"text":"effective","start":168,"end":177,"id":23,"ws":true},{"text":"treatment","start":178,"end":187,"id":24,"ws":true},{"text":"strategies","start":188,"end":198,"id":25,"ws":true},{"text":"can","start":199,"end":202,"id":26,"ws":true},{"text":"be","start":203,"end":205,"id":27,"ws":true},{"text":"designed","start":206,"end":214,"id":28,"ws":true},{"text":"for","start":215,"end":218,"id":29,"ws":true},{"text":"multiple","start":219,"end":227,"id":30,"ws":true},{"text":"myeloma","start":228,"end":235,"id":31,"ws":true},{"text":"by","start":236,"end":238,"id":32,"ws":true},{"text":"combining","start":239,"end":248,"id":33,"ws":true},{"text":"daratumumab","start":249,"end":260,"id":34,"ws":true},{"text":"with","start":261,"end":265,"id":35,"ws":true},{"text":"agents","start":266,"end":272,"id":36,"ws":true},{"text":"that","start":273,"end":277,"id":37,"ws":true},{"text":"independently","start":278,"end":291,"id":38,"ws":true},{"text":"modulate","start":292,"end":300,"id":39,"ws":true},{"text":"natural","start":301,"end":308,"id":40,"ws":true},{"text":"killer","start":309,"end":315,"id":41,"ws":true},{"text":"cell","start":316,"end":320,"id":42,"ws":true},{"text":"function","start":321,"end":329,"id":43,"ws":true},{"text":".","start":330,"end":331,"id":44,"ws":false}],"spans":[{"start":128,"end":140,"token_start":17,"token_end":17,"label":"DRUG"},{"start":249,"end":260,"token_start":34,"token_end":34,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25510242/","_input_hash":582595095,"_task_hash":-625758571,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":17,"child":34,"head_span":{"start":128,"end":140,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":249,"end":260,"token_start":34,"token_end":34,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Both liposomal doxorubicin ( LD ) and docetaxel ( D ) have a broad range of activity against solid tumors , including advanced pancreatic cancer ( APC ) , as single agents , while their combination has produced encouraging response rates in the treatment of several malignancies .","paragraph":"<h3><u>A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer.</u></h3> <b style='color:DodgerBlue;'><i>Both</i></b> <b style='color:DodgerBlue;'><i>liposomal</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>D</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>broad</i></b> <b style='color:DodgerBlue;'><i>range</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>solid</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>pancreatic</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>APC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>produced</i></b> <b style='color:DodgerBlue;'><i>encouraging</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>several</i></b> <b style='color:DodgerBlue;'><i>malignancies</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We have conducted a Phase-II study in order to evaluate the tolerance and efficacy of their combination as front-line treatment in patients with APC. ### Patients And Methods Twenty-one chemotherapy-na\u00efve patients with unresectable, locally-advanced or metastatic pancreatic cancer were enrolled. These included 16 males and 5 females with median age 66 years (range 57-80). Performance status (PS) was 0 (n = 10 pts), 1 (n = 7 pts) and 2 (n = 4 pts). D (80 mg/m2), and LD (30 mg/m2) were administered on day 1, every 3 weeks. RhG-CSF s.c. was given to all patients. At the time of analysis, all included patients were evaluated for toxicity and for response. ### results A total of 92 cycles were administered (4.38 cycles/patient). Partial response was achieved in 6 patients, with a median duration of response of 3 months. Stable disease was observed in 7 patients and progressive disease in 8 patients. The median duration of survival was 10 months (95% CI, 6-14 months) and the actuarial 1-year survival rate was 33.33%. With regard to toxicity, grades 3,4 neutropenia occurred in 8 (38%) patients and grades 3,4 thrombocytopenia in 4 (19%) patients. Non-hematological toxicity was recorded in 15 (71%) patients: grades 3,4 diarrhea (3 pts, 14%), hypersensitivity reactions (3 pt, 14%), grade 2 neurotoxicity (6 pts, 29%) and palmar-plantar erythrodysesthesia (9 pts, 43%). ### conclusion The <b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> combination was well-tolerated by these poor prognosis patients. Although both drugs have a marginal activity in pancreatic cancer, most patients experienced significant clinical improvement, with acceptable toxicity.","tokens":[{"text":"Both","start":0,"end":4,"id":0,"ws":true},{"text":"liposomal","start":5,"end":14,"id":1,"ws":true},{"text":"doxorubicin","start":15,"end":26,"id":2,"ws":true},{"text":"(","start":27,"end":28,"id":3,"ws":true},{"text":"LD","start":29,"end":31,"id":4,"ws":true},{"text":")","start":32,"end":33,"id":5,"ws":true},{"text":"and","start":34,"end":37,"id":6,"ws":true},{"text":"docetaxel","start":38,"end":47,"id":7,"ws":true},{"text":"(","start":48,"end":49,"id":8,"ws":true},{"text":"D","start":50,"end":51,"id":9,"ws":true},{"text":")","start":52,"end":53,"id":10,"ws":true},{"text":"have","start":54,"end":58,"id":11,"ws":true},{"text":"a","start":59,"end":60,"id":12,"ws":true},{"text":"broad","start":61,"end":66,"id":13,"ws":true},{"text":"range","start":67,"end":72,"id":14,"ws":true},{"text":"of","start":73,"end":75,"id":15,"ws":true},{"text":"activity","start":76,"end":84,"id":16,"ws":true},{"text":"against","start":85,"end":92,"id":17,"ws":true},{"text":"solid","start":93,"end":98,"id":18,"ws":true},{"text":"tumors","start":99,"end":105,"id":19,"ws":true},{"text":",","start":106,"end":107,"id":20,"ws":true},{"text":"including","start":108,"end":117,"id":21,"ws":true},{"text":"advanced","start":118,"end":126,"id":22,"ws":true},{"text":"pancreatic","start":127,"end":137,"id":23,"ws":true},{"text":"cancer","start":138,"end":144,"id":24,"ws":true},{"text":"(","start":145,"end":146,"id":25,"ws":true},{"text":"APC","start":147,"end":150,"id":26,"ws":true},{"text":")","start":151,"end":152,"id":27,"ws":true},{"text":",","start":153,"end":154,"id":28,"ws":true},{"text":"as","start":155,"end":157,"id":29,"ws":true},{"text":"single","start":158,"end":164,"id":30,"ws":true},{"text":"agents","start":165,"end":171,"id":31,"ws":true},{"text":",","start":172,"end":173,"id":32,"ws":true},{"text":"while","start":174,"end":179,"id":33,"ws":true},{"text":"their","start":180,"end":185,"id":34,"ws":true},{"text":"combination","start":186,"end":197,"id":35,"ws":true},{"text":"has","start":198,"end":201,"id":36,"ws":true},{"text":"produced","start":202,"end":210,"id":37,"ws":true},{"text":"encouraging","start":211,"end":222,"id":38,"ws":true},{"text":"response","start":223,"end":231,"id":39,"ws":true},{"text":"rates","start":232,"end":237,"id":40,"ws":true},{"text":"in","start":238,"end":240,"id":41,"ws":true},{"text":"the","start":241,"end":244,"id":42,"ws":true},{"text":"treatment","start":245,"end":254,"id":43,"ws":true},{"text":"of","start":255,"end":257,"id":44,"ws":true},{"text":"several","start":258,"end":265,"id":45,"ws":true},{"text":"malignancies","start":266,"end":278,"id":46,"ws":true},{"text":".","start":279,"end":280,"id":47,"ws":false}],"spans":[{"start":15,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},{"start":38,"end":47,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12552960/","_input_hash":-2076036099,"_task_hash":-313014095,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":2,"child":7,"head_span":{"start":15,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":38,"end":47,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Immune/endocrine measures included blood counts of lymphocytes , granulocytes , monocytes and natural killer ( NK ) cells ; levels of several cell surface markers ; NK cytotoxicity ; plasma levels of interleukin (IL)-6 , IL-10 , dehydroepiandrosterone and neuropeptide Y , and plasma and salivary cortisol levels .","paragraph":"<h3><u>Resilience of the immune system in healthy young students to 30-hour sleep deprivation with psychological stress.</u></h3>Young adults often encounter sleep deprivation and stressful events. Both have been separately reported to modulate immunity, and occasionally they occur simultaneously. We assessed the combined effects of these conditions on immune competence in healthy students. ### methods Twenty-three participants (mean age 24 years; SD 1.86; 14 females) were exposed to 30 h of sleep deprivation during which they conducted physiological, social and cognitive tasks. The control group consisted of 18 participants (mean age 23.67 years; SD 1.46; 11 females). All participants underwent cognitive and psychological evaluations at 10:00 AM, followed by blood and saliva collection, 3 days before sleep deprivation induction and on the morning following it. <b style='color:DodgerBlue;'><i>Immune/endocrine</i></b> <b style='color:DodgerBlue;'><i>measures</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>counts</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>lymphocytes</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>granulocytes</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>monocytes</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>natural</i></b> <b style='color:DodgerBlue;'><i>killer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NK</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>several</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>surface</i></b> <b style='color:DodgerBlue;'><i>markers</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>NK</i></b> <b style='color:DodgerBlue;'><i>cytotoxicity</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>interleukin</i></b> <b style='color:DodgerBlue;'><i>(IL)-6</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>IL-10</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>dehydroepiandrosterone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>neuropeptide</i></b> <b style='color:DodgerBlue;'><i>Y</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>salivary</i></b> <b style='color:DodgerBlue;'><i>cortisol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Although the experimental protocol significantly elevated state anxiety and psychological dissociation levels, no effects were evident in any of the immunological/endocrine indices. In contrast, expected sex differences in immune measures were found, including significantly higher NK cytotoxicity and monocyte counts in males, validating the integrity of the measurements. ### conclusions The findings suggest resilience of the immune system to a combined sleep deprivation and stressful exposure in young adults, while previous studies reported immune perturbations following either of these conditions separately. These apparent contradictions might reflect differences in the study design or in the methodology used for immunological assessments, including the time of sample collection, the combination of sleep deprivation with stress and our in vivo assessment of cytokine levels.","tokens":[{"text":"Immune/endocrine","start":0,"end":16,"id":0,"ws":true},{"text":"measures","start":17,"end":25,"id":1,"ws":true},{"text":"included","start":26,"end":34,"id":2,"ws":true},{"text":"blood","start":35,"end":40,"id":3,"ws":true},{"text":"counts","start":41,"end":47,"id":4,"ws":true},{"text":"of","start":48,"end":50,"id":5,"ws":true},{"text":"lymphocytes","start":51,"end":62,"id":6,"ws":true},{"text":",","start":63,"end":64,"id":7,"ws":true},{"text":"granulocytes","start":65,"end":77,"id":8,"ws":true},{"text":",","start":78,"end":79,"id":9,"ws":true},{"text":"monocytes","start":80,"end":89,"id":10,"ws":true},{"text":"and","start":90,"end":93,"id":11,"ws":true},{"text":"natural","start":94,"end":101,"id":12,"ws":true},{"text":"killer","start":102,"end":108,"id":13,"ws":true},{"text":"(","start":109,"end":110,"id":14,"ws":true},{"text":"NK","start":111,"end":113,"id":15,"ws":true},{"text":")","start":114,"end":115,"id":16,"ws":true},{"text":"cells","start":116,"end":121,"id":17,"ws":true},{"text":";","start":122,"end":123,"id":18,"ws":true},{"text":"levels","start":124,"end":130,"id":19,"ws":true},{"text":"of","start":131,"end":133,"id":20,"ws":true},{"text":"several","start":134,"end":141,"id":21,"ws":true},{"text":"cell","start":142,"end":146,"id":22,"ws":true},{"text":"surface","start":147,"end":154,"id":23,"ws":true},{"text":"markers","start":155,"end":162,"id":24,"ws":true},{"text":";","start":163,"end":164,"id":25,"ws":true},{"text":"NK","start":165,"end":167,"id":26,"ws":true},{"text":"cytotoxicity","start":168,"end":180,"id":27,"ws":true},{"text":";","start":181,"end":182,"id":28,"ws":true},{"text":"plasma","start":183,"end":189,"id":29,"ws":true},{"text":"levels","start":190,"end":196,"id":30,"ws":true},{"text":"of","start":197,"end":199,"id":31,"ws":true},{"text":"interleukin","start":200,"end":211,"id":32,"ws":true},{"text":"(IL)-6","start":212,"end":218,"id":33,"ws":true},{"text":",","start":219,"end":220,"id":34,"ws":true},{"text":"IL-10","start":221,"end":226,"id":35,"ws":true},{"text":",","start":227,"end":228,"id":36,"ws":true},{"text":"dehydroepiandrosterone","start":229,"end":251,"id":37,"ws":true},{"text":"and","start":252,"end":255,"id":38,"ws":true},{"text":"neuropeptide","start":256,"end":268,"id":39,"ws":true},{"text":"Y","start":269,"end":270,"id":40,"ws":true},{"text":",","start":271,"end":272,"id":41,"ws":true},{"text":"and","start":273,"end":276,"id":42,"ws":true},{"text":"plasma","start":277,"end":283,"id":43,"ws":true},{"text":"and","start":284,"end":287,"id":44,"ws":true},{"text":"salivary","start":288,"end":296,"id":45,"ws":true},{"text":"cortisol","start":297,"end":305,"id":46,"ws":true},{"text":"levels","start":306,"end":312,"id":47,"ws":true},{"text":".","start":313,"end":314,"id":48,"ws":false}],"spans":[{"start":229,"end":251,"token_start":37,"token_end":37,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23635771/","_input_hash":-678503294,"_task_hash":-1173281487,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Triple</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ranitidine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lansoprazole</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Helicobacter</i></b> <b style='color:DodgerBlue;'><i>pylori-associated</i></b> <b style='color:DodgerBlue;'><i>duodenal</i></b> <b style='color:DodgerBlue;'><i>ulcer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The aim of this study was to verify the efficacy--in the cure of duodenal ulcer associated H. pylori infection--of <b style='color:Tomato;'><i>ranitidine</i></b> 300 mg taken late in the evening or <b style='color:Tomato;'><i>lansoprazole</i></b> 30 mg taken before breakfast, coupled with <b style='color:Tomato;'><i>clarithromycin</i></b> and <b style='color:Tomato;'><i>met<b style='color:Tomato;'><i>ronidazole</i></b></i></b>. ### methods Eighty patients with endoscopically proven active duodenal ulcer were randomized to take <b style='color:Tomato;'><i>ranitidine</i></b> or <b style='color:Tomato;'><i>lansoprazole</i></b> for 4-8 wk, together with <b style='color:Tomato;'><i>clarithromycin</i></b> 250 mg b.i.d. and <b style='color:Tomato;'><i>met<b style='color:Tomato;'><i>ronidazole</i></b></i></b> 500 mg b.id. for the first 2 wk. Endoscopic controls, as well as histological and urease tests for H. pylori, were performed at entry and after 4 and 8 wk. ### results According to intent-to-treat analysis, ulcers were healed after 4 wk in 36/40 patients (90%) with <b style='color:Tomato;'><i>ranitidine</i></b> and in 38/40 (95%) with <b style='color:Tomato;'><i>lansoprazole</i></b>. After 8 wk, the healing percentage with <b style='color:Tomato;'><i>ranitidine</i></b> and <b style='color:Tomato;'><i>lansoprazole</i></b> was 97% (39/40) and 95% (38/40), respectively. H. pylori was eradicated in 85% of the patients taking <b style='color:Tomato;'><i>ranitidine</i></b> and in 90% of those taking lanzoprazole. Side effects were reported in 25% of the patients in both groups. ### conclusions Our results confirm that the combination of <b style='color:Tomato;'><i>ranitidine</i></b>, <b style='color:Tomato;'><i>clarithromycin</i></b>, and <b style='color:Tomato;'><i>met<b style='color:Tomato;'><i>ronidazole</i></b></i></b> can be considered an alternative to proton pump inhibitors in terms of clinical efficacy and economy.","tokens":[{"text":"Triple","start":0,"end":6,"id":0,"ws":true},{"text":"therapy","start":7,"end":14,"id":1,"ws":true},{"text":"with","start":15,"end":19,"id":2,"ws":true},{"text":"ranitidine","start":20,"end":30,"id":3,"ws":true},{"text":"or","start":31,"end":33,"id":4,"ws":true},{"text":"lansoprazole","start":34,"end":46,"id":5,"ws":true},{"text":"in","start":47,"end":49,"id":6,"ws":true},{"text":"the","start":50,"end":53,"id":7,"ws":true},{"text":"treatment","start":54,"end":63,"id":8,"ws":true},{"text":"of","start":64,"end":66,"id":9,"ws":true},{"text":"Helicobacter","start":67,"end":79,"id":10,"ws":true},{"text":"pylori-associated","start":80,"end":97,"id":11,"ws":true},{"text":"duodenal","start":98,"end":106,"id":12,"ws":true},{"text":"ulcer","start":107,"end":112,"id":13,"ws":true},{"text":".","start":113,"end":114,"id":14,"ws":false}],"spans":[{"start":20,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},{"start":34,"end":46,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9128316/","_input_hash":-353700267,"_task_hash":1936915150,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"A study on the effect of cimetidine and L-carnitine on myoglobinuric acute kidney injury in male rats .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cimetidine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>L-carnitine</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>myoglobinuric</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>kidney</i></b> <b style='color:DodgerBlue;'><i>injury</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>male</i></b> <b style='color:DodgerBlue;'><i>rats</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Myoglobinuric acute renal failure is the most important life threatening complication of rhabdomyolysis. Iron, free radicals, nitric oxide and cytochrome p450 are involved in the pathogenesis of mARF. The aim of this study is to compare the effect of <b style='color:Tomato;'><i>cimetidine</i></b>, <b style='color:Tomato;'><i>l-carnitine</i></b> and both agents together on mARF in rats. Forty rats were divided into 5 groups; group I: control rats, group II: myoglobinuric ARF rats, group III: mARF rats received <b style='color:Tomato;'><i>l-carnitine</i></b> (200mg/kg, i.p.), group IV: mARF rats received <b style='color:Tomato;'><i>cimetidine</i></b> (150mg/kg i.p.) and group V: mARF rats received both agents together. 48h after glycerol injection, systolic blood pressure was measured. Urine and blood samples were collected to evaluate urine volume, GFR, BUN, creatinine, K, Na, serum creatine kinase, NO and glutathione levels. Kidney specimens were taken to investigate renal cytochrome p450 and for histological examinations. <b style='color:Tomato;'><i>cimetidine</i></b> treatment significantly decreased creatinine, BUN, K, Na, SBP and creatine kinase and increased GFR and urine volume compared to group II. <b style='color:Tomato;'><i>l-carnitine</i></b> exerted similar changes except for the effect on K and GFR. NO was significantly decreased, while renal glutathione and cytochrome p450 were significantly increased in groups treated with <b style='color:Tomato;'><i>l-carnitine</i></b> or <b style='color:Tomato;'><i>cimetidine</i></b> as compared to group II. Combined treatment further improved renal functions, creatine kinase, oxidative stress parameters and SBP as compared to each therapy alone. The histological changes confirmed the biochemical findings. <b style='color:Tomato;'><i>cimetidine</i></b> and <b style='color:Tomato;'><i>l-carnitine</i></b> have protective effects - almost equally - against mARF. Using both agents together, minimises the renal injury.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"study","start":2,"end":7,"id":1,"ws":true},{"text":"on","start":8,"end":10,"id":2,"ws":true},{"text":"the","start":11,"end":14,"id":3,"ws":true},{"text":"effect","start":15,"end":21,"id":4,"ws":true},{"text":"of","start":22,"end":24,"id":5,"ws":true},{"text":"cimetidine","start":25,"end":35,"id":6,"ws":true},{"text":"and","start":36,"end":39,"id":7,"ws":true},{"text":"L-carnitine","start":40,"end":51,"id":8,"ws":true},{"text":"on","start":52,"end":54,"id":9,"ws":true},{"text":"myoglobinuric","start":55,"end":68,"id":10,"ws":true},{"text":"acute","start":69,"end":74,"id":11,"ws":true},{"text":"kidney","start":75,"end":81,"id":12,"ws":true},{"text":"injury","start":82,"end":88,"id":13,"ws":true},{"text":"in","start":89,"end":91,"id":14,"ws":true},{"text":"male","start":92,"end":96,"id":15,"ws":true},{"text":"rats","start":97,"end":101,"id":16,"ws":true},{"text":".","start":102,"end":103,"id":17,"ws":false}],"spans":[{"start":25,"end":35,"token_start":6,"token_end":6,"label":"DRUG"},{"start":40,"end":51,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25930980/","_input_hash":1590305965,"_task_hash":55740094,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":25,"end":35,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":40,"end":51,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Importantly , MAPK and/or MTOR complex1 ( MTORC1 ) activity were upregulated in AML cells made resistant to several FLT3 inhibitors , including crenolanib , quizartinib , or sorafenib .","paragraph":"<h3><u>Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.</u></h3>Drug resistance impedes the long-term effect of targeted therapies in acute myeloid leukemia (AML), necessitating the identification of mechanisms underlying resistance. Approximately 25% of AML patients carry FLT3 mutations and develop post-treatment insensitivity to FLT3 inhibitors, including <b style='color:Tomato;'><i>sorafenib</i></b>. Using a genome-wide CRISPR screen, we identified LZTR1, NF1, TSC1 or TSC2, negative regulators of the MAPK and MTOR pathways, as mediators of <b style='color:Tomato;'><i>sorafenib</i></b> resistance. Analyses of ex vivo drug sensitivity assays in FLT3-ITD AML patient samples revealed lower expression of LZTR1, NF1, and TSC2 correlated with <b style='color:Tomato;'><i>sorafenib</i></b> sensitivity. <b style='color:DodgerBlue;'><i>Importantly</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:DodgerBlue;'><i>MTOR</i></b> <b style='color:DodgerBlue;'><i>complex1</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MTORC1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>upregulated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>made</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>several</i></b> <b style='color:DodgerBlue;'><i>FLT3</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>crenolanib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>quizartinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These cells were sensitive to MEK inhibitors, and the combination of FLT3 and MEK inhibitors showed enhanced efficacy, suggesting its effectiveness in AML patients with FLT3 mutations and those with resistance to FLT3 inhibitors.","tokens":[{"text":"Importantly","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"MAPK","start":14,"end":18,"id":2,"ws":true},{"text":"and/or","start":19,"end":25,"id":3,"ws":true},{"text":"MTOR","start":26,"end":30,"id":4,"ws":true},{"text":"complex1","start":31,"end":39,"id":5,"ws":true},{"text":"(","start":40,"end":41,"id":6,"ws":true},{"text":"MTORC1","start":42,"end":48,"id":7,"ws":true},{"text":")","start":49,"end":50,"id":8,"ws":true},{"text":"activity","start":51,"end":59,"id":9,"ws":true},{"text":"were","start":60,"end":64,"id":10,"ws":true},{"text":"upregulated","start":65,"end":76,"id":11,"ws":true},{"text":"in","start":77,"end":79,"id":12,"ws":true},{"text":"AML","start":80,"end":83,"id":13,"ws":true},{"text":"cells","start":84,"end":89,"id":14,"ws":true},{"text":"made","start":90,"end":94,"id":15,"ws":true},{"text":"resistant","start":95,"end":104,"id":16,"ws":true},{"text":"to","start":105,"end":107,"id":17,"ws":true},{"text":"several","start":108,"end":115,"id":18,"ws":true},{"text":"FLT3","start":116,"end":120,"id":19,"ws":true},{"text":"inhibitors","start":121,"end":131,"id":20,"ws":true},{"text":",","start":132,"end":133,"id":21,"ws":true},{"text":"including","start":134,"end":143,"id":22,"ws":true},{"text":"crenolanib","start":144,"end":154,"id":23,"ws":true},{"text":",","start":155,"end":156,"id":24,"ws":true},{"text":"quizartinib","start":157,"end":168,"id":25,"ws":true},{"text":",","start":169,"end":170,"id":26,"ws":true},{"text":"or","start":171,"end":173,"id":27,"ws":true},{"text":"sorafenib","start":174,"end":183,"id":28,"ws":true},{"text":".","start":184,"end":185,"id":29,"ws":false}],"spans":[{"start":144,"end":154,"token_start":23,"token_end":23,"label":"DRUG"},{"start":157,"end":168,"token_start":25,"token_end":25,"label":"DRUG"},{"start":174,"end":183,"token_start":28,"token_end":28,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33375770/","_input_hash":-89744534,"_task_hash":-1737484190,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We tested whether varenicline , a partial nicotine agonist , would also increase future quit attempts .","paragraph":"<h3><u>Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial.</u></h3><b style='color:Tomato;'><i>nicotine</i></b> replacement therapy to aid smoking reduction increases the probability of a future quit attempt among smokers not currently planning to quit smoking. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>tested</i></b> <b style='color:DodgerBlue;'><i>whether</i></b> <b style='color:MediumOrchid;'><i>varenicline</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:MediumOrchid;'><i>nicotine</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>would</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>future</i></b> <b style='color:DodgerBlue;'><i>quit</i></b> <b style='color:DodgerBlue;'><i>attempts</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This randomized, placebo-controlled trial recruited 218 smokers who were interested in quitting but had no plans to quit in the next month. Participants used <b style='color:Tomato;'><i>varenicline</i></b> (2 mg/day) or placebo for 2-8 weeks plus received brief counseling on methods to reduce cigarettes/day. The primary measure was the incidence of a quit attempt within 6 months of study entry. Secondary measures were point prevalence abstinence, motivation to stop smoking, and reduction in cigarettes/day. ### results <b style='color:Tomato;'><i>varenicline</i></b> increased the incidence of a quit attempt more than placebo at the Nebraska site (73% vs. 41%; p < .001) but not at the Vermont site (45% vs. 51%; p = .45). <b style='color:Tomato;'><i>varenicline</i></b> increased most other measures of quit attempts, motivation and abstinence, independent of site. The beneficial effects of <b style='color:Tomato;'><i>varenicline</i></b> in quit attempts appeared to be mediated by greater reductions in cigarettes/day, dependence, craving, and cigarette satisfaction. <b style='color:Tomato;'><i>varenicline</i></b> had a greater effect on quit attempts in less-dependent smokers, in minority smokers, and in those who had less prior cessation or reduction activity. Adverse events were minimal. ### conclusions <b style='color:Tomato;'><i>varenicline</i></b> increased quit attempts in smokers who are not currently trying to quit at one of the two study sites and improved most all secondary outcomes independent of site. This appeared to be due to decreasing cigarettes/day and level of dependence.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"tested","start":3,"end":9,"id":1,"ws":true},{"text":"whether","start":10,"end":17,"id":2,"ws":true},{"text":"varenicline","start":18,"end":29,"id":3,"ws":true},{"text":",","start":30,"end":31,"id":4,"ws":true},{"text":"a","start":32,"end":33,"id":5,"ws":true},{"text":"partial","start":34,"end":41,"id":6,"ws":true},{"text":"nicotine","start":42,"end":50,"id":7,"ws":true},{"text":"agonist","start":51,"end":58,"id":8,"ws":true},{"text":",","start":59,"end":60,"id":9,"ws":true},{"text":"would","start":61,"end":66,"id":10,"ws":true},{"text":"also","start":67,"end":71,"id":11,"ws":true},{"text":"increase","start":72,"end":80,"id":12,"ws":true},{"text":"future","start":81,"end":87,"id":13,"ws":true},{"text":"quit","start":88,"end":92,"id":14,"ws":true},{"text":"attempts","start":93,"end":101,"id":15,"ws":true},{"text":".","start":102,"end":103,"id":16,"ws":false}],"spans":[{"start":18,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},{"start":42,"end":50,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21652735/","_input_hash":-687691192,"_task_hash":-142610382,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"However , combination of pioglitazone and sulfasalazine has shown greater efficacy .","paragraph":"<h3><u>Comparative evaluation of different doses of PPAR-\u03b3 agonist alone and in combination with sulfasalazine in experimentally induced inflammatory bowel disease in rats.</u></h3>Inflammatory bowel disease (IBD) is an idiopathic, chronic inflammatory condition, which affects the gastrointestinal tract and has no curative treatment. The present study aimed to investigate the effect of different doses of <b style='color:Tomato;'><i>pioglitazone</i></b> alone and in combination with <b style='color:Tomato;'><i>sulfasalazine</i></b> in TNBS (trinitrobenzenesulfonic acid)-induced inflammatory bowel disease (IBD) in rats. ### methods A total of 36 animals were included in the study. Animals were divided into five groups (n = 6): group I--vehicle (ethanol), group II--TNBS + ethanol, group IIIA--TNBS + <b style='color:Tomato;'><i>pioglitazone</i></b> (15 mg/kg), group IIIB--TNBS + <b style='color:Tomato;'><i>pioglitazone</i></b> (30 mg/kg), group IV--TNBS + <b style='color:Tomato;'><i>sulfasalazine</i></b> (360 mg/kg), group V--TNBS + <b style='color:Tomato;'><i>sulfasalazine</i></b> (360 mg/kg) + <b style='color:Tomato;'><i>pioglitazone</i></b> (least effective dose found in group III). Group III was divided into two subgroups, namely IIIA and IIIB, on the basis of different doses of <b style='color:Tomato;'><i>pioglitazone</i></b> used. After completion of two weeks of treatment, rats were sacrificed under ether anesthesia by cervical dislocation for assessment of intestinal inflammation, histological analysis, myeloperoxidase assay, malondialdehyde assay and TNF-\u03b1 estimation. ### results All the drug-treated groups showed both gross morphological and microscopic score either 1 or 2. None of them showed score of > 2 on both gross and microscopic morphological examination. Both MDA levels and MPO activity were significantly reduced in the drug-treated groups, with maximum reduction seen in the combination group. TNF-\u03b1 was reduced in <b style='color:Tomato;'><i>pioglitazone</i></b> group. It was highly reduced in <b style='color:Tomato;'><i>sulfasalazine</i></b> group (group V) as compared to TNBS group thereby indicating that <b style='color:Tomato;'><i>pioglitazone</i></b> is protective in TNBS-induced inflammatory bowel disease. ### conclusion The present study showed reduction in lipid peroxidation, malondialdehyde levels and TNF-\u03b1 levels in <b style='color:Tomato;'><i>pioglitazone</i></b>-treated group and hence, there was significant improvement in gross and microscopic features, too. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pioglitazone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sulfasalazine</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"combination","start":10,"end":21,"id":2,"ws":true},{"text":"of","start":22,"end":24,"id":3,"ws":true},{"text":"pioglitazone","start":25,"end":37,"id":4,"ws":true},{"text":"and","start":38,"end":41,"id":5,"ws":true},{"text":"sulfasalazine","start":42,"end":55,"id":6,"ws":true},{"text":"has","start":56,"end":59,"id":7,"ws":true},{"text":"shown","start":60,"end":65,"id":8,"ws":true},{"text":"greater","start":66,"end":73,"id":9,"ws":true},{"text":"efficacy","start":74,"end":82,"id":10,"ws":true},{"text":".","start":83,"end":84,"id":11,"ws":false}],"spans":[{"start":25,"end":37,"token_start":4,"token_end":4,"label":"DRUG"},{"start":42,"end":55,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24145089/","_input_hash":2109137854,"_task_hash":-782628125,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":6,"child":4,"head_span":{"start":42,"end":55,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":25,"end":37,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"At time 2 , genotypic resistance to zidovudine was found in 11 out of 12 cases ( 41L : two cases ; 41L , 215Y : six cases ; 41L , 210W , 215Y : two cases ; M41L , D67N , L210W , T215Y : one case ) with a mean 18.9 + /- 8.8-fold increase in the IC50 to zidovudine and 1.4 + /- 0.4-fold to stavudine","paragraph":"<h3><u>Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.</u></h3>To assess phenotypic and genotypic cross-resistance to nucleoside reverse transcriptase inhibitors in patients treated with a combination including <b style='color:Tomato;'><i>zidovudine</i></b>, who were switched to a combination including <b style='color:Tomato;'><i>stavudine</i></b>. ### methods We analysed 24 clinical HIV-1 isolates from 12 patients before and several months after therapeutic switching. Plasma HIV-1 RNA was measured using quantitative polymerase chain reaction (Roche). Genotypic resistance was measured by sequencing the reverse transcriptase gene from plasma HIV-1 RNA. Phenotypic resistance was measured using a recombinant assay (Virco). ### results Patients were treated with a combination including <b style='color:Tomato;'><i>zidovudine</i></b> for a mean (+/- SEM) period of 21.8 +/- 3.5 months and had a plasma viral load of 4.1 +/- 0.2 log HIV-1 RNA copies/mL (time 1). After a mean period of 19.3 +/- 1.6 months following the therapeutic change, the plasma viral load was 3.6 +/- 0.1 log copies/mL (time 2). At time 1, genotypic resistance to <b style='color:Tomato;'><i>zidovudine</i></b> was found in all cases (41L: four cases; 41L, 215Y: five cases; 41L, 210W, 215Y: two cases; K70R: one case) with a mean 6.6 +/- 1.6-fold increase in the median inhibitory concentration (IC50) to <b style='color:Tomato;'><i>zidovudine</i></b> and 1.7 +/- 0.4-fold to <b style='color:Tomato;'><i>stavudine</i></b>. <b style='color:DodgerBlue;'><i>At</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>genotypic</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>zidovudine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>11</i></b> <b style='color:DodgerBlue;'><i>out</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>41L</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>41L</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>215Y</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>41L</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>210W</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>215Y</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>M41L</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>D67N</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>L210W</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>T215Y</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>case</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>18.9</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>/-</i></b> <b style='color:DodgerBlue;'><i>8.8-fold</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>IC50</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>zidovudine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>1.4</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>/-</i></b> <b style='color:DodgerBlue;'><i>0.4-fold</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>stavudine</i></b> ### conclusions In this clinical series of patients with suboptimal control of plasma HIV-1 RNA using a combination including <b style='color:Tomato;'><i>zidovudine</i></b>, the presence of <b style='color:Tomato;'><i>zidovudine</i></b>-related mutations was associated with a decreased phenotypic sensitivity to this drug. Despite persistent HIV-1 replication, switching to <b style='color:Tomato;'><i>stavudine</i></b> was associated with a further decrease in phenotypic sensitivity to <b style='color:Tomato;'><i>zidovudine</i></b> but not to <b style='color:Tomato;'><i>stavudine</i></b> after 19 months. These data suggest that <b style='color:Tomato;'><i>stavudine</i></b> remains a possible option in <b style='color:Tomato;'><i>zidovudine</i></b>-experienced patients.","tokens":[{"text":"At","start":0,"end":2,"id":0,"ws":true},{"text":"time","start":3,"end":7,"id":1,"ws":true},{"text":"2","start":8,"end":9,"id":2,"ws":true},{"text":",","start":10,"end":11,"id":3,"ws":true},{"text":"genotypic","start":12,"end":21,"id":4,"ws":true},{"text":"resistance","start":22,"end":32,"id":5,"ws":true},{"text":"to","start":33,"end":35,"id":6,"ws":true},{"text":"zidovudine","start":36,"end":46,"id":7,"ws":true},{"text":"was","start":47,"end":50,"id":8,"ws":true},{"text":"found","start":51,"end":56,"id":9,"ws":true},{"text":"in","start":57,"end":59,"id":10,"ws":true},{"text":"11","start":60,"end":62,"id":11,"ws":true},{"text":"out","start":63,"end":66,"id":12,"ws":true},{"text":"of","start":67,"end":69,"id":13,"ws":true},{"text":"12","start":70,"end":72,"id":14,"ws":true},{"text":"cases","start":73,"end":78,"id":15,"ws":true},{"text":"(","start":79,"end":80,"id":16,"ws":true},{"text":"41L","start":81,"end":84,"id":17,"ws":true},{"text":":","start":85,"end":86,"id":18,"ws":true},{"text":"two","start":87,"end":90,"id":19,"ws":true},{"text":"cases","start":91,"end":96,"id":20,"ws":true},{"text":";","start":97,"end":98,"id":21,"ws":true},{"text":"41L","start":99,"end":102,"id":22,"ws":true},{"text":",","start":103,"end":104,"id":23,"ws":true},{"text":"215Y","start":105,"end":109,"id":24,"ws":true},{"text":":","start":110,"end":111,"id":25,"ws":true},{"text":"six","start":112,"end":115,"id":26,"ws":true},{"text":"cases","start":116,"end":121,"id":27,"ws":true},{"text":";","start":122,"end":123,"id":28,"ws":true},{"text":"41L","start":124,"end":127,"id":29,"ws":true},{"text":",","start":128,"end":129,"id":30,"ws":true},{"text":"210W","start":130,"end":134,"id":31,"ws":true},{"text":",","start":135,"end":136,"id":32,"ws":true},{"text":"215Y","start":137,"end":141,"id":33,"ws":true},{"text":":","start":142,"end":143,"id":34,"ws":true},{"text":"two","start":144,"end":147,"id":35,"ws":true},{"text":"cases","start":148,"end":153,"id":36,"ws":true},{"text":";","start":154,"end":155,"id":37,"ws":true},{"text":"M41L","start":156,"end":160,"id":38,"ws":true},{"text":",","start":161,"end":162,"id":39,"ws":true},{"text":"D67N","start":163,"end":167,"id":40,"ws":true},{"text":",","start":168,"end":169,"id":41,"ws":true},{"text":"L210W","start":170,"end":175,"id":42,"ws":true},{"text":",","start":176,"end":177,"id":43,"ws":true},{"text":"T215Y","start":178,"end":183,"id":44,"ws":true},{"text":":","start":184,"end":185,"id":45,"ws":true},{"text":"one","start":186,"end":189,"id":46,"ws":true},{"text":"case","start":190,"end":194,"id":47,"ws":true},{"text":")","start":195,"end":196,"id":48,"ws":true},{"text":"with","start":197,"end":201,"id":49,"ws":true},{"text":"a","start":202,"end":203,"id":50,"ws":true},{"text":"mean","start":204,"end":208,"id":51,"ws":true},{"text":"18.9","start":209,"end":213,"id":52,"ws":true},{"text":"+","start":214,"end":215,"id":53,"ws":true},{"text":"/-","start":216,"end":218,"id":54,"ws":true},{"text":"8.8-fold","start":219,"end":227,"id":55,"ws":true},{"text":"increase","start":228,"end":236,"id":56,"ws":true},{"text":"in","start":237,"end":239,"id":57,"ws":true},{"text":"the","start":240,"end":243,"id":58,"ws":true},{"text":"IC50","start":244,"end":248,"id":59,"ws":true},{"text":"to","start":249,"end":251,"id":60,"ws":true},{"text":"zidovudine","start":252,"end":262,"id":61,"ws":true},{"text":"and","start":263,"end":266,"id":62,"ws":true},{"text":"1.4","start":267,"end":270,"id":63,"ws":true},{"text":"+","start":271,"end":272,"id":64,"ws":true},{"text":"/-","start":273,"end":275,"id":65,"ws":true},{"text":"0.4-fold","start":276,"end":284,"id":66,"ws":true},{"text":"to","start":285,"end":287,"id":67,"ws":true},{"text":"stavudine","start":288,"end":297,"id":68,"ws":false}],"spans":[{"start":36,"end":46,"token_start":7,"token_end":7,"label":"DRUG"},{"start":252,"end":262,"token_start":61,"token_end":61,"label":"DRUG"},{"start":288,"end":297,"token_start":68,"token_end":68,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11737402/","_input_hash":-1545540457,"_task_hash":-718519890,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin , 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Sorafenib</i></b> <b style='color:DodgerBlue;'><i>Combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>Concurrent</i></b> <b style='color:DodgerBlue;'><i>Hepatic</i></b> <b style='color:DodgerBlue;'><i>Arterial</i></b> <b style='color:DodgerBlue;'><i>Infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>5-Fluorouracil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Leucovorin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>Unresectable</i></b> <b style='color:DodgerBlue;'><i>Hepatocellular</i></b> <b style='color:DodgerBlue;'><i>Carcinoma</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>Major</i></b> <b style='color:DodgerBlue;'><i>Portal</i></b> <b style='color:DodgerBlue;'><i>Vein</i></b> <b style='color:DodgerBlue;'><i>Thrombosis</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>sorafenib</i></b> is recommended for the first-line treatment of advanced hepatocellular carcinoma (HCC). However, the median progression-free survival (PFS) of patients with HCC and major portal vein tumor thrombosis treated with <b style='color:Tomato;'><i>sorafenib</i></b> monotherapy is no more than 3\u00a0months. A prospective single-arm phase II study was conducted to determine whether adding hepatic arterial infusion chemotherapy of <b style='color:Tomato;'><i>oxaliplatin</i></b>, 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and <b style='color:Tomato;'><i>leucovorin</i></b> to <b style='color:Tomato;'><i>sorafenib</i></b> could improve on these results. ### methods Thirty five patients were treated with <b style='color:Tomato;'><i>sorafenib</i></b> 400\u00a0mg orally twice a day, <b style='color:Tomato;'><i>oxaliplatin</i></b> 85\u00a0mg/m ### results The 3-, 6-, and 12-month PFS rates were 82.9, 51.4, and 22.9%, respectively. The median PFS and overall survival was 6.7 and 13.2\u00a0months, respectively. The objective response rate was 40%, and the disease control rate was 77.1% by RECIST criteria. Five (14.3%) patients achieved conversion to complete resection after the study treatment, and one of them experienced a pathological complete response. Treatment-related deaths did not occur. Grade 3-4 toxicities consisted of increases in aspartate aminotransferase (31.4%), hand-foot syndrome (17.1%), thrombocytopenia (14.3%), and neutropenia (8.6%). ### conclusions The combination treatment met the pre-specified end point of a 3-month progression free survival rate exceeding 65% and was clinical tolerable. The merits of this approach need to be established with a phase III trial. Clinical trial number http://ClinicalTrials.gov (No. NCT02981498).","tokens":[{"text":"Phase","start":0,"end":5,"id":0,"ws":true},{"text":"II","start":6,"end":8,"id":1,"ws":true},{"text":"Study","start":9,"end":14,"id":2,"ws":true},{"text":"of","start":15,"end":17,"id":3,"ws":true},{"text":"Sorafenib","start":18,"end":27,"id":4,"ws":true},{"text":"Combined","start":28,"end":36,"id":5,"ws":true},{"text":"with","start":37,"end":41,"id":6,"ws":true},{"text":"Concurrent","start":42,"end":52,"id":7,"ws":true},{"text":"Hepatic","start":53,"end":60,"id":8,"ws":true},{"text":"Arterial","start":61,"end":69,"id":9,"ws":true},{"text":"Infusion","start":70,"end":78,"id":10,"ws":true},{"text":"of","start":79,"end":81,"id":11,"ws":true},{"text":"Oxaliplatin","start":82,"end":93,"id":12,"ws":true},{"text":",","start":94,"end":95,"id":13,"ws":true},{"text":"5-Fluorouracil","start":96,"end":110,"id":14,"ws":true},{"text":"and","start":111,"end":114,"id":15,"ws":true},{"text":"Leucovorin","start":115,"end":125,"id":16,"ws":true},{"text":"for","start":126,"end":129,"id":17,"ws":true},{"text":"Unresectable","start":130,"end":142,"id":18,"ws":true},{"text":"Hepatocellular","start":143,"end":157,"id":19,"ws":true},{"text":"Carcinoma","start":158,"end":167,"id":20,"ws":true},{"text":"with","start":168,"end":172,"id":21,"ws":true},{"text":"Major","start":173,"end":178,"id":22,"ws":true},{"text":"Portal","start":179,"end":185,"id":23,"ws":true},{"text":"Vein","start":186,"end":190,"id":24,"ws":true},{"text":"Thrombosis","start":191,"end":201,"id":25,"ws":true},{"text":".","start":202,"end":203,"id":26,"ws":false}],"spans":[{"start":18,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},{"start":82,"end":93,"token_start":12,"token_end":12,"label":"DRUG"},{"start":96,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},{"start":115,"end":125,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29327075/","_input_hash":1930676336,"_task_hash":-326411908,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":4,"child":12,"head_span":{"start":18,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":82,"end":93,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":14,"head_span":{"start":82,"end":93,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":96,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":14,"child":16,"head_span":{"start":96,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":115,"end":125,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Sprague-Dawley male rats were treated with levodopa ( LD ) , betaine ( Bet ) , levodopa plus betaine ( LD/Bet ) , levodopa plus benserazide ( LD/Ben ) , levodopa plus betaine-benserazide ( LD/Bet-Ben ) , and the controls with vehicle for 10 consecutive days , orally .","paragraph":"<h3><u>Betaine protects cerebellum from oxidative stress following levodopa and benserazide administration in rats.</u></h3>The aim of the present study was to evaluate antioxidant and methyl donor effects of <b style='color:Tomato;'><i>betaine</i></b> in cerebellum following <b style='color:Tomato;'><i>levodopa</i></b> and <b style='color:Tomato;'><i>benserazide</i></b> administration in rats. ### Materials And Methods <b style='color:DodgerBlue;'><i>Sprague-Dawley</i></b> <b style='color:DodgerBlue;'><i>male</i></b> <b style='color:DodgerBlue;'><i>rats</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>levodopa</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>betaine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Bet</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>levodopa</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>betaine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LD/Bet</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>levodopa</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>benserazide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LD/Ben</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>levodopa</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>betaine-benserazide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LD/Bet-Ben</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>controls</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>vehicle</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Treatment of rats with LD and <b style='color:Tomato;'><i>benserazide</i></b> significantly increased total homocysteine in plasma of the LD/Ben group when compared to the other groups. Lipid peroxidation of cerebellum increased significantly in LD-treated rats when compared to the other groups. In contrast, glutathione peroxidase activity and glutathione content in cerebellum were significantly higher in the <b style='color:Tomato;'><i>betaine</i></b>-treated rats when compared to the LD and LD/Ben groups. Serum dopamine concentration increased significantly in LD-treated rats in comparison with the LD/Ben group. LD/Bet-treated rats also demonstrated significantly higher dopamine levels when compared to the LD/Ben group. ### conclusion We observed valuable effects of Bet in combination with LD and <b style='color:Tomato;'><i>benserazide</i></b>, which routinely were used for Parkinson's disease (PD) treatment, in experimentally-induced oxidative stress and hyperhomocysteinemia in rats. Therefore, it seems that Bet is a vital and promising agent regarding PD for future clinical trials in humans.","tokens":[{"text":"Sprague-Dawley","start":0,"end":14,"id":0,"ws":true},{"text":"male","start":15,"end":19,"id":1,"ws":true},{"text":"rats","start":20,"end":24,"id":2,"ws":true},{"text":"were","start":25,"end":29,"id":3,"ws":true},{"text":"treated","start":30,"end":37,"id":4,"ws":true},{"text":"with","start":38,"end":42,"id":5,"ws":true},{"text":"levodopa","start":43,"end":51,"id":6,"ws":true},{"text":"(","start":52,"end":53,"id":7,"ws":true},{"text":"LD","start":54,"end":56,"id":8,"ws":true},{"text":")","start":57,"end":58,"id":9,"ws":true},{"text":",","start":59,"end":60,"id":10,"ws":true},{"text":"betaine","start":61,"end":68,"id":11,"ws":true},{"text":"(","start":69,"end":70,"id":12,"ws":true},{"text":"Bet","start":71,"end":74,"id":13,"ws":true},{"text":")","start":75,"end":76,"id":14,"ws":true},{"text":",","start":77,"end":78,"id":15,"ws":true},{"text":"levodopa","start":79,"end":87,"id":16,"ws":true},{"text":"plus","start":88,"end":92,"id":17,"ws":true},{"text":"betaine","start":93,"end":100,"id":18,"ws":true},{"text":"(","start":101,"end":102,"id":19,"ws":true},{"text":"LD/Bet","start":103,"end":109,"id":20,"ws":true},{"text":")","start":110,"end":111,"id":21,"ws":true},{"text":",","start":112,"end":113,"id":22,"ws":true},{"text":"levodopa","start":114,"end":122,"id":23,"ws":true},{"text":"plus","start":123,"end":127,"id":24,"ws":true},{"text":"benserazide","start":128,"end":139,"id":25,"ws":true},{"text":"(","start":140,"end":141,"id":26,"ws":true},{"text":"LD/Ben","start":142,"end":148,"id":27,"ws":true},{"text":")","start":149,"end":150,"id":28,"ws":true},{"text":",","start":151,"end":152,"id":29,"ws":true},{"text":"levodopa","start":153,"end":161,"id":30,"ws":true},{"text":"plus","start":162,"end":166,"id":31,"ws":true},{"text":"betaine-benserazide","start":167,"end":186,"id":32,"ws":true},{"text":"(","start":187,"end":188,"id":33,"ws":true},{"text":"LD/Bet-Ben","start":189,"end":199,"id":34,"ws":true},{"text":")","start":200,"end":201,"id":35,"ws":true},{"text":",","start":202,"end":203,"id":36,"ws":true},{"text":"and","start":204,"end":207,"id":37,"ws":true},{"text":"the","start":208,"end":211,"id":38,"ws":true},{"text":"controls","start":212,"end":220,"id":39,"ws":true},{"text":"with","start":221,"end":225,"id":40,"ws":true},{"text":"vehicle","start":226,"end":233,"id":41,"ws":true},{"text":"for","start":234,"end":237,"id":42,"ws":true},{"text":"10","start":238,"end":240,"id":43,"ws":true},{"text":"consecutive","start":241,"end":252,"id":44,"ws":true},{"text":"days","start":253,"end":257,"id":45,"ws":true},{"text":",","start":258,"end":259,"id":46,"ws":true},{"text":"orally","start":260,"end":266,"id":47,"ws":true},{"text":".","start":267,"end":268,"id":48,"ws":false}],"spans":[{"start":43,"end":51,"token_start":6,"token_end":6,"label":"DRUG"},{"start":61,"end":68,"token_start":11,"token_end":11,"label":"DRUG"},{"start":79,"end":87,"token_start":16,"token_end":16,"label":"DRUG"},{"start":93,"end":100,"token_start":18,"token_end":18,"label":"DRUG"},{"start":114,"end":122,"token_start":23,"token_end":23,"label":"DRUG"},{"start":128,"end":139,"token_start":25,"token_end":25,"label":"DRUG"},{"start":153,"end":161,"token_start":30,"token_end":30,"label":"DRUG"},{"start":167,"end":186,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26730328/","_input_hash":931066312,"_task_hash":-1360372455,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":23,"child":25,"head_span":{"start":114,"end":122,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":128,"end":139,"token_start":25,"token_end":25,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":30,"child":32,"head_span":{"start":153,"end":161,"token_start":30,"token_end":30,"label":"DRUG"},"child_span":{"start":167,"end":186,"token_start":32,"token_end":32,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":16,"child":18,"head_span":{"start":79,"end":87,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":93,"end":100,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11"],"answer":"accept"}
{"text":"We designed a phase I trial to determine the maximum-tolerated dose ( MTD ) and pharmacodynamic effects of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer refractory to standard therapies .","paragraph":"<h3><u>A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.</u></h3>The mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer. In preclinical studies, the antitumor activity of mTOR inhibitors is attenuated by feedback up-regulation of AKT mediated in part by Insulin-like growth factor type 1 receptor (IGF-1R). <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>designed</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>maximum-tolerated</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MTD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>pharmacodynamic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>IGF-1R</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:MediumOrchid;'><i>Cixutumumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>temsirolimus</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A 3 + 3 Phase I design was chosen. Tem<b style='color:Tomato;'><i>sirolimus</i></b> and <b style='color:Tomato;'><i>cixutumumab</i></b> were administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle. Of the 26 patients enrolled, four did not complete cycle 1 because of disease progression (n = 3) or comorbid condition (n = 1) and were replaced. The MTD was determined from the remaining 22 patients, aged 34-72 (median 48) years. Most patients (86 %) had estrogen receptor positive cancer. The median number of prior chemotherapy regimens for metastatic disease was 3. The MTD was determined to be <b style='color:Tomato;'><i>cixutumumab</i></b> 4 mg/kg and tem<b style='color:Tomato;'><i>sirolimus</i></b> 15 mg weekly. Dose-limiting toxicities (DLTs) included mucositis, neutropenia, and thrombocytopenia. Other adverse events included grade 1/2 fatigue, anemia, and hyperglycemia. No objective responses were observed, but four patients experienced stable disease that lasted for at least 4 months. Compared with baseline, there was a significant increase in the serum levels of IGF-1 (p < 0.001) and IGFBP-3 (p = 0.019) on day 2. Compared with day 2, there were significant increases in the serum levels of IGF-1 (p < 0.001), IGF-2 (p = 0.001), and IGFBP-3 (p = 0.019) on day 8. A phase II study in women with metastatic breast cancer is ongoing.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"designed","start":3,"end":11,"id":1,"ws":true},{"text":"a","start":12,"end":13,"id":2,"ws":true},{"text":"phase","start":14,"end":19,"id":3,"ws":true},{"text":"I","start":20,"end":21,"id":4,"ws":true},{"text":"trial","start":22,"end":27,"id":5,"ws":true},{"text":"to","start":28,"end":30,"id":6,"ws":true},{"text":"determine","start":31,"end":40,"id":7,"ws":true},{"text":"the","start":41,"end":44,"id":8,"ws":true},{"text":"maximum-tolerated","start":45,"end":62,"id":9,"ws":true},{"text":"dose","start":63,"end":67,"id":10,"ws":true},{"text":"(","start":68,"end":69,"id":11,"ws":true},{"text":"MTD","start":70,"end":73,"id":12,"ws":true},{"text":")","start":74,"end":75,"id":13,"ws":true},{"text":"and","start":76,"end":79,"id":14,"ws":true},{"text":"pharmacodynamic","start":80,"end":95,"id":15,"ws":true},{"text":"effects","start":96,"end":103,"id":16,"ws":true},{"text":"of","start":104,"end":106,"id":17,"ws":true},{"text":"the","start":107,"end":110,"id":18,"ws":true},{"text":"IGF-1R","start":111,"end":117,"id":19,"ws":true},{"text":"antibody","start":118,"end":126,"id":20,"ws":true},{"text":"Cixutumumab","start":127,"end":138,"id":21,"ws":true},{"text":"in","start":139,"end":141,"id":22,"ws":true},{"text":"combination","start":142,"end":153,"id":23,"ws":true},{"text":"with","start":154,"end":158,"id":24,"ws":true},{"text":"temsirolimus","start":159,"end":171,"id":25,"ws":true},{"text":"in","start":172,"end":174,"id":26,"ws":true},{"text":"patients","start":175,"end":183,"id":27,"ws":true},{"text":"with","start":184,"end":188,"id":28,"ws":true},{"text":"metastatic","start":189,"end":199,"id":29,"ws":true},{"text":"breast","start":200,"end":206,"id":30,"ws":true},{"text":"cancer","start":207,"end":213,"id":31,"ws":true},{"text":"refractory","start":214,"end":224,"id":32,"ws":true},{"text":"to","start":225,"end":227,"id":33,"ws":true},{"text":"standard","start":228,"end":236,"id":34,"ws":true},{"text":"therapies","start":237,"end":246,"id":35,"ws":true},{"text":".","start":247,"end":248,"id":36,"ws":false}],"spans":[{"start":127,"end":138,"token_start":21,"token_end":21,"label":"DRUG"},{"start":159,"end":171,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23605083/","_input_hash":1785265927,"_task_hash":1212698959,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":21,"child":25,"head_span":{"start":127,"end":138,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":159,"end":171,"token_start":25,"token_end":25,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Forty-seven percent of patients were sequentially treated with an amphotericin B-containing product followed by itraconazole , 31 % received itraconazole alone , and 7 % received an amphotericin B-containing product only .","paragraph":"<h3><u>Systemic histoplasmosis: a 15-year retrospective institutional review of 111 patients.</u></h3>To our knowledge, an institutional review of systemic histoplasmosis has not been conducted in the United States since the major outbreaks in Indianapolis in 1978-4982. We conducted a retrospective review of all patients with systemic histoplasmosis diagnosed at Mayo Clinic over a 15-year period. The case definitions employed were based on an international consensus statement by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC/IFICG) and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG). One hundred eleven patients with systemic histoplasmosis were identified between January 1, 1991, and December 31, 2005. Of these, 78 patients had disseminated histoplasmosis and 55 patients had Histoplasma capsulatum fungemia. The mean age of patients was 55 years, 66% were male, and 98% were white. Fifty-nine percent of patients were immunocompromised. Fever was the most frequently reported symptom (63%), followed by respiratory complaints (43%) and weight loss (37%). The peripheral white blood cell count was <3000 cells/mm in 28%, hemoglobin was <10 g/dL in 29%, and platelet count was <150,000 cells/mm in 41% of patients. Liver enzymes were elevated (alanine aminotransferase >60 U/L in 39%, aspartate aminotransferase >60 U/L in 27%), alkaline phosphatase was >200 U/L in 55%, and albumin was <3.5 g/dL in 70%. Serologic and histopathologic examinations were each positive in 75% of cases, Histoplasma urine antigen screening was positive in 80%, and H. capsulatum was culture positive in 84%. <b style='color:DodgerBlue;'><i>Forty-seven</i></b> <b style='color:DodgerBlue;'><i>percent</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>sequentially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B-containing</i></b> <b style='color:DodgerBlue;'><i>product</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>itraconazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>31</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>itraconazole</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B-containing</i></b> <b style='color:DodgerBlue;'><i>product</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Another 13% of patients did not receive antifungal treatment, and the remaining 2% did not have treatment data available. Sixty percent of patients required hospitalization, and in hospital mortality was 6% with a median survival time of 61 days. The relapse rate was 9%, with a median relapse-free survival of 857 days. Systemic histoplasmosis should be suspected in patients who have lived in endemic areas with fever, bone marrow suppression, and elevated hepatic enzymes, particularly if they are immunocompromised. Evaluation including a combination of Histoplasma serologic screening, urine antigen assay, and fungal culture will secure the diagnosis in most cases.","tokens":[{"text":"Forty-seven","start":0,"end":11,"id":0,"ws":true},{"text":"percent","start":12,"end":19,"id":1,"ws":true},{"text":"of","start":20,"end":22,"id":2,"ws":true},{"text":"patients","start":23,"end":31,"id":3,"ws":true},{"text":"were","start":32,"end":36,"id":4,"ws":true},{"text":"sequentially","start":37,"end":49,"id":5,"ws":true},{"text":"treated","start":50,"end":57,"id":6,"ws":true},{"text":"with","start":58,"end":62,"id":7,"ws":true},{"text":"an","start":63,"end":65,"id":8,"ws":true},{"text":"amphotericin","start":66,"end":78,"id":9,"ws":true},{"text":"B-containing","start":79,"end":91,"id":10,"ws":true},{"text":"product","start":92,"end":99,"id":11,"ws":true},{"text":"followed","start":100,"end":108,"id":12,"ws":true},{"text":"by","start":109,"end":111,"id":13,"ws":true},{"text":"itraconazole","start":112,"end":124,"id":14,"ws":true},{"text":",","start":125,"end":126,"id":15,"ws":true},{"text":"31","start":127,"end":129,"id":16,"ws":true},{"text":"%","start":130,"end":131,"id":17,"ws":true},{"text":"received","start":132,"end":140,"id":18,"ws":true},{"text":"itraconazole","start":141,"end":153,"id":19,"ws":true},{"text":"alone","start":154,"end":159,"id":20,"ws":true},{"text":",","start":160,"end":161,"id":21,"ws":true},{"text":"and","start":162,"end":165,"id":22,"ws":true},{"text":"7","start":166,"end":167,"id":23,"ws":true},{"text":"%","start":168,"end":169,"id":24,"ws":true},{"text":"received","start":170,"end":178,"id":25,"ws":true},{"text":"an","start":179,"end":181,"id":26,"ws":true},{"text":"amphotericin","start":182,"end":194,"id":27,"ws":true},{"text":"B-containing","start":195,"end":207,"id":28,"ws":true},{"text":"product","start":208,"end":215,"id":29,"ws":true},{"text":"only","start":216,"end":220,"id":30,"ws":true},{"text":".","start":221,"end":222,"id":31,"ws":false}],"spans":[{"start":66,"end":78,"token_start":9,"token_end":9,"label":"DRUG"},{"start":112,"end":124,"token_start":14,"token_end":14,"label":"DRUG"},{"start":141,"end":153,"token_start":19,"token_end":19,"label":"DRUG"},{"start":182,"end":194,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17505255/","_input_hash":-1484708279,"_task_hash":730040802,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":9,"child":14,"head_span":{"start":66,"end":78,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":112,"end":124,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"From August 2008 to May 2011 , consecutive chemo-na\u00efve patients with stage IV non-squamous non-small cell lung cancer ( NSCLC ) received pemetrexed 500mg/m(2 ) , oxaliplatin 100mg/m(2 ) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles , in the outpatient setting .","paragraph":"<h3><u>Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.</u></h3><b style='color:Tomato;'><i>oxaliplatin</i></b> has less haematological toxicity than cisplatin and <b style='color:Tomato;'><i>carboplatin</i></b>. The combination of <b style='color:Tomato;'><i>pemetrexed</i></b>, <b style='color:Tomato;'><i>oxaliplatin</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b> appeared well tolerated and active as second- or third-line treatment in a previous phase II study. Its role as first-line therapy remains to define. ### Patients And Methods <b style='color:DodgerBlue;'><i>From</i></b> <b style='color:DodgerBlue;'><i>August</i></b> <b style='color:DodgerBlue;'><i>2008</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>May</i></b> <b style='color:DodgerBlue;'><i>2011</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>chemo-na\u00efve</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>non-squamous</i></b> <b style='color:DodgerBlue;'><i>non-small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>500mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>100mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>7.5mg/kg</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>outpatient</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Maintenance therapy including <b style='color:Tomato;'><i>pemetrexed</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b> was given to patients with non-progressive disease. The primary evaluation criterion was safety. Secondary evaluation criteria were response rate, progression-free survival (PFS) and overall survival (OS). ### results Thirty-eight patients (50% males, median age: 55 years, range 38-76) received a total of 199 cycles (median per patient: 6, range 2-6), plus 98 cycles of maintenance therapy. Twenty patients (52.6%) had a PS of 2, and 6 (15.8%) had brain metastases. The most frequent toxicities were hypertension (all grades: 42.1%) and peripheral neuropathy (grade 2-3: 21.1%). Haematological toxicities included grade 4 neutropenia, grade 3 anaemia and thrombopenia (5.3% each). Neither febrile neutropenia nor arterial thrombo-embolic event occurred. The objective response rate was 55.3% (95%CI: 39.5-71.1). The median PFS and OS were 6.2 (95%CI: 5.4-9.0) and 14.6 (95%CI: 9.8-19.5) months, respectively. ### conclusions In this single centre experience, the combination of <b style='color:Tomato;'><i>pemetrexed</i></b>, <b style='color:Tomato;'><i>oxaliplatin</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b> was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC.","tokens":[{"text":"From","start":0,"end":4,"id":0,"ws":true},{"text":"August","start":5,"end":11,"id":1,"ws":true},{"text":"2008","start":12,"end":16,"id":2,"ws":true},{"text":"to","start":17,"end":19,"id":3,"ws":true},{"text":"May","start":20,"end":23,"id":4,"ws":true},{"text":"2011","start":24,"end":28,"id":5,"ws":true},{"text":",","start":29,"end":30,"id":6,"ws":true},{"text":"consecutive","start":31,"end":42,"id":7,"ws":true},{"text":"chemo-na\u00efve","start":43,"end":54,"id":8,"ws":true},{"text":"patients","start":55,"end":63,"id":9,"ws":true},{"text":"with","start":64,"end":68,"id":10,"ws":true},{"text":"stage","start":69,"end":74,"id":11,"ws":true},{"text":"IV","start":75,"end":77,"id":12,"ws":true},{"text":"non-squamous","start":78,"end":90,"id":13,"ws":true},{"text":"non-small","start":91,"end":100,"id":14,"ws":true},{"text":"cell","start":101,"end":105,"id":15,"ws":true},{"text":"lung","start":106,"end":110,"id":16,"ws":true},{"text":"cancer","start":111,"end":117,"id":17,"ws":true},{"text":"(","start":118,"end":119,"id":18,"ws":true},{"text":"NSCLC","start":120,"end":125,"id":19,"ws":true},{"text":")","start":126,"end":127,"id":20,"ws":true},{"text":"received","start":128,"end":136,"id":21,"ws":true},{"text":"pemetrexed","start":137,"end":147,"id":22,"ws":true},{"text":"500mg/m(2","start":148,"end":157,"id":23,"ws":true},{"text":")","start":158,"end":159,"id":24,"ws":true},{"text":",","start":160,"end":161,"id":25,"ws":true},{"text":"oxaliplatin","start":162,"end":173,"id":26,"ws":true},{"text":"100mg/m(2","start":174,"end":183,"id":27,"ws":true},{"text":")","start":184,"end":185,"id":28,"ws":true},{"text":"and","start":186,"end":189,"id":29,"ws":true},{"text":"bevacizumab","start":190,"end":201,"id":30,"ws":true},{"text":"7.5mg/kg","start":202,"end":210,"id":31,"ws":true},{"text":"every","start":211,"end":216,"id":32,"ws":true},{"text":"3","start":217,"end":218,"id":33,"ws":true},{"text":"weeks","start":219,"end":224,"id":34,"ws":true},{"text":"for","start":225,"end":228,"id":35,"ws":true},{"text":"6","start":229,"end":230,"id":36,"ws":true},{"text":"cycles","start":231,"end":237,"id":37,"ws":true},{"text":",","start":238,"end":239,"id":38,"ws":true},{"text":"in","start":240,"end":242,"id":39,"ws":true},{"text":"the","start":243,"end":246,"id":40,"ws":true},{"text":"outpatient","start":247,"end":257,"id":41,"ws":true},{"text":"setting","start":258,"end":265,"id":42,"ws":true},{"text":".","start":266,"end":267,"id":43,"ws":false}],"spans":[{"start":137,"end":147,"token_start":22,"token_end":22,"label":"DRUG"},{"start":162,"end":173,"token_start":26,"token_end":26,"label":"DRUG"},{"start":190,"end":201,"token_start":30,"token_end":30,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22364783/","_input_hash":-1612750781,"_task_hash":-1416257521,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":22,"child":26,"head_span":{"start":137,"end":147,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":162,"end":173,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":26,"child":30,"head_span":{"start":162,"end":173,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":190,"end":201,"token_start":30,"token_end":30,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"To determine if antiseptic central venous catheters impregnated with silver sulfadiazine and chlorhexidine ( antiseptic ) reduce bacterial adherence and biofilm formation without producing local or systemic toxicity .","paragraph":"<h3><u>Decreased bacterial adherence and biofilm formation on chlorhexidine and silver sulfadiazine-impregnated central venous catheters implanted in swine.</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>if</i></b> <b style='color:DodgerBlue;'><i>antiseptic</i></b> <b style='color:DodgerBlue;'><i>central</i></b> <b style='color:DodgerBlue;'><i>venous</i></b> <b style='color:DodgerBlue;'><i>catheters</i></b> <b style='color:DodgerBlue;'><i>impregnated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>silver</i></b> <b style='color:MediumOrchid;'><i>sulfadiazine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>chlorhexidine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>antiseptic</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>reduce</i></b> <b style='color:DodgerBlue;'><i>bacterial</i></b> <b style='color:DodgerBlue;'><i>adherence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>biofilm</i></b> <b style='color:DodgerBlue;'><i>formation</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>producing</i></b> <b style='color:DodgerBlue;'><i>local</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### design Prospective, randomized, controlled trial. ### setting Experimental laboratory in a university teaching hospital. ### subjects Ten outbred New Hampshire pigs. ### interventions Nonimpregnated (control) and antiseptic-impregnated catheters were inserted intravascularly into swine for 7 days. After explantation, the catheters were assessed for bacterial adherence and biofilm formation, and the surrounding tissue was assessed for signs of toxicity. Before retrieval, systemic concentrations of antimicrobials were determined. ### Measurements And Main Results Sequential roll plate and centrifuging were used to detect moderately and tightly adherent bacteria on the outer and luminal surfaces of the catheter. The presence of biofilm was detected by scanning electron microscopy. Tissues surrounding the catheters were examined histopathologically; systemic concentrations of <b style='color:Tomato;'><i>chlorhexidine</i></b>, <b style='color:Tomato;'><i>sulfadiazine</i></b>, and silver were determined by atomic absorption and high-performance liquid chromatography. As compared with the controls, antiseptic catheters had significantly (p < .01) fewer moderately and tightly adherent bacteria on outer and luminal surfaces, and fewer adherent bacteria when outer surfaces alone were examined (p < .01). Scanning electron microscopy showed bacterial biofilm and adherence on the control catheters but not on the antiseptic catheters. There were no abnormal histopathologic changes associated with the test catheter, and serum concentrations of the antibacterial agents were shown to be within nontoxic ranges. ### conclusion The antiseptic-impregnated catheters prevented bacterial adherence and biofilm formation and produced no local or systemic toxicity.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"determine","start":3,"end":12,"id":1,"ws":true},{"text":"if","start":13,"end":15,"id":2,"ws":true},{"text":"antiseptic","start":16,"end":26,"id":3,"ws":true},{"text":"central","start":27,"end":34,"id":4,"ws":true},{"text":"venous","start":35,"end":41,"id":5,"ws":true},{"text":"catheters","start":42,"end":51,"id":6,"ws":true},{"text":"impregnated","start":52,"end":63,"id":7,"ws":true},{"text":"with","start":64,"end":68,"id":8,"ws":true},{"text":"silver","start":69,"end":75,"id":9,"ws":true},{"text":"sulfadiazine","start":76,"end":88,"id":10,"ws":true},{"text":"and","start":89,"end":92,"id":11,"ws":true},{"text":"chlorhexidine","start":93,"end":106,"id":12,"ws":true},{"text":"(","start":107,"end":108,"id":13,"ws":true},{"text":"antiseptic","start":109,"end":119,"id":14,"ws":true},{"text":")","start":120,"end":121,"id":15,"ws":true},{"text":"reduce","start":122,"end":128,"id":16,"ws":true},{"text":"bacterial","start":129,"end":138,"id":17,"ws":true},{"text":"adherence","start":139,"end":148,"id":18,"ws":true},{"text":"and","start":149,"end":152,"id":19,"ws":true},{"text":"biofilm","start":153,"end":160,"id":20,"ws":true},{"text":"formation","start":161,"end":170,"id":21,"ws":true},{"text":"without","start":171,"end":178,"id":22,"ws":true},{"text":"producing","start":179,"end":188,"id":23,"ws":true},{"text":"local","start":189,"end":194,"id":24,"ws":true},{"text":"or","start":195,"end":197,"id":25,"ws":true},{"text":"systemic","start":198,"end":206,"id":26,"ws":true},{"text":"toxicity","start":207,"end":215,"id":27,"ws":true},{"text":".","start":216,"end":217,"id":28,"ws":false}],"spans":[{"start":76,"end":88,"token_start":10,"token_end":10,"label":"DRUG"},{"start":93,"end":106,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7736748/","_input_hash":1639377939,"_task_hash":-1316568852,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":76,"end":88,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":93,"end":106,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In multivariate analysis , LDP and LAP were significantly associated with stavudine ( d4 T ) use , while LAP was also associated with zidovudine ( ZDV ) treatment .","paragraph":"<h3><u>The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition.</u></h3>This study's objective was to determine the prevalence of body shape changes and metabolic abnormalities in an ambulant population with HIV infection. Three different definitions of lipodystrophy were used to assess these changes. Patients' anthropometric measures and dual-energy X-ray absorptiometry (DEXA) scans were compared in order to estimate fat distribution in this population. We sought to evaluate potential predictors for lipodystrophy according to each of the three definitions. ### methods We performed a cross-sectional study in the outpatient clinic of a tertiary referral hospital in Melbourne, Australia. We enrolled a total of 167 HIV-infected ambulatory patients over 3 months in mid-1998. Data on 159 males, 149 of whom were receiving triple combination antiretroviral therapy, were evaluated. Anthropometric measures, clinical examination, self-report of body shape changes, biochemical measures and DEXA scan were used to assess lipodystrophy and risk factors for cardiovascular disease. Patients described body shape changes in the face, trunk, arms and legs. Laboratory parameters measured included fasting triglyceride (TG), cholesterol, high-density lipoproteins (HDL), glucose, insulin, CD4 cell count and plasma HIV RNA. Current and past antiretroviral therapies were ascertained. ### results According to one proposed Australian national definition of lipodystrophy (LDNC), the prevalence of lipodystrophy in this population was 65%. This definition included an objective assessment with major and minor criteria. Patient-defined lipodystrophy (LDP), which involved a subjective assessment of thinning arms and legs and central adiposity, occurred in 19%. Patient-defined lipoatrophy (LAP), which involved a subjective assessment of thinning arms and legs without central adiposity, occurred in 21.3%. No change in body habitus was noted by 37% of the cohort. Hypercholesterolaemia was recorded in 44%, hypertriglyceridaemia in 52% and elevated insulin levels in 23%. Anthropometry was predictive of the per cent total body fat recorded by DEXA scan, but produced consistently lower values. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>multivariate</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>LDP</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>LAP</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>stavudine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>d4</i></b> <b style='color:DodgerBlue;'><i>T</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>LAP</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>zidovudine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ZDV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There were no treatment associations with LDNC. Protease inhibitor (PI) exposure was associated with metabolic changes but not patient perceived body shape changes, while d4T and ZDV exposure was associated with increased triglycerides and reduced peripheral fat stores. ### conclusions The prevalence of body shape changes in a single population varied depending on the definition applied. The LDNC definition overestimated body shape abnormalities in comparison with patient perception. LAP was associated with significantly lower fat stores measured by anthropometry and DEXA scan than those identified under the LDNC definition. In contrast to LDNC, LAP was associated with d4T exposure, nucleoside reverse transcriptase inhibitor (NRTI) and ZDV duration of use, but not PI use. Until a consensus definition for lipodystrophy is developed, including agreement on objective measurement and thresholds for abnormality, careful description of the individual components of the syndrome is required to enable cohort comparisons so that predictors of the syndrome can be assessed more accurately and outcome studies made feasible.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"multivariate","start":3,"end":15,"id":1,"ws":true},{"text":"analysis","start":16,"end":24,"id":2,"ws":true},{"text":",","start":25,"end":26,"id":3,"ws":true},{"text":"LDP","start":27,"end":30,"id":4,"ws":true},{"text":"and","start":31,"end":34,"id":5,"ws":true},{"text":"LAP","start":35,"end":38,"id":6,"ws":true},{"text":"were","start":39,"end":43,"id":7,"ws":true},{"text":"significantly","start":44,"end":57,"id":8,"ws":true},{"text":"associated","start":58,"end":68,"id":9,"ws":true},{"text":"with","start":69,"end":73,"id":10,"ws":true},{"text":"stavudine","start":74,"end":83,"id":11,"ws":true},{"text":"(","start":84,"end":85,"id":12,"ws":true},{"text":"d4","start":86,"end":88,"id":13,"ws":true},{"text":"T","start":89,"end":90,"id":14,"ws":true},{"text":")","start":91,"end":92,"id":15,"ws":true},{"text":"use","start":93,"end":96,"id":16,"ws":true},{"text":",","start":97,"end":98,"id":17,"ws":true},{"text":"while","start":99,"end":104,"id":18,"ws":true},{"text":"LAP","start":105,"end":108,"id":19,"ws":true},{"text":"was","start":109,"end":112,"id":20,"ws":true},{"text":"also","start":113,"end":117,"id":21,"ws":true},{"text":"associated","start":118,"end":128,"id":22,"ws":true},{"text":"with","start":129,"end":133,"id":23,"ws":true},{"text":"zidovudine","start":134,"end":144,"id":24,"ws":true},{"text":"(","start":145,"end":146,"id":25,"ws":true},{"text":"ZDV","start":147,"end":150,"id":26,"ws":true},{"text":")","start":151,"end":152,"id":27,"ws":true},{"text":"treatment","start":153,"end":162,"id":28,"ws":true},{"text":".","start":163,"end":164,"id":29,"ws":false}],"spans":[{"start":74,"end":83,"token_start":11,"token_end":11,"label":"DRUG"},{"start":134,"end":144,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11737398/","_input_hash":568861518,"_task_hash":1152226490,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"KARs , new semisynthetic antitumor bis-indole derivatives , were found to be inhibitors of tubulin polymerization with lower toxicity than vinblastine or vincristine , used in chemotherapy .","paragraph":"<h3><u>A new bis-indole, KARs, induces selective M arrest with specific spindle aberration in neuroblastoma cell line SH-SY5Y.</u></h3> <b style='color:DodgerBlue;'><i>KARs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>semisynthetic</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>bis-indole</i></b> <b style='color:DodgerBlue;'><i>derivatives</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>tubulin</i></b> <b style='color:DodgerBlue;'><i>polymerization</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we compare the effect of KARs with those of <b style='color:Tomato;'><i>vinblastine</i></b> and <b style='color:Tomato;'><i>vincristine</i></b> on cell viability, cell proliferation, and cell cycle in neuroblastoma cell line (SH-SY5Y). At concentrations of the different compounds equivalent in causing 50% of inhibition of cell growth, KARs induced a complete arrest in the G2/M phase, whereas <b style='color:Tomato;'><i>vinblastine</i></b> and <b style='color:Tomato;'><i>vincristine</i></b> induced a partial arrest in both G0/G1 and G2/M. Moreover, a combination of KAR-2 and W13 (an anticalmodulin drug) qualitatively caused a similar arrest in both G0/G1 and G2/M than <b style='color:Tomato;'><i>vinblastine</i></b>. Levels of cyclin A and B1 were higher in KARs-treated cells than in <b style='color:Tomato;'><i>vinblastine</i></b>- or <b style='color:Tomato;'><i>vincristine</i></b>-treated cells. Cdc2 activity was much higher in KAR-2 than in <b style='color:Tomato;'><i>vinblastine</i></b>-treated cells, indicating a stronger mitotic arrest. The effect of KAR2 and <b style='color:Tomato;'><i>vinblastine</i></b> on microtubules network was analyzed by immunostaining with anti-tubulin antibody. Results indicated that KAR-2-induces the formation of aberrant mitotic spindles, with not apparent effect on interphase microtubules, whereas <b style='color:Tomato;'><i>vinblastine</i></b> partially destroyed interphase microtubules coexisting with normal and aberrant mitotic spindles.","tokens":[{"text":"KARs","start":0,"end":4,"id":0,"ws":true},{"text":",","start":5,"end":6,"id":1,"ws":true},{"text":"new","start":7,"end":10,"id":2,"ws":true},{"text":"semisynthetic","start":11,"end":24,"id":3,"ws":true},{"text":"antitumor","start":25,"end":34,"id":4,"ws":true},{"text":"bis-indole","start":35,"end":45,"id":5,"ws":true},{"text":"derivatives","start":46,"end":57,"id":6,"ws":true},{"text":",","start":58,"end":59,"id":7,"ws":true},{"text":"were","start":60,"end":64,"id":8,"ws":true},{"text":"found","start":65,"end":70,"id":9,"ws":true},{"text":"to","start":71,"end":73,"id":10,"ws":true},{"text":"be","start":74,"end":76,"id":11,"ws":true},{"text":"inhibitors","start":77,"end":87,"id":12,"ws":true},{"text":"of","start":88,"end":90,"id":13,"ws":true},{"text":"tubulin","start":91,"end":98,"id":14,"ws":true},{"text":"polymerization","start":99,"end":113,"id":15,"ws":true},{"text":"with","start":114,"end":118,"id":16,"ws":true},{"text":"lower","start":119,"end":124,"id":17,"ws":true},{"text":"toxicity","start":125,"end":133,"id":18,"ws":true},{"text":"than","start":134,"end":138,"id":19,"ws":true},{"text":"vinblastine","start":139,"end":150,"id":20,"ws":true},{"text":"or","start":151,"end":153,"id":21,"ws":true},{"text":"vincristine","start":154,"end":165,"id":22,"ws":true},{"text":",","start":166,"end":167,"id":23,"ws":true},{"text":"used","start":168,"end":172,"id":24,"ws":true},{"text":"in","start":173,"end":175,"id":25,"ws":true},{"text":"chemotherapy","start":176,"end":188,"id":26,"ws":true},{"text":".","start":189,"end":190,"id":27,"ws":false}],"spans":[{"start":139,"end":150,"token_start":20,"token_end":20,"label":"DRUG"},{"start":154,"end":165,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11723230/","_input_hash":129190743,"_task_hash":1901281055,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"More than one-third ( 36 % ) of AA patients in our study received Danazol as monotherapy , whereas less than a third ( 32 % ) each received standard doses of IST with equine Anti Thymocyte Globulin ( ATG ) and Cyclosporine combination , or Cyclosporine and Danazol combination , respectively .","paragraph":"<h3><u>Danazol increases T regulatory cells in patients with aplastic anemia.</u></h3><b style='color:Tomato;'><i>danazol</i></b> is an attenuated androgen and is used in the treatment of aplastic anemia (AA) in resource constraint settings. We chose to study the role of CD4+ CD25 ### methods T-regs' percentages of 25 acquired idiopathic AA patients and 25 healthy controls who completed study protocol were analyzed by performing multicolor flowcytometry on peripheral blood samples. ### results <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>one-third</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>36</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>AA</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>our</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>Danazol</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>third</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>32</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>IST</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>equine</i></b> <b style='color:DodgerBlue;'><i>Anti</i></b> <b style='color:DodgerBlue;'><i>Thymocyte</i></b> <b style='color:DodgerBlue;'><i>Globulin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ATG</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Cyclosporine</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>Cyclosporine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Danazol</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Results showed that all AA patients had a significantly lower percentage of T-regs at the time of diagnosis when compared to healthy controls (p\u2009<\u20090.0001), implicating their role in the pathophysiology. On treatment, all 25 patients showed a significant rise in the percentage of T-regs when compared to baseline (p\u2009<\u20090.0001). ### discussion The rise in T-regs' percentage was higher in patients treated with <b style='color:Tomato;'><i>danazol</i></b> alone when compared to standard IST (ATG with <b style='color:Tomato;'><i>cyclosporin</i></b>e), or <b style='color:Tomato;'><i>cyclosporin</i></b>e with <b style='color:Tomato;'><i>danazol</i></b> combinations (p\u2009=\u20090.585). ### conclusion We conclude that <b style='color:Tomato;'><i>danazol</i></b> also leads to increase in T-regs in acquired idiopathic AA.","tokens":[{"text":"More","start":0,"end":4,"id":0,"ws":true},{"text":"than","start":5,"end":9,"id":1,"ws":true},{"text":"one-third","start":10,"end":19,"id":2,"ws":true},{"text":"(","start":20,"end":21,"id":3,"ws":true},{"text":"36","start":22,"end":24,"id":4,"ws":true},{"text":"%","start":25,"end":26,"id":5,"ws":true},{"text":")","start":27,"end":28,"id":6,"ws":true},{"text":"of","start":29,"end":31,"id":7,"ws":true},{"text":"AA","start":32,"end":34,"id":8,"ws":true},{"text":"patients","start":35,"end":43,"id":9,"ws":true},{"text":"in","start":44,"end":46,"id":10,"ws":true},{"text":"our","start":47,"end":50,"id":11,"ws":true},{"text":"study","start":51,"end":56,"id":12,"ws":true},{"text":"received","start":57,"end":65,"id":13,"ws":true},{"text":"Danazol","start":66,"end":73,"id":14,"ws":true},{"text":"as","start":74,"end":76,"id":15,"ws":true},{"text":"monotherapy","start":77,"end":88,"id":16,"ws":true},{"text":",","start":89,"end":90,"id":17,"ws":true},{"text":"whereas","start":91,"end":98,"id":18,"ws":true},{"text":"less","start":99,"end":103,"id":19,"ws":true},{"text":"than","start":104,"end":108,"id":20,"ws":true},{"text":"a","start":109,"end":110,"id":21,"ws":true},{"text":"third","start":111,"end":116,"id":22,"ws":true},{"text":"(","start":117,"end":118,"id":23,"ws":true},{"text":"32","start":119,"end":121,"id":24,"ws":true},{"text":"%","start":122,"end":123,"id":25,"ws":true},{"text":")","start":124,"end":125,"id":26,"ws":true},{"text":"each","start":126,"end":130,"id":27,"ws":true},{"text":"received","start":131,"end":139,"id":28,"ws":true},{"text":"standard","start":140,"end":148,"id":29,"ws":true},{"text":"doses","start":149,"end":154,"id":30,"ws":true},{"text":"of","start":155,"end":157,"id":31,"ws":true},{"text":"IST","start":158,"end":161,"id":32,"ws":true},{"text":"with","start":162,"end":166,"id":33,"ws":true},{"text":"equine","start":167,"end":173,"id":34,"ws":true},{"text":"Anti","start":174,"end":178,"id":35,"ws":true},{"text":"Thymocyte","start":179,"end":188,"id":36,"ws":true},{"text":"Globulin","start":189,"end":197,"id":37,"ws":true},{"text":"(","start":198,"end":199,"id":38,"ws":true},{"text":"ATG","start":200,"end":203,"id":39,"ws":true},{"text":")","start":204,"end":205,"id":40,"ws":true},{"text":"and","start":206,"end":209,"id":41,"ws":true},{"text":"Cyclosporine","start":210,"end":222,"id":42,"ws":true},{"text":"combination","start":223,"end":234,"id":43,"ws":true},{"text":",","start":235,"end":236,"id":44,"ws":true},{"text":"or","start":237,"end":239,"id":45,"ws":true},{"text":"Cyclosporine","start":240,"end":252,"id":46,"ws":true},{"text":"and","start":253,"end":256,"id":47,"ws":true},{"text":"Danazol","start":257,"end":264,"id":48,"ws":true},{"text":"combination","start":265,"end":276,"id":49,"ws":true},{"text":",","start":277,"end":278,"id":50,"ws":true},{"text":"respectively","start":279,"end":291,"id":51,"ws":true},{"text":".","start":292,"end":293,"id":52,"ws":false}],"spans":[{"start":66,"end":73,"token_start":14,"token_end":14,"label":"DRUG"},{"start":174,"end":197,"token_start":35,"token_end":37,"label":"DRUG"},{"start":210,"end":222,"token_start":42,"token_end":42,"label":"DRUG"},{"start":240,"end":252,"token_start":46,"token_end":46,"label":"DRUG"},{"start":257,"end":264,"token_start":48,"token_end":48,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29415633/","_input_hash":-40495284,"_task_hash":1777601925,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":46,"child":48,"head_span":{"start":240,"end":252,"token_start":46,"token_end":46,"label":"DRUG"},"child_span":{"start":257,"end":264,"token_start":48,"token_end":48,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":37,"child":42,"head_span":{"start":174,"end":197,"token_start":35,"token_end":37,"label":"DRUG"},"child_span":{"start":210,"end":222,"token_start":42,"token_end":42,"label":"DRUG"},"color":"#ffdaf9","label":"NEG2"}],"radio":["NEG11","NEG21"],"answer":"accept"}
{"text":"Similarly , antibodies raised against CYP3A4 almost completely abolished colchicine demethylation and nifedipine oxidase activity , but preimmune IgG had no effect .","paragraph":"<h3><u>Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.</u></h3><b style='color:Tomato;'><i>colchicine</i></b> disposition involves both active biliary and renal excretion of parent drug, and at least in mammals a substantial fraction undergoes hepatic demethylation prior to excretion. We investigated the biotransformation of [3H]<b style='color:Tomato;'><i>colchicine</i></b> in a panel of microsomal preparations obtained from sixteen human liver samples. The production rate of the main metabolites of <b style='color:Tomato;'><i>colchicine</i></b>'s 3-demethyl<b style='color:Tomato;'><i>colchicine</i></b> (3DMC) and 2-demethyl<b style='color:Tomato;'><i>colchicine</i></b> (2DMC), was linear in relation to incubation time, cytochrome (P450) content, and substrate concentration. Following the incubation of <b style='color:Tomato;'><i>colchicine</i></b> (5 nM) with microsomes in the presence of an NADPH-generating system for 60 min, 9.8% and 5.5% of the substrate were metabolized to 3DMC and 2DMC, respectively. The formation rate of <b style='color:Tomato;'><i>colchicine</i></b> metabolites exhibited a marked variation between the different microsomal preparations. The formation rates of both <b style='color:Tomato;'><i>colchicine</i></b> metabolites were correlated significantly with <b style='color:Tomato;'><i>nifedipine</i></b> oxidase activity, a marker of CYP3A4 activity (r = 0.96, P < 0.001), but not with the metabolic markers of CYP2A6, CYP2C19, CYP2C9, CYP2D6, and CYP2E1 activities. Chemical inhibition of CYP3A4 by preincubation with <b style='color:Tomato;'><i>gestodene</i></b> (40 microM) or troleandomycin (40 microM) reduced the formation of 3DMC and 2DMC by 70 and 80%, respectively, whereas <b style='color:Tomato;'><i>quinidine</i></b>, diethyldithiocarbamate, and <b style='color:Tomato;'><i>sulfaphenazole</i></b> had no inhibitory effect. <b style='color:DodgerBlue;'><i>Similarly</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>antibodies</i></b> <b style='color:DodgerBlue;'><i>raised</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>CYP3A4</i></b> <b style='color:DodgerBlue;'><i>almost</i></b> <b style='color:DodgerBlue;'><i>completely</i></b> <b style='color:DodgerBlue;'><i>abolished</i></b> <b style='color:MediumOrchid;'><i>colchicine</i></b> <b style='color:DodgerBlue;'><i>demethylation</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nifedipine</i></b> <b style='color:DodgerBlue;'><i>oxidase</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>preimmune</i></b> <b style='color:DodgerBlue;'><i>IgG</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In conclusion, <b style='color:Tomato;'><i>colchicine</i></b> was metabolized to 3DMC and 2DMC by human liver microsomes. The production of <b style='color:Tomato;'><i>colchicine</i></b> metabolites was mediated by CYP3A4, and its rate varied greatly between microsomal preparations obtained from different liver samples. The coadministration of <b style='color:Tomato;'><i>colchicine</i></b> with known inhibitors or substrates of CYP3A4 may inhibit <b style='color:Tomato;'><i>colchicine</i></b> metabolism, resulting in concentration-related toxicity.","tokens":[{"text":"Similarly","start":0,"end":9,"id":0,"ws":true},{"text":",","start":10,"end":11,"id":1,"ws":true},{"text":"antibodies","start":12,"end":22,"id":2,"ws":true},{"text":"raised","start":23,"end":29,"id":3,"ws":true},{"text":"against","start":30,"end":37,"id":4,"ws":true},{"text":"CYP3A4","start":38,"end":44,"id":5,"ws":true},{"text":"almost","start":45,"end":51,"id":6,"ws":true},{"text":"completely","start":52,"end":62,"id":7,"ws":true},{"text":"abolished","start":63,"end":72,"id":8,"ws":true},{"text":"colchicine","start":73,"end":83,"id":9,"ws":true},{"text":"demethylation","start":84,"end":97,"id":10,"ws":true},{"text":"and","start":98,"end":101,"id":11,"ws":true},{"text":"nifedipine","start":102,"end":112,"id":12,"ws":true},{"text":"oxidase","start":113,"end":120,"id":13,"ws":true},{"text":"activity","start":121,"end":129,"id":14,"ws":true},{"text":",","start":130,"end":131,"id":15,"ws":true},{"text":"but","start":132,"end":135,"id":16,"ws":true},{"text":"preimmune","start":136,"end":145,"id":17,"ws":true},{"text":"IgG","start":146,"end":149,"id":18,"ws":true},{"text":"had","start":150,"end":153,"id":19,"ws":true},{"text":"no","start":154,"end":156,"id":20,"ws":true},{"text":"effect","start":157,"end":163,"id":21,"ws":true},{"text":".","start":164,"end":165,"id":22,"ws":false}],"spans":[{"start":73,"end":83,"token_start":9,"token_end":9,"label":"DRUG"},{"start":102,"end":112,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8960070/","_input_hash":1376555483,"_task_hash":994721832,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Furthermore , our group has shown that the combination of paclitaxel and carboplatin is effective in anthracycline-resistant ABC .","paragraph":"<h3><u>First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group.</u></h3>To evaluate the activity and toxicity of the combination of <b style='color:Tomato;'><i>paclitaxel</i></b> given by three-hour infusion, and <b style='color:Tomato;'><i>carboplatin</i></b> as first-line chemotherapy in patients with advanced breast cancer (ABC). ### background <b style='color:Tomato;'><i>paclitaxel</i></b> is an active agent in ABC. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>our</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>anthracycline-resistant</i></b> <b style='color:DodgerBlue;'><i>ABC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods From January 1996 until March 1997, 66 women with ABC were treated with <b style='color:Tomato;'><i>paclitaxel</i></b> (175 mg/m2) by three-hour infusion followed by <b style='color:Tomato;'><i>carboplatin</i></b> at an AUC of 6 mg x min/ml every three weeks. The median age of the patients was 56 years (range 28-75). A total of 39 patients had received adjuvant chemotherapy and 22 of them were treated with an anthracycline or <b style='color:Tomato;'><i>mitoxantrone</i></b>-containing regimen. ### results A total of 324 cycles (median: six) were administered, 273 (85%) of them at full dose. The median number of delivered cycles was six. The median delivered dose intensity (DI) of <b style='color:Tomato;'><i>paclitaxel</i></b> was 55.1 mg/m2/week (range 30.5-69.3) and the relative DI was 0.95 (range 0.5-1.2). Eight patients (12%, 95% confidence interval (CI): 5%-22%) achieved complete and 28 (42%, 95% CI: 30%-55%) partial responses. Grade 3-4 toxicities included anemia (5%), granulocytopenia (24%), thrombocytopenia, nausea/vomiting and allergic reaction (3% each), myalgias/arthralgias and neurotoxicity (1.5% each). Febrile neutropenia occurred in eight (12%) patients. Alopecia was universal. After a median follow-up of 17.3 (range 0.07-24.5) months, 48 (72%) patients have demonstrated tumor progression and 24 (36%) have died. Median time to progression was 8.6 (range 0.07-23+) months and median survival 20.4 (range 0.07-24.5+) months. ### conclusions The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> has moderate activity in ABC and can be easily delivered on an outpatient basis with manageable toxicity. This regimen may be useful especially in patients to whom anthracyclines or cisplatin administration is precluded because of other concomitant diseases.","tokens":[{"text":"Furthermore","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"our","start":14,"end":17,"id":2,"ws":true},{"text":"group","start":18,"end":23,"id":3,"ws":true},{"text":"has","start":24,"end":27,"id":4,"ws":true},{"text":"shown","start":28,"end":33,"id":5,"ws":true},{"text":"that","start":34,"end":38,"id":6,"ws":true},{"text":"the","start":39,"end":42,"id":7,"ws":true},{"text":"combination","start":43,"end":54,"id":8,"ws":true},{"text":"of","start":55,"end":57,"id":9,"ws":true},{"text":"paclitaxel","start":58,"end":68,"id":10,"ws":true},{"text":"and","start":69,"end":72,"id":11,"ws":true},{"text":"carboplatin","start":73,"end":84,"id":12,"ws":true},{"text":"is","start":85,"end":87,"id":13,"ws":true},{"text":"effective","start":88,"end":97,"id":14,"ws":true},{"text":"in","start":98,"end":100,"id":15,"ws":true},{"text":"anthracycline-resistant","start":101,"end":124,"id":16,"ws":true},{"text":"ABC","start":125,"end":128,"id":17,"ws":true},{"text":".","start":129,"end":130,"id":18,"ws":false}],"spans":[{"start":58,"end":68,"token_start":10,"token_end":10,"label":"DRUG"},{"start":73,"end":84,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9818080/","_input_hash":-826562579,"_task_hash":-1171638425,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":58,"end":68,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":73,"end":84,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Cyclosporine ( 25 mg/kg per day , s.c . ) was given for 7 days to rats either alone or in combination with resveratrol ( 10 mg/kg per day , i.p . ) .","paragraph":"<h3><u>Resveratrol ameliorates the cyclosporine-induced vascular and renal impairments: possible impact of the modulation of renin-angiotensin system.</u></h3><b style='color:Tomato;'><i>cyclosporin</i></b>e, an immunosuppressive drug, exhibits a toxic effect on renal and vascular systems. The present study investigated whether <b style='color:Tomato;'><i>resveratrol</i></b> treatment alleviates renal and vascular injury induced by <b style='color:Tomato;'><i>cyclosporin</i></b>e. <b style='color:MediumOrchid;'><i>Cyclosporine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>s.c</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>rats</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>resveratrol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Relaxation and contraction responses of aorta were examined. Serum levels of blood urea nitrogen, creatinine, angiotensin II, and <b style='color:Tomato;'><i>angiotensin 1-7</i></b> were measured. Histopathological examinations as well as immunostaining for 4-hydroxynonenal and nitrotyrosine were performed in the kidney. RNA expressions of renin-angiotensin system components were also measured in renal and aortic tissues. <b style='color:Tomato;'><i>cyclosporin</i></b>e decreased the endothelium-dependent relaxation and increased vascular contraction in the aorta. It caused renal tubular degeneration and increased immunostaining for 4-hydroxynonenal, an oxidative stress marker. <b style='color:Tomato;'><i>cyclosporin</i></b>e also caused upregulations of the vasoconstrictive renin-angiotensin system components in renal (angiotensin-converting enzyme) and aortic (angiotensin II type 1 receptor) tissues. <b style='color:Tomato;'><i>resveratrol</i></b> co-treatment prevented the <b style='color:Tomato;'><i>cyclosporin</i></b>e-related deteriorations. Moreover, it induced the expressions of vasodilatory effective angiotensin-converting enzyme 2 and angiotensin II type 2 receptor in aorta and kidney, respectively. We conclude that <b style='color:Tomato;'><i>resveratrol</i></b> may be effective in preventing <b style='color:Tomato;'><i>cyclosporin</i></b>e-induced renal tubular degeneration and vascular dysfunction at least in part by modulating the renin-angiotensin system.","tokens":[{"text":"Cyclosporine","start":0,"end":12,"id":0,"ws":true},{"text":"(","start":13,"end":14,"id":1,"ws":true},{"text":"25","start":15,"end":17,"id":2,"ws":true},{"text":"mg/kg","start":18,"end":23,"id":3,"ws":true},{"text":"per","start":24,"end":27,"id":4,"ws":true},{"text":"day","start":28,"end":31,"id":5,"ws":true},{"text":",","start":32,"end":33,"id":6,"ws":true},{"text":"s.c","start":34,"end":37,"id":7,"ws":true},{"text":".","start":38,"end":39,"id":8,"ws":true},{"text":")","start":40,"end":41,"id":9,"ws":true},{"text":"was","start":42,"end":45,"id":10,"ws":true},{"text":"given","start":46,"end":51,"id":11,"ws":true},{"text":"for","start":52,"end":55,"id":12,"ws":true},{"text":"7","start":56,"end":57,"id":13,"ws":true},{"text":"days","start":58,"end":62,"id":14,"ws":true},{"text":"to","start":63,"end":65,"id":15,"ws":true},{"text":"rats","start":66,"end":70,"id":16,"ws":true},{"text":"either","start":71,"end":77,"id":17,"ws":true},{"text":"alone","start":78,"end":83,"id":18,"ws":true},{"text":"or","start":84,"end":86,"id":19,"ws":true},{"text":"in","start":87,"end":89,"id":20,"ws":true},{"text":"combination","start":90,"end":101,"id":21,"ws":true},{"text":"with","start":102,"end":106,"id":22,"ws":true},{"text":"resveratrol","start":107,"end":118,"id":23,"ws":true},{"text":"(","start":119,"end":120,"id":24,"ws":true},{"text":"10","start":121,"end":123,"id":25,"ws":true},{"text":"mg/kg","start":124,"end":129,"id":26,"ws":true},{"text":"per","start":130,"end":133,"id":27,"ws":true},{"text":"day","start":134,"end":137,"id":28,"ws":true},{"text":",","start":138,"end":139,"id":29,"ws":true},{"text":"i.p","start":140,"end":143,"id":30,"ws":true},{"text":".","start":144,"end":145,"id":31,"ws":true},{"text":")","start":146,"end":147,"id":32,"ws":true},{"text":".","start":148,"end":149,"id":33,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":107,"end":118,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31613143/","_input_hash":1646759540,"_task_hash":1343464350,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":0,"child":23,"head_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":107,"end":118,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The diagnosis was confirmed by comparative double diagnostic block of the medial branch with bupivacaine and lidocaine .","paragraph":"<h3><u>Efficacy of combined treatment with medial branch radiofrequency neurotomy and steroid block in lumbar facet joint arthropathy.</u></h3>To evaluate the long-term efficacy of combined radiofrequency (RF) neurotomy and steroid nerve block in patients with lumbar facet joint arthropathy. ### Materials And Methods Combined RF neurotomy and steroid nerve block was performed in 34 patients with chronic paravertebral low back pain. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>diagnosis</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>confirmed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>comparative</i></b> <b style='color:DodgerBlue;'><i>double</i></b> <b style='color:DodgerBlue;'><i>diagnostic</i></b> <b style='color:DodgerBlue;'><i>block</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>branch</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Under fluoroscopy, RF thermal ablation of the medial branch was performed (at RF needle tip temperature 85\u00b0C for 90 seconds), three times for each target nerve. At the end of the procedure, 20 mg of <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> acetate (sustained-release preparation) was infiltrated on each ablated nerve. Outcome variable was the degree of improvement in pain using visual analog scale (VAS) and numerical rating scale (NRS). Improvement in the quality of life was assessed using the Roland-Morris (RM) questionnaire. The procedure was repeated in cases of unbearable pain (>5 VAS score). ### results Patients had a mean VAS score of 8.6 before the procedure. Thereafter, VAS score was 0.91 immediately after the procedure and 3.0, 2.8, 3.7, and 3.6 at 1 month, 2 months, 6 months, and 1 year. NRS showed pain relief after the procedure of 85%, 65%, 78%, 62%, and 59.5% at the same time points. RM score was 18 before the procedure, 7.6 at 6 months after the procedure, and 8.5 at 1 year after the procedure. No major complication was noted except local pain in all patients and numbness of the back in six patients after the procedure. ### conclusions Combined RF neurotomy and steroid nerve block produced substantial improvement in terms of long-term pain relief and quality of life.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"diagnosis","start":4,"end":13,"id":1,"ws":true},{"text":"was","start":14,"end":17,"id":2,"ws":true},{"text":"confirmed","start":18,"end":27,"id":3,"ws":true},{"text":"by","start":28,"end":30,"id":4,"ws":true},{"text":"comparative","start":31,"end":42,"id":5,"ws":true},{"text":"double","start":43,"end":49,"id":6,"ws":true},{"text":"diagnostic","start":50,"end":60,"id":7,"ws":true},{"text":"block","start":61,"end":66,"id":8,"ws":true},{"text":"of","start":67,"end":69,"id":9,"ws":true},{"text":"the","start":70,"end":73,"id":10,"ws":true},{"text":"medial","start":74,"end":80,"id":11,"ws":true},{"text":"branch","start":81,"end":87,"id":12,"ws":true},{"text":"with","start":88,"end":92,"id":13,"ws":true},{"text":"bupivacaine","start":93,"end":104,"id":14,"ws":true},{"text":"and","start":105,"end":108,"id":15,"ws":true},{"text":"lidocaine","start":109,"end":118,"id":16,"ws":true},{"text":".","start":119,"end":120,"id":17,"ws":false}],"spans":[{"start":93,"end":104,"token_start":14,"token_end":14,"label":"DRUG"},{"start":109,"end":118,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23177113/","_input_hash":-382739426,"_task_hash":-506566995,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":93,"end":104,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":109,"end":118,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Pemetrexed with bortezomib is feasible and tolerable at recommended single-agent doses .","paragraph":"<h3><u>Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.</u></h3><b style='color:Tomato;'><i>bortezomib</i></b> and <b style='color:Tomato;'><i>pemetrexed</i></b> are approved anticancer agents with non-overlapping mechanisms of action and toxicity. We examined the safety and tolerability of <b style='color:Tomato;'><i>pemetrexed</i></b> in combination with two different schedules of <b style='color:Tomato;'><i>bortezomib</i></b> in patients with advanced solid tumors. ### methods Two separate dose-escalating arms (arm A and arm B) were conducted simultaneously. Patients received <b style='color:Tomato;'><i>pemetrexed</i></b> on day 1 (D1) (500-600 mg/m2 IV) every 21 days. In arm A, <b style='color:Tomato;'><i>bortezomib</i></b> was given twice weekly (0.7-1.3 mg/m2 on D1, 4, 8, and 11). In arm B, <b style='color:Tomato;'><i>bortezomib</i></b> was given weekly (1.0-1.6 mg/m2 on D1 and 8). ### results We treated 27 patients on four dose levels in arm A and three dose levels in arm B. Tumor types included lung (n = 16), adenoid cystic carcinoma (n = 2), prostate (n = 2), sarcoma (n = 2), breast (n = 1), thymus (n = 1), head and neck (n = 1), and gastrointestinal(n = 2). Dose-limiting toxicities were seen in arm A only; grade 3 asthenia (n = 2), grade 3 transaminitis and dehydration (n = 1). The most common grade 3/4 toxicity was neutropenia. Of 26 evaluable patients, 2 patients had partial response (1 in arm A and 1 in arm B), 13 had stable disease (7 in arm A and 6 in arm B), and 11 had progression (6 in arm A and 5 in arm B). Of the 16 patients with non-small cell lung cancer, 2 (12.5%) had partial response and 9 had stable disease, for a disease control rate of 68.8%. Recommended phase II dose for arm A is <b style='color:Tomato;'><i>pemetrexed</i></b> 500 mg/m2 and <b style='color:Tomato;'><i>bortezomib</i></b> 1.3 mg/m2 twice weekly. For arm B, the recommended dose is <b style='color:Tomato;'><i>pemetrexed</i></b> 500 mg/m2, <b style='color:Tomato;'><i>bortezomib</i></b> 1.6 mg/m2 weekly. ### conclusions <b style='color:MediumOrchid;'><i>Pemetrexed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>feasible</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>tolerable</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>single-agent</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Based on the observed efficacy, a phase II study in non-small cell lung cancer is warranted.","tokens":[{"text":"Pemetrexed","start":0,"end":10,"id":0,"ws":true},{"text":"with","start":11,"end":15,"id":1,"ws":true},{"text":"bortezomib","start":16,"end":26,"id":2,"ws":true},{"text":"is","start":27,"end":29,"id":3,"ws":true},{"text":"feasible","start":30,"end":38,"id":4,"ws":true},{"text":"and","start":39,"end":42,"id":5,"ws":true},{"text":"tolerable","start":43,"end":52,"id":6,"ws":true},{"text":"at","start":53,"end":55,"id":7,"ws":true},{"text":"recommended","start":56,"end":67,"id":8,"ws":true},{"text":"single-agent","start":68,"end":80,"id":9,"ws":true},{"text":"doses","start":81,"end":86,"id":10,"ws":true},{"text":".","start":87,"end":88,"id":11,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":16,"end":26,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18090584/","_input_hash":-120738471,"_task_hash":1512372812,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":16,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy ( TANIA ): an open-label , randomised phase 3 trial .","paragraph":"<h3><u><b style='color:MediumOrchid;'><i>Bevacizumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-negative</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TANIA</i></b> <b style='color:DodgerBlue;'><i>):</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>open-label</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>randomised</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Combining <b style='color:Tomato;'><i>bevacizumab</i></b> with first-line or second-line chemotherapy improves progression-free survival in HER2-negative locally recurrent or metastatic breast cancer. We assessed the efficacy and safety of further <b style='color:Tomato;'><i>bevacizumab</i></b> therapy in patients with locally recurrent or metastatic breast cancer whose disease had progressed after treatment with <b style='color:Tomato;'><i>bevacizumab</i></b> plus chemotherapy. ### methods In this open-label, randomised, phase 3 trial, we recruited patients who had HER2-negative locally recurrent or metastatic breast cancer that had progressed after receiving 12 weeks or more of first-line <b style='color:Tomato;'><i>bevacizumab</i></b> plus chemotherapy from 118 centres in 12 countries. Patients were randomly assigned (1:1) by use of a central interactive voice response system using a block randomisation schedule (block size four) stratified by hormone receptor status, first-line progression-free survival, selected chemotherapy, and lactate dehydrogenase concentration, to receive second-line single-agent chemotherapy either alone or with <b style='color:Tomato;'><i>bevacizumab</i></b> (15 mg/kg every 3 weeks or 10 mg/kg every 2 weeks). Second-line therapy was continued until disease progression, unacceptable toxicity, or consent withdrawal. At progression, patients randomly assigned to chemotherapy alone received third-line chemotherapy without <b style='color:Tomato;'><i>bevacizumab</i></b>; those randomly assigned to <b style='color:Tomato;'><i>bevacizumab</i></b> continued <b style='color:Tomato;'><i>bevacizumab</i></b> with third-line chemotherapy. The primary endpoint was progression-free survival from randomisation to second-line progression or death in the intention-to-treat population. This trial is ongoing, and registered with ClinicalTrials.gov, number NCT01250379. ### findings Between Feb 17, 2011, and April 3, 2013, 494 patients were randomly assigned to treatment (247 in each group). The median duration of follow-up at the time of this prespecified primary progression-free survival analysis was 15\u00b79 months (IQR 9\u00b71-21\u00b77) in the chemotherapy-alone group and 16\u00b71 months (10\u00b76-22\u00b77) in the combination group. Progression-free survival was significantly longer for those patients treated with <b style='color:Tomato;'><i>bevacizumab</i></b> plus chemotherapy than for those with chemotherapy alone (median: 6\u00b73 months [95% CI 5\u00b74-7\u00b72] vs 4\u00b72 months [3\u00b79-4\u00b77], respectively, stratified hazard ratio [HR] 0\u00b775 [95% CI 0\u00b761-0\u00b793], two-sided stratified log-rank p=0\u00b70068). The most common grade 3 or more adverse events were hypertension (33 [13%] of 245 patients receiving <b style='color:Tomato;'><i>bevacizumab</i></b> plus chemotherapy vs 17 [7%] of 238 patients receiving chemotherapy alone), neutropenia (29 [12%] vs 20 [8%]), and hand-foot syndrome (27 [11%] vs 25 [11%]). Grade 3 proteinuria occurred in 17 (7%) of 245 patients receiving combination therapy and one (<1%) of 238 patients receiving chemotherapy alone. Serious adverse events were reported in 61 (25%) of 245 patients receiving <b style='color:Tomato;'><i>bevacizumab</i></b> plus chemotherapy versus 44 (18%) of 238 patients receiving chemotherapy alone. ### interpretation These results suggest that continued VEGF inhibition with further <b style='color:Tomato;'><i>bevacizumab</i></b> is a valid treatment option for patients with locally recurrent or metastatic HER2-negative breast cancer whose disease was stabilised or responded to first-line <b style='color:Tomato;'><i>bevacizumab</i></b> with chemotherapy. ### funding F Hoffmann-La Roche.","tokens":[{"text":"Bevacizumab","start":0,"end":11,"id":0,"ws":true},{"text":"plus","start":12,"end":16,"id":1,"ws":true},{"text":"chemotherapy","start":17,"end":29,"id":2,"ws":true},{"text":"versus","start":30,"end":36,"id":3,"ws":true},{"text":"chemotherapy","start":37,"end":49,"id":4,"ws":true},{"text":"alone","start":50,"end":55,"id":5,"ws":true},{"text":"as","start":56,"end":58,"id":6,"ws":true},{"text":"second-line","start":59,"end":70,"id":7,"ws":true},{"text":"treatment","start":71,"end":80,"id":8,"ws":true},{"text":"for","start":81,"end":84,"id":9,"ws":true},{"text":"patients","start":85,"end":93,"id":10,"ws":true},{"text":"with","start":94,"end":98,"id":11,"ws":true},{"text":"HER2-negative","start":99,"end":112,"id":12,"ws":true},{"text":"locally","start":113,"end":120,"id":13,"ws":true},{"text":"recurrent","start":121,"end":130,"id":14,"ws":true},{"text":"or","start":131,"end":133,"id":15,"ws":true},{"text":"metastatic","start":134,"end":144,"id":16,"ws":true},{"text":"breast","start":145,"end":151,"id":17,"ws":true},{"text":"cancer","start":152,"end":158,"id":18,"ws":true},{"text":"after","start":159,"end":164,"id":19,"ws":true},{"text":"first-line","start":165,"end":175,"id":20,"ws":true},{"text":"treatment","start":176,"end":185,"id":21,"ws":true},{"text":"with","start":186,"end":190,"id":22,"ws":true},{"text":"bevacizumab","start":191,"end":202,"id":23,"ws":true},{"text":"plus","start":203,"end":207,"id":24,"ws":true},{"text":"chemotherapy","start":208,"end":220,"id":25,"ws":true},{"text":"(","start":221,"end":222,"id":26,"ws":true},{"text":"TANIA","start":223,"end":228,"id":27,"ws":true},{"text":"):","start":229,"end":231,"id":28,"ws":true},{"text":"an","start":232,"end":234,"id":29,"ws":true},{"text":"open-label","start":235,"end":245,"id":30,"ws":true},{"text":",","start":246,"end":247,"id":31,"ws":true},{"text":"randomised","start":248,"end":258,"id":32,"ws":true},{"text":"phase","start":259,"end":264,"id":33,"ws":true},{"text":"3","start":265,"end":266,"id":34,"ws":true},{"text":"trial","start":267,"end":272,"id":35,"ws":true},{"text":".","start":273,"end":274,"id":36,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":191,"end":202,"token_start":23,"token_end":23,"label":"DRUG"},{"start":223,"end":228,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25273342/","_input_hash":-846003018,"_task_hash":53639698,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":23,"child":27,"head_span":{"start":191,"end":202,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":223,"end":228,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Goserelin plus tamoxifen after cyclophosphamide , doxorubicin and 5-fluorouracil ( CAF ) chemotherapy resulted in improved disease-free survival compared with CAF alone .","paragraph":"<h3><u>Goserelin ('Zoladex')--offering patients more choice in early breast cancer.</u></h3>The luteinising hormone-releasing hormone analogue <b style='color:Tomato;'><i>goserelin</i></b> ('Zoladex') suppresses ovarian oestrogen production in pre- and perimenopausal women. <b style='color:Tomato;'><i>goserelin</i></b> is a biodegradable, sustained-release 3.6 mg depot that is administered by subcutaneous injection every 28 days. Clinical trials in premenopausal women with hormone-sensitive early breast cancer have demonstrated that <b style='color:Tomato;'><i>goserelin</i></b> alone, or in combination with <b style='color:Tomato;'><i>tamoxifen</i></b>, is at least as effective as <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, 5-<b style='color:Tomato;'><i>fluorouracil</i></b> (CMF) chemotherapy. <b style='color:MediumOrchid;'><i>Goserelin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CAF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>disease-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CAF</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These trials have also shown that <b style='color:Tomato;'><i>goserelin</i></b> is well tolerated and is associated with less acute toxicity than cytotoxic chemotherapy. Early improvements in quality of life over the first 3-6 months of <b style='color:Tomato;'><i>goserelin</i></b> treatment support the use of this agent as an alternative to chemotherapy in this patient population. Patients should be provided with information on the benefits and risks associated with available treatment options so that they can be involved in the decision-making process.","tokens":[{"text":"Goserelin","start":0,"end":9,"id":0,"ws":true},{"text":"plus","start":10,"end":14,"id":1,"ws":true},{"text":"tamoxifen","start":15,"end":24,"id":2,"ws":true},{"text":"after","start":25,"end":30,"id":3,"ws":true},{"text":"cyclophosphamide","start":31,"end":47,"id":4,"ws":true},{"text":",","start":48,"end":49,"id":5,"ws":true},{"text":"doxorubicin","start":50,"end":61,"id":6,"ws":true},{"text":"and","start":62,"end":65,"id":7,"ws":true},{"text":"5-fluorouracil","start":66,"end":80,"id":8,"ws":true},{"text":"(","start":81,"end":82,"id":9,"ws":true},{"text":"CAF","start":83,"end":86,"id":10,"ws":true},{"text":")","start":87,"end":88,"id":11,"ws":true},{"text":"chemotherapy","start":89,"end":101,"id":12,"ws":true},{"text":"resulted","start":102,"end":110,"id":13,"ws":true},{"text":"in","start":111,"end":113,"id":14,"ws":true},{"text":"improved","start":114,"end":122,"id":15,"ws":true},{"text":"disease-free","start":123,"end":135,"id":16,"ws":true},{"text":"survival","start":136,"end":144,"id":17,"ws":true},{"text":"compared","start":145,"end":153,"id":18,"ws":true},{"text":"with","start":154,"end":158,"id":19,"ws":true},{"text":"CAF","start":159,"end":162,"id":20,"ws":true},{"text":"alone","start":163,"end":168,"id":21,"ws":true},{"text":".","start":169,"end":170,"id":22,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},{"start":31,"end":47,"token_start":4,"token_end":4,"label":"DRUG"},{"start":50,"end":61,"token_start":6,"token_end":6,"label":"DRUG"},{"start":66,"end":80,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15590321/","_input_hash":-201480382,"_task_hash":1906082175,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":2,"child":4,"head_span":{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":31,"end":47,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":4,"child":6,"head_span":{"start":31,"end":47,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":50,"end":61,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":6,"child":8,"head_span":{"start":50,"end":61,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":66,"end":80,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"An 82-year-old white female developed a 36-hour episode of unresponsiveness/drowsiness after a single dose of triazolam 0.5 mg in combination with cimetidine .","paragraph":"<h3><u>Prolonged hypnotic response to triazolam-cimetidine combination in an elderly patient.</u></h3> <b style='color:DodgerBlue;'><i>An</i></b> <b style='color:DodgerBlue;'><i>82-year-old</i></b> <b style='color:DodgerBlue;'><i>white</i></b> <b style='color:DodgerBlue;'><i>female</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>36-hour</i></b> <b style='color:DodgerBlue;'><i>episode</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>unresponsiveness/drowsiness</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>triazolam</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cimetidine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This case illustrates the need for careful dose-titration of drug therapy in the elderly, particularly when a drug with the potential to impair drug metabolism is coadministered. <b style='color:Tomato;'><i>cimetidine</i></b>, when coadministered with <b style='color:Tomato;'><i>triazolam</i></b>, may increase the intensity and duration of action of single doses of <b style='color:Tomato;'><i>triazolam</i></b>.","tokens":[{"text":"An","start":0,"end":2,"id":0,"ws":true},{"text":"82-year-old","start":3,"end":14,"id":1,"ws":true},{"text":"white","start":15,"end":20,"id":2,"ws":true},{"text":"female","start":21,"end":27,"id":3,"ws":true},{"text":"developed","start":28,"end":37,"id":4,"ws":true},{"text":"a","start":38,"end":39,"id":5,"ws":true},{"text":"36-hour","start":40,"end":47,"id":6,"ws":true},{"text":"episode","start":48,"end":55,"id":7,"ws":true},{"text":"of","start":56,"end":58,"id":8,"ws":true},{"text":"unresponsiveness/drowsiness","start":59,"end":86,"id":9,"ws":true},{"text":"after","start":87,"end":92,"id":10,"ws":true},{"text":"a","start":93,"end":94,"id":11,"ws":true},{"text":"single","start":95,"end":101,"id":12,"ws":true},{"text":"dose","start":102,"end":106,"id":13,"ws":true},{"text":"of","start":107,"end":109,"id":14,"ws":true},{"text":"triazolam","start":110,"end":119,"id":15,"ws":true},{"text":"0.5","start":120,"end":123,"id":16,"ws":true},{"text":"mg","start":124,"end":126,"id":17,"ws":true},{"text":"in","start":127,"end":129,"id":18,"ws":true},{"text":"combination","start":130,"end":141,"id":19,"ws":true},{"text":"with","start":142,"end":146,"id":20,"ws":true},{"text":"cimetidine","start":147,"end":157,"id":21,"ws":true},{"text":".","start":158,"end":159,"id":22,"ws":false}],"spans":[{"start":110,"end":119,"token_start":15,"token_end":15,"label":"DRUG"},{"start":147,"end":157,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6150838/","_input_hash":937980821,"_task_hash":-610081997,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":15,"child":21,"head_span":{"start":110,"end":119,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":147,"end":157,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"The combination of melatonin at concentrations of 50 \u03bcM with increasing doses of irinotecan ( 7.5 , 15 , 30 , and 60 \u03bcM ) resulted in an increase in the amount of DNA damage in A549 and HT29 cancer cells , but was not effective in inducing DNA damage in healthy human lymphocytes .","paragraph":"<h3><u>The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells.</u></h3>Drug-target interactions can be modified by adding modulatory agents to increase treatment efficacy and clinical outcome. Combination chemotherapy has become increasingly important because drugs acting synergistically can achieve therapeutic effects at substantially lower doses and with a limited spectrum of side effects. <b style='color:Tomato;'><i>irinotecan</i></b>, known as one of the camptothecin analogs, has shown a broad spectrum of antitumor activity against various malignancies. In this study, we evaluated the effect of <b style='color:Tomato;'><i>melatonin</i></b> on the genotoxic activity of <b style='color:Tomato;'><i>irinotecan</i></b> in healthy human lymphocytes and a lung cancer cell line (A549) and a colorectal adenocarcinoma cell line (HT29) in vitro. <b style='color:Tomato;'><i>irinotecan</i></b>, as a single agent, was shown to induce DNA damage in all types of analyzed cells. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>melatonin</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>\u03bcM</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>increasing</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>7.5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>\u03bcM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>amount</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>DNA</i></b> <b style='color:DodgerBlue;'><i>damage</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>A549</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>HT29</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>inducing</i></b> <b style='color:DodgerBlue;'><i>DNA</i></b> <b style='color:DodgerBlue;'><i>damage</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>healthy</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>lymphocytes</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Analysis of the efficacy of DNA repair, performed after 60 and 120 minutes of postincubation, showed the gradual decrease of DNA percentage in comet tails during repair postincubation in all experimental samples. Our results indicate that <b style='color:Tomato;'><i>melatonin</i></b> can modulate the genotoxic activity of <b style='color:Tomato;'><i>irinotecan</i></b> and DNA repair efficacy in human cancer cells in vitro. These findings may be supportive for the optimization of therapeutic efficacy in <b style='color:Tomato;'><i>irinotecan</i></b> treatment.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combination","start":4,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"melatonin","start":19,"end":28,"id":3,"ws":true},{"text":"at","start":29,"end":31,"id":4,"ws":true},{"text":"concentrations","start":32,"end":46,"id":5,"ws":true},{"text":"of","start":47,"end":49,"id":6,"ws":true},{"text":"50","start":50,"end":52,"id":7,"ws":true},{"text":"\u03bcM","start":53,"end":55,"id":8,"ws":true},{"text":"with","start":56,"end":60,"id":9,"ws":true},{"text":"increasing","start":61,"end":71,"id":10,"ws":true},{"text":"doses","start":72,"end":77,"id":11,"ws":true},{"text":"of","start":78,"end":80,"id":12,"ws":true},{"text":"irinotecan","start":81,"end":91,"id":13,"ws":true},{"text":"(","start":92,"end":93,"id":14,"ws":true},{"text":"7.5","start":94,"end":97,"id":15,"ws":true},{"text":",","start":98,"end":99,"id":16,"ws":true},{"text":"15","start":100,"end":102,"id":17,"ws":true},{"text":",","start":103,"end":104,"id":18,"ws":true},{"text":"30","start":105,"end":107,"id":19,"ws":true},{"text":",","start":108,"end":109,"id":20,"ws":true},{"text":"and","start":110,"end":113,"id":21,"ws":true},{"text":"60","start":114,"end":116,"id":22,"ws":true},{"text":"\u03bcM","start":117,"end":119,"id":23,"ws":true},{"text":")","start":120,"end":121,"id":24,"ws":true},{"text":"resulted","start":122,"end":130,"id":25,"ws":true},{"text":"in","start":131,"end":133,"id":26,"ws":true},{"text":"an","start":134,"end":136,"id":27,"ws":true},{"text":"increase","start":137,"end":145,"id":28,"ws":true},{"text":"in","start":146,"end":148,"id":29,"ws":true},{"text":"the","start":149,"end":152,"id":30,"ws":true},{"text":"amount","start":153,"end":159,"id":31,"ws":true},{"text":"of","start":160,"end":162,"id":32,"ws":true},{"text":"DNA","start":163,"end":166,"id":33,"ws":true},{"text":"damage","start":167,"end":173,"id":34,"ws":true},{"text":"in","start":174,"end":176,"id":35,"ws":true},{"text":"A549","start":177,"end":181,"id":36,"ws":true},{"text":"and","start":182,"end":185,"id":37,"ws":true},{"text":"HT29","start":186,"end":190,"id":38,"ws":true},{"text":"cancer","start":191,"end":197,"id":39,"ws":true},{"text":"cells","start":198,"end":203,"id":40,"ws":true},{"text":",","start":204,"end":205,"id":41,"ws":true},{"text":"but","start":206,"end":209,"id":42,"ws":true},{"text":"was","start":210,"end":213,"id":43,"ws":true},{"text":"not","start":214,"end":217,"id":44,"ws":true},{"text":"effective","start":218,"end":227,"id":45,"ws":true},{"text":"in","start":228,"end":230,"id":46,"ws":true},{"text":"inducing","start":231,"end":239,"id":47,"ws":true},{"text":"DNA","start":240,"end":243,"id":48,"ws":true},{"text":"damage","start":244,"end":250,"id":49,"ws":true},{"text":"in","start":251,"end":253,"id":50,"ws":true},{"text":"healthy","start":254,"end":261,"id":51,"ws":true},{"text":"human","start":262,"end":267,"id":52,"ws":true},{"text":"lymphocytes","start":268,"end":279,"id":53,"ws":true},{"text":".","start":280,"end":281,"id":54,"ws":false}],"spans":[{"start":19,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},{"start":81,"end":91,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23126525/","_input_hash":-2068542512,"_task_hash":-419256772,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":3,"child":13,"head_span":{"start":19,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":81,"end":91,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Peripheral blood progenitor cells were harvested by leukapheresis after treatment with cyclophosphamide and filgrastim and then re-infused after the high-dose cycle .","paragraph":"<h3><u>Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.</u></h3>Breast cancer patients with four or more positive axillary lymph nodes who are treated with conventional adjuvant therapy have a poor prognosis. In uncontrolled studies, high-dose chemotherapy produced much better results than conventional therapy. We compared the benefits of a single cycle of high-dose chemotherapy and the benefits of conventional chemotherapy in patients with high-risk breast cancer in a prospective, unblinded, randomized trial. ### methods Between February 23, 1995, and June 29, 1999, 605 patients with breast cancer who had four or more positive lymph nodes were randomly assigned to treatment (307 to high-dose therapy and 298 to conventional therapy). The conventional chemotherapy regimen was four cycles of <b style='color:Tomato;'><i>doxorubicin</i></b> (75 mg/m2) followed by eight cycles of CMF (<b style='color:Tomato;'><i>cyclophosphamide</i></b> [600 mg/m2], <b style='color:Tomato;'><i>methotrexate</i></b> [50 mg/m2], and 5-<b style='color:Tomato;'><i>fluorouracil</i></b> [600 mg/m2]), all given intravenously on day 1 of a 21-day cycle. The high-dose regimen was four cycles of <b style='color:Tomato;'><i>doxorubicin</i></b> (75 mg/m2), followed by a single cycle of intermediate-dose <b style='color:Tomato;'><i>cyclophosphamide</i></b> (4000 mg/m2) supported by <b style='color:Tomato;'><i>filgrastim</i></b> (300 microg/day) for up to 10 days followed by high-dose <b style='color:Tomato;'><i>cyclophosphamide</i></b> (6000 mg/m2) and <b style='color:Tomato;'><i>thiotepa</i></b> (800 mg/m2). <b style='color:DodgerBlue;'><i>Peripheral</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>progenitor</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>harvested</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>leukapheresis</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>filgrastim</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>then</i></b> <b style='color:DodgerBlue;'><i>re-infused</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Log-rank tests were used to compare survival rates. All statistical analyses were two-sided. ### results At a median follow-up of 6 years, no statistically significant differences were detected between the arms in 5-year relapse-free survival (high-dose arm = 57%, 95% confidence interval [CI] = 51% to 63%; conventional-dose arm = 54%, 95% CI = 48% to 61% (P =.73) or in 5-year overall survival (high-dose arm = 62%, 95% CI = 56% to 68%; conventional-dose arm = 64%, 95% CI = 57% to 70%) (P =.38). ### conclusion Autograft-supported, high-dose therapy is not superior to conventional chemotherapy in patients with breast cancer who have multiple involved lymph nodes. This conclusion should be viewed in the context of improving the success of conventional chemotherapy.","tokens":[{"text":"Peripheral","start":0,"end":10,"id":0,"ws":true},{"text":"blood","start":11,"end":16,"id":1,"ws":true},{"text":"progenitor","start":17,"end":27,"id":2,"ws":true},{"text":"cells","start":28,"end":33,"id":3,"ws":true},{"text":"were","start":34,"end":38,"id":4,"ws":true},{"text":"harvested","start":39,"end":48,"id":5,"ws":true},{"text":"by","start":49,"end":51,"id":6,"ws":true},{"text":"leukapheresis","start":52,"end":65,"id":7,"ws":true},{"text":"after","start":66,"end":71,"id":8,"ws":true},{"text":"treatment","start":72,"end":81,"id":9,"ws":true},{"text":"with","start":82,"end":86,"id":10,"ws":true},{"text":"cyclophosphamide","start":87,"end":103,"id":11,"ws":true},{"text":"and","start":104,"end":107,"id":12,"ws":true},{"text":"filgrastim","start":108,"end":118,"id":13,"ws":true},{"text":"and","start":119,"end":122,"id":14,"ws":true},{"text":"then","start":123,"end":127,"id":15,"ws":true},{"text":"re-infused","start":128,"end":138,"id":16,"ws":true},{"text":"after","start":139,"end":144,"id":17,"ws":true},{"text":"the","start":145,"end":148,"id":18,"ws":true},{"text":"high-dose","start":149,"end":158,"id":19,"ws":true},{"text":"cycle","start":159,"end":164,"id":20,"ws":true},{"text":".","start":165,"end":166,"id":21,"ws":false}],"spans":[{"start":87,"end":103,"token_start":11,"token_end":11,"label":"DRUG"},{"start":108,"end":118,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15265969/","_input_hash":-1630352697,"_task_hash":1719538473,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":87,"end":103,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":108,"end":118,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Although cisplatin is generally the favoured platinum agent , gemcitabine partnered with carboplatin is convenient to administer and has a favourable toxicity profile .","paragraph":"<h3><u>Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer.</u></h3>The universally accepted first-line treatment for advanced (stage IIIB effusion/IV) non-small-cell lung cancer in patients with a good performance status is a platinum drug in combination with one of <b style='color:Tomato;'><i>gemcitabine</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, <b style='color:Tomato;'><i>vinorelbine</i></b> or <b style='color:Tomato;'><i>docetaxel</i></b>. <b style='color:DodgerBlue;'><i>Although</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>generally</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>favoured</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>partnered</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>convenient</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>administer</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>favourable</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>profile</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, the pharmacology, preclinical and clinical data to support the use of this regimen for the treatment of advanced non-small-cell lung cancer is evaluated.","tokens":[{"text":"Although","start":0,"end":8,"id":0,"ws":true},{"text":"cisplatin","start":9,"end":18,"id":1,"ws":true},{"text":"is","start":19,"end":21,"id":2,"ws":true},{"text":"generally","start":22,"end":31,"id":3,"ws":true},{"text":"the","start":32,"end":35,"id":4,"ws":true},{"text":"favoured","start":36,"end":44,"id":5,"ws":true},{"text":"platinum","start":45,"end":53,"id":6,"ws":true},{"text":"agent","start":54,"end":59,"id":7,"ws":true},{"text":",","start":60,"end":61,"id":8,"ws":true},{"text":"gemcitabine","start":62,"end":73,"id":9,"ws":true},{"text":"partnered","start":74,"end":83,"id":10,"ws":true},{"text":"with","start":84,"end":88,"id":11,"ws":true},{"text":"carboplatin","start":89,"end":100,"id":12,"ws":true},{"text":"is","start":101,"end":103,"id":13,"ws":true},{"text":"convenient","start":104,"end":114,"id":14,"ws":true},{"text":"to","start":115,"end":117,"id":15,"ws":true},{"text":"administer","start":118,"end":128,"id":16,"ws":true},{"text":"and","start":129,"end":132,"id":17,"ws":true},{"text":"has","start":133,"end":136,"id":18,"ws":true},{"text":"a","start":137,"end":138,"id":19,"ws":true},{"text":"favourable","start":139,"end":149,"id":20,"ws":true},{"text":"toxicity","start":150,"end":158,"id":21,"ws":true},{"text":"profile","start":159,"end":166,"id":22,"ws":true},{"text":".","start":167,"end":168,"id":23,"ws":false}],"spans":[{"start":9,"end":18,"token_start":1,"token_end":1,"label":"DRUG"},{"start":62,"end":73,"token_start":9,"token_end":9,"label":"DRUG"},{"start":89,"end":100,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18035969/","_input_hash":314691127,"_task_hash":-1070409302,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":9,"child":12,"head_span":{"start":62,"end":73,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":89,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"In group B , epirubicin 90 mg/m2 was combined with paclitaxel 175 mg/m2 , given in the same manner as in group A.","paragraph":"<h3><u>Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.</u></h3><b style='color:Tomato;'><i>paclitaxel</i></b> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), the first taxane used in routine clinical practice, has aroused considerable interest for its high single-agent activity against breast cancer and for its novel mechanism of action. <b style='color:Tomato;'><i>epirubicin</i></b>, the 4' epimer of <b style='color:Tomato;'><i>doxorubicin</i></b>, is another agent with a high activity against breast cancer and is known for its lower rate of toxic side effects, especially toxic cardiac events, compared with its mother compound. The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>doxorubicin</i></b> yielded response rates between 63% and 93% in phase I/II studies. In these studies, however, the investigators reported severe cardiac toxic events. The rationale for the current study was therefore to evaluate the combination of <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>epirubicin</i></b>, focusing mainly on cardiac toxicity. In two groups, 85 patients with metastatic breast cancer entered the study. Approximately 20% of the patients had primary metastatic breast cancer with large tumors at the primary site. Half of the patients had received adjuvant chemotherapy. Study medication in group A consisted of <b style='color:Tomato;'><i>epirubicin</i></b> 60 mg/m2 given intravenously over 1 hour, followed by <b style='color:Tomato;'><i>paclitaxel</i></b> 175 mg/m2 administered as a 3-hour intravenous infusion after premedication with steroids, antihistamines, and H2-blockers. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>90</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>manner</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>A.</i></b> Dose escalation to 225 mg/m2 <b style='color:Tomato;'><i>paclitaxel</i></b> was planned in both groups. The main toxicity in both groups was neutropenia (73% World Health Organization grade 3/4 in group A and 93% in group B). Other hematologic side effects were rare. No febrile neutropenia was reported in group A, but two episodes occurred in group B. Peripheral neuropathy, arthralgia, and myalgia were mild (only World Health Organization grades 1 and 2). Alopecia was universal. In group A, the <b style='color:Tomato;'><i>paclitaxel</i></b> dose could be escalated to 200 mg/m2 in 15 patients and to 225 mg/m2 in seven patients. Dose reduction due to severe neutropenia was necessary in 11 patients. No cardiac events were reported in group A. In group B, the <b style='color:Tomato;'><i>paclitaxel</i></b> dose could be escalated to 200 mg/m2 in only one patient, and no patient reached 225 mg/m2. Three patients needed a dose reduction. In this group, one patient had a greater than 10% decrease in the left ventricular ejection fraction with no clinical signs. In group A, 43 patients were evaluable for response; in group B, 25 patients were evaluable. Thirteen patients were out of protocol with only bone metastasis, and two patients had more than one prior chemotherapy for metastatic disease. The response rate was identical in both groups, with five complete remissions and 24 partial remissions in group A and three complete responses and 14 partial remissions in group B. The duration of response was 8.2 months in both groups. The median cumulative <b style='color:Tomato;'><i>epirubicin</i></b> dose was 420 mg/m2 in group A and 630 mg/m2 in group B. The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> 175 mg/m2 and <b style='color:Tomato;'><i>epirubicin</i></b> 60 or 90 mg/m2 can be administered safely to patients with metastatic breast cancer. Although response was not the primary end point of this trial, the response data are nonetheless encouraging and suggest that further evaluation of this combination-line treatment of metastatic breast cancer is warranted.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"group","start":3,"end":8,"id":1,"ws":true},{"text":"B","start":9,"end":10,"id":2,"ws":true},{"text":",","start":11,"end":12,"id":3,"ws":true},{"text":"epirubicin","start":13,"end":23,"id":4,"ws":true},{"text":"90","start":24,"end":26,"id":5,"ws":true},{"text":"mg/m2","start":27,"end":32,"id":6,"ws":true},{"text":"was","start":33,"end":36,"id":7,"ws":true},{"text":"combined","start":37,"end":45,"id":8,"ws":true},{"text":"with","start":46,"end":50,"id":9,"ws":true},{"text":"paclitaxel","start":51,"end":61,"id":10,"ws":true},{"text":"175","start":62,"end":65,"id":11,"ws":true},{"text":"mg/m2","start":66,"end":71,"id":12,"ws":true},{"text":",","start":72,"end":73,"id":13,"ws":true},{"text":"given","start":74,"end":79,"id":14,"ws":true},{"text":"in","start":80,"end":82,"id":15,"ws":true},{"text":"the","start":83,"end":86,"id":16,"ws":true},{"text":"same","start":87,"end":91,"id":17,"ws":true},{"text":"manner","start":92,"end":98,"id":18,"ws":true},{"text":"as","start":99,"end":101,"id":19,"ws":true},{"text":"in","start":102,"end":104,"id":20,"ws":true},{"text":"group","start":105,"end":110,"id":21,"ws":true},{"text":"A.","start":111,"end":113,"id":22,"ws":false}],"spans":[{"start":13,"end":23,"token_start":4,"token_end":4,"label":"DRUG"},{"start":51,"end":61,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9374090/","_input_hash":-240574657,"_task_hash":557158158,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":4,"child":10,"head_span":{"start":13,"end":23,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":51,"end":61,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"We assessed the safety and activity of ceritinib plus nivolumab in these patients .","paragraph":"<h3><u>Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.</u></h3>Induction of programmed death ligand 1 (PD-L1) expression due to constitutive oncogenic signaling has been reported in NSCLC models harboring echinoderm microtubule associated protein like 4 gene (EML4)-ALK receptor tyrosine kinase gene (ALK) rearrangements. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>assessed</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ceritinib</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods In this open-label, phase 1B, multicenter, dose escalation and expansion study, previously treated (with ALK receptor tyrosine kinase [ALK] inhibitor [ALKI]/chemotherapy) or treatment-naive patients with stage IIIB or IV ALK-rearranged NSCLC received <b style='color:Tomato;'><i>nivolumab</i></b>, 3 mg/kg intravenously every 2 weeks, plus <b style='color:Tomato;'><i>ceritinib</i></b>, 450 mg/300 mg daily, with a low-fat meal. ### results In total, 36 patients were treated (a 450-mg cohort [n=14] and a 300-mg cohort [n=22]). In the 450-mg cohort, four patients experienced dose-limiting toxicities. In the 300-mg cohort, two patients experienced dose-limiting toxicities. Among ALKI-naive patients, the overall response rate (ORR) was 83% (95% confidence interval [CI]: 35.9-99.6) in the 450-mg cohort and 60% (95% CI: 26.2-87.8) in the 300-mg cohort. Among ALKI-pretreated patients, the ORR was 50% (95% CI: 15.7-84.3) in the 450-mg cohort and 25% (95% CI: 5.5-57.2) in the 300-mg cohort. The ORR point estimate was observed to be greater in patients who were positive for PD-L1 than in those who were negative for PD-L1, with overlapping CIs (e.g., at a cutoff \u22651% PD-L1, 64% of patients [95% CI: 35.1-87.2] had confirmed responses as compared with those with negative PD-L1 staining (31% [95% CI: 11.0-58.7]). The most frequently reported grade 3 or 4 adverse events were increased alanine aminotransferase level (25%), increased gamma-glutamyl transferase level (22%), increased amylase level (14%), increased lipase level (11%), and maculopapular rash (11%). The incidence of all-grade rash (grouped term) was 64% in both cohorts; grade 3 rash was reported in 29% and 14% of patients in the 450-mg and 300-mg cohorts, respectively; no grade 4 rash was reported. ### conclusion <b style='color:Tomato;'><i>ceritinib</i></b> plus <b style='color:Tomato;'><i>nivolumab</i></b> has activity; ORR appears to correlate with PD-L1 at baseline. Toxicity, especially rash, is more common than with either single agent.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"assessed","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"safety","start":16,"end":22,"id":3,"ws":true},{"text":"and","start":23,"end":26,"id":4,"ws":true},{"text":"activity","start":27,"end":35,"id":5,"ws":true},{"text":"of","start":36,"end":38,"id":6,"ws":true},{"text":"ceritinib","start":39,"end":48,"id":7,"ws":true},{"text":"plus","start":49,"end":53,"id":8,"ws":true},{"text":"nivolumab","start":54,"end":63,"id":9,"ws":true},{"text":"in","start":64,"end":66,"id":10,"ws":true},{"text":"these","start":67,"end":72,"id":11,"ws":true},{"text":"patients","start":73,"end":81,"id":12,"ws":true},{"text":".","start":82,"end":83,"id":13,"ws":false}],"spans":[{"start":39,"end":48,"token_start":7,"token_end":7,"label":"DRUG"},{"start":54,"end":63,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31634667/","_input_hash":409838923,"_task_hash":1342572660,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":39,"end":48,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":54,"end":63,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Incubation with somatostatin , 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Incubation</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>5-aza</i></b> <b style='color:MediumOrchid;'><i>decitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>trichostatin</i></b> <b style='color:DodgerBlue;'><i>up-regulates</i></b> <b style='color:MediumOrchid;'><i>somatostatin</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>somatostatin</i></b> (SMS), binds to its specific receptors (SSTRs) and transduces growth inhibitory, anti-secretory and apoptotic signals. Several human cancers express SSTRs, including prostate cancer, and therefore SMS is of interest for anti-cancer therapy. DNA methylation and histone modifications are involved in normal cell development, gene imprinting and human carcinogenesis. Reversing DNA methylation is an attractive therapeutic possibility, since epigenetic modifications change gene expression without changing the gene function. DNA methylation inhibitors such as 5-aza-2'-deoxycytidine (5'-aza, <b style='color:Tomato;'><i>decitabine</i></b>) have been used to treat several types of haematological malignancies. Histone deacetylase inhibitors such as trichostatin (TSA), are a new class of 'targeted anti-cancer agents'. TSA and <b style='color:Tomato;'><i>decitabine</i></b> can induce growth arrest, apoptosis or terminal differentiation in a variety of solid and haematological cancers in advanced disease patients. In the present study, the LNCaP cell line (prostate cancer) was incubated with SMS or Somadex (an SMS polymer conjugate) for three days, 1 nM per day, and the untreated cells were the negative control. For DNA demethylation, cells were grown in the presence of 2.5 microM 5-aza for 120 h, and re-fed with 5-aza-containing fresh medium at day 3. The total incubation time with 5-aza was 120 h. TSA at 1.0 microM was added into the cultured cells for 24 h. The combined treatment of 5-aza and TSA was performed by incubating the cells with 5-aza for 120 h followed by a 24-h exposure to TSA. Using cDNA obtained from these cell lines, the difference in the expression level of SSTR mRNA transcripts before and after 5-aza and TSA treatments was analyzed by RT-PCR. An increased induction of mRNA expression of the five SSTR subtypes was observed in the LNCaP cells when incubated with SMS/Somadex (dose-dependent). The inhibition of DNA methylation and histone acetylation resulted in the up-regulation of SSTR5 mRNA expression. The results demonstrate a positive feedback loop between SMS and its receptors. This regulation pathway may enhance the anti-tumor activity of <b style='color:Tomato;'><i>somatostatin</i></b>. To benefit from this effect in a clinical setting, the dose, dose frequency and pan affinity of the SMS derivative are important factors. The epigenetic manipulation with DNA methylation or histone deacetylase inhibitors, combined with SMS, may offer a novel alternative for the treatment of advanced prostate cancer.","tokens":[{"text":"Incubation","start":0,"end":10,"id":0,"ws":true},{"text":"with","start":11,"end":15,"id":1,"ws":true},{"text":"somatostatin","start":16,"end":28,"id":2,"ws":true},{"text":",","start":29,"end":30,"id":3,"ws":true},{"text":"5-aza","start":31,"end":36,"id":4,"ws":true},{"text":"decitabine","start":37,"end":47,"id":5,"ws":true},{"text":"and","start":48,"end":51,"id":6,"ws":true},{"text":"trichostatin","start":52,"end":64,"id":7,"ws":true},{"text":"up-regulates","start":65,"end":77,"id":8,"ws":true},{"text":"somatostatin","start":78,"end":90,"id":9,"ws":true},{"text":"receptor","start":91,"end":99,"id":10,"ws":true},{"text":"expression","start":100,"end":110,"id":11,"ws":true},{"text":"in","start":111,"end":113,"id":12,"ws":true},{"text":"prostate","start":114,"end":122,"id":13,"ws":true},{"text":"cancer","start":123,"end":129,"id":14,"ws":true},{"text":"cells","start":130,"end":135,"id":15,"ws":true},{"text":".","start":136,"end":137,"id":16,"ws":false}],"spans":[{"start":16,"end":28,"token_start":2,"token_end":2,"label":"DRUG"},{"start":37,"end":47,"token_start":5,"token_end":5,"label":"DRUG"},{"start":52,"end":64,"token_start":7,"token_end":7,"label":"DRUG"},{"start":78,"end":90,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18575731/","_input_hash":586182900,"_task_hash":-1419144685,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"This study was conducted to determine whether famotidine , a H2 antagonist , is effective in the treatment of acute urticaria and compare its effect with that of the H1 antagonist diphenhydramine .","paragraph":"<h3><u>Famotidine in the treatment of acute urticaria.</u></h3>Recent studies suggest that histamine H2-receptor antagonists may be useful in the treatment of urticaria. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>whether</i></b> <b style='color:MediumOrchid;'><i>famotidine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>H2</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>urticaria</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>H1</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:MediumOrchid;'><i>diphenhydramine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this prospective, double-blind, controlled trial, 25 patients with urticaria of less than 72 h duration were randomized to receive a single dose of either <b style='color:Tomato;'><i>famotidine</i></b> 20 mg i.m. or <b style='color:Tomato;'><i>diphenhydramine</i></b> 50 mg i.m. Prior to treatment and 30 min after treatment, patients rated pruritus and sedation using visual analogue scales, while physicians evaluated intensity of urticaria and percentage of body surface area involved by urticaria. <b style='color:Tomato;'><i>famotidine</i></b> was found to reduce pruritus associated with acute urticaria, intensity of urticaria, and body surface area affected by urticaria without causing sedation. <b style='color:Tomato;'><i>famotidine</i></b> was comparable to <b style='color:Tomato;'><i>diphenhydramine</i></b> in efficacy; however, there was a (nonsignificant) trend for <b style='color:Tomato;'><i>diphenhydramine</i></b> to be more effective than <b style='color:Tomato;'><i>famotidine</i></b> in the treatment of pruritus, and for <b style='color:Tomato;'><i>famotidine</i></b> to be more effective in the reduction of surface area of involvement. It is concluded that <b style='color:Tomato;'><i>famotidine</i></b> merits further investigation as a potential medication for treatment of urticaria.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"study","start":5,"end":10,"id":1,"ws":true},{"text":"was","start":11,"end":14,"id":2,"ws":true},{"text":"conducted","start":15,"end":24,"id":3,"ws":true},{"text":"to","start":25,"end":27,"id":4,"ws":true},{"text":"determine","start":28,"end":37,"id":5,"ws":true},{"text":"whether","start":38,"end":45,"id":6,"ws":true},{"text":"famotidine","start":46,"end":56,"id":7,"ws":true},{"text":",","start":57,"end":58,"id":8,"ws":true},{"text":"a","start":59,"end":60,"id":9,"ws":true},{"text":"H2","start":61,"end":63,"id":10,"ws":true},{"text":"antagonist","start":64,"end":74,"id":11,"ws":true},{"text":",","start":75,"end":76,"id":12,"ws":true},{"text":"is","start":77,"end":79,"id":13,"ws":true},{"text":"effective","start":80,"end":89,"id":14,"ws":true},{"text":"in","start":90,"end":92,"id":15,"ws":true},{"text":"the","start":93,"end":96,"id":16,"ws":true},{"text":"treatment","start":97,"end":106,"id":17,"ws":true},{"text":"of","start":107,"end":109,"id":18,"ws":true},{"text":"acute","start":110,"end":115,"id":19,"ws":true},{"text":"urticaria","start":116,"end":125,"id":20,"ws":true},{"text":"and","start":126,"end":129,"id":21,"ws":true},{"text":"compare","start":130,"end":137,"id":22,"ws":true},{"text":"its","start":138,"end":141,"id":23,"ws":true},{"text":"effect","start":142,"end":148,"id":24,"ws":true},{"text":"with","start":149,"end":153,"id":25,"ws":true},{"text":"that","start":154,"end":158,"id":26,"ws":true},{"text":"of","start":159,"end":161,"id":27,"ws":true},{"text":"the","start":162,"end":165,"id":28,"ws":true},{"text":"H1","start":166,"end":168,"id":29,"ws":true},{"text":"antagonist","start":169,"end":179,"id":30,"ws":true},{"text":"diphenhydramine","start":180,"end":195,"id":31,"ws":true},{"text":".","start":196,"end":197,"id":32,"ws":false}],"spans":[{"start":46,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},{"start":180,"end":195,"token_start":31,"token_end":31,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10844490/","_input_hash":348316246,"_task_hash":1502162503,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"On the other hand , a diphenylhydantoin-induced increase in the total number of specific benzodiazepine binding sites seems of minor importance since clonazepam ( with a high affinity for these sites ) and chlordiazepoxide ( with a low affinity ) were equipotent in the enhancement of the combined treatment efficacy .","paragraph":"<h3><u>Effect of combined treatment of diphenylhydantoin with clonazepam and chlordiazepoxide on the threshold for maximal electroconvulsions in mice.</u></h3>The anticonvulsant effect of either <b style='color:Tomato;'><i>clonazepam</i></b> (0.2-6.4 mg/kg) or <b style='color:Tomato;'><i>chlordiazepoxide</i></b> (2.5-40 mg/kg) alone or in combination with diphenylhydantoin (4-16 mg/kg) was studied against electroconvulsions in mice. All drugs were injected intraperitoneally, diphenylhydantoin - 75 min and the benzodiazepines - 60 min before the test. Adding either <b style='color:Tomato;'><i>clonazepam</i></b> or <b style='color:Tomato;'><i>chlordiazepoxide</i></b> (in doses moderately increasing the convulsive threshold) was more effective than doubling the dose of diphenylhydantoin. Both the interaction between benzodiazepines and diphenylhydantoin at the level of the receptor for picrotoxin-barbiturates and benzodiazepine-induced potentiation of specific diphenylhydantoin binding are likely to contribute to the observed phenomenon. <b style='color:DodgerBlue;'><i>On</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>hand</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>diphenylhydantoin-induced</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>number</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>specific</i></b> <b style='color:DodgerBlue;'><i>benzodiazepine</i></b> <b style='color:DodgerBlue;'><i>binding</i></b> <b style='color:DodgerBlue;'><i>sites</i></b> <b style='color:DodgerBlue;'><i>seems</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>minor</i></b> <b style='color:DodgerBlue;'><i>importance</i></b> <b style='color:DodgerBlue;'><i>since</i></b> <b style='color:MediumOrchid;'><i>clonazepam</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>affinity</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>sites</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>chlordiazepoxide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>low</i></b> <b style='color:DodgerBlue;'><i>affinity</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>equipotent</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>enhancement</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"On","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"other","start":7,"end":12,"id":2,"ws":true},{"text":"hand","start":13,"end":17,"id":3,"ws":true},{"text":",","start":18,"end":19,"id":4,"ws":true},{"text":"a","start":20,"end":21,"id":5,"ws":true},{"text":"diphenylhydantoin-induced","start":22,"end":47,"id":6,"ws":true},{"text":"increase","start":48,"end":56,"id":7,"ws":true},{"text":"in","start":57,"end":59,"id":8,"ws":true},{"text":"the","start":60,"end":63,"id":9,"ws":true},{"text":"total","start":64,"end":69,"id":10,"ws":true},{"text":"number","start":70,"end":76,"id":11,"ws":true},{"text":"of","start":77,"end":79,"id":12,"ws":true},{"text":"specific","start":80,"end":88,"id":13,"ws":true},{"text":"benzodiazepine","start":89,"end":103,"id":14,"ws":true},{"text":"binding","start":104,"end":111,"id":15,"ws":true},{"text":"sites","start":112,"end":117,"id":16,"ws":true},{"text":"seems","start":118,"end":123,"id":17,"ws":true},{"text":"of","start":124,"end":126,"id":18,"ws":true},{"text":"minor","start":127,"end":132,"id":19,"ws":true},{"text":"importance","start":133,"end":143,"id":20,"ws":true},{"text":"since","start":144,"end":149,"id":21,"ws":true},{"text":"clonazepam","start":150,"end":160,"id":22,"ws":true},{"text":"(","start":161,"end":162,"id":23,"ws":true},{"text":"with","start":163,"end":167,"id":24,"ws":true},{"text":"a","start":168,"end":169,"id":25,"ws":true},{"text":"high","start":170,"end":174,"id":26,"ws":true},{"text":"affinity","start":175,"end":183,"id":27,"ws":true},{"text":"for","start":184,"end":187,"id":28,"ws":true},{"text":"these","start":188,"end":193,"id":29,"ws":true},{"text":"sites","start":194,"end":199,"id":30,"ws":true},{"text":")","start":200,"end":201,"id":31,"ws":true},{"text":"and","start":202,"end":205,"id":32,"ws":true},{"text":"chlordiazepoxide","start":206,"end":222,"id":33,"ws":true},{"text":"(","start":223,"end":224,"id":34,"ws":true},{"text":"with","start":225,"end":229,"id":35,"ws":true},{"text":"a","start":230,"end":231,"id":36,"ws":true},{"text":"low","start":232,"end":235,"id":37,"ws":true},{"text":"affinity","start":236,"end":244,"id":38,"ws":true},{"text":")","start":245,"end":246,"id":39,"ws":true},{"text":"were","start":247,"end":251,"id":40,"ws":true},{"text":"equipotent","start":252,"end":262,"id":41,"ws":true},{"text":"in","start":263,"end":265,"id":42,"ws":true},{"text":"the","start":266,"end":269,"id":43,"ws":true},{"text":"enhancement","start":270,"end":281,"id":44,"ws":true},{"text":"of","start":282,"end":284,"id":45,"ws":true},{"text":"the","start":285,"end":288,"id":46,"ws":true},{"text":"combined","start":289,"end":297,"id":47,"ws":true},{"text":"treatment","start":298,"end":307,"id":48,"ws":true},{"text":"efficacy","start":308,"end":316,"id":49,"ws":true},{"text":".","start":317,"end":318,"id":50,"ws":false}],"spans":[{"start":150,"end":160,"token_start":22,"token_end":22,"label":"DRUG"},{"start":206,"end":222,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6855341/","_input_hash":-1004290920,"_task_hash":-1280627369,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive , Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer ( NEO-ORB ) .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>Randomized</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Neoadjuvant</i></b> <b style='color:MediumOrchid;'><i>Letrozole</i></b> <b style='color:DodgerBlue;'><i>Plus</i></b> <b style='color:MediumOrchid;'><i>Alpelisib</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>Hormone</i></b> <b style='color:DodgerBlue;'><i>Receptor-Positive</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Human</i></b> <b style='color:DodgerBlue;'><i>Epidermal</i></b> <b style='color:DodgerBlue;'><i>Growth</i></b> <b style='color:DodgerBlue;'><i>Factor</i></b> <b style='color:DodgerBlue;'><i>Receptor</i></b> <b style='color:DodgerBlue;'><i>2-Negative</i></b> <b style='color:DodgerBlue;'><i>Breast</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NEO-ORB</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Addition of <b style='color:Tomato;'><i>alpelisib</i></b> to <b style='color:Tomato;'><i>fulvestrant</i></b> significantly extended progression-free survival in ### results In total, 257 patients were assigned to <b style='color:Tomato;'><i>letrozole</i></b> plus <b style='color:Tomato;'><i>alpelisib</i></b> (131 patients) or placebo (126 patients). Grade \u22653 adverse events (\u22655% of patients) in the <b style='color:Tomato;'><i>alpelisib</i></b> arm were hyperglycemia (27%), rash (12%), and maculo-papular rash (8%). The primary objective was not met; ORR in the <b style='color:Tomato;'><i>alpelisib</i></b> versus placebo arm was 43% versus 45% and 63% versus 61% in the ### conclusions In contrast to initial results in advanced/metastatic disease, addition of <b style='color:Tomato;'><i>alpelisib</i></b> to 24-week neoadjuvant <b style='color:Tomato;'><i>letrozole</i></b> treatment did not improve response in patients with HR","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"Phase","start":2,"end":7,"id":1,"ws":true},{"text":"II","start":8,"end":10,"id":2,"ws":true},{"text":"Randomized","start":11,"end":21,"id":3,"ws":true},{"text":"Study","start":22,"end":27,"id":4,"ws":true},{"text":"of","start":28,"end":30,"id":5,"ws":true},{"text":"Neoadjuvant","start":31,"end":42,"id":6,"ws":true},{"text":"Letrozole","start":43,"end":52,"id":7,"ws":true},{"text":"Plus","start":53,"end":57,"id":8,"ws":true},{"text":"Alpelisib","start":58,"end":67,"id":9,"ws":true},{"text":"for","start":68,"end":71,"id":10,"ws":true},{"text":"Hormone","start":72,"end":79,"id":11,"ws":true},{"text":"Receptor-Positive","start":80,"end":97,"id":12,"ws":true},{"text":",","start":98,"end":99,"id":13,"ws":true},{"text":"Human","start":100,"end":105,"id":14,"ws":true},{"text":"Epidermal","start":106,"end":115,"id":15,"ws":true},{"text":"Growth","start":116,"end":122,"id":16,"ws":true},{"text":"Factor","start":123,"end":129,"id":17,"ws":true},{"text":"Receptor","start":130,"end":138,"id":18,"ws":true},{"text":"2-Negative","start":139,"end":149,"id":19,"ws":true},{"text":"Breast","start":150,"end":156,"id":20,"ws":true},{"text":"Cancer","start":157,"end":163,"id":21,"ws":true},{"text":"(","start":164,"end":165,"id":22,"ws":true},{"text":"NEO-ORB","start":166,"end":173,"id":23,"ws":true},{"text":")","start":174,"end":175,"id":24,"ws":true},{"text":".","start":176,"end":177,"id":25,"ws":false}],"spans":[{"start":43,"end":52,"token_start":7,"token_end":7,"label":"DRUG"},{"start":58,"end":67,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30723140/","_input_hash":-1159941605,"_task_hash":140152805,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":9,"child":7,"head_span":{"start":58,"end":67,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":43,"end":52,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Treatment with bromocriptine and pyridoxine showed no improvement .","paragraph":"<h3><u>Aromatic amino Acid decarboxylase deficiency not responding to pyridoxine and bromocriptine therapy: case report and review of response to treatment.</u></h3>Aromatic L-amino acid decarboxylase (AADC) deficiency (MIM #608643) is an autosomal recessive inborn error of monoamines. It is caused by a mutation in the DDC gene that leads to a deficiency in the AADC enzyme. The clinical features of this condition include a combination of dopamine, noradrenaline, and serotonin deficiencies, and a patient may present with hypotonia, oculogyric crises, sweating, hypersalivation, autonomic dysfunction, and progressive encephalopathy with severe developmental delay. We report the case of an 8-month-old boy who presented with the abovementioned symptoms and who was diagnosed with AADC deficiency based on clinical, biochemical, and molecular investigations. <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bromocriptine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>pyridoxine</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>improvement</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These data support the findings observed among previously reported cohorts that showed poor response of this disease to current regimens. Alternative therapies are needed to ameliorate the clinical complications associated with this disorder.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"with","start":10,"end":14,"id":1,"ws":true},{"text":"bromocriptine","start":15,"end":28,"id":2,"ws":true},{"text":"and","start":29,"end":32,"id":3,"ws":true},{"text":"pyridoxine","start":33,"end":43,"id":4,"ws":true},{"text":"showed","start":44,"end":50,"id":5,"ws":true},{"text":"no","start":51,"end":53,"id":6,"ws":true},{"text":"improvement","start":54,"end":65,"id":7,"ws":true},{"text":".","start":66,"end":67,"id":8,"ws":false}],"spans":[{"start":15,"end":28,"token_start":2,"token_end":2,"label":"DRUG"},{"start":33,"end":43,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24453523/","_input_hash":-184354775,"_task_hash":-405039238,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":15,"end":28,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":33,"end":43,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"Bactericidal activity of trimethoprim alone and in combination with sulfamethoxazole on susceptible and resistant Escherichia coli K-12 .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Bactericidal</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>trimethoprim</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>sulfamethoxazole</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>susceptible</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>Escherichia</i></b> <b style='color:DodgerBlue;'><i>coli</i></b> <b style='color:DodgerBlue;'><i>K-12</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The combined effects of <b style='color:Tomato;'><i>trimethoprim</i></b> and <b style='color:Tomato;'><i>sulfamethoxazole</i></b> on the viability of Escherichia coli K-12 and resistant strains possessing resistance plasmids were examined in minimal medium. When methionine, glycine, and adenine were present, <b style='color:Tomato;'><i>sulfamethoxazole</i></b> could enhance <b style='color:Tomato;'><i>trimethoprim</i></b> activity against E. coli K-12 so that the combination was bactericidal. However, this enhancement occurred over a narrow range of <b style='color:Tomato;'><i>trimethoprim</i></b> concentrations (0.04 to 0.2 mg liter-1) and only when the <b style='color:Tomato;'><i>sulfamethoxazole</i></b> concentration was more than 10 times that of <b style='color:Tomato;'><i>trimethoprim</i></b>. Under certain conditions, <b style='color:Tomato;'><i>sulfamethoxazole</i></b> enhanced <b style='color:Tomato;'><i>trimethoprim</i></b> bactericidal activity against E. coli K-12 carrying plasmid R1 at concentrations of <b style='color:Tomato;'><i>sulfamethoxazole</i></b> far below those required to inhibit the organism, but there was no such enhancement with the same host containing the SSu plasmid. Similar differences were found with strains possessing <b style='color:Tomato;'><i>trimethoprim</i></b> resistance plasmids R483 and R751. <b style='color:Tomato;'><i>sulfamethoxazole</i></b> can promote a bactericidal response with <b style='color:Tomato;'><i>trimethoprim</i></b> in E. coli K-12 and some of its resistant derivatives, but only under a narrow range of concentrations.","tokens":[{"text":"Bactericidal","start":0,"end":12,"id":0,"ws":true},{"text":"activity","start":13,"end":21,"id":1,"ws":true},{"text":"of","start":22,"end":24,"id":2,"ws":true},{"text":"trimethoprim","start":25,"end":37,"id":3,"ws":true},{"text":"alone","start":38,"end":43,"id":4,"ws":true},{"text":"and","start":44,"end":47,"id":5,"ws":true},{"text":"in","start":48,"end":50,"id":6,"ws":true},{"text":"combination","start":51,"end":62,"id":7,"ws":true},{"text":"with","start":63,"end":67,"id":8,"ws":true},{"text":"sulfamethoxazole","start":68,"end":84,"id":9,"ws":true},{"text":"on","start":85,"end":87,"id":10,"ws":true},{"text":"susceptible","start":88,"end":99,"id":11,"ws":true},{"text":"and","start":100,"end":103,"id":12,"ws":true},{"text":"resistant","start":104,"end":113,"id":13,"ws":true},{"text":"Escherichia","start":114,"end":125,"id":14,"ws":true},{"text":"coli","start":126,"end":130,"id":15,"ws":true},{"text":"K-12","start":131,"end":135,"id":16,"ws":true},{"text":".","start":136,"end":137,"id":17,"ws":false}],"spans":[{"start":25,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},{"start":68,"end":84,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7041815/","_input_hash":568309043,"_task_hash":-949526067,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[{"head":3,"child":9,"head_span":{"start":25,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":68,"end":84,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"New effective and well tolerated agents are urgently needed because of increasing resistance to antimalarials such as chloroquine and proguanil , and real and perceived intolerance to standard drugs such as mefloquine .","paragraph":"<h3><u>Current status and replies to frequently posed questions on atovaquone plus proguanil (Malarone) for the prevention of malaria.</u></h3>Each year at least 30 000 Western travellers acquire malaria and approximately 1-4% of those who acquire Plasmodium falciparum malaria will die as a result of infection. Almost all cases and fatalities are preventable with the use of measures to reduce mosquito bites and appropriate chemoprophylaxis for those at high risk of infection. There are currently a limited number of licensed drugs available to prevent malaria in travellers. <b style='color:DodgerBlue;'><i>New</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>tolerated</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>increasing</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>antimalarials</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>proguanil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>real</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>perceived</i></b> <b style='color:DodgerBlue;'><i>intolerance</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mefloquine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A newly licensed antimalarial (<b style='color:Tomato;'><i>atovaquone</i></b> plus <b style='color:Tomato;'><i>proguanil</i></b>; Malarone) compares favourably with other drug options, although some prescribers may be unfamiliar with the specific advantages and disadvantages of this antimalarial. This article reviews recent clinical experience and randomised controlled trial data in order to address frequently asked questions about this new combination drug.","tokens":[{"text":"New","start":0,"end":3,"id":0,"ws":true},{"text":"effective","start":4,"end":13,"id":1,"ws":true},{"text":"and","start":14,"end":17,"id":2,"ws":true},{"text":"well","start":18,"end":22,"id":3,"ws":true},{"text":"tolerated","start":23,"end":32,"id":4,"ws":true},{"text":"agents","start":33,"end":39,"id":5,"ws":true},{"text":"are","start":40,"end":43,"id":6,"ws":true},{"text":"urgently","start":44,"end":52,"id":7,"ws":true},{"text":"needed","start":53,"end":59,"id":8,"ws":true},{"text":"because","start":60,"end":67,"id":9,"ws":true},{"text":"of","start":68,"end":70,"id":10,"ws":true},{"text":"increasing","start":71,"end":81,"id":11,"ws":true},{"text":"resistance","start":82,"end":92,"id":12,"ws":true},{"text":"to","start":93,"end":95,"id":13,"ws":true},{"text":"antimalarials","start":96,"end":109,"id":14,"ws":true},{"text":"such","start":110,"end":114,"id":15,"ws":true},{"text":"as","start":115,"end":117,"id":16,"ws":true},{"text":"chloroquine","start":118,"end":129,"id":17,"ws":true},{"text":"and","start":130,"end":133,"id":18,"ws":true},{"text":"proguanil","start":134,"end":143,"id":19,"ws":true},{"text":",","start":144,"end":145,"id":20,"ws":true},{"text":"and","start":146,"end":149,"id":21,"ws":true},{"text":"real","start":150,"end":154,"id":22,"ws":true},{"text":"and","start":155,"end":158,"id":23,"ws":true},{"text":"perceived","start":159,"end":168,"id":24,"ws":true},{"text":"intolerance","start":169,"end":180,"id":25,"ws":true},{"text":"to","start":181,"end":183,"id":26,"ws":true},{"text":"standard","start":184,"end":192,"id":27,"ws":true},{"text":"drugs","start":193,"end":198,"id":28,"ws":true},{"text":"such","start":199,"end":203,"id":29,"ws":true},{"text":"as","start":204,"end":206,"id":30,"ws":true},{"text":"mefloquine","start":207,"end":217,"id":31,"ws":true},{"text":".","start":218,"end":219,"id":32,"ws":false}],"spans":[{"start":118,"end":129,"token_start":17,"token_end":17,"label":"DRUG"},{"start":134,"end":143,"token_start":19,"token_end":19,"label":"DRUG"},{"start":207,"end":217,"token_start":31,"token_end":31,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12785875/","_input_hash":425421221,"_task_hash":-1583128875,"_session_id":"drug_drug_pilot_split2c-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"When given in repeated doses from 6 h on , 50 g followed by 12.5 g at 6-h intervals , charcoal shortened the serum half-life of amitriptyline by 20 % and that of nortriptyline by 35 % ( p less than 0.05 ) .","paragraph":"<h3><u>Pharmacokinetics of amitriptyline influenced by oral charcoal and urine pH.</u></h3>The effects of orally given <b style='color:Tomato;'><i>activated charcoal</i></b>, sodium bicarbonate and ammonium chloride on the pharmacokinetics of <b style='color:Tomato;'><i>amitriptyline</i></b> were studied in 6 volunteers in a randomized, cross-over study. The serum and urine concentrations of <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b> were determined by HPLC for up to 72 h. <b style='color:Tomato;'><i>activated charcoal</i></b> (50 g), given within 5 min of the <b style='color:Tomato;'><i>amitriptyline</i></b> hydrochloride dose (75 mg), reduced its absorption by 99%. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>repeated</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>g</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>12.5</i></b> <b style='color:DodgerBlue;'><i>g</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>6-h</i></b> <b style='color:DodgerBlue;'><i>intervals</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>charcoal</i></b> <b style='color:DodgerBlue;'><i>shortened</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>half-life</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amitriptyline</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nortriptyline</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>0.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The renal excretions of <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b> increased 1000-fold by the acidification of urine pH to 4. However, the cumulative excretion of <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b> even into acidic urine only accounted for up to 5% of the dose during 72 h. Since urinary pH has a great influence on the ratio of urinary versus serum <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b> concentrations, pH should be taken into consideration, when the clinical significance of their concentrations in urine is evaluated. <b style='color:Tomato;'><i>activated charcoal</i></b> in adequate doses very effectively prevents the absorption of that fraction of <b style='color:Tomato;'><i>amitriptyline</i></b> which is in the stomach at the time of charcoal administration. Furthermore, given in repeated oral doses, charcoal increases, to some extent, the rate of elimination of <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b>, probably by interrupting their enterohepatic or enteroenteric circulation.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"given","start":5,"end":10,"id":1,"ws":true},{"text":"in","start":11,"end":13,"id":2,"ws":true},{"text":"repeated","start":14,"end":22,"id":3,"ws":true},{"text":"doses","start":23,"end":28,"id":4,"ws":true},{"text":"from","start":29,"end":33,"id":5,"ws":true},{"text":"6","start":34,"end":35,"id":6,"ws":true},{"text":"h","start":36,"end":37,"id":7,"ws":true},{"text":"on","start":38,"end":40,"id":8,"ws":true},{"text":",","start":41,"end":42,"id":9,"ws":true},{"text":"50","start":43,"end":45,"id":10,"ws":true},{"text":"g","start":46,"end":47,"id":11,"ws":true},{"text":"followed","start":48,"end":56,"id":12,"ws":true},{"text":"by","start":57,"end":59,"id":13,"ws":true},{"text":"12.5","start":60,"end":64,"id":14,"ws":true},{"text":"g","start":65,"end":66,"id":15,"ws":true},{"text":"at","start":67,"end":69,"id":16,"ws":true},{"text":"6-h","start":70,"end":73,"id":17,"ws":true},{"text":"intervals","start":74,"end":83,"id":18,"ws":true},{"text":",","start":84,"end":85,"id":19,"ws":true},{"text":"charcoal","start":86,"end":94,"id":20,"ws":true},{"text":"shortened","start":95,"end":104,"id":21,"ws":true},{"text":"the","start":105,"end":108,"id":22,"ws":true},{"text":"serum","start":109,"end":114,"id":23,"ws":true},{"text":"half-life","start":115,"end":124,"id":24,"ws":true},{"text":"of","start":125,"end":127,"id":25,"ws":true},{"text":"amitriptyline","start":128,"end":141,"id":26,"ws":true},{"text":"by","start":142,"end":144,"id":27,"ws":true},{"text":"20","start":145,"end":147,"id":28,"ws":true},{"text":"%","start":148,"end":149,"id":29,"ws":true},{"text":"and","start":150,"end":153,"id":30,"ws":true},{"text":"that","start":154,"end":158,"id":31,"ws":true},{"text":"of","start":159,"end":161,"id":32,"ws":true},{"text":"nortriptyline","start":162,"end":175,"id":33,"ws":true},{"text":"by","start":176,"end":178,"id":34,"ws":true},{"text":"35","start":179,"end":181,"id":35,"ws":true},{"text":"%","start":182,"end":183,"id":36,"ws":true},{"text":"(","start":184,"end":185,"id":37,"ws":true},{"text":"p","start":186,"end":187,"id":38,"ws":true},{"text":"less","start":188,"end":192,"id":39,"ws":true},{"text":"than","start":193,"end":197,"id":40,"ws":true},{"text":"0.05","start":198,"end":202,"id":41,"ws":true},{"text":")","start":203,"end":204,"id":42,"ws":true},{"text":".","start":205,"end":206,"id":43,"ws":false}],"spans":[{"start":128,"end":141,"token_start":26,"token_end":26,"label":"DRUG"},{"start":162,"end":175,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/3015809/","_input_hash":1971499379,"_task_hash":889539826,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The molecular subtypes of breast cancer can predict responses to the combinational treatment of doxorubicin with docetaxel , and ERBB2","paragraph":"<h3><u>Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer.</u></h3>The aim of this study is to characterize the effect of chemotherapy drug <b style='color:Tomato;'><i>doxorubicin</i></b> with neoadjuvant drug <b style='color:Tomato;'><i>docetaxel</i></b> for different molecular subtypes. ### methods A total of 83 patients with late-stage breast cancer were chosen to undergo treatment and compared to these patients to the combinational treatment to identify the molecular characteristics that can predict the responses. ### results Total response rate is 81.9% (68/83 patients). Among them, 7 patients show pathological complete response of 8.4%, 12 patients show clinical complete response of 14.5%, 49 patients show partial response of 59%, and 15 patients show stable disease of 18.1%. The comparison among different subtypes of breast cancer, including luminal A, luminal B, basal-like, and ERBB2 ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>molecular</i></b> <b style='color:DodgerBlue;'><i>subtypes</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>predict</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combinational</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>ERBB2</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"molecular","start":4,"end":13,"id":1,"ws":true},{"text":"subtypes","start":14,"end":22,"id":2,"ws":true},{"text":"of","start":23,"end":25,"id":3,"ws":true},{"text":"breast","start":26,"end":32,"id":4,"ws":true},{"text":"cancer","start":33,"end":39,"id":5,"ws":true},{"text":"can","start":40,"end":43,"id":6,"ws":true},{"text":"predict","start":44,"end":51,"id":7,"ws":true},{"text":"responses","start":52,"end":61,"id":8,"ws":true},{"text":"to","start":62,"end":64,"id":9,"ws":true},{"text":"the","start":65,"end":68,"id":10,"ws":true},{"text":"combinational","start":69,"end":82,"id":11,"ws":true},{"text":"treatment","start":83,"end":92,"id":12,"ws":true},{"text":"of","start":93,"end":95,"id":13,"ws":true},{"text":"doxorubicin","start":96,"end":107,"id":14,"ws":true},{"text":"with","start":108,"end":112,"id":15,"ws":true},{"text":"docetaxel","start":113,"end":122,"id":16,"ws":true},{"text":",","start":123,"end":124,"id":17,"ws":true},{"text":"and","start":125,"end":128,"id":18,"ws":true},{"text":"ERBB2","start":129,"end":134,"id":19,"ws":false}],"spans":[{"start":96,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},{"start":113,"end":122,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32508292/","_input_hash":2029760008,"_task_hash":37814328,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":96,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":113,"end":122,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The median overall survival time was 22.7 months in the docetaxel arm and 22.4 months in the paclitaxel arm .","paragraph":"<h3><u>A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis.</u></h3>The purpose of the study is to compare two taxanes/cisplatin combinations for metastatic breast cancer in terms of time to disease progression, response rates and toxicity. ### methods Between April 2000 and December 2002, 101 patients with advanced breast carcinoma, previously treated with an anthracycline but not with a taxane, were enrolled. Fifty patients were treated with <b style='color:Tomato;'><i>docetaxel</i></b> 60 mg/m2 and cisplatin 50 mg/m2, and 51 patients were treated with <b style='color:Tomato;'><i>paclitaxel</i></b> 175 mg/m2 and cisplatin 50 mg/m2. Each cycle repeated every 3 weeks. ### results The overall response rate was 62.5 and 42.6% in the <b style='color:Tomato;'><i>docetaxel</i></b> and palcitaxel groups respectively (P = 0.06). Median time to disease progression was 9.8 and 6.5 months in <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> groups respectively (P = 0.15). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>22.7</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>22.4</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Grade 3/4 arthralgia/myalgia, sensory neuropathy and anemia occurred more frequently in the <b style='color:Tomato;'><i>paclitaxel</i></b> arm, while more mucositis, fatigue and neutropenia occurred in the <b style='color:Tomato;'><i>docetaxel</i></b> arm. ### conclusion Taxane/cisplatin combinations were active for advanced breast cancer, while there appeared to be evidence in favor of a <b style='color:Tomato;'><i>docetaxel</i></b>/cisplatin combination. The toxicity in favor of <b style='color:Tomato;'><i>docetaxel</i></b>/cisplatin warrants future first-line clinical trials.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"median","start":4,"end":10,"id":1,"ws":true},{"text":"overall","start":11,"end":18,"id":2,"ws":true},{"text":"survival","start":19,"end":27,"id":3,"ws":true},{"text":"time","start":28,"end":32,"id":4,"ws":true},{"text":"was","start":33,"end":36,"id":5,"ws":true},{"text":"22.7","start":37,"end":41,"id":6,"ws":true},{"text":"months","start":42,"end":48,"id":7,"ws":true},{"text":"in","start":49,"end":51,"id":8,"ws":true},{"text":"the","start":52,"end":55,"id":9,"ws":true},{"text":"docetaxel","start":56,"end":65,"id":10,"ws":true},{"text":"arm","start":66,"end":69,"id":11,"ws":true},{"text":"and","start":70,"end":73,"id":12,"ws":true},{"text":"22.4","start":74,"end":78,"id":13,"ws":true},{"text":"months","start":79,"end":85,"id":14,"ws":true},{"text":"in","start":86,"end":88,"id":15,"ws":true},{"text":"the","start":89,"end":92,"id":16,"ws":true},{"text":"paclitaxel","start":93,"end":103,"id":17,"ws":true},{"text":"arm","start":104,"end":107,"id":18,"ws":true},{"text":".","start":108,"end":109,"id":19,"ws":false}],"spans":[{"start":56,"end":65,"token_start":10,"token_end":10,"label":"DRUG"},{"start":93,"end":103,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17172351/","_input_hash":307082636,"_task_hash":1430457115,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We hypothesized that Aurora A kinase ( AK ) contributes to castrate resistance in prostate cancer ( PCa ) and that inhibiting AK with alisertib can resensitize PCa cells to androgen receptor ( AR ) inhibitor abiraterone .","paragraph":"<h3><u>A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.</u></h3>Patients with metastatic castration-resistant prostate cancer did not tolerate the combination of <b style='color:Tomato;'><i>alisertib</i></b> with <b style='color:Tomato;'><i>abiraterone</i></b> and <b style='color:Tomato;'><i>prednisone</i></b>.There was no clear signal indicating that adding <b style='color:Tomato;'><i>alisertib</i></b> might be beneficial for those patients progressing on <b style='color:Tomato;'><i>abiraterone</i></b>. ### background <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>hypothesized</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>Aurora</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>kinase</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AK</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>contributes</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>castrate</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PCa</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>inhibiting</i></b> <b style='color:DodgerBlue;'><i>AK</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>alisertib</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>resensitize</i></b> <b style='color:DodgerBlue;'><i>PCa</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>androgen</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This was a phase I/II trial to determine the safety and efficacy of <b style='color:Tomato;'><i>alisertib</i></b> when given in combination with <b style='color:Tomato;'><i>abiraterone</i></b> plus <b style='color:Tomato;'><i>prednisone</i></b> (AP). Metastatic castration-resistant prostate cancer (mCRPC) patients were treated with dose escalation (<b style='color:Tomato;'><i>alisertib</i></b> at 30, 40, and 50 mg orally b.i.d., days 1-7 every 21 days) per standard 3+3 design. ### results Nine of 43 planned subjects were enrolled. The maximum tolerated dose (MTD) was not reached, and the dose-limiting toxicities (DLTs) included neutropenic fever (1 of 9), neutropenia (1 of 9), fatigue with memory impairment (1 of 9), and diarrhea/mucositis (1 of 9). No prostate-specific antigen (PSA) decrease or circulating tumor cell (CTC) changes were observed during the study. Pharmacodynamically, adding <b style='color:Tomato;'><i>alisertib</i></b> did not affect total testosterone or <b style='color:Tomato;'><i>dehydroepiandrosterone</i></b> (DHEA) levels. There was some change in neuroendocrine markers after therapy. Mean duration on study was 2.5 months. The trial was terminated early. ### conclusion A tolerable dose of <b style='color:Tomato;'><i>alisertib</i></b> in combination with AP in mCRPC was not established in this study. There was no clear signal indicating that <b style='color:Tomato;'><i>alisertib</i></b> might be beneficial for patients with mCRPC progressing on <b style='color:Tomato;'><i>abiraterone</i></b>.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"hypothesized","start":3,"end":15,"id":1,"ws":true},{"text":"that","start":16,"end":20,"id":2,"ws":true},{"text":"Aurora","start":21,"end":27,"id":3,"ws":true},{"text":"A","start":28,"end":29,"id":4,"ws":true},{"text":"kinase","start":30,"end":36,"id":5,"ws":true},{"text":"(","start":37,"end":38,"id":6,"ws":true},{"text":"AK","start":39,"end":41,"id":7,"ws":true},{"text":")","start":42,"end":43,"id":8,"ws":true},{"text":"contributes","start":44,"end":55,"id":9,"ws":true},{"text":"to","start":56,"end":58,"id":10,"ws":true},{"text":"castrate","start":59,"end":67,"id":11,"ws":true},{"text":"resistance","start":68,"end":78,"id":12,"ws":true},{"text":"in","start":79,"end":81,"id":13,"ws":true},{"text":"prostate","start":82,"end":90,"id":14,"ws":true},{"text":"cancer","start":91,"end":97,"id":15,"ws":true},{"text":"(","start":98,"end":99,"id":16,"ws":true},{"text":"PCa","start":100,"end":103,"id":17,"ws":true},{"text":")","start":104,"end":105,"id":18,"ws":true},{"text":"and","start":106,"end":109,"id":19,"ws":true},{"text":"that","start":110,"end":114,"id":20,"ws":true},{"text":"inhibiting","start":115,"end":125,"id":21,"ws":true},{"text":"AK","start":126,"end":128,"id":22,"ws":true},{"text":"with","start":129,"end":133,"id":23,"ws":true},{"text":"alisertib","start":134,"end":143,"id":24,"ws":true},{"text":"can","start":144,"end":147,"id":25,"ws":true},{"text":"resensitize","start":148,"end":159,"id":26,"ws":true},{"text":"PCa","start":160,"end":163,"id":27,"ws":true},{"text":"cells","start":164,"end":169,"id":28,"ws":true},{"text":"to","start":170,"end":172,"id":29,"ws":true},{"text":"androgen","start":173,"end":181,"id":30,"ws":true},{"text":"receptor","start":182,"end":190,"id":31,"ws":true},{"text":"(","start":191,"end":192,"id":32,"ws":true},{"text":"AR","start":193,"end":195,"id":33,"ws":true},{"text":")","start":196,"end":197,"id":34,"ws":true},{"text":"inhibitor","start":198,"end":207,"id":35,"ws":true},{"text":"abiraterone","start":208,"end":219,"id":36,"ws":true},{"text":".","start":220,"end":221,"id":37,"ws":false}],"spans":[{"start":134,"end":143,"token_start":24,"token_end":24,"label":"DRUG"},{"start":208,"end":219,"token_start":36,"token_end":36,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/28178640/","_input_hash":-849461923,"_task_hash":-275457113,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":24,"child":36,"head_span":{"start":134,"end":143,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":208,"end":219,"token_start":36,"token_end":36,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Tanespimycin plus trastuzumab is well tolerated and has antitumor activity in patients with HER-2 + breast cancer whose tumors have progressed during treatment with trastuzumab .","paragraph":"<h3><u>Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.</u></h3>This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor <b style='color:Tomato;'><i>tanespimycin</i></b> (17-AAG; KOS-953) could be administered safely in combination with <b style='color:Tomato;'><i>trastuzumab</i></b> at a dose that inhibits Hsp90 function in vivo in lymphocytes. ### Patients And Methods Patients with an advanced solid tumor progressing during standard therapy were eligible. Patients were treated with weekly <b style='color:Tomato;'><i>trastuzumab</i></b> followed by intravenous <b style='color:Tomato;'><i>tanespimycin</i></b>, assessed in escalating dose levels. ### results Twenty-five patients were enrolled onto four <b style='color:Tomato;'><i>tanespimycin</i></b> dose levels: 225 (n = 4), 300 (n = 3), 375 (n = 8), and 450 mg/m2 (n = 10). Dose-limiting toxicity (DLT) was observed at the third and fourth cohort (1 patient each): more than 2-week delay for grade 4 fatigue/grade 2 nausea and anorexia (375 mg/m2); more than 2-week delay for thrombocytopenia (450 mg/m2). Drug-related grade 3 toxicity included emesis, increased ALT, hypersensitivity reactions (two patients each), and drug-induced thrombocytopenia (n = 1). Common mild to moderate toxicities included fatigue, nausea, diarrhea, emesis, headache, rash/pruritus, increased AST/ALT, and anorexia. Pharmacokinetic analysis demonstrated no difference in <b style='color:Tomato;'><i>tanespimycin</i></b> kinetics with or without <b style='color:Tomato;'><i>trastuzumab</i></b>. Pharmacodynamic testing showed reactive induction of Hsp70 (a marker of Hsp90 inhibition) in lymphocytes at all dose levels. Antitumor activity was noted (partial response, n = 1; minor response, n = 4; stable disease > or = 4 months, n = 4). Tumor regressions were seen only in patients with human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. ### conclusion <b style='color:MediumOrchid;'><i>Tanespimycin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>tolerated</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER-2</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>whose</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>progressed</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These data suggest that Hsp90 function can be inhibited in vivo to a degree sufficient to cause inhibition of tumor growth.","tokens":[{"text":"Tanespimycin","start":0,"end":12,"id":0,"ws":true},{"text":"plus","start":13,"end":17,"id":1,"ws":true},{"text":"trastuzumab","start":18,"end":29,"id":2,"ws":true},{"text":"is","start":30,"end":32,"id":3,"ws":true},{"text":"well","start":33,"end":37,"id":4,"ws":true},{"text":"tolerated","start":38,"end":47,"id":5,"ws":true},{"text":"and","start":48,"end":51,"id":6,"ws":true},{"text":"has","start":52,"end":55,"id":7,"ws":true},{"text":"antitumor","start":56,"end":65,"id":8,"ws":true},{"text":"activity","start":66,"end":74,"id":9,"ws":true},{"text":"in","start":75,"end":77,"id":10,"ws":true},{"text":"patients","start":78,"end":86,"id":11,"ws":true},{"text":"with","start":87,"end":91,"id":12,"ws":true},{"text":"HER-2","start":92,"end":97,"id":13,"ws":true},{"text":"+","start":98,"end":99,"id":14,"ws":true},{"text":"breast","start":100,"end":106,"id":15,"ws":true},{"text":"cancer","start":107,"end":113,"id":16,"ws":true},{"text":"whose","start":114,"end":119,"id":17,"ws":true},{"text":"tumors","start":120,"end":126,"id":18,"ws":true},{"text":"have","start":127,"end":131,"id":19,"ws":true},{"text":"progressed","start":132,"end":142,"id":20,"ws":true},{"text":"during","start":143,"end":149,"id":21,"ws":true},{"text":"treatment","start":150,"end":159,"id":22,"ws":true},{"text":"with","start":160,"end":164,"id":23,"ws":true},{"text":"trastuzumab","start":165,"end":176,"id":24,"ws":true},{"text":".","start":177,"end":178,"id":25,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":18,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},{"start":165,"end":176,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18048823/","_input_hash":-2143703813,"_task_hash":1502847177,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":18,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"It contains data on prophylaxis with mefloquine ( n = 48,264 ) , with chloroquine ( 6,752 ) , with chloroquine plus proguanil ( 19,727 ) , and with no prophylaxis ( 3,871 ) .","paragraph":"<h3><u>Tolerability and Effectiveness of Malaria Chemoprophylaxis with Mefloquine or Chloroquine with or without Co-medication.</u></h3>Background: To determine the relevance of drug interactions with co-medication for effectiveness and tolerability of antimalarial chemoprophylaxis. Method: A database (MALPRO2) on travelers on their flight home from Africa to Europe between July 1988 and December 1991 was reanalyzed. <b style='color:DodgerBlue;'><i>It</i></b> <b style='color:DodgerBlue;'><i>contains</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>prophylaxis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>mefloquine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>48,264</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>6,752</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>proguanil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>19,727</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>prophylaxis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3,871</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The comparison of rates of malaria incidence and adverse events (AEs) between users and nonusers of co-medication was expressed by relative risk (RR). Results: Fifty-three percent of travelers (63% of females, 43% of males) used co-medication in all prophylaxis groups, with an average of 1.35 additional drugs per person and about two AEs reported per person. With the exception of antidiarrheals plus <b style='color:Tomato;'><i>mefloquine</i></b>, malaria incidence with co-medication was lower (RR = 0.8) than without co-medication. In all regimens, the proportion of travelers reporting AEs was about 1.5-fold with co-medication (p<.01); that reporting severe AEs was twice as high as compared to with no co-medication. <b style='color:Tomato;'><i>mefloquine</i></b> AE rates for various classes of co-medication were similar to that of <b style='color:Tomato;'><i>chloroquine</i></b>, with highest AE and severity rates with neuropsychiatric drugs (excluding antiepileptics, RR = 1.9 and 2.9), and lowest rates with cardiovasculars (RR = 1.1 and 1.0). Various co-medications were used with different frequencies in males and females, and the latter reported more AEs. Conclusion: These data suggest that co-medications commonly used by travelers have no significant clinical impact on safety and effectiveness of prophylaxis with <b style='color:Tomato;'><i>mefloquine</i></b> or <b style='color:Tomato;'><i>chloroquine</i></b>. Increased frequency and severity of AEs when using co-medication rather is explained by underlying illness.","tokens":[{"text":"It","start":0,"end":2,"id":0,"ws":true},{"text":"contains","start":3,"end":11,"id":1,"ws":true},{"text":"data","start":12,"end":16,"id":2,"ws":true},{"text":"on","start":17,"end":19,"id":3,"ws":true},{"text":"prophylaxis","start":20,"end":31,"id":4,"ws":true},{"text":"with","start":32,"end":36,"id":5,"ws":true},{"text":"mefloquine","start":37,"end":47,"id":6,"ws":true},{"text":"(","start":48,"end":49,"id":7,"ws":true},{"text":"n","start":50,"end":51,"id":8,"ws":true},{"text":"=","start":52,"end":53,"id":9,"ws":true},{"text":"48,264","start":54,"end":60,"id":10,"ws":true},{"text":")","start":61,"end":62,"id":11,"ws":true},{"text":",","start":63,"end":64,"id":12,"ws":true},{"text":"with","start":65,"end":69,"id":13,"ws":true},{"text":"chloroquine","start":70,"end":81,"id":14,"ws":true},{"text":"(","start":82,"end":83,"id":15,"ws":true},{"text":"6,752","start":84,"end":89,"id":16,"ws":true},{"text":")","start":90,"end":91,"id":17,"ws":true},{"text":",","start":92,"end":93,"id":18,"ws":true},{"text":"with","start":94,"end":98,"id":19,"ws":true},{"text":"chloroquine","start":99,"end":110,"id":20,"ws":true},{"text":"plus","start":111,"end":115,"id":21,"ws":true},{"text":"proguanil","start":116,"end":125,"id":22,"ws":true},{"text":"(","start":126,"end":127,"id":23,"ws":true},{"text":"19,727","start":128,"end":134,"id":24,"ws":true},{"text":")","start":135,"end":136,"id":25,"ws":true},{"text":",","start":137,"end":138,"id":26,"ws":true},{"text":"and","start":139,"end":142,"id":27,"ws":true},{"text":"with","start":143,"end":147,"id":28,"ws":true},{"text":"no","start":148,"end":150,"id":29,"ws":true},{"text":"prophylaxis","start":151,"end":162,"id":30,"ws":true},{"text":"(","start":163,"end":164,"id":31,"ws":true},{"text":"3,871","start":165,"end":170,"id":32,"ws":true},{"text":")","start":171,"end":172,"id":33,"ws":true},{"text":".","start":173,"end":174,"id":34,"ws":false}],"spans":[{"start":37,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},{"start":70,"end":81,"token_start":14,"token_end":14,"label":"DRUG"},{"start":99,"end":110,"token_start":20,"token_end":20,"label":"DRUG"},{"start":116,"end":125,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9815496/","_input_hash":-419400048,"_task_hash":1005784915,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We hypothesized that the brain damage mitigating effect of mild hypothermia after cardiac arrest can be enhanced with thiopental loading , and even more so with the further addition of phenytoin and methylprednisolone .","paragraph":"<h3><u>Thiopental combination treatments for cerebral resuscitation after prolonged cardiac arrest in dogs. Exploratory outcome study.</u></h3>We postulate that mitigating the multifactorial pathogenesis of postischemic encephalopathy requires multifaceted treatments. In preparation for expensive definitive studies, we are reporting here the results of small exploratory series, compared with historic controls with the same model. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>hypothesized</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>brain</i></b> <b style='color:DodgerBlue;'><i>damage</i></b> <b style='color:DodgerBlue;'><i>mitigating</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>mild</i></b> <b style='color:DodgerBlue;'><i>hypothermia</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cardiac</i></b> <b style='color:DodgerBlue;'><i>arrest</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>enhanced</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>thiopental</i></b> <b style='color:DodgerBlue;'><i>loading</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>so</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>phenytoin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twenty-four dogs (four groups of six dogs each) received VF 12.5 min no-flow, reversed with brief cardiopulmonary bypass (CPB), controlled ventilation to 20 h, and intensive care to 96 h. Group 1 with normothermia throughout and randomized group 2 with mild hypothermia (from reperfusion to 2 h) were controls. Then, group 3 received in addition, thiopental 90 mg/kg i.v. over the first 6 h. Then, group 4 received, in addition to group 2 treatment, thiopental 30 mg/kg i.v. over the first 90 min (because the larger dose had produced cardiopulmonary complications), plus <b style='color:Tomato;'><i>phenytoin</i></b> 15 mg/kg i.v. at 15 min after reperfusion, and <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> 130 mg/kg i.v. over 20 h. All dogs survived. Best overall performance categories (OPC) achieved (OPC 1 = normal, OPC 5 = brain death) were better in group 2 than group 1 (< 0.05) and numerically better in groups 3 or 4 than in groups 1 or 2. Good cerebral outcome (OPC 1 or 2) was achieved by all six dogs only in group 4 (P < 0.05 group 4 vs. 2). Best NDS were 44 +/- 3% in group 1; 20 +/- 14% in group 2 (P = 0.002); 21 +/- 15% in group 3 (NS vs. group 2); and 7 +/- 8% in group 4 (P = 0.08 vs. group 2). Total brain histologic damage scores (HDS) at 96 h were 156 +/- 38 in group 1; 81 +/- 12 in group 2 (P < 0.001 vs. group 1); 53 +/- 25 in group 3 (P = 0.02 vs. group 2); and 48 +/- 5 in group 4 (P = 0.02 vs. group 2). We conclude that after prolonged cardiac arrest, the already established brain damage mitigating effect of mild immediate postarrest hypothermia might be enhanced by thiopental, and perhaps then further enhanced by adding <b style='color:Tomato;'><i>phenytoin</i></b> and <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b>.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"hypothesized","start":3,"end":15,"id":1,"ws":true},{"text":"that","start":16,"end":20,"id":2,"ws":true},{"text":"the","start":21,"end":24,"id":3,"ws":true},{"text":"brain","start":25,"end":30,"id":4,"ws":true},{"text":"damage","start":31,"end":37,"id":5,"ws":true},{"text":"mitigating","start":38,"end":48,"id":6,"ws":true},{"text":"effect","start":49,"end":55,"id":7,"ws":true},{"text":"of","start":56,"end":58,"id":8,"ws":true},{"text":"mild","start":59,"end":63,"id":9,"ws":true},{"text":"hypothermia","start":64,"end":75,"id":10,"ws":true},{"text":"after","start":76,"end":81,"id":11,"ws":true},{"text":"cardiac","start":82,"end":89,"id":12,"ws":true},{"text":"arrest","start":90,"end":96,"id":13,"ws":true},{"text":"can","start":97,"end":100,"id":14,"ws":true},{"text":"be","start":101,"end":103,"id":15,"ws":true},{"text":"enhanced","start":104,"end":112,"id":16,"ws":true},{"text":"with","start":113,"end":117,"id":17,"ws":true},{"text":"thiopental","start":118,"end":128,"id":18,"ws":true},{"text":"loading","start":129,"end":136,"id":19,"ws":true},{"text":",","start":137,"end":138,"id":20,"ws":true},{"text":"and","start":139,"end":142,"id":21,"ws":true},{"text":"even","start":143,"end":147,"id":22,"ws":true},{"text":"more","start":148,"end":152,"id":23,"ws":true},{"text":"so","start":153,"end":155,"id":24,"ws":true},{"text":"with","start":156,"end":160,"id":25,"ws":true},{"text":"the","start":161,"end":164,"id":26,"ws":true},{"text":"further","start":165,"end":172,"id":27,"ws":true},{"text":"addition","start":173,"end":181,"id":28,"ws":true},{"text":"of","start":182,"end":184,"id":29,"ws":true},{"text":"phenytoin","start":185,"end":194,"id":30,"ws":true},{"text":"and","start":195,"end":198,"id":31,"ws":true},{"text":"methylprednisolone","start":199,"end":217,"id":32,"ws":true},{"text":".","start":218,"end":219,"id":33,"ws":false}],"spans":[{"start":185,"end":194,"token_start":30,"token_end":30,"label":"DRUG"},{"start":199,"end":217,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10950320/","_input_hash":-209864772,"_task_hash":1917055471,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Caspase-independent mechanisms , mainly based on increased oxidative stress , result from 2-methoxyestradiol , Artesunate , ascorbic acid , Dihydroartemisinin , Evodiamine , b-AP15 , VLX1570 , Erw-ASNase , and TAK-242 .","paragraph":"<h3><u>Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma.</u></h3>Multiple myeloma (MM) remains an incurable tumor due to the high rate of relapse that still occurs. Acquired drug resistance represents the most challenging obstacle to the extension of survival and several studies have been conducted to understand the mechanisms of this phenomenon. Mitochondrial pathways have been extensively investigated, demonstrating that cancer cells become resistant to drugs by reprogramming their metabolic assessment. MM cells acquire resistance to proteasome inhibitors (PIs), activating protection programs, such as a reduction in oxidative stress, down-regulating pro-apoptotic, and up-regulating anti-apoptotic signals. Knowledge of the mechanisms through which tumor cells escape control of the immune system and acquire resistance to drugs has led to the creation of new compounds that can restore the response by leading to cell death. In this scenario, based on all literature data available, our review represents the first collection of anti-mitochondrial compounds able to overcome drug resistance in MM. <b style='color:DodgerBlue;'><i>Caspase-independent</i></b> <b style='color:DodgerBlue;'><i>mechanisms</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>mainly</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>oxidative</i></b> <b style='color:DodgerBlue;'><i>stress</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>result</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>2-methoxyestradiol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Artesunate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ascorbic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Dihydroartemisinin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Evodiamine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>b-AP15</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>VLX1570</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Erw-ASNase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>TAK-242</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Other agents restore PIs' efficacy through caspase-dependent tools, such as CDDO-Im, NOXA-inhibitors, FTY720, GCS-100, LBH589, a derivative of ellipticine, AT-101, KD5170, SMAC-mimetics, glutaminase-1 (GLS1)-inhibitors, and thenoyltrifluoroacetone. Each of these substances improved the efficacy rates when employed in combination with the most frequently used antimyeloma drugs.","tokens":[{"text":"Caspase-independent","start":0,"end":19,"id":0,"ws":true},{"text":"mechanisms","start":20,"end":30,"id":1,"ws":true},{"text":",","start":31,"end":32,"id":2,"ws":true},{"text":"mainly","start":33,"end":39,"id":3,"ws":true},{"text":"based","start":40,"end":45,"id":4,"ws":true},{"text":"on","start":46,"end":48,"id":5,"ws":true},{"text":"increased","start":49,"end":58,"id":6,"ws":true},{"text":"oxidative","start":59,"end":68,"id":7,"ws":true},{"text":"stress","start":69,"end":75,"id":8,"ws":true},{"text":",","start":76,"end":77,"id":9,"ws":true},{"text":"result","start":78,"end":84,"id":10,"ws":true},{"text":"from","start":85,"end":89,"id":11,"ws":true},{"text":"2-methoxyestradiol","start":90,"end":108,"id":12,"ws":true},{"text":",","start":109,"end":110,"id":13,"ws":true},{"text":"Artesunate","start":111,"end":121,"id":14,"ws":true},{"text":",","start":122,"end":123,"id":15,"ws":true},{"text":"ascorbic","start":124,"end":132,"id":16,"ws":true},{"text":"acid","start":133,"end":137,"id":17,"ws":true},{"text":",","start":138,"end":139,"id":18,"ws":true},{"text":"Dihydroartemisinin","start":140,"end":158,"id":19,"ws":true},{"text":",","start":159,"end":160,"id":20,"ws":true},{"text":"Evodiamine","start":161,"end":171,"id":21,"ws":true},{"text":",","start":172,"end":173,"id":22,"ws":true},{"text":"b-AP15","start":174,"end":180,"id":23,"ws":true},{"text":",","start":181,"end":182,"id":24,"ws":true},{"text":"VLX1570","start":183,"end":190,"id":25,"ws":true},{"text":",","start":191,"end":192,"id":26,"ws":true},{"text":"Erw-ASNase","start":193,"end":203,"id":27,"ws":true},{"text":",","start":204,"end":205,"id":28,"ws":true},{"text":"and","start":206,"end":209,"id":29,"ws":true},{"text":"TAK-242","start":210,"end":217,"id":30,"ws":true},{"text":".","start":218,"end":219,"id":31,"ws":false}],"spans":[{"start":111,"end":121,"token_start":14,"token_end":14,"label":"DRUG"},{"start":140,"end":158,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33669515/","_input_hash":442754413,"_task_hash":392199556,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In the xenograft model , more augmented effects were achieved when bortezomib was combined with gemcitabine than gemcitabine alone .","paragraph":"<h3><u>Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.</u></h3>Earlier studies that dealt with the combination therapy of <b style='color:Tomato;'><i>gemcitabine</i></b> and histone deacetylation inhibitors for pancreatic cancer revealed unsatisfactory results. The activation of nuclear factor \u03baB (NF-\u03baB) was referred as one of the attributable causes, and we attempted to overcome this resistance by the addition of a proteasome inhibitor. ### methods The influences of suberoylanilide hydroxamic acid (<b style='color:Tomato;'><i>vorinostat</i></b>, SAHA), a histone deacetylase inhibitor, and <b style='color:Tomato;'><i>bortezomib</i></b>, a novel selective antagonist of 26S proteasome, with or without <b style='color:Tomato;'><i>gemcitabine</i></b> on cell growth and apoptosis and the expressions of related proteins were observed in pancreatic cancer cell lines (MiaPaCa-2 and ASPC-1). The xenograft model of pancreatic cancer was used to notice effects in vivo. ### results <b style='color:Tomato;'><i>vorinostat</i></b> and <b style='color:Tomato;'><i>bortezomib</i></b> had independent inhibitory effects and potentiated the antitumor property of <b style='color:Tomato;'><i>gemcitabine</i></b> in vitro. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>xenograft</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>augmented</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>achieved</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The down-regulation of pAkt and suppression of NF-\u03baB activity was induced by the triple combination. ### conclusions The triple combination of <b style='color:Tomato;'><i>vorinostat</i></b>, <b style='color:Tomato;'><i>bortezomib</i></b>, and <b style='color:Tomato;'><i>gemcitabine</i></b> resulted in the strongest antitumor effects both in vitro and in vivo and pAkt and NF-\u03baB seems to be involved in this process.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"xenograft","start":7,"end":16,"id":2,"ws":true},{"text":"model","start":17,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"more","start":25,"end":29,"id":5,"ws":true},{"text":"augmented","start":30,"end":39,"id":6,"ws":true},{"text":"effects","start":40,"end":47,"id":7,"ws":true},{"text":"were","start":48,"end":52,"id":8,"ws":true},{"text":"achieved","start":53,"end":61,"id":9,"ws":true},{"text":"when","start":62,"end":66,"id":10,"ws":true},{"text":"bortezomib","start":67,"end":77,"id":11,"ws":true},{"text":"was","start":78,"end":81,"id":12,"ws":true},{"text":"combined","start":82,"end":90,"id":13,"ws":true},{"text":"with","start":91,"end":95,"id":14,"ws":true},{"text":"gemcitabine","start":96,"end":107,"id":15,"ws":true},{"text":"than","start":108,"end":112,"id":16,"ws":true},{"text":"gemcitabine","start":113,"end":124,"id":17,"ws":true},{"text":"alone","start":125,"end":130,"id":18,"ws":true},{"text":".","start":131,"end":132,"id":19,"ws":false}],"spans":[{"start":67,"end":77,"token_start":11,"token_end":11,"label":"DRUG"},{"start":96,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},{"start":113,"end":124,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21487323/","_input_hash":-559122592,"_task_hash":-1979398455,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":11,"child":15,"head_span":{"start":67,"end":77,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":96,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The effectiveness of combination therapy with afatinib and bevacizumab may provide a new therapeutic option for these patients .","paragraph":"<h3><u>Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification: A case report.</u></h3>Acquired resistance to reversible EGFR tyrosine kinase inhibitors remains a significant obstacle, and acquired ERBB2 amplification is the most common \"bypass\" mechanism. For patients with sensitizing EGFR mutation who experience resistance via ERBB2 amplification, no targeted drug has been demonstrated to be effective. ### Patient Concerns A 56-year-old female nonsmoker suffered from left leg paralysis and low back pain. Imaging examination revealed a mass in the anterior segment of the right upper lobe lung and possible multiple metastases in the right hilar, mediastinal lymph nodes, bone metastases, and soft tissue invasion. ### diagnosis Transbronchial lung biopsy revealed a moderately differentiated adenocarcinoma (cT4N2M1c, stage IV). An EGFR exon 19 deletion was identified using amplification refractory mutation system. ### interventions After the patient was treated with <b style='color:Tomato;'><i>gefitinib</i></b> initiation (250\u200amg/d) for 15\u200amonths, the tumor progressed with ERBB2 amplification revealed by next-generation sequencing test. Then, the patient was started on <b style='color:Tomato;'><i>afatinib</i></b> (40\u200amg/d) plus <b style='color:Tomato;'><i>bevacizumab</i></b> (7.5\u200amg/kg every 3\u200aweeks). ### outcomes The combination therapy of <b style='color:Tomato;'><i>afatinib</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b> in this patient was effective with some slight side effects. Computed tomography scans showed the tumor shrinkage and the pleural effusion disappeared in the right lung. The overall survival was 23.5\u200amonths. ### conclusion To date, there is no targeted therapy approved and demonstrated to be effective for non-small cell lung cancer patients with EGFR sensitizing mutations, and ERBB2 amplification. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effectiveness</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>afatinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>provide</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>option</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"effectiveness","start":4,"end":17,"id":1,"ws":true},{"text":"of","start":18,"end":20,"id":2,"ws":true},{"text":"combination","start":21,"end":32,"id":3,"ws":true},{"text":"therapy","start":33,"end":40,"id":4,"ws":true},{"text":"with","start":41,"end":45,"id":5,"ws":true},{"text":"afatinib","start":46,"end":54,"id":6,"ws":true},{"text":"and","start":55,"end":58,"id":7,"ws":true},{"text":"bevacizumab","start":59,"end":70,"id":8,"ws":true},{"text":"may","start":71,"end":74,"id":9,"ws":true},{"text":"provide","start":75,"end":82,"id":10,"ws":true},{"text":"a","start":83,"end":84,"id":11,"ws":true},{"text":"new","start":85,"end":88,"id":12,"ws":true},{"text":"therapeutic","start":89,"end":100,"id":13,"ws":true},{"text":"option","start":101,"end":107,"id":14,"ws":true},{"text":"for","start":108,"end":111,"id":15,"ws":true},{"text":"these","start":112,"end":117,"id":16,"ws":true},{"text":"patients","start":118,"end":126,"id":17,"ws":true},{"text":".","start":127,"end":128,"id":18,"ws":false}],"spans":[{"start":46,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},{"start":59,"end":70,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33663050/","_input_hash":-1094798157,"_task_hash":-258752655,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":46,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":59,"end":70,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Clinical</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>men</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The optimal sequencing of the multiple active agents now available for metastatic castration-resistant prostate cancer (mCRPC) is unclear. Prior reports have suggested diminished responses to sequential lines of androgen receptor (AR)-targeted therapies, but it is unknown whether subsequent taxane-based chemotherapy may be more effective than sequential AR-targeting treatment. We sought to evaluate the clinical activity of <b style='color:Tomato;'><i>enzalutamide</i></b> versus <b style='color:Tomato;'><i>docetaxel</i></b> in men with mCRPC who progressed on <b style='color:Tomato;'><i>abiraterone</i></b>. ### methods We performed a single-institution retrospective analysis of consecutive mCRPC patients who had progressed on <b style='color:Tomato;'><i>abiraterone</i></b> therapy and subsequently received either <b style='color:Tomato;'><i>enzalutamide</i></b> (n=30) or <b style='color:Tomato;'><i>docetaxel</i></b> (n=31). We evaluated clinical outcomes including prostate-specific antigen decline of >30% (PSA30) or >50% (PSA50), PSA-progression-free survival (PSA-PFS), and clinical/radiographic PFS. We performed multivariable modeling to control for baseline and on-treatment differences between groups. ### results Compared to subjects who received <b style='color:Tomato;'><i>enzalutamide</i></b> post-<b style='color:Tomato;'><i>abiraterone</i></b>, subjects who received <b style='color:Tomato;'><i>docetaxel</i></b> post-<b style='color:Tomato;'><i>abiraterone</i></b> had more bone metastases, more visceral metastases, higher baseline PSA, and had more frequent PSA tests while on-treatment. There were no significant differences in PSA30 (41% for <b style='color:Tomato;'><i>enzalutamide</i></b> vs. 53% for <b style='color:Tomato;'><i>docetaxel</i></b>) or PSA50 (34% vs. 40%) response rates between the two groups; there remained no difference after stratifying by presence/absence of prior response to <b style='color:Tomato;'><i>abiraterone</i></b>. Median PSA-PFS was 4.1 versus 4.1 months for the <b style='color:Tomato;'><i>enzalutamide</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> cohorts, respectively (HR 1.35, 95% CI, 0.53-3.66, P=0.502). Median PFS was 4.7 versus 4.4 months, respectively (HR 1.44, 95% CI, 0.77-2.71, P=0.257). PSA-PFS and PFS did not differ after stratifying by prior response to <b style='color:Tomato;'><i>abiraterone</i></b>. In multivariable analyses, there were no significant differences in PSA-PFS or PFS between the two groups. ### conclusions Treatment with either <b style='color:Tomato;'><i>enzalutamide</i></b> or <b style='color:Tomato;'><i>docetaxel</i></b> produced modest PSA responses and PFS intervals in this <b style='color:Tomato;'><i>abiraterone</i></b>-pretreated mCRPC population. In this retrospective study with small sample size, no significant differences in outcomes were observed between groups. Therefore, either <b style='color:Tomato;'><i>enzalutamide</i></b> or <b style='color:Tomato;'><i>docetaxel</i></b> may be a reasonable option in men who have progressed on <b style='color:Tomato;'><i>abiraterone</i></b>.","tokens":[{"text":"Clinical","start":0,"end":8,"id":0,"ws":true},{"text":"activity","start":9,"end":17,"id":1,"ws":true},{"text":"of","start":18,"end":20,"id":2,"ws":true},{"text":"enzalutamide","start":21,"end":33,"id":3,"ws":true},{"text":"versus","start":34,"end":40,"id":4,"ws":true},{"text":"docetaxel","start":41,"end":50,"id":5,"ws":true},{"text":"in","start":51,"end":53,"id":6,"ws":true},{"text":"men","start":54,"end":57,"id":7,"ws":true},{"text":"with","start":58,"end":62,"id":8,"ws":true},{"text":"castration-resistant","start":63,"end":83,"id":9,"ws":true},{"text":"prostate","start":84,"end":92,"id":10,"ws":true},{"text":"cancer","start":93,"end":99,"id":11,"ws":true},{"text":"progressing","start":100,"end":111,"id":12,"ws":true},{"text":"after","start":112,"end":117,"id":13,"ws":true},{"text":"abiraterone","start":118,"end":129,"id":14,"ws":true},{"text":".","start":130,"end":131,"id":15,"ws":false}],"spans":[{"start":21,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},{"start":41,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},{"start":118,"end":129,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25053178/","_input_hash":-60183356,"_task_hash":-289039574,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":3,"child":14,"head_span":{"start":21,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":118,"end":129,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":14,"head_span":{"start":41,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":118,"end":129,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"The use of cyclophosphamide in patients with NSVN is controversial , but recent retrospective data suggest that those treated with prednisone and cyclophosphamide from the outset fare better than those initially treated only with prednisone .","paragraph":"<h3><u>Therapy for vasculitic neuropathies.</u></h3>The term vasculitis refers to a pathologic condition defined by inflammatory cell infiltration and destruction of blood vessels. Systemic vasculitis is classified as primary (eg, polyarteritis nodosa, Churg-Strauss syndrome) or secondary, the latter associated with connective tissue disorders, infections, medications, and rarely, as a paraneoplastic phenomenon. Neuropathy is a common complication of systemic vasculitis and is related to ischemic nerve fiber damage with axon loss. Peripheral neuropathy may be the sole manifestation of vasculitis, a condition termed nonsystemic vasculitic neuropathy (NSVN). Treatment of vasculitic neuropathy requires long-term immunosuppressive therapies with potential side effects. The diagnosis of vasculitis should be established by tissue (preferably nerve) biopsy. High-dose <b style='color:Tomato;'><i>prednisone</i></b> is the standard platform therapy for patients with systemic and NSVN; for those with systemic vasculitis, at least 3 to 12 months of treatment with <b style='color:Tomato;'><i>cyclophosphamide</i></b> (monthly intravenous pulse or daily oral therapy) is also necessary to sustain remission and allow successful <b style='color:Tomato;'><i>prednisone</i></b> tapering. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NSVN</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>controversial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>recent</i></b> <b style='color:DodgerBlue;'><i>retrospective</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>outset</i></b> <b style='color:DodgerBlue;'><i>fare</i></b> <b style='color:DodgerBlue;'><i>better</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> If <b style='color:Tomato;'><i>prednisone</i></b> is administered as monotherapy, <b style='color:Tomato;'><i>cyclophosphamide</i></b> should be added after several months if there is no improvement or relapse occurs with tapering of <b style='color:Tomato;'><i>prednisone</i></b>. Intravenous pulse and daily oral <b style='color:Tomato;'><i>cyclophosphamide</i></b> probably offer similar efficacy, although the risk of complications is greater with oral therapy. <b style='color:Tomato;'><i>azathioprine</i></b> can be safely substituted for <b style='color:Tomato;'><i>cyclophosphamide</i></b> after 3 months without an increased relapse rate. <b style='color:Tomato;'><i>azathioprine</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, intravenous immune globulin, <b style='color:Tomato;'><i>mycophenolate</i></b> mofetil, plasma exchange, and <b style='color:Tomato;'><i>rituximab</i></b> can be offered to patients who are intolerant or have a contraindication to <b style='color:Tomato;'><i>cyclophosphamide</i></b>. However, efficacy is unproven for any of these therapies. Interferon-alpha, sometimes combined with plasma exchange, is used to treat vasculitis associated with hepatitis B infection. Some patients also may improve with corticosteroids. The classification of diabetic lumbosacral radiculoplexus neuropathy as a vasculitic disorder remains controversial. However, there is compelling pathological evidence that this condition represents a T-cell-mediated microvasculitis. Some patients treated with intravenous corticosteroids may have greater recovery and improved pain control.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"use","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"cyclophosphamide","start":11,"end":27,"id":3,"ws":true},{"text":"in","start":28,"end":30,"id":4,"ws":true},{"text":"patients","start":31,"end":39,"id":5,"ws":true},{"text":"with","start":40,"end":44,"id":6,"ws":true},{"text":"NSVN","start":45,"end":49,"id":7,"ws":true},{"text":"is","start":50,"end":52,"id":8,"ws":true},{"text":"controversial","start":53,"end":66,"id":9,"ws":true},{"text":",","start":67,"end":68,"id":10,"ws":true},{"text":"but","start":69,"end":72,"id":11,"ws":true},{"text":"recent","start":73,"end":79,"id":12,"ws":true},{"text":"retrospective","start":80,"end":93,"id":13,"ws":true},{"text":"data","start":94,"end":98,"id":14,"ws":true},{"text":"suggest","start":99,"end":106,"id":15,"ws":true},{"text":"that","start":107,"end":111,"id":16,"ws":true},{"text":"those","start":112,"end":117,"id":17,"ws":true},{"text":"treated","start":118,"end":125,"id":18,"ws":true},{"text":"with","start":126,"end":130,"id":19,"ws":true},{"text":"prednisone","start":131,"end":141,"id":20,"ws":true},{"text":"and","start":142,"end":145,"id":21,"ws":true},{"text":"cyclophosphamide","start":146,"end":162,"id":22,"ws":true},{"text":"from","start":163,"end":167,"id":23,"ws":true},{"text":"the","start":168,"end":171,"id":24,"ws":true},{"text":"outset","start":172,"end":178,"id":25,"ws":true},{"text":"fare","start":179,"end":183,"id":26,"ws":true},{"text":"better","start":184,"end":190,"id":27,"ws":true},{"text":"than","start":191,"end":195,"id":28,"ws":true},{"text":"those","start":196,"end":201,"id":29,"ws":true},{"text":"initially","start":202,"end":211,"id":30,"ws":true},{"text":"treated","start":212,"end":219,"id":31,"ws":true},{"text":"only","start":220,"end":224,"id":32,"ws":true},{"text":"with","start":225,"end":229,"id":33,"ws":true},{"text":"prednisone","start":230,"end":240,"id":34,"ws":true},{"text":".","start":241,"end":242,"id":35,"ws":false}],"spans":[{"start":11,"end":27,"token_start":3,"token_end":3,"label":"DRUG"},{"start":131,"end":141,"token_start":20,"token_end":20,"label":"DRUG"},{"start":146,"end":162,"token_start":22,"token_end":22,"label":"DRUG"},{"start":230,"end":240,"token_start":34,"token_end":34,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16464407/","_input_hash":1157918086,"_task_hash":-2064001050,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":131,"end":141,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":146,"end":162,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"This was a multi-center randomized , two-armed , double-blinded phase II study comparing cediranib plus gefitinib versus cediranib plus placebo in subjects with first relapse/first progression of glioblastoma following surgery and chemoradiotherapy .","paragraph":"<h3><u>Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.</u></h3><b style='color:Tomato;'><i>cediranib</i></b>, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, failed to show benefit over <b style='color:Tomato;'><i>lomustine</i></b> in relapsed glioblastoma. One resistance mechanism for <b style='color:Tomato;'><i>cediranib</i></b> is up-regulation of epidermal growth factor receptor (EGFR). This study aimed to determine if dual therapy with <b style='color:Tomato;'><i>cediranib</i></b> and the oral EGFR inhibitor <b style='color:Tomato;'><i>gefitinib</i></b> improved outcome in recurrent glioblastoma. ### Methods And Findings <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multi-center</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two-armed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>double-blinded</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:MediumOrchid;'><i>cediranib</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>cediranib</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>subjects</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>relapse/first</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>glioblastoma</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemoradiotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary outcome measure was progression free survival (PFS). Secondary outcome measures included overall survival (OS) and radiologic response rate. Recruitment was terminated early following suspension of the <b style='color:Tomato;'><i>cediranib</i></b> program. 38 subjects (112 planned) were enrolled with 19 subjects in each treatment arm. Median PFS with <b style='color:Tomato;'><i>cediranib</i></b> plus <b style='color:Tomato;'><i>gefitinib</i></b> was 3.6 months compared to 2.8 months for <b style='color:Tomato;'><i>cediranib</i></b> plus placebo (HR; 0.72, 90% CI; 0.41 to 1.26). Median OS was 7.2 months with <b style='color:Tomato;'><i>cediranib</i></b> plus <b style='color:Tomato;'><i>gefitinib</i></b> and 5.5 months with <b style='color:Tomato;'><i>cediranib</i></b> plus placebo (HR; 0.68, 90% CI; 0.39 to 1.19). Eight subjects (42%) had a partial response in the <b style='color:Tomato;'><i>cediranib</i></b> plus <b style='color:Tomato;'><i>gefitinib</i></b> arm versus five patients (26%) in the <b style='color:Tomato;'><i>cediranib</i></b> plus placebo arm. ### conclusions <b style='color:Tomato;'><i>cediranib</i></b> and <b style='color:Tomato;'><i>gefitinib</i></b> in combination is tolerated in patients with glioblastoma. Incomplete recruitment led to the study being underpowered. However, a trend towards improved survival and response rates with the addition of <b style='color:Tomato;'><i>gefitinib</i></b> to <b style='color:Tomato;'><i>cediranib</i></b> was observed. Further studies of the combination incorporating EGFR and VEGF inhibition are warranted. ### Trial Registration ClinicalTrials.gov NCT01310855.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"was","start":5,"end":8,"id":1,"ws":true},{"text":"a","start":9,"end":10,"id":2,"ws":true},{"text":"multi-center","start":11,"end":23,"id":3,"ws":true},{"text":"randomized","start":24,"end":34,"id":4,"ws":true},{"text":",","start":35,"end":36,"id":5,"ws":true},{"text":"two-armed","start":37,"end":46,"id":6,"ws":true},{"text":",","start":47,"end":48,"id":7,"ws":true},{"text":"double-blinded","start":49,"end":63,"id":8,"ws":true},{"text":"phase","start":64,"end":69,"id":9,"ws":true},{"text":"II","start":70,"end":72,"id":10,"ws":true},{"text":"study","start":73,"end":78,"id":11,"ws":true},{"text":"comparing","start":79,"end":88,"id":12,"ws":true},{"text":"cediranib","start":89,"end":98,"id":13,"ws":true},{"text":"plus","start":99,"end":103,"id":14,"ws":true},{"text":"gefitinib","start":104,"end":113,"id":15,"ws":true},{"text":"versus","start":114,"end":120,"id":16,"ws":true},{"text":"cediranib","start":121,"end":130,"id":17,"ws":true},{"text":"plus","start":131,"end":135,"id":18,"ws":true},{"text":"placebo","start":136,"end":143,"id":19,"ws":true},{"text":"in","start":144,"end":146,"id":20,"ws":true},{"text":"subjects","start":147,"end":155,"id":21,"ws":true},{"text":"with","start":156,"end":160,"id":22,"ws":true},{"text":"first","start":161,"end":166,"id":23,"ws":true},{"text":"relapse/first","start":167,"end":180,"id":24,"ws":true},{"text":"progression","start":181,"end":192,"id":25,"ws":true},{"text":"of","start":193,"end":195,"id":26,"ws":true},{"text":"glioblastoma","start":196,"end":208,"id":27,"ws":true},{"text":"following","start":209,"end":218,"id":28,"ws":true},{"text":"surgery","start":219,"end":226,"id":29,"ws":true},{"text":"and","start":227,"end":230,"id":30,"ws":true},{"text":"chemoradiotherapy","start":231,"end":248,"id":31,"ws":true},{"text":".","start":249,"end":250,"id":32,"ws":false}],"spans":[{"start":89,"end":98,"token_start":13,"token_end":13,"label":"DRUG"},{"start":104,"end":113,"token_start":15,"token_end":15,"label":"DRUG"},{"start":121,"end":130,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27232884/","_input_hash":1881848093,"_task_hash":-212303019,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":89,"end":98,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":104,"end":113,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"This study aims to compare the biological , molecular , pharmacological , and clinical characteristics of these three treatment modalities for SARS-COV-2 infections , Chloroquine and Hydroxychloroquine , Convalescent Plasma , and Remdesivir .","paragraph":"<h3><u>Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.</u></h3>The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, also known as COVID-19 pandemic has caused an alarming situation worldwide. Since the first detection, in December 2019, there have been no effective drug therapy options for treating the SARS-CoV-2 pandemic. However, healthcare professionals are using <b style='color:Tomato;'><i>chloroquine</i></b>, hydroxy<b style='color:Tomato;'><i>chloroquine</i></b>, <b style='color:Tomato;'><i>remdesivir</i></b>, convalescent plasma and some other options of treatments. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>aims</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>biological</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>molecular</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>pharmacological</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>characteristics</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>modalities</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>SARS-COV-2</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Chloroquine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Hydroxychloroquine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Convalescent</i></b> <b style='color:DodgerBlue;'><i>Plasma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Remdesivir</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A search was conducted in the \"Institute of Science Information (ISI)-Web of Science, PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library databases, Scopus, and Google Scholar\" for peer reviewed, published studies and clinical trials through July 30, 2020. The search was based on keywords \"COVID-19\" SARS-COV-2, <b style='color:Tomato;'><i>chloroquine</i></b>, hydroxy<b style='color:Tomato;'><i>chloroquine</i></b>, convalescent plasma, <b style='color:Tomato;'><i>remdesivir</i></b> and treatment modalities. ### results As of July 30, 2020, a total of 36,640 relevant documents were published. From them 672 peer reviewed, published articles, and clinical trials were screened. We selected 17 relevant published original articles and clinical trials: 05 for <b style='color:Tomato;'><i>chloroquine</i></b> and/or hydroxy<b style='color:Tomato;'><i>chloroquine</i></b> with total sample size (n\u202f=\u202f220), 05 for <b style='color:Tomato;'><i>remdesivir</i></b> (n\u202f=\u202f1,781), and 07 for Convalescent Plasma therapy (n\u202f=\u202f398), with a combined total sample size (n\u202f=\u202f2,399). Based on the available data, convalescent plasma therapy showed clinical advantages in SARS-COV-2 patients. ### conclusions All three treatment modalities have both favorable and unfavorable characteristics, but none showed clear evidence of benefit for early outpatient disease or prophylaxis. Based on the current available data, convalescent plasma therapy appears to show clinical advantages for inpatient use. In the future, ongoing large sample size randomized controlled clinical trials may further clarify the comparative efficacy and safety of these three treatment classes, to conclusively determine whom to treat with which drug and when to treat them.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"study","start":5,"end":10,"id":1,"ws":true},{"text":"aims","start":11,"end":15,"id":2,"ws":true},{"text":"to","start":16,"end":18,"id":3,"ws":true},{"text":"compare","start":19,"end":26,"id":4,"ws":true},{"text":"the","start":27,"end":30,"id":5,"ws":true},{"text":"biological","start":31,"end":41,"id":6,"ws":true},{"text":",","start":42,"end":43,"id":7,"ws":true},{"text":"molecular","start":44,"end":53,"id":8,"ws":true},{"text":",","start":54,"end":55,"id":9,"ws":true},{"text":"pharmacological","start":56,"end":71,"id":10,"ws":true},{"text":",","start":72,"end":73,"id":11,"ws":true},{"text":"and","start":74,"end":77,"id":12,"ws":true},{"text":"clinical","start":78,"end":86,"id":13,"ws":true},{"text":"characteristics","start":87,"end":102,"id":14,"ws":true},{"text":"of","start":103,"end":105,"id":15,"ws":true},{"text":"these","start":106,"end":111,"id":16,"ws":true},{"text":"three","start":112,"end":117,"id":17,"ws":true},{"text":"treatment","start":118,"end":127,"id":18,"ws":true},{"text":"modalities","start":128,"end":138,"id":19,"ws":true},{"text":"for","start":139,"end":142,"id":20,"ws":true},{"text":"SARS-COV-2","start":143,"end":153,"id":21,"ws":true},{"text":"infections","start":154,"end":164,"id":22,"ws":true},{"text":",","start":165,"end":166,"id":23,"ws":true},{"text":"Chloroquine","start":167,"end":178,"id":24,"ws":true},{"text":"and","start":179,"end":182,"id":25,"ws":true},{"text":"Hydroxychloroquine","start":183,"end":201,"id":26,"ws":true},{"text":",","start":202,"end":203,"id":27,"ws":true},{"text":"Convalescent","start":204,"end":216,"id":28,"ws":true},{"text":"Plasma","start":217,"end":223,"id":29,"ws":true},{"text":",","start":224,"end":225,"id":30,"ws":true},{"text":"and","start":226,"end":229,"id":31,"ws":true},{"text":"Remdesivir","start":230,"end":240,"id":32,"ws":true},{"text":".","start":241,"end":242,"id":33,"ws":false}],"spans":[{"start":167,"end":178,"token_start":24,"token_end":24,"label":"DRUG"},{"start":183,"end":201,"token_start":26,"token_end":26,"label":"DRUG"},{"start":230,"end":240,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32921965/","_input_hash":-1164581320,"_task_hash":-1670352699,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":24,"child":26,"head_span":{"start":167,"end":178,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":183,"end":201,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Patients received a mean ( \u00b1standard deviation ) of 8.8 \u00b1 4.9 intravitreal bevacizumab injections prior to the switch to intravitreal ranibizumab .","paragraph":"<h3><u>Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).</u></h3>To evaluate the outcome of second-line intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> treatment in eyes with diabetic macular edema having persistent edema following initial therapy with intravitreal <b style='color:Tomato;'><i>bevacizumab</i></b>. ### Methods Diabetic macular edema treated with <b style='color:Tomato;'><i>ranibizumab</i></b> following <b style='color:Tomato;'><i>bevacizumab</i></b> failure in Israel was a retrospective, multi-center study. Consecutive eyes with persistent diabetic macular edema following at least three previous intravitreal <b style='color:Tomato;'><i>bevacizumab</i></b> injections prior to intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b>, at least three-monthly intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> injections and at least 12\u2009months of follow-up were included. Data collected included demographics, ocular findings, diabetes control, details of intravitreal <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>ranibizumab</i></b> injections, and visual and anatomical measurements before and after intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> treatment. ### Results In total, 202 eyes of 162 patients treated at 11 medical centers across Israel were included. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>\u00b1standard</i></b> <b style='color:DodgerBlue;'><i>deviation</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>8.8</i></b> <b style='color:DodgerBlue;'><i>\u00b1</i></b> <b style='color:DodgerBlue;'><i>4.9</i></b> <b style='color:DodgerBlue;'><i>intravitreal</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>injections</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>switch</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>intravitreal</i></b> <b style='color:MediumOrchid;'><i>ranibizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A mean of 7.0\u2009\u00b1\u20092.7 intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> injections were given during the 12\u2009months following the switch to intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b>. The median central subfield retinal thickness (\u00b1interquartile range) by spectral-domain optical coherence tomography decreased from 436\u2009\u00b1\u2009162\u2009\u00b5m at baseline to 319\u2009\u00b1\u2009113\u2009\u00b5m at month 12 (p\u2009<\u20090.001). Median logMAR visual acuity (\u00b1interquartile range) improved from 0.40\u2009\u00b1\u20090.48 at baseline to 0.38\u2009\u00b1\u20090.40 at month 12 (p\u2009=\u20090.001). Linear regression suggested that higher number of intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> injections and higher pre-switch central subfield retinal thickness were associated with favorable visual outcome. Higher number of intravitreal <b style='color:Tomato;'><i>bevacizumab</i></b> injections and the presence of intraretinal fluid before the switch lessened the odds of favorable outcome. ### Conclusion Switching from <b style='color:Tomato;'><i>bevacizumab</i></b> to <b style='color:Tomato;'><i>ranibizumab</i></b> in persistent diabetic macular edema was associated with anatomical improvement in the majority of eyes and \u2a7e2 lines of vision improvement in 22% of eyes.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"received","start":9,"end":17,"id":1,"ws":true},{"text":"a","start":18,"end":19,"id":2,"ws":true},{"text":"mean","start":20,"end":24,"id":3,"ws":true},{"text":"(","start":25,"end":26,"id":4,"ws":true},{"text":"\u00b1standard","start":27,"end":36,"id":5,"ws":true},{"text":"deviation","start":37,"end":46,"id":6,"ws":true},{"text":")","start":47,"end":48,"id":7,"ws":true},{"text":"of","start":49,"end":51,"id":8,"ws":true},{"text":"8.8","start":52,"end":55,"id":9,"ws":true},{"text":"\u00b1","start":56,"end":57,"id":10,"ws":true},{"text":"4.9","start":58,"end":61,"id":11,"ws":true},{"text":"intravitreal","start":62,"end":74,"id":12,"ws":true},{"text":"bevacizumab","start":75,"end":86,"id":13,"ws":true},{"text":"injections","start":87,"end":97,"id":14,"ws":true},{"text":"prior","start":98,"end":103,"id":15,"ws":true},{"text":"to","start":104,"end":106,"id":16,"ws":true},{"text":"the","start":107,"end":110,"id":17,"ws":true},{"text":"switch","start":111,"end":117,"id":18,"ws":true},{"text":"to","start":118,"end":120,"id":19,"ws":true},{"text":"intravitreal","start":121,"end":133,"id":20,"ws":true},{"text":"ranibizumab","start":134,"end":145,"id":21,"ws":true},{"text":".","start":146,"end":147,"id":22,"ws":false}],"spans":[{"start":75,"end":86,"token_start":13,"token_end":13,"label":"DRUG"},{"start":134,"end":145,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29916263/","_input_hash":571835589,"_task_hash":1057049130,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Combinations of penicillin and streptomycin and penicillin and amikacin were synergistic only against those strains that were not highly resistant to streptomycin and kanamycin , respectively .","paragraph":"<h3><u>Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis.</u></h3>Combinations of penicillin with various aminoglycosidic aminocyclitols were tested against a collection of clinical isolates of Streptococcus faecium in vitro and were used to treat endocarditis caused by S. faecium in the rabbit model. S. faecium proved more resistant to penicillin than Streptococcus faecalis. Even more striking, however, was the resistance to in vitro synergism by combinations of penicillin and various aminoglycosides. At clinically achievable concentrations, penicillin-<b style='color:Tomato;'><i>gentamicin</i></b> was the only combination that was synergistic against all strains that were tested. <b style='color:DodgerBlue;'><i>Combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amikacin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>strains</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>highly</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>kanamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Combinations of penicillin with <b style='color:Tomato;'><i>kanamycin</i></b>, <b style='color:Tomato;'><i>tobramycin</i></b>, <b style='color:Tomato;'><i>sisomicin</i></b>, or <b style='color:Tomato;'><i>netilmicin</i></b> failed to produce synergism against any of these strains. The possible clinical significance of these findings was verified by use of the rabbit model of endocarditis. Combinations of penicillin with <b style='color:Tomato;'><i>gentamicin</i></b> or <b style='color:Tomato;'><i>streptomycin</i></b> were synergistic in the therapy of endocarditis that was produced by a strain of S. faecium that did not have a high level of resistance to aminoglycosides. However, the combination of penicillin and <b style='color:Tomato;'><i>netilmicin</i></b> was no more effective than penicillin alone.","tokens":[{"text":"Combinations","start":0,"end":12,"id":0,"ws":true},{"text":"of","start":13,"end":15,"id":1,"ws":true},{"text":"penicillin","start":16,"end":26,"id":2,"ws":true},{"text":"and","start":27,"end":30,"id":3,"ws":true},{"text":"streptomycin","start":31,"end":43,"id":4,"ws":true},{"text":"and","start":44,"end":47,"id":5,"ws":true},{"text":"penicillin","start":48,"end":58,"id":6,"ws":true},{"text":"and","start":59,"end":62,"id":7,"ws":true},{"text":"amikacin","start":63,"end":71,"id":8,"ws":true},{"text":"were","start":72,"end":76,"id":9,"ws":true},{"text":"synergistic","start":77,"end":88,"id":10,"ws":true},{"text":"only","start":89,"end":93,"id":11,"ws":true},{"text":"against","start":94,"end":101,"id":12,"ws":true},{"text":"those","start":102,"end":107,"id":13,"ws":true},{"text":"strains","start":108,"end":115,"id":14,"ws":true},{"text":"that","start":116,"end":120,"id":15,"ws":true},{"text":"were","start":121,"end":125,"id":16,"ws":true},{"text":"not","start":126,"end":129,"id":17,"ws":true},{"text":"highly","start":130,"end":136,"id":18,"ws":true},{"text":"resistant","start":137,"end":146,"id":19,"ws":true},{"text":"to","start":147,"end":149,"id":20,"ws":true},{"text":"streptomycin","start":150,"end":162,"id":21,"ws":true},{"text":"and","start":163,"end":166,"id":22,"ws":true},{"text":"kanamycin","start":167,"end":176,"id":23,"ws":true},{"text":",","start":177,"end":178,"id":24,"ws":true},{"text":"respectively","start":179,"end":191,"id":25,"ws":true},{"text":".","start":192,"end":193,"id":26,"ws":false}],"spans":[{"start":16,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},{"start":31,"end":43,"token_start":4,"token_end":4,"label":"DRUG"},{"start":63,"end":71,"token_start":8,"token_end":8,"label":"DRUG"},{"start":150,"end":162,"token_start":21,"token_end":21,"label":"DRUG"},{"start":167,"end":176,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/113469/","_input_hash":175357667,"_task_hash":-1271017010,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":16,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":31,"end":43,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":6,"child":8,"head_span":{"start":48,"end":58,"token_start":6,"token_end":6,"label":null},"child_span":{"start":63,"end":71,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"Treatment with a combination chemotherapeutic regimen consisting of cyclophosphamide , vincristine , and dacarbazine for malignant paraganglioma with hepatic metastasis is reported .","paragraph":"<h3><u>Combination chemotherapy for malignant paraganglioma.</u></h3> <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapeutic</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>malignant</i></b> <b style='color:DodgerBlue;'><i>paraganglioma</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>hepatic</i></b> <b style='color:DodgerBlue;'><i>metastasis</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A 51-year-old male presented with tumors in the retroperitoneal space and liver. The patient was diagnosed as having paraganglioma based on elevated levels of serum neuron-specific enolase, urinary catecholamine and vanillylmandelic acid, and on histological findings of the liver specimen. The patient was treated with this combination chemotherapy in repeated 21-day cycles. Temporary improvement in laboratory findings and a 20% reduction in the size of the hepatic masses were observed without severe adverse effects.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"with","start":10,"end":14,"id":1,"ws":true},{"text":"a","start":15,"end":16,"id":2,"ws":true},{"text":"combination","start":17,"end":28,"id":3,"ws":true},{"text":"chemotherapeutic","start":29,"end":45,"id":4,"ws":true},{"text":"regimen","start":46,"end":53,"id":5,"ws":true},{"text":"consisting","start":54,"end":64,"id":6,"ws":true},{"text":"of","start":65,"end":67,"id":7,"ws":true},{"text":"cyclophosphamide","start":68,"end":84,"id":8,"ws":true},{"text":",","start":85,"end":86,"id":9,"ws":true},{"text":"vincristine","start":87,"end":98,"id":10,"ws":true},{"text":",","start":99,"end":100,"id":11,"ws":true},{"text":"and","start":101,"end":104,"id":12,"ws":true},{"text":"dacarbazine","start":105,"end":116,"id":13,"ws":true},{"text":"for","start":117,"end":120,"id":14,"ws":true},{"text":"malignant","start":121,"end":130,"id":15,"ws":true},{"text":"paraganglioma","start":131,"end":144,"id":16,"ws":true},{"text":"with","start":145,"end":149,"id":17,"ws":true},{"text":"hepatic","start":150,"end":157,"id":18,"ws":true},{"text":"metastasis","start":158,"end":168,"id":19,"ws":true},{"text":"is","start":169,"end":171,"id":20,"ws":true},{"text":"reported","start":172,"end":180,"id":21,"ws":true},{"text":".","start":181,"end":182,"id":22,"ws":false}],"spans":[{"start":68,"end":84,"token_start":8,"token_end":8,"label":"DRUG"},{"start":87,"end":98,"token_start":10,"token_end":10,"label":"DRUG"},{"start":105,"end":116,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9058098/","_input_hash":-1922423655,"_task_hash":-164068088,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":68,"end":84,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":87,"end":98,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":13,"head_span":{"start":87,"end":98,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":105,"end":116,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"An 8-week , randomized , parallel-group , double-blind international trial comparing the once-daily single-pill combination of telmisartan 80 mg and amlodipine 10 mg ( T/A ; n = 352 ) with once-daily amlodipine 10 mg ( A ; n = 354 ) in patients with type 2 diabetes mellitus and stage 1 or 2 hypertension ( systolic BP [ SBP ] > 150 mm Hg ) .","paragraph":"<h3><u>Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.</u></h3>Hypertensive patients with diabetes often require combination therapy to achieve a blood pressure (BP) goal, and evidence suggests that time to BP goal is crucial to decrease cardiovascular risk. ### objective The aim of the study was to investigate whether the single-pill combination of <b style='color:Tomato;'><i>telmisartan</i></b> and <b style='color:Tomato;'><i>amlodipine</i></b> was superior to <b style='color:Tomato;'><i>amlodipine</i></b> alone as initial antihypertensive therapy in patients with diabetes and hypertension. ### methods <b style='color:DodgerBlue;'><i>An</i></b> <b style='color:DodgerBlue;'><i>8-week</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>parallel-group</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>international</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>once-daily</i></b> <b style='color:DodgerBlue;'><i>single-pill</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>telmisartan</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amlodipine</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>T/A</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>352</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>once-daily</i></b> <b style='color:MediumOrchid;'><i>amlodipine</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>354</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>type</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>diabetes</i></b> <b style='color:DodgerBlue;'><i>mellitus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>hypertension</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>systolic</i></b> <b style='color:DodgerBlue;'><i>BP</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>SBP</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>150</i></b> <b style='color:DodgerBlue;'><i>mm</i></b> <b style='color:DodgerBlue;'><i>Hg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Patient demographics were similar between treatment groups, with an mean (SD) age of 60.5 (10.1) years; 51.7% were male, the mean (SD) body mass index was 32.0 (6.1) and the mean (SD) duration of hypertension was 8.8 (7.9) years. After 8 weeks (primary end point) as well as after 1, 2, and 4 weeks (key secondary end points), significantly greater decreases in the in-clinic mean seated trough cuff SBP with T/A versus A were achieved (-29.0 mm Hg vs -22.9 mm Hg at 8 weeks; P < 0.0001). After 8 weeks, 71.4% versus 53.8% of patients achieved the BP goal (<140/90 mm Hg) with T/A versus A, with mean SBPs of 131.9 and 137.9 mm Hg, respectively. Similar results were observed in the obese (metabolic syndrome) subpopulation. The more stringent goal (<130/80 mm Hg) was achieved by 36.4% and 17.9% patients in the T/A and A groups, respectively. The most common adverse events were peripheral edema, headache, and dizziness. ### conclusions In this selected population of patients with diabetes and hypertension, T/A provided prompt and greater BP decreases compared with A monotherapy, with the majority of patients achieving the BP goal (<140/90 mm Hg).","tokens":[{"text":"An","start":0,"end":2,"id":0,"ws":true},{"text":"8-week","start":3,"end":9,"id":1,"ws":true},{"text":",","start":10,"end":11,"id":2,"ws":true},{"text":"randomized","start":12,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"parallel-group","start":25,"end":39,"id":5,"ws":true},{"text":",","start":40,"end":41,"id":6,"ws":true},{"text":"double-blind","start":42,"end":54,"id":7,"ws":true},{"text":"international","start":55,"end":68,"id":8,"ws":true},{"text":"trial","start":69,"end":74,"id":9,"ws":true},{"text":"comparing","start":75,"end":84,"id":10,"ws":true},{"text":"the","start":85,"end":88,"id":11,"ws":true},{"text":"once-daily","start":89,"end":99,"id":12,"ws":true},{"text":"single-pill","start":100,"end":111,"id":13,"ws":true},{"text":"combination","start":112,"end":123,"id":14,"ws":true},{"text":"of","start":124,"end":126,"id":15,"ws":true},{"text":"telmisartan","start":127,"end":138,"id":16,"ws":true},{"text":"80","start":139,"end":141,"id":17,"ws":true},{"text":"mg","start":142,"end":144,"id":18,"ws":true},{"text":"and","start":145,"end":148,"id":19,"ws":true},{"text":"amlodipine","start":149,"end":159,"id":20,"ws":true},{"text":"10","start":160,"end":162,"id":21,"ws":true},{"text":"mg","start":163,"end":165,"id":22,"ws":true},{"text":"(","start":166,"end":167,"id":23,"ws":true},{"text":"T/A","start":168,"end":171,"id":24,"ws":true},{"text":";","start":172,"end":173,"id":25,"ws":true},{"text":"n","start":174,"end":175,"id":26,"ws":true},{"text":"=","start":176,"end":177,"id":27,"ws":true},{"text":"352","start":178,"end":181,"id":28,"ws":true},{"text":")","start":182,"end":183,"id":29,"ws":true},{"text":"with","start":184,"end":188,"id":30,"ws":true},{"text":"once-daily","start":189,"end":199,"id":31,"ws":true},{"text":"amlodipine","start":200,"end":210,"id":32,"ws":true},{"text":"10","start":211,"end":213,"id":33,"ws":true},{"text":"mg","start":214,"end":216,"id":34,"ws":true},{"text":"(","start":217,"end":218,"id":35,"ws":true},{"text":"A","start":219,"end":220,"id":36,"ws":true},{"text":";","start":221,"end":222,"id":37,"ws":true},{"text":"n","start":223,"end":224,"id":38,"ws":true},{"text":"=","start":225,"end":226,"id":39,"ws":true},{"text":"354","start":227,"end":230,"id":40,"ws":true},{"text":")","start":231,"end":232,"id":41,"ws":true},{"text":"in","start":233,"end":235,"id":42,"ws":true},{"text":"patients","start":236,"end":244,"id":43,"ws":true},{"text":"with","start":245,"end":249,"id":44,"ws":true},{"text":"type","start":250,"end":254,"id":45,"ws":true},{"text":"2","start":255,"end":256,"id":46,"ws":true},{"text":"diabetes","start":257,"end":265,"id":47,"ws":true},{"text":"mellitus","start":266,"end":274,"id":48,"ws":true},{"text":"and","start":275,"end":278,"id":49,"ws":true},{"text":"stage","start":279,"end":284,"id":50,"ws":true},{"text":"1","start":285,"end":286,"id":51,"ws":true},{"text":"or","start":287,"end":289,"id":52,"ws":true},{"text":"2","start":290,"end":291,"id":53,"ws":true},{"text":"hypertension","start":292,"end":304,"id":54,"ws":true},{"text":"(","start":305,"end":306,"id":55,"ws":true},{"text":"systolic","start":307,"end":315,"id":56,"ws":true},{"text":"BP","start":316,"end":318,"id":57,"ws":true},{"text":"[","start":319,"end":320,"id":58,"ws":true},{"text":"SBP","start":321,"end":324,"id":59,"ws":true},{"text":"]","start":325,"end":326,"id":60,"ws":true},{"text":">","start":327,"end":328,"id":61,"ws":true},{"text":"150","start":329,"end":332,"id":62,"ws":true},{"text":"mm","start":333,"end":335,"id":63,"ws":true},{"text":"Hg","start":336,"end":338,"id":64,"ws":true},{"text":")","start":339,"end":340,"id":65,"ws":true},{"text":".","start":341,"end":342,"id":66,"ws":false}],"spans":[{"start":127,"end":138,"token_start":16,"token_end":16,"label":"DRUG"},{"start":149,"end":159,"token_start":20,"token_end":20,"label":"DRUG"},{"start":200,"end":210,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22386829/","_input_hash":1420509013,"_task_hash":-220521991,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":16,"child":20,"head_span":{"start":127,"end":138,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":149,"end":159,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Pharmacokinetic studies evaluating the concurrent use of tenofovir and didanosine have been performed in healthy volunteers .","paragraph":"<h3><u>Effect of tenofovir on didanosine absorption in patients with HIV.</u></h3>To evaluate the pharmacokinetic interaction between <b style='color:Tomato;'><i>tenofovir</i></b> and <b style='color:Tomato;'><i>didanosine</i></b> when used in combination as a highly active antiretroviral therapy regimen. ### Data Sources Literature retrieval was accessed through MEDLINE (1966-January 2003) using the terms <b style='color:Tomato;'><i>tenofovir</i></b> and <b style='color:Tomato;'><i>didanosine</i></b>. Abstracts from recent meetings, including the International AIDS Society, Interscience Conference on Antimicrobial Agents and Chemotherapy, and the Infectious Diseases Society of America, were reviewed for relevant abstracts and poster presentations. ### Data Synthesis <b style='color:DodgerBlue;'><i>Pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>evaluating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concurrent</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tenofovir</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>didanosine</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>healthy</i></b> <b style='color:DodgerBlue;'><i>volunteers</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>tenofovir</i></b> 300 mg administered concurrently with 400 mg <b style='color:Tomato;'><i>didanosine</i></b> results in a 48-64% increase in the <b style='color:Tomato;'><i>didanosine</i></b> maximum plasma concentration and AUC with no significant alterations in the <b style='color:Tomato;'><i>tenofovir</i></b> pharmacokinetic parameters. <b style='color:Tomato;'><i>tenofovir</i></b> 300 mg and <b style='color:Tomato;'><i>didanosine</i></b> 250 mg has been compared with <b style='color:Tomato;'><i>didanosine</i></b> 400 mg alone. The results demonstrated equivalent <b style='color:Tomato;'><i>didanosine</i></b> AUCs. ### conclusions When used concurrently, <b style='color:Tomato;'><i>tenofovir</i></b> significantly increases the maximum plasma concentration and the AUC of <b style='color:Tomato;'><i>didanosine</i></b>. Additional data in HIV-infected patients are needed to determine the long-term toxicities of this combination therapy. <b style='color:Tomato;'><i>didanosine</i></b> dose reduction should be considered when these 2 agents are used concurrently.","tokens":[{"text":"Pharmacokinetic","start":0,"end":15,"id":0,"ws":true},{"text":"studies","start":16,"end":23,"id":1,"ws":true},{"text":"evaluating","start":24,"end":34,"id":2,"ws":true},{"text":"the","start":35,"end":38,"id":3,"ws":true},{"text":"concurrent","start":39,"end":49,"id":4,"ws":true},{"text":"use","start":50,"end":53,"id":5,"ws":true},{"text":"of","start":54,"end":56,"id":6,"ws":true},{"text":"tenofovir","start":57,"end":66,"id":7,"ws":true},{"text":"and","start":67,"end":70,"id":8,"ws":true},{"text":"didanosine","start":71,"end":81,"id":9,"ws":true},{"text":"have","start":82,"end":86,"id":10,"ws":true},{"text":"been","start":87,"end":91,"id":11,"ws":true},{"text":"performed","start":92,"end":101,"id":12,"ws":true},{"text":"in","start":102,"end":104,"id":13,"ws":true},{"text":"healthy","start":105,"end":112,"id":14,"ws":true},{"text":"volunteers","start":113,"end":123,"id":15,"ws":true},{"text":".","start":124,"end":125,"id":16,"ws":false}],"spans":[{"start":57,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},{"start":71,"end":81,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12921517/","_input_hash":810721498,"_task_hash":1472186623,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":57,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":71,"end":81,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"This comparative phase III trial of mitoxantrone+vinorelbine ( MV ) versus 5-fluorouracil+cyclophosphamide+either doxorubicin or epirubicin ( FAC/FEC ) in the treatment of metastatic breast cancer was conducted to determine whether MV would produce equivalent efficacy , while resulting in an improved tolerance in relation to alopecia and nausea/vomiting .","paragraph":"<h3><u>Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.</u></h3> <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>comparative</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>mitoxantrone+vinorelbine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil+cyclophosphamide+either</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FAC/FEC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>whether</i></b> <b style='color:DodgerBlue;'><i>MV</i></b> <b style='color:DodgerBlue;'><i>would</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>equivalent</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>resulting</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>tolerance</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>relation</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>alopecia</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>nausea/vomiting</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This multicentre study recruited and randomised 281 patients with metastatic breast cancer; 280 were evaluable for response survival and toxicity (138 received FAC/FEC, 142 received MV). Patient characteristics were matched in each arm and stratification for prior exposure to adjuvant therapy was made prospectively. The overall response rate (ORR) was equivalent in the two arms (33.3% for FAC/FEC versus 34.5% for MV), but MV was more effective in patients who had received prior adjuvant therapy (13% (95% confidence interval (CI) 3-23) for FAC/FEC versus 33% (95% CI 20-47) for MV P=0.025) with a better progression-free survival (PFS) (5 months (range 1-18 months) versus 8 months (range 1-27 months); P=0.0007 for FAC/FEC versus MV, respectively) while FAC/FEC was more effective in previously untreated patients (ORR 43% (95% CI 33-53) versus 35% (95% CI 25-45), P=0.26; PFS 9 months (range 0-29 months) versus 6 months (range 0-26 months) P=0.014). Toxicity was monitored through the initial six cycles of therapy; febrile neutropenia and delayed haematological recovery was more frequent for MV (P=0.001), while nausea/vomiting of grades 3-4 was greater for FAC/FEC (P=0.031), as was alopecia (P=0.0001), cardiotoxicity was the same for the two regimens. MV represents a chemotherapy combination with equivalent efficacy to standard FAC/FEC and improved results for patients who have previously received adjuvant chemotherapy. Toxicity must be balanced to allow for increased haematological suppression and risk of febrile neutropenia with MV compared with a higher risk of subjectively unpleasant side-effects such as nausea/vomiting and alopecia with FAC/FEC.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"comparative","start":5,"end":16,"id":1,"ws":true},{"text":"phase","start":17,"end":22,"id":2,"ws":true},{"text":"III","start":23,"end":26,"id":3,"ws":true},{"text":"trial","start":27,"end":32,"id":4,"ws":true},{"text":"of","start":33,"end":35,"id":5,"ws":true},{"text":"mitoxantrone+vinorelbine","start":36,"end":60,"id":6,"ws":true},{"text":"(","start":61,"end":62,"id":7,"ws":true},{"text":"MV","start":63,"end":65,"id":8,"ws":true},{"text":")","start":66,"end":67,"id":9,"ws":true},{"text":"versus","start":68,"end":74,"id":10,"ws":true},{"text":"5-fluorouracil+cyclophosphamide+either","start":75,"end":113,"id":11,"ws":true},{"text":"doxorubicin","start":114,"end":125,"id":12,"ws":true},{"text":"or","start":126,"end":128,"id":13,"ws":true},{"text":"epirubicin","start":129,"end":139,"id":14,"ws":true},{"text":"(","start":140,"end":141,"id":15,"ws":true},{"text":"FAC/FEC","start":142,"end":149,"id":16,"ws":true},{"text":")","start":150,"end":151,"id":17,"ws":true},{"text":"in","start":152,"end":154,"id":18,"ws":true},{"text":"the","start":155,"end":158,"id":19,"ws":true},{"text":"treatment","start":159,"end":168,"id":20,"ws":true},{"text":"of","start":169,"end":171,"id":21,"ws":true},{"text":"metastatic","start":172,"end":182,"id":22,"ws":true},{"text":"breast","start":183,"end":189,"id":23,"ws":true},{"text":"cancer","start":190,"end":196,"id":24,"ws":true},{"text":"was","start":197,"end":200,"id":25,"ws":true},{"text":"conducted","start":201,"end":210,"id":26,"ws":true},{"text":"to","start":211,"end":213,"id":27,"ws":true},{"text":"determine","start":214,"end":223,"id":28,"ws":true},{"text":"whether","start":224,"end":231,"id":29,"ws":true},{"text":"MV","start":232,"end":234,"id":30,"ws":true},{"text":"would","start":235,"end":240,"id":31,"ws":true},{"text":"produce","start":241,"end":248,"id":32,"ws":true},{"text":"equivalent","start":249,"end":259,"id":33,"ws":true},{"text":"efficacy","start":260,"end":268,"id":34,"ws":true},{"text":",","start":269,"end":270,"id":35,"ws":true},{"text":"while","start":271,"end":276,"id":36,"ws":true},{"text":"resulting","start":277,"end":286,"id":37,"ws":true},{"text":"in","start":287,"end":289,"id":38,"ws":true},{"text":"an","start":290,"end":292,"id":39,"ws":true},{"text":"improved","start":293,"end":301,"id":40,"ws":true},{"text":"tolerance","start":302,"end":311,"id":41,"ws":true},{"text":"in","start":312,"end":314,"id":42,"ws":true},{"text":"relation","start":315,"end":323,"id":43,"ws":true},{"text":"to","start":324,"end":326,"id":44,"ws":true},{"text":"alopecia","start":327,"end":335,"id":45,"ws":true},{"text":"and","start":336,"end":339,"id":46,"ws":true},{"text":"nausea/vomiting","start":340,"end":355,"id":47,"ws":true},{"text":".","start":356,"end":357,"id":48,"ws":false}],"spans":[{"start":114,"end":125,"token_start":12,"token_end":12,"label":"DRUG"},{"start":129,"end":139,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11378344/","_input_hash":966972887,"_task_hash":576970413,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"Overnight urinary oxytocin and vasopressin levels were obtained from 62 healthy males ( age range : 18 - 26 years ) to compare with trait measures of trust and aggressive behavior .","paragraph":"<h3><u>Oxytocin, vasopressin and trust: Associations with aggressive behavior in healthy young males.</u></h3><b style='color:Tomato;'><i>oxytocin</i></b> enhances trust during social interactions and reduces the tendency for social betrayal. Animal studies have revealed that <b style='color:Tomato;'><i>oxytocin</i></b> is also an important factor in the establishment and regulation of aggression, for which social interaction is a critical precondition. In humans, however, the effects of <b style='color:Tomato;'><i>oxytocin</i></b> appear more nuanced and influenced by social context and personality traits. Moreover, the pro-social effects of <b style='color:Tomato;'><i>oxytocin</i></b> are not mirrored by <b style='color:Tomato;'><i>vasopressin</i></b>, despite their high chemical similarity. Rather, <b style='color:Tomato;'><i>vasopressin</i></b> has been associated with an increase of aggressive responses. Therefore, we sought to investigate the association of <b style='color:Tomato;'><i>oxytocin</i></b> and <b style='color:Tomato;'><i>vasopressin</i></b> with trust and aggressive behavior. <b style='color:DodgerBlue;'><i>Overnight</i></b> <b style='color:DodgerBlue;'><i>urinary</i></b> <b style='color:MediumOrchid;'><i>oxytocin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vasopressin</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>obtained</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>62</i></b> <b style='color:DodgerBlue;'><i>healthy</i></b> <b style='color:DodgerBlue;'><i>males</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>age</i></b> <b style='color:DodgerBlue;'><i>range</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>26</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>trait</i></b> <b style='color:DodgerBlue;'><i>measures</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>trust</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>aggressive</i></b> <b style='color:DodgerBlue;'><i>behavior</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We found a significant interaction of <b style='color:Tomato;'><i>oxytocin</i></b> and trust on aggression in which low trait measures of trust, in combination with low levels of <b style='color:Tomato;'><i>oxytocin</i></b>, were associated with a history of aggressive behavior. Notably, we found no significant associations for <b style='color:Tomato;'><i>vasopressin</i></b>. Although both <b style='color:Tomato;'><i>oxytocin</i></b> and <b style='color:Tomato;'><i>vasopressin</i></b> have been shown to be important in the emergence of violent behavior, our study suggests that <b style='color:Tomato;'><i>oxytocin</i></b> may be particularly modified by affiliative behaviors. These findings provide insights into the neuropsychological influences of <b style='color:Tomato;'><i>oxytocin</i></b>, and highlights the potential for clinical translation regarding the treatment of patients who exhibit recurrent aggressive behavior.","tokens":[{"text":"Overnight","start":0,"end":9,"id":0,"ws":true},{"text":"urinary","start":10,"end":17,"id":1,"ws":true},{"text":"oxytocin","start":18,"end":26,"id":2,"ws":true},{"text":"and","start":27,"end":30,"id":3,"ws":true},{"text":"vasopressin","start":31,"end":42,"id":4,"ws":true},{"text":"levels","start":43,"end":49,"id":5,"ws":true},{"text":"were","start":50,"end":54,"id":6,"ws":true},{"text":"obtained","start":55,"end":63,"id":7,"ws":true},{"text":"from","start":64,"end":68,"id":8,"ws":true},{"text":"62","start":69,"end":71,"id":9,"ws":true},{"text":"healthy","start":72,"end":79,"id":10,"ws":true},{"text":"males","start":80,"end":85,"id":11,"ws":true},{"text":"(","start":86,"end":87,"id":12,"ws":true},{"text":"age","start":88,"end":91,"id":13,"ws":true},{"text":"range","start":92,"end":97,"id":14,"ws":true},{"text":":","start":98,"end":99,"id":15,"ws":true},{"text":"18","start":100,"end":102,"id":16,"ws":true},{"text":"-","start":103,"end":104,"id":17,"ws":true},{"text":"26","start":105,"end":107,"id":18,"ws":true},{"text":"years","start":108,"end":113,"id":19,"ws":true},{"text":")","start":114,"end":115,"id":20,"ws":true},{"text":"to","start":116,"end":118,"id":21,"ws":true},{"text":"compare","start":119,"end":126,"id":22,"ws":true},{"text":"with","start":127,"end":131,"id":23,"ws":true},{"text":"trait","start":132,"end":137,"id":24,"ws":true},{"text":"measures","start":138,"end":146,"id":25,"ws":true},{"text":"of","start":147,"end":149,"id":26,"ws":true},{"text":"trust","start":150,"end":155,"id":27,"ws":true},{"text":"and","start":156,"end":159,"id":28,"ws":true},{"text":"aggressive","start":160,"end":170,"id":29,"ws":true},{"text":"behavior","start":171,"end":179,"id":30,"ws":true},{"text":".","start":180,"end":181,"id":31,"ws":false}],"spans":[{"start":18,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},{"start":31,"end":42,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30802507/","_input_hash":852254592,"_task_hash":-940615028,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"Additionally , the combined effect of Lapatinib together with Herceptin or Cetuximab on cell-mediated cytotoxicity was evaluated .","paragraph":"<h3><u>Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.</u></h3><b style='color:Tomato;'><i>lapatinib</i></b> is a dual tyrosine kinase inhibitor of the EGFR and HER2 tyrosine kinase domains. EGFR is expressed in 33.3% and HER2 in 30.3% of esophageal squamous cell carcinomas (ESCCs). To explore the potential utility of <b style='color:Tomato;'><i>lapatinib</i></b> for therapy of ESCC patients, we evaluated the effect of <b style='color:Tomato;'><i>lapatinib</i></b> on a panel of ESCC cell lines. EGFR and HER2 expression by the cell lines was established, and the effects of <b style='color:Tomato;'><i>lapatinib</i></b> on inhibition of the phosphorylation of HER2, antiproliferative effect, apoptosis-inducing activity and accumulation of HER2 and EGFR on cell surface were evaluated. <b style='color:DodgerBlue;'><i>Additionally</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Lapatinib</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>Herceptin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>Cetuximab</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>cell-mediated</i></b> <b style='color:DodgerBlue;'><i>cytotoxicity</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>lapatinib</i></b> inhibited HER2 phosphorylation in HER2-overexpressing, HER2 gene amplification positive ESCC cell line. <b style='color:Tomato;'><i>lapatinib</i></b> also inhibited cell proliferation, induced apoptosis and caused the surface accumulation of HER2 and EGFR in ESCC cell lines. Addition of <b style='color:Tomato;'><i>lapatinib</i></b> increased Herceptin-mediated antibody-dependent cell-mediated cytotoxicity by 15-25% with three ESCC target cell lines. Similarly, <b style='color:Tomato;'><i>cetuximab</i></b>-mediated antibody-dependent cell-mediated cytotoxicity also increased by 15-30% in two ESCC cell lines on addition of <b style='color:Tomato;'><i>lapatinib</i></b>. Cumulatively, the data indicate that <b style='color:Tomato;'><i>lapatinib</i></b> has activity in EGFR- and/or HER2-expressing ESCC cells, and the combination therapy of <b style='color:Tomato;'><i>lapatinib</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>/Herceptin is a promising strategy in ESCC.","tokens":[{"text":"Additionally","start":0,"end":12,"id":0,"ws":true},{"text":",","start":13,"end":14,"id":1,"ws":true},{"text":"the","start":15,"end":18,"id":2,"ws":true},{"text":"combined","start":19,"end":27,"id":3,"ws":true},{"text":"effect","start":28,"end":34,"id":4,"ws":true},{"text":"of","start":35,"end":37,"id":5,"ws":true},{"text":"Lapatinib","start":38,"end":47,"id":6,"ws":true},{"text":"together","start":48,"end":56,"id":7,"ws":true},{"text":"with","start":57,"end":61,"id":8,"ws":true},{"text":"Herceptin","start":62,"end":71,"id":9,"ws":true},{"text":"or","start":72,"end":74,"id":10,"ws":true},{"text":"Cetuximab","start":75,"end":84,"id":11,"ws":true},{"text":"on","start":85,"end":87,"id":12,"ws":true},{"text":"cell-mediated","start":88,"end":101,"id":13,"ws":true},{"text":"cytotoxicity","start":102,"end":114,"id":14,"ws":true},{"text":"was","start":115,"end":118,"id":15,"ws":true},{"text":"evaluated","start":119,"end":128,"id":16,"ws":true},{"text":".","start":129,"end":130,"id":17,"ws":false}],"spans":[{"start":38,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},{"start":62,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},{"start":75,"end":84,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21207425/","_input_hash":-45206025,"_task_hash":-1333586876,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":6,"child":9,"head_span":{"start":38,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":62,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":6,"child":11,"head_span":{"start":38,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":75,"end":84,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"In a case-control study , we compared 52 consecutive patients undergoing isolated CABG on aspirin and clopidogrel 75mg/d versus 50 controls on aspirin monotherapy .","paragraph":"<h3><u>Preoperative platelet aggregation predicts perioperative blood loss and rethoracotomy for bleeding in patients receiving dual antiplatelet treatment prior to coronary surgery.</u></h3>Patients scheduled for coronary artery bypass graft surgery (CABG) are commonly treated with <b style='color:Tomato;'><i>clopidogrel</i></b>. We sought to assess the relation between preoperative platelet aggregation and bleeds in CABG patients on <b style='color:Tomato;'><i>clopidogrel</i></b>. ### Material And Methods <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>case-control</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>52</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>undergoing</i></b> <b style='color:DodgerBlue;'><i>isolated</i></b> <b style='color:DodgerBlue;'><i>CABG</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>75mg/d</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>controls</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Platelet aggregation induced by 10\u03bcmol/l adenosine di-phosphate (ADP) in platelet-rich plasma was measured in subjects on <b style='color:Tomato;'><i>clopidogrel</i></b> within 5days prior to surgery. ADP-induced aggregation of \u226550% was used to define subjects with satisfactory inhibition of platelet reactivity. ### results In 29 patients with preoperative ADP-induced aggregation \u226550%, compared with 23 subjects with aggregation <50%, lower chest-tube drainage volumes (after 6h, p=0.002; and 12h, p=0.001) and fewer rethoracotomies were observed (p=0.03). The former group was characterized with lower transfusion rates of packed red blood cells (p=0.009), platelet concentrate (p=0.04) and fresh frozen plasma (p=0.001). Patients with ADP-induced aggregation \u226550% did not differ from untreated controls regarding the postoperative drainage, transfusions and rethoracotomy. The incidence of thromboembolic events and death during perioperative period were similar in all groups. Multivariate logistic regression identified ADP-induced aggregation <50% as the only independent predictor of rethoracotomy (OR=2.94 [1.12-7.75], p=0.029). ### conclusions Patients on <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> <5days before CABG who had preoperative ADP-induced platelet aggregation \u226550% have bleeding risk similar to those receiving <b style='color:Tomato;'><i>aspirin</i></b> monotherapy. Reduced platelet reactivity to ADP can predict postoperative bleeding in CABG patients on dual antiplatelet therapy.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"a","start":3,"end":4,"id":1,"ws":true},{"text":"case-control","start":5,"end":17,"id":2,"ws":true},{"text":"study","start":18,"end":23,"id":3,"ws":true},{"text":",","start":24,"end":25,"id":4,"ws":true},{"text":"we","start":26,"end":28,"id":5,"ws":true},{"text":"compared","start":29,"end":37,"id":6,"ws":true},{"text":"52","start":38,"end":40,"id":7,"ws":true},{"text":"consecutive","start":41,"end":52,"id":8,"ws":true},{"text":"patients","start":53,"end":61,"id":9,"ws":true},{"text":"undergoing","start":62,"end":72,"id":10,"ws":true},{"text":"isolated","start":73,"end":81,"id":11,"ws":true},{"text":"CABG","start":82,"end":86,"id":12,"ws":true},{"text":"on","start":87,"end":89,"id":13,"ws":true},{"text":"aspirin","start":90,"end":97,"id":14,"ws":true},{"text":"and","start":98,"end":101,"id":15,"ws":true},{"text":"clopidogrel","start":102,"end":113,"id":16,"ws":true},{"text":"75mg/d","start":114,"end":120,"id":17,"ws":true},{"text":"versus","start":121,"end":127,"id":18,"ws":true},{"text":"50","start":128,"end":130,"id":19,"ws":true},{"text":"controls","start":131,"end":139,"id":20,"ws":true},{"text":"on","start":140,"end":142,"id":21,"ws":true},{"text":"aspirin","start":143,"end":150,"id":22,"ws":true},{"text":"monotherapy","start":151,"end":162,"id":23,"ws":true},{"text":".","start":163,"end":164,"id":24,"ws":false}],"spans":[{"start":90,"end":97,"token_start":14,"token_end":14,"label":"DRUG"},{"start":102,"end":113,"token_start":16,"token_end":16,"label":"DRUG"},{"start":143,"end":150,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26003782/","_input_hash":-891249684,"_task_hash":1955769063,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":90,"end":97,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":102,"end":113,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"The MBCs were 1 to 2 tubes higher than the broth dilution MICs for levofloxacin , 1 to 3 tubes higher than the broth dilution MICs for ofloxacin , 1 to 3 tubes higher than the broth dilution MICs for erythromycin , and the same as the broth dilution MICs for rifampin .","paragraph":"<h3><u>Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.</u></h3>The susceptibilities of 56 Legionella pneumophila isolates (43 clinical and 15 environmental isolates) to <b style='color:Tomato;'><i>levofloxacin</i></b>, ofloxacin, <b style='color:Tomato;'><i>erythromycin</i></b>, and <b style='color:Tomato;'><i>rifampin</i></b> were studied with buffered charcoal yeast extract (BCYE) agar (inoculum, 10(4) CFU per spot), and the susceptibilities of five isolates were studied with buffered yeast extract (BYE) broth (inoculum, 10(5) CFU/ml). The MICs inhibiting 90% of strains tested on BCYE agar were 0.125, 0.25, 1.0, and < or = 0.004 micrograms/ml for <b style='color:Tomato;'><i>levofloxacin</i></b>, ofloxacin, <b style='color:Tomato;'><i>erythromycin</i></b>, and <b style='color:Tomato;'><i>rifampin</i></b>, respectively. The MICs by the BYE broth dilution method were 1 to 3, 2, 1 to 2, and 1 tube lower than those by the agar dilution method for <b style='color:Tomato;'><i>levofloxacin</i></b>, ofloxacin, <b style='color:Tomato;'><i>erythromycin</i></b>, and <b style='color:Tomato;'><i>rifampin</i></b>, respectively. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>MBCs</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>tubes</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>tubes</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>ofloxacin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>tubes</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>erythromycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>rifampin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In kinetic time-kill curve studies, at drug concentrations of 1.0 and 2.0 times the MIC, the most active drugs were <b style='color:Tomato;'><i>levofloxacin</i></b> and <b style='color:Tomato;'><i>rifampin</i></b>. At 72 h, concentrations of <b style='color:Tomato;'><i>levofloxacin</i></b> and <b style='color:Tomato;'><i>rifampin</i></b> of 2.0 times the MIC demonstrated a bactericidal effect against L. pneumophila. In contrast, at concentrations of 1.0 and 2.0 times the MICs regrowth was observed with ofloxacin and only a gradual decrease in the numbers of CFU per milliliter was observed with <b style='color:Tomato;'><i>erythromycin</i></b>. Only a minor inhibitory effect was observed with 0.25 or 0.5 time the MICs of all drugs at 24 to 48 h, with regrowth occurring at 72 h. In contrast to <b style='color:Tomato;'><i>erythromycin</i></b> or ofloxacin plus <b style='color:Tomato;'><i>rifampin</i></b> at 0.25 time the MICs, only <b style='color:Tomato;'><i>levofloxacin</i></b> plus <b style='color:Tomato;'><i>rifampin</i></b> demonstrated synergy. Thus, <b style='color:Tomato;'><i>levofloxacin</i></b> demonstrated the best inhibitory and bactericidal effects against L. pneumophila when it was studied alone or in a combination with <b style='color:Tomato;'><i>rifampin</i></b>.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"MBCs","start":4,"end":8,"id":1,"ws":true},{"text":"were","start":9,"end":13,"id":2,"ws":true},{"text":"1","start":14,"end":15,"id":3,"ws":true},{"text":"to","start":16,"end":18,"id":4,"ws":true},{"text":"2","start":19,"end":20,"id":5,"ws":true},{"text":"tubes","start":21,"end":26,"id":6,"ws":true},{"text":"higher","start":27,"end":33,"id":7,"ws":true},{"text":"than","start":34,"end":38,"id":8,"ws":true},{"text":"the","start":39,"end":42,"id":9,"ws":true},{"text":"broth","start":43,"end":48,"id":10,"ws":true},{"text":"dilution","start":49,"end":57,"id":11,"ws":true},{"text":"MICs","start":58,"end":62,"id":12,"ws":true},{"text":"for","start":63,"end":66,"id":13,"ws":true},{"text":"levofloxacin","start":67,"end":79,"id":14,"ws":true},{"text":",","start":80,"end":81,"id":15,"ws":true},{"text":"1","start":82,"end":83,"id":16,"ws":true},{"text":"to","start":84,"end":86,"id":17,"ws":true},{"text":"3","start":87,"end":88,"id":18,"ws":true},{"text":"tubes","start":89,"end":94,"id":19,"ws":true},{"text":"higher","start":95,"end":101,"id":20,"ws":true},{"text":"than","start":102,"end":106,"id":21,"ws":true},{"text":"the","start":107,"end":110,"id":22,"ws":true},{"text":"broth","start":111,"end":116,"id":23,"ws":true},{"text":"dilution","start":117,"end":125,"id":24,"ws":true},{"text":"MICs","start":126,"end":130,"id":25,"ws":true},{"text":"for","start":131,"end":134,"id":26,"ws":true},{"text":"ofloxacin","start":135,"end":144,"id":27,"ws":true},{"text":",","start":145,"end":146,"id":28,"ws":true},{"text":"1","start":147,"end":148,"id":29,"ws":true},{"text":"to","start":149,"end":151,"id":30,"ws":true},{"text":"3","start":152,"end":153,"id":31,"ws":true},{"text":"tubes","start":154,"end":159,"id":32,"ws":true},{"text":"higher","start":160,"end":166,"id":33,"ws":true},{"text":"than","start":167,"end":171,"id":34,"ws":true},{"text":"the","start":172,"end":175,"id":35,"ws":true},{"text":"broth","start":176,"end":181,"id":36,"ws":true},{"text":"dilution","start":182,"end":190,"id":37,"ws":true},{"text":"MICs","start":191,"end":195,"id":38,"ws":true},{"text":"for","start":196,"end":199,"id":39,"ws":true},{"text":"erythromycin","start":200,"end":212,"id":40,"ws":true},{"text":",","start":213,"end":214,"id":41,"ws":true},{"text":"and","start":215,"end":218,"id":42,"ws":true},{"text":"the","start":219,"end":222,"id":43,"ws":true},{"text":"same","start":223,"end":227,"id":44,"ws":true},{"text":"as","start":228,"end":230,"id":45,"ws":true},{"text":"the","start":231,"end":234,"id":46,"ws":true},{"text":"broth","start":235,"end":240,"id":47,"ws":true},{"text":"dilution","start":241,"end":249,"id":48,"ws":true},{"text":"MICs","start":250,"end":254,"id":49,"ws":true},{"text":"for","start":255,"end":258,"id":50,"ws":true},{"text":"rifampin","start":259,"end":267,"id":51,"ws":true},{"text":".","start":268,"end":269,"id":52,"ws":false}],"spans":[{"start":67,"end":79,"token_start":14,"token_end":14,"label":"DRUG"},{"start":200,"end":212,"token_start":40,"token_end":40,"label":"DRUG"},{"start":259,"end":267,"token_start":51,"token_end":51,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7486896/","_input_hash":2130824282,"_task_hash":-706415713,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":14,"child":51,"head_span":{"start":67,"end":79,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":259,"end":267,"token_start":51,"token_end":51,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":14,"child":40,"head_span":{"start":67,"end":79,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":200,"end":212,"token_start":40,"token_end":40,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["POS11","NEG11"],"answer":"accept"}
{"text":"Ketanserin ( a 5-HT2 antagonist , 10 mumol/L ) and tropisetron ( a 5-HT3 antagonist , 1 mumol/L ) had no effect .","paragraph":"<h3><u>Ketotifen modulates noncholinergic contraction in guinea pig airways in vitro by a prejunctional nonhistamine receptor.</u></h3>In guinea pig airways, electrical field stimulation (50 V, 0.5 msec, 8 Hz for 20 seconds) produces a rapid contraction, which is followed by a long-lasting contraction, at least in the lower part of the trachea and in the bronchi. The latter contraction is due to the release of neuropeptides from airway sensory nerves. <b style='color:Tomato;'><i>ketotifen</i></b> fumarate has been demonstrated to inhibit the noncholinergic contraction in guinea pig airways in vitro, but no attempt has been made to identify the receptor type. Therefore we have performed an in vitro study to investigate which receptor is responsible for the inhibitory effects of <b style='color:Tomato;'><i>ketotifen</i></b> on noncholinergic contraction in guinea pig airways. <b style='color:Tomato;'><i>ketotifen</i></b> (3 to 100 mumol/L) produced a concentration-dependent inhibition of the noncholinergic contraction, with a maximum inhibition of 74% +/- 7% at 8 Hz stimulation (p < 0.001; n = 5). Pretreatment of the tissues with either <b style='color:Tomato;'><i>cimetidine</i></b> (10 mumol/L) or thioperamide (10 mumol/L) or <b style='color:Tomato;'><i>phentolamine</i></b> (10 mumol/L) did not prevent the inhibitory effect of <b style='color:Tomato;'><i>ketotifen</i></b> (10 mumol/L). <b style='color:Tomato;'><i>cetirizine</i></b> (10 mumol/L), on the other hand, produced no inhibition of the noncholinergic contraction at all. Metitepine (0.1 mumol/L) and <b style='color:Tomato;'><i>methysergide</i></b> (1 mumol/L), both 5-HT1 antagonists, attenuated the inhibitory effect of <b style='color:Tomato;'><i>ketotifen</i></b> (10 mumol/L). <b style='color:MediumOrchid;'><i>Ketanserin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>5-HT2</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mumol/L</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tropisetron</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>5-HT3</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>mumol/L</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ketoifen (100 mumol/L) did not affect the cumulative dose-response relationship to exogenous substance P (0.01 mumol/L to 10 mmol/L).(ABSTRACT TRUNCATED AT 250 WORDS)","tokens":[{"text":"Ketanserin","start":0,"end":10,"id":0,"ws":true},{"text":"(","start":11,"end":12,"id":1,"ws":true},{"text":"a","start":13,"end":14,"id":2,"ws":true},{"text":"5-HT2","start":15,"end":20,"id":3,"ws":true},{"text":"antagonist","start":21,"end":31,"id":4,"ws":true},{"text":",","start":32,"end":33,"id":5,"ws":true},{"text":"10","start":34,"end":36,"id":6,"ws":true},{"text":"mumol/L","start":37,"end":44,"id":7,"ws":true},{"text":")","start":45,"end":46,"id":8,"ws":true},{"text":"and","start":47,"end":50,"id":9,"ws":true},{"text":"tropisetron","start":51,"end":62,"id":10,"ws":true},{"text":"(","start":63,"end":64,"id":11,"ws":true},{"text":"a","start":65,"end":66,"id":12,"ws":true},{"text":"5-HT3","start":67,"end":72,"id":13,"ws":true},{"text":"antagonist","start":73,"end":83,"id":14,"ws":true},{"text":",","start":84,"end":85,"id":15,"ws":true},{"text":"1","start":86,"end":87,"id":16,"ws":true},{"text":"mumol/L","start":88,"end":95,"id":17,"ws":true},{"text":")","start":96,"end":97,"id":18,"ws":true},{"text":"had","start":98,"end":101,"id":19,"ws":true},{"text":"no","start":102,"end":104,"id":20,"ws":true},{"text":"effect","start":105,"end":111,"id":21,"ws":true},{"text":".","start":112,"end":113,"id":22,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":51,"end":62,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8064073/","_input_hash":302106594,"_task_hash":-1626692204,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"This three-phase study was designed to determine if a pharmacokinetic drug-drug interaction exists between zidovudine and oxazepam .","paragraph":"<h3><u>Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient.</u></h3> <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>three-phase</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>designed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>if</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>drug-drug</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>exists</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>zidovudine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxazepam</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Six individuals infected with human immunodeficiency virus (HIV) and receiving <b style='color:Tomato;'><i>zidovudine</i></b> at 500 mg daily, with normal renal and hepatic function, were enrolled. During phase I, <b style='color:Tomato;'><i>zidovudine</i></b> pharmacokinetics were studied after steady-state oral administration (100 mg every 4 h) and after a single dose (70 mg) of intravenous <b style='color:Tomato;'><i>zidovudine</i></b>. Phase II consisted of a single oral dose (30 mg) of <b style='color:Tomato;'><i>oxazepam</i></b> followed by a 48-h blood sampling period. Phase III began with 48 h of concomitant <b style='color:Tomato;'><i>zidovudine</i></b>, 100 mg orally every 4 h, and <b style='color:Tomato;'><i>oxazepam</i></b>, 15 mg orally every 8 h, followed by concomitant dosing of intravenous <b style='color:Tomato;'><i>zidovudine</i></b> and oral <b style='color:Tomato;'><i>oxazepam</i></b>. <b style='color:Tomato;'><i>zidovudine</i></b> concentrations were determined by radioimmunoassay. <b style='color:Tomato;'><i>oxazepam</i></b> concentrations were determined with use of a fluorescence polarization immunoassay. The calculated bioavailability was 0.61 for <b style='color:Tomato;'><i>zidovudine</i></b> alone and 0.75 when administered in combination with <b style='color:Tomato;'><i>oxazepam</i></b> (p = 0.16). Plasma half-life for oral <b style='color:Tomato;'><i>zidovudine</i></b> alone and in combination with <b style='color:Tomato;'><i>oxazepam</i></b> was 1.17 h versus 0.99 h, respectively (p = 0.25), and 1.38 h versus 1.15 h (p = 0.38) for intravenous <b style='color:Tomato;'><i>zidovudine</i></b> during single and combination therapy, respectively. Total body clearance of <b style='color:Tomato;'><i>zidovudine</i></b> was not significantly altered by <b style='color:Tomato;'><i>oxazepam</i></b> (93 L/h vs. 109 L/h, p = 0.16). The mean pharmacokinetic parameters determined for a single 30-mg dose of <b style='color:Tomato;'><i>oxazepam</i></b> for oral clearance, apparent volume of distribution, and plasma half-life were 9.8 L/h, 65.7 L, and 5.1 h, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"three-phase","start":5,"end":16,"id":1,"ws":true},{"text":"study","start":17,"end":22,"id":2,"ws":true},{"text":"was","start":23,"end":26,"id":3,"ws":true},{"text":"designed","start":27,"end":35,"id":4,"ws":true},{"text":"to","start":36,"end":38,"id":5,"ws":true},{"text":"determine","start":39,"end":48,"id":6,"ws":true},{"text":"if","start":49,"end":51,"id":7,"ws":true},{"text":"a","start":52,"end":53,"id":8,"ws":true},{"text":"pharmacokinetic","start":54,"end":69,"id":9,"ws":true},{"text":"drug-drug","start":70,"end":79,"id":10,"ws":true},{"text":"interaction","start":80,"end":91,"id":11,"ws":true},{"text":"exists","start":92,"end":98,"id":12,"ws":true},{"text":"between","start":99,"end":106,"id":13,"ws":true},{"text":"zidovudine","start":107,"end":117,"id":14,"ws":true},{"text":"and","start":118,"end":121,"id":15,"ws":true},{"text":"oxazepam","start":122,"end":130,"id":16,"ws":true},{"text":".","start":131,"end":132,"id":17,"ws":false}],"spans":[{"start":107,"end":117,"token_start":14,"token_end":14,"label":"DRUG"},{"start":122,"end":130,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8417175/","_input_hash":-1195466658,"_task_hash":-883831583,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"Patients with apical CFTR protein showed higher residual chloride secretion than those without ( amiloride to isoprenaline value of 4.59 and 0.56 mV , respectively , p = 0.01 ) .","paragraph":"<h3><u>Correlation between nasal potential difference measurements, genotype and clinical condition in patients with cystic fibrosis.</u></h3>In cystic fibrosis (CF), the clinical condition of patients correlates poorly with genotype. One possible explanation is that clinical status is influenced by net preserved chloride secretion rather than the CF mutation. We tested the relationships between residual chloride secretion, as measured by nasal potential difference (PD) and the type of mutation (genotypes expressing apical cystic fibrosis transmembrane conductance regulator (CFTR) protein versus those that do not) and clinical status. Twenty two CF patients (mean age 25.7 yrs, 11 females and 11 males, mean forced expiratory volume in one second (FEV1) 53.1% of predicted) with defined genotypes were recruited. Nasal PD was measured using a standard protocol involving the perfusion of the nasal epithelium with a sodium channel blocker (<b style='color:Tomato;'><i>amiloride</i></b>), followed by a solution of low chloride and finally with <b style='color:Tomato;'><i>isoprenaline</i></b>. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>apical</i></b> <b style='color:DodgerBlue;'><i>CFTR</i></b> <b style='color:DodgerBlue;'><i>protein</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>residual</i></b> <b style='color:DodgerBlue;'><i>chloride</i></b> <b style='color:DodgerBlue;'><i>secretion</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>amiloride</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>isoprenaline</i></b> <b style='color:DodgerBlue;'><i>value</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>4.59</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.56</i></b> <b style='color:DodgerBlue;'><i>mV</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.01</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There was no correlation between mutation type and clinical condition. When these patients were recategorized as \"high\" (> 10 mV <b style='color:Tomato;'><i>amiloride</i></b> to <b style='color:Tomato;'><i>isoprenaline</i></b> response) or \"low\" (10 mV or less) chloride secretors, we found that the former group had a significantly higher FEV1 (67.7 versus 48.3% pred) and a better pulmonary radiological score (4.14 versus 7.07, by Northern scoring system). These results suggest that some cystic fibrosis patients, regardless of genotype, have an ability to secrete chloride when stimulated with chloride secretatagogues, and this is correlated with a better lung function. These results also have implications for the use of potential difference measurements in novel cystic fibrosis transmembrane conductance regulator replacement trials.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"with","start":9,"end":13,"id":1,"ws":true},{"text":"apical","start":14,"end":20,"id":2,"ws":true},{"text":"CFTR","start":21,"end":25,"id":3,"ws":true},{"text":"protein","start":26,"end":33,"id":4,"ws":true},{"text":"showed","start":34,"end":40,"id":5,"ws":true},{"text":"higher","start":41,"end":47,"id":6,"ws":true},{"text":"residual","start":48,"end":56,"id":7,"ws":true},{"text":"chloride","start":57,"end":65,"id":8,"ws":true},{"text":"secretion","start":66,"end":75,"id":9,"ws":true},{"text":"than","start":76,"end":80,"id":10,"ws":true},{"text":"those","start":81,"end":86,"id":11,"ws":true},{"text":"without","start":87,"end":94,"id":12,"ws":true},{"text":"(","start":95,"end":96,"id":13,"ws":true},{"text":"amiloride","start":97,"end":106,"id":14,"ws":true},{"text":"to","start":107,"end":109,"id":15,"ws":true},{"text":"isoprenaline","start":110,"end":122,"id":16,"ws":true},{"text":"value","start":123,"end":128,"id":17,"ws":true},{"text":"of","start":129,"end":131,"id":18,"ws":true},{"text":"4.59","start":132,"end":136,"id":19,"ws":true},{"text":"and","start":137,"end":140,"id":20,"ws":true},{"text":"0.56","start":141,"end":145,"id":21,"ws":true},{"text":"mV","start":146,"end":148,"id":22,"ws":true},{"text":",","start":149,"end":150,"id":23,"ws":true},{"text":"respectively","start":151,"end":163,"id":24,"ws":true},{"text":",","start":164,"end":165,"id":25,"ws":true},{"text":"p","start":166,"end":167,"id":26,"ws":true},{"text":"=","start":168,"end":169,"id":27,"ws":true},{"text":"0.01","start":170,"end":174,"id":28,"ws":true},{"text":")","start":175,"end":176,"id":29,"ws":true},{"text":".","start":177,"end":178,"id":30,"ws":false}],"spans":[{"start":97,"end":106,"token_start":14,"token_end":14,"label":"DRUG"},{"start":110,"end":122,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9311495/","_input_hash":637326166,"_task_hash":23831742,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":97,"end":106,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":110,"end":122,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"African American men were more likely to receive ketoconazole than abiraterone , enzalutamide , or docetaxel ( AME , 2.8 % ; 95 % CI , 0.7%-4.9 % ) .","paragraph":"<h3><u>Factors influencing treatment of veterans with advanced prostate cancer.</u></h3>Treatments for metastatic castration-resistant prostate cancer (CRPC) differ in toxicity, administration, and evidence. In this study, clinical and nonclinical factors associated with the first-line treatment for CRPC in a national delivery system were evaluated. ### methods National electronic laboratory and clinical data from the Veterans Health Administration were used to identify patients with CRPC (ie, rising prostate-specific antigen [PSA] on androgen deprivation) who received <b style='color:Tomato;'><i>abiraterone</i></b>, <b style='color:Tomato;'><i>enzalutamide</i></b>, <b style='color:Tomato;'><i>docetaxel</i></b>, or <b style='color:Tomato;'><i>ketoconazole</i></b> from 2010 through 2017. It was determined whether clinical (eg, PSA) and nonclinical factors (eg, race, facility) were associated with the first-line treatment selection using multilevel, multinomial logistic regression. The average marginal effects (AMEs) were calculated of patient, disease, and facility characteristics on <b style='color:Tomato;'><i>ketoconazole</i></b> versus more appropriate CRPC therapy. ### results There were 4998 patients identified with CRPC who received first-line <b style='color:Tomato;'><i>ketoconazole</i></b>, <b style='color:Tomato;'><i>docetaxel</i></b>, <b style='color:Tomato;'><i>abiraterone</i></b>, or <b style='color:Tomato;'><i>enzalutamide</i></b>. After adjustment, increasing age was associated with receipt of <b style='color:Tomato;'><i>abiraterone</i></b> (adjusted odds ratio [aOR], 1.07; 95% credible interval [CrI], 1.06-1.09) or <b style='color:Tomato;'><i>enzalutamide</i></b> (aOR, 1.10; 95% CrI, 1.08-1.11) versus <b style='color:Tomato;'><i>docetaxel</i></b>. Greater preexisting comorbidity was associated with <b style='color:Tomato;'><i>enzalutamide</i></b> versus <b style='color:Tomato;'><i>abiraterone</i></b> (aOR, 1.53; 95% CrI, 1.23-1.91). Patients with higher PSA values at the start of treatment were more likely to receive <b style='color:Tomato;'><i>docetaxel</i></b> than oral agents and less likely to receive <b style='color:Tomato;'><i>ketoconazole</i></b> than other oral agents. <b style='color:DodgerBlue;'><i>African</i></b> <b style='color:DodgerBlue;'><i>American</i></b> <b style='color:DodgerBlue;'><i>men</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>likely</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:MediumOrchid;'><i>ketoconazole</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AME</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>2.8</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>95</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>CI</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>0.7%-4.9</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This effect was attenuated when adjusting for facility characteristics (AME, 1.9%; 95% CI, -0.4% to 4.1%). ### conclusions Clinical factors had an expected effect on the first-line treatment selection. Race may be associated with the receipt of a guideline-discordant first-line treatment.","tokens":[{"text":"African","start":0,"end":7,"id":0,"ws":true},{"text":"American","start":8,"end":16,"id":1,"ws":true},{"text":"men","start":17,"end":20,"id":2,"ws":true},{"text":"were","start":21,"end":25,"id":3,"ws":true},{"text":"more","start":26,"end":30,"id":4,"ws":true},{"text":"likely","start":31,"end":37,"id":5,"ws":true},{"text":"to","start":38,"end":40,"id":6,"ws":true},{"text":"receive","start":41,"end":48,"id":7,"ws":true},{"text":"ketoconazole","start":49,"end":61,"id":8,"ws":true},{"text":"than","start":62,"end":66,"id":9,"ws":true},{"text":"abiraterone","start":67,"end":78,"id":10,"ws":true},{"text":",","start":79,"end":80,"id":11,"ws":true},{"text":"enzalutamide","start":81,"end":93,"id":12,"ws":true},{"text":",","start":94,"end":95,"id":13,"ws":true},{"text":"or","start":96,"end":98,"id":14,"ws":true},{"text":"docetaxel","start":99,"end":108,"id":15,"ws":true},{"text":"(","start":109,"end":110,"id":16,"ws":true},{"text":"AME","start":111,"end":114,"id":17,"ws":true},{"text":",","start":115,"end":116,"id":18,"ws":true},{"text":"2.8","start":117,"end":120,"id":19,"ws":true},{"text":"%","start":121,"end":122,"id":20,"ws":true},{"text":";","start":123,"end":124,"id":21,"ws":true},{"text":"95","start":125,"end":127,"id":22,"ws":true},{"text":"%","start":128,"end":129,"id":23,"ws":true},{"text":"CI","start":130,"end":132,"id":24,"ws":true},{"text":",","start":133,"end":134,"id":25,"ws":true},{"text":"0.7%-4.9","start":135,"end":143,"id":26,"ws":true},{"text":"%","start":144,"end":145,"id":27,"ws":true},{"text":")","start":146,"end":147,"id":28,"ws":true},{"text":".","start":148,"end":149,"id":29,"ws":false}],"spans":[{"start":49,"end":61,"token_start":8,"token_end":8,"label":"DRUG"},{"start":67,"end":78,"token_start":10,"token_end":10,"label":"DRUG"},{"start":81,"end":93,"token_start":12,"token_end":12,"label":"DRUG"},{"start":99,"end":108,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33764537/","_input_hash":-986323573,"_task_hash":-904230234,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"These observations are important in the development of vorinostat , and may have clinical implications on other cancer and noncancer drugs that are UGT2B17 substrates such as exemestane and ibuprofen .","paragraph":"<h3><u>Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.</u></h3><b style='color:Tomato;'><i>vorinostat</i></b>, a histone deacetylase inhibitor being actively evaluated in solid tumors, is metabolized by UGT2B17. UGT2B17 null genotype (UGT2B17*2) has been shown in vitro to reduce UGT2B17 activity. This variant is common in Asians but rare in Caucasians, and we studied its impact on <b style='color:Tomato;'><i>vorinostat</i></b> pharmacokinetics and pharmacodynamics in a clinical study in Asian patients with metastatic breast cancer. ### methods Eligible patients received 400 mg of <b style='color:Tomato;'><i>vorinostat</i></b> monotherapy daily in a lead-in phase I followed by a phase II study. Patients were genotyped for UGT2B17*2, which was correlated with <b style='color:Tomato;'><i>vorinostat</i></b> pharmacokinetics and clinical outcomes. ### results Twenty-six patients were treated with no complete response, one partial response, six stable disease lasting for 12 weeks or more, and 19 progressive disease. Sixteen patients (62%) were UGT2B17*2 homozygotes and had significantly lower mean area under the curve ratio of <b style='color:Tomato;'><i>vorinostat</i></b>-O-glucuronide/<b style='color:Tomato;'><i>vorinostat</i></b> (1.84 vs. 2.51 on day 1, P=0.02; 1.63 vs. 2.38 on day 15, P=0.028), and trended toward having higher <b style='color:Tomato;'><i>vorinostat</i></b> area under the curve (399.02 vs. 318.40, P=0.188), more serious adverse events (31 vs. 0%, P=0.121), higher clinical benefit rate (40 vs. 10%, P=0.179), and longer median progression-free survival (3.0 vs. 1.5 months, P=0.087) than patients with at least one wild-type allele. ### conclusion UGT2B17*2 genotype reduces <b style='color:Tomato;'><i>vorinostat</i></b> glucuronidation and may increase <b style='color:Tomato;'><i>vorinostat</i></b> efficacy and toxicity. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>observations</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>important</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>development</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vorinostat</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>implications</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>noncancer</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>UGT2B17</i></b> <b style='color:DodgerBlue;'><i>substrates</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ibuprofen</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"observations","start":6,"end":18,"id":1,"ws":true},{"text":"are","start":19,"end":22,"id":2,"ws":true},{"text":"important","start":23,"end":32,"id":3,"ws":true},{"text":"in","start":33,"end":35,"id":4,"ws":true},{"text":"the","start":36,"end":39,"id":5,"ws":true},{"text":"development","start":40,"end":51,"id":6,"ws":true},{"text":"of","start":52,"end":54,"id":7,"ws":true},{"text":"vorinostat","start":55,"end":65,"id":8,"ws":true},{"text":",","start":66,"end":67,"id":9,"ws":true},{"text":"and","start":68,"end":71,"id":10,"ws":true},{"text":"may","start":72,"end":75,"id":11,"ws":true},{"text":"have","start":76,"end":80,"id":12,"ws":true},{"text":"clinical","start":81,"end":89,"id":13,"ws":true},{"text":"implications","start":90,"end":102,"id":14,"ws":true},{"text":"on","start":103,"end":105,"id":15,"ws":true},{"text":"other","start":106,"end":111,"id":16,"ws":true},{"text":"cancer","start":112,"end":118,"id":17,"ws":true},{"text":"and","start":119,"end":122,"id":18,"ws":true},{"text":"noncancer","start":123,"end":132,"id":19,"ws":true},{"text":"drugs","start":133,"end":138,"id":20,"ws":true},{"text":"that","start":139,"end":143,"id":21,"ws":true},{"text":"are","start":144,"end":147,"id":22,"ws":true},{"text":"UGT2B17","start":148,"end":155,"id":23,"ws":true},{"text":"substrates","start":156,"end":166,"id":24,"ws":true},{"text":"such","start":167,"end":171,"id":25,"ws":true},{"text":"as","start":172,"end":174,"id":26,"ws":true},{"text":"exemestane","start":175,"end":185,"id":27,"ws":true},{"text":"and","start":186,"end":189,"id":28,"ws":true},{"text":"ibuprofen","start":190,"end":199,"id":29,"ws":true},{"text":".","start":200,"end":201,"id":30,"ws":false}],"spans":[{"start":55,"end":65,"token_start":8,"token_end":8,"label":"DRUG"},{"start":175,"end":185,"token_start":27,"token_end":27,"label":"DRUG"},{"start":190,"end":199,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21849928/","_input_hash":1897274692,"_task_hash":1201564489,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"Additional results from MTT cell viability assays demonstrated that H1975 cell proliferation was not significantly decreased after Wnt inhibition by XAV939 , but combination treatment with everolimus ( mTOR inhibitor ) and erlotinib resulted in synergistic cell growth inhibition .","paragraph":"<h3><u>Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.</u></h3>Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when administered individually or in combination to non-small cell lung cancer (NSCLC) patients. However, the overall efficacies of TKIs are limited due to the development of drug resistance. Therefore, it is important to elucidate mechanisms of EGFR and c-Met TKI resistance in order to develop more effective therapies. Model NSCLC cell lines H1975 and H2170 were used to study the similarities and differences in mechanisms of EGFR/c-Met TKI resistance. H1975 cells are positive for the T790M EGFR mutation, which confers resistance to current EGFR TKI therapies, while H2170 cells are EGFR wild-type. Previously, H2170 cells were made resistant to the EGFR TKI <b style='color:Tomato;'><i>erlotinib</i></b> and the c-Met TKI SU11274 by exposure to progressively increasing concentrations of TKIs. In H2170 and H1975 TKI-resistant cells, key Wnt and mTOR proteins were found to be differentially modulated. Wnt signaling transducer, active \u03b2-catenin was upregulated in TKI-resistant H2170 cells when compared to parental cells. GATA-6, a transcriptional activator of Wnt, was also found to be upregulated in resistant H2170 cells. In H2170 <b style='color:Tomato;'><i>erlotinib</i></b> resistant cells, upregulation of inactive GSK3\u03b2 (p-GSK3\u03b2) was observed, indicating activation of Wnt and mTOR pathways which are otherwise inhibited by its active form. However, in H1975 cells, Wnt modulators such as active \u03b2-catenin, GATA-6 and p-GSK3\u03b2 were downregulated. <b style='color:DodgerBlue;'><i>Additional</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>MTT</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>viability</i></b> <b style='color:DodgerBlue;'><i>assays</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>H1975</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>proliferation</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>Wnt</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>XAV939</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mTOR</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Thus, in H2170 cells and H1975 cells, simultaneous inhibition of key Wnt or mTOR pathway proteins in addition to EGFR and c-Met may be a promising strategy for overcoming EGFR and c-Met TKI resistance in NSCLC patients.","tokens":[{"text":"Additional","start":0,"end":10,"id":0,"ws":true},{"text":"results","start":11,"end":18,"id":1,"ws":true},{"text":"from","start":19,"end":23,"id":2,"ws":true},{"text":"MTT","start":24,"end":27,"id":3,"ws":true},{"text":"cell","start":28,"end":32,"id":4,"ws":true},{"text":"viability","start":33,"end":42,"id":5,"ws":true},{"text":"assays","start":43,"end":49,"id":6,"ws":true},{"text":"demonstrated","start":50,"end":62,"id":7,"ws":true},{"text":"that","start":63,"end":67,"id":8,"ws":true},{"text":"H1975","start":68,"end":73,"id":9,"ws":true},{"text":"cell","start":74,"end":78,"id":10,"ws":true},{"text":"proliferation","start":79,"end":92,"id":11,"ws":true},{"text":"was","start":93,"end":96,"id":12,"ws":true},{"text":"not","start":97,"end":100,"id":13,"ws":true},{"text":"significantly","start":101,"end":114,"id":14,"ws":true},{"text":"decreased","start":115,"end":124,"id":15,"ws":true},{"text":"after","start":125,"end":130,"id":16,"ws":true},{"text":"Wnt","start":131,"end":134,"id":17,"ws":true},{"text":"inhibition","start":135,"end":145,"id":18,"ws":true},{"text":"by","start":146,"end":148,"id":19,"ws":true},{"text":"XAV939","start":149,"end":155,"id":20,"ws":true},{"text":",","start":156,"end":157,"id":21,"ws":true},{"text":"but","start":158,"end":161,"id":22,"ws":true},{"text":"combination","start":162,"end":173,"id":23,"ws":true},{"text":"treatment","start":174,"end":183,"id":24,"ws":true},{"text":"with","start":184,"end":188,"id":25,"ws":true},{"text":"everolimus","start":189,"end":199,"id":26,"ws":true},{"text":"(","start":200,"end":201,"id":27,"ws":true},{"text":"mTOR","start":202,"end":206,"id":28,"ws":true},{"text":"inhibitor","start":207,"end":216,"id":29,"ws":true},{"text":")","start":217,"end":218,"id":30,"ws":true},{"text":"and","start":219,"end":222,"id":31,"ws":true},{"text":"erlotinib","start":223,"end":232,"id":32,"ws":true},{"text":"resulted","start":233,"end":241,"id":33,"ws":true},{"text":"in","start":242,"end":244,"id":34,"ws":true},{"text":"synergistic","start":245,"end":256,"id":35,"ws":true},{"text":"cell","start":257,"end":261,"id":36,"ws":true},{"text":"growth","start":262,"end":268,"id":37,"ws":true},{"text":"inhibition","start":269,"end":279,"id":38,"ws":true},{"text":".","start":280,"end":281,"id":39,"ws":false}],"spans":[{"start":189,"end":199,"token_start":26,"token_end":26,"label":"DRUG"},{"start":223,"end":232,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26301867/","_input_hash":-1669066164,"_task_hash":1355258483,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":26,"child":32,"head_span":{"start":189,"end":199,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":223,"end":232,"token_start":32,"token_end":32,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Calcifediol was significantly lower in patients with morbid obesity ( for calcifediol , P < 0.05 ) .","paragraph":"<h3><u>Prevalence of exocrine pancreatic insufficiency in women with obesity syndrome: assessment by pancreatic fecal elastase 1.</u></h3>Background. Previous research on the combined association of 25-hydroxyvitamin D [25(OH)D] and exocrine pancreas insufficiency may have been limited by restricted age variability and a lack of representation of both body weight and body mass index. There are still too few conclusive reports about conspicuous vitamin D metabolism according to pancreatic fecal elastase 1 (FE1) in obese patients. Methods. Between May 2004 and July 2008, we investigated in 125 female patients with obesity syndrome at an average age of approximately 52.9 years as well as in age-matched 80 healthy female controls the prevalence of pancreas insufficiency. Serum levels of PTH, total calcium, and D(3) vitamins calcitriol and <b style='color:Tomato;'><i>calcifediol</i></b>, as well as the concentration of fecal elastase 1 (FE1) were determined in patients and controls. Results. In 75 female nondiabetic patients with obesity syndrome (BMI 35 \u2264 40\u2009kg/m(2)), <b style='color:Tomato;'><i>calcifediol</i></b> was markedly decreased (25.0 \u00b1 4.9\u2009ng/mL) compared to controls (50.2 \u00b1 14.7\u2009nmol/L; P < 0.01). FE1 level was significantly decreased in obese subjects compared to controls (\u00a0P < 0.01). <b style='color:MediumOrchid;'><i>Calcifediol</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>morbid</i></b> <b style='color:DodgerBlue;'><i>obesity</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>calcifediol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>0.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Conclusion. In obese females, pancreatic FE1 in feces confirms the extent of vitamin D supply, and thus shows a vitamin D(3) deficiency, depending on the loss of stool content. There seems to be a connection between the loss of exocrine function and the increasing body mass index. Pancreas insufficiency, as detected by low FE1 concentrations, is frequent in obese patients. However, the BMI is an additional factor for lowered fecal excretion of FE1.","tokens":[{"text":"Calcifediol","start":0,"end":11,"id":0,"ws":true},{"text":"was","start":12,"end":15,"id":1,"ws":true},{"text":"significantly","start":16,"end":29,"id":2,"ws":true},{"text":"lower","start":30,"end":35,"id":3,"ws":true},{"text":"in","start":36,"end":38,"id":4,"ws":true},{"text":"patients","start":39,"end":47,"id":5,"ws":true},{"text":"with","start":48,"end":52,"id":6,"ws":true},{"text":"morbid","start":53,"end":59,"id":7,"ws":true},{"text":"obesity","start":60,"end":67,"id":8,"ws":true},{"text":"(","start":68,"end":69,"id":9,"ws":true},{"text":"for","start":70,"end":73,"id":10,"ws":true},{"text":"calcifediol","start":74,"end":85,"id":11,"ws":true},{"text":",","start":86,"end":87,"id":12,"ws":true},{"text":"P","start":88,"end":89,"id":13,"ws":true},{"text":"<","start":90,"end":91,"id":14,"ws":true},{"text":"0.05","start":92,"end":96,"id":15,"ws":true},{"text":")","start":97,"end":98,"id":16,"ws":true},{"text":".","start":99,"end":100,"id":17,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":74,"end":85,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22111014/","_input_hash":-322297655,"_task_hash":-1749272829,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"The addition of dexmedetomidine to bupivacaine 0.5 % in EUS-CPN demonstrated beneficial effects as regards the degree and duration of pain relieve with negligible effect on the patient survival .","paragraph":"<h3><u>Value of Adding Dexmedetomidine in Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis for Treatment of Pancreatic Cancer-Associated Pain.</u></h3>Abdominal and back pain is present in up to 80% of patients with pancreatic cancer and represents a significant cause of morbidity. Celiac plexus neurolysis (CPN) demonstrated good results in relief of pain of upper abdominal malignancy. Dexme<b style='color:Tomato;'><i>detomidine</i></b> is alpha-2 adrenoceptor highly selective agonist approved for procedural sedation use. ### Patients And Methods Fifty patients divided in two groups with locally advanced pancreatic cancer-associated abdominal pain underwent endoscopic ultrasound (EUS)-guided CPN using <b style='color:Tomato;'><i>bupivacaine</i></b> 0.5% alone with alcohol for the first group and <b style='color:Tomato;'><i>bupivacaine</i></b> 0.5% plus dexme<b style='color:Tomato;'><i>detomidine</i></b> in the second. Patients scored their pain according to the Numeric Rating Scale (NRS-11) before, 2, 4, 6, 8, 12, 16, and 24\u00a0week after the procedure. ### results The study has included 50 patient in two groups. There was no significant difference between the two groups as regards medical, laboratory, or tumor characters. The median pain score decreases from 8.32\u2009\u00b1\u20090.75 before the procedure to 3.75\u2009\u00b1\u20093.72 24\u00a0week after the procedure in group 1 and from 8.08\u2009\u00b1\u20090.86 before to 1.67\u2009\u00b1\u20092.3 24\u00a0week after the procedure in group 2. However, there was no significant difference between the two groups in the median pain score during the first 4\u00a0weeks. There was no statistically significant difference between the two groups as regards the median survival time. ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>dexmedetomidine</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>EUS-CPN</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>regards</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>degree</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>duration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>relieve</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>negligible</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"addition","start":4,"end":12,"id":1,"ws":true},{"text":"of","start":13,"end":15,"id":2,"ws":true},{"text":"dexmedetomidine","start":16,"end":31,"id":3,"ws":true},{"text":"to","start":32,"end":34,"id":4,"ws":true},{"text":"bupivacaine","start":35,"end":46,"id":5,"ws":true},{"text":"0.5","start":47,"end":50,"id":6,"ws":true},{"text":"%","start":51,"end":52,"id":7,"ws":true},{"text":"in","start":53,"end":55,"id":8,"ws":true},{"text":"EUS-CPN","start":56,"end":63,"id":9,"ws":true},{"text":"demonstrated","start":64,"end":76,"id":10,"ws":true},{"text":"beneficial","start":77,"end":87,"id":11,"ws":true},{"text":"effects","start":88,"end":95,"id":12,"ws":true},{"text":"as","start":96,"end":98,"id":13,"ws":true},{"text":"regards","start":99,"end":106,"id":14,"ws":true},{"text":"the","start":107,"end":110,"id":15,"ws":true},{"text":"degree","start":111,"end":117,"id":16,"ws":true},{"text":"and","start":118,"end":121,"id":17,"ws":true},{"text":"duration","start":122,"end":130,"id":18,"ws":true},{"text":"of","start":131,"end":133,"id":19,"ws":true},{"text":"pain","start":134,"end":138,"id":20,"ws":true},{"text":"relieve","start":139,"end":146,"id":21,"ws":true},{"text":"with","start":147,"end":151,"id":22,"ws":true},{"text":"negligible","start":152,"end":162,"id":23,"ws":true},{"text":"effect","start":163,"end":169,"id":24,"ws":true},{"text":"on","start":170,"end":172,"id":25,"ws":true},{"text":"the","start":173,"end":176,"id":26,"ws":true},{"text":"patient","start":177,"end":184,"id":27,"ws":true},{"text":"survival","start":185,"end":193,"id":28,"ws":true},{"text":".","start":194,"end":195,"id":29,"ws":false}],"spans":[{"start":16,"end":31,"token_start":3,"token_end":3,"label":"DRUG"},{"start":35,"end":46,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32621112/","_input_hash":-1100243710,"_task_hash":1787770347,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":16,"end":31,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":35,"end":46,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The incidence of carcinoma , confirmed microscopically , was : control 14/20 ( 70 % ) ; high-dose gefitinib , 7/20 ( 35 % ) ; low-dose gefitinib , 7/20 ( 35 % ) ; high-dose meloxicam 7/21 ( 33 % ) ; and low-dose meloxicam , 12/20 ( 60 % ) .","paragraph":"<h3><u>Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis.</u></h3>To examine the chemopreventive effects of a selective cyclooxygenase (COX)-2 inhibitor, <b style='color:Tomato;'><i>meloxicam</i></b>, and a selective epidermal growth factor (EGF)-receptor tyrosine kinase inhibitor, <b style='color:Tomato;'><i>gefitinib</i></b> (as a single agent) on a carcinogen-induced rodent bladder carcinogenesis model. ### Materials And Methods The study comprised 103 male Fisher-344 rats (8 weeks old); after initial carcinogen treatment for 8 weeks with 0.05%N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in drinking water, the rats were divided into five groups, i.e. group 1, control (vehicle only); group 2, <b style='color:Tomato;'><i>gefitinib</i></b> high-dose (15 mg/kg by gavage once daily); group 3, <b style='color:Tomato;'><i>gefitinib</i></b> low-dose (5 mg/kg); group 4, <b style='color:Tomato;'><i>meloxicam</i></b> high-dose (1.8 mg/kg by gavage once daily); and group 5, <b style='color:Tomato;'><i>meloxicam</i></b> low-dose (0.6 mg/kg). Twelve weeks later the rats were killed; after fixing the bladder in 10% formalin, the number and size of hyperplasia and carcinoma foci were recorded microscopically in sections stained with haematoxylin and eosin, submitted entirely as multiple strips. ### results <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>incidence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>confirmed</i></b> <b style='color:DodgerBlue;'><i>microscopically</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>14/20</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>70</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>7/20</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>low-dose</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>7/20</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>meloxicam</i></b> <b style='color:DodgerBlue;'><i>7/21</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>33</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>low-dose</i></b> <b style='color:MediumOrchid;'><i>meloxicam</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>12/20</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The mean numbers of carcinomas per bladder in groups 1-5 were 1.2, 0.5, 0.4, 0.5 and 1.1, respectively. The incidence and the mean number of carcinomas per bladder were significantly lower in the treatment groups (P < 0.05) than in the control group, except in the low-dose <b style='color:Tomato;'><i>meloxicam</i></b> group. There were no significant adverse effects. ### conclusion Both <b style='color:Tomato;'><i>meloxicam</i></b> and <b style='color:Tomato;'><i>gefitinib</i></b> have inhibitory effects on rat bladder carcinogenesis with no significant adverse effects. A combination of these drugs would be worth studying for their synergistic effects.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"incidence","start":4,"end":13,"id":1,"ws":true},{"text":"of","start":14,"end":16,"id":2,"ws":true},{"text":"carcinoma","start":17,"end":26,"id":3,"ws":true},{"text":",","start":27,"end":28,"id":4,"ws":true},{"text":"confirmed","start":29,"end":38,"id":5,"ws":true},{"text":"microscopically","start":39,"end":54,"id":6,"ws":true},{"text":",","start":55,"end":56,"id":7,"ws":true},{"text":"was","start":57,"end":60,"id":8,"ws":true},{"text":":","start":61,"end":62,"id":9,"ws":true},{"text":"control","start":63,"end":70,"id":10,"ws":true},{"text":"14/20","start":71,"end":76,"id":11,"ws":true},{"text":"(","start":77,"end":78,"id":12,"ws":true},{"text":"70","start":79,"end":81,"id":13,"ws":true},{"text":"%","start":82,"end":83,"id":14,"ws":true},{"text":")","start":84,"end":85,"id":15,"ws":true},{"text":";","start":86,"end":87,"id":16,"ws":true},{"text":"high-dose","start":88,"end":97,"id":17,"ws":true},{"text":"gefitinib","start":98,"end":107,"id":18,"ws":true},{"text":",","start":108,"end":109,"id":19,"ws":true},{"text":"7/20","start":110,"end":114,"id":20,"ws":true},{"text":"(","start":115,"end":116,"id":21,"ws":true},{"text":"35","start":117,"end":119,"id":22,"ws":true},{"text":"%","start":120,"end":121,"id":23,"ws":true},{"text":")","start":122,"end":123,"id":24,"ws":true},{"text":";","start":124,"end":125,"id":25,"ws":true},{"text":"low-dose","start":126,"end":134,"id":26,"ws":true},{"text":"gefitinib","start":135,"end":144,"id":27,"ws":true},{"text":",","start":145,"end":146,"id":28,"ws":true},{"text":"7/20","start":147,"end":151,"id":29,"ws":true},{"text":"(","start":152,"end":153,"id":30,"ws":true},{"text":"35","start":154,"end":156,"id":31,"ws":true},{"text":"%","start":157,"end":158,"id":32,"ws":true},{"text":")","start":159,"end":160,"id":33,"ws":true},{"text":";","start":161,"end":162,"id":34,"ws":true},{"text":"high-dose","start":163,"end":172,"id":35,"ws":true},{"text":"meloxicam","start":173,"end":182,"id":36,"ws":true},{"text":"7/21","start":183,"end":187,"id":37,"ws":true},{"text":"(","start":188,"end":189,"id":38,"ws":true},{"text":"33","start":190,"end":192,"id":39,"ws":true},{"text":"%","start":193,"end":194,"id":40,"ws":true},{"text":")","start":195,"end":196,"id":41,"ws":true},{"text":";","start":197,"end":198,"id":42,"ws":true},{"text":"and","start":199,"end":202,"id":43,"ws":true},{"text":"low-dose","start":203,"end":211,"id":44,"ws":true},{"text":"meloxicam","start":212,"end":221,"id":45,"ws":true},{"text":",","start":222,"end":223,"id":46,"ws":true},{"text":"12/20","start":224,"end":229,"id":47,"ws":true},{"text":"(","start":230,"end":231,"id":48,"ws":true},{"text":"60","start":232,"end":234,"id":49,"ws":true},{"text":"%","start":235,"end":236,"id":50,"ws":true},{"text":")","start":237,"end":238,"id":51,"ws":true},{"text":".","start":239,"end":240,"id":52,"ws":false}],"spans":[{"start":98,"end":107,"token_start":18,"token_end":18,"label":"DRUG"},{"start":135,"end":144,"token_start":27,"token_end":27,"label":"DRUG"},{"start":173,"end":182,"token_start":36,"token_end":36,"label":"DRUG"},{"start":212,"end":221,"token_start":45,"token_end":45,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16469040/","_input_hash":1104357333,"_task_hash":1209744864,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":18,"child":36,"head_span":{"start":98,"end":107,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":173,"end":182,"token_start":36,"token_end":36,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Patients with incurable cancer causing chronic pain rated above 6/10 on a numerical scale while receiving high-dose opioid therapy ( more than 200 mg/d of oral morphine equivalent ) and/or exhibiting severe opioid-related adverse events received intrathecal infusions of ziconotide combined with morphine , ropivacaine , and clonidine .","paragraph":"<h3><u>Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.</u></h3>Ziconotide is a new analgesic agent administered intrathecally. It is challenging to use and can induce several and sometimes serious adverse events. A low initial dosage followed by slow titration may reduce serious adverse events. ### objective To determine whether a low starting dosage of ziconotide, followed by slow titration, decreases the incidence of major adverse events associated with ziconotide when used for intractable cancer pain. ### Study Design Observational cohort study. ### setting Three French cancer centers. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>incurable</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>causing</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>rated</i></b> <b style='color:DodgerBlue;'><i>above</i></b> <b style='color:DodgerBlue;'><i>6/10</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>numerical</i></b> <b style='color:DodgerBlue;'><i>scale</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>opioid</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/d</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>morphine</i></b> <b style='color:DodgerBlue;'><i>equivalent</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:DodgerBlue;'><i>exhibiting</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>opioid-related</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>intrathecal</i></b> <b style='color:DodgerBlue;'><i>infusions</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ziconotide</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>morphine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ropivacaine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clonidine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Seventy-seven patients were included. Adverse events were recorded in 57% of them; moderate adverse events occurred in 51%. Adverse events required treatment discontinuation in 7  (9%) including 5  (6%) for whom a causal role for ziconotide was highly likely; among them 4  (5%) were serious. All patients experienced a significant and lasting decrease in pain intensity  (by 48%) in response to intrathecal analgesic therapy that included ziconotide. ### limitations Limitations include the nonrandomized, observational nature of the study. Determining the relative contributions of each drug to adverse events was difficult, and some of the adverse events manifested as clinical symptoms of a subjective nature. ### conclusions The rates of minor and moderate adverse events were consistent with previous reports. However, the rate of serious adverse events was substantially lower. Our study confirms the efficacy of intrathecal analgesia with ziconotide for relieving refractory cancer pain. These results indicate that multimodal intrathecal analgesia in patients with cancer pain should include ziconotide from the outset in order to provide time for subsequent slow titration.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"with","start":9,"end":13,"id":1,"ws":true},{"text":"incurable","start":14,"end":23,"id":2,"ws":true},{"text":"cancer","start":24,"end":30,"id":3,"ws":true},{"text":"causing","start":31,"end":38,"id":4,"ws":true},{"text":"chronic","start":39,"end":46,"id":5,"ws":true},{"text":"pain","start":47,"end":51,"id":6,"ws":true},{"text":"rated","start":52,"end":57,"id":7,"ws":true},{"text":"above","start":58,"end":63,"id":8,"ws":true},{"text":"6/10","start":64,"end":68,"id":9,"ws":true},{"text":"on","start":69,"end":71,"id":10,"ws":true},{"text":"a","start":72,"end":73,"id":11,"ws":true},{"text":"numerical","start":74,"end":83,"id":12,"ws":true},{"text":"scale","start":84,"end":89,"id":13,"ws":true},{"text":"while","start":90,"end":95,"id":14,"ws":true},{"text":"receiving","start":96,"end":105,"id":15,"ws":true},{"text":"high-dose","start":106,"end":115,"id":16,"ws":true},{"text":"opioid","start":116,"end":122,"id":17,"ws":true},{"text":"therapy","start":123,"end":130,"id":18,"ws":true},{"text":"(","start":131,"end":132,"id":19,"ws":true},{"text":"more","start":133,"end":137,"id":20,"ws":true},{"text":"than","start":138,"end":142,"id":21,"ws":true},{"text":"200","start":143,"end":146,"id":22,"ws":true},{"text":"mg/d","start":147,"end":151,"id":23,"ws":true},{"text":"of","start":152,"end":154,"id":24,"ws":true},{"text":"oral","start":155,"end":159,"id":25,"ws":true},{"text":"morphine","start":160,"end":168,"id":26,"ws":true},{"text":"equivalent","start":169,"end":179,"id":27,"ws":true},{"text":")","start":180,"end":181,"id":28,"ws":true},{"text":"and/or","start":182,"end":188,"id":29,"ws":true},{"text":"exhibiting","start":189,"end":199,"id":30,"ws":true},{"text":"severe","start":200,"end":206,"id":31,"ws":true},{"text":"opioid-related","start":207,"end":221,"id":32,"ws":true},{"text":"adverse","start":222,"end":229,"id":33,"ws":true},{"text":"events","start":230,"end":236,"id":34,"ws":true},{"text":"received","start":237,"end":245,"id":35,"ws":true},{"text":"intrathecal","start":246,"end":257,"id":36,"ws":true},{"text":"infusions","start":258,"end":267,"id":37,"ws":true},{"text":"of","start":268,"end":270,"id":38,"ws":true},{"text":"ziconotide","start":271,"end":281,"id":39,"ws":true},{"text":"combined","start":282,"end":290,"id":40,"ws":true},{"text":"with","start":291,"end":295,"id":41,"ws":true},{"text":"morphine","start":296,"end":304,"id":42,"ws":true},{"text":",","start":305,"end":306,"id":43,"ws":true},{"text":"ropivacaine","start":307,"end":318,"id":44,"ws":true},{"text":",","start":319,"end":320,"id":45,"ws":true},{"text":"and","start":321,"end":324,"id":46,"ws":true},{"text":"clonidine","start":325,"end":334,"id":47,"ws":true},{"text":".","start":335,"end":336,"id":48,"ws":false}],"spans":[{"start":307,"end":318,"token_start":44,"token_end":44,"label":"DRUG"},{"start":325,"end":334,"token_start":47,"token_end":47,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22996851/","_input_hash":-1775288786,"_task_hash":-1814032713,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Both adalimumab and etanercept were more effective than methotrexate in slowing radiographic joint damage .","paragraph":"<h3><u>A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.</u></h3>This report reviews the clinical effectiveness and cost-effectiveness of <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>etanercept</i></b> and <b style='color:Tomato;'><i>infliximab</i></b>, agents that inhibit tumour necrosis factor-alpha (TNF-alpha), when used in the treatment of rheumatoid arthritis (RA) in adults. ### Data Sources Electronic databases were searched up to February 2005. ### Review Methods Systematic reviews of the literature on effectiveness and cost-effectiveness were undertaken and industry submissions to the National Institute for Health and Clinical Excellence (NICE) were reviewed. Meta-analyses of effectiveness data were also undertaken for each agent. The Birmingham Rheumatoid Arthritis Model (BRAM), a simulation model, was further developed and used to produce an incremental cost-effectiveness analysis. ### results Twenty-nine randomised controlled trials (RCTs), most of high quality, were included. The only head-to-head comparisons were against <b style='color:Tomato;'><i>methotrexate</i></b>. For patients with short disease duration (<or=3 years) who were na\u00efve to <b style='color:Tomato;'><i>methotrexate</i></b>, <b style='color:Tomato;'><i>adalimumab</i></b> was marginally less and <b style='color:Tomato;'><i>etanercept</i></b> was marginally more effective than <b style='color:Tomato;'><i>methotrexate</i></b> in reducing symptoms of RA. <b style='color:Tomato;'><i>etanercept</i></b> was better tolerated than <b style='color:Tomato;'><i>methotrexate</i></b>. <b style='color:DodgerBlue;'><i>Both</i></b> <b style='color:MediumOrchid;'><i>adalimumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etanercept</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>slowing</i></b> <b style='color:DodgerBlue;'><i>radiographic</i></b> <b style='color:DodgerBlue;'><i>joint</i></b> <b style='color:DodgerBlue;'><i>damage</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>etanercept</i></b> was also marginally more effective and better tolerated than <b style='color:Tomato;'><i>methotrexate</i></b> in patients with longer disease durations who had not failed <b style='color:Tomato;'><i>methotrexate</i></b> treatment. <b style='color:Tomato;'><i>infliximab</i></b> is only licensed for use with <b style='color:Tomato;'><i>methotrexate</i></b>. All three agents, either alone (where so licensed) or in combination with ongoing disease-modifying antirheumatic drugs (DMARDs), were effective in reducing the symptoms and signs of RA in patients with established disease. At the licensed dose, the numbers needed to treat (NNTs) (95% CI) required to produce an American College for Rheumatology (ACR) response compared with placebo were: ACR20: <b style='color:Tomato;'><i>adalimumab</i></b> 3.6 (3.1 to 4.2), <b style='color:Tomato;'><i>etanercept</i></b> 2.1 (1.9 to 2.4), <b style='color:Tomato;'><i>infliximab</i></b> 3.2 (2.7 to 4.0); ACR50: <b style='color:Tomato;'><i>adalimumab</i></b> 4.2 (3.7 to 5.0), <b style='color:Tomato;'><i>etanercept</i></b> 3.1 (2.7 to 3.6), <b style='color:Tomato;'><i>infliximab</i></b> 5.0 (3.8 to 6.7); and ACR70: <b style='color:Tomato;'><i>adalimumab</i></b> 7.7 (5.9 to 11.1), <b style='color:Tomato;'><i>etanercept</i></b> 7.7 (6.3 to 10.0), <b style='color:Tomato;'><i>infliximab</i></b> 11.1 (7.7 to 20.0). In patients who were na\u00efve to <b style='color:Tomato;'><i>methotrexate</i></b>, or who had not previously failed <b style='color:Tomato;'><i>methotrexate</i></b> treatment, a TNF inhibitor combined with <b style='color:Tomato;'><i>methotrexate</i></b> was significantly more effective than <b style='color:Tomato;'><i>methotrexate</i></b> alone. <b style='color:Tomato;'><i>infliximab</i></b> combined with <b style='color:Tomato;'><i>methotrexate</i></b> had an increased risk of serious infections. All ten published economic evaluations met standard criteria for quality, but the incremental cost-effectiveness ratios (ICERs) ranged from being within established thresholds to being very high because of varying assumptions and parameters. All three sponsors who submitted economic models made assumptions favourable to their product. BRAM incorporates improvements in quality of life and mortality, but assumes no effect of TNF inhibitors on joint replacement. For use in accordance with current NICE guidance as the third DMARD in a sequence of DMARDs, the base-case ICER was around pound30,000 per quality-adjusted life-year (QALY) in early RA and pound50,000 per QALY in late RA. Sensitivity analyses showed that the results were sensitive to the estimates of Health Assessment Questionnaire (HAQ) progression while on TNF inhibitors and the effectiveness of DMARDs, but not to changes in mortality ratios per unit HAQ. TNF inhibitors are most cost-effective when used last. The ICER for <b style='color:Tomato;'><i>etanercept</i></b> used last is pound24,000 per QALY, substantially lower than for <b style='color:Tomato;'><i>adalimumab</i></b> ( pound30,000 per QALY) or <b style='color:Tomato;'><i>infliximab</i></b> ( pound38,000 per QALY). First line use as monotherapy generates ICERs around pound50,000 per QALY for <b style='color:Tomato;'><i>adalimumab</i></b> and <b style='color:Tomato;'><i>etanercept</i></b>. Using the combination of <b style='color:Tomato;'><i>methotrexate</i></b> and a TNF inhibitor as first line treatment generates much higher ICERs, as it precludes subsequent use of <b style='color:Tomato;'><i>methotrexate</i></b>, which is cheap. The ICERs for sequential use are of the same order as using the TNF inhibitor alone. ### conclusions <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>etanercept</i></b> and <b style='color:Tomato;'><i>infliximab</i></b> are effective treatments compared with placebo for RA patients who are not well controlled by conventional DMARDs, improving control of symptoms, improving physical function, and slowing radiographic changes in joints. The combination of a TNF inhibitor with <b style='color:Tomato;'><i>methotrexate</i></b> was more effective than <b style='color:Tomato;'><i>methotrexate</i></b> alone in early RA, although the clinical relevance of this additional benefit is yet to be established, particularly in view of the well-established effectiveness of MTX alone. An increased risk of serious infection cannot be ruled out for the combination of <b style='color:Tomato;'><i>methotrexate</i></b> with <b style='color:Tomato;'><i>adalimumab</i></b> or <b style='color:Tomato;'><i>infliximab</i></b>. The results of the economic evaluation based on BRAM are consistent with the observations from the review of clinical effectiveness, including the ranking of treatments. TNF inhibitors are most cost-effective when used as last active therapy. In this analysis, other things being equal, <b style='color:Tomato;'><i>etanercept</i></b> may be the TNF inhibitor of choice, although this may also depend on patient preference as to route of administration. The next most cost-effective use of TNF inhibitors is third line, as recommended in the 2002 NICE guidance. Direct comparative RCTs of TNF inhibitors against each other and against other DMARDs, and sequential use in patients who have failed a previous TNF inhibitor, are needed. Longer term studies of the quality of life in patients with RA and the impact of DMARDs on this are needed, as are longer studies that directly assess effects on joint replacement, other morbidity and mortality.","tokens":[{"text":"Both","start":0,"end":4,"id":0,"ws":true},{"text":"adalimumab","start":5,"end":15,"id":1,"ws":true},{"text":"and","start":16,"end":19,"id":2,"ws":true},{"text":"etanercept","start":20,"end":30,"id":3,"ws":true},{"text":"were","start":31,"end":35,"id":4,"ws":true},{"text":"more","start":36,"end":40,"id":5,"ws":true},{"text":"effective","start":41,"end":50,"id":6,"ws":true},{"text":"than","start":51,"end":55,"id":7,"ws":true},{"text":"methotrexate","start":56,"end":68,"id":8,"ws":true},{"text":"in","start":69,"end":71,"id":9,"ws":true},{"text":"slowing","start":72,"end":79,"id":10,"ws":true},{"text":"radiographic","start":80,"end":92,"id":11,"ws":true},{"text":"joint","start":93,"end":98,"id":12,"ws":true},{"text":"damage","start":99,"end":105,"id":13,"ws":true},{"text":".","start":106,"end":107,"id":14,"ws":false}],"spans":[{"start":5,"end":15,"token_start":1,"token_end":1,"label":"DRUG"},{"start":20,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},{"start":56,"end":68,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17049139/","_input_hash":-141818609,"_task_hash":654054989,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Combination chemotherapy with gemcitabine ( Gem ) , doxorubicin ( Dox ) , and paclitaxel ( Pac ) ( GAT ) has been considered attractive as first-line treatment in metastatic breast cancer .","paragraph":"<h3><u>Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines.</u></h3> <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Gem</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Dox</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Pac</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>GAT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>attractive</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We compared the potential of various schedules of GAT to induce apoptosis on MDA-MB-231, MCF7, and T47D human breast cancer cell lines. The extent of apoptotic induction was analyzed by flow cytometry with 7-aminoactinomycin D (7AAD) staining. Differences between various schedules in terms of apoptotic induction were statistically significant (P < 0.05). The most effective apoptotic induction regimen was achieved by the sequence: Dox for 16 h followed by Pac + Gem. Schedules employing a 16-h interval between drug administrations induced higher levels of apoptosis in human breast cancer cell lines compared with schedules using a 4-h interval. The therapeutic efficacy of the experimental results shown in this paper has been clinically corroborated in a phase II trial in metastatic breast cancer patients.","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"chemotherapy","start":12,"end":24,"id":1,"ws":true},{"text":"with","start":25,"end":29,"id":2,"ws":true},{"text":"gemcitabine","start":30,"end":41,"id":3,"ws":true},{"text":"(","start":42,"end":43,"id":4,"ws":true},{"text":"Gem","start":44,"end":47,"id":5,"ws":true},{"text":")","start":48,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"doxorubicin","start":52,"end":63,"id":8,"ws":true},{"text":"(","start":64,"end":65,"id":9,"ws":true},{"text":"Dox","start":66,"end":69,"id":10,"ws":true},{"text":")","start":70,"end":71,"id":11,"ws":true},{"text":",","start":72,"end":73,"id":12,"ws":true},{"text":"and","start":74,"end":77,"id":13,"ws":true},{"text":"paclitaxel","start":78,"end":88,"id":14,"ws":true},{"text":"(","start":89,"end":90,"id":15,"ws":true},{"text":"Pac","start":91,"end":94,"id":16,"ws":true},{"text":")","start":95,"end":96,"id":17,"ws":true},{"text":"(","start":97,"end":98,"id":18,"ws":true},{"text":"GAT","start":99,"end":102,"id":19,"ws":true},{"text":")","start":103,"end":104,"id":20,"ws":true},{"text":"has","start":105,"end":108,"id":21,"ws":true},{"text":"been","start":109,"end":113,"id":22,"ws":true},{"text":"considered","start":114,"end":124,"id":23,"ws":true},{"text":"attractive","start":125,"end":135,"id":24,"ws":true},{"text":"as","start":136,"end":138,"id":25,"ws":true},{"text":"first-line","start":139,"end":149,"id":26,"ws":true},{"text":"treatment","start":150,"end":159,"id":27,"ws":true},{"text":"in","start":160,"end":162,"id":28,"ws":true},{"text":"metastatic","start":163,"end":173,"id":29,"ws":true},{"text":"breast","start":174,"end":180,"id":30,"ws":true},{"text":"cancer","start":181,"end":187,"id":31,"ws":true},{"text":".","start":188,"end":189,"id":32,"ws":false}],"spans":[{"start":30,"end":41,"token_start":3,"token_end":3,"label":"DRUG"},{"start":52,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},{"start":78,"end":88,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12036452/","_input_hash":-151814940,"_task_hash":1801711831,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":3,"child":8,"head_span":{"start":30,"end":41,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":52,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":14,"head_span":{"start":52,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":78,"end":88,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Anti-cancer agents like adriamycin , mitomycin-C , bleomycin , and etoposide express their cell-killing activity partly through oxygen radicals .","paragraph":"<h3><u>Overcoming of cross-resistance to the cell-killing activity of oxygen radicals in VCR-resistant hematologic cell lines with cyclosporin-A.</u></h3> <b style='color:DodgerBlue;'><i>Anti-cancer</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>like</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>mitomycin-C</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>express</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>cell-killing</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>partly</i></b> <b style='color:DodgerBlue;'><i>through</i></b> <b style='color:DodgerBlue;'><i>oxygen</i></b> <b style='color:DodgerBlue;'><i>radicals</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Since <b style='color:Tomato;'><i>vincristine</i></b> (VCR)-resistant cells show cross-resistance to oxygen radicals, this study was designed to study whether the combined effects of oxygen radicals derived from hypoxanthine-xanthine oxidase plus enhancers of anti-cancer drugs such as <b style='color:Tomato;'><i>verapamil</i></b> (Ver), <b style='color:Tomato;'><i>dipyridamole</i></b> (Dip), and <b style='color:Tomato;'><i>cyclosporin</i></b>-A (Cy-A) overcome the cross-resistance for oxygen radicals in VCR-resistant human leukemia/lymphoma cell lines. We found that 3 micrograms/mL Cy-A enhances the cidal effect of oxygen radicals on two of five types of wild type and two of five VCR-resistant cell lines and it could overcome the cross-resistance to oxygen radicals in VCR-resistant cells. Neither Ver nor Dip showed any effect on the cidal activity of oxygen radicals. Thus, it was suggested that Cy-A works with different mechanisms from those of Ver or Dip, and Cy-A may be useful in reducing the doses of anti-neoplastic agents that exert their activity via oxygen radicals in the clinical treatment.","tokens":[{"text":"Anti-cancer","start":0,"end":11,"id":0,"ws":true},{"text":"agents","start":12,"end":18,"id":1,"ws":true},{"text":"like","start":19,"end":23,"id":2,"ws":true},{"text":"adriamycin","start":24,"end":34,"id":3,"ws":true},{"text":",","start":35,"end":36,"id":4,"ws":true},{"text":"mitomycin-C","start":37,"end":48,"id":5,"ws":true},{"text":",","start":49,"end":50,"id":6,"ws":true},{"text":"bleomycin","start":51,"end":60,"id":7,"ws":true},{"text":",","start":61,"end":62,"id":8,"ws":true},{"text":"and","start":63,"end":66,"id":9,"ws":true},{"text":"etoposide","start":67,"end":76,"id":10,"ws":true},{"text":"express","start":77,"end":84,"id":11,"ws":true},{"text":"their","start":85,"end":90,"id":12,"ws":true},{"text":"cell-killing","start":91,"end":103,"id":13,"ws":true},{"text":"activity","start":104,"end":112,"id":14,"ws":true},{"text":"partly","start":113,"end":119,"id":15,"ws":true},{"text":"through","start":120,"end":127,"id":16,"ws":true},{"text":"oxygen","start":128,"end":134,"id":17,"ws":true},{"text":"radicals","start":135,"end":143,"id":18,"ws":true},{"text":".","start":144,"end":145,"id":19,"ws":false}],"spans":[{"start":51,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":67,"end":76,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9673368/","_input_hash":-676357944,"_task_hash":1952396913,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>isepamicin</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>amikacin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>intra-abdominal</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>This multicentre, randomised, open-label, parallel group study compared the efficacy and safety of <b style='color:Tomato;'><i>isepamicin</i></b> (15 mg/kg once daily) and <b style='color:Tomato;'><i>amikacin</i></b> (7.5 mg/kg twice daily) when given intravenously in combination with <b style='color:Tomato;'><i>met<b style='color:Tomato;'><i>ronidazole</i></b></i></b> to 267 hospitalised adults with intra-abdominal infections. Clinical cure or improvement was achieved in 96.3% (130/135) evaluable patients (efficacy population) in the <b style='color:Tomato;'><i>isepamicin</i></b> group and 94.3% (66/70) patients in the <b style='color:Tomato;'><i>amikacin</i></b> group. Bacteriological elimination occurred in 93.3% (126/135) evaluable <b style='color:Tomato;'><i>isepamicin</i></b> patients and 95.7% (67/170) <b style='color:Tomato;'><i>amikacin</i></b> patients. there was not statistically significant differences between the groups. Adverse events were reported by 9% of patients in the <b style='color:Tomato;'><i>isepamicin</i></b> group (16/178) and 10% of patients in the <b style='color:Tomato;'><i>amikacin</i></b> group (9/89). Events considered to be related to treatment occurred in 6% of patients in both groups. The most frequent adverse events were diarrhoea, nausea and vomiting. Renal problems caused three patients (2 <b style='color:Tomato;'><i>isepamicin</i></b>, 1 <b style='color:Tomato;'><i>amikacin</i></b>) to withdraw from the study. Ototoxicity (detected by audiometric testing) occurred in one patient (treated with <b style='color:Tomato;'><i>isepamicin</i></b>). In conclusion, <b style='color:Tomato;'><i>isepamicin</i></b> at a dose of 15 mg/kg once daily was shown to be as effective as <b style='color:Tomato;'><i>amikacin</i></b> (7.5 mg/kg twice daily) in the treatment of intra-abdominal infections in hospitalised adults also treated with <b style='color:Tomato;'><i>met<b style='color:Tomato;'><i>ronidazole</i></b></i></b>. Both treatments were well tolerated.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"efficacy","start":4,"end":12,"id":1,"ws":true},{"text":"and","start":13,"end":16,"id":2,"ws":true},{"text":"safety","start":17,"end":23,"id":3,"ws":true},{"text":"of","start":24,"end":26,"id":4,"ws":true},{"text":"isepamicin","start":27,"end":37,"id":5,"ws":true},{"text":"compared","start":38,"end":46,"id":6,"ws":true},{"text":"with","start":47,"end":51,"id":7,"ws":true},{"text":"amikacin","start":52,"end":60,"id":8,"ws":true},{"text":"in","start":61,"end":63,"id":9,"ws":true},{"text":"the","start":64,"end":67,"id":10,"ws":true},{"text":"treatment","start":68,"end":77,"id":11,"ws":true},{"text":"of","start":78,"end":80,"id":12,"ws":true},{"text":"intra-abdominal","start":81,"end":96,"id":13,"ws":true},{"text":"infections","start":97,"end":107,"id":14,"ws":true},{"text":".","start":108,"end":109,"id":15,"ws":false}],"spans":[{"start":27,"end":37,"token_start":5,"token_end":5,"label":"DRUG"},{"start":52,"end":60,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8622103/","_input_hash":-1423308203,"_task_hash":454917263,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Imipenem was compared with nafcillin and with penicillin plus gentamicin in the therapy of experimental endocarditis induced in rabbits by Staph . aureus and Str . faecalis , respectively .","paragraph":"<h3><u>Imipenem therapy of experimental Staphylococcus aureus and Streptococcus faecalis endocarditis.</u></h3><b style='color:Tomato;'><i>imipenem</i></b> was very active in vitro against 36 Staphylococcus aureus isolates from cases of infective endocarditis; the MBC90 was 0.06 mg/l (four- to eight-fold more active than <b style='color:Tomato;'><i>nafcillin</i></b>). The in-vitro activity of <b style='color:Tomato;'><i>imipenem</i></b> against 22 Streptococcus faecalis isolates from proven endocarditis cases was similar to that of penicillin G (MBC90 = 8 mg/l). <b style='color:MediumOrchid;'><i>Imipenem</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>nafcillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>endocarditis</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>rabbits</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>Staph</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>aureus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Str</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>faecalis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The dosages were chosen to simulate closely serum antibiotic concentrations found in humans receiving standard parenteral regimens. <b style='color:Tomato;'><i>imipenem</i></b> was more rapidly bactericidal than <b style='color:Tomato;'><i>nafcillin</i></b> in experimental staphylococcal endocarditis. The mean +/- S.D. Staph. aureus concentrations within aortic valve vegetations (log10 cfu/g) after 5 days of therapy were as follows: <b style='color:Tomato;'><i>imipenem</i></b> = 1.39 +/- 0.61 versus <b style='color:Tomato;'><i>nafcillin</i></b> 2.39 +/- 0.36 (P less than 0.02). Both the <b style='color:Tomato;'><i>imipenem</i></b> and <b style='color:Tomato;'><i>nafcillin</i></b> regimens resulted in 'sterile' vegetations in congruent to 50% of rabbits with experimental staphylococcal endocarditis after 5 days of therapy (P greater than 0.05). <b style='color:Tomato;'><i>imipenem</i></b> was also equivalent to penicillin plus <b style='color:Tomato;'><i>gentamicin</i></b> in the therapy of experimental enterococcal endocarditis for 5 days, as assessed by the mean cfu/g vegetation and the percentage of vegetations rendered sterile. However, 7 days of therapy cured experimental enterococcal endocarditis in 72% of rabbits receiving penicillin plus <b style='color:Tomato;'><i>gentamicin</i></b> versus 20% for <b style='color:Tomato;'><i>imipenem</i></b> alone (P less than 0.05). <b style='color:Tomato;'><i>imipenem</i></b> deserves further evaluation in the therapy of infective endocarditis, both in experimental animal models of infection and in humans. This agent may prove useful in the therapy of staphylococcal endocarditis in a variety of difficult clinical situations. Therapy of enterococcal endocarditis with <b style='color:Tomato;'><i>imipenem</i></b> alone is not advisable, pending further data.","tokens":[{"text":"Imipenem","start":0,"end":8,"id":0,"ws":true},{"text":"was","start":9,"end":12,"id":1,"ws":true},{"text":"compared","start":13,"end":21,"id":2,"ws":true},{"text":"with","start":22,"end":26,"id":3,"ws":true},{"text":"nafcillin","start":27,"end":36,"id":4,"ws":true},{"text":"and","start":37,"end":40,"id":5,"ws":true},{"text":"with","start":41,"end":45,"id":6,"ws":true},{"text":"penicillin","start":46,"end":56,"id":7,"ws":true},{"text":"plus","start":57,"end":61,"id":8,"ws":true},{"text":"gentamicin","start":62,"end":72,"id":9,"ws":true},{"text":"in","start":73,"end":75,"id":10,"ws":true},{"text":"the","start":76,"end":79,"id":11,"ws":true},{"text":"therapy","start":80,"end":87,"id":12,"ws":true},{"text":"of","start":88,"end":90,"id":13,"ws":true},{"text":"experimental","start":91,"end":103,"id":14,"ws":true},{"text":"endocarditis","start":104,"end":116,"id":15,"ws":true},{"text":"induced","start":117,"end":124,"id":16,"ws":true},{"text":"in","start":125,"end":127,"id":17,"ws":true},{"text":"rabbits","start":128,"end":135,"id":18,"ws":true},{"text":"by","start":136,"end":138,"id":19,"ws":true},{"text":"Staph","start":139,"end":144,"id":20,"ws":true},{"text":".","start":145,"end":146,"id":21,"ws":true},{"text":"aureus","start":147,"end":153,"id":22,"ws":true},{"text":"and","start":154,"end":157,"id":23,"ws":true},{"text":"Str","start":158,"end":161,"id":24,"ws":true},{"text":".","start":162,"end":163,"id":25,"ws":true},{"text":"faecalis","start":164,"end":172,"id":26,"ws":true},{"text":",","start":173,"end":174,"id":27,"ws":true},{"text":"respectively","start":175,"end":187,"id":28,"ws":true},{"text":".","start":188,"end":189,"id":29,"ws":false}],"spans":[{"start":0,"end":8,"token_start":0,"token_end":0,"label":"DRUG"},{"start":27,"end":36,"token_start":4,"token_end":4,"label":"DRUG"},{"start":46,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},{"start":62,"end":72,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6421794/","_input_hash":1926321652,"_task_hash":653025822,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":46,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":62,"end":72,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The total dose of paclitaxel ( 175 - 200 mg/m2 ) ; cisplatin ( 75 mg/m2 ) ; and etoposide ( 175 - 200 mg/m2 ) was divided into five daily doses administered over 3 h with cycles repeated at 21 - 28 days .","paragraph":"<h3><u>Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer.</u></h3>In this phase II study, <b style='color:Tomato;'><i>paclitaxel</i></b> was added to the combination of cisplatin and <b style='color:Tomato;'><i>etoposide</i></b> (TPE regimen), in 37 patients with advanced non-small cell lung cancer, using a multifractionated dosing schedule. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>divided</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>five</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>repeated</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>28</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>.</i></b> 15 patients had stage III A or B disease and 22 stage IV disease. 32 patients were evaluable for toxicity and 37 for response. Neutropenia was the most prominent toxicity. Grade 3 or grade 4 neutropenia was observed in 12 (38%) and 9 (25%) of the patients, respectively and 11 patients required hospitalisation. 3 patients died secondary to chemotherapy related sepsis. Diarrhoea (grade 3, 3 patients; grade 4, 2 patients) was the only other significant non-haematological acute toxicity. The optimal dose rate for this multifractionated regimen was <b style='color:Tomato;'><i>paclitaxel</i></b> 35 or 40 mg/m2/fraction; cisplatin 15 mg/m2/fraction; <b style='color:Tomato;'><i>etoposide</i></b> 35 or 40 mg/m2/fraction. Responses were observed in 28 of 37 evaluable patients (3 complete response; 25 partial responses [76%]. 22 patients are alive; 8 with stage III B disease received radiation or surgery (3 had minimal or no tumour in the pathology specimen). TPE is a highly active regimen for non-small cell lung cancer and multifractionated dose scheduling is a feasible and well tolerated system.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"total","start":4,"end":9,"id":1,"ws":true},{"text":"dose","start":10,"end":14,"id":2,"ws":true},{"text":"of","start":15,"end":17,"id":3,"ws":true},{"text":"paclitaxel","start":18,"end":28,"id":4,"ws":true},{"text":"(","start":29,"end":30,"id":5,"ws":true},{"text":"175","start":31,"end":34,"id":6,"ws":true},{"text":"-","start":35,"end":36,"id":7,"ws":true},{"text":"200","start":37,"end":40,"id":8,"ws":true},{"text":"mg/m2","start":41,"end":46,"id":9,"ws":true},{"text":")","start":47,"end":48,"id":10,"ws":true},{"text":";","start":49,"end":50,"id":11,"ws":true},{"text":"cisplatin","start":51,"end":60,"id":12,"ws":true},{"text":"(","start":61,"end":62,"id":13,"ws":true},{"text":"75","start":63,"end":65,"id":14,"ws":true},{"text":"mg/m2","start":66,"end":71,"id":15,"ws":true},{"text":")","start":72,"end":73,"id":16,"ws":true},{"text":";","start":74,"end":75,"id":17,"ws":true},{"text":"and","start":76,"end":79,"id":18,"ws":true},{"text":"etoposide","start":80,"end":89,"id":19,"ws":true},{"text":"(","start":90,"end":91,"id":20,"ws":true},{"text":"175","start":92,"end":95,"id":21,"ws":true},{"text":"-","start":96,"end":97,"id":22,"ws":true},{"text":"200","start":98,"end":101,"id":23,"ws":true},{"text":"mg/m2","start":102,"end":107,"id":24,"ws":true},{"text":")","start":108,"end":109,"id":25,"ws":true},{"text":"was","start":110,"end":113,"id":26,"ws":true},{"text":"divided","start":114,"end":121,"id":27,"ws":true},{"text":"into","start":122,"end":126,"id":28,"ws":true},{"text":"five","start":127,"end":131,"id":29,"ws":true},{"text":"daily","start":132,"end":137,"id":30,"ws":true},{"text":"doses","start":138,"end":143,"id":31,"ws":true},{"text":"administered","start":144,"end":156,"id":32,"ws":true},{"text":"over","start":157,"end":161,"id":33,"ws":true},{"text":"3","start":162,"end":163,"id":34,"ws":true},{"text":"h","start":164,"end":165,"id":35,"ws":true},{"text":"with","start":166,"end":170,"id":36,"ws":true},{"text":"cycles","start":171,"end":177,"id":37,"ws":true},{"text":"repeated","start":178,"end":186,"id":38,"ws":true},{"text":"at","start":187,"end":189,"id":39,"ws":true},{"text":"21","start":190,"end":192,"id":40,"ws":true},{"text":"-","start":193,"end":194,"id":41,"ws":true},{"text":"28","start":195,"end":197,"id":42,"ws":true},{"text":"days","start":198,"end":202,"id":43,"ws":true},{"text":".","start":203,"end":204,"id":44,"ws":false}],"spans":[{"start":18,"end":28,"token_start":4,"token_end":4,"label":"DRUG"},{"start":80,"end":89,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9713270/","_input_hash":1052186597,"_task_hash":-1301155451,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":4,"child":12,"head_span":{"start":18,"end":28,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":51,"end":60,"token_start":12,"token_end":12,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":19,"child":12,"head_span":{"start":80,"end":89,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":51,"end":60,"token_start":12,"token_end":12,"label":null},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In this phase 3 trial , we randomly assigned ( in a 1:1:1 ratio ) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib ( 20 mg orally once daily ) plus pembrolizumab ( 200 mg intravenously once every 3 weeks ) , lenvatinib ( 18 mg orally once daily ) plus everolimus ( 5 mg orally once daily ) , or sunitinib ( 50 mg orally once daily , alternating 4 weeks receiving treatment and 2 weeks without treatment ) .","paragraph":"<h3><u>Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.</u></h3><b style='color:Tomato;'><i>lenvatinib</i></b> in combination with <b style='color:Tomato;'><i>pembrolizumab</i></b> or <b style='color:Tomato;'><i>everolimus</i></b> has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of <b style='color:Tomato;'><i>sunitinib</i></b> is unclear. ### methods <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>1:1:1</i></b> <b style='color:DodgerBlue;'><i>ratio</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>previous</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:MediumOrchid;'><i>lenvatinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>lenvatinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alternating</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end point was progression-free survival, as assessed by an independent review committee in accordance with Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival and safety were also evaluated. ### results A total of 1069 patients were randomly assigned to receive <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b> (355 patients), <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b> (357), or <b style='color:Tomato;'><i>sunitinib</i></b> (357). Progression-free survival was longer with <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b> than with <b style='color:Tomato;'><i>sunitinib</i></b> (median, 23.9 vs. 9.2 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.32 to 0.49; P<0.001) and was longer with <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b> than with <b style='color:Tomato;'><i>sunitinib</i></b> (median, 14.7 vs. 9.2 months; hazard ratio, 0.65; 95% CI, 0.53 to 0.80; P<0.001). Overall survival was longer with <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b> than with <b style='color:Tomato;'><i>sunitinib</i></b> (hazard ratio for death, 0.66; 95% CI, 0.49 to 0.88; P\u2009=\u20090.005) but was not longer with <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b> than with <b style='color:Tomato;'><i>sunitinib</i></b> (hazard ratio, 1.15; 95% CI, 0.88 to 1.50; P\u2009=\u20090.30). Grade 3 or higher adverse events emerged or worsened during treatment in 82.4% of the patients who received <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b>, 83.1% of those who received <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b>, and 71.8% of those who received <b style='color:Tomato;'><i>sunitinib</i></b>. Grade 3 or higher adverse events occurring in at least 10% of the patients in any group included hypertension, diarrhea, and elevated lipase levels. ### conclusions <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b> was associated with significantly longer progression-free survival and overall survival than <b style='color:Tomato;'><i>sunitinib</i></b>. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"this","start":3,"end":7,"id":1,"ws":true},{"text":"phase","start":8,"end":13,"id":2,"ws":true},{"text":"3","start":14,"end":15,"id":3,"ws":true},{"text":"trial","start":16,"end":21,"id":4,"ws":true},{"text":",","start":22,"end":23,"id":5,"ws":true},{"text":"we","start":24,"end":26,"id":6,"ws":true},{"text":"randomly","start":27,"end":35,"id":7,"ws":true},{"text":"assigned","start":36,"end":44,"id":8,"ws":true},{"text":"(","start":45,"end":46,"id":9,"ws":true},{"text":"in","start":47,"end":49,"id":10,"ws":true},{"text":"a","start":50,"end":51,"id":11,"ws":true},{"text":"1:1:1","start":52,"end":57,"id":12,"ws":true},{"text":"ratio","start":58,"end":63,"id":13,"ws":true},{"text":")","start":64,"end":65,"id":14,"ws":true},{"text":"patients","start":66,"end":74,"id":15,"ws":true},{"text":"with","start":75,"end":79,"id":16,"ws":true},{"text":"advanced","start":80,"end":88,"id":17,"ws":true},{"text":"renal","start":89,"end":94,"id":18,"ws":true},{"text":"cell","start":95,"end":99,"id":19,"ws":true},{"text":"carcinoma","start":100,"end":109,"id":20,"ws":true},{"text":"and","start":110,"end":113,"id":21,"ws":true},{"text":"no","start":114,"end":116,"id":22,"ws":true},{"text":"previous","start":117,"end":125,"id":23,"ws":true},{"text":"systemic","start":126,"end":134,"id":24,"ws":true},{"text":"therapy","start":135,"end":142,"id":25,"ws":true},{"text":"to","start":143,"end":145,"id":26,"ws":true},{"text":"receive","start":146,"end":153,"id":27,"ws":true},{"text":"lenvatinib","start":154,"end":164,"id":28,"ws":true},{"text":"(","start":165,"end":166,"id":29,"ws":true},{"text":"20","start":167,"end":169,"id":30,"ws":true},{"text":"mg","start":170,"end":172,"id":31,"ws":true},{"text":"orally","start":173,"end":179,"id":32,"ws":true},{"text":"once","start":180,"end":184,"id":33,"ws":true},{"text":"daily","start":185,"end":190,"id":34,"ws":true},{"text":")","start":191,"end":192,"id":35,"ws":true},{"text":"plus","start":193,"end":197,"id":36,"ws":true},{"text":"pembrolizumab","start":198,"end":211,"id":37,"ws":true},{"text":"(","start":212,"end":213,"id":38,"ws":true},{"text":"200","start":214,"end":217,"id":39,"ws":true},{"text":"mg","start":218,"end":220,"id":40,"ws":true},{"text":"intravenously","start":221,"end":234,"id":41,"ws":true},{"text":"once","start":235,"end":239,"id":42,"ws":true},{"text":"every","start":240,"end":245,"id":43,"ws":true},{"text":"3","start":246,"end":247,"id":44,"ws":true},{"text":"weeks","start":248,"end":253,"id":45,"ws":true},{"text":")","start":254,"end":255,"id":46,"ws":true},{"text":",","start":256,"end":257,"id":47,"ws":true},{"text":"lenvatinib","start":258,"end":268,"id":48,"ws":true},{"text":"(","start":269,"end":270,"id":49,"ws":true},{"text":"18","start":271,"end":273,"id":50,"ws":true},{"text":"mg","start":274,"end":276,"id":51,"ws":true},{"text":"orally","start":277,"end":283,"id":52,"ws":true},{"text":"once","start":284,"end":288,"id":53,"ws":true},{"text":"daily","start":289,"end":294,"id":54,"ws":true},{"text":")","start":295,"end":296,"id":55,"ws":true},{"text":"plus","start":297,"end":301,"id":56,"ws":true},{"text":"everolimus","start":302,"end":312,"id":57,"ws":true},{"text":"(","start":313,"end":314,"id":58,"ws":true},{"text":"5","start":315,"end":316,"id":59,"ws":true},{"text":"mg","start":317,"end":319,"id":60,"ws":true},{"text":"orally","start":320,"end":326,"id":61,"ws":true},{"text":"once","start":327,"end":331,"id":62,"ws":true},{"text":"daily","start":332,"end":337,"id":63,"ws":true},{"text":")","start":338,"end":339,"id":64,"ws":true},{"text":",","start":340,"end":341,"id":65,"ws":true},{"text":"or","start":342,"end":344,"id":66,"ws":true},{"text":"sunitinib","start":345,"end":354,"id":67,"ws":true},{"text":"(","start":355,"end":356,"id":68,"ws":true},{"text":"50","start":357,"end":359,"id":69,"ws":true},{"text":"mg","start":360,"end":362,"id":70,"ws":true},{"text":"orally","start":363,"end":369,"id":71,"ws":true},{"text":"once","start":370,"end":374,"id":72,"ws":true},{"text":"daily","start":375,"end":380,"id":73,"ws":true},{"text":",","start":381,"end":382,"id":74,"ws":true},{"text":"alternating","start":383,"end":394,"id":75,"ws":true},{"text":"4","start":395,"end":396,"id":76,"ws":true},{"text":"weeks","start":397,"end":402,"id":77,"ws":true},{"text":"receiving","start":403,"end":412,"id":78,"ws":true},{"text":"treatment","start":413,"end":422,"id":79,"ws":true},{"text":"and","start":423,"end":426,"id":80,"ws":true},{"text":"2","start":427,"end":428,"id":81,"ws":true},{"text":"weeks","start":429,"end":434,"id":82,"ws":true},{"text":"without","start":435,"end":442,"id":83,"ws":true},{"text":"treatment","start":443,"end":452,"id":84,"ws":true},{"text":")","start":453,"end":454,"id":85,"ws":true},{"text":".","start":455,"end":456,"id":86,"ws":false}],"spans":[{"start":154,"end":164,"token_start":28,"token_end":28,"label":"DRUG"},{"start":198,"end":211,"token_start":37,"token_end":37,"label":"DRUG"},{"start":258,"end":268,"token_start":48,"token_end":48,"label":"DRUG"},{"start":302,"end":312,"token_start":57,"token_end":57,"label":"DRUG"},{"start":345,"end":354,"token_start":67,"token_end":67,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33616314/","_input_hash":-318641375,"_task_hash":-1256770653,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":28,"child":37,"head_span":{"start":154,"end":164,"token_start":28,"token_end":28,"label":"DRUG"},"child_span":{"start":198,"end":211,"token_start":37,"token_end":37,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":48,"child":57,"head_span":{"start":258,"end":268,"token_start":48,"token_end":48,"label":"DRUG"},"child_span":{"start":302,"end":312,"token_start":57,"token_end":57,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"Only chemotherapy by intravenous administration of 2 courses of 120 - 150 mg ACNU ( 1.7 - 2.2 mg/kg ) and 4 mg vincristine ( 0.06 mg/kg ) with intrathecal administration of methotrexate was given at this time .","paragraph":"<h3><u>A long surviving case of recurrent medulloblastoma displaying effectiveness of ACNU/vincristine chemotherapy.</u></h3>A favorable case of recurrent medulloblastoma, in which 19 years has elapsed with combination therapy due to surgery, radiation and chemotherapy since the initial operation, is reported. The case was a male of age 12 who was admitted due to medulloblastoma of the classical type. Tumor recurrences were observed 3 times within 7 years after the initial operation and radiation treatment. At the 3rd recurrence, a large tumor was found in the cerebellar vermis and left cerebellar hemisphere on CT with CSF dissemination and a high NSE level in the CSF (62 ng/ml). <b style='color:DodgerBlue;'><i>Only</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>courses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>150</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>ACNU</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1.7</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2.2</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.06</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intrathecal</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The tumor image and gait disturbance with radicular pain disappeared completely and the NSE level in the CSF improved to within the normal range (5.4 ng/ml). The patient continues in complete remission, with a Karnovsky performance status of 100% at 4 years after the 3rd recurrence. We report full details of this case in which active treatments consisting mainly of chemotherapy proved to be effective for recurrent medulloblastoma, even though its prognosis is generally very unfavorable.","tokens":[{"text":"Only","start":0,"end":4,"id":0,"ws":true},{"text":"chemotherapy","start":5,"end":17,"id":1,"ws":true},{"text":"by","start":18,"end":20,"id":2,"ws":true},{"text":"intravenous","start":21,"end":32,"id":3,"ws":true},{"text":"administration","start":33,"end":47,"id":4,"ws":true},{"text":"of","start":48,"end":50,"id":5,"ws":true},{"text":"2","start":51,"end":52,"id":6,"ws":true},{"text":"courses","start":53,"end":60,"id":7,"ws":true},{"text":"of","start":61,"end":63,"id":8,"ws":true},{"text":"120","start":64,"end":67,"id":9,"ws":true},{"text":"-","start":68,"end":69,"id":10,"ws":true},{"text":"150","start":70,"end":73,"id":11,"ws":true},{"text":"mg","start":74,"end":76,"id":12,"ws":true},{"text":"ACNU","start":77,"end":81,"id":13,"ws":true},{"text":"(","start":82,"end":83,"id":14,"ws":true},{"text":"1.7","start":84,"end":87,"id":15,"ws":true},{"text":"-","start":88,"end":89,"id":16,"ws":true},{"text":"2.2","start":90,"end":93,"id":17,"ws":true},{"text":"mg/kg","start":94,"end":99,"id":18,"ws":true},{"text":")","start":100,"end":101,"id":19,"ws":true},{"text":"and","start":102,"end":105,"id":20,"ws":true},{"text":"4","start":106,"end":107,"id":21,"ws":true},{"text":"mg","start":108,"end":110,"id":22,"ws":true},{"text":"vincristine","start":111,"end":122,"id":23,"ws":true},{"text":"(","start":123,"end":124,"id":24,"ws":true},{"text":"0.06","start":125,"end":129,"id":25,"ws":true},{"text":"mg/kg","start":130,"end":135,"id":26,"ws":true},{"text":")","start":136,"end":137,"id":27,"ws":true},{"text":"with","start":138,"end":142,"id":28,"ws":true},{"text":"intrathecal","start":143,"end":154,"id":29,"ws":true},{"text":"administration","start":155,"end":169,"id":30,"ws":true},{"text":"of","start":170,"end":172,"id":31,"ws":true},{"text":"methotrexate","start":173,"end":185,"id":32,"ws":true},{"text":"was","start":186,"end":189,"id":33,"ws":true},{"text":"given","start":190,"end":195,"id":34,"ws":true},{"text":"at","start":196,"end":198,"id":35,"ws":true},{"text":"this","start":199,"end":203,"id":36,"ws":true},{"text":"time","start":204,"end":208,"id":37,"ws":true},{"text":".","start":209,"end":210,"id":38,"ws":false}],"spans":[{"start":77,"end":81,"token_start":13,"token_end":13,"label":"DRUG"},{"start":111,"end":122,"token_start":23,"token_end":23,"label":"DRUG"},{"start":173,"end":185,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8057133/","_input_hash":1591607984,"_task_hash":-814820846,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":13,"child":23,"head_span":{"start":77,"end":81,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":111,"end":122,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":32,"child":32,"head_span":{"start":173,"end":185,"token_start":32,"token_end":32,"label":"DRUG"},"child_span":{"start":173,"end":185,"token_start":32,"token_end":32,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In first-line treatment of intermediate- to poor-risk patients , the CheckMate 214 study demonstrated a significant survival advantage for nivolumab and ipilimumab versus sunitinib .","paragraph":"<h3><u>A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.</u></h3>The treatment paradigm of advanced renal cell carcinoma (RCC) has changed rapidly in recent years. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>intermediate-</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>poor-risk</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>CheckMate</i></b> <b style='color:DodgerBlue;'><i>214</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The high cost of combined immune-modulating agents warrants an understanding of the combination's value by considering both efficacy and cost. The objective of this study was to estimate the cost-effectiveness of <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> compared with <b style='color:Tomato;'><i>sunitinib</i></b> for first-line treatment of intermediate- to poor-risk advanced RCC from the U.S. payer perspective. ### Materials And Methods A Markov model was developed to compare the costs and effectiveness of <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> with those of <b style='color:Tomato;'><i>sunitinib</i></b> in the first-line treatment of intermediate- to poor-risk advanced RCC. Health outcomes were measured in life-years and quality-adjusted life-years (QALYs). Drug costs were based on Medicare reimbursement rates in 2017. We extrapolated survival beyond the trial closure using Weibull distribution. Model robustness was addressed in univariable and probabilistic sensitivity analyses. ### results The total mean cost per-patient of <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> versus <b style='color:Tomato;'><i>sunitinib</i></b> was $292,308 and $169,287, respectfully. <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> generated a gain of 0.978 QALYs over <b style='color:Tomato;'><i>sunitinib</i></b>. The incremental cost-effectiveness ratio (ICER) for <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> was $125,739/QALY versus <b style='color:Tomato;'><i>sunitinib</i></b>. ### conclusion Our analysis established that the base case ICER in the model for <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> versus <b style='color:Tomato;'><i>sunitinib</i></b> is below what some would consider the upper limit of the theoretical willingness-to-pay threshold in the U.S. ($150,000/QALY) and is thus estimated to be cost-effective. ### Implications For Practice This article assessed the cost-effectiveness of <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> versus <b style='color:Tomato;'><i>sunitinib</i></b> for treatment of patients with intermediate- to poor-risk metastatic kidney cancer, from the U.S. payer perspective. It would cost $125,739 to gain 1 quality-adjusted life-year with <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> versus <b style='color:Tomato;'><i>sunitinib</i></b> in these patients.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"first-line","start":3,"end":13,"id":1,"ws":true},{"text":"treatment","start":14,"end":23,"id":2,"ws":true},{"text":"of","start":24,"end":26,"id":3,"ws":true},{"text":"intermediate-","start":27,"end":40,"id":4,"ws":true},{"text":"to","start":41,"end":43,"id":5,"ws":true},{"text":"poor-risk","start":44,"end":53,"id":6,"ws":true},{"text":"patients","start":54,"end":62,"id":7,"ws":true},{"text":",","start":63,"end":64,"id":8,"ws":true},{"text":"the","start":65,"end":68,"id":9,"ws":true},{"text":"CheckMate","start":69,"end":78,"id":10,"ws":true},{"text":"214","start":79,"end":82,"id":11,"ws":true},{"text":"study","start":83,"end":88,"id":12,"ws":true},{"text":"demonstrated","start":89,"end":101,"id":13,"ws":true},{"text":"a","start":102,"end":103,"id":14,"ws":true},{"text":"significant","start":104,"end":115,"id":15,"ws":true},{"text":"survival","start":116,"end":124,"id":16,"ws":true},{"text":"advantage","start":125,"end":134,"id":17,"ws":true},{"text":"for","start":135,"end":138,"id":18,"ws":true},{"text":"nivolumab","start":139,"end":148,"id":19,"ws":true},{"text":"and","start":149,"end":152,"id":20,"ws":true},{"text":"ipilimumab","start":153,"end":163,"id":21,"ws":true},{"text":"versus","start":164,"end":170,"id":22,"ws":true},{"text":"sunitinib","start":171,"end":180,"id":23,"ws":true},{"text":".","start":181,"end":182,"id":24,"ws":false}],"spans":[{"start":139,"end":148,"token_start":19,"token_end":19,"label":"DRUG"},{"start":153,"end":163,"token_start":21,"token_end":21,"label":"DRUG"},{"start":171,"end":180,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30710066/","_input_hash":448328555,"_task_hash":136127527,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":19,"child":21,"head_span":{"start":139,"end":148,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":153,"end":163,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"In addition , docetaxel has a longer retention time in tumor cells than paclitaxel because of greater uptake and slower efflux .","paragraph":"<h3><u>Preclinical pharmacology of the taxanes: implications of the differences.</u></h3>Taxanes are one of the most powerful classes of compounds among all chemotherapeutic drugs. Only 30 years separate the isolation of the first taxane from the results of direct clinical comparisons in metastatic breast, ovarian, and lung cancer between the two taxanes available in routine clinical practice. These results suggest a more favorable benefit-to-risk ratio for <b style='color:Tomato;'><i>docetaxel</i></b> compared to <b style='color:Tomato;'><i>paclitaxel</i></b> when these drugs are used as single agents or in combination with other chemotherapeutic agents in an every-3-week dosing regimen. Pharmacological data support the difference between the taxanes, likely explaining the clinical results. Considering the molecular pharmacology of the two drugs, <b style='color:Tomato;'><i>docetaxel</i></b> appears to bind to beta-tubulin with greater affinity and has a wider cell cycle activity than <b style='color:Tomato;'><i>paclitaxel</i></b>. <b style='color:Tomato;'><i>docetaxel</i></b> also appears to have direct antitumoral activity via an apoptotic effect mediated by bcl-2 phosphorylation. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>longer</i></b> <b style='color:DodgerBlue;'><i>retention</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>uptake</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>slower</i></b> <b style='color:DodgerBlue;'><i>efflux</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pharmacokinetics and pharmacodynamics of the taxanes show both agents to be extensively metabolized in the liver, and <b style='color:Tomato;'><i>paclitaxel</i></b> has a nonlinear pharmacokinetic behavior while <b style='color:Tomato;'><i>docetaxel</i></b> has linear pharmacokinetics. These differences explain the more simple treatment schedule and favorable results for <b style='color:Tomato;'><i>docetaxel</i></b> as a single agent and in combination therapy. Last, but not least, there is a pharmacokinetic interaction between <b style='color:Tomato;'><i>paclitaxel</i></b> and the anthracyclines, an active class of compounds commonly used in the treatment of breast cancer. This pharmacokinetic interaction is associated with greater cardio- and myelotoxicities, which are sequence dependent. These pharmacological data likely explain the different clinical development strategies for the two molecules as well as the different clinical results from individual trials and direct comparisons.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"addition","start":3,"end":11,"id":1,"ws":true},{"text":",","start":12,"end":13,"id":2,"ws":true},{"text":"docetaxel","start":14,"end":23,"id":3,"ws":true},{"text":"has","start":24,"end":27,"id":4,"ws":true},{"text":"a","start":28,"end":29,"id":5,"ws":true},{"text":"longer","start":30,"end":36,"id":6,"ws":true},{"text":"retention","start":37,"end":46,"id":7,"ws":true},{"text":"time","start":47,"end":51,"id":8,"ws":true},{"text":"in","start":52,"end":54,"id":9,"ws":true},{"text":"tumor","start":55,"end":60,"id":10,"ws":true},{"text":"cells","start":61,"end":66,"id":11,"ws":true},{"text":"than","start":67,"end":71,"id":12,"ws":true},{"text":"paclitaxel","start":72,"end":82,"id":13,"ws":true},{"text":"because","start":83,"end":90,"id":14,"ws":true},{"text":"of","start":91,"end":93,"id":15,"ws":true},{"text":"greater","start":94,"end":101,"id":16,"ws":true},{"text":"uptake","start":102,"end":108,"id":17,"ws":true},{"text":"and","start":109,"end":112,"id":18,"ws":true},{"text":"slower","start":113,"end":119,"id":19,"ws":true},{"text":"efflux","start":120,"end":126,"id":20,"ws":true},{"text":".","start":127,"end":128,"id":21,"ws":false}],"spans":[{"start":14,"end":23,"token_start":3,"token_end":3,"label":"DRUG"},{"start":72,"end":82,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15161985/","_input_hash":1766096591,"_task_hash":-393739801,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The total sample size was 103 , consisting of 31 , 23 , and 19 patients in olanzapine , risperidone , and clozapine groups , respectively and 30 controls .","paragraph":"<h3><u>Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia.</u></h3>Sexual dysfunctions have been a major side effect of the second generation anti-psychotic drugs which often affects treatment compliance in patients with schizophrenia. There is no/few systematic review or research addressing sexual dysfunction and their effect on serum prolactin level among different atypical antipsychotics in India. ### aims To determine and compare the frequency of sexual dysfunction associated with <b style='color:Tomato;'><i>olanzapine</i></b>, <b style='color:Tomato;'><i>risperidone</i></b>, and <b style='color:Tomato;'><i>clozapine</i></b> and their effect on serum prolactin level in remitted patients with schizophrenia. ### Settings And Design Cross-sectional hospital-based study. Recruitment by purposive sampling. Estimation of serum prolactin was done using enzyme-linked immunosorbent assay technique. ### Materials And Methods <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>sample</i></b> <b style='color:DodgerBlue;'><i>size</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>103</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>31</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>23</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>19</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:MediumOrchid;'><i>olanzapine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>risperidone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clozapine</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>controls</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A Brief Psychiatric Rating Scale, Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale and Sexual Functioning Questionnaire were administered. Analysis of variance was used to compare clinical variables. Chi-square test was used to identify the frequency of sexual dysfunction. Kruskal-Wallis test was used to compare UKU side effect, sexual dysfunction, and blood parameters across the study groups. ### Results And Conclusion Eighty-six percentage reported sexual dysfunction in one or more domains of sexual functioning in <b style='color:Tomato;'><i>risperidone</i></b> group as compared to 48.3% in <b style='color:Tomato;'><i>olanzapine</i></b> and 31% in <b style='color:Tomato;'><i>clozapine</i></b> groups, respectively. Prolactin level elevation was statistically significant in <b style='color:Tomato;'><i>risperidone</i></b> group followed by <b style='color:Tomato;'><i>clozapine</i></b> and <b style='color:Tomato;'><i>olanzapine</i></b> groups, respectively.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"total","start":4,"end":9,"id":1,"ws":true},{"text":"sample","start":10,"end":16,"id":2,"ws":true},{"text":"size","start":17,"end":21,"id":3,"ws":true},{"text":"was","start":22,"end":25,"id":4,"ws":true},{"text":"103","start":26,"end":29,"id":5,"ws":true},{"text":",","start":30,"end":31,"id":6,"ws":true},{"text":"consisting","start":32,"end":42,"id":7,"ws":true},{"text":"of","start":43,"end":45,"id":8,"ws":true},{"text":"31","start":46,"end":48,"id":9,"ws":true},{"text":",","start":49,"end":50,"id":10,"ws":true},{"text":"23","start":51,"end":53,"id":11,"ws":true},{"text":",","start":54,"end":55,"id":12,"ws":true},{"text":"and","start":56,"end":59,"id":13,"ws":true},{"text":"19","start":60,"end":62,"id":14,"ws":true},{"text":"patients","start":63,"end":71,"id":15,"ws":true},{"text":"in","start":72,"end":74,"id":16,"ws":true},{"text":"olanzapine","start":75,"end":85,"id":17,"ws":true},{"text":",","start":86,"end":87,"id":18,"ws":true},{"text":"risperidone","start":88,"end":99,"id":19,"ws":true},{"text":",","start":100,"end":101,"id":20,"ws":true},{"text":"and","start":102,"end":105,"id":21,"ws":true},{"text":"clozapine","start":106,"end":115,"id":22,"ws":true},{"text":"groups","start":116,"end":122,"id":23,"ws":true},{"text":",","start":123,"end":124,"id":24,"ws":true},{"text":"respectively","start":125,"end":137,"id":25,"ws":true},{"text":"and","start":138,"end":141,"id":26,"ws":true},{"text":"30","start":142,"end":144,"id":27,"ws":true},{"text":"controls","start":145,"end":153,"id":28,"ws":true},{"text":".","start":154,"end":155,"id":29,"ws":false}],"spans":[{"start":75,"end":85,"token_start":17,"token_end":17,"label":"DRUG"},{"start":88,"end":99,"token_start":19,"token_end":19,"label":"DRUG"},{"start":106,"end":115,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26816428/","_input_hash":1935711712,"_task_hash":-240299774,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The relative analgesic potency ratios were 0.65 ( 0.56 - 0.76 ) for ropivacaine : bupivacaine , 0.80 ( 0.70 - 0.92 ) for ropivacaine : levobupivacaine , and 0.81 ( 0.69 - 0.94 ) for levobupivacaine : bupivacaine .","paragraph":"<h3><u>Minimum local analgesic doses of ropivacaine, levobupivacaine, and bupivacaine for intrathecal labor analgesia.</u></h3>Doses for intrathecal opioid-local anesthetic mixtures have been arbitrarily chosen. The aim of this study was to compare the analgesic efficacies of intrathecal <b style='color:Tomato;'><i>ropivacaine</i></b>, levo<b style='color:Tomato;'><i>bupivacaine</i></b>, and <b style='color:Tomato;'><i>bupivacaine</i></b> for labor analgesia and to determine the analgesic potency ratios for these three drugs. For this purpose, the authors used the up-down sequential allocation model, which estimates the minimum local analgesic dose for intrathecal local anesthetic. ### methods Ninety-seven nulliparous term parturients in spontaneous labor, requesting combined spinal-epidural analgesia, were randomly allocated to one of three groups to receive 0.25% spinal <b style='color:Tomato;'><i>ropivacaine</i></b>, levo<b style='color:Tomato;'><i>bupivacaine</i></b>, or <b style='color:Tomato;'><i>bupivacaine</i></b>. The initial dose of the local anesthetic drug was chosen to be 2.5 mg, and the testing interval was set at 0.25 mg. The subsequent doses were determined by the response of the previous parturient. Efficacy was accepted if the visual analog pain score decreased to 10 mm or less on a 100-mm scale within 30 min. The minimum local analgesic dose was calculated using the method of Dixon and Massey. ### results The intrathecal minimum local analgesic dose was 3.64 mg (95% confidence interval, 3.33-3.96 mg) for <b style='color:Tomato;'><i>ropivacaine</i></b>, 2.94 (2.73-3.16) mg for levo<b style='color:Tomato;'><i>bupivacaine</i></b>, and 2.37 (2.17-2.58) mg for <b style='color:Tomato;'><i>bupivacaine</i></b>. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>relative</i></b> <b style='color:DodgerBlue;'><i>analgesic</i></b> <b style='color:DodgerBlue;'><i>potency</i></b> <b style='color:DodgerBlue;'><i>ratios</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>0.65</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.56</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>0.76</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>ropivacaine</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>0.80</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.70</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>0.92</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>ropivacaine</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>levobupivacaine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.81</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.69</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>0.94</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>levobupivacaine</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There were significant trends (P </= 0.021) for greater motor block with <b style='color:Tomato;'><i>bupivacaine</i></b> and levo<b style='color:Tomato;'><i>bupivacaine</i></b>. ### conclusions This study suggests a potency hierarchy of spinal <b style='color:Tomato;'><i>bupivacaine</i></b> > levo<b style='color:Tomato;'><i>bupivacaine</i></b> > <b style='color:Tomato;'><i>ropivacaine</i></b>.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"relative","start":4,"end":12,"id":1,"ws":true},{"text":"analgesic","start":13,"end":22,"id":2,"ws":true},{"text":"potency","start":23,"end":30,"id":3,"ws":true},{"text":"ratios","start":31,"end":37,"id":4,"ws":true},{"text":"were","start":38,"end":42,"id":5,"ws":true},{"text":"0.65","start":43,"end":47,"id":6,"ws":true},{"text":"(","start":48,"end":49,"id":7,"ws":true},{"text":"0.56","start":50,"end":54,"id":8,"ws":true},{"text":"-","start":55,"end":56,"id":9,"ws":true},{"text":"0.76","start":57,"end":61,"id":10,"ws":true},{"text":")","start":62,"end":63,"id":11,"ws":true},{"text":"for","start":64,"end":67,"id":12,"ws":true},{"text":"ropivacaine","start":68,"end":79,"id":13,"ws":true},{"text":":","start":80,"end":81,"id":14,"ws":true},{"text":"bupivacaine","start":82,"end":93,"id":15,"ws":true},{"text":",","start":94,"end":95,"id":16,"ws":true},{"text":"0.80","start":96,"end":100,"id":17,"ws":true},{"text":"(","start":101,"end":102,"id":18,"ws":true},{"text":"0.70","start":103,"end":107,"id":19,"ws":true},{"text":"-","start":108,"end":109,"id":20,"ws":true},{"text":"0.92","start":110,"end":114,"id":21,"ws":true},{"text":")","start":115,"end":116,"id":22,"ws":true},{"text":"for","start":117,"end":120,"id":23,"ws":true},{"text":"ropivacaine","start":121,"end":132,"id":24,"ws":true},{"text":":","start":133,"end":134,"id":25,"ws":true},{"text":"levobupivacaine","start":135,"end":150,"id":26,"ws":true},{"text":",","start":151,"end":152,"id":27,"ws":true},{"text":"and","start":153,"end":156,"id":28,"ws":true},{"text":"0.81","start":157,"end":161,"id":29,"ws":true},{"text":"(","start":162,"end":163,"id":30,"ws":true},{"text":"0.69","start":164,"end":168,"id":31,"ws":true},{"text":"-","start":169,"end":170,"id":32,"ws":true},{"text":"0.94","start":171,"end":175,"id":33,"ws":true},{"text":")","start":176,"end":177,"id":34,"ws":true},{"text":"for","start":178,"end":181,"id":35,"ws":true},{"text":"levobupivacaine","start":182,"end":197,"id":36,"ws":true},{"text":":","start":198,"end":199,"id":37,"ws":true},{"text":"bupivacaine","start":200,"end":211,"id":38,"ws":true},{"text":".","start":212,"end":213,"id":39,"ws":false}],"spans":[{"start":68,"end":79,"token_start":13,"token_end":13,"label":"DRUG"},{"start":82,"end":93,"token_start":15,"token_end":15,"label":"DRUG"},{"start":121,"end":132,"token_start":24,"token_end":24,"label":"DRUG"},{"start":135,"end":150,"token_start":26,"token_end":26,"label":"DRUG"},{"start":182,"end":197,"token_start":36,"token_end":36,"label":"DRUG"},{"start":200,"end":211,"token_start":38,"token_end":38,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15731605/","_input_hash":-88937528,"_task_hash":-1639390727,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Lapatinib ( LPT ) could sensitize human epidermal growth factor receptor-2 ( HER-2 ) positive breast cancer to paclitaxel ( PTX ) and induce synergetic action with PTX in preclinical test and phase II/III trial .","paragraph":"<h3><u>A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.</u></h3> <b style='color:MediumOrchid;'><i>Lapatinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LPT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>could</i></b> <b style='color:DodgerBlue;'><i>sensitize</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>epidermal</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>receptor-2</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HER-2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>induce</i></b> <b style='color:DodgerBlue;'><i>synergetic</i></b> <b style='color:DodgerBlue;'><i>action</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>PTX</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>preclinical</i></b> <b style='color:DodgerBlue;'><i>test</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II/III</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, LPT-conjugated poly (ethylene glycol) (PEG) and poly (lactic acid) (PLA) (LPT-PEG-PLA) was first synthesized and confirmed with \u00b9H Nuclear Magnetic Resonance and Matrix-Assisted Laser Desorption/ Ionization Time of Flight Mass Spectrometry, which was used for the preparation of a novel PEG-PLA combined micelles of LPT and PTX (PPM-LP). The obtained PPM-LP exhibited uniform, spherical shape with a size of 25.80 \u00b1 0.47 nm and zeta potential of -3.17 \u00b1 0.15 mv. PTX existed in molecular or amorphous forms in the micelles and superficial LPT could better delay PTX release. The cytotoxicity of PPM-LP with LPT conjugation against SKBr-3 cells (HER-2 positive) was found to be significantly increasing as compared with PPM-PTX, whereas there was no significant difference against MDA-MB-231 cells (HER-2 negative). PPM-LP could escape from endosomes and be distributed into cytoplasm and led to cell arrest in G2/M and G1/S phases simultaneously. Results of nucleus staining and flow cytometry confirmed that LPT could remarkably increase antineoplastic effect of PTX against SKBr-3 cells. All these results demonstrated that PPM-LP may be a promising drug delivery system for HER-2 positive breast cancer.","tokens":[{"text":"Lapatinib","start":0,"end":9,"id":0,"ws":true},{"text":"(","start":10,"end":11,"id":1,"ws":true},{"text":"LPT","start":12,"end":15,"id":2,"ws":true},{"text":")","start":16,"end":17,"id":3,"ws":true},{"text":"could","start":18,"end":23,"id":4,"ws":true},{"text":"sensitize","start":24,"end":33,"id":5,"ws":true},{"text":"human","start":34,"end":39,"id":6,"ws":true},{"text":"epidermal","start":40,"end":49,"id":7,"ws":true},{"text":"growth","start":50,"end":56,"id":8,"ws":true},{"text":"factor","start":57,"end":63,"id":9,"ws":true},{"text":"receptor-2","start":64,"end":74,"id":10,"ws":true},{"text":"(","start":75,"end":76,"id":11,"ws":true},{"text":"HER-2","start":77,"end":82,"id":12,"ws":true},{"text":")","start":83,"end":84,"id":13,"ws":true},{"text":"positive","start":85,"end":93,"id":14,"ws":true},{"text":"breast","start":94,"end":100,"id":15,"ws":true},{"text":"cancer","start":101,"end":107,"id":16,"ws":true},{"text":"to","start":108,"end":110,"id":17,"ws":true},{"text":"paclitaxel","start":111,"end":121,"id":18,"ws":true},{"text":"(","start":122,"end":123,"id":19,"ws":true},{"text":"PTX","start":124,"end":127,"id":20,"ws":true},{"text":")","start":128,"end":129,"id":21,"ws":true},{"text":"and","start":130,"end":133,"id":22,"ws":true},{"text":"induce","start":134,"end":140,"id":23,"ws":true},{"text":"synergetic","start":141,"end":151,"id":24,"ws":true},{"text":"action","start":152,"end":158,"id":25,"ws":true},{"text":"with","start":159,"end":163,"id":26,"ws":true},{"text":"PTX","start":164,"end":167,"id":27,"ws":true},{"text":"in","start":168,"end":170,"id":28,"ws":true},{"text":"preclinical","start":171,"end":182,"id":29,"ws":true},{"text":"test","start":183,"end":187,"id":30,"ws":true},{"text":"and","start":188,"end":191,"id":31,"ws":true},{"text":"phase","start":192,"end":197,"id":32,"ws":true},{"text":"II/III","start":198,"end":204,"id":33,"ws":true},{"text":"trial","start":205,"end":210,"id":34,"ws":true},{"text":".","start":211,"end":212,"id":35,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":111,"end":121,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25421492/","_input_hash":-435231815,"_task_hash":-1109865721,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":0,"child":18,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":111,"end":121,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Two of nine patients received 15 mg/kg bevacizumab IV , 90 mg/m(2 ) irinotecan orally for five consecutive days , 100 mg/m(2)/day temozolomide IV for 5 days , and 1.5 mg/m(2 ) vincristine IV , each administered every 21 days .","paragraph":"<h3><u>Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.</u></h3>Chemotherapy for relapsed medulloblastoma has been inadequate, and most patients succumb to disease. ### methods We retrospectively reviewed nine cases of relapsed medulloblastoma treated with <b style='color:Tomato;'><i>bevacizumab</i></b>, <b style='color:Tomato;'><i>irinotecan</i></b>, \u00b1\u2009<b style='color:Tomato;'><i>temozolomide</i></b>. Patients received one to three prior therapeutic regimens. Five patients received 10 mg/kg <b style='color:Tomato;'><i>bevacizumab</i></b> and 125-150 mg/m(2) <b style='color:Tomato;'><i>irinotecan</i></b> IV every 2 weeks, with <b style='color:Tomato;'><i>temozolomide</i></b>, starting at a median dose of 150 mg/m(2) orally for 5 days monthly. Two patients received <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b>, but not <b style='color:Tomato;'><i>temozolomide</i></b>, due to provider preference. <b style='color:DodgerBlue;'><i>Two</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>nine</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>90</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>five</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m(2)/day</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>1.5</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Median time to progression was 11 months. Median overall survival was 13 months. Objective tumor response at 3 months was 67 %, including six patients with partial response (PR) and three patients with stable disease (SD). At 6 months, objective response was 55 %, with two patients with PR and three with complete response. Additionally, one patient had SD and three had PD. Two patients remain alive and progression free at 15 and 55 months; another is alive with disease at 20 months. Toxicities included two patients with grade III neutropenia, two with grade III thrombocytopenia, one with grade III elevation of liver function tests, and one patient with grade III diarrhea. ### conclusions The combination of <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b>, with or without <b style='color:Tomato;'><i>temozolomide</i></b>, produces objective responses with minimal toxicity in children with recurrent medulloblastoma. Prospective clinical trials are needed to evaluate the efficacy of this strategy.","tokens":[{"text":"Two","start":0,"end":3,"id":0,"ws":true},{"text":"of","start":4,"end":6,"id":1,"ws":true},{"text":"nine","start":7,"end":11,"id":2,"ws":true},{"text":"patients","start":12,"end":20,"id":3,"ws":true},{"text":"received","start":21,"end":29,"id":4,"ws":true},{"text":"15","start":30,"end":32,"id":5,"ws":true},{"text":"mg/kg","start":33,"end":38,"id":6,"ws":true},{"text":"bevacizumab","start":39,"end":50,"id":7,"ws":true},{"text":"IV","start":51,"end":53,"id":8,"ws":true},{"text":",","start":54,"end":55,"id":9,"ws":true},{"text":"90","start":56,"end":58,"id":10,"ws":true},{"text":"mg/m(2","start":59,"end":65,"id":11,"ws":true},{"text":")","start":66,"end":67,"id":12,"ws":true},{"text":"irinotecan","start":68,"end":78,"id":13,"ws":true},{"text":"orally","start":79,"end":85,"id":14,"ws":true},{"text":"for","start":86,"end":89,"id":15,"ws":true},{"text":"five","start":90,"end":94,"id":16,"ws":true},{"text":"consecutive","start":95,"end":106,"id":17,"ws":true},{"text":"days","start":107,"end":111,"id":18,"ws":true},{"text":",","start":112,"end":113,"id":19,"ws":true},{"text":"100","start":114,"end":117,"id":20,"ws":true},{"text":"mg/m(2)/day","start":118,"end":129,"id":21,"ws":true},{"text":"temozolomide","start":130,"end":142,"id":22,"ws":true},{"text":"IV","start":143,"end":145,"id":23,"ws":true},{"text":"for","start":146,"end":149,"id":24,"ws":true},{"text":"5","start":150,"end":151,"id":25,"ws":true},{"text":"days","start":152,"end":156,"id":26,"ws":true},{"text":",","start":157,"end":158,"id":27,"ws":true},{"text":"and","start":159,"end":162,"id":28,"ws":true},{"text":"1.5","start":163,"end":166,"id":29,"ws":true},{"text":"mg/m(2","start":167,"end":173,"id":30,"ws":true},{"text":")","start":174,"end":175,"id":31,"ws":true},{"text":"vincristine","start":176,"end":187,"id":32,"ws":true},{"text":"IV","start":188,"end":190,"id":33,"ws":true},{"text":",","start":191,"end":192,"id":34,"ws":true},{"text":"each","start":193,"end":197,"id":35,"ws":true},{"text":"administered","start":198,"end":210,"id":36,"ws":true},{"text":"every","start":211,"end":216,"id":37,"ws":true},{"text":"21","start":217,"end":219,"id":38,"ws":true},{"text":"days","start":220,"end":224,"id":39,"ws":true},{"text":".","start":225,"end":226,"id":40,"ws":false}],"spans":[{"start":39,"end":50,"token_start":7,"token_end":7,"label":"DRUG"},{"start":68,"end":78,"token_start":13,"token_end":13,"label":"DRUG"},{"start":130,"end":142,"token_start":22,"token_end":22,"label":"DRUG"},{"start":176,"end":187,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23296323/","_input_hash":-1934185768,"_task_hash":-1998585097,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":7,"child":13,"head_span":{"start":39,"end":50,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":68,"end":78,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":22,"child":13,"head_span":{"start":130,"end":142,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":68,"end":78,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"These findings may help clinicians identify patients for whom acamprosate and naltrexone may be most beneficial .","paragraph":"<h3><u>Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.</u></h3>The COMBINE study evaluated the effects of <b style='color:Tomato;'><i>acamprosate</i></b>, <b style='color:Tomato;'><i>naltrexone</i></b>, and the Combined Behavioral Intervention (CBI). In secondary analyses, our goals were to identify trajectories of any drinking prior to randomization, to characterize subjects in these trajectories, and to assess whether prerandomization trajectories predict drinking outcomes and moderate treatment response. ### methods We analyzed daily indicators of any drinking in 90 days prior to randomization using a trajectory-based approach. General linear models and generalized logistic regression assessed main and interactive effects of prerandomization drinking trajectories and treatment on summary drinking measures during active treatment. ### results We identified five trajectories of any drinking prior to randomization: \"T1: frequent drinkers\", \"T2: very frequent drinkers\", \"T3: nearly daily drinkers\", \"T4: consistent daily drinkers\", and \"T5: daily drinkers stopping early\". During treatment, \"T3: nearly daily drinkers\" and \"T4: consistent daily drinkers\" had significantly worse drinking outcomes than \"T1: frequent drinkers\", while \"T5: daily drinkers stopping early\" had comparable drinking outcomes to \"T1: frequent drinkers\". <b style='color:Tomato;'><i>acamprosate</i></b> significantly increased the chance of abstinence from heavy drinking for the \"T2: very frequent drinking\" trajectory but decreased the chance of abstinence from heavy drinking for \"T5: daily drinkers stopping early\". <b style='color:Tomato;'><i>naltrexone</i></b> differentially improved rates of continuous abstinence for very frequent drinkers. ### conclusions <b style='color:Tomato;'><i>acamprosate</i></b> benefited very frequent drinkers and contrary to expectations was associated with poorer response compared to placebo for consistent daily drinkers who had longer durations of pretreatment abstinence (e.g., \u226514 days). Baseline drinking trajectories also moderated <b style='color:Tomato;'><i>naltrexone</i></b> effects. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>findings</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>help</i></b> <b style='color:DodgerBlue;'><i>clinicians</i></b> <b style='color:DodgerBlue;'><i>identify</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>whom</i></b> <b style='color:MediumOrchid;'><i>acamprosate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>naltrexone</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"findings","start":6,"end":14,"id":1,"ws":true},{"text":"may","start":15,"end":18,"id":2,"ws":true},{"text":"help","start":19,"end":23,"id":3,"ws":true},{"text":"clinicians","start":24,"end":34,"id":4,"ws":true},{"text":"identify","start":35,"end":43,"id":5,"ws":true},{"text":"patients","start":44,"end":52,"id":6,"ws":true},{"text":"for","start":53,"end":56,"id":7,"ws":true},{"text":"whom","start":57,"end":61,"id":8,"ws":true},{"text":"acamprosate","start":62,"end":73,"id":9,"ws":true},{"text":"and","start":74,"end":77,"id":10,"ws":true},{"text":"naltrexone","start":78,"end":88,"id":11,"ws":true},{"text":"may","start":89,"end":92,"id":12,"ws":true},{"text":"be","start":93,"end":95,"id":13,"ws":true},{"text":"most","start":96,"end":100,"id":14,"ws":true},{"text":"beneficial","start":101,"end":111,"id":15,"ws":true},{"text":".","start":112,"end":113,"id":16,"ws":false}],"spans":[{"start":62,"end":73,"token_start":9,"token_end":9,"label":"DRUG"},{"start":78,"end":88,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21143249/","_input_hash":548050658,"_task_hash":-570129931,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"From August 2002 to August 2004 , 42 patients with metastatic breast cancer were recruited for treatment with pegylated liposomal doxorubicin 40 mg/m(2 ) intravenously ( i.v . ) on day 1 and vinorelbine 30 mg/m(2 ) i.v . on days 1 and 15 every 4 weeks .","paragraph":"<h3><u>Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.</u></h3>This multicenter phase II trial was conducted to analyze the clinical activity and toxicity of the combination of pegylated liposomal <b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> as first-line treatment in elderly patients with metastatic breast cancer. ### Patients And Methods <b style='color:DodgerBlue;'><i>From</i></b> <b style='color:DodgerBlue;'><i>August</i></b> <b style='color:DodgerBlue;'><i>2002</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>August</i></b> <b style='color:DodgerBlue;'><i>2004</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>42</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>recruited</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>pegylated</i></b> <b style='color:DodgerBlue;'><i>liposomal</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results The median age of the patients in this trial was 68 years (range 60-82). 40% of patients had 2 or more sites of metastasis, 33 (78%) had predominantly visceral metastasis, and 7 (16%) mostly bone metastasis. Just 2 (5%) patients had only lymphogenous or soft tissue metastasis. All patients had an ECOG performance status of 0-1, but 70% of the patients had relevant comorbidities. In an intention-to-treat analysis, the overall clinical response rate was 36%, the complete response rate was 2%, and the rate of partial remissions was 34%; stable disease occurred in 30%, and progressive disease was observed in 36%. Median duration of response was 10 months. Median time to progression was 4 months, and median overall survival time was 24 months. ### conclusion The combination of pegylated liposomal <b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> is an active and well tolerated regimen in elderly patients with metastatic breast cancer in first-line treatment.","tokens":[{"text":"From","start":0,"end":4,"id":0,"ws":true},{"text":"August","start":5,"end":11,"id":1,"ws":true},{"text":"2002","start":12,"end":16,"id":2,"ws":true},{"text":"to","start":17,"end":19,"id":3,"ws":true},{"text":"August","start":20,"end":26,"id":4,"ws":true},{"text":"2004","start":27,"end":31,"id":5,"ws":true},{"text":",","start":32,"end":33,"id":6,"ws":true},{"text":"42","start":34,"end":36,"id":7,"ws":true},{"text":"patients","start":37,"end":45,"id":8,"ws":true},{"text":"with","start":46,"end":50,"id":9,"ws":true},{"text":"metastatic","start":51,"end":61,"id":10,"ws":true},{"text":"breast","start":62,"end":68,"id":11,"ws":true},{"text":"cancer","start":69,"end":75,"id":12,"ws":true},{"text":"were","start":76,"end":80,"id":13,"ws":true},{"text":"recruited","start":81,"end":90,"id":14,"ws":true},{"text":"for","start":91,"end":94,"id":15,"ws":true},{"text":"treatment","start":95,"end":104,"id":16,"ws":true},{"text":"with","start":105,"end":109,"id":17,"ws":true},{"text":"pegylated","start":110,"end":119,"id":18,"ws":true},{"text":"liposomal","start":120,"end":129,"id":19,"ws":true},{"text":"doxorubicin","start":130,"end":141,"id":20,"ws":true},{"text":"40","start":142,"end":144,"id":21,"ws":true},{"text":"mg/m(2","start":145,"end":151,"id":22,"ws":true},{"text":")","start":152,"end":153,"id":23,"ws":true},{"text":"intravenously","start":154,"end":167,"id":24,"ws":true},{"text":"(","start":168,"end":169,"id":25,"ws":true},{"text":"i.v","start":170,"end":173,"id":26,"ws":true},{"text":".","start":174,"end":175,"id":27,"ws":true},{"text":")","start":176,"end":177,"id":28,"ws":true},{"text":"on","start":178,"end":180,"id":29,"ws":true},{"text":"day","start":181,"end":184,"id":30,"ws":true},{"text":"1","start":185,"end":186,"id":31,"ws":true},{"text":"and","start":187,"end":190,"id":32,"ws":true},{"text":"vinorelbine","start":191,"end":202,"id":33,"ws":true},{"text":"30","start":203,"end":205,"id":34,"ws":true},{"text":"mg/m(2","start":206,"end":212,"id":35,"ws":true},{"text":")","start":213,"end":214,"id":36,"ws":true},{"text":"i.v","start":215,"end":218,"id":37,"ws":true},{"text":".","start":219,"end":220,"id":38,"ws":true},{"text":"on","start":221,"end":223,"id":39,"ws":true},{"text":"days","start":224,"end":228,"id":40,"ws":true},{"text":"1","start":229,"end":230,"id":41,"ws":true},{"text":"and","start":231,"end":234,"id":42,"ws":true},{"text":"15","start":235,"end":237,"id":43,"ws":true},{"text":"every","start":238,"end":243,"id":44,"ws":true},{"text":"4","start":244,"end":245,"id":45,"ws":true},{"text":"weeks","start":246,"end":251,"id":46,"ws":true},{"text":".","start":252,"end":253,"id":47,"ws":false}],"spans":[{"start":130,"end":141,"token_start":20,"token_end":20,"label":"DRUG"},{"start":191,"end":202,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19209014/","_input_hash":-1438243699,"_task_hash":-1653343456,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":20,"child":33,"head_span":{"start":130,"end":141,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":191,"end":202,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The aim of the present study was to investigate the combined effects of simvastatin and exemestane on MCF-7 human breast cancer cells .","paragraph":"<h3><u>Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells.</u></h3>Breast cancer is associated with high levels of incidence, morbidity and mortality; therefore, the identification of effective chemopreventive strategies is crucial. It is important for clinicians to be able to identify the populations at risk who would benefit from chemoprevention, and the interventions that are effective and safe. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The anti-proliferative effects of <b style='color:Tomato;'><i>simvastatin</i></b> and <b style='color:Tomato;'><i>exemestane</i></b>, alone and in combination, on the growth of MCF-7 human breast cancer cells were assessed by MTT assay. The synergism between the two drugs was determined in vitro using the combination index (CI) analysis. Cell cycle distribution and apoptosis were analyzed by flow cytometry, and alterations to the signaling pathway in MCF-7 cells were examined by immunoblotting following treatment with various regimens. The results of the MTT assay indicated that the combined treatment of <b style='color:Tomato;'><i>simvastatin</i></b> and <b style='color:Tomato;'><i>exemestane</i></b> significantly decreased the viability of MCF-7 estrogen receptor-positive (ER+) human breast cancer cells, as compared with those that were treated with the individual drugs (CI<1). In addition, coadministration of <b style='color:Tomato;'><i>exemestane</i></b> and <b style='color:Tomato;'><i>simvastatin</i></b> was shown to result in marked inhibition of tumor cell proliferation, significant cell cycle arrest at G0/G1 phase and induction of apoptosis, as compared with that of the control and individual drug-treated cells. Furthermore, the results of the present study indicated that these synergistic effects may be associated with the B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein apoptotic pathway and the mitogen-activated protein kinase/mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b>/p70S6 kinase growth pathway. The combination of <b style='color:Tomato;'><i>exemestane</i></b> and <b style='color:Tomato;'><i>simvastatin</i></b> generated synergistic effects on MCF-7 ER+ breast cancer cells, indicating that the combination of these drugs may be a potential therapeutic strategy for the treatment of hormone-dependent breast cancer. The combination of the two inhibitors markedly increased the efficacy, as compared with the single-agent treatment, suggesting that combination treatment could become a highly effective approach for breast cancer. The results of the present study suggested that this combination of drugs has therapeutic potential, and requires further mechanistic and biomarker investigations in clinical trials.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"the","start":11,"end":14,"id":3,"ws":true},{"text":"present","start":15,"end":22,"id":4,"ws":true},{"text":"study","start":23,"end":28,"id":5,"ws":true},{"text":"was","start":29,"end":32,"id":6,"ws":true},{"text":"to","start":33,"end":35,"id":7,"ws":true},{"text":"investigate","start":36,"end":47,"id":8,"ws":true},{"text":"the","start":48,"end":51,"id":9,"ws":true},{"text":"combined","start":52,"end":60,"id":10,"ws":true},{"text":"effects","start":61,"end":68,"id":11,"ws":true},{"text":"of","start":69,"end":71,"id":12,"ws":true},{"text":"simvastatin","start":72,"end":83,"id":13,"ws":true},{"text":"and","start":84,"end":87,"id":14,"ws":true},{"text":"exemestane","start":88,"end":98,"id":15,"ws":true},{"text":"on","start":99,"end":101,"id":16,"ws":true},{"text":"MCF-7","start":102,"end":107,"id":17,"ws":true},{"text":"human","start":108,"end":113,"id":18,"ws":true},{"text":"breast","start":114,"end":120,"id":19,"ws":true},{"text":"cancer","start":121,"end":127,"id":20,"ws":true},{"text":"cells","start":128,"end":133,"id":21,"ws":true},{"text":".","start":134,"end":135,"id":22,"ws":false}],"spans":[{"start":72,"end":83,"token_start":13,"token_end":13,"label":"DRUG"},{"start":88,"end":98,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25738757/","_input_hash":620057444,"_task_hash":-1389614691,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":72,"end":83,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":88,"end":98,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Synergy of Omeprazole and Praziquantel In Vitro Treatment against Schistosoma mansoni Adult Worms .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Synergy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Omeprazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Praziquantel</i></b> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>Vitro</i></b> <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>Schistosoma</i></b> <b style='color:DodgerBlue;'><i>mansoni</i></b> <b style='color:DodgerBlue;'><i>Adult</i></b> <b style='color:DodgerBlue;'><i>Worms</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Treatment and morbidity control of schistosomiasis relies on a single drug, <b style='color:Tomato;'><i>praziquantel</i></b> (PZQ), and the selection of resistant worms under repeated treatment is a concern. Therefore, there is a pressing need to understand the molecular effects of PZQ on schistosomes and to investigate alternative or synergistic drugs against schistosomiasis. ### methodology We used a custom-designed Schistosoma mansoni expression microarray to explore the effects of sublethal doses of PZQ on large-scale gene expression of adult paired males and females and unpaired mature females. We also assessed the efficacy of PZQ, <b style='color:Tomato;'><i>omeprazole</i></b> (OMP) or their combination against S. mansoni adult worms with a survival in vitro assay. ### Principal Findings We identified sets of genes that were affected by PZQ in paired and unpaired mature females, however with opposite gene expression patterns (up-regulated in paired and down-regulated in unpaired mature females), indicating that PZQ effects are heavily influenced by the mating status. We also identified genes that were similarly affected by PZQ in males and females. Functional analyses of gene interaction networks were performed with parasite genes that were differentially expressed upon PZQ treatment, searching for proteins encoded by these genes whose human homologs are targets of different drugs used for other diseases. Based on these results, OMP, a widely prescribed proton pump inhibitor known to target the ATP1A2 gene product, was chosen and tested. Sublethal doses of PZQ combined with OMP significantly increased worm mortality in vitro when compared with PZQ or OMP alone, thus evidencing a synergistic effect. ### conclusions Functional analysis of gene interaction networks is an important approach that can point to possible novel synergistic drug candidates. We demonstrated the potential of this strategy by showing that PZQ in combination with OMP displayed increased efficiency against S. mansoni adult worms in vitro when compared with either drug alone.","tokens":[{"text":"Synergy","start":0,"end":7,"id":0,"ws":true},{"text":"of","start":8,"end":10,"id":1,"ws":true},{"text":"Omeprazole","start":11,"end":21,"id":2,"ws":true},{"text":"and","start":22,"end":25,"id":3,"ws":true},{"text":"Praziquantel","start":26,"end":38,"id":4,"ws":true},{"text":"In","start":39,"end":41,"id":5,"ws":true},{"text":"Vitro","start":42,"end":47,"id":6,"ws":true},{"text":"Treatment","start":48,"end":57,"id":7,"ws":true},{"text":"against","start":58,"end":65,"id":8,"ws":true},{"text":"Schistosoma","start":66,"end":77,"id":9,"ws":true},{"text":"mansoni","start":78,"end":85,"id":10,"ws":true},{"text":"Adult","start":86,"end":91,"id":11,"ws":true},{"text":"Worms","start":92,"end":97,"id":12,"ws":true},{"text":".","start":98,"end":99,"id":13,"ws":false}],"spans":[{"start":11,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":26,"end":38,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26402251/","_input_hash":-1559857653,"_task_hash":-512461566,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":11,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":26,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
